
<html lang="en"     class="pb-page"  data-request-id="bdc43acf-6da5-4242-93cb-ff39d5803f13"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-12;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b01297;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury" /></meta><meta name="dc.Creator" content="Merrie  Mosedale" /></meta><meta name="dc.Creator" content="Paul B.  Watkins" /></meta><meta name="dc.Description" content="Idiosyncratic adverse drug reactions (IADRs) encompass a diverse group of toxicities that can vary by drug and patient. The complex and unpredictable nature of IADRs combined with the fact that the..." /></meta><meta name="Description" content="Idiosyncratic adverse drug reactions (IADRs) encompass a diverse group of toxicities that can vary by drug and patient. The complex and unpredictable nature of IADRs combined with the fact that the..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 9, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01297" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01297" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01297" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01297" /></link>
        
    
    

<title>Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01297" /></meta><meta property="og:title" content="Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/large/jm9b01297_0005.jpeg" /></meta><meta property="og:description" content="Idiosyncratic adverse drug reactions (IADRs) encompass a diverse group of toxicities that can vary by drug and patient. The complex and unpredictable nature of IADRs combined with the fact that they are rare makes them particularly difficult to predict, diagnose, and treat. Common clinical characteristics, the identification of human leukocyte antigen risk alleles, and drug-induced proliferation of lymphocytes isolated from patients support a role for the adaptive immune system in the pathogenesis of IADRs. Significant evidence also suggests a requirement for direct, drug-induced stress, neoantigen formation, and stimulation of an innate response, which can be influenced by properties intrinsic to both the drug and the patient. This Perspective will provide an overview of the clinical profile, mechanisms, and risk factors underlying IADRs as well as new approaches to study these reactions, focusing on idiosyncratic drug-induced liver injury." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01297"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01297">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01297&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01297&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01297&amp;href=/doi/10.1021/acs.jmedchem.9b01297" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 6436-6461</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01365" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.9b01159" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Merrie Mosedale</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Merrie Mosedale</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Drug Safety Sciences and Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina 27599, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#d8b5bdaaaab1bd98adb6bbf6bdbcad"><span class="__cf_email__" data-cfemail="d7bab2a5a5beb297a2b9b4f9b2b3a2">[email protected]</span></a>. Phone: (919) 226-3143.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Merrie++Mosedale">Merrie Mosedale</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1968-6666" title="Orcid link">http://orcid.org/0000-0003-1968-6666</a></div></div></span></li><span class="comma-separator"> and </span><li><span><span class="hlFld-ContribAuthor">Paul B. Watkins</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul B. Watkins</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Drug Safety Sciences and Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina 27599, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul+B.++Watkins">Paul B. Watkins</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01297&amp;href=/doi/10.1021%2Facs.jmedchem.9b01297" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 6436–6461</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 9, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>8 August 2019</li><li><span class="item_label"><b>Published</b> online</span>9 February 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 June 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01297" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01297</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6436%26pageCount%3D26%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMerrie%2BMosedale%252C%2BPaul%2BB.%2BWatkins%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D12%26contentID%3Dacs.jmedchem.9b01297%26title%3DUnderstanding%2BIdiosyncratic%2BToxicity%253A%2BLessons%2BLearned%2Bfrom%2BDrug-Induced%2BLiver%2BInjury%26numPages%3D26%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6461%26publicationDate%3DJune%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01297"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3573</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">11</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01297" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Merrie&quot;,&quot;last_name&quot;:&quot;Mosedale&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;B. Watkins&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;6436-6461&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01297&quot;},&quot;abstract&quot;:&quot;Idiosyncratic adverse drug reactions (IADRs) encompass a diverse group of toxicities that can vary by drug and patient. The complex and unpredictable nature of IADRs combined with the fact that they are rare makes them particularly difficult to predict, diagnose, and treat. Common clinical characteristics, the identification of human leukocyte antigen risk alleles, and drug-induced proliferation of lymphocytes isolated from patients support a role for the adaptive immune system in the pathogenesis of IADRs. Significant evidence also suggests a requirement for direct, drug-induced stress, neoantigen formation, and stimulation of an innate response, which can be influenced by properties intrinsic to both the drug and the patient. This Perspective will provide an overview of the clinical profile, mechanisms, and risk factors underlying IADRs as well as new approaches to study these reactions, focusing on idiosyncratic drug-induced liver injury.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01297&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01297" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01297&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01297" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01297&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01297" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01297&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01297&amp;href=/doi/10.1021/acs.jmedchem.9b01297" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01297" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01297" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01297%26sid%3Dliteratum%253Aachs%26pmid%3D32037821%26genre%3Darticle%26aulast%3DMosedale%26date%3D2020%26atitle%3DUnderstanding%2BIdiosyncratic%2BToxicity%253A%2BLessons%2BLearned%2Bfrom%2BDrug-Induced%2BLiver%2BInjury%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D12%26spage%3D6436%26epage%3D6461%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=292143" title="Metabolism">Metabolism</a>,</li><li><a href="/action/doSearch?ConceptID=291720" title="Antigens">Antigens</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/jmcmar.2020.63.issue-12/20200625/jmcmar.2020.63.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/medium/jm9b01297_0005.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/large/jm9b01297_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01297&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Idiosyncratic adverse drug reactions (IADRs) encompass a diverse group of toxicities that can vary by drug and patient. The complex and unpredictable nature of IADRs combined with the fact that they are rare makes them particularly difficult to predict, diagnose, and treat. Common clinical characteristics, the identification of human leukocyte antigen risk alleles, and drug-induced proliferation of lymphocytes isolated from patients support a role for the adaptive immune system in the pathogenesis of IADRs. Significant evidence also suggests a requirement for direct, drug-induced stress, neoantigen formation, and stimulation of an innate response, which can be influenced by properties intrinsic to both the drug and the patient. This Perspective will provide an overview of the clinical profile, mechanisms, and risk factors underlying IADRs as well as new approaches to study these reactions, focusing on idiosyncratic drug-induced liver injury.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar/63/12"><issue-title>Drug Metabolism and Toxicology</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87117" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87117" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Adverse drug reactions (ADRs) are broadly described as either intrinsic or idiosyncratic. Intrinsic reactions are dose-dependent, occur within days of starting the drug, and are usually predicted by nonclinical studies. Acetaminophen is an example of an intrinsic toxicant where all patients will develop an adverse response if they receive a high enough dose. In contrast, idiosyncratic adverse drug reactions (IADRs) lack a clear dose–response relationship, can occur weeks to months after the initial drug exposure, and are not easily predicted by nonclinical or even small clinical studies. With a true idiosyncratic toxicant, serious injury occurs in only a small number of patients taking the drug (typically less than 1 in 10000), and therefore the possibility of this kind of liability is not recognized until the late stages of clinical development.</div><div class="NLM_p">Drugs that cause IADRs are also frequently associated with more mild and asymptomatic injuries in a larger percentage of the population. However, the prevalence and magnitude of these responses does not correlate well with the risk for severe IADRs, and there are no tests available to distinguish between benign responses and the potential for more serious reactions. As a result, once a drug has been associated with a safety signal, regulators are often forced to request additional and more comprehensive clinical studies to better characterize the risk. Such requests can delay the approval of a new drug resulting in reduced access of patients to potentially life-saving new therapies as well as increasing the cost of these and other drugs. Furthermore, drugs that have any risk may require restrictive postmarket safety programs that involve additional testing or limit the drug to a specific subpopulation of patients. Not surprisingly, many companies will terminate drug programs once indications of IADRs emerge at any stage of nonclinical or clinical development. This practice most certainly results in the abandonment of potentially beneficial new therapies that could be taken safely by the majority of the patient population.</div><div class="NLM_p last">Taken together, IADRs are the most problematic type of ADRs for patients, health care providers, drug developers, and drug regulators. Fortunately, improved access to patient data, collaboration among immunologists and toxicologists, and the development of new models to study IADRs has helped to provide a better understanding of the mechanisms underlying these reactions. This Perspective will provide an overview of what is known about the clinical characteristics, pathogenesis, and risk factors for IADRs, with a focus on idiosyncratic drug-induced liver injury (IDILI). It will also describe new tools and approaches to improve the prediction and understanding of IADRs and emerging topics in the field.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Clinical Characteristics</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07444" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07444" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Types</h3><div class="NLM_p">Many organs are affected by IADRs, but the most common targets are skin and liver.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Some drugs may induce IADRs in only one organ and other drugs may cause IADRs in multiple organs, sometimes in the same individual and sometimes simultaneously.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The most common type of IADRs are skin rashes, likely because a rash is visible whereas mild injury to an internal organ could go undiagnosed. Skin is also immunologically very active, which may further contribute to IADR susceptibility.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Liver on the other hand is the organ likely to see highest drug exposure due to the first pass effect. Most drug metabolism also occurs in the liver putting it at risk for the accumulation of reactive metabolites, which have been implicated in the mechanism of IADRs.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">Some of the most common cutaneous reactions are maculopapular rash, urticaria (hives), and fixed drug eruption.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> These rashes are not serious and may resolve despite continued treatment. However, some rashes that initially appear less serious can progress into more significant skin reactions. The most severe cutaneous adverse reactions (SCARs) are drug reaction with eosinophilia and systemic symptoms (DRESS), toxic epidermal necrolysis (TEN), and Stevens–Johnson syndrome (SJS). DRESS, also referred to as drug-induced hypersensitivity syndrome (DIHS), is a highly variable syndrome characterized by the rapid development of skin rash, fever, lymphadenopathy, hematologic abnormalities, and injury to one or more other organs.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> However, the presentation can vary among patients and skin rashes are not always observed. DRESS is associated with a 10% mortality rate, which results mainly from liver failure. The most severe skin reaction is TEN, where mortality is as high as 30%.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> SJS is a milder form of TEN involving less of the skin. The presentation of SJS/TEN usually begins with fever and general discomfort and progresses to a painful rash that is sensitive to the touch. Eventually, widespread keratinocyte apoptosis leads to dermo-epidermal separation and bullae.</div><div class="NLM_p">Clinically, the presentation of drug-induced liver injury (DILI) is classified according to the “<i>R</i>” value, defined by the ratio of serum alanine aminotransferase (ALT) to alkaline phosphatase (ALP), both expressed as multiples of the upper limit of normal (ULN).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> By convention, an <i>R</i> ratio of >5 indicates hepatocellular, <2 cholestatic, and 2–5 mixed injury. These classifications roughly correspond to the type of injured target cells where hepatocellular injury involves primarily hepatocytes, cholestatic injury involves biliary epithelial cells (cholangiocytes), and mixed injuries involve a combination of both. Hepatocellular injury is the most common type observed (>50%) and is more likely to be fatal.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> However, cholestatic injury now accounts for a quarter of DILI cases and is more likely to be prolonged and result in chronic injury. As a result, cholestatic DILI is an issue of rising concern among drug makers and regulators.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">It should be noted that toxicologists frequently refer to DILI resulting from alterations in bile acid homeostasis as “cholestatic injury”. However, this can be confusing as DILI resulting from bile acid transporter inhibition typically presents as a hepatocellular or mixed pattern of injury (i.e., <i>R</i> ratio >2). Therefore, it is important to define the term “cholestatic injury” as either a clinical pattern of enzyme elevations that reflect injury to cholangiocytes or a mechanism of toxicity depending on the context of use.</div><div class="NLM_p last">IADRs also include systemic reactions such as hematologic disorders and autoimmune syndromes.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Hematologic IADRs result from alterations in the production or destruction of blood cells. The most common drug-induced hematologic disorders include aplastic anemia, agranulocytosis, megaloblastic anemia, hemolytic anemia, and thrombocytopenia.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Drug-induced autoimmunity can present as a skin, liver, or hematologic reaction but can also present as a more systemic reaction with characteristics like lupus.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> One main characteristic of drug-induced reactions is that the autoimmune symptoms resolve once the drug is discontinued. Other less common target organs of IADRs include kidney, lung, and colon.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Patterns</h3><div class="NLM_p">While individual drugs will often cause a specific clinical pattern of injury, there are certain characteristics common to most IADRs. An important characteristic is that the onset of these reactions is generally delayed.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> While there are some examples in which a reaction occurs immediately after starting the drug, this is the exception. In most cases, there is the delay on the order of weeks to months between starting the drug and the onset of the adverse reaction (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The specific time frame is different for different types of reactions. For example, some common skin rashes occur within 1 to 2 weeks of treatment.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> IDILI occurs most commonly between 1 and 3 months after starting therapy.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> But the exact profile also varies with the drug and the patient. For example, tolvaptan-induced liver injury was observed in some patients >1 year after initiating therapy.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/medium/jm9b01297_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/large/jm9b01297_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Serum liver chemistries of a patient experiencing idiosyncratic drug-induced liver injury (IDILI). Serial values of serum alkaline phosphate (ALP), aspartate aminotransferase (AST), total bilirubin (BILI), and alanine aminotransferase (ALT) are plotted as times the upper limit of normal (×ULN) against number of days since first drug exposure for a patient in the TEMPO 3:4 (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) clinical trial (NCT00428948). The shaded areas correspond to periods of active treatment. Figure used with permission from Otsuka Pharmaceutical Development and Commercialization, Inc.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/large/jm9b01297_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01297&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another common characteristic is the rapid onset of a reaction in response to a rechallenge with the same drug (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). In these cases, patients demonstrate a delay in onset upon first exposure but have a much more immediate reaction the second time they are exposed to the same drug.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Data on rechallenge responses is lacking for many drugs because for severe reactions, it is not regularly performed. Of course, the time to onset of rechallenge response profile also varies by drug and patient. In rare cases the onset of symptoms upon rechallenge is also delayed.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> And in other patients a rechallenge reaction may not even occur, suggesting adaptation to the initial insult.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">Drugs associated with clinically significant IADRs usually also cause more mild symptoms in a larger number of patients that resolve even while continuing drug treatment (i.e., adaptation).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> In the case of liver injury, this has been termed “Temple’s corollary” referring to the quadrant of an eDISH (evaluation of drug-induced serious hepatotoxicity) plot that reflects subjects with ALT elevations in the absence of elevated bilirubin<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). However, the relative numbers of patients experiencing mild ALT elevations to those with more serious liver injury is different with different drugs, and there are drugs that cause mild injuries but never cause any serious reactions.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/medium/jm9b01297_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/large/jm9b01297_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Example eDISH (evaluation of Drug-Induced Serious Hepatotoxicity) plot. The peak total serum bilirubin and peak serum alanine aminotransferase (ALT) values expressed as times upper limit of normal (×ULN) are plotted on a log<sub>10</sub> scale for each subject in a clinical trial. The plot is divided into 4 quadrants by a horizontal line corresponding to a serum bilirubin 2×ULN and a vertical line corresponding to ALT 3×ULN. This eDISH plot was created from an actual clinical trial that included more than 3900 subjects randomized to either the experimental drug “X” in red triangles or the control drug “C” as a comparator in green circle (1:1). There is an imbalance of drug “X” patients in the upper right (Hy’s law) and lower right (Temple’s corollary) quadrants suggesting abnormal liver chemistries are the result of the study drug. The eDISH plot shown here was provided by Dr. John Senior and is used with his permission. Dr. Senior has not published this figure elsewhere.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/large/jm9b01297_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01297&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Unfortunately, there are no nonclinical or clinical tests that can distinguish benign serum ALT elevations from those that portend more serious IDILI potential.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Currently, the only way to confirm IDILI liability is to continue treating patients after they develop asymptomatic elevations in serum ALT to see if they also develop elevations in serum bilirubin, which would be indicative of global liver function. However, continuing to treat clinical trial subjects with asymptomatic ALT elevations, even under close observation, places these patients at risk for potentially lethal consequences.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Hepatocellular injuries significant enough to impair bilirubin excretion will cause liver failure in at least 10% of subjects.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> This observation was first made by Dr. Hy Zimmerman, has proven to be the case in international DILI registries,<a onclick="showRef(event, 'ref9 ref22'); return false;" href="javascript:void(0);" class="ref ref9 ref22">(9,22)</a> and is now commonly referred to as “Hy’s law”.</div><div class="NLM_p last">Finally, IADRs of all types also commonly involve an immune response. Drug-specific T-cells are frequently observed in the blood and target organs of patients during and after a response.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In the case of skin reactions, leukocyte infiltration is often associated with the rash, and these can look very similar to immunologically mediated rashes caused by viruses. In the case of liver injury, microscopic findings vary, but there is usually some mononuclear infiltrate present and eosinophils can be observed even without other signs of an allergic reaction.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Some drugs can even cause IDILI that is indistinguishable from idiopathic liver failure or viral hepatitis other than the key diagnostic feature that injury resolves once the drug is discontinued. And drug-induced autoimmune syndromes are by definition immune-mediated.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> For example, the resolution of symptoms from stopping a drug or previous knowledge that a drug is known to cause an autoimmune syndrome is the only way to differentiate drug-induced lupus from that which is idiopathic in nature.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Diagnosis</h3><div class="NLM_p">Because of the prolonged latency and the similarity of IADRs to other pathologies, they are particularly difficult to diagnose.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Most diagnoses are based on suspicion of an adverse drug reaction and exclusion of competing causes of injury. However, this can be confounded by the effects of preexisting disease. Furthermore, it can be difficult to confidently identify the drug causing the reaction when patients are taking multiple medications. A positive rechallenge is considered solid evidence for drug causality, but this presents risks for the patient and is only recommended in certain circumstances. The gold standard for diagnosis and causality assessment is expert review of available clinical information, including patient history and implicated drugs.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Unfortunately, expert review is not widely available in clinical practice, a major drawback of this approach.</div><div class="NLM_p last">Point-based scoring systems have been developed to allow for assessment without expert opinion, and computerized variations have been suggested to reduce error in calculations and subjectivity in interpretation.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Several efforts to develop <i>in vitro</i> methods to identify drugs that cause skin and liver injury in patients have also been explored. The lymphocyte transformation test (LTT) involves measuring the proliferation of lymphocytes isolated from a patient with an IADR when exposed to a drug <i>ex vivo</i>. Expansion of the lymphocytes indicates that a patient has been previously exposed to the culprit drug. Promising responses have been observed using frozen and thawed PBMCs from patients with liver injury due to isoniazid, but responses to other IDILI drugs have been inconsistent.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Another test involves generating monocyte-derived hepatocyte-like (MH) cells from blood cells isolated from patients with IDILI.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> MH cells are incubated with drugs to which each patient had been exposed, and toxicity is measured based on release of lactate dehydrogenase. In a study of 13 patients with DILI, the MH test identified drugs that cause liver injury with 92.3% sensitivity and 100% specificity.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> However, MH and LTT approaches currently take weeks to perform and may also be difficult to implement in routine clinical practice.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Treatment</h3><div class="NLM_p">Treatment of IADRs also remains a challenge. The standard of care is to discontinue the suspect drug.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Unfortunately, without confidently knowing which drug caused the reaction, physicians may resolve to terminate or substitute multiple treatments resulting in less than optimal treatment of the patient’s underlying disease and introducing the potential for new adverse drug responses. Corticosteroids are used to treat some skin and liver injuries. However, they are associated with higher rates of infections, and no clinical benefit has been observed in two placebo-controlled studies of patients with acute liver failure.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><div class="NLM_p">Several recent studies have demonstrated the potential of stem cell-derived exosomes to prevent and treat liver injury in rodent models, including those that are drug-induced.<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30−32)</a> Stem-cell derived exosomes can be obtained from renewable sources, including a patient’s own bone marrow or adipose tissue and are thought to support tissue regeneration via secretion of paracrine factors.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Clinical investigations using mesenchymal stem cells to treat a broad spectrum of degenerative diseases have been increasing steadily in recent years. With such a low incidence, it will be difficult to perform controlled clinical trials for IADRs, but organizations like the Drug-Induced Liver Injury Network (DILIN) have successfully recruited large numbers of patients into their national registry to collect and analyze biospecimens and clinical data and are planning a pilot therapeutic trial (P. Watkins, personal communication). Another challenge will be demonstrating substantial improvement over the current practice. For example, the risk for stem-cell derived exosome therapy may be lower than the use of a small molecule or whole-cell approaches, but it is unlikely to be lower risk or less expensive than simply stopping the suspect drug.</div><div class="NLM_p last">Finally, current biomarkers have little prognostic value in IADRs, and thus there is no way to predict the potential for a patient to recover from the reaction or develop a more serious injury with lethal consequences.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> As a result, all patients diagnosed with IADRs require close monitoring until they recover. DILIN is using serum collected from IDILI patients enrolled in a retrospective study to test the prognostic potential of novel biomarkers. They have identified several promising candidates to predict prognosis during an acute DILI event.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> However, a serial assessment of these biomarkers in large prospective studies will be needed to further delineate their role in DILI diagnosis and management. Given the relationship between cytokines and cytolytic molecules released by immune cells, the type of immune response, and the seriousness of organ injury, it may be useful to explore serum levels of secreted immune factors as biomarkers for prognosis as well.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Mechanisms</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52840" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52840" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Adaptive Immune Response</h3><div class="NLM_p">The clinical profile strongly supports a role for the adaptive immune system in the pathogenesis of most IADRs (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). For example, the delay in onset of an IADR is characteristic of an adaptive immune response and reflects, in part, the time required to activate and expand a population of lymphocytes specific to a new antigen. Once memory cells have been created, they can more quickly differentiate into effector cells upon a second encounter with the same antigen, dramatically shortening the time required to mount an effective response. This is observed as a more rapid rechallenge response to a drug that initially caused an IADR with prolonged latency. Additionally, a more severe reaction is often observed after rechallenge because the memory immune cells are capable of mounting stronger response.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/medium/jm9b01297_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/large/jm9b01297_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Proposed pathogeneses of idiosyncratic adverse drug reactions (IADRs). Most IADRs appear to be immune-mediated and are triggered by the release of danger signals from stress cells, which facilitate an adaptive immune attack. Underlying cell stress and the presentation of drug-induced neoantigen by human leukocyte antigen (HLA) risk alleles make certain individuals more susceptible to clinically significant injury. Some evidence also suggests the potential for heterologous immunity to support an adaptive immune attack in the absence of danger signals as well as a non-immune-mediated pathway whereby cellular stress results in overt injury without an adaptive immune attack.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/large/jm9b01297_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01297&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">IADRs are also characterized by an accumulation of T- and B-lymphocytes and other immune cell types in the target organ and blood.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Increases in proinflammatory cytokines and the formation of antidrug antibodies have also been observed.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> While the presence of immune cells, antibodies, and other inflammatory markers does not confirm that lymphocytes are responsible for the injury, several other pieces of evidence support a contributing role. Histological examinations have revealed T-cells near apoptotic hepatocytes suggesting that these lymphocytes directly participate in cell killing.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The rate of CD8+ T-cell migration to skin and the ability of these cells to be activated by drug-induced neoantigen likely contribute to the severity of the IADR.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The type of T-cell, cytokines, and cytolytic molecules released also appear to contribute to the overall immune response and injury severity. Finally, some skin and systemic reactions respond to immunosuppression, which suggests that these reactions are at least in part immune-mediated.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">Positive LTTs have been detected using peripheral blood mononuclear cells (PBMCs) isolated from patients with IDILI, and the response increases when cells are cultured in the presence of a prostaglandin inhibitor.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Subsequent studies have demonstrated a high degree of specificity (absence of such responses in tolerant patients) as well.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The LTT has also been used to characterize the phenotype of drug-responsive T-cells. For example, CD4+ and 8+ T-cells that are responsive to the drug flucloxacillin have been isolated from the blood of patients having experienced flucloxacillin-induced liver injury.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Following flucloxacillin stimulation, T-cell clones express CCR4 and CCR9, migrate toward CCL17 and CCL25, and secrete interferon-gamma (IFNγ), T helper (Th)2 cytokines, perforin, granzyme B, and FasL. Drug-responsive CD4+ and CD8+ T-cells have also been isolated from the blood of a patient with fatal liver injury caused by antituberculosis drugs.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> These T-cells were activated to proliferate by ethambutol and rifampicin and secreted IFN-γ, Il-13, and granzyme B in response to drug treatment.</div><div class="NLM_p">Finally, evidence supporting the contribution of the adaptive immune system to IADRs is provided by the identification of strong associations between specific HLA genotypes and susceptibility to idiosyncratic reactions from a number of drugs (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). HLA genes encode the major histocompatibility complex (MHC) proteins in humans. These cell surface proteins present antigenic peptides to T-cells, which results in their activation. Prior to antigen presentation, proteins are degraded to potentially antigenic peptides by either cytosolic proteases in the proteasome or lysosome-associated enzymes in the maturing endosomes. These peptides are then loaded onto MHC molecules, transported to the plasma membrane, and presented to T-cells as potential antigens. Generally speaking, the antigenic peptides presented by MHC class I (HLA-A, -B, and -C, present on all cells) come from proteins that are expressed endogenously and presented to CD8+ T-cells, while peptides presented by MHC class II (HLA-DR, -DQ, and -DP, present only on immune cells) are derived from internalized exogenous proteins and presented to CD4+ T-cells. Antigen presentation and T-cell activation are affected by HLA polymorphisms in multiple ways, and mechanisms by which these impact drug interactions are discussed below.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Some Human Leukocyte Antigen (HLA) Alleles Associated with Idiosyncratic Toxicity</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">HLA</th><th class="colsep0 rowsep0" align="center">population</th><th class="colsep0 rowsep0" align="center">approximate odds ratio</th><th class="colsep0 rowsep0" align="center">toxicity</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">abacavir</td><td class="colsep0 rowsep0" align="left">B*57:01</td><td class="colsep0 rowsep0" align="left">Caucasian, African, Thai, and Cambodian</td><td class="colsep0 rowsep0" align="left">>800</td><td class="colsep0 rowsep0" align="left">hypersensitivity</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">allopurinol</td><td class="colsep0 rowsep0" align="left">B*58:01</td><td class="colsep0 rowsep0" align="left">Han Chinese, Thai, Malay, Korean, Caucasian, and Japanese</td><td class="colsep0 rowsep0" align="left">50–500</td><td class="colsep0 rowsep0" align="left">skin</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">anti-TB drugs (isoniazid, rifampicin, pyrazinamide)</td><td class="colsep0 rowsep0" align="left">DQA1*01:02</td><td class="colsep0 rowsep0" align="left">Indian</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">liver</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DQB1*02:01</td><td class="colsep0 rowsep0" align="left">Indian</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="5" align="left">amoxicillin–clavulanate</td><td class="colsep0 rowsep0" align="left">A*02:01</td><td class="colsep0 rowsep0" align="left">Caucasian</td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">liver</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A*30:02</td><td class="colsep0 rowsep0" align="left">Caucasian</td><td class="colsep0 rowsep0" align="left">6.7</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">B*18:01</td><td class="colsep0 rowsep0" align="left">Caucasian</td><td class="colsep0 rowsep0" align="left">2.8</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DRB1*07</td><td class="colsep0 rowsep0" align="left">Caucasian</td><td class="colsep0 rowsep0" align="left">0.18</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DRB1*15:01–DQB1*06:02<a class="ref internalNav" href="#t1fn2" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">Caucasian</td><td class="colsep0 rowsep0" align="left">2.3–10</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">carbamazepine</td><td class="colsep0 rowsep0" align="left">A*31:01</td><td class="colsep0 rowsep0" align="left">Han Chinese, Caucasian, Japanese, and Korean</td><td class="colsep0 rowsep0" align="left">10–25</td><td class="colsep0 rowsep0" align="left">skin</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">B*15:02</td><td class="colsep0 rowsep0" align="left">Han Chinese, Thai, Malay, and Indian</td><td class="colsep0 rowsep0" align="left">>800</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">clozapine</td><td class="colsep0 rowsep0" align="left">B*38</td><td class="colsep0 rowsep0" align="left">Caucasian</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">blood</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">B*59:01</td><td class="colsep0 rowsep0" align="left">Japanese</td><td class="colsep0 rowsep0" align="left">6.3–15</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">DRB5*02:01</td><td class="colsep0 rowsep0" align="left">Caucasian</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">flucloxacillin</td><td class="colsep0 rowsep0" align="left">B*57:01</td><td class="colsep0 rowsep0" align="left">Caucasian</td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">liver</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">B*57:03</td><td class="colsep0 rowsep0" align="left">Caucasian</td><td class="colsep0 rowsep0" align="left">79</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DRB*07:01–DQB1*03:03</td><td class="colsep0 rowsep0" align="left">Caucasian</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">flupirtine</td><td class="colsep0 rowsep0" align="left">DRB1*16:01–DQB1*05:02<a class="ref internalNav" href="#t1fn2" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">Caucasian</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">liver</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lapatinib</td><td class="colsep0 rowsep0" align="left">DQB1*02:02</td><td class="colsep0 rowsep0" align="left">Caucasian</td><td class="colsep0 rowsep0" align="left">6.9–8.6</td><td class="colsep0 rowsep0" align="left">liver</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">DRB1*07:01–DQA1*02:01<a class="ref internalNav" href="#t1fn2" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">Caucasian</td><td class="colsep0 rowsep0" align="left">2.6–9</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lumiracoxib</td><td class="colsep0 rowsep0" align="left">DRB1*15:01–DQA1*01:02–DQB1*06:02–DRB5*01:01<a class="ref internalNav" href="#t1fn2" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">Caucasian</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">liver</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">methazolamide</td><td class="colsep0 rowsep0" align="left">B*59:01</td><td class="colsep0 rowsep0" align="left">Korean and Japanese</td><td class="colsep0 rowsep0" align="left">>250</td><td class="colsep0 rowsep0" align="left">skin</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nevirapine</td><td class="colsep0 rowsep0" align="left">DRB1*01</td><td class="colsep0 rowsep0" align="left">Caucasian</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">B*35:05</td><td class="colsep0 rowsep0" align="left">Thai</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">skin</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phenytoin</td><td class="colsep0 rowsep0" align="left">B*15:02</td><td class="colsep0 rowsep0" align="left">Thai and Han Chinese</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ticlopidine</td><td class="colsep0 rowsep0" align="left">A*33:03</td><td class="colsep0 rowsep0" align="left">Japanese</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">liver</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">B*44:03</td><td class="colsep0 rowsep0" align="left">Japanese</td><td class="colsep0 rowsep0" align="left">6.7</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Cw*14:03</td><td class="colsep0 rowsep0" align="left">Japanese</td><td class="colsep0 rowsep0" align="left">7.3</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">DRB1*13:02</td><td class="colsep0 rowsep0" align="left">Japanese</td><td class="colsep0 rowsep0" align="left">9.0</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">DQB1*06:04</td><td class="colsep0 rowsep0" align="left">Japanese</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sulfamethoxazole/trimethoprim</td><td class="colsep0 rowsep0" align="left">HLA-B*15:02–C*08:01<a class="ref internalNav" href="#t1fn2" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">Thai</td><td class="colsep0 rowsep0" align="left">4.8</td><td class="colsep0 rowsep0" align="left">skin</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ximelagatran</td><td class="colsep0 rowsep0" align="left">DRB1*07:01–DQA1*02:01<a class="ref internalNav" href="#t1fn2" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">Caucasian</td><td class="colsep0 rowsep0" align="left">4.4</td><td class="colsep0 rowsep0" align="left">liver</td></tr></tbody></table></div><div class="attrib">Adapted from refs <a onclick="showRef(event, 'ref3 ref41'); return false;" href="javascript:void(0);" class="ref ref3 ref41">(3and41)</a> and updated with findings from ref <a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a>.</div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn2"><div class="footnote" id="t1fn2"><sup><sup>a</sup></sup><p class="last">Indicates associated haplotype associations.</p></div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Neoantigen</h3><div class="NLM_p">HLA-mediated antigen presentation is needed to stimulate the activation of T-cells and a subsequent adaptive immune response. There are a variety of hypotheses for the source of antigen and the mechanism by which it stimulates T-cell activation (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). However, in all cases the stimulating antigen is new in the sense that it is first presented in response to the drug treatment. The term “neoantigen” is used here to describe all new antigens (self and nonself) regardless of the mechanism of antigen presentation.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/medium/jm9b01297_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/large/jm9b01297_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Hypotheses for neoantigen presentation. Three main hypotheses explain how human leukocyte antigen (HLA) molecules stimulate T-cell activation during an idiosyncratic adverse drug reaction. In the hapten model, HLA molecules present drug-modified peptides formed by covalent binding of reactive metabolites to cellular proteins. In the pharmacological interaction model, a drug binds noncovalently to either the HLA molecule or the T-cell receptor resulting in peptide-independent T-cell activation. In the altered peptide binding repertoire model, drugs or their metabolites bind noncovalently to the peptide-binding pocket of the HLA molecule, changing its chemistry and altering the self-peptide repertoire presented by the HLA molecule.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/large/jm9b01297_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01297&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The longest standing model of drug-induced neoantigen presentation is the “hapten hypothesis”. This model is based on the metabolism of the parent drug resulting in the production of a reactive intermediate. Hapten–protein adducts are generated when the reactive metabolite binds covalently to cellular proteins. Adducts are then degraded into peptides with chemical modifications and presented by HLA molecules as neoantigens. T-cells recognize hapten-derived neoantigens as “foreign”, which triggers a response by the adaptive immune system. Most IADR-causing drugs can generate reactive metabolites, which will covalently bind proteins, thus lending support to this hypothesis.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In addition, several LTT studies have demonstrated a requirement for antigen presenting cells (APCs) to be exposed to the parent drug for a lengthy period of time in order to mount a response in T-cell clones, and inhibiting antigen processing will abrogate the proliferative and cytokine response.<a onclick="showRef(event, 'ref39 ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref39 ref43 ref44">(39,43,44)</a> This kind of delay suggests that an adaptive immune response requires hapten formation to occur prior to neoantigen presentation.</div><div class="NLM_p">The hapten hypothesis is also supported by the tissue specificity of many IADRs. Most reactive metabolites are too unstable to travel throughout system circulation. Therefore, it is more likely that IADRs occur at the site where the reactive metabolite is generated. The liver is the major source of drug metabolism and the organ likely to see the highest exposure of drug metabolites due to the first pass effect. The skin is also a metabolically competent organ and can form reactive metabolites through a variety of mechanisms.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Interestingly, while the strongest risk factor genes for susceptibility to IADRs are specific HLA molecules, associations with polymorphisms in a variety of drug metabolizing enzyme and transporter (DMET) genes have also been reported, <named-content content-type="anchor" rid="tbl1" type="simple"></named-content><named-content content-type="anchor" rid="fig4" type="simple"></named-content><a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. DMET Risk Alleles</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">gene</th><th class="colsep0 rowsep0" align="center">toxicity</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">amoxicillin–clavulanate</td><td class="colsep0 rowsep0" align="left">GSTM1, GSTT1</td><td class="colsep0 rowsep0" align="left">liver</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bosentan</td><td class="colsep0 rowsep0" align="left">CYP2C9</td><td class="colsep0 rowsep0" align="left">liver</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">diclofenac</td><td class="colsep0 rowsep0" align="left">UGT2B7, ABCC2</td><td class="colsep0 rowsep0" align="left">liver</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">efavirenz</td><td class="colsep0 rowsep0" align="left">CYP2B6</td><td class="colsep0 rowsep0" align="left">liver</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">isoniazid</td><td class="colsep0 rowsep0" align="left">CYP2E1, NAT2</td><td class="colsep0 rowsep0" align="left">liver</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nevirapine</td><td class="colsep0 rowsep0" align="left">ABCB1</td><td class="colsep0 rowsep0" align="left">liver</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CYP2B6</td><td class="colsep0 rowsep0" align="left">skin</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">perhexiline</td><td class="colsep0 rowsep0" align="left">CYP2D6</td><td class="colsep0 rowsep0" align="left">liver</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phenytoin</td><td class="colsep0 rowsep0" align="left">CYP2C9</td><td class="colsep0 rowsep0" align="left">skin</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tacrine</td><td class="colsep0 rowsep0" align="left">GSTM1, GSTT1</td><td class="colsep0 rowsep0" align="left">liver</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ticlopidine</td><td class="colsep0 rowsep0" align="left">CYP2B6</td><td class="colsep0 rowsep0" align="left">liver</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tolcapone</td><td class="colsep0 rowsep0" align="left">UGT1A6</td><td class="colsep0 rowsep0" align="left">liver</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">troglitizone</td><td class="colsep0 rowsep0" align="left">GSTM1, GSTT1</td><td class="colsep0 rowsep0" align="left">liver</td></tr></tbody></table></div><div class="attrib">Adapted from refs <a onclick="showRef(event, 'ref41 ref45'); return false;" href="javascript:void(0);" class="ref ref41 ref45">(41and45)</a>.</div></div><div class="NLM_p">Recently, hapten neoantigens were identified in exosomes secreted from primary human hepatocytes exposed to amoxicillin, flucloxacillin, and nitroso-sulfamethoxazole.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> When applied to monocyte-derived dendritic cells, these hepatocyte-derived exosomes were phagocytosed, resulting in the internalization of the exosomes and their haptenized content. Drug-modified peptides contained within the exosomes were also capable of activating naive T-cells from human donors carrying drug-specific HLA risk alleles.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Previous studies have demonstrated that hepatocytes release small extracellular vesicles (<150 nm) called exosomes, which can travel into systemic circulation through the holes or fenestrations in the liver’s sinusoidal endothelium. Under basal conditions, hepatocyte-derived exosomes are readily detected in plasma, and drug-induced changes in the abundance and cargo of hepatocyte-derived exosomes have been observed earlier than and even without overt cell death.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> The demonstration that exosomes can carry hapten neoantigens provides further support of the hapten hypothesis and suggests that haptens (as opposed to hapten-generating reactive metabolites) can be trafficked from the cell of origin to APCs. This may help to explain genetic associations with HLA class II alleles where antigen is thought to be derived from cells containing only HLA class I alleles (e.g., hepatocytes).</div><div class="NLM_p">Other hypotheses for neoantigen presentation propose that T-cell activation is the result of the direct interaction of a drug (or its metabolites) with immune receptors.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The “pharmacological interaction” or “p-i” model, for example, describes the direct noncovalent interaction of a drug or its metabolites with the HLA molecule or T-cell receptor, which results in peptide-independent T-cell activation. Evidence for the p-i hypothesis was originally provided in studies of sulfamethoxazole<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50,51)</a> and lidocaine where the kinetics of activation for certain drug-specific T-cell clones were shown to be too rapid to involve antigen processing.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> More recently, this has been proposed as the mechanism of neoantigen presentation for carbamazepine- and allopurinol-induced SJS/TEN where in both cases, the response of T-cells does not necessitate intracellular metabolism or antigen processing.<a onclick="showRef(event, 'ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref53 ref54 ref55">(53−55)</a> In the case of IDILI associated with isoniazid (INH), both mechanisms may be at play. Patients who develop mild isoniazid-induced IDILI only had a positive LTT when lymphocytes were exposed to INH-modified proteins.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> However, patients who develop severe INH-induced IDILI had a positive LTT to both INH-modified proteins and INH itself.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></div><div class="NLM_p">A second direct interaction hypothesis is referred to as the “altered peptide repertoire” model. This hypothesis suggests that noncovalent interaction of the drug or metabolite can result in alterations in the peptide binding cleft and thus change the self-peptide repertoire that is presented. Only a small percentage of intracellular peptides are recognized as self from having been presented by HLA molecules previously. Therefore, the presentation of new peptides, even if they are self peptides, may trigger a reaction because they are seen by T-cells as neoantigens, despite the fact that they are not “new” to the cell. Drug interaction with the peptide binding pocket of HLA-B*57:01 resulting in an altered repertoire of presented self peptides has been shown to occur in abacavir hypersensitivity reactions.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> More recent work has explored how alteration of the chemical structure of abacavir impacts HLA-B*57:01 binding, peptide display, and the ability to active T-cells.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Although less compelling, some evidence also supports altered self-peptide repertoires as the mechanism for carbamazepine toxicity.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div><div class="NLM_p">Polymorphisms in HLA risk alleles affect the chemistry and affinity of the peptide-binding cleft and can impact neoantigen presentation in several ways. In the case of the “hapten hypothesis”, it is likely that HLA risk alleles can present drug-modified peptides that other HLA alleles do not. In the case of the “p-i” model, HLA risk alleles must allow an interaction with the drug in a peptide independent manner that provides binding energy to stimulate a T-cell proliferative response. Finally, in the case of the “altered peptide repertoire” model, HLA risk alleles likely interact with the drug in a way that allows for a change in the peptides presented such that self peptides not originally recognized as such during initial immune surveillance are now presented and considered neoantigens. Furthermore, it appears that HLA molecules can present continuous segments derived from intracellular proteins as well as noncontiguous peptides generated by both cis-splicing of segments from distinct regions of same antigen and trans-splicing of two distinct proteins.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> This may have implications for the overall repertoire of peptides that can be presented by HLA risk alleles.</div><div class="NLM_p last">The importance of the HLA risk alleles in the propagation of T-cell response has been definitively established by LTT assays performed with T-cell clones from drug-naive healthy donors. For example, cells from donors carrying HLA-B*57:01 who have never taken flucloxacillin will expand in a “priming assay” where drug is cultured with the donor’s T-cells and dendritic cells for a lengthy period of time, but cells from donors without this risk allele will not.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> However, it is important to note that while many HLA associations are very sensitive, they may lack specificity leaving a significant portion of individual patient risk unexplained. For example, HLA-B*57:01 is very strongly associated with the risk of flucloxacillin DILI; however, only ∼1 in 500 HLA-B*57:01 carriers will develop DILI if treated with the drug.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Furthermore, transgenic mouse models expressing human HLA risk alleles have not reliably replicated associated IADRs without concurrently inducing cellular stress.<a onclick="showRef(event, 'ref61 ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref61 ref62 ref63">(61−63)</a> This supports the requirement for other necessary but not sufficient steps to facilitate a T-cell response and the likelihood for individual susceptibility within these early events.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Danger Signals</h3><div class="NLM_p">It is widely accepted that activation of an innate immune response is required to stimulate a T-cell mediated attack.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64,65)</a> This is based on the observation that exposure to a variety of nonself proteins does not trigger an adaptive immune response in the absence of tissue inflammation. Innate immune cells are activated by “danger signals”, likely released by the target organ. The necessity of danger signals and innate immune activation to facilitate an adaptive immune attack may explain the lengthy delay between drug exposure and an IADR. Some amount of time is required before sufficient drug-induced stress to the target organ has occurred to result in the release of danger signals and an adaptive immune response.</div><div class="NLM_p">In drug-induced injury, cellular stress results in the release of danger signals called damage associated molecular patterns (DAMPs). Examples of DAMPs include heat shock proteins (HSPs), S100 proteins, and high mobility group box 1 protein (HMGB1).<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> DAMPs work by helping to induce the expression of co-stimulatory molecules on professional APCs and the release of cytokines and chemokines, which help to direct other cells of the adaptive immune system to the damaged tissue.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Certain cytokines including IFNγ and tumor necrosis factor-alpha (TNFα) have been shown to increase the susceptibility of hepatocytes to drug-related cellular stress by promoting cell death over cell survival as the primary response.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> As a result, underlying inflammation that is not caused directly by the drug has been proposed as a risk factor for IADRs.</div><div class="NLM_p">In the case of IDILI, danger signals may also come in the form of exosomes.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Interestingly, a recent report suggests that the constitutive release of hepatocyte-derived exosomes (HDEs) has an immunosuppressive effect on monocytes and their derivatives.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> The authors propose that hepatocyte-derived exosomes may function primarily to maintain immune homeostasis and that IDILI drugs promote the loss of homeostatic HDE signaling.</div><div class="NLM_p last">Mounting evidence supports that danger signals can be released into circulation without overt cell death. For example, drug responsive T-cells have been identified in blood collected from a patient with isoniazid-induced liver injury before elevations in serum ALT were observed.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> In addition, recent work from several groups describes cytokine elevations in cultured monocytes and their derivatives in response to conditioned medium from hepatocytes that have been exposed to subtoxic concentrations of IDILI drugs.<a onclick="showRef(event, 'ref71 ref72 ref73 ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref71 ref72 ref73 ref74 ref75">(71−75)</a> Furthermore, in clinical trials of lapatinib,<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> lumiracoxib,<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> and ximelagatran,<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> HLA risk alleles were identified for even low level increases in serum ALT. This suggests that relatively minor ALT elevations may be indicative of a T-cell mediated response that occurred without overt liver injury. The lack of a requirement for cell death to trigger an immune response may help to explain why significant liver injury is not observed in nonclinical animal studies, even when very high doses of IDILI causing drugs are used. The observations that an adaptive immune attack can occur without the requirement for overt liver injury is in line with other liver pathologies, such as hepatitis B infection. The hepatitis B virus is not cytolytic but can initiate a liver-specific adaptive immune attack resulting in clinically significant hepatocellular injury.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Interestingly, microscopic analyses of liver biopsies from patients with IDILI look similar to those from patients with viral hepatitis, suggesting a common mechanism is at play.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Direct Toxicity</h3><div class="NLM_p">Danger signals are likely released in response to a direct effect of the drug on the parenchymal cells of the target organ (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The mechanism for direct drug-induced stress in idiosyncratic reactions may be similar to that observed in response to compounds that cause intrinsic toxicity. The development of several cellular assays based on such mechanisms and having some sensitivity and specificity for the prediction of IDILI liability in the absence of nonparenchymal cells suggests that immune cells are not required for direct stress.<a onclick="showRef(event, 'ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref80 ref81">(80,81)</a> Furthermore, responses can be measured in cells from random donors. Because the majority of these donors are unlikely to carry a relevant risk allele, it suggests that most patients exposed to a drug probably experience some direct, drug-induced stress, which may be more frequent or more significant if these patients are treated with higher concentrations. However, there may also be factors influencing individual susceptibility to direct drug-induced stress by (1) increasing the concentration of the relevant drug or metabolite that induces stress, (2) increasing sensitivity to the stress response at all concentrations of the drug, or (3) impacting the ability to adapt to the stress response. These additional susceptibility factors may help to explain why very sensitive HLA risk alleles explain only some individual risk.</div><div class="NLM_p">In DILI reactions, mitochondrial dysfunction, oxidative stress, and alterations in bile acid homeostasis appear to contribute to the majority of direct, drug-induced hepatocyte stress. Studies that have demonstrated good accuracy in identifying compounds with DILI liability by measuring the ability of drugs to cause toxicity via one of these three mechanisms have provided good support for the importance of their contribution to hepatotoxicity.<a onclick="showRef(event, 'ref82 ref83 ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref82 ref83 ref84 ref85">(82−85)</a> Mitochondria play a vital role in maintaining cellular function through the production of ATP. Mitochondrial function can be impacted by drugs in several ways, which result in the loss of ATP, reduced cell function, and ultimately loss of cell viability.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Oxidative stress results from an overaccumulation of reactive oxygen species (ROS). In mammalian cells, the negative impacts of ROS can be counteracted by the transcription factor nuclear factor erythroid 3 related factor 2 (NRF2), which regulates a transcriptional network of antioxidant genes.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> However, some drugs induce ROS accumulation beyond the capacity of NRF2 to prevent a pathological response.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> In this case, ROS induces damage to critical cellular constituents and endoplasmic reticulum stress, which eventually results in loss of cell viability. Drug-modified proteins (haptens) generated by oxidative stress can also become neoantigens and trigger a T-cell response. Finally, some drugs that cause IDILI interfere with the ability of the liver to transport bile acids from blood into bile, resulting in altered bile acid homeostasis. One way drugs do this is through the inhibition of bile acid transporter proteins such as bile salt export pump (BSEP).<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Inhibition of bile acid transport can cause toxic bile acids to accumulate in hepatocytes, which impairs mitochondrial function and causes cell death.</div><div class="NLM_p last">Mitochondrial dysfunction, oxidative stress, and alterations in bile acid homeostasis each individually contribute to cellular injury; however more often they are interdependent.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> For example, ROS increases in response to mitochondrial damage, and mitochondrial dysfunction can occur in response to ROS-induced damage of mitochondrial DNA and proteins. Declining ATP production in response to mitochondrial dysfunction can impair the ability of BSEP to transfer bile acids into the canaliculi, because this process is ATP dependent. Similarly, mitochondria can be damaged by the accumulation of toxic bile acids. Apart from altered bile acid homeostasis, these same mechanisms are likely to account for direct cell stress associated with skin reactions and other target organs.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Immune Tolerance</h3><div class="NLM_p">Finally, mounting evidence supports a role for immune tolerance, both in the events leading up to an IADR and in its resolution. An important advance in this area has been the development of a mouse model of IDILI by simultaneously blocking two important checkpoint inhibitors that induce immune tolerance: programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> IDILI drug-induced responses in this model are delayed and involved the innate and adaptive immune system. PD-1 and CTLA-4 are selectively expressed on infiltrating lymphocytes in a several types of cancers.<a onclick="showRef(event, 'ref88 ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref88 ref89 ref90">(88−90)</a> PD-L1, the major PD-1 ligand, is also expressed at high levels on tumor cells from many cancers.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> The expression of these molecules promotes immune tolerance and protects the tumors from immune attack. As a result, drugs that inhibit their action (checkpoint inhibitors) have been very promising additions to cancer treatment regimens. However, checkpoint inhibitors have also been associated with immune-mediated skin, liver, lung, and colon injuries.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a></div><div class="NLM_p">While it is becoming clear that immune tolerance plays a role in IADRs, the exact mechanism for this remains to be determined. Clinically there is evidence to support the contribution of immune tolerance to the resolution of injury once it has occurred. As noted previously, many IDILI causing drugs are also associated with low-level and transient elevations in serum ALT that are self-resolving even when drug treatment is continued. When analyzed, these asymptomatic ALT elevations are linked to the same HLA risk alleles as clinically significant liver injuries, suggesting that immune tolerance may play a role in reversing a drug-induced adaptive immune attack even once it has been initiated. And although rapid onset of a reaction on rechallenge is common to many drugs that cause IDILI, occasionally a second exposure will not generate a reaction, or the second reaction will also be delayed in onset. This is most common if a mild reaction was observed initially. For example, liver injuries associated with the drugs isoniazid and ximelagatran usually do not elicit rechallenge responses. In the case of isoniazid, a sensitizing protocol with gradual dose escalation can be used to safety restart patients on drug.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Adaptation may be possible in response to more significant injuries as well.</div><div class="NLM_p last">However, mechanistic studies have also suggested that a loss of immune tolerance may be as important to the initiation of the reaction as gain of immune tolerance during injury resolution. The liver, for example, is a highly immune tolerant organ due to many factors including the production of high levels of checkpoint inhibitor molecules, anti-inflammatory cytokines, and CD4+CD25+Foxp3+ regulatory T-cells.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Hepatocyte-derived exosomes may also help to maintain this tolerogenic state.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Therefore, the default response to drug exposure is immune tolerance. However, constitutive exosome release has been shown to decrease in some hepatocyte donors in response to treatment with IDILI drugs, which may facilitate a T-cell response (unpublished data, Merrie Mosedale). Immune tolerance may be another step at which interindividual susceptibility to IADRs is introduced. While no variants in PD-1 or CTLA-4 have been linked to IADR susceptibility to date, a recent manuscript from DILIN describes the identification of missense variant in the protein tyrosine phosphatase, nonreceptor type 22 gene (<i>PTPN22</i>) as a general risk factor for IDILI as opposed to DILI associated with a specific drug.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> PTPN22 plays numerous roles in T-cell receptor signaling including regulatory T-cell function<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> and variation in this gene has been linked to autoimmune disorders.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a></div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Molecular Mimicry and Heterologous Immunity</h3><div class="NLM_p">Less studied but still convincing hypotheses that also support a role for an adaptive immune response are molecular mimicry and heterologous immunity (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). These models suggest that previous exposure to an unrelated antigen may prime the immune system to respond to drug-induced neoantigen without the need for direct toxicity or danger signals.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> This has been partially demonstrated in a study where mice previously immunized with amodiaquine-modified proteins mount a more robust liver-injury response to amodiaquine compared to mice treated with amodiaquine alone.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> An important aspect in achieving the response was the use of anti-CTLA-4 and anti-PD-1 antibodies in order to overcome immune tolerance during the initial exposure. Although this experiment used a similar antigen for the immunization as would be generated during subsequent drug exposure, the molecular mimicry model hypothesizes that unrelated antigens may be responsible for the priming. In immunology, the recognition of similar epitopes on different molecules is referred to as “cross reactivity”.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> This is an attractive hypothesis to explain the idiosyncratic nature of reactions and may explain why some IADRs occur relatively quickly (such as IDILI associated with antibiotics).</div><div class="NLM_p last">Heterologous immunity is a broader concept that describes how previously encountered pathogens can alter responses to unrelated antigens through mechanisms other than just cross-reactive priming. For example, heterologous immunity can induce alterations in T-cell immunodominance hierarchies or compromise the memory response against an antigen encountered previously.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> A strong immune response to the initial antigen would still be required but could be achieved with DAMPs.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Clinical support for this hypothesis is provided by the ability of some patients to develop hypersensitivity reactions within 48 h following first exposure to abacavir. Lucas et al. demonstrated the presence of abacavir reactive memory T-cells isolated from drug-naive healthy donors carrying the HLA-B*57:01 risk allele.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Having not been exposed to abacavir previously, these pre-existing abacavir-reactive memory CD8+ T-cell responses must have been primed by earlier exposure to another pathogen or foreign antigen and respond to the abacavir-HLA-B*57:01-endogenous peptide ligand complex.</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Non-Immune-Mediated Mechanisms</h3><div class="NLM_p">Several explanations for IADRs that do not involve immune-mediated toxicity have also been proposed. IDILI drugs may cause direct stress that simply takes time to reach a tipping point before the injury occurs (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). This hypothesis is well supported by quantitative systems pharmacology (QSP) modeling. For example, the clinical incidence and profile of IDILI associated with troglitazone, including a four month mean latency, was recapitulated in a QSP model of DILI using only altered bile acid homeostasis as the mechanism of toxicity.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> The gradual accumulation of a BSEP-inhibiting sulfate metabolite, competitive BSEP inhibition (rather than noncompetitive), and a compensatory regulation of bile acid transporters mediated by farnesoid X receptor helped to explain the latency in the model. It is not clear whether an adaptive immune response also contributed to troglitazone-induced liver injury, as this drug is no longer on the market, rechallenge was not well documented, and to our knowledge, DNA is not available from troglitazone-treated patients.</div><div class="NLM_p last">The clinical incidence and profile of IDILI associated with tolvaptan in patients with autosomal dominant polycystic kidney disease has also been modeled without including immune-mediated mechanisms of injury.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> In this model, the clinical incidence and delay in onset resulted from BSEP inhibition and interference with mitochondrial respiration by both the parent drug and a major metabolite. However, latency to the onset of enzyme elevations was greater than one year in some patients,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> which was not captured in the modeling. It was suggested that the long delay between exposure and injury in some patients may be due a decrease in the threshold for toxicity resulting from disease progression. However, a faster time to response with drug rechallenge has been observed in some patients who have recovered from tolvaptan DILI, which would suggest that adaptive immune system is involved.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Therefore, the possibility exists that QSP modeling overestimates the impact of non-immune-mediated events by failing to account for adaptation or other mechanisms that help to dampen the response.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Risk Factors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34421" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34421" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Properties of both the drug and the host have been shown to contribute to IADR risk (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Not all drugs within a therapeutic class will cause serious IADRs. For example, troglitazone rosiglitazone, and pioglitazone are all thiazolidinediones developed for the treatment of type 2 diabetes, but only troglitazone was withdrawn from the market due to fatal hepatotoxicity, whereas the other drugs have limited DILI concern.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> And among telaprevir and boceprevir, similar α-ketoamide protease inhibitors used for the treatment of hepatitis C, only telaprevir has been associated with TEN and carries a black box warning for cutaneous reactions.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> This indicates that “off target” properties rather than “on target” effects are the root cause of IADR liability. Drug-associated risk factors include daily dose and physiochemical properties. Patient-specific risk factors can be divided into two categories: nongenetic (physiological and environmental) and genetic. Both the drug and patient factors play a role in multiple mechanisms and likely work together at multiple steps of an IADR to impact overall susceptibility, clinical response, and outcome.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Potential Risk Factors for Idiosyncratic Toxicity</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">host properties</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug properties</th><th class="colsep0 rowsep0" align="center">nongenetic factors</th><th class="colsep0 rowsep0" align="center">genetic factors</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">biliary elimination</td><td class="colsep0 rowsep0" align="left">age</td><td class="colsep0 rowsep0" align="left">DMET genes</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose</td><td class="colsep0 rowsep0" align="left">drug–drug interactions</td><td class="colsep0 rowsep0" align="left">epigenetic changes</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lipophilicity</td><td class="colsep0 rowsep0" align="left">nutritional and disease status</td><td class="colsep0 rowsep0" align="left">HLA alleles</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">metabolism</td><td class="colsep0 rowsep0" align="left">sex</td><td class="colsep0 rowsep0" align="left">mechanistic modulators</td></tr></tbody></table></div></div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Drug-Specific Risk Factors</h3><div class="NLM_p">Drugs that cause IADRs are thought to be safe for most patients treated at therapeutic doses. As a result, is has been previously stated that IADRs are not dose dependent. However, studies spanning multiple drugs have highlighted the relationship between dose and the likelihood of response and there is growing support for the idea of a dose threshold for IADR liability. For example, it has been shown that most IDILI causing drugs are used at a dose of ≥50 mg daily.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> This observation suggested that a focus of new drugs should be to develop more potent compounds that could be effective at a <50 mg/day dose.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> A dose threshold may also explain the why tolvaptan was associated with IDILI in clinical trials for autosomal dominant polycystic kidney disease where patients took the drug at relatively high (>100 mg/day) doses but not in patients with hyponatremia, heart failure, or cirrhosis where lower doses are used.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> While other risk factors such as disease state or duration of exposure may contribute to tolvaptan IDILI, the association of risk with increased dose may reflect an increase likelihood of cell stress via direct mechanisms at higher concentrations. Furthermore, a higher dose could also result in more significant accumulation of drug-related neoantigen, thereby making an immune response more likely. However, increased exposure is only one of the many variables that increase susceptibility to IADRs. This may explain why in the case of tolvaptan, no clear association of liver injury with dose or systemic exposure was found in clinical trials for autosomal dominant polycystic kidney disease.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Furthermore, there are numerous drugs taken safely at higher doses; therefore other drug-specific properties likely contribute to overall IADR risk.</div><div class="NLM_p">Lipophilicity is a physiochemical property that impacts drug absorption, distribution, metabolism, and excretion, and has been described as a risk factor for IDILI. Higher lipophilicity drugs are associated with increased uptake into hepatocytes and may also require metabolism-driven elimination thus increasing the potential for a drug to promote cell stress via a direct mechanism like mitochondrial dysfunction, oxidative stress, or alterations in bile acid homeostasis. The lipophilicity of a compound is described by a partition coefficient, log <i>P</i>, which is the ratio of the concentration of the un-ionized compound at equilibrium between organic and aqueous solvents. Higher lipophilicity defined as log <i>P</i> ≥ 3 has been linked to a greater risk for hepatotoxicity with an odds ratio (OR) = 1.63.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> The combination of both log <i>P</i> ≥ 3 and daily dose ≥100 mg/day increases the risk further and is associated with an OR = 14.05. The combination of high lipophilicity and daily dose has been termed the rule-of-2 (RO2). The use of these two properties together has demonstrated a 96% positive predictive value for DILI liability among a large test set of drugs.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> However, the negative predictive value for this test set was only 39%.</div><div class="NLM_p">Reactive metabolic intermediates are thought to contribute to immune-mediated IADRs.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Not surprisingly, compounds with significant hepatic metabolism (>50%) are associated with a greater risk of IADRs.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> The formation of reactive metabolites has been added to the RO2, which further improves the specificity of DILI prediction and also permits a quantitative assessment of the risk of clinical DILI.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></div><div class="NLM_p">In the case of IDILI, compounds with biliary excretion may also increase the risk for an IADR. Drugs that undergo biliary elimination are associated with a higher frequency of jaundice (74% versus 40%) compared to those that do not.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> This could be due to the increased potential for BSEP inhibition or the formation of reactive metabolic intermediates. It may also contribute to the cholangiocyte damage resulting in cholestatic liver injury.</div><div class="NLM_p last">Related measurements are included in the biopharmaceutics drug disposition classification system (BDDCS), which appears to have an accuracy comparable to that of other current <i>in vitro</i> and computational methods for identifying IDILI compounds when dose is not considered.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Drugs in the BDDCS are classified according to the rate of membrane permeability and their aqueous solubility.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> BDDCS features are classified by high and low values of each characteristic, which place drugs into one of four categories. Class 2 drugs, which have high permeability and metabolism and low solubility, are associated with the most IDILI concern.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Patient-Specific Risk Factors</h3><div class="NLM_p">Age is an example of a nongenetic risk factors that has been shown to affect IADR susceptibility. However, age is not a significant risk factor for IADRs associated with all drugs, and the exact relationship between age and risk can vary by drug. For example, the risk of IDILI associated with amoxicillin–clavulanate, nitrofurantoin, flucloxacillin, and isoniazid increases with older age.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> This may be due to the impact of aging on renal function and hepatic physiology that influence drug metabolism and pharmacokinetics. It may also be related to the increased use of many drugs (polypharmacy) among the older individuals. Finally, the increased susceptibility to IADRs with age may be related to decreases in mitochondrial function and other mechanisms that support adaptation to injury and liver regeneration. However, the association of IDILI risk with age is not observed across multiple drugs in larger cohorts, although this may be in part due to decreased registry referral.<a onclick="showRef(event, 'ref113 ref114'); return false;" href="javascript:void(0);" class="ref ref113 ref114">(113,114)</a></div><div class="NLM_p">The opposite relationship is observed for some antiepileptic drugs such as valproic acid, where younger age appears to increase the risk of IDILI.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> However, it is unclear whether this association is due to the increased use in children or perhaps underlying genetic factors associated with the requirement for these drugs. In a recent study, younger patients were shown to be at increased risk for IDILI associated with the cancer drug idelalisib.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> The risk was also increased in patients who received idelalisib as a front-line therapy. The authors conclude that idelalisib hepatotoxicity is the result of an on-target, immune-mediated event and suggest that the increased susceptibility may be due to younger patients and those patients who received idelalisib as a front-line therapy having more robust immune systems.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Finally, age also appears to impact the type of liver injury observed. Cholestatic injury is observed more frequently in older patients, whereas younger patients present more commonly with hepatocellular injury.<a onclick="showRef(event, 'ref114 ref116'); return false;" href="javascript:void(0);" class="ref ref114 ref116">(114,116)</a> The explanation for this is not clear.</div><div class="NLM_p">Sex is another factor that appears to impact IADR susceptibility. However, like age, sex effects are different depending on the drug. Women are more prevalent than men among cases enrolled in the DILIN U.S. registry.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> However, it does not appear that women are more susceptible to IDILI than men overall.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Women, for example, appear to have increased susceptibility to IDILI associated with drugs halothane, flucloxacillin, and isoniazid, but men are more susceptible to liver injury associated with azathioprine.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> There is also an apparent relationship between sex and type of DILI, similar to what has been described for age. Hepatocellular injury and drug-induced autoimmune hepatitis are more common in women.<a onclick="showRef(event, 'ref9 ref119'); return false;" href="javascript:void(0);" class="ref ref9 ref119">(9,119)</a> Sex differences in susceptibility or the type of IDILI may be caused by differences in sex hormones, which can impact drug metabolism and immune response. For example, glucuronidation rates are higher in men and thus men have a higher clearance rate of acetaminophen.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Women, on the other hand, have more of the major phase 1 drug metabolizing enzyme CYP3A4.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Finally, clinical outcome of IADRs can differ by sex. For example, women are more likely to suffer morbidity and mortality associated with IDILI than men.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> The reasons behind this are not clear.</div><div class="NLM_p">Nutritional state and associated disease status also appear to influence IADR susceptibility. Certain drug metabolizing enzymes can be altered by nutritional status as can antioxidant reserve and inflammatory response. For example, fasting and malnutrition are associated with an increased risk of acetaminophen-induced liver injury.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> This may be due to reduced levels of the antioxidant glutathione, which plays an important role in the detoxification of the reactive metabolite NAPQI. It may also reflect a reduction in the ability to detoxify acetaminophen via glucuronidation. The risk of acetaminophen-induced liver injury is also higher in response to alcohol consumption, likely due to the induction of CYP2E1, a major enzyme involved in acetaminophen metabolism. However, this association may be confounded by other factors associated with excessive alcohol consumption such as increased use of acetaminophen and the likelihood of malnourishment.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> Finally, chronic alcohol use can result in alcoholic liver disease, which is associated with the accumulation of fat, increased inflammation, and liver injury. This factors alone may contribute to impaired mitochondrial function or oxidative stress, putting individuals at greater risk for an IADR.</div><div class="NLM_p">Over nutrition may also increase the risk of IDILI, and there are two main hypotheses to explain this association.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> First, more drugs are taken by obese patients than nonobese individuals increasing the likelihood for an adverse drug reaction. Second, obesity is associated with an increased risk for nonalcoholic fatty liver disease (NAFLD), which appears to make patients more susceptible IDILI. Reduced mitochondrial function has been observed in NALFD patients, which may increase the susceptibility to drug-induced mitochondrial injury.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> The enzyme CYP2E1 is also increased in NAFLD, which may contribute to the overproduction of ROS and increase the susceptibility to oxidative stress.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> The risk for both halothane and acetaminophen toxicity is increased in obese and NAFLD patients, which may be explained by the CYP2E1-mediated transformation of both drugs into highly reactive metabolites.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Activities of CYP2C9 and CYP2D6 are reportedly increased in NAFLD as well. However, there is less concern about changes in these enzymes as they do not produce ROS during their catalytic cycles.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> In contrast, obesity and NAFLD are associated with lower CYP3A4 expression and activity.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> More recent data has also supported differences in transporter expression and function in NAFLD patients.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> The most consistently reported effects are increases in the expression and activity of the sinusoidal efflux transporter MRP3, leading to increased efflux of substrates into plasma.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Alterations in both metabolizing enzymes and transporters contribute to differences in drug exposure and likely also drug toxicity. However, it remains to be to be determined how most enzymes and transporters are influenced by NAFLD.</div><div class="NLM_p">Inflammatory stress is another environmental factor that may increase susceptibility to IADRs.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> The original data supporting this hypothesis came from the demonstration that coadministration of the IDILI drugs trovafloxacin, diclofenac, and amiodarone along with lipopolysaccharide (LPS) to induce acute inflammation could enhance toxicity in both animal and in vitro models.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> These findings support the idea that the dose threshold for hepatotoxicity is lower under conditions of acute inflammatory stress. A drug may also amplify existing inflammation resulting in injury from a non-drug related source. The source of inflammation may be underlying infection or disease. Interestingly, cytokines released during inflammation have been shown to decrease the level and activity of drug enzymes and transporters.<a onclick="showRef(event, 'ref132 ref133'); return false;" href="javascript:void(0);" class="ref ref132 ref133">(132,133)</a> Taken together, this may suggest that underlying inflammation reduces the ability to detoxify and eliminate potentially harmful drug substances. This would increase the risk of direct cell stress and possibly IADRs. As noted previously, some cytokines such as IFNγ and TNFα can shift cellular responses away from survival and toward necrosis, thereby making hepatocytes more susceptible to injury.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> However, if the delay in onset of an IADR were the result of a random episode of inflammation, presumably the reaction would occur at very different times in different individuals. While the time to onset can vary by drug, and to some extent by patient, it is not random as a fairly well-defined window of susceptibility is often observed.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">Pre-existing disease may also contribute to IADR susceptibility, although this is more controversial. In the case of IDILI, it has been widely stated that pre-existing liver disease is not a risk factor for a reaction. However, this may be drug and disease specific. For example, an increased risk of IDILI from antituberculosis drugs (rifampicin, isoniazid, and pyrazinamide) has been reported in patients with hepatitis C and B infections. This may be explained by changes in drug exposure and metabolism resulting from liver inflammation and disease.<a onclick="showRef(event, 'ref134 ref135'); return false;" href="javascript:void(0);" class="ref ref134 ref135">(134,135)</a> However, hepatitis does not appear to increase the risk for liver injury with all IDILI causing drugs, and many drugs that cause IDILI have been used safely in patients with existing liver disease.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Liver disease that results in increases in toxic bile acids may also contribute to IDILI susceptibility, particularly for drugs that are known to cause toxicity via inhibition of bile acid transport.<a onclick="showRef(event, 'ref104 ref137'); return false;" href="javascript:void(0);" class="ref ref104 ref137">(104,137)</a> In this case, the effect may become more pronounced with increasing disease progression Pre-existing liver disease also appears to increase the likelihood of worse IDILI outcomes once a reaction has occurred.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">The contribution of drug–drug interaction to IADRs is also controversial. Many drugs inhibit or induce drug metabolizing enzymes and transporters, which would alter metabolism and exposure.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> It stands to reason, that if dose or exposure is a factor contributing to IADRs, drug–drug interactions (DDIs) may present a risk. However, the data to support DDIs as a risk for IDILI are conflicting.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> Several studies have reported an increased risk of IDILI with coadministration of antiepileptic drugs,<a onclick="showRef(event, 'ref140 ref141'); return false;" href="javascript:void(0);" class="ref ref140 ref141">(140,141)</a> of the antituberculous drugs isoniazid and rifampicin,<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> and with combinations of acetaminophen and other hepatotoxic drugs.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> However, other studies have reported no link between polypharmacy and increased risk of IDILI.<a onclick="showRef(event, 'ref144 ref145'); return false;" href="javascript:void(0);" class="ref ref144 ref145">(144,145)</a></div><div class="NLM_p">Although not well-studied in the context of IADRs, there is growing evidence that the microbiome contributes significantly to variability in drug response.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> The gut microbiome has been shown to directly influence drug toxicity via metabolism by microbial enzymes and alterations in gastrointestinal pH, which can change drug stability and bioavailability. Some drugs have also been shown to induce shortening of the intestinal microvilli, which causes gut leakage and translocation of bacterial through the gastrointestinal membrane.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> This could contribute to liver inflammation, a risk factor for IDILI previously described. Not surprisingly the diet remains an important extrinsic factor that directly regulates the gut microbiome,<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> which suggests that many of these risk factors are inextricably linked.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Alterations in the gut microbiome may also explain the significant number of antibiotics associated with IDILI. The contribution of microbiome in other environments to differences in drug response such as the skin, urogenital tract, and vagina have also been demonstrated.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></div><div class="NLM_p">Finally, significant evidence supports the contribution of genetic variation to IADR susceptibility. To date, the strongest genetic associations identified for IADR susceptibility have been in loci within the HLA region on chromosome 6 of the genome. HLA risk alleles have been identified for several IADR causing drugs using both genome-wide association study (GWAS) and candidate gene approaches (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The most robust HLA associations identified have been with carbamazepine and abacavir toxicities. In a candidate gene study focusing on cytochromes-P450 and HLA-A, HLA-B, HLA-C, and HLA-DRB1 alleles, <i>HLA-B*15:02</i> was found to be associated with carbamazepine-induced SJS/TEN in Han Chinese patients with an odds ratio (OR) of 895.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> According to the FDA-approved label, testing for <i>HLA-B*15:02</i> is now required for all patients of Asian ancestry, prior to initiating carbamazepine therapy. <i>HLA-B*15:02</i> does not appear to be a risk factor for more common mild skin rash reactions induced by carbamazepine nor does the association extend to most other ethnic groups, at least in part because the frequency of HLA-<i>B*15:02</i> is lower.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> However, carbamazepine-induced skin reactions of varying severity and more recently liver injury have been associated with <i>HLA-A*31:01</i> in European and Japanese individuals.<a onclick="showRef(event, 'ref149 ref150 ref151'); return false;" href="javascript:void(0);" class="ref ref149 ref150 ref151">(149−151)</a></div><div class="NLM_p">A candidate gene approach was initially used to identify an association between abacavir hypersensitivity and <i>HLA-B*57:01</i> with an OR of 800.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> This finding was later confirmed in other cohorts<a onclick="showRef(event, 'ref153 ref154'); return false;" href="javascript:void(0);" class="ref ref153 ref154">(153,154)</a> and a larger randomized controlled trial.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Together, these findings have led to the implementation of genetic testing of <i>HLA-B*57:01</i> for abacavir treatment and a dramatic reduction in ADRs. Interestingly, carbamazepine and abacavir reactions and also allopurinol-induced SCARs, which have association with HLA-B*58:01 with an OR of 400, appear to involve a direct interaction of the drug with the HLA molecule as opposed to a hapten-mediated approach.<a onclick="showRef(event, 'ref49 ref53 ref54 ref55 ref58'); return false;" href="javascript:void(0);" class="ref ref49 ref53 ref54 ref55 ref58">(49,53−55,58)</a> The association between IDILI associated with the antibiotic flucloxacillin and the allele <i>HLA-B*57:01</i> is the most robust HLA association with DILI identified to date, with a reported OR of 80.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Results from mechanistic studies suggest that both p-i<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> and hapten mechanisms<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> may contribute to flucloxacillin T-cell reactivity.</div><div class="NLM_p">Polymorphisms in DMET genes have also been reported as susceptibility factors for various IADR causing drugs (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). For example, variants in CYP2C, including CYP2C9*3, were identified as genetic factors associated with phenytoin-related SCARs in a GWAS of cases with Asian descent.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> The <i>CYP2C9*3</i> allele codes for a CYP enzyme with decreased activity and is known to reduce drug clearance, which may help inform the mechanism of this reaction. Interestingly, <i>HLA-B*15:02</i> has also been identified as a risk factor for phenytoin-related SCARs in Asians by a candidate gene approach.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> DMET associations with IDILI susceptibility have been less convincing. The contribution of polymorphisms in DMET genes to toxicity susceptibility that were identified from candidate gene approaches have not been supported by unbiased approaches such as GWAS. Furthermore, many of the published studies describing the identification of DMET risk alleles through targeted approaches have not been replicated in other DILI cohorts.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><div class="NLM_p">Polymorphism in genes other than HLA alleles and genes involved in drug metabolism have also been reported as risk factors for toxicity susceptibility. Many of these genes have functions that suggest they may modulate an IADR response. For example, polymorphisms in manganese superoxide dismutase (<i>MnSOD2</i>) have been reported to increase the risk of toxicities associated with several drugs.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> Some support for this association is provided by subsequent studies demonstrating an increased susceptibility in patients with homozygous polymorphisms in MnSOD for IDILI from drugs that produce reactive intermediates or are hazardous to the mitochondria.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> MnSOD is an antioxidant that plays a role in the clearance of ROS from mitochondria and has been shown to confer protection against cell death. A polymorphism in another antioxidant gene, glutathione peroxidase I (<i>GPX1</i>) has also been reported to increase the risk for IDILI associated with a number of drugs.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> As the main glutathione peroxidase in liver, GPX1 is responsible for the prevention of mitochondrial oxidative stress. Not surprisingly, patients with both of the risk alleles appear to be at increased risk for IDILI compared to patients having just a single risk allele or none.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a></div><div class="NLM_p">More recent reports have identified polymorphisms in keratins 8 and 18 (<i>K8/K18</i>) as increasing the risk of IDILI associated with a variety of drugs.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> These keratins are cytoskeletal proteins that play a role in protecting hepatocytes from apoptosis. Disruption of the keratin filament network was observed in a study where recombinant K8/K18 expressing the risk variants were transfected into NIH 3T3 cells.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> This may result in multiple cellular dysfunctions that contribute to the development and progression of DILI including hepatocyte fragility, increased susceptibility to apoptosis and necrosis, and impairment in intracellular organ positioning leading to mitochondrial dysfunction and oxidative stress.</div><div class="NLM_p">Polymorphisms in non-HLA immune genes have also been described. For example, links between polymorphisms in cytokines an immune response have been reported in candidate gene studies. However, many of these findings were relatively small effects that have not been replicated in other studies.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> An analysis of 285 DILI patients indicated a trend toward an association between hepatocellular injury and a polymorphism in signal transducer and activator of transcription 4 (<i>STAT4</i>),<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> a finding that was confirmed in a larger study over 800 patients.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a><i>STAT4</i> is a transcription factor that promotes activation of naive T-cells and IFNγ in response to IL-12 and IL-23.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> However, the associations with DILI were only suggestive. An association with a variant in <i>PTPN22</i> was also found in a GWAS of 201 Caucasian cases of DILI associated with amoxicillin–clavulanate. This finding was recently confirmed in a larger study of multiple drugs, which suggests that the <i>PTPN22</i> variant is a general risk factor for DILI as opposed to liver injury associated with a specific drug.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Gene-based association methods such as PrediXcan are now being explored to provide mechanistic insight into significant associations between intronic variants and liver transcript levels.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a></div><div class="NLM_p last">Clearly, much variation in IADR susceptibility remains unexplained. This may be the result of rare variants that would not be detected by genome-wide association studies. It has recently been demonstrated that rare variants are responsible for approximately 40% of the functional variability in drug response.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> Rare variants that have a minor allele frequency of less than 5% would require whole-genome sequencing to be detected. IADRs may also be polygenic traits where many variants contribute to overall susceptibility. Newer approaches like the genome-wide polygenic risk scores<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> may be more useful estimating risk and could even help inform the mechanisms of IADRs via pathway enrichment analysis on the associated genes. Finally, epigenetic changes may also play a role, particularly in the liver, which is sensitive to environmental exposures.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> New technologies that integrate transcriptomic and epigenetic studies have begun to reveal the dynamic nature and extent of the epigenetic changes induced by different environmental exposures, including xenobiotics. However, organ-level epigenetic changes are unlikely to translate to easily discernible changes in common clinical biospecimens like blood or urine. Therefore, tissue biopsies such as those being collected by DILIN will be required for such analyses.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Investigative Tools</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38888" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38888" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Animal Models</h3><div class="NLM_p">Prior to clinical development, all new drugs will undergo some animal testing to ensure that they are safe. Typical preclinical studies to evaluate drug safety are performed in two species, a rodent model like mouse or rat and a nonrodent model like dog or monkey.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> It is difficult to assess the accuracy of these models in detecting intrinsic toxicity, but in one comprehensive analysis, skin and liver injury appeared to be some of the most difficult toxicities to predict.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> Furthermore, it is widely appreciated that standard preclinical toxicology models do a poor job of predicting IADR liability. This may, in part, be due to the use of outbred stocks, which have several limitations. First, outbred animals benefit from heterosis or outbreeding enhancement, which makes them overall more resistant to any toxicity. Second, outbreeding introduces limited yet uncontrolled genetic diversity into a population, which reduces the capacity to identify toxicities resulting from genetic risk factors.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> Several animal models that exhibit certain clinical aspects of IADRs, have more human-relevant physiology, and enable the assessment of population-level responses have been proposed as better alternatives.</div><div class="NLM_p">One of the first animal models developed for IDILI was based on the hypothesis that underlying inflammatory stress was required for overt injury. In this model, coadministration of LPS is used to induce acute inflammation, which has been shown to enhance sensitivity to the IDILI drugs trovafloxacin, diclofenac, and amiodarone.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> There are some differences in the LPS model compared to the clinical presentation of DILI including the absence of a delay in onset and the observations that neutrophils rather than lymphocytes accumulate in the liver. This model is based on the hypothesis that in humans a random occurrence of inflammation contributes to the timing and susceptibility of an IADR. However, the time to onset of injury for a specific drug typically occurs within a well-defined window of susceptibility, which suggest that the factors facilitating an adaptive immune response do not occur at random. Different batches of LPS have also been reported to cause some difficulty in replicating experiments.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a></div><div class="NLM_p">Certain aspects of clinical IDILI associated with nevirapine, isoniazid, and amodiaquine have also been replicated in the PD-1<sup>–/–</sup> mice treated with an anti-CTLA-4 antibody.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> PD-1 and CTLA-4 are immune checkpoint receptors that play a role in immune tolerance. This model is based on the hypothesis that blocking immune tolerance is important to make the liver more susceptible to a T-cell mediated attack. While some aspects of clinical IDILI are recapitulated in PD-1<sup>–/–</sup> mice treated with an anti-CTLA-4, significant liver injury is not observed. The lack of a robust response may be due to the requirement for genetic susceptibility factors such as human specific HLA alleles to elicit overt injury.</div><div class="NLM_p">Certain animal models appear to be sensitive to some drugs that cause IADRs in humans in the absence of immunomodulation. For example, female Brown Norway rats are susceptible to nevirapine-induced skin reactions, and the profile of injury is very similar to that in humans.<a onclick="showRef(event, 'ref174 ref175'); return false;" href="javascript:void(0);" class="ref ref174 ref175">(174,175)</a> Specifically, it takes 3-weeks for the onset of injury, and the rash is dependent on CD4+ T-cells. Female patients are also more susceptible to nevirapine skin rashes than males.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> This model has been used to demonstrate a role for cutaneous sulfotransferase metabolism in the mechanism of injury.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> Brown Norway rats are also susceptible to penicillamine toxicity and develop a lupus-like syndrome after 3 weeks of exposure.<a onclick="showRef(event, 'ref177 ref178'); return false;" href="javascript:void(0);" class="ref ref177 ref178">(177,178)</a> These reactions are not induced to the same degree in other strains or stocks, and it appears that underlying differences in both drug metabolism and immune response may contribute.</div><div class="NLM_p">There are also several examples of humanized models that recapitulate some aspects of IADRs. The use of immunodeficient mice allows for transplantation of human cells without rejection. A mouse model of drug-induced SJS/TEN was created by injecting PBMCs and grafting skin from SJS/TEN patients into immunocompromised mice along with concurrent oral administration of a causative drug.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> Mice injected with PBMCs from patients with SJS/TEN and given the causative drug showed marked conjunctival congestion, epithelial cell death, and darkening of the skin-grafted areas indicating the presence of dead keratinocytes. While this model is quite promising, additional studies are needed to explore how the model can be utilized to predict and understand SCARs.</div><div class="NLM_p">Several studies have reported minor elevations in ALT or bile acid in response to IDILI drugs in mice with humanized livers, suggesting that this model is sufficient to replicate the early steps that proceed an adaptive immune attack and more significant liver injury.<a onclick="showRef(event, 'ref180 ref181'); return false;" href="javascript:void(0);" class="ref ref180 ref181">(180,181)</a> A particularly impressive humanized liver model is derived from the NOG mouse expressing a thymidine kinase transgene (TK-NOG). A recent study in TK-NOG mice demonstrated both a humanized profile of biliary excretion as well as cholestatic liver injury after 1 week of treatment with bosentan.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> There have also been reports of mice that have humanized livers and human immune systems, but it does not appear that these animals are widely available.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> With advancements in the field, it may be possible to use induced pluripotent stem cells in the future to create mice that have hepatocytes and immune systems derived from IADR patients.</div><div class="NLM_p">Transgenic mouse models expressing human HLA risk alleles have been generated to investigate the mechanism of HLA involvement in IADRs. Topical application of abacavir to the ears of HLA-B*57:01 transgenic mice induced proliferation of CD8+ lymphocytes in local lymph nodes,<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> but oral administration did not induce liver injury without coexposure to the toll-like receptor agonist CpG oligodeoxynucleotide.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Oral administration of ximelagatran for 28 days to HLA-DR7 (HLA-DRB1*0701, −DRA*0102), and HLA-DQ2 (HLA-DQB1*0202, ±DQA1*0201) transgenic mice revealed no signs of DILI when biomarkers for liver toxicity were measured and histopathology was evaluated.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Findings from these models support the requirement for other immune-stimulating events in order to trigger an adaptive immune attack.</div><div class="NLM_p">Finally, numerous reports have supported the utility of genetically diverse mouse populations to model human toxicity responses better than traditional preclinical species.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> Specific types of populations, such as mouse genetic reference populations (GRPs) can also be used for GWAS-type studies to identify candidate risk factor genes and to investigate mechanisms associated adverse drug response.<a onclick="showRef(event, 'ref184 ref185 ref186'); return false;" href="javascript:void(0);" class="ref ref184 ref185 ref186">(184−186)</a> Importantly, findings from GRPs have been validated in human studies suggesting that GRPs can be used to facilitate a hypothesis-driven approach to identifying genetic risk factors in clinical data.<a onclick="showRef(event, 'ref185 ref187'); return false;" href="javascript:void(0);" class="ref ref185 ref187">(185,187)</a></div><div class="NLM_p">The Collaborative Cross (CC) is a highly sophisticated GRP of multiparental recombinant inbred lines that was strategically designed to reduce blind spots of genetic variation and decrease population structure that were limitations of previous models.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> Several studies have shown that the diversity of responses observed in the CC are more extensive than standard inbred populations.<a onclick="showRef(event, 'ref189 ref190'); return false;" href="javascript:void(0);" class="ref ref189 ref190">(189,190)</a> The CC population has been used to identify mechanisms and risk factors for DILI associated with tolvaptan<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> and idelalisib.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> This platform may be applicable to studying the early events that precede an adaptive immune attack and risk factors associated with IADRs. However, careful consideration of the end points used and likely some innovative approaches will be required to translate findings for IADRs in the CC to humans.</div><div class="NLM_p last">As discussed previously, it is thought that overt injury from most IADRs involve an adaptive immune attack on the target organ, which may be restricted to individuals carrying a human-specific HLA risk allele. However, drug-induced stress at the level of the target organ is required to initiate the immune cascade. Although this stress may not result in overt necrosis measurable microscopically or by changes in serum biomarkers of cell death (e.g., ALT), it may be detected by measuring the release of danger signals such as DAMPs or exosomes. Both DAMPs and exosomes can be measured in biofluids such as serum and urine, and methods to measure changes in exosomes derived from specific organs such as liver have been proposed.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> These methods could be applied to population-based studies in the CC to look for risk factors of early drug-induced cellular stress. mRNA profiling has also been used to look at early drug-induced stress in the absence of overt necrosis.<a onclick="showRef(event, 'ref194 ref195'); return false;" href="javascript:void(0);" class="ref ref194 ref195">(194,195)</a> Gene expression profiling combined with pathway enrichment analysis can be used to inform mechanisms of toxicity, as well as new quantitative molecular phenotypes at the gene or pathway level for genetic mapping.<a onclick="showRef(event, 'ref189 ref190'); return false;" href="javascript:void(0);" class="ref ref189 ref190">(189,190)</a> There are also efforts underway to develop an <i>in vitro</i> platform containing primary cells isolated from the CC mice to enable the rapid and cost-effective identification of gene-by-treatment interactions associated with adverse drug response.<a onclick="showRef(event, 'ref196 ref198'); return false;" href="javascript:void(0);" class="ref ref196 ref198">(196,197)</a> In addition to looking at DAMPs and changes in the gene expression profile, imaging-based end points could also be used to look at the activation of stress response pathways in <i>in vitro</i> systems in the absence of overt injury.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>In Vitro</i> Models</h3><div class="NLM_p"><i>In vitro</i> models utilizing human-derived cells have also proved useful for the identification of toxicity liabilities early in drug development and to gain a better understanding of the mechanisms associated with IADRs. In the case of liver injury, many cell culture models are available. Cell lines derived from human hepatocytes are one of the most convenient, reliable, and cost-effective models for screening toxicity liabilities <i>in vitro</i>. However, a limitation of this model is the low expression of drug metabolizing enzymes and transporters compared to native liver. When cultured in a sandwich format, primary human hepatocytes remain metabolically competent and have proper localization of basolateral and canalicular transporters with functional bile networks.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(198)</a> However, they too have limitations including significant donor-to-donor variability, inadequate availability, and the loss of a robust and physiologically relevant phenotype with long-term culture.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(198)</a></div><div class="NLM_p">An effort to improve the phenotypic relevance and extend viability of existing models has resulted in promising new approaches such as cocultures with nonparenchymal cells, 3D models, and the addition of dynamic fluid flow to mimic shear stress and circulate nutrients.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(198)</a> The inclusion of nonparenchymal cells in coculture models helps to increase the longevity of hepatocytes and facilitate transcellular interactions that may be important for modulating a DILI response.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(199)</a> Cultivation of human hepatocytes in a 3D configuration has been shown to better preserve the <i>in vivo</i> phenotype due to the extensive formation of cell–cell contacts, reestablishment of cell polarity, and endogenous production of extracellular matrices.<a onclick="showRef(event, 'ref201 ref202'); return false;" href="javascript:void(0);" class="ref ref201 ref202">(200,201)</a> Recent studies have demonstrated that hepatocytes in 3D spheroid cultures closely resemble the <i>in vivo</i> liver proteome, have functional bile canaliculi, and have stable liver-specific functionalities such as enzyme activity for at least 5 weeks of culture.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(202)</a> Several groups have also reported that the benefits of culturing hepatocytes together with nonparenchymal cells can be extended to 3D models.<a onclick="showRef(event, 'ref203 ref204 ref205'); return false;" href="javascript:void(0);" class="ref ref203 ref204 ref205">(202−204)</a> Multidimensional primary liver tissues that have nonparenchymal cells strategically placed at appropriate locations throughout the model to closely mimic the <i>in vivo</i> system and facilitate the assessment of organ-level responses have been developed through use of bioprinting.<a onclick="showRef(event, 'ref206 ref207'); return false;" href="javascript:void(0);" class="ref ref206 ref207">(205,206)</a> Finally, the addition of flow to these systems helps to better model shear stress, clearance properties, and oxygen tension more closely reflecting what occurs <i>in vivo</i>.<a onclick="showRef(event, 'ref208 ref209'); return false;" href="javascript:void(0);" class="ref ref208 ref209">(207,208)</a></div><div class="NLM_p">A newer alternative to cell lines and primary cells is the use of stem cell-based models. Stem cells can come from an embryonic source or an adult source, or they can be generated by reprogramming adult tissue to a pluripotent state, so-called induced-pluripotent stem cells (iPSCs). All three types can potentially be used for the generation of relevant parenchymal cells such as iPSC-derived hepatocytes. However, the use of iPSC technology offers the promise of a less-invasive method to obtain a potentially unlimited supply of cells. Furthermore, cells can be isolated from patients that have experienced an IADR and carry an associated risk allele. Unfortunately, the current protocols used to differentiate iPSC cells into hepatocytes result in significant phenotypic variability with limited phenotypic similarity to mature human hepatocytes.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(199)</a> However, the functionality of patient-derived iPSC hepatocytes is likely to be enhanced when coupled with emerging culture techniques like 3D and microphysiological systems.<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(209)</a></div><div class="NLM_p">One of the major benefits of utilizing in vitro models is the ability to survey specific mechanisms relevant to IADRs through the development of targeted assays. A variety of approaches have been described to look at direct effects such as mitochondrial dysfunction and oxidative stress. For example, the glucose–galactose assay is a common approach to assess mitochondrial toxicity using the HepG2 hepatocyte cell line.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> This assay is performed by growing HepG2 cells in either media containing glucose or galactose-based media that forces cells to use oxidative phosphorylation in order to generate ATP. Cells are more susceptible to mitochondrial toxicity in galactose-based medium. Therefore, mitochondrial liabilities can be identified by quantifying the difference between toxicity measured in the two medias. Mitochondrial toxicity can also be assessed using the Seahorse platform, which measures differences in oxygen consumption rate and extracellular acidification rate in response to drugs. This type of analysis can inform whether the mitochondrial toxicity is due to ETC inhibition, uncoupling, or another mechanism. Finally, cellular imaging with functional probes that measure mitochondrial membrane potential can also be used to assess mitochondrial toxicity.</div><div class="NLM_p">Another mechanism of toxicity commonly measured in <i>in vitro</i> studies is oxidative stress. Oxidative stress can be evaluated using standard plate reader assays that quantify GSH depletion or ROS production. Using high-content imaging, functional probes can also assess oxidative stress at the subcellular level alongside other mechanisms of toxicity. Other commonly used approaches include covalent binding studies using liver microsomes and reactive metabolite trapping.</div><div class="NLM_p">The effect of drugs on bile acid homeostasis in the liver can also be evaluated <i>in vitro</i>. Bile acid-mediated toxicity is mainly assessed by calculating transporter inhibition potential using membrane vesicles, transfected cell lines, or sandwich-cultured hepatocytes.<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(210)</a> However, the correlation between effects on transporter inhibition and toxicity is poor, even when adjusted for drug exposure. Newer approaches may improve the ability to relate bile acid transporter inhibition to functional hepatocyte change. For example, several groups have described a method to detect toxicities resulting from alterations in bile acid by measuring cytotoxicity in hepatocyte cell lines or in primary hepatocytes in the presence and absence of a pool of exogenous bile acids added to the culture medium at human-relevant concentrations.<a onclick="showRef(event, 'ref212 ref213'); return false;" href="javascript:void(0);" class="ref ref212 ref213">(211,212)</a> A leftward shift in toxicity susceptibility is observed in response to drugs that inhibit bile acid transport when they are cultured in the presence of exogenous bile acids. Compounds that cause alterations in bile acids are identified by quantifying the difference between toxicity measured in the presence and absence of bile acids and relating it to clinical drug exposure. Imaging-based approaches may also be used to assess bile acid-mediated toxicity. Several studies have shown that alterations in bile canaliculi dynamics and canalicular network formation are indicative of compounds with the potential to cause alterations in bile acids <i>in vivo</i>.<a onclick="showRef(event, 'ref81 ref214 ref215'); return false;" href="javascript:void(0);" class="ref ref81 ref214 ref215">(81,213,214)</a> These changes can be measured by high-content imaging.</div><div class="NLM_p">Indirect immune-mediated responses can also be evaluated <i>in vitro</i>. For example, the LTT measures <i>in vitro</i> proliferation of T-cells in response to a drug. Several studies have shown drug-induced proliferation of lymphocytes from patients that have previously experienced an IADR, some of which are dependent on antigen processing.<a onclick="showRef(event, 'ref39 ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref39 ref43 ref44">(39,43,44)</a> Excitingly, drug responses have also been observed in lymphocytes from drug naive patients that carry a drug-specific HLA risk allele.<a onclick="showRef(event, 'ref46 ref216'); return false;" href="javascript:void(0);" class="ref ref46 ref216">(46,215)</a> These findings may be useful for the development of a preclinical assay to predict IADRs.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> However, responses have yet to be shown for class II HLA associations, and in order to be predictive, the risk allele would need to be known in advance.</div><div class="NLM_p">The MH assay may also have value in understanding and predicting IDILI. In this assay, hepatocyte-like cells are generated from monocytes of IDILI patients.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Patient-specific MH cells appear to be more sensitive to direct toxicity induced by the causative agent than other drugs, and MH cells from healthy donors are reported to be unresponsive to any drugs. It has been suggested that the immune origin of the hepatocyte-like cells may contribute to the apparent predictiveness of the assay, and further mechanistic studies are warranted to explore this hypothesis. It would also be interesting to determine if this assay would show a similar susceptibility in MH cells from drug-naive patients with HLA risk alleles, as has been demonstrated for the LTT.</div><div class="NLM_p">Another promising approach to evaluating IADRs examines innate immune activation in monocytes and their derivatives in response to conditioned medium from drug-exposed hepatocytes or hepatocyte-like cells. Increased cytokine levels have been observed in monocytes exposed to conditioned medium from IDILI drug exposed hepatocytes compared to conditioned medium from drugs that do not cause DILI or vehicle control.<a onclick="showRef(event, 'ref71 ref72 ref73 ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref71 ref72 ref73 ref74 ref75">(71−75)</a> In the case of IDILI drugs, inflammasome activation appears to occur in the absence of any direct effect of the drug on monocytes,<a onclick="showRef(event, 'ref71 ref75'); return false;" href="javascript:void(0);" class="ref ref71 ref75">(71,75)</a> whereas drugs that cause SCARs may activate the inflammasome directly.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> The conditioned medium is likely to contain a variety of DAMPs including HMGB-1, HSPs, S100 proteins, and exosomes. Current efforts are underway to explore if enriching for specific danger signals such as are contained in exosomes may improve the sensitivity and specificity of the immune response.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></div><div class="NLM_p last">Finally, several groups have proposed using a combination of <i>in vitro</i> assays for predicting IADR risk. Given that some drugs may operate through multiple mechanisms a “weight of evidence” or multivariate approach may provide a more robust evaluation of risk. However, the approach to evaluating performance of both univariate and multivariate approaches must be carefully considered. Experts have noted that predictive assays are often developed and then tested using a higher percentage of IADR positive than negative compounds, despite the fact that only a small percentage of drugs actually cause these types of toxicity.<a onclick="showRef(event, 'ref217'); return false;" href="javascript:void(0);" class="ref ref217">(216)</a> This may skew commonly used performance metrics like positive predictive value (PPV) and negative predictive value (NPV) to appear better than they might achieve in a real-world scenario. Two solutions have been proposed to prevent this bias: (1) continue the use of standard performance metrics like positive predictive value and negative predictive value but make it standard to use the same small percentage of IADR positive agents (e.g., 10%) or (2) use metrics that are normalized for the known approximate prevalence of hepatotoxicity among new drugs entering clinical trials such as likelihood ratios (easily determined from sensitivity and specificity) and a known prevalence (also called pretest probability) and give estimates of real-world predictive value.<a onclick="showRef(event, 'ref217'); return false;" href="javascript:void(0);" class="ref ref217">(216)</a></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>In Silico</i> Models</h3><div class="NLM_p">Significant progress has also been made in computational modeling and its application to IADRs, particularly for IDILI. <i>In silico</i> models are a valuable complement to preclinical and clinical studies that can be used to estimate risk and understand the contribution of individual mechanisms to toxicity. One type of computational model uses statistical approaches to link existing data about the drug to a known clinical outcome to derive an estimation of IADR risk. Several models developed using this approach have demonstrated good accuracy in predicting the IDILI risk. These include methods such as deep learning,<a onclick="showRef(event, 'ref218'); return false;" href="javascript:void(0);" class="ref ref218">(217)</a> naive Bayes classification,<a onclick="showRef(event, 'ref219'); return false;" href="javascript:void(0);" class="ref ref219">(218)</a> and substructure pattern recognition<a onclick="showRef(event, 'ref220'); return false;" href="javascript:void(0);" class="ref ref220">(219)</a> that use only chemical descriptors as well as approaches that combine chemical data with exposure information<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> or quantitative data from mechanistic <i>in vitro</i> assays.<a onclick="showRef(event, 'ref110 ref221'); return false;" href="javascript:void(0);" class="ref ref110 ref221">(110,220)</a> To date, most of these models are not widely accepted for the prediction of IADRs; however they have been used by drug developers to help with lead candidate selection and by researchers to understand the contribution of various mechanisms to IDILI.</div><div class="NLM_p">Another kind of model is QSP, which mathematically describes the physiology of biological systems and can be used to relate the impact of drug exposure to changes at the molecular and functional level. The development of QSP models is somewhat more challenging as it requires not only a deep understanding of the relevant physiologic and pathologic processes at play but a quantitative description and integration of these processes too. QSP models have shown great promise in the prediction and understanding of IADRs and support for their use is growing among drug developers and drug regulators.</div><div class="NLM_p">To date, the DILI-sim Initiative (<a href="http://Dilisym.com" class="ext-link">Dilisym.com</a>), a public–private partnership involving scientists from industry, academia, and the US Food and Drug Administration, has led the most advanced QSP modeling effort for DILI.<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(221)</a> The Initiative has used QSP to develop DILIsym, a quantitative mechanistic model that can be used to describe DILI observed in humans and several preclinical species.<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(221)</a> DILIsym software integrates drug exposure with mechanisms of intrinsic drug toxicity and innate immunity to model how drug exposure impacts an organism from the cell to the system level.<a onclick="showRef(event, 'ref222 ref223'); return false;" href="javascript:void(0);" class="ref ref222 ref223">(221,222)</a> Adaptive immune responses are not currently included in DILIsym but are part of ongoing development to be included in future versions of the modeling software.<a onclick="showRef(event, 'ref224'); return false;" href="javascript:void(0);" class="ref ref224">(223)</a></div><div class="NLM_p">DILIsym was developed as a “middle-out” model including representation of relevant liver cell populations, intracellular biochemical systems, and whole-body dynamics but only describing cellular mechanisms necessary to account for the observed liver toxicity. DILIsym was parametrized using available experimental data from model compounds where significant data on the liver safety profile across multiple species has been made publicly available.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> DILIsym has been updated across multiple versions to include new submodels of DILI processes as well as SimPops, a simulated population of heterogeneous individuals developed by expressing variability in key parameters related to susceptibility to various mechanisms of toxicity. SimPops enables the representation of DILI in large populations and can be used to optimize clinical trial design to reduce DILI events. While DILIsym was initially developed to model liver injury and inform mechanisms of toxicity, more recently it has been applied to predict liver safety for new drug candidates, and the accuracy will be tested in upcoming clinical trials.<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(221)</a></div><div class="NLM_p last">Finally, <i>in silico</i> approaches to evaluate HLA–drug interactions may also help the understanding and prediction of IADRs. Computational docking methods performed by Auto Dock or ACEdock software have confirmed associations between specific HLA alleles and toxic drugs retrospectively.<a onclick="showRef(event, 'ref53 ref58 ref225'); return false;" href="javascript:void(0);" class="ref ref53 ref58 ref225">(53,58,224)</a> Docking software has also been used to show differences in drug and metabolite binding, which can help explain the mechanisms behind HLA associations.<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(225)</a> There is some evidence to support that this approach could be used prospectively to identify possible HLA–drug interactions.<a onclick="showRef(event, 'ref227'); return false;" href="javascript:void(0);" class="ref ref227">(226)</a></div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Emerging Issues</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55555" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55555" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Checkpoint Inhibitors</h3><div class="NLM_p">Immune checkpoint inhibitors are monoclonal antibodies designed to block inhibitors of T-cell activation and function. They target CTLA-4 (e.g., ipilimumab), PD1 (e.g., nivolumab, pembrolizumab), and PD-L1 (e.g., atezolizumab, avelumab, durvalumab). Checkpoint inhibitors have been shown to have beneficial effects in more than 14 different cancers, and these effects have persisted in some patients for more than 5 years.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> However, checkpoint inhibitors have been associated with immune-mediated skin, liver, lung, and colon injuries.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Similar injuries have been observed with small molecule drugs that also inhibit immune tolerance pathways.<a onclick="showRef(event, 'ref115 ref228'); return false;" href="javascript:void(0);" class="ref ref115 ref228">(115,227)</a> In many ways, these toxicities exhibit characteristics of IADRs including a low incidence of severe injuries with a higher prevalence of mild reactions, a delay in onset from exposure to injury, and a clear involvement of the immune system.<a onclick="showRef(event, 'ref92 ref229'); return false;" href="javascript:void(0);" class="ref ref92 ref229">(92,228)</a> However, several differences also exist between checkpoint inhibitor-mediated reactions and true IADRs. For example, a higher percentage of clinically significant liver injury is observed with checkpoint inhibitors (1–2%) compared to what has been generally reported for IDILI (1 in 10000). Furthermore, checkpoint inhibitor reactions exhibit a true dose–response relationship with significantly higher percentages of patients experiencing reactions with dose escalation.<a onclick="showRef(event, 'ref229'); return false;" href="javascript:void(0);" class="ref ref229">(228)</a> This suggests that the mechanism of toxicity associated with checkpoint inhibitors may differ from IADRs and involve on-target immune-mediated events. Interestingly, no association with HLA or other risk alleles has been reported for checkpoint inhibitor-mediated toxicities, although the extent to which this has been investigated is unknown.</div><div class="NLM_p last">The PD-1<sup>–/–</sup> and anti-CTLA-4 mouse model has provided some insight into the mechanism of these reactions by demonstrating that inhibition of immune tolerance alone is not sufficient to cause significant liver injury.<a onclick="showRef(event, 'ref230'); return false;" href="javascript:void(0);" class="ref ref230">(229)</a> Similarly, knockout model animals for other checkpoint inhibitors<a onclick="showRef(event, 'ref231'); return false;" href="javascript:void(0);" class="ref ref231">(230)</a> and small molecule targets of immune tolerance do not spontaneously develop liver injury.<a onclick="showRef(event, 'ref232 ref233'); return false;" href="javascript:void(0);" class="ref ref232 ref233">(231,232)</a> As a result, it has been proposed that while toxicity susceptibility is due, in part, to on-target, immune-mediated events, effects at the level of the target tissue may also play a role. This is supported by recent studies demonstrating a role for oxidative stress and other direct effects in the mechanism of idelalisib-induced liver injury (Merrie Mosedale, unpublished data). Idelalisib is a small molecule drug that is metabolized in the liver, which may contribute to cellular stress. Most checkpoint inhibitors, however, are monoclonal antibodies that presumably are not generating reactive metabolites. These molecules may interact directly activate stress response pathways through the interaction with receptors on hepatocytes.<a onclick="showRef(event, 'ref234'); return false;" href="javascript:void(0);" class="ref ref234">(233)</a></div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Herbal and Dietary Supplements</h3><div class="NLM_p">Finally, herbal and dietary supplement (HDS) use is increasing worldwide, and there is mounting evidence that these compounds can also cause IADRs.<a onclick="showRef(event, 'ref235'); return false;" href="javascript:void(0);" class="ref ref235">(234)</a> The true incidence is unknown but about 20% of the new cases enrolled in DILIN have been attributed to HDSs.<a onclick="showRef(event, 'ref236'); return false;" href="javascript:void(0);" class="ref ref236">(235)</a> Little is known about HDS-induced IADRs for several reasons. First, the observation of IADRs with HDSs is fairly new and manufactures are not required to demonstrate that a product is both safe and effective prior to US marketing per the Dietary Supplement Health and Education Act of 1994.<a onclick="showRef(event, 'ref237'); return false;" href="javascript:void(0);" class="ref ref237">(236)</a> Second, HDSs are notoriously challenging to study because many products contain a variety of individual components that are unknown, and the properties of these individual constituents may be quite different when combined.<a onclick="showRef(event, 'ref238'); return false;" href="javascript:void(0);" class="ref ref238">(237)</a> Third, adulteration and false labeling of HDS products complicates the ability to identify the relevant chemical constituents.<a onclick="showRef(event, 'ref239'); return false;" href="javascript:void(0);" class="ref ref239">(238)</a> Finally, there are currently no validated tools or approaches to study or diagnose these reactions.<a onclick="showRef(event, 'ref235'); return false;" href="javascript:void(0);" class="ref ref235">(234)</a></div><div class="NLM_p">Genetic and mechanistic analyses have been undertaken for the most common HDS-induced IADRs, IDILI associated with green tea extract, OxyELITE Pro weight loss product, and bodybuilding supplements containing anabolic steroids. The toxicity of green tea extract is thought to be due to epigallocatechin gallate (EGCG), the most abundant catechin in tea that has numerous purported health benefits. In a study where animals from a genetically diverse mouse population were administered high doses of EGCG, significant livery injury was observed in a small percentage of mice 24 h after IP injection.<a onclick="showRef(event, 'ref240'); return false;" href="javascript:void(0);" class="ref ref240">(239)</a> The fold change in serum ALT values from the mice was used for genetic mapping, and the mapping identified almost 50 candidate risk factor genes associated with the hepatotoxic response. Polymorphisms in the human orthologues of these genes were tested in genotyping data from patients with purported EGCG-induced liver injury, and polymorphisms in 3 mitochondrial-related genes were found to have suggestive associations that supported a role for mitochondrial dysfunction in the reaction.<a onclick="showRef(event, 'ref240'); return false;" href="javascript:void(0);" class="ref ref240">(239)</a> GTE was also shown to induce hepatotoxicity in the PD-1<sup>–/–</sup> and anti-CTLA-4 mouse model.<a onclick="showRef(event, 'ref241'); return false;" href="javascript:void(0);" class="ref ref241">(240)</a></div><div class="NLM_p last">Significant mortality was observed in both outbred and inbred models given clinically relevant doses of OxyELITE Pro-New Formula.<a onclick="showRef(event, 'ref242'); return false;" href="javascript:void(0);" class="ref ref242">(241)</a> Aegeline, a compound previously linked to adverse events, has been identified in various formulations of OxyELITE and may contribute to hepatotoxicity.<a onclick="showRef(event, 'ref243'); return false;" href="javascript:void(0);" class="ref ref243">(242)</a> Finally, anabolic steroids were identified in the products taken by individuals experiencing cholestatic toxicity associated with consumption of bodybuilding supplements.<a onclick="showRef(event, 'ref244'); return false;" href="javascript:void(0);" class="ref ref244">(243)</a> A candidate gene analysis of SNPs among these cases identified a higher prevalence of mutations in the gene that codes for BSEP (present in up to 20%) compared to ethnically matched controls. These findings bolster safety and efficacy concerns for HDSs and support the need for pre- and postmarket safety studies within the dietary supplement industry.</div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42813" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42813" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">IADRs encompass a diverse group of toxicities that can vary by drug and by individual in the severity of injury, duration of reaction, and response to treatment. However, most IADRs display common clinical characteristics such as a delay in onset from initial drug exposure, rapid response with rechallenge, and an immune response. These clinical characteristics along with the identification of HLA alleles as risk factor and the observation that lymphocytes isolated from patients with IADRs or with HLA risk alleles proliferate in culture in response to causative drugs support a role for the adaptive immune system in the overt injuries. However, the significant delay in injury and lack of specificity for most HLA associations support the requirement for multiple events that precede the adaptive immune response including drug-induced stress directly to the target organ, formation of neoantigen, release of danger signals, and stimulation of an innate immune response. These early events may occur in the absence of cell death and involve risk factors impacting cellular stress and the ability to mount immune tolerance. While other mechanisms have been proposed, the strongest weight of evidence supports a danger-signal mediated adaptive immune attack as mechanism for most IADRs (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Proposed Mechanisms of Idiosyncratic Toxicities and Weight of Evidence</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">pathway</th><th class="colsep0 rowsep0" align="center">supportive evidence</th><th class="colsep0 rowsep0" align="center">weight of evidence</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="7" align="left">adaptive immune attack</td><td class="colsep0 rowsep0" align="left">accumulation of T- and B-lymphocytes in target organ and blood</td><td class="colsep0 rowsep0" rowspan="7" align="left">strong</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">increased levels of proinflammatory cytokines</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">formation of antidrug antibodies</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">histological observations of T-cells near apoptotic cells</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">response to immunosuppressants</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">positive LTT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HLA risk alleles</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="7" align="left">danger-signal mediated (requires direct, drug-induced cellular stress)</td><td class="colsep0 rowsep0" align="left">exposure to nonself proteins alone does not trigger an immune attack</td><td class="colsep0 rowsep0" rowspan="7" align="left">strong</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">delay in onset of reaction</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rapid rechallenge response</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">more severe reaction with rechallenge</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">low specificity of HLA risk alleles</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lack of toxicity in humanized HLA mouse models</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">drug-induced changes in DAMPs and exosomes</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">heterologous immunity (does not require cell stress or danger signals)</td><td class="colsep0 rowsep0" align="left">more robust responses in amodiaquine-immunized mice</td><td class="colsep0 rowsep0" rowspan="2" align="left">weak (convincing but understudied)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">abacavir reactive memory T-cells isolated from healthy, drug naive HLA*B-57:01 carriers</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">non-immune-mediated</td><td class="colsep0 rowsep0" align="left">QSP modeling</td><td class="colsep0 rowsep0" align="left">weak (convincing but limited sources)</td></tr></tbody></table></div></div><div class="NLM_p">The complex nature of these reactions combined with the fact that they are so rare make them particularly difficult to predict, diagnose, and treat. However, the development of new animal, <i>in vitro</i>, and <i>in silico</i> tools that can recapitulate certain aspects of the clinical profile have helped to inform mechanisms and risk factors for IADRs (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Models that combine <i>in vivo</i>, <i>in vitro</i>, and <i>in silico</i> approaches are most likely to also improve the prediction of IADR liabilities and eventually the ability to distinguish benign responses from those that portend more serious injury.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Overall Usefulness of Proposed Nonclinical Models for Understanding and Predicting Idiosyncratic Toxicity</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">model</th><th class="colsep0 rowsep0" align="center">advantage</th><th class="colsep0 rowsep0" align="center">disadvantage</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Animal (limited utility)</td><td class="colsep0 rowsep0" align="left">Physiologically relevant system</td><td class="colsep0 rowsep0" align="left">May not be human-relevant</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">standard preclinical models</td><td class="colsep0 rowsep0" align="left">readily available and widely accepted</td><td class="colsep0 rowsep0" align="left">poor predictive capacity for idiosyncratic toxicity</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LPS-treated rodent model</td><td class="colsep0 rowsep0" align="left">has demonstrated enhanced sensitivity to IDILI drugs</td><td class="colsep0 rowsep0" align="left">not reflective of clinical phenotype</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PD-1<sup>–/–</sup> mice treated with anti-CTLA-4 antibody</td><td class="colsep0 rowsep0" align="left">recapitulates some aspects of clinical IDILI</td><td class="colsep0 rowsep0" align="left">significant liver injury is not observed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">female Brown Norway rats</td><td class="colsep0 rowsep0" align="left">recapitulates many aspects of nevirapine-induced skin reactions</td><td class="colsep0 rowsep0" align="left">limited to certain drugs</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">humanized mouse models</td><td class="colsep0 rowsep0" align="left">recapitulates many aspects of clinical SCARs</td><td class="colsep0 rowsep0" align="left">not widely available</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">transgenic mice expressing HLA risk alleles</td><td class="colsep0 rowsep0" align="left">has informed role of HLA alleles</td><td class="colsep0 rowsep0" align="left">only useful if HLA risk allele is known</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse genetic reference populations</td><td class="colsep0 rowsep0" align="left">has helped identify genetic risk factors for IDILI</td><td class="colsep0 rowsep0" align="left">uses large numbers of animals</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">In vitro (some utility)</td><td class="colsep0 rowsep0" align="left">Human relevant system</td><td class="colsep0 rowsep0" align="left">May have limited physiological relevance</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">primary cells</td><td class="colsep0 rowsep0" align="left">simple system</td><td class="colsep0 rowsep0" align="left">lacks immune component</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">organotypic liver culture models</td><td class="colsep0 rowsep0" align="left">improved phenotype, viability, longevity</td><td class="colsep0 rowsep0" align="left">increasing complexity and cost</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">stem cell-based models</td><td class="colsep0 rowsep0" align="left">can test responses in IADR patients</td><td class="colsep0 rowsep0" align="left">immature phenotype</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mechanistic <i>in vitro</i> assays</td><td class="colsep0 rowsep0" align="left">inform specific mechanisms contributing to early events</td><td class="colsep0 rowsep0" align="left">limited to only known mechanisms</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LTT</td><td class="colsep0 rowsep0" align="left">has provided strong support for role of adaptive immune system</td><td class="colsep0 rowsep0" align="left">requires a priori knowledge of specific HLA risk alleles</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MH</td><td class="colsep0 rowsep0" align="left">useful in causality assessment</td><td class="colsep0 rowsep0" align="left">biology is not well understood</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">conditioned medium assays</td><td class="colsep0 rowsep0" align="left">has informed the contribution of danger signals to IADRs</td><td class="colsep0 rowsep0" align="left">limited evidence to support predictive capacity</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">In silico (some utility)</td><td class="colsep0 rowsep0" align="left">Can be utilized prior to preclinical studies</td><td class="colsep0 rowsep0" align="left">Provides little mechanistic understanding</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SARs</td><td class="colsep0 rowsep0" align="left">limited information required</td><td class="colsep0 rowsep0" align="left">does not factor in clinical exposure</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">drug properties</td><td class="colsep0 rowsep0" align="left">only standard biochemical information required</td><td class="colsep0 rowsep0" align="left">limited predictive capacity</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Combination (greatest utility)</td><td class="colsep0 rowsep0" align="left">Demonstrated success in risk assessment</td><td class="colsep0 rowsep0" align="left">Requires significant resources</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">multiparametric approach</td><td class="colsep0 rowsep0" align="left">unbiased</td><td class="colsep0 rowsep0" align="left">requires significant high-quality data to develop</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">QSP</td><td class="colsep0 rowsep0" align="left">grounded in physiology</td><td class="colsep0 rowsep0" align="left">slow turnaround time</td></tr></tbody></table></div></div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01297" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37728" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37728" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Merrie Mosedale</span> - <span class="hlFld-Affiliation affiliation">Institute
for Drug Safety Sciences and Division of Pharmacotherapy and Experimental
Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina 27599, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1968-6666" title="Orcid link">http://orcid.org/0000-0003-1968-6666</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9cf1f9eeeef5f9dce9f2ffb2f9f8e9"><span class="__cf_email__" data-cfemail="177a7265657e725762797439727362">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul B. Watkins</span> - <span class="hlFld-Affiliation affiliation">Institute
for Drug Safety Sciences and Division of Pharmacotherapy and Experimental
Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina 27599, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): P.B.W. chairs the Scientific Advisory Committee of the DILI-sim Initiative and has financial interest in DILIsym Service, Inc.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40170" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40170" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Merrie Mosedale</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01297&amp;id=BIO-d7e2513-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Merrie Mosedale</b> is a research assistant professor in the Division of Pharmacotherapy and Experimental Therapeutics and assistant director of the Institute for Drug Safety Sciences at the UNC Eshelman School of Pharmacy. She leads translational pharmacogenomics research focused on solving drug safety problems by integrating cutting-edge pharmacogenomics approaches with novel <i>in vivo</i>, <i>in vitro</i>, and <i>in silico</i> platforms. Prior to joining UNC, Dr. Mosedale was a research investigator at the Hamner Institutes for Health Sciences. She received her B.S. from Duke University and her Ph.D. from the University of California, San Diego.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Paul B. Watkins</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01297&amp;id=BIO-d7e2527-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Paul B. Watkins</b> is the Howard Q. Ferguson Distinguished Professor in the Division of Pharmacotherapy and Experimental Therapeutics and the director of the Institute for Drug Safety Sciences at the UNC Eshelman School of Pharmacy. His research spans preclinical models to patients in clinical trials and utilizes current genomics technologies, including genetics, transcriptomics, and metabolomics to identify mechanisms that underlie drug-induced liver injury. Prior to joining UNC, Dr. Watkins was on the faculty at the University of Michigan and the Medical College of Virginia. He received his B.S. and M.D. from Cornell University.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00710" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00710" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Funding for M.M. was provided, in part, by an Innovation in Regulatory Science Award from the Burroughs Wellcome Fund. Funding for P.B.W. was provided by the National Institute of Diabetes and Digestive and Kidney Diseases, Project Number UO1 DK065201.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ADR</td><td class="NLM_def"><p class="first last">adverse drug reactions</p></td></tr><tr><td class="NLM_term">ALP</td><td class="NLM_def"><p class="first last">alkaline phosphatase</p></td></tr><tr><td class="NLM_term">ALT</td><td class="NLM_def"><p class="first last">alanine aminotransferase</p></td></tr><tr><td class="NLM_term">AST</td><td class="NLM_def"><p class="first last">aspartate aminotransferase</p></td></tr><tr><td class="NLM_term">BDDCs</td><td class="NLM_def"><p class="first last">biopharmaceutics drug disposition classification system</p></td></tr><tr><td class="NLM_term">BILI</td><td class="NLM_def"><p class="first last">total bilirubin</p></td></tr><tr><td class="NLM_term">BSEP</td><td class="NLM_def"><p class="first last">bile salt export protein</p></td></tr><tr><td class="NLM_term">CC</td><td class="NLM_def"><p class="first last">Collaborative Cross</p></td></tr><tr><td class="NLM_term">CTLA-4</td><td class="NLM_def"><p class="first last">cytotoxic T-lymphocyte-associated protein 4</p></td></tr><tr><td class="NLM_term">DAMP</td><td class="NLM_def"><p class="first last">damage associated molecular pattern</p></td></tr><tr><td class="NLM_term">DDI</td><td class="NLM_def"><p class="first last">drug–drug interaction</p></td></tr><tr><td class="NLM_term">DIHS</td><td class="NLM_def"><p class="first last">drug-induced hypersensitivity syndrome</p></td></tr><tr><td class="NLM_term">DILIN</td><td class="NLM_def"><p class="first last">Drug-Induced Liver Injury Network</p></td></tr><tr><td class="NLM_term">DMET</td><td class="NLM_def"><p class="first last">drug metabolizing enzyme and transporter</p></td></tr><tr><td class="NLM_term">DRESS</td><td class="NLM_def"><p class="first last">drug reaction with eosinophilia and systemic symptoms</p></td></tr><tr><td class="NLM_term">eDISH</td><td class="NLM_def"><p class="first last">evaluation of drug-induced serious hepatotoxicity</p></td></tr><tr><td class="NLM_term">EGCG</td><td class="NLM_def"><p class="first last">epigallocatechin gallate</p></td></tr><tr><td class="NLM_term">GPX1</td><td class="NLM_def"><p class="first last">glutathione peroxidase I</p></td></tr><tr><td class="NLM_term">GRP</td><td class="NLM_def"><p class="first last">genetic reference population</p></td></tr><tr><td class="NLM_term">HDS</td><td class="NLM_def"><p class="first last">herbal and dietary supplement</p></td></tr><tr><td class="NLM_term">HLA</td><td class="NLM_def"><p class="first last">human leukocyte antigen</p></td></tr><tr><td class="NLM_term">HMGB1</td><td class="NLM_def"><p class="first last">high mobility group box 1 protein</p></td></tr><tr><td class="NLM_term">HSP</td><td class="NLM_def"><p class="first last">heat shock protein</p></td></tr><tr><td class="NLM_term">IADR</td><td class="NLM_def"><p class="first last">idiosyncratic adverse drug reaction</p></td></tr><tr><td class="NLM_term">IDILI</td><td class="NLM_def"><p class="first last">idiosyncratic drug-induced liver injury</p></td></tr><tr><td class="NLM_term">IFN-γ</td><td class="NLM_def"><p class="first last">interferon-γ</p></td></tr><tr><td class="NLM_term">iPSC</td><td class="NLM_def"><p class="first last">induced pluripotent stem cells</p></td></tr><tr><td class="NLM_term"><i>K8/18</i></td><td class="NLM_def"><p class="first last">keratins 8 and 18</p></td></tr><tr><td class="NLM_term">LPS</td><td class="NLM_def"><p class="first last">lipopolysaccharide</p></td></tr><tr><td class="NLM_term">LTT</td><td class="NLM_def"><p class="first last">lymphocyte transformation test</p></td></tr><tr><td class="NLM_term">MH</td><td class="NLM_def"><p class="first last">monocyte-derived hepatocyte-like</p></td></tr><tr><td class="NLM_term">MHC</td><td class="NLM_def"><p class="first last">major histocompatibility complex</p></td></tr><tr><td class="NLM_term"><i>MnSOD2</i></td><td class="NLM_def"><p class="first last">manganese superoxide dismutase</p></td></tr><tr><td class="NLM_term">NAFLD</td><td class="NLM_def"><p class="first last">nonalcoholic fatty liver disease</p></td></tr><tr><td class="NLM_term">NPV</td><td class="NLM_def"><p class="first last">negative predictive value</p></td></tr><tr><td class="NLM_term">OR</td><td class="NLM_def"><p class="first last">odds ratio</p></td></tr><tr><td class="NLM_term">PAMP</td><td class="NLM_def"><p class="first last">pathogen associated molecular pattern</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood mononuclear cell</p></td></tr><tr><td class="NLM_term">PD-1</td><td class="NLM_def"><p class="first last">programmed cell death 1</p></td></tr><tr><td class="NLM_term">PPV</td><td class="NLM_def"><p class="first last">positive predictive value</p></td></tr><tr><td class="NLM_term">PTPN22</td><td class="NLM_def"><p class="first last">protein tyrosine phosphatase nonreceptor type 22</p></td></tr><tr><td class="NLM_term">QSP</td><td class="NLM_def"><p class="first last">quantitative systems pharmacology</p></td></tr><tr><td class="NLM_term">RO2</td><td class="NLM_def"><p class="first last">rule-of-2</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SCAR</td><td class="NLM_def"><p class="first last">severe cutaneous adverse reaction</p></td></tr><tr><td class="NLM_term">SJS</td><td class="NLM_def"><p class="first last">Stevens–Johnson syndrome</p></td></tr><tr><td class="NLM_term"><i>STAT4</i></td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription 4</p></td></tr><tr><td class="NLM_term">TCR</td><td class="NLM_def"><p class="first last">T-cell receptor</p></td></tr><tr><td class="NLM_term">TEN</td><td class="NLM_def"><p class="first last">toxic epidermal necrolysis</p></td></tr><tr><td class="NLM_term">ULN</td><td class="NLM_def"><p class="first last">upper limit of normal</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10637" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10637" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 243 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Usui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Human Leukocyte Antigen and Idiosyncratic Adverse Drug Reactions</span>. <i>Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1016/j.dmpk.2016.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.dmpk.2016.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28017537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCgtb7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=21-30&author=T.+Usuiauthor=D.+J.+Naisbitt&title=Human+Leukocyte+Antigen+and+Idiosyncratic+Adverse+Drug+Reactions&doi=10.1016%2Fj.dmpk.2016.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Human leukocyte antigen and idiosyncratic adverse drug reactions</span></div><div class="casAuthors">Usui, Toru; Naisbitt, Dean J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-30</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A clin. assocn. between a specific human leukocyte antigen (HLA) allele and idiosyncratic adverse drug reactions (IADRs) is a strong indication that IADRs are mediated by the adaptive immune system.  For example, it is well-established that HLA-B*15:02 and HLA-B*57:01 are assocd. with carbamazepine-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and abacavir-induced hypersensitivity/flucloxacillin-induced liver injury, resp.  Drug-specific T-cells whose response is restricted by specific HLA risk alleles have been detected from IADR patients, also suggesting an adaptive immune pathogenesis.  T-cells from carbamazepine SJS/TEN patients are activated by direct pharmacol. interaction between carbamazepine and HLA-B*15:02 expressed on antigen presenting cells (APCs).  Abacavir-specific, HLA-B*57:01-restricted T-cells are activated by APCs presenting peptides which are only displayed by the HLA mol. when abacavir is bound during peptide loading.  Finally, HLA-B*57:01-restricted activation of T-cells from patients with flucloxacillin-induced liver injury is dependent on processing of drug protein adducts.  Based on these observations, it is now possible to utilize blood from healthy drug-na.ovrddot.ive volunteers to study the priming of na.ovrddot.ive T-cells to drugs.  Future development of these methodologies may lead to the development of assays that predict intrinsic immunogenicity of drugs and chems. at the preclin. stage of drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0jKwp87-Gt7Vg90H21EOLACvtfcHk0ljv89a3XYlozQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCgtb7L&md5=74802983719a85747be51fb3161912e4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.dmpk.2016.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dmpk.2016.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DUsui%26aufirst%3DT.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DHuman%2520Leukocyte%2520Antigen%2520and%2520Idiosyncratic%2520Adverse%2520Drug%2520Reactions%26jtitle%3DDrug%2520Metab.%2520Pharmacokinet.%26date%3D2017%26volume%3D32%26spage%3D21%26epage%3D30%26doi%3D10.1016%2Fj.dmpk.2016.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Idiosyncratic Adverse Drug Reactions: Current Concepts</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">808</span>, <span class="refDoi"> DOI: 10.1124/pr.113.007450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fpr.113.007450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23476052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslCjurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=779-808&author=J.+Uetrechtauthor=D.+J.+Naisbitt&title=Idiosyncratic+Adverse+Drug+Reactions%3A+Current+Concepts&doi=10.1124%2Fpr.113.007450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Idiosyncratic adverse drug reactions: current concepts</span></div><div class="casAuthors">Uetrecht, Jack; Naisbitt, Dean J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">779-808, 30 pp.</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Idiosyncratic drug reactions are a significant cause of morbidity and mortality for patients; they also markedly increase the uncertainty of drug development.  The major targets are skin, liver, and bone marrow.  Clin. characteristics suggest that IDRs are immune mediated, and there is substantive evidence that most, but not all, IDRs are caused by chem. reactive species.  However, rigorous mechanistic studies are very difficult to perform, esp. in the absence of valid animal models.  Models to explain how drugs or reactive metabolites interact with the MHC/T-cell receptor complex include the hapten and P-I models, and most recently it was found that abacavir can interact reversibly with MHC to alter the endogenous peptides that are presented to T cells.  The discovery of HLA mols. as important risk factors for some IDRs has also significantly contributed to our understanding of these adverse reactions, but it is not yet clear what fraction of IDRs have a strong HLA dependence.  In addn., with the exception of abacavir, most patients who have the HLA that confers a higher IDR risk with a specific drug will not have an IDR when treated with that drug.  Interindividual differences in T-cell receptors and other factors also presumably play a role in detg. which patients will have an IDR.  The immune response represents a delicate balance, and immune tolerance may be the dominant response to a drug that can cause IDRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-edQNrNURDbVg90H21EOLACvtfcHk0ljv89a3XYlozQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslCjurc%253D&md5=4c64ceb706119a57010fd5085510d8f0</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1124%2Fpr.113.007450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.113.007450%26sid%3Dliteratum%253Aachs%26aulast%3DUetrecht%26aufirst%3DJ.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DIdiosyncratic%2520Adverse%2520Drug%2520Reactions%253A%2520Current%2520Concepts%26jtitle%3DPharmacol.%2520Rev.%26date%3D2013%26volume%3D65%26spage%3D779%26epage%3D808%26doi%3D10.1124%2Fpr.113.007450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, S.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, J.</span></span> <span> </span><span class="NLM_article-title">The Skin as a Metabolic and Immune-Competent Organ: Implications for Drug-Induced Skin Rash</span>. <i>J. Immunotoxicol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1080/1547691X.2018.1514444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1080%2F1547691X.2018.1514444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30318948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFSqtbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=1-12&author=A.+Sharmaauthor=Y.+Saitoauthor=S.-I.+Hungauthor=D.+Naisbittauthor=J.+Uetrechtauthor=J.+Bussiere&title=The+Skin+as+a+Metabolic+and+Immune-Competent+Organ%3A+Implications+for+Drug-Induced+Skin+Rash&doi=10.1080%2F1547691X.2018.1514444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The skin as a metabolic and immune-competent organ: implications fordrug-induced skin rash</span></div><div class="casAuthors">Sharma, Amy; Saito, Yoshiro; Hung, Shuen-Iu; Naisbitt, Dean; Uetrecht, Jack; Bussiere, Jeanine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunotoxicology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">JIOMAP</span>;
        ISSN:<span class="NLM_cas:issn">1547-691X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Current advances in the study of cutaneous adverse drug reactions can be attributed to the recent understanding that the skin is both a metabolically and immunol. competent organ.  The ability of the skin to serve as a protective barrier with limited drug biotransformation ability, yet highly active immune function, has provided insights into its biol. capability.  While the immune response of the skin to drugs is vastly different from that of the liver due to evolutionary conditioning, it frequently occurs in response to various drug classes and manifests as a spectrum of hypersensitivity reactions.  The skin is a common site of adverse and idiosyncratic drug reactions; drug-specific T-cells, as well as involvement of an innate immune response, appear to be key mechanistic drivers in such scenarios.  Assocn. of other factors such as human leukocyte antigen (HLA) polymorphisms may play a significant role for particular drugs.  This review aims to integrate emerging findings into proposed mechanisms of drug metab. and immunity in the skin that are likely responsible for rashes and other local allergic responses.  These unique biol. aspects of the skin, and their translation into implications for drug development and the use of animal models, will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrIZYXUQ2TorVg90H21EOLACvtfcHk0ljv89a3XYlozQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFSqtbbJ&md5=8b25ef5392836e209c4b0b594a730b2b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1080%2F1547691X.2018.1514444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1547691X.2018.1514444%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DSaito%26aufirst%3DY.%26aulast%3DHung%26aufirst%3DS.-I.%26aulast%3DNaisbitt%26aufirst%3DD.%26aulast%3DUetrecht%26aufirst%3DJ.%26aulast%3DBussiere%26aufirst%3DJ.%26atitle%3DThe%2520Skin%2520as%2520a%2520Metabolic%2520and%2520Immune-Competent%2520Organ%253A%2520Implications%2520for%2520Drug-Induced%2520Skin%2520Rash%26jtitle%3DJ.%2520Immunotoxicol.%26date%3D2019%26volume%3D16%26spage%3D1%26epage%3D12%26doi%3D10.1080%2F1547691X.2018.1514444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">How Reactive Metabolites Induce an Immune Response That Sometimes Leads to an Idiosyncratic Drug Reaction</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.6b00357</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.6b00357" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslagsb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2017&pages=295-314&author=T.+Choauthor=J.+Uetrecht&title=How+Reactive+Metabolites+Induce+an+Immune+Response+That+Sometimes+Leads+to+an+Idiosyncratic+Drug+Reaction&doi=10.1021%2Facs.chemrestox.6b00357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">How Reactive Metabolites Induce an Immune Response That Sometimes Leads to an Idiosyncratic Drug Reaction</span></div><div class="casAuthors">Cho, Tiffany; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">295-314</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Little is known with certainty about the mechanisms of idiosyncratic drug reactions (IDRs); however, there is substantive evidence that reactive metabolites are involved in most, but not all, IDRs.  In addn., evidence also suggests that most IDRs are immune mediated.  That raises the question of how reactive metabolites induce an immune response that can lead to an IDR.  The dominant hypotheses are the hapten and danger hypotheses.  These are complementary hypotheses: a reactive metabolite can act as a hapten to produce neoantigens, and it can also cause cell damage leading to the release of danger-assocd. mol. pattern mols. that activate antigen presenting cells.  Both are required for an immune response.  In addn., drugs may induce an immune response through inflammasome activation.  The authors have found examples in which the ability to activate inflammasomes differentiated drugs that cause IDRs from similar drugs that do not.  There are other hypotheses that do not involve an immune mechanism such as mitochondrial injury and bile salt export pump (BSEP) inhibition.  With some possible exception, these hypotheses are unlikely to be able to completely explain IDRs.  However, some types of mitochondrial injury or BSEP inhibition could produce danger signals.  The major mechanism that protects individuals from IDRs appears to be immune tolerance.  Consistent with this hypothesis, the authors used checkpoint inhibition to develop the first animal model of idiosyncratic drug-induced liver injury that has the same characteristics as the idiosyncratic injury in humans.  This was accomplished by treating Pd-1-/- mice with anti-CTLA-4 antibodies and amodiaquine.  The combination of the Pd-1-/- mouse and anti-CTLA-4 also unmasks the ability of other drugs such as isoniazid to cause delayed type liver injury.  This model should allow rigorous testing of mechanistic hypotheses that was impossible in the past.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHhl49wBgcXLVg90H21EOLACvtfcHk0lj-FfwYtkeqMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslagsb3M&md5=04137ee96f32fea06c39a22eea4e4200</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.6b00357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.6b00357%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DT.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DHow%2520Reactive%2520Metabolites%2520Induce%2520an%2520Immune%2520Response%2520That%2520Sometimes%2520Leads%2520to%2520an%2520Idiosyncratic%2520Drug%2520Reaction%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2017%26volume%3D30%26spage%3D295%26epage%3D314%26doi%3D10.1021%2Facs.chemrestox.6b00357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gates, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nykamp, D.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Hypersensitivity Reactions: Cutaneous Eruptions</span>. <i>US Pharmacist</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=32-36&author=A.+Gatesauthor=S.+Cullenauthor=D.+Nykamp&title=Drug-Induced+Hypersensitivity+Reactions%3A+Cutaneous+Eruptions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGates%26aufirst%3DA.%26aulast%3DCullen%26aufirst%3DS.%26aulast%3DNykamp%26aufirst%3DD.%26atitle%3DDrug-Induced%2520Hypersensitivity%2520Reactions%253A%2520Cutaneous%2520Eruptions%26jtitle%3DUS%2520Pharmacist%26date%3D2017%26volume%3D42%26spage%3D32%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms</span>. <i>J. Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2018</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.1155/2018/5163129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1155%2F2018%2F5163129" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2018&publication_year=2018&pages=1&author=H.+Watanabe&title=Recent+Advances+in+Drug-Induced+Hypersensitivity+Syndrome%2FDrug+Reaction+with+Eosinophilia+and+Systemic+Symptoms&doi=10.1155%2F2018%2F5163129"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1155%2F2018%2F5163129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2018%252F5163129%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DH.%26atitle%3DRecent%2520Advances%2520in%2520Drug-Induced%2520Hypersensitivity%2520Syndrome%252FDrug%2520Reaction%2520with%2520Eosinophilia%2520and%2520Systemic%2520Symptoms%26jtitle%3DJ.%2520Immunol.%2520Res.%26date%3D2018%26volume%3D2018%26spage%3D1%26doi%3D10.1155%2F2018%2F5163129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoetzenecker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saulite, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glatz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid-Grendelmeier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guenova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozzio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, L. E.</span></span> <span> </span><span class="NLM_article-title">Toxic Epidermal Necrolysis</span>. <i>F1000Research</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">951</span>, <span class="refDoi"> DOI: 10.12688/f1000research.7574.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.12688%2Ff1000research.7574.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmslSmsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=951&author=W.+Hoetzeneckerauthor=T.+Mehraauthor=I.+Sauliteauthor=M.+Glatzauthor=P.+Schmid-Grendelmeierauthor=E.+Guenovaauthor=A.+Cozzioauthor=L.+E.+French&title=Toxic+Epidermal+Necrolysis&doi=10.12688%2Ff1000research.7574.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Toxic epidermal necrolysis [version 1; referees: 3 approved]</span></div><div class="casAuthors">Hoetzenecker, Wolfram; Mehra, Tarun; Saulite, Ieva; Glatz, Martin; Schmid-Grendelmeier, Peter; Guenova, Emmanuella; Cozzio, Antonio; French, Lars E.</div><div class="citationInfo"><span class="NLM_cas:title">F1000Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">951/1-951/9</span>CODEN:
                <span class="NLM_cas:coden">FRESJL</span>;
        ISSN:<span class="NLM_cas:issn">2046-1402</span>.
    
            (<span class="NLM_cas:orgname">F1000 Research Ltd.</span>)
        </div><div class="casAbstract">Toxic epidermal necrolysis (TEN) is a rare, life-threatening drug-induced skindisease with a mortality rate of approx. 30%.  The clin. hallmark of TENis a marked skin detachment caused by extensive keratinocyte cell deathassocd. with mucosal involvement.  The exact pathogenic mechanism ofTEN is still uncertain.  Recent advances in this field have led to the identificationof several factors that might contribute to the induction of excessive apoptosisof keratinocytes.  In addn., specific human leukocyte antigen types seem tobe assocd. with certain drugs and the development of TEN.  Aswell-controlled studies are lacking, patients are treated with variousimmunomodulators (e.g. i.v. Ig) in addn. to the bestsupportive care.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH69EM19oG1bVg90H21EOLACvtfcHk0lj-FfwYtkeqMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmslSmsLs%253D&md5=924e30ee037c4cbde26cfafa570d876f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.12688%2Ff1000research.7574.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12688%252Ff1000research.7574.1%26sid%3Dliteratum%253Aachs%26aulast%3DHoetzenecker%26aufirst%3DW.%26aulast%3DMehra%26aufirst%3DT.%26aulast%3DSaulite%26aufirst%3DI.%26aulast%3DGlatz%26aufirst%3DM.%26aulast%3DSchmid-Grendelmeier%26aufirst%3DP.%26aulast%3DGuenova%26aufirst%3DE.%26aulast%3DCozzio%26aufirst%3DA.%26aulast%3DFrench%26aufirst%3DL.%2BE.%26atitle%3DToxic%2520Epidermal%2520Necrolysis%26jtitle%3DF1000Research%26date%3D2016%26volume%3D5%26spage%3D951%26doi%3D10.12688%2Ff1000research.7574.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span> <i>LiverTox Database</i>. <a href="https://livertox.nlm.nih.gov" class="extLink">https://livertox.nlm.nih.gov</a> (accessed Jul 16, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+LiverTox+Database.+https%3A%2F%2Flivertox.nlm.nih.gov+%28accessed+Jul+16%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DLiverTox%2520Database%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonkovsky, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talwalkar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bach, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beavers, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonkovsky, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvo, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conjeevaram, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dieterich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPaola, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durazo, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everhart, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghabril, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalreddy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoofnagle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplowitz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liangpunsakul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherker, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuppalanchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacks, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesney, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groseclose, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFadden, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melgoza, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikhail, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milstein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morlan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosado, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yalamanchili, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClanahan-Crowder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragavan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rostami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puglisi-Scharenbroich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrance, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Raaphorst, R.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">1340</span>– <span class="NLM_lpage">1352</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2015.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1053%2Fj.gastro.2015.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25754159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC2MnisVamtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2015&pages=1340-1352&author=N.+Chalasaniauthor=H.+L.+Bonkovskyauthor=R.+Fontanaauthor=W.+Leeauthor=A.+Stolzauthor=J.+Talwalkarauthor=K.+R.+Reddyauthor=P.+B.+Watkinsauthor=V.+Navarroauthor=H.+Barnhartauthor=J.+Guauthor=J.+Serranoauthor=J.+Ahmadauthor=N.+Bachauthor=M.+Bansalauthor=H.+X.+Barnhartauthor=K.+Beaversauthor=H.+Bonkovskyauthor=F.+O.+Calvoauthor=C.+Changauthor=H.+Conjeevaramauthor=G.+Connerauthor=J.+Darlingauthor=Y.+de+Boerauthor=D.+Dieterichauthor=F.+DiPaolaauthor=F.+A.+Durazoauthor=J.+E.+Everhartauthor=R.+J.+Fontanaauthor=M.+S.+Ghabrilauthor=D.+Goldsteinauthor=V.+Gopalreddyauthor=P.+Grewalauthor=P.+H.+Hayashiauthor=J.+Hoofnagleauthor=N.+Kaplowitzauthor=S.+Liangpunsakulauthor=S.+Lichtmanauthor=L.+Liuauthor=V.+J.+Navarroauthor=J.+Odinauthor=S.+Rossiauthor=M.+Russoauthor=T.+Schianoauthor=J.+Serranoauthor=A.+H.+Sherkerauthor=R.+Vuppalanchiauthor=P.+Watkinsauthor=S.+Zacksauthor=A.+Balascoauthor=K.+Chesneyauthor=A.+Corneauthor=S.+Cummingsauthor=G.+Grosecloseauthor=A.+Hammettauthor=J.+Hookerauthor=V.+Kesarauthor=S.+Maoauthor=K.+Marksauthor=R.+McFaddenauthor=Y.+Melgozaauthor=S.+Mikhailauthor=S.+Milsteinauthor=W.+Morlanauthor=V.+Peacockauthor=N.+Rosadoauthor=T.+Russellauthor=M.+Vegaauthor=M.+Vermaauthor=P.+Walkerauthor=R.+Yalamanchiliauthor=M.+McClanahan-Crowderauthor=K.+Galanauthor=T.+Chauauthor=K.+Ragavanauthor=H.+Rostamiauthor=C.+Puglisi-Scharenbroichauthor=R.+J.+Torranceauthor=R.+Van+Raaphorst&title=Features+and+Outcomes+of+899+Patients+With+Drug-Induced+Liver+Injury%3A+The+DILIN+Prospective+Study&doi=10.1053%2Fj.gastro.2015.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study</span></div><div class="casAuthors">Chalasani Naga; Bonkovsky Herbert L; Fontana Robert; Lee William; Stolz Andrew; Talwalkar Jayant; Reddy K Rajendar; Watkins Paul B; Navarro Victor; Barnhart Huiman; Gu Jiezhun; Serrano Jose</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1340-52.e7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND & AIMS:  The Drug-Induced Liver Injury Network is conducting a prospective study of patients with DILI in the United States.  We present characteristics and subgroup analyses from the first 1257 patients enrolled in the study.  METHODS:  In an observational longitudinal study, we began collecting data on eligible individuals with suspected DILI in 2004, following them for 6 months or longer.  Subjects were evaluated systematically for other etiologies, causes, and severity of DILI.  RESULTS:  Among 1257 enrolled subjects with suspected DILI, the causality was assessed in 1091 patients, and 899 were considered to have definite, highly likely, or probable DILI.  Ten percent of patients died or underwent liver transplantation, and 17% had chronic liver injury.  In the 89 patients (10%) with pre-existing liver disease, DILI appeared to be more severe than in those without (difference not statistically significant; P = .09) and mortality was significantly higher (16% vs 5.2%; P < .001).  Azithromycin was the implicated agent in a higher proportion of patients with pre-existing liver disease compared with those without liver disease (6.7% vs 1.5%; P = .006).  Forty-one cases with latency ≤7 days were caused predominantly by antimicrobial agents (71%).  Two most common causes for 60 DILI cases with latency >365 days were nitrofurantoin (25%) or minocycline (17%).  There were no differences in outcomes of patients with short vs long latency of DILI.  Compared with individuals younger than 65 years, individuals 65 years or older (n = 149) were more likely to have cholestatic injury, although mortality and rate of liver transplantation did not differ.  Nine patients (1%) had concomitant severe skin reactions; implicated agents were lamotrigine, azithromycin, carbamazepine, moxifloxacin, cephalexin, diclofenac, and nitrofurantoin.  Four of these patients died.  CONCLUSIONS:  Mortality from DILI is significantly higher in individuals with pre-existing liver disease or concomitant severe skin reactions compared with patients without.  Additional studies are needed to confirm the association between azithromycin and increased DILI in patients with chronic liver disease.  Older age and short or long latencies are not associated with DILI mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsG7qp96NL_5ZoeNcnHOQ9fW6udTcc2eZnNQbetMlhorntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnisVamtA%253D%253D&md5=e91d2b1872162ec5b9fa2f991851a5fe</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2015.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2015.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DBonkovsky%26aufirst%3DH.%2BL.%26aulast%3DFontana%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DStolz%26aufirst%3DA.%26aulast%3DTalwalkar%26aufirst%3DJ.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DNavarro%26aufirst%3DV.%26aulast%3DBarnhart%26aufirst%3DH.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DAhmad%26aufirst%3DJ.%26aulast%3DBach%26aufirst%3DN.%26aulast%3DBansal%26aufirst%3DM.%26aulast%3DBarnhart%26aufirst%3DH.%2BX.%26aulast%3DBeavers%26aufirst%3DK.%26aulast%3DBonkovsky%26aufirst%3DH.%26aulast%3DCalvo%26aufirst%3DF.%2BO.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DConjeevaram%26aufirst%3DH.%26aulast%3DConner%26aufirst%3DG.%26aulast%3DDarling%26aufirst%3DJ.%26aulast%3Dde%2BBoer%26aufirst%3DY.%26aulast%3DDieterich%26aufirst%3DD.%26aulast%3DDiPaola%26aufirst%3DF.%26aulast%3DDurazo%26aufirst%3DF.%2BA.%26aulast%3DEverhart%26aufirst%3DJ.%2BE.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DGhabril%26aufirst%3DM.%2BS.%26aulast%3DGoldstein%26aufirst%3DD.%26aulast%3DGopalreddy%26aufirst%3DV.%26aulast%3DGrewal%26aufirst%3DP.%26aulast%3DHayashi%26aufirst%3DP.%2BH.%26aulast%3DHoofnagle%26aufirst%3DJ.%26aulast%3DKaplowitz%26aufirst%3DN.%26aulast%3DLiangpunsakul%26aufirst%3DS.%26aulast%3DLichtman%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNavarro%26aufirst%3DV.%2BJ.%26aulast%3DOdin%26aufirst%3DJ.%26aulast%3DRossi%26aufirst%3DS.%26aulast%3DRusso%26aufirst%3DM.%26aulast%3DSchiano%26aufirst%3DT.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DSherker%26aufirst%3DA.%2BH.%26aulast%3DVuppalanchi%26aufirst%3DR.%26aulast%3DWatkins%26aufirst%3DP.%26aulast%3DZacks%26aufirst%3DS.%26aulast%3DBalasco%26aufirst%3DA.%26aulast%3DChesney%26aufirst%3DK.%26aulast%3DCorne%26aufirst%3DA.%26aulast%3DCummings%26aufirst%3DS.%26aulast%3DGroseclose%26aufirst%3DG.%26aulast%3DHammett%26aufirst%3DA.%26aulast%3DHooker%26aufirst%3DJ.%26aulast%3DKesar%26aufirst%3DV.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DMarks%26aufirst%3DK.%26aulast%3DMcFadden%26aufirst%3DR.%26aulast%3DMelgoza%26aufirst%3DY.%26aulast%3DMikhail%26aufirst%3DS.%26aulast%3DMilstein%26aufirst%3DS.%26aulast%3DMorlan%26aufirst%3DW.%26aulast%3DPeacock%26aufirst%3DV.%26aulast%3DRosado%26aufirst%3DN.%26aulast%3DRussell%26aufirst%3DT.%26aulast%3DVega%26aufirst%3DM.%26aulast%3DVerma%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DP.%26aulast%3DYalamanchili%26aufirst%3DR.%26aulast%3DMcClanahan-Crowder%26aufirst%3DM.%26aulast%3DGalan%26aufirst%3DK.%26aulast%3DChau%26aufirst%3DT.%26aulast%3DRagavan%26aufirst%3DK.%26aulast%3DRostami%26aufirst%3DH.%26aulast%3DPuglisi-Scharenbroich%26aufirst%3DC.%26aulast%3DTorrance%26aufirst%3DR.%2BJ.%26aulast%3DVan%2BRaaphorst%26aufirst%3DR.%26atitle%3DFeatures%2520and%2520Outcomes%2520of%2520899%2520Patients%2520With%2520Drug-Induced%2520Liver%2520Injury%253A%2520The%2520DILIN%2520Prospective%2520Study%26jtitle%3DGastroenterology%26date%3D2015%26volume%3D148%26spage%3D1340%26epage%3D1352%26doi%3D10.1053%2Fj.gastro.2015.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sundaram, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björnsson, E. S.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Cholestasis</span>. <i>Hepatology Communications</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">726</span>– <span class="NLM_lpage">735</span>, <span class="refDoi"> DOI: 10.1002/hep4.1088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep4.1088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29404489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC1MvnslCntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=726-735&author=V.+Sundaramauthor=E.+S.+Bj%C3%B6rnsson&title=Drug-Induced+Cholestasis&doi=10.1002%2Fhep4.1088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced cholestasis</span></div><div class="casAuthors">Sundaram Vinay; Bjornsson Einar S; Bjornsson Einar S</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">726-735</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cholestatic drug-induced liver injury (DILI) can be a diagnostic challenge due to a large differential diagnosis, variability in clinical presentation, and lack of serologic biomarkers associated with this condition.  The clinical presentation of drug-induced cholestasis includes bland cholestasis, cholestatic hepatitis, secondary sclerosing cholangitis, and vanishing bile duct syndrome.  The associate mortality of cholestatic DILI can be as high as 10%, and thus prompt recognition and removal of the offending agent is of critical importance.  Several risk factors have been identified for drug-induced cholestasis, including older age, genetic determinants, and properties of certain medications.  Antibiotics, particularly amoxicillin/clavulanate, remain the predominant cause of cholestatic DILI, although a variety of other medications associated with this condition have been identified.  In this review, we summarize the presentation, clinical approach, risk factors, implicated medications, and management of drug-induced cholestatic liver injury. (Hepatology Communications 2017;1:726-735).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRmYTpNzQyiyyjiVMCqkKxVfW6udTcc2eZnNQbetMlhorntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvnslCntA%253D%253D&md5=8f71169b72194615d27fc38caa5d9d63</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fhep4.1088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep4.1088%26sid%3Dliteratum%253Aachs%26aulast%3DSundaram%26aufirst%3DV.%26aulast%3DBj%25C3%25B6rnsson%26aufirst%3DE.%2BS.%26atitle%3DDrug-Induced%2520Cholestasis%26jtitle%3DHepatology%2520Communications%26date%3D2017%26volume%3D1%26spage%3D726%26epage%3D735%26doi%3D10.1002%2Fhep4.1088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, K. V.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Hematologic Disorders</span>. In  <i>Pharmacotherapy: A Pathophysiologic Approach [Online]</i>, <span class="NLM_contrib-group"><span class="NLM_string-name">DiPiro, J. T.</span>, <span class="NLM_string-name">Talbert, R. L.</span>, <span class="NLM_string-name">Yee, G. C.</span>, <span class="NLM_string-name">Matzke, G. R.</span>, <span class="NLM_string-name">Wells, B. G.</span>, <span class="NLM_string-name">Posey, L. M.</span></span>, Eds; <span class="NLM_publisher-name">The McGraw-Hill Companies</span>: <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">2014</span>; <a href="http://accesspharmacy.mhmedical.com/content.aspx?bookid=689&amp;sectionid=48811451" class="extLink">http://accesspharmacy.mhmedical.com/content.aspx?bookid=689&sectionid=48811451</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=K.+V.+Raoauthor=J.+T.+DiPiro&author=R.+L.+Talbert&author=G.+C.+Yee&author=G.+R.+Matzke&author=B.+G.+Wells&author=L.+M.+Posey&title=Pharmacotherapy%3A+A+Pathophysiologic+Approach+%5BOnline%5D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DK.%2BV.%26atitle%3DDrug-Induced%2520Hematologic%2520Disorders%26btitle%3DPharmacotherapy%253A%2520A%2520Pathophysiologic%2520Approach%2520%255BOnline%255D%26aulast%3DDiPiro%26aufirst%3DJ.%2BT.%26pub%3DThe%2520McGraw-Hill%2520Companies%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, N. J.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Autoimmunity</span>. <i>Best Practice & Research Clinical Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">688</span>, <span class="refDoi"> DOI: 10.1016/j.berh.2004.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.berh.2004.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=15454126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvVyrt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=677-688&author=N.+J.+Olsen&title=Drug-Induced+Autoimmunity&doi=10.1016%2Fj.berh.2004.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced autoimmunity</span></div><div class="casAuthors">Olsen, Nancy J.</div><div class="citationInfo"><span class="NLM_cas:title">Best Practice & Research, Clinical Rheumatology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">677-688</span>CODEN:
                <span class="NLM_cas:coden">BPRCC7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Drug induced autoimmune syndromes have been recognized for many years.  The classical presentation is that of drug-induced lupus, a generally milder version of the idiopathic disorder that is assocd. with prodn. of antihistone antibodies.  This pattern is now changing, in part due to the many new drugs that have been introduced into clin. practice for treatment of autoimmune diseases, including both conventional pharmaceuticals and biologicals.  The no. and complexity of drug-induced autoimmune syndromes has increased, and many are now assocd. with autoantibodies that have been classically defined as limited to idiopathic disease states.  Furthermore, some of these drug-induced syndromes have life-threatening complications, so that recognition of drug-induced disease has become more difficult at a time when it is more urgent to establish a correct diagnosis.  Many reports are limited to case descriptions, and few controlled investigations have been carried out.  Nevertheless, it is possible to derive an approach to considering possible mechanisms by which these processes may take place.  This chapter will consider these proposed mechanisms, using some of the implicated drugs to illustrate possible pathogenetic pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC9NIY-PLgeLVg90H21EOLACvtfcHk0liR0t66_wTrvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvVyrt7o%253D&md5=0acc4f7ceb3a1ced935de6f0eb6b44ca</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.berh.2004.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.berh.2004.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DOlsen%26aufirst%3DN.%2BJ.%26atitle%3DDrug-Induced%2520Autoimmunity%26jtitle%3DBest%2520Practice%2520%2526%2520Research%2520Clinical%2520Rheumatology%26date%3D2004%26volume%3D18%26spage%3D677%26epage%3D688%26doi%3D10.1016%2Fj.berh.2004.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Liver Injury: Advances in Mechanistic Understanding that will Inform Risk Management</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1002/cpt.564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fcpt.564" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27861792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC2snnvVKktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2017&pages=469-480&author=M.+Mosedaleauthor=P.+B.+Watkins&title=Drug-Induced+Liver+Injury%3A+Advances+in+Mechanistic+Understanding+that+will+Inform+Risk+Management&doi=10.1002%2Fcpt.564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management</span></div><div class="casAuthors">Mosedale M; Watkins P B</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">469-480</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug-induced liver injury (DILI) is a major public health problem.  Intrinsic (dose-dependent) DILI associated with acetaminophen overdose is the number one cause of acute liver failure in the US.  However, the most problematic type of DILI impacting drug development is idiosyncratic, occurring only very rarely among treated patients and often only after several weeks or months of treatment with the offending drug.  Recent advances in our understanding of the pathogenesis of DILI suggest that three mechanisms may underlie most hepatocyte effects in response to both intrinsic and idiosyncratic DILI drugs: mitochondrial dysfunction, oxidative stress, and alterations in bile acid homeostasis.  However, in some cases hepatocyte stress promotes an immune response that results in clinically important idiosyncratic DILI.  This review discusses recent advances in our understanding of the pathogenesis of both intrinsic and idiosyncratic DILI as well as emerging tools and techniques that will likely improve DILI risk identification and management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR25FSIZrIShTDnmmyUf5qOfW6udTcc2ebVY9P_xKp6M7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snnvVKktw%253D%253D&md5=e1a7d722b411b70d71cd539caf3c74f4</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fcpt.564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.564%26sid%3Dliteratum%253Aachs%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DDrug-Induced%2520Liver%2520Injury%253A%2520Advances%2520in%2520Mechanistic%2520Understanding%2520that%2520will%2520Inform%2520Risk%2520Management%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2017%26volume%3D101%26spage%3D469%26epage%3D480%26doi%3D10.1002%2Fcpt.564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplowitz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alpers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blais, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smotzer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwiec, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, C.</span></span> <span> </span><span class="NLM_article-title">Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1103</span>– <span class="NLM_lpage">1113</span>, <span class="refDoi"> DOI: 10.1007/s40264-015-0327-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs40264-015-0327-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26188764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1WqtrnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2015&pages=1103-1113&author=P.+Watkinsauthor=J.+Lewisauthor=N.+Kaplowitzauthor=D.+Alpersauthor=J.+Blaisauthor=D.+Smotzerauthor=H.+Krasaauthor=J.+Ouyangauthor=V.+Torresauthor=F.+Czerwiecauthor=C.+Zimmer&title=Clinical+Pattern+of+Tolvaptan-Associated+Liver+Injury+in+Subjects+with+Autosomal+Dominant+Polycystic+Kidney+Disease%3A+Analysis+of+Clinical+Trials+Database&doi=10.1007%2Fs40264-015-0327-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database</span></div><div class="casAuthors">Watkins, Paul B.; Lewis, James H.; Kaplowitz, Neil; Alpers, David H.; Blais, Jaime D.; Smotzer, Dan M.; Krasa, Holly; Ouyang, John; Torres, Vicente E.; Czerwiec, Frank S.; Zimmer, Christopher A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1103-1113</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Introduction: Subjects with autosomal dominant polycystic kidney disease (ADPKD) who were taking tolvaptan experienced aminotransferase elevations more frequently than those on placebo in the TEMPO 3:4 (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) clin. trial.  Methods: An independent, blinded, expert Hepatic Adjudication Committee re-examd. data from TEMPO 3:4 and its open-label extension TEMPO 4:4, as well as from long-term (>14 mo) non-ADPKD tolvaptan trials, using the 5-point Drug-Induced Liver Injury Network classification.  Results: In TEMPO 3:4, 1445 subjects were randomized 2:1 (tolvaptan vs. placebo) and 1441 had post-baseline assessments of hepatic injury.  Sixteen patients on tolvaptan and one on placebo had significant aminotransferase elevations judged to be at least probably related to study drug.  No assocn. with dose or systemic exposure was found.  Two of 957 subjects taking tolvaptan (0.2 %) and zero of 484 taking placebo met the definition of a Hy's Law case.  One addnl. Hy's Law case was identified in a TEMPO 4:4 subject who had received placebo in the lead study.  The onset of a hepatocellular injury occurred between 3 and 18 mo after starting tolvaptan, with gradual resoln. over the subsequent 1-4 mo.  None of the events were assocd. with liver failure or chronic liver injury/dysfunction.  No imbalance in hepatic events was obsd. between tolvaptan and placebo in lower-dose clin. trials of patients with hyponatremia, heart failure, or cirrhosis.  Conclusions: Although hepatocellular injury following long-term tolvaptan treatment in ADPKD subjects was infrequent and reversible, the potential for serious irreversible injury exists.  Regular monitoring of transaminase levels is warranted in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR0To30kwUDLVg90H21EOLACvtfcHk0liMlqFABWphlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1WqtrnM&md5=25e79ef6354010591b01ef150ad069af</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs40264-015-0327-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40264-015-0327-3%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DP.%26aulast%3DLewis%26aufirst%3DJ.%26aulast%3DKaplowitz%26aufirst%3DN.%26aulast%3DAlpers%26aufirst%3DD.%26aulast%3DBlais%26aufirst%3DJ.%26aulast%3DSmotzer%26aufirst%3DD.%26aulast%3DKrasa%26aufirst%3DH.%26aulast%3DOuyang%26aufirst%3DJ.%26aulast%3DTorres%26aufirst%3DV.%26aulast%3DCzerwiec%26aufirst%3DF.%26aulast%3DZimmer%26aufirst%3DC.%26atitle%3DClinical%2520Pattern%2520of%2520Tolvaptan-Associated%2520Liver%2520Injury%2520in%2520Subjects%2520with%2520Autosomal%2520Dominant%2520Polycystic%2520Kidney%2520Disease%253A%2520Analysis%2520of%2520Clinical%2520Trials%2520Database%26jtitle%3DDrug%2520Saf.%26date%3D2015%26volume%3D38%26spage%3D1103%26epage%3D1113%26doi%3D10.1007%2Fs40264-015-0327-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guest, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokoluk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacCrimmon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">Examination of Possible Toxic and Immune Mechanisms of Clozapine-Induced Agranulocytosis</span>. <i>Toxicology</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1016/S0300-483X(98)00110-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2FS0300-483X%2898%2900110-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=9881934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADyaK1MXjs1artA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=1998&pages=53-65&author=I.+Guestauthor=B.+Sokolukauthor=J.+MacCrimmonauthor=J.+Uetrecht&title=Examination+of+Possible+Toxic+and+Immune+Mechanisms+of+Clozapine-Induced+Agranulocytosis&doi=10.1016%2FS0300-483X%2898%2900110-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis</span></div><div class="casAuthors">Guest, I.; Sokoluk, B.; MacCrimmon, J.; Uetrecht, J.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-65</span>CODEN:
                <span class="NLM_cas:coden">TXCYAC</span>;
        ISSN:<span class="NLM_cas:issn">0300-483X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">Three patients who developed agranulocytosis and 7 patients who demonstrated neutropenia during therapy with clozapine were investigated, as well as 5 patients who were asymptomatic while on clozapine.  One of the 3 agranulocytic patients had previously developed severe neutropenia during clozapine therapy.  Mature neutrophils were examd. to det. if these cells demonstrated increased susceptibility to clozapine or clozapine oxidn. products that had been generated chem.  Increased susceptibility was found in the cells of some patients, but this was not a consistent finding.  The effects of clozapine or its chem. generated oxidn. products were examd. on the development of hematopoietic precursor cells derived from the peripheral blood.  Clozapine oxidn. products, but not clozapine, concn.-dependently and directly inhibited colony formation of all lineages; there was no evidence of a specific sensitivity of the myeloid precursors.  Serum from one of the 3 patients who developed agranulocytosis was inhibitory to the growth of all precursor cells at a concn. of 10% but none of the plasmas were inhibitory.  In 6 patients with neutropenia or agranulocytosis, attempts were made to isolate antigen-specific T cells, wherein the antigen was a hapten carrier complex of clozapine oxidn. products covalently bound to leukocyte macromols.  No clozapine product-specific clones to these antigens were detected.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowGuTpweE_A7Vg90H21EOLACvtfcHk0liMlqFABWphlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjs1artA%253D%253D&md5=b326874fa7b165f04af31c283cd9607e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0300-483X%2898%2900110-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0300-483X%252898%252900110-3%26sid%3Dliteratum%253Aachs%26aulast%3DGuest%26aufirst%3DI.%26aulast%3DSokoluk%26aufirst%3DB.%26aulast%3DMacCrimmon%26aufirst%3DJ.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DExamination%2520of%2520Possible%2520Toxic%2520and%2520Immune%2520Mechanisms%2520of%2520Clozapine-Induced%2520Agranulocytosis%26jtitle%3DToxicology%26date%3D1998%26volume%3D131%26spage%3D53%26epage%3D65%26doi%3D10.1016%2FS0300-483X%2898%2900110-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunk, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annan, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, C. D.</span></span> <span> </span><span class="NLM_article-title">Rechallenge with Clozapine Following Leucopenia or Neutropenia During Previous Therapy</span>. <i>Br. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1192/bjp.188.3.255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1192%2Fbjp.188.3.255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=16507968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD287itVakuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2006&pages=255-263&author=L.+R.+Dunkauthor=L.+J.+Annanauthor=C.+D.+Andrews&title=Rechallenge+with+Clozapine+Following+Leucopenia+or+Neutropenia+During+Previous+Therapy&doi=10.1192%2Fbjp.188.3.255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Rechallenge with clozapine following leucopenia or neutropenia during previous therapy</span></div><div class="casAuthors">Dunk Louisa R; Annan Linda J; Andrews Christopher D</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of psychiatry : the journal of mental science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">255-63</span>
        ISSN:<span class="NLM_cas:issn">0007-1250</span>.
    </div><div class="casAbstract">BACKGROUND:  Further treatment with clozapine is contraindicated in any patient who has previously experienced leucopenia or neutropenia during clozapine therapy.  AIMS:  To investigate the results of such a rechallenge in 53 patients.  METHOD:  An analysis was made of the demographic, haematological and outcome data of patients in the UK and Ireland who were rechallenged with clozapine following leucopenia or neutropenia during previous clozapine therapy.  RESULTS:  Of 53 patients who were rechallenged, 20 (38%) experienced a further blood dyscrasia.  In 17 of these 20 patients (85%) the second blood dyscrasia was more severe (P<0.001), in 12 (60%) it lasted longer (P=0.0368) and in 17 (85%) it occurred more quickly on rechallenge (P<0.001).  Of the original 53 patients, 55% (29 patients) are still receiving clozapine.  CONCLUSIONS:  No clear risk factor for repeat blood dyscrasias was identified.  Despite this, after risks and benefits have been considered, rechallenge may well be justified in some patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSK6av-76959X6HPRus0rAafW6udTcc2eZv3tloDNxLWrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287itVakuw%253D%253D&md5=1cada1ab10ce36f544a870ecb9bd24d4</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1192%2Fbjp.188.3.255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1192%252Fbjp.188.3.255%26sid%3Dliteratum%253Aachs%26aulast%3DDunk%26aufirst%3DL.%2BR.%26aulast%3DAnnan%26aufirst%3DL.%2BJ.%26aulast%3DAndrews%26aufirst%3DC.%2BD.%26atitle%3DRechallenge%2520with%2520Clozapine%2520Following%2520Leucopenia%2520or%2520Neutropenia%2520During%2520Previous%2520Therapy%26jtitle%3DBr.%2520J.%2520Psychiatry%26date%3D2006%26volume%3D188%26spage%3D255%26epage%3D263%26doi%3D10.1192%2Fbjp.188.3.255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senior, J. R.</span></span> <span> </span><span class="NLM_article-title">Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1007/s40264-014-0182-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs40264-014-0182-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24190573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFWhurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2014&pages=9-17&author=J.+R.+Senior&title=Evolution+of+the+Food+and+Drug+Administration+Approach+to+Liver+Safety+Assessment+for+New+Drugs%3A+Current+Status+and+Challenges&doi=10.1007%2Fs40264-014-0182-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges</span></div><div class="casAuthors">Senior, John R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">S1</span>),
    <span class="NLM_cas:pages">9-17</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Prompted by approval in 1997 of troglitazone and bromfenac, two drugs that promptly began to show serious and sometimes fatal liver toxicity, we began at the Food and Drug Administration (FDA) a series of annual conferences in 1999 to consider issues of drug-induced liver injury (DILI).  First inviting reviewers of new drug applications we opened the audiences in 2001 to pharmaceutical industry and academic consultants to industry and FDA, and slides shown at the meetings were posted on the internet to be available at the website of the American Assocn. for the Study of Liver Diseases (AASLD)-go to (http://www.aasld.org/dili/Pages/default.aspx).  Observations by Dr. Hyman J. Zimmerman that "drug-induced hepatocellular jaundice is a serious lesion" with possible mortality formed a basis for developing a computer program to plot peak serum values for alanine aminotransferase (ALT) and total bilirubin (TBL) in an x-y log-log graph for all subjects enrolled in clin. trials.  This program had the capability to show the time course of all liver tests for individuals who had both hepatocellular injury and reduced whole liver function, plus clin. narratives to diagnose the severity and most likely cause of the abnormalities.  We called the program eDISH (for evaluation of Drug-Induced Serious Hepatotoxicity), and began in 2004 to use it to assess DILI in clin. trial subjects.  From 2008, comments made by the presenters at the conferences about their slides and ensuing discussions have been added to the website.  All this has raised awareness of the problem, and since 1997, the FDA has not had to withdraw a single drug because of post-marketing hepatotoxicity.  Many issues still remain to be resolved; among the most controversial is the best method to est. likelihood that a given liver injury was actually caused by the drug in question.  On Nov. 9, 2012, a workshop was convened to discuss the best practices for the assessment of drug-induced liver injury (DILI) in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj6ysSzll7_7Vg90H21EOLACvtfcHk0lh9LscZ3-NgYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFWhurfN&md5=6d7cb5602cdead46918aaa30be6e7aa9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs40264-014-0182-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40264-014-0182-7%26sid%3Dliteratum%253Aachs%26aulast%3DSenior%26aufirst%3DJ.%2BR.%26atitle%3DEvolution%2520of%2520the%2520Food%2520and%2520Drug%2520Administration%2520Approach%2520to%2520Liver%2520Safety%2520Assessment%2520for%2520New%2520Drugs%253A%2520Current%2520Status%2520and%2520Challenges%26jtitle%3DDrug%2520Saf.%26date%3D2014%26volume%3D37%26spage%3D9%26epage%3D17%26doi%3D10.1007%2Fs40264-014-0182-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrill, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fier, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaddy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoine, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishimoto, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisetsky, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">The Effects of Heparins on the Liver: Application of Mechanistic Serum Biomarkers in a Randomized Study in Healthy Volunteers</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1038/clpt.2012.40</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fclpt.2012.40" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22739141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOmt77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=214-220&author=A.+H.+Harrillauthor=J.+Roachauthor=I.+Fierauthor=J.+S.+Eaddyauthor=C.+L.+Kurtzauthor=D.+J.+Antoineauthor=D.+M.+Spencerauthor=T.+K.+Kishimotoauthor=D.+S.+Pisetskyauthor=B.+K.+Parkauthor=P.+B.+Watkins&title=The+Effects+of+Heparins+on+the+Liver%3A+Application+of+Mechanistic+Serum+Biomarkers+in+a+Randomized+Study+in+Healthy+Volunteers&doi=10.1038%2Fclpt.2012.40"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The Effects of Heparins on the Liver: Application of Mechanistic Serum Biomarkers in a Randomized Study in Healthy Volunteers</span></div><div class="casAuthors">Harrill, A. H.; Roach, J.; Fier, I.; Eaddy, J. S.; Kurtz, C. L.; Antoine, D. J.; Spencer, D. M.; Kishimoto, T. K.; Pisetsky, D. S.; Park, B. K.; Watkins, P. B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">214-220</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Heparins have been reported to cause elevations in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) but have not been assocd. with clin. significant liver injury.  The mechanisms underlying these benign lab. abnormalities are unknown.  Forty-eight healthy men were randomized to receive s.c. injections of unfractionated heparin (UFH; 150 U/kg), enoxaparin sodium (1 mg/kg), dalteparin sodium (120 IU/kg), or adomiparin sodium (125 IU/kg; a novel heparin) every 12 h for 4.5 days.  Asymptomatic elevations in serum ALT or AST were obsd. in >90% of the subjects.  Elevations were also obsd. in the levels of serum sorbitol dehydrogenase (SDH), glutamate dehydrogenase (GLDH), miR-122, high-mobility group box-1 protein (including the acetylated form), full-length keratin 18, and DNA.  Keratin 18 fragments, which are apoptosis biomarkers, were not detected.  Biomarker profiles did not differ significantly across heparin treatments.  We conclude that heparins as a class cause self-limited and mild hepatocyte necrosis with secondary activation of an innate immune response.  Clin. Pharmacol. & Therapeutics (2012); 92 2, 214-220. doi:10.1038/clpt.2012.40.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj70owfsaO2bVg90H21EOLACvtfcHk0lh9LscZ3-NgYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOmt77N&md5=dc304ec6d6338fe7bad99414c47c8035</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2012.40&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2012.40%26sid%3Dliteratum%253Aachs%26aulast%3DHarrill%26aufirst%3DA.%2BH.%26aulast%3DRoach%26aufirst%3DJ.%26aulast%3DFier%26aufirst%3DI.%26aulast%3DEaddy%26aufirst%3DJ.%2BS.%26aulast%3DKurtz%26aufirst%3DC.%2BL.%26aulast%3DAntoine%26aufirst%3DD.%2BJ.%26aulast%3DSpencer%26aufirst%3DD.%2BM.%26aulast%3DKishimoto%26aufirst%3DT.%2BK.%26aulast%3DPisetsky%26aufirst%3DD.%2BS.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DThe%2520Effects%2520of%2520Heparins%2520on%2520the%2520Liver%253A%2520Application%2520of%2520Mechanistic%2520Serum%2520Biomarkers%2520in%2520a%2520Randomized%2520Study%2520in%2520Healthy%2520Volunteers%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D92%26spage%3D214%26epage%3D220%26doi%3D10.1038%2Fclpt.2012.40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrill, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menguy-Vacheron, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayyosi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benzerdjeb, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Benign Elevations in Serum Aminotransferases and Biomarkers of Hepatotoxicity in Healthy Volunteers Treated with Cholestyramine</span>. <i>BMC Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">42</span>, <span class="refDoi"> DOI: 10.1186/2050-6511-15-42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1186%2F2050-6511-15-42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25086653" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVymsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=42&author=R.+Singhalauthor=A.+H.+Harrillauthor=F.+Menguy-Vacheronauthor=Z.+Jayyosiauthor=H.+Benzerdjebauthor=P.+B.+Watkins&title=Benign+Elevations+in+Serum+Aminotransferases+and+Biomarkers+of+Hepatotoxicity+in+Healthy+Volunteers+Treated+with+Cholestyramine&doi=10.1186%2F2050-6511-15-42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine</span></div><div class="casAuthors">Singhal, Rohit; Harrill, Alison H.; Menguy-Vacheron, Francoise; Jayyosi, Zaid; Benzerdjeb, Hadj; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42/1-42/7, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">BPTMAB</span>;
        ISSN:<span class="NLM_cas:issn">2050-6511</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: There are currently no serum biomarkers capable of distinguishing elevations in serum alanine aminotransferase (ALT) that portend serious liver injury potential from benign elevations such as those occurring during cholestyramine treatment.  The aim of the research was to test the hypothesis that newly proposed biomarkers of hepatotoxicity would not significantly rise in serum during elevations in serum ALT assocd. with cholestyramine treatment, which has never been assocd. with clin. relevant liver injury.  Methods: In a double-blind placebo-controlled trial, cholestyramine (8g) was administered for 11 days to healthy adult volunteers.  Serum from subjects with elevations in alanine aminotransferase (ALT) exceeding three-fold the upper limit of normal (ULN) were utilized for biomarker quantification.  Results: In 11 of 67 subjects, cholestyramine treatment resulted in ALT elevation by >3x ULN (mean 6.9 fold; range 3-28 fold).  In these 11 subjects, there was a 22.4-fold mean increase in serum levels of miR-122 relative to baseline, supporting a liver origin of the serum ALT.  Significant elevations were noted in mean levels of necrosis biomarkers sorbitol dehydrogenase (8.1 fold), cytokeratin 18 (2.1 fold) and HMGB1 (1.7 fold).  Caspase-cleaved cytokeratin 18, a biomarker of apoptosis was also significantly elevated (1.7 fold).  A rise in glutamate dehydrogenase (7.3 fold) may support mitochondrial dysfunction.  Conclusion: All toxicity biomarkers measured in this study were elevated along with ALT, confirming the liver origin and reflecting both hepatocyte necrosis and apoptosis.  Since cholestyramine treatment has no clin. liver safety concerns, we conclude that interpretation of the biomarkers studied may not be straightforward in the context of assessing liver safety of new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3WPNvNbROvLVg90H21EOLACvtfcHk0lh9LscZ3-NgYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVymsL3K&md5=476887066d141eb23b94d7309a6fca9a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1186%2F2050-6511-15-42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2050-6511-15-42%26sid%3Dliteratum%253Aachs%26aulast%3DSinghal%26aufirst%3DR.%26aulast%3DHarrill%26aufirst%3DA.%2BH.%26aulast%3DMenguy-Vacheron%26aufirst%3DF.%26aulast%3DJayyosi%26aufirst%3DZ.%26aulast%3DBenzerdjeb%26aufirst%3DH.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DBenign%2520Elevations%2520in%2520Serum%2520Aminotransferases%2520and%2520Biomarkers%2520of%2520Hepatotoxicity%2520in%2520Healthy%2520Volunteers%2520Treated%2520with%2520Cholestyramine%26jtitle%3DBMC%2520Pharmacol.%2520Toxicol.%26date%3D2014%26volume%3D15%26spage%3D42%26doi%3D10.1186%2F2050-6511-15-42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Drug Safety Sciences and the Bottleneck in Drug Development</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">788</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.1038/clpt.2011.63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fclpt.2011.63" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21593756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC3MrjtlWqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=788-790&author=P.+B.+Watkins&title=Drug+Safety+Sciences+and+the+Bottleneck+in+Drug+Development&doi=10.1038%2Fclpt.2011.63"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Drug safety sciences and the bottleneck in drug development</span></div><div class="casAuthors">Watkins P B</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">788-90</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">During a recent review of a new drug application for treatment of a chronic disease, US Food and Drug Administration (FDA) regulators agreed with the sponsor's assessment of efficacy.  However, it was noted that two subjects receiving active treatment experienced abnormal liver chemistries that possibly, but not definitely, indicated a liver safety liability.  The sponsor was told that a prerequisite for approval would be a new clinical trial involving 20,000 patients treated for 1 year, with 10,000 receiving the new drug and 10,000 receiving a comparator treatment.  The sponsor is now faced with the substantial costs involved in undertaking such a large study, the loss of patent life during the conduct and analysis of the study, and the prospect of losing in-class market position.  If the drug is ultimately approved, this detour will result in costs and potential revenue loss to the sponsor of well over $1 billion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWkDdhCnw1Wrt7lRqEFUJVfW6udTcc2eb9mVfh4HjMmrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrjtlWqtw%253D%253D&md5=cfa06a5bf9b31277c106d5e99b0c9931</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2011.63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2011.63%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DDrug%2520Safety%2520Sciences%2520and%2520the%2520Bottleneck%2520in%2520Drug%2520Development%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2011%26volume%3D89%26spage%3D788%26epage%3D790%26doi%3D10.1038%2Fclpt.2011.63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Temple, R. R.</span></span> <span> </span><span class="NLM_article-title">Hy’s Law: Predicting Serious Hepatotoxicity</span>. <i>Pharmacoepidemiol. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1002/pds.1211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fpds.1211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=16552790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD287nsVCltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2006&pages=241-243&author=R.+R.+Temple&title=Hy%E2%80%99s+Law%3A+Predicting+Serious+Hepatotoxicity&doi=10.1002%2Fpds.1211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Hy's law: predicting serious hepatotoxicity</span></div><div class="casAuthors">Temple Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacoepidemiology and drug safety</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">241-3</span>
        ISSN:<span class="NLM_cas:issn">1053-8569</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmBz12ppIx2fx2phytoz6_fW6udTcc2eb9mVfh4HjMmrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287nsVCltQ%253D%253D&md5=c2f8d93ccdab933ef7f3aea6e95067fe</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fpds.1211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpds.1211%26sid%3Dliteratum%253Aachs%26aulast%3DTemple%26aufirst%3DR.%2BR.%26atitle%3DHy%25E2%2580%2599s%2520Law%253A%2520Predicting%2520Serious%2520Hepatotoxicity%26jtitle%3DPharmacoepidemiol.%2520Drug%2520Saf.%26date%3D2006%26volume%3D15%26spage%3D241%26epage%3D243%26doi%3D10.1002%2Fpds.1211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucena, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelaez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachkoria, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ruiz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Munoz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Grande, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizarro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duran, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero-Gomez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borras, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmeron, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Vivaldi, R.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-year Period</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2005.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1053%2Fj.gastro.2005.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=16083708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD2MvhvFyktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2005&pages=512-521&author=R.+J.+Andradeauthor=M.+I.+Lucenaauthor=M.+C.+Fernandezauthor=G.+Pelaezauthor=K.+Pachkoriaauthor=E.+Garcia-Ruizauthor=B.+Garcia-Munozauthor=R.+Gonzalez-Grandeauthor=A.+Pizarroauthor=J.+A.+Duranauthor=M.+Jimenezauthor=L.+Rodrigoauthor=M.+Romero-Gomezauthor=J.+M.+Navarroauthor=R.+Planasauthor=J.+Costaauthor=A.+Borrasauthor=A.+Solerauthor=J.+Salmeronauthor=R.+Martin-Vivaldi&title=Drug-Induced+Liver+Injury%3A+An+Analysis+of+461+Incidences+Submitted+to+the+Spanish+Registry+Over+a+10-year+Period&doi=10.1053%2Fj.gastro.2005.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period</span></div><div class="casAuthors">Andrade Raul J; Lucena M Isabel; Fernandez M Carmen; Pelaez Gloria; Pachkoria Ketevan; Garcia-Ruiz Elena; Garcia-Munoz Beatriz; Gonzalez-Grande Rocio; Pizarro Angeles; Duran Jose Antonio; Jimenez Manuel; Rodrigo Luis; Romero-Gomez Manuel; Navarro Jose Maria; Planas Ramon; Costa Joan; Borras Africa; Soler Aina; Salmeron Javier; Martin-Vivaldi Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">512-21</span>
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    </div><div class="casAbstract">BACKGROUND & AIMS:  Progress in the understanding of susceptibility factors to drug-induced liver injury (DILI) and outcome predictability are hampered by the lack of systematic programs to detect bona fide cases.  METHODS:  A cooperative network was created in 1994 in Spain to identify all suspicions of DILI following a prospective structured report form.  The liver damage was characterized according to hepatocellular, cholestatic, and mixed laboratory criteria and to histologic criteria when available.  Further evaluation of causality assessment was centrally performed.  RESULTS:  Since April 1994 to August 2004, 461 out of 570 submitted cases, involving 505 drugs, were deemed to be related to DILI.  The antiinfective group of drugs was the more frequently incriminated, amoxicillin-clavulanate accounting for the 12.8% of the whole series.  The hepatocellular pattern of damage was the most common (58%), was inversely correlated with age (P < .0001), and had the worst outcome (Cox regression, P < .034).  Indeed, the incidence of liver transplantation and death in this group was 11.7% if patients had jaundice at presentation, whereas the corresponding figure was 3.8% in nonjaundiced patients (P < .04).  Factors associated with the development of fulminant hepatic failure were female sex (OR = 25; 95% CI: 4.1-151; P < .0001), hepatocellular damage (OR = 7.9; 95% CI: 1.6-37; P < .009), and higher baseline plasma bilirubin value (OR = 1.15; 95% CI: 1.09-1.22; P < .0001).  CONCLUSIONS:  Patients with drug-induced hepatocellular jaundice have 11.7% chance of progressing to death or transplantation.  Amoxicillin-clavulanate stands out as the most common drug related to DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQdodEUXiJBaUh5eUSa2oe_fW6udTcc2eb9mVfh4HjMmrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MvhvFyktQ%253D%253D&md5=11589fa53b8a0aed57ac3c2ce40d9372</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2005.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2005.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3DLucena%26aufirst%3DM.%2BI.%26aulast%3DFernandez%26aufirst%3DM.%2BC.%26aulast%3DPelaez%26aufirst%3DG.%26aulast%3DPachkoria%26aufirst%3DK.%26aulast%3DGarcia-Ruiz%26aufirst%3DE.%26aulast%3DGarcia-Munoz%26aufirst%3DB.%26aulast%3DGonzalez-Grande%26aufirst%3DR.%26aulast%3DPizarro%26aufirst%3DA.%26aulast%3DDuran%26aufirst%3DJ.%2BA.%26aulast%3DJimenez%26aufirst%3DM.%26aulast%3DRodrigo%26aufirst%3DL.%26aulast%3DRomero-Gomez%26aufirst%3DM.%26aulast%3DNavarro%26aufirst%3DJ.%2BM.%26aulast%3DPlanas%26aufirst%3DR.%26aulast%3DCosta%26aufirst%3DJ.%26aulast%3DBorras%26aufirst%3DA.%26aulast%3DSoler%26aufirst%3DA.%26aulast%3DSalmeron%26aufirst%3DJ.%26aulast%3DMartin-Vivaldi%26aufirst%3DR.%26atitle%3DDrug-Induced%2520Liver%2520Injury%253A%2520An%2520Analysis%2520of%2520461%2520Incidences%2520Submitted%2520to%2520the%2520Spanish%2520Registry%2520Over%2520a%252010-year%2520Period%26jtitle%3DGastroenterology%26date%3D2005%26volume%3D129%26spage%3D512%26epage%3D521%26doi%3D10.1053%2Fj.gastro.2005.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleiner, D. E.</span></span> <span> </span><span class="NLM_article-title">Histopathological Evaluation of Drug-Induced Liver Disease</span>. In  <i>Drug-Induced Liver Disease</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplowitz, N.</span>, <span class="NLM_string-name">DeLeve, L. D.</span></span>, Eds; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Boston</span>, <span class="NLM_year">2013</span>; pp  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">263</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2FB978-0-12-387817-5.00015-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=241-263&author=D.+E.+Kleinerauthor=N.+Kaplowitz&author=L.+D.+DeLeve&title=Drug-Induced+Liver+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-387817-5.00015-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-387817-5.00015-7%26sid%3Dliteratum%253Aachs%26aulast%3DKleiner%26aufirst%3DD.%2BE.%26atitle%3DHistopathological%2520Evaluation%2520of%2520Drug-Induced%2520Liver%2520Disease%26btitle%3DDrug-Induced%2520Liver%2520Disease%26aulast%3DKaplowitz%26aufirst%3DN.%26pub%3DAcademic%2520Press%26date%3D2013%26spage%3D241%26epage%3D263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Czaja, A. J.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Autoimmune-Like Hepatitis</span>. <i>Dig. Dis. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">958</span>– <span class="NLM_lpage">976</span>, <span class="refDoi"> DOI: 10.1007/s10620-011-1611-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs10620-011-1611-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21327704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjt1Ggtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2011&pages=958-976&author=A.+J.+Czaja&title=Drug-Induced+Autoimmune-Like+Hepatitis&doi=10.1007%2Fs10620-011-1611-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Induced Autoimmune-Like Hepatitis</span></div><div class="casAuthors">Czaja, Albert J.</div><div class="citationInfo"><span class="NLM_cas:title">Digestive Diseases and Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">958-976</span>CODEN:
                <span class="NLM_cas:coden">DDSCDJ</span>;
        ISSN:<span class="NLM_cas:issn">0163-2116</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The clin. phenotype of classical autoimmune hepatitis can be mimicked by idiosyncratic drug-induced liver injury, and differentiation can be difficult.  The goals of this review are to enumerate the major agents of drug-induced autoimmune-like hepatitis, describe the clin. findings and risk factors assocd. with it, detail the clin. tools by which to assess causality, discuss putative pathogenic mechanisms, and describe treatment and outcome.  The frequency of drug-induced autoimmune-like hepatitis among patients with classical features of autoimmune hepatitis is 9%.  Minocycline and nitrofurantoin are implicated in 90% of cases.  Female predominance, acute onset, and absence of cirrhosis at presentation are important clin. manifestations.  Genetic factors affecting phase I and phase II transformations of the drug, polymorphisms that protect against cellular oxidative stress, and human leukocyte antigens that modulate the immune response may be important pathogenic components.  Clin. judgment is the mainstay of diagnosis as structured diagnostic methods for drug-induced liver injury are imperfect.  The covalent binding of a reactive drug metabolite to a hepatocyte surface protein (commonly a phase I or phase II enzyme), formation of a neoantigen, activation of CD8 T lymphocytes with nonselective antigen receptors, and deficient immune regulatory mechanisms are the main bases for a transient loss of self-tolerance.  Discontinuation of the offending drug is the essential treatment.  Spontaneous improvement usually ensues within 1 mo.  Corticosteroid therapy is warranted for symptomatic severe disease, and it is almost invariably effective.  Relapse after corticosteroid withdrawal probably does not occur, and its absence distinguishes drug-induced disease from classical autoimmune hepatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm1OZEGHbs0bVg90H21EOLACvtfcHk0ljjqz0l58OqXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjt1Ggtb0%253D&md5=346cf130bb3bdd66d956f1d8aba00eb4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs10620-011-1611-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10620-011-1611-4%26sid%3Dliteratum%253Aachs%26aulast%3DCzaja%26aufirst%3DA.%2BJ.%26atitle%3DDrug-Induced%2520Autoimmune-Like%2520Hepatitis%26jtitle%3DDig.%2520Dis.%2520Sci.%26date%3D2011%26volume%3D56%26spage%3D958%26epage%3D976%26doi%3D10.1007%2Fs10620-011-1611-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">How to Diagnose and Exclude Drug-Induced Liver Injury</span>. <i>Digestive Diseases</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">472</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1159/000374091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1159%2F000374091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FhvVerug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=472-476&author=P.+B.+Watkins&title=How+to+Diagnose+and+Exclude+Drug-Induced+Liver+Injury&doi=10.1159%2F000374091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">How to Diagnose and Exclude Drug-Induced Liver Injury</span></div><div class="casAuthors">Watkins Paul B</div><div class="citationInfo"><span class="NLM_cas:title">Digestive diseases (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">472-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The diagnosis of drug-induced liver injury (DILI) is largely a diagnosis of exclusion because, with the possible exception of protein:drug adducts in paracetamol overdose, there are no laboratory, biopsy or imaging tests that alone are capable of establishing an unequivocal diagnosis of DILI.  However, it is increasingly appreciated that drugs that cause DILI typically have characteristic clinical presentations or 'signatures' that can be very useful in the diagnosis of DILI.  Indeed, knowing a drug's DILI signature (or sometimes signatures) and the incidence rate of DILI during treatment with that drug are perhaps the most useful pieces of historical information in arriving at the diagnosis of DILI.  Components of the signature include the typical latency from the onset of treatment, whether there are extrahepatic manifestations, whether the injury is hepatocellular, cholestatic or mixed, and sometimes characteristic features on biopsy or serological testing (e.g. liver autoantibodies).  A major advance has been the establishment of the LiverTox website (http://livertox.nih.gov/) which provides open access to standardized entries for over 600 different drugs, including the characteristic clinical presentations of DILI when known.  LiverTox will also calculate the causality score for individual cases using the RUCAM instrument and case-specific data entered by the site user.  However, the problem with standard diagnostic instruments such as the RUCAM is that DILI signatures are not incorporated into the scoring system.  The person entering data must therefore subjectively weigh the RUCAM score with the characteristic DILI signature(s) of the drug to arrive at a diagnosis.  In the future, it should be possible to construct improved diagnostic instruments that objectively incorporate DILI signatures, data-based estimates of the incidence rates of DILI from each implicated drug, and perhaps genetic variants associated with the risk of DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREa92slMahjzAyhZbj3lKdfW6udTcc2eZg2kz1rI_GBLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FhvVerug%253D%253D&md5=ac12afa642c94e2343940d0be7f3a709</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1159%2F000374091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000374091%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DHow%2520to%2520Diagnose%2520and%2520Exclude%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DDigestive%2520Diseases%26date%3D2015%26volume%3D33%26spage%3D472%26epage%3D476%26doi%3D10.1159%2F000374091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tillmann, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockey, D. C.</span></span> <span> </span><span class="NLM_article-title">Novel Approaches to Causality Adjudication in Drug-Induced Liver Disease</span>. <i>Current Hepatology Reports</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">276</span>– <span class="NLM_lpage">282</span>, <span class="refDoi"> DOI: 10.1007/s11901-018-0416-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs11901-018-0416-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30766772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BB3cfjslejsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=276-282&author=H.+L.+Tillmannauthor=H.+X.+Barnhartauthor=J.+Serranoauthor=D.+C.+Rockey&title=Novel+Approaches+to+Causality+Adjudication+in+Drug-Induced+Liver+Disease&doi=10.1007%2Fs11901-018-0416-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Approaches to Causality Adjudication in Drug-Induced Liver Disease</span></div><div class="casAuthors">Tillmann Hans L; Barnhart Huiman X; Serrano Jose; Rockey Don C</div><div class="citationInfo"><span class="NLM_cas:title">Current hepatology reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">276-282</span>
        ISSN:<span class="NLM_cas:issn">2195-9595</span>.
    </div><div class="casAbstract">Purpose of Review:  Drug induced liver injury (DILI) is a complex diagnosis dominantly based of exclusion.  Recent Findings:  Currently available causality assessment instruments are considered to be suboptimal.  Expert opinion appears to be best method to adjudicate causality, but is impractical to implement on a wide scale basis.  Thus, new approaches are needed, for example improving the specificity of current scoring systems.  A further option would be to develop a system that utilizes computer-based scoring - which would reduce human error.  Additionally, it would be ideal to have available drug specific scoring systems, based on drugs' characteristic "phenotypes" (presentation and pattern of injury).  Eventually, a validated system could be integrated within the electronic health information system.  Summary:  This review highlights an avenue to an improved Causality Assessment Tool.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRNezzR2Kp6CsKL0FlyGHDofW6udTcc2eZg2kz1rI_GBLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfjslejsw%253D%253D&md5=2e005370d0d5633d351e69c5874d9137</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2Fs11901-018-0416-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11901-018-0416-8%26sid%3Dliteratum%253Aachs%26aulast%3DTillmann%26aufirst%3DH.%2BL.%26aulast%3DBarnhart%26aufirst%3DH.%2BX.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DRockey%26aufirst%3DD.%2BC.%26atitle%3DNovel%2520Approaches%2520to%2520Causality%2520Adjudication%2520in%2520Drug-Induced%2520Liver%2520Disease%26jtitle%3DCurrent%2520Hepatology%2520Reports%26date%3D2018%26volume%3D17%26spage%3D276%26epage%3D282%26doi%3D10.1007%2Fs11901-018-0416-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whritenour, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tartaro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Volkenburg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonkovsky, H. L.</span></span> <span> </span><span class="NLM_article-title">Development of a Modified Lymphocyte Transformation Test for Diagnosing Drug-Induced Liver Injury Associated with an Adaptive Immune Response</span>. <i>J. Immunotoxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1080/1547691X.2016.1254305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1080%2F1547691X.2016.1254305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28121193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1WksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=31-38&author=J.+Whritenourauthor=M.+Koauthor=Q.+Zongauthor=J.+Wangauthor=K.+Tartaroauthor=P.+Schneiderauthor=E.+Olsonauthor=M.+Van+Volkenburgauthor=J.+Serranoauthor=P.+Hayashiauthor=R.+Fontanaauthor=N.+Chalasaniauthor=H.+L.+Bonkovsky&title=Development+of+a+Modified+Lymphocyte+Transformation+Test+for+Diagnosing+Drug-Induced+Liver+Injury+Associated+with+an+Adaptive+Immune+Response&doi=10.1080%2F1547691X.2016.1254305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response</span></div><div class="casAuthors">Whritenour, Jessica; Ko, Mira; Zong, Qing; Wang, Jianying; Tartaro, Karrie; Schneider, Patricia; Olson, Ellen; Van Volkenburg, Maria; Serrano, Jose; Hayashi, Paul; Fontana, Robert; Chalasani, Naga; Bonkovsky, Herbert L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunotoxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-38</span>CODEN:
                <span class="NLM_cas:coden">JIOMAP</span>;
        ISSN:<span class="NLM_cas:issn">1547-691X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">In this test, peripheral blood mononuclear cells (PBMC) collected from a subject are incubated with drug(s) suspected of causing the reaction.  Cell proliferation, measured by the incorporation of [3H]-thymidine into new DNA, is considered evidence of a drug-specific immune response.  The objectives of the current studies were to: (1) develop and optimize a modified version of the LTT (mLTT) and (2) investigate the feasibility of using the mLTT for diagnosing DILI assocd. with an adaptive immune response and identifying the responsible drug.  PBMC collected from donors with a history of drug hypersensitivity reactions to specific drugs (manifested as skin rash) were used as pos. controls for assay optimization.  Following optimization, samples collected from 24 subjects enrolled in the U.  S. Drug-Induced Liver Injury Network (DILIN) were tested in the mLTT.  Using cytokine and granzyme B prodn. as the primary endpoints to demonstrate lymphocyte sensitization to a specific drug, most samples from the DILIN subjects failed to respond.  However, robust pos. mLTT responses were obsd. for two of four samples from three DILIN subjects with hepatitis due to isoniazid (INH).  We conclude that the mLTT, as performed here on frozen and thawed PBMC, is not a reliable test for diagnosing DILI caused by all drugs, but that it may be useful for confirming the role of the adaptive immune response in DILI ascribed to INH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmjypgYZ-O97Vg90H21EOLACvtfcHk0lj7QdlpU201DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1WksLk%253D&md5=7ae0eec7baadb62eaee400e3a33479c3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1080%2F1547691X.2016.1254305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1547691X.2016.1254305%26sid%3Dliteratum%253Aachs%26aulast%3DWhritenour%26aufirst%3DJ.%26aulast%3DKo%26aufirst%3DM.%26aulast%3DZong%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTartaro%26aufirst%3DK.%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DOlson%26aufirst%3DE.%26aulast%3DVan%2BVolkenburg%26aufirst%3DM.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DHayashi%26aufirst%3DP.%26aulast%3DFontana%26aufirst%3DR.%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DBonkovsky%26aufirst%3DH.%2BL.%26atitle%3DDevelopment%2520of%2520a%2520Modified%2520Lymphocyte%2520Transformation%2520Test%2520for%2520Diagnosing%2520Drug-Induced%2520Liver%2520Injury%2520Associated%2520with%2520an%2520Adaptive%2520Immune%2520Response%26jtitle%3DJ.%2520Immunotoxicol.%26date%3D2017%26volume%3D14%26spage%3D31%26epage%3D38%26doi%3D10.1080%2F1547691X.2016.1254305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benesic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragoi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchholtz, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerbes, A. L.</span></span> <span> </span><span class="NLM_article-title">Development and Validation of a Test to Identify Drugs That Cause Idiosyncratic Drug-Induced Liver Injury</span>. <i>Clin. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1488</span>– <span class="NLM_lpage">1494</span>, <span class="refDoi"> DOI: 10.1016/j.cgh.2018.04.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.cgh.2018.04.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29723689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVelsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=1488-1494&author=A.+Benesicauthor=I.+Rotterauthor=D.+Dragoiauthor=S.+Weberauthor=M.+L.+Buchholtzauthor=A.+L.+Gerbes&title=Development+and+Validation+of+a+Test+to+Identify+Drugs+That+Cause+Idiosyncratic+Drug-Induced+Liver+Injury&doi=10.1016%2Fj.cgh.2018.04.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Development and Validation of a Test to Identify Drugs That Cause Idiosyncratic Drug-Induced Liver Injury</span></div><div class="casAuthors">Benesic, Andreas; Rotter, Isabelle; Dragoi, Diana; Weber, Sabine; Buchholtz, Marie-Luise; Gerbes, Alexander L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Gastroenterology and Hepatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1488-1494.e5</span>CODEN:
                <span class="NLM_cas:coden">CGHLAW</span>;
        ISSN:<span class="NLM_cas:issn">1542-3565</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Idiosyncratic drug-induced liver injury (iDILI) is one of the most challenging diagnoses in hepatol.  It is frequently impossible to identify the agent that has caused iDILI in patients who take multiple medicines.  We developed an in vitro method to identify drugs that cause liver injury in patients, based on drug toxicity to monocyte-derived hepatocyte-like (MH) cells from patient blood samples.  We then collected data on patients who were re-exposed to drugs found to be toxic in the MH test to validate test performance.We performed a prospective study of patients referred to the University Hospital in Munich, Germany, with acute liver injury believed to be caused by medications (300 patients were enrolled in the study and we present data from 40 patients with iDILI and re-exposure to implicated drugs).  We collected data from patients on medical history, lab. test and imaging results, findings from biopsy analyses, and medications taken.  Blood samples were collected from all patients and MH cells were isolated and cultured for 10 days.  MH cells were then incubated with drugs to which each patient had been exposed, and toxicity was measured based on release of lactate dehydrogenase.  Agents found to be toxic to MH cells were considered as candidates for the cause of liver injury.  Patients were followed up for up to 6 mo after liver injury and data on drug re-exposures and subsequent liver damage within the following 3 to 24 mo were assocd. with findings from MH tests.Our test identified 10 drugs that were toxic to MH cells from 13 patients (amoxicillin/clavulanate to cells from 2 patients; diclofenac to cells from 2 patients; methylprednisolone to cells from 2 patients; and atorvastatin, metamizole, pembrolizumab, piperacillin/tazobactam, moxifloxacin, duloxetine, or sertraline each to cells from 1 patient).  Thirteen patients had a recurrence of liver injury after inadvertent re-exposure to a single drug, and the MH test correctly identified 12 of the 13 drugs that caused these liver re-injury events.  All 86 drugs that were not toxic to MH cells in our assay were safely resumed by patients and were not assocd. with liver re-injury in 27 patients.  Therefore, the MH test identifies drugs that cause liver injury with 92.3% sensitivity and 100% specificity (1 false-neg. and 12 true-pos. results).We developed a test to identify drugs that cause liver injury in patients based on their toxicity to MH cells isolated from patients with DILI.  We validated results from the assay and found it to identify drugs that cause DILI with 92.3% sensitivity and 100% specificity.  The MH cell test could be a tool to identify causes of iDILI, even in patients taking multiple medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTpp8A27bGm7Vg90H21EOLACvtfcHk0lj7QdlpU201DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVelsLw%253D&md5=0da2f11bd70b211b4158bcd934df55d8</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.cgh.2018.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cgh.2018.04.049%26sid%3Dliteratum%253Aachs%26aulast%3DBenesic%26aufirst%3DA.%26aulast%3DRotter%26aufirst%3DI.%26aulast%3DDragoi%26aufirst%3DD.%26aulast%3DWeber%26aufirst%3DS.%26aulast%3DBuchholtz%26aufirst%3DM.%2BL.%26aulast%3DGerbes%26aufirst%3DA.%2BL.%26atitle%3DDevelopment%2520and%2520Validation%2520of%2520a%2520Test%2520to%2520Identify%2520Drugs%2520That%2520Cause%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DClin.%2520Gastroenterol.%2520Hepatol.%26date%3D2018%26volume%3D16%26spage%3D1488%26epage%3D1494%26doi%3D10.1016%2Fj.cgh.2018.04.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonkovsky, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span> <span> </span><span class="NLM_article-title">ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury</span>. <i>Am. J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">950</span>– <span class="NLM_lpage">966</span>, <span class="refDoi"> DOI: 10.1038/ajg.2014.131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fajg.2014.131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24935270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC2cfivFarug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2014&pages=950-966&author=N.+P.+Chalasaniauthor=P.+H.+Hayashiauthor=H.+L.+Bonkovskyauthor=V.+J.+Navarroauthor=W.+M.+Leeauthor=R.+J.+Fontana&title=ACG+Clinical+Guideline%3A+The+Diagnosis+and+Management+of+Idiosyncratic+Drug-Induced+Liver+Injury&doi=10.1038%2Fajg.2014.131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury</span></div><div class="casAuthors">Chalasani Naga P; Hayashi Paul H; Bonkovsky Herbert L; Navarro Victor J; Lee William M; Fontana Robert J</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">950-66; quiz 967</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Idiosyncratic drug-induced liver injury (DILI) is a rare adverse drug reaction and it can lead to jaundice, liver failure, or even death.  Antimicrobials and herbal and dietary supplements are among the most common therapeutic classes to cause DILI in the Western world.  DILI is a diagnosis of exclusion and thus careful history taking and thorough work-up for competing etiologies are essential for its timely diagnosis.  In this ACG Clinical Guideline, the authors present an evidence-based approach to diagnosis and management of DILI with special emphasis on DILI due to herbal and dietary supplements and DILI occurring in individuals with underlying liver disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqpcTQqrOghUewzGPswiWOfW6udTcc2eZZTJhcvEkPPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfivFarug%253D%253D&md5=1f44c3ef81598631d299a029efb2756c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fajg.2014.131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fajg.2014.131%26sid%3Dliteratum%253Aachs%26aulast%3DChalasani%26aufirst%3DN.%2BP.%26aulast%3DHayashi%26aufirst%3DP.%2BH.%26aulast%3DBonkovsky%26aufirst%3DH.%2BL.%26aulast%3DNavarro%26aufirst%3DV.%2BJ.%26aulast%3DLee%26aufirst%3DW.%2BM.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26atitle%3DACG%2520Clinical%2520Guideline%253A%2520The%2520Diagnosis%2520and%2520Management%2520of%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DAm.%2520J.%2520Gastroenterol.%26date%3D2014%26volume%3D109%26spage%3D950%26epage%3D966%26doi%3D10.1038%2Fajg.2014.131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, C.</span></span> <span> </span><span class="NLM_article-title">Exosomes Derived from Human Menstrual Blood-Derived Stem Cells Alleviate Fulminant Hepatic Failure</span>. <i>Stem Cell Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">9</span>, <span class="refDoi"> DOI: 10.1186/s13287-016-0453-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1186%2Fs13287-016-0453-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28115012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVahtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=9&author=L.+Chenauthor=B.+Xiangauthor=X.+Wangauthor=C.+Xiang&title=Exosomes+Derived+from+Human+Menstrual+Blood-Derived+Stem+Cells+Alleviate+Fulminant+Hepatic+Failure&doi=10.1186%2Fs13287-016-0453-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Exosomes derived from human menstrual blood-derived stem cells alleviate fulminant hepatic failure</span></div><div class="casAuthors">Chen, Lu; Xiang, Bingyu; Wang, Xiaojun; Xiang, Charlie</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cell Research & Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9/1-9/15</span>CODEN:
                <span class="NLM_cas:coden">SCRTEK</span>;
        ISSN:<span class="NLM_cas:issn">1757-6512</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Human menstrual blood-derived stem cells (MenSCs) are a novel source of MSCs that provide the advantage of being easy to collect and isolate.  Exosomes contain some mRNAs and adhesion mols. that can potentially impact cellular and animal physiol.  This study aimed to investigate the therapeutic potential of MenSC-derived exosomes (MenSC-Ex) on AML12 cells (in vitro) and D-GalN/LPS-induced FHF mice (in vivo).  Methods: Transmission electron microscopy and Western blot were used to identify MenSC-Ex.  Antibody array was used to examine cytokine levels on MenSC-Ex.  MenSC-Ex were treated in D-GalN/LPS-induced AML12 in vitro.  Cell proliferation and apoptosis were measured.  MenSC-Ex were injected into the tail veins of mice 24 h before treatment with D-GalN/LPS.  Blood and liver tissues served as physiol. and biochem. indexes.  The no. of liver mononuclear cells (MNCs) and the amt. of the active apoptotic protein caspase-3 were detd. to elaborate the mechanism of hepatoprotective activity.  Results: Human menstrual blood-derived stem cell-derived exosomes (MenSC-Ex) are bi-lipid membrane vesicles that have a round, ball-like shape with a diam. of approx. 30-100 nm.  Cytokine arrays have shown that MenSC-Ex expressed cytokines, including ICAM-1, angiopoietin-2, Axl, angiogenin, IGFBP-6, osteoprotegerin, IL-6, and IL-8.  MenSC-Ex markedly improved liver function, enhanced survival rates, and inhibited liver cell apoptosis at 6 h after transplantation.  MenSC-Ex migrated to sites of injury and to AML12 cells (a mouse hepatocyte cell line), resp.  Moreover, MenSC-Ex reduced the no. of liver mononuclear cells (MNCs) and the amt. of the active apoptotic protein caspase-3 in injured livers.  Conclusions: In conclusion, our results provide preliminary evidence for the anti-apoptotic capacity of MenSC-Ex in FHF and suggest that MenSC-Ex may be an alternative therapeutic approach to treat FHF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9kJmxHJd9-LVg90H21EOLACvtfcHk0liIwZGtfV-6yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVahtrc%253D&md5=e23837efa46a114ce1ed8560a4ed897a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1186%2Fs13287-016-0453-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13287-016-0453-6%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DXiang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXiang%26aufirst%3DC.%26atitle%3DExosomes%2520Derived%2520from%2520Human%2520Menstrual%2520Blood-Derived%2520Stem%2520Cells%2520Alleviate%2520Fulminant%2520Hepatic%2520Failure%26jtitle%3DStem%2520Cell%2520Res.%2520Ther.%26date%3D2017%26volume%3D8%26spage%3D9%26doi%3D10.1186%2Fs13287-016-0453-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Q.</span></span> <span> </span><span class="NLM_article-title">Extracellular Vesicles Secreted by Human Adipose-derived Stem Cells (hASCs) Improve Survival Rate of Rats with Acute Liver Failure by Releasing lncRNA H19</span>. <i>EBioMedicine</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1016/j.ebiom.2018.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.ebiom.2018.07.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30077720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ltFWltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2018&pages=231-242&author=Y.+Jinauthor=J.+Wangauthor=H.+Liauthor=S.+Gaoauthor=R.+Shiauthor=D.+Yangauthor=X.+Wangauthor=X.+Wangauthor=L.+Zhuauthor=X.+Wangauthor=C.+Chenauthor=K.+Ningauthor=Z.+Gaoauthor=J.+Xuauthor=Q.+Fu&title=Extracellular+Vesicles+Secreted+by+Human+Adipose-derived+Stem+Cells+%28hASCs%29+Improve+Survival+Rate+of+Rats+with+Acute+Liver+Failure+by+Releasing+lncRNA+H19&doi=10.1016%2Fj.ebiom.2018.07.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular Vesicles Secreted by Human Adipose-derived Stem Cells (hASCs) Improve Survival Rate of Rats with Acute Liver Failure by Releasing lncRNA H19</span></div><div class="casAuthors">Jin Yinpeng; Fu Qingchun; Wang Junyi; Li Hongchao; Wang Xiaojin; Chen Chengwei; Gao Shane; Yang Danjing; Zhu Liang; Shi Rongfeng; Wang Xianli; Wang Xi; Ning Ke; Gao Zhengliang; Xu Jun</div><div class="citationInfo"><span class="NLM_cas:title">EBioMedicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">231-242</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">It has previously been reported that human adipose-derived stem cells (hASCs) can promote the regeneration of damaged tissues in rats with liver failure through a 'paracrine effect'.  Here we demonstrate a therapeutic effect of hASCs derived Extracellular Vesicles (EVs) on rat models with acute liver failure, as shown by the improvement of the survival rate by >70% compared to controls.  Gene sequencing of rat liver revealed an increase in human long-chain non-coding RNA (lncRNA) H19 after hASC-derived EVs transplantation.  When the H19 coding sequence was silenced in hASCs and EVs were then collected for treatment of rats with liver failure, we saw a decrease in the survival rate to 40%, compared to treatment with EVs generated from non-silenced hASCs.  These data indicate that lncRNA H19 may be a potential therapeutic target for the treatment of liver failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZqYsXdx6sLBLDWw4HIq2sfW6udTcc2eZAhq17hegcjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ltFWltQ%253D%253D&md5=dae51f757bf502340b05d643bad34206</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.ebiom.2018.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ebiom.2018.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DNing%26aufirst%3DK.%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DQ.%26atitle%3DExtracellular%2520Vesicles%2520Secreted%2520by%2520Human%2520Adipose-derived%2520Stem%2520Cells%2520%2528hASCs%2529%2520Improve%2520Survival%2520Rate%2520of%2520Rats%2520with%2520Acute%2520Liver%2520Failure%2520by%2520Releasing%2520lncRNA%2520H19%26jtitle%3DEBioMedicine%26date%3D2018%26volume%3D34%26spage%3D231%26epage%3D242%26doi%3D10.1016%2Fj.ebiom.2018.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Damania, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaiman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teotia, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span> <span> </span><span class="NLM_article-title">Mesenchymal Stromal Cell-Derived Exosome-Rich Fractionated Secretome Confers a Hepatoprotective Effect in Liver Injury</span>. <i>Stem Cell Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">31</span>, <span class="refDoi"> DOI: 10.1186/s13287-017-0752-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1186%2Fs13287-017-0752-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29409540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsVOnsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=31&author=A.+Damaniaauthor=D.+Jaimanauthor=A.+K.+Teotiaauthor=A.+Kumar&title=Mesenchymal+Stromal+Cell-Derived+Exosome-Rich+Fractionated+Secretome+Confers+a+Hepatoprotective+Effect+in+Liver+Injury&doi=10.1186%2Fs13287-017-0752-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Mesenchymal stromal cell-derived exosome-rich fractionated secretome confers a hepatoprotective effect in liver injury</span></div><div class="casAuthors">Damania, Apeksha; Jaiman, Deepika; Teotia, Arun Kumar; Kumar, Ashok</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cell Research & Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31</span>CODEN:
                <span class="NLM_cas:coden">SCRTEK</span>;
        ISSN:<span class="NLM_cas:issn">1757-6512</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Mesenchymal stromal cells (MSCs) are an attractive therapeutic agent in regenerative medicine.  Recently, there has been a paradigm shift from differentiation of MSCs to their paracrine effects at the injury site.  Several reports elucidate the role of trophic factors secreted by MSCs toward the repair of injured tissues.  We hypothesize that fractionating the MSC secretome will enrich exosomes contg. sol. bioactive mols., improving its therapeutic potential for liver failure.  Methods: Rat bone marrow MSCs were isolated and the conditioned media filtered, concd. and ultracentrifuged to generate fractionated secretome.  This secretome was characterized for the presence of exosomes and recovery from liver injury assessed in in-vitro liver injury models.  The results were further validated in vivo.  Results: Studies on in-vitro liver injury models using acetaminophen and hydrogen peroxide show better cell recovery and reduced cytotoxicity in the presence of fractionated as opposed to unfractionated secretome.  Further, the cells showed reduced oxidative stress in the presence of fractionated secretome, suggesting a potential antioxidative effect.  These results were further validated in vivo in liver failure models, wherein improved liver regeneration in the presence of fractionated secretome (0.819 ± 0.035) was obsd. as compared to unfractionated secretome (0.718 ± 0.042).  Conclusions: The work presented is a proof of concept that fractionating the secretome enriches certain bioactive mols. involved in the repair and recovery of injured liver tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS3PyU0drJ1rVg90H21EOLACvtfcHk0liIwZGtfV-6yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsVOnsrs%253D&md5=94fbf271520e952ac07548c1083923c1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1186%2Fs13287-017-0752-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13287-017-0752-6%26sid%3Dliteratum%253Aachs%26aulast%3DDamania%26aufirst%3DA.%26aulast%3DJaiman%26aufirst%3DD.%26aulast%3DTeotia%26aufirst%3DA.%2BK.%26aulast%3DKumar%26aufirst%3DA.%26atitle%3DMesenchymal%2520Stromal%2520Cell-Derived%2520Exosome-Rich%2520Fractionated%2520Secretome%2520Confers%2520a%2520Hepatoprotective%2520Effect%2520in%2520Liver%2520Injury%26jtitle%3DStem%2520Cell%2520Res.%2520Ther.%26date%3D2018%26volume%3D9%26spage%3D31%26doi%3D10.1186%2Fs13287-017-0752-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fiore, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzolini, G. D.</span></span> <span> </span><span class="NLM_article-title">Taking Advantage of the Potential of Mesenchymal Stromal Cells in Liver Regeneration: Cells and Extracellular Vesicles as Therapeutic Strategies</span>. <i>World Journal of Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2427</span>– <span class="NLM_lpage">2440</span>, <span class="refDoi"> DOI: 10.3748/wjg.v24.i23.2427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.3748%2Fwjg.v24.i23.2427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29930465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Cnt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=2427-2440&author=E.+J.+Fioreauthor=L.+M.+Dominguezauthor=J.+Bayoauthor=M.+G.+Garciaauthor=G.+D.+Mazzolini&title=Taking+Advantage+of+the+Potential+of+Mesenchymal+Stromal+Cells+in+Liver+Regeneration%3A+Cells+and+Extracellular+Vesicles+as+Therapeutic+Strategies&doi=10.3748%2Fwjg.v24.i23.2427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Taking advantage of the potential of mesenchymal stromal cells in liver regeneration: cells and extracellular vesicles as therapeutic strategies</span></div><div class="casAuthors">Fiore, Esteban Juan; Dominguez, Luciana Maria; Bayo, Juan; Garcia, Mariana Gabriela; Mazzolini, Guillermo Daniel</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2427-2440</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">2219-2840</span>.
    
            (<span class="NLM_cas:orgname">Baishideng Publishing Group Inc.</span>)
        </div><div class="casAbstract">Cell-based therapies for acute and chronic liver diseases are under continuous progress.  Mesenchymal stem/stromal cells (MSCs) are multipotent cells able to migrate selectively to damaged tissue and contribute to its healing and regeneration.  The MSC pro-regenerative effect occurs due to their immunomodulatory capacity and their ability to produce factors that promote cell protection and survival.  Likewise, it has been obsd. that part of their paracrine effect is mediated by MSC-derived extracellular vesicles (EVs).  EVs contain proteins, lipids and nucleic acids (DNA, mRNA, miRNA, lncRNA) from the cell of origin, allowing for intercellular communication.  Recently, different studies have demonstrated that MSC-derived EVs could reproduce, at least in part, the biol. effects obtained by MSC-based therapies.  Moreover, due to EVs' stability for long periods of time and easy isolation methods they have become a therapeutic option to MSCs treatments.  This review summarizes the latest results achieved in clin. trials using MSCs as cell therapy for liver regeneration, the role of EVs in liver physiopathol. and the potential of MSCderived EVs as intercellular mediators and therapeutic tools in liver diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1f-E7ppLEF7Vg90H21EOLACvtfcHk0liIwZGtfV-6yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Cnt78%253D&md5=d082b7a2e22108da260a4ff9e7e48017</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v24.i23.2427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v24.i23.2427%26sid%3Dliteratum%253Aachs%26aulast%3DFiore%26aufirst%3DE.%2BJ.%26aulast%3DDominguez%26aufirst%3DL.%2BM.%26aulast%3DBayo%26aufirst%3DJ.%26aulast%3DGarcia%26aufirst%3DM.%2BG.%26aulast%3DMazzolini%26aufirst%3DG.%2BD.%26atitle%3DTaking%2520Advantage%2520of%2520the%2520Potential%2520of%2520Mesenchymal%2520Stromal%2520Cells%2520in%2520Liver%2520Regeneration%253A%2520Cells%2520and%2520Extracellular%2520Vesicles%2520as%2520Therapeutic%2520Strategies%26jtitle%3DWorld%2520Journal%2520of%2520Gastroenterology%26date%3D2018%26volume%3D24%26spage%3D2427%26epage%3D2440%26doi%3D10.3748%2Fwjg.v24.i23.2427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Church, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kullak-Ublick, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubrecht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonkovsky, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goepfert, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, N. M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcinak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ormarsdottir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schomaker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuppe-Koistinen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolenski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arber, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Bommel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poynard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Candidate Biomarkers for the Diagnosis and Prognosis of Drug-Induced Liver Injury: An International Collaborative Effort</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">773</span>, <span class="refDoi"> DOI: 10.1002/hep.29802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.29802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29357190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2019&pages=760-773&author=R.+J.+Churchauthor=G.+A.+Kullak-Ublickauthor=J.+Aubrechtauthor=H.+L.+Bonkovskyauthor=N.+Chalasaniauthor=R.+J.+Fontanaauthor=J.+C.+Goepfertauthor=F.+Hackmanauthor=N.+M.+P.+Kingauthor=S.+Kirbyauthor=P.+Kirbyauthor=J.+Marcinakauthor=S.+Ormarsdottirauthor=S.+J.+Schomakerauthor=I.+Schuppe-Koistinenauthor=F.+Wolenskiauthor=N.+Arberauthor=M.+Merzauthor=J.+M.+Sauerauthor=R.+J.+Andradeauthor=F.+van+Bommelauthor=T.+Poynardauthor=P.+B.+Watkins&title=Candidate+Biomarkers+for+the+Diagnosis+and+Prognosis+of+Drug-Induced+Liver+Injury%3A+An+International+Collaborative+Effort&doi=10.1002%2Fhep.29802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort</span></div><div class="casAuthors">Church, Rachel J.; Kullak-Ublick, Gerd A.; Aubrecht, Jiri; Bonkovsky, Herbert L.; Chalasani, Naga; Fontana, Robert J.; Goepfert, Jens C.; Hackman, Frances; King, Nicholas M. P.; Kirby, Simon; Kirby, Patrick; Marcinak, John; Ormarsdottir, Sif; Schomaker, Shelli J.; Schuppe-Koistinen, Ina; Wolenski, Francis; Arber, Nadir; Merz, Michael; Sauer, John-Michael; Andrade, Raul J.; van Boemmel, Florian; Poynard, Thierry; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">760-773</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Current blood biomarkers are suboptimal in detecting drug-induced liver injury (DILI) and predicting its outcome.  We sought to characterize the natural variabilty and performance characteristics of 14 promising DILI biomarker candidates.  Serum or plasma from multiple cohorts of healthy volunteers (n = 192 and n = 81), subjects who safely took potentially hepatotoxic drugs without adverse effects (n = 55 and n = 92) and DILI patients (n = 98, n = 28, and n = 143) were assayed for microRNA-122 (miR-122), glutamate dehydrogenase (GLDH), total cytokeratin 18 (K18), caspase cleaved K18, glutathione S-transferase α, alpha-fetoprotein, arginase-1, osteopontin (OPN), sorbitol dehydrogenase, fatty acid binding protein, cadherin-5, macrophage colony-stimulating factor receptor (MCSFR), paraoxonase 1 (normalized to prothrombin protein), and leukocyte cell-derived chemotaxin-2.  Most candidate biomarkers were significantly altered in DILI cases compared with healthy volunteers.  GLDH correlated more closely with gold std. alanine aminotransferase than miR-122, and there was a surprisingly wide inter- and intra-individual variability of miR-122 levels among healthy volunteers.  Serum K18, OPN, and MCSFR levels were most strongly assocd. with liver-related death or transplantation within 6 mo of DILI onset.  Prediction of prognosis among DILI patients using the Model for End-Stage Liver Disease was improved by incorporation of K18 and MCSFR levels.  Conclusion: GLDH appears to be more useful than miR-122 in identifying DILI patients, and K18, OPN, and MCSFR are promising candidates for prediction of prognosis during an acute DILI event.  Serial assessment of these biomarkers in large prospective studies will help further delineate their role in DILI diagnosis and management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT0gXwr0GW4rVg90H21EOLACvtfcHk0lhdK9-XTVnb7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKit7k%253D&md5=c5a84dcfbc1e0c5e7bc7d90d6b6b1a30</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fhep.29802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.29802%26sid%3Dliteratum%253Aachs%26aulast%3DChurch%26aufirst%3DR.%2BJ.%26aulast%3DKullak-Ublick%26aufirst%3DG.%2BA.%26aulast%3DAubrecht%26aufirst%3DJ.%26aulast%3DBonkovsky%26aufirst%3DH.%2BL.%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DGoepfert%26aufirst%3DJ.%2BC.%26aulast%3DHackman%26aufirst%3DF.%26aulast%3DKing%26aufirst%3DN.%2BM.%2BP.%26aulast%3DKirby%26aufirst%3DS.%26aulast%3DKirby%26aufirst%3DP.%26aulast%3DMarcinak%26aufirst%3DJ.%26aulast%3DOrmarsdottir%26aufirst%3DS.%26aulast%3DSchomaker%26aufirst%3DS.%2BJ.%26aulast%3DSchuppe-Koistinen%26aufirst%3DI.%26aulast%3DWolenski%26aufirst%3DF.%26aulast%3DArber%26aufirst%3DN.%26aulast%3DMerz%26aufirst%3DM.%26aulast%3DSauer%26aufirst%3DJ.%2BM.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3Dvan%2BBommel%26aufirst%3DF.%26aulast%3DPoynard%26aufirst%3DT.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DCandidate%2520Biomarkers%2520for%2520the%2520Diagnosis%2520and%2520Prognosis%2520of%2520Drug-Induced%2520Liver%2520Injury%253A%2520An%2520International%2520Collaborative%2520Effort%26jtitle%3DHepatology%26date%3D2019%26volume%3D69%26spage%3D760%26epage%3D773%26doi%3D10.1002%2Fhep.29802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">Immune Mechanisms of Idiosyncratic Drug-Induced Liver Injury</span>. <i>Journal of Clinical and Translational Research</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.18053/jctres.03.2017S1.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.18053%2Fjctres.03.2017S1.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30873473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFKjtbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=145-156&author=A.+Makauthor=J.+Uetrecht&title=Immune+Mechanisms+of+Idiosyncratic+Drug-Induced+Liver+Injury&doi=10.18053%2Fjctres.03.2017S1.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Immune mechanisms of idiosyncratic drug-induced liver injury</span></div><div class="casAuthors">Mak, Alastair; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical and Translational Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">Spec.Iss.1</span>),
    <span class="NLM_cas:pages">145-156</span>CODEN:
                <span class="NLM_cas:coden">JCTRGT</span>;
        ISSN:<span class="NLM_cas:issn">2424-810X</span>.
    
            (<span class="NLM_cas:orgname">Whioce Publishing Pte. Ltd.</span>)
        </div><div class="casAbstract">Idiosyncratic drug reactions (IDRs) continue to be an important issue.  Specifically, idiosyncratic drug-induced liver injury (IDILI) is the most likely IDR to lead to drug withdrawal, and it accounts for a significant portion of all cases of acute liver failure.  In addn., IDRs are unpredictable and their mechanisms are not well understood.  There is increasing clin. evidence that most IDILI is immune mediated.  Several immune mediated mechanistic hypotheses exist such as the hapten and danger hypothesis; however, they do not completely explain the idiosyn-cratic nature of these reactions.  Extensive mechanistic studies are needed to better understand these reactions; however, it is impossible to do controlled expts. in humans, and previous animal models did not properly model IDILI.  If IDILI is immune mediated and the major factor preventing liver injury in patients is immune tolerance, then a plausible method to develop an animal model of IDILI would be to impair immune tolerance.  This hypothesis has shown promise in developing valid animal models of IDILI as demonstrated by a halothane induced liver injury mouse model developed by depleting myeloid derived suppressor cells (MDSCs), as well as an amodiaquine-, isoniazid- and nevirapine-induced liver injury mouse model developed by impairing immune tolerance by blocking PD-1 and CTLA-4, two immune checkpoint inhibitors.  Further characterization and validation of these models is required; however, it is likely that they will make it possible to perform mechanistic studies that have been impossible in the past.  Relevance for patients: Idiosyncratic drug-induced liver injury can be serious leading to liver transplantation or death.  Their idiosyncratic nature makes mechanistic studies very difficult.  However, with the development of the first animal model that is similar to the liver injury that occurs in humans, it will be possible to study the mechanisms involved.  With a better mechanistic understanding it should be possible to test drug candidates and produce safer drugs.  In addn., it should be possible to design better treatments when drug-induced liver injury does occur.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJWvDxGcnjELVg90H21EOLACvtfcHk0lhdK9-XTVnb7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFKjtbvF&md5=6e7295c2d9294d0c1533025c5a18cf40</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.18053%2Fjctres.03.2017S1.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18053%252Fjctres.03.2017S1.001%26sid%3Dliteratum%253Aachs%26aulast%3DMak%26aufirst%3DA.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DImmune%2520Mechanisms%2520of%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DJournal%2520of%2520Clinical%2520and%2520Translational%2520Research%26date%3D2017%26volume%3D3%26spage%3D145%26epage%3D156%26doi%3D10.18053%2Fjctres.03.2017S1.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mennicke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawodniak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yawalkar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stickel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keogh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inderbitzin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candinas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, W. J.</span></span> <span> </span><span class="NLM_article-title">Fulminant Liver Failure After Vancomycin in a Sulfasalazine-Induced DRESS Syndrome: Fatal Recurrence After Liver Transplantation</span>. <i>Am. J. Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2197</span>– <span class="NLM_lpage">2202</span>, <span class="refDoi"> DOI: 10.1111/j.1600-6143.2009.02788.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1111%2Fj.1600-6143.2009.02788.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19706026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD1MrnvFOhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=2197-2202&author=M.+Mennickeauthor=A.+Zawodniakauthor=M.+Kellerauthor=L.+Wilkensauthor=N.+Yawalkarauthor=F.+Stickelauthor=A.+Keoghauthor=D.+Inderbitzinauthor=D.+Candinasauthor=W.+J.+Pichler&title=Fulminant+Liver+Failure+After+Vancomycin+in+a+Sulfasalazine-Induced+DRESS+Syndrome%3A+Fatal+Recurrence+After+Liver+Transplantation&doi=10.1111%2Fj.1600-6143.2009.02788.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation</span></div><div class="casAuthors">Mennicke M; Zawodniak A; Keller M; Wilkens L; Yawalkar N; Stickel F; Keogh A; Inderbitzin D; Candinas D; Pichler W J</div><div class="citationInfo"><span class="NLM_cas:title">American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2197-202</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">DRESS syndrome (drug rash with eosinophilia and systemic symptoms) is a rare drug hypersensitivity reaction with a significant mortality.  We describe a 60-year-old man with polyarthritis treated with sulfasalazine who developed DRESS and fulminant liver failure after additional vancomycin treatment.  Liver histology revealed infiltration of granzymeB+ CD3+ lymphocytes in close proximity to apoptotic hepatocytes.  After a superurgent liver transplantation and initial recovery, the patient developed recurrent generalized exanthema and eosinophilia, but only moderate hepatitis.  Histology showed infiltration of FasL+ lymphocytes and eosinophils in the transplanted liver.  Treatment with high-dose methylprednisolone was unsuccessful.  Postmortem examination revealed extensive necrosis of the liver transplant.  This case report illustrates that patients with DRESS may develop fulminant liver failure and that DRESS recurrence can recur in the transplanted liver.  Histological and immunological investigations suggest an important role of granzymeB and FasL mediated cell death in DRESS associated hepatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7_g-4lumu8u3MPKNEWB5RfW6udTcc2eZ69JJXmcLMX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrnvFOhsw%253D%253D&md5=eaa9c39e6ecc32c2e4a43342928bb7c9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-6143.2009.02788.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-6143.2009.02788.x%26sid%3Dliteratum%253Aachs%26aulast%3DMennicke%26aufirst%3DM.%26aulast%3DZawodniak%26aufirst%3DA.%26aulast%3DKeller%26aufirst%3DM.%26aulast%3DWilkens%26aufirst%3DL.%26aulast%3DYawalkar%26aufirst%3DN.%26aulast%3DStickel%26aufirst%3DF.%26aulast%3DKeogh%26aufirst%3DA.%26aulast%3DInderbitzin%26aufirst%3DD.%26aulast%3DCandinas%26aufirst%3DD.%26aulast%3DPichler%26aufirst%3DW.%2BJ.%26atitle%3DFulminant%2520Liver%2520Failure%2520After%2520Vancomycin%2520in%2520a%2520Sulfasalazine-Induced%2520DRESS%2520Syndrome%253A%2520Fatal%2520Recurrence%2520After%2520Liver%2520Transplantation%26jtitle%3DAm.%2520J.%2520Transplant.%26date%3D2009%26volume%3D9%26spage%3D2197%26epage%3D2202%26doi%3D10.1111%2Fj.1600-6143.2009.02788.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maria, V. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Victorino, R. M. M.</span></span> <span> </span><span class="NLM_article-title">Diagnostic Value of Specific T-cell Reactivity to Drugs in 95 cases of Drug-Induced Liver Injury</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.1136/gut.41.4.534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1136%2Fgut.41.4.534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=9391255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADyaK1c%252Flt1Kntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1997&pages=534-540&author=V.+A.+J.+Mariaauthor=R.+M.+M.+Victorino&title=Diagnostic+Value+of+Specific+T-cell+Reactivity+to+Drugs+in+95+cases+of+Drug-Induced+Liver+Injury&doi=10.1136%2Fgut.41.4.534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury</span></div><div class="casAuthors">Maria V A; Victorino R M</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">534-40</span>
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    </div><div class="casAbstract">BACKGROUND:  Diagnosis of drug induced liver injury is usually based on a temporal relation between drug intake and clinical picture as well as on the exclusion of alternative causes.  More precise diagnosis has been attempted by using in vitro specific T cell reactivity to drugs but the test has never reached general acceptability because of frequent negative results which could be explained, in part, by prostaglandin producing suppressor cells (PPSC).  AIM:  To analyse the diagnostic value of a modified test where lymphocyte responses to drugs are detected in the presence of a prostaglandin inhibitor.  PATIENTS:  Ninety five patients with a clinical diagnosis of drug induced liver injury, 106 healthy controls, 35 individuals with recent exposure to the same drugs without adverse effects, and 15 patients with liver disease unrelated to drugs.  METHODS:  Peripheral blood mononuclear cells (PBMC) were cultured in the presence of drugs alone and in the presence of drugs and a prostaglandin inhibitor.  Responses were assessed by 3H-thymidine incorporation in lymphocytes.  Results were expressed as counts per minute and as stimulation indexes (SI).  RESULTS:  When PBMC were stimulated with drugs alone, lymphocyte sensitisation to drugs (SI > 2) was detected in 26% of the cases.  This was noticeably increased (56%) when a prostaglandin inhibitor was added to the cultures.  No reactivity was found in controls.  In patients with possible sensitivity to several drugs, lymphocyte reactivity was detected to only one drug.  The severity of the lesions, as assessed by aminotransferase concentrations and disease duration, was lower in patients with evidence of PPSC.  CONCLUSIONS:  This new approach is useful for the diagnosis of drug induced liver injury, particularly in patients exposed to more than one drug; furthermore, the presence of putative PPSC is associated with less severe forms of drug induced hepatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRw9JTpmjfHwZVVjGoY74BafW6udTcc2eZ69JJXmcLMX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c%252Flt1Kntg%253D%253D&md5=e234d0af23bd224a8da6f3ec29f91048</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1136%2Fgut.41.4.534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgut.41.4.534%26sid%3Dliteratum%253Aachs%26aulast%3DMaria%26aufirst%3DV.%2BA.%2BJ.%26aulast%3DVictorino%26aufirst%3DR.%2BM.%2BM.%26atitle%3DDiagnostic%2520Value%2520of%2520Specific%2520T-cell%2520Reactivity%2520to%2520Drugs%2520in%252095%2520cases%2520of%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DGut%26date%3D1997%26volume%3D41%26spage%3D534%26epage%3D540%26doi%3D10.1136%2Fgut.41.4.534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Q. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Set Up Drug Lymphocyte Simtulation Test (3H-TdR) and Observe its Application in Drug-Induced Liver Injury</span>. <i>Chinese Journal of Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">190</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.3760/cma.j.issn.1007-3418.2012.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.3760%2Fcma.j.issn.1007-3418.2012.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22475137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC38nlsFWltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=190-192&author=G.+Y.+Chenauthor=C.+W.+Chenauthor=Q.+C.+Fuauthor=X.+J.+Wangauthor=L.+D.+Niauthor=X.+H.+Jiangauthor=F.+Zhouauthor=L.+Q.+Shiauthor=R.+T.+Laiauthor=J.+Yang&title=Set+Up+Drug+Lymphocyte+Simtulation+Test+%283H-TdR%29+and+Observe+its+Application+in+Drug-Induced+Liver+Injury&doi=10.3760%2Fcma.j.issn.1007-3418.2012.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Set up drug lymphocyte stimulation test (3H-TdR) and observe its application in drug-induced liver injury</span></div><div class="casAuthors">Chen Gao-yan; Chen Cheng-wei; Fu Qing-chun; Wang Xiao-jin; Ni Liu-da; Jiang Xiao-hua; Zhou Feng; Shi Li-qin; Lai Rong-tao; Yang Jun</div><div class="citationInfo"><span class="NLM_cas:title">Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">190-2</span>
        ISSN:<span class="NLM_cas:issn">1007-3418</span>.
    </div><div class="casAbstract">OBJECTIVE:  To set up the drug lymphocyte stimulation test (DLST), as a diagnosis means for DILI which was immunity idiosyncrasy, improve the Diagnosis, level of DILI.  METHOD:  For the 59 patients who diagnosed as DILI, we separated their PBMC, exploring to the suspicious drug which caused DILI, then use the methods 3H-TdR to test, according to the mixed degree to clear the PBMC count which specific activated by drug.We also set up drug group, negative control and Positive control at the same time.  Preliminary experiments was including the best dose of PHA and the best concentration of the drug.  We set up 40 healthy group in our experiments as a control, and explore them on the same drug every time.  We test the two groups at the same time.  We handled the results use t-test.  RESULTS:  The methods 3H-TdR could be exactly reflect the PBMC's proliferation degree nearly the same when they were be stimulation by PHA or the sensitive drug.  When the DILI patients were explore to the suspicious drug, their stimulation index (SI) Obviously higher than 1.8.  Form this test, there were 28 in 59 patients of DILI's group were positive (47.46%), SI was from 1.9 to 43.08, the average was 22.49, the healthy group SI was lower than 1.8, the SI of DILI's group was significantly higher than healthy group (5.78+/-0.75/1.16+/-0.25, P less than 0.05).  Our test suggested DLST has Higher specificity (94.92%) and sensitivity (47.46%).  CONCLUSION:  DLST was significance for the patients who diagnosed as immunity idiosyncrasy's DILI, it's reflected these patients' Proliferation of PBMC when explored to the suspicious drug for the second time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRx1x9qp9bAtjjk2McQZ6XmfW6udTcc2eZ69JJXmcLMX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38nlsFWltA%253D%253D&md5=8cd79be34300ee0a1c09655ace8e5c66</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.3760%2Fcma.j.issn.1007-3418.2012.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3760%252Fcma.j.issn.1007-3418.2012.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%2BY.%26aulast%3DChen%26aufirst%3DC.%2BW.%26aulast%3DFu%26aufirst%3DQ.%2BC.%26aulast%3DWang%26aufirst%3DX.%2BJ.%26aulast%3DNi%26aufirst%3DL.%2BD.%26aulast%3DJiang%26aufirst%3DX.%2BH.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DL.%2BQ.%26aulast%3DLai%26aufirst%3DR.%2BT.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DSet%2520Up%2520Drug%2520Lymphocyte%2520Simtulation%2520Test%2520%25283H-TdR%2529%2520and%2520Observe%2520its%2520Application%2520in%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DChinese%2520Journal%2520of%2520Hepatology%26date%3D2012%26volume%3D20%26spage%3D190%26epage%3D192%26doi%3D10.3760%2Fcma.j.issn.1007-3418.2012.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monshi, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulkner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earnshaw, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfirevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cederbrant, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Human Leukocyte Antigen (HLA)-B*57:01-Restricted Activation of Drug-Specific T-cells Provides the Immunological Basis for Flucloxacillin-Induced Liver Injury</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1002/hep.26077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.26077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22987284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Wgsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=727-739&author=M.+M.+Monshiauthor=L.+Faulknerauthor=A.+Gibsonauthor=R.+E.+Jenkinsauthor=J.+Farrellauthor=C.+J.+Earnshawauthor=A.+Alfirevicauthor=K.+Cederbrantauthor=A.+K.+Dalyauthor=N.+Frenchauthor=M.+Pirmohamedauthor=B.+K.+Parkauthor=D.+J.+Naisbitt&title=Human+Leukocyte+Antigen+%28HLA%29-B*57%3A01-Restricted+Activation+of+Drug-Specific+T-cells+Provides+the+Immunological+Basis+for+Flucloxacillin-Induced+Liver+Injury&doi=10.1002%2Fhep.26077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury</span></div><div class="casAuthors">Monshi, Manal M.; Faulkner, Lee; Gibson, Andrew; Jenkins, Rosalind E.; Farrell, John; Earnshaw, Caroline J.; Alfirevic, Ana; Cederbrant, Karin; Daly, Ann K.; French, Neil; Pirmohamed, Munir; Park, B. Kevin; Naisbitt, Dean J.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">727-739</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The role of the adaptive immune system in adverse drug reactions that target the liver has not been defined.  For flucloxacillin, a delay in the reaction onset and identification of human leukocyte antigen (HLA)-B*57:01 as a susceptibility factor are indicative of an immune pathogenesis.  Thus, we characterize flucloxacillin-responsive CD4+ and CD8+ T cells from patients with liver injury and show that naive CD45RA+CD8+ T cells from volunteers expressing HLA-B*57:01 are activated with flucloxacillin when dendritic cells present the drug antigen.  T-cell clones expressing CCR4 and CCR9 migrated toward CCL17 and CCL 25, and secreted interferon-gamma (IFN-γ), T helper (Th)2 cytokines, perforin, granzyme B, and FasL following drug stimulation.  Flucloxacillin bound covalently to selective lysine residues on albumin in a time-dependent manner and the level of binding correlated directly with the stimulation of clones.  Activation of CD8+ clones with flucloxacillin was processing-dependent and restricted by HLA-B*57:01 and the closely related HLA-B*58:01.  Clones displayed addnl. reactivity against β-lactam antibiotics including oxacillin, cloxacillin, and dicloxacillin, but not abacavir or nitroso sulfamethoxazole.  Conclusion: This work defines the immune basis for flucloxacillin-induced liver injury and links the genetic assocn. to the iatrogenic disease. (HEPATOl. 2013;).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3-F3d0GIwbrVg90H21EOLACvtfcHk0lgM5Gp862CcfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Wgsrw%253D&md5=6f96155f39ac26549bd2b6c64a9bad6d</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fhep.26077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26077%26sid%3Dliteratum%253Aachs%26aulast%3DMonshi%26aufirst%3DM.%2BM.%26aulast%3DFaulkner%26aufirst%3DL.%26aulast%3DGibson%26aufirst%3DA.%26aulast%3DJenkins%26aufirst%3DR.%2BE.%26aulast%3DFarrell%26aufirst%3DJ.%26aulast%3DEarnshaw%26aufirst%3DC.%2BJ.%26aulast%3DAlfirevic%26aufirst%3DA.%26aulast%3DCederbrant%26aufirst%3DK.%26aulast%3DDaly%26aufirst%3DA.%2BK.%26aulast%3DFrench%26aufirst%3DN.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DHuman%2520Leukocyte%2520Antigen%2520%2528HLA%2529-B%252A57%253A01-Restricted%2520Activation%2520of%2520Drug-Specific%2520T-cells%2520Provides%2520the%2520Immunological%2520Basis%2520for%2520Flucloxacillin-Induced%2520Liver%2520Injury%26jtitle%3DHepatology%26date%3D2013%26volume%3D57%26spage%3D727%26epage%3D739%26doi%3D10.1002%2Fhep.26077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Usui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitaker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoine, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Detection of Drug-Responsive T-Lymphocytes in a Case of Fatal Antituberculosis Drug-Related Liver Injury</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1795</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.6b00393</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.6b00393" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslyms7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=1793-1795&author=T.+Usuiauthor=P.+Whitakerauthor=X.+Mengauthor=J.+Watsonauthor=D.+J.+Antoineauthor=N.+S.+Frenchauthor=B.+K.+Parkauthor=D.+J.+Naisbitt&title=Detection+of+Drug-Responsive+T-Lymphocytes+in+a+Case+of+Fatal+Antituberculosis+Drug-Related+Liver+Injury&doi=10.1021%2Facs.chemrestox.6b00393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of Drug-Responsive T-Lymphocytes in a Case of Fatal Antituberculosis Drug-Related Liver Injury</span></div><div class="casAuthors">Usui, Toru; Whitaker, Paul; Meng, Xiaoli; Watson, John; Antoine, Daniel J.; French, Neil S.; Park, B. Kevin; Naisbitt, Dean J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1793-1795</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antituberculosis (TB) drug exposure is assocd. with a mild elevation of liver enzymes that occasionally develops into severe liver injury.  Herein, we identify ethambutol- and rifampicin-specific CD4+ and CD8+ T-cell clones in a patient with fatal anti TB-related liver injury.  The clones were activated to proliferate and secrete IFN-γ, Il-13, and granzyme B following drug treatment.  Drug-responsive T-cells may contribute to the pathogenesis of antituberculosis-related liver failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMUCjx14Dns7Vg90H21EOLACvtfcHk0lgM5Gp862CcfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslyms7fI&md5=8fca79d3da776eea74b89da16ce24be0</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.6b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.6b00393%26sid%3Dliteratum%253Aachs%26aulast%3DUsui%26aufirst%3DT.%26aulast%3DWhitaker%26aufirst%3DP.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DWatson%26aufirst%3DJ.%26aulast%3DAntoine%26aufirst%3DD.%2BJ.%26aulast%3DFrench%26aufirst%3DN.%2BS.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DDetection%2520of%2520Drug-Responsive%2520T-Lymphocytes%2520in%2520a%2520Case%2520of%2520Fatal%2520Antituberculosis%2520Drug-Related%2520Liver%2520Injury%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26spage%3D1793%26epage%3D1795%26doi%3D10.1021%2Facs.chemrestox.6b00393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span> <span> </span><span class="NLM_article-title">Pharmacogenomics of Adverse Drug Reactions</span>. <i>Genome Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">5</span>, <span class="refDoi"> DOI: 10.1186/gm409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1186%2Fgm409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23360680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1yktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=5&author=A.+K.+Daly&title=Pharmacogenomics+of+Adverse+Drug+Reactions&doi=10.1186%2Fgm409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacogenomics of adverse drug reactions</span></div><div class="casAuthors">Daly, Ann K.</div><div class="citationInfo"><span class="NLM_cas:title">Genome Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5</span>CODEN:
                <span class="NLM_cas:coden">GMEECG</span>;
        ISSN:<span class="NLM_cas:issn">1756-994X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Considerable progress has been made in identifying genetic risk factors for idiosyncratic adverse drug reactions in the past 30 years.  These reactions can affect various tissues and organs, including liver, skin, muscle and heart, in a drug-dependent manner.  Using both candidate gene and genome-wide assocn. studies, various genes that make contributions of varying extents to each of these forms of reactions have been identified.  Many of the assocns. identified for reactions affecting the liver and skin involve human leukocyte antigen (HLA) genes and for reactions relating to the drugs abacavir and carbamazepine, HLA genotyping is now in routine use prior to drug prescription.  Other HLA assocns. are not sufficiently specific for translation but are still of interest in relation to underlying mechanisms for the reactions.  Progress on non-HLA genes affecting adverse drug reactions has been less, but some important assocns., such as those of SLCO1B1 and statin myopathy, KCNE1 and drug-induced QT prolongation and NAT2 and isoniazid-induced liver injury, are considered.  Future prospects for identification of addnl. genetic risk factors for the various adverse drug reactions are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXuYo7jkxMqbVg90H21EOLACvtfcHk0lgM5Gp862CcfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1yktL4%253D&md5=aa5107124ec6df9f6897148249dda11f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1186%2Fgm409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgm409%26sid%3Dliteratum%253Aachs%26aulast%3DDaly%26aufirst%3DA.%2BK.%26atitle%3DPharmacogenomics%2520of%2520Adverse%2520Drug%2520Reactions%26jtitle%3DGenome%2520Med.%26date%3D2013%26volume%3D5%26spage%3D5%26doi%3D10.1186%2Fgm409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicoletti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulthard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alshabeeb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grove, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucena, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitland-van
der Zee, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molokhia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadelius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">245</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1002/cpt.1375</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fcpt.1375" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30661239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlegsrzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2019&pages=245-253&author=P.+Nicolettiauthor=G.+P.+Aithalauthor=T.+C.+Chamberlainauthor=S.+Coulthardauthor=M.+Alshabeebauthor=J.+I.+Groveauthor=R.+J.+Andradeauthor=E.+Bjornssonauthor=J.+F.+Dillonauthor=P.+Hallbergauthor=M.+I.+Lucenaauthor=A.+H.+Maitland-van%0Ader+Zeeauthor=J.+H.+Martinauthor=M.+Molokhiaauthor=M.+Pirmohamedauthor=M.+Wadeliusauthor=Y.+Shenauthor=M.+R.+Nelsonauthor=A.+K.+Daly&title=Drug-Induced+Liver+Injury+due+to+Flucloxacillin%3A+Relevance+of+Multiple+Human+Leukocyte+Antigen+Alleles&doi=10.1002%2Fcpt.1375"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles</span></div><div class="casAuthors">Nicoletti, Paola; Aithal, Guruprasad P.; Chamberlain, Thomas C.; Coulthard, Sally; Alshabeeb, Mohammad; Grove, Jane I.; Andrade, Raul J.; Bjornsson, Einar; Dillon, John F.; Hallberg, Par; Lucena, M. Isabel; Maitland-van der Zee, Anke H.; Martin, Jennifer H.; Molokhia, Mariam; Pirmohamed, Munir; Wadelius, Mia; Shen, Yufeng; Nelson, Matthew R.; Daly, Ann K.; the International Drug-Induced Liver Injury Consortium</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">245-253</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Some patients prescribed flucloxacillin (∼ 0.01%) develop drug-induced liver injury (DILI).  HLA-B*57:01 is an established genetic risk factor for flucloxacillin DILI.  To consolidate this finding, identify addnl. genetic factors, and assess relevance of risk factors for flucloxacillin DILI in relation to DILI due to other penicillins, we performed a genomewide assocn. study involving 197 flucloxacillin DILI cases and 6,835 controls.  We imputed single-nucleotide polymorphism and human leukocyte antigen (HLA) genotypes.  HLA-B*57:01 was the major risk factor (allelic odds ratio (OR) = 36.62; P = 2.67 × 10-97).  HLA-B*57:03 also showed an assocn. (OR = 79.21; P = 1.2 × 10-6).  Within the HLA-B protein sequence, imputation showed valine97, common to HLA-B*57:01 and HLA-B*57:03, had the largest effect (OR = 38.1; P = 9.7 × 10-97).  We found no HLA-B*57 assocn. with DILI due to other isoxazolyl penicillins (n = 6) or amoxicillin (n = 15) and no significant non-HLA signals for any penicillin-related DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoACu10fRdvrbVg90H21EOLACvtfcHk0ljqE7zgVe5TLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlegsrzI&md5=5d4d4432d7fbe3803a97367fa9b26ac2</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fcpt.1375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.1375%26sid%3Dliteratum%253Aachs%26aulast%3DNicoletti%26aufirst%3DP.%26aulast%3DAithal%26aufirst%3DG.%2BP.%26aulast%3DChamberlain%26aufirst%3DT.%2BC.%26aulast%3DCoulthard%26aufirst%3DS.%26aulast%3DAlshabeeb%26aufirst%3DM.%26aulast%3DGrove%26aufirst%3DJ.%2BI.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3DBjornsson%26aufirst%3DE.%26aulast%3DDillon%26aufirst%3DJ.%2BF.%26aulast%3DHallberg%26aufirst%3DP.%26aulast%3DLucena%26aufirst%3DM.%2BI.%26aulast%3DMaitland-van%2Bder%2BZee%26aufirst%3DA.%2BH.%26aulast%3DMartin%26aufirst%3DJ.%2BH.%26aulast%3DMolokhia%26aufirst%3DM.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DWadelius%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DNelson%26aufirst%3DM.%2BR.%26aulast%3DDaly%26aufirst%3DA.%2BK.%26atitle%3DDrug-Induced%2520Liver%2520Injury%2520due%2520to%2520Flucloxacillin%253A%2520Relevance%2520of%2520Multiple%2520Human%2520Leukocyte%2520Antigen%2520Alleles%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2019%26volume%3D106%26spage%3D245%26epage%3D253%26doi%3D10.1002%2Fcpt.1375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saide, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulkner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tailor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Characterization of Amoxicillin- and Clavulanic Acid-Specific T-cells in Patients with Amoxicillin-Clavulanate–Induced Liver Injury</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">887</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1002/hep.27912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.27912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25998949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVSnt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=887-899&author=S.-H.+Kimauthor=K.+Saideauthor=J.+Farrellauthor=L.+Faulknerauthor=A.+Tailorauthor=M.+Ogeseauthor=A.+K.+Dalyauthor=M.+Pirmohamedauthor=B.+K.+Parkauthor=D.+J.+Naisbitt&title=Characterization+of+Amoxicillin-+and+Clavulanic+Acid-Specific+T-cells+in+Patients+with+Amoxicillin-Clavulanate%E2%80%93Induced+Liver+Injury&doi=10.1002%2Fhep.27912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury</span></div><div class="casAuthors">Kim, Seung-Hyun; Saide, Katy; Farrell, John; Faulkner, Lee; Tailor, Arun; Ogese, Monday; Daly, Ann K.; Pirmohamed, Munir; Park, B. Kevin; Naisbitt, Dean J.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">887-899</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) frequently has a delayed onset with several human leukocyte antigen (HLA) genotypes affecting susceptibility, indicating a potential role for the adaptive immune system in the disease.  The aim of this study was to investigate whether drug-responsive T lymphocytes are detectable in patients who developed DILI with the combination, antimicrobial amoxicillin-clavulanate.  Lymphocytes from 6 of 7 patients were found to proliferate and/or secrete interferon-gamma (IFN-γ) when cultured with amoxicillin and/or clavulanic acid.  Amoxicillin (n = 105) and clavulanic acid (n = 16) responsive CD4+ and CD8+ T-cell clones expressing CCR, chemokine (C-C motif) receptor 4, CCR9, and chemokine (C-X-C motif) receptor 3 were generated from patients with and without HLA risk alleles; no cross-reactivity was obsd. between the two drug antigens.  Amoxicillin clones were found to secrete a heterogeneous panel of mediators, including IFN-γ, interleukin-22 and cytolytic mols.  In contrast, cytokine secretion by the clavulanic acid clones was more restricted.  CD4+ and CD8+ clones were major histocompatibility complex class II and I restricted, resp., with the drug antigen being presented to CD4+ clones in the context of HLA-DR mols.  Several pieces of evidence indicate that the clones were activated by a hapten mechanism: First, professional antigen-presenting cells (APCs) were required for optimal activation; second, pulsing APCs for 4-16 h activated the clones; and third, inhibition of processing abrogated the proliferative response and cytokine release.  Conclusion: Both amoxicillin- and clavulanic acid-specific T cells participate in the liver injury that develops in certain patients exposed to amoxicillin-clavulanate. (Hepatol. 2015;62:887-899).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrFlLkmOMif7Vg90H21EOLACvtfcHk0ljqE7zgVe5TLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVSnt73O&md5=caa23f4135999e0a1b5d30109161a4bd</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fhep.27912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27912%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DSaide%26aufirst%3DK.%26aulast%3DFarrell%26aufirst%3DJ.%26aulast%3DFaulkner%26aufirst%3DL.%26aulast%3DTailor%26aufirst%3DA.%26aulast%3DOgese%26aufirst%3DM.%26aulast%3DDaly%26aufirst%3DA.%2BK.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DCharacterization%2520of%2520Amoxicillin-%2520and%2520Clavulanic%2520Acid-Specific%2520T-cells%2520in%2520Patients%2520with%2520Amoxicillin-Clavulanate%25E2%2580%2593Induced%2520Liver%2520Injury%26jtitle%3DHepatology%26date%3D2015%26volume%3D62%26spage%3D887%26epage%3D899%26doi%3D10.1002%2Fhep.27912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nattrass, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulkner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocanson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoine, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Activation of Flucloxacillin-Specific CD8+ T-Cells With the Potential to Promote Hepatocyte Cytotoxicity in a Mouse Model</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfv077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfv077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25877613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFSrur3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2015&pages=146-156&author=R.+Nattrassauthor=L.+Faulknerauthor=M.+Vocansonauthor=D.+J.+Antoineauthor=A.+Kiparauthor=G.+Kennaauthor=J.-F.+Nicolasauthor=B.+K.+Parkauthor=D.+J.+Naisbitt&title=Activation+of+Flucloxacillin-Specific+CD8%2B+T-Cells+With+the+Potential+to+Promote+Hepatocyte+Cytotoxicity+in+a+Mouse+Model&doi=10.1093%2Ftoxsci%2Fkfv077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of flucloxacillin-specific CD8+ T-cells with the potential to promote hepatocyte cytotoxicity in a mouse model</span></div><div class="casAuthors">Nattrass, Ryan; Faulkner, Lee; Vocanson, Marc; Antoine, Daniel J.; Kipar, Anja; Kenna, Gerry; Nicolas, Jean-Francois; Park, B. Kevin; Naisbitt, Dean J.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">146-156</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">There are currently no animal models of drug-induced liver injury (DILI) where the adaptive immune system has been shown to damage the liver.  Thus, it is difficult to explore the mechanistic basis of the tissue injury.  The aim of this study was to use C57BL/6 CD4+-deficient mice with a mutation in the αβ gene encoding for Major histocompatibilty complex (MHC) class II mols. to (1) develop a mouse model of flucloxacillin sensitization, (2) explore whether drug-specific CD8+ kill primary hepatocytes, and (3) analyze perturbations in liver integrity following oral exposure to flucloxacillin.  CD8+ T-cells from lymph nodes of flucloxacillin-sensitized mice were stimulated to proliferate, secrete interferon (IFN-γ) and granzyme B, and induce hepatocyte apoptosis in a concn.-dependent manner following ex vivo stimulation.  The T-cell response was antigen-specific; T-cells were not activated with other β-lactam antibiotics.  Furthermore, T-cell responses only occurred in the presence of flucloxacillin-pulsed antigen presenting cells.  In sep. expts., flucloxacillin-specific T-cells were induced to migrate to the mesenteric lymph nodes using retinoic acid, prior to administration of oral flucloxacillin, and anal. of plasma biomarkers of liver injury.  Oral exposure to flucloxacillin resulted in mild elevations in alanine aminotransferase, liver, and gall bladder leukocyte infiltration and a marked swelling of the gall bladder.  Thus, CD4+-deficient mice represent a promising model to study the role of the adaptive immune system in DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQyA9aFnqx6LVg90H21EOLACvtfcHk0ljqE7zgVe5TLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFSrur3I&md5=7b249008d0ab4db014dfa5dcbdc67b61</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfv077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfv077%26sid%3Dliteratum%253Aachs%26aulast%3DNattrass%26aufirst%3DR.%26aulast%3DFaulkner%26aufirst%3DL.%26aulast%3DVocanson%26aufirst%3DM.%26aulast%3DAntoine%26aufirst%3DD.%2BJ.%26aulast%3DKipar%26aufirst%3DA.%26aulast%3DKenna%26aufirst%3DG.%26aulast%3DNicolas%26aufirst%3DJ.-F.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DActivation%2520of%2520Flucloxacillin-Specific%2520CD8%252B%2520T-Cells%2520With%2520the%2520Potential%2520to%2520Promote%2520Hepatocyte%2520Cytotoxicity%2520in%2520a%2520Mouse%2520Model%26jtitle%3DToxicol.%2520Sci.%26date%3D2015%26volume%3D146%26spage%3D146%26epage%3D156%26doi%3D10.1093%2Ftoxsci%2Fkfv077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urban, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G. P.</span></span> <span> </span><span class="NLM_article-title">Genetic Basis of Drug-Induced Liver Injury: Present and Future</span>. <i>Semin. Liver Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1055/s-0034-1375954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1055%2Fs-0034-1375954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24879978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFKktLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=123-133&author=T.+J.+Urbanauthor=A.+K.+Dalyauthor=G.+P.+Aithal&title=Genetic+Basis+of+Drug-Induced+Liver+Injury%3A+Present+and+Future&doi=10.1055%2Fs-0034-1375954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic basis of drug-induced liver injury: present and future</span></div><div class="casAuthors">Urban, Thomas J.; Daly, Ann K.; Aithal, Guruprasad P.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Liver Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-133</span>CODEN:
                <span class="NLM_cas:coden">SLDIEE</span>;
        ISSN:<span class="NLM_cas:issn">0272-8087</span>.
    
            (<span class="NLM_cas:orgname">Thieme Medical Publishers, Inc.</span>)
        </div><div class="casAbstract">A review.  There is considerable evidence that susceptibility to idiosyncratic drug-induced liver injury (DILI) is genetically detd.  Though genetic assocns. with DILI have been reported since the 1980s, the development of genome-wide assocn. studies has enabled genetic risk factors for DILI, in common with other diseases, to be detected and confirmed more confidently.  Human leukocyte antigen (HLA) genotype has been demonstrated to be a strong risk factor for development of DILI with a range of drugs and the underlying mechanism, probably involving presentation of a drug-peptide complex to T cells is increasingly well understood.  However, specific HLA alleles are not assocd. with all forms of DILI and non-HLA genetic risk factors, esp. those relating to drug disposition, also appear to contribute.  For some drugs, there is evidence of a dual role for HLA and drug metab. genes.  Though the assocns. with non-HLA genes have been less well replicated than the HLA assocns., there is increasing evidence that drug metab. genes such as NAT2 and UGT2B7 contribute to some forms of DILI.  Translating current genetic findings on DILI susceptibility to the clinic has been relatively slow, but some progress is now being made.  In the future, DNA sequencing may lead to the identification of rare variants that contribute to DILI.  Developments in the related area of epigenomics and in the development of improved models for DILI by use of genetically defined induced pluripotent stem cells should improve understanding of the biol. of DILI and inform drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyBRvYDxpDarVg90H21EOLACvtfcHk0lg4tZtpWNLGNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFKktLbM&md5=cbd2144470fc55bed98056f11ac4ccfd</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1055%2Fs-0034-1375954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0034-1375954%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DT.%2BJ.%26aulast%3DDaly%26aufirst%3DA.%2BK.%26aulast%3DAithal%26aufirst%3DG.%2BP.%26atitle%3DGenetic%2520Basis%2520of%2520Drug-Induced%2520Liver%2520Injury%253A%2520Present%2520and%2520Future%26jtitle%3DSemin.%2520Liver%2520Dis.%26date%3D2014%26volume%3D34%26spage%3D123%26epage%3D133%26doi%3D10.1055%2Fs-0034-1375954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogese, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adair, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tailor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulkner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enyindah, B. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz-Nieto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ressel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eagle, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitteringham, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betts, C.</span></span> <span> </span><span class="NLM_article-title">Exosomal Transport of Hepatocyte-Derived Drug-Modified Proteins to the Immune System</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1732</span>– <span class="NLM_lpage">1749</span>, <span class="refDoi"> DOI: 10.1002/hep.30701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.30701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=31070244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVCltLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2019&pages=1732-1749&author=M.+O.+Ogeseauthor=R.+E.+Jenkinsauthor=K.+Adairauthor=A.+Tailorauthor=X.+Mengauthor=L.+Faulknerauthor=B.+O.+Enyindahauthor=A.+Schofieldauthor=R.+Diaz-Nietoauthor=L.+Resselauthor=G.+L.+Eagleauthor=N.+R.+Kitteringhamauthor=C.+E.+Goldringauthor=B.+K.+Parkauthor=D.+J.+Naisbittauthor=C.+Betts&title=Exosomal+Transport+of+Hepatocyte-Derived+Drug-Modified+Proteins+to+the+Immune+System&doi=10.1002%2Fhep.30701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Exosomal Transport of Hepatocyte-Derived Drug-Modified Proteins to the Immune System</span></div><div class="casAuthors">Ogese, Monday O.; Jenkins, Rosalind E.; Adair, Kareena; Tailor, Arun; Meng, Xiaoli; Faulkner, Lee; Enyindah, Bright O.; Schofield, Amy; Diaz-Nieto, Rafael; Ressel, Lorenzo; Eagle, Gina L.; Kitteringham, Neil R.; Goldring, Chris E.; Park, B. Kevin; Naisbitt, Dean J.; Betts, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1732-1749</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Idiosyncratic drug-induced liver injury (DILI) is a rare, often difficult-to-predict adverse reaction with complex pathomechanisms.  However, it is now evident that certain forms of DILI are immune-mediated and may involve the activation of drug-specific T cells.  Exosomes are cell-derived vesicles that carry RNA, lipids, and protein cargo from their cell of origin to distant cells, and they may play a role in immune activation.  Herein, primary human hepatocytes were treated with drugs assocd. with a high incidence of DILI (flucloxacillin, amoxicillin, isoniazid, and nitroso-sulfamethoxazole) to characterize the proteins packaged within exosomes that are subsequently transported to dendritic cells for processing.  Exosomes measured between 50 and 100 nm and expressed enriched CD63.  Liq. chromatog.-tandem mass spectrometry (LC/MS-MS) identified 2,109 proteins, with 608 proteins being quantified across all exosome samples.  Data are available through ProteomeXchange with identifier PXD010760.  Anal. of gene ontologies revealed that exosomes mirrored whole human liver tissue in terms of the families of proteins present, regardless of drug treatment.  However, exosomes from nitroso-sulfamethoxazole-treated hepatocytes selectively packaged a specific subset of proteins.  LC/MS-MS also revealed the presence of hepatocyte-derived exosomal proteins covalently modified with amoxicillin, flucloxacillin, and nitroso-sulfamethoxazole.  Uptake of exosomes by monocyte-derived dendritic cells occurred silently, mainly through phagocytosis, and was inhibited by latrunculin A. An amoxicillin-modified 9-mer peptide derived from the exosomal transcription factor protein SRY (sex detg. region Y)-box 30 activated naive T cells from human leukocyte antigen A*02:01-pos. human donors.  Conclusion: This study shows that exosomes have the potential to transmit drug-specific hepatocyte-derived signals to the immune system and provide a pathway for the induction of drug hapten-specific T-cell responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodQeCN-3P47LVg90H21EOLACvtfcHk0lg4tZtpWNLGNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVCltLjN&md5=0952f8d99dbc0499d352db5cb9d8d5c3</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fhep.30701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.30701%26sid%3Dliteratum%253Aachs%26aulast%3DOgese%26aufirst%3DM.%2BO.%26aulast%3DJenkins%26aufirst%3DR.%2BE.%26aulast%3DAdair%26aufirst%3DK.%26aulast%3DTailor%26aufirst%3DA.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DFaulkner%26aufirst%3DL.%26aulast%3DEnyindah%26aufirst%3DB.%2BO.%26aulast%3DSchofield%26aufirst%3DA.%26aulast%3DDiaz-Nieto%26aufirst%3DR.%26aulast%3DRessel%26aufirst%3DL.%26aulast%3DEagle%26aufirst%3DG.%2BL.%26aulast%3DKitteringham%26aufirst%3DN.%2BR.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DBetts%26aufirst%3DC.%26atitle%3DExosomal%2520Transport%2520of%2520Hepatocyte-Derived%2520Drug-Modified%2520Proteins%2520to%2520the%2520Immune%2520System%26jtitle%3DHepatology%26date%3D2019%26volume%3D70%26spage%3D1732%26epage%3D1749%26doi%3D10.1002%2Fhep.30701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holman, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCluyse, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Subtoxic Alterations in Hepatocyte-Derived Exosomes: An Early Step in Drug-Induced Liver Injury?</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">375</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfw047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfw047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26962055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGntb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2016&pages=365-375&author=N.+S.+Holmanauthor=M.+Mosedaleauthor=K.+K.+Wolfauthor=E.+L.+LeCluyseauthor=P.+B.+Watkins&title=Subtoxic+Alterations+in+Hepatocyte-Derived+Exosomes%3A+An+Early+Step+in+Drug-Induced+Liver+Injury%3F&doi=10.1093%2Ftoxsci%2Fkfw047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Subtoxic alterations in hepatocyte-derived exosomes: an early step in drug-induced liver injury?</span></div><div class="casAuthors">Holman, Natalie S.; Mosedale, Merrie; Wolf, Kristina K.; LeCluyse, Edward L.; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">365-375</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a significant clin. and economic problem in the United States, yet the mechanisms that underlie DILI remain poorly understood.  Resent evidence suggests that signaling mols. released by stressed hepatocytes can trigger immune responses that may be common across DILI mechanisms.  Extracellular vesicles released by hepatocytes, principally hepatocyte-derived exosomes (HDEs), may constitute one such signal.  To examine HDE alterations as a function of drug-induced stress, this work utilized prototypical hepatotoxicant acetaminophen (APAP) in male Sprague-Dawley (SD) rats, SD rat hepatocytes, and primary human hepatocytes.  HDE were isolated using ExoQuick pptn. reagent and analyzed by quantification of the liver-specific RNAs albumin and microRNA-122 (miR-122).  In vivo, significant elevations in circulating exosomal albumin mRNA were obsd. at subtoxic APAP exposures.  Significant increases in exosomal albumin mRNA were also obsd. in primary rat hepatocytes at subtoxic APAP concns.  In primary human hepatocytes, APAP elicited increases in both exosomal albumin mRNA and exosomal miR-122 without overt cytotoxicity.  However, the no. of HDE produced in vitro in response to APAP did not increase with exosomal RNA quantity.  The authors conclude that significant drug-induced alterations in the liver-specific RNA content of HDE occur at subtoxic APAP exposures in vivo and in vitro, and that these changes appear to reflect selective packaging rather than changes in exosome no.  The current findings demonstrate that translationally relevant HDE alterations occur in the absence of overt hepatocellular toxicity, and support the hypothesis that HDE released by stressed hepatocytes may mediate early immune responses in DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroiwY93SPy6rVg90H21EOLACvtfcHk0lg4tZtpWNLGNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGntb7J&md5=ac3ce5a27e6d283d768d49cc9d9ee01b</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfw047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfw047%26sid%3Dliteratum%253Aachs%26aulast%3DHolman%26aufirst%3DN.%2BS.%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DWolf%26aufirst%3DK.%2BK.%26aulast%3DLeCluyse%26aufirst%3DE.%2BL.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DSubtoxic%2520Alterations%2520in%2520Hepatocyte-Derived%2520Exosomes%253A%2520An%2520Early%2520Step%2520in%2520Drug-Induced%2520Liver%2520Injury%253F%26jtitle%3DToxicol.%2520Sci.%26date%3D2016%26volume%3D151%26spage%3D365%26epage%3D375%26doi%3D10.1093%2Ftoxsci%2Fkfw047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaddy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trask, J. O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holman, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCluyse, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khetani, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brock, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">miR-122 Release in Exosomes Precedes Overt Tolvaptan-Induced Necrosis in a Primary Human Hepatocyte Micropatterned Coculture Model</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfx206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfx206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29029277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFelsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2018&pages=149-158&author=M.+Mosedaleauthor=J.+S.+Eaddyauthor=J.+O.+J.+Traskauthor=N.+S.+Holmanauthor=K.+K.+Wolfauthor=E.+LeCluyseauthor=B.+R.+Wareauthor=S.+R.+Khetaniauthor=J.+Luauthor=W.+J.+Brockauthor=S.+E.+Rothauthor=P.+B.+Watkins&title=miR-122+Release+in+Exosomes+Precedes+Overt+Tolvaptan-Induced+Necrosis+in+a+Primary+Human+Hepatocyte+Micropatterned+Coculture+Model&doi=10.1093%2Ftoxsci%2Fkfx206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">miR-122 release in exosomes precedes overt tolvaptan-induced necrosis in a primary human hepatocyte micropatterned coculture model</span></div><div class="casAuthors">Mosedale, Merrie; Eaddy, J. Scott; Trask, O. Joseph Jr.; Holman, Natalie S.; Wolf, Kristina K.; LeCluyse, Edward; Ware, Brenton R.; Khetani, Salman R.; Lu, Jingtao; Brock, William J.; Roth, Sharin E.; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">149-158</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Idiosyncratic drug-induced liver injury (IDILI) is thought to often result froman adaptive immune attack on the liver.  However, it has been proposed that the cascade of events culminating in an adaptive immune response begins with drug-induced hepatocyte stress, release of exosomal danger signals, and innate immune activation, all of which may occur in the absence of significant hepatocelluar death.  A micropatterned coculture model (HepatoPac) was used to explore the possibility that changes in exosome content precede overt necrosis in response to the IDILI drug tolvaptan.  Hepatocytes from 3 human donors were exposed to a range of tolvaptan concns. bracketing plasma Cmax or DMSO control continuously for 4, 24, or 72 h.  Although alanine aminotransferase release was not significantly affected at any concn., tolvaptan exposures at approx. 30-fold median plasma Cmax resulted in increased release of exosomal microRNA-122 (miR-122) into the medium.  Cellular imaging and microarray anal. revealed that the most significant increases in exosomal miR-122 were assocd. with programmed cell death and small increases in membrane permeability.  However, early increases in exosome miR-122 were more assocd. with mitochondrial-induced apoptosis and oxidative stress.  Taken together, these data suggest that tolvaptan treatment induces cellular stress and exosome release of miR-122 in primary human hepatocytes in the absence of overt necrosis, providing direct demonstration of this with a drug capable of causing IDILI.  In susceptible individuals, these early events may occur at pharmacol. concns. of tolvaptan and may promote an adaptive immune attack that ultimately results in clin. significant liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjwmACAPa6i7Vg90H21EOLACvtfcHk0lieMNXIQDMPvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFelsbvI&md5=4f440e3508b5d29ac6fc39d64d3d2eac</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfx206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfx206%26sid%3Dliteratum%253Aachs%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DEaddy%26aufirst%3DJ.%2BS.%26aulast%3DTrask%26aufirst%3DJ.%2BO.%2BJ.%26aulast%3DHolman%26aufirst%3DN.%2BS.%26aulast%3DWolf%26aufirst%3DK.%2BK.%26aulast%3DLeCluyse%26aufirst%3DE.%26aulast%3DWare%26aufirst%3DB.%2BR.%26aulast%3DKhetani%26aufirst%3DS.%2BR.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DBrock%26aufirst%3DW.%2BJ.%26aulast%3DRoth%26aufirst%3DS.%2BE.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DmiR-122%2520Release%2520in%2520Exosomes%2520Precedes%2520Overt%2520Tolvaptan-Induced%2520Necrosis%2520in%2520a%2520Primary%2520Human%2520Hepatocyte%2520Micropatterned%2520Coculture%2520Model%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D161%26spage%3D149%26epage%3D158%26doi%3D10.1093%2Ftoxsci%2Fkfx206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, S.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, E. J.</span></span> <span> </span><span class="NLM_article-title">Evolving Models of the Immunopathogenesis of T-cell-Mediated Drug Allergy: The Role of Host, Pathogens, and Drug Response</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2015.05.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jaci.2015.05.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26254049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12rsbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2015&pages=219-234&author=K.+D.+Whiteauthor=W.-H.+Chungauthor=S.-I.+Hungauthor=S.+Mallalauthor=E.+J.+Phillips&title=Evolving+Models+of+the+Immunopathogenesis+of+T-cell-Mediated+Drug+Allergy%3A+The+Role+of+Host%2C+Pathogens%2C+and+Drug+Response&doi=10.1016%2Fj.jaci.2015.05.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response</span></div><div class="casAuthors">White, Katie D.; Chung, Wen-Hung; Hung, Shuen-Iu; Mallal, Simon; Phillips, Elizabeth J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-234</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Immune-mediated (IM) adverse drug reactions (ADRs) are an underrecognized source of preventable morbidity, mortality, and cost.  Increasingly, genetic variation in the HLA loci is assocd. with risk of severe reactions, highlighting the importance of T-cell immune responses in the mechanisms of both B cell-mediated and primary T cell-mediated IM-ADRs.  In this review we summarize the role of host genetics, microbes, and drugs in IM-ADR development; expand on the existing models of IM-ADR pathogenesis to address multiple unexplained observations; discuss the implications of this work in clin. practice today; and describe future applications for preclin. drug toxicity screening, drug design, and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2lSDJLiAjDrVg90H21EOLACvtfcHk0lieMNXIQDMPvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12rsbjN&md5=09693c0e84273d633373bd79c20849dd</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2015.05.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2015.05.050%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DK.%2BD.%26aulast%3DChung%26aufirst%3DW.-H.%26aulast%3DHung%26aufirst%3DS.-I.%26aulast%3DMallal%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DE.%2BJ.%26atitle%3DEvolving%2520Models%2520of%2520the%2520Immunopathogenesis%2520of%2520T-cell-Mediated%2520Drug%2520Allergy%253A%2520The%2520Role%2520of%2520Host%252C%2520Pathogens%252C%2520and%2520Drug%2520Response%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2015%26volume%3D136%26spage%3D219%26epage%3D234%26doi%3D10.1016%2Fj.jaci.2015.05.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castrejon, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Ghaiesh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Stimulation of Human T-cells with Sulfonamides and Sulfonamide Metabolites</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2009.10.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jaci.2009.10.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=20159253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitVKhsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2010&pages=411-418&author=J.+L.+Castrejonauthor=N.+Berryauthor=S.+El-Ghaieshauthor=B.+Gerberauthor=W.+J.+Pichlerauthor=B.+K.+Parkauthor=D.+J.+Naisbitt&title=Stimulation+of+Human+T-cells+with+Sulfonamides+and+Sulfonamide+Metabolites&doi=10.1016%2Fj.jaci.2009.10.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of human T cells with sulfonamides and sulfonamide metabolites</span></div><div class="casAuthors">Castrejon, J. Luis; Berry, Neil; El-Ghaiesh, Sabah; Gerber, Basil; Pichler, Werner J.; Park, B. Kevin; Naisbitt, Dean J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">411-418, S411/1-S411/4</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Exposure to sulfonamides is assocd. with a high incidence of hypersensitivity reactions.  Antigen-specific T cells are involved in the pathogenesis; however, the nature of the antigen interacting with specific T-cell receptors is not fully defined.  We sought to explore the frequency of sulfamethoxazole (SMX)- and SMX metabolite-specific T cells in hypersensitive patients, delineate the specificity of clones, define mechanisms of presentation, and explore addnl. reactivity with structurally related sulfonamide metabolites.  SMX- and SMX metabolite-specific T-cell clones were generated from 3 patients.  Antigen specificity, mechanisms of antigen presentation, and cross-reactivity of specific clones were then explored.  Low-lying energy conformations of drugs (metabolites) were modeled, and the energies available for protein binding was estd.  Lymphocytes proliferated with parent drugs (SMX, sulfadiazine, and sulfapyridine) and both hydroxylamine and nitroso metabolites.  Three patterns of drug (metabolite) stimulation were seen: 44% were SMX metabolite specific, 43% were stimulated with SMX metabolites and SMX, and 14% were stimulated with SMX alone.  Most metabolite-responsive T cells were stimulated with nitroso SMX-modified protein through a hapten mechanism involving processing.  In contrast to SMX-responsive clones, which were highly specific, greater than 50% of nitroso SMX-specific clones were stimulated with nitroso metabolites of sulfapyridine and sulfadiazine but not nitrosobenzene.  Pharmacophore modeling showed that the summation of available binding energies for protein interactions and the preferred spatial arrangement of atoms in each mol. det. a drug's potential to stimulate specific T cells.  Nitroso sulfonamide metabolites form potent antigenic determinants for T cells from hypersensitive patients.  T-cell responses against drugs (metabolites) bound directly to MHC or MHC/peptide complexes can occur through cross-reactivity with the haptenic immunogen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxff8n31sG1LVg90H21EOLACvtfcHk0lieMNXIQDMPvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitVKhsbo%253D&md5=bebcd1e7c74d6eaa47f50ca2de14acfa</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2009.10.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2009.10.031%26sid%3Dliteratum%253Aachs%26aulast%3DCastrejon%26aufirst%3DJ.%2BL.%26aulast%3DBerry%26aufirst%3DN.%26aulast%3DEl-Ghaiesh%26aufirst%3DS.%26aulast%3DGerber%26aufirst%3DB.%26aulast%3DPichler%26aufirst%3DW.%2BJ.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DStimulation%2520of%2520Human%2520T-cells%2520with%2520Sulfonamides%2520and%2520Sulfonamide%2520Metabolites%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2010%26volume%3D125%26spage%3D411%26epage%3D418%26doi%3D10.1016%2Fj.jaci.2009.10.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schnyder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhart, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnyder-Frutig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Greyerz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, W. J.</span></span> <span> </span><span class="NLM_article-title">Recognition of Sulfamethoxazole and Its Reactive Metabolites by Drug-Specific CD4+ T-cells from Allergic Individuals</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">6647</span>– <span class="NLM_lpage">6654</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.164.12.6647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.4049%2Fjimmunol.164.12.6647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10843725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktFWlu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2000&pages=6647-6654&author=B.+Schnyderauthor=C.+Burkhartauthor=K.+Schnyder-Frutigauthor=S.+von+Greyerzauthor=D.+J.+Naisbittauthor=M.+Pirmohamedauthor=B.+K.+Parkauthor=W.+J.+Pichler&title=Recognition+of+Sulfamethoxazole+and+Its+Reactive+Metabolites+by+Drug-Specific+CD4%2B+T-cells+from+Allergic+Individuals&doi=10.4049%2Fjimmunol.164.12.6647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals</span></div><div class="casAuthors">Schnyder, Benno; Burkhart, Christoph; Schnyder-Frutig, Karin; Von Greyerz, Salome; Naisbitt, Dean J.; Pirmohamed, Munir; Park, B. Kevin; Pichler, Werner J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6647-6654</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The recognition of the antibiotic sulfamethoxazole (SMX) by T cells is usually explained with the hapten-carrier model.  However, recent investigations have revealed a MHC-restricted but processing- and metab.-independent pathway of drug presentation.  This suggested a labile, low-affinity binding of SMX to MHC-peptide complexes on APC.  To study the role of covalent vs. noncovalent drug presentation in SMX allergy, we analyzed the proliferative response of PBMC and T cell clones from patients with SMX allergy to SMX and its reactive oxidative metabolites SMX-hydroxylamine and nitroso-SMX.  Although the great majority of T cell clones were specific for noncovalently bound SMX, PBMC and a small fraction of clones responded to nitroso-SMX-modified cells or were cross-reactive.  Rapid down-regulation of TCR expression in T cell clones upon stimulation indicated a processing-independent activation irresp. of specificity for covalently or noncovalently presented Ag.  In conclusion, our data show that recognition of SMX presented in covalent and noncovalent bound form is possible by the same TCR but that the former is the exception rather than the rule.  The scarcity of cross-reactivity between covalently and noncovalently bound SMX suggests that the primary stimulation may be directed to the noncovalently bound SMX.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJO6K4Vbe0PrVg90H21EOLACvtfcHk0ljvWg-BzZMMWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktFWlu7w%253D&md5=a5ab55b68f0f566dd9b0c6aa220521aa</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.164.12.6647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.164.12.6647%26sid%3Dliteratum%253Aachs%26aulast%3DSchnyder%26aufirst%3DB.%26aulast%3DBurkhart%26aufirst%3DC.%26aulast%3DSchnyder-Frutig%26aufirst%3DK.%26aulast%3Dvon%2BGreyerz%26aufirst%3DS.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DPichler%26aufirst%3DW.%2BJ.%26atitle%3DRecognition%2520of%2520Sulfamethoxazole%2520and%2520Its%2520Reactive%2520Metabolites%2520by%2520Drug-Specific%2520CD4%252B%2520T-cells%2520from%2520Allergic%2520Individuals%26jtitle%3DJ.%2520Immunol.%26date%3D2000%26volume%3D164%26spage%3D6647%26epage%3D6654%26doi%3D10.4049%2Fjimmunol.164.12.6647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, W. J.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Interaction of Drugs with Antigen-Specific Immune Receptors: The P-I Concept</span>. <i>Current Opinion in Allergy and Clinical Immunology</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1097/00130832-200208000-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1097%2F00130832-200208000-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=12130944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD38zotFKktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=301-305&author=W.+J.+Pichler&title=Pharmacological+Interaction+of+Drugs+with+Antigen-Specific+Immune+Receptors%3A+The+P-I+Concept&doi=10.1097%2F00130832-200208000-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept</span></div><div class="casAuthors">Pichler Werner J</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in allergy and clinical immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">301-5</span>
        ISSN:<span class="NLM_cas:issn">1528-4050</span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  Drug allergies are examples of immune reactions to small molecular compounds.  In many drug allergies drug specific CD4+ and CD8+ T-cells can be detected, which recognize small chemicals via their alphabeta-T-cell receptor in a major histocompatibility complex dependent way.  In this review a new concept of drug presentation to T-cells is presented.  RECENT FINDINGS:  Drugs were stimulatory for T-cells if they bound covalently to peptides or proteins, but also if the drug had structural features allowing it to bind in a labile way (noncovalently) to the major histocompatibility peptide complex.  This latter binding method has some similarities to superantigen stimulations and can explain allergies to drugs that are not metabolized.  It has been described in patients with maculopapular, bullous and neutrophilic drug eruption, as well as in contact dermatitis.  SUMMARY:  Noncovalent drug presentation leads to the stimulation of immune cells, namely T-cells.  The drug needs two surface molecules (one inert serving as a scaffold, major histocompatibility complex, and one reactive, T-cell receptor) to exert its function.  Although two receptor structures are involved, the process is reminiscent of a pharmacological interaction between a drug and its receptors and, from the phrase pharmacological interaction with immune receptors, was thus termed the p-i concept.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQPU8-88-HE48K3uFsUIZtkfW6udTcc2eb8gbQCzPmvD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38zotFKktw%253D%253D&md5=6bd40e531934a8e8993dbe1e9bc14697</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1097%2F00130832-200208000-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00130832-200208000-00003%26sid%3Dliteratum%253Aachs%26aulast%3DPichler%26aufirst%3DW.%2BJ.%26atitle%3DPharmacological%2520Interaction%2520of%2520Drugs%2520with%2520Antigen-Specific%2520Immune%2520Receptors%253A%2520The%2520P-I%2520Concept%26jtitle%3DCurrent%2520Opinion%2520in%2520Allergy%2520and%2520Clinical%2520Immunology%26date%3D2002%26volume%3D2%26spage%3D301%26epage%3D305%26doi%3D10.1097%2F00130832-200208000-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, S. I.</span></span> <span> </span><span class="NLM_article-title">Direct Interaction Between HLA-B and Carbamazepine Activates T-cells in Patients with Stevens-Johnson Syndrome</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">1562</span>– <span class="NLM_lpage">1569</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2011.12.990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jaci.2011.12.990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22322005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvVSis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2012&pages=1562-1569&author=C.+Y.+Weiauthor=W.+H.+Chungauthor=H.+W.+Huangauthor=Y.+T.+Chenauthor=S.+I.+Hung&title=Direct+Interaction+Between+HLA-B+and+Carbamazepine+Activates+T-cells+in+Patients+with+Stevens-Johnson+Syndrome&doi=10.1016%2Fj.jaci.2011.12.990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome</span></div><div class="casAuthors">Wei, Chun-Yu; Chung, Wen-Hung; Huang, Hsiao-Wen; Chen, Yuan-Tsong; Hung, Shuen-Iu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1562-1569.e5</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Increasing studies have revealed that HLA alleles are the major genetic determinants of drug hypersensitivity; however, the underlying mol. mechanism remains unclear.  We adopted the HLA-B*1502 genetic predisposition to carbamazepine (CBZ)-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) as a model to study the pathol. role of HLA in delayed-type drug hypersensitivity.  We in vitro expanded CBZ-specific cytotoxic T lymphocytes (CTLs) from patients with CBZ-induced SJS/TEN and analyzed the interaction between HLA-B and CBZ analogs based on CTL response, surface plasmon resonance, peptide-binding assay, site-directed mutagenesis, and computer modeling.  The endogenous peptide-loaded HLA-B*1502 mol. presented CBZ to CTLs without the involvement of intracellular drug metab. or antigen processing.  The HLA-B*1502/peptide/β2-microglobulin protein complex showed binding affinity toward chems. sharing 5-carboxamide on the tricyclic ring, as with CBZ.  However, modifications of the ring structure of CBZ altered HLA-B*1502 binding and CTL response.  In addn. to HLA-B*1502, other HLA-B75 family members could also present CBZ to activate CTLs, whereas members of the HLA-B62 and HLA-B72 families could not.  Three residues (Asn63, Ile95, and Leu156) in the peptide-binding groove of HLA-B*1502 were involved in CBZ presentation and CTL activation.  In particular, Asn63 shared by members of the B75 family was the key residue.  Computer simulations revealed a preferred mol. conformation of the 5-carboxamide group of CBZ and the side chain of Arg62 on the B pocket of HLA-B*1502.  This study demonstrates a direct interaction of HLA with drugs, provides a detailed mol. mechanism of HLA-assocd. drug hypersensitivity, and has clin. correlations for CBZ-related drug-induced SJS/TEN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7V-QcS3xDUbVg90H21EOLACvtfcHk0ljvWg-BzZMMWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvVSis7c%253D&md5=885e402115e3681b3bd8e83b94b99c3f</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2011.12.990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2011.12.990%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DC.%2BY.%26aulast%3DChung%26aufirst%3DW.%2BH.%26aulast%3DHuang%26aufirst%3DH.%2BW.%26aulast%3DChen%26aufirst%3DY.%2BT.%26aulast%3DHung%26aufirst%3DS.%2BI.%26atitle%3DDirect%2520Interaction%2520Between%2520HLA-B%2520and%2520Carbamazepine%2520Activates%2520T-cells%2520in%2520Patients%2520with%2520Stevens-Johnson%2520Syndrome%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2012%26volume%3D129%26spage%3D1562%26epage%3D1569%26doi%3D10.1016%2Fj.jaci.2011.12.990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenfels, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogese, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCluskey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfirevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span> <span> </span><span class="NLM_article-title">HLA Restriction of Carbamazepine-Specific T-Cell Clones from an HLA-A*31:01-Positive Hypersensitive Patient</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1021/tx400460w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx400460w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVCjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=175-177&author=M.+Lichtenfelsauthor=J.+Farrellauthor=M.+O.+Ogeseauthor=C.+C.+Bellauthor=S.+Eckleauthor=J.+McCluskeyauthor=B.+K.+Parkauthor=A.+Alfirevicauthor=D.+J.+Naisbittauthor=M.+Pirmohamed&title=HLA+Restriction+of+Carbamazepine-Specific+T-Cell+Clones+from+an+HLA-A*31%3A01-Positive+Hypersensitive+Patient&doi=10.1021%2Ftx400460w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">HLA Restriction of Carbamazepine-Specific T-Cell Clones from an HLA-A*31:01-Positive Hypersensitive Patient</span></div><div class="casAuthors">Lichtenfels, Maike; Farrell, John; Ogese, Monday O.; Bell, Catherine C.; Eckle, Sidonia; McCluskey, James; Park, B. Kevin; Alfirevic, Ana; Naisbitt, Dean J.; Pirmohamed, Munir</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-177</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HLA-A*31:01 is assocd. with carbamazepine (CBZ) hypersensitivity in Caucasian and Japanese populations.  Herein, we show that HLA-A*31:01+ restricted the activation of carbamazepine-specific CD8+ T-cells, which provides an immunol. basis for the genetic assocn.  Furthermore, CD4+ T-cells were activated with carbamazepine in a HLA-DRB1*04:04-restricted manner, indicating that a common HLA haplotype may contribute to the multiclonal T-cell response seen in European patients with CBZ hypersensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-DGTPJO8k9bVg90H21EOLACvtfcHk0ljN4A7a12YUJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVCjt7g%253D&md5=f2351fd4240680583e4b8603232b7321</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Ftx400460w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx400460w%26sid%3Dliteratum%253Aachs%26aulast%3DLichtenfels%26aufirst%3DM.%26aulast%3DFarrell%26aufirst%3DJ.%26aulast%3DOgese%26aufirst%3DM.%2BO.%26aulast%3DBell%26aufirst%3DC.%2BC.%26aulast%3DEckle%26aufirst%3DS.%26aulast%3DMcCluskey%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DAlfirevic%26aufirst%3DA.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DPirmohamed%26aufirst%3DM.%26atitle%3DHLA%2520Restriction%2520of%2520Carbamazepine-Specific%2520T-Cell%2520Clones%2520from%2520an%2520HLA-A%252A31%253A01-Positive%2520Hypersensitive%2520Patient%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2014%26volume%3D27%26spage%3D175%26epage%3D177%26doi%3D10.1021%2Ftx400460w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenfels, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfirevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachulski, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Activation of Carbamazepine-Responsive T-cell Clones with Metabolically Inert Halogenated Derivatives</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">495</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2013.02.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jaci.2013.02.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23672781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnslChsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2013&pages=493-495&author=J.+Farrellauthor=M.+Lichtenfelsauthor=A.+Sullivanauthor=E.+C.+Elliottauthor=A.+Alfirevicauthor=A.+V.+Stachulskiauthor=M.+Pirmohamedauthor=D.+J.+Naisbittauthor=B.+K.+Park&title=Activation+of+Carbamazepine-Responsive+T-cell+Clones+with+Metabolically+Inert+Halogenated+Derivatives&doi=10.1016%2Fj.jaci.2013.02.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of carbamazepine-responsive T-cell clones with metabolically inert halogenated derivatives</span></div><div class="casAuthors">Farrell, John; Lichtenfels, Maike; Sullivan, Andrew; Elliott, Emma C.; Alfirevic, Ana; Stachulski, Andrew V.; Pirmohamed, Munir; Naisbitt, Dean J.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">493-495</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  This article presents the activation of carbamazepine (CBZ)-responsive T-cell clones with metabolically inert halogenated derivs.  CBZ-responsive CD4+ and CD8+ T lymphocytes have been isolated from patients presenting with reactions of varying severity and characterized in terms of immunol. function and drug cross-reactivity.  They developed an alternative strategy to explore whether CBZ-responsive T cells are activated via a metab. independent pathway.  Two series of derivs. of CBZ, namely, 2-monohalo and 2,8-dihalo compds., were prepd. and their ability to activate CBZ-responsive T-cell clones was explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre3mPl_9Ev0LVg90H21EOLACvtfcHk0ljN4A7a12YUJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnslChsrg%253D&md5=2b8ee1560f83a77058a30fbcbc106d8c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2013.02.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2013.02.045%26sid%3Dliteratum%253Aachs%26aulast%3DFarrell%26aufirst%3DJ.%26aulast%3DLichtenfels%26aufirst%3DM.%26aulast%3DSullivan%26aufirst%3DA.%26aulast%3DElliott%26aufirst%3DE.%2BC.%26aulast%3DAlfirevic%26aufirst%3DA.%26aulast%3DStachulski%26aufirst%3DA.%2BV.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DActivation%2520of%2520Carbamazepine-Responsive%2520T-cell%2520Clones%2520with%2520Metabolically%2520Inert%2520Halogenated%2520Derivatives%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2013%26volume%3D132%26spage%3D493%26epage%3D495%26doi%3D10.1016%2Fj.jaci.2013.02.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warrington, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorski, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwenk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehon, A. H.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Isoniazid-Associated Hepatitis by Immunological Tests</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">104</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=668195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADyaE1c3htlGruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1978&pages=97-104&author=R.+J.+Warringtonauthor=K.+S.+Tseauthor=B.+A.+Gorskiauthor=R.+Schwenkauthor=A.+H.+Sehon&title=Evaluation+of+Isoniazid-Associated+Hepatitis+by+Immunological+Tests"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of isoniazid-associated hepatitis by immunological tests</span></div><div class="casAuthors">Warrington R J; Tse K S; Gorski B A; Schwenk R; Sehon A H</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and experimental immunology</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-104</span>
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    </div><div class="casAbstract">In a retrospective study of patients developing hepatitis or persistent serum glutamic oxaloacetic transaminase (SGOT) elevations while receiving isoniazid, it was found that the lymphocyte transformation test (LTT) was positive in nineteen cases (95%) in response to stimulation by isoniazid, isonicotinic acid and conjugates of these compounds with human serum albumin.  However, no significant amount of antibody against isoniazid was detected in the sera of these patients by a sensitive radioimmunoassay.  By contrast, no positive LTT was seen in normal controls or in patients receiving isoniazid without evidence of liver damage, while in patients with transient SGOT abnormalities, the LTT was positive only at the time of liver dysfunction.  There was no correlation between the degree of lymphocyte transformation and the severity of liver damage.  However, there were differences in the patterns of response to the four stimulatory preparations used.  Thus patients with overt hepatitis most frequently responded to isoniazid, while individuals with only SGOT abnormalities showed stimulation in the LTT more often with a conjugate of isonicotinic acid and human serum albumin.  It appears, therefore, that the presence of isoniazid-induced liver damage is associated with the presence of cellular hypersensitivity to the drug.  The differences in lymphocyte reactivity in the two groups might indicate a potential means of predicting which individuals are at increased risk of developing overt hepatitis when exhibiting evidence of minor liver dysfunction while receiving isoniazid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHo2nJZaPdlkNHe_gFldTbfW6udTcc2eaQVc_Dhdj64bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE1c3htlGruw%253D%253D&md5=7f3919ec2c35d189fbb271db8bc5f371</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWarrington%26aufirst%3DR.%2BJ.%26aulast%3DTse%26aufirst%3DK.%2BS.%26aulast%3DGorski%26aufirst%3DB.%2BA.%26aulast%3DSchwenk%26aufirst%3DR.%26aulast%3DSehon%26aufirst%3DA.%2BH.%26atitle%3DEvaluation%2520of%2520Isoniazid-Associated%2520Hepatitis%2520by%2520Immunological%2520Tests%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D1978%26volume%3D32%26spage%3D97%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illing, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhaidari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Modification of the Cyclopropyl Moiety of Abacavir Provides Insight into the Structure Activity Relationship Between HLA-B*57:01 Binding and T-cell Activation</span>. <i>Allergy</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="refDoi"> DOI: 10.1111/all.14057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1111%2Fall.14057" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=P.+J.+Thomsonauthor=P.+T.+Illingauthor=J.+Farrellauthor=M.+Alhaidariauthor=C.+C.+Bellauthor=N.+Berryauthor=P.+M.+O%E2%80%99Neillauthor=A.+W.+Purcellauthor=K.+B.+Parkauthor=D.+J.+Naisbitt&title=Modification+of+the+Cyclopropyl+Moiety+of+Abacavir+Provides+Insight+into+the+Structure+Activity+Relationship+Between+HLA-B*57%3A01+Binding+and+T-cell+Activation&doi=10.1111%2Fall.14057"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1111%2Fall.14057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fall.14057%26sid%3Dliteratum%253Aachs%26aulast%3DThomson%26aufirst%3DP.%2BJ.%26aulast%3DIlling%26aufirst%3DP.%2BT.%26aulast%3DFarrell%26aufirst%3DJ.%26aulast%3DAlhaidari%26aufirst%3DM.%26aulast%3DBell%26aufirst%3DC.%2BC.%26aulast%3DBerry%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26aulast%3DPurcell%26aufirst%3DA.%2BW.%26aulast%3DPark%26aufirst%3DK.%2BB.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DModification%2520of%2520the%2520Cyclopropyl%2520Moiety%2520of%2520Abacavir%2520Provides%2520Insight%2520into%2520the%2520Structure%2520Activity%2520Relationship%2520Between%2520HLA-B%252A57%253A01%2520Binding%2520and%2520T-cell%2520Activation%26jtitle%3DAllergy%26date%3D2019%26doi%3D10.1111%2Fall.14057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Illing, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivian, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharadwaj, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjer-Nielsen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gras, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossjohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCluskey, J.</span></span> <span> </span><span class="NLM_article-title">Immune Self-Reactivity Triggered by Drug-Modified HLA-Peptide Repertoire</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>486</i></span>,  <span class="NLM_fpage">554</span>– <span class="NLM_lpage">558</span>, <span class="refDoi"> DOI: 10.1038/nature11147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fnature11147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22722860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVSqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=554-558&author=P.+T.+Illingauthor=J.+P.+Vivianauthor=N.+L.+Dudekauthor=L.+Kostenkoauthor=Z.+Chenauthor=M.+Bharadwajauthor=J.+J.+Milesauthor=L.+Kjer-Nielsenauthor=S.+Grasauthor=N.+A.+Williamsonauthor=S.+R.+Burrowsauthor=A.+W.+Purcellauthor=J.+Rossjohnauthor=J.+McCluskey&title=Immune+Self-Reactivity+Triggered+by+Drug-Modified+HLA-Peptide+Repertoire&doi=10.1038%2Fnature11147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Immune self-reactivity triggered by drug-modified HLA-peptide repertoire</span></div><div class="casAuthors">Illing, Patricia T.; Vivian, Julian P.; Dudek, Nadine L.; Kostenko, Lyudmila; Chen, Zhenjun; Bharadwaj, Mandvi; Miles, John J.; Kjer-Nielsen, Lars; Gras, Stephanie; Williamson, Nicholas A.; Burrows, Scott R.; Purcell, Anthony W.; Rossjohn, Jamie; McCluskey, James</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7404</span>),
    <span class="NLM_cas:pages">554-558</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human leukocyte antigens (HLAs) are highly polymorphic proteins that initiate immunity by presenting pathogen-derived peptides to T cells.  HLA polymorphisms mostly map to the antigen-binding cleft, thereby diversifying the repertoire of self-derived and pathogen-derived peptide antigens selected by different HLA allotypes.  A growing no. of immunol. based drug reactions, including abacavir hypersensitivity syndrome (AHS) and carbamazepine-induced Stevens-Johnson syndrome (SJS), are assocd. with specific HLA alleles.  However, little is known about the underlying mechanisms of these assocns., including AHS, a prototypical HLA-assocd. drug reaction occurring exclusively in individuals with the common histocompatibility allele HLA-B*57:01, and with a relative risk of more than 1,000 (refs. 6, 7).  We show that unmodified abacavir binds non-covalently to HLA-B*57:01, lying across the bottom of the antigen-binding cleft and reaching into the F-pocket, where a carboxy-terminal tryptophan typically anchors peptides bound to HLA-B*57:01.  Abacavir binds with exquisite specificity to HLA-B*57:01, changing the shape and chem. of the antigen-binding cleft, thereby altering the repertoire of endogenous peptides that can bind HLA-B*57:01.  In this way, abacavir guides the selection of new endogenous peptides, inducing a marked alteration in immunol. self'.  The resultant peptide-centric altered self' activates abacavir-specific T-cells, thereby driving polyclonal CD8 T-cell activation and a systemic reaction manifesting as AHS.  We also show that carbamazepine, a widely used anti-epileptic drug assocd. with hypersensitivity reactions in HLA-B*15:02 individuals, binds to this allotype, producing alterations in the repertoire of presented self peptides.  Our findings simultaneously highlight the importance of HLA polymorphism in the evolution of pharmacogenomics and provide a general mechanism for some of the growing no. of HLA-linked hypersensitivities that involve small-mol. drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGremSgwwlcpEbVg90H21EOLACvtfcHk0lgyu9lPmOF8jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVSqu7c%253D&md5=ff02cbeb2f129205c0269a2c7fbee4ed</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fnature11147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11147%26sid%3Dliteratum%253Aachs%26aulast%3DIlling%26aufirst%3DP.%2BT.%26aulast%3DVivian%26aufirst%3DJ.%2BP.%26aulast%3DDudek%26aufirst%3DN.%2BL.%26aulast%3DKostenko%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DBharadwaj%26aufirst%3DM.%26aulast%3DMiles%26aufirst%3DJ.%2BJ.%26aulast%3DKjer-Nielsen%26aufirst%3DL.%26aulast%3DGras%26aufirst%3DS.%26aulast%3DWilliamson%26aufirst%3DN.%2BA.%26aulast%3DBurrows%26aufirst%3DS.%2BR.%26aulast%3DPurcell%26aufirst%3DA.%2BW.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DMcCluskey%26aufirst%3DJ.%26atitle%3DImmune%2520Self-Reactivity%2520Triggered%2520by%2520Drug-Modified%2520HLA-Peptide%2520Repertoire%26jtitle%3DNature%26date%3D2012%26volume%3D486%26spage%3D554%26epage%3D558%26doi%3D10.1038%2Fnature11147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faridi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramarathinam, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivian, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illing, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mifsud, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gearing, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertzog, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ternette, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossjohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croft, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, A. W.</span></span> <span> </span><span class="NLM_article-title">A Subset of HLA-I Peptides are not Genomically Templated: Evidence for Cis- and Trans-Spliced Peptide Ligands</span>. <i>Science Immunology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">eaar3947</span>, <span class="refDoi"> DOI: 10.1126/sciimmunol.aar3947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1126%2Fsciimmunol.aar3947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30315122" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=eaar3947&author=P.+Faridiauthor=C.+Liauthor=S.+H.+Ramarathinamauthor=J.+P.+Vivianauthor=P.+T.+Illingauthor=N.+A.+Mifsudauthor=R.+Ayalaauthor=J.+Songauthor=L.+J.+Gearingauthor=P.+J.+Hertzogauthor=N.+Ternetteauthor=J.+Rossjohnauthor=N.+P.+Croftauthor=A.+W.+Purcell&title=A+Subset+of+HLA-I+Peptides+are+not+Genomically+Templated%3A+Evidence+for+Cis-+and+Trans-Spliced+Peptide+Ligands&doi=10.1126%2Fsciimmunol.aar3947"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1126%2Fsciimmunol.aar3947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciimmunol.aar3947%26sid%3Dliteratum%253Aachs%26aulast%3DFaridi%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DRamarathinam%26aufirst%3DS.%2BH.%26aulast%3DVivian%26aufirst%3DJ.%2BP.%26aulast%3DIlling%26aufirst%3DP.%2BT.%26aulast%3DMifsud%26aufirst%3DN.%2BA.%26aulast%3DAyala%26aufirst%3DR.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DGearing%26aufirst%3DL.%2BJ.%26aulast%3DHertzog%26aufirst%3DP.%2BJ.%26aulast%3DTernette%26aufirst%3DN.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DCroft%26aufirst%3DN.%2BP.%26aulast%3DPurcell%26aufirst%3DA.%2BW.%26atitle%3DA%2520Subset%2520of%2520HLA-I%2520Peptides%2520are%2520not%2520Genomically%2520Templated%253A%2520Evidence%2520for%2520Cis-%2520and%2520Trans-Spliced%2520Peptide%2520Ligands%26jtitle%3DScience%2520Immunology%26date%3D2018%26volume%3D3%26spage%3Deaar3947%26doi%3D10.1126%2Fsciimmunol.aar3947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donaldson, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatnagar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pe’er, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floratos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernal, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordell, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, C. P.</span></span> <span> </span><span class="NLM_article-title">HLA-B*5701 Genotype is a Major Determinant of Drug-Induced Liver Injury Due to Flucloxacillin</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">816</span>– <span class="NLM_lpage">819</span>, <span class="refDoi"> DOI: 10.1038/ng.379</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fng.379" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19483685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1alu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2009&pages=816-819&author=A.+K.+Dalyauthor=P.+T.+Donaldsonauthor=P.+Bhatnagarauthor=Y.+Shenauthor=I.+Pe%E2%80%99erauthor=A.+Floratosauthor=M.+J.+Dalyauthor=D.+B.+Goldsteinauthor=S.+Johnauthor=M.+R.+Nelsonauthor=J.+Grahamauthor=B.+K.+Parkauthor=J.+F.+Dillonauthor=W.+Bernalauthor=H.+J.+Cordellauthor=M.+Pirmohamedauthor=G.+P.+Aithalauthor=C.+P.+Day&title=HLA-B*5701+Genotype+is+a+Major+Determinant+of+Drug-Induced+Liver+Injury+Due+to+Flucloxacillin&doi=10.1038%2Fng.379"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin</span></div><div class="casAuthors">Daly, Ann K.; Donaldson, Peter T.; Bhatnagar, Pallav; Shen, Yufeng; Pe'er, Itsik; Floratos, Aris; Daly, Mark J.; Goldstein, David B.; John, Sally; Nelson, Matthew R.; Graham, Julia; Park, B. Kevin; Dillon, John F.; Bernal, William; Cordell, Heather J.; Pirmohamed, Munir; Aithal, Guruprasad P.; Day, Christopher P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">816-819</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is an important cause of serious liver disease.  The antimicrobial agent flucloxacillin is a common cause of DILI, but the genetic basis for susceptibility remains unclear.  We conducted a genome-wide assocn. (GWA) study using 866,399 markers in 51 cases of flucloxacillin DILI and 282 controls matched for sex and ancestry.  The GWA showed an assocn. peak in the major histocompatibility complex (MHC) region with the strongest assocn. (P = 8.7 × 10-33) seen for rs2395029[G], a marker in complete linkage disequil. (LD) with HLA-B*5701.  Further MHC genotyping, which included 64 flucloxacillin-tolerant controls, confirmed the assocn. with HLA-B*5701 (OR = 80.6, P = 9.0 × 10-19).  The assocn. was replicated in a second cohort of 23 cases.  In HLA-B*5701 carrier cases, rs10937275 in ST6GAL1 on chromosome 3 also showed genome-wide significance (OR = 4.1, P = 1.4 × 10-8).  These findings provide new insights into the mechanism of flucloxacillin DILI and have the potential to substantially improve diagnosis of this serious disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPN1H1yEwIN7Vg90H21EOLACvtfcHk0lhPPo2_RqZ1bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1alu7o%253D&md5=d147759fd2863b2f575595a73723ac10</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fng.379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.379%26sid%3Dliteratum%253Aachs%26aulast%3DDaly%26aufirst%3DA.%2BK.%26aulast%3DDonaldson%26aufirst%3DP.%2BT.%26aulast%3DBhatnagar%26aufirst%3DP.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DPe%25E2%2580%2599er%26aufirst%3DI.%26aulast%3DFloratos%26aufirst%3DA.%26aulast%3DDaly%26aufirst%3DM.%2BJ.%26aulast%3DGoldstein%26aufirst%3DD.%2BB.%26aulast%3DJohn%26aufirst%3DS.%26aulast%3DNelson%26aufirst%3DM.%2BR.%26aulast%3DGraham%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DDillon%26aufirst%3DJ.%2BF.%26aulast%3DBernal%26aufirst%3DW.%26aulast%3DCordell%26aufirst%3DH.%2BJ.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DAithal%26aufirst%3DG.%2BP.%26aulast%3DDay%26aufirst%3DC.%2BP.%26atitle%3DHLA-B%252A5701%2520Genotype%2520is%2520a%2520Major%2520Determinant%2520of%2520Drug-Induced%2520Liver%2520Injury%2520Due%2520to%2520Flucloxacillin%26jtitle%3DNat.%2520Genet.%26date%3D2009%26volume%3D41%26spage%3D816%26epage%3D819%26doi%3D10.1038%2Fng.379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinsson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cederbrant, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jirholt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mucs, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madeyski-Bengtson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havarinasab, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hultman, P.</span></span> <span> </span><span class="NLM_article-title">HLA-DR7 and HLA-DQ2: Transgenic Mouse Strains Tested as a Model System for Ximelagatran Hepatotoxicity</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e0184744</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0184744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1371%2Fjournal.pone.0184744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28934241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVyktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e0184744&author=H.+Lundgrenauthor=K.+Martinssonauthor=K.+Cederbrantauthor=J.+Jirholtauthor=D.+Mucsauthor=K.+Madeyski-Bengtsonauthor=S.+Havarinasabauthor=P.+Hultman&title=HLA-DR7+and+HLA-DQ2%3A+Transgenic+Mouse+Strains+Tested+as+a+Model+System+for+Ximelagatran+Hepatotoxicity&doi=10.1371%2Fjournal.pone.0184744"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">HLA-DR7 and HLA-DQ2: Transgenic mouse strains tested as a model system for ximelagatran</span></div><div class="casAuthors">Lundgren, Hanna; Martinsson, Klara; Cederbrant, Karin; Jirholt, Johan; Mucs, Daniel; Madeyski-Bengtson, Katja; Havarinasab, Said; Hultman, Per</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0184744/1-e0184744/16</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The oral thrombin inhibitor ximelagatran was withdrawn in the late clin. trial phase because it adversely affected the liver.  In approx. 8% of treated patients, druginduced liver injury (DILI) was expressed as transient alanine transaminase (ALT) elevations.  No evidence of DILI had been revealed in the pre-clin. in vivo studies.  A whole genome scan study performed on the clin. study material identified a strong genetic assocn. between the major histocompatibility complex alleles for human leukocyte antigens (HLA) (HLA-DR7 and HLA-DQ2) and elevated ALT levels in treated patients.  An immunemediated pathogenesis was suggested.  Here, we evaluated whether HLA transgenic mice models could be used to investigate whether the expression of relevant HLA mols. was enough to reproduce the DILI effects in humans.  In silico modeling performed in this study revealed assocn. of both ximelagatran (pro-drug) and melagatran (active drug) to the antigen-presenting groove of the homol. modelled HLA-DR7 mol. suggesting "altered repertoire" as a key initiating event driving development of DILI in humans.  Transgenic mouse strains (tgms) expressing HLA of serotype HLA-DR7 (HLA-DRB1 *0701, -DRA*0102), and HLA-DQ2 (HLA-DQB1 *0202,-DQA1 *0201) were created.  These two lines were crossed with a human (h)CD4 transgenic line, generating the two tgms DR7xhCD4 and DQ2xhCD4.  To investigate whether the DILI effects obsd. in humans could be reproduced in tgms, the mice were treated for 28 days with ximelagatran.  Results revealed no signs of DILI when biomarkers for liver toxicity were measured and histopathol. was evaluated.  In the ximelagatran case, presence of relevant HLA-expression in a preclin. model did not fulfil the prerequisite for reproducing DILI obsd. in patients.  Nonetheless, for the first time an HLA-transgenic mouse model has been investigated for use in HLA-assocd. DILI induced by a low mol. wt. compd.  This study shows that mimicking of genetic susceptibility, expressed as DILI-assocd. HLA-types in mice, is not sufficient for reproducing the complex pathogenesis leading to DILI in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnsKHH13qUfrVg90H21EOLACvtfcHk0lhPPo2_RqZ1bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVyktro%253D&md5=9687fb0a68fa79c91b5b9955c8dc30a8</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0184744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0184744%26sid%3Dliteratum%253Aachs%26aulast%3DLundgren%26aufirst%3DH.%26aulast%3DMartinsson%26aufirst%3DK.%26aulast%3DCederbrant%26aufirst%3DK.%26aulast%3DJirholt%26aufirst%3DJ.%26aulast%3DMucs%26aufirst%3DD.%26aulast%3DMadeyski-Bengtson%26aufirst%3DK.%26aulast%3DHavarinasab%26aufirst%3DS.%26aulast%3DHultman%26aufirst%3DP.%26atitle%3DHLA-DR7%2520and%2520HLA-DQ2%253A%2520Transgenic%2520Mouse%2520Strains%2520Tested%2520as%2520a%2520Model%2520System%2520for%2520Ximelagatran%2520Hepatotoxicity%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26spage%3De0184744%26doi%3D10.1371%2Fjournal.pone.0184744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Susukida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span> <span> </span><span class="NLM_article-title">An Animal Model of Abacavir-Induced HLA-Mediated Liver Injury</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">723</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfy001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfy001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29319822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGjtL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2018&pages=713-723&author=B.+Songauthor=S.+Aokiauthor=C.+Liuauthor=T.+Susukidaauthor=K.+Ito&title=An+Animal+Model+of+Abacavir-Induced+HLA-Mediated+Liver+Injury&doi=10.1093%2Ftoxsci%2Fkfy001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">An animal model of abacavir-induced HLA-mediated liver injury</span></div><div class="casAuthors">Song, Binbin; Aoki, Shigeki; Liu, Cong; Susukida, Takeshi; Ito, Kousei</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">713-723</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Genome-wide assocn. studies indicate that several idiosyncratic adverse drug reactions are highly assocd. with specific human leukocyte antigen (HLA) alleles.  For instance, abacavir, a human immunodeficiency virus reverse transcriptase inhibitor, induces multiorgan toxicity exclusively in patients carrying the HLA-B*57:01 allele.  However, the underlying mechanism is unclear due to a lack of appropriate animal models.  Previously, the authors developed HLA-B*57:01 transgenic mice and found that topical application of abacavir to the ears induced proliferation of CD8+ lymphocytes in local lymph nodes.  Here, the authors attempted to reproduce abacavir-induced liver injury in these mice.  However, oral administration of abacavir alone to HLA-B*57:01 transgenic mice did not increase levels of the liver injury marker alanine aminotransferase.  Considering the importance of innate immune activation in mouse liver, the authors treated mice with CpG oligodeoxynucleotide, a toll-like receptor 9 agonist, plus abacavir.  This resulted in a marked increase in alanine aminotransferase, pathol. changes in liver, increased nos. of activated CD8+ T cells, and tissue infiltration by immune cells exclusively in HLA-B*57:01 transgenic mice.  These results indicate that CpG oligodeoxynucleotide-induced inflammatory reactions and/or innate immune activation are necessary for abacavir-induced HLA-mediated liver injury characterized by infiltration of CD8+ T cells.  Thus, the authors developed the first mouse model of HLA-mediated abacavir-induced idiosyncratic liver injury.  Further investigation will show that the proposed HLA-mediated liver injury model can be applied to other combinations of drugs and HLA types, thereby improving drug development and contributing to the development of personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW7EsMjfSMO7Vg90H21EOLACvtfcHk0lgR4dLazwYEkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGjtL3J&md5=b124c2e2eaf3d83757cfc5ee240fdf26</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfy001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfy001%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DB.%26aulast%3DAoki%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DSusukida%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DK.%26atitle%3DAn%2520Animal%2520Model%2520of%2520Abacavir-Induced%2520HLA-Mediated%2520Liver%2520Injury%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D162%26spage%3D713%26epage%3D723%26doi%3D10.1093%2Ftoxsci%2Fkfy001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Susukida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Immune-Mediated Idiosyncratic Drug Toxicity Using Chimeric HLA Transgenic Mice</span>. <i>Arch. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">1177</span>– <span class="NLM_lpage">1188</span>, <span class="refDoi"> DOI: 10.1007/s00204-017-2112-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs00204-017-2112-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29150704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVaru73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2018&pages=1177-1188&author=T.+Susukidaauthor=S.+Aokiauthor=K.+Kogoauthor=S.+Fujimoriauthor=B.+Songauthor=C.+Liuauthor=S.+Sekineauthor=K.+Ito&title=Evaluation+of+Immune-Mediated+Idiosyncratic+Drug+Toxicity+Using+Chimeric+HLA+Transgenic+Mice&doi=10.1007%2Fs00204-017-2112-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of immune-mediated idiosyncratic drug toxicity using chimeric HLA transgenic mice</span></div><div class="casAuthors">Susukida, Takeshi; Aoki, Shigeki; Kogo, Kotaro; Fujimori, Sota; Song, Binbin; Liu, Cong; Sekine, Shuichi; Ito, Kousei</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Toxicology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1177-1188</span>CODEN:
                <span class="NLM_cas:coden">ARTODN</span>;
        ISSN:<span class="NLM_cas:issn">0340-5761</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Immune-mediated idiosyncratic drug toxicity (IDT) is a rare adverse drug reaction, potentially resulting in death.  Although genome-wide assocn. studies suggest that the occurrence of immune-mediated IDT is strongly assocd. with specific human leukocyte antigen (HLA) allotypes, these assocns. have not yet been prospectively demonstrated.  In this study, we focused on HLA-B*57:01 and abacavir (ABC)-induced immune-mediated IDT, and constructed transgenic mice carrying chimeric HLA-B*57:01 (B*57:01-Tg) to det. if this in vivo model may be useful for evaluating immune-mediated IDT.  Local lymph node assay (LLNA) results demonstrated that percentages of BrdU+, IL-2+, and IFN-γ+ in CD8+ T cells of ABC (50 mg/kg/day)-applied B*57:01-Tg mice were significantly higher than those in littermates (LMs), resulting in the infiltration of inflammatory cells into the ear.  These immune responses were not obsd. in B*57:03-Tg mice (neg. control).  Furthermore, oral administration of 1% (vol./vol.) ABC significantly increased the percentage of CD44highCD62Llow CD8+ memory T cells in lymph nodes and spleen derived from B*57:01-Tg mice, but not in those from B*57:03-Tg mice and LMs.  These results suggest that B*57:01-Tg mice potentially enable the reprodn. and evaluation of HLA-B*57:01 and ABC-induced immune-mediated IDT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJRVkP4iJdnLVg90H21EOLACvtfcHk0lgR4dLazwYEkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVaru73M&md5=d9355684f8b8e8a8379a9f78707ab5a5</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1007%2Fs00204-017-2112-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00204-017-2112-9%26sid%3Dliteratum%253Aachs%26aulast%3DSusukida%26aufirst%3DT.%26aulast%3DAoki%26aufirst%3DS.%26aulast%3DKogo%26aufirst%3DK.%26aulast%3DFujimori%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DSekine%26aufirst%3DS.%26aulast%3DIto%26aufirst%3DK.%26atitle%3DEvaluation%2520of%2520Immune-Mediated%2520Idiosyncratic%2520Drug%2520Toxicity%2520Using%2520Chimeric%2520HLA%2520Transgenic%2520Mice%26jtitle%3DArch.%2520Toxicol.%26date%3D2018%26volume%3D92%26spage%3D1177%26epage%3D1188%26doi%3D10.1007%2Fs00204-017-2112-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J. P.</span></span> <span> </span><span class="NLM_article-title">The Danger Hypothesis Applied to Idiosyncratic Drug Reactions</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>196</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1007/978-3-642-00663-0_18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2F978-3-642-00663-0_18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvVymsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=196&publication_year=2010&pages=493-509&author=J.+Liauthor=J.+P.+Uetrecht&title=The+Danger+Hypothesis+Applied+to+Idiosyncratic+Drug+Reactions&doi=10.1007%2F978-3-642-00663-0_18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The danger hypothesis applied to idiosyncratic drug reactions</span></div><div class="casAuthors">Li, Jinze; Uetrecht, Jack P.</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">196</span>
        (<span class="NLM_cas:issue">Adverse Drug Reactions</span>),
    <span class="NLM_cas:pages">493-509</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  The danger hypothesis has had a profound effect on the way immunologists view the immune response.  This hypothesis proposes that the major determinant of whether an immune response is mounted against some agent is detd. by whether that agent causes some type of cell damage.  Assuming that most idiosyncratic drug reactions (IDRs) are immune-mediated, this hypothesis also has the potential to explain many aspects of the mechanism of these adverse drug reactions.  For example, most IDRs appear to be caused by chem. metabolites rather than the parent drug, but not all drugs that form reactive metabolites are assocd. with a significant incidence of IDRs.  Therefore, using the danger hypothesis, one feature of a drug candidate that may predict whether it causes an IDR is whether the drug, or more likely its reactive metabolites, cause cell damage.  Although the range of mols. that can act as danger signals is unknown, the most attractive candidates are high mobility group box 1 protein (HMGB1), heat shock proteins, and S100 proteins.  These mols. act through the same receptors (toll-like receptors) as pathogen-assocd. mols. that stimulate the immune system.  Therefore, other environmental factors such as infections or trauma might det. which patients would be at increased risk for IDRs.  Although there are examples where this appears to be the case, in most cases there are no obvious environmental factors that det. IDR risk.  In addn., in animal models of immune-mediated reactions, stimulation of toll-like receptors often does not increase the immune response, and depending on the timing, it can actually be protective.  Therefore, there may be addnl. unknown control mechanisms that are involved.  A better understanding of these fundamental immune mechanisms has the potential to have a significant impact on many areas of medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKLzlKF4sicrVg90H21EOLACvtfcHk0lgR4dLazwYEkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvVymsrg%253D&md5=e1b075a21b78cf86be7f7db001b66e13</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-00663-0_18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-00663-0_18%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DUetrecht%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520Danger%2520Hypothesis%2520Applied%2520to%2520Idiosyncratic%2520Drug%2520Reactions%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2010%26volume%3D196%26spage%3D493%26epage%3D509%26doi%3D10.1007%2F978-3-642-00663-0_18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matzinger, P.</span></span> <span> </span><span class="NLM_article-title">Tolerance, Danger, and the Extended Family</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">1045</span>, <span class="refDoi"> DOI: 10.1146/annurev.iy.12.040194.005015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1146%2Fannurev.iy.12.040194.005015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=8011301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADyaK2c3otVOqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1994&pages=991-1045&author=P.+Matzinger&title=Tolerance%2C+Danger%2C+and+the+Extended+Family&doi=10.1146%2Fannurev.iy.12.040194.005015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Tolerance, danger, and the extended family</span></div><div class="casAuthors">Matzinger P</div><div class="citationInfo"><span class="NLM_cas:title">Annual review of immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">991-1045</span>
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    </div><div class="casAbstract">For many years immunologists have been well served by the viewpoint that the immune system's primary goal is to discriminate between self and non-self.  I believe that it is time to change viewpoints and, in this essay, I discuss the possibility that the immune system does not care about self and non-self, that its primary driving force is the need to detect and protect against danger, and that it does not do the job alone, but receives positive and negative communications from an extended network of other bodily tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTVb5k9OJxBRAwxfk_AGB-EfW6udTcc2eb6vqmvKgpWQLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c3otVOqsA%253D%253D&md5=c806a2e1f1e03be07f55f01e69c11e77</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1146%2Fannurev.iy.12.040194.005015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.iy.12.040194.005015%26sid%3Dliteratum%253Aachs%26aulast%3DMatzinger%26aufirst%3DP.%26atitle%3DTolerance%252C%2520Danger%252C%2520and%2520the%2520Extended%2520Family%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D1994%26volume%3D12%26spage%3D991%26epage%3D1045%26doi%3D10.1146%2Fannurev.iy.12.040194.005015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittkowski, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Disease: a ’DAMP’ View of Inflammatory Arthritis</span>. <i>Nat. Clin. Pract. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">382</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1038/ncprheum0531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fncprheum0531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=17599072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntVCitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=382-390&author=D.+Foellauthor=H.+Wittkowskiauthor=J.+Roth&title=Mechanisms+of+Disease%3A+a+%E2%80%99DAMP%E2%80%99+View+of+Inflammatory+Arthritis&doi=10.1038%2Fncprheum0531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Disease: a 'DAMP' view of inflammatory arthritis</span></div><div class="casAuthors">Foell, Dirk; Wittkowski, Helmut; Roth, Johannes</div><div class="citationInfo"><span class="NLM_cas:title">Nature Clinical Practice Rheumatology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">382-390</span>CODEN:
                <span class="NLM_cas:coden">NCPRCF</span>;
        ISSN:<span class="NLM_cas:issn">1745-8382</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Innate immunity achieves our primary host defense by recognizing invading microorganisms through pathogen-assocd. mol. patterns (PAMPs) and by reacting to tissue damage signals called damage-assocd. mol. patterns (DAMPs).  DAMP mols., including high mobility group box 1 protein (HMGB-1), heat-shock proteins (HSPs), uric acid, altered matrix proteins, and S100 proteins, represent important danger signals that mediate inflammatory responses through the receptor for advanced glycation end-products (RAGE, also known as AGER) and Toll-like receptors, after release from activated or necrotic cells.  The terms 'alarmins' and 'endokines' have also been proposed for DAMP mols.  A prototypic DAMP mol., the nuclear protein HMGB-1, is either passively released by necrotic cells or actively secreted with delay by activated cells.  S100A8, S100A9, and S100A12 are calcium-binding proteins expressed in the cytoplasm of phagocytes.  They are rapidly secreted by activated monocytes or neutrophils, which are abundant in inflamed synovial tissue.  HSPs are involved in the crosstalk between innate and adaptive immune systems, and primarily mediate immune regulatory functions.  Multiple pos. feedback loops between DAMPs and PAMPs and their overlapping receptors temporally and spatially drive these processes and may represent the mol. basis for the observation that infections, as well as nonspecific stress factors, can trigger flares in rheumatic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwzk-PVFew-bVg90H21EOLACvtfcHk0ljx1nJ8S_TbsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntVCitr0%253D&md5=2edaed8247735e833fc62ca2a417b250</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fncprheum0531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncprheum0531%26sid%3Dliteratum%253Aachs%26aulast%3DFoell%26aufirst%3DD.%26aulast%3DWittkowski%26aufirst%3DH.%26aulast%3DRoth%26aufirst%3DJ.%26atitle%3DMechanisms%2520of%2520Disease%253A%2520a%2520%25E2%2580%2599DAMP%25E2%2580%2599%2520View%2520of%2520Inflammatory%2520Arthritis%26jtitle%3DNat.%2520Clin.%2520Pract.%2520Rheumatol.%26date%3D2007%26volume%3D3%26spage%3D382%26epage%3D390%26doi%3D10.1038%2Fncprheum0531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Murphy, B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, C.</span></span> <span> </span><span class="NLM_article-title">The Role of Damage Associated Molecular Pattern Molecules in Acetaminophen-Induced Liver Injury in Mice</span>. <i>Toxicol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">387</span>, <span class="refDoi"> DOI: 10.1016/j.toxlet.2009.11.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.toxlet.2009.11.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19931603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1yltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2010&pages=387&author=B.+V.+Martin-Murphyauthor=M.+P.+Holtauthor=C.+Ju&title=The+Role+of+Damage+Associated+Molecular+Pattern+Molecules+in+Acetaminophen-Induced+Liver+Injury+in+Mice&doi=10.1016%2Fj.toxlet.2009.11.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">The role of damage associated molecular pattern molecules in acetaminophen-induced liver injury in mice</span></div><div class="casAuthors">Martin-Murphy, Brittany V.; Holt, Michael P.; Ju, Cynthia</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">387-394</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The idiosyncratic nature, severity and poor diagnosis of drug-induced liver injury (DILI) make these reactions a major safety issue during drug development, as well as the most common cause for the withdrawal of drugs from the pharmaceutical market.  Elucidation of the underlying mechanism(s) is necessary for identifying predisposing factors and developing strategies in the treatment and prevention of DILI.  Acetaminophen (APAP) is a widely used over the counter therapeutic that is known to be effective and safe at therapeutic doses.  However, in overdose situations fatal and non-fatal hepatic necrosis can result.  Evidence suggests that the chem. reactive metabolite of the drug initiates hepatocyte damage and that inflammatory innate immune responses also occur within the liver, leading to the exacerbation and progression of tissue injury.  Here we investigate whether following APAP-induced liver injury (AILI) damaged hepatocytes release "danger" signals or damage assocd. mol. pattern (DAMP) mols., which induce pro-inflammatory activation of hepatic macrophages, further contributing to the progression of liver injury.  Our study demonstrated a clear activation of Kupffer cells following early exposure to APAP (1 h).  Activation of a murine macrophage cell line, RAW cells, was also obsd. following treatment with liver perfusate from APAP-treated mice, or with culture supernatant of APAP-challenged hepatocytes.  Moreover, in these media, the DAMP mols., heat-shock protein-70 (HSP-70) and high mobility group box-1 (HMGB1) were detected.  Overall, these findings reveal that DAMP mols. released from damaged and necrotic hepatocytes may serve as a crucial link between the initial hepatocyte damage and the activation of innate immune cells following APAP-exposure, and that DAMPs may represent a potential therapeutic target for AILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSwUyM34SGDbVg90H21EOLACvtfcHk0ljx1nJ8S_TbsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1yltLs%253D&md5=ce792cac71b7ca60e4251527cebf3c7a</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.toxlet.2009.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.toxlet.2009.11.016%26sid%3Dliteratum%253Aachs%26aulast%3DMartin-Murphy%26aufirst%3DB.%2BV.%26aulast%3DHolt%26aufirst%3DM.%2BP.%26aulast%3DJu%26aufirst%3DC.%26atitle%3DThe%2520Role%2520of%2520Damage%2520Associated%2520Molecular%2520Pattern%2520Molecules%2520in%2520Acetaminophen-Induced%2520Liver%2520Injury%2520in%2520Mice%26jtitle%3DToxicol.%2520Lett.%26date%3D2010%26volume%3D192%26spage%3D387%26doi%3D10.1016%2Fj.toxlet.2009.11.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maiuri, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breier, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gora, L. F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkins, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganey, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, R. A.</span></span> <span> </span><span class="NLM_article-title">Cytotoxic Synergy Between Cytokines and NSAIDs Associated With Idiosyncratic Hepatotoxicity Is Driven by Mitogen-Activated Protein Kinases</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfv091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfv091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25953702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC2Mfhsl2itA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2015&pages=265-280&author=A.+R.+Maiuriauthor=A.+B.+Breierauthor=L.+F.+J.+Goraauthor=R.+V.+Parkinsauthor=P.+E.+Ganeyauthor=R.+A.+Roth&title=Cytotoxic+Synergy+Between+Cytokines+and+NSAIDs+Associated+With+Idiosyncratic+Hepatotoxicity+Is+Driven+by+Mitogen-Activated+Protein+Kinases&doi=10.1093%2Ftoxsci%2Fkfv091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Cytotoxic Synergy Between Cytokines and NSAIDs Associated With Idiosyncratic Hepatotoxicity Is Driven by Mitogen-Activated Protein Kinases</span></div><div class="casAuthors">Maiuri Ashley R; Breier Anna B; Gora Lukas F J; Parkins Robert V; Ganey Patricia E; Roth Robert A</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological sciences : an official journal of the Society of Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">265-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most frequent causes of idiosyncratic, drug-induced liver injury (IDILI).  Mechanisms of IDILI are unknown, but immune responses are suspected to underlie them.  In animal models of IDILI, the cytokines tumor necrosis factor-alpha (TNFα) and interferon-gamma (IFNγ) are essential to the pathogenesis.  Some drugs associated with IDILI interact with cytokines to kill hepatocytes in vitro, and mitogen-activated protein kinases (MAPKs) might play a role.  We tested the hypothesis that caspases and MAPKs are involved in NSAID/cytokine-induced cytotoxicity.  NSAIDs that are acetic acid (AA) derivatives and associated with IDILI synergized with TNFα in causing cytotoxicity in HepG2 cells, and IFNγ enhanced this interaction.  NSAIDs that are propionic acid (PA) derivatives and cause IDILI that is of less clinical concern also synergized with TNFα, but IFNγ was without effect.  Caspase inhibition prevented cytotoxicity from AA and PA derivative/cytokine treatment.  Treatment with a representative AA or PA derivative induced activation of the MAPKs c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK), and p38.  Inhibition of either JNK or ERK reduced cytotoxicity from cytokine interactions with AA derivatives.  In contrast, an ERK inhibitor potentiated cytotoxicity from cytokine interactions with PA derivatives.  An AA derivative but not a PA derivative enhanced IFNγ-mediated activation of STAT-1, and this enhancement was ERK-dependent.  These findings raise the possibility that some IDILI reactions result from drug/cytokine synergy involving caspases and MAPKs and suggest that, even for drugs within the same pharmacologic class, synergy with cytokines occurs by different kinase signaling mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnlTZNshuJKbBItaL1WaVAfW6udTcc2eb6vqmvKgpWQLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mfhsl2itA%253D%253D&md5=e6154caabbf62b0847ed2b373100504a</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfv091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfv091%26sid%3Dliteratum%253Aachs%26aulast%3DMaiuri%26aufirst%3DA.%2BR.%26aulast%3DBreier%26aufirst%3DA.%2BB.%26aulast%3DGora%26aufirst%3DL.%2BF.%2BJ.%26aulast%3DParkins%26aufirst%3DR.%2BV.%26aulast%3DGaney%26aufirst%3DP.%2BE.%26aulast%3DRoth%26aufirst%3DR.%2BA.%26atitle%3DCytotoxic%2520Synergy%2520Between%2520Cytokines%2520and%2520NSAIDs%2520Associated%2520With%2520Idiosyncratic%2520Hepatotoxicity%2520Is%2520Driven%2520by%2520Mitogen-Activated%2520Protein%2520Kinases%26jtitle%3DToxicol.%2520Sci.%26date%3D2015%26volume%3D146%26spage%3D265%26epage%3D280%26doi%3D10.1093%2Ftoxsci%2Fkfv091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holman, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nautiyal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thacker, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otieno, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCluyse, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span> <span> </span><span class="NLM_article-title">Hepatocyte-Derived Exosomes Promote Liver Immune Tolerance: Possible Implications for Idiosyncratic Drug-Induced Liver Injury</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfz112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfz112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=31093666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFSmsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2019&pages=499-508&author=N.+S.+Holmanauthor=R.+J.+Churchauthor=M.+Nautiyalauthor=K.+A.+Roseauthor=S.+E.+Thackerauthor=M.+A.+Otienoauthor=K.+K.+Wolfauthor=E.+LeCluyseauthor=P.+B.+Watkinsauthor=M.+Mosedale&title=Hepatocyte-Derived+Exosomes+Promote+Liver+Immune+Tolerance%3A+Possible+Implications+for+Idiosyncratic+Drug-Induced+Liver+Injury&doi=10.1093%2Ftoxsci%2Fkfz112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatocyte-derived exosomes promote liver immune tolerance: possible implications for idiosyncratic drug-induced liver injury</span></div><div class="casAuthors">Holman, Natalie S.; Church, Rachel J.; Nautiyal, Manisha; Rose, Kelly A.; Thacker, Sarah E.; Otieno, Monicah A.; Wolf, Kristina K.; LeCluyse, Edward; Watkins, Paul B.; Mosedale, Merrie</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">499-508</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Most idiosyncratic drug-induced liver injury appears to result from an adaptive immune attack on the liver.  Recent evidence suggests that the T-cell response may be facilitated by the loss of immune tolerance.  In this study, we explored the hypothesis that constitutively released hepatocyte-derived exosomes (HDE) are important for maintaining normal liver immune tolerance.  Exosomes were isolated from the conditioned medium of primary human hepatocytes via polymer pptn.  Mock controls were prepd. by processing fresh medium that was not hepatocyte exposed with pptn. reagent.  THP-1 monocytes were then treated with HDE or an equiv. vol. of mock control for 24 h, followed by a 6-h stimulation with LPS.  HDE exposure resulted in a significant decrease in the LPS-induced media levels of interleukin-1β and interleukin-8.  Gene expression profiling performed in THP-1 cells just prior to LPS-induced stimulation identified a significant decrease among genes assocd. with innate immune response.  MicroRNA (miRNA) profiling was performed on the HDE to identify exosome contents that may drive immune suppression.  Many of the predicted mRNA target genes for the most abundant microRNAs in HDE were among the differentially expressed genes in THP-1 cells.  Taken together, our data suggest that HDE play a role in maintaining normal liver immune tolerance.  Future expts. will explore the possibility that drugs causing idiosyncratic liver injury promote the loss of homeostatic HDE signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBGUZREf5DlrVg90H21EOLACvtfcHk0li2ewYIEYM27g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFSmsr8%253D&md5=0ef0bd7f4acfd31fdc8571dccee64f6e</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfz112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfz112%26sid%3Dliteratum%253Aachs%26aulast%3DHolman%26aufirst%3DN.%2BS.%26aulast%3DChurch%26aufirst%3DR.%2BJ.%26aulast%3DNautiyal%26aufirst%3DM.%26aulast%3DRose%26aufirst%3DK.%2BA.%26aulast%3DThacker%26aufirst%3DS.%2BE.%26aulast%3DOtieno%26aufirst%3DM.%2BA.%26aulast%3DWolf%26aufirst%3DK.%2BK.%26aulast%3DLeCluyse%26aufirst%3DE.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DMosedale%26aufirst%3DM.%26atitle%3DHepatocyte-Derived%2520Exosomes%2520Promote%2520Liver%2520Immune%2520Tolerance%253A%2520Possible%2520Implications%2520for%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DToxicol.%2520Sci.%26date%3D2019%26volume%3D170%26spage%3D499%26epage%3D508%26doi%3D10.1093%2Ftoxsci%2Fkfz112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warrington, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhilips-Feener, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutherford, W. J.</span></span> <span> </span><span class="NLM_article-title">The Predictive Value of the Lymphocyte Transformation Test in Isoniazid-Associated Hepatitis</span>. <i>Clin. Exp. Allergy</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2222.1982.tb02521.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1111%2Fj.1365-2222.1982.tb02521.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1982&pages=217-222&author=R.+J.+Warringtonauthor=S.+McPhilips-Feenerauthor=W.+J.+Rutherford&title=The+Predictive+Value+of+the+Lymphocyte+Transformation+Test+in+Isoniazid-Associated+Hepatitis&doi=10.1111%2Fj.1365-2222.1982.tb02521.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2222.1982.tb02521.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2222.1982.tb02521.x%26sid%3Dliteratum%253Aachs%26aulast%3DWarrington%26aufirst%3DR.%2BJ.%26aulast%3DMcPhilips-Feener%26aufirst%3DS.%26aulast%3DRutherford%26aufirst%3DW.%2BJ.%26atitle%3DThe%2520Predictive%2520Value%2520of%2520the%2520Lymphocyte%2520Transformation%2520Test%2520in%2520Isoniazid-Associated%2520Hepatitis%26jtitle%3DClin.%2520Exp.%2520Allergy%26date%3D1982%26volume%3D12%26spage%3D217%26epage%3D222%26doi%3D10.1111%2Fj.1365-2222.1982.tb02521.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">Supernatant from Hepatocyte Cultures with Drugs That Cause Idiosyncratic Liver Injury Activates Macrophage Inflammasomes</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1327</span>– <span class="NLM_lpage">1332</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.7b00065</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.7b00065" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVWrsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2017&pages=1327-1332&author=R.+Katoauthor=J.+Uetrecht&title=Supernatant+from+Hepatocyte+Cultures+with+Drugs+That+Cause+Idiosyncratic+Liver+Injury+Activates+Macrophage+Inflammasomes&doi=10.1021%2Facs.chemrestox.7b00065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Supernatant from Hepatocyte Cultures with Drugs That Cause Idiosyncratic Liver Injury Activates Macrophage Inflammasomes</span></div><div class="casAuthors">Kato, Ryuji; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1327-1332</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is increasing evidence that most idiosyncratic drug-induced liver injury (IDILI) is immune mediated, and in most cases reactive metabolites appear to be responsible for induction of this immune response.  Reactive metabolites can cause cell damage with the release of damage-assocd. mol. patterns (DAMPs), which is thought to be involved in immune activation.  Presumably the reason that the liver is a common target of idiosyncratic drug reactions is because it is the major site of drug metab. and reactive metabolite formation.  Inflammasomes can be activated by DAMPs, and this may be a common mechanism by which DAMPs initiate an immune response.  In this study we tested the ability of drugs to induce the release of DAMPs that activate inflammasomes.  The drugs tested were amodiaquine and nevirapine; both are assocd. with significant incidences of severe IDILI.  The hepatocytes were a human hepatocarcinoma functional liver cell-4 (FLC-4) cell line.  For detection of inflammasome activation we used the human macrophage cell line, THP-1 cells.  We found that the supernatant from the incubation of both drugs with FLC-4 cells for 7 days led to increased caspase-1 activity and prodn. of IL-1β by THP-1 cells.  However, amodiaquine alone also directly activated THP-1 cells.  This is presumably because the myeloperoxidase in THP-1 cells can bioactivate amodiaquine to a reactive metabolite.  In contrast, nevirapine, requires cytochromes P 450 for reactive metabolite formation, and therefore required incubation with hepatocytes.  These results support the hypothesis that reactive metabolites of drugs can cause the release of DAMPs, which in turn can activate inflammasomes.  Inflammasome activation may be an important step in the activation of the immune system by drugs, which in some patients can lead to IDILI.  Our in vitro model is simple and convenient for evaluating inflammasome activation, and this may be a method to screen drugs for IDILI risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppuorD391X5bVg90H21EOLACvtfcHk0li2ewYIEYM27g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVWrsL0%253D&md5=65a15e116b586703ccdcb5dcd463db82</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.7b00065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.7b00065%26sid%3Dliteratum%253Aachs%26aulast%3DKato%26aufirst%3DR.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DSupernatant%2520from%2520Hepatocyte%2520Cultures%2520with%2520Drugs%2520That%2520Cause%2520Idiosyncratic%2520Liver%2520Injury%2520Activates%2520Macrophage%2520Inflammasomes%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2017%26volume%3D30%26spage%3D1327%26epage%3D1332%26doi%3D10.1021%2Facs.chemrestox.7b00065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span> <span> </span><span class="NLM_article-title">A Novel Cell-Based Assay for the Evaluation of Immune- and Inflammatory-Related Gene Expression as Biomarkers for the Risk Assessment of Drug-Induced Liver Injury</span>. <i>Toxicol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>241</i></span>,  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/j.toxlet.2015.10.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.toxlet.2015.10.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26546780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWiurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=241&publication_year=2016&pages=60-70&author=S.+Odaauthor=K.+Matsuoauthor=A.+Nakajimaauthor=T.+Yokoi&title=A+Novel+Cell-Based+Assay+for+the+Evaluation+of+Immune-+and+Inflammatory-Related+Gene+Expression+as+Biomarkers+for+the+Risk+Assessment+of+Drug-Induced+Liver+Injury&doi=10.1016%2Fj.toxlet.2015.10.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">A novel cell-based assay for the evaluation of immune- and inflammatory-related gene expression as biomarkers for the risk assessment of drug-induced liver injury</span></div><div class="casAuthors">Oda, Shingo; Matsuo, Kentaro; Nakajima, Akira; Yokoi, Tsuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">241</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">60-70</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a major problem in drug development.  Although some in vitro methods assessing DILI risk that utilize hepatic cell death or cellular stress as markers have been developed, the predictive ability of these tests is low.  In this study, we sought to develop a novel cell-based assay for the risk assessment of DILI that considers drug metab. as well as immune- and inflammatory-related gene expression.  To accomplish this goal, human hepatoma HepaRG or HepG2 cells were treated with 96 drugs with different clin. DILI risks.  The conditioned media were subsequently used to treat human promyelocytic leukemia HL-60 cells, and the mRNA expression levels of immune- and inflammatory-related genes in the cells were measured.  An area under the receiver operating characteristic curve (ROC-AUC) was calcd. to evaluate the predictive performance of the mRNA levels as markers to discriminate DILI risk.  The expression of interleukin-8 (IL-8) in HL-60 cells treated with conditioned media from HepaRG cells (HL-60/HepaRG) exhibited the highest ROC-AUC value of 0.758, followed by the expression of IL-1β in HL-60/HepaRG (ROC-AUC: 0.726).  Notably, the ROC-AUC values of these genes were higher in HL-60/HepaRG than in HL-60/HepG2, which suggests that HL-60/HepaRG has a higher potential for detecting the metabolic activation of drugs.  An integrated score calcd. from the levels of S100 calcium-binding protein A9 (S100A9), IL-1β, and IL-8 more precisely detd. the DILI risks than individual gene expression did.  The developed cell-based assay that utilizes immune-related gene expression would aid in the assessment of potential DILI risks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolp_CRnBjbYLVg90H21EOLACvtfcHk0li2ewYIEYM27g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWiurrI&md5=447abef4f90e655cdbf54415cb0c486d</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.toxlet.2015.10.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.toxlet.2015.10.029%26sid%3Dliteratum%253Aachs%26aulast%3DOda%26aufirst%3DS.%26aulast%3DMatsuo%26aufirst%3DK.%26aulast%3DNakajima%26aufirst%3DA.%26aulast%3DYokoi%26aufirst%3DT.%26atitle%3DA%2520Novel%2520Cell-Based%2520Assay%2520for%2520the%2520Evaluation%2520of%2520Immune-%2520and%2520Inflammatory-Related%2520Gene%2520Expression%2520as%2520Biomarkers%2520for%2520the%2520Risk%2520Assessment%2520of%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DToxicol.%2520Lett.%26date%3D2016%26volume%3D241%26spage%3D60%26epage%3D70%26doi%3D10.1016%2Fj.toxlet.2015.10.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kegel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeiffer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhardt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeilinger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nüssler, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seehofer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damm, G.</span></span> <span> </span><span class="NLM_article-title">Subtoxic Concentrations of Hepatotoxic Drugs Lead to Kupffer Cell Activation in a Human In Vitro Liver Model: An Approach to Study DILI</span>. <i>Mediators Inflammation</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.1155/2015/640631</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1155%2F2015%2F640631" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=1&author=V.+Kegelauthor=E.+Pfeifferauthor=B.+Burkhardtauthor=J.+L.+Liuauthor=K.+Zeilingerauthor=A.+K.+N%C3%BCsslerauthor=D.+Seehoferauthor=G.+Damm&title=Subtoxic+Concentrations+of+Hepatotoxic+Drugs+Lead+to+Kupffer+Cell+Activation+in+a+Human+In+Vitro+Liver+Model%3A+An+Approach+to+Study+DILI&doi=10.1155%2F2015%2F640631"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1155%2F2015%2F640631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F640631%26sid%3Dliteratum%253Aachs%26aulast%3DKegel%26aufirst%3DV.%26aulast%3DPfeiffer%26aufirst%3DE.%26aulast%3DBurkhardt%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%2BL.%26aulast%3DZeilinger%26aufirst%3DK.%26aulast%3DN%25C3%25BCssler%26aufirst%3DA.%2BK.%26aulast%3DSeehofer%26aufirst%3DD.%26aulast%3DDamm%26aufirst%3DG.%26atitle%3DSubtoxic%2520Concentrations%2520of%2520Hepatotoxic%2520Drugs%2520Lead%2520to%2520Kupffer%2520Cell%2520Activation%2520in%2520a%2520Human%2520In%2520Vitro%2520Liver%2520Model%253A%2520An%2520Approach%2520to%2520Study%2520DILI%26jtitle%3DMediators%2520Inflammation%26date%3D2015%26volume%3D2015%26spage%3D1%26doi%3D10.1155%2F2015%2F640631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogese, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulkner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copple, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoine, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmasry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betts, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Characterization of Drug-Specific Signaling Between Primary Human Hepatocytes and Immune Cells</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">76</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfx069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfx069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28444390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2017&pages=76-89&author=M.+O.+Ogeseauthor=L.+Faulknerauthor=R.+E.+Jenkinsauthor=N.+S.+Frenchauthor=I.+M.+Coppleauthor=D.+J.+Antoineauthor=M.+Elmasryauthor=H.+Malikauthor=C.+E.+Goldringauthor=B.+K.+Parkauthor=C.+J.+Bettsauthor=D.+J.+Naisbitt&title=Characterization+of+Drug-Specific+Signaling+Between+Primary+Human+Hepatocytes+and+Immune+Cells&doi=10.1093%2Ftoxsci%2Fkfx069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of drug-specific signaling between primary human hepatocytes and immune cells</span></div><div class="casAuthors">Ogese, Monday O.; Faulkner, Lee; Jenkins, Roz E.; French, Neil S.; Copple, Ian M.; Antoine, Daniel J.; Elmasry, Mohamed; Malik, Hasan; Goldring, Christopher E.; Park, Brian Kevin; Betts, Catherine J.; Naisbitt, Dean J.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">76-89</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">It is now apparent that antigen-specific T-cells are activated in certain patients with drug-induced liver injury (DILI).  Since cross-talk between hepatocytes and immune cells is likely to be crit. in detg. the outcome of drug exposure, the aim of this study was to profile the signals released by drug-treated hepatocytes and to characterize the impact of these mols. on dendritic cells.  Human hepatocytes were exposed to 3 drugs (flucloxacillin, amoxicillin, and isoniazid) assocd. with DILI potentially mediated by the adaptive immune system as drug-specific T-cells have been isolated from DILI patients, and the metabolite nitroso-sulfamethoxazole (SMX-NO).  Hepatocyte toxicity, cytokine release and activation of oxidative stress pathways were measured.  Supernatants were transferred to monocyte-derived dendritic cells and cell phenotype and function were assessed.  High-mobility group box 1 protein (HMGB1) and lactate dehydrogenase release as well as ATP depletion occurred in a drug-, time-, and concn.-dependent manner with SMX-NO and flucloxacillin, whereas isoniazid and amoxicillin were nontoxic.  Furthermore, drug-induced activation of nuclear factor (erythroid-derived 2)-like 2 marker genes was obsd. when hepatocytes were exposed to test drugs.  The disulfide isoform of HMGB1 stimulated dendritic cell cytokine release and enhanced the priming of naive T-cells.  Incubation of dendritic cells with supernatant from drug-treated hepatocytes resulted in 2 distinct cytokine profiles.  SMX-NO/flucloxacillin stimulated secretion of TNF-α, IL-6, IL-1α, and IL-1-β.  Isoniazid which did not induce significant hepatocyte toxicity, compared with SMX-NO and flucloxacillin, stimulated the release of a panel of cytokines including the above and IFN-γ, IL-12, IL-17A, IP-10, and IL-10.  Collectively, our study identifies drug-specific signaling pathways between hepatocytes and immune cells that could influence whether drug exposure will result in an immune response and tissue injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdL9BBxr7IyrVg90H21EOLACvtfcHk0lhNq3y8B-xAWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOjtLg%253D&md5=9df2f3b00b5e497d4fe21ffb7a070caf</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfx069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfx069%26sid%3Dliteratum%253Aachs%26aulast%3DOgese%26aufirst%3DM.%2BO.%26aulast%3DFaulkner%26aufirst%3DL.%26aulast%3DJenkins%26aufirst%3DR.%2BE.%26aulast%3DFrench%26aufirst%3DN.%2BS.%26aulast%3DCopple%26aufirst%3DI.%2BM.%26aulast%3DAntoine%26aufirst%3DD.%2BJ.%26aulast%3DElmasry%26aufirst%3DM.%26aulast%3DMalik%26aufirst%3DH.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DBetts%26aufirst%3DC.%2BJ.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DCharacterization%2520of%2520Drug-Specific%2520Signaling%2520Between%2520Primary%2520Human%2520Hepatocytes%2520and%2520Immune%2520Cells%26jtitle%3DToxicol.%2520Sci.%26date%3D2017%26volume%3D158%26spage%3D76%26epage%3D89%26doi%3D10.1093%2Ftoxsci%2Fkfx069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weston, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">An Impaired Immune Tolerance Animal Model Distinguishes the Potential of Troglitazone/Pioglitazone and Tolcapone/Entacapone to Cause IDILI</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">412</span>– <span class="NLM_lpage">420</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfx219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfx219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29087505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFelsbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2018&pages=412-420&author=A.+Makauthor=R.+Katoauthor=K.+Westonauthor=A.+Hayesauthor=J.+Uetrecht&title=An+Impaired+Immune+Tolerance+Animal+Model+Distinguishes+the+Potential+of+Troglitazone%2FPioglitazone+and+Tolcapone%2FEntacapone+to+Cause+IDILI&doi=10.1093%2Ftoxsci%2Fkfx219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">An Impaired Immune Tolerance Animal Model Distinguishes the potential of troglitazone/pioglitazone and tolcapone/entacapone to cause IDILI</span></div><div class="casAuthors">Mak, Alastair; Kato, Ryuji; Weston, Kyle; Hayes, Anthony; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">412-420</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The authors have developed an animal model of amodiaquine-induced liver injury that has characteristics very similar to idiosyncratic drug-induced liver injury (IDILI) in humans by impairing immune tolerance using a PD1-/- mouse and cotreatment with anti-CTLA-4.  To test the usefulness of this model as a general model for human IDILI risk, pairs of drugs with similar structures were tested, one of which is assocd. with a relatively high risk of IDILI and the other not.  One such pair is troglitazone and pioglitazone; troglitazone has caused fatal cases of IDILI while pioglitazone is quite safe.  Another pair is tolcapone and entacapone; tolcapone can cause serious IDILI; in contrast, although entacapone has been reported to cause liver injury, it is relatively safe.  PD1-/- mice treated with anti-CTLA-4 and troglitazone or tolcapone displayed liver injury as detd. by ALT levels and histol., while pioglitazone and entacapone showed less signs of liver injury.  One possible mechanism by which drugs could induce an immune response leading to IDILI is by causing the release of danger-assocd. mol. pattern mols. that activate inflammasomes.  The authors found that the supernatants from incubations of troglitazone, tolcapone, or entacapone with hepatocytes were also able to activate inflammasomes in macrophages, while the supernatant from pioglitazone incubations did not.  These results are consistent with an immune mechanism for troglitazone- and tolcapone-induced IDILI and add to the evidence that this may be a general model for IDILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0YdeyLT3wMbVg90H21EOLACvtfcHk0lhNq3y8B-xAWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFelsbbE&md5=4ecb0b2a5b1c9c808fd1b6c37aead328</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfx219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfx219%26sid%3Dliteratum%253Aachs%26aulast%3DMak%26aufirst%3DA.%26aulast%3DKato%26aufirst%3DR.%26aulast%3DWeston%26aufirst%3DK.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DAn%2520Impaired%2520Immune%2520Tolerance%2520Animal%2520Model%2520Distinguishes%2520the%2520Potential%2520of%2520Troglitazone%252FPioglitazone%2520and%2520Tolcapone%252FEntacapone%2520to%2520Cause%2520IDILI%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D161%26spage%3D412%26epage%3D420%26doi%3D10.1093%2Ftoxsci%2Fkfx219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spraggs, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budde, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briley, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bing, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooser, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardon, L. R.</span></span> <span> </span><span class="NLM_article-title">HLA-DQA1*02:01 is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women with Advanced Breast Cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">667</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1200/JCO.2010.31.3197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1200%2FJCO.2010.31.3197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21245432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvVSrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=667-673&author=C.+F.+Spraggsauthor=L.+R.+Buddeauthor=L.+P.+Brileyauthor=N.+Bingauthor=C.+J.+Coxauthor=K.+S.+Kingauthor=J.+C.+Whittakerauthor=V.+E.+Mooserauthor=A.+J.+Prestonauthor=S.+H.+Steinauthor=L.+R.+Cardon&title=HLA-DQA1*02%3A01+is+a+Major+Risk+Factor+for+Lapatinib-Induced+Hepatotoxicity+in+Women+with+Advanced+Breast+Cancer&doi=10.1200%2FJCO.2010.31.3197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">HLA-DQA1 02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer</span></div><div class="casAuthors">Spraggs, Colin F.; Budde, Laura R.; Briley, Linda P.; Bing, Nan; Cox, Charles J.; King, Karen S.; Whittaker, John C.; Mooser, Vincent E.; Preston, Alaknanda J.; Stein, Steven H.; Cardon, Lon R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">667-673</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Hepatobiliary adverse events (AEs) have been obsd. in a small proportion of patients with metastatic breast cancer (MBC) treated with lapatinib.  This study sought to identify gene variants assocd. with lapatinib-induced ALT elevation and hepatobiliary AEs.  A two-stage pharmacogenetic investigation of ALT elevation was conducted in lapatinib-treated patients with MBC.  Exploratory marker identification evaluated classical HLA alleles, candidate genes, and genome-wide screening in 37 cases with ALT greater than 3 times the upper limit of normal (ULN) and 286 controls with ALT ≤ 1 × ULN, selected from 901 lapatinib-treated patients in 12 trials.  Markers achieving prespecified assocn. thresholds were progressed to an independent confirmatory data set of 24 ALT cases and 155 controls selected from a subsequent trial of 374 lapatinib-treated patients.  Of 58 variants assocd. with ALT elevation in the exploratory data set, four exceeded the prespecified significance threshold in the confirmatory anal.  These variants reside in the same MHC genomic locus and include HLA-DQA1*02:01.  In the confirmatory study, DQA1*02:01 allele carriage was present in 71 % of ALT cases and in 21 % of controls (P <.001; odds ratio, 9.0; 95% CI, 3.2 to 27.4).  As a predictor of liver safety risk in ALT cases vs. noncases, DQA1*02:01 had neg. and pos. predictive values of 0.97 (95% CI, 0.95 to 0.99) and 0.17 (95% CI 0.10 to 0.26), resp.  These results support a role for immune mechanisms in lapatinib-induced hepatotoxicity.  Further work is required to det. whether testing for DQA1*02:01 allele carriage is clin. useful in managing liver safety risk during lapatinib treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5sBETh7j-ZbVg90H21EOLACvtfcHk0lhnDSz84WPMUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvVSrsr8%253D&md5=ad80f1ca768b431c1172d6e980f2ddd5</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.31.3197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.31.3197%26sid%3Dliteratum%253Aachs%26aulast%3DSpraggs%26aufirst%3DC.%2BF.%26aulast%3DBudde%26aufirst%3DL.%2BR.%26aulast%3DBriley%26aufirst%3DL.%2BP.%26aulast%3DBing%26aufirst%3DN.%26aulast%3DCox%26aufirst%3DC.%2BJ.%26aulast%3DKing%26aufirst%3DK.%2BS.%26aulast%3DWhittaker%26aufirst%3DJ.%2BC.%26aulast%3DMooser%26aufirst%3DV.%2BE.%26aulast%3DPreston%26aufirst%3DA.%2BJ.%26aulast%3DStein%26aufirst%3DS.%2BH.%26aulast%3DCardon%26aufirst%3DL.%2BR.%26atitle%3DHLA-DQA1%252A02%253A01%2520is%2520a%2520Major%2520Risk%2520Factor%2520for%2520Lapatinib-Induced%2520Hepatotoxicity%2520in%2520Women%2520with%2520Advanced%2520Breast%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D667%26epage%3D673%26doi%3D10.1200%2FJCO.2010.31.3197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singer, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewitzky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klickstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulding, C. A.</span></span> <span> </span><span class="NLM_article-title">A Genome-Wide Study Identifies HLA Alleles Associated with Lumiracoxib-Related Liver Injury</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">714</span>, <span class="refDoi"> DOI: 10.1038/ng.632</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fng.632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=20639878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFCgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=711-714&author=J.+B.+Singerauthor=S.+Lewitzkyauthor=E.+Leroyauthor=F.+Yangauthor=X.+Zhaoauthor=L.+Klicksteinauthor=T.+M.+Wrightauthor=J.+Meyerauthor=C.+A.+Paulding&title=A+Genome-Wide+Study+Identifies+HLA+Alleles+Associated+with+Lumiracoxib-Related+Liver+Injury&doi=10.1038%2Fng.632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury</span></div><div class="casAuthors">Singer, Jonathan B.; Lewitzky, Steve; Leroy, Elisabeth; Yang, Fan; Zhao, Xiaojun; Klickstein, Lloyd; Wright, Timothy M.; Meyer, Joanne; Paulding, Charles A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">711-714</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Lumiracoxib is a selective cyclooxygenase-2 inhibitor developed for the symptomatic treatment of osteoarthritis and acute pain.  Concerns over hepatotoxicity have contributed to the withdrawal or non-approval of lumiracoxib in most major drug markets worldwide.  We performed a case-control genome-wide assocn. study on 41 lumiracoxib-treated patients with liver injury (cases) and 176 matched lumiracoxib-treated patients without liver injury (controls).  Several SNPs from the MHC class II region showed strong evidence of assocn. (the top SNP was rs9270986 with P = 2.8 × 10-10).  These findings were replicated in an independent set of 98 lumiracoxib-treated cases and 405 matched lumiracoxib-treated controls (top SNP rs3129900, P = 4.4 × 10-12).  Fine mapping identified a strong assocn. to a common HLA haplotype (HLA-DRB1*1501-HLA-DQB1*0602-HLA-DRB5*0101-HLA-DQA1*0102, most significant allele P = 6.8 × 10-25, allelic odds ratio = 5.0, 95% CI 3.6-7.0).  These results offer the potential to improve the safety profile of lumiracoxib by identifying individuals at elevated risk for liver injury and excluding them from lumiracoxib treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc6MCbQPbb0rVg90H21EOLACvtfcHk0lhnDSz84WPMUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFCgur4%253D&md5=f2ce43639e3ddc3ca0a3757095feae54</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1038%2Fng.632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.632%26sid%3Dliteratum%253Aachs%26aulast%3DSinger%26aufirst%3DJ.%2BB.%26aulast%3DLewitzky%26aufirst%3DS.%26aulast%3DLeroy%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DKlickstein%26aufirst%3DL.%26aulast%3DWright%26aufirst%3DT.%2BM.%26aulast%3DMeyer%26aufirst%3DJ.%26aulast%3DPaulding%26aufirst%3DC.%2BA.%26atitle%3DA%2520Genome-Wide%2520Study%2520Identifies%2520HLA%2520Alleles%2520Associated%2520with%2520Lumiracoxib-Related%2520Liver%2520Injury%26jtitle%3DNat.%2520Genet.%26date%3D2010%26volume%3D42%26spage%3D711%26epage%3D714%26doi%3D10.1038%2Fng.632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kindmark, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jawaid, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbron, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barratt, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bengtsson, O. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cederbrant, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagerstrom-Fermer, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dukes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firth, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrod, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinel, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billing-Clason, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardon, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">March, R. E.</span></span> <span> </span><span class="NLM_article-title">Genome-Wide Pharmacogenetic Investigation of a Hepatic Adverse Event Without Clinical Signs of Immunopathology Suggests an Underlying Immune Pathogenesis</span>. <i>Pharmacogenomics J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">195</span>, <span class="refDoi"> DOI: 10.1038/sj.tpj.6500458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fsj.tpj.6500458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=17505501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVagsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=186-195&author=A.+Kindmarkauthor=A.+Jawaidauthor=C.+G.+Harbronauthor=B.+J.+Barrattauthor=O.+F.+Bengtssonauthor=T.+B.+Anderssonauthor=S.+Carlssonauthor=K.+E.+Cederbrantauthor=N.+J.+Gibsonauthor=M.+Armstrongauthor=M.+E.+Lagerstrom-Fermerauthor=A.+Dellsenauthor=E.+M.+Brownauthor=M.+Thorntonauthor=C.+Dukesauthor=S.+C.+Jenkinsauthor=M.+A.+Firthauthor=G.+O.+Harrodauthor=T.+H.+Pinelauthor=S.+M.+Billing-Clasonauthor=L.+R.+Cardonauthor=R.+E.+March&title=Genome-Wide+Pharmacogenetic+Investigation+of+a+Hepatic+Adverse+Event+Without+Clinical+Signs+of+Immunopathology+Suggests+an+Underlying+Immune+Pathogenesis&doi=10.1038%2Fsj.tpj.6500458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis</span></div><div class="casAuthors">Kindmark, A.; Jawaid, A.; Harbron, C. G.; Barratt, B. J.; Bengtsson, O. F.; Andersson, T. B.; Carlsson, S.; Cederbrant, K. E.; Gibson, N. J.; Armstrong, M.; Lagerstroem-Fermer, M. E.; Dellsen, A.; Brown, E. M.; Thornton, M.; Dukes, C.; Jenkins, S. C.; Firth, M. A.; Harrod, G. O.; Pinel, T. H.; Billing-Clason, S. M. E.; Cardon, L. R.; March, R. E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenomics Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">186-195</span>CODEN:
                <span class="NLM_cas:coden">PJHOAZ</span>;
        ISSN:<span class="NLM_cas:issn">1470-269X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">One of the major goals of pharmacogenetics is to elucidate mechanisms and identify patients at increased risk of adverse events (AEs).  To date, however, there have been only a few successful examples of this type of approach.  In this paper, we describe a retrospective case-control pharmacogenetic study of an AE of unknown mechanism, characterized by elevated levels of serum alanine aminotransferase (ALAT) during long-term treatment with the oral direct thrombin inhibitor ximelagatran.  The study was based on 74 cases and 130 treated controls and included both a genome-wide tag single nucleotide polymorphism and large-scale candidate gene anal.  A strong genetic assocn. between elevated ALAT and the MHC alleles DRB1*07 and DQA1*02 was discovered and replicated, suggesting a possible immune pathogenesis.  Consistent with this hypothesis, immunol. studies suggest that ximelagatran may have the ability to act as a contact sensitizer, and hence be able to stimulate an adaptive immune response.  Published online 15 May 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6dn3QDHI3urVg90H21EOLACvtfcHk0lhnDSz84WPMUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVagsb0%253D&md5=38bd24cda5f22464cd73e2b2f45c98a8</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fsj.tpj.6500458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.tpj.6500458%26sid%3Dliteratum%253Aachs%26aulast%3DKindmark%26aufirst%3DA.%26aulast%3DJawaid%26aufirst%3DA.%26aulast%3DHarbron%26aufirst%3DC.%2BG.%26aulast%3DBarratt%26aufirst%3DB.%2BJ.%26aulast%3DBengtsson%26aufirst%3DO.%2BF.%26aulast%3DAndersson%26aufirst%3DT.%2BB.%26aulast%3DCarlsson%26aufirst%3DS.%26aulast%3DCederbrant%26aufirst%3DK.%2BE.%26aulast%3DGibson%26aufirst%3DN.%2BJ.%26aulast%3DArmstrong%26aufirst%3DM.%26aulast%3DLagerstrom-Fermer%26aufirst%3DM.%2BE.%26aulast%3DDellsen%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DE.%2BM.%26aulast%3DThornton%26aufirst%3DM.%26aulast%3DDukes%26aufirst%3DC.%26aulast%3DJenkins%26aufirst%3DS.%2BC.%26aulast%3DFirth%26aufirst%3DM.%2BA.%26aulast%3DHarrod%26aufirst%3DG.%2BO.%26aulast%3DPinel%26aufirst%3DT.%2BH.%26aulast%3DBilling-Clason%26aufirst%3DS.%2BM.%26aulast%3DCardon%26aufirst%3DL.%2BR.%26aulast%3DMarch%26aufirst%3DR.%2BE.%26atitle%3DGenome-Wide%2520Pharmacogenetic%2520Investigation%2520of%2520a%2520Hepatic%2520Adverse%2520Event%2520Without%2520Clinical%2520Signs%2520of%2520Immunopathology%2520Suggests%2520an%2520Underlying%2520Immune%2520Pathogenesis%26jtitle%3DPharmacogenomics%2520J.%26date%3D2008%26volume%3D8%26spage%3D186%26epage%3D195%26doi%3D10.1038%2Fsj.tpj.6500458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chisari, F. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isogawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieland, S. F.</span></span> <span> </span><span class="NLM_article-title">Pathogenesis of Hepatitis B Virus Infection</span>. <i>Pathol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">258</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.1016/j.patbio.2009.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.patbio.2009.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=20116937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvV2jsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2010&pages=258-266&author=F.+V.+Chisariauthor=M.+Isogawaauthor=S.+F.+Wieland&title=Pathogenesis+of+Hepatitis+B+Virus+Infection&doi=10.1016%2Fj.patbio.2009.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Pathogenesis of hepatitis B virus infection</span></div><div class="casAuthors">Chisari, F. V.; Isogawa, M.; Wieland., S. F.</div><div class="citationInfo"><span class="NLM_cas:title">Pathologie Biologie</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">258-266</span>CODEN:
                <span class="NLM_cas:coden">PTBIAN</span>;
        ISSN:<span class="NLM_cas:issn">0369-8114</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The adaptive immune response is thought to be responsible for viral clearance and disease pathogenesis during hepatitis B virus infection.  It is generally acknowledged that the humoral antibody response contributes to the clearance of circulating virus particles and the prevention of viral spread within the host while the cellular immune response eliminates infected cells.  The T cell response to the hepatitis B virus (HBV) is vigorous, polyclonal and multispecific in acutely infected patients who successfully clear the virus and relatively weak and narrowly focussed in chronically infected patients, suggesting that clearance of HBV is T cell dependent.  The pathogenetic and antiviral potential of the cytotoxic T lymphocyte (CTL) response to HBV has been proven by the induction of a severe necroinflammatory liver disease following the adoptive transfer of HBsAg specific CTL into HBV transgenic mice.  Remarkably, the CTLs also purge HBV replicative intermediates from the liver by secreting type 1 inflammatory cytokines thereby limiting virus spread to uninfected cells and reducing the degree of immunopathol. required to terminate the infection.  Persistent HBV infection is characterized by a weak adaptive immune response, thought to be due to inefficient CD4+ T cell priming early in the infection and subsequent development of a quant. and qual. ineffective CD8+ T cell response.  Other factors that could contribute to viral persistence are immunol. tolerance, mutational epitope inactivation, T cell receptor antagonism, incomplete down-regulation of viral replication and infection of immunol. privileged tissues.  However, these pathways become apparent only in the setting of an ineffective immune response, which is, therefore, the fundamental underlying cause.  Persistent infection is characterized by chronic liver cell injury, regeneration, inflammation, widespread DNA damage and insertional deregulation of cellular growth control genes, which, collectively, lead to cirrhosis of the liver and hepatocellular carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnEg6GUmggjbVg90H21EOLACvtfcHk0lgjbBCUg3raow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvV2jsrg%253D&md5=2194598068d4a6a248c5f848d4cdad8a</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.patbio.2009.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.patbio.2009.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DChisari%26aufirst%3DF.%2BV.%26aulast%3DIsogawa%26aufirst%3DM.%26aulast%3DWieland%26aufirst%3DS.%2BF.%26atitle%3DPathogenesis%2520of%2520Hepatitis%2520B%2520Virus%2520Infection%26jtitle%3DPathol.%2520Biol.%26date%3D2010%26volume%3D58%26spage%3D258%26epage%3D266%26doi%3D10.1016%2Fj.patbio.2009.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garside, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoe, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesnut-Speelman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerry Kenna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrior, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgartner, J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the Use of Imaging Parameters for the Detection of Compound-Induced Hepatotoxicity in 384-Well Cultures of HepG2 Cells and Cryopreserved Primary Human Hepatocytes</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2013.10.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.tiv.2013.10.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24189122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2l" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=171-181&author=H.+Garsideauthor=K.+F.+Marcoeauthor=J.+Chesnut-Speelmanauthor=A.+J.+Fosterauthor=D.+Muthasauthor=J.+Gerry+Kennaauthor=U.+Warriorauthor=J.+Bowesauthor=J.+Baumgartner&title=Evaluation+of+the+Use+of+Imaging+Parameters+for+the+Detection+of+Compound-Induced+Hepatotoxicity+in+384-Well+Cultures+of+HepG2+Cells+and+Cryopreserved+Primary+Human+Hepatocytes&doi=10.1016%2Fj.tiv.2013.10.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes</span></div><div class="casAuthors">Garside, Helen; Marcoe, Karen F.; Chesnut-Speelman, Jessica; Foster, Alison J.; Muthas, Daniel; Gerry Kenna, J.; Warrior, Usha; Bowes, Joanne; Baumgartner, James</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171-181</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a major cause of failed drug development, withdrawal and restricted usage.  Therefore screening assays which aid selection of candidate drugs with reduced propensity to cause DILI are required.  We have investigated the toxicity of 144 drugs, 108 of which caused DILI, using assays identified in the literature as having some predictivity for hepatotoxicity.  The validated assays utilized either HepG2 cells, HepG2 cells in the presence of rat S9 fraction or isolated human hepatocytes.  All parameters were quantified by multiplexed and automated high content fluorescence microscopy, at appropriate time points after compd. administration (4, 24 or 48 h).  The individual endpoint which identified drugs that caused DILI with greatest precision was maximal fold induction in CM-H2DFFDA staining in hepatocytes after 24 h (41% sensitivity, 86% specificity).  However, hierarchical clustering anal. of all endpoints provided the most sensitive identification of drugs which caused DILI (58% sensitivity, 75% specificity).  We conclude that multi-parametric high content cell toxicity assays can enable in vitro detection of drugs that have high propensity to cause DILI in vivo but that many DILI compds. exhibit few in vitro signals when evaluated using these assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjbBh0hQC-vrVg90H21EOLACvtfcHk0lgjbBCUg3raow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2l&md5=e7ab3e52c8972b18fd1d9dc256b1a9a4</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2013.10.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2013.10.015%26sid%3Dliteratum%253Aachs%26aulast%3DGarside%26aufirst%3DH.%26aulast%3DMarcoe%26aufirst%3DK.%2BF.%26aulast%3DChesnut-Speelman%26aufirst%3DJ.%26aulast%3DFoster%26aufirst%3DA.%2BJ.%26aulast%3DMuthas%26aufirst%3DD.%26aulast%3DGerry%2BKenna%26aufirst%3DJ.%26aulast%3DWarrior%26aufirst%3DU.%26aulast%3DBowes%26aufirst%3DJ.%26aulast%3DBaumgartner%26aufirst%3DJ.%26atitle%3DEvaluation%2520of%2520the%2520Use%2520of%2520Imaging%2520Parameters%2520for%2520the%2520Detection%2520of%2520Compound-Induced%2520Hepatotoxicity%2520in%2520384-Well%2520Cultures%2520of%2520HepG2%2520Cells%2520and%2520Cryopreserved%2520Primary%2520Human%2520Hepatocytes%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2014%26volume%3D28%26spage%3D171%26epage%3D181%26doi%3D10.1016%2Fj.tiv.2013.10.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takemura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Bile Canalicular Network Formation in Rat Sandwich Cultured Hepatocytes by Drugs Associated with Risk of Severe Liver Injury</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2016.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.tiv.2016.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27256767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVygtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=121-130&author=A.+Takemuraauthor=A.+Izakiauthor=S.+Sekineauthor=K.+Ito&title=Inhibition+of+Bile+Canalicular+Network+Formation+in+Rat+Sandwich+Cultured+Hepatocytes+by+Drugs+Associated+with+Risk+of+Severe+Liver+Injury&doi=10.1016%2Fj.tiv.2016.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of bile canalicular network formation in rat sandwich cultured hepatocytes by drugs associated with risk of severe liver injury</span></div><div class="casAuthors">Takemura, Akinori; Izaki, Aya; Sekine, Shuichi; Ito, Kousei</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">121-130</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Idiosyncratic drug-induced liver injury is a clin. concern with serious consequences.  Although many preclin. screening methods have been proposed, it remains difficult to identify compds. assocd. with this rare but potentially fatal liver condition.  Here, the authors propose a novel assay system to assess the risk of liver injury.  Rat primary hepatocytes were cultured in a sandwich configuration, which enables the formation of a typical bile canalicular network.  From day 2 to 3, test drugs, mostly selected from a list of cholestatic drugs, were administered, and the length of the network was semi-quant. measured by immunofluorescence.  Liver injury risk information was collected from drug labels and was compared with in vitro measurements.  Of 23 test drugs examd., 15 exhibited potent inhibition of bile canalicular network formation (<60% of control).  Effects on cell viability were negligible or minimal as confirmed by lactose dehydrogenase leakage and cellular ATP content assays.  For the potent 15 drugs, IC50 values were detd.  Finally, max. daily dose divided by the inhibition const. gave good sepn. of the highest risk of severe liver toxicity drugs such as troglitazone, benzbromarone, flutamide, and amiodarone from lower risk drugs.  In conclusion, inhibitory effect on the bile canalicular network formation obsd. in in vitro sandwich cultured hepatocytes evaluates a new aspect of drug toxicity, particularly assocd. with aggravation of liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8z2P9vsiA2rVg90H21EOLACvtfcHk0lgjbBCUg3raow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVygtLc%253D&md5=e386a9850ce87c1426a0236f1b713ad7</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2016.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2016.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DTakemura%26aufirst%3DA.%26aulast%3DIzaki%26aufirst%3DA.%26aulast%3DSekine%26aufirst%3DS.%26aulast%3DIto%26aufirst%3DK.%26atitle%3DInhibition%2520of%2520Bile%2520Canalicular%2520Network%2520Formation%2520in%2520Rat%2520Sandwich%2520Cultured%2520Hepatocytes%2520by%2520Drugs%2520Associated%2520with%2520Risk%2520of%2520Severe%2520Liver%2520Injury%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2016%26volume%3D35%26spage%3D121%26epage%3D130%26doi%3D10.1016%2Fj.tiv.2016.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Staden, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyanaraman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalanzi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afshari, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamadeh, H. K.</span></span> <span> </span><span class="NLM_article-title">A Multifactorial Approach to Hepatobiliary Transporter Assessment Enables Improved Therapeutic Compound Development</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">216</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kft176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkft176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23956101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslyktLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2013&pages=216-241&author=R.+E.+Morganauthor=C.+J.+van+Stadenauthor=Y.+Chenauthor=N.+Kalyanaramanauthor=J.+Kalanziauthor=R.+T.+Dunnauthor=C.+A.+Afshariauthor=H.+K.+Hamadeh&title=A+Multifactorial+Approach+to+Hepatobiliary+Transporter+Assessment+Enables+Improved+Therapeutic+Compound+Development&doi=10.1093%2Ftoxsci%2Fkft176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">A Multifactorial Approach to Hepatobiliary Transporter Assessment Enables Improved Therapeutic Compound Development</span></div><div class="casAuthors">Morgan, Ryan E.; van Staden, Carlo J.; Chen, Yuan; Kalyanaraman, Natarajan; Kalanzi, Jackson; Dunn, Robert T., II; Afshari, Cynthia A.; Hamadeh, Hisham K.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">216-241</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The bile salt export pump (BSEP) is expressed at the canalicular domain of hepatocytes, where it serves as the primary route of elimination for monovalent bile acids (BAs) into the bile canaliculi.  The most compelling evidence linking dysfunction in BA transport with liver injury in humans is found with carriers of mutations that render BSEP nonfunctional.  Based on mounting evidence, there appears to be a strong assocn. between drug-induced BSEP interference and liver injury in humans; however, causality has not been established.  For this reason, drug-induced BSEP interference is best considered a susceptibility factor for liver injury as other host- or drug-related properties may contribute to the development of hepatotoxicity.  To better understand the assocn. between BSEP interference and liver injury in humans, over 600 marketed or withdrawn drugs were evaluated in BSEP expressing membrane vesicles.  The example of a compd. that failed during phase 1 human trials is also described, AMG 009.  AMG 009 showed evidence of liver injury in humans that was not predicted by preclin. safety studies, and BSEP inhibition was implicated.  For 109 of the drugs with some effect on in vitro BSEP function, clin. use, assocns. with hepatotoxicity, pharmacokinetic data, and other information were annotated.  A steady state concn. (Css) for each of these annotated drugs was estd., and a ratio between this value and measured IC50 potency values were calcd. in an attempt to relate exposure to in vitro potencies.  When factoring for exposure, 95% of the annotated compds. with a Css/BSEP IC50 ratio ≥ 0.1 were assocd. with some form of liver injury.  We then investigated the relationship between clin. evidence of liver injury and effects to multidrug resistance-assocd. proteins (MRPs) believed to play a role in BA homeostasis.  The effect of 600+ drugs on MRP2, MRP3, and MRP4 function was also evaluated in membrane vesicle assays.  Drugs with a Css/BSEP IC50 ratio ≥ 0.1 and a Css/MRP IC50 ratio ≥ 0.1 had almost a 100% correlation with some evidence of liver injury in humans.  These data suggest that integration of exposure data, and knowledge of an effect to not only BSEP but also one or more of the MRPs, is a useful tool for informing the potential for liver injury due to altered BA transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpD5nu_33Zak7Vg90H21EOLACvtfcHk0lg5ge2d-kHZPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslyktLzF&md5=4a8875a08056620e4c398049c43e2e5b</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkft176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkft176%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DR.%2BE.%26aulast%3Dvan%2BStaden%26aufirst%3DC.%2BJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKalyanaraman%26aufirst%3DN.%26aulast%3DKalanzi%26aufirst%3DJ.%26aulast%3DDunn%26aufirst%3DR.%2BT.%26aulast%3DAfshari%26aufirst%3DC.%2BA.%26aulast%3DHamadeh%26aufirst%3DH.%2BK.%26atitle%3DA%2520Multifactorial%2520Approach%2520to%2520Hepatobiliary%2520Transporter%2520Assessment%2520Enables%2520Improved%2520Therapeutic%2520Compound%2520Development%26jtitle%3DToxicol.%2520Sci.%26date%3D2013%26volume%3D136%26spage%3D216%26epage%3D241%26doi%3D10.1093%2Ftoxsci%2Fkft176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Lechón, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolosa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donato, M. T.</span></span> <span> </span><span class="NLM_article-title">Metabolic Activation and Drug-Induced LiverIinjury: In Vitro Approaches for the Safety Risk Assessment of New Drugs</span>. <i>J. Appl. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">752</span>– <span class="NLM_lpage">768</span>, <span class="refDoi"> DOI: 10.1002/jat.3277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fjat.3277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26691983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGgtbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=752-768&author=M.+J.+G%C3%B3mez-Lech%C3%B3nauthor=L.+Tolosaauthor=M.+T.+Donato&title=Metabolic+Activation+and+Drug-Induced+LiverIinjury%3A+In+Vitro+Approaches+for+the+Safety+Risk+Assessment+of+New+Drugs&doi=10.1002%2Fjat.3277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs</span></div><div class="casAuthors">Gomez-Lechon, M. Jose; Tolosa, Laia; Donato, M. Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">752-768</span>CODEN:
                <span class="NLM_cas:coden">JJATDK</span>;
        ISSN:<span class="NLM_cas:issn">0260-437X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a significant leading cause of hepatic dysfunction, drug failure during clin. trials and post-market withdrawal of approved drugs.  Many cases of DILI are unexpected reactions of an idiosyncratic nature that occur in a small group of susceptible individuals.  Intensive research efforts have been made to understand better the idiosyncratic DILI and to identify potential risk factors.  Metabolic bioactivation of drugs to form reactive metabolites is considered an initiation mechanism for idiosyncratic DILI.  Reactive species may interact irreversibly with cell macromols. (covalent binding, oxidative damage), and alter their structure and activity.  This review focuses on proposed in vitro screening strategies to predict and reduce idiosyncratic hepatotoxicity assocd. with drug bioactivation.  Compd. incubation with metabolically competent biol. systems (liver-derived cells, subcellular fractions), in combination with methods to reveal the formation of reactive intermediates (e.g., formation of adducts with liver proteins, metabolite trapping or enzyme inhibition assays), are approaches commonly used to screen the reactivity of new mols. in early drug development.  Several cell-based assays have also been proposed for the safety risk assessment of bioactivable compds.  Copyright © 2015 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQyrfU4dgs07Vg90H21EOLACvtfcHk0lg5ge2d-kHZPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGgtbzN&md5=364ff94e07264c106f9509d61d4e9a1f</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1002%2Fjat.3277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjat.3277%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25B3mez-Lech%25C3%25B3n%26aufirst%3DM.%2BJ.%26aulast%3DTolosa%26aufirst%3DL.%26aulast%3DDonato%26aufirst%3DM.%2BT.%26atitle%3DMetabolic%2520Activation%2520and%2520Drug-Induced%2520LiverIinjury%253A%2520In%2520Vitro%2520Approaches%2520for%2520the%2520Safety%2520Risk%2520Assessment%2520of%2520New%2520Drugs%26jtitle%3DJ.%2520Appl.%2520Toxicol.%26date%3D2016%26volume%3D36%26spage%3D752%26epage%3D768%26doi%3D10.1002%2Fjat.3277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swiss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Human Drug-Induced Liver Injury Severity is Highly Associated with Dual Inhibition of Liver Mitochondrial Function and Bile Salt Export Pump</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1015</span>– <span class="NLM_lpage">1022</span>, <span class="refDoi"> DOI: 10.1002/hep.27206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.27206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24799086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=1015-1022&author=M.+D.+Aleoauthor=Y.+Luoauthor=R.+Swissauthor=P.+D.+Boninauthor=D.+M.+Potterauthor=Y.+Will&title=Human+Drug-Induced+Liver+Injury+Severity+is+Highly+Associated+with+Dual+Inhibition+of+Liver+Mitochondrial+Function+and+Bile+Salt+Export+Pump&doi=10.1002%2Fhep.27206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump</span></div><div class="casAuthors">Aleo, Michael D.; Luo, Yi; Swiss, Rachel; Bonin, Paul D.; Potter, David M.; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1015-1022</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) accounts for 20-40% of all instances of clin. hepatic failure and is a common reason for withdrawal of an approved drug or discontinuation of a potentially new drug from clin./nonclin. development.  Numerous individual risk factors contribute to the susceptibility to human DILI and its severity that are either compd.- and/or patient-specific.  Compd.-specific primary mechanisms linked to DILI include: cytotoxicity, reactive metabolite formation, inhibition of bile salt export pump (BSEP), and mitochondrial dysfunction.  Since BSEP is an energy-dependent protein responsible for the efflux of bile acids from hepatocytes, it was hypothesized that humans exposed to drugs that impair both mitochondrial energetics and BSEP functional activity are more sensitive to more severe manifestations of DILI than drugs that only have a single liability factor.  As annotated in the United States National Center for Toxicol. Research Liver Toxicity Knowledge Base (NCTR-LTKB), the inhibitory properties of 24 Most-DILI-, 28 Less-DILI-, and 20 No-DILI-concern drugs were investigated.  Drug potency for inhibiting BSEP or mitochondrial activity was generally correlated across human DILI concern categories.  However, drugs with dual potency as mitochondrial and BSEP inhibitors were highly assocd. with more severe human DILI, more restrictive product safety labeling related to liver injury, and appear more sensitive to the drug exposure (Cmax) where more restrictive labeling occurs.  Conclusion: These data affirm that severe manifestations of human DILI are multifactorial, highly assocd. with combinations of drug potency specifically related to known mechanisms of DILI (like mitochondrial and BSEP inhibition), and, along with patient-specific factors, lead to differences in the severity and exposure thresholds assocd. with clin. DILI. (Hepatol. 2014;60:1015-1022).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIKfBrKEsFMbVg90H21EOLACvtfcHk0lg5ge2d-kHZPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtbnJ&md5=9bc646d27738ab811ebc526d520c83bf</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1002%2Fhep.27206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27206%26sid%3Dliteratum%253Aachs%26aulast%3DAleo%26aufirst%3DM.%2BD.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DSwiss%26aufirst%3DR.%26aulast%3DBonin%26aufirst%3DP.%2BD.%26aulast%3DPotter%26aufirst%3DD.%2BM.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DHuman%2520Drug-Induced%2520Liver%2520Injury%2520Severity%2520is%2520Highly%2520Associated%2520with%2520Dual%2520Inhibition%2520of%2520Liver%2520Mitochondrial%2520Function%2520and%2520Bile%2520Salt%2520Export%2520Pump%26jtitle%3DHepatology%26date%3D2014%26volume%3D60%26spage%3D1015%26epage%3D1022%26doi%3D10.1002%2Fhep.27206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dykens, J.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial Toxicity Assessment in Industry – A Decade of Technology Development and Insight</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1061</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1517/17425255.2014.939628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1517%2F17425255.2014.939628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25023361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC2cbisVKnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=1061-1067&author=Y.+Willauthor=J.+Dykens&title=Mitochondrial+Toxicity+Assessment+in+Industry+%E2%80%93+A+Decade+of+Technology+Development+and+Insight&doi=10.1517%2F17425255.2014.939628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial toxicity assessment in industry--a decade of technology development and insight</span></div><div class="casAuthors">Will Yvonne; Dykens James</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on drug metabolism & toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1061-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpQipcnBZdL6cY7HFp97qMfW6udTcc2ebJFGZrKalYFrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbisVKnsw%253D%253D&md5=9e0d90f03938471154fec1353ebce3fe</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1517%2F17425255.2014.939628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2014.939628%26sid%3Dliteratum%253Aachs%26aulast%3DWill%26aufirst%3DY.%26aulast%3DDykens%26aufirst%3DJ.%26atitle%3DMitochondrial%2520Toxicity%2520Assessment%2520in%2520Industry%2520%25E2%2580%2593%2520A%2520Decade%2520of%2520Technology%2520Development%2520and%2520Insight%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2014%26volume%3D10%26spage%3D1061%26epage%3D1067%26doi%3D10.1517%2F17425255.2014.939628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Q.</span></span> <span> </span><span class="NLM_article-title">Role of Nrf2 in Oxidative Stress and Toxicity</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">426</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-011112-140320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1146%2Fannurev-pharmtox-011112-140320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23294312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjt1Wguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=401-426&author=Q.+Ma&title=Role+of+Nrf2+in+Oxidative+Stress+and+Toxicity&doi=10.1146%2Fannurev-pharmtox-011112-140320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Nrf2 in oxidative stress and toxicity</span></div><div class="casAuthors">Ma, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">401-426</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Organismal life encounters reactive oxidants from internal metab. and environmental toxicant exposure.  Reactive oxygen and nitrogen species cause oxidative stress and are traditionally viewed as being harmful.  On the other hand, controlled prodn. of oxidants in normal cells serves useful purposes to regulate signaling pathways.  Reactive oxidants are counterbalanced by complex antioxidant defense systems regulated by a web of pathways to ensure that the response to oxidants is adequate for the body's needs.  A recurrent theme in oxidant signaling and antioxidant defense is reactive cysteine thiol-based redox signaling.  The nuclear factor erythroid 2-related factor 2 (Nrf2) is an emerging regulator of cellular resistance to oxidants.  Nrf2 controls the basal and induced expression of an array of antioxidant response element-dependent genes to regulate the physiol. and pathophysiol. outcomes of oxidant exposure.  This review discusses the impact of Nrf2 on oxidative stress and toxicity and how Nrf2 senses oxidants and regulates antioxidant defense.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3hN1BQDMlrbVg90H21EOLACvtfcHk0lhX7iKYSVBJpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjt1Wguro%253D&md5=71d4fbc6734d49f3e9b2c262057d7288</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-011112-140320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-011112-140320%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DQ.%26atitle%3DRole%2520of%2520Nrf2%2520in%2520Oxidative%2520Stress%2520and%2520Toxicity%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2013%26volume%3D53%26spage%3D401%26epage%3D426%26doi%3D10.1146%2Fannurev-pharmtox-011112-140320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">The Combination of Anti-CTLA-4 and PD1–/– Mice Unmasks the Potential of Isoniazid and Nevirapine To Cause Liver Injury</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2287</span>– <span class="NLM_lpage">2291</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.5b00305</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.5b00305" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGms7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=2287-2291&author=A.+Makauthor=J.+Uetrecht&title=The+Combination+of+Anti-CTLA-4+and+PD1%E2%80%93%2F%E2%80%93+Mice+Unmasks+the+Potential+of+Isoniazid+and+Nevirapine+To+Cause+Liver+Injury&doi=10.1021%2Facs.chemrestox.5b00305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">The Combination of Anti-CTLA-4 and PD1-/- Mice Unmasks the Potential of Isoniazid and Nevirapine To Cause Liver Injury</span></div><div class="casAuthors">Mak, Alastair; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2287-2291</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Our lab. recently reported what we believe is the first valid animal model of idiosyncratic drug-induced liver injury (IDILI) by treating PD1-/- mice with an anti-CTLA-4 antibody and amodiaquine (AQ).  PD1 and CTLA-4 are important immune checkpoint receptors that are involved in inducing immune tolerance.  This model was able to produce significant liver injury that looks very similar to the liver injury seen in humans.  Although this model was shown to work with AQ, the question becomes whether blocking immune tolerance would unmask the potential of other drugs to cause IDILI.  In this study, we tested isoniazid and nevirapine, both drugs with significant histories of causing IDILI in humans even though they do not cause significant injury in animals with doses that result in therapeutic blood levels.  Both drugs in combination with these immune checkpoint inhibitors caused mild but significant delayed onset liver injury, which is similar to the mild injury that they can cause in humans.  INH-induced liver injury in this model was assocd. with an increase in NK cells, while NVP-induced liver injury was assocd. with a greater increase in CD8 T cells.  Although the liver injury caused by these drugs in this model was mild, these results suggest that impairing immune tolerance may be a general method for unmasking the potential of drugs to cause IDILI and therefore provide a screening tool for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob4JP-cXxhkrVg90H21EOLACvtfcHk0lhX7iKYSVBJpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGms7fK&md5=be8bcacb6398f26a4c62a36c59e30492</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.5b00305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.5b00305%26sid%3Dliteratum%253Aachs%26aulast%3DMak%26aufirst%3DA.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DThe%2520Combination%2520of%2520Anti-CTLA-4%2520and%2520PD1%25E2%2580%2593%252F%25E2%2580%2593%2520Mice%2520Unmasks%2520the%2520Potential%2520of%2520Isoniazid%2520and%2520Nevirapine%2520To%2520Cause%2520Liver%2520Injury%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2015%26volume%3D28%26spage%3D2287%26epage%3D2291%26doi%3D10.1021%2Facs.chemrestox.5b00305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thalhofer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leidner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, A.</span></span> <span> </span><span class="NLM_article-title">OX40, PD-1 and CTLA-4 are Selectively Expressed on Tumor-Infiltrating T-cells in Head and Neck Cancer</span>. <i>Clin. Transl. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e70</span>, <span class="refDoi"> DOI: 10.1038/cti.2016.16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fcti.2016.16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27195113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFSkurfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=e70&author=R.+Montlerauthor=R.+B.+Bellauthor=C.+Thalhoferauthor=R.+Leidnerauthor=Z.+Fengauthor=B.+A.+Foxauthor=A.+C.+Chengauthor=T.+G.+Buiauthor=C.+Tuckerauthor=H.+Hoenauthor=A.+Weinberg&title=OX40%2C+PD-1+and+CTLA-4+are+Selectively+Expressed+on+Tumor-Infiltrating+T-cells+in+Head+and+Neck+Cancer&doi=10.1038%2Fcti.2016.16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer</span></div><div class="casAuthors">Montler, Ryan; Bell, R. Bryan; Thalhofer, Colin; Leidner, Rom; Feng, Zipei; Fox, Bernard A.; Cheng, Allen C.; Bui, Tuan G.; Tucker, Christopher; Hoen, Helena; Weinberg, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e70/1-e70/8</span>CODEN:
                <span class="NLM_cas:coden">CTILBR</span>;
        ISSN:<span class="NLM_cas:issn">2050-0068</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">The tumor microenvironment of squamous cell carcinoma of the head and neck (SCCHN) has been shown to be immune suppressive.  Therefore, strategies aimed at overcoming this issue could have a pos. therapeutic impact.  Hence, we investigated the expression of the known immune-modulatory proteins OX40, programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-assocd. protein 4 (CTLA-4) in SCCHN on different T-cell subsets of tumor-infiltrating lymphocytes (TIL) to ascertain whether these proteins could potentially be targeted alone or in combination for future clin. trials.  T cells from peripheral blood (PBL) and tumor were analyzed for the expression of OX40, PD-1 and CTLA-4 in 29 patients undergoing surgery.  These proteins were all expressed significantly higher in T-cell subsets isolated from tumors compared with PBL of the same patient.  OX40 expression was significantly greater in the TIL regulatory T-cell (Treg) population relative to conventional CD4 and CD8 TIL or the Treg isolated from PBL.  PD-1 expression was increased in all T-cell subsets relative to PBL.  CTLA-4 was also increased in all TIL subsets relative to blood, and similar to OX40, its highest level of expression was obsd. in the Treg TIL.  The highest frequency of PD-1, CTLA-4 and OX40 triple-pos. cells were found in the Treg population isolated from the tumor.  We analyzed both human papilloma virus-pos. and -neg. patients and found similar levels and expression patterns of these two patient populations for all three proteins.  These data suggest that there may be therapeutic advantages of targeting these pathways independently or in combination for patients with this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsLAIBXx5IL7Vg90H21EOLACvtfcHk0liM-Fpkaq48LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFSkurfM&md5=0003a5c6c4332927cef1185a742f7e65</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1038%2Fcti.2016.16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcti.2016.16%26sid%3Dliteratum%253Aachs%26aulast%3DMontler%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DR.%2BB.%26aulast%3DThalhofer%26aufirst%3DC.%26aulast%3DLeidner%26aufirst%3DR.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DFox%26aufirst%3DB.%2BA.%26aulast%3DCheng%26aufirst%3DA.%2BC.%26aulast%3DBui%26aufirst%3DT.%2BG.%26aulast%3DTucker%26aufirst%3DC.%26aulast%3DHoen%26aufirst%3DH.%26aulast%3DWeinberg%26aufirst%3DA.%26atitle%3DOX40%252C%2520PD-1%2520and%2520CTLA-4%2520are%2520Selectively%2520Expressed%2520on%2520Tumor-Infiltrating%2520T-cells%2520in%2520Head%2520and%2520Neck%2520Cancer%26jtitle%3DClin.%2520Transl.%2520Immunol.%26date%3D2016%26volume%3D5%26spage%3De70%26doi%3D10.1038%2Fcti.2016.16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sfanos, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeker, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marzo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span> <span> </span><span class="NLM_article-title">Human Prostate-Infiltrating CD8+ T Lymphocytes are Oligoclonal and PD-1+</span>. <i>Prostate</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1694</span>– <span class="NLM_lpage">1703</span>, <span class="refDoi"> DOI: 10.1002/pros.21020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fpros.21020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19670224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSntr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=1694-1703&author=K.+S.+Sfanosauthor=T.+C.+Brunoauthor=A.+K.+Meekerauthor=A.+M.+De+Marzoauthor=W.+B.+Isaacsauthor=C.+G.+Drake&title=Human+Prostate-Infiltrating+CD8%2B+T+Lymphocytes+are+Oligoclonal+and+PD-1%2B&doi=10.1002%2Fpros.21020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-I+</span></div><div class="casAuthors">Sfanos, Karen S.; Bruno, Tullia C.; Meeker, Alan K.; de Marzo, Angelo M.; Isaacs, William B.; Drake, Charles G.</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1694-1703</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Prostate-infiltrating CD8+ T lymphocytes (CD8+ PIL) are prevalent in men with prostate cancer (PCa), however, it is unclear whether the presence of such cells reflects a non-specific immune infiltrate or an oligoclonal, antigen-driven adaptive immune response.  We investigated the complexity of the T-cell receptor (TCR) repertoire in the prostate gland by examg. the diversity of CD8+ TCR β chain variable region (Vβ) gene sequences in both the peripheral blood and prostates of cancer patients.  Vβ repertoire anal. was performed by family-specific Vβ spectratyping and flow cytometry, as well as direct sequence anal. (5' RACE and cloning).  Programmed cell death 1 (PD-1 or PDCD1) expression on peripheral blood CD8+ T cells and CD8+ PIL was analyzed by flow cytometry.  CD8+ PIL isolated from cancer patients exhibited restricted TCR Vβ gene usage, and identical clones were identified in multiple sites within the prostate.  Furthermore, CD8+ PIL express high levels of the inhibitory receptor PD-1, a cell surface protein assocd. with an "exhausted" CD8+ T-cell phenotype.  CD8+ PIL appear to have undergone clonal expansion in response to an as yet unidentified antigen; however, due to the high expression of PD-1, these cells are likely incapable of mounting an effective immune response.  The results provide an important basis for further efforts aimed at the identification of specific antigens involved in prostatic inflammation, and suggest that PD-1 blockade may be useful in immunotherapy for PCa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX5j8BOnqzDrVg90H21EOLACvtfcHk0liM-Fpkaq48LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSntr%252FI&md5=27b14cc6b8325ac891216c9609b6fd49</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1002%2Fpros.21020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpros.21020%26sid%3Dliteratum%253Aachs%26aulast%3DSfanos%26aufirst%3DK.%2BS.%26aulast%3DBruno%26aufirst%3DT.%2BC.%26aulast%3DMeeker%26aufirst%3DA.%2BK.%26aulast%3DDe%2BMarzo%26aufirst%3DA.%2BM.%26aulast%3DIsaacs%26aufirst%3DW.%2BB.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26atitle%3DHuman%2520Prostate-Infiltrating%2520CD8%252B%2520T%2520Lymphocytes%2520are%2520Oligoclonal%2520and%2520PD-1%252B%26jtitle%3DProstate%26date%3D2009%26volume%3D69%26spage%3D1694%26epage%3D1703%26doi%3D10.1002%2Fpros.21020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadzadeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heemskerk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunderlich, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. A.</span></span> <span> </span><span class="NLM_article-title">Tumor Antigen-Specific CD8 T-cells Infiltrating the Tumor Express High Levels of PD-1 and are Functionally Impaired</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">1537</span>– <span class="NLM_lpage">1544</span>, <span class="refDoi"> DOI: 10.1182/blood-2008-12-195792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1182%2Fblood-2008-12-195792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19423728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVyiur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=1537-1544&author=M.+Ahmadzadehauthor=L.+A.+Johnsonauthor=B.+Heemskerkauthor=J.+R.+Wunderlichauthor=M.+E.+Dudleyauthor=D.+E.+Whiteauthor=S.+A.+Rosenberg&title=Tumor+Antigen-Specific+CD8+T-cells+Infiltrating+the+Tumor+Express+High+Levels+of+PD-1+and+are+Functionally+Impaired&doi=10.1182%2Fblood-2008-12-195792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired</span></div><div class="casAuthors">Ahmadzadeh, Mojgan; Johnson, Laura A.; Heemskerk, Bianca; Wunderlich, John R.; Dudley, Mark E.; White, Donald E.; Rosenberg, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1537-1544</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Tumor antigen-specific T cells are found within melanomas, yet tumors continue to grow.  Although the tumor microenvironment is thought to influence the suppression of tumor-reactive T cells, the underlying mechanisms for this T-cell dysfunction are not clear.  Here, we report that the majority of tumor infiltrating T lymphocytes (TIL), including MART-1/Melan-A melanoma antigen-specific CD8 T cells, predominantly expressed PD-1, in contrast to T cells in normal tissues and peripheral blood T lymphocytes (PBL).  PD-1+ TIL expressed CTLA-4 and Ki-67, markers that were not expressed by PD-1- TIL and T cells in the normal tissues and PBL.  Moreover, PD-1+ TIL were primarily HLA-DR+ and CD127-, in contrast to PD-1- TIL.  Effector cytokine prodn. by PD-1+ TIL was impaired compared with PD-1- TIL and PBL.  Collectively, the phenotypic and functional characterizations of TIL revealed a significantly higher frequency and level of PD-1 expression on TIL compared with normal tissue T-cell infiltrates and PBL, and PD-1 expression correlated with an exhausted phenotype and impaired effector function.  These findings suggest that the tumor microenvironment can lead to up-regulation of PD-1 on tumor-reactive T cells and contribute to impaired antitumor immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP9XeRjO6F3LVg90H21EOLACvtfcHk0liM-Fpkaq48LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVyiur3K&md5=81e4f19724e3a03abc8df9982e32ea90</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-12-195792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-12-195792%26sid%3Dliteratum%253Aachs%26aulast%3DAhmadzadeh%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DL.%2BA.%26aulast%3DHeemskerk%26aufirst%3DB.%26aulast%3DWunderlich%26aufirst%3DJ.%2BR.%26aulast%3DDudley%26aufirst%3DM.%2BE.%26aulast%3DWhite%26aufirst%3DD.%2BE.%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26atitle%3DTumor%2520Antigen-Specific%2520CD8%2520T-cells%2520Infiltrating%2520the%2520Tumor%2520Express%2520High%2520Levels%2520of%2520PD-1%2520and%2520are%2520Functionally%2520Impaired%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D1537%26epage%3D1544%26doi%3D10.1182%2Fblood-2008-12-195792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span> <span> </span><span class="NLM_article-title">PD-L1 Expression in Human Cancers and its Association with Clinical Outcomes</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">5023</span>– <span class="NLM_lpage">5039</span>, <span class="refDoi"> DOI: 10.2147/OTT.S105862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.2147%2FOTT.S105862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27574444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsFyjsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=5023-5039&author=X.+Wangauthor=F.+Tengauthor=L.+Kongauthor=J.+Yu&title=PD-L1+Expression+in+Human+Cancers+and+its+Association+with+Clinical+Outcomes&doi=10.2147%2FOTT.S105862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L1 expression in human cancers and its association with clinical outcomes</span></div><div class="casAuthors">Wang, Xin; Teng, Feifei; Kong, Li; Yu, Jinming</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5023-5039</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">PD-L1 is an immunoinhibitory mol. that suppresses the activation of T cells, leading to the progression of tumors.  Overexpression of PD-L1 in cancers such as gastric cancer, hepatocellular carcinoma, renal cell carcinoma, esophageal cancer, pancreatic cancer, ovarian cancer, and bladder cancer is assocd. with poor clin. outcomes.  In contrast, PD-L1 expression correlates with better clin. outcomes in breast cancer and merkel cell carcinoma.  The prognostic value of PD-L1 expression in lung cancer, colorectal cancer, and melanoma is controversial.  Blocking antibodies that target PD-1 and PD-L1 have achieved remarkable response rates in cancer patients who have PD-L1-overexpressing tumors.  However, using PD-L1 as an exclusive predictive biomarker for cancer immunotherapy is questionable due to the low accuracy of PD-L1 immunohistochem. staining.  Factors that affect the accuracy of PD-L1 immunohistochem. staining are as follows.  First, antibodies used in different studies have different sensitivity.  Second, in different studies, the cut-off value of PD-L1 staining positivity is different.  Third, PD-L1 expression in tumors is not uniform, and sampling time and location may affect the results of PD-L1 staining.  Therefore, better understanding of tumor microenvironment and use of other biomarkers such as gene marker and combined index are necessary to better identify patients who will benefit from PD-1/PD-L1 checkpoint blockade therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp67AMdNDVDzLVg90H21EOLACvtfcHk0liM-Fpkaq48LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsFyjsbk%253D&md5=3042a7ee3c4c3ebedbee389c61a189fb</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.2147%2FOTT.S105862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S105862%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTeng%26aufirst%3DF.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DJ.%26atitle%3DPD-L1%2520Expression%2520in%2520Human%2520Cancers%2520and%2520its%2520Association%2520with%2520Clinical%2520Outcomes%26jtitle%3DOncoTargets%2520Ther.%26date%3D2016%26volume%3D9%26spage%3D5023%26epage%3D5039%26doi%3D10.2147%2FOTT.S105862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span> <span> </span><span class="NLM_article-title">Immune Checkpoint Inhibitor Toxicity in 2018Immune Checkpoint Inhibitor ToxicityImmune Checkpoint Inhibitor Toxicity</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>320</i></span>,  <span class="NLM_fpage">1702</span>– <span class="NLM_lpage">1703</span>, <span class="refDoi"> DOI: 10.1001/jama.2018.13995</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1001%2Fjama.2018.13995" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30286224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BB3czlvVGqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2018&pages=1702-1703&author=D.+B.+Johnsonauthor=S.+Chandraauthor=J.+A.+Sosman&title=Immune+Checkpoint+Inhibitor+Toxicity+in+2018Immune+Checkpoint+Inhibitor+ToxicityImmune+Checkpoint+Inhibitor+Toxicity&doi=10.1001%2Fjama.2018.13995"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Immune Checkpoint Inhibitor Toxicity in 2018</span></div><div class="casAuthors">Johnson Douglas B; Johnson Douglas B; Chandra Sunandana; Sosman Jeffrey A; Chandra Sunandana; Sosman Jeffrey A</div><div class="citationInfo"><span class="NLM_cas:title">JAMA</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1702-1703</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTthrEhc_RnYZdYoSR9eyvsfW6udTcc2ebTGVTfFnL3dLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czlvVGqsQ%253D%253D&md5=60fe59cb297bff50df9de6ab6b0c30b3</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1001%2Fjama.2018.13995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2018.13995%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BB.%26aulast%3DChandra%26aufirst%3DS.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26atitle%3DImmune%2520Checkpoint%2520Inhibitor%2520Toxicity%2520in%25202018Immune%2520Checkpoint%2520Inhibitor%2520ToxicityImmune%2520Checkpoint%2520Inhibitor%2520Toxicity%26jtitle%3DJAMA%26date%3D2018%26volume%3D320%26spage%3D1702%26epage%3D1703%26doi%3D10.1001%2Fjama.2018.13995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thong, B. Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chia, F. L.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, T.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, K.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. W.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G. Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, H.-H.</span></span> <span> </span><span class="NLM_article-title">A Retrospective Study on Sequential Desensitization-Rechallenge for Antituberculosis Drug Allergy</span>. <i>Asia Pacific Allergy</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.5415/apallergy.2014.4.3.156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.5415%2Fapallergy.2014.4.3.156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25097851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC2cbptlKqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=156-163&author=B.+Y.-H.+Thongauthor=F.+L.-A.+Chiaauthor=S.-C.+Tanauthor=T.-C.+Tanauthor=K.-P.+Leongauthor=J.+W.-L.+Tanauthor=C.-Y.+Tangauthor=J.-F.+Houauthor=G.+Y.-L.+Chanauthor=H.-H.+Chng&title=A+Retrospective+Study+on+Sequential+Desensitization-Rechallenge+for+Antituberculosis+Drug+Allergy&doi=10.5415%2Fapallergy.2014.4.3.156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">A retrospective study on sequential desensitization-rechallenge for antituberculosis drug allergy</span></div><div class="casAuthors">Thong Bernard Yu-Hor; Chia Faith Li-Ann; Tan Sze-Chin; Tan Teck-Choon; Leong Khai-Pang; Tan Justina Wei-Lyn; Tang Chwee-Ying; Hou Jin-Feng; Chan Grace Yin-Lai; Chng Hiok-Hee</div><div class="citationInfo"><span class="NLM_cas:title">Asia Pacific allergy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">156-63</span>
        ISSN:<span class="NLM_cas:issn">2233-8276</span>.
    </div><div class="casAbstract">BACKGROUND:  Antituberculosis (anti-TB) drug allergy often involves multiple concurrently administered drugs which subsequently need to be reinitiated as no better alternatives exist.  OBJECTIVE:  To describe the results of tailored sequential desensitization-rechallenge (D-R) for anti-TB drug allergy.  METHODS:  Consecutive patients who had undergone D-R to anti-TB drugs between 1 September 1997 and 31 January 2012 were recruited.  Following resolution of the acute reaction, anti-TB drug was restarted at 1:6,000 to 1:3 of the final daily dose (FDD), with gradual single or multiple step daily dose escalation to the FDD.  Subsequent drugs were sequentially added ≥3 days later when the preceding drug was tolerated.  Full blood count and liver function tests were monitored prior to addition of each new drug.  RESULTS:  There were 11 patients of whom 10 were male, predominantly Chinese (8 patients).  Regimens comprised at least 3 drugs: isoniazid (INH), rifampicin (RIF), ethambutol (EMB), pyrazinamide (PZA), or streptomycin.  All patients had nonimmediate reactions, with cutaneous eruptions, where maculopapular exanthema (MPE) was the most common (8 patients).  Drug-induced hypersensitivity syndrome (DIHS) occurred in 6 patients, and Stevens Johnson syndrome (SJS) in 2 patients.  D-R to INH was successful in 7/9 patients (77.8%) and to RIF/EMB/PZA/streptomycin in all.  Of the 2 patients who failed INH D-R, 1 developed fever and MPE on day 3, the other MPE on day 8.  D-R with INH and RIF respectively was successful in 2 patients with SJS.  Among DIHS patients, 1 failed D-R with INH (fever and MPE on day 3).  There were 23/25 (92%) successful D-R among the 11 patients.  All patients completed TB treatment of ≥5 months' duration with no cases of drug-resistant TB.  CONCLUSION:  Tailored sequential TB drug D-R is successful where no better alternative therapies are available, with careful dose escalation and close monitoring, and after a careful risk-benefit assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYiFuHFerby669lAbTj9rGfW6udTcc2ebTGVTfFnL3dLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbptlKqtQ%253D%253D&md5=4ba392bb795c4aad9d7ccf0f33e233c6</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.5415%2Fapallergy.2014.4.3.156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5415%252Fapallergy.2014.4.3.156%26sid%3Dliteratum%253Aachs%26aulast%3DThong%26aufirst%3DB.%2BY.-H.%26aulast%3DChia%26aufirst%3DF.%2BL.-A.%26aulast%3DTan%26aufirst%3DS.-C.%26aulast%3DTan%26aufirst%3DT.-C.%26aulast%3DLeong%26aufirst%3DK.-P.%26aulast%3DTan%26aufirst%3DJ.%2BW.-L.%26aulast%3DTang%26aufirst%3DC.-Y.%26aulast%3DHou%26aufirst%3DJ.-F.%26aulast%3DChan%26aufirst%3DG.%2BY.-L.%26aulast%3DChng%26aufirst%3DH.-H.%26atitle%3DA%2520Retrospective%2520Study%2520on%2520Sequential%2520Desensitization-Rechallenge%2520for%2520Antituberculosis%2520Drug%2520Allergy%26jtitle%3DAsia%2520Pacific%2520Allergy%26date%3D2014%26volume%3D4%26spage%3D156%26epage%3D163%26doi%3D10.5415%2Fapallergy.2014.4.3.156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tiegs, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohse, A. W.</span></span> <span> </span><span class="NLM_article-title">Immune Tolerance: What is Unique About the Liver</span>. <i>J. Autoimmun.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1016/j.jaut.2009.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jaut.2009.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19717280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlGjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=1-6&author=G.+Tiegsauthor=A.+W.+Lohse&title=Immune+Tolerance%3A+What+is+Unique+About+the+Liver&doi=10.1016%2Fj.jaut.2009.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Immune tolerance: What is unique about the liver</span></div><div class="casAuthors">Tiegs, Gisa; Lohse, Ansgar W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Autoimmunity</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">JOAUEP</span>;
        ISSN:<span class="NLM_cas:issn">0896-8411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The liver tolerance effect' mediates local and systemic tolerance to self and foreign antigens and has been attributed to specialized resident cells expressing anti-inflammatory mediators and inhibitory cell surface ligands for T cell activation.  Non-parenchymal liver cells responsible for the tolerogenic properties of the liver are the resident dendritic cells (DCs), which comprise myeloid as well as plasmacytoid DCs, liver sinusoidal endothelial cells (LSECs), Kupffer cells (KCs) as well as hepatic stellate cells (HSCs), also known as Ito cells.  These cells mediate immunosuppression by prodn. of anti-inflammatory cytokines such as IL-10 and TGFβ as well as by expression of the neg. co-stimulator for T cell activation programmed cell death ligand-1 (PD-L1).  An interesting observation in this context is that knockout of IL-10 or PD-L1 (or the receptor PD-1) does not necessarily result in inflammatory liver damage whereas transgenic inhibition of TGFβ signaling induces liver disease in mice resembling chronic cholangitis.  However, depending on the mouse model and on the type of injury, e.g. autoimmune disease, allograft rejection or viral infection, IL-10 or TGFβ and/or PD-1 as well as cytotoxic T lymphocyte antigen-4 (CTLA-4) contribute to the immunosuppressive mechanisms of CD4+CD25+Foxp3+ regulatory T cells (Tregs), which seem to be converted in the liver from infiltrating conventional naive CD4+ T cells and/or effector CD4+ T cells to control the disease.  Finally, hepatocytes also contribute to the liver tolerance effect' by expression of MHC class II mols., probably low levels of co-stimulatory mols. and high levels of the co-inhibitory mol. PD-L1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTUl_U-lwVm7Vg90H21EOLACvtfcHk0ljlvNMEUb4VCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlGjsb4%253D&md5=20308fb0ed7a86d8404ee75caff8e3a9</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.jaut.2009.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaut.2009.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DTiegs%26aufirst%3DG.%26aulast%3DLohse%26aufirst%3DA.%2BW.%26atitle%3DImmune%2520Tolerance%253A%2520What%2520is%2520Unique%2520About%2520the%2520Liver%26jtitle%3DJ.%2520Autoimmun.%26date%3D2010%26volume%3D34%26spage%3D1%26epage%3D6%26doi%3D10.1016%2Fj.jaut.2009.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cirulli, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicoletti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucena, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molokhia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafnar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">1707</span>– <span class="NLM_lpage">1716</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2019.01.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1053%2Fj.gastro.2019.01.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30664875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXns1GltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2019&pages=1707-1716&author=E.+T.+Cirulliauthor=P.+Nicolettiauthor=K.+Abramsonauthor=R.+J.+Andradeauthor=E.+S.+Bjornssonauthor=N.+Chalasaniauthor=R.+J.+Fontanaauthor=P.+Hallbergauthor=Y.+J.+Liauthor=M.+I.+Lucenaauthor=N.+Longauthor=M.+Molokhiaauthor=M.+R.+Nelsonauthor=J.+A.+Odinauthor=M.+Pirmohamedauthor=T.+Rafnarauthor=J.+Serranoauthor=K.+Stefanssonauthor=A.+Stolzauthor=A.+K.+Dalyauthor=G.+P.+Aithalauthor=P.+B.+Watkins&title=A+Missense+Variant+in+PTPN22+is+a+Risk+Factor+for+Drug-induced+Liver+Injury&doi=10.1053%2Fj.gastro.2019.01.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury</span></div><div class="casAuthors">Cirulli, Elizabeth T.; Nicoletti, Paola; Abramson, Karen; Andrade, Raul J.; Bjornsson, Einar S.; Chalasani, Naga; Fontana, Robert J.; Hallberg, Par; Li, Yi Ju; Lucena, M. Isabel; Long, Nanye; Molokhia, Mariam; Nelson, Matthew R.; Odin, Joseph A.; Pirmohamed, Munir; Rafnar, Thorunn; Serrano, Jose; Stefansson, Kari; Stolz, Andrew; Daly, Ann K.; Aithal, Guruprasad P.; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1707-1716.e2</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We performed genetic analyses of a multiethnic cohort of patients with idiosyncratic drug-induced liver injury (DILI) to identify variants assocd. with susceptibility.  We performed a genome-wide assocn. study of 2048 individuals with DILI (cases) and 12,429 individuals without (controls).  Our anal. included subjects of European (1806 cases and 10,397 controls), African American (133 cases and 1,314 controls), and Hispanic (109 cases and 718 controls) ancestry.  We analyzed DNA from 113 Icelandic cases and 239,304 controls to validate our findings.  We assocd. idiosyncratic DILI with rs2476601, a nonsynonymous polymorphism that encodes a substitution of tryptophan with arginine in the protein tyrosine phosphatase, nonreceptor type 22 gene (PTPN22) (odds ratio [OR] 1.44; 95% confidence interval [CI] 1.28-1.62; P = 1.2 × 10-9 and replicated the finding in the validation set (OR 1.48; 95% CI 1.09-1.99; P = .01)).  The minor allele frequency showed the same effect size (OR > 1) among ethnic groups.  The strongest assocn. was with amoxicillin and clavulanate-assocd. DILI in persons of European ancestry (OR 1.62; 95% CI 1.32-1.98; P = 4.0 × 10-6; allele frequency = 13.3%), but the polymorphism was assocd. with DILI of other causes (OR 1.37; 95% CI 1.21-1.56; P = 1.5 × 10-6; allele frequency = 11.5%).  Among amoxicillin- and clavulanate-assocd. cases of European ancestry, rs2476601 doubled the risk for DILI among those with the HLA risk alleles A*02:01 and DRB1*15:01.  In a genome-wide assocn. study, we identified rs2476601 in PTPN22 as a non-HLA variant that assocs. with risk of liver injury caused by multiple drugs and validated our finding in a sep. cohort.  This variant has been assocd. with increased risk of autoimmune diseases, providing support for the concept that alterations in immune regulation contribute to idiosyncratic DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptv1LCetJnerVg90H21EOLACvtfcHk0lirjuZpuTAGkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXns1GltbY%253D&md5=d63acc4a517bcab6fc1e4276ef2f766c</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2019.01.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2019.01.034%26sid%3Dliteratum%253Aachs%26aulast%3DCirulli%26aufirst%3DE.%2BT.%26aulast%3DNicoletti%26aufirst%3DP.%26aulast%3DAbramson%26aufirst%3DK.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3DBjornsson%26aufirst%3DE.%2BS.%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DHallberg%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DY.%2BJ.%26aulast%3DLucena%26aufirst%3DM.%2BI.%26aulast%3DLong%26aufirst%3DN.%26aulast%3DMolokhia%26aufirst%3DM.%26aulast%3DNelson%26aufirst%3DM.%2BR.%26aulast%3DOdin%26aufirst%3DJ.%2BA.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DRafnar%26aufirst%3DT.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DStefansson%26aufirst%3DK.%26aulast%3DStolz%26aufirst%3DA.%26aulast%3DDaly%26aufirst%3DA.%2BK.%26aulast%3DAithal%26aufirst%3DG.%2BP.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DA%2520Missense%2520Variant%2520in%2520PTPN22%2520is%2520a%2520Risk%2520Factor%2520for%2520Drug-induced%2520Liver%2520Injury%26jtitle%3DGastroenterology%26date%3D2019%26volume%3D156%26spage%3D1707%26epage%3D1716%26doi%3D10.1053%2Fj.gastro.2019.01.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burn, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Blanco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cope, A. P.</span></span> <span> </span><span class="NLM_article-title">Why is PTPN22 a Good Candidate Susceptibility Gene for Autoimmune Disease?</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>585</i></span>,  <span class="NLM_fpage">3689</span>– <span class="NLM_lpage">3698</span>, <span class="refDoi"> DOI: 10.1016/j.febslet.2011.04.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.febslet.2011.04.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21515266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFSis7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=585&publication_year=2011&pages=3689-3698&author=G.+L.+Burnauthor=L.+Svenssonauthor=C.+Sanchez-Blancoauthor=M.+Sainiauthor=A.+P.+Cope&title=Why+is+PTPN22+a+Good+Candidate+Susceptibility+Gene+for+Autoimmune+Disease%3F&doi=10.1016%2Fj.febslet.2011.04.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Why is PTPN22 a good candidate susceptibility gene for autoimmune disease?</span></div><div class="casAuthors">Burn, Garth L.; Svensson, Lena; Sanchez-Blanco, Cristina; Saini, Manoj; Cope, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">585</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3689-3698</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The PTPN22 locus is one of the strongest risk factors outside of the major histocompatibility complex that assocs. with autoimmune diseases.  PTPN22 encodes lymphoid protein tyrosine phosphatase (Lyp) which is expressed exclusively in immune cells.  A single base change in the coding region of this gene resulting in an arginine to tryptophan amino acid substitution within a polyproline binding motif assocs. with type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosis, Hashimoto's thyroiditis, Graves disease, Addison's disease, Myasthenia Gravis, vitiligo, systemic sclerosis juvenile idiopathic arthritis and psoriatic arthritis.  Here, the authors review the current understanding of the PTPN22 locus from a genetic, geog., biochem. and functional perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOSppGQyuZ57Vg90H21EOLACvtfcHk0lirjuZpuTAGkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFSis7%252FL&md5=4521c8655b07be45008dad58a801d1c0</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2011.04.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2011.04.032%26sid%3Dliteratum%253Aachs%26aulast%3DBurn%26aufirst%3DG.%2BL.%26aulast%3DSvensson%26aufirst%3DL.%26aulast%3DSanchez-Blanco%26aufirst%3DC.%26aulast%3DSaini%26aufirst%3DM.%26aulast%3DCope%26aufirst%3DA.%2BP.%26atitle%3DWhy%2520is%2520PTPN22%2520a%2520Good%2520Candidate%2520Susceptibility%2520Gene%2520for%2520Autoimmune%2520Disease%253F%26jtitle%3DFEBS%2520Lett.%26date%3D2011%26volume%3D585%26spage%3D3689%26epage%3D3698%26doi%3D10.1016%2Fj.febslet.2011.04.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stanford, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottini, N.</span></span> <span> </span><span class="NLM_article-title">PTPN22: The Archetypal Non-HLA Autoimmunity Gene</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">602</span>– <span class="NLM_lpage">611</span>, <span class="refDoi"> DOI: 10.1038/nrrheum.2014.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fnrrheum.2014.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25003765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFCkt77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=602-611&author=S.+M.+Stanfordauthor=N.+Bottini&title=PTPN22%3A+The+Archetypal+Non-HLA+Autoimmunity+Gene&doi=10.1038%2Fnrrheum.2014.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">PTPN22: the archetypal non-HLA autoimmunity gene</span></div><div class="casAuthors">Stanford, Stephanie M.; Bottini, Nunzio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">602-611</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  PTPN22 encodes a tyrosine phosphatase that is expressed by haematopoietic cells and functions as a key regulator of immune homeostasis by inhibiting T-cell receptor signalling and by selectively promoting type I interferon responses after activation of myeloid-cell pattern-recognition receptors.  A single nucleotide polymorphism of PTPN22, 1858C>T (rs2476601), disrupts an interaction motif in the protein, and is the most important non-HLA genetic risk factor for rheumatoid arthritis and the second most important for juvenile idiopathic arthritis.  PTPN22 exemplifies a shared autoimmunity gene, affecting the pathogenesis of systemic lupus erythematosus, vasculitis and other autoimmune diseases.  In this Review, we explore the role of PTPN22 in autoimmune connective tissue disease, with particular emphasis on candidate-gene and genome-wide assocn. studies and clin. variability of disease.  We also propose a no. of PTPN22-dependent functional models of the pathogenesis of autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdec0zXDfJr7Vg90H21EOLACvtfcHk0lirjuZpuTAGkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFCkt77E&md5=d4f9f8fa45baa963c27c212755e05456</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2014.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2014.109%26sid%3Dliteratum%253Aachs%26aulast%3DStanford%26aufirst%3DS.%2BM.%26aulast%3DBottini%26aufirst%3DN.%26atitle%3DPTPN22%253A%2520The%2520Archetypal%2520Non-HLA%2520Autoimmunity%2520Gene%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2014%26volume%3D10%26spage%3D602%26epage%3D611%26doi%3D10.1038%2Fnrrheum.2014.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">Effects of Immunization and Checkpoint Inhibition on Amodiaquine-Induced Liver Injury</span>. <i>J. Immunotoxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1080/1547691X.2017.1290716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1080%2F1547691X.2017.1290716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28279082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktFWjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=89-94&author=A.+Makauthor=A.+Johnstonauthor=J.+Uetrecht&title=Effects+of+Immunization+and+Checkpoint+Inhibition+on+Amodiaquine-Induced+Liver+Injury&doi=10.1080%2F1547691X.2017.1290716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of immunization and checkpoint inhibition on amodiaquine-induced liver injury</span></div><div class="casAuthors">Mak, Alastair; Johnston, Alexander; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunotoxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-94</span>CODEN:
                <span class="NLM_cas:coden">JIOMAP</span>;
        ISSN:<span class="NLM_cas:issn">1547-691X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">If idiosyncratic drug-induced liver injury (IDILI) is immune-mediated, it is possible that an individual's prior exposure to antigens may affect their susceptibility to IDILI.  An individual's repertoire of memory immune cells is shaped by every past exposure to antigens.  Subsequent drug-induced adverse drug reactions may therefore involve an immune cell's cross reactivity between a prior antigen and resulting drug-modified proteins.  Therefore in this expt., mice were immunized with amodiaquine (AQ)-modified hepatic proteins to mimic a previous exposure; treated with a RIBI adjuvant and anti-CD40 antibodies to stimulate an immune response; and, treated with anti-PD1 and anti-CTLA-4 antibodies prior to AQ treatment in order to overcome immune tolerance.  This treatment led to greater liver injury than treatment with AQ alone.  However, the mice did not develop serious liver injury.  PD1-/- mice were then immunized and treated with AQ and anti-CTLA-4 antibodies so that immune tolerance would be impaired, both during immunization and also during AQ treatment.  However, even this did not result in liver failure, and the liver injury was not significantly increased relative to un-immunized PD1-/- mice treated with anti-CTLA-4 and AQ.  From these results we conclude that, although previous antigen exposure may affect the risk of IDILI, it appears that a very strong stimulus is required, and impairing immune tolerance remains the most effective method for producing an animal model of IDILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLUPDIbD5Z0bVg90H21EOLACvtfcHk0liGZhN4mPeJ0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktFWjt7Y%253D&md5=2c4c7f1565bee1d31ea492ed97f686f8</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1080%2F1547691X.2017.1290716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1547691X.2017.1290716%26sid%3Dliteratum%253Aachs%26aulast%3DMak%26aufirst%3DA.%26aulast%3DJohnston%26aufirst%3DA.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DEffects%2520of%2520Immunization%2520and%2520Checkpoint%2520Inhibition%2520on%2520Amodiaquine-Induced%2520Liver%2520Injury%26jtitle%3DJ.%2520Immunotoxicol.%26date%3D2017%26volume%3D14%26spage%3D89%26epage%3D94%26doi%3D10.1080%2F1547691X.2017.1290716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Depta, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, W. J.</span></span> <span> </span><span class="NLM_article-title">Cross-Reactivity with Drugs at the T-cell Level</span>. <i>Current Opinion in Allergy and Clinical Immunology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1097/00130832-200308000-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1097%2F00130832-200308000-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=12865769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptlahu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=261-267&author=J.+P.+Deptaauthor=W.+J.+Pichler&title=Cross-Reactivity+with+Drugs+at+the+T-cell+Level&doi=10.1097%2F00130832-200308000-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Cross-reactivity with drugs at the T cell level</span></div><div class="casAuthors">Depta, Jan P. H.; Pichler, Werner J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">261-267</span>CODEN:
                <span class="NLM_cas:coden">COACCS</span>;
        ISSN:<span class="NLM_cas:issn">1528-4050</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Purpose of review Cross-reactivity with drugs is an important clin. problem in drug hypersensitivity.  Once a patient is labeled 'drug-allergic' all drugs of the same class are withheld and future therapeutic interventions are limited.  Here the authors review cross-reactivity with drugs at the T cell level.  Recent findings Anal. of T cell recognition of various classes of drugs (β-lactam antibiotics, sulfonamides, local anesthetics) using T cell clones suggests that at the T cell level the whole structure, in particular the core and to a lesser degree side chains, are recognized.  Summary It is necessary to differentiate cross-reactivity mediated by T cells and antibodies as only the latter seem to recognize side chains exclusively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjsGqKpA1lRbVg90H21EOLACvtfcHk0liGZhN4mPeJ0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptlahu70%253D&md5=9ec4c3ec858f5d3cded7afc85c7a94ad</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1097%2F00130832-200308000-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00130832-200308000-00005%26sid%3Dliteratum%253Aachs%26aulast%3DDepta%26aufirst%3DJ.%2BP.%26aulast%3DPichler%26aufirst%3DW.%2BJ.%26atitle%3DCross-Reactivity%2520with%2520Drugs%2520at%2520the%2520T-cell%2520Level%26jtitle%3DCurrent%2520Opinion%2520in%2520Allergy%2520and%2520Clinical%2520Immunology%26date%3D2003%26volume%3D3%26spage%3D261%26epage%3D267%26doi%3D10.1097%2F00130832-200308000-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, P. G.</span></span> <span> </span><span class="NLM_article-title">The Two Faces of Heterologous Immunity: Protection or Immunopathology</span>. <i>J. Leukocyte Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1189/jlb.0713386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1189%2Fjlb.0713386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24212098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVOisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2014&pages=405-416&author=S.+Sharmaauthor=P.+G.+Thomas&title=The+Two+Faces+of+Heterologous+Immunity%3A+Protection+or+Immunopathology&doi=10.1189%2Fjlb.0713386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">The two faces of heterologous immunity: protection or immunopathology</span></div><div class="casAuthors">Sharma, Shalini; Thomas, Paul G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-416, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Society for Leukocyte Biology</span>)
        </div><div class="casAbstract">A review.  Immunity to previously encountered viruses can alter responses to unrelated pathogens.  This phenomenon, which is known as heterologous immunity, has been well established in animal model systems.  Heterologous immunity appears to be relatively common and may be beneficial by boosting protective responses.  However, heterologous reactivity can also result in severe immunopathol.  The key features that define heterologous immune modulation include alterations in the CD4+ and CD8- T cell compartments and changes in viral dynamics and disease progression.  In this review, we discuss recent advances and the current understanding of antiviral immunity in heterologous infections.  The difficulties of studying these complex heterologous infections in humans are discussed, with special ref. to the variations in HLA haplotypes and uncertainties about individuals' infection history.  Despite these limitations, epidemiol. analyses in humans and the data from mouse models of coinfection can be applied toward advancing the design of therapeutics and vaccination strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx0Ka-JDzfd7Vg90H21EOLACvtfcHk0liGZhN4mPeJ0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVOisbc%253D&md5=42fc699256776ad36c83926825fb15d9</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1189%2Fjlb.0713386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.0713386%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DP.%2BG.%26atitle%3DThe%2520Two%2520Faces%2520of%2520Heterologous%2520Immunity%253A%2520Protection%2520or%2520Immunopathology%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2014%26volume%3D95%26spage%3D405%26epage%3D416%26doi%3D10.1189%2Fjlb.0713386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pavlos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanjalla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallal, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, E. J.</span></span> <span> </span><span class="NLM_article-title">Severe Delayed Drug Reactions: Role of Genetics and Viral Infections</span>. <i>Immunol. Allergy Clin. North Am.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">785</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1016/j.iac.2017.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.iac.2017.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28965641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FktVOitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=785-815&author=R.+Pavlosauthor=K.+D.+Whiteauthor=C.+Wanjallaauthor=S.+A.+Mallalauthor=E.+J.+Phillips&title=Severe+Delayed+Drug+Reactions%3A+Role+of+Genetics+and+Viral+Infections&doi=10.1016%2Fj.iac.2017.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Severe Delayed Drug Reactions: Role of Genetics and Viral Infections</span></div><div class="casAuthors">Pavlos Rebecca; White Katie D; Wanjalla Celestine; Mallal Simon A; Phillips Elizabeth J</div><div class="citationInfo"><span class="NLM_cas:title">Immunology and allergy clinics of North America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">785-815</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Adverse drug reactions (ADRs) are a significant source of patient morbidity and mortality and represent a major burden to health care systems and drug development.  Up to 50% of such reactions are preventable.  Although many ADRs can be predicted based on the on-target pharmacologic activity, ADRs arising from drug interactions with off-target receptors are recognized.  Off-target ADRs include the immune-mediated ADRs (IM-ADRs) and pharmacologic drug effects.  In this review, we discuss what is known about the immunogenetics and pathogenesis of IM-ADRs and the hypothesized role of heterologous immunity in the development of IM-ADRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQp7-aOJsEAoZcXNb62YGmbfW6udTcc2eZPRIF-M-_0Abntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FktVOitg%253D%253D&md5=21f9835291cfffeae352236238db4d3b</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.iac.2017.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.iac.2017.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DPavlos%26aufirst%3DR.%26aulast%3DWhite%26aufirst%3DK.%2BD.%26aulast%3DWanjalla%26aufirst%3DC.%26aulast%3DMallal%26aufirst%3DS.%2BA.%26aulast%3DPhillips%26aufirst%3DE.%2BJ.%26atitle%3DSevere%2520Delayed%2520Drug%2520Reactions%253A%2520Role%2520of%2520Genetics%2520and%2520Viral%2520Infections%26jtitle%3DImmunol.%2520Allergy%2520Clin.%2520North%2520Am.%26date%3D2017%26volume%3D37%26spage%3D785%26epage%3D815%26doi%3D10.1016%2Fj.iac.2017.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strhyn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keane, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinnon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer-Pannwitt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudieri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Orsogna, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrov, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, E.</span></span> <span> </span><span class="NLM_article-title">Abacavir-Reactive Memory T-cells are Present in Drug Naive Individuals</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e0117160</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0117160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1371%2Fjournal.pone.0117160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25674793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVGrsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0117160&author=A.+Lucasauthor=M.+Lucasauthor=A.+Strhynauthor=N.+M.+Keaneauthor=E.+McKinnonauthor=R.+Pavlosauthor=E.+M.+Moranauthor=V.+Meyer-Pannwittauthor=S.+Gaudieriauthor=L.+D%E2%80%99Orsognaauthor=S.+Kalamsauthor=D.+A.+Ostrovauthor=S.+Buusauthor=B.+Petersauthor=S.+Mallalauthor=E.+Phillips&title=Abacavir-Reactive+Memory+T-cells+are+Present+in+Drug+Naive+Individuals&doi=10.1371%2Fjournal.pone.0117160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Abacavir-reactive memory T cells are present in drug naive individuals</span></div><div class="casAuthors">Lucas, Andrew; Lucas, Michaela; Strhyn, Anette; Keane, Niamh M.; McKinnon, Elizabeth; Pavlos, Rebecca; Moran, Ellen M.; Meyer-Pannwitt, Viola; Gaudieri, Silvana; D'Orsogna, Lloyd; Kalams, Spyros; Ostrov, David A.; Buus, Soeren; Peters, Bjoern; Mallal, Simon; Phillips, Elizabeth</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e0117160/1-e0117160/16</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Fifty-five percent of individuals with HLA-B*57:01 exposed to the antiretroviral drug abacavir develop a hypersensitivity reaction (HSR) that has been attributed to naive T-cell responses to neo-antigen generated by the drug.  Immunol. confirmed abacavir HSR can manifest clin. in less than 48 h following first exposure suggesting that, at least in some cases, abacavir HSR is due to re-stimulation of a pre-existing memory T-cell population rather than priming of a high frequency naive T-cell population.  Methods: To det. whether a pre-existing abacavir reactive memory T-cell population contributes to early abacavir HSR symptoms, we studied the abacavir specific naive or memory T-cell response using HLA-B*57:01 pos. HSR patients or healthy controls using ELISpot assay, intra-cellular cytokine staining and tetramer labeling.  Results: Abacavir reactive CD8+ T-cell responses were detected in vitro in one hundred percent of abacavir unexposed HLA-B*57:01 pos. healthy donors.  Abacavir-specific CD8+ T cells from such donors can be expanded from sorted memory, and sorted naive, CD8+ T cells without need for autologous CD4+ T cells.  Conclusions: We propose that these pre-existing abacavir-reactive memory CD8+ T-cell responses must have been primed by earlier exposure to another foreign antigen and that these T cells cross-react with an abacavir-HLA-B*57:01-endogenous peptide ligand complex, in keeping with the model of heterologous immunity proposed in transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGP2OSzHNfaLVg90H21EOLACvtfcHk0lhG7h_Z1VSIug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVGrsrvJ&md5=278bb38997ebc639c1ee1868d9d95443</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0117160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0117160%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DA.%26aulast%3DLucas%26aufirst%3DM.%26aulast%3DStrhyn%26aufirst%3DA.%26aulast%3DKeane%26aufirst%3DN.%2BM.%26aulast%3DMcKinnon%26aufirst%3DE.%26aulast%3DPavlos%26aufirst%3DR.%26aulast%3DMoran%26aufirst%3DE.%2BM.%26aulast%3DMeyer-Pannwitt%26aufirst%3DV.%26aulast%3DGaudieri%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Orsogna%26aufirst%3DL.%26aulast%3DKalams%26aufirst%3DS.%26aulast%3DOstrov%26aufirst%3DD.%2BA.%26aulast%3DBuus%26aufirst%3DS.%26aulast%3DPeters%26aufirst%3DB.%26aulast%3DMallal%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DE.%26atitle%3DAbacavir-Reactive%2520Memory%2520T-cells%2520are%2520Present%2520in%2520Drug%2520Naive%2520Individuals%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0117160%26doi%3D10.1371%2Fjournal.pone.0117160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, K. L.</span></span> <span> </span><span class="NLM_article-title">Systems Pharmacology Modeling Predicts Delayed Presentation and Species Differences in Bile Acid-Mediated Troglitazone Hepatotoxicity</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">598</span>, <span class="refDoi"> DOI: 10.1038/clpt.2014.158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fclpt.2014.158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25068506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyltrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2014&pages=589-598&author=K.+Yangauthor=J.+L.+Woodheadauthor=P.+B.+Watkinsauthor=B.+A.+Howellauthor=K.+L.+Brouwer&title=Systems+Pharmacology+Modeling+Predicts+Delayed+Presentation+and+Species+Differences+in+Bile+Acid-Mediated+Troglitazone+Hepatotoxicity&doi=10.1038%2Fclpt.2014.158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Systems Pharmacology Modeling Predicts Delayed Presentation and Species Differences in Bile Acid-Mediated Troglitazone Hepatotoxicity</span></div><div class="casAuthors">Yang, K.; Woodhead, J. L.; Watkins, P. B.; Howell, B. A.; Brouwer, K. L. R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">589-598</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Troglitazone (TGZ) causes delayed, life-threatening drug-induced liver injury in some patients but was not hepatotoxic in rats.  This study investigated altered bile acid homeostasis as a mechanism of TGZ hepatotoxicity using a systems pharmacol. model incorporating drug/metabolite disposition, bile acid physiol./pathophysiol., hepatocyte life cycle, and liver injury biomarkers.  In the simulated human population, TGZ (200-600 mg/day × 6 mo) resulted in delayed increases in serum alanine transaminase >3× the upper limit of normal in 0.3-5.1%, with concomitant bilirubin elevations >2× the upper limit of normal in 0.3-3.6%, of the population.  By contrast, pioglitazone (15-45 mg/day × 6 mo) did not elicit hepatotoxicity, consistent with clin. data.  TGZ was not hepatotoxic in the simulated rat population.  In summary, mechanistic modeling based only on bile acid effects accurately predicted the incidence, delayed presentation, and species differences in TGZ hepatotoxicity, in addn. to predicting the relative liver safety of pioglitazone.  Systems pharmacol. models integrating physiol. and exptl. data can evaluate drug-induced liver injury mechanisms and may be useful to predict the hepatotoxic potential of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSRsvjs2JmfLVg90H21EOLACvtfcHk0lhG7h_Z1VSIug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyltrrP&md5=4167aafc1abad72d6a30c20c2f82c318</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2014.158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2014.158%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DK.%26aulast%3DWoodhead%26aufirst%3DJ.%2BL.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DHowell%26aufirst%3DB.%2BA.%26aulast%3DBrouwer%26aufirst%3DK.%2BL.%26atitle%3DSystems%2520Pharmacology%2520Modeling%2520Predicts%2520Delayed%2520Presentation%2520and%2520Species%2520Differences%2520in%2520Bile%2520Acid-Mediated%2520Troglitazone%2520Hepatotoxicity%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2014%26volume%3D96%26spage%3D589%26epage%3D598%26doi%3D10.1038%2Fclpt.2014.158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brock, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoaf, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grammatopoulos, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siler, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoda, L. K.</span></span> <span> </span><span class="NLM_article-title">Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfw193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfw193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27655350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFajt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2017&pages=61-74&author=J.+L.+Woodheadauthor=W.+J.+Brockauthor=S.+E.+Rothauthor=S.+E.+Shoafauthor=K.+L.+Brouwerauthor=R.+Churchauthor=T.+N.+Grammatopoulosauthor=L.+Stilesauthor=S.+Q.+Silerauthor=B.+A.+Howellauthor=M.+Mosedaleauthor=P.+B.+Watkinsauthor=L.+K.+Shoda&title=Application+of+a+Mechanistic+Model+to+Evaluate+Putative+Mechanisms+of+Tolvaptan+Drug-Induced+Liver+Injury+and+Identify+Patient+Susceptibility+Factors&doi=10.1093%2Ftoxsci%2Fkfw193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Application of a mechanistic model to evaluate putative mechanisms of tolvaptan drug-induced liver injury and identify patient susceptibility factors</span></div><div class="casAuthors">Woodhead, Jeffrey L.; Brock, William J.; Roth, Sharin E.; Shoaf, Susan E.; Brouwer, Kim L. R.; Church, Rachel; Grammatopoulos, Tom N.; Stiles, Linsey; Siler, Scott Q.; Howell, Brett A.; Mosedale, Merrie; Watkins, Paul B.; Shoda, Lisl K. M.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-74</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Tolvaptan is a selective vasopressin V2 receptor antagonist, approved in several countries for the treatment of hyponatremia and autosomal dominant polycystic kidney disease (ADPKD).  No liver injury has been obsd. with tolvaptan treatment in healthy subjects and in non-ADPKD indications, but ADPKD clin. trials showed evidence of drug-induced liver injury (DILI).  Although all DILI events resolved, addnl. monitoring in tolvaptan-treated ADPKD patients is required.  In vitro assays identified alterations in bile acid disposition and inhibition of mitochondrial respiration as potential mechanisms underlying tolvaptan hepatotoxicity.  This report details the application of DILIsym software to det. whether these mechanisms could account for the liver safety profile of tolvaptan obsd. in ADPKD clin. trials.  DILIsym simulations included physiol. based pharmacokinetic ests. of hepatic exposure for tolvaptan and 2 metabolites, and their effects on hepatocyte bile acid transporters and mitochondrial respiration.  The frequency of predicted alanine aminotransferase (ALT) elevations, following simulated 90/30 mg split daily dosing, was 7.9% compared with clin. observations of 4.4% in ADPKD trials.  Toxicity was multifactorial as inhibition of bile acid transporters and mitochondrial respiration contributed to the simulated DILI.  Furthermore, simulation anal. identified both pre-treatment risk factors and on-treatment biomarkers predictive of simulated DILI.  The simulations demonstrated that in vivo hepatic exposure to tolvaptan and the DM-4103 metabolite, combined with these 2 mechanisms of toxicity, were sufficient to account for the initiation of tolvaptan-mediated DILI.  Identification of putative risk-factors and potential novel biomarkers provided insight for the development of mechanism-based tolvaptan risk-mitigation strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpiYRo4rMfDLVg90H21EOLACvtfcHk0lhG7h_Z1VSIug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFajt7Y%253D&md5=4a4f9d8389bf27b898eb2ed1adf5bb69</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfw193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfw193%26sid%3Dliteratum%253Aachs%26aulast%3DWoodhead%26aufirst%3DJ.%2BL.%26aulast%3DBrock%26aufirst%3DW.%2BJ.%26aulast%3DRoth%26aufirst%3DS.%2BE.%26aulast%3DShoaf%26aufirst%3DS.%2BE.%26aulast%3DBrouwer%26aufirst%3DK.%2BL.%26aulast%3DChurch%26aufirst%3DR.%26aulast%3DGrammatopoulos%26aufirst%3DT.%2BN.%26aulast%3DStiles%26aufirst%3DL.%26aulast%3DSiler%26aufirst%3DS.%2BQ.%26aulast%3DHowell%26aufirst%3DB.%2BA.%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DShoda%26aufirst%3DL.%2BK.%26atitle%3DApplication%2520of%2520a%2520Mechanistic%2520Model%2520to%2520Evaluate%2520Putative%2520Mechanisms%2520of%2520Tolvaptan%2520Drug-Induced%2520Liver%2520Injury%2520and%2520Identify%2520Patient%2520Susceptibility%2520Factors%26jtitle%3DToxicol.%2520Sci.%26date%3D2017%26volume%3D155%26spage%3D61%26epage%3D74%26doi%3D10.1093%2Ftoxsci%2Fkfw193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isley, W. L.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxicity of Thiazolidinediones</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">586</span>, <span class="refDoi"> DOI: 10.1517/14740338.2.6.581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1517%2F14740338.2.6.581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=14585066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvFertrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=581-586&author=W.+L.+Isley&title=Hepatotoxicity+of+Thiazolidinediones&doi=10.1517%2F14740338.2.6.581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity of thiazolidinediones</span></div><div class="casAuthors">Isley, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">581-586</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Thiazolidinediones are insulin sensitizers now widely used for the treatment of Type 2 diabetes mellitus.  The initial marketed drug in this class, troglitazone, was removed from the market worldwide after approx. 3 yr of use due to rare but severe hepatotoxicity, which sometimes resulted in liver failure leading to the need for liver transplantation, or even death.  The unpredictability of such liver toxicity made the use of troglitazone highly problematic.  Fortunately, the two newer drugs in this class, rosiglitazone and pioglitazone, have a much larger margin of safety for liver toxicity.  Very rare reports of liver toxicity, usually milder and reversible, have been seen with these drugs.  Therefore, while pharmacovigilance for hepatotoxicity is probably still warranted, the practitioner and patient can be fairly confident that these drugs are safe from a liver standpoint.  Finally, recent work would suggest that these agents may prove useful to reduce hepatic fat in patients with non-alc. steatohepatitis, and may possibly protect against adverse metabolic consequences and the ultimate development of cirrhosis in patients with fatty livers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQgG8CxGlRbLVg90H21EOLACvtfcHk0lhqegkdlg84kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvFertrg%253D&md5=2b69829bb735bf4851d2130be0004c80</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1517%2F14740338.2.6.581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.2.6.581%26sid%3Dliteratum%253Aachs%26aulast%3DIsley%26aufirst%3DW.%2BL.%26atitle%3DHepatotoxicity%2520of%2520Thiazolidinediones%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2003%26volume%3D2%26spage%3D581%26epage%3D586%26doi%3D10.1517%2F14740338.2.6.581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weston, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">Activation of Inflammasomes by Agents Causing Idiosyncratic Skin Reactions: A Possible Biomarker</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">951</span>, <span class="refDoi"> DOI: 10.1021/tx5001333</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx5001333" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVGmt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=949-951&author=J.+K.+Westonauthor=J.+Uetrecht&title=Activation+of+Inflammasomes+by+Agents+Causing+Idiosyncratic+Skin+Reactions%3A+A+Possible+Biomarker&doi=10.1021%2Ftx5001333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of Inflammasomes by Agents Causing Idiosyncratic Skin Reactions: A Possible Biomarker</span></div><div class="casAuthors">Weston, J. Kyle; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">949-951</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chem. reactive drugs and drugs that form reactive metabolites often cause idiosyncratic drug reactions (IDRs); however, not all such drugs are assocd. with IDRs.  Most IDRs appear to be immune mediated; therefore, the ability of a drug to induce an immune response may be the determinant of which drugs will cause IDRs.  Inflammasome activation plays an important role in the initiation of an immune response.  In this study, we studied two pairs of similar chem. reactive drugs, telaprevir/boceprevir and di-Me fumarate/ethacrynic acid.  In both pairs, the drug assocd. with skin reactions activated inflammasomes in THP-1 cells, and the drug not assocd. with skin reactions did not.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFQpmKwqoQibVg90H21EOLACvtfcHk0lhqegkdlg84kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVGmt7w%253D&md5=264b29824e6f6487f8294adbc2393f71</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Ftx5001333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx5001333%26sid%3Dliteratum%253Aachs%26aulast%3DWeston%26aufirst%3DJ.%2BK.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DActivation%2520of%2520Inflammasomes%2520by%2520Agents%2520Causing%2520Idiosyncratic%2520Skin%2520Reactions%253A%2520A%2520Possible%2520Biomarker%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2014%26volume%3D27%26spage%3D949%26epage%3D951%26doi%3D10.1021%2Ftx5001333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lammert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einarsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niklasson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span> <span> </span><span class="NLM_article-title">Relationship Between Daily Dose of Oral Medications and Idiosyncratic Drug-Induced Liver Injury: Search for Signals</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2003</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1002/hep.22272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.22272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=18454504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVagt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=2003-2009&author=C.+Lammertauthor=S.+Einarssonauthor=C.+Sahaauthor=A.+Niklassonauthor=E.+Bjornssonauthor=N.+Chalasani&title=Relationship+Between+Daily+Dose+of+Oral+Medications+and+Idiosyncratic+Drug-Induced+Liver+Injury%3A+Search+for+Signals&doi=10.1002%2Fhep.22272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals</span></div><div class="casAuthors">Lammert, Craig; Einarsson, Stefan; Saha, Chandan; Niklasson, Anna; Bjornsson, Einar; Chalasani, Naga</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2003-2009</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Idiosyncratic drug-induced liver injury (DILI) is traditionally thought not to be dose-related.  However, it has been pointed out that most medicines that were withdrawn from marketing or received a black-box warning because of hepatotoxicity were prescribed at daily doses greater than 50 mg/day.  To examine the relationship between daily dose of medications and idiosyncratic DILI, we conducted a study with two aims.  First, using two pharmaceutical databases, we examd. the relationship between daily dose of commonly prescribed medicines in the United States and reported frequency of their selected hepatic adverse events.  Second, we examd. serious DILI cases reported to the Swedish Adverse Drug Reactions Advisory Committee (1970-2004) for any signals supporting the relationship between daily dose and idiosyncratic DILI.  Medications were categorized into ≤10 mg/day, 11-49 mg/day, and ≥50 mg/day groups.  Among US prescription medicines, a statistically significant relationship was obsd. between daily dose of oral medicines and reports of liver failure (P = 0.009), liver transplantation (P < 0.001), and death caused by DILI (P = 0.004) but not alanine aminotransferase (ALT) > 3 × upper limit of normal (P = 0.10) or jaundice (P = 0.16).  Of 598 eligible Swedish DILI cases, 9% belonged to the ≤10 mg/day group, 14.2% to the 11-49 mg/day group, and 77% of cases were caused by medications given at dose ≥50 mg/day.  A statistically significant relationship was noted between daily dose and poor outcome (death or liver transplantation) of Swedish DILI cases (2%, 9.4%, and 13.2% in ≤10, 11-49, and ≥50 mg/day groups, resp., P = 0.03).  Conclusion: These data suggest a relationship between daily doses of oral prescription medications and idiosyncratic DILI.  More studies are needed to validate these observations and to explore their implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-pByO6X3Hk7Vg90H21EOLACvtfcHk0lhqegkdlg84kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVagt7w%253D&md5=f497d61a5253cc653c2d955232471d65</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1002%2Fhep.22272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.22272%26sid%3Dliteratum%253Aachs%26aulast%3DLammert%26aufirst%3DC.%26aulast%3DEinarsson%26aufirst%3DS.%26aulast%3DSaha%26aufirst%3DC.%26aulast%3DNiklasson%26aufirst%3DA.%26aulast%3DBjornsson%26aufirst%3DE.%26aulast%3DChalasani%26aufirst%3DN.%26atitle%3DRelationship%2520Between%2520Daily%2520Dose%2520of%2520Oral%2520Medications%2520and%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%253A%2520Search%2520for%2520Signals%26jtitle%3DHepatology%26date%3D2008%26volume%3D47%26spage%3D2003%26epage%3D2009%26doi%3D10.1002%2Fhep.22272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lammert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niklasson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span> <span> </span><span class="NLM_article-title">Oral Medications with Significant Hepatic Metabolism at Higher Risk for Hepatic Adverse Events</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">615</span>– <span class="NLM_lpage">620</span>, <span class="refDoi"> DOI: 10.1002/hep.23317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.23317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19839004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisVGnsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=615-620&author=C.+Lammertauthor=E.+Bjornssonauthor=A.+Niklassonauthor=N.+Chalasani&title=Oral+Medications+with+Significant+Hepatic+Metabolism+at+Higher+Risk+for+Hepatic+Adverse+Events&doi=10.1002%2Fhep.23317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events</span></div><div class="casAuthors">Lammert, Craig; Bjornsson, Einar; Niklasson, Anna; Chalasani, Naga</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">615-620</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Reactive metabolites generated by hepatic metab. are thought to play an important role in the pathogenesis of drug-induced liver injury (DILI), but supporting data are limited.  If this is true, then compds. with significant hepatic metab. should cause more DILI than those without it.  We conducted a study to examine the relationship between hepatic metab. and DILI of prescription medications.  We systematically extd. the metab. characteristics of 207 of the most widely prescribed oral medications in the United States.  Compds. with >50% hepatic metab. were characterized as those with significant hepatic metab. (n = 149).  Hepatic adverse events of interest were alanine aminotransferase >3 times the upper limit of normal, jaundice, liver failure, liver transplantation, or fatal DILI.  Compared with compds. with lesser hepatic metab., compds. belonging to the significant hepatic metab. group had significantly higher frequency of alanine aminotransferase >3 times the upper limit of normal (35% vs. 11%, P = 0.001), liver failure (28% vs. 9%, P = 0.004), and fatal DILI (23% vs. 4%, P = 0.001), but not jaundice (46% vs. 35%, P = 0.2) or liver transplantation (9% vs. 2%, P = 0.11).  Twelve compds. with no hepatic metab. had no reports of liver failure, liver transplantation, or fatal DILI.  When the relationship between hepatic adverse events and combination of hepatic metab. and daily dose was examd., compds. with both significant hepatic metab. and daily dose >50 mg (n = 50) were significantly more hepatotoxic than compds. belonging to other groups.  Compared with medications without biliary excretion, compds. with biliary excretion (n = 50) had significantly higher frequency of jaundice (74% vs. 40%, P = 0.0001).  Conclusion: Our study finds an important relationship between a compd.'s metab. profile and reports of hepatic adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG7fKH0KK8ObVg90H21EOLACvtfcHk0lhz9gOVjLldnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisVGnsr8%253D&md5=ba90a857ce677fddb63ac6f3136c6b3b</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1002%2Fhep.23317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.23317%26sid%3Dliteratum%253Aachs%26aulast%3DLammert%26aufirst%3DC.%26aulast%3DBjornsson%26aufirst%3DE.%26aulast%3DNiklasson%26aufirst%3DA.%26aulast%3DChalasani%26aufirst%3DN.%26atitle%3DOral%2520Medications%2520with%2520Significant%2520Hepatic%2520Metabolism%2520at%2520Higher%2520Risk%2520for%2520Hepatic%2520Adverse%2520Events%26jtitle%3DHepatology%26date%3D2010%26volume%3D51%26spage%3D615%26epage%3D620%26doi%3D10.1002%2Fhep.23317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borlak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span> <span> </span><span class="NLM_article-title">High Lipophilicity and High Daily Dose of Oral Medications are Associated with Significant Eisk for Drug-Induced Liver Injury</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1002/hep.26208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.26208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23258593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVaisrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=388-396&author=M.+Chenauthor=J.+Borlakauthor=W.+Tong&title=High+Lipophilicity+and+High+Daily+Dose+of+Oral+Medications+are+Associated+with+Significant+Eisk+for+Drug-Induced+Liver+Injury&doi=10.1002%2Fhep.26208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury</span></div><div class="casAuthors">Chen, Minjun; Borlak, Juergen; Tong, Weida</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">388-396</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a leading cause of drug failure in clin. trials and a major reason for drug withdrawals from the market.  Although there is evidence that dosages of ≥100 mg/day are assocd. with increased risk for hepatotoxicity, many drugs are safe at such dosages.  There is an unmet need to predict risk for DILI more reliably, and lipophilicity might be a contributing factor.  We analyzed the combined factors of daily dose and lipophilicity for 164 US Food and Drug Administration-approved oral medications and obsd. high risk for hepatotoxicity (odds ratio [OR], 14.05; P < 0.001) for drugs given at dosages ≥100 mg/day and octanol-water partition coeff. (logP) ≥3.  This defined the "rule-of-two.".  Similar results were obtained for an independent set of 179 oral medications with 85% of the rule-of-two positives being assocd. with hepatotoxicity (OR, 3.89; P < 0.01).  Using the World Health Organization's Anatomical Therapeutic Chem. classification system, the rule-of-two performed best in predicting DILI in seven therapeutic categories.  Among 15 rule-of-two positives, 14 were withdrawn from hepatotoxic drugs, and one was over-the-counter medication labeled for liver injury.  We addnl. examd. drug pairs that have similar chem. structures and act on the same mol. target but differ in their potential for DILI.  Again, the rule-of-two predicted hepatotoxicity reliably.  Finally, the rule-of-two was applied to clin. case studies to identify hepatotoxic drugs in complex comedication regimes to further demonstrate its use.  Conclusion: Apart from dose, lipophilicity contributes significantly to risk for hepatotoxicity.  Applying the rule-of-two is an appropriate means of estg. risk for DILI compared with dose alone. (HEPATOl. 2013).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1EE02L_JCdLVg90H21EOLACvtfcHk0lhz9gOVjLldnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVaisrrM&md5=a88e02ff29653bdeee53b59a4da46d06</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1002%2Fhep.26208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26208%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DBorlak%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DW.%26atitle%3DHigh%2520Lipophilicity%2520and%2520High%2520Daily%2520Dose%2520of%2520Oral%2520Medications%2520are%2520Associated%2520with%2520Significant%2520Eisk%2520for%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DHepatology%26date%3D2013%26volume%3D58%26spage%3D388%26epage%3D396%26doi%3D10.1002%2Fhep.26208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borlak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span> <span> </span><span class="NLM_article-title">A Model to Predict Severity of Drug-Induced Liver Injury in Humans</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">931</span>– <span class="NLM_lpage">940</span>, <span class="refDoi"> DOI: 10.1002/hep.28678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.28678" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27302180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOnu7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=931-940&author=M.+Chenauthor=J.+Borlakauthor=W.+Tong&title=A+Model+to+Predict+Severity+of+Drug-Induced+Liver+Injury+in+Humans&doi=10.1002%2Fhep.28678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A Model to predict severity of drug-induced liver injury in humans</span></div><div class="casAuthors">Chen, Minjun; Borlak, Juergen; Tong, Weida</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">931-940</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a major public health concern, and improving its prediction remains an unmet challenge.  Recently, we reported the Rule-of-2 (RO2) and found lipophilicity (logP ≥3) and daily dose ≥100 mg of oral medications to be assocd. with significant risk for DILI; however, the RO2 failed to est. grades of DILI severity.  In an effort to develop a quant. metrics, we analyzed the assocn. of daily dose, logP, and formation of reactive metabolites (RM) in a large set of Food and Drug Administration-approved oral medications and found factoring RM into the RO2 to highly improve DILI prediction.  Based on these parameters and by considering n = 354 drugs, an algorithm to assign a DILI score was developed.  In univariate and multivariate logistic regression analyses the algorithm (i.e., DILI score model) defined the relative contribution of daily dose, logP, and RM and permitted a quant. assessment of risk of clin. DILI.  Furthermore, a clear relationship between calcd. DILI scores and DILI risk was obtained when applied to three independent studies.  The DILI score model was also functional with drug pairs defined by similar chem. structure and mode of action but divergent toxicities.  Specifically, for drug pairs where the RO2 failed, the DILI score correctly identified toxic drugs.  Finally, the model was applied to n = 159 clin. cases collected from the National Institutes of Health's LiverTox database to demonstrate that the DILI score correlated with the severity of clin. outcome.  Conclusions: Based on daily dose, lipophilicity, and RM, a DILI score algorithm was developed that provides a scale of assessing the severity of DILI risk in humans assocd. with oral medications. (Hepatol. 2016;64:931-940).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA-kETAgqI3rVg90H21EOLACvtfcHk0lhz9gOVjLldnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOnu7bF&md5=5970854540c3f9230be77bde710c4d99</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1002%2Fhep.28678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.28678%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DBorlak%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DW.%26atitle%3DA%2520Model%2520to%2520Predict%2520Severity%2520of%2520Drug-Induced%2520Liver%2520Injury%2520in%2520Humans%26jtitle%3DHepatology%26date%3D2016%26volume%3D64%26spage%3D931%26epage%3D940%26doi%3D10.1002%2Fhep.28678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the Relevance of DILI Predictive Hypotheses in Early Drug Development: Review of In Vitro Methodologies vs BDDCS Classification</span>. <i>Toxicol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.1039/C8TX00016F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1039%2FC8TX00016F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnvVSrsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=358-370&author=R.+Chanauthor=L.+Z.+Benet&title=Evaluation+of+the+Relevance+of+DILI+Predictive+Hypotheses+in+Early+Drug+Development%3A+Review+of+In+Vitro+Methodologies+vs+BDDCS+Classification&doi=10.1039%2FC8TX00016F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the relevance of DILI predictive hypotheses in early drug development: review of in vitro methodologies vs. BDDCS classification</span></div><div class="casAuthors">Chan, Rosa; Benet, Leslie Z.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Research (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">358-370</span>CODEN:
                <span class="NLM_cas:coden">TROEE8</span>;
        ISSN:<span class="NLM_cas:issn">2045-4538</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a major safety concern; it occurs frequently; it is idiosyncratic; it cannot be adequately predicted; and a multitude of underlying mechanisms has been postulated.  A no. of exptl. approaches to predict human DILI have been proposed utilizing in vitro screening such as inhibition of mitochondrial function, hepatobiliary transporter inhibition, reactive metabolite formation with and without covalent binding, and cellular health, but they have achieved only minimal success.  Several studies have shown total administered dose alone or in combination with drug lipophilicity to be correlated with a higher risk of DILI.  However, it would be best to have a predictive DILI methodol. early in drug development, long before the clin. dose is known.  Here we discuss the extent to which Biopharmaceutics Drug Disposition Classification System (BDDCS) defining characteristics, independent of knowing actual drug pharmacokinetics/pharmacodynamics and dose, can be used to evaluate prior published predictive proposals.  Our results show that BDDCS Class 2 drugs exhibit the highest DILI severity, and that all of the short-lived published methodologies evaluated here, except when daily dose is known, do not yield markedly better predictions than BDDCS.  The assertion that extensively metabolized compds. are at higher risk of developing DILI is confirmed, but can be enhanced by differentiating BDDCS Class 2 from Class 1 drugs.  Conclusion: Our published analyses suggest that comparison of proposed DILI prediction methodologies with BDDCS classification is a useful tool to evaluate the potential reliability of newly proposed algorithms, although BDDCS classification itself is not sufficiently predictive.  Almost all of the predictive DILI metrics do no better than just avoiding BDDCS Class 2 drugs, although some early data with microliver platforms enabling long-enduring metabolic competency show promising results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDY0LjdtqlS7Vg90H21EOLACvtfcHk0lj0miW9RtbpKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnvVSrsrc%253D&md5=de8366882fcfab9866301c784f57c264</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1039%2FC8TX00016F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8TX00016F%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DR.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26atitle%3DEvaluation%2520of%2520the%2520Relevance%2520of%2520DILI%2520Predictive%2520Hypotheses%2520in%2520Early%2520Drug%2520Development%253A%2520Review%2520of%2520In%2520Vitro%2520Methodologies%2520vs%2520BDDCS%2520Classification%26jtitle%3DToxicol.%2520Res.%26date%3D2018%26volume%3D7%26spage%3D358%26epage%3D370%26doi%3D10.1039%2FC8TX00016F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broccatelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span> <span> </span><span class="NLM_article-title">BDDCS Applied to Over 900 Drugs</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">547</span>, <span class="refDoi"> DOI: 10.1208/s12248-011-9290-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1208%2Fs12248-011-9290-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21818695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFamsbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=519-547&author=L.+Z.+Benetauthor=F.+Broccatelliauthor=T.+I.+Oprea&title=BDDCS+Applied+to+Over+900+Drugs&doi=10.1208%2Fs12248-011-9290-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">BDDCS Applied to Over 900 Drugs</span></div><div class="casAuthors">Benet, Leslie Z.; Broccatelli, Fabio; Oprea, Tudor I.</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">519-547</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Here, we compile the Biopharmaceutics Drug Disposition Classification System (BDDCS) classification for 927 drugs, which include 30 active metabolites.  Of the 897 parent drugs, 78.8% (707) are administered orally.  Where the lowest measured soly. is found, this value is reported for 72.7% (513) of these orally administered drugs and a dose no. is recorded.  The measured values are reported for percent excreted unchanged in urine, LogP, and LogD 7.4 when available.  For all 927 compds., the in silico parameters for predicted Log soly. in water, calcd. LogP, polar surface area, and the no. of hydrogen bond acceptors and hydrogen bond donors for the active moiety are also provided, thereby allowing comparison analyses for both in silico and exptl. measured values.  We discuss the potential use of BDDCS to est. the disposition characteristics of novel chems. (new mol. entities) in the early stages of drug discovery and development.  Transporter effects in the intestine and the liver are not clin. relevant for BDDCS class 1 drugs, but potentially can have a high impact for class 2 (efflux in the gut, and efflux and uptake in the liver) and class 3 (uptake and efflux in both gut and liver) drugs.  A combination of high dose and low soly. is likely to cause BDDCS class 4 to be underpopulated in terms of approved drugs (N = 53 compared with over 200 each in classes 1-3).  The influence of several measured and in silico parameters in the process of BDDCS category assignment is discussed in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSAqjf7Z_OBLVg90H21EOLACvtfcHk0lj0miW9RtbpKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFamsbfE&md5=911d3f2df96e05a2fbf5955abfb2917c</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1208%2Fs12248-011-9290-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-011-9290-9%26sid%3Dliteratum%253Aachs%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26aulast%3DBroccatelli%26aufirst%3DF.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26atitle%3DBDDCS%2520Applied%2520to%2520Over%2520900%2520Drugs%26jtitle%3DAAPS%2520J.%26date%3D2011%26volume%3D13%26spage%3D519%26epage%3D547%26doi%3D10.1208%2Fs12248-011-9290-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonkovsky, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davern, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochon, J.</span></span> <span> </span><span class="NLM_article-title">Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">1924</span>– <span class="NLM_lpage">1934</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2008.09.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1053%2Fj.gastro.2008.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=18955056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252FhvFGhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2008&pages=1924-1934&author=N.+Chalasaniauthor=R.+J.+Fontanaauthor=H.+L.+Bonkovskyauthor=P.+B.+Watkinsauthor=T.+Davernauthor=J.+Serranoauthor=H.+Yangauthor=J.+Rochon&title=Causes%2C+Clinical+Features%2C+and+Outcomes+From+a+Prospective+Study+of+Drug-Induced+Liver+Injury+in+the+United+States&doi=10.1053%2Fj.gastro.2008.09.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States</span></div><div class="casAuthors">Chalasani Naga; Fontana Robert J; Bonkovsky Herbert L; Watkins Paul B; Davern Timothy; Serrano Jose; Yang Hongqiu; Rochon James</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1924-34, 1934.e1-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND & AIMS:  Idiosyncratic drug-induced liver injury (DILI) is among the most common causes of acute liver failure in the United States, accounting for approximately 13% of cases.  A prospective study was begun in 2003 to recruit patients with suspected DILI and create a repository of biological samples for analysis.  This report summarizes the causes, clinical features, and outcomes from the first 300 patients enrolled.  METHODS:  Patients with suspected DILI were enrolled based on predefined criteria and followed up for at least 6 months.  Patients with acetaminophen liver injury were excluded.  RESULTS:  DILI was caused by a single prescription medication in 73% of the cases, by dietary supplements in 9%, and by multiple agents in 18%.  More than 100 different agents were associated with DILI; antimicrobials (45.5%) and central nervous system agents (15%) were the most common.  Causality was considered to be definite in 32%, highly likely in 41%, probable in 14%, possible in 10%, and unlikely in 3%.  Acute hepatitis C virus (HCV) infection was the final diagnosis in 4 of 9 unlikely cases.  Six months after enrollment, 14% of patients had persistent laboratory abnormalities and 8% had died; the cause of death was liver related in 44%.  CONCLUSIONS:  DILI is caused by a wide array of medications, herbal supplements, and dietary supplements.  Antibiotics are the single largest class of agents that cause DILI.  Acute HCV infection should be excluded in patients with suspected DILI by HCV RNA testing.  The overall 6-month mortality was 8%, but the majority of deaths were not liver related.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQT5sqgDsZJNhpyrDyM_m9cfW6udTcc2eas8d6aVe_s27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252FhvFGhsg%253D%253D&md5=59c54e59eb7304f7e4c0e8599a866b31</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2008.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2008.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DBonkovsky%26aufirst%3DH.%2BL.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DDavern%26aufirst%3DT.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DRochon%26aufirst%3DJ.%26atitle%3DCauses%252C%2520Clinical%2520Features%252C%2520and%2520Outcomes%2520From%2520a%2520Prospective%2520Study%2520of%2520Drug-Induced%2520Liver%2520Injury%2520in%2520the%2520United%2520States%26jtitle%3DGastroenterology%26date%3D2008%26volume%3D135%26spage%3D1924%26epage%3D1934%26doi%3D10.1053%2Fj.gastro.2008.09.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucena, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplowitz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Cortes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero-Gomez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruguera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robles-Diaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-González, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmeron, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Odriozola, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Alvarez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borraz, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, R.</span></span> <span> </span><span class="NLM_article-title">Phenotypic Characterization of Idiosyncratic Drug-Induced Liver Injury: The Influence of Age and Sex</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2001</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1002/hep.22895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.22895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19475693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD1Mzos1yrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=2001-2009&author=M.+I.+Lucenaauthor=R.+J.+Andradeauthor=N.+Kaplowitzauthor=M.+Garc%C3%ADa-Cortesauthor=M.+C.+Fern%C3%A1ndezauthor=M.+Romero-Gomezauthor=M.+Brugueraauthor=H.+Hallalauthor=M.+Robles-Diazauthor=J.+F.+Rodriguez-Gonz%C3%A1lezauthor=J.+M.+Navarroauthor=J.+Salmeronauthor=P.+Martinez-Odriozolaauthor=R.+P%C3%A9rez-Alvarezauthor=Y.+Borrazauthor=R.+Hidalgo&title=Phenotypic+Characterization+of+Idiosyncratic+Drug-Induced+Liver+Injury%3A+The+Influence+of+Age+and+Sex&doi=10.1002%2Fhep.22895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex</span></div><div class="casAuthors">Lucena M Isabel; Andrade Raul J; Kaplowitz Neil; Garcia-Cortes Miren; Fernandez M Carmen; Romero-Gomez Manuel; Bruguera Miguel; Hallal Hacibe; Robles-Diaz Mercedes; Rodriguez-Gonzalez Jose F; Navarro Jose Maria; Salmeron Javier; Martinez-Odriozola Pedro; Perez-Alvarez Ramon; Borraz Yolanda; Hidalgo Ramon</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Baltimore, Md.)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2001-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Increased age and female sex are suggested risk factors for drug-induced hepatotoxicity (DILI).  We studied the influence of these variables on the propensity to develop DILI, as well as its clinical expression and outcome.  All cases of DILI submitted to the Spanish Registry between April 1994 and August 2007 were analyzed.  Six hundred three DILI cases (310 men; mean age, 54 years) showed a similar sex distribution, reaching two peaks in the 40- to 49-year-old and 60- to 69-year-old age groups.  No cases were recorded in the 20- to 29-year-old group.  Patients aged > or =60 years accounted for 46% of the cases, with a male predominance (158 males, 118 females; P= 0.009), as opposed to younger patients.  Older age was independently associated with cholestatic type of injury (odds ratio for an age interval for 1 year: 1.024 [95% confidence interval: 1.010-1.038]; male/female ratio, 1:2; P = 0.001) and younger age with hepatocellular damage (odds ratio: 0.983 [95% confidence interval: 0.972-0.994]; female/male ratio, 1:2; P = 0.002).  In the mixed group, no age effect was evident.  Outcome with fulminant liver failure/liver transplantation was more frequently encountered in women (P < 0.01). conclusion: Neither older age nor female sex are predisposing factors to overall DILI.  However, older age is a determinant for cholestatic damage with a male predominance, whereas younger age is associated with cytolytic damage and a female overrepresentation.  Women distinctly exhibit the worst outcome.  Knowledge of these phenotypic associations could guide differential diagnosis and attribution of causality in DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRVzo3zCJgVG2hHGZei4OW9fW6udTcc2eas8d6aVe_s27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mzos1yrtA%253D%253D&md5=aad2355fabd27cdfecefe3ba053007be</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1002%2Fhep.22895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.22895%26sid%3Dliteratum%253Aachs%26aulast%3DLucena%26aufirst%3DM.%2BI.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3DKaplowitz%26aufirst%3DN.%26aulast%3DGarc%25C3%25ADa-Cortes%26aufirst%3DM.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DM.%2BC.%26aulast%3DRomero-Gomez%26aufirst%3DM.%26aulast%3DBruguera%26aufirst%3DM.%26aulast%3DHallal%26aufirst%3DH.%26aulast%3DRobles-Diaz%26aufirst%3DM.%26aulast%3DRodriguez-Gonz%25C3%25A1lez%26aufirst%3DJ.%2BF.%26aulast%3DNavarro%26aufirst%3DJ.%2BM.%26aulast%3DSalmeron%26aufirst%3DJ.%26aulast%3DMartinez-Odriozola%26aufirst%3DP.%26aulast%3DP%25C3%25A9rez-Alvarez%26aufirst%3DR.%26aulast%3DBorraz%26aufirst%3DY.%26aulast%3DHidalgo%26aufirst%3DR.%26atitle%3DPhenotypic%2520Characterization%2520of%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%253A%2520The%2520Influence%2520of%2520Age%2520and%2520Sex%26jtitle%3DHepatology%26date%3D2009%26volume%3D49%26spage%3D2001%26epage%3D2009%26doi%3D10.1002%2Fhep.22895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lampson, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasar, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matos, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassenti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davids, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freedman, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnason, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipps, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span> <span> </span><span class="NLM_article-title">Idelalisib Given Front-Line for Treatment of Chronic Lymphocytic Leukemia Causes Frequent Immune-Mediated Hepatotoxicity</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-03-707133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1182%2Fblood-2016-03-707133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27247136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1egtrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=195-203&author=B.+L.+Lampsonauthor=S.+N.+Kasarauthor=T.+R.+Matosauthor=E.+A.+Morganauthor=L.+Rassentiauthor=M.+S.+Davidsauthor=D.+C.+Fisherauthor=A.+S.+Freedmanauthor=C.+A.+Jacobsonauthor=P.+Armandauthor=J.+S.+Abramsonauthor=J.+E.+Arnasonauthor=T.+J.+Kippsauthor=J.+Feinauthor=S.+Fernandesauthor=J.+Hannaauthor=J.+Ritzauthor=H.+T.+Kimauthor=J.+R.+Brown&title=Idelalisib+Given+Front-Line+for+Treatment+of+Chronic+Lymphocytic+Leukemia+Causes+Frequent+Immune-Mediated+Hepatotoxicity&doi=10.1182%2Fblood-2016-03-707133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity</span></div><div class="casAuthors">Lampson, Benjamin L.; Kasar, Siddha N.; Matos, Tiago R.; Morgan, Elizabeth A.; Rassenti, Laura; Davids, Matthew S.; Fisher, David C.; Freedman, Arnold S.; Jacobson, Caron A.; Armand, Philippe; Abramson, Jeremy S.; Arnason, Jon E.; Kipps, Thomas J.; Fein, Joshua; Fernandes, Stacey; Hanna, John; Ritz, Jerome; Kim, Haesook T.; Brown, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-203</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Idelalisib is a small-mol. inhibitor of PI3Kδ with demonstrated efficacy for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL).  To evaluate idelalisib as front-line therapy, we enrolled 24 subjects in a phase 2 study consisting of 2 mo of idelalisib monotherapy followed by 6 mo of combination therapy with idelalisib and the anti-CD20 antibody ofatumumab.  After a median follow-up period of 14.7 mo, hepatotoxicity was found to be a frequent and often severe adverse event.  A total of 19 subjects (79%) experienced either grade ≥1 ALT or AST elevation during the study, and 13 subjects (54%) experienced grade ≥3 transaminitis.  The median time to development of transaminitis was 28 days, occurring before ofatumumab introduction.  Younger age and mutated Ig heavy chain status were significant risk factors for the development of hepatotoxicity.  Multiple lines of evidence suggest that this hepatotoxicity was immune mediated.  A lymphocytic infiltrate was seen on liver biopsy specimens taken from 2 subjects with transaminitis, and levels of the proinflammatory cytokines CCL-3 and CCL-4 were higher in subjects experiencing hepatotoxicity.  All cases of transaminitis resolved either by holding the drug, initiating immunosuppressants, or both, and rates of recurrent toxicity were lower in patients taking steroids when idelalisib was reinitiated.  A decrease in peripheral blood regulatory T cells was seen in patients experiencing toxicity on therapy, which is consistent with an immune-mediated mechanism.  These results suggest that caution should be taken as drugs within this class are developed for CLL, particularly in younger patients who have not received prior disease-specific therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFWd0SBaN9E7Vg90H21EOLACvtfcHk0liMPyzAorhbCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1egtrfK&md5=eec3c52d470b0b70266f7ecc3f7d8de0</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-03-707133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-03-707133%26sid%3Dliteratum%253Aachs%26aulast%3DLampson%26aufirst%3DB.%2BL.%26aulast%3DKasar%26aufirst%3DS.%2BN.%26aulast%3DMatos%26aufirst%3DT.%2BR.%26aulast%3DMorgan%26aufirst%3DE.%2BA.%26aulast%3DRassenti%26aufirst%3DL.%26aulast%3DDavids%26aufirst%3DM.%2BS.%26aulast%3DFisher%26aufirst%3DD.%2BC.%26aulast%3DFreedman%26aufirst%3DA.%2BS.%26aulast%3DJacobson%26aufirst%3DC.%2BA.%26aulast%3DArmand%26aufirst%3DP.%26aulast%3DAbramson%26aufirst%3DJ.%2BS.%26aulast%3DArnason%26aufirst%3DJ.%2BE.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26aulast%3DFein%26aufirst%3DJ.%26aulast%3DFernandes%26aufirst%3DS.%26aulast%3DHanna%26aufirst%3DJ.%26aulast%3DRitz%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DH.%2BT.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26atitle%3DIdelalisib%2520Given%2520Front-Line%2520for%2520Treatment%2520of%2520Chronic%2520Lymphocytic%2520Leukemia%2520Causes%2520Frequent%2520Immune-Mediated%2520Hepatotoxicity%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D195%26epage%3D203%26doi%3D10.1182%2Fblood-2016-03-707133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirnadel-Farrant, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span> <span> </span><span class="NLM_article-title">Age-Related Differences in Reporting of Drug-Associated Liver Injury: Data-Mining of WHO Safety Report Database</span>. <i>Regul. Toxicol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">526</span>, <span class="refDoi"> DOI: 10.1016/j.yrtph.2014.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.yrtph.2014.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25236535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFylu7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2014&pages=519-526&author=C.+M.+Huntauthor=N.+A.+Yuenauthor=H.+A.+Stirnadel-Farrantauthor=A.+Suzuki&title=Age-Related+Differences+in+Reporting+of+Drug-Associated+Liver+Injury%3A+Data-Mining+of+WHO+Safety+Report+Database&doi=10.1016%2Fj.yrtph.2014.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Age-related differences in reporting of drug-associated liver injury: Data-mining of WHO Safety Report Database</span></div><div class="casAuthors">Hunt, Christine M.; Yuen, Nancy A.; Stirnadel-Farrant, Heide A.; Suzuki, Ayako</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Toxicology and Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">519-526</span>CODEN:
                <span class="NLM_cas:coden">RTOPDW</span>;
        ISSN:<span class="NLM_cas:issn">0273-2300</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Age-differences in the frequency and manifestations of drug-induced liver injury are not fully characterized.  Data-mining analyses were performed to assess the impact of age on liver event reporting frequency with different phenotypes and agents.  236 Drugs assocd. with hepatotoxicity were evaluated using the Empirical Bayes Geometric Mean (EBGM) of the relative reporting ratio with 90% confidence interval (EB05 and EB95) calcd. for the age groups: 0-17, 18-64, and ≥ 65 years (or elderly), for overall, serious (acute liver failure), hepatocellular, and cholestatic liver injury, using the WHO Safety Report Database.  Overall, cases of age 0-17, 18-64, and 65 years or older comprised 6%, 62%, and 32% of liver event reports.  Acute liver failure and hepatocellular injury were more frequently reported among children compared to adults and the elderly while reports with cholestatic injury were more frequent among the elderly (p < 0.00001).  A potential to cause mitochondrial dysfunction was more prevalent among the drugs with increased pediatric reporting frequency while high lipophilicity and biliary excretion were more common among the drugs assocd. with higher reporting frequency in the elderly.  Age-specific phenotypes and potential drug properties assocd. with age-specific hepatotoxicity were identified in reported liver events; further analyses are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVgXetphoe4rVg90H21EOLACvtfcHk0liMPyzAorhbCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFylu7fI&md5=5874a7d5ed45b1d332d2ad2e217c3a21</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.yrtph.2014.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yrtph.2014.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DHunt%26aufirst%3DC.%2BM.%26aulast%3DYuen%26aufirst%3DN.%2BA.%26aulast%3DStirnadel-Farrant%26aufirst%3DH.%2BA.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DAge-Related%2520Differences%2520in%2520Reporting%2520of%2520Drug-Associated%2520Liver%2520Injury%253A%2520Data-Mining%2520of%2520WHO%2520Safety%2520Report%2520Database%26jtitle%3DRegul.%2520Toxicol.%2520Pharmacol.%26date%3D2014%26volume%3D70%26spage%3D519%26epage%3D526%26doi%3D10.1016%2Fj.yrtph.2014.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J. H.</span></span> <span> </span><span class="NLM_article-title">Causality Assessment of Drug-Induced Hepatotoxicity: Promises and Pitfalls</span>. <i>Clinics in Liver Disease</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">505</span>, <span class="refDoi"> DOI: 10.1016/j.cld.2007.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.cld.2007.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=17723916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD2srgsVGgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=477-505&author=M.+A.+Shapiroauthor=J.+H.+Lewis&title=Causality+Assessment+of+Drug-Induced+Hepatotoxicity%3A+Promises+and+Pitfalls&doi=10.1016%2Fj.cld.2007.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Causality assessment of drug-induced hepatotoxicity: promises and pitfalls</span></div><div class="casAuthors">Shapiro Max A; Lewis James H</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in liver disease</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">477-505, v</span>
        ISSN:<span class="NLM_cas:issn">1089-3261</span>.
    </div><div class="casAbstract">Drug-induced liver injury is the leading cause of acute liver failure in the United States, but the ability to ascribe hepatic injury confidently to a specific drug remains a challenging and often difficult pursuit.  This article explores the ongoing challenges inherent in what is currently a clinical process of elimination made in the attempt of assigning causality in drug-induced liver injury.  In particular, it points out the shortcomings and pitfalls that often limit the applicability of the causality-assessment methodologies currently in use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSMBsH1AK2WBQ8IxFYvehhofW6udTcc2eaGGDWHRMVG17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srgsVGgsA%253D%253D&md5=0dbe5e5d01a6b1c79df99249b246904d</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.cld.2007.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cld.2007.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DM.%2BA.%26aulast%3DLewis%26aufirst%3DJ.%2BH.%26atitle%3DCausality%2520Assessment%2520of%2520Drug-Induced%2520Hepatotoxicity%253A%2520Promises%2520and%2520Pitfalls%26jtitle%3DClinics%2520in%2520Liver%2520Disease%26date%3D2007%26volume%3D11%26spage%3D477%26epage%3D505%26doi%3D10.1016%2Fj.cld.2007.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björnsson, E.</span></span> <span> </span><span class="NLM_article-title">Risk Factors for Idiosyncratic Drug-Induced Liver Injury</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">2246</span>– <span class="NLM_lpage">2259</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2010.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1053%2Fj.gastro.2010.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=20394749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnslaku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2010&pages=2246-2259&author=N.+Chalasaniauthor=E.+Bj%C3%B6rnsson&title=Risk+Factors+for+Idiosyncratic+Drug-Induced+Liver+Injury&doi=10.1053%2Fj.gastro.2010.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Risk factors for idiosyncratic drug-induced liver injury</span></div><div class="casAuthors">Chalasani, Naga; Bjornsson, Einar</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2246-2259</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Idiosyncratic drug-induced liver injury (DILI) is a rare disorder that is not related directly to dosage and little is known about individuals who are at increased risk.  There are no suitable preclin. models for the study of idiosyncratic DILI and its pathogenesis is poorly understood.  It is likely to arise from complex interactions among genetic, nongenetic host susceptibility, and environmental factors.  Nongenetic risk factors include age, sex, and other diseases (eg, chronic liver disease or human immunodeficiency virus infection).  Compd.-specific risk factors include daily dose, metab. characteristics, and propensity for drug interactions.  Alc. consumption has been proposed as a risk factor for DILI from medications, but there is insufficient evidence to support this.  Many studies have explored genetic defects that might be involved in pathogenesis and focused on genes involved in drug metab. and the immune response.  Multicenter databases of patients with DILI (the United States Drug Induced Liver Injury Network, DILIGEN, and the Spanish DILI registry) are important tools for clin. and genetic research.  A genome-wide assocn. study of flucloxacillin hepatotoxicity has yielded groundbreaking results and many similar studies are underway.  Nonetheless, DILI is challenging to investigate because of its rarity, the lack of exptl. models, the no. of medications that might cause it, and challenges to diagnosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8ybOkEsO25rVg90H21EOLACvtfcHk0ljlu8RP04kpow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnslaku7c%253D&md5=ed4fc7b289b9ffadeca654a26f4f2d5d</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2010.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2010.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DBj%25C3%25B6rnsson%26aufirst%3DE.%26atitle%3DRisk%2520Factors%2520for%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DGastroenterology%26date%3D2010%26volume%3D138%26spage%3D2246%26epage%3D2259%26doi%3D10.1053%2Fj.gastro.2010.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Björnsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidsdottir, L.</span></span> <span> </span><span class="NLM_article-title">The Long-Term Follow-Up After Idiosyncratic Drug-Induced Liver Injury with Jaundice</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">511</span>– <span class="NLM_lpage">517</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2008.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jhep.2008.10.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19155082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD1M7jtVyhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=511-517&author=E.+Bj%C3%B6rnssonauthor=L.+Davidsdottir&title=The+Long-Term+Follow-Up+After+Idiosyncratic+Drug-Induced+Liver+Injury+with+Jaundice&doi=10.1016%2Fj.jhep.2008.10.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice</span></div><div class="casAuthors">Bjornsson Einar; Davidsdottir Loa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hepatology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">511-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND/AIMS:  Chronic evolution after drug-induced liver injury (DILI) has been reported.  How often this leads to liver-related morbidity and mortality is unexplored.  METHODS:  Patients who survived DILI and concomitant jaundice reported to the Swedish Adverse Drug Reaction Advisory Committee (1970-2004) were linked to the Swedish Hospital Discharge and Cause of Death Registries.  RESULTS:  Among the 712 survivors, 27 could not be retrieved but 685 patients could be linked to the registries, 392 females (57.2%) and 293 males (42.8%) median age 58 (41-74), a mean follow-up of 10 years.  A total of 23/685 (3.4%) patients had been hospitalized for liver disease and 5 had liver-related mortality.  Eight patients developed cirrhosis (7 decompensated, 5 died), 5 had "cryptogenic" cirrhosis in which DILI might have played a role in this development.  Duration of therapy before DILI was longer in patients with liver-related morbidity/mortality (135+/-31 days vs. 53+/-3; p<0.0001).  Autoimmune hepatitis developed in 5/23 (22%), all of female gender after a mean of 5.8 years.  CONCLUSIONS:  Development of clinically important liver disease after severe DILI associated with jaundice is rare after acute DILI.  However decompensated "cryptogenic" cirrhosis developed in some patients with fatal outcome in which DILI might have played a role in this development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRg9_4T70gbzN1QT_1O5WBYfW6udTcc2eZcFstpQi2mibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M7jtVyhuw%253D%253D&md5=2512fe7c905edb38578722b689bb02ae</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2008.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2008.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DBj%25C3%25B6rnsson%26aufirst%3DE.%26aulast%3DDavidsdottir%26aufirst%3DL.%26atitle%3DThe%2520Long-Term%2520Follow-Up%2520After%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%2520with%2520Jaundice%26jtitle%3DJ.%2520Hepatol.%26date%3D2009%26volume%3D50%26spage%3D511%26epage%3D517%26doi%3D10.1016%2Fj.jhep.2008.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waxman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, M. G.</span></span> <span> </span><span class="NLM_article-title">Sex Differences in the Expression of Hepatic Drug Metabolizing Enzymes</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1124/mol.109.056705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fmol.109.056705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19483103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlehu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2009&pages=215-228&author=D.+J.+Waxmanauthor=M.+G.+Holloway&title=Sex+Differences+in+the+Expression+of+Hepatic+Drug+Metabolizing+Enzymes&doi=10.1124%2Fmol.109.056705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Sex differences in the expression of hepatic drug metabolizing enzymes</span></div><div class="casAuthors">Waxman, David J.; Holloway, Minita G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">215-228</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Sex differences in pharmacokinetics and pharmacodynamics characterize many drugs and contribute to individual differences in drug efficacy and toxicity.  Sex-based differences in drug metab. are the primary cause of sex-dependent pharmacokinetics and reflect underlying sex differences in the expression of hepatic enzymes active in the metab. of drugs, steroids, fatty acids and environmental chems., including cytochromes P 450 (P450s), sulfotransferases, glutathione transferases, and UDP-glucuronosyltransferases.  Studies in the rat and mouse liver models have identified more than 1000 genes whose expression is sex-dependent; together, these genes impart substantial sexual dimorphism to liver metabolic function and pathophysiol.  Sex differences in drug metab. and pharmacokinetics also occur in humans and are due in part to the female-predominant expression of CYP3A4, the most important P 450 catalyst of drug metab. in human liver.  The sexually dimorphic expression of P450s and other liver-expressed genes is regulated by the temporal pattern of plasma growth hormone (GH) release by the pituitary gland, which shows significant sex differences.  These differences are most pronounced in rats and mice, where plasma GH profiles are highly pulsatile (intermittent) in male animals vs. more frequent (nearly continuous) in female animals.  This review discusses key features of the cell signaling and mol. regulatory mechanisms by which these sex-dependent plasma GH patterns impart sex specificity to the liver.  Moreover, the essential role proposed for the GH-activated transcription factor signal transducer and activator of transcription (STAT) 5b, and for hepatic nuclear factor (HNF) 4α, as mediators of the sex-dependent effects of GH on the liver, is evaluated.  Together, these studies of the cellular, mol., and gene regulatory mechanisms that underlie sex-based differences in liver gene expression have provided novel insights into the physiol. regulation of both xenobiotic and endobiotic metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrzB5ktzQW-bVg90H21EOLACvtfcHk0ljlu8RP04kpow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlehu74%253D&md5=2aa405139f26021e6833bc16aa8bc873</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1124%2Fmol.109.056705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.109.056705%26sid%3Dliteratum%253Aachs%26aulast%3DWaxman%26aufirst%3DD.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BG.%26atitle%3DSex%2520Differences%2520in%2520the%2520Expression%2520of%2520Hepatic%2520Drug%2520Metabolizing%2520Enzymes%26jtitle%3DMol.%2520Pharmacol.%26date%3D2009%26volume%3D76%26spage%3D215%26epage%3D228%26doi%3D10.1124%2Fmol.109.056705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westerkam, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stave, G. M.</span></span> <span> </span><span class="NLM_article-title">Effect of Age and Gender on the Activity of Human Hepatic CYP3A</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(92)90010-G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2F0006-2952%2892%2990010-G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1642641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADyaK38XlsVakurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1992&pages=275-283&author=C.+M.+Huntauthor=W.+R.+Westerkamauthor=G.+M.+Stave&title=Effect+of+Age+and+Gender+on+the+Activity+of+Human+Hepatic+CYP3A&doi=10.1016%2F0006-2952%2892%2990010-G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of age and gender on the activity of human hepatic CYP3A</span></div><div class="casAuthors">Hunt, Christine M.; Westerkam, William R.; Stave, Gregg M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-83</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">Many pharmacokinetic investigations in the elderly population reveal decreased clearance of lipophilic drugs metabolized by the cytochrome P 450 enzymes; however, few studies have evaluated aging-dependent or gender-related changes in specific cytochrome P 450 enzymes.  The clearance of quinidine, midazolam, triazolam, erythromycin, and lidocaine declines with age; these drugs are metabolized by the isoform, CYP3A.  To det. whether these metabolic effects are due to changes in CYP3A, the effects of age and gender on CYP3A activity were examd.  The activity of the human hepatic cytochrome P 450, CYP3A, was quantified in vitro as erythromycin N-demethylation in microsomes prepd. from forty-three resected human liver specimens obtained from patients, age 27 to 83, with normal liver function.  Erythromycin N-demethylation varied 5-fold in human liver microsomes.  CYP3A activity was 24% higher in females than males.  CYP3A activity did not correlate with age, smoking status, ethanol consumption or percent ideal body wt.  Large interindividual differences and a small female-specific increase in CYP3A activity were obtained.  However, CYP3A activity was unaffected by age over the range of 27-83 yr, suggesting that the aging-related alteration in the clearance of CYP3A substrates is secondary to changes in liver blood flow, size, or drug binding and distribution with aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQbRM_ZoUzhbVg90H21EOLACvtfcHk0lhwqnfV8WX78w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlsVakurk%253D&md5=e2ceb29451028f837e2ec85107b14c73</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2892%2990010-G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252892%252990010-G%26sid%3Dliteratum%253Aachs%26aulast%3DHunt%26aufirst%3DC.%2BM.%26aulast%3DWesterkam%26aufirst%3DW.%2BR.%26aulast%3DStave%26aufirst%3DG.%2BM.%26atitle%3DEffect%2520of%2520Age%2520and%2520Gender%2520on%2520the%2520Activity%2520of%2520Human%2520Hepatic%2520CYP3A%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1992%26volume%3D44%26spage%3D275%26epage%3D283%26doi%3D10.1016%2F0006-2952%2892%2990010-G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitcomb, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, G. D.</span></span> <span> </span><span class="NLM_article-title">Association of Acetaminophen Hepatotoxicity with Fasting and Ethanol Use</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">1845</span>– <span class="NLM_lpage">1850</span>, <span class="refDoi"> DOI: 10.1001/jama.1994.03520230055038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1001%2Fjama.1994.03520230055038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=7990219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADyaK2MXjsVehtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1994&pages=1845-1850&author=D.+C.+Whitcombauthor=G.+D.+Block&title=Association+of+Acetaminophen+Hepatotoxicity+with+Fasting+and+Ethanol+Use&doi=10.1001%2Fjama.1994.03520230055038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Association of acetaminophen hepatotoxicity with fasting and ethanol use</span></div><div class="casAuthors">Whitcomb, David C.; Block, Geoffrey D.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">1845-50</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    </div><div class="casAbstract">The authors evaluated the assocn. of fasting and alc. use with hepatotoxicity from acetaminophen ingested for therapeutic reasons.  A total of 126,779 discharge summaries from Jan. 1987 to July 1993 were reviewed using a comprehensive, whole-text-indexed medical database to identify all patients with acetaminophen ingestion and hepatotoxicity.  These patients were categorized according to the intended acetaminophen use and dose of acetaminophen ingested.  The independent variables of chronic alc. use, recent alc. use, and recent fasting were detd. for all patients.  Forty-nine patients with acetaminophen hepatotoxicity (aspartate aminotransferase >1000 U/L) were identified.  Twenty-one patients (43%) ingested acetaminophen for therapeutic purposes.  All patients with hepatotoxicity took more than the recommended limit of 4 g/d.  Recent fasting was more common than recent alc. use among those who suffered hepatotoxicity after a dose of 4 to 10 g of acetaminophen per day.  Recent alc. use was more common in the group who took more than 10 g/d than in those who took 4 to 10 g/d.  Acetaminophen hepatotoxicity after a dose of 4 to 10 g/d was assocd. with fasting and less commonly with alc. use.  Patients who developed hepatotoxicity after taking acetaminophen doses of greater than 10 g/d for therapeutic purposes were alc. users.  Acetaminophen hepatotoxicity after an overdose appears to be enhanced by fasting in addn. to alc. ingestion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreLEcGgu-PcbVg90H21EOLACvtfcHk0lhwqnfV8WX78w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjsVehtr0%253D&md5=bd72da1b4f5dcde3e0802880ab286777</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1001%2Fjama.1994.03520230055038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.1994.03520230055038%26sid%3Dliteratum%253Aachs%26aulast%3DWhitcomb%26aufirst%3DD.%2BC.%26aulast%3DBlock%26aufirst%3DG.%2BD.%26atitle%3DAssociation%2520of%2520Acetaminophen%2520Hepatotoxicity%2520with%2520Fasting%2520and%2520Ethanol%2520Use%26jtitle%3DJAMA%26date%3D1994%26volume%3D272%26spage%3D1845%26epage%3D1850%26doi%3D10.1001%2Fjama.1994.03520230055038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fromenty, B.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Liver Injury in Obesity</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">824</span>– <span class="NLM_lpage">826</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2012.12.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jhep.2012.12.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23298629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC3s3ns1ykug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=824-826&author=B.+Fromenty&title=Drug-Induced+Liver+Injury+in+Obesity&doi=10.1016%2Fj.jhep.2012.12.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced liver injury in obesity</span></div><div class="casAuthors">Fromenty Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">824-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQo_N9NDTw3XjEC-75aqa5AfW6udTcc2eYqr1nOlKlQzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3ns1ykug%253D%253D&md5=b31b0ad9fe440e8d1f56d1ea799e2f76</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.12.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.12.018%26sid%3Dliteratum%253Aachs%26aulast%3DFromenty%26aufirst%3DB.%26atitle%3DDrug-Induced%2520Liver%2520Injury%2520in%2520Obesity%26jtitle%3DJ.%2520Hepatol.%26date%3D2013%26volume%3D58%26spage%3D824%26epage%3D826%26doi%3D10.1016%2Fj.jhep.2012.12.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Begriche, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robin, M.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgne-Sanchez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromenty, B.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Toxicity on Mitochondria and Lipid Metabolism: Mechanistic Diversity and Deleterious Consequences for the Liver</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">794</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2010.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jhep.2010.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21145849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjs12hsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=773-794&author=K.+Begricheauthor=J.+Massartauthor=M.-A.+Robinauthor=A.+Borgne-Sanchezauthor=B.+Fromenty&title=Drug-Induced+Toxicity+on+Mitochondria+and+Lipid+Metabolism%3A+Mechanistic+Diversity+and+Deleterious+Consequences+for+the+Liver&doi=10.1016%2Fj.jhep.2010.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced toxicity on mitochondria and lipid metabolism: Mechanistic diversity and deleterious consequences for the liver</span></div><div class="casAuthors">Begriche, Karima; Massart, Julie; Robin, Marie-Anne; Borgne-Sanchez, Annie; Fromenty, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">773-794</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Numerous investigations have shown that mitochondrial dysfunction is a major mechanism of drug-induced liver injury, which involves the parent drug or a reactive metabolite generated through cytochromes P 450.  Depending of their nature and their severity, the mitochondrial alterations are able to induce mild to fulminant hepatic cytolysis and steatosis (lipid accumulation), which can have different clin. and pathol. features.  Microvesicular steatosis, a potentially severe liver lesion usually assocd. with liver failure and profound hypoglycemia, is due to a major inhibition of mitochondrial fatty acid oxidn. (FAO).  Macrovacuolar steatosis, a relatively benign liver lesion in the short term, can be induced not only by a moderate redn. of mitochondrial FAO but also by an increased hepatic de novo lipid synthesis and a decreased secretion of VLDL-assocd. triglycerides.  Moreover, recent investigations suggest that some drugs could favor lipid deposition in the liver through primary alterations of white adipose tissue (WAT) homeostasis.  If the treatment is not interrupted, steatosis can evolve toward steatohepatitis, which is characterized not only by lipid accumulation but also by necroinflammation and fibrosis.  Although the mechanisms involved in this aggravation are not fully characterized, it appears that overprodn. of reactive oxygen species by the damaged mitochondria could play a salient role.  Numerous factors could favor drug-induced mitochondrial and metabolic toxicity, such as the structure of the parent mol., genetic predispositions (in particular those involving mitochondrial enzymes), alc. intoxication, hepatitis virus C infection, and obesity.  In obese and diabetic patients, some drugs may induce acute liver injury more frequently while others may worsen the pre-existent steatosis (or steatohepatitis).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodLkniNhTZzLVg90H21EOLACvtfcHk0lhwqnfV8WX78w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjs12hsr8%253D&md5=ff6a28895ffcc230cb438565b164f207</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2010.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2010.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DBegriche%26aufirst%3DK.%26aulast%3DMassart%26aufirst%3DJ.%26aulast%3DRobin%26aufirst%3DM.-A.%26aulast%3DBorgne-Sanchez%26aufirst%3DA.%26aulast%3DFromenty%26aufirst%3DB.%26atitle%3DDrug-Induced%2520Toxicity%2520on%2520Mitochondria%2520and%2520Lipid%2520Metabolism%253A%2520Mechanistic%2520Diversity%2520and%2520Deleterious%2520Consequences%2520for%2520the%2520Liver%26jtitle%3DJ.%2520Hepatol.%26date%3D2011%26volume%3D54%26spage%3D773%26epage%3D794%26doi%3D10.1016%2Fj.jhep.2010.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aubert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begriche, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knockaert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromenty, B.</span></span> <span> </span><span class="NLM_article-title">Increased Expression of Cytochrome P450 2E1 in Nonalcoholic Fatty Liver Disease: Mechanisms and Pathophysiological Role</span>. <i>Clin. Res. Hepatol. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">630</span>– <span class="NLM_lpage">637</span>, <span class="refDoi"> DOI: 10.1016/j.clinre.2011.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.clinre.2011.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21664213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKkt73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2011&pages=630-637&author=J.+Aubertauthor=K.+Begricheauthor=L.+Knockaertauthor=M.+A.+Robinauthor=B.+Fromenty&title=Increased+Expression+of+Cytochrome+P450+2E1+in+Nonalcoholic+Fatty+Liver+Disease%3A+Mechanisms+and+Pathophysiological+Role&doi=10.1016%2Fj.clinre.2011.04.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: Mechanisms and pathophysiological role</span></div><div class="casAuthors">Aubert, J.; Begriche, K.; Knockaert, L.; Robin, M. A.; Fromenty, B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinics and Research in Hepatology and Gastroenterology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">630-637</span>CODEN:
                <span class="NLM_cas:coden">CRHGAQ</span>;
        ISSN:<span class="NLM_cas:issn">2210-7401</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Summary: Due to the worldwide surge in obesity and type 2 diabetes, the increased incidence of nonalcoholic fatty liver disease (NAFLD) is a major concern for the public health.  Indeed, NAFLD encompasses a large spectrum of conditions ranging from fatty liver to nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis in some patients.  A better understanding of the mechanisms involved in fatty liver and its progression into NASH is important in order to develop efficient drugs able to alleviate these liver diseases.  Although numerous investigations pointed to reactive oxygen species (ROS) as key players in the progression of fatty liver to NASH, their exact source is still uncertain.  Besides the mitochondrial respiratory chain, cytochrome P 450 2E1 (CYP2E1) has recently emerged as another potentially important cause of ROS overprodn.  Indeed, higher hepatic CYP2E1 expression and activity have been frequently obsd. in the context of obesity and NAFLD.  It is currently unknown why CYP2E1 is enhanced in these dysmetabolic diseases, although increased hepatic levels of fatty acids and insulin resistance might play a role.  Nonetheless, higher hepatic CYP2E1 could play a significant role in the pathophysiol. of NASH by inducing lipid peroxidn. and oxidative damage of key cellular components.  Moreover, CYP2E1-mediated overprodn. of ROS could promote hepatic insulin resistance, which can further aggravate fatty liver.  Since a significant amt. of CYP2E1 can be located within liver mitochondria, higher levels of CYP2E1 in NAFLD could also have detrimental effects on mitochondrial function.  Finally, increased CYP2E1 activity during NAFLD could enhance the susceptibility of some patients to the hepatotoxicity of different xenobiotics through the CYP2E1-mediated generation of harmful reactive metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon0hpSrJzUPLVg90H21EOLACvtfcHk0lgO2zJmV0O0zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKkt73J&md5=c2673f123a705b69cd65812c9228886f</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.clinre.2011.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinre.2011.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DAubert%26aufirst%3DJ.%26aulast%3DBegriche%26aufirst%3DK.%26aulast%3DKnockaert%26aufirst%3DL.%26aulast%3DRobin%26aufirst%3DM.%2BA.%26aulast%3DFromenty%26aufirst%3DB.%26atitle%3DIncreased%2520Expression%2520of%2520Cytochrome%2520P450%25202E1%2520in%2520Nonalcoholic%2520Fatty%2520Liver%2520Disease%253A%2520Mechanisms%2520and%2520Pathophysiological%2520Role%26jtitle%3DClin.%2520Res.%2520Hepatol.%2520Gastroenterol.%26date%3D2011%26volume%3D35%26spage%3D630%26epage%3D637%26doi%3D10.1016%2Fj.clinre.2011.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Massart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begriche, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromenty, B.</span></span> <span> </span><span class="NLM_article-title">Role of Nonalcoholic Fatty Liver Disease as Risk Factor for Drug-Induced Hepatotoxicity</span>. <i>Journal of Clinical and Translational Research</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.18053/jctres.03.2017S1.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.18053%2Fjctres.03.2017S1.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28691103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFKjtbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=212-232&author=J.+Massartauthor=K.+Begricheauthor=C.+Moreauauthor=B.+Fromenty&title=Role+of+Nonalcoholic+Fatty+Liver+Disease+as+Risk+Factor+for+Drug-Induced+Hepatotoxicity&doi=10.18053%2Fjctres.03.2017S1.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity</span></div><div class="casAuthors">Massart, Julie; Begriche, Karima; Moreau, Caroline; Fromenty, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical and Translational Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">Spec.Iss.1</span>),
    <span class="NLM_cas:pages">212-232</span>CODEN:
                <span class="NLM_cas:coden">JCTRGT</span>;
        ISSN:<span class="NLM_cas:issn">2424-810X</span>.
    
            (<span class="NLM_cas:orgname">Whioce Publishing Pte. Ltd.</span>)
        </div><div class="casAbstract">Background: Obesity is often assocd. with nonalcoholic fatty liver disease (NAFLD), which refers to a large spectrum of hepatic lesions including fatty liver, nonalcoholic steatohepatitis (NASH) and cirrhosis.  Different investigations showed or suggested that obesity and NAFLD are able to increase the risk of hepatotoxicity of different drugs.  Some of these drugs could induce more frequently an acute hepatitis in obese individuals whereas others could worsen pre-existing NAFLD.  Aim: The main objective of the present review was to collect the available information regarding the role of NAFLD as risk factor for drug-induced hepatotoxicity.  For this purpose, we performed a data-mining anal. using different queries including drug-induced liver injury (or DILI), drug-induced hepatotoxicity, fatty liver, nonalcoholic fatty liver disease (or NAFLD), steatosis and obesity.  The main data from the collected articles are reported in this review and when available, some pathophysiol. hypotheses are put forward.  Relevance for patients: Drugs that could pose a potential risk in obese patients include compds. belonging to different pharmacol. classes such as acetaminophen, halothane, methotrexate, rosiglitazone, stavudine and tamoxifen.  For some of these drugs, exptl. investigations in obese rodents confirmed the clin. observations and unveiled different pathophysiol. mechanisms which could explain why these pharmaceuticals are particularly hepatotoxic in obesity and NAFLD.  Other drugs such as pentoxifylline, phenobarbital and omeprazole might also pose a risk but more investigations are required to det. whether this risk is significant or not.  Because obese people often take several drugs for the treatment of different obesity-related diseases such as type 2 diabetes, hyperlipidemia and coronary heart disease, it is urgent to identify the main pharmaceuticals that can cause acute hepatitis on a fatty liver background or induce NAFLD worsening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBLqPxfWSHXrVg90H21EOLACvtfcHk0lgO2zJmV0O0zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFKjtbjO&md5=8b314f290b17146340a1a3cdb6d4085a</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.18053%2Fjctres.03.2017S1.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18053%252Fjctres.03.2017S1.006%26sid%3Dliteratum%253Aachs%26aulast%3DMassart%26aufirst%3DJ.%26aulast%3DBegriche%26aufirst%3DK.%26aulast%3DMoreau%26aufirst%3DC.%26aulast%3DFromenty%26aufirst%3DB.%26atitle%3DRole%2520of%2520Nonalcoholic%2520Fatty%2520Liver%2520Disease%2520as%2520Risk%2520Factor%2520for%2520Drug-Induced%2520Hepatotoxicity%26jtitle%3DJournal%2520of%2520Clinical%2520and%2520Translational%2520Research%26date%3D2017%26volume%3D3%26spage%3D212%26epage%3D232%26doi%3D10.18053%2Fjctres.03.2017S1.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woolsey, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirona, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaton, M. D.</span></span> <span> </span><span class="NLM_article-title">CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1484</span>, <span class="refDoi"> DOI: 10.1124/dmd.115.065979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fdmd.115.065979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26231377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVOhs7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=1484&author=S.+J.+Woolseyauthor=S.+E.+Mansellauthor=R.+B.+Kimauthor=R.+G.+Tironaauthor=M.+D.+Beaton&title=CYP3A+Activity+and+Expression+in+Nonalcoholic+Fatty+Liver+Disease&doi=10.1124%2Fdmd.115.065979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">CYP3A activity and expression in nonalcoholic fatty liver disease</span></div><div class="casAuthors">Woolsey, Sarah J.; Mansell, Sara E.; Kim, Richard B.; Tirona, Rommel G.; Beaton, Melanie D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1484-1490</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease in the Western world, given its assocn. with obesity, type 2 diabetes, and dyslipidemia.  Medications are widely used in NAFLD to manage comorbid conditions, and there is significant interest in developing new drug therapies to treat the disease.  Despite this, little is known about the effects of NAFLD on drug metab.  We examd. the activity and expression of the major drug-metabolizing enzyme subfamily, CYP3A, in subjects with NAFLD as well as in mouse and cellular models.  CYP3A activity was detd. in healthy volunteers and subjects with biopsy-proven NAFLD by oral midazolam phenotyping and measurement of plasma 4β-hydroxycholesterol, an endogenous metabolic biomarker.  CYP3A4 transcriptional activity, metabolic activity, and expression were also assessed in a mouse and cellular model of NAFLD.  Subjects with nonalcoholic steatohepatitis (NASH) had 2.4-fold higher plasma midazolam levels compared with controls.  Plasma 4β-hydroxycholesterol was 51% and 37% lower than controls in subjects with simple steatosis and NASH, resp.  Fibrosis was assocd. with 57% lower plasma 4β-hydroxycholesterol levels than controls.  Furthermore, hepatic CYP3A4 mRNA expression in NASH was 69% lower than control livers.  CYP3A4 gene luciferase activity in the livers of NAFLD mice was 38% lower than that of controls.  Lipid-loaded Huh7 human hepatoma cells had a 38% redn. in CYP3A4 activity and 80% lower CYP3A4 mRNA expression compared with the control.  CYP3A activity is reduced in human NAFLD in addn. to mouse and in vitro cell models of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE7X6u5ZS-WLVg90H21EOLACvtfcHk0lgO2zJmV0O0zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVOhs7bK&md5=3ce7d7219ebd23b6c3150a9fcff5d19e</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.065979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.065979%26sid%3Dliteratum%253Aachs%26aulast%3DWoolsey%26aufirst%3DS.%2BJ.%26aulast%3DMansell%26aufirst%3DS.%2BE.%26aulast%3DKim%26aufirst%3DR.%2BB.%26aulast%3DTirona%26aufirst%3DR.%2BG.%26aulast%3DBeaton%26aufirst%3DM.%2BD.%26atitle%3DCYP3A%2520Activity%2520and%2520Expression%2520in%2520Nonalcoholic%2520Fatty%2520Liver%2520Disease%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D1484%26doi%3D10.1124%2Fdmd.115.065979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cobbina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhlaghi, F.</span></span> <span> </span><span class="NLM_article-title">Non-Alcoholic Fatty Liver Disease - Pathogenesis, Classification, and Effect on Drug Metabolizing Enzymes and Transporters</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1080/03602532.2017.1293683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1080%2F03602532.2017.1293683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28303724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXks1Kiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=197-211&author=E.+Cobbinaauthor=F.+Akhlaghi&title=Non-Alcoholic+Fatty+Liver+Disease+-+Pathogenesis%2C+Classification%2C+and+Effect+on+Drug+Metabolizing+Enzymes+and+Transporters&doi=10.1080%2F03602532.2017.1293683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters</span></div><div class="casAuthors">Cobbina, Enoch; Akhlaghi, Fatemeh</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-211</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Non-alc. fatty liver disease (NAFLD) is a spectrum of liver disorders.  It is defined by the presence of steatosis in more than 5% of hepatocytes with little or no alc. consumption.  Insulin resistance, the metabolic syndrome or type 2 diabetes and genetic variants of PNPLA3 or TM6SF2 seem to play a role in the pathogenesis of NAFLD.  The pathol. progression of NAFLD follows tentatively a "three-hit" process namely steatosis, lipotoxicity and inflammation.  The presence of steatosis, oxidative stress and inflammatory mediators like TNF-α and IL-6 has been implicated in the alterations of nuclear factors such as CAR, PXR, PPAR-α in NAFLD.  These factors may result in altered expression and activity of drug metabolizing enzymes (DMEs) or transporters.  Existing evidence suggests that the effect of NAFLD on CYP3A4, CYP2E1 and MRP3 is more consistent across rodent and human studies.  CYP3A4 activity is down-regulated in NASH whereas the activity of CYP2E1 and the efflux transporter MRP3 is up-regulated.  However, it is not clear how the majority of CYPs, UGTs, SULTs and transporters are influenced by NAFLD either in vivo or in vitro.  The alterations assocd. with NAFLD could be a potential source of drug variability in patients and could have serious implications for the safety and efficacy of xenobiotics.  In this review, we summarize the effects of NAFLD on the regulation, expression and activity of major DMEs and transporters.  We also discuss the potential mechanisms underlying these alterations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTPTZhmrzaNbVg90H21EOLACvtfcHk0lgzTVxAT8FYfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXks1Kiur0%253D&md5=333c5a64d395a86c668b768665250ea5</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1080%2F03602532.2017.1293683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F03602532.2017.1293683%26sid%3Dliteratum%253Aachs%26aulast%3DCobbina%26aufirst%3DE.%26aulast%3DAkhlaghi%26aufirst%3DF.%26atitle%3DNon-Alcoholic%2520Fatty%2520Liver%2520Disease%2520-%2520Pathogenesis%252C%2520Classification%252C%2520and%2520Effect%2520on%2520Drug%2520Metabolizing%2520Enzymes%2520and%2520Transporters%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2017%26volume%3D49%26spage%3D197%26epage%3D211%26doi%3D10.1080%2F03602532.2017.1293683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dzierlenga, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargraves, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ainslie, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderah, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paine, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherrington, N.</span></span> <span> </span><span class="NLM_article-title">J. Mechanistic Basis of Altered Morphine Disposition in Nonalcoholic Steatohepatitis</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.220764</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fjpet.114.220764" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25512370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVKnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=462-470&author=A.+L.+Dzierlengaauthor=J.+D.+Clarkeauthor=T.+L.+Hargravesauthor=G.+R.+Ainslieauthor=T.+W.+Vanderahauthor=M.+F.+Paineauthor=N.+Cherrington&title=J.+Mechanistic+Basis+of+Altered+Morphine+Disposition+in+Nonalcoholic+Steatohepatitis&doi=10.1124%2Fjpet.114.220764"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis</span></div><div class="casAuthors">Dzierlenga, Anika L.; Clarke, John D.; Hargraves, Tiffanie L.; Ainslie, Garrett R.; Vanderah, Todd W.; Paine, Mary F.; Cherrington, Nathan J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">462-470/1-462-470/9, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Morphine is metabolized in humans to morphine-3-glucuronide (M3G) and the pharmacol. active morphine-6-glucuronide (M6G).  The hepatobiliary disposition of both metabolites relies upon multidrug resistance-assocd. proteins Mrp3 and Mrp2, located on the sinusoidal and canalicularmembrane, resp.  Nonalcoholic steatohepatitis (NASH), the severe stage of nonalcoholic fatty liver disease, alters xenobiotic metabolizing enzyme and transporter function.  The purpose of this study was to det. whether NASH contributes to the large interindividual variability and postoperative adverse events assocd. with morphine therapy.  Male Sprague-Dawley rats were fed a control diet or a methionine- and choline-deficient diet to induce NASH.  Radiolabeled morphine (2.5 mg/kg, 30 μCi/kg) was administered i.v., and plasma and bile (0-150 or 0-240 min), liver and kidney, and cumulative urine were analyzed formorphine and M3G.  The antinociceptive response to M6G (5 mg/kg) was assessed (0-12 h) after direct i.p. administration since rats do not produce M6G.  NASH caused a net decrease in morphine concns. in the bile and plasma and a net increase in theM3G/morphine plasma area under the concn.-time curve ratio, consistent with upregulation of UDP-glucuronosyltransferase Ugt2b1.  Despite increased systemic exposure to M3G, NASH resulted in decreased biliary excretion and hepatic accumulation of M3G.  This shift toward systemic retention is consistent with the mislocalization of canalicular Mrp2 and increased expression of sinusoidalMrp3 in NASH andmay correlate to increased antinociception by M6G.  Increased metab. and altered transporter regulation in NASH provide a mechanistic basis for interindividual variability in morphine disposition that may lead to opioid-related toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR82k_nEVe-bVg90H21EOLACvtfcHk0lgzTVxAT8FYfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVKnt74%253D&md5=8765d9b42b2495b629272c7234ff8302</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220764&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220764%26sid%3Dliteratum%253Aachs%26aulast%3DDzierlenga%26aufirst%3DA.%2BL.%26aulast%3DClarke%26aufirst%3DJ.%2BD.%26aulast%3DHargraves%26aufirst%3DT.%2BL.%26aulast%3DAinslie%26aufirst%3DG.%2BR.%26aulast%3DVanderah%26aufirst%3DT.%2BW.%26aulast%3DPaine%26aufirst%3DM.%2BF.%26aulast%3DCherrington%26aufirst%3DN.%26atitle%3DJ.%2520Mechanistic%2520Basis%2520of%2520Altered%2520Morphine%2520Disposition%2520in%2520Nonalcoholic%2520Steatohepatitis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D462%26epage%3D470%26doi%3D10.1124%2Fjpet.114.220764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganey, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, R. A.</span></span> <span> </span><span class="NLM_article-title">Idiosyncratic Drug-Induced Liver Injury and the Role of Inflammatory Stress with an Emphasis on an Animal Model of Trovafloxacin Hepatotoxicity</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfq168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfq168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=20538741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlSmtbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2010&pages=7-18&author=P.+J.+Shawauthor=P.+E.+Ganeyauthor=R.+A.+Roth&title=Idiosyncratic+Drug-Induced+Liver+Injury+and+the+Role+of+Inflammatory+Stress+with+an+Emphasis+on+an+Animal+Model+of+Trovafloxacin+Hepatotoxicity&doi=10.1093%2Ftoxsci%2Fkfq168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Idiosyncratic Drug-Induced Liver Injury and the Role of Inflammatory Stress with an Emphasis on an Animal Model of Trovafloxacin Hepatotoxicity</span></div><div class="casAuthors">Shaw, Patrick J.; Ganey, Patricia E.; Roth, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-18</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Idiosyncratic adverse drug reactions (IADRs) occur in a minority of patients yet account for the majority of postmarketing use restrictions by the Food and Drug Administration.  Despite the impact of these toxicities, the underlying mechanisms are still poorly understood.  Animal models of IADRs would be beneficial in understanding mechanisms and in developing assays with predictive potential.  Recent work exploring the interactions between inflammatory stress and drugs assocd. with human idiosyncratic drug-induced liver injury (IDILI) has led to the development of the first animal models that apply to a range of drugs.  Here, we discuss hypotheses for the mechanisms of IDILI and focus on a murine model of trovafloxacin-induced hepatotoxicity as an example related to the inflammatory stress hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVzwriDrT1ArVg90H21EOLACvtfcHk0lgzTVxAT8FYfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlSmtbfI&md5=464b676027dd284cd1f17a917626c678</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfq168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfq168%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DP.%2BJ.%26aulast%3DGaney%26aufirst%3DP.%2BE.%26aulast%3DRoth%26aufirst%3DR.%2BA.%26atitle%3DIdiosyncratic%2520Drug-Induced%2520Liver%2520Injury%2520and%2520the%2520Role%2520of%2520Inflammatory%2520Stress%2520with%2520an%2520Emphasis%2520on%2520an%2520Animal%2520Model%2520of%2520Trovafloxacin%2520Hepatotoxicity%26jtitle%3DToxicol.%2520Sci.%26date%3D2010%26volume%3D118%26spage%3D7%26epage%3D18%26doi%3D10.1093%2Ftoxsci%2Fkfq168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganey, P. E.</span></span> <span> </span><span class="NLM_article-title">Animal Models of Idiosyncratic Drug-Induced Liver Injury-Current Status</span>. <i>Crit. Rev. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">723</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.3109/10408444.2011.575765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.3109%2F10408444.2011.575765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21726137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2jtLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=723-739&author=R.+A.+Rothauthor=P.+E.+Ganey&title=Animal+Models+of+Idiosyncratic+Drug-Induced+Liver+Injury-Current+Status&doi=10.3109%2F10408444.2011.575765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of idiosyncratic drug-induced liver injury-Current status</span></div><div class="casAuthors">Roth, Robert A.; Ganey, Patricia E.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">723-739</span>CODEN:
                <span class="NLM_cas:coden">CRTXB2</span>;
        ISSN:<span class="NLM_cas:issn">1040-8444</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The infrequent occurrence of idiosyncratic reactions and their dependence on individual sensitivity factors allow them to go undetected in current preclin. safety evaluation using conventional animal tests.  Better predictive models for idiosyncratic, drug-induced liver injury (IDILI) would enable the preclin. elimination of drug candidates with idiosyncrasy liability and could provide evidence for a mode of action for these responses, suggest early biomarkers of IDILI, and lead to the development of mechanism-based, in vitro screens.  Desirable characteristics of an animal model include the prodn. of liver injury in a large fraction of animals of relatively inexpensive species/strains and the ability to distinguish drugs that cause IDILI in humans from ones that do not.  The mechanistic basis for idiosyncratic reactions remains poorly understood.  However, attempts at animal model development have been made based on several hypothesized modes of action of IDILI.  These hypotheses have centered on drug disposition polymorphisms, adaptive immunity, mitochondrial dysfunction, failure to adapt to modest injury, inflammatory stress, and multiple determinants, and the success in achieving animal models of liver injury for each of these is discussed.  Despite numerous challenges assocd. with animal models of IDILI, some models have emerged and are proving useful in exploring potential mechanisms.  Current animal models are not perfect, but they hold promise for increasing the prediction and understanding of human idiosyncratic drug reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrysTJ_2vetHLVg90H21EOLACvtfcHk0ljTDgZ1aA9HAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2jtLbP&md5=bb2bc8b56819940b421ccfeb95104bc8</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.3109%2F10408444.2011.575765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10408444.2011.575765%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DR.%2BA.%26aulast%3DGaney%26aufirst%3DP.%2BE.%26atitle%3DAnimal%2520Models%2520of%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury-Current%2520Status%26jtitle%3DCrit.%2520Rev.%2520Toxicol.%26date%3D2011%26volume%3D41%26spage%3D723%26epage%3D739%26doi%3D10.3109%2F10408444.2011.575765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, E. T.</span></span> <span> </span><span class="NLM_article-title">Regulation of Cytochromes P450 During Inflammation and Infection</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1129</span>– <span class="NLM_lpage">1188</span>, <span class="refDoi"> DOI: 10.3109/03602539709002246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.3109%2F03602539709002246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=9421688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADyaK1cXhtlGqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1997&pages=1129-1188&author=E.+T.+Morgan&title=Regulation+of+Cytochromes+P450+During+Inflammation+and+Infection&doi=10.3109%2F03602539709002246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of cytochromes P450 during inflammation and infection</span></div><div class="casAuthors">Morgan, Edward T.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1129-1188</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Marcel Dekker, Inc.</span>)
        </div><div class="casAbstract">A review with 281 refs.  Major topics include: the cytochrome P 450 system; effects of inflammation and infection in vivo, role of cytokines and interferons; other possible mediators; mechanisms, signaling pathways and second messengers; effects of extrahepatic P 450.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi-01bksaCt7Vg90H21EOLACvtfcHk0ljTDgZ1aA9HAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtlGqsw%253D%253D&md5=b14bc73ff99167f69c9ea26306141959</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.3109%2F03602539709002246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602539709002246%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DE.%2BT.%26atitle%3DRegulation%2520of%2520Cytochromes%2520P450%2520During%2520Inflammation%2520and%2520Infection%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D1997%26volume%3D29%26spage%3D1129%26epage%3D1188%26doi%3D10.3109%2F03602539709002246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Theken, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kannon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poloyac, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. R.</span></span> <span> </span><span class="NLM_article-title">Activation of the Acute Inflammatory Response Alters Cytochrome P450 Expression and Eicosanoid Metabolism</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.035287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fdmd.110.035287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=20947618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1emsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=22-29&author=K.+N.+Thekenauthor=Y.+Dengauthor=M.+A.+Kannonauthor=T.+M.+Millerauthor=S.+M.+Poloyacauthor=C.+R.+Lee&title=Activation+of+the+Acute+Inflammatory+Response+Alters+Cytochrome+P450+Expression+and+Eicosanoid+Metabolism&doi=10.1124%2Fdmd.110.035287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism</span></div><div class="casAuthors">Theken, Katherine N.; Deng, Yangmei; Kannon, M. Alison; Miller, Tricia M.; Poloyac, Samuel M.; Lee, Craig R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-29</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cytochrome P 450 (P 450)-mediated metab. of arachidonic acid regulates inflammation in hepatic and extrahepatic tissue.  CYP2C/CYP2J-derived epoxyeicosatrienoic and dihydroxyeicosatrienoic acids (EET+DHET) elicit anti-inflammatory effects, whereas CYP4A/CYP4F-derived 20-hydroxyeicosatetraenoic acid (20-HETE) is proinflammatory.  Because the impact of inflammation on P 450-mediated formation of endogenous eicosanoids is unclear, we evaluated P 450 mRNA levels and P 450 epoxygenase (EET+DHET) and ω-hydroxylase (20-HETE) metabolic activity in liver, kidney, lung, and heart in mice 3, 6, 24, and 48 h after i.p. lipopolysaccharide (LPS) (1mg/kg) or saline administration.  Hepatic Cyp2c29, Cyp2c44, and Cyp2j5 mRNA levels and EET+DHET formation were significantly lower 24 and 48 h after LPS administration.  Hepatic Cyp4a12a, Cyp4a12b, and Cyp4f13 mRNA levels and 20-HETE formation were also significantly lower at 24 h, but recovered to baseline at 48 h, resulting in a significantly higher 20-HETE/EET+DHET formation rate ratio compared with that for saline-treated mice.  Renal P 450 mRNA levels and P 450-mediated eicosanoid metab. were similarly suppressed 24 h after LPS treatment.  Pulmonary EET+DHET formation was lower at all time points after LPS administration, whereas 20-HETE formation was suppressed in a time-dependent manner, with the lowest formation rate obsd. at 24 h.  No differences in EET+DHET or 20-HETE formation were obsd. in heart.  Collectively, these data demonstrate that acute activation of the innate immune response alters P 450 expression and eicosanoid metab. in mice in an isoform-, tissue-, and time-dependent manner.  Further study is necessary to det. whether therapeutic restoration of the functional balance between the P 450 epoxygenase and ω-hydroxylase pathways is an effective anti-inflammatory strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq32OfpeaemhbVg90H21EOLACvtfcHk0ljTDgZ1aA9HAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1emsw%253D%253D&md5=00b9c04ab16f0b948381857a25309990</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.035287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.035287%26sid%3Dliteratum%253Aachs%26aulast%3DTheken%26aufirst%3DK.%2BN.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DKannon%26aufirst%3DM.%2BA.%26aulast%3DMiller%26aufirst%3DT.%2BM.%26aulast%3DPoloyac%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DC.%2BR.%26atitle%3DActivation%2520of%2520the%2520Acute%2520Inflammatory%2520Response%2520Alters%2520Cytochrome%2520P450%2520Expression%2520and%2520Eicosanoid%2520Metabolism%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D22%26epage%3D29%26doi%3D10.1124%2Fdmd.110.035287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikemura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, M.</span></span> <span> </span><span class="NLM_article-title">Altered Functions and Expressions of Drug Transporters in Liver, Kidney and Intestine in Disorders of Local and Remote Organs: Possible Role of Oxidative Stress in the Pathogenesis</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">907</span>– <span class="NLM_lpage">920</span>, <span class="refDoi"> DOI: 10.1517/17425250903008525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1517%2F17425250903008525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19619071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovVCjur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=907-920&author=K.+Ikemuraauthor=T.+Iwamotoauthor=M.+Okuda&title=Altered+Functions+and+Expressions+of+Drug+Transporters+in+Liver%2C+Kidney+and+Intestine+in+Disorders+of+Local+and+Remote+Organs%3A+Possible+Role+of+Oxidative+Stress+in+the+Pathogenesis&doi=10.1517%2F17425250903008525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Altered functions and expressions of drug transporters in liver, kidney and intestine in disorders of local and remote organs: possible role of oxidative stress in the pathogenesis</span></div><div class="casAuthors">Ikemura, Kenji; Iwamoto, Takuya; Okuda, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">907-920</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Oxidative stress is important in the pathogenesis of various diseases.  Drug transporters expressed in the liver, kidney and intestine regulate the distribution, elimination and absorption of drugs.  These procedures of drugs in diseases of these organs, mediated by drug transporters, often fluctuate and thereby cause inter- and intra-individual pharmacokinetic variability.  Objective: In the present review article, we explore recent reports demonstrating the variance of expressions and/or functions of drug transporters in diseases of the liver, kidney and intestine, in which oxidative stress is involved at least in part in their etiol., and summarize perspectives for further study and the application to clin. situations.  Results/conclusion: Various ATP binding cassette and solute carrier transporter expressions were up- or down-regulated in remote organs as well as in the local organ of diseases when these organs were injured, at least in part by oxidative stress, suggesting that oxidative stress is a factor affecting the expression and function of drug transporters.  The present review provides useful information for further investigation on the roles of drug transporters in inter- and intra-individual pharmacokinetic variability and for refining dosing regimens in the state of organ diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphyDUV1wbypLVg90H21EOLACvtfcHk0ljTDgZ1aA9HAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovVCjur0%253D&md5=8d4f8b193695fd71c3f8c08cd881c2a0</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1517%2F17425250903008525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425250903008525%26sid%3Dliteratum%253Aachs%26aulast%3DIkemura%26aufirst%3DK.%26aulast%3DIwamoto%26aufirst%3DT.%26aulast%3DOkuda%26aufirst%3DM.%26atitle%3DAltered%2520Functions%2520and%2520Expressions%2520of%2520Drug%2520Transporters%2520in%2520Liver%252C%2520Kidney%2520and%2520Intestine%2520in%2520Disorders%2520of%2520Local%2520and%2520Remote%2520Organs%253A%2520Possible%2520Role%2520of%2520Oxidative%2520Stress%2520in%2520the%2520Pathogenesis%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2009%26volume%3D5%26spage%3D907%26epage%3D920%26doi%3D10.1517%2F17425250903008525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verbeeck, R. K.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and Dosage Adjustment in Patients with Hepatic Dysfunction</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1147</span>, <span class="refDoi"> DOI: 10.1007/s00228-008-0553-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs00228-008-0553-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=18762933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVCktL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2008&pages=1147&author=R.+K.+Verbeeck&title=Pharmacokinetics+and+Dosage+Adjustment+in+Patients+with+Hepatic+Dysfunction&doi=10.1007%2Fs00228-008-0553-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction</span></div><div class="casAuthors">Verbeeck, Roger K.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1147-1161</span>CODEN:
                <span class="NLM_cas:coden">EJCPAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The liver plays a central role in the pharmacokinetics of the majority of drugs.  Liver dysfunction may not only reduce the blood/plasma clearance of drugs eliminated by hepatic metab. or biliary excretion, it can also affect plasma protein binding, which in turn could influence the processes of distribution and elimination.  Portal-systemic shunting, which is common in advanced liver cirrhosis, may substantially decrease the presystemic elimination (i.e., first-pass effect) of high extn. drugs following their oral administration, thus leading to a significant increase in the extent of absorption.  Chronic liver diseases are assocd. with variable and non-uniform redns. in drug-metabolizing activities.  For example, the activity of the various CYP450 enzymes seems to be differentially affected in patients with cirrhosis.  Glucuronidation is often considered to be affected to a lesser extent than CYP450-mediated reactions in mild to moderate cirrhosis but can also be substantially impaired in patients with advanced cirrhosis.  Patients with advanced cirrhosis often have impaired renal function and dose adjustment may, therefore, also be necessary for drugs eliminated by renal exctretion.  In addn., patients with liver cirrhosis are more sensitive to the central adverse effects of opioid analgesics and the renal adverse effects of NSAIDs.  In contrast, a decreased therapeutic effect has been noted in cirrhotic patients with β-adrenoceptor antagonists and certain diuretics.  Unfortunately, there is no simple endogenous marker to predict hepatic function with respect to the elimination capacity of specific drugs.  Several quant. liver tests that measure the elimination of marker substrates such as galactose, sorbitol, antipyrine, caffeine, erythromycin, and midazolam, have been developed and evaluated, but no single test has gained widespread clin. use to adjust dosage regimens for drugs in patients with hepatic dysfunction.  The semi-quant. Child-Pugh score is frequently used to assess the severity of liver function impairment, but only offers the clinician rough guidance for dosage adjustment because it lacks the sensitivity to quantitate the specific ability of the liver to metabolize individual drugs.  The recommendations of the Food and Drug Administration (FDA) and the European Medicines Evaluation Agency (EMEA) to study the effect of liver disease on the pharmacokinetics of drugs under development is clearly aimed at generating, if possible, specific dosage recommendations for patients with hepatic dysfunction.  However, the limitations of the Child-Pugh score are acknowledged, and further research is needed to develop more sensitive liver function tests to guide drug dosage adjustment in patients with hepatic dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr50zLqmEKs_rVg90H21EOLACvtfcHk0lgWlfIzOFccjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVCktL3F&md5=2c521b5fd0e5037c692cc47385186116</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1007%2Fs00228-008-0553-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-008-0553-z%26sid%3Dliteratum%253Aachs%26aulast%3DVerbeeck%26aufirst%3DR.%2BK.%26atitle%3DPharmacokinetics%2520and%2520Dosage%2520Adjustment%2520in%2520Patients%2520with%2520Hepatic%2520Dysfunction%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D64%26spage%3D1147%26doi%3D10.1007%2Fs00228-008-0553-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J. H.</span></span> <span> </span><span class="NLM_article-title">The Rational Use of Potentially Hepatotoxic Medications in Patients with Underlying Liver Disease</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1517/14740338.1.2.159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1517%2F14740338.1.2.159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=12904150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslOlt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=159-172&author=J.+H.+Lewis&title=The+Rational+Use+of+Potentially+Hepatotoxic+Medications+in+Patients+with+Underlying+Liver+Disease&doi=10.1517%2F14740338.1.2.159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">The rational use of potentially hepatotoxic medications in patients with underlying liver disease</span></div><div class="casAuthors">Lewis, James H.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-172</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Given the fact that as many as 9% of all adverse drug reactions involve toxic effects on the liver and with upwards of 50% of all cases of fulminant hepatic failure being ascribed to acetaminophen and other agents, the safe use of medications takes on an even greater importance whenever the prescription of potentially hepatotoxic drugs to patients with underlying liver disease is considered.  In general, it is thought that most drugs can be safely administered in the setting of liver disease without an increased risk of hepatotoxicity, although the evidence on which this statement is based often relies more on clin. judgement than on clin. studies.  Several drugs appear to have an increased risk of hepatotoxicity in patients with underlying liver disease based on either clin. reports or extrapolated pharmacol. data.  These agents, including methotrexate, niacin, and the antiretroviral and antituberculosis drugs, carry warnings about their use in patients with a variety of liver conditions.  The data supporting the hepatotoxic risk of scores of addnl. drugs, such as the 3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors ("statins"), the newer thiazolidinediones (rosiglitazone, pioglitazone), and tamoxifen, among others, in patients with liver disease are generally lacking by evidence-based studies.  However, clin. and biochem. monitoring is routinely recommended or required, often to make up for the lack of information on the true risk of clin. significant liver toxicity of these agents in individuals both with and without underlying liver disease.  This article will review what is and what is not known about prescribing in the setting of acute and chronic liver disease and offers recommendations to help promote the safe and rational use of potentially hepatotoxic medications in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk0KI0C9cZtrVg90H21EOLACvtfcHk0lgWlfIzOFccjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslOlt78%253D&md5=9571cfa4427e1d5a41aaa884f6519c65</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1517%2F14740338.1.2.159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.1.2.159%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DJ.%2BH.%26atitle%3DThe%2520Rational%2520Use%2520of%2520Potentially%2520Hepatotoxic%2520Medications%2520in%2520Patients%2520with%2520Underlying%2520Liver%2520Disease%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2002%26volume%3D1%26spage%3D159%26epage%3D172%26doi%3D10.1517%2F14740338.1.2.159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munoz-Garrido, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marin, J. J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perugorria, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urribarri, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erice, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sáez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uriz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarvide, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Concepcion, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monte, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos-Laso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hijona, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Agüero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzioni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuers, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masyuk, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaRusso, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bujanda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drenth, J. P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banales, J. M.</span></span> <span> </span><span class="NLM_article-title">Ursodeoxycholic Acid Inhibits Hepatic Cystogenesis in Experimental Models of Polycystic Liver Disease</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">952</span>– <span class="NLM_lpage">961</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2015.05.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jhep.2015.05.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26044126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Gru7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2015&pages=952-961&author=P.+Munoz-Garridoauthor=J.+J.+G.+Marinauthor=M.+J.+Perugorriaauthor=A.+D.+Urribarriauthor=O.+Ericeauthor=E.+S%C3%A1ezauthor=M.+Urizauthor=S.+Sarvideauthor=A.+Portuauthor=A.+R.+Concepcionauthor=M.+R.+Romeroauthor=M.+J.+Monteauthor=A.+Santos-Lasoauthor=E.+Hijonaauthor=R.+Jimenez-Ag%C3%BCeroauthor=M.+Marzioniauthor=U.+Beuersauthor=T.+V.+Masyukauthor=N.+F.+LaRussoauthor=J.+Prietoauthor=L.+Bujandaauthor=J.+P.+H.+Drenthauthor=J.+M.+Banales&title=Ursodeoxycholic+Acid+Inhibits+Hepatic+Cystogenesis+in+Experimental+Models+of+Polycystic+Liver+Disease&doi=10.1016%2Fj.jhep.2015.05.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease</span></div><div class="casAuthors">Munoz-Garrido, Patricia; Marin, Jose J. G.; Perugorria, Maria J.; Urribarri, Aura D.; Erice, Oihane; Saez, Elena; Uriz, Miriam; Sarvide, Sarai; Portu, Ainhoa; Concepcion, Axel R.; Romero, Marta R.; Monte, Maria J.; Santos-Laso, Alvaro; Hijona, Elizabeth; Jimenez-Aguero, Raul; Marzioni, Marco; Beuers, Ulrich; Masyuk, Tatyana V.; LaRusso, Nicholas F.; Prieto, Jesus; Bujanda, Luis; Drenth, Joost P. H.; Banales, Jesus M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">952-961</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Polycystic liver diseases (PLDs) are genetic disorders characterized by progressive biliary cystogenesis.  Current therapies show short-term and/or modest beneficial effects.  Cystic cholangiocytes hyperproliferate as a consequence of diminished intracellular calcium levels ([Ca2+]i).  Here, the therapeutic value of ursodeoxycholic acid (UDCA) was investigated.Effect of UDCA was examd. in vitro and in polycystic (PCK) rats.  Hepatic cystogenesis and fibrosis, and the bile acid (BA) content were evaluated from the liver, bile, serum, and kidneys by HPLC-MS/MS.Chronic treatment of PCK rats with UDCA inhibits hepatic cystogenesis and fibrosis, and improves their motor behavior.  As compared to wild-type animals, PCK rats show increased BA concn. ([BA]) in liver, similar hepatic Cyp7a1 mRNA levels, and diminished [BA] in bile.  Likewise, [BA] is increased in cystic fluid of PLD patients compared to their matched serum levels.  In PCK rats, UDCA decreases the intrahepatic accumulation of cytotoxic BA, normalizes their diminished [BA] in bile, increases the BA secretion in bile and diminishes the increased [BA] in kidneys.  In vitro, UDCA inhibits the hyperproliferation of polycystic human cholangiocytes via a PI3K/AKT/MEK/ERK1/2-dependent mechanism without affecting apoptosis.  Finally, the presence of glycodeoxycholic acid promotes the proliferation of polycystic human cholangiocytes, which is inhibited by both UDCA and tauro-UDCA.UDCA was able to halt the liver disease of a rat model of PLD through inhibiting cystic cholangiocyte hyperproliferation and decreasing the levels of cytotoxic BA species in the liver, which suggests the use of UDCA as a potential therapeutic tool for PLD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS2p7ZhTEokbVg90H21EOLACvtfcHk0lgWlfIzOFccjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Gru7fM&md5=7195e515a1315a842a1b6f10017c110a</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2015.05.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2015.05.023%26sid%3Dliteratum%253Aachs%26aulast%3DMunoz-Garrido%26aufirst%3DP.%26aulast%3DMarin%26aufirst%3DJ.%2BJ.%2BG.%26aulast%3DPerugorria%26aufirst%3DM.%2BJ.%26aulast%3DUrribarri%26aufirst%3DA.%2BD.%26aulast%3DErice%26aufirst%3DO.%26aulast%3DS%25C3%25A1ez%26aufirst%3DE.%26aulast%3DUriz%26aufirst%3DM.%26aulast%3DSarvide%26aufirst%3DS.%26aulast%3DPortu%26aufirst%3DA.%26aulast%3DConcepcion%26aufirst%3DA.%2BR.%26aulast%3DRomero%26aufirst%3DM.%2BR.%26aulast%3DMonte%26aufirst%3DM.%2BJ.%26aulast%3DSantos-Laso%26aufirst%3DA.%26aulast%3DHijona%26aufirst%3DE.%26aulast%3DJimenez-Ag%25C3%25BCero%26aufirst%3DR.%26aulast%3DMarzioni%26aufirst%3DM.%26aulast%3DBeuers%26aufirst%3DU.%26aulast%3DMasyuk%26aufirst%3DT.%2BV.%26aulast%3DLaRusso%26aufirst%3DN.%2BF.%26aulast%3DPrieto%26aufirst%3DJ.%26aulast%3DBujanda%26aufirst%3DL.%26aulast%3DDrenth%26aufirst%3DJ.%2BP.%2BH.%26aulast%3DBanales%26aufirst%3DJ.%2BM.%26atitle%3DUrsodeoxycholic%2520Acid%2520Inhibits%2520Hepatic%2520Cystogenesis%2520in%2520Experimental%2520Models%2520of%2520Polycystic%2520Liver%2520Disease%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D63%26spage%3D952%26epage%3D961%26doi%3D10.1016%2Fj.jhep.2015.05.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span> <span> </span><span class="NLM_article-title">High Daily Dose and Being a Substrate of Cytochrome P450 Enzymes Are Two Important Predictors of Drug-Induced Liver Injury</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">744</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1124/dmd.113.056267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fdmd.113.056267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24464804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosFGktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=744-750&author=K.+Yuauthor=X.+Gengauthor=M.+Chenauthor=J.+Zhangauthor=B.+Wangauthor=K.+Ilicauthor=W.+Tong&title=High+Daily+Dose+and+Being+a+Substrate+of+Cytochrome+P450+Enzymes+Are+Two+Important+Predictors+of+Drug-Induced+Liver+Injury&doi=10.1124%2Fdmd.113.056267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury</span></div><div class="casAuthors">Yu, Ke; Geng, Xingchao; Chen, Minjun; Zhang, Jie; Wang, Bingshun; Ilic, Katarina; Tong, Weida</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">744-750, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is complicated and difficult to predict.  It has been obsd. that drugs with extensive hepatic metab. have a higher likelihood of causing DILI.  Cytochrome P 450 (P 450) enzymes are primarily involved in hepatic metab.  Identifying the assocns. of DILI with drugs that are P 450 substrates, inhibitors, or inducers will be extremely helpful to clinicians during the decision-making process of caring for a patient suspected of having DILI.  We collected metab. data on P 450 enzymes for 254 orally administered drugs in the Liver Toxicity Knowledge Base Benchmark Dataset with a known daily dose, and applied logistic regression to identify these assocns.  We revealed that drugs that are substrates of P 450 enzymes have a higher likelihood of causing DILI [odds ratio (OR), 3.99; 95% confidence interval (95% CI), 2.07-7.67; P < 0.0001], which is dose-independent, and drugs that are P 450 inhibitors have a higher likelihood of generating DILI only when they are administered at high daily doses (OR, 6.03; 95% CI, 1.32-27.5; P = 0.0098).  However, drugs that are P 450 inducers are not obsd. to be assocd. with DILI (OR, 1.55; 95% CI, 0.65-3.68; P = 0.3246).  Our findings will be useful in identifying the suspected medication as a cause of liver injury in clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1ZV-WvbMYx7Vg90H21EOLACvtfcHk0liPW8K1S0zHHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosFGktbc%253D&md5=167814960cb745e13e343242709bb585</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1124%2Fdmd.113.056267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.113.056267%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.%26aulast%3DGeng%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DIlic%26aufirst%3DK.%26aulast%3DTong%26aufirst%3DW.%26atitle%3DHigh%2520Daily%2520Dose%2520and%2520Being%2520a%2520Substrate%2520of%2520Cytochrome%2520P450%2520Enzymes%2520Are%2520Two%2520Important%2520Predictors%2520of%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2014%26volume%3D42%26spage%3D744%26epage%3D750%26doi%3D10.1124%2Fdmd.113.056267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Björnsson, E. S.</span></span> <span> </span><span class="NLM_article-title">Epidemiology and Risk Factors for Idiosyncratic Drug-Induced Liver Injury</span>. <i>Semin. Liver Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1055/s-0034-1375953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1055%2Fs-0034-1375953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24879977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFKktLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=115-122&author=E.+S.+Bj%C3%B6rnsson&title=Epidemiology+and+Risk+Factors+for+Idiosyncratic+Drug-Induced+Liver+Injury&doi=10.1055%2Fs-0034-1375953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology and risk factors for idiosyncratic drug-induced liver injury</span></div><div class="casAuthors">Bjornsson, Einar S.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Liver Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-122</span>CODEN:
                <span class="NLM_cas:coden">SLDIEE</span>;
        ISSN:<span class="NLM_cas:issn">0272-8087</span>.
    
            (<span class="NLM_cas:orgname">Thieme Medical Publishers, Inc.</span>)
        </div><div class="casAbstract">A review.  Idiosyncratic drug-induced liver injury (DILI) is, like other adverse effects of drugs, underreported and underestimated in most epidemiol. studies based on registries of DILI cases and reporting systems (e.g., Medwatch).  The same is probably true for prospective population-based studies, although they are much more likely to mirror the true incidence of DILI.  Despite these challenges, the epidemiol. of DILI remains of utmost importance and is gradually coming into better focus.  A recent population based study found a crude incidence of ∼19 cases per 100,000 per yr.  Certain agents are particularly noteworthy for their DILI risk.  Amoxicillin-clavulanate continues to be the most commonly implicated agent occurring in ∼1 out of 2,300 users.  Some others that standout with significantly higher risk include azathioprine and infliximab.  Although statin-induced hepatotoxicity has been well documented, the risk is probably quite low.  Overall, the majority of DILI in children and adults is assocd. with either antibiotics or anticonvulsants.  Drug-induced liver injury assocd. with i.v. given drugs does not show any major differences from DILI due to orally administered agents.  Unfortunately, our understanding of pretherapy risk assessment remains rudimentary for the most part.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE_OCTKYzViLVg90H21EOLACvtfcHk0liPW8K1S0zHHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFKktLnL&md5=21644cb03bd63872249a1937e94cab4b</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1055%2Fs-0034-1375953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0034-1375953%26sid%3Dliteratum%253Aachs%26aulast%3DBj%25C3%25B6rnsson%26aufirst%3DE.%2BS.%26atitle%3DEpidemiology%2520and%2520Risk%2520Factors%2520for%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DSemin.%2520Liver%2520Dis.%26date%3D2014%26volume%3D34%26spage%3D115%26epage%3D122%26doi%3D10.1055%2Fs-0034-1375953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thiele, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazurkiewicz-Beldzinska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benbadis, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommerville, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gawlowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazurkiewicz
Beldzinska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitosek
Szewczyk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinborn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zolnowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benbadis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciliberto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dlugos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filloux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flamini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haut, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraddi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenfeld, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seltzer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellhaas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiele, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thio, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilfong, A.</span></span> <span> </span><span class="NLM_article-title">Cannabidiol in Patients with Seizures Associated with Lennox-Gastaut Syndrome (GWPCARE4): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>391</i></span>,  <span class="NLM_fpage">1085</span>– <span class="NLM_lpage">1096</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)30136-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2FS0140-6736%2818%2930136-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29395273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlWltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=2018&pages=1085-1096&author=E.+A.+Thieleauthor=E.+D.+Marshauthor=J.+A.+Frenchauthor=M.+Mazurkiewicz-Beldzinskaauthor=S.+R.+Benbadisauthor=C.+Joshiauthor=P.+D.+Lyonsauthor=A.+Taylorauthor=C.+Robertsauthor=K.+Sommervilleauthor=B.+Gunningauthor=J.+Gawlowiczauthor=P.+Lisewskiauthor=M.+Mazurkiewicz%0ABeldzinskaauthor=K.+Mitosek%0ASzewczykauthor=B.+Steinbornauthor=M.+Zolnowskaauthor=E.+Hughesauthor=A.+McLellanauthor=S.+Benbadisauthor=M.+Cilibertoauthor=G.+Clarkauthor=D.+Dlugosauthor=F.+Fillouxauthor=R.+Flaminiauthor=J.+Frenchauthor=M.+Frostauthor=S.+Hautauthor=C.+Joshiauthor=S.+Kapoorauthor=S.+Kesslerauthor=L.+Lauxauthor=P.+Lyonsauthor=E.+Marshauthor=D.+Mooreauthor=R.+Morseauthor=V.+Nagaraddiauthor=W.+Rosenfeldauthor=L.+Seltzerauthor=R.+Shellhaasauthor=J.+Sullivanauthor=E.+Thieleauthor=L.+L.+Thioauthor=D.+Wangauthor=A.+Wilfong&title=Cannabidiol+in+Patients+with+Seizures+Associated+with+Lennox-Gastaut+Syndrome+%28GWPCARE4%29%3A+A+Randomised%2C+Double-Blind%2C+Placebo-Controlled+Phase+3+Trial&doi=10.1016%2FS0140-6736%2818%2930136-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial</span></div><div class="casAuthors">Thiele, Elizabeth A.; Marsh, Eric D.; French, Jacqueline A.; Mazurkiewicz-Beldzinska, Maria; Benbadis, Selim R.; Joshi, Charuta; Lyons, Paul D.; Taylor, Adam; Roberts, Claire; Sommerville, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">391</span>
        (<span class="NLM_cas:issue">10125</span>),
    <span class="NLM_cas:pages">1085-1096</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with Lennox-Gastaut syndrome, a rare, severe form of epileptic encephalopathy, are frequently treatment resistant to available medications.  No controlled studies have investigated the use of cannabidiol for patients with seizures assocd. with Lennox-Gastaut syndrome.  We therefore assessed the efficacy and safety of cannabidiol as an add-on anticonvulsant therapy in this population of patients.  In this randomised, double-blind, placebo-controlled trial done at 24 clin. sites in the USA, the Netherlands, and Poland, we investigated the efficacy of cannabidiol as add-on therapy for drop seizures in patients with treatment-resistant Lennox-Gastaut syndrome.  Eligible patients (aged 2-55 years) had Lennox-Gastaut syndrome, including a history of slow (<3 Hz) spike-and-wave patterns on EEG, evidence of more than one type of generalised seizure for at least 6 mo, at least two drop seizures per wk during the 4-wk baseline period, and had not responded to treatment with at least two antiepileptic drugs.  Patients were randomly assigned (1:1) using an interactive voice response system, stratified by age group, to receive 20 mg/kg oral cannabidiol daily or matched placebo for 14 wk.  All patients, caregivers, investigators, and individuals assessing data were masked to group assignment.  The primary endpoint was percentage change from baseline in monthly frequency of drop seizures during the treatment period, analyzed in all patients who received at least one dose of study drug and had post-baseline efficacy data.  All randomly assigned patients were included in the safety analyses.  This study is registered with ClinicalTrials.gov, no. NCT02224690.  Between Apr. 28, 2015, and Oct 15, 2015, we randomly assigned 171 patients to receive cannabidiol (n=86) or placebo (n=85). 14 patients in the cannabidiol group and one in the placebo group discontinued study treatment; all randomly assigned patients received at least one dose of study treatment and had post-baseline efficacy data.  The median percentage redn. in monthly drop seizure frequency from baseline was 43·9% (IQR -69·6 to -1·9) in the cannibidiol group and 21·8% (IQR -45·7 to 1·7) in the placebo group.  The estd. median difference between the treatment groups was -17·21 (95% CI -30·32 to -4·09; p=0·0135) during the 14-wk treatment period.  Adverse events occurred in 74 (86%) of 86 patients in the cannabidiol group and 59 (69%) of 85 patients in the placebo group; most were mild or moderate.  The most common adverse events were diarrhoea, somnolence, pyrexia, decreased appetite, and vomiting. 12 (14%) patients in the cannabidiol group and one (1%) patient in the placebo group withdrew from the study because of adverse events.  One patient (1%) died in the cannabidiol group, but this was considered unrelated to treatment.  Add-on cannabidiol is efficacious for the treatment of patients with drop seizures assocd. with Lennox-Gastaut syndrome and is generally well tolerated.  The long-term efficacy and safety of cannabidiol is currently being assessed in the open-label extension of this trial.GW Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFsV2mzpliMbVg90H21EOLACvtfcHk0lhjbm-HRX-G5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlWltb8%253D&md5=f414a696a22a0cf480eaa19c380eae7a</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2930136-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252930136-3%26sid%3Dliteratum%253Aachs%26aulast%3DThiele%26aufirst%3DE.%2BA.%26aulast%3DMarsh%26aufirst%3DE.%2BD.%26aulast%3DFrench%26aufirst%3DJ.%2BA.%26aulast%3DMazurkiewicz-Beldzinska%26aufirst%3DM.%26aulast%3DBenbadis%26aufirst%3DS.%2BR.%26aulast%3DJoshi%26aufirst%3DC.%26aulast%3DLyons%26aufirst%3DP.%2BD.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DRoberts%26aufirst%3DC.%26aulast%3DSommerville%26aufirst%3DK.%26aulast%3DGunning%26aufirst%3DB.%26aulast%3DGawlowicz%26aufirst%3DJ.%26aulast%3DLisewski%26aufirst%3DP.%26aulast%3DMazurkiewicz%2BBeldzinska%26aufirst%3DM.%26aulast%3DMitosek%2BSzewczyk%26aufirst%3DK.%26aulast%3DSteinborn%26aufirst%3DB.%26aulast%3DZolnowska%26aufirst%3DM.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DMcLellan%26aufirst%3DA.%26aulast%3DBenbadis%26aufirst%3DS.%26aulast%3DCiliberto%26aufirst%3DM.%26aulast%3DClark%26aufirst%3DG.%26aulast%3DDlugos%26aufirst%3DD.%26aulast%3DFilloux%26aufirst%3DF.%26aulast%3DFlamini%26aufirst%3DR.%26aulast%3DFrench%26aufirst%3DJ.%26aulast%3DFrost%26aufirst%3DM.%26aulast%3DHaut%26aufirst%3DS.%26aulast%3DJoshi%26aufirst%3DC.%26aulast%3DKapoor%26aufirst%3DS.%26aulast%3DKessler%26aufirst%3DS.%26aulast%3DLaux%26aufirst%3DL.%26aulast%3DLyons%26aufirst%3DP.%26aulast%3DMarsh%26aufirst%3DE.%26aulast%3DMoore%26aufirst%3DD.%26aulast%3DMorse%26aufirst%3DR.%26aulast%3DNagaraddi%26aufirst%3DV.%26aulast%3DRosenfeld%26aufirst%3DW.%26aulast%3DSeltzer%26aufirst%3DL.%26aulast%3DShellhaas%26aufirst%3DR.%26aulast%3DSullivan%26aufirst%3DJ.%26aulast%3DThiele%26aufirst%3DE.%26aulast%3DThio%26aufirst%3DL.%2BL.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWilfong%26aufirst%3DA.%26atitle%3DCannabidiol%2520in%2520Patients%2520with%2520Seizures%2520Associated%2520with%2520Lennox-Gastaut%2520Syndrome%2520%2528GWPCARE4%2529%253A%2520A%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Phase%25203%2520Trial%26jtitle%3DLancet%26date%3D2018%26volume%3D391%26spage%3D1085%26epage%3D1096%26doi%3D10.1016%2FS0140-6736%2818%2930136-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gopaul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, F.</span></span> <span> </span><span class="NLM_article-title">Effects of Age and Polytherapy, Risk Factors of Valproic Acid (VPA) Hepatotoxicity, on the Excretion of Thiol Conjugates of (E)-2,4-diene VPA in People with Epilepsy Taking VPA</span>. <i>Epilepsia</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">322</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1046/j.1528-1157.2003.07202.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1046%2Fj.1528-1157.2003.07202.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=12614387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD3sXislejs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=322-328&author=S.+Gopaulauthor=K.+Farrellauthor=F.+Abbott&title=Effects+of+Age+and+Polytherapy%2C+Risk+Factors+of+Valproic+Acid+%28VPA%29+Hepatotoxicity%2C+on+the+Excretion+of+Thiol+Conjugates+of+%28E%29-2%2C4-diene+VPA+in+People+with+Epilepsy+Taking+VPA&doi=10.1046%2Fj.1528-1157.2003.07202.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (E)-2,4-diene VPA in people with epilepsy taking VPA</span></div><div class="casAuthors">Gopaul, Sashi; Farrell, Kevin; Abbott, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsia</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">322-328</span>CODEN:
                <span class="NLM_cas:coden">EPILAK</span>;
        ISSN:<span class="NLM_cas:issn">0013-9580</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">Valproic acid (VPA) is an antiepileptic drug (AED) used for generalized and absence seizures.  It has a rare but potentially fatal hepatotoxicity side effect, and many researchers believe that reactive metabolites of VPA could be involved.  We demonstrated here that the thiol conjugates of (E)-2,4-diene VPA were significantly elevated in a high-risk group of patients.  Thirty-four patients with seizures were divided into three groups.  Group A (n = 14) were being treated with VPA; group B (n = 12) received VPA as well as other AEDs that do not induce P 450-VPA metab.; and group C (n = 8) received VPA and AEDs that induce P 450-VPA metab.  The NAC conjugates of (E)-2,4-diene VPA (NAC I and NAC II) were identified in the urine of patients by gas chromatog./mass spectrog. NICI anal.  VPA monotherapy (group A) or VPA polytherapy with non-P 450-enzyme-inducing drugs (group B), showed that patients younger than 7.5 yr excreted significantly higher concns. of the two conjugates compared with older patients (older than 7.5 yr) in the same groups (p < 0.05).  Patients receiving VPA polytherapy with P 450-enzyme-inducing drugs were all older than 7.5 yr (group C).  They excreted significantly higher concns. of NAC I and NAC II compared with patients in groups A and B who were older than 7.5 yr (p < 0.05).  There were no significant differences in the excretion of NAC I and NAC II between patients in group C and those who were 7.5 yr or younger in groups A and B.  High doses of VPA also were a significant factor assocd. with elevated NAC I and NAC II among young patients and in polytherapy patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgfL67k65A1bVg90H21EOLACvtfcHk0lhjbm-HRX-G5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXislejs7g%253D&md5=ae958701597c9f28ae9579dc75631c43</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1046%2Fj.1528-1157.2003.07202.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1528-1157.2003.07202.x%26sid%3Dliteratum%253Aachs%26aulast%3DGopaul%26aufirst%3DS.%26aulast%3DFarrell%26aufirst%3DK.%26aulast%3DAbbott%26aufirst%3DF.%26atitle%3DEffects%2520of%2520Age%2520and%2520Polytherapy%252C%2520Risk%2520Factors%2520of%2520Valproic%2520Acid%2520%2528VPA%2529%2520Hepatotoxicity%252C%2520on%2520the%2520Excretion%2520of%2520Thiol%2520Conjugates%2520of%2520%2528E%2529-2%252C4-diene%2520VPA%2520in%2520People%2520with%2520Epilepsy%2520Taking%2520VPA%26jtitle%3DEpilepsia%26date%3D2003%26volume%3D44%26spage%3D322%26epage%3D328%26doi%3D10.1046%2Fj.1528-1157.2003.07202.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steele, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DesPrez, R. M.</span></span> <span> </span><span class="NLM_article-title">Toxic Hepatitis with Isoniazid and Rifampin: A Meta-analysis</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1378/chest.99.2.465</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1378%2Fchest.99.2.465" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1824929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADyaK3M7hsVCisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1991&pages=465-471&author=M.+A.+Steeleauthor=R.+F.+Burkauthor=R.+M.+DesPrez&title=Toxic+Hepatitis+with+Isoniazid+and+Rifampin%3A+A+Meta-analysis&doi=10.1378%2Fchest.99.2.465"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Toxic hepatitis with isoniazid and rifampin. A meta-analysis</span></div><div class="casAuthors">Steele M A; Burk R F; DesPrez R M</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">465-71</span>
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR_mzx6NCDNniO2kE7krGOBfW6udTcc2eYQ3_27SGauBLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3M7hsVCisA%253D%253D&md5=63005c74fb861178efd94a9bdc4275d1</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1378%2Fchest.99.2.465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.99.2.465%26sid%3Dliteratum%253Aachs%26aulast%3DSteele%26aufirst%3DM.%2BA.%26aulast%3DBurk%26aufirst%3DR.%2BF.%26aulast%3DDesPrez%26aufirst%3DR.%2BM.%26atitle%3DToxic%2520Hepatitis%2520with%2520Isoniazid%2520and%2520Rifampin%253A%2520A%2520Meta-analysis%26jtitle%3DChest%26date%3D1991%26volume%3D99%26spage%3D465%26epage%3D471%26doi%3D10.1378%2Fchest.99.2.465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Abajo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madurga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez, L. A. G.</span></span> <span> </span><span class="NLM_article-title">Acute and Clinically Relevant Drug-Induced Liver Injury: A Population Based Case-Control Study</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2004.02133.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1111%2Fj.1365-2125.2004.02133.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=15206996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD2czgsFWrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2004&pages=71-80&author=F.+J.+de+Abajoauthor=D.+Monteroauthor=M.+Madurgaauthor=L.+A.+G.+Rodr%C3%ADguez&title=Acute+and+Clinically+Relevant+Drug-Induced+Liver+Injury%3A+A+Population+Based+Case-Control+Study&doi=10.1111%2Fj.1365-2125.2004.02133.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Acute and clinically relevant drug-induced liver injury: a population based case-control study</span></div><div class="casAuthors">de Abajo Francisco J; Montero Dolores; Madurga Mariano; Garcia Rodriguez Luis A</div><div class="citationInfo"><span class="NLM_cas:title">British journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">71-80</span>
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    </div><div class="casAbstract">AIMS:  To provide quantitative information about the absolute and relative risks of acute and clinically relevant drug-induced liver injury.  METHODS:  We performed a population-based case-control study using the UK-based General Practice Research Database as the source of information.  A total of 1,636,792 persons subjects aged 5-75 years old registered in the database from 1 January, 1994 to 31 December, 1999 were followed-up for a total of 5,404,705 person-years.  Cases were identified by an exhaustive computer search, then reviewed manually and finally validated against the clinical records.  Only idiopathic cases serious enough to be referred to hospital or a consultant were selected.  A total of 5000 controls were randomly sampled from the person-time of study cohort.  Current users were defined if a prescription ended within 15 days of the index date, and nonusers if there was no prescription before the index date.  RESULTS:  One hundred and twenty-eight patients were considered as valid cases, being the crude incidence rate of 2.4 (95% confidence interval: 2.0, 2.8) per 100 000 person-years.  The strongest associations were found with chlorpromazine (adjusted odds ratio (AOR); 95% CI = 416; 45, 3840), amoxicillin/clavulanic acid (AOR = 94.8; 27.8, 323), flucloxacillin (AOR = 17.7; 4.4, 71.0), macrolides (AOR = 6.9; 2.3, 21.0), tetracyclines (AOR = 6.2; 2.4, 15.8); metoclopramide (AOR = 6.2; 1.8, 21.3); chlorpheniramine (AOR = 9.6; 1.9, 49.7); betahistine (AOR = 15.3; 2.9, 80.7); sulphasalazine (AOR = 25.5; 6.0, 109); azathioprine (AOR = 10.5; 1.4, 76.4), diclofenac (AOR = 4.1; 1.9, 8.8) and antiepileptics (AOR = 5.1; 1.9, 13.7).  A dose-effect was apparent for diclofenac, amoxicillin/clavulanic acid and flucloxacillin.  The combination of two or more hepatotoxic drugs increased the risk by a factor of 6.  The highest crude incidence rates were found for chlorpromazine, azathioprine, and sulfasalazine (about 1 per 1000 users).  CONCLUSIONS:  Idiopathic, acute and clinically relevant liver injury, which has the use of drugs as the most probable aetiology, is a rare event in the general population.  The relative risks of 40 drugs/therapeutic classes are provided, along with the crude incidence rates for 15 of them where a statistical association was found.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAed3RzDrPsQ5nADWVYHg1fW6udTcc2eYRRX2_hUhkIbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czgsFWrsQ%253D%253D&md5=575c1cf4631f60ccd88c534b49d92c77</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2004.02133.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2004.02133.x%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BAbajo%26aufirst%3DF.%2BJ.%26aulast%3DMontero%26aufirst%3DD.%26aulast%3DMadurga%26aufirst%3DM.%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DL.%2BA.%2BG.%26atitle%3DAcute%2520and%2520Clinically%2520Relevant%2520Drug-Induced%2520Liver%2520Injury%253A%2520A%2520Population%2520Based%2520Case-Control%2520Study%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2004%26volume%3D58%26spage%3D71%26epage%3D80%26doi%3D10.1111%2Fj.1365-2125.2004.02133.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagheri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapeyre-Mestre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cambus, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdiguié, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montastruc, J. L.</span></span> <span> </span><span class="NLM_article-title">Detection and Incidence of Drug-Induced Liver Injuries in Hospital: A Prospective Analysis from Laboratory Signals</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2125.2000.00282.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1046%2Fj.1365-2125.2000.00282.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=11069443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD3cXos1OltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2000&pages=479-484&author=H.+Bagheriauthor=F.+Michelauthor=M.+Lapeyre-Mestreauthor=E.+Lagierauthor=J.+P.+Cambusauthor=P.+Valdigui%C3%A9author=J.+L.+Montastruc&title=Detection+and+Incidence+of+Drug-Induced+Liver+Injuries+in+Hospital%3A+A+Prospective+Analysis+from+Laboratory+Signals&doi=10.1046%2Fj.1365-2125.2000.00282.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals</span></div><div class="casAuthors">Bagheri, H.; Michel, F.; Lapeyre-Mestre, M.; Lagier, E.; Cambus, J. P.; Valdiguie, P.; Montastruc, J. L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">479-484</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Aims: Liver damage remains the most frequent type of adverse drug reaction (ADRs) that can lead to the withdrawal of a drug from the market.  The abnormal lab. data identified by computerized hospital information systems can be used in order to improve the detection of ADRs.  Our objectives were to assess the detection and incidence of drug-induced liver abnormalities in a university hospital inpatient population and to evaluate the underreporting rate of drug-induced liver injury.  Methods: We conducted a prospective study performed 1 wk per mo from June to Oct. 1997.  We selected patients by a computerized process using biochem. lab. data, based on serum enzyme values, alanine aminotransferase (over 2 fold normal) and alk. phosphatase (over 1.5 fold normal).  Results: Among 1976 ALT and 1814 AP assays performed during the period of the study, 156 (7.9%) and 159 (8.8%) tests, resp., fell into the selected criteria.  These concerned 147 patients.  Among these patients, 13 (8.8%) cases of drug-induced liver injuries were suspected.  Seven cases were asymptomatic.  Six cases were classified as serious by these criteria: hospitalization to investigate the cause of health status impairment (4 patients), prolongation of hospitalization (1 patient) and life-threatening (1 patient).  Using the hospitalization database, the incidence of drug-induced liver injuries was estd. as 6.6 per 1000 inpatients a week.  Only 1 case was reported by physicians in the same period.  Conclusions: Computerization of biochem. data would allow the development of systems to improve detection of drug-induced injury.  Moreover, underreporting remains important for such potentially serious ADRs, even in a university hospital.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQe7ootxixvbVg90H21EOLACvtfcHk0liCnrL_sbZC5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXos1OltLw%253D&md5=6b4ae7abec357ac5ecaf66f35bbe08ed</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2125.2000.00282.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2125.2000.00282.x%26sid%3Dliteratum%253Aachs%26aulast%3DBagheri%26aufirst%3DH.%26aulast%3DMichel%26aufirst%3DF.%26aulast%3DLapeyre-Mestre%26aufirst%3DM.%26aulast%3DLagier%26aufirst%3DE.%26aulast%3DCambus%26aufirst%3DJ.%2BP.%26aulast%3DValdigui%25C3%25A9%26aufirst%3DP.%26aulast%3DMontastruc%26aufirst%3DJ.%2BL.%26atitle%3DDetection%2520and%2520Incidence%2520of%2520Drug-Induced%2520Liver%2520Injuries%2520in%2520Hospital%253A%2520A%2520Prospective%2520Analysis%2520from%2520Laboratory%2520Signals%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2000%26volume%3D50%26spage%3D479%26epage%3D484%26doi%3D10.1046%2Fj.1365-2125.2000.00282.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Björnsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalaitzakis, E.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxicity Associated with Statins: Reports of Idiosyncratic Liver Injury Post-Marketing</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">374</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2011.07.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jhep.2011.07.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21889469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC387ltFWrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=374-380&author=E.+Bj%C3%B6rnssonauthor=E.+I.+Jacobsenauthor=E.+Kalaitzakis&title=Hepatotoxicity+Associated+with+Statins%3A+Reports+of+Idiosyncratic+Liver+Injury+Post-Marketing&doi=10.1016%2Fj.jhep.2011.07.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing</span></div><div class="casAuthors">Bjornsson Einar; Jacobsen Elin I; Kalaitzakis Evangelos</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hepatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">374-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND & AIMS:  Limited data exist on drug-induced liver injury (DILI) associated with statins.  METHODS:  Reports on adverse reactions suspected to be due to statins received by the Swedish Adverse Drug Reactions Advisory Committe 1988-2010 were analyzed.  Only cases with >5×upper limit of normal (ULN) in aminotransferases and/or alkaline phosphatase >2×ULN were included.  RESULTS:  The most common types of ADRs suspected were DILI in 124/217 (57%) cases.  A total of 73/124 (59%) cases had at least possible relationship, median age 64 years (57-73), 55% males, whereas 25/124 cases (20%) were excluded due to mild elevations of liver tests and 26 due to unlikely relationship and/or lack of data.  A statin-related DILI episode was reported in 1.2/100,000 users.  Atorvastatin was implicated in 30/73 (41%) cases, simvastatin in 28 (38%), fluvastatin (15%), and others.  Two patients died of acute liver failure, one underwent liver transplantation and 25 (34%) had jaundice.  Three patients were rechallenged with the same statin producing similar patterns of liver injury.  The median duration of therapy was 90 days (30-120), 120 (39-248) for atorvastatin, and 75 (30-150) for simvastatin (NS).  Cholestatic/mixed injury was more common with atorvastatin, 17/30 (56%) than with simvastatin, 7/28 (24%) (p=0.018).  CONCLUSIONS:  Idiosyncratic liver injury associated with statins is rare but can be severe.  After recovery, a similar pattern of liver injury can be reproduced on re-exposure.  Most patients experience liver injury 3-4 months after start of therapy.  Atorvastatin is mostly associated with cholestatic liver injury whereas hepatocellular injury is more common with simvastatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSj20RUU6aR1-98rul4nhSdfW6udTcc2ebJ0rSkxHEB2bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387ltFWrsA%253D%253D&md5=16c57d35cc321bbe57cdcaa9c14b30b3</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2011.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2011.07.023%26sid%3Dliteratum%253Aachs%26aulast%3DBj%25C3%25B6rnsson%26aufirst%3DE.%26aulast%3DJacobsen%26aufirst%3DE.%2BI.%26aulast%3DKalaitzakis%26aufirst%3DE.%26atitle%3DHepatotoxicity%2520Associated%2520with%2520Statins%253A%2520Reports%2520of%2520Idiosyncratic%2520Liver%2520Injury%2520Post-Marketing%26jtitle%3DJ.%2520Hepatol.%26date%3D2012%26volume%3D56%26spage%3D374%26epage%3D380%26doi%3D10.1016%2Fj.jhep.2011.07.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, J. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1002/cpt.1437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fcpt.1437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30937887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FgslKjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2019&pages=317-328&author=A.+Sharmaauthor=M.+M.+Buschmannauthor=J.+A.+Gilbert&title=Pharmacomicrobiomics%3A+The+Holy+Grail+to+Variability+in+Drug+Response%3F&doi=10.1002%2Fcpt.1437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?</span></div><div class="casAuthors">Sharma Anukriti; Gilbert Jack A; Buschmann Mary M; Gilbert Jack A</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">317-328</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The human body, with 3.0 × 10(13) cells and more than 3.8 × 10(13) microorganisms, has nearly a one-to-one ratio of resident microbes to human cells.  Initiatives like the Human Microbiome Project, American Gut, and Flemish Gut have identified associations between microbial taxa and human health.  The study of interactions between microbiome and pharmaceutical agents, i.e., pharmacomicrobiomics, has revealed an instrumental role of the microbiome in modulating drug response that alters the therapeutic outcomes.  In this review, we present our current comprehension of the relationship of the microbiome, host biology, and pharmaceutical agents such as cardiovascular drugs, analgesics, and chemotherapeutic agents to human disease and treatment outcomes.  We also discuss the significance of studying diet-gene-drug interactions and further address the key challenges associated with pharmacomicrobiomics.  Finally, we examine proposed models employing systems biology for the application of pharmacomicrobiomics and other -omics data, and provide approaches to elucidate microbiome-drug interactions to improve future translation to personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQS1WiW-1KCW7HHuJhbyicZfW6udTcc2ebJ0rSkxHEB2bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FgslKjtg%253D%253D&md5=b29c6bba4bd8b4a2c88ff3d4e6317542</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1002%2Fcpt.1437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.1437%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DBuschmann%26aufirst%3DM.%2BM.%26aulast%3DGilbert%26aufirst%3DJ.%2BA.%26atitle%3DPharmacomicrobiomics%253A%2520The%2520Holy%2520Grail%2520to%2520Variability%2520in%2520Drug%2520Response%253F%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2019%26volume%3D106%26spage%3D317%26epage%3D328%26doi%3D10.1002%2Fcpt.1437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Viaud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccheri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mignot, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daillere, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enot, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfirschke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engblom, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittet, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlitzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginhoux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apetoh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chachaty, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woerther, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecobichon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clermont, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bizet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaboriau-Routhiau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerf-Bensussan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opolon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yessaad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryffel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elson, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dore, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepage, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boneca, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiringhelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zitvogel, L.</span></span> <span> </span><span class="NLM_article-title">The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>342</i></span>,  <span class="NLM_fpage">971</span>– <span class="NLM_lpage">976</span>, <span class="refDoi"> DOI: 10.1126/science.1240537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1126%2Fscience.1240537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24264990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2htL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2013&pages=971-976&author=S.+Viaudauthor=F.+Saccheriauthor=G.+Mignotauthor=T.+Yamazakiauthor=R.+Daillereauthor=D.+Hannaniauthor=D.+P.+Enotauthor=C.+Pfirschkeauthor=C.+Engblomauthor=M.+J.+Pittetauthor=A.+Schlitzerauthor=F.+Ginhouxauthor=L.+Apetohauthor=E.+Chachatyauthor=P.+L.+Woertherauthor=G.+Eberlauthor=M.+Berardauthor=C.+Ecobichonauthor=D.+Clermontauthor=C.+Bizetauthor=V.+Gaboriau-Routhiauauthor=N.+Cerf-Bensussanauthor=P.+Opolonauthor=N.+Yessaadauthor=E.+Vivierauthor=B.+Ryffelauthor=C.+O.+Elsonauthor=J.+Doreauthor=G.+Kroemerauthor=P.+Lepageauthor=I.+G.+Bonecaauthor=F.+Ghiringhelliauthor=L.+Zitvogel&title=The+Intestinal+Microbiota+Modulates+the+Anticancer+Immune+Effects+of+Cyclophosphamide&doi=10.1126%2Fscience.1240537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide</span></div><div class="casAuthors">Viaud, Sophie; Saccheri, Fabiana; Mignot, Gregoire; Yamazaki, Takahiro; Daillere, Romain; Hannani, Dalil; Enot, David P.; Pfirschke, Christina; Engblom, Camilla; Pittet, Mikael J.; Schlitzer, Andreas; Ginhoux, Florent; Apetoh, Lionel; Chachaty, Elisabeth; Woerther, Paul-Louis; Eberl, Gerard; Berard, Marion; Ecobichon, Chantal; Clermont, Dominique; Bizet, Chantal; Gaboriau-Routhiau, Valerie; Cerf-Bensussan, Nadine; Opolon, Paule; Yessaad, Nadia; Vivier, Eric; Ryffel, Bernhard; Elson, Charles O.; Dore, Joel; Kroemer, Guido; Lepage, Patricia; Boneca, Ivo Gomperts; Ghiringhelli, Francois; Zitvogel, Laurence</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">6161</span>),
    <span class="NLM_cas:pages">971-976</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Cyclophosphamide is one of several clin. important cancer drugs whose therapeutic efficacy is due in part to their ability to stimulate antitumor immune responses.  Studying mouse models, we demonstrate that cyclophosphamide alters the compn. of microbiota in the small intestine and induces the translocation of selected species of Gram-pos. bacteria into secondary lymphoid organs.  There, these bacteria stimulate the generation of a specific subset of "pathogenic" T helper 17 (pTH17) cells and memory TH1 immune responses.  Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram-pos. bacteria showed a redn. in pTH17 responses, and their tumors were resistant to cyclophosphamide.  Adoptive transfer of pTH17 cells partially restored the antitumor efficacy of cyclophosphamide.  These results suggest that the gut microbiota help shape the anticancer immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpBoPVll8hyrVg90H21EOLACvtfcHk0lglIIqKgP3LOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2htL3P&md5=dc90561d9098bf963ea7bf39effe78d1</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1126%2Fscience.1240537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1240537%26sid%3Dliteratum%253Aachs%26aulast%3DViaud%26aufirst%3DS.%26aulast%3DSaccheri%26aufirst%3DF.%26aulast%3DMignot%26aufirst%3DG.%26aulast%3DYamazaki%26aufirst%3DT.%26aulast%3DDaillere%26aufirst%3DR.%26aulast%3DHannani%26aufirst%3DD.%26aulast%3DEnot%26aufirst%3DD.%2BP.%26aulast%3DPfirschke%26aufirst%3DC.%26aulast%3DEngblom%26aufirst%3DC.%26aulast%3DPittet%26aufirst%3DM.%2BJ.%26aulast%3DSchlitzer%26aufirst%3DA.%26aulast%3DGinhoux%26aufirst%3DF.%26aulast%3DApetoh%26aufirst%3DL.%26aulast%3DChachaty%26aufirst%3DE.%26aulast%3DWoerther%26aufirst%3DP.%2BL.%26aulast%3DEberl%26aufirst%3DG.%26aulast%3DBerard%26aufirst%3DM.%26aulast%3DEcobichon%26aufirst%3DC.%26aulast%3DClermont%26aufirst%3DD.%26aulast%3DBizet%26aufirst%3DC.%26aulast%3DGaboriau-Routhiau%26aufirst%3DV.%26aulast%3DCerf-Bensussan%26aufirst%3DN.%26aulast%3DOpolon%26aufirst%3DP.%26aulast%3DYessaad%26aufirst%3DN.%26aulast%3DVivier%26aufirst%3DE.%26aulast%3DRyffel%26aufirst%3DB.%26aulast%3DElson%26aufirst%3DC.%2BO.%26aulast%3DDore%26aufirst%3DJ.%26aulast%3DKroemer%26aufirst%3DG.%26aulast%3DLepage%26aufirst%3DP.%26aulast%3DBoneca%26aufirst%3DI.%2BG.%26aulast%3DGhiringhelli%26aufirst%3DF.%26aulast%3DZitvogel%26aufirst%3DL.%26atitle%3DThe%2520Intestinal%2520Microbiota%2520Modulates%2520the%2520Anticancer%2520Immune%2520Effects%2520of%2520Cyclophosphamide%26jtitle%3DScience%26date%3D2013%26volume%3D342%26spage%3D971%26epage%3D976%26doi%3D10.1126%2Fscience.1240537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsih, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. T.</span></span> <span> </span><span class="NLM_article-title">Medical Genetics: A Marker for Stevens-Johnson Syndrome</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>428</i></span>,  <span class="NLM_fpage">486</span>, <span class="refDoi"> DOI: 10.1038/428486a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2F428486a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=15057820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=428&publication_year=2004&pages=486&author=W.+H.+Chungauthor=S.+I.+Hungauthor=H.+S.+Hongauthor=M.+S.+Hsihauthor=L.+C.+Yangauthor=H.+C.+Hoauthor=J.+Y.+Wuauthor=Y.+T.+Chen&title=Medical+Genetics%3A+A+Marker+for+Stevens-Johnson+Syndrome&doi=10.1038%2F428486a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Medical genetics: A marker for Stevens-Johnson syndrome</span></div><div class="casAuthors">Chung, Wen-Hung; Hung, Shuen-Iu; Hong, Hong-Shang; Hsih, Mo-Song; Yang, Li-Cheng; Ho, Hsin-Chun; Wu, Jer-Yuarn; Chen, Yuan-Tsong</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">428</span>
        (<span class="NLM_cas:issue">6982</span>),
    <span class="NLM_cas:pages">486</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here authors show that there is a strong assocn. in Han Chinese between a genetic marker, the human leukocyte antigen HLA-B*1502, and Stevens-Johnson syndrome induced by carbamazepine, a drug commonly prescribed for the treatment of seizures.  We studied 44 patients with carbamazepine-induced Stevens-Johnson syndrome (CBZ-SJS), including five with overlapping toxic epidermal necrolysis, in whom the clin. morphol. fulfilled Roujeau's diagnostic criteria.  All participants were Han Chinese residing in Taiwan.  We found that, compared with controls, there was no significant assocn. between any of the cytochrome-P 450 single-nucleotide polymorphisms and occurrence of CBZ-SJS.  However, the alleles B*1502, Cw*0801, A*101 and DRBI*1202 within the HLA region occurred at increased frequency in CBZ-SJS patients relative to the controls.  In particular, HLA-B*1502 was present in 100 % (44/44) of CBZ-SJS patients but in only 3 % (3/101) of CBZ-tolerant patients and in 8.6 % (8/93) of the general population.  Carbamazepine is the drug most commonly assocd. with the syndrome in Asians (accounting for 25-33 % of cases), whereas only 5-6 % of Caucasian CBZ-SJS cases are caused by it.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvVRYJCxSi4LVg90H21EOLACvtfcHk0lhEsJKXUbLfXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gksro%253D&md5=846bf7823089da347fa3c2446479ba64</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2F428486a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F428486a%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DW.%2BH.%26aulast%3DHung%26aufirst%3DS.%2BI.%26aulast%3DHong%26aufirst%3DH.%2BS.%26aulast%3DHsih%26aufirst%3DM.%2BS.%26aulast%3DYang%26aufirst%3DL.%2BC.%26aulast%3DHo%26aufirst%3DH.%2BC.%26aulast%3DWu%26aufirst%3DJ.%2BY.%26aulast%3DChen%26aufirst%3DY.%2BT.%26atitle%3DMedical%2520Genetics%253A%2520A%2520Marker%2520for%2520Stevens-Johnson%2520Syndrome%26jtitle%3DNature%26date%3D2004%26volume%3D428%26spage%3D486%26doi%3D10.1038%2F428486a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ozeki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushiroda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yowang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirakata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikezawa, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iijima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamatani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span></span> <span> </span><span class="NLM_article-title">Genome-Wide Association Study Identifies HLA-A*3101 Allele as a Genetic Risk Factor for Carbamazepine-Induced Cutaneous Adverse Drug Reactions in Japanese Population</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1034</span>– <span class="NLM_lpage">1041</span>, <span class="refDoi"> DOI: 10.1093/hmg/ddq537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Fhmg%2Fddq537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21149285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=1034-1041&author=T.+Ozekiauthor=T.+Mushirodaauthor=A.+Yowangauthor=A.+Takahashiauthor=M.+Kuboauthor=Y.+Shirakataauthor=Z.+Ikezawaauthor=M.+Iijimaauthor=T.+Shioharaauthor=K.+Hashimotoauthor=N.+Kamataniauthor=Y.+Nakamura&title=Genome-Wide+Association+Study+Identifies+HLA-A*3101+Allele+as+a+Genetic+Risk+Factor+for+Carbamazepine-Induced+Cutaneous+Adverse+Drug+Reactions+in+Japanese+Population&doi=10.1093%2Fhmg%2Fddq537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population</span></div><div class="casAuthors">Ozeki, Takeshi; Mushiroda, Taisei; Yowang, Amara; Takahashi, Atsushi; Kubo, Michiaki; Shirakata, Yuji; Ikezawa, Zenro; Iijima, Masafumi; Shiohara, Tetsuo; Hashimoto, Koji; Kamatani, Naoyuki; Nakamura, Yusuke</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1034-1041</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">An anticonvulsant, carbamazepine (CBZ), is known to show incidences of cutaneous adverse drug reactions (cADRs) including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug-induced hypersensitivity syndrome (DIHS).  To identify a gene(s) susceptible to CBZ-induced cADRs, we conducted a genome-wide assocn. study (GWAS) in 53 subjects with the CBZ-induced cADRs, including SJS, TEN and DIHS, and 882 subjects of a general population in Japan.  Among the single nucleotide polymorphisms (SNPs) analyzed in the GWAS, 12 SNPs showed significant assocn. with CBZ-induced cADRs, and rs1633021 showed the smallest P-value for assocn. with CBZ-induced cADRs (P = 1.18 × 10-13).  These SNPs were located within a 430 kb linkage disequil. block on chromosome 6p21.33, including the HLA-A locus.  Thus, we genotyped the individual HLA-A alleles in 61 cases and 376 patients who showed no cADRs by administration of CBZ (CBZ-tolerant controls) and found that HLA-A*3101 was present in 60.7% (37/61) of the patients with CBZ-induced cADRs, but in only 12.5% (47/376) of the CBZ-tolerant controls (odds ratio = 10.8, 95% confidence interval 5.9-19.6, P = 3.64 × 10-15), implying that this allele has the 60.7% sensitivity and 87.5% specificity when we apply HLA-A*3101 as a risk predictor for CBZ-induced cADRs.  Although DIHS is clin. distinguished from SJS and TEN, our data presented here have indicated that they share a common genetic factor as well as a common pathophysiol. mechanism.  Our findings should provide useful information for making a decision of individualized medication of anticonvulsants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_q8MQFTFQ8rVg90H21EOLACvtfcHk0lhEsJKXUbLfXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylsL8%253D&md5=b40ce17f94927af4ca1732fe8f482afc</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddq537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddq537%26sid%3Dliteratum%253Aachs%26aulast%3DOzeki%26aufirst%3DT.%26aulast%3DMushiroda%26aufirst%3DT.%26aulast%3DYowang%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DA.%26aulast%3DKubo%26aufirst%3DM.%26aulast%3DShirakata%26aufirst%3DY.%26aulast%3DIkezawa%26aufirst%3DZ.%26aulast%3DIijima%26aufirst%3DM.%26aulast%3DShiohara%26aufirst%3DT.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DKamatani%26aufirst%3DN.%26aulast%3DNakamura%26aufirst%3DY.%26atitle%3DGenome-Wide%2520Association%2520Study%2520Identifies%2520HLA-A%252A3101%2520Allele%2520as%2520a%2520Genetic%2520Risk%2520Factor%2520for%2520Carbamazepine-Induced%2520Cutaneous%2520Adverse%2520Drug%2520Reactions%2520in%2520Japanese%2520Population%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2011%26volume%3D20%26spage%3D1034%26epage%3D1041%26doi%3D10.1093%2Fhmg%2Fddq537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfirevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourgeois, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasperaviciute, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sills, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bakker, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinthapalli, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molokhia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaila, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhusaini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shianna, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radtke, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinzen, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walley, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandolfo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depondt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sisodiya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deloukas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delanty, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalleri, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span> <span> </span><span class="NLM_article-title">HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">1134</span>– <span class="NLM_lpage">1143</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1013297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1056%2FNEJMoa1013297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21428769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVyhurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=1134-1143&author=M.+McCormackauthor=A.+Alfirevicauthor=S.+Bourgeoisauthor=J.+J.+Farrellauthor=D.+Kasperaviciuteauthor=M.+Carringtonauthor=G.+J.+Sillsauthor=T.+Marsonauthor=X.+Jiaauthor=P.+I.+de+Bakkerauthor=K.+Chinthapalliauthor=M.+Molokhiaauthor=M.+R.+Johnsonauthor=G.+D.+O%E2%80%99Connorauthor=E.+Chailaauthor=S.+Alhusainiauthor=K.+V.+Shiannaauthor=R.+A.+Radtkeauthor=E.+L.+Heinzenauthor=N.+Walleyauthor=M.+Pandolfoauthor=W.+Pichlerauthor=B.+K.+Parkauthor=C.+Depondtauthor=S.+M.+Sisodiyaauthor=D.+B.+Goldsteinauthor=P.+Deloukasauthor=N.+Delantyauthor=G.+L.+Cavalleriauthor=M.+Pirmohamed&title=HLA-A*3101+and+Carbamazepine-Induced+Hypersensitivity+Reactions+in+Europeans&doi=10.1056%2FNEJMoa1013297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans</span></div><div class="casAuthors">McCormack, Mark; Alfirevic, Ana; Bourgeois, Stephane; Farrell, John J.; Kasperaviciute, Dalia; Carrington, Mary; Sills, Graeme J.; Marson, Tony; Jia, Xiaoming; de Bakker, Paul I. W.; Chinthapalli, Krishna; Molokhia, Mariam; Johnson, Michael R.; O'Connor, Gerard D.; Chaila, Elijah; Alhusaini, Saud; Shianna, Kevin V.; Radtke, Rodney A.; Heinzen, Erin L.; Pandolfo, Massimo; Pichler, Werner; Park, Kevin; Depondt, Chantal; Sisodiya, Sanjay M.; Goldstein, David B.; Deloukas, Panos; Delanty, Norman; Cavalleri, Gianpiero L.; Pirmohamed, Munir</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1134-1143</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Carbamazepine causes various forms of hypersensitivity reactions, ranging from maculopapular exanthema to severe blistering reactions.  The HLA-B*1502 allele was shown to be strongly correlated with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) in the Han Chinese and other Asian populations but not in European populations.  The authors performed a genome wide assocn. study of samples obtained from 22 subjects with carbamazepine-induced hypersensitivity syndrome, 43 subjects with carbamazepine-induced maculopapular exanthema, and 3987 control subjects, all of European descent.  The authors tested for an assocn. between disease and HLA alleles through proxy single-nucleotide polymorphisms and imputation, confirming assocns. by high-resoln. sequence-based HLA typing.  The authors replicated the assocns. in samples from 145 subjects with carbamazepine-induced hypersensitivity reactions.  The HLA-A*3101 allele, which has a prevalence of 2 to 5% in Northern European populations, was significantly assocd. with the hypersensitivity syndrome. An independent genome wide assocn. study of samples from subjects with maculopapular exanthema also showed an assocn. with the HLA-A*3101 allele.  Follow-up genotyping confirmed the variant as a risk factor for the hypersensitivity syndrome (odds ratio, 12.41; 95% confidence interval [CI], 1.27 to 121.03), maculopapular exanthema (odds ratio, 8.33; 95% CI, 3.59 to 19.36), and SJS-TEN (odds ratio, 25.93; 95% CI, 4.93 to 116.18).  The presence of the HLA-A*3101 allele was assocd. with carbamazepine-induced hypersensitivity reactions among subjects of Northern European ancestry.  The presence of the allele increased the risk from 5.0% to 26.0%, whereas its absence reduced the risk from 5.0% to 3.8%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGvFkpTSvSKbVg90H21EOLACvtfcHk0lhEsJKXUbLfXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVyhurs%253D&md5=740cf875c2de09f30c95303ce9a5dc43</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1013297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1013297%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormack%26aufirst%3DM.%26aulast%3DAlfirevic%26aufirst%3DA.%26aulast%3DBourgeois%26aufirst%3DS.%26aulast%3DFarrell%26aufirst%3DJ.%2BJ.%26aulast%3DKasperaviciute%26aufirst%3DD.%26aulast%3DCarrington%26aufirst%3DM.%26aulast%3DSills%26aufirst%3DG.%2BJ.%26aulast%3DMarson%26aufirst%3DT.%26aulast%3DJia%26aufirst%3DX.%26aulast%3Dde%2BBakker%26aufirst%3DP.%2BI.%26aulast%3DChinthapalli%26aufirst%3DK.%26aulast%3DMolokhia%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DM.%2BR.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DG.%2BD.%26aulast%3DChaila%26aufirst%3DE.%26aulast%3DAlhusaini%26aufirst%3DS.%26aulast%3DShianna%26aufirst%3DK.%2BV.%26aulast%3DRadtke%26aufirst%3DR.%2BA.%26aulast%3DHeinzen%26aufirst%3DE.%2BL.%26aulast%3DWalley%26aufirst%3DN.%26aulast%3DPandolfo%26aufirst%3DM.%26aulast%3DPichler%26aufirst%3DW.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DDepondt%26aufirst%3DC.%26aulast%3DSisodiya%26aufirst%3DS.%2BM.%26aulast%3DGoldstein%26aufirst%3DD.%2BB.%26aulast%3DDeloukas%26aufirst%3DP.%26aulast%3DDelanty%26aufirst%3DN.%26aulast%3DCavalleri%26aufirst%3DG.%2BL.%26aulast%3DPirmohamed%26aufirst%3DM.%26atitle%3DHLA-A%252A3101%2520and%2520Carbamazepine-Induced%2520Hypersensitivity%2520Reactions%2520in%2520Europeans%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D1134%26epage%3D1143%26doi%3D10.1056%2FNEJMoa1013297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicoletti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEvoy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucena, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadelius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kainu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molokhia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shear, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sills, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanno, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floratos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfirevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span> <span> </span><span class="NLM_article-title">Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">1028</span>– <span class="NLM_lpage">1036</span>, <span class="refDoi"> DOI: 10.1002/cpt.1493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fcpt.1493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=31066027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSjurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2019&pages=1028-1036&author=P.+Nicolettiauthor=S.+Barrettauthor=L.+McEvoyauthor=A.+K.+Dalyauthor=G.+Aithalauthor=M.+I.+Lucenaauthor=R.+J.+Andradeauthor=M.+Wadeliusauthor=P.+Hallbergauthor=C.+Stephensauthor=E.+S.+Bjornssonauthor=P.+Friedmannauthor=K.+Kainuauthor=T.+Laitinenauthor=A.+Marsonauthor=M.+Molokhiaauthor=E.+Phillipsauthor=W.+Pichlerauthor=A.+Romanoauthor=N.+Shearauthor=G.+Sillsauthor=L.+K.+Tannoauthor=A.+Swaleauthor=A.+Floratosauthor=Y.+Shenauthor=M.+R.+Nelsonauthor=P.+B.+Watkinsauthor=M.+J.+Dalyauthor=A.+P.+Morrisauthor=A.+Alfirevicauthor=M.+Pirmohamed&title=Shared+Genetic+Risk+Factors+Across+Carbamazepine-Induced+Hypersensitivity+Reactions&doi=10.1002%2Fcpt.1493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions</span></div><div class="casAuthors">Nicoletti, Paola; Barrett, Sarah; McEvoy, Laurence; Daly, Ann K.; Aithal, Guruprasad; Lucena, M. Isabel; Andrade, Raul J.; Wadelius, Mia; Hallberg, Paer; Stephens, Camilla; Bjornsson, Einar S.; Friedmann, Peter; Kainu, Kati; Laitinen, Tarja; Marson, Anthony; Molokhia, Mariam; Phillips, Elizabeth; Pichler, Werner; Romano, Antonino; Shear, Neil; Sills, Graeme; Tanno, Luciana K.; Swale, Ashley; Floratos, Aris; Shen, Yufeng; Nelson, Matthew R.; Watkins, Paul B.; Daly, Mark J.; Morris, Andrew P.; Alfirevic, Ana; Pirmohamed, Munir</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1028-1036</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Meta-anal. of shared genetic risk factors across carbamazepine-induced hypersensitivity reactions in European populations.  Carbamazepine (CBZ) causes life-threating T-cell-mediated hypersensitivity reactions, including serious cutaneous adverse reactions (SCARs) and drug-induced liver injury (CBZ-DILI).  In order to evaluate shared or phenotype-specific genetic predisposing factors for CBZ hypersensitivity reactions, we performed a meta-anal. of two genomewide assocn. studies (GWAS) on a total of 43 well-phenotyped Northern and Southern European CBZ-SCAR cases and 10,701 population controls and a GWAS on 12 CBZ-DILI cases and 8,438 ethnically matched population controls.  HLA-A*31:01 was identified as the strongest genetic predisposing factor for both CBZ-SCAR (odds ratio (OR) = 8.0; 95% CI 4.10-15.80; P = 1.2 × 10-9) and CBZ-DILI (OR = 7.3; 95% CI 2.47-23.67; P = 0.0004) in European populations.  The assocn. with HLA-A*31:01 in patients with SCAR was mainly driven by hypersensitivity syndrome (OR = 12.9; P = 2.1 × 10-9) rather than by Stevens-Johnson syndrome/toxic epidermal necrolysis cases, which showed an assocn. with HLA-B*57:01.  We also identified a novel risk locus mapping to ALK only for CBZ-SCAR cases, which needs replication in addnl. cohorts and functional evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroGgeHufcsLbVg90H21EOLACvtfcHk0licliVh3qpvOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSjurvL&md5=e0115f78175ec7ba7c5bb413526cc309</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1002%2Fcpt.1493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.1493%26sid%3Dliteratum%253Aachs%26aulast%3DNicoletti%26aufirst%3DP.%26aulast%3DBarrett%26aufirst%3DS.%26aulast%3DMcEvoy%26aufirst%3DL.%26aulast%3DDaly%26aufirst%3DA.%2BK.%26aulast%3DAithal%26aufirst%3DG.%26aulast%3DLucena%26aufirst%3DM.%2BI.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3DWadelius%26aufirst%3DM.%26aulast%3DHallberg%26aufirst%3DP.%26aulast%3DStephens%26aufirst%3DC.%26aulast%3DBjornsson%26aufirst%3DE.%2BS.%26aulast%3DFriedmann%26aufirst%3DP.%26aulast%3DKainu%26aufirst%3DK.%26aulast%3DLaitinen%26aufirst%3DT.%26aulast%3DMarson%26aufirst%3DA.%26aulast%3DMolokhia%26aufirst%3DM.%26aulast%3DPhillips%26aufirst%3DE.%26aulast%3DPichler%26aufirst%3DW.%26aulast%3DRomano%26aufirst%3DA.%26aulast%3DShear%26aufirst%3DN.%26aulast%3DSills%26aufirst%3DG.%26aulast%3DTanno%26aufirst%3DL.%2BK.%26aulast%3DSwale%26aufirst%3DA.%26aulast%3DFloratos%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DNelson%26aufirst%3DM.%2BR.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DDaly%26aufirst%3DM.%2BJ.%26aulast%3DMorris%26aufirst%3DA.%2BP.%26aulast%3DAlfirevic%26aufirst%3DA.%26aulast%3DPirmohamed%26aufirst%3DM.%26atitle%3DShared%2520Genetic%2520Risk%2520Factors%2520Across%2520Carbamazepine-Induced%2520Hypersensitivity%2520Reactions%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2019%26volume%3D106%26spage%3D1028%26epage%3D1036%26doi%3D10.1002%2Fcpt.1493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mallal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamotte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, F. T.</span></span> <span> </span><span class="NLM_article-title">Association Between Presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and Hypersensitivity to HIV-1 Reverse-Transcriptase Inhibitor Abacavir</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(02)07873-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2FS0140-6736%2802%2907873-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=11888582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvVWhsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2002&pages=727-732&author=S.+Mallalauthor=D.+Nolanauthor=C.+Wittauthor=G.+Maselauthor=A.+M.+Martinauthor=C.+Mooreauthor=D.+Sayerauthor=A.+Castleyauthor=C.+Mamotteauthor=D.+Maxwellauthor=I.+Jamesauthor=F.+T.+Christiansen&title=Association+Between+Presence+of+HLA-B*5701%2C+HLA-DR7%2C+and+HLA-DQ3+and+Hypersensitivity+to+HIV-1+Reverse-Transcriptase+Inhibitor+Abacavir&doi=10.1016%2FS0140-6736%2802%2907873-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir</span></div><div class="casAuthors">Mallal, S.; Nolan, D.; Witt, C.; Masel, G.; Martin, A. M.; Moore, C.; Sayer, D.; Castley, A.; Mamotte, C.; Maxwell, D.; James, I.; Christiansen, F. T.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">9308</span>),
    <span class="NLM_cas:pages">727-732</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Lancet Publishing Group</span>)
        </div><div class="casAbstract">The use of abacavir, a potent HIV-1 nucleoside-analog reverse-transcriptase inhibitor, is complicated by a potentially life-threatening hypersensitivity syndrome in about 5% of cases.  Genetic factors influencing the immune response to abacavir might confer susceptibility.  We aimed to find assocns. between MHC alleles and abacavir hypersensitivity in HIV-1-pos. individuals treated with abacavir.  MHC region typing was done in the first 200 Western Australian HIV Cohort Study participants exposed to abacavir.  Definite abacavir hypersensitivity was identified in 18 cases, and was excluded in 167 individuals with more than 6 wk exposure to the drug (abacavir tolerant).  Fifteen individuals experienced some symptoms but did not meet criteria for abacavir hypersensitivity.  The p values were cor. for comparisons of multiple HLA alleles (pc) by multiplication of the raw p value by the estd. no. of HLA alleles present within the loci examd.  HLA-B*5701 was present in 14 (78%) of the 18 patients with abacavir hypersensitivity, and in four (2%) of the 167 abacavir tolerant patients (odds ratio 117 [95% CI 29-481], pc<0.0001), and the HLA-DR7 and HLA-DQ3 combination was found in 13 (72%) of hypersensitive and five (3%) of tolerant patients (73 [20-268], pc<0.0001).  HLA-B*5701, HLA-DR7, and HLA-DQ3 were present in combination in 13 (72%) hypersensitive patients and none of the tolerant patients (822 [43-15 675], pc<0.0001).  Other MHC markers also present on the 57.1 ancestral haplotype to which the three markers above belong confirmed the presence of haplotype-specific linkage disequil., and mapped potential susceptibility loci to a region bounded by C4A6 and HLA-C.  Within the entire abacavir-exposed cohort (n=200), presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 had a pos. predictive value for hypersensitivity of 100%, and a neg. predictive value of 97%.  Thus, genetic susceptibility to abacavir hypersensitivity is carried on the 57.1 ancestral haplotype.  In our population, withholding abacavir in those with HLA-B*5701, HLA-DR7, and HLA-DQ3 should reduce the prevalence of hypersensitivity from 9% to 2.5% without inappropriately denying abacavir to any patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9p8i0yTY3kLVg90H21EOLACvtfcHk0lgwNfg5I0gbGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvVWhsbY%253D&md5=783b93a506a0a930e493e96239de125b</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2802%2907873-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252802%252907873-X%26sid%3Dliteratum%253Aachs%26aulast%3DMallal%26aufirst%3DS.%26aulast%3DNolan%26aufirst%3DD.%26aulast%3DWitt%26aufirst%3DC.%26aulast%3DMasel%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DMoore%26aufirst%3DC.%26aulast%3DSayer%26aufirst%3DD.%26aulast%3DCastley%26aufirst%3DA.%26aulast%3DMamotte%26aufirst%3DC.%26aulast%3DMaxwell%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DI.%26aulast%3DChristiansen%26aufirst%3DF.%2BT.%26atitle%3DAssociation%2520Between%2520Presence%2520of%2520HLA-B%252A5701%252C%2520HLA-DR7%252C%2520and%2520HLA-DQ3%2520and%2520Hypersensitivity%2520to%2520HIV-1%2520Reverse-Transcriptase%2520Inhibitor%2520Abacavir%26jtitle%3DLancet%26date%3D2002%26volume%3D359%26spage%3D727%26epage%3D732%26doi%3D10.1016%2FS0140-6736%2802%2907873-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hetherington, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosteller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shortino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spreen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dow, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fling, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurmond, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roses, A. D.</span></span> <span> </span><span class="NLM_article-title">Genetic Variations in HLA-B Region and Hypersensitivity Reactions to Abacavir</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">1121</span>– <span class="NLM_lpage">1122</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(02)08158-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2FS0140-6736%2802%2908158-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=11943262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1ehsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2002&pages=1121-1122&author=S.+Hetheringtonauthor=A.+R.+Hughesauthor=M.+Mostellerauthor=D.+Shortinoauthor=K.+L.+Bakerauthor=W.+Spreenauthor=E.+Laiauthor=K.+Daviesauthor=A.+Handleyauthor=D.+J.+Dowauthor=M.+E.+Flingauthor=M.+Stocumauthor=C.+Bowmanauthor=L.+M.+Thurmondauthor=A.+D.+Roses&title=Genetic+Variations+in+HLA-B+Region+and+Hypersensitivity+Reactions+to+Abacavir&doi=10.1016%2FS0140-6736%2802%2908158-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic variations in HLA-B region and hypersensitivity reactions to abacavir</span></div><div class="casAuthors">Hetherington, Seth; Hughes, Arlene R.; Mosteller, Michael; Shortino, Denise; Baker, Katherine L.; Spreen, William; Lai, Eric; Davies, Kirstie; Handley, Abigail; Dow, David J.; Fling, Mary E.; Stocum, Michael; Bowman, Clive; Thurmond, Linda M.; Roses, Allen D.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">9312</span>),
    <span class="NLM_cas:pages">1121-1122</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Lancet Publishing Group</span>)
        </div><div class="casAbstract">Hypersensitivity to abacavir affects about 4% of patients who receive the drug for HIV-1 infection.  The authors did a retrospective, case-control study to identify multiple markers in the vicinity of HLA-B assocd. with hypersensitivity reactions.  HLA-B57 was present in 39 (46%) of 84 patients vs. 4 (4%) of 113 controls.  However, because of low nos. of women and other ethnic groups enrolled, these findings relate largely to white men.  The lower sensitivity of HLA-B57 for predicting hypersensitivity to abacavir identified in this study compared with a previous report highlights that predictive values for markers will vary across populations.  Clin. monitoring and management of hypersensitivity reactions among patients receiving abacavir must remain unchanged.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSCmus_J04RbVg90H21EOLACvtfcHk0lgwNfg5I0gbGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1ehsLw%253D&md5=5550e472c7dc48fcaa2e2e040113c593</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2802%2908158-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252802%252908158-8%26sid%3Dliteratum%253Aachs%26aulast%3DHetherington%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DA.%2BR.%26aulast%3DMosteller%26aufirst%3DM.%26aulast%3DShortino%26aufirst%3DD.%26aulast%3DBaker%26aufirst%3DK.%2BL.%26aulast%3DSpreen%26aufirst%3DW.%26aulast%3DLai%26aufirst%3DE.%26aulast%3DDavies%26aufirst%3DK.%26aulast%3DHandley%26aufirst%3DA.%26aulast%3DDow%26aufirst%3DD.%2BJ.%26aulast%3DFling%26aufirst%3DM.%2BE.%26aulast%3DStocum%26aufirst%3DM.%26aulast%3DBowman%26aufirst%3DC.%26aulast%3DThurmond%26aufirst%3DL.%2BM.%26aulast%3DRoses%26aufirst%3DA.%2BD.%26atitle%3DGenetic%2520Variations%2520in%2520HLA-B%2520Region%2520and%2520Hypersensitivity%2520Reactions%2520to%2520Abacavir%26jtitle%3DLancet%26date%3D2002%26volume%3D359%26spage%3D1121%26epage%3D1122%26doi%3D10.1016%2FS0140-6736%2802%2908158-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilar, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfirevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span> <span> </span><span class="NLM_article-title">Cost-Effectiveness Analysis of HLA B*5701 Genotyping in Preventing Abacavir Hypersensitivity</span>. <i>Pharmacogenetics</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.1097/00008571-200406000-00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1097%2F00008571-200406000-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=15247625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD2czlsVCltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=335-342&author=D.+A.+Hughesauthor=F.+J.+Vilarauthor=C.+C.+Wardauthor=A.+Alfirevicauthor=B.+K.+Parkauthor=M.+Pirmohamed&title=Cost-Effectiveness+Analysis+of+HLA+B*5701+Genotyping+in+Preventing+Abacavir+Hypersensitivity&doi=10.1097%2F00008571-200406000-00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity</span></div><div class="casAuthors">Hughes Dyfrig A; Vilar F Javier; Ward Charlotte C; Alfirevic Ana; Park B Kevin; Pirmohamed Munir</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">335-42</span>
        ISSN:<span class="NLM_cas:issn">0960-314X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Abacavir, a human immunodeficiency virus-1 (HIV-1) nucleoside-analogue reverse transcriptase inhibitor, causes severe hypersensitivity in 4-8% of patients.  HLA B*5701 is a known genetic risk factor for abacavir hypersensitivity in Caucasians.  Our aim was to confirm the presence of this genetic factor in our patients, and to determine whether genotyping for HLA B*5701 would be a cost-effective use of healthcare resources.  METHODS:  Patients with and without abacavir hypersensitivity were identified from a UK HIV clinic.  Patients were genotyped for HLA B*5701, and pooled data used for calculation of test characteristics.  The cost-effectiveness analysis incorporated the cost of testing, cost of treating abacavir hypersensitivity, and the cost and selection of alternative antiretroviral regimens.  A probabilistic decision analytic model (comparing testing versus no testing) was formulated and Monte Carlo simulations performed.  RESULTS:  Of the abacavir hypersensitive patients, six (46%) were HLA B*5701 positive, compared to five (10%) of the non-hypersensitive patients (odds ratio 7.9 [95% confidence intervals 1.5-41.4], P = 0.006).  Pooling of our data on HLA B*5701 with published data resulted in a pooled odds ratio of 29 (95% CI 6.4-132.3; P < 0.0001).  The cost-effectiveness model demonstrated that depending on the choice of comparator, routine testing for HLA B*5701 ranged from being a dominant strategy (less expensive and more beneficial than not testing) to an incremental cost-effectiveness ratio (versus no testing) of Euro 22,811 per hypersensitivity reaction avoided.  CONCLUSIONS:  Abacavir hypersensitivity is associated with HLA B*5701, and pre-prescription pharmacogenetic testing for this appears to be a cost-effective use of healthcare resources.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZ8wMZhrtbR4kFb3mqPUYDfW6udTcc2eYHSv3ulXxmubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czlsVCltQ%253D%253D&md5=302d6f4264d5d393f34d016d37508a65</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1097%2F00008571-200406000-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00008571-200406000-00002%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%2BA.%26aulast%3DVilar%26aufirst%3DF.%2BJ.%26aulast%3DWard%26aufirst%3DC.%2BC.%26aulast%3DAlfirevic%26aufirst%3DA.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DPirmohamed%26aufirst%3DM.%26atitle%3DCost-Effectiveness%2520Analysis%2520of%2520HLA%2520B%252A5701%2520Genotyping%2520in%2520Preventing%2520Abacavir%2520Hypersensitivity%26jtitle%3DPharmacogenetics%26date%3D2004%26volume%3D14%26spage%3D335%26epage%3D342%26doi%3D10.1097%2F00008571-200406000-00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mallal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carosi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomažič, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jägel-Guedes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugina, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozyrev, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cid, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitch, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorborn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benbow, A.</span></span> <span> </span><span class="NLM_article-title">HLA-B*5701 Screening for Hypersensitivity to Abacavir</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">568</span>– <span class="NLM_lpage">579</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0706135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1056%2FNEJMoa0706135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=18256392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FpvF2rsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2008&pages=568-579&author=S.+Mallalauthor=E.+Phillipsauthor=G.+Carosiauthor=J.-M.+Molinaauthor=C.+Workmanauthor=J.+Toma%C5%BEi%C4%8Dauthor=E.+J%C3%A4gel-Guedesauthor=S.+Ruginaauthor=O.+Kozyrevauthor=J.+F.+Cidauthor=P.+Hayauthor=D.+Nolanauthor=S.+Hughesauthor=A.+Hughesauthor=S.+Ryanauthor=N.+Fitchauthor=D.+Thorbornauthor=A.+Benbow&title=HLA-B*5701+Screening+for+Hypersensitivity+to+Abacavir&doi=10.1056%2FNEJMoa0706135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">HLA-B*5701 screening for hypersensitivity to abacavir</span></div><div class="casAuthors">Mallal Simon; Phillips Elizabeth; Carosi Giampiero; Molina Jean-Michel; Workman Cassy; Tomazic Janez; Jagel-Guedes Eva; Rugina Sorin; Kozyrev Oleg; Cid Juan Flores; Hay Phillip; Nolan David; Hughes Sara; Hughes Arlene; Ryan Susanna; Fitch Nicholas; Thorborn Daren; Benbow Alastair</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">568-79</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Hypersensitivity reaction to abacavir is strongly associated with the presence of the HLA-B*5701 allele.  This study was designed to establish the effectiveness of prospective HLA-B*5701 screening to prevent the hypersensitivity reaction to abacavir.  METHODS:  This double-blind, prospective, randomized study involved 1956 patients from 19 countries, who were infected with human immunodeficiency virus type 1 and who had not previously received abacavir.  We randomly assigned patients to undergo prospective HLA-B*5701 screening, with exclusion of HLA-B*5701-positive patients from abacavir treatment (prospective-screening group), or to undergo a standard-of-care approach of abacavir use without prospective HLA-B*5701 screening (control group).  All patients who started abacavir were observed for 6 weeks.  To immunologically confirm, and enhance the specificity of, the clinical diagnosis of hypersensitivity reaction to abacavir, we performed epicutaneous patch testing with the use of abacavir.  RESULTS:  The prevalence of HLA-B*5701 was 5.6% (109 of 1956 patients).  Of the patients receiving abacavir, 72% were men, 84% were white, and 18% had not previously received antiretroviral therapy.  Screening eliminated immunologically confirmed hypersensitivity reaction (0% in the prospective-screening group vs. 2.7% in the control group, P<0.001), with a negative predictive value of 100% and a positive predictive value of 47.9%.  Hypersensitivity reaction was clinically diagnosed in 93 patients, with a significantly lower incidence in the prospective-screening group (3.4%) than in the control group (7.8%) (P<0.001).  CONCLUSIONS:  HLA-B*5701 screening reduced the risk of hypersensitivity reaction to abacavir.  In predominantly white populations, similar to the one in this study, 94% of patients do not carry the HLA-B*5701 allele and are at low risk for hypersensitivity reaction to abacavir.  Our results show that a pharmacogenetic test can be used to prevent a specific toxic effect of a drug. (ClinicalTrials.gov number, NCT00340080.)</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeqda-fRQMhoJKJbLTgsvCfW6udTcc2eYHSv3ulXxmubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FpvF2rsw%253D%253D&md5=0427497c47a4c695dc083092f4f5f9d5</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0706135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0706135%26sid%3Dliteratum%253Aachs%26aulast%3DMallal%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DE.%26aulast%3DCarosi%26aufirst%3DG.%26aulast%3DMolina%26aufirst%3DJ.-M.%26aulast%3DWorkman%26aufirst%3DC.%26aulast%3DToma%25C5%25BEi%25C4%258D%26aufirst%3DJ.%26aulast%3DJ%25C3%25A4gel-Guedes%26aufirst%3DE.%26aulast%3DRugina%26aufirst%3DS.%26aulast%3DKozyrev%26aufirst%3DO.%26aulast%3DCid%26aufirst%3DJ.%2BF.%26aulast%3DHay%26aufirst%3DP.%26aulast%3DNolan%26aufirst%3DD.%26aulast%3DHughes%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DS.%26aulast%3DFitch%26aufirst%3DN.%26aulast%3DThorborn%26aufirst%3DD.%26aulast%3DBenbow%26aufirst%3DA.%26atitle%3DHLA-B%252A5701%2520Screening%2520for%2520Hypersensitivity%2520to%2520Abacavir%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D358%26spage%3D568%26epage%3D579%26doi%3D10.1056%2FNEJMoa0706135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wuillemin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krähenbühl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yerly, D.</span></span> <span> </span><span class="NLM_article-title">HLA Haplotype Determines Hapten or p-i T Cell Reactivity to Flucloxacillin</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">4956</span>– <span class="NLM_lpage">4964</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1202949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.4049%2Fjimmunol.1202949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23596311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFyqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2013&pages=4956-4964&author=N.+Wuilleminauthor=J.+Adamauthor=S.+Fontanaauthor=S.+Kr%C3%A4henb%C3%BChlauthor=W.+J.+Pichlerauthor=D.+Yerly&title=HLA+Haplotype+Determines+Hapten+or+p-i+T+Cell+Reactivity+to+Flucloxacillin&doi=10.4049%2Fjimmunol.1202949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">HLA Haplotype Determines Hapten or p-i T Cell Reactivity to Flucloxacillin</span></div><div class="casAuthors">Wuillemin, Natascha; Adam, Jacqueline; Fontana, Stefano; Kraehenbuehl, Stephan; Pichler, Werner J.; Yerly, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4956-4964</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a main cause of drug withdrawal.  A particularly interesting example is flucloxacillin (FLUX)-DILI, which is assocd. with the HLA-B*57:01 allele.  At present, the mechanism of FLUX-DILI is not understood, but the HLA assocn. suggests a role for activated T cells in the pathomechanism of liver damage.  To understand the interaction among FLUX, HLA mols., and T cells, we generated FLUX-reacting T cells from FLUX-naive HLA-B*57:01+ and HLA-B*57:01- healthy donors and investigated the mechanism of T cell stimulation.  We found that FLUX stimulates CD8+ T cells in two distinct manners.  On one hand, FLUX was stably presented on various HLA mols., resistant to extensive washing and dependent on proteasomal processing, suggesting a hapten mechanism.  On the other hand, in HLA-B*57:01+ individuals, we obsd. a pharmacol. interaction with immune receptors (p-i)-based T cell reactivity.  FLUX was presented in a labile manner that was further characterized by independence of proteasomal processing and immediate T cell clone activation upon stimulation with FLUX in soln.  This p-i-based T cell stimulation was restricted to the HLA-B*57:01 allele.  We conclude that the presence of HLA-B*57:01 drives CD8+ T cell responses to the penicillin-deriv. FLUX toward nonhapten mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDSgHu8CXs2rVg90H21EOLACvtfcHk0lgvg4sSzW1pXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFyqu70%253D&md5=8e90dd3b91a1adadee1eca2975863406</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1202949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1202949%26sid%3Dliteratum%253Aachs%26aulast%3DWuillemin%26aufirst%3DN.%26aulast%3DAdam%26aufirst%3DJ.%26aulast%3DFontana%26aufirst%3DS.%26aulast%3DKr%25C3%25A4henb%25C3%25BChl%26aufirst%3DS.%26aulast%3DPichler%26aufirst%3DW.%2BJ.%26aulast%3DYerly%26aufirst%3DD.%26atitle%3DHLA%2520Haplotype%2520Determines%2520Hapten%2520or%2520p-i%2520T%2520Cell%2520Reactivity%2520to%2520Flucloxacillin%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D190%26spage%3D4956%26epage%3D4964%26doi%3D10.4049%2Fjimmunol.1202949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yaseen, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saide, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monshi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tailor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulkner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Promiscuous T-cell Responses to Drugs and Drug-Haptens</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">474</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2015.02.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jaci.2015.02.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25910715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntVCitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2015&pages=474-476&author=F.+S.+Yaseenauthor=K.+Saideauthor=S.-H.+Kimauthor=M.+Monshiauthor=A.+Tailorauthor=S.+Woodauthor=X.+Mengauthor=R.+Jenkinsauthor=L.+Faulknerauthor=A.+K.+Dalyauthor=M.+Pirmohamedauthor=B.+K.+Parkauthor=D.+J.+Naisbitt&title=Promiscuous+T-cell+Responses+to+Drugs+and+Drug-Haptens&doi=10.1016%2Fj.jaci.2015.02.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Promiscuous T-cell responses to drugs and drug-haptens</span></div><div class="casAuthors">Yaseen, Fiazia S.; Saide, Katy; Kim, Seung-Hyun; Monshi, Manal; Tailor, Arun; Wood, Sally; Meng, Xiaoli; Jenkins, Rosalind; Faulkner, Lee; Daly, Ann K.; Pirmohamed, Munir; Park, B. Kevin; Naisbitt, Dean J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">474-476.e8</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">This paper describes on promiscuous T-cell responses to drugs and drug-haptens.  β-Lactam-induced liver injury has shown T cells are activated through hapten.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKpwe8BAJ7_bVg90H21EOLACvtfcHk0ljBfp04MgufzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntVCitbs%253D&md5=dc9494342fb70bd8c37d6d5baef40eb9</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2015.02.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2015.02.036%26sid%3Dliteratum%253Aachs%26aulast%3DYaseen%26aufirst%3DF.%2BS.%26aulast%3DSaide%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DMonshi%26aufirst%3DM.%26aulast%3DTailor%26aufirst%3DA.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DJenkins%26aufirst%3DR.%26aulast%3DFaulkner%26aufirst%3DL.%26aulast%3DDaly%26aufirst%3DA.%2BK.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DPromiscuous%2520T-cell%2520Responses%2520to%2520Drugs%2520and%2520Drug-Haptens%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2015%26volume%3D136%26spage%3D474%26epage%3D476%26doi%3D10.1016%2Fj.jaci.2015.02.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R. C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsih, M.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, P.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choon, S.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaniwa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azukizawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, S.-I.</span></span> <span> </span><span class="NLM_article-title">Genetic Variants Associated with Phenytoin-Related Severe Cutaneous Adverse Reactions</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>312</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">534</span>, <span class="refDoi"> DOI: 10.1001/jama.2014.7859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1001%2Fjama.2014.7859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25096692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC2cbptlSjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2014&pages=525-534&author=W.-H.+Chungauthor=W.-C.+Changauthor=Y.-S.+Leeauthor=Y.-Y.+Wuauthor=C.-H.+Yangauthor=H.-C.+Hoauthor=M.-J.+Chenauthor=J.-Y.+Linauthor=R.+C.-Y.+Huiauthor=J.-C.+Hoauthor=W.-M.+Wuauthor=T.-J.+Chenauthor=T.+Wuauthor=Y.-R.+Wuauthor=M.-S.+Hsihauthor=P.-H.+Tuauthor=C.-N.+Changauthor=C.-N.+Hsuauthor=T.-L.+Wuauthor=S.-E.+Choonauthor=C.-K.+Hsuauthor=D.-Y.+Chenauthor=C.-S.+Liuauthor=C.-Y.+Linauthor=N.+Kaniwaauthor=Y.+Saitoauthor=Y.+Takahashiauthor=R.+Nakamuraauthor=H.+Azukizawaauthor=Y.+Shiauthor=T.-H.+Wangauthor=S.-S.+Chuangauthor=S.-F.+Tsaiauthor=C.-J.+Changauthor=Y.-S.+Changauthor=S.-I.+Hung&title=Genetic+Variants+Associated+with+Phenytoin-Related+Severe+Cutaneous+Adverse+Reactions&doi=10.1001%2Fjama.2014.7859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic variants associated with phenytoin-related severe cutaneous adverse reactions</span></div><div class="casAuthors">Chung Wen-Hung; Chang Wan-Chun; Wu Ying-Ying; Hung Shuen-Iu; Lee Yun-Shien; Yang Chih-Hsun; Chen Ming-Jing; Hui Rosaline Chung-Yee; Ho Hsin-Chun; Lin Jing-Yi; Ho Ji-Chen; Wu Wei-Ming; Chen Ting-Jui; Wu Tony; Wu Yih-Ru; Hsih Mo-Song; Tu Po-Hsun; Chang Chen-Nen; Hsu Chien-Ning; Wu Tsu-Lan; Choon Siew-Eng; Hsu Chao-Kai; Chen Der-Yuan; Liu Chin-San; Lin Ching-Yuang; Kaniwa Nahoko; Saito Yoshiro; Nakamura Ryosuke; Takahashi Yukitoshi; Azukizawa Hiroaki; Shi Yongyong; Wang Tzu-Hao; Chuang Shiow-Shuh; Tsai Shih-Feng; Chang Chee-Jen; Chang Yu-Sun</div><div class="citationInfo"><span class="NLM_cas:title">JAMA</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">525-34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">IMPORTANCE:  The antiepileptic drug phenytoin can cause cutaneous adverse reactions, ranging from maculopapular exanthema to severe cutaneous adverse reactions, which include drug reactions with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis.  The pharmacogenomic basis of phenytoin-related severe cutaneous adverse reactions remains unknown.  OBJECTIVE:  To investigate the genetic factors associated with phenytoin-related severe cutaneous adverse reactions.  DESIGN, SETTING, AND PARTICIPANTS:  Case-control study conducted in 2002-2014 among 105 cases with phenytoin-related severe cutaneous adverse reactions (n=61 Stevens-Johnson syndrome/toxic epidermal necrolysis and n=44 drug reactions with eosinophilia and systemic symptoms), 78 cases with maculopapular exanthema, 130 phenytoin-tolerant control participants, and 3655 population controls from Taiwan, Japan, and Malaysia.  A genome-wide association study (GWAS), direct sequencing of the associated loci, and replication analysis were conducted using the samples from Taiwan.  The initial GWAS included samples of 60 cases with phenytoin-related severe cutaneous adverse reactions and 412 population controls from Taiwan.  The results were validated in (1) 30 cases with severe cutaneous adverse reactions and 130 phenytoin-tolerant controls from Taiwan, (2) 9 patients with Stevens-Johnson syndrome/toxic epidermal necrolysis and 2869 population controls from Japan, and (3) 6 cases and 374 population controls from Malaysia.  MAIN OUTCOMES AND MEASURES:  Specific genetic factors associated with phenytoin-related severe cutaneous adverse reactions.  RESULTS:  The GWAS discovered a cluster of 16 single-nucleotide polymorphisms in CYP2C genes at 10q23.33 that reached genome-wide significance.  Direct sequencing of CYP2C identified missense variant rs1057910 (CYP2C9*3) that showed significant association with phenytoin-related severe cutaneous adverse reactions (odds ratio, 12; 95% CI, 6.6-20; P=1.1 × 10(-17)).  The statistically significant association between CYP2C9*3 and phenytoin-related severe cutaneous adverse reactions was observed in additional samples from Taiwan, Japan, and Malaysia.  A meta-analysis using the data from the 3 populations showed an overall odds ratio of 11 (95% CI, 6.2-18; z=8.58; P < .00001) for CYP2C9*3 association with phenytoin-related severe cutaneous adverse reactions.  Delayed clearance of plasma phenytoin was detected in patients with severe cutaneous adverse reactions, especially CYP2C9*3 carriers, providing a functional link of the associated variants to the disease.  CONCLUSIONS AND RELEVANCE:  This study identified CYP2C variants, including CYP2C9*3, known to reduce drug clearance, as important genetic factors associated with phenytoin-related severe cutaneous adverse reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTu3CMxmr6mMpw7prLlxLOzfW6udTcc2eYJi0b5An0xJLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbptlSjtQ%253D%253D&md5=68b9cb8e5fff2b3f4ffc07a398a60ebd</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1001%2Fjama.2014.7859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2014.7859%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DW.-H.%26aulast%3DChang%26aufirst%3DW.-C.%26aulast%3DLee%26aufirst%3DY.-S.%26aulast%3DWu%26aufirst%3DY.-Y.%26aulast%3DYang%26aufirst%3DC.-H.%26aulast%3DHo%26aufirst%3DH.-C.%26aulast%3DChen%26aufirst%3DM.-J.%26aulast%3DLin%26aufirst%3DJ.-Y.%26aulast%3DHui%26aufirst%3DR.%2BC.-Y.%26aulast%3DHo%26aufirst%3DJ.-C.%26aulast%3DWu%26aufirst%3DW.-M.%26aulast%3DChen%26aufirst%3DT.-J.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DY.-R.%26aulast%3DHsih%26aufirst%3DM.-S.%26aulast%3DTu%26aufirst%3DP.-H.%26aulast%3DChang%26aufirst%3DC.-N.%26aulast%3DHsu%26aufirst%3DC.-N.%26aulast%3DWu%26aufirst%3DT.-L.%26aulast%3DChoon%26aufirst%3DS.-E.%26aulast%3DHsu%26aufirst%3DC.-K.%26aulast%3DChen%26aufirst%3DD.-Y.%26aulast%3DLiu%26aufirst%3DC.-S.%26aulast%3DLin%26aufirst%3DC.-Y.%26aulast%3DKaniwa%26aufirst%3DN.%26aulast%3DSaito%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DR.%26aulast%3DAzukizawa%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.-H.%26aulast%3DChuang%26aufirst%3DS.-S.%26aulast%3DTsai%26aufirst%3DS.-F.%26aulast%3DChang%26aufirst%3DC.-J.%26aulast%3DChang%26aufirst%3DY.-S.%26aulast%3DHung%26aufirst%3DS.-I.%26atitle%3DGenetic%2520Variants%2520Associated%2520with%2520Phenytoin-Related%2520Severe%2520Cutaneous%2520Adverse%2520Reactions%26jtitle%3DJAMA%26date%3D2014%26volume%3D312%26spage%3D525%26epage%3D534%26doi%3D10.1001%2Fjama.2014.7859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hung, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsih, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. T.</span></span> <span> </span><span class="NLM_article-title">Common Risk Allele in Aromatic Antiepileptic-Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Han Chinese</span>. <i>Pharmacogenomics</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.2217/pgs.09.162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.2217%2Fpgs.09.162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=20235791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFSksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=349-356&author=S.+I.+Hungauthor=W.+H.+Chungauthor=Z.+S.+Liuauthor=C.+H.+Chenauthor=M.+S.+Hsihauthor=R.+C.+Huiauthor=C.+Y.+Chuauthor=Y.+T.+Chen&title=Common+Risk+Allele+in+Aromatic+Antiepileptic-Drug-Induced+Stevens-Johnson+Syndrome+and+Toxic+Epidermal+Necrolysis+in+Han+Chinese&doi=10.2217%2Fpgs.09.162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese</span></div><div class="casAuthors">Hung, Shuen-Iu; Chung, Wen-Hung; Liu, Zhi-Sheng; Chen, Chien-Hsiun; Hsih, Mo-Song; Hui, Rosaline Chung-yee; Chu, Chia-Yu; Chen, Yuan-Tsong</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenomics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">349-356</span>CODEN:
                <span class="NLM_cas:coden">PARMFL</span>;
        ISSN:<span class="NLM_cas:issn">1462-2416</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Aims: Compared with other categories of drugs, such as antibiotics and NSAIDs, antiepileptic therapies are assocd. with a high incidence of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  We previously reported that carbamazepine (CBZ)-SJS/TEN is strongly assocd. with the HLA-B*1502 in Han Chinese, which has been confirmed in other Southeast Asian countries where the allele is prevalent.  Here, we extend the study of HLA susceptibility to three different antiepileptic drugs, phenytoin (PHT), lamotrigine (LTG) and oxcarbazepine (OXC), which have structure similarity to CBZ.  Materials & methods: We carried out a case-control assocn. study.  We enrolled 26 PHT-, six LTG- and three OXC-induced SJS/TEN patients, 113 PHT-tolerant and 67 LTG-tolerant subjects who were on the drug, resp., for more than 3 mo without the adverse reactions, and 93 normal subjects from the general population.  The HLA-A, B, C and DRB1 genotypes were detd.  Results: We found that HLA-B*1502 was present in eight out of 26 (30.8%) PHT-SJS/TEN (OR: 5.1; 95% CI: 1.8-15.1; p = 0.0041), two out of six (33%) LTG-SJS (odds ratio [OR]: 5.1; 95% CI: 0.8-33.8; p = 0.1266) and three out of three (100%) OXC-SJS (OR: 80.7; 95% CI: 3.8-1714.4; p = 8.4 × 10-4) patients.  In addn., HLA-B*1301, Cw*0801 and DRB1*1602 also showed an assocn. with PHT-SJS/TEN (p = 0.0128-0.0281; OR: 3.0-4.3).  Conclusion: Our results indicate that OXC, PHT and LTG, which possess an arom. ring just as CBZ does, when causing SJS/TEN, share a common risk allele.  Arom. antiepileptic drugs causing SJS/TEN in HLA-B*1502 carriers may act on a similar pathogenetic mechanism, although other genetic/nongenetic factor(s) may also contribute to the pathomechanism of the disease.  We suggest that arom. antiepileptic drugs, including CBZ, OXC and PHT, should be avoided in the B*1502 carrier and caution should also be exercised for LTG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfWW1PRvCZhLVg90H21EOLACvtfcHk0ljBfp04MgufzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFSksLw%253D&md5=532c0cc0489e7225b540df904cc5115a</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.2217%2Fpgs.09.162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fpgs.09.162%26sid%3Dliteratum%253Aachs%26aulast%3DHung%26aufirst%3DS.%2BI.%26aulast%3DChung%26aufirst%3DW.%2BH.%26aulast%3DLiu%26aufirst%3DZ.%2BS.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DHsih%26aufirst%3DM.%2BS.%26aulast%3DHui%26aufirst%3DR.%2BC.%26aulast%3DChu%26aufirst%3DC.%2BY.%26aulast%3DChen%26aufirst%3DY.%2BT.%26atitle%3DCommon%2520Risk%2520Allele%2520in%2520Aromatic%2520Antiepileptic-Drug-Induced%2520Stevens-Johnson%2520Syndrome%2520and%2520Toxic%2520Epidermal%2520Necrolysis%2520in%2520Han%2520Chinese%26jtitle%3DPharmacogenomics%26date%3D2010%26volume%3D11%26spage%3D349%26epage%3D356%26doi%3D10.2217%2Fpgs.09.162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, F.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-D.</span></span> <span> </span><span class="NLM_article-title">Genetic Polymorphisms of Manganese Superoxide Dismutase, NAD(P)H:quinone Oxidoreductase, Glutathione S-Transferase M1 and T1, and the Susceptibility to Drug-Induced Liver Injury</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2007.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jhep.2007.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=17400324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVahtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=128-134&author=Y.-S.+Huangauthor=W.-J.+Suauthor=Y.-H.+Huangauthor=C.-Y.+Chenauthor=F.-Y.+Changauthor=H.-C.+Linauthor=S.-D.+Lee&title=Genetic+Polymorphisms+of+Manganese+Superoxide+Dismutase%2C+NAD%28P%29H%3Aquinone+Oxidoreductase%2C+Glutathione+S-Transferase+M1+and+T1%2C+and+the+Susceptibility+to+Drug-Induced+Liver+Injury&doi=10.1016%2Fj.jhep.2007.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury</span></div><div class="casAuthors">Huang, Yi-Shin; Su, Wei-Juin; Huang, Yi-Hsiang; Chen, Chih-Yen; Chang, Full-Young; Lin, Han-Chieh; Lee, Shou-Dong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-134</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Drug metabolizing enzymes may be related to drug-induced liver injury (DILI).  Manganese superoxide dismutase (MnSOD), NAD(P)H:quinone oxidoreductase (NQO1), and glutathione S-transferase (GST) are important drug metabolizing enzymes.  We aimed to elucidate the relationship between genetic polymorphisms of these enzymes and the susceptibility to DILI.  A total of 115 patients with DILI and 115 drug-, sex-, and age-matched controls were enrolled.  Their genetic polymorphisms of MnSOD, NQO1, GSTM1, and GSTT1 were assayed.  Sixty-three (54.8%) of DILI patients were incriminated to anti-tuberculosis drugs.  Subjects with a mutant C allele (T/C or C/C genotype) of MnSOD had a higher risk of DILI than those with MnSOD T/T genotype, both in overall drugs studied (adjusted OR: 2.44, 95% C.I.: 1.38-4.30, P = 0.002), and in sub-category of anti-tuberculosis drugs (adjusted OR: 2.47, 95% C.I.: 1.13-5.39, P = 0.02).  In addn., subjects carrying GSTM1 null genotype had increased risk of anti-tuberculosis DILI (adjusted OR: 2.23, 95% C.I.: 1.07-4.67, P = 0.03).  The MnSOD mutant C allele may increase the susceptibility to DILI, and GSTM1 null genotype may be related to anti-tuberculosis drug-induced hepatotoxicity.  Detn. of the MnSOD and GSTM1 genotypes may help identify patients at high risk for DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiBXCXlRUfxbVg90H21EOLACvtfcHk0lgcU7cnV1jgnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVahtL4%253D&md5=7f04ee34efd309bc61bbe33ab36afbb4</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2007.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2007.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.-S.%26aulast%3DSu%26aufirst%3DW.-J.%26aulast%3DHuang%26aufirst%3DY.-H.%26aulast%3DChen%26aufirst%3DC.-Y.%26aulast%3DChang%26aufirst%3DF.-Y.%26aulast%3DLin%26aufirst%3DH.-C.%26aulast%3DLee%26aufirst%3DS.-D.%26atitle%3DGenetic%2520Polymorphisms%2520of%2520Manganese%2520Superoxide%2520Dismutase%252C%2520NAD%2528P%2529H%253Aquinone%2520Oxidoreductase%252C%2520Glutathione%2520S-Transferase%2520M1%2520and%2520T1%252C%2520and%2520the%2520Susceptibility%2520to%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DJ.%2520Hepatol.%26date%3D2007%26volume%3D47%26spage%3D128%26epage%3D134%26doi%3D10.1016%2Fj.jhep.2007.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucena, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Martín, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulzurrun, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero-Gomez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castiella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durán, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Dios, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guarner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borraz, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agundez, J. A. G.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial Superoxide Dismutase and Glutathione Peroxidase in Idiosyncratic Drug-Induced Liver Injury</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1002/hep.23668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.23668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=20578157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFShtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2010&pages=303-312&author=M.+I.+Lucenaauthor=E.+Garc%C3%ADa-Mart%C3%ADnauthor=R.+J.+Andradeauthor=C.+Mart%C3%ADnezauthor=C.+Stephensauthor=J.+D.+Ruizauthor=E.+Ulzurrunauthor=M.+C.+Fernandezauthor=M.+Romero-Gomezauthor=A.+Castiellaauthor=R.+Planasauthor=J.+A.+Dur%C3%A1nauthor=A.+M.+De+Diosauthor=C.+Guarnerauthor=G.+Sorianoauthor=Y.+Borrazauthor=J.+A.+G.+Agundez&title=Mitochondrial+Superoxide+Dismutase+and+Glutathione+Peroxidase+in+Idiosyncratic+Drug-Induced+Liver+Injury&doi=10.1002%2Fhep.23668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury</span></div><div class="casAuthors">Lucena, M. Isabel; Garcia-Martin, Elena; Andrade, Raul J.; Martinez, Carmen; Stephens, Camilla; Ruiz, Jhon D.; Ulzurrun, Eugenia; Fernandez, M. Carmen; Romero-Gomez, Manuel; Castiella, Augustin; Planas, Ramon; Duran, Jose Antonio; De Dios, Ana Melcon; Guarner, Carlos; Soriano, German; Borraz, Yolanda; Agundez, Jose A. G.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">303-312</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) susceptibility has a potential genetic basis.  We have evaluated possible assocns. between the risk of developing DILI and common genetic variants of the manganese superoxide dismutase (SOD2 Val16Ala) and glutathione peroxidase (GPX1 Pro200Leu) genes, which are involved in mitochondrial oxidative stress management.  Genomic DNA from 185 DILI patients assessed by the Council for International Organizations of Medical Science scale and 270 sex- and age-matched controls were analyzed.  The SOD2 and GPX1 genotyping was performed using polymerase chain reaction restriction fragment length polymorphism and TaqMan probed quant. polymerase chain reaction, resp.  The statistical power to detect the effect of variant alleles with the obsd. odds ratio (OR) was 98.2% and 99.7% for bilateral assocn. of SOD2 and GPX1, resp.  The SOD2 Ala/Ala genotype was assocd. with cholestatic/mixed damage (OR = 2.3; 95% confidence interval [CI] = 1.4-3.8; cor. P [Pc] = 0.0058), whereas the GPX1 Leu/Leu genotype was assocd. with cholestatic injury (OR = 5.1; 95%CI = 1.6-16.0; Pc = 0.0112).  The presence of two or more combined risk alleles (SOD2 Ala and GPX1 Leu) was more frequent in DILI patients (OR = 2.1; 95%CI = 1.4-3.0; Pc = 0.0006).  Patients with cholestatic/mixed injury induced by mitochondria hazardous drugs were more prone to have the SOD2 Ala/Ala genotype (OR = 3.6; 95%CI = 1.4-9.3; Pc = 0.02).  This genotype was also more frequent in cholestatic/mixed DILI induced by pharmaceuticals producing quinone-like or epoxide metabolites (OR = 3.0; 95%CI = 1.7-5.5; Pc = 0.0008) and S-oxides, diazines, nitroanion radicals, or iminium ions (OR = 16.0; 95%CI = 1.8-146.1; Pc = 0.009).  Patients homozygous for the SOD2 Ala allele and the GPX1 Leu allele are at higher risk of developing cholestatic DILI.  SOD2 Ala homozygotes may be more prone to suffer DILI from drugs that are mitochondria hazardous or produce reactive intermediates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKPBg5do7ypbVg90H21EOLACvtfcHk0lgcU7cnV1jgnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFShtbc%253D&md5=72eb0f4a53f44f51e1604e8a991fb47b</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1002%2Fhep.23668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.23668%26sid%3Dliteratum%253Aachs%26aulast%3DLucena%26aufirst%3DM.%2BI.%26aulast%3DGarc%25C3%25ADa-Mart%25C3%25ADn%26aufirst%3DE.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DC.%26aulast%3DRuiz%26aufirst%3DJ.%2BD.%26aulast%3DUlzurrun%26aufirst%3DE.%26aulast%3DFernandez%26aufirst%3DM.%2BC.%26aulast%3DRomero-Gomez%26aufirst%3DM.%26aulast%3DCastiella%26aufirst%3DA.%26aulast%3DPlanas%26aufirst%3DR.%26aulast%3DDur%25C3%25A1n%26aufirst%3DJ.%2BA.%26aulast%3DDe%2BDios%26aufirst%3DA.%2BM.%26aulast%3DGuarner%26aufirst%3DC.%26aulast%3DSoriano%26aufirst%3DG.%26aulast%3DBorraz%26aufirst%3DY.%26aulast%3DAgundez%26aufirst%3DJ.%2BA.%2BG.%26atitle%3DMitochondrial%2520Superoxide%2520Dismutase%2520and%2520Glutathione%2520Peroxidase%2520in%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DHepatology%26date%3D2010%26volume%3D52%26spage%3D303%26epage%3D312%26doi%3D10.1002%2Fhep.23668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Usachov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omary, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, P.</span></span> <span> </span><span class="NLM_article-title">Prevalence of Genetic Variants of Keratins 8 and 18 in Patients with Drug-Induced Liver Injury</span>. <i>BMC Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">196</span>, <span class="refDoi"> DOI: 10.1186/s12916-015-0418-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1186%2Fs12916-015-0418-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26286715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1Snsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=196&author=V.+Usachovauthor=T.+J.+Urbanauthor=R.+J.+Fontanaauthor=A.+Grossauthor=S.+Iyerauthor=M.+B.+Omaryauthor=P.+Strnad&title=Prevalence+of+Genetic+Variants+of+Keratins+8+and+18+in+Patients+with+Drug-Induced+Liver+Injury&doi=10.1186%2Fs12916-015-0418-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury</span></div><div class="casAuthors">Usachov, Valentyn; Urban, Thomas J.; Fontana, Robert J.; Gross, Annika; Iyer, Sapna; Omary, M. Bishr; Strnad, Pavel</div><div class="citationInfo"><span class="NLM_cas:title">BMC Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">196/1-196/12</span>CODEN:
                <span class="NLM_cas:coden">BMMECZ</span>;
        ISSN:<span class="NLM_cas:issn">1741-7015</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Keratin 8 and 18 (K8/K18) cytoskeletal proteins protect hepatocytes from undergoing apoptosis and their mutations predispose to adverse outcomes in acute liver failure (ALF).  All known K8/K18 variants occur at relatively non-conserved residues and do not cause keratin cytoskeleton reorganization, whereas epidermal keratin-conserved residue mutations disrupt the keratin cytoskeleton and cause severe skin disease.  The aim of our study was to identify keratin variants in idiosyncratic drug-induced liver injury (DILI).  Methods: Genomic DNA was isolated from 800 patients enrolled in an ongoing US multicenter study, with DILI attributed to a wide range of drugs.  Specific K8/K18 exonic regions were PCR-amplified and screened by denaturing HPLC followed by DNA sequencing.  The functional impact of keratin variants was assessed using cell transfection and immune staining.  Results: Heterozygous and compd. amino acid-altering K8/K18 variants were identified in 86 DILI patients and non-coding variants in 15 subjects.  Five novel amino acid-altering (K8 Lys393Arg, K8 Ala351Val, K8 Ala358Val, K8 Ile346Val, K18 Asp89His) and two non-coding variants were obsd.  Several variants segregated with specific ethnic backgrounds but were found at similar frequencies in DILI subjects and ethnically matched population controls.  Notably, variants in highly conserved residues of K8 Lys393Arg (ezetimibe/simvastatin-related) and K18 Asp89His (isoniazid-related) were found in patients with fatal DILI.  These novel variants also led to keratin network disruption in transfected cells.  Conclusions: Novel K8/K18 cytoskeleton-disrupting variants were identified in two patients and segregated with fatal DILI.  Other non-cytoskeleton-disrupting keratin variants did not preferentially assoc. with DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhgiJGw0iPfbVg90H21EOLACvtfcHk0ljYkbF0vyf7nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1Snsrs%253D&md5=0de4f39ed4979aa0f630785af8b0801f</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1186%2Fs12916-015-0418-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12916-015-0418-0%26sid%3Dliteratum%253Aachs%26aulast%3DUsachov%26aufirst%3DV.%26aulast%3DUrban%26aufirst%3DT.%2BJ.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DGross%26aufirst%3DA.%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DOmary%26aufirst%3DM.%2BB.%26aulast%3DStrnad%26aufirst%3DP.%26atitle%3DPrevalence%2520of%2520Genetic%2520Variants%2520of%2520Keratins%25208%2520and%252018%2520in%2520Patients%2520with%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DBMC%2520Med.%26date%3D2015%26volume%3D13%26spage%3D196%26doi%3D10.1186%2Fs12916-015-0418-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urban, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shianna, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucena, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molokhia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floratos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pe’er, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonkovsky, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davern, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talwalkar, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Limited Contribution of Common Genetic Variants to Risk for Liver Injury Due to a Variety of Drugs</span>. <i>Pharmacogenet. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">784</span>– <span class="NLM_lpage">795</span>, <span class="refDoi"> DOI: 10.1097/FPC.0b013e3283589a76</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1097%2FFPC.0b013e3283589a76" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22968431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKgsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=784-795&author=T.+J.+Urbanauthor=Y.+Shenauthor=A.+Stolzauthor=N.+Chalasaniauthor=R.+J.+Fontanaauthor=J.+Rochonauthor=D.+Geauthor=K.+V.+Shiannaauthor=A.+K.+Dalyauthor=M.+I.+Lucenaauthor=M.+R.+Nelsonauthor=M.+Molokhiaauthor=G.+P.+Aithalauthor=A.+Floratosauthor=I.+Pe%E2%80%99erauthor=J.+Serranoauthor=H.+Bonkovskyauthor=T.+J.+Davernauthor=W.+M.+Leeauthor=V.+J.+Navarroauthor=J.+A.+Talwalkarauthor=D.+B.+Goldsteinauthor=P.+B.+Watkins&title=Limited+Contribution+of+Common+Genetic+Variants+to+Risk+for+Liver+Injury+Due+to+a+Variety+of+Drugs&doi=10.1097%2FFPC.0b013e3283589a76"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs</span></div><div class="casAuthors">Urban, Thomas J.; Shen, Yufeng; Stolz, Andrew; Chalasani, Naga; Fontana, Robert J.; Rochon, James; Ge, Dongliang; Shianna, Kevin V.; Daly, Ann K.; Lucena, M. Isabel; Nelson, Matthew R.; Molokhia, Mariam; Aithal, Guruprasad P.; Floratos, Aris; Pe'er, Itsik; Serrano, Jose; Bonkovsky, Herbert; Davern, Timothy J.; Lee, William M.; Navarro, Victor J.; Talwalkar, Jayant A.; Goldstein, David B.; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics and Genomics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">784-795</span>CODEN:
                <span class="NLM_cas:coden">PGHEAI</span>;
        ISSN:<span class="NLM_cas:issn">1744-6872</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background and aims: Drug-induced liver injury (DILI) is a serious adverse drug event that is suspected to have a heritable component.  We carried out a genome-wide assocn. study of 783 individuals of European ancestry who experienced DILI due to more than 200 implicated drugs.  Methods: DILI patients from the US-based Drug-Induced Liver Injury Network (n=401) and three international registries (n=382) were genotyped with the Illumina 1Mduo BeadChip and compared with population controls (n=3001).  Potential assocns. were tested in 307 independent Drug-Induced Liver Injury Network cases.  Results: After accounting for known major histocompatibility complex risk alleles for flucloxacillin-DILI and amoxicillin/clavulanate-DILI, there were no genome-wide significant assocns., including in the major histocompatibility complex region.  Stratification of DILI cases according to clin. phenotypes (injury type, latency, age of onset) also did not show significant assocns.  An anal. of hepatocellular DILI (n=285) restricted to 193 single-nucleotide polymorphisms previously assocd. with autoimmune disease showed a trend assocn. for rs7574865, in the vicinity of signal transducer and activator of transcription 4 (STAT4) (P=4.5×10).  This assocn. was replicated in an independent cohort of 168 hepatocellular DILI cases (P=0.011 and 1.5×10 for combined cohorts).  No significant assocns. were found with stratification by other clin. or demog. variables.  Conclusion: Although not significant at the genome-wide level, the assocn. between hepatocellular DILI and STAT4 is consistent with the emerging role of the immune system in DILI.  However, the lack of genome-wide assocn. study findings supports the idea that strong genetic determinants of DILI may be largely drug-specific or may reflect rare genetic variations, which were not assessed in our study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFgO-sTGumTLVg90H21EOLACvtfcHk0ljYkbF0vyf7nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKgsrrP&md5=1071d36d7efb376675f350daf717f5ba</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1097%2FFPC.0b013e3283589a76&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFPC.0b013e3283589a76%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DT.%2BJ.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DStolz%26aufirst%3DA.%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DRochon%26aufirst%3DJ.%26aulast%3DGe%26aufirst%3DD.%26aulast%3DShianna%26aufirst%3DK.%2BV.%26aulast%3DDaly%26aufirst%3DA.%2BK.%26aulast%3DLucena%26aufirst%3DM.%2BI.%26aulast%3DNelson%26aufirst%3DM.%2BR.%26aulast%3DMolokhia%26aufirst%3DM.%26aulast%3DAithal%26aufirst%3DG.%2BP.%26aulast%3DFloratos%26aufirst%3DA.%26aulast%3DPe%25E2%2580%2599er%26aufirst%3DI.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DBonkovsky%26aufirst%3DH.%26aulast%3DDavern%26aufirst%3DT.%2BJ.%26aulast%3DLee%26aufirst%3DW.%2BM.%26aulast%3DNavarro%26aufirst%3DV.%2BJ.%26aulast%3DTalwalkar%26aufirst%3DJ.%2BA.%26aulast%3DGoldstein%26aufirst%3DD.%2BB.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DLimited%2520Contribution%2520of%2520Common%2520Genetic%2520Variants%2520to%2520Risk%2520for%2520Liver%2520Injury%2520Due%2520to%2520a%2520Variety%2520of%2520Drugs%26jtitle%3DPharmacogenet.%2520Genomics%26date%3D2012%26volume%3D22%26spage%3D784%26epage%3D795%26doi%3D10.1097%2FFPC.0b013e3283589a76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urban, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Genetic Basis of Susceptibility to Drug-Induced Liver Injury: What Have We Learned and Where Do We Go from Here?</span>. <i>Pharmacogenomics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">738</span>, <span class="refDoi"> DOI: 10.2217/pgs.12.45</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.2217%2Fpgs.12.45" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22594502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFygu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=735-738&author=T.+J.+Urbanauthor=D.+B.+Goldsteinauthor=P.+B.+Watkins&title=Genetic+Basis+of+Susceptibility+to+Drug-Induced+Liver+Injury%3A+What+Have+We+Learned+and+Where+Do+We+Go+from+Here%3F&doi=10.2217%2Fpgs.12.45"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?</span></div><div class="casAuthors">Urban, Thomas J.; Goldstein, David B.; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenomics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">735-738</span>CODEN:
                <span class="NLM_cas:coden">PARMFL</span>;
        ISSN:<span class="NLM_cas:issn">1462-2416</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Drug-induced liver injury (DILI) represents a particularly significant problem, both in terms of its clin. impact and its economic effects.  Beyond its cost in terms of patient morbidity and mortality, DILI is among the most frequent reasons for late termination of drug development programs and regulatory actions including withdrawal of drugs from the market, resulting in large financial losses to the drug industry that are inevitably passed on to consumers.  For these reasons, much effort has been taken to identify causes of DILI and methods to predict its occurrence.  In line with this, the DILI genetics in the genomic era is reported.  Notably, genetic studies of DILI registries have been successful in identifying unsuspected variants as risk factors and many addnl. insights can be expected as these registries grow and the anal. technol. continues to advance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHl0ub_M1_1rVg90H21EOLACvtfcHk0ljYkbF0vyf7nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFygu7w%253D&md5=e57a9062c5575ef8d8c20d19955a256a</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.2217%2Fpgs.12.45&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fpgs.12.45%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DT.%2BJ.%26aulast%3DGoldstein%26aufirst%3DD.%2BB.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DGenetic%2520Basis%2520of%2520Susceptibility%2520to%2520Drug-Induced%2520Liver%2520Injury%253A%2520What%2520Have%2520We%2520Learned%2520and%2520Where%2520Do%2520We%2520Go%2520from%2520Here%253F%26jtitle%3DPharmacogenomics%26date%3D2012%26volume%3D13%26spage%3D735%26epage%3D738%26doi%3D10.2217%2Fpgs.12.45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korman, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregersen, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remmers, E. F.</span></span> <span> </span><span class="NLM_article-title">STAT4: Genetics, Mechanisms, and Implications for Autoimmunity</span>. <i>Curr. Allergy Asthma Rep.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">398</span>– <span class="NLM_lpage">403</span>, <span class="refDoi"> DOI: 10.1007/s11882-008-0077-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs11882-008-0077-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=18682104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtV2mu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=398-403&author=B.+D.+Kormanauthor=D.+L.+Kastnerauthor=P.+K.+Gregersenauthor=E.+F.+Remmers&title=STAT4%3A+Genetics%2C+Mechanisms%2C+and+Implications+for+Autoimmunity&doi=10.1007%2Fs11882-008-0077-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">STAT4: genetics, mechanisms, and implications for autoimmunity</span></div><div class="casAuthors">Korman, Benjamin D.; Kastner, Daniel L.; Gregersen, Peter K.; Remmers, Elaine F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Allergy and Asthma Reports</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">398-403</span>CODEN:
                <span class="NLM_cas:coden">CAARC9</span>;
        ISSN:<span class="NLM_cas:issn">1529-7322</span>.
    
            (<span class="NLM_cas:orgname">Current Medicine Group LLC</span>)
        </div><div class="casAbstract">A review.  Recent advances in genetics and technol. have led to breakthroughs in understanding the genes that predispose individuals to autoimmune diseases.  A common haplotype of the signal transducer and activator of transcription 4 (STAT4) gene has been shown to be assocd. with susceptibility to rheumatoid arthritis, systemic lupus erythematosus, and primary Sjogren's syndrome.  STAT4 is a transcription factor that transduces interleukin-12, interleukin-23, and type 1 interferon cytokine signals in T cells and monocytes, leading to T-helper type 1 and T-helper type 17 differentiation, monocyte activation, and interferon-γ prodn.  Although the evidence for this assocn. is very strong and well replicated, the exact mechanism by which polymorphisms in this gene lead to disease remains unknown.  In concert with the identification of other disease-assocd. loci, elucidating how the variant form of STAT4 modulates immune function should lead to an improved understanding of the pathophysiol. of autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrpvYj_KwTA7Vg90H21EOLACvtfcHk0lhUHCM2h8BogA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtV2mu7fN&md5=f3c5d0a47fbee5e18f195123832b64de</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1007%2Fs11882-008-0077-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11882-008-0077-8%26sid%3Dliteratum%253Aachs%26aulast%3DKorman%26aufirst%3DB.%2BD.%26aulast%3DKastner%26aufirst%3DD.%2BL.%26aulast%3DGregersen%26aufirst%3DP.%2BK.%26aulast%3DRemmers%26aufirst%3DE.%2BF.%26atitle%3DSTAT4%253A%2520Genetics%252C%2520Mechanisms%252C%2520and%2520Implications%2520for%2520Autoimmunity%26jtitle%3DCurr.%2520Allergy%2520Asthma%2520Rep.%26date%3D2008%26volume%3D8%26spage%3D398%26epage%3D403%26doi%3D10.1007%2Fs11882-008-0077-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gamazon, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozaffari, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aquino-Michaels, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyler, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, J. C.</span></span>; <span class="NLM_contrib-group">GTEx Consortium</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolae, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, H. K.</span></span> <span> </span><span class="NLM_article-title">A Gene-Based Association Method for Mapping Traits Using Reference Transcriptome Data</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1091</span>– <span class="NLM_lpage">1098</span>, <span class="refDoi"> DOI: 10.1038/ng.3367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fng.3367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26258848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSnurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2015&pages=1091-1098&author=E.+R.+Gamazonauthor=H.+E.+Wheelerauthor=K.+P.+Shahauthor=S.+V.+Mozaffariauthor=K.+Aquino-Michaelsauthor=R.+J.+Carrollauthor=A.+E.+Eylerauthor=J.+C.+Dennyauthor=GTEx+Consortiumauthor=D.+L.+Nicolaeauthor=N.+J.+Coxauthor=H.+K.+Im&title=A+Gene-Based+Association+Method+for+Mapping+Traits+Using+Reference+Transcriptome+Data&doi=10.1038%2Fng.3367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">A gene-based association method for mapping traits using reference transcriptome data</span></div><div class="casAuthors">Gamazon, Eric R.; Wheeler, Heather E.; Shah, Kaanan P.; Mozaffari, Sahar V.; Aquino-Michaels, Keston; Carroll, Robert J.; Eyler, Anne E.; Denny, Joshua C.; Nicolae, Dan L.; Cox, Nancy J.; Im, Hae Kyung</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1091-1098</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Genome-wide assocn. studies (GWAS) have identified thousands of variants robustly assocd. with complex traits.  However, the biol. mechanisms underlying these assocns. are, in general, not well understood.  We propose a gene-based assocn. method called PrediXcan that directly tests the mol. mechanisms through which genetic variation affects phenotype.  The approach ests. the component of gene expression detd. by an individual's genetic profile and correlates 'imputed' gene expression with the phenotype under investigation to identify genes involved in the etiol. of the phenotype.  Genetically regulated gene expression is estd. using whole-genome tissue-dependent prediction models trained with ref. transcriptome data sets.  PrediXcan enjoys the benefits of gene-based approaches such as reduced multiple-testing burden and a principled approach to the design of follow-up expts.  Our results demonstrate that PrediXcan can detect known and new genes assocd. with disease traits and provide insights into the mechanism of these assocns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9YzUegwecY7Vg90H21EOLACvtfcHk0lhUHCM2h8BogA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSnurbM&md5=6a2090092fef663aa910996d21b09068</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1038%2Fng.3367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.3367%26sid%3Dliteratum%253Aachs%26aulast%3DGamazon%26aufirst%3DE.%2BR.%26aulast%3DWheeler%26aufirst%3DH.%2BE.%26aulast%3DShah%26aufirst%3DK.%2BP.%26aulast%3DMozaffari%26aufirst%3DS.%2BV.%26aulast%3DAquino-Michaels%26aufirst%3DK.%26aulast%3DCarroll%26aufirst%3DR.%2BJ.%26aulast%3DEyler%26aufirst%3DA.%2BE.%26aulast%3DDenny%26aufirst%3DJ.%2BC.%26aulast%3D%26aulast%3DNicolae%26aufirst%3DD.%2BL.%26aulast%3DCox%26aufirst%3DN.%2BJ.%26aulast%3DIm%26aufirst%3DH.%2BK.%26atitle%3DA%2520Gene-Based%2520Association%2520Method%2520for%2520Mapping%2520Traits%2520Using%2520Reference%2520Transcriptome%2520Data%26jtitle%3DNat.%2520Genet.%26date%3D2015%26volume%3D47%26spage%3D1091%26epage%3D1098%26doi%3D10.1038%2Fng.3367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozyra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingelman-Sundberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M.</span></span> <span> </span><span class="NLM_article-title">Rare Genetic Variants in Cellular Transporters, Metabolic Enzymes, and Nuclear Receptors Can be Important Determinants of Interindividual Differences in Drug Response</span>. <i>Genet. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">20</span>, <span class="refDoi"> DOI: 10.1038/gim.2016.33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fgim.2016.33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27101133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVSkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=20&author=M.+Kozyraauthor=M.+Ingelman-Sundbergauthor=V.+M.+Lauschke&title=Rare+Genetic+Variants+in+Cellular+Transporters%2C+Metabolic+Enzymes%2C+and+Nuclear+Receptors+Can+be+Important+Determinants+of+Interindividual+Differences+in+Drug+Response&doi=10.1038%2Fgim.2016.33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response</span></div><div class="casAuthors">Kozyra, Mikael; Ingelman-Sundberg, Magnus; Lauschke, Volker M.</div><div class="citationInfo"><span class="NLM_cas:title">Genetics in Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-29</span>CODEN:
                <span class="NLM_cas:coden">GEMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1098-3600</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Purpose: In this study we characterized the genetic variability of 146 clin. relevant genes influencing drug pharmacokinetics in African and European subpopulations, which are key determinants for interindividual variations in drug efficacy and adverse drug reactions.  Results: In total, we found 12,152 SNVs in exons, 312 of which were novel.  The majority of variants were rare (minor allele frequency (MAF) <1%; 92.9%) and nonsynonymous (56.2%).  We calcd. that individuals of European and African descent harbor, on av., 100.8 and 121.4 variants across the 146 pharmacogenes studied, resp.  Addnl., by analyzing variation patterns across these populations, we pinpointed potential priority genes for population-adjusted genetic profiling strategies.  Furthermore, we estd., based on our variant frequency analyses, that approx. 30-40% of functional variability in pharmacogenes can be attributed to rare variants.  Conclusions: Our results indicate that these clin. important genes are genetically highly variable and differ considerably between populations.  Furthermore, the large extent of rare variants emphasizes the need for sequencing-based approaches and effective functionality predictions to allow for true personalized medicine.  Genet Med19 1, 20-29.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodEM1G6w3_E7Vg90H21EOLACvtfcHk0lhUHCM2h8BogA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVSkuw%253D%253D&md5=61a99ed4639030a950ab2946c8ad29df</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1038%2Fgim.2016.33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fgim.2016.33%26sid%3Dliteratum%253Aachs%26aulast%3DKozyra%26aufirst%3DM.%26aulast%3DIngelman-Sundberg%26aufirst%3DM.%26aulast%3DLauschke%26aufirst%3DV.%2BM.%26atitle%3DRare%2520Genetic%2520Variants%2520in%2520Cellular%2520Transporters%252C%2520Metabolic%2520Enzymes%252C%2520and%2520Nuclear%2520Receptors%2520Can%2520be%2520Important%2520Determinants%2520of%2520Interindividual%2520Differences%2520in%2520Drug%2520Response%26jtitle%3DGenet.%2520Med.%26date%3D2017%26volume%3D19%26spage%3D20%26doi%3D10.1038%2Fgim.2016.33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khera, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaffin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aragam, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roselli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lander, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubitz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellinor, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kathiresan, S.</span></span> <span> </span><span class="NLM_article-title">Genome-Wide Polygenic Scores for Common Diseases Identify Individuals with Risk Equivalent to Monogenic Mutations</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1219</span>– <span class="NLM_lpage">1224</span>, <span class="refDoi"> DOI: 10.1038/s41588-018-0183-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fs41588-018-0183-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30104762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFSqtbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=1219-1224&author=A.+V.+Kheraauthor=M.+Chaffinauthor=K.+G.+Aragamauthor=M.+E.+Haasauthor=C.+Roselliauthor=S.+H.+Choiauthor=P.+Natarajanauthor=E.+S.+Landerauthor=S.+A.+Lubitzauthor=P.+T.+Ellinorauthor=S.+Kathiresan&title=Genome-Wide+Polygenic+Scores+for+Common+Diseases+Identify+Individuals+with+Risk+Equivalent+to+Monogenic+Mutations&doi=10.1038%2Fs41588-018-0183-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations</span></div><div class="casAuthors">Khera, Amit V.; Chaffin, Mark; Aragam, Krishna G.; Haas, Mary E.; Roselli, Carolina; Choi, Seung Hoan; Natarajan, Pradeep; Lander, Eric S.; Lubitz, Steven A.; Ellinor, Patrick T.; Kathiresan, Sekar</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1219-1224</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A key public health need is to identify individuals at high risk for a given disease to enable enhanced screening or preventive therapies.  Because most common diseases have a genetic component, one important approach is to stratify individuals based on inherited DNA variation1.  Proposed clin. applications have largely focused on finding carriers of rare monogenic mutations at several-fold increased risk.  Although most disease risk is polygenic in nature2-5, it has not yet been possible to use polygenic predictors to identify individuals at risk comparable to monogenic mutations.  Here, we develop and validate genome-wide polygenic scores for five common diseases.  The approach identifies 8.0, 6.1, 3.5, 3.2, and 1.5% of the population at greater than threefold increased risk for coronary artery disease, atrial fibrillation, type 2 diabetes, inflammatory bowel disease, and breast cancer, resp.  For coronary artery disease, this prevalence is 20-fold higher than the carrier frequency of rare monogenic mutations conferring comparable risk6.  We propose that it is time to contemplate the inclusion of polygenic risk prediction in clin. care, and discuss relevant issues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp3C1W_UEEELVg90H21EOLACvtfcHk0liywGmChCUg_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFSqtbbI&md5=18d34103bd53bccddfab5f6db9fb0787</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1038%2Fs41588-018-0183-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41588-018-0183-z%26sid%3Dliteratum%253Aachs%26aulast%3DKhera%26aufirst%3DA.%2BV.%26aulast%3DChaffin%26aufirst%3DM.%26aulast%3DAragam%26aufirst%3DK.%2BG.%26aulast%3DHaas%26aufirst%3DM.%2BE.%26aulast%3DRoselli%26aufirst%3DC.%26aulast%3DChoi%26aufirst%3DS.%2BH.%26aulast%3DNatarajan%26aufirst%3DP.%26aulast%3DLander%26aufirst%3DE.%2BS.%26aulast%3DLubitz%26aufirst%3DS.%2BA.%26aulast%3DEllinor%26aufirst%3DP.%2BT.%26aulast%3DKathiresan%26aufirst%3DS.%26atitle%3DGenome-Wide%2520Polygenic%2520Scores%2520for%2520Common%2520Diseases%2520Identify%2520Individuals%2520with%2520Risk%2520Equivalent%2520to%2520Monogenic%2520Mutations%26jtitle%3DNat.%2520Genet.%26date%3D2018%26volume%3D50%26spage%3D1219%26epage%3D1224%26doi%3D10.1038%2Fs41588-018-0183-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moggs, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meehan, R. R.</span></span> <span> </span><span class="NLM_article-title">Epigenetic Profiles as Defined Signatures of Xenobiotic Exposure</span>. <i>Mutat. Res., Genet. Toxicol. Environ. Mutagen.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>764–765</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1016/j.mrgentox.2013.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.mrgentox.2013.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24001620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVOnt7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=764%E2%80%93765&publication_year=2014&pages=3-9&author=J.+P.+Thomsonauthor=J.+G.+Moggsauthor=C.+R.+Wolfauthor=R.+R.+Meehan&title=Epigenetic+Profiles+as+Defined+Signatures+of+Xenobiotic+Exposure&doi=10.1016%2Fj.mrgentox.2013.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic profiles as defined signatures of xenobiotic exposure</span></div><div class="casAuthors">Thomson, John P.; Moggs, Jonathan G.; Wolf, C. Roland; Meehan, Richard R.</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research, Genetic Toxicology and Environmental Mutagenesis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">764-765</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3-9</span>CODEN:
                <span class="NLM_cas:coden">MRGMFI</span>;
        ISSN:<span class="NLM_cas:issn">1383-5718</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  With the advent of high resoln. sequencing technologies there has been increasing interest in the study of genome-wide epigenetic modification patterns that govern the underlying gene expression events of a particular cell or tissue type.  There is now mounting evidence that perturbations to the epigenetic landscape occur during a host of cellular processes including normal proliferation/differentiation and aberrant outcomes such as carcinogenesis.  Furthermore, epigenetic perturbations have been assocd. with exposure to a range of drugs and toxicants, including non-genotoxic carcinogens (NGCs).  Although a variety of epigenetic modifications induced by NGCs have been studied previously, recent genome-wide integrated epigenomic and transcriptomic studies reveal for the first time the extent and dynamic nature of the epigenetic perturbations resulting from xenobiotic exposure.  The interrogation and integration of one such epigenetic mark, the newly discovered 5-hydroxymethylcytosine (5hmC) modification, reveals that drug treatment assocd. perturbations of the epigenome can result in unique epigenetic signatures.  This review focuses on how recent advances in the field of epigenetics can enhance our mechanistic understanding of xenobiotic exposure and provide novel safety biomarkers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKBFN5ST1B97Vg90H21EOLACvtfcHk0liywGmChCUg_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVOnt7jM&md5=8719f213f1c117fac193f515843ad5c6</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.mrgentox.2013.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mrgentox.2013.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DThomson%26aufirst%3DJ.%2BP.%26aulast%3DMoggs%26aufirst%3DJ.%2BG.%26aulast%3DWolf%26aufirst%3DC.%2BR.%26aulast%3DMeehan%26aufirst%3DR.%2BR.%26atitle%3DEpigenetic%2520Profiles%2520as%2520Defined%2520Signatures%2520of%2520Xenobiotic%2520Exposure%26jtitle%3DMutat.%2520Res.%252C%2520Genet.%2520Toxicol.%2520Environ.%2520Mutagen.%26date%3D2014%26volume%3D764%25E2%2580%2593765%26spage%3D3%26epage%3D9%26doi%3D10.1016%2Fj.mrgentox.2013.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span> <i>Guidance for Industry: M3(R2) Nonclinical Safety
Studies for the
Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals</i>. <span class="NLM_publisher-name">U.S. Department of Health and Human Services, U.S.
Food and Drug Administration, Center for Drug Evaluation and Research,
Center for Biologics Evaluation and Research</span>: <span class="NLM_publisher-loc">Washington, DC</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Guidance+for+Industry%3A+M3%28R2%29+Nonclinical+Safety%0AStudies+for+the%0AConduct+of+Human+Clinical+Trials+and+Marketing+Authorization+for+Pharmaceuticals.+U.S.+Department+of+Health+and+Human+Services%2C+U.S.%0AFood+and+Drug+Administration%2C+Center+for+Drug+Evaluation+and+Research%2C%0ACenter+for+Biologics+Evaluation+and+Research%3A+Washington%2C+DC%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGuidance%2520for%2520Industry%253A%2520M3%2528R2%2529%2520Nonclinical%2520Safety%250AStudies%2520for%2520the%250AConduct%2520of%2520Human%2520Clinical%2520Trials%2520and%2520Marketing%2520Authorization%2520for%2520Pharmaceuticals%26pub%3DU.S.%2520Department%2520of%2520Health%2520and%2520Human%2520Services%252C%2520U.S.%250AFood%2520and%2520Drug%2520Administration%252C%2520Center%2520for%2520Drug%2520Evaluation%2520and%2520Research%252C%250ACenter%2520for%2520Biologics%2520Evaluation%2520and%2520Research%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolaja, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lilly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sipes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracken, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Deun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller, A.</span></span> <span> </span><span class="NLM_article-title">Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals</span>. <i>Regul. Toxicol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1006/rtph.2000.1399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1006%2Frtph.2000.1399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=11029269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntF2gu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2000&pages=56-67&author=H.+Olsonauthor=G.+Bettonauthor=D.+Robinsonauthor=K.+Thomasauthor=A.+Monroauthor=G.+Kolajaauthor=P.+Lillyauthor=J.+Sandersauthor=G.+Sipesauthor=W.+Brackenauthor=M.+Doratoauthor=K.+Van+Deunauthor=P.+Smithauthor=B.+Bergerauthor=A.+Heller&title=Concordance+of+the+Toxicity+of+Pharmaceuticals+in+Humans+and+in+Animals&doi=10.1006%2Frtph.2000.1399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals</span></div><div class="casAuthors">Olson, Harry; Betton, Graham; Robinson, Denise; Thomas, Karluss; Monro, Alastair; Kolaja, Gerald; Lilly, Patrick; Sanders, James; Sipes, Glenn; Bracken, William; Dorato, Michael; Van Deun, Koen; Smith, Peter; Berger, Bruce; Heller, Allen</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Toxicology and Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-67</span>CODEN:
                <span class="NLM_cas:coden">RTOPDW</span>;
        ISSN:<span class="NLM_cas:issn">0273-2300</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review is given with 29 refs. on the results of a multinational pharmaceutical company survey and the outcome of an International Life Sciences Institute (ILSI) Workshop (Apr. 1999), which served to better understand concordance of the toxicity of pharmaceuticals obsd. in humans with that obsd. in exptl. animals.  The Workshop included representatives from academia, the multinational pharmaceutical industry, and international regulatory scientists.  The main aim of this project was to examine the strengths and weaknesses of animal studies to predict human toxicity (HT).  The database was developed from a survey which covered only those compds. where HTs were identified during clin. development of new pharmaceuticals, detg. whether animal toxicity studies identified concordant target organ toxicities in humans.  Data collected included codified compds., therapeutic category, the HT organ system affected, and the species and duration of studies in which the corresponding HT was either 1st identified or not obsd.  This survey includes input from 12 pharmaceutical companies with data compiled from 150 compds. with 221 HT events reported.  Multiple HTs were reported in 47 cases.  The results showed the true pos. HT concordance rate of 71% for rodent and nonrodent species, with nonrodents alone being predictive for 63% of HTs and rodents alone for 43%.  The highest incidence of overall concordance was seen in hematol., gastrointestinal, and cardiovascular HTs, and the least was seen in cutaneous HT.  Where animal models, in 1 or more species, identified concordant HT, 94% were 1st obsd. in studies of 1 mo or less in duration.  These survey results support the value of in vivo toxicol. studies to predict for many significant HTs assocd. with pharmaceuticals and have helped to identify HT categories that may benefit from improved methods.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEmD_XsaoSaLVg90H21EOLACvtfcHk0liywGmChCUg_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntF2gu7k%253D&md5=8555af1a059d6e3811ade843d77e5f04</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1006%2Frtph.2000.1399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Frtph.2000.1399%26sid%3Dliteratum%253Aachs%26aulast%3DOlson%26aufirst%3DH.%26aulast%3DBetton%26aufirst%3DG.%26aulast%3DRobinson%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DK.%26aulast%3DMonro%26aufirst%3DA.%26aulast%3DKolaja%26aufirst%3DG.%26aulast%3DLilly%26aufirst%3DP.%26aulast%3DSanders%26aufirst%3DJ.%26aulast%3DSipes%26aufirst%3DG.%26aulast%3DBracken%26aufirst%3DW.%26aulast%3DDorato%26aufirst%3DM.%26aulast%3DVan%2BDeun%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DBerger%26aufirst%3DB.%26aulast%3DHeller%26aufirst%3DA.%26atitle%3DConcordance%2520of%2520the%2520Toxicity%2520of%2520Pharmaceuticals%2520in%2520Humans%2520and%2520in%2520Animals%26jtitle%3DRegul.%2520Toxicol.%2520Pharmacol.%26date%3D2000%26volume%3D32%26spage%3D56%26epage%3D67%26doi%3D10.1006%2Frtph.2000.1399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Festing, M. W.</span></span> <span> </span><span class="NLM_article-title">Improving Toxicity Screening and Drug Development by Using Genetically Defined Strains</span>. In  <i>Mouse Models for Drug Discovery</i> [Online], <span class="NLM_contrib-group"><span class="NLM_string-name">Proetzel, G.</span>, <span class="NLM_string-name">Wiles, M. V.</span></span>, Eds; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">Totowa, NJ</span>, <span class="NLM_year">2010</span>; pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">21</span>, <a href="https://link.springer.com/protocol/10.1007%2F978-1-60761-058-8_1" class="extLink">https://link.springer.com/protocol/10.1007%2F978-1-60761-058-8_1</a>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2F978-1-60761-058-8_1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=1-21&author=M.+W.+Festingauthor=G.+Proetzel&author=M.+V.+Wiles&title=Mouse+Models+for+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1007%2F978-1-60761-058-8_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-60761-058-8_1%26sid%3Dliteratum%253Aachs%26aulast%3DFesting%26aufirst%3DM.%2BW.%26atitle%3DImproving%2520Toxicity%2520Screening%2520and%2520Drug%2520Development%2520by%2520Using%2520Genetically%2520Defined%2520Strains%26btitle%3DMouse%2520Models%2520for%2520Drug%2520Discovery%26aulast%3DProetzel%26aufirst%3DG.%26pub%3DHumana%2520Press%26date%3D2010%26spage%3D1%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballet, F.</span></span> <span> </span><span class="NLM_article-title">Preventing Drug-Induced Liver Injury: How Useful Are Animal Models?</span>. <i>Digestive Diseases</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">485</span>, <span class="refDoi"> DOI: 10.1159/000374093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1159%2F000374093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FhvVeruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=477-485&author=F.+Ballet&title=Preventing+Drug-Induced+Liver+Injury%3A+How+Useful+Are+Animal+Models%3F&doi=10.1159%2F000374093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Preventing Drug-Induced Liver Injury: How Useful Are Animal Models?</span></div><div class="casAuthors">Ballet Francois</div><div class="citationInfo"><span class="NLM_cas:title">Digestive diseases (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">477-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug-induced liver injury (DILI) is the most common organ toxicity encountered in regulatory animal toxicology studies required prior to the clinical development of new drug candidates.  Very few reports have evaluated the value of these studies for predicting DILI in humans.  Indeed, compounds inducing liver toxicity in regulatory toxicology studies are not always correlated with a risk of DILI in humans.  Conversely, compounds associated with the occurrence of DILI in phase 3 studies or after market release are often tested negative in regulatory toxicology studies.  Idiosyncratic DILI is a rare event that is precipitated in an individual by the simultaneous occurrence of several critical factors.  These factors may relate to the host (e.g. human leukocyte antigen polymorphism, inflammation), the drug (e.g. reactive metabolites) or the environment (e.g. diet/microbiota).  This type of toxicity therefore cannot be detected in conventional animal toxicology studies.  Several animal models have recently been proposed for the identification of drugs with the potential to cause idiosyncratic DILI: rats treated with lipopolysaccharide, Sod2(+/-) mice, panels of inbred mouse strains or chimeric mice with humanized livers.  These models are not suitable for use in the prospective screening of new drug candidates.  Humans therefore constitute the best model for predicting and assessing idiopathic DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREa92slMahj0NHe_gFldTbfW6udTcc2eaDlW_g_GBrhrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FhvVeruw%253D%253D&md5=5467900bc48ca5b22eb9eae9cfca76da</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1159%2F000374093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000374093%26sid%3Dliteratum%253Aachs%26aulast%3DBallet%26aufirst%3DF.%26atitle%3DPreventing%2520Drug-Induced%2520Liver%2520Injury%253A%2520How%2520Useful%2520Are%2520Animal%2520Models%253F%26jtitle%3DDigestive%2520Diseases%26date%3D2015%26volume%3D33%26spage%3D477%26epage%3D485%26doi%3D10.1159%2F000374093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shenton, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J. P.</span></span> <span> </span><span class="NLM_article-title">Evidence of an Immune-Mediated Mechanism for an Idiosyncratic Nevirapine-Induced Reaction in the Female Brown Norway Rat</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1799</span>– <span class="NLM_lpage">813</span>, <span class="refDoi"> DOI: 10.1021/tx0501132</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx0501132" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1WmtLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=1799-813&author=J.+M.+Shentonauthor=M.+Popovicauthor=J.+Chenauthor=M.+J.+Massonauthor=J.+P.+Uetrecht&title=Evidence+of+an+Immune-Mediated+Mechanism+for+an+Idiosyncratic+Nevirapine-Induced+Reaction+in+the+Female+Brown+Norway+Rat&doi=10.1021%2Ftx0501132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence of an Immune-Mediated Mechanism for an Idiosyncratic Nevirapine-Induced Reaction in the Female Brown Norway Rat</span></div><div class="casAuthors">Shenton, Jacintha M.; Popovic, Marija; Chen, Jie; Masson, Mary Jane; Uetrecht, Jack P.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1799-1813</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Previously, the authors reported a new animal model of an idiosyncratic drug reaction in which nevirapine causes a skin rash in some rats that has characteristics similar to the reaction that occurs in humans.  Strong evidence that the reaction is immune-mediated was found; specifically, low-dose pretreatment induced tolerance, while with rechallenge, the time to onset decreased and the severity increased.  Furthermore, splenocytes from rechallenged rats transferred rash susceptibility to naive recipients.  The authors now report the results of studies to explore the immune aspects of this reaction.  T cells were found to play an important role, as demonstrated by their ability to adoptively transfer susceptibility to the skin reaction.  Of these T cells, CD4+ cells are the likely effectors because they were capable of transferring susceptibility and the reaction was delayed in rats partially depleted of CD4+ T cells.  In contrast, it appears that CD8+ T cells are not essential, as CD8+ T cells were unable to transfer sensitivity to a naive animal and rats depleted of CD8+ T cells still developed skin rash.  Unlike the penicillamine model, where the authors have demonstrated that the tolerance induced by low-dose treatment is immune-mediated, tolerance induced by low-dose nevirapine appears to be largely due to induction of metab. as it can be overcome by inhibition of cytochrome P 450.  Pretreatment with the immunosuppressants, cyclosporine and tacrolimus, prevented the rash and even led to resoln. of the rash during nevirapine treatment.  These studies reinforce the hypothesis that the reaction in this model is similar to that which occurs in humans.  In particular, the finding that CD4+ T cells may play a central role in this model fits with the observation that the incidence of idiosyncratic reactions to nevirapine in humans appears to be lower in patients with low CD4+ counts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrVpZSoKuQBbVg90H21EOLACvtfcHk0ljuQySEeEprxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1WmtLnK&md5=38b5c9bcd0afcd4c4521dc64663f88e0</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1021%2Ftx0501132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx0501132%26sid%3Dliteratum%253Aachs%26aulast%3DShenton%26aufirst%3DJ.%2BM.%26aulast%3DPopovic%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMasson%26aufirst%3DM.%2BJ.%26aulast%3DUetrecht%26aufirst%3DJ.%2BP.%26atitle%3DEvidence%2520of%2520an%2520Immune-Mediated%2520Mechanism%2520for%2520an%2520Idiosyncratic%2520Nevirapine-Induced%2520Reaction%2520in%2520the%2520Female%2520Brown%2520Norway%2520Rat%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2005%26volume%3D18%26spage%3D1799%26epage%3D813%26doi%3D10.1021%2Ftx0501132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. S.</span></span> <span> </span><span class="NLM_article-title">Sex Differences in Nevirapine Rash</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">2096</span>– <span class="NLM_lpage">2097</span>, <span class="refDoi"> DOI: 10.1086/324088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1086%2F324088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=11712101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD3MnmsFGrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2001&pages=2096-2097&author=K.+H.+Wongauthor=K.+C.+W.+Chanauthor=S.+S.+Lee&title=Sex+Differences+in+Nevirapine+Rash&doi=10.1086%2F324088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Sex differences in nevirapine rash</span></div><div class="casAuthors">Wong K H; Chan K C; Lee S S</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2096-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLq5PIOwr5z6__Jf7-eMvJfW6udTcc2eaDlW_g_GBrhrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnmsFGrtA%253D%253D&md5=4f315dc55aa3d1913b1e05a3320e8927</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1086%2F324088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F324088%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DK.%2BH.%26aulast%3DChan%26aufirst%3DK.%2BC.%2BW.%26aulast%3DLee%26aufirst%3DS.%2BS.%26atitle%3DSex%2520Differences%2520in%2520Nevirapine%2520Rash%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2001%26volume%3D33%26spage%3D2096%26epage%3D2097%26doi%3D10.1086%2F324088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novalen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">Bioactivation of Nevirapine to a Reactive Quinone Methide: Implications for Liver Injury</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1708</span>– <span class="NLM_lpage">1719</span>, <span class="refDoi"> DOI: 10.1021/tx300172s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx300172s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVaktr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=1708-1719&author=A.+M.+Sharmaauthor=Y.+Liauthor=M.+Novalenauthor=M.+A.+Hayesauthor=J.+Uetrecht&title=Bioactivation+of+Nevirapine+to+a+Reactive+Quinone+Methide%3A+Implications+for+Liver+Injury&doi=10.1021%2Ftx300172s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Bioactivation of Nevirapine to a Reactive Quinone Methide: Implications for Liver Injury</span></div><div class="casAuthors">Sharma, Amy M.; Li, Yan; Novalen, Maria; Hayes, M. Anthony; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1708-1719</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nevirapine (NVP) treatment is assocd. with a significant incidence of liver injury.  We developed an anti-NVP antiserum to det. the presence and pattern of covalent binding of NVP to mouse, rat, and human hepatic tissues.  Covalent binding to hepatic microsomes from male C57BL/6 mice and male Brown Norway rats was detected on Western blots; the major protein had a mass of ∼55 kDa.  Incubation of NVP with rat CYP3A1 and 2C11 or human CYP3A4 also led to covalent binding.  Treatment of female Brown Norway rats or C57BL/6 mice with NVP led to extensive covalent binding to a wide range of proteins.  Co-treatment with 1-aminobenzotriazole dramatically changed the pattern of binding.  The covalent binding of 12-hydroxy-NVP, the pathway that leads to a skin rash, was much less than that of NVP, both in vitro and in vivo.  An analog of NVP in which the Me hydrogens were replaced by deuterium also produced less covalent binding than NVP.  These data provide strong evidence that covalent binding of NVP in the liver is due to a quinone methide formed by oxidn. of the Me group.  Attempts were made to develop an animal model of NVP-induced liver injury in mice.  There was a small increase in ALT in some NVP-treated male C57BL/6 mice at 3 wk that resolved despite continued treatment.  Male Cbl-b-/- mice dosed with NVP had an increase in ALT of >200 U/L, which also resolved despite continued treatment.  Liver histol. in these animals showed focal areas of complete necrosis, while most of the liver appeared normal.  This is a different pattern from the histol. of NVP-induced liver injury in humans.  This is the first study to report hepatic covalent binding of NVP and also liver injury in mice.  It is likely that the quinone methide metabolite is responsible for NVP-induced liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYYNCsPNMXnbVg90H21EOLACvtfcHk0lgxPNxdbKf7KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVaktr3O&md5=c2f53129a4cd77706c95c391661c96ca</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1021%2Ftx300172s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx300172s%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DA.%2BM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DNovalen%26aufirst%3DM.%26aulast%3DHayes%26aufirst%3DM.%2BA.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DBioactivation%2520of%2520Nevirapine%2520to%2520a%2520Reactive%2520Quinone%2520Methide%253A%2520Implications%2520for%2520Liver%2520Injury%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2012%26volume%3D25%26spage%3D1708%26epage%3D1719%26doi%3D10.1021%2Ftx300172s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venuto, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vladutiu, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brentjens, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andres, G. A.</span></span> <span> </span><span class="NLM_article-title">Effects of Prolonged Administration of D-Penicillamine or Captopril in Various Strains of Rats: Brown Norway Rats Treated with D-penicillamine Develop Autoantibodies, Circulating Immune Complexes, and Disseminated Intravascular Coagulation</span>. <i>Clin. Immunol. Immunopathol.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">142</span>– <span class="NLM_lpage">155</span>, <span class="refDoi"> DOI: 10.1016/0090-1229(84)90015-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2F0090-1229%2884%2990015-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=6365381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADyaL2cXps1KksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1984&pages=142-155&author=A.+J.+Donkerauthor=R.+C.+Venutoauthor=A.+O.+Vladutiuauthor=J.+R.+Brentjensauthor=G.+A.+Andres&title=Effects+of+Prolonged+Administration+of+D-Penicillamine+or+Captopril+in+Various+Strains+of+Rats%3A+Brown+Norway+Rats+Treated+with+D-penicillamine+Develop+Autoantibodies%2C+Circulating+Immune+Complexes%2C+and+Disseminated+Intravascular+Coagulation&doi=10.1016%2F0090-1229%2884%2990015-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of prolonged administration of D-penicillamine or captopril in various strains of rats.  Brown Norway rats treated with D-penicillamine develop autoantibodies, circulating immune complexes, and disseminated intravascular coagulation</span></div><div class="casAuthors">Donker, Ab J.; Venuto, Rocco C.; Vladutiu, Adrian O.; Brentjens, Jan R.; Andres, Giuseppe A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology and Immunopathology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">142-55</span>CODEN:
                <span class="NLM_cas:coden">CLIIAT</span>;
        ISSN:<span class="NLM_cas:issn">0090-1229</span>.
    </div><div class="casAbstract">D-Penicillamine  [52-67-5] and captopril  [62571-86-2], 2 drugs that induce autoimmune manifestations in man, were administered orally for 5 - 10 mo to various strains of rats.  Three to 8 wk after D-penicillamine administration in a dosage of 20-50 mg daily, 73% of Brown Norway (BN) rats became ill.  The disease was characterized by wt. loss, dermatitis, and a high mortality presumably caused by disseminated intravascular coagulation.  Microscopy revealed widespread granulomatous and necrotic lesions.  The plasma of these animals contained antinulcear antibodies and immune complexes.  In the kidney deposits of IgG were found in a linear pattern along the glomerular basement membrane.  IgG eluted from diseased kidneys bound both in vitro and in vivo to kidney basement membranes.  BN rats initially receiving 5 mg of D-penicillamine daily and subsequently 20 and 50 mg daily did not develop disease.  No adverse effects were noted in Lewis (LEW) and Sprague-Dawley (SD) rats treated with 20 or 50 mg of D-penicillamine daily, nor in BN and LEW rats treated with 20 mg of captopril daily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZbrY2u0xY7rVg90H21EOLACvtfcHk0lgxPNxdbKf7KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXps1KksA%253D%253D&md5=c11b77d857d51da9c9e931fdbf40c7d2</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2F0090-1229%2884%2990015-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0090-1229%252884%252990015-1%26sid%3Dliteratum%253Aachs%26aulast%3DDonker%26aufirst%3DA.%2BJ.%26aulast%3DVenuto%26aufirst%3DR.%2BC.%26aulast%3DVladutiu%26aufirst%3DA.%2BO.%26aulast%3DBrentjens%26aufirst%3DJ.%2BR.%26aulast%3DAndres%26aufirst%3DG.%2BA.%26atitle%3DEffects%2520of%2520Prolonged%2520Administration%2520of%2520D-Penicillamine%2520or%2520Captopril%2520in%2520Various%2520Strains%2520of%2520Rats%253A%2520Brown%2520Norway%2520Rats%2520Treated%2520with%2520D-penicillamine%2520Develop%2520Autoantibodies%252C%2520Circulating%2520Immune%2520Complexes%252C%2520and%2520Disseminated%2520Intravascular%2520Coagulation%26jtitle%3DClin.%2520Immunol.%2520Immunopathol.%26date%3D1984%26volume%3D30%26spage%3D142%26epage%3D155%26doi%3D10.1016%2F0090-1229%2884%2990015-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tournade, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vial, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druet, P.</span></span> <span> </span><span class="NLM_article-title">D-Penicillamine-Induced Autoimmunity in Brown-Norway Rats. Similarities with HgCl2-Induced Autoimmunity</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">2985</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=2139074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADyaK3cXit12nt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=1990&pages=2985&author=H.+Tournadeauthor=L.+Pelletierauthor=R.+Pasquierauthor=M.+C.+Vialauthor=C.+Mandetauthor=P.+Druet&title=D-Penicillamine-Induced+Autoimmunity+in+Brown-Norway+Rats.+Similarities+with+HgCl2-Induced+Autoimmunity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">D-Penicillamine-induced autoimmunity in Brown-Norway rats.  Similarities with mercury(II) chloride-induced autoimmunity</span></div><div class="casAuthors">Tournade, Herve; Pelletier, Lucette; Pasquier, Regine; Vial, Marie Cecile; Mandet, Chantal; Druet, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2985-91</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    </div><div class="casAbstract">p-Penicillamine (DP) has been previously shown to induce an autoimmune disease in Brown-Norway (BN) rats, characterized by a dermatitis, by the prodn. of antinuclear antibodies, by the formation of circulating immune complexes, and by linear IgG deposits along the glomerular basement membrane.  These manifestations are quite similar to those obsd. in mercuric chloride (HgCl2)-induced autoimmunity.  The mechanism of the latter disease has been recently partly elucidated.  The aim of this study was to compare DP and HgCl2-induced autoimmunity in BN rats and to compare the mechanisms involved in both situations.  A transient increase in the no. of spleen cells, affecting B cells and CD4+ T cells, and an increase in serum IgE concn., previously reported in HgCl2-induced autoimmunity, were obsd. during DP treatment.  Autoreactive anti-class II T cells able to proliferate not only in the presence of autologous B cells but also in the presence of syngeneic normal B cells were found in DP-treated BN rats.  Spontaneous regulation occurred, assocd. with the disappearance of autoreactive T cells.  Suppressor CD8+ T cells were not involved in this phenomenon.  Mechanisms involved in both the induction and the regulation of DP-induced autoimmunity seem to be quite similar to those reported in HgCl2-induced autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI81XQfeyASbVg90H21EOLACvtfcHk0lgxPNxdbKf7KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXit12nt78%253D&md5=385ab1d0d2ba61f6906b81151cc4d045</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTournade%26aufirst%3DH.%26aulast%3DPelletier%26aufirst%3DL.%26aulast%3DPasquier%26aufirst%3DR.%26aulast%3DVial%26aufirst%3DM.%2BC.%26aulast%3DMandet%26aufirst%3DC.%26aulast%3DDruet%26aufirst%3DP.%26atitle%3DD-Penicillamine-Induced%2520Autoimmunity%2520in%2520Brown-Norway%2520Rats.%2520Similarities%2520with%2520HgCl2-Induced%2520Autoimmunity%26jtitle%3DJ.%2520Immunol.%26date%3D1990%26volume%3D144%26spage%3D2985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saito, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kase, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitaichi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, H.</span></span> <span> </span><span class="NLM_article-title">Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Mouse Model Generated by Using PBMCs and the Skin of Patients</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">434</span>– <span class="NLM_lpage">441</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2012.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jaci.2012.09.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23111236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2hsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2013&pages=434-441&author=N.+Saitoauthor=N.+Yoshiokaauthor=R.+Abeauthor=H.+Qiaoauthor=Y.+Fujitaauthor=D.+Hoshinaauthor=A.+Sutoauthor=S.+Kaseauthor=N.+Kitaichiauthor=M.+Ozakiauthor=H.+Shimizu&title=Stevens-Johnson+Syndrome%2FToxic+Epidermal+Necrolysis+Mouse+Model+Generated+by+Using+PBMCs+and+the+Skin+of+Patients&doi=10.1016%2Fj.jaci.2012.09.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients</span></div><div class="casAuthors">Saito, Nao; Yoshioka, Naoya; Abe, Riichiro; Qiao, Hongjiang; Fujita, Yasuyuki; Hoshina, Daichi; Suto, Asuka; Kase, Satoru; Kitaichi, Nobuyoshi; Ozaki, Michitaka; Shimizu, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">434-441.e9</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening cutaneous reactions caused by drugs or infections and exhibiting widespread epidermal necrosis.  Currently, there is no animal model that reproduces SJS/TEN symptoms.  We sought to develop a novel mouse model of SJS/TEN by using PBMCs and skin from patients who had recovered from SJS/TEN.  For our mouse model, patients' PBMCs were injected i.v. into immunocompromised NOD/Shi-scid, IL-2Rγnull (NOG) mice, followed by oral administration of a causative drug.  Subsequently, to replace human skin, unaffected skin specimens obtained from patients who had recovered from SJS/TEN were grafted onto NOG mice, after which patient-derived PBMCs and the causative drug were applied.  Mice injected with PBMCs from patients with SJS/TEN and given the causative drug showed marked conjunctival congestion and numerous cell death of conjunctival epithelium, whereas there were no symptoms in mice injected with PBMCs from patients with ordinary drug skin reactions.  CD8+ T lymphocyte-depleted PBMCs from patients with SJS/TEN did not elicit these symptoms.  In addn., skin-grafted mice showed darkening of the skin-grafted areas.  Cleaved caspase-3 staining showed that dead keratinocytes were more numerous in the skin-grafted mice than in the healthy control animals.We have established a novel human-oriented SJS/TEN mouse model and proved the importance of CD8+ T lymphocytes in SJS/TEN pathogenesis.  The mouse model promises to promote diagnostic and therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobR9oslIGMi7Vg90H21EOLACvtfcHk0ligIvTIpBfB-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2hsbvE&md5=0bf206589ce1be23523e9b683a181cf7</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2012.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2012.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DSaito%26aufirst%3DN.%26aulast%3DYoshioka%26aufirst%3DN.%26aulast%3DAbe%26aufirst%3DR.%26aulast%3DQiao%26aufirst%3DH.%26aulast%3DFujita%26aufirst%3DY.%26aulast%3DHoshina%26aufirst%3DD.%26aulast%3DSuto%26aufirst%3DA.%26aulast%3DKase%26aufirst%3DS.%26aulast%3DKitaichi%26aufirst%3DN.%26aulast%3DOzaki%26aufirst%3DM.%26aulast%3DShimizu%26aufirst%3DH.%26atitle%3DStevens-Johnson%2520Syndrome%252FToxic%2520Epidermal%2520Necrolysis%2520Mouse%2520Model%2520Generated%2520by%2520Using%2520PBMCs%2520and%2520the%2520Skin%2520of%2520Patients%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2013%26volume%3D131%26spage%3D434%26epage%3D441%26doi%3D10.1016%2Fj.jaci.2012.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kakuni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tateno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span> <span> </span><span class="NLM_article-title">Chimeric Mice with a Humanized Liver as an Animal Model of Troglitazone-Induced Liver Injury</span>. <i>Toxicol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>214</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.toxlet.2012.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.toxlet.2012.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22902350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGqt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=2012&pages=9-18&author=M.+Kakuniauthor=M.+Moritaauthor=K.+Matsuoauthor=Y.+Katohauthor=M.+Nakajimaauthor=C.+Tatenoauthor=T.+Yokoi&title=Chimeric+Mice+with+a+Humanized+Liver+as+an+Animal+Model+of+Troglitazone-Induced+Liver+Injury&doi=10.1016%2Fj.toxlet.2012.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury</span></div><div class="casAuthors">Kakuni, Masakazu; Morita, Mayu; Matsuo, Kentaro; Katoh, Yumiko; Nakajima, Miki; Tateno, Chise; Yokoi, Tsuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-18</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Troglitazone (Tro) is a thiazolidinedione antidiabetic drug that was withdrawn from the market due to its assocn. with idiosyncratic severe liver injury.  Tro has never induced liver injury in exptl. animals in vivo.  It was assumed that the species differences between human and exptl. animals in the pharmaco- or toxicokinetics of Tro might be assocd. with these observations.  In this study, we investigated whether a chimeric mouse with a humanized liver that we previously established, whose replacement index with human hepatocytes is up to 92% can reproduce Tro-induced liver injury.  When the chimeric mice were orally administered Tro for 14 or 23 days (1000 mg/kg/day), serum alanine aminotransferase (ALT) was significantly increased by 2.1- and 3.6-fold, resp.  Co-administration of L-buthionine sulfoximine (10 mM in drinking water), an inhibitor of glutathione (GSH) synthesis, unexpectedly prevented the Tro-dependent increase of ALT, which suggests that the GSH scavenging pathway will not be involved in Tro-induced liver injury.  To elucidate the mechanism of the onset of liver injury, hepatic GSH content, the level of oxidative stress markers and phase I and phase II drug metabolizing enzymes were detd.  However, these factors were not assocd. with Tro-induced liver injury.  An immune-mediated reaction may be assocd. with Tro-induced liver toxicity in vivo, because the chimeric mouse is derived from an immunodeficient SCID mouse.  In conclusion, we successfully reproduced Tro-induced liver injury using chimeric mice with a humanized liver, which provides a new animal model for studying idiosyncratic drug-induced liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM-Wl_A79CkrVg90H21EOLACvtfcHk0ligIvTIpBfB-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGqt7fK&md5=fad97513650e303a766d15c2175cfaad</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2Fj.toxlet.2012.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.toxlet.2012.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DKakuni%26aufirst%3DM.%26aulast%3DMorita%26aufirst%3DM.%26aulast%3DMatsuo%26aufirst%3DK.%26aulast%3DKatoh%26aufirst%3DY.%26aulast%3DNakajima%26aufirst%3DM.%26aulast%3DTateno%26aufirst%3DC.%26aulast%3DYokoi%26aufirst%3DT.%26atitle%3DChimeric%2520Mice%2520with%2520a%2520Humanized%2520Liver%2520as%2520an%2520Animal%2520Model%2520of%2520Troglitazone-Induced%2520Liver%2520Injury%26jtitle%3DToxicol.%2520Lett.%26date%3D2012%26volume%3D214%26spage%3D9%26epage%3D18%26doi%3D10.1016%2Fj.toxlet.2012.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanoh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugahara, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizane, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tateno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotake, Y.</span></span> <span> </span><span class="NLM_article-title">Changes in Bile Acid Concentrations after Administration of Ketoconazole or Rifampicin to Chimeric Mice with Humanized Liver</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1366</span>– <span class="NLM_lpage">1375</span>, <span class="refDoi"> DOI: 10.1248/bpb.b19-00249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1248%2Fbpb.b19-00249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=31366871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjt1WntL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2019&pages=1366-1375&author=S.+Sanohauthor=Y.+Tamuraauthor=C.+Fujinoauthor=G.+Sugaharaauthor=Y.+Yoshizaneauthor=A.+Yanagiauthor=K.+Kisohauthor=Y.+Ishidaauthor=C.+Tatenoauthor=S.+Ohtaauthor=Y.+Kotake&title=Changes+in+Bile+Acid+Concentrations+after+Administration+of+Ketoconazole+or+Rifampicin+to+Chimeric+Mice+with+Humanized+Liver&doi=10.1248%2Fbpb.b19-00249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Changes in bile acid concentrations after administration of ketoconazole or rifampicin to chimeric mice with humanized liver</span></div><div class="casAuthors">Sanoh, Seigo; Tamura, Yuka; Fujino, Chieri; Sugahara, Go; Yoshizane, Yasumi; Yanagi, Ami; Kisoh, Keishi; Ishida, Yuji; Tateno, Chise; Ohta, Shigeru; Kotake, Yaichiro</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1366-1375</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a common side effect of several medications and is considered a major factor responsible for the discontinuation of drugs during their development.  Cholestasis is a DILI that results from impairment of bile acid transporters, such as the bile salt export pump (BSEP), leading to accumulation of bile acids.  Both in vitro and in vivo studies are required to predict the risk of drug-induced cholestasis.  In the present study, we used chimeric mice with humanized liver as a model to study drug-induced cholestasis.  Administration of a single dose of ketoconazole or rifampicin, known to potentially cause cholestasis by inhibiting BSEP, did not result in elevated levels of alk. phosphatase (ALP), which are known hepatic biomarkers.  The concn. of taurodeoxycholic acid increased in the liver after ketoconazole administration, whereas rifampicin resulted in increased tauromuricholic acid and taurocholic acid (TCA) levels in the liver and plasma.  Furthermore, rifampicin resulted in an increase in the uniform distribution of a compd. with m/z 514.3, presumed as TCA through imaging mass spectrometry.  The mRNA levels of bile acid-related genes were also altered after treatment with ketoconazole or rifampicin.  We believe these observations to be a part of a feedback mechanism to decrease bile acid concns.  The changes in bile acid concns. results may reflect the initial responses of the human body to cholestasis.  Furthermore, these findings may contribute to the screening of drug candidates, thereby avoiding drug-induced cholestasis during clin. trials and drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhoXuor93-97Vg90H21EOLACvtfcHk0ligIvTIpBfB-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjt1WntL8%253D&md5=1c86982ef829ee21850198d0977e00a3</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1248%2Fbpb.b19-00249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.b19-00249%26sid%3Dliteratum%253Aachs%26aulast%3DSanoh%26aufirst%3DS.%26aulast%3DTamura%26aufirst%3DY.%26aulast%3DFujino%26aufirst%3DC.%26aulast%3DSugahara%26aufirst%3DG.%26aulast%3DYoshizane%26aufirst%3DY.%26aulast%3DYanagi%26aufirst%3DA.%26aulast%3DKisoh%26aufirst%3DK.%26aulast%3DIshida%26aufirst%3DY.%26aulast%3DTateno%26aufirst%3DC.%26aulast%3DOhta%26aufirst%3DS.%26aulast%3DKotake%26aufirst%3DY.%26atitle%3DChanges%2520in%2520Bile%2520Acid%2520Concentrations%2520after%2520Administration%2520of%2520Ketoconazole%2520or%2520Rifampicin%2520to%2520Chimeric%2520Mice%2520with%2520Humanized%2520Liver%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2019%26volume%3D42%26spage%3D1366%26epage%3D1375%26doi%3D10.1248%2Fbpb.b19-00249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michie, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillgren, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span> <span> </span><span class="NLM_article-title">Chimeric TK-NOG Mice: A Predictive Model for Cholestatic Human Liver Toxicity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.220798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fjpet.114.220798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25424997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=274-80&author=D.+Xuauthor=M.+Wuauthor=S.+Nishimuraauthor=T.+Nishimuraauthor=S.+A.+Michieauthor=M.+Zhengauthor=Z.+Yangauthor=A.+J.+Yatesauthor=J.+S.+Dayauthor=K.+M.+Hillgrenauthor=S.+T.+Takedaauthor=Y.+Guanauthor=Y.+Guoauthor=G.+Peltz&title=Chimeric+TK-NOG+Mice%3A+A+Predictive+Model+for+Cholestatic+Human+Liver+Toxicity&doi=10.1124%2Fjpet.114.220798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric TK-NOG mice: a predictive model for cholestatic human liver toxicity</span></div><div class="casAuthors">Xu, Dan; Wu, Manhong; Nishimura, Sachiko; Nishimura, Toshihiko; Michie, Sara A.; Zheng, Ming; Yang, Zicheng; Yates, Alexander John; Day, Jeffrey S.; Hillgren, Kathleen M.; Takeda, Saori Takedai; Guan, Yuan; Guo, Yingying; Peltz, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">274-280/1-274-280/7, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Due to the substantial interspecies differences in drug metab. and disposition, drug-induced liver injury (DILI) in humans is often not predicted by studies performed in animal species.  For example, a drug (bosentan) used to treat pulmonary artery hypertension caused unexpected cholestatic liver toxicity in humans, which was not predicted by preclin. toxicol. studies in multiple animal species.  In this study, we demonstrate that NOG mice expressing a thymidine kinase transgene (TK-NOG) with humanized livers have a humanized profile of biliary excretion of a test (cefmetazole) drug, which was shown by an in situ perfusion study to result from interspecies differences in the rate of biliary transport and in liver retention of this drug.  We also found that readily detectable cholestatic liver injury develops in TK-NOG mice with humanized livers after 1 wk of treatment with bosentan (160, 32, or 6 mg/kg per day by mouth), whereas liver toxicity did not develop in control mice after 1 mo of treatment.  The lab. and histol. features of bosentan-induced liver toxicity in humanized mice mirrored that of human subjects.  Because DILI has become a significant public health problem, drug safety could be improved if preclin. toxicol. studies were performed using humanized TK-NOG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5khL8nmAAJrVg90H21EOLACvtfcHk0lhzA0S9mrmQ4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOgsrk%253D&md5=cc802f944e90d89cfea6b888f04d093a</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220798%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DNishimura%26aufirst%3DS.%26aulast%3DNishimura%26aufirst%3DT.%26aulast%3DMichie%26aufirst%3DS.%2BA.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYates%26aufirst%3DA.%2BJ.%26aulast%3DDay%26aufirst%3DJ.%2BS.%26aulast%3DHillgren%26aufirst%3DK.%2BM.%26aulast%3DTakeda%26aufirst%3DS.%2BT.%26aulast%3DGuan%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DPeltz%26aufirst%3DG.%26atitle%3DChimeric%2520TK-NOG%2520Mice%253A%2520A%2520Predictive%2520Model%2520for%2520Cholestatic%2520Human%2520Liver%2520Toxicity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D274%26epage%3D80%26doi%3D10.1124%2Fjpet.114.220798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bility, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, L.</span></span> <span> </span><span class="NLM_article-title">Modeling Hepatitis B Virus Infection, Immunopathology and Therapy in Mice</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2015.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.antiviral.2015.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26099683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVyiur3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=1-8&author=L.+Chengauthor=F.+Liauthor=M.+T.+Bilityauthor=C.+M.+Murphyauthor=L.+Su&title=Modeling+Hepatitis+B+Virus+Infection%2C+Immunopathology+and+Therapy+in+Mice&doi=10.1016%2Fj.antiviral.2015.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling hepatitis B virus infection, immunopathology and therapy in mice</span></div><div class="casAuthors">Cheng, Liang; Li, Feng; Bility, Moses T.; Murphy, Christopher M.; Su, Lishan</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Despite the availability of a preventive vaccine, chronic hepatitis B virus (HBV) infection-induced liver diseases continue to be a major global public health problem.  HBV naturally infects only humans and chimpanzees.  This narrow host range has hindered our ability to study the characteristics of the virus and how it interacts with its host.  It is thus important to establish small animal models to study HBV infection, persistence, clearance and the immunopathogenesis of chronic hepatitis B.  In this review, we briefly summarize currently available animal models for HBV research, then focus on mouse models, esp. the recently developed humanized mice that can support HBV infection and immunopathogenesis in vivo.  This article is part of a symposium in Antiviral Research on "From the discovery of the Australia antigen to the development of new curative therapies for hepatitis B: an unfinished story.".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCH0J63BWnB7Vg90H21EOLACvtfcHk0lhzA0S9mrmQ4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVyiur3M&md5=f368a373c70c50c27f1bba05561e18ba</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2015.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2015.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DBility%26aufirst%3DM.%2BT.%26aulast%3DMurphy%26aufirst%3DC.%2BM.%26aulast%3DSu%26aufirst%3DL.%26atitle%3DModeling%2520Hepatitis%2520B%2520Virus%2520Infection%252C%2520Immunopathology%2520and%2520Therapy%2520in%2520Mice%26jtitle%3DAntiviral%2520Res.%26date%3D2015%26volume%3D121%26spage%3D1%26epage%3D8%26doi%3D10.1016%2Fj.antiviral.2015.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrill, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeSmet, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaddy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paine, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tidwell, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">A Mouse Diversity Panel Approach Reveals the Potential for Clinical Kidney Injury Due to DB289 Not Predicted by Classical Rodent Models</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">426</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfs238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfs238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22940726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs12ltbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2012&pages=416-426&author=A.+H.+Harrillauthor=K.+D.+DeSmetauthor=K.+K.+Wolfauthor=A.+S.+Bridgesauthor=J.+S.+Eaddyauthor=C.+L.+Kurtzauthor=J.+E.+Hallauthor=M.+F.+Paineauthor=R.+R.+Tidwellauthor=P.+B.+Watkins&title=A+Mouse+Diversity+Panel+Approach+Reveals+the+Potential+for+Clinical+Kidney+Injury+Due+to+DB289+Not+Predicted+by+Classical+Rodent+Models&doi=10.1093%2Ftoxsci%2Fkfs238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">A Mouse Diversity Panel Approach Reveals the Potential for Clinical Kidney Injury Due to DB289 Not Predicted by Classical Rodent Models</span></div><div class="casAuthors">Harrill, Alison H.; DeSmet, Kristina D.; Wolf, Kristina K.; Bridges, Arlene S.; Eaddy, J. Scott; Kurtz, C. Lisa; Hall, J. Ed.; Paine, Mary F.; Tidwell, Richard R.; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">416-426</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">DB289 is the first oral drug shown in clin. trials to have efficacy in treating African trypanosomiasis (African sleeping sickness).  Mild liver toxicity was noted but was not treatment limiting.  However, development of DB289 was terminated when several treated subjects developed severe kidney injury, a liability not predicted from preclin. testing.  We tested the hypothesis that the kidney safety liability of DB289 would be detected in a mouse diversity panel (MDP) comprised of 34 genetically diverse inbred mouse strains.  MDP mice received 10 days of oral treatment with DB289 or vehicle and classical renal biomarkers blood urea nitrogen (BUN) and serum creatinine (sCr), as well as urine biomarkers of kidney injury were measured.  While BUN and sCr remained within ref. ranges, marked elevations were obsd. for kidney injury mol.-1 (KIM-1) in the urine of sensitive mouse strains.  KIM-1 elevations were not always coincident with elevations in alanine aminotransferase (ALT), suggesting that renal injury was not linked to hepatic injury.  Genome-wide assocn. analyses of KIM-1 elevations indicated that genes participating in cholesterol and lipid biosynthesis and transport, oxidative stress, and cytokine release may play a role in DB289 renal injury.  Taken together, the data resulting from this study highlight the utility of using an MDP to predict clin. relevant toxicities, to identify relevant toxicity biomarkers that may translate into the clinic, and to identify potential mechanisms underlying toxicities.  In addn., the sensitive mouse strains identified in this study may be useful in screening next-in-class compds. for renal injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRrTVMJbDVJbVg90H21EOLACvtfcHk0lhzA0S9mrmQ4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs12ltbzO&md5=1420cc12c19db122bf10edf12253c731</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfs238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfs238%26sid%3Dliteratum%253Aachs%26aulast%3DHarrill%26aufirst%3DA.%2BH.%26aulast%3DDeSmet%26aufirst%3DK.%2BD.%26aulast%3DWolf%26aufirst%3DK.%2BK.%26aulast%3DBridges%26aufirst%3DA.%2BS.%26aulast%3DEaddy%26aufirst%3DJ.%2BS.%26aulast%3DKurtz%26aufirst%3DC.%2BL.%26aulast%3DHall%26aufirst%3DJ.%2BE.%26aulast%3DPaine%26aufirst%3DM.%2BF.%26aulast%3DTidwell%26aufirst%3DR.%2BR.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DA%2520Mouse%2520Diversity%2520Panel%2520Approach%2520Reveals%2520the%2520Potential%2520for%2520Clinical%2520Kidney%2520Injury%2520Due%2520to%2520DB289%2520Not%2520Predicted%2520by%2520Classical%2520Rodent%2520Models%26jtitle%3DToxicol.%2520Sci.%26date%3D2012%26volume%3D130%26spage%3D416%26epage%3D426%26doi%3D10.1093%2Ftoxsci%2Fkfs238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrill, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbourt, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stylianou, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boorman, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sackler, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tennant, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paigen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contractor, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiltshire, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusyn, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Threadgill, D. W.</span></span> <span> </span><span class="NLM_article-title">Mouse Population-Guided Resequencing Reveals that Variants in CD44 Contribute to Acetaminophen-Induced Liver Injury in Humans</span>. <i>Genome Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1507</span>– <span class="NLM_lpage">1515</span>, <span class="refDoi"> DOI: 10.1101/gr.090241.108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1101%2Fgr.090241.108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19416960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCjsLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1507-1515&author=A.+H.+Harrillauthor=P.+B.+Watkinsauthor=S.+Suauthor=P.+K.+Rossauthor=D.+E.+Harbourtauthor=I.+M.+Stylianouauthor=G.+A.+Boormanauthor=M.+W.+Russoauthor=R.+S.+Sacklerauthor=S.+C.+Harrisauthor=P.+C.+Smithauthor=R.+Tennantauthor=M.+Bogueauthor=K.+Paigenauthor=C.+Harrisauthor=T.+Contractorauthor=T.+Wiltshireauthor=I.+Rusynauthor=D.+W.+Threadgill&title=Mouse+Population-Guided+Resequencing+Reveals+that+Variants+in+CD44+Contribute+to+Acetaminophen-Induced+Liver+Injury+in+Humans&doi=10.1101%2Fgr.090241.108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans</span></div><div class="casAuthors">Harrill, Alison H.; Watkins, Paul B.; Su, Stephen; Ross, Pamela K.; Harbourt, David E.; Stylianou, Ioannis M.; Boorman, Gary A.; Russo, Mark W.; Sackler, Richard S.; Harris, Stephen C.; Smith, Philip C.; Tennant, Raymond; Bogue, Molly; Paigen, Kenneth; Harris, Christopher; Contractor, Tanupriya; Wiltshire, Timothy; Rusyn, Ivan; Threadgill, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Genome Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1507-1515</span>CODEN:
                <span class="NLM_cas:coden">GEREFS</span>;
        ISSN:<span class="NLM_cas:issn">1088-9051</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Interindividual variability in response to chems. and drugs is a common regulatory concern.  It is assumed that xenobiotic-induced adverse reactions have a strong genetic basis, but many mechanism-based investigations have not been successful in identifying susceptible individuals.  While recent advances in pharmacogenetics of adverse drug reactions show promise, the small size of the populations susceptible to important adverse events limits the utility of whole-genome assocn. studies conducted entirely in humans.  We present a strategy to identify genetic polymorphisms that may underlie susceptibility to adverse drug reactions.  First, in a cohort of healthy adults who received the max. recommended dose of acetaminophen (4 g/d × 7 d), we confirm that about one third of subjects develop elevations in serum alanine aminotransferase, indicative of liver injury.  To identify the genetic basis for this susceptibility, a panel of 36 inbred mouse strains was used to model genetic diversity.  Mice were treated with 300 mg/kg or a range of addnl. acetaminophen doses, and the extent of liver injury was quantified.  We then employed whole-genome assocn. anal. and targeted sequencing to det. that polymorphisms in Ly86, Cd44, Cd59a, and Capn8 correlate strongly with liver injury and demonstrated that dose-curves vary with background.  Finally, we demonstrated that variation in the orthologous human gene, CD44, is assocd. with susceptibility to acetaminophen in two independent cohorts.  Our results indicate a role for CD44 in modulation of susceptibility to acetaminophen hepatotoxicity.  These studies demonstrate that a diverse mouse population can be used to understand and predict adverse toxicity in heterogeneous human populations through guided resequencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdp8pLW2ETNbVg90H21EOLACvtfcHk0liO6KLf5PesCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCjsLrN&md5=6d5bc91005f3c7ebb0da039bdfdf3c04</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1101%2Fgr.090241.108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgr.090241.108%26sid%3Dliteratum%253Aachs%26aulast%3DHarrill%26aufirst%3DA.%2BH.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DSu%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DP.%2BK.%26aulast%3DHarbourt%26aufirst%3DD.%2BE.%26aulast%3DStylianou%26aufirst%3DI.%2BM.%26aulast%3DBoorman%26aufirst%3DG.%2BA.%26aulast%3DRusso%26aufirst%3DM.%2BW.%26aulast%3DSackler%26aufirst%3DR.%2BS.%26aulast%3DHarris%26aufirst%3DS.%2BC.%26aulast%3DSmith%26aufirst%3DP.%2BC.%26aulast%3DTennant%26aufirst%3DR.%26aulast%3DBogue%26aufirst%3DM.%26aulast%3DPaigen%26aufirst%3DK.%26aulast%3DHarris%26aufirst%3DC.%26aulast%3DContractor%26aufirst%3DT.%26aulast%3DWiltshire%26aufirst%3DT.%26aulast%3DRusyn%26aufirst%3DI.%26aulast%3DThreadgill%26aufirst%3DD.%2BW.%26atitle%3DMouse%2520Population-Guided%2520Resequencing%2520Reveals%2520that%2520Variants%2520in%2520CD44%2520Contribute%2520to%2520Acetaminophen-Induced%2520Liver%2520Injury%2520in%2520Humans%26jtitle%3DGenome%2520Res.%26date%3D2009%26volume%3D19%26spage%3D1507%26epage%3D1515%26doi%3D10.1101%2Fgr.090241.108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adkins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrill, A. H.</span></span> <span> </span><span class="NLM_article-title">Dysregulation of Protein Degradation Pathways May Mediate the Liver Injury and Phospholipidosis Associated with a Cationic Amphiphilic Antibiotic Drug</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2014.06.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.taap.2014.06.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24967691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ylurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2014&pages=21-29&author=M.+Mosedaleauthor=H.+Wuauthor=C.+L.+Kurtzauthor=S.+P.+Schmidtauthor=K.+Adkinsauthor=A.+H.+Harrill&title=Dysregulation+of+Protein+Degradation+Pathways+May+Mediate+the+Liver+Injury+and+Phospholipidosis+Associated+with+a+Cationic+Amphiphilic+Antibiotic+Drug&doi=10.1016%2Fj.taap.2014.06.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Dysregulation of protein degradation pathways may mediate the liver injury and phospholipidosis associated with a cationic amphiphilic antibiotic drug</span></div><div class="casAuthors">Mosedale, Merrie; Wu, Hong; Kurtz, C. Lisa; Schmidt, Stephen P.; Adkins, Karissa; Harrill, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-29</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A large no. of antibiotics are known to cause drug-induced liver injury in the clinic; however, interpreting clin. risk is not straightforward owing to a lack of predictivity of the toxicity by std. preclin. species and a poor understanding of the mechanisms of toxicity.  An example is PF-04287881, a novel ketolide antibiotic that caused elevations in liver function tests in Phase I clin. studies.  In this study, a mouse diversity panel (MDP), comprised of 34 genetically diverse, inbred mouse strains, was utilized to model the toxicity obsd. with PF-04287881 treatment and investigate potential mechanisms that may mediate the liver response.  Significant elevations in serum alanine aminotransferase (ALT) levels in PF-04287881-treated animals relative to vehicle-treated controls were obsd. in the majority (88%) of strains tested following a seven day exposure.  The av. fold elevation in ALT varied by genetic background and correlated with microscopic findings of hepatocellular hypertrophy, hepatocellular single cell necrosis, and Kupffer cell vacuolation (confirmed as phospholipidosis) in the liver.  Global liver mRNA expression was evaluated in a subset of four strains to identify transcript and pathway differences that distinguish susceptible mice from resistant mice in the context of PF-04287881 treatment.  The protein ubiquitination pathway was highly enriched among genes assocd. with PF-04287881-induced hepatocellular necrosis.  Expression changes assocd. with PF-04287881-induced phospholipidosis included genes involved in drug transport, phospholipid metab., and lysosomal function.  The findings suggest that perturbations in genes involved in protein degrdn. leading to accumulation of oxidized proteins may mediate the liver injury induced by this drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNLHHUlGcgfrVg90H21EOLACvtfcHk0liO6KLf5PesCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ylurbM&md5=1444245692c443411401dd03c8d4b282</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2014.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2014.06.013%26sid%3Dliteratum%253Aachs%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DKurtz%26aufirst%3DC.%2BL.%26aulast%3DSchmidt%26aufirst%3DS.%2BP.%26aulast%3DAdkins%26aufirst%3DK.%26aulast%3DHarrill%26aufirst%3DA.%2BH.%26atitle%3DDysregulation%2520of%2520Protein%2520Degradation%2520Pathways%2520May%2520Mediate%2520the%2520Liver%2520Injury%2520and%2520Phospholipidosis%2520Associated%2520with%2520a%2520Cationic%2520Amphiphilic%2520Antibiotic%2520Drug%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2014%26volume%3D280%26spage%3D21%26epage%3D29%26doi%3D10.1016%2Fj.taap.2014.06.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Court, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazarika, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasiadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenblatt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span> <span> </span><span class="NLM_article-title">Candidate Gene Polymorphisms in Patients with Acetaminophen-Induced Acute Liver Failure</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1124/dmd.113.053546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fdmd.113.053546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24104197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=28-32&author=M.+H.+Courtauthor=I.+Peterauthor=S.+Hazarikaauthor=M.+Vasiadiauthor=D.+J.+Greenblattauthor=W.+Lee&title=Candidate+Gene+Polymorphisms+in+Patients+with+Acetaminophen-Induced+Acute+Liver+Failure&doi=10.1124%2Fdmd.113.053546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Candidate gene polymorphisms in patients with acetaminophen-induced acute liver failure</span></div><div class="casAuthors">Court, Michael H.; Peter, Inga; Hazarika, Suwagami; Vasiadi, Magdalini; Greenblatt, David J.; Lee, William M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-32</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Acetaminophen is a leading cause of acute liver failure (ALF).  Genetic differences might predispose some individuals to develop ALF.  In this exploratory study, we evaluated genotype frequency differences among patients enrolled by the ALF Study Group who had developed ALF either intentionally from a single-time-point overdose of acetaminophen (n = 78), unintentionally after chronic high doses of acetaminophen (n = 79), or from causes other than acetaminophen (n = 103).  The polymorphisms evaluated included those in genes encoding putative acetaminophen-metabolizing enzymes (UGT1A1, UGT1A6, UGT1A9, UGT2B15, SULT1A1, CYP2E1, and CYP3A5) as well as CD44 and BHMT1.  Individuals carrying the CYP3A5 rs776746 A allele were overrepresented among ALF patients who had intentionally overdosed with acetaminophen, with an odds ratio of 2.3 (95% confidence interval, 1.1-4.9; P = 0.034) compared with all other ALF patients.  This finding is consistent with the enhanced bioactivation of acetaminophen by the CYP3A5 enzyme.  Persons homozygous for the CD44 rs1467558 A allele were also overrepresented among patients who had unintentionally developed ALF from chronic acetaminophen use, with an odds ratio of 4.0 (1.0-17.2, P = 0.045) compared with all other ALF subjects.  This finding confirms a prior study that found elevated serum liver enzyme levels in healthy volunteers with the CD44 rs1467558 AA genotype who had consumed high doses of acetaminophen for up to 2 wk.  However, both genetic assocns. were considered relatively weak, and they were not statistically significant after adjustment for multiple comparisons testing.  Nevertheless, both CYP3A5 rs776746 and CD44 rs1467558 warrant further investigation as potential genomic markers of enhanced risk of acetaminophen-induced ALF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy9fglTdO0F7Vg90H21EOLACvtfcHk0liO6KLf5PesCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOntA%253D%253D&md5=3d53dcc38b8fed63ee45608f2c03637d</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1124%2Fdmd.113.053546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.113.053546%26sid%3Dliteratum%253Aachs%26aulast%3DCourt%26aufirst%3DM.%2BH.%26aulast%3DPeter%26aufirst%3DI.%26aulast%3DHazarika%26aufirst%3DS.%26aulast%3DVasiadi%26aufirst%3DM.%26aulast%3DGreenblatt%26aufirst%3DD.%2BJ.%26aulast%3DLee%26aufirst%3DW.%26atitle%3DCandidate%2520Gene%2520Polymorphisms%2520in%2520Patients%2520with%2520Acetaminophen-Induced%2520Acute%2520Liver%2520Failure%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2014%26volume%3D42%26spage%3D28%26epage%3D32%26doi%3D10.1124%2Fdmd.113.053546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group">Collaborative Cross Consortium</span> <span> </span><span class="NLM_article-title">The Genome Architecture of the Collaborative Cross
Mouse Genetic Reference Population</span>. <i>Genetics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1534/genetics.111.132639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1534%2Fgenetics.111.132639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22345608" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2012&pages=389-401&author=Collaborative+Cross+Consortium&title=The+Genome+Architecture+of+the+Collaborative+Cross%0AMouse+Genetic+Reference+Population&doi=10.1534%2Fgenetics.111.132639"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1534%2Fgenetics.111.132639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1534%252Fgenetics.111.132639%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DThe%2520Genome%2520Architecture%2520of%2520the%2520Collaborative%2520Cross%250AMouse%2520Genetic%2520Reference%2520Population%26jtitle%3DGenetics%26date%3D2012%26volume%3D190%26spage%3D389%26epage%3D401%26doi%3D10.1534%2Fgenetics.111.132639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelada, S. N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aylor, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chines, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutledge, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesler, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchill, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo-Manuel de Villena, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, F. S.</span></span> <span> </span><span class="NLM_article-title">Integrative Genetic Analysis of Allergic Inflammation in the Murine Lung</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">436</span>– <span class="NLM_lpage">445</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2013-0501OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1165%2Frcmb.2013-0501OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24693920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yqt7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2014&pages=436-445&author=S.+N.+P.+Keladaauthor=D.+E.+Carpenterauthor=D.+L.+Aylorauthor=P.+Chinesauthor=H.+Rutledgeauthor=E.+J.+Cheslerauthor=G.+A.+Churchillauthor=F.+Pardo-Manuel+de+Villenaauthor=D.+A.+Schwartzauthor=F.+S.+Collins&title=Integrative+Genetic+Analysis+of+Allergic+Inflammation+in+the+Murine+Lung&doi=10.1165%2Frcmb.2013-0501OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Integrative genetic analysis of allergic inflammation in the murine lung</span></div><div class="casAuthors">Kelada, Samir N. P.; Carpenter, Danielle E.; Aylor, David L.; Chines, Peter; Rutledge, Holly; Chesler, Elissa J.; Churchill, Gary A.; de Villena, Fernando Pardo-Manuel; Schwartz, David A.; Collins, Francis S.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">436-445</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Airway allergen exposure induces inflammation among individuals with atopy that is characterized by altered airway gene expression, elevated levels of T helper type 2 cytokines, mucus hypersecretion, and airflow obstruction.  To identify the genetic determinants of the airway allergen response, we employed a systems genetics approach.  We applied a house dust mite mouse model of allergic airway disease to 151 incipient lines of the Collaborative Cross, a new mouse genetic ref. population, and measured serum IgE, airway eosinophilia, and gene expression in the lung.  Allergen-induced serum IgE and airway eosinophilia were not correlated.  We detected quant. trait loci (QTL) for airway eosinophilia on chromosome (Chr) 11 (71.802-87.098 megabases [Mb]) and allergen-induced IgE on Chr 4 (13.950-31.660 Mb).  More than 4,500 genes expressed in the lung had gene expression QTL (eQTL), the majority of which were located near the gene itself.  However, we also detected approx. 1,700 trans-eQTL, and many of these trans-eQTL clustered into two regions on Chr 2.  We show that one of these loci (at 147.6 Mb) is assocd. with the expression of more than 100 genes, and, using bioinformatics resources, fine-map this locus to a 53 kb-long interval.  We also use the gene expression and eQTL data to identify a candidate gene, Tlcd2, for the eosinophil QTL.  Our results demonstrate that hallmark allergic airway disease phenotypes are assocd. with distinct genetic loci on Chrs 4 and 11, and that gene expression in the allergically inflamed lung is controlled by both cis and trans regulatory factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0rzmqd-rT17Vg90H21EOLACvtfcHk0lhznNWFa9AVRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yqt7rM&md5=c8e917b86757045ca2080d5bb0a3bd29</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2013-0501OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2013-0501OC%26sid%3Dliteratum%253Aachs%26aulast%3DKelada%26aufirst%3DS.%2BN.%2BP.%26aulast%3DCarpenter%26aufirst%3DD.%2BE.%26aulast%3DAylor%26aufirst%3DD.%2BL.%26aulast%3DChines%26aufirst%3DP.%26aulast%3DRutledge%26aufirst%3DH.%26aulast%3DChesler%26aufirst%3DE.%2BJ.%26aulast%3DChurchill%26aufirst%3DG.%2BA.%26aulast%3DPardo-Manuel%2Bde%2BVillena%26aufirst%3DF.%26aulast%3DSchwartz%26aufirst%3DD.%2BA.%26aulast%3DCollins%26aufirst%3DF.%2BS.%26atitle%3DIntegrative%2520Genetic%2520Analysis%2520of%2520Allergic%2520Inflammation%2520in%2520the%2520Murine%2520Lung%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2014%26volume%3D51%26spage%3D436%26epage%3D445%26doi%3D10.1165%2Frcmb.2013-0501OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rutledge, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aylor, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chines, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrowski, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesler, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchill, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Villena, F. P.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelada, S. N. P.</span></span> <span> </span><span class="NLM_article-title">Genetic Regulation of Zfp30, CXCL1, and Neutrophilic Inflammation in Murine Lung</span>. <i>Genetics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>198</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">745</span>, <span class="refDoi"> DOI: 10.1534/genetics.114.168138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1534%2Fgenetics.114.168138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25114278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFGhurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2014&pages=735-745&author=H.+Rutledgeauthor=D.+L.+Aylorauthor=D.+E.+Carpenterauthor=B.+C.+Peckauthor=P.+Chinesauthor=L.+E.+Ostrowskiauthor=E.+J.+Cheslerauthor=G.+A.+Churchillauthor=F.+P.-M.+de+Villenaauthor=S.+N.+P.+Kelada&title=Genetic+Regulation+of+Zfp30%2C+CXCL1%2C+and+Neutrophilic+Inflammation+in+Murine+Lung&doi=10.1534%2Fgenetics.114.168138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic regulation of Zfp30, CXCL1, and neutrophilic inflammation in murine lung</span></div><div class="casAuthors">Rutledge, Holly; Aylor, David L.; Carpenter, Danielle E.; Peck, Bailey C.; Chines, Peter; Ostrowski, Lawrence E.; Chesler, Elissa J.; Churchill, Gary A.; de Villena, Fernando Pardo-Manuel; Kelada, Samir N. P.</div><div class="citationInfo"><span class="NLM_cas:title">Genetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">735-745</span>CODEN:
                <span class="NLM_cas:coden">GENTAE</span>;
        ISSN:<span class="NLM_cas:issn">0016-6731</span>.
    
            (<span class="NLM_cas:orgname">Genetics Society of America</span>)
        </div><div class="casAbstract">Allergic asthma is a complex disease characterized in part by granulocytic inflammation of the airways.  In addn. to eosinophils, neutrophils (PMN) are also present, particularly in cases of severe asthma.  We sought to identify the genetic determinants of neutrophilic inflammation in a mouse model of house dust mite (HDM)-induced asthma.  We applied an HDM model of allergic asthma to the eight founder strains of the Collaborative Cross (CC) and 151 incipient lines of the CC (preCC).  Lung lavage fluid was analyzed for PMN count and the concn. of CXCL1, a hallmark PMN chemokine.  PMN and CXCL1 were strongly correlated in preCC mice.  We used quant. trait locus (QTL) mapping to identify three variants affecting PMN, one of which colocalized with a QTL for CXCL1 on chromosome (Chr) 7.  We used lung eQTL data to implicate a variant in the gene Zfp30 in the CXCL1/PMN response.  This genetic variant regulates both CXCL1 and PMN by altering Zfp30 expression, and we model the relationships between the QTL and these three endophenotypes.  We show that Zfp30 is expressed in airway epithelia in the normal mouse lung and that altering Zfp30 expression in vitro affects CXCL1 responses to an immune stimulus.  Our results provide strong evidence that Zfp30 is a novel regulator of neutrophilic airway inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr1IcZKYAhBrVg90H21EOLACvtfcHk0lhznNWFa9AVRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFGhurzO&md5=39652996ab332d4eb74a91e9b52ef16c</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1534%2Fgenetics.114.168138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1534%252Fgenetics.114.168138%26sid%3Dliteratum%253Aachs%26aulast%3DRutledge%26aufirst%3DH.%26aulast%3DAylor%26aufirst%3DD.%2BL.%26aulast%3DCarpenter%26aufirst%3DD.%2BE.%26aulast%3DPeck%26aufirst%3DB.%2BC.%26aulast%3DChines%26aufirst%3DP.%26aulast%3DOstrowski%26aufirst%3DL.%2BE.%26aulast%3DChesler%26aufirst%3DE.%2BJ.%26aulast%3DChurchill%26aufirst%3DG.%2BA.%26aulast%3Dde%2BVillena%26aufirst%3DF.%2BP.-M.%26aulast%3DKelada%26aufirst%3DS.%2BN.%2BP.%26atitle%3DGenetic%2520Regulation%2520of%2520Zfp30%252C%2520CXCL1%252C%2520and%2520Neutrophilic%2520Inflammation%2520in%2520Murine%2520Lung%26jtitle%3DGenetics%26date%3D2014%26volume%3D198%26spage%3D735%26epage%3D745%26doi%3D10.1534%2Fgenetics.114.168138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brock, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiltshire, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaddy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keele, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corty, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdar, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfw269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfw269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28115652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2017&pages=438-54&author=M.+Mosedaleauthor=Y.+Kimauthor=W.+J.+Brockauthor=S.+E.+Rothauthor=T.+Wiltshireauthor=J.+S.+Eaddyauthor=G.+R.+Keeleauthor=R.+W.+Cortyauthor=Y.+Xieauthor=W.+Valdarauthor=P.+B.+Watkins&title=Candidate+Risk+Factors+and+Mechanisms+for+Tolvaptan-Induced+Liver+Injury+Are+Identified+Using+a+Collaborative+Cross+Approach&doi=10.1093%2Ftoxsci%2Fkfw269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Candidate risk factors and mechanisms for tolvaptan-induced liver injury are identified using a collaborative cross approach</span></div><div class="casAuthors">Mosedale, Merrie; Kim, Yunjung; Brock, William J.; Roth, Sharin E.; Wiltshire, Tim; Eaddy, J. Scott; Keele, Gregory R.; Corty, Robert W.; Xie, Yuying; Valdar, William; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">438-454</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Clin. trials of tolvaptan showed it to be a promising candidate for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) but also revealed potential for idiosyncratic drug-induced liver injury (DILI) in this patient population.  To identify risk factors and mechanisms underlying tolvaptan DILI, 8 mice in each of 45 strains of the genetically diverse Collaborative Cross (CC) mouse population were treated with a single oral dose of either tolvaptan or vehicle.  Significant elevations in plasma alanine aminotransferase (ALT) were obsd. in tolvaptan-treated animals in 3 of the 45 strains.  Genetic mapping coupled with transcriptomic anal. in the liver was used to identify several candidate susceptibility genes including epoxide hydrolase 2, interferon regulatory factor 3, and mitochondrial fission factor.  Gene pathway anal. revealed that oxidative stress and immune response pathways were activated in response to tolvaptan treatment across all strains, but genes involved in regulation of bile acid homeostasis were most assocd. with tolvaptan-induced elevations in ALT.  Secretory leukocyte peptidase inhibitor (Slpi) mRNA was also induced in the susceptible strains and was assocd. with increased plasma levels of Slpi protein, suggesting a potential serum marker for DILI susceptibility.  In summary, tolvaptan induced signs of oxidative stress, mitochondrial dysfunction, and innate immune response in all strains, but variation in bile acid homeostasis was most assocd. with susceptibility to the liver response.  This CC study has indicated potential mechanisms underlying tolvaptan DILI and biomarkers of susceptibility that may be useful in managing the risk of DILI in ADPKD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr17_b9VGbVSLVg90H21EOLACvtfcHk0lhznNWFa9AVRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOrtLc%253D&md5=5957b4b87f571986f5e63cb08dd9e388</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfw269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfw269%26sid%3Dliteratum%253Aachs%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DBrock%26aufirst%3DW.%2BJ.%26aulast%3DRoth%26aufirst%3DS.%2BE.%26aulast%3DWiltshire%26aufirst%3DT.%26aulast%3DEaddy%26aufirst%3DJ.%2BS.%26aulast%3DKeele%26aufirst%3DG.%2BR.%26aulast%3DCorty%26aufirst%3DR.%2BW.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DValdar%26aufirst%3DW.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DCandidate%2520Risk%2520Factors%2520and%2520Mechanisms%2520for%2520Tolvaptan-Induced%2520Liver%2520Injury%2520Are%2520Identified%2520Using%2520a%2520Collaborative%2520Cross%2520Approach%26jtitle%3DToxicol.%2520Sci.%26date%3D2017%26volume%3D156%26spage%3D438%26epage%3D54%26doi%3D10.1093%2Ftoxsci%2Fkfw269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaddy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corty, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nautiyal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdar, W.</span></span> <span> </span><span class="NLM_article-title">Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">278</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfz199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfz199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=31501888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BB3MrmvVKisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2019&pages=265-278&author=M.+Mosedaleauthor=Y.+Caiauthor=J.+S.+Eaddyauthor=R.+W.+Cortyauthor=M.+Nautiyalauthor=P.+B.+Watkinsauthor=W.+Valdar&title=Identification+of+Candidate+Risk+Factor+Genes+for+Human+Idelalisib+Toxicity+Using+a+Collaborative+Cross+Approach&doi=10.1093%2Ftoxsci%2Fkfz199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach</span></div><div class="casAuthors">Mosedale Merrie; Cai Yanwei; Eaddy John Scott; Nautiyal Manisha; Watkins Paul B; Mosedale Merrie; Watkins Paul B; Cai Yanwei; Corty Robert W; Valdar William; Valdar William</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological sciences : an official journal of the Society of Toxicology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">265-278</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Idelalisib is a phosphatidylinositol 3-kinase inhibitor highly selective for the delta isoform that has shown good efficacy in treating chronic lymphocytic leukemia and follicular lymphoma.  In clinical trials, however, idelalisib was associated with rare, but potentially serious liver and lung toxicities.  In this study, we used the Collaborative Cross (CC) mouse population to identify genetic factors associated with the drug response that may inform risk management strategies for idelalisib in humans.  Eight male mice (4 matched pairs) from 50 CC lines were treated once daily for 14 days by oral gavage with either vehicle or idelalisib at a dose selected to achieve clinically relevant peak plasma concentrations (150 mg/kg/day).  The drug was well tolerated across all CC lines, and there were no observations of overt liver injury.  Differences across CC lines were seen in drug concentration in plasma samples collected at the approximate Tmax on study Days 1, 7, and 14.  There were also small but statistically significant treatment-induced alterations in plasma total bile acids and microRNA-122, and these may indicate early hepatocellular stress required for immune-mediated hepatotoxicity in humans.  Idelalisib treatment further induced significant elevations in the total cell count of terminal bronchoalveolar lavage fluid, which may be analogous to pneumonitis observed in the clinic.  Genetic mapping identified loci associated with interim plasma idelalisib concentration and the other 3 treatment-related endpoints.  Thirteen priority candidate quantitative trait genes identified in CC mice may now guide interrogation of risk factors for adverse drug responses associated with idelalisib in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcST5jzZDklkoyA3UY9EwTNrfW6udTcc2eaTJZ4-lrGAB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrmvVKisg%253D%253D&md5=63ccb346610d3a5b875d04937debb07c</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfz199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfz199%26sid%3Dliteratum%253Aachs%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DEaddy%26aufirst%3DJ.%2BS.%26aulast%3DCorty%26aufirst%3DR.%2BW.%26aulast%3DNautiyal%26aufirst%3DM.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DValdar%26aufirst%3DW.%26atitle%3DIdentification%2520of%2520Candidate%2520Risk%2520Factor%2520Genes%2520for%2520Human%2520Idelalisib%2520Toxicity%2520Using%2520a%2520Collaborative%2520Cross%2520Approach%26jtitle%3DToxicol.%2520Sci.%26date%3D2019%26volume%3D172%26spage%3D265%26epage%3D278%26doi%3D10.1093%2Ftoxsci%2Fkfz199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norona, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presnell, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Bioprinted Liver Provides Early Insight Into the Role of Kupffer Cells in TGF-β1 and Methotrexate-Induced Fibrogenesis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">e0208958</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0208958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1371%2Fjournal.pone.0208958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30601836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtFemsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=e0208958&author=L.+M.+Noronaauthor=D.+G.+Nguyenauthor=D.+A.+Gerberauthor=S.+C.+Presnellauthor=M.+Mosedaleauthor=P.+B.+Watkins&title=Bioprinted+Liver+Provides+Early+Insight+Into+the+Role+of+Kupffer+Cells+in+TGF-%CE%B21+and+Methotrexate-Induced+Fibrogenesis&doi=10.1371%2Fjournal.pone.0208958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Bioprinted liver provides early insight into the role of Kupffer cells in TGF-β1 and methotrexate-induced fibrogenesis</span></div><div class="casAuthors">Norona, Leah M.; Nguyen, Deborah G.; Gerber, David A.; Presnell, Sharon C.; Mosedale, Merrie; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0208958</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Hepatic fibrosis develops from a series of complex interactions among resident and recruited cells making it a challenge to replicate using std. in vitro approaches.  While studies have demonstrated the importance of macrophages in fibrogenesis, the role of Kupffer cells (KCs) in modulating the initial response remains elusive.  Previous work demonstrated utility of 3D bioprinted liver to recapitulate basic fibrogenic features following treatment with fibrosis-assocd. agents.  In the present study, culture conditions were modified to recapitulate a gradual accumulation of collagen within the tissues over an extended exposure timeframe.  Under these conditions, KCs were added to the model to examine their impact on the injury/fibrogenic response following cytokine and drug stimuli.  A 28-day exposure to 10 ng/mL TGF-β1 and 0.209μM methotrexate (MTX) resulted in sustained LDH release which was attenuated when KCs were incorporated in the model.  Assessment of miR-122 confirmed early hepatocyte injury in response to TGF-β1 that appeared delayed in the presence of KCs, whereas MTX-induced increases in miR-122 were obsd. when KCs were incorporated in the model.  Although the collagen responses were mild under the conditions tested to mimic early fibrotic injury, a global redn. in cytokines was obsd. in the KC-modified tissue model following treatment.  Furthermore, gene expression profiling suggests KCs have a significant impact on baseline tissue function over time and an important modulatory role dependent on the context of injury.  Although the no. of differentially expressed genes across treatments was comparable, pathway enrichment suggests distinct, KC- and time-dependent changes in the transcriptome for each agent.  As such, the incorporation of KCs and impact on baseline tissue homeostasis may be important in recapitulating temporal dynamics of the fibrogenic response to different agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy4mffnFbGT7Vg90H21EOLACvtfcHk0lhXvLk-DHv1Qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtFemsrs%253D&md5=48818594853bc65261ccd75d9f16ef4a</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0208958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0208958%26sid%3Dliteratum%253Aachs%26aulast%3DNorona%26aufirst%3DL.%2BM.%26aulast%3DNguyen%26aufirst%3DD.%2BG.%26aulast%3DGerber%26aufirst%3DD.%2BA.%26aulast%3DPresnell%26aufirst%3DS.%2BC.%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DBioprinted%2520Liver%2520Provides%2520Early%2520Insight%2520Into%2520the%2520Role%2520of%2520Kupffer%2520Cells%2520in%2520TGF-%25CE%25B21%2520and%2520Methotrexate-Induced%2520Fibrogenesis%26jtitle%3DPLoS%2520One%26date%3D2019%26volume%3D14%26spage%3De0208958%26doi%3D10.1371%2Fjournal.pone.0208958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laifenfeld, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swiss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macoritto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younis, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawton, M.</span></span> <span> </span><span class="NLM_article-title">Utilization of Causal Reasoning of Hepatic Gene Expression in Rats to Identify Molecular Pathways of Idiosyncratic Drug-Induced Liver Injury</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">234</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kft232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkft232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24136188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslKi" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2014&pages=234-248&author=D.+Laifenfeldauthor=L.+Qiuauthor=R.+Swissauthor=J.+Parkauthor=M.+Macorittoauthor=Y.+Willauthor=H.+S.+Younisauthor=M.+Lawton&title=Utilization+of+Causal+Reasoning+of+Hepatic+Gene+Expression+in+Rats+to+Identify+Molecular+Pathways+of+Idiosyncratic+Drug-Induced+Liver+Injury&doi=10.1093%2Ftoxsci%2Fkft232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Utilization of Causal Reasoning of Hepatic Gene Expression in Rats to Identify Molecular Pathways of Idiosyncratic Drug-Induced Liver Injury</span></div><div class="casAuthors">Laifenfeld, Daphna; Qiu, Luping; Swiss, Rachel; Park, Jennifer; Macoritto, Michael; Will, Yvonne; Younis, Husam S.; Lawton, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">234-248</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) represents a leading cause of acute liver failure.  Although DILI can be discovered in preclin. animal toxicol. studies and/or early clin. trials, some human DILI reactions, termed idiosyncratic DILI (IDILI), are less predictable, occur in a small no. of individuals, and do not follow a clear dose-response relationship.  The emergence of IDILI poses a crit. health challenge for patients and a financial challenge for the pharmaceutical industry.  Understanding the cellular and mol. mechanisms underlying IDILI is key to the development of models that can assess potential IDILI risk.  This study used Reverse Causal Reasoning (RCR), a method to assess activation of mol. signaling pathways, on gene expression data from rats treated with IDILI or pharmacol./chem. comparators (NON-DILI) at the max. tolerated dose to identify mechanistic pathways underlying IDILI.  Detailed mol. networks involved in mitochondrial injury, inflammation, and endoplasmic reticulum (ER) stress were found in response to IDILI drugs but not neg. controls (NON-DILI).  In vitro assays assessing mitochondrial or ER function confirmed the effect of IDILI compds. on these systems.  Together our work suggests that using gene expression data can aid in understanding mechanisms underlying IDILI and can guide in vitro screening for IDILI.  Specifically, RCR should be considered for compds. that do not show evidence of DILI in preclin. animal studies pos. for mitochondrial dysfunction and ER stress assays, esp. when the therapeutic index toward projected human max. drug plasma concn. is low.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUMD1yuyUx8bVg90H21EOLACvtfcHk0lhXvLk-DHv1Qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslKi&md5=7c705c16d5f51e5d1fa94ae16444b6a8</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkft232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkft232%26sid%3Dliteratum%253Aachs%26aulast%3DLaifenfeld%26aufirst%3DD.%26aulast%3DQiu%26aufirst%3DL.%26aulast%3DSwiss%26aufirst%3DR.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DMacoritto%26aufirst%3DM.%26aulast%3DWill%26aufirst%3DY.%26aulast%3DYounis%26aufirst%3DH.%2BS.%26aulast%3DLawton%26aufirst%3DM.%26atitle%3DUtilization%2520of%2520Causal%2520Reasoning%2520of%2520Hepatic%2520Gene%2520Expression%2520in%2520Rats%2520to%2520Identify%2520Molecular%2520Pathways%2520of%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DToxicol.%2520Sci.%26date%3D2014%26volume%3D137%26spage%3D234%26epage%3D248%26doi%3D10.1093%2Ftoxsci%2Fkft232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandon Parker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piechta, L.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark
Kao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jim Proctor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheyen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillian, M. K.</span></span> <span> </span><span class="NLM_article-title">Oxidative Stress/Reactive Metabolite Gene Expression Signature in Rat Liver Detects Idiosyncratic Hepatotoxicants</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2014.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.taap.2014.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24486436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlSrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2014&pages=189-197&author=A.+Leoneauthor=A.+Nieauthor=J.+Brandon+Parkerauthor=S.+Sawantauthor=L.-A.+Piechtaauthor=M.+F.+Kelleyauthor=L.+Mark%0AKaoauthor=S.+Jim+Proctorauthor=G.+Verheyenauthor=M.+D.+Johnsonauthor=P.+G.+Lordauthor=M.+K.+McMillian&title=Oxidative+Stress%2FReactive+Metabolite+Gene+Expression+Signature+in+Rat+Liver+Detects+Idiosyncratic+Hepatotoxicants&doi=10.1016%2Fj.taap.2014.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress/reactive metabolite gene expression signature in rat liver detects idiosyncratic hepatotoxicants</span></div><div class="casAuthors">Leone, Angelique; Nie, Alex; Brandon Parker, J.; Sawant, Sharmilee; Piechta, Leigh-Anne; Kelley, Michael F.; Mark Kao, L.; Jim Proctor, S.; Verheyen, Geert; Johnson, Mark D.; Lord, Peter G.; McMillian, Michael K.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">189-197</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Previously we reported a gene expression signature in rat liver for detecting a specific type of oxidative stress (OS) related to reactive metabolites (RM).  High doses of the drugs disulfiram, ethinyl estradiol and nimesulide were used with another dozen paradigm OS/RM compds., and three other drugs flutamide, phenacetin and sulindac were identified by this signature.  In a second study, antiepileptic drugs were compared for covalent binding and their effects on OS/RM; felbamate, carbamazepine, and phenobarbital produced robust OS/RM gene expression.  In the present study, liver RNA samples from drug-treated rats from more recent expts. were examd. for statistical fit to the OS/RM signature.  Of all 97 drugs examd., in addn. to the nine drugs noted above, 19 more were identified as OS/RM-producing compds.-chlorpromazine, clozapine, cyproterone acetate, dantrolene, dipyridamole, glibenclamide, isoniazid, ketoconazole, methapyrilene, naltrexone, nifedipine, sulfamethoxazole, tamoxifen, coumarin, ritonavir, amitriptyline, valproic acid, enalapril, and chloramphenicol.  Importantly, all of the OS/RM drugs listed above have been linked to idiosyncratic hepatotoxicity, excepting chloramphenicol, which does not have a package label for hepatotoxicity, but does have a black box warning for idiosyncratic bone marrow suppression.  Most of these drugs are not acutely toxic in the rat.  The OS/RM signature should be useful to avoid idiosyncratic hepatotoxicity of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov3sR9PpDDorVg90H21EOLACvtfcHk0liVCSvMP4EQuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlSrsLk%253D&md5=88c5135241b01e996b0b5022aa0e5dab</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2014.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2014.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DLeone%26aufirst%3DA.%26aulast%3DNie%26aufirst%3DA.%26aulast%3DBrandon%2BParker%26aufirst%3DJ.%26aulast%3DSawant%26aufirst%3DS.%26aulast%3DPiechta%26aufirst%3DL.-A.%26aulast%3DKelley%26aufirst%3DM.%2BF.%26aulast%3DMark%2BKao%26aufirst%3DL.%26aulast%3DJim%2BProctor%26aufirst%3DS.%26aulast%3DVerheyen%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DM.%2BD.%26aulast%3DLord%26aufirst%3DP.%2BG.%26aulast%3DMcMillian%26aufirst%3DM.%2BK.%26atitle%3DOxidative%2520Stress%252FReactive%2520Metabolite%2520Gene%2520Expression%2520Signature%2520in%2520Rat%2520Liver%2520Detects%2520Idiosyncratic%2520Hepatotoxicants%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2014%26volume%3D275%26spage%3D189%26epage%3D197%26doi%3D10.1016%2Fj.taap.2014.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span> <span> </span><span class="NLM_article-title">Mouse Population-Based Approaches to Investigate Adverse Drug Reactions</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1787</span>– <span class="NLM_lpage">1795</span>, <span class="refDoi"> DOI: 10.1124/dmd.118.082834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fdmd.118.082834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30045843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVeitbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=1787-1795&author=M.+Mosedale&title=Mouse+Population-Based+Approaches+to+Investigate+Adverse+Drug+Reactions&doi=10.1124%2Fdmd.118.082834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Mouse population-based approaches to investigate adverse drug reactions</span></div><div class="casAuthors">Mosedale, Merrie</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1787-1795</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Genetic variation is now recognized as a key factor in the toxicity of pharmaceutical agents.  However, genetic diversity is not present in std. nonclin. toxicol. models, and small clin. studies (phase I/II) may not include enough subjects to identify toxicity liabilities assocd. with less common susceptibility factors.  As a result, many drugs pass through preclin. and early clin. studies before safety concerns are realized.  Furthermore, when adverse drug reactions are idiosyncratic in nature, suggesting a role for rare genetic variants in the toxicity susceptibility, even large clin. studies (phase III) are often underpowered (due to low population frequency and/or small effect size of the risk factor) to identify assocns. that may be used for precision medicine risk mitigation strategies.  Genetically diverse mouse populations can be used to help overcome the limitations of std. nonclin. and clin. studies and to model toxicity responses that require genetic susceptibility factors.  Furthermore, mouse population-based approaches can be used to: 1) identify sensitive strains that canserveasascreening tool for next-in-class compds., 2) identify genetic susceptibility factors that can be used for risk mitigation strategies, and 3) studymechanisms underlying drug toxicity.  This review describes genetically diverse mouse populations and provides examples of their utility in investigating adverse drug response.  It also explores recent efforts to adapt mouse population-based approaches to in vitro platforms, thereby enabling the incorporation of genetic diversity and the identification of genetic risk factors and mechanisms assocd. with drug toxicity susceptibility at all stages of drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfF60XymZkv7Vg90H21EOLACvtfcHk0liVCSvMP4EQuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVeitbfI&md5=fe98211b89bf87206f2d050c978123ad</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1124%2Fdmd.118.082834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.118.082834%26sid%3Dliteratum%253Aachs%26aulast%3DMosedale%26aufirst%3DM.%26atitle%3DMouse%2520Population-Based%2520Approaches%2520to%2520Investigate%2520Adverse%2520Drug%2520Reactions%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26spage%3D1787%26epage%3D1795%26doi%3D10.1124%2Fdmd.118.082834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuberi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, C.</span></span> <span> </span><span class="NLM_article-title">Mouse Models for Drug Discovery. Can New Tools and Technology Improve Translational Power?</span>. <i>ILAR J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1093/ilar/ilw021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Filar%2Filw021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28053071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGqtLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=178-185&author=A.+Zuberiauthor=C.+Lutz&title=Mouse+Models+for+Drug+Discovery.+Can+New+Tools+and+Technology+Improve+Translational+Power%3F&doi=10.1093%2Filar%2Filw021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Mouse models for drug discovery. can new tools and technology improve translational power?</span></div><div class="casAuthors">Zuberi, Aamir; Lutz, Cathleen</div><div class="citationInfo"><span class="NLM_cas:title">ILAR Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">178-185</span>CODEN:
                <span class="NLM_cas:coden">IJLOAC</span>;
        ISSN:<span class="NLM_cas:issn">1084-2020</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The use of mouse models in biomedical research and preclin. drug evaluation is on the rise.  The advent of new mol. genome-altering technologies such as CRISPR/Cas9 allows for genetic mutations to be introduced into the germ line of a mouse faster and less expensively than previous methods.  In addn., the rapid progress in the development and use of somatic transgenesis using viral vectors, as well as manipulations of gene expression with siRNAs and antisense oligonucleotides, allow for even greater exploration into genomics and systems biol.  These technol. advances come at a time when cost redns. in genome sequencing have led to the identification of pathogenic mutations in patient populations, providing unprecedented opportunities in the use of mice to model human disease.  The ease of genetic engineering in mice also offers a potential paradigm shift in resource sharing and the speed by which models are made available in the public domain.  Predictively, the knowledge alone that a model can be quickly remade will provide relief to resources encumbered by licensing and Material Transfer Agreements.  For decades, mouse strains have provided an exquisite exptl. tool to study the pathophysiol. of the disease and assess therapeutic options in a genetically defined system.  However, a major limitation of the mouse has been the limited genetic diversity assocd. with common lab. mice.  This has been overcome with the recent development of the Collaborative Cross and Diversity Outbred mice.  These strains provide new tools capable of replicating genetic diversity to that approaching the diversity found in human populations.  The Collaborative Cross and Diversity Outbred strains thus provide a means to observe and characterize toxicity or efficacy of new therapeutic drugs for a given population.  The combination of traditional and contemporary mouse genome editing tools, along with the addn. of genetic diversity in new modeling systems, are synergistic and serve to make the mouse a better model for biomedical research, enhancing the potential for preclin. drug discovery and personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGcnARubI6j7Vg90H21EOLACvtfcHk0liVCSvMP4EQuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGqtLvI&md5=bbfb508bc9b6ec366a0491fd57971b6f</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1093%2Filar%2Filw021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Filar%252Filw021%26sid%3Dliteratum%253Aachs%26aulast%3DZuberi%26aufirst%3DA.%26aulast%3DLutz%26aufirst%3DC.%26atitle%3DMouse%2520Models%2520for%2520Drug%2520Discovery.%2520Can%2520New%2520Tools%2520and%2520Technology%2520Improve%2520Translational%2520Power%253F%26jtitle%3DILAR%2520J.%26date%3D2016%26volume%3D57%26spage%3D178%26epage%3D185%26doi%3D10.1093%2Filar%2Filw021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Godoy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolleyn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böttger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braeuning, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budinsky, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhardt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camussi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig Rowlands, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damm, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirsch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donato, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drasdo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eakins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonsato, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraczek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebhardt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glanemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Lechón, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groothuis, G. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustavsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guyot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallifax, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Häussinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellerbrand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoehme, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzhütter, H.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeschke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keitel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelm, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kevin Park, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kordes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kullak-Ublick, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCluyse, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luebke-Wheeler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maltman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matz-Soja, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMullen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merfort, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mwinyi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussler, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinga, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pampaloni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przyborski, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogiers, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schelcher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stelzer, E. H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stieger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stöber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thasler, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaecke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinken, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarborough, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hengstler, J. G.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in 2D and 3D In Vitro Systems Using Primary Hepatocytes, Alternative Hepatocyte Sources and Non-parenchymal Liver Cells and Their Use in Investigating Mechanisms of Hepatotoxicity, Cell Signaling and ADME</span>. <i>Arch. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">1315</span>– <span class="NLM_lpage">1530</span>, <span class="refDoi"> DOI: 10.1007/s00204-013-1078-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs00204-013-1078-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23974980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlahtr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=1315-1530&author=P.+Godoyauthor=N.+J.+Hewittauthor=U.+Albrechtauthor=M.+E.+Andersenauthor=N.+Ansariauthor=S.+Bhattacharyaauthor=J.+G.+Bodeauthor=J.+Bolleynauthor=C.+Bornerauthor=J.+B%C3%B6ttgerauthor=A.+Braeuningauthor=R.+A.+Budinskyauthor=B.+Burkhardtauthor=N.+R.+Cameronauthor=G.+Camussiauthor=C.-S.+Choauthor=Y.-J.+Choiauthor=J.+Craig+Rowlandsauthor=U.+Dahmenauthor=G.+Dammauthor=O.+Dirschauthor=M.+T.+Donatoauthor=J.+Dongauthor=S.+Dooleyauthor=D.+Drasdoauthor=R.+Eakinsauthor=K.+S.+Ferreiraauthor=V.+Fonsatoauthor=J.+Fraczekauthor=R.+Gebhardtauthor=A.+Gibsonauthor=M.+Glanemannauthor=C.+E.+P.+Goldringauthor=M.+J.+G%C3%B3mez-Lech%C3%B3nauthor=G.+M.+M.+Groothuisauthor=L.+Gustavssonauthor=C.+Guyotauthor=D.+Hallifaxauthor=S.+Hammadauthor=A.+Haywardauthor=D.+H%C3%A4ussingerauthor=C.+Hellerbrandauthor=P.+Hewittauthor=S.+Hoehmeauthor=H.-G.+Holzh%C3%BCtterauthor=J.+B.+Houstonauthor=J.+Hrachauthor=K.+Itoauthor=H.+Jaeschkeauthor=V.+Keitelauthor=J.+M.+Kelmauthor=B.+Kevin+Parkauthor=C.+Kordesauthor=G.+A.+Kullak-Ublickauthor=E.+L.+LeCluyseauthor=P.+Luauthor=J.+Luebke-Wheelerauthor=A.+Lutzauthor=D.+J.+Maltmanauthor=M.+Matz-Sojaauthor=P.+McMullenauthor=I.+Merfortauthor=S.+Messnerauthor=C.+Meyerauthor=J.+Mwinyiauthor=D.+J.+Naisbittauthor=A.+K.+Nusslerauthor=P.+Olingaauthor=F.+Pampaloniauthor=J.+Piauthor=L.+Plutaauthor=S.+A.+Przyborskiauthor=A.+Ramachandranauthor=V.+Rogiersauthor=C.+Roweauthor=C.+Schelcherauthor=K.+Schmichauthor=M.+Schwarzauthor=B.+Singhauthor=E.+H.+K.+Stelzerauthor=B.+Stiegerauthor=R.+St%C3%B6berauthor=Y.+Sugiyamaauthor=C.+Tettaauthor=W.+E.+Thaslerauthor=T.+Vanhaeckeauthor=M.+Vinkenauthor=T.+S.+Weissauthor=A.+Wideraauthor=C.+G.+Woodsauthor=J.+J.+Xuauthor=K.+M.+Yarboroughauthor=J.+G.+Hengstler&title=Recent+Advances+in+2D+and+3D+In+Vitro+Systems+Using+Primary+Hepatocytes%2C+Alternative+Hepatocyte+Sources+and+Non-parenchymal+Liver+Cells+and+Their+Use+in+Investigating+Mechanisms+of+Hepatotoxicity%2C+Cell+Signaling+and+ADME&doi=10.1007%2Fs00204-013-1078-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME</span></div><div class="casAuthors">Godoy, Patricio; Hewitt, Nicola J.; Albrecht, Ute; Andersen, Melvin E.; Ansari, Nariman; Bhattacharya, Sudin; Bode, Johannes Georg; Bolleyn, Jennifer; Borner, Christoph; Boettger, Jan; Braeuning, Albert; Budinsky, Robert A.; Burkhardt, Britta; Cameron, Neil R.; Camussi, Giovanni; Cho, Chong-Su; Choi, Yun-Jaie; Craig Rowlands, J.; Dahmen, Uta; Damm, Georg; Dirsch, Olaf; Donato, Maria Teresa; Dong, Jian; Dooley, Steven; Drasdo, Dirk; Eakins, Rowena; Ferreira, Karine Sa; Fonsato, Valentina; Fraczek, Joanna; Gebhardt, Rolf; Gibson, Andrew; Glanemann, Matthias; Goldring, Chris E. P.; Gomez-Lechon, Maria Jose; Groothuis, Geny M. M.; Gustavsson, Lena; Guyot, Christelle; Hallifax, David; Hammad, Seddik; Hayward, Adam; Haeussinger, Dieter; Hellerbrand, Claus; Hewitt, Philip; Hoehme, Stefan; Holzhuetter, Hermann-Georg; Houston, J. Brian; Hrach, Jens; Ito, Kiyomi; Jaeschke, Hartmut; Keitel, Verena; Kelm, Jens M.; Kevin Park, B.; Kordes, Claus; Kullak-Ublick, Gerd A.; LeCluyse, Edward L.; Lu, Peng; Luebke-Wheeler, Jennifer; Lutz, Anna; Maltman, Daniel J.; Matz-Soja, Madlen; McMullen, Patrick; Merfort, Irmgard; Messner, Simon; Meyer, Christoph; Mwinyi, Jessica; Naisbitt, Dean J.; Nussler, Andreas K.; Olinga, Peter; Pampaloni, Francesco; Pi, Jingbo; Pluta, Linda; Przyborski, Stefan A.; Ramachandran, Anup; Rogiers, Vera; Rowe, Cliff; Schelcher, Celine; Schmich, Kathrin; Schwarz, Michael; Singh, Bijay; Stelzer, Ernst H. K.; Stieger, Bruno; Stoeber, Regina; Sugiyama, Yuichi; Tetta, Ciro; Thasler, Wolfgang E.; Vanhaecke, Tamara; Vinken, Mathieu; Weiss, Thomas S.; Widera, Agata; Woods, Courtney G.; Xu, Jinghai James; Yarborough, Kathy M.; Hengstler, Jan G.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1315-1530</span>CODEN:
                <span class="NLM_cas:coden">ARTODN</span>;
        ISSN:<span class="NLM_cas:issn">0340-5761</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This review encompasses the most important advances in liver functions and hepatotoxicity and analyzes which mechanisms can be studied in vitro.  In a complex architecture of nested, zonated lobules, the liver consists of approx. 80 % hepatocytes and 20 % non-parenchymal cells, the latter being involved in a secondary phase that may dramatically aggravate the initial damage.  Hepatotoxicity, as well as hepatic metab., is controlled by a set of nuclear receptors (including PXR, CAR, HNF-4α, FXR, LXR, SHP, VDR and PPAR) and signaling pathways.  When isolating liver cells, some pathways are activated, e.g., the RAS/MEK/ERK pathway, whereas others are silenced (e.g. HNF-4α), resulting in up- and downregulation of hundreds of genes.  An understanding of these changes is crucial for a correct interpretation of in vitro data.  The possibilities and limitations of the most useful liver in vitro systems are summarized, including three-dimensional culture techniques, co-cultures with non-parenchymal cells, hepatospheres, precision cut liver slices and the isolated perfused liver.  Also discussed is how closely hepatoma, stem cell and iPS cell-derived hepatocyte-like-cells resemble real hepatocytes.  Finally, a summary is given of the state of the art of liver in vitro and math. modeling systems that are currently used in the pharmaceutical industry with an emphasis on drug metab., prediction of clearance, drug interaction, transporter studies and hepatotoxicity.  One key message is that despite our enthusiasm for in vitro systems, we must never lose sight of the in vivo situation.  Although hepatocytes have been isolated for decades, the hunt for relevant alternative systems has only just begun.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowud2b2y7hPrVg90H21EOLACvtfcHk0lhUMKA48BYEbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlahtr3N&md5=7a6e41a2612c81c6c67fc89362c01e2d</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1007%2Fs00204-013-1078-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00204-013-1078-5%26sid%3Dliteratum%253Aachs%26aulast%3DGodoy%26aufirst%3DP.%26aulast%3DHewitt%26aufirst%3DN.%2BJ.%26aulast%3DAlbrecht%26aufirst%3DU.%26aulast%3DAndersen%26aufirst%3DM.%2BE.%26aulast%3DAnsari%26aufirst%3DN.%26aulast%3DBhattacharya%26aufirst%3DS.%26aulast%3DBode%26aufirst%3DJ.%2BG.%26aulast%3DBolleyn%26aufirst%3DJ.%26aulast%3DBorner%26aufirst%3DC.%26aulast%3DB%25C3%25B6ttger%26aufirst%3DJ.%26aulast%3DBraeuning%26aufirst%3DA.%26aulast%3DBudinsky%26aufirst%3DR.%2BA.%26aulast%3DBurkhardt%26aufirst%3DB.%26aulast%3DCameron%26aufirst%3DN.%2BR.%26aulast%3DCamussi%26aufirst%3DG.%26aulast%3DCho%26aufirst%3DC.-S.%26aulast%3DChoi%26aufirst%3DY.-J.%26aulast%3DCraig%2BRowlands%26aufirst%3DJ.%26aulast%3DDahmen%26aufirst%3DU.%26aulast%3DDamm%26aufirst%3DG.%26aulast%3DDirsch%26aufirst%3DO.%26aulast%3DDonato%26aufirst%3DM.%2BT.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DDooley%26aufirst%3DS.%26aulast%3DDrasdo%26aufirst%3DD.%26aulast%3DEakins%26aufirst%3DR.%26aulast%3DFerreira%26aufirst%3DK.%2BS.%26aulast%3DFonsato%26aufirst%3DV.%26aulast%3DFraczek%26aufirst%3DJ.%26aulast%3DGebhardt%26aufirst%3DR.%26aulast%3DGibson%26aufirst%3DA.%26aulast%3DGlanemann%26aufirst%3DM.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%2BP.%26aulast%3DG%25C3%25B3mez-Lech%25C3%25B3n%26aufirst%3DM.%2BJ.%26aulast%3DGroothuis%26aufirst%3DG.%2BM.%2BM.%26aulast%3DGustavsson%26aufirst%3DL.%26aulast%3DGuyot%26aufirst%3DC.%26aulast%3DHallifax%26aufirst%3DD.%26aulast%3DHammad%26aufirst%3DS.%26aulast%3DHayward%26aufirst%3DA.%26aulast%3DH%25C3%25A4ussinger%26aufirst%3DD.%26aulast%3DHellerbrand%26aufirst%3DC.%26aulast%3DHewitt%26aufirst%3DP.%26aulast%3DHoehme%26aufirst%3DS.%26aulast%3DHolzh%25C3%25BCtter%26aufirst%3DH.-G.%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26aulast%3DHrach%26aufirst%3DJ.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DJaeschke%26aufirst%3DH.%26aulast%3DKeitel%26aufirst%3DV.%26aulast%3DKelm%26aufirst%3DJ.%2BM.%26aulast%3DKevin%2BPark%26aufirst%3DB.%26aulast%3DKordes%26aufirst%3DC.%26aulast%3DKullak-Ublick%26aufirst%3DG.%2BA.%26aulast%3DLeCluyse%26aufirst%3DE.%2BL.%26aulast%3DLu%26aufirst%3DP.%26aulast%3DLuebke-Wheeler%26aufirst%3DJ.%26aulast%3DLutz%26aufirst%3DA.%26aulast%3DMaltman%26aufirst%3DD.%2BJ.%26aulast%3DMatz-Soja%26aufirst%3DM.%26aulast%3DMcMullen%26aufirst%3DP.%26aulast%3DMerfort%26aufirst%3DI.%26aulast%3DMessner%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DC.%26aulast%3DMwinyi%26aufirst%3DJ.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DNussler%26aufirst%3DA.%2BK.%26aulast%3DOlinga%26aufirst%3DP.%26aulast%3DPampaloni%26aufirst%3DF.%26aulast%3DPi%26aufirst%3DJ.%26aulast%3DPluta%26aufirst%3DL.%26aulast%3DPrzyborski%26aufirst%3DS.%2BA.%26aulast%3DRamachandran%26aufirst%3DA.%26aulast%3DRogiers%26aufirst%3DV.%26aulast%3DRowe%26aufirst%3DC.%26aulast%3DSchelcher%26aufirst%3DC.%26aulast%3DSchmich%26aufirst%3DK.%26aulast%3DSchwarz%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DStelzer%26aufirst%3DE.%2BH.%2BK.%26aulast%3DStieger%26aufirst%3DB.%26aulast%3DSt%25C3%25B6ber%26aufirst%3DR.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DTetta%26aufirst%3DC.%26aulast%3DThasler%26aufirst%3DW.%2BE.%26aulast%3DVanhaecke%26aufirst%3DT.%26aulast%3DVinken%26aufirst%3DM.%26aulast%3DWeiss%26aufirst%3DT.%2BS.%26aulast%3DWidera%26aufirst%3DA.%26aulast%3DWoods%26aufirst%3DC.%2BG.%26aulast%3DXu%26aufirst%3DJ.%2BJ.%26aulast%3DYarborough%26aufirst%3DK.%2BM.%26aulast%3DHengstler%26aufirst%3DJ.%2BG.%26atitle%3DRecent%2520Advances%2520in%25202D%2520and%25203D%2520In%2520Vitro%2520Systems%2520Using%2520Primary%2520Hepatocytes%252C%2520Alternative%2520Hepatocyte%2520Sources%2520and%2520Non-parenchymal%2520Liver%2520Cells%2520and%2520Their%2520Use%2520in%2520Investigating%2520Mechanisms%2520of%2520Hepatotoxicity%252C%2520Cell%2520Signaling%2520and%2520ADME%26jtitle%3DArch.%2520Toxicol.%26date%3D2013%26volume%3D87%26spage%3D1315%26epage%3D1530%26doi%3D10.1007%2Fs00204-013-1078-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolters, J. E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van
Breda, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinjans, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kok, T. M.</span></span> <span> </span><span class="NLM_article-title">Development of Novel Tools for the In Vitro Investigation of Drug-Induced Liver Injury</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1523</span>– <span class="NLM_lpage">1537</span>, <span class="refDoi"> DOI: 10.1517/17425255.2015.1065814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1517%2F17425255.2015.1065814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26155718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsl2ntbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=1523-1537&author=J.+Jiangauthor=J.+E.+J.+Woltersauthor=S.+G.+van%0ABredaauthor=J.+C.+Kleinjansauthor=T.+M.+de+Kok&title=Development+of+Novel+Tools+for+the+In+Vitro+Investigation+of+Drug-Induced+Liver+Injury&doi=10.1517%2F17425255.2015.1065814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Development of novel tools for the in vitro investigation of drug-induced liver injury</span></div><div class="casAuthors">Jiang, Jian; Wolters, Jarno EJ; van Breda, Simone G.; Kleinjans, Jos C.; de Kok, Theo M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1523-1537</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Due to its complex mechanisms and unpredictable occurrence, drug-induced liver injury (DILI) complicates drug identification and classification.  Since species-specific differences in metab. and pharmacokinetics exist, data obtained from animal studies may not be sufficient to predict DILI in humans.  Over the last few decades, numerous in vitro models have been developed to replace animal testing.  The advantages and disadvantages of commonly used liver-derived in vitro models (e.g., cell lines, hepatocyte models, liver slices, three-dimensional (3D) hepatospheres, etc.) are discussed.  Toxicogenomics-based methodologies (genomics, epigenomics, transcriptomics, proteomics and metabolomics) and next-generation sequencing have also been used to enhance the reliability of DILI prediction.  This review presents an overview of the currently used alternative toxicol. models and of the most advanced approaches in the field of DILI research.  It seems unlikely that a single in vitro system will be able to mimic the complex interactions in the human liver.  Three-dimensional multicellular systems may bridge the gap between conventional 2D models and in vivo clin. studies in humans and provide a reliable basis for hepatic toxicity assay development.  Next-generation sequencing technologies, in comparison to microarray-based technologies, may overcome the current limitations and are promising for the development of predictive models in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_sXCiIcEkYrVg90H21EOLACvtfcHk0lhUMKA48BYEbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsl2ntbvF&md5=af6cd477d64ae1fdc65701827f4ef39b</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1517%2F17425255.2015.1065814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2015.1065814%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWolters%26aufirst%3DJ.%2BE.%2BJ.%26aulast%3Dvan%2BBreda%26aufirst%3DS.%2BG.%26aulast%3DKleinjans%26aufirst%3DJ.%2BC.%26aulast%3Dde%2BKok%26aufirst%3DT.%2BM.%26atitle%3DDevelopment%2520of%2520Novel%2520Tools%2520for%2520the%2520In%2520Vitro%2520Investigation%2520of%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2015%26volume%3D11%26spage%3D1523%26epage%3D1537%26doi%3D10.1517%2F17425255.2015.1065814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Messner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarkova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelm, J. M.</span></span> <span> </span><span class="NLM_article-title">Multi-Cell Type Human Liver Microtissues for Hepatotoxicity Testing</span>. <i>Arch. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1007/s00204-012-0968-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs00204-012-0968-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23143619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Cqtr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=209-213&author=S.+Messnerauthor=I.+Agarkovaauthor=W.+Moritzauthor=J.+M.+Kelm&title=Multi-Cell+Type+Human+Liver+Microtissues+for+Hepatotoxicity+Testing&doi=10.1007%2Fs00204-012-0968-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-cell type human liver microtissues for hepatotoxicity testing</span></div><div class="casAuthors">Messner, S.; Agarkova, I.; Moritz, W.; Kelm, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">209-213</span>CODEN:
                <span class="NLM_cas:coden">ARTODN</span>;
        ISSN:<span class="NLM_cas:issn">0340-5761</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Current 2-dimensional hepatic model systems often fail to predict chem. induced hepatotoxicity due to the loss of a hepatocyte-specific phenotype in culture.  For more predictive in vitro models, hepatocytes have to be maintained in a 3-dimensional environment that allows for polarization and cell-cell contacts.  Preferably, the model will reflect an in vivo-like multi-cell type environment necessary for liver-like responses.  Here, we report the characterization of a multi-cell type microtissue model, generated from primary human hepatocytes and liver-derived non-parenchymal cells.  Liver microtissues were stable and functional for 5 wk in culture enabling, for example, long-term toxicity testing of acetaminophen and diclofenac.  In addn., Kupffer cells were responsive to inflammatory stimuli such as LPS demonstrating the possibility to detect inflammation-mediated toxicity as exemplified by the drug trovafloxacin.  Herewith, we present a novel 3D liver model for routine testing in 96-well format capable of reducing the risk of unwanted toxic effects in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQq2Hv7htlwLVg90H21EOLACvtfcHk0lgjhViR4PzI8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Cqtr%252FE&md5=c7a46017126bb80d6983c09bf71c3592</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1007%2Fs00204-012-0968-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00204-012-0968-2%26sid%3Dliteratum%253Aachs%26aulast%3DMessner%26aufirst%3DS.%26aulast%3DAgarkova%26aufirst%3DI.%26aulast%3DMoritz%26aufirst%3DW.%26aulast%3DKelm%26aufirst%3DJ.%2BM.%26atitle%3DMulti-Cell%2520Type%2520Human%2520Liver%2520Microtissues%2520for%2520Hepatotoxicity%2520Testing%26jtitle%3DArch.%2520Toxicol.%26date%3D2013%26volume%3D87%26spage%3D209%26epage%3D213%26doi%3D10.1007%2Fs00204-012-0968-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tostões, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leite, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björquist, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrondo, M. J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alves, P. M.</span></span> <span> </span><span class="NLM_article-title">Human Liver Cell Spheroids in Extended Perfusion Bioreactor Culture for Repeated-Dose Drug Testing</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1227</span>– <span class="NLM_lpage">1236</span>, <span class="refDoi"> DOI: 10.1002/hep.24760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.24760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22031499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1yjs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1227-1236&author=R.+M.+Tost%C3%B5esauthor=S.+B.+Leiteauthor=M.+Serraauthor=J.+Jensenauthor=P.+Bj%C3%B6rquistauthor=M.+J.+T.+Carrondoauthor=C.+Britoauthor=P.+M.+Alves&title=Human+Liver+Cell+Spheroids+in+Extended+Perfusion+Bioreactor+Culture+for+Repeated-Dose+Drug+Testing&doi=10.1002%2Fhep.24760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Human liver cell spheroids in extended perfusion bioreactor culture for repeated-dose drug testing</span></div><div class="casAuthors">Tostoes, Rui M.; Leite, Sofia B.; Serra, Margarida; Jensen, Janne; Bjoerquist, Petter; Carrondo, Manuel J. T.; Brito, Catarina; Alves, Paula M.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1227-1236</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Primary cultures of human hepatocyte spheroids are a promising in vitro model for long-term studies of hepatic metab. and cytotoxicity.  The lack of robust methodologies to culture cell spheroids, as well as a poor characterization of human hepatocyte spheroid architecture and liver-specific functionality, have hampered a widespread adoption of this three-dimensional culture format.  In this work, an automated perfusion bioreactor was used to obtain and maintain human hepatocyte spheroids.  These spheroids were cultured for 3-4 wk in serum-free conditions, sustaining their phase I enzyme expression and permitting repeated induction during long culture times; rate of albumin and urea synthesis, as well as phase I and II drug-metabolizing enzyme gene expression and activity of spheroid hepatocyte cultures, presented reproducible profiles, despite basal interdonor variability (n = 3 donors).  Immunofluorescence microscopy of human hepatocyte spheroids after 3-4 wk of long-term culture confirmed the presence of the liver-specific markers, hepatocyte nuclear factor 4α, albumin, cytokeratin 18, and cytochrome P 450 3A.  Moreover, immunostaining of the atypical protein kinase C apical marker, as well as the excretion of a fluorescent dye, evidenced that these spheroids spontaneously assemble a functional bile canaliculi network, extending from the surface to the interior of the spheroids, after 3-4 wk of culture.  Conclusion: Perfusion bioreactor cultures of primary human hepatocyte spheroids maintain a liver-specific activity and architecture and are thus suitable for drug testing in a long-term, repeated-dose format. (HEPATOl. 2012).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppAQ4NtBK0grVg90H21EOLACvtfcHk0lgjhViR4PzI8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1yjs70%253D&md5=a20fe734e748c3d84ec5b90cab1d498d</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1002%2Fhep.24760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.24760%26sid%3Dliteratum%253Aachs%26aulast%3DTost%25C3%25B5es%26aufirst%3DR.%2BM.%26aulast%3DLeite%26aufirst%3DS.%2BB.%26aulast%3DSerra%26aufirst%3DM.%26aulast%3DJensen%26aufirst%3DJ.%26aulast%3DBj%25C3%25B6rquist%26aufirst%3DP.%26aulast%3DCarrondo%26aufirst%3DM.%2BJ.%2BT.%26aulast%3DBrito%26aufirst%3DC.%26aulast%3DAlves%26aufirst%3DP.%2BM.%26atitle%3DHuman%2520Liver%2520Cell%2520Spheroids%2520in%2520Extended%2520Perfusion%2520Bioreactor%2520Culture%2520for%2520Repeated-Dose%2520Drug%2520Testing%26jtitle%3DHepatology%26date%3D2012%26volume%3D55%26spage%3D1227%26epage%3D1236%26doi%3D10.1002%2Fhep.24760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, D. F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moro, S. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renblom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredriksson
Puigvert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dankers, A. C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeys, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sison-Young, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordling, Å.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mkrtchian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitteringham, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingelman-Sundberg, M.</span></span> <span> </span><span class="NLM_article-title">Characterization of Primary Human Hepatocyte Spheroids as a Model System for Drug-Induced Liver Injury, Liver Function and Disease</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">25187</span>, <span class="refDoi"> DOI: 10.1038/srep25187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fsrep25187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27143246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsVenurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=25187&author=C.+C.+Bellauthor=D.+F.+G.+Hendriksauthor=S.+M.+L.+Moroauthor=E.+Ellisauthor=J.+Walshauthor=A.+Renblomauthor=L.+Fredriksson%0APuigvertauthor=A.+C.+A.+Dankersauthor=F.+Jacobsauthor=J.+Snoeysauthor=R.+L.+Sison-Youngauthor=R.+E.+Jenkinsauthor=%C3%85.+Nordlingauthor=S.+Mkrtchianauthor=B.+K.+Parkauthor=N.+R.+Kitteringhamauthor=C.+E.+P.+Goldringauthor=V.+M.+Lauschkeauthor=M.+Ingelman-Sundberg&title=Characterization+of+Primary+Human+Hepatocyte+Spheroids+as+a+Model+System+for+Drug-Induced+Liver+Injury%2C+Liver+Function+and+Disease&doi=10.1038%2Fsrep25187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease</span></div><div class="casAuthors">Bell, Catherine C.; Hendriks, Delilah F. G.; Moro, Sabrina M. L.; Ellis, Ewa; Walsh, Joanne; Renblom, Anna; Fredriksson Puigvert, Lisa; Dankers, Anita C. A.; Jacobs, Frank; Snoeys, Jan; Sison-Young, Rowena L.; Jenkins, Rosalind E.; Nordling, Aasa; Mkrtchian, Souren; Park, B. Kevin; Kitteringham, Neil R.; Goldring, Christopher E. P.; Lauschke, Volker M.; Ingelman-Sundberg, Magnus</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25187</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Liver biol. and function, drug-induced liver injury (DILI) and liver diseases are difficult to study using current in vitro models such as primary human hepatocyte (PHH) monolayer cultures, as their rapid de-differentiation restricts their usefulness substantially.  Thus, we have developed and extensively characterized an easily scalable 3D PHH spheroid system in chem.-defined, serum-free conditions.  Using whole proteome analyses, we found that PHH spheroids cultured this way were similar to the liver in vivo and even retained their inter-individual variability.  Furthermore, PHH spheroids remained phenotypically stable and retained morphol., viability, and hepatocyte-specific functions for culture periods of at least 5 wk.  We show that under chronic exposure, the sensitivity of the hepatocytes drastically increased and toxicity of a set of hepatotoxins was detected at clin. relevant concns.  An interesting example was the chronic toxicity of fialuridine for which hepatotoxicity was mimicked after repeated-dosing in the PHH spheroid model, not possible to detect using previous in vitro systems.  Addnl., we provide proof-of-principle that PHH spheroids can reflect liver pathologies such as cholestasis, steatosis and viral hepatitis.  Combined, our results demonstrate that the PHH spheroid system presented here constitutes a versatile and promising in vitro system to study liver function, liver diseases, drug targets and long-term DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXCMcqP2wXk7Vg90H21EOLACvtfcHk0lgjhViR4PzI8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsVenurs%253D&md5=ffb2cbc26578c469a618a2ebe8590e1a</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1038%2Fsrep25187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep25187%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DC.%2BC.%26aulast%3DHendriks%26aufirst%3DD.%2BF.%2BG.%26aulast%3DMoro%26aufirst%3DS.%2BM.%2BL.%26aulast%3DEllis%26aufirst%3DE.%26aulast%3DWalsh%26aufirst%3DJ.%26aulast%3DRenblom%26aufirst%3DA.%26aulast%3DFredriksson%2BPuigvert%26aufirst%3DL.%26aulast%3DDankers%26aufirst%3DA.%2BC.%2BA.%26aulast%3DJacobs%26aufirst%3DF.%26aulast%3DSnoeys%26aufirst%3DJ.%26aulast%3DSison-Young%26aufirst%3DR.%2BL.%26aulast%3DJenkins%26aufirst%3DR.%2BE.%26aulast%3DNordling%26aufirst%3D%25C3%2585.%26aulast%3DMkrtchian%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DKitteringham%26aufirst%3DN.%2BR.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%2BP.%26aulast%3DLauschke%26aufirst%3DV.%2BM.%26aulast%3DIngelman-Sundberg%26aufirst%3DM.%26atitle%3DCharacterization%2520of%2520Primary%2520Human%2520Hepatocyte%2520Spheroids%2520as%2520a%2520Model%2520System%2520for%2520Drug-Induced%2520Liver%2520Injury%252C%2520Liver%2520Function%2520and%2520Disease%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D25187%26doi%3D10.1038%2Fsrep25187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramaiahgari, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waidyanatha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVito, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paules, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, S. S.</span></span> <span> </span><span class="NLM_article-title">Three-Dimensional (3D) HepaRG Spheroid Model With Physiologically Relevant Xenobiotic Metabolism Competence and Hepatocyte Functionality for Liver Toxicity Screening</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfx194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfx194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29077947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOrsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2017&pages=189-190&author=S.+C.+Ramaiahgariauthor=S.+Waidyanathaauthor=D.+Dixonauthor=M.+J.+DeVitoauthor=R.+S.+Paulesauthor=S.+S.+Ferguson&title=Three-Dimensional+%283D%29+HepaRG+Spheroid+Model+With+Physiologically+Relevant+Xenobiotic+Metabolism+Competence+and+Hepatocyte+Functionality+for+Liver+Toxicity+Screening&doi=10.1093%2Ftoxsci%2Fkfx194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Three-dimensional (3D) HepaRG spheroid model with physiologically relevant xenobiotic metabolism competence and hepatocyte functionality for liver toxicity screening [Erratum to document cited in CA168:323580]</span></div><div class="casAuthors">Ramaiahgari, Sreenivasa C.; Waidyanatha, Suramya; Dixon, Darlene; DeVito, Michael J.; Paules, Richard S.; Ferguson, Stephen S.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">189-190</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqppm5oIHdSK7Vg90H21EOLACvtfcHk0lio7ZFtR5nibg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOrsLzI&md5=99d9adb48c2e79d4d4d65231093f1ede</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfx194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfx194%26sid%3Dliteratum%253Aachs%26aulast%3DRamaiahgari%26aufirst%3DS.%2BC.%26aulast%3DWaidyanatha%26aufirst%3DS.%26aulast%3DDixon%26aufirst%3DD.%26aulast%3DDeVito%26aufirst%3DM.%2BJ.%26aulast%3DPaules%26aufirst%3DR.%2BS.%26aulast%3DFerguson%26aufirst%3DS.%2BS.%26atitle%3DThree-Dimensional%2520%25283D%2529%2520HepaRG%2520Spheroid%2520Model%2520With%2520Physiologically%2520Relevant%2520Xenobiotic%2520Metabolism%2520Competence%2520and%2520Hepatocyte%2520Functionality%2520for%2520Liver%2520Toxicity%2520Screening%26jtitle%3DToxicol.%2520Sci.%26date%3D2017%26volume%3D160%26spage%3D189%26epage%3D190%26doi%3D10.1093%2Ftoxsci%2Fkfx194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kermanizadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Løhr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roursgaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunness, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelm, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Møller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loft, S.</span></span> <span> </span><span class="NLM_article-title">Hepatic Toxicology Following Single and Multiple Exposure of Engineered Nanomaterials Utilising a Novel Primary Human 3D Liver Microtissue Model</span>. <i>Part. Fibre Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">56</span>, <span class="refDoi"> DOI: 10.1186/s12989-014-0056-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1186%2Fs12989-014-0056-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25326698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVyhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=56&author=A.+Kermanizadehauthor=M.+L%C3%B8hrauthor=M.+Roursgaardauthor=S.+Messnerauthor=P.+Gunnessauthor=J.+M.+Kelmauthor=P.+M%C3%B8llerauthor=V.+Stoneauthor=S.+Loft&title=Hepatic+Toxicology+Following+Single+and+Multiple+Exposure+of+Engineered+Nanomaterials+Utilising+a+Novel+Primary+Human+3D+Liver+Microtissue+Model&doi=10.1186%2Fs12989-014-0056-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatic toxicology following single and multiple exposure of engineered nanomaterials utilising a novel primary human 3D liver microtissue model</span></div><div class="casAuthors">Kermanizadeh, Ali; Loehr, Mille; Roursgaard, Martin; Messner, Simon; Gunness, Patrina; Kelm, Jens M.; Moeller, Peter; Stone, Vicki; Loft, Steffen</div><div class="citationInfo"><span class="NLM_cas:title">Particle and Fibre Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">56/1-56/30, 30 pp.</span>CODEN:
                <span class="NLM_cas:coden">PFTABQ</span>;
        ISSN:<span class="NLM_cas:issn">1743-8977</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background The liver has a crucial role in metabolic homeostasis as well as being the principal detoxification center of the body, removing xenobiotics and waste products which could potentially include some nanomaterials (NM).  With the ever increasing public and occupational exposure assocd. with accumulative prodn. of nanomaterials, there is an urgent need to consider the possibility of detrimental health consequences of engineered NM exposure.  It has been shown that exposure via inhalation, intratracheal instillation or ingestion can result in NM translocation to the liver.  Traditional in vitro or ex vivo hepatic nanotoxicol. models are often limiting and/or troublesome (i.e. reduced metab. enzymes, lacking important cell populations, unstable with very high variability, etc.).  Methods In order to rectify these issues and for the very first time we have utilized a 3D human liver microtissue model to investigate the toxicol. effects assocd. with a single or multiple exposure of a panel of engineered NMs (Ag, ZnO, MWCNT and a pos. charged TiO2).  Results Here we demonstrate that the repeated exposure of the NMs is more damaging to the liver tissue as in comparison to a single exposure with the adverse effects more significant following treatment with the Ag and ZnO as compared with the TiO2 and MWCNT NMs (in terms of cytotoxicity, cytokine secretion, lipid peroxidn. and genotoxicity).  Conclusions Overall, this study demonstrates that the human microtissue model utilized herein is an excellent candidate for replacement of traditional in vitro single cell hepatic models and further progression of liver nanotoxicol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoun93iSUGt37Vg90H21EOLACvtfcHk0lio7ZFtR5nibg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVyhtg%253D%253D&md5=0a1b9f92c787dcea01ff149102ac8128</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1186%2Fs12989-014-0056-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12989-014-0056-2%26sid%3Dliteratum%253Aachs%26aulast%3DKermanizadeh%26aufirst%3DA.%26aulast%3DL%25C3%25B8hr%26aufirst%3DM.%26aulast%3DRoursgaard%26aufirst%3DM.%26aulast%3DMessner%26aufirst%3DS.%26aulast%3DGunness%26aufirst%3DP.%26aulast%3DKelm%26aufirst%3DJ.%2BM.%26aulast%3DM%25C3%25B8ller%26aufirst%3DP.%26aulast%3DStone%26aufirst%3DV.%26aulast%3DLoft%26aufirst%3DS.%26atitle%3DHepatic%2520Toxicology%2520Following%2520Single%2520and%2520Multiple%2520Exposure%2520of%2520Engineered%2520Nanomaterials%2520Utilising%2520a%2520Novel%2520Primary%2520Human%25203D%2520Liver%2520Microtissue%2520Model%26jtitle%3DPart.%2520Fibre%2520Toxicol.%26date%3D2014%26volume%3D11%26spage%3D56%26doi%3D10.1186%2Fs12989-014-0056-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crogan-Grundy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presnell, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, A. B.</span></span> <span> </span><span class="NLM_article-title">Bioprinted 3D Primary Liver Tissues Allow Assessment of Organ-Level Response to Clinical Drug Induced Toxicity</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0158674</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0158674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1371%2Fjournal.pone.0158674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27387377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVKnurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0158674&author=D.+G.+Nguyenauthor=J.+Funkauthor=J.+B.+Robbinsauthor=C.+Crogan-Grundyauthor=S.+C.+Presnellauthor=T.+Singerauthor=A.+B.+Roth&title=Bioprinted+3D+Primary+Liver+Tissues+Allow+Assessment+of+Organ-Level+Response+to+Clinical+Drug+Induced+Toxicity&doi=10.1371%2Fjournal.pone.0158674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro</span></div><div class="casAuthors">Nguyen, Deborah G.; Funk, Juergen; Robbins, Justin B.; Crogan-Grundy, Candace; Presnell, Sharon C.; Singer, Thomas; Roth, Adrian B.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e0158674/1-e0158674/17</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Modeling clin. relevant tissue responses using cell models poses a significant challenge for drug development, in particular for drug induced liver injury (DILI).  This is mainly because existing liver models lack longevity and tissue-level complexity which limits their utility in predictive toxicol.  In this study, we established and characterized novel bioprinted human liver tissue mimetics comprised of patient-derived hepatocytes and nonparenchymal cells in a defined architecture.  Scaffold-free assembly of different cell types in an in vivo-relevant architecture allowed for histol. anal. that revealed distinct intercellular hepatocyte junctions, CD31+ endothelial networks, and desmin pos., smooth muscle actin neg. quiescent stellates.  Unlike what was seen in 2D hepatocyte cultures, the tissues maintained levels of ATP, Albumin as well as expression and drug-induced enzyme activity of Cytochrome P450s over 4 wk in culture.  To assess the ability of the 3D liver cultures to model tissue-level DILI, dose responses of Trovafloxacin, a drug whose hepatotoxic potential could not be assessed by std. pre-clin. models, were compared to the structurally related non-toxic drug Levofloxacin.  Trovafloxacin induced significant, dosedependent toxicity at clin. relevant doses (≤ 4uM).  Interestingly, Trovafloxacin toxicity was obsd. without lipopolysaccharide stimulation and in the absence of resident macrophages in contrast to earlier reports.  Together, these results demonstrate that 3D bioprinted liver tissues can both effectively model DILI and distinguish between highly related compds. with differential profile.  Thus, the combination of patient-derived primary cells with bioprinting technol. here for the first time demonstrates superior performance in terms of mimicking human drug response in a known target organ at the tissue level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYl7I6xmS4qrVg90H21EOLACvtfcHk0liTYZUHDKXlxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVKnurnI&md5=3444083b1e6affcca18ae9063c66ae90</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0158674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0158674%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DD.%2BG.%26aulast%3DFunk%26aufirst%3DJ.%26aulast%3DRobbins%26aufirst%3DJ.%2BB.%26aulast%3DCrogan-Grundy%26aufirst%3DC.%26aulast%3DPresnell%26aufirst%3DS.%2BC.%26aulast%3DSinger%26aufirst%3DT.%26aulast%3DRoth%26aufirst%3DA.%2BB.%26atitle%3DBioprinted%25203D%2520Primary%2520Liver%2520Tissues%2520Allow%2520Assessment%2520of%2520Organ-Level%2520Response%2520to%2520Clinical%2520Drug%2520Induced%2520Toxicity%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0158674%26doi%3D10.1371%2Fjournal.pone.0158674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norona, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presnell, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCluyse, E. L.</span></span> <span> </span><span class="NLM_article-title">Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfw169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfw169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27605418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktlWltbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2016&pages=354-367&author=L.+M.+Noronaauthor=D.+G.+Nguyenauthor=D.+A.+Gerberauthor=S.+C.+Presnellauthor=E.+L.+LeCluyse&title=Modeling+Compound-Induced+Fibrogenesis+In+Vitro+Using+Three-Dimensional+Bioprinted+Human+Liver+Tissues&doi=10.1093%2Ftoxsci%2Fkfw169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling compound-induced fibrogenesis in vitro using three-dimensional bioprinted human liver tissues</span></div><div class="casAuthors">Norona, Leah M.; Nguyen, Deborah G.; Gerber, David A.; Presnell, Sharon C.; LeCluyse, Edward L.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">354-367</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Compd.-induced liver injury leading to fibrosis remains a challenge for the development of an Adverse Outcome Pathway useful for human risk assessment.  Latency to detection and lack of early, systematically detectable biomarkers make it difficult to characterize the dynamic and complex intercellular interactions that occur during progressive liver injury.  Here, we demonstrate the utility of bioprinted tissue constructs comprising primary hepatocytes, hepatic stellate cells, and endothelial cells to model methotrexate- and thioacetamide-induced liver injury leading to fibrosis.  Repeated, low-concn. exposure to these compds. enabled the detection and differentiation of multiple modes of liver injury, including hepatocellular damage, and progressive fibrogenesis characterized by the deposition and accumulation of fibrillar collagens in patterns analogous to those described in clin. samples obtained from patients with fibrotic liver injury.  Transient cytokine prodn. and upregulation of fibrosis-assocd. genes ACTA2 and COL1A1 mimics hallmark features of a classic wound-healing response.  A surge in proinflammatory cytokines (eg, IL-8, IL-1β) during the early culture time period is followed by concn.- and treatment-dependent alterations in immunomodulatory and chemotactic cytokines such as IL-13, IL-6, and MCP-1.  These combined data provide strong proof-of-concept that 3D bioprinted liver tissues can recapitulate drug-, chem.-, and TGF-β1-induced fibrogenesis at the cellular, mol., and histol. levels and underscore the value of the model for further exploration of compd.-specific fibrogenic responses.  This novel system will enable a more comprehensive characterization of key attributes unique to fibrogenic agents during the onset and progression of liver injury as well as mechanistic insights, thus improving compd. risk assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS9EosUREC5rVg90H21EOLACvtfcHk0liTYZUHDKXlxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktlWltbo%253D&md5=e3174cf98f9138eb75aa18abde6bcaba</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfw169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfw169%26sid%3Dliteratum%253Aachs%26aulast%3DNorona%26aufirst%3DL.%2BM.%26aulast%3DNguyen%26aufirst%3DD.%2BG.%26aulast%3DGerber%26aufirst%3DD.%2BA.%26aulast%3DPresnell%26aufirst%3DS.%2BC.%26aulast%3DLeCluyse%26aufirst%3DE.%2BL.%26atitle%3DModeling%2520Compound-Induced%2520Fibrogenesis%2520In%2520Vitro%2520Using%2520Three-Dimensional%2520Bioprinted%2520Human%2520Liver%2520Tissues%26jtitle%3DToxicol.%2520Sci.%26date%3D2016%26volume%3D154%26spage%3D354%26epage%3D367%26doi%3D10.1093%2Ftoxsci%2Fkfw169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vivares, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salle-Lefort, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arabeyre-Fabre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penarier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremond, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moliner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallas, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klieber, S.</span></span> <span> </span><span class="NLM_article-title">Morphological Behaviour and Metabolic Capacity of Cryopreserved Human Primary Hepatocytes Cultivated in a Perfused Multiwell Device</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.3109/00498254.2014.944612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.3109%2F00498254.2014.944612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25068923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVaqsL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=29-44&author=A.+Vivaresauthor=S.+Salle-Lefortauthor=C.+Arabeyre-Fabreauthor=R.+Ngoauthor=G.+Penarierauthor=M.+Bremondauthor=P.+Molinerauthor=J.-F.+Gallasauthor=G.+Fabreauthor=S.+Klieber&title=Morphological+Behaviour+and+Metabolic+Capacity+of+Cryopreserved+Human+Primary+Hepatocytes+Cultivated+in+a+Perfused+Multiwell+Device&doi=10.3109%2F00498254.2014.944612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device</span></div><div class="casAuthors">Vivares, Aurelie; Salle-Lefort, Sandrine; Arabeyre-Fabre, Catherine; Ngo, Robert; Penarier, Geraldine; Bremond, Michele; Moliner, Patricia; Gallas, Jean-Francois; Fabre, Gerard; Klieber, Sylvie</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-44</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">1. The quant. prediction of the pharmacokinetic parameters of a drug from data obtained using human in vitro systems remains a significant challenge i.e. prediction of metabolic clearance in humans and estn. of the relative contribution of enzymes involved in the clearance.  This has become particularly problematic for low turnover compds.  2. Having human hepatocytes with stable cellular function over several days that adequately mimic the complexity of the physiol. environment would be a major advance.  Thus, we evaluated human hepatocytes, maintained in culture during 7 days in the microfluidic LiverChip® system, in terms of morphol. appearance, relative mRNA expression of phase I and II enzymes and transporters as a function of time, and metabolic capacity using probe substrates.  3. The results showed that mRNA levels of the major genes for enzymes involved in drug metab. were well-maintained over a 7-day period of culture.  Furthermore, after 4 days of culture, in the Liverchip® device, human hepatocytes exhibited higher or similar CYPs activities compared to 1 day of culture in 2D-static conditions.  4. The functional data were supported by light/electron microscopies and immunohistochem. showing viable tissue structure and well-differentiated human hepatocytes: presence of cell junctions, glycogen storage, and bile canaliculi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4Ixn_wkAcULVg90H21EOLACvtfcHk0liTYZUHDKXlxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVaqsL3J&md5=d905bfe7b3092d34fae2230e434d769e</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.3109%2F00498254.2014.944612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2014.944612%26sid%3Dliteratum%253Aachs%26aulast%3DVivares%26aufirst%3DA.%26aulast%3DSalle-Lefort%26aufirst%3DS.%26aulast%3DArabeyre-Fabre%26aufirst%3DC.%26aulast%3DNgo%26aufirst%3DR.%26aulast%3DPenarier%26aufirst%3DG.%26aulast%3DBremond%26aufirst%3DM.%26aulast%3DMoliner%26aufirst%3DP.%26aulast%3DGallas%26aufirst%3DJ.-F.%26aulast%3DFabre%26aufirst%3DG.%26aulast%3DKlieber%26aufirst%3DS.%26atitle%3DMorphological%2520Behaviour%2520and%2520Metabolic%2520Capacity%2520of%2520Cryopreserved%2520Human%2520Primary%2520Hepatocytes%2520Cultivated%2520in%2520a%2520Perfused%2520Multiwell%2520Device%26jtitle%3DXenobiotica%26date%3D2015%26volume%3D45%26spage%3D29%26epage%3D44%26doi%3D10.3109%2F00498254.2014.944612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terelius, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figler, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marukian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collado, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackey, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qualls, C. W.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackman, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wamhoff, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dash, A.</span></span> <span> </span><span class="NLM_article-title">Transcriptional Profiling Suggests that Nevirapine and Ritonavir Cause Drug-Induced Liver Injury Through Distinct Mechanisms in Primary Human Hepatocytes</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>255</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2015.11.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.cbi.2015.11.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26626330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVemtL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=2016&pages=31-44&author=Y.+Tereliusauthor=R.+A.+Figlerauthor=S.+Marukianauthor=M.+S.+Colladoauthor=M.+J.+Lawsonauthor=A.+J.+Mackeyauthor=D.+Mankaauthor=C.+W.+Quallsauthor=B.+R.+Blackmanauthor=B.+R.+Wamhoffauthor=A.+Dash&title=Transcriptional+Profiling+Suggests+that+Nevirapine+and+Ritonavir+Cause+Drug-Induced+Liver+Injury+Through+Distinct+Mechanisms+in+Primary+Human+Hepatocytes&doi=10.1016%2Fj.cbi.2015.11.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes</span></div><div class="casAuthors">Terelius, Ylva; Figler, Robert A.; Marukian, Svetlana; Collado, Maria S.; Lawson, Mark J.; Mackey, Aaron J.; Manka, David; Qualls, Charles W. Jr.; Blackman, Brett R.; Wamhoff, Brian R.; Dash, Ajit</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">255</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-44</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Drug induced liver injury (DILI), a major cause of pre- and post-approval failure, is challenging to predict pre-clin. due to varied underlying direct and indirect mechanisms.  Nevirapine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) and Ritonavir, a protease inhibitor, are antiviral drugs that cause clin. DILI with different phenotypes via different mechanisms.  Assessing DILI in vitro in hepatocyte cultures typically requires drug exposures significantly higher than clin. plasma Cmax concns., making clin. interpretations of mechanistic pathway changes challenging.  We previously described a system that uses liver-derived hemodynamic blood flow and transport parameters to restore primary human hepatocyte biol., and drug responses at concns. relevant to in vivo or clin. exposure levels.  Using this system, primary hepatocytes from 5 human donors were exposed to concns. approximating clin. therapeutic and supra-therapeutic levels of Nevirapine (11.3 and 175.0 μM) and Ritonavir (3.5 and 62.4 μM) for 48 h.  Whole genome transcriptomics was performed by RNAseq along with functional assays for metabolic activity and function.  We obsd. effects at both doses, but a greater no. of genes were differentially expressed with higher probability at the toxic concns.  At the toxic doses, both drugs showed direct cholestatic potential with Nevirapine increasing bile synthesis and Ritonavir inhibiting bile acid transport.  Clear differences in antigen presentation were noted, with marked activation of MHC Class I by Nevirapine and suppression by Ritonavir.  This suggests CD8+ T cell involvement for Nevirapine and possibly NK Killer cells for Ritonavir.  Both compds. induced several drug metabolizing genes (including CYP2B6, CYP3A4 and UGT1A1), mediated by CAR activation in Nevirapine and PXR in Ritonavir.  Unlike Ritonavir, Nevirapine did not increase fatty acid synthesis or activate the respiratory electron chain with simultaneous mitochondrial uncoupling supporting clin. reports of a lower propensity for steatosis.  This in vitro study offers insights into the disparate direct and immune-mediated toxicity mechanisms underlying Nevirapine and Ritonavir toxicity in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPJRgkob9Ig7Vg90H21EOLACvtfcHk0li91diy4X7MZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVemtL3P&md5=6859f4b344b3c7e3e7186dda03fb999d</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2015.11.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2015.11.023%26sid%3Dliteratum%253Aachs%26aulast%3DTerelius%26aufirst%3DY.%26aulast%3DFigler%26aufirst%3DR.%2BA.%26aulast%3DMarukian%26aufirst%3DS.%26aulast%3DCollado%26aufirst%3DM.%2BS.%26aulast%3DLawson%26aufirst%3DM.%2BJ.%26aulast%3DMackey%26aufirst%3DA.%2BJ.%26aulast%3DManka%26aufirst%3DD.%26aulast%3DQualls%26aufirst%3DC.%2BW.%26aulast%3DBlackman%26aufirst%3DB.%2BR.%26aulast%3DWamhoff%26aufirst%3DB.%2BR.%26aulast%3DDash%26aufirst%3DA.%26atitle%3DTranscriptional%2520Profiling%2520Suggests%2520that%2520Nevirapine%2520and%2520Ritonavir%2520Cause%2520Drug-Induced%2520Liver%2520Injury%2520Through%2520Distinct%2520Mechanisms%2520in%2520Primary%2520Human%2520Hepatocytes%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2016%26volume%3D255%26spage%3D31%26epage%3D44%26doi%3D10.1016%2Fj.cbi.2015.11.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span> <span> </span><span class="NLM_article-title">Application of Hepatocyte-Like Cells to Enhance Hepatic Safety Risk Assessment in Drug Discovery</span>. <i>Philos. Trans. R. Soc., B</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">20170228</span>, <span class="refDoi"> DOI: 10.1098/rstb.2017.0228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1098%2Frstb.2017.0228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29786562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Olt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2018&pages=20170228&author=D.+P.+Williams&title=Application+of+Hepatocyte-Like+Cells+to+Enhance+Hepatic+Safety+Risk+Assessment+in+Drug+Discovery&doi=10.1098%2Frstb.2017.0228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Application of hepatocyte-like cells to enhance hepatic safety risk assessment in drug discovery</span></div><div class="casAuthors">Williams, Dominic P.</div><div class="citationInfo"><span class="NLM_cas:title">Philosophical Transactions of the Royal Society, B: Biological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">1750</span>),
    <span class="NLM_cas:pages">20170228/1-20170228/8</span>CODEN:
                <span class="NLM_cas:coden">PTRBAE</span>;
        ISSN:<span class="NLM_cas:issn">0962-8436</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">Hepatic stress and injury from drugs continues to be a major concern within the pharmaceutical industry, leading to preclin. and clin. attrition precautionary warnings and post-market withdrawal of drugs.  There is a requirement for more predictive and mechanistically accurate models to aid risk assessment.  Primary human hepatocytes, subject to isolation stress, cryopreservation, donor-to-donor variation and a relatively short period of functional capability in two-dimensional cultures, are not suitable for high-throughput screening procedures.  There are two areas within the drug discovery pipeline that the generation of a stable, metabolically functional hepatocyte-like cell with unlimited supply would have major impact.  First, in routine, cell health risk-assessment assays where hepatic cell lines are typically deployed.  Second, at later stages of the drug discovery pipeline approaching candidate nomination where bespoke/investigational studies refining and understanding the risk to patients use patient-derived induced pluripotent stem cell (iPSC) hepatocytes retaining characteristics from the patient, e.g.  HLA susceptibility alleles, iPSC hepatocytes with defined disease phenotypes or genetic characteristics that have the potential to make the hepatocyte more sensitive to a particular stress mechanism.  Functionality of patient-centric hepatocyte- like cells is likely to be enhanced when coupled with emerging culture systems, such as three-dimensional spheroids or microphysiol. systems.  Ultimately, the aspiration to confidently use human-relevant in vitro models to predict human-specific hepatic toxicity depends on the integration of promising emerging technologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof8RZ4jjszpbVg90H21EOLACvtfcHk0li91diy4X7MZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Olt7g%253D&md5=e29e9972bc5afbb753af387b76cf3169</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1098%2Frstb.2017.0228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frstb.2017.0228%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26atitle%3DApplication%2520of%2520Hepatocyte-Like%2520Cells%2520to%2520Enhance%2520Hepatic%2520Safety%2520Risk%2520Assessment%2520in%2520Drug%2520Discovery%26jtitle%3DPhilos.%2520Trans.%2520R.%2520Soc.%252C%2520B%26date%3D2018%26volume%3D373%26spage%3D20170228%26doi%3D10.1098%2Frstb.2017.0228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Claire, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, K. R.</span></span> <span> </span><span class="NLM_article-title">Automated Applications of Sandwich-Cultured Hepatocytes in the Evaluation of Hepatic Drug Transport</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1177/1087057111400192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1177%2F1087057111400192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21393626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVKgtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=427-435&author=C.+H.+Perryauthor=W.+R.+Smithauthor=R.+L.+St.+Claireauthor=K.+R.+Brouwer&title=Automated+Applications+of+Sandwich-Cultured+Hepatocytes+in+the+Evaluation+of+Hepatic+Drug+Transport&doi=10.1177%2F1087057111400192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Automated applications of sandwich-cultured hepatocytes in the evaluation of hepatic drug transport</span></div><div class="casAuthors">Perry, Cassandra H.; Smith, William R.; St. Claire, Robert L., III; Brouwer, Kenneth R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">427-435</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Predictions of the absorption, distribution, metab., excretion, and toxicity of compds. in pharmaceutical development are essential aspects of the drug discovery process.  B-CLEAR is an in vitro system that uses sandwich-cultured hepatocytes to evaluate and predict in vivo hepatobiliary disposition (hepatic uptake, biliary excretion, and biliary clearance), transporter-based hepatic drug-drug interactions, and potential drug-induced hepatotoxicity.  Automation of predictive technologies is an advantageous and preferred format in drug discovery.  In this study, manual and automated studies are investigated and equivalence is demonstrated.  In addn., automated applications using model probe substrates and inhibitors to assess the cholestatic potential of drugs and evaluate hepatic drug transport are examd.  The successful automation of this technol. provides a more reproducible and less labor-intensive approach, reducing potential operator error in complex studies and facilitating technol. transfer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS5dDgVCuY2bVg90H21EOLACvtfcHk0li91diy4X7MZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVKgtr0%253D&md5=236fcfaca75cca5c05cc2f60b6b22a02</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1177%2F1087057111400192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057111400192%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DC.%2BH.%26aulast%3DSmith%26aufirst%3DW.%2BR.%26aulast%3DSt.%2BClaire%26aufirst%3DR.%2BL.%26aulast%3DBrouwer%26aufirst%3DK.%2BR.%26atitle%3DAutomated%2520Applications%2520of%2520Sandwich-Cultured%2520Hepatocytes%2520in%2520the%2520Evaluation%2520of%2520Hepatic%2520Drug%2520Transport%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2011%26volume%3D16%26spage%3D427%26epage%3D435%26doi%3D10.1177%2F1087057111400192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Susukida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nozaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokizono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span> <span> </span><span class="NLM_article-title">Prediction of the Clinical Risk of Drug-Induced Cholestatic Liver Injury Using an In Vitro Sandwich Cultured Hepatocyte Assay</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1760</span>– <span class="NLM_lpage">1768</span>, <span class="refDoi"> DOI: 10.1124/dmd.115.065425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fdmd.115.065425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26329788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjtlyhtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=1760-1768&author=T.+Susukidaauthor=S.+Sekineauthor=M.+Nozakiauthor=M.+Tokizonoauthor=K.+Ito&title=Prediction+of+the+Clinical+Risk+of+Drug-Induced+Cholestatic+Liver+Injury+Using+an+In+Vitro+Sandwich+Cultured+Hepatocyte+Assay&doi=10.1124%2Fdmd.115.065425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of the clinical risk of drug-induced cholestatic liver injury using an in vitro sandwich cultured hepatocyte assay</span></div><div class="casAuthors">Susukida, Takeshi; Sekine, Shuichi; Nozaki, Mayuka; Tokizono, Mayuko; Ito, Kousei</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1760-1768</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is of concern to the pharmaceutical industry, and reliable preclin. screens are required.  Previously, we established an in vitro bile acid-dependent hepatotoxicity assay that mimics cholestatic DILI in vivo.  Here, we confirmed that this assay can predict cholestatic DILI in clin. situations by comparing in vitro cytotoxicity data with in vivo risk.  For 38 drugs, the frequencies of abnormal increases in serum alk. phosphatase (ALP), transaminases, gamma glutamyltranspeptidase (γGT), and bilirubin were collected from interview forms.  Drugs with frequencies of serum marker increases higher than 1% were classified as high DILI risk compds.  In vitro cytotoxicity was assessed by monitoring lactate dehydrogenase release from rat and human sandwich-cultured hepatocytes (SCRHs and SCHHs) incubated with the test drugs (50 μM) for 24 h in the absence or presence of a bile acids mixt.  Receiver operating characteristic analyses gave optimal cutoff toxicity values of 19.5% and 9.2% for ALP and transaminases in SCRHs, resp.  Using this cutoff, high- and low-risk drugs were sepd. with 65.4-78.6% sensitivity and 66.7-79.2% specificity.  Good sepn. was also achieved using SCHHs.  In conclusion, cholestatic DILI risk can be successfully predicted using a sandwich-cultured hepatocyte-based assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGOSZmxhKYD7Vg90H21EOLACvtfcHk0li91diy4X7MZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjtlyhtbg%253D&md5=41ab968eddd9f1c4e87a6062c93d5671</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.065425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.065425%26sid%3Dliteratum%253Aachs%26aulast%3DSusukida%26aufirst%3DT.%26aulast%3DSekine%26aufirst%3DS.%26aulast%3DNozaki%26aufirst%3DM.%26aulast%3DTokizono%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DK.%26atitle%3DPrediction%2520of%2520the%2520Clinical%2520Risk%2520of%2520Drug-Induced%2520Cholestatic%2520Liver%2520Injury%2520Using%2520an%2520In%2520Vitro%2520Sandwich%2520Cultured%2520Hepatocyte%2520Assay%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D1760%26epage%3D1768%26doi%3D10.1124%2Fdmd.115.065425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oorts, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachellier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacharias, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annaert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Cholestasis Risk Assessment in Sandwich-Cultured Human Hepatocytes</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2016.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.tiv.2016.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27046439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVynt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=179-186&author=M.+Oortsauthor=A.+Bazeauthor=P.+Bachellierauthor=B.+Heydauthor=T.+Zachariasauthor=P.+Annaertauthor=L.+Richert&title=Drug-Induced+Cholestasis+Risk+Assessment+in+Sandwich-Cultured+Human+Hepatocytes&doi=10.1016%2Fj.tiv.2016.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced cholestasis risk assessment in sandwich-cultured human hepatocytes</span></div><div class="casAuthors">Oorts, Marlies; Baze, Audrey; Bachellier, Philippe; Heyd, Bruno; Zacharias, Thomas; Annaert, Pieter; Richert, Lysiane</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">179-186</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drug-induced cholestasis (DIC) is recognized as one of the prime mechanisms for DILI.  Hence, earlier detection of drug candidates with cholestatic signature is crucial.  Recently, the authors introduced an in vitro model for DIC and evaluated its performance with several cholestatic drugs.  The authors presently expand on the validation of this model by 14 training compds. (TCs) of the EU-EFPIA IMI project MIP-DILI.  Several batches of human hepatocytes in sandwich-culture were qualified for DIC assessment by verifying the bile acid-dependent increase in sensitivity to the toxic effects of cyclosporin A.  The cholestatic potential of the TCs was expressed by detg. the drug-induced cholestasis index (DICI).  A safety margin (SM) was calcd. as the ratio of the lowest TC concn. with a DICI ≤0.80 to the Cmax,total.  Nefazodone, bosentan, perhexiline and troglitazone were flagged for cholestasis (SM <30).  The hepatotoxic (but non-cholestatic) compds., amiodarone, diclofenac, fialuridine and ximelagatran, and all non-hepatotoxic compds. were cleared as "safe" for DIC.  Tolcapone and paracetamol yielded DICI-based SM values equal to or higher than those based on cytotoxicity, thus excluding DIC as a DILI mechanism.  This hepatocyte-based in vitro assay provides a unique tool for early and reliable identification of drug candidates with cholestasis risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE3lS_2gwnVbVg90H21EOLACvtfcHk0lhE0dvfzlDwJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVynt7o%253D&md5=0026ecbc5a6631f15e88daf497c675ae</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2016.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2016.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DOorts%26aufirst%3DM.%26aulast%3DBaze%26aufirst%3DA.%26aulast%3DBachellier%26aufirst%3DP.%26aulast%3DHeyd%26aufirst%3DB.%26aulast%3DZacharias%26aufirst%3DT.%26aulast%3DAnnaert%26aufirst%3DP.%26aulast%3DRichert%26aufirst%3DL.%26atitle%3DDrug-Induced%2520Cholestasis%2520Risk%2520Assessment%2520in%2520Sandwich-Cultured%2520Human%2520Hepatocytes%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2016%26volume%3D34%26spage%3D179%26epage%3D186%26doi%3D10.1016%2Fj.tiv.2016.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burbank, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burban, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharanek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guguen-Guillouzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillouzo, A.</span></span> <span> </span><span class="NLM_article-title">Early Alterations of Bile Canaliculi Dynamics and the Rho Kinase/Myosin Light Chain Kinase Pathway Are Characteristics of Drug-Induced Intrahepatic Cholestasis</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1780</span>– <span class="NLM_lpage">1793</span>, <span class="refDoi"> DOI: 10.1124/dmd.116.071373</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fdmd.116.071373" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27538918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=1780-1793&author=M.+G.+Burbankauthor=A.+Burbanauthor=A.+Sharanekauthor=R.+J.+Weaverauthor=C.+Guguen-Guillouzoauthor=A.+Guillouzo&title=Early+Alterations+of+Bile+Canaliculi+Dynamics+and+the+Rho+Kinase%2FMyosin+Light+Chain+Kinase+Pathway+Are+Characteristics+of+Drug-Induced+Intrahepatic+Cholestasis&doi=10.1124%2Fdmd.116.071373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Early alterations of bile canaliculi dynamics and the Rho Kinase/myosin light chain kinase pathway are characteristics of drug-induced intrahepatic cholestasis</span></div><div class="casAuthors">Burbank, Matthew G.; Burban, Audrey; Sharanek, Ahmad; Weaver, Richard J.; Guguen-Guillouzo, Christiane; Guillouzo, Andre</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1780-1793</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Intrahepatic cholestasis represents 20%-40%of drug-induced injuries from which a large proportion remains unpredictable.  We aimed to investigate mechanisms underlying drug-induced cholestasis and improve its early detection using human HepaRG cells and a set of 12 cholestatic drugs and six noncholestatic drugs.  In this study, we analyzed bile canaliculi dynamics, Rho kinase (ROCK)/myosin light chain kinase (MLCK) pathway implication, efflux inhibition of taurocholate [a predominant bile salt export pump (BSEP) substrate], and expression of the major canalicular and basolateral bile acid transporters.  We demonstrated that 12 cholestatic drugs classified on the basis of reported clin. findings caused disturbances of both bile canaliculi dynamics, characterized by either dilatation or constriction, and alteration of the ROCK/MLCK signaling pathway, whereas noncholestatic compds., by contrast, had no effect.  Cotreatment with ROCK inhibitor Y-27632 [4-(1-aminoethyl)-N-(4-pyridyl) cyclohexanecarboxamide dihydrochloride] and MLCK activator calmodulin reduced bile canaliculi constriction and dilatation, resp., confirming the role of these pathways in drug-induced intrahepatic cholestasis.  By contrast, inhibition of taurocholate efflux and/or human BSEP overexpressed in membrane vesicles was not obsd. with all cholestatic drugs; moreover, examples of noncholestatic compds. were reportedly found to inhibit BSEP.  Transcripts levels of major bile acid transporters were detd. after 24-h treatment.  BSEP, Na+-taurocholate cotransporting polypeptide, and org. anion transporting polypeptide B were downregulated with most cholestatic and some noncholestatic drugs, whereas deregulation of multidrug resistance-assocd. proteins was more variable, probably mainly reflecting secondary effects.  Together, our results show that cholestatic drugs consistently cause an early alteration of bile canaliculi dynamics assocd. with modulation of ROCK/MLCK and these changes are more specific than efflux inhibition measurements alone as predictive nonclin. markers of drug-induced cholestasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrco-uclmICXrVg90H21EOLACvtfcHk0lhE0dvfzlDwJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKqsr8%253D&md5=3dc99c76abf38da1c8d8aaa12ee0b6d9</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.071373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.071373%26sid%3Dliteratum%253Aachs%26aulast%3DBurbank%26aufirst%3DM.%2BG.%26aulast%3DBurban%26aufirst%3DA.%26aulast%3DSharanek%26aufirst%3DA.%26aulast%3DWeaver%26aufirst%3DR.%2BJ.%26aulast%3DGuguen-Guillouzo%26aufirst%3DC.%26aulast%3DGuillouzo%26aufirst%3DA.%26atitle%3DEarly%2520Alterations%2520of%2520Bile%2520Canaliculi%2520Dynamics%2520and%2520the%2520Rho%2520Kinase%252FMyosin%2520Light%2520Chain%2520Kinase%2520Pathway%2520Are%2520Characteristics%2520of%2520Drug-Induced%2520Intrahepatic%2520Cholestasis%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2016%26volume%3D44%26spage%3D1780%26epage%3D1793%26doi%3D10.1124%2Fdmd.116.071373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharanek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burban, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burbank, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Guevel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillouzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guguen-Guillouzo, C.</span></span> <span> </span><span class="NLM_article-title">Rho-Kinase/Myosin Light Chain Kinase Pathway Plays a Key Role in the Impairment of Bile Canaliculi Dynamics Induced by Cholestatic Drugs</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>, <span class="refDoi"> DOI: 10.1038/srep24709</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fsrep24709" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27169750" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=A.+Sharanekauthor=A.+Burbanauthor=M.+Burbankauthor=R.+Le+Guevelauthor=R.+Liauthor=A.+Guillouzoauthor=C.+Guguen-Guillouzo&title=Rho-Kinase%2FMyosin+Light+Chain+Kinase+Pathway+Plays+a+Key+Role+in+the+Impairment+of+Bile+Canaliculi+Dynamics+Induced+by+Cholestatic+Drugs&doi=10.1038%2Fsrep24709"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1038%2Fsrep24709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep24709%26sid%3Dliteratum%253Aachs%26aulast%3DSharanek%26aufirst%3DA.%26aulast%3DBurban%26aufirst%3DA.%26aulast%3DBurbank%26aufirst%3DM.%26aulast%3DLe%2BGuevel%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DGuillouzo%26aufirst%3DA.%26aulast%3DGuguen-Guillouzo%26aufirst%3DC.%26atitle%3DRho-Kinase%252FMyosin%2520Light%2520Chain%2520Kinase%2520Pathway%2520Plays%2520a%2520Key%2520Role%2520in%2520the%2520Impairment%2520of%2520Bile%2520Canaliculi%2520Dynamics%2520Induced%2520by%2520Cholestatic%2520Drugs%26jtitle%3DSci.%2520Rep.%26date%3D2016%26doi%3D10.1038%2Fsrep24709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faulkner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinsson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoyo-Castelazo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cederbrant, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuppe-Koistinen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tugwood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">The Development of In Vitro Culture Methods to Characterize Primary T-Cell Responses to Drugs</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfs080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfs080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22331489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtVaqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2012&pages=150-158&author=L.+Faulknerauthor=K.+Martinssonauthor=A.+Santoyo-Castelazoauthor=K.+Cederbrantauthor=I.+Schuppe-Koistinenauthor=H.+Powellauthor=J.+Tugwoodauthor=D.+J.+Naisbittauthor=B.+K.+Park&title=The+Development+of+In+Vitro+Culture+Methods+to+Characterize+Primary+T-Cell+Responses+to+Drugs&doi=10.1093%2Ftoxsci%2Fkfs080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">The Development of In Vitro Culture Methods to Characterize Primary T-Cell Responses to Drugs</span></div><div class="casAuthors">Faulkner, Lee; Martinsson, Klara; Santoyo-Castelazo, Anahi; Cederbrant, Karin; Schuppe-Koistinen, Ina; Powell, Helen; Tugwood, Jonathan; Naisbitt, Dean J.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">150-158</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Editor's Highlight: This paper reports an in vitro cell culture system from human donors for the prediction of the allergic potential of drugs.  Naive T cells were cultured in the presence of a drug and tested for transformation of the naive phenotype into a memory phenotype.  These results demonstrate a system that can predict possible drug allergy resulting in serious adverse effects in a system that does not utilize exptl. animals.  Adverse drug reactions represent a major stumbling block to drug development and those with an immune etiol. are the most difficult to predict.  We have developed an in vitro T-cell priming culture method using peripheral blood from healthy volunteers to assess the allergenic potential of drugs.  The drug metabolite nitroso sulfamethoxazole (SMX-NO) was used as a model drug allergen to establish optimum assay conditions.  Naive T cells were cocultured with monocyte-derived dendritic cells at a ratio of 25:1 in the presence of the drug for a period of 8 days, to expand the no. of drug-responsive T cells.  The T cells were then incubated with fresh dendritic cells, and drug and their antigen responsiveness analyzed using readouts for proliferation, cytokine secretion, and cell phenotype.  All five volunteers showed dose-dependent proliferation as measured by 5-(and 6)-carboxyfluorescein diacetate succinimidyl ester content and by 3H-thymidine uptake.  CD4 T cells that had divided in the presence of SMX-NO had changed from a naive phenotype (CD45RA+) to a memory phenotype (CD45RO+).  These memory T cells expressed the chemokine receptors CCR2, CCR4, and CXCR3 suggesting a mixt. of TH1 and TH2 cells in the responding population, with a propensity for homing to the skin.  Drug stimulation was also assocd. with the secretion of a mixt. of TH1 cytokines (interferon γ) and TH2 cytokines (interleukin [IL]-5 and IL-13) as detected by ELISpot.  We are currently developing this approach to investigate the allergenic potential of other drugs, including those where an assocn. between specific human leukocyte antigen alleles and susceptibility to an immunol. reaction has been established.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYOaBDU6Mb8bVg90H21EOLACvtfcHk0ljFLiimJFqSpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtVaqsbs%253D&md5=c3625da18d39f0b0a9ce667f61186cb7</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfs080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfs080%26sid%3Dliteratum%253Aachs%26aulast%3DFaulkner%26aufirst%3DL.%26aulast%3DMartinsson%26aufirst%3DK.%26aulast%3DSantoyo-Castelazo%26aufirst%3DA.%26aulast%3DCederbrant%26aufirst%3DK.%26aulast%3DSchuppe-Koistinen%26aufirst%3DI.%26aulast%3DPowell%26aufirst%3DH.%26aulast%3DTugwood%26aufirst%3DJ.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DThe%2520Development%2520of%2520In%2520Vitro%2520Culture%2520Methods%2520to%2520Characterize%2520Primary%2520T-Cell%2520Responses%2520to%2520Drugs%26jtitle%3DToxicol.%2520Sci.%26date%3D2012%26volume%3D127%26spage%3D150%26epage%3D158%26doi%3D10.1093%2Ftoxsci%2Fkfs080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGill, M. R.</span></span> <span> </span><span class="NLM_article-title">The Problem With Predictive Values: Are We Using the Right Metrics for Preclinical Prediction of Drug Hepatotoxicity?</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfy157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfy157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30165627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovFSgur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2018&pages=3-4&author=M.+R.+McGill&title=The+Problem+With+Predictive+Values%3A+Are+We+Using+the+Right+Metrics+for+Preclinical+Prediction+of+Drug+Hepatotoxicity%3F&doi=10.1093%2Ftoxsci%2Fkfy157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">The problem with predictive values: are we using the right metrics for preclinical prediction of drug hepatotoxicity?</span></div><div class="casAuthors">McGill, Mitchell R.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-5</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A polemic in response to Vorrink et al. ((2018), 163(2), 655-665).  Vorrink et al used predictive values as a way of expressing the ability of novel in vitro model systems to predict drug-induced liver injury (DILI), and as metrics that can be used to compare those systems, however, the author believes use of predictive values in that way is problematic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU_IIGlc7QhbVg90H21EOLACvtfcHk0ljFLiimJFqSpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovFSgur0%253D&md5=7ecebfd6929ed1bfa1a92e69eaa400a1</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfy157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfy157%26sid%3Dliteratum%253Aachs%26aulast%3DMcGill%26aufirst%3DM.%2BR.%26atitle%3DThe%2520Problem%2520With%2520Predictive%2520Values%253A%2520Are%2520We%2520Using%2520the%2520Right%2520Metrics%2520for%2520Preclinical%2520Prediction%2520of%2520Drug%2520Hepatotoxicity%253F%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D165%26spage%3D3%26epage%3D4%26doi%3D10.1093%2Ftoxsci%2Fkfy157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">Deep Learning for Drug-Induced Liver Injury</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2085</span>– <span class="NLM_lpage">2093</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.5b00238</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.5b00238" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1ShsLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=2085-2093&author=Y.+Xuauthor=Z.+Daiauthor=F.+Chenauthor=S.+Gaoauthor=J.+Peiauthor=L.+Lai&title=Deep+Learning+for+Drug-Induced+Liver+Injury&doi=10.1021%2Facs.jcim.5b00238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Deep Learning for Drug-Induced Liver Injury</span></div><div class="casAuthors">Xu, Youjun; Dai, Ziwei; Chen, Fangjin; Gao, Shuaishi; Pei, Jianfeng; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2085-2093</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) has been the single most frequent cause of safety-related drug marketing withdrawals for the past 50 years.  Recently, deep learning (DL) has been successfully applied in many fields due to its exceptional and automatic learning ability.  In this study, DILI prediction models were developed using DL architectures, and the best model trained on 475 drugs predicted an external validation set of 198 drugs with an accuracy of 86.9%, sensitivity of 82.5%, specificity of 92.9%, and area under the curve of 0.955, which is better than the performance of previously described DILI prediction models.  Furthermore, with deep anal., we also identified important mol. features that are related to DILI.  Such DL models could improve the prediction of DILI risk in humans.  The DL DILI prediction models are freely available at http://www.repharma.cn/DILIserver/DILI_home.php.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrELKXx1N9qkLVg90H21EOLACvtfcHk0ljFLiimJFqSpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1ShsLvO&md5=fad73f248e2caab2fb17dd0b1191e6e5</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.5b00238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.5b00238%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26aulast%3DDai%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DDeep%2520Learning%2520for%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2015%26volume%3D55%26spage%3D2085%26epage%3D2093%26doi%3D10.1021%2Facs.jcim.5b00238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, W.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Predicting Drug-Induced Liver Injury in Human With Naive Bayes Classifier Approach</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">889</span>– <span class="NLM_lpage">898</span>, <span class="refDoi"> DOI: 10.1007/s10822-016-9972-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs10822-016-9972-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27640149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFart7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=889-898&author=H.+Zhangauthor=L.+Dingauthor=Y.+Zouauthor=S.-Q.+Huauthor=H.-G.+Huangauthor=W.-B.+Kongauthor=J.+Zhang&title=Predicting+Drug-Induced+Liver+Injury+in+Human+With+Naive+Bayes+Classifier+Approach&doi=10.1007%2Fs10822-016-9972-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting drug-induced liver injury in human with Naive Bayes classifier approach</span></div><div class="casAuthors">Zhang, Hui; Ding, Lan; Zou, Yi; Hu, Shui-Qing; Huang, Hai-Guo; Kong, Wei-Bao; Zhang, Ji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">889-898</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is one of the major safety concerns in drug development.  Although various toxicol. studies assessing DILI risk have been developed, these methods were not sufficient in predicting DILI in humans.  Thus, developing new tools and approaches to better predict DILI risk in humans has become an important and urgent task.  In this study, we aimed to develop a computational model for assessment of the DILI risk with using a larger scale human dataset and Naive Bayes classifier.  The established Naive Bayes prediction model was evaluated by 5-fold cross validation and an external test set.  For the training set, the overall prediction accuracy of the 5-fold cross validation was 94.0 %.  The sensitivity, specificity, pos. predictive value and neg. predictive value were 97.1, 89.2, 93.5 and 95.1 %, resp.  The test set with the concordance of 72.6 %, sensitivity of 72.5 %, specificity of 72.7 %, pos. predictive value of 80.4 %, neg. predictive value of 63.2 %.  Furthermore, some important mol. descriptors related to DILI risk and some toxic/non-toxic fragments were identified.  Thus, we hope the prediction model established here would be employed for the assessment of human DILI risk, and the obtained mol. descriptors and substructures should be taken into consideration in the design of new candidate compds. to help medicinal chemists rationally select the chems. with the best prospects to be effective and safe.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-qMnd2ladibVg90H21EOLACvtfcHk0ljFLiimJFqSpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFart7fK&md5=0b614b8703babf37fd675515b8ccd37b</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1007%2Fs10822-016-9972-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-016-9972-6%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DS.-Q.%26aulast%3DHuang%26aufirst%3DH.-G.%26aulast%3DKong%26aufirst%3DW.-B.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DPredicting%2520Drug-Induced%2520Liver%2520Injury%2520in%2520Human%2520With%2520Naive%2520Bayes%2520Classifier%2520Approach%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2016%26volume%3D30%26spage%3D889%26epage%3D898%26doi%3D10.1007%2Fs10822-016-9972-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span> <span> </span><span class="NLM_article-title">In silico Prediction of Drug Induced Liver Toxicity Using Substructure Pattern Recognition Method</span>. <i>Mol. Inf.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">136</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1002/minf.201500055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fminf.201500055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27491923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVShsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=136-144&author=C.+Zhangauthor=F.+Chengauthor=W.+Liauthor=G.+Liuauthor=P.+W.+Leeauthor=Y.+Tang&title=In+silico+Prediction+of+Drug+Induced+Liver+Toxicity+Using+Substructure+Pattern+Recognition+Method&doi=10.1002%2Fminf.201500055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">In silico Prediction of Drug Induced Liver Toxicity Using Substructure Pattern Recognition Method</span></div><div class="casAuthors">Zhang, Chen; Cheng, Feixiong; Li, Weihua; Liu, Guixia; Lee, Philip W.; Tang, Yun</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Informatics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">136-144</span>CODEN:
                <span class="NLM_cas:coden">MIONBS</span>;
        ISSN:<span class="NLM_cas:issn">1868-1743</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a leading cause of acute liver failure in the US and less severe liver injury worldwide.  It is also one of the major reasons of drug withdrawal from the market.  Thus, DILI has become one of the most important concerns of drugs, and should be predicted in very early stage of drug discovery process.  In this study, a comprehensive data set contg. 1317 diverse compds. was collected from publications.  Then, high accuracy classification models were built using five machine learning methods based on MACCS and FP4 fingerprints after evaluating by substructure pattern recognition method.  The best model was built using SVM method together with FP4 fingerprint at the IG value threshold of 0.0005.  Its overall predictive accuracies were 79.7 % and 64.5 % for the training and test sets, sep., which yielded overall accuracy of 75.0 % for the external validation dataset, consisting of 88 compds. collected from a benchmark DILI database - the Liver Toxicity Knowledge Base.  This model could be used for drug-induced liver toxicity prediction.  Moreover, some key substructure patterns correlated with drug-induced liver toxicity were also identified as structural alerts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo6jbeXslRa7Vg90H21EOLACvtfcHk0lhvoi0q9pb-MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVShsb8%253D&md5=7c13fa883243c41f61b037c3b579f490</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1002%2Fminf.201500055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fminf.201500055%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DCheng%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DP.%2BW.%26aulast%3DTang%26aufirst%3DY.%26atitle%3DIn%2520silico%2520Prediction%2520of%2520Drug%2520Induced%2520Liver%2520Toxicity%2520Using%2520Substructure%2520Pattern%2520Recognition%2520Method%26jtitle%3DMol.%2520Inf.%26date%3D2016%26volume%3D35%26spage%3D136%26epage%3D144%26doi%3D10.1002%2Fminf.201500055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pekthong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varnek, A.</span></span> <span> </span><span class="NLM_article-title">Prediction of Drug Induced Liver Injury Using Molecular and Biological Descriptors</span>. <i>Comb. Chem. High Throughput Screening</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.2174/1386207318666150305144650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.2174%2F1386207318666150305144650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25747442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsFynsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2015&pages=315-322&author=C.+Mullerauthor=D.+Pekthongauthor=E.+Alexandreauthor=G.+Marcouauthor=D.+Horvathauthor=L.+Richertauthor=A.+Varnek&title=Prediction+of+Drug+Induced+Liver+Injury+Using+Molecular+and+Biological+Descriptors&doi=10.2174%2F1386207318666150305144650"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Drug Induced Liver Injury Using Molecular and Biological Descriptors</span></div><div class="casAuthors">Muller, Christophe; Pekthong, Dumrongsak; Alexandre, Eliane; Marcou, Gilles; Horvath, Dragos; Richert, Lysiane; Varnek, Alexandre</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry & High Throughput Screening</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">315-322</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">In this paper we report quant. structure-activity models linking in vivo Drug-Induced Liver Injury (DILI) of org. mols. with some parameters both measured exptl. in vitro and calcd. theor. from the mol. structure.  At the first step, a small database contg. information of DILI in humans was created and annotated by exptl. obsd. information concerning hepatotoxic effects.  Thus, for each compd. a binary annotation 'yes/no' was applied to DILI and seven endpoints causing different liver pathologies in humans: Cholestasis (CH), Oxidative Stress (OS), Mitochondrial injury (MT), Cirrhosis and Steatosis (CS), Hepatitis (HS), Hepatocellular (HC), and Reactive Metabolite (RM).  Different machine-learning methods were used to build classification models linking DILI with mol. structure: Support Vector Machines, Artificial Neural Networks and Random Forests.  Three types of models were developed: (i) involving mol. descriptors calcd. directly from chem. structure, (ii) involving selected endpoints as 'biol.' descriptors, and (iii) involving both types of descriptors.  It has been found that the models based solely on mol. descriptors have much weaker prediction performance than those involving in vivo measured endpoints.  Taking into account difficulties in obtaining of in vivo data, at the validation stage we used instead five endpoints (CH, CS, HC, MT and OS) measured in vitro in human hepatocyte cultures.  The models involving either some of exptl. in vitro endpoints or their combination with theor. calcd. ones correctly predict DILI for 9 out of 10 ref. compds. of the external test set.  This opens an interesting perspective to use for DILI predictions a combination of theor. calcd. parameters and measured in vitro biol. data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1Pul5Lc9XSbVg90H21EOLACvtfcHk0lhvoi0q9pb-MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsFynsL0%253D&md5=71853f6a83715ca61ea1d55a8c4a330f</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.2174%2F1386207318666150305144650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1386207318666150305144650%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DPekthong%26aufirst%3DD.%26aulast%3DAlexandre%26aufirst%3DE.%26aulast%3DMarcou%26aufirst%3DG.%26aulast%3DHorvath%26aufirst%3DD.%26aulast%3DRichert%26aufirst%3DL.%26aulast%3DVarnek%26aufirst%3DA.%26atitle%3DPrediction%2520of%2520Drug%2520Induced%2520Liver%2520Injury%2520Using%2520Molecular%2520and%2520Biological%2520Descriptors%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2015%26volume%3D18%26spage%3D315%26epage%3D322%26doi%3D10.2174%2F1386207318666150305144650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P.</span></span> <span> </span><span class="NLM_article-title">The DILI-sim Initiative: Insights into Hepatotoxicity Mechanisms and Biomarker Interpretation</span>. <i>Clinical and Translational Science</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1111/cts.12629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1111%2Fcts.12629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30762301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BB3cfjt1ygug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=122-129&author=P.+Watkins&title=The+DILI-sim+Initiative%3A+Insights+into+Hepatotoxicity+Mechanisms+and+Biomarker+Interpretation&doi=10.1111%2Fcts.12629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">The DILI-sim Initiative: Insights into Hepatotoxicity Mechanisms and Biomarker Interpretation</span></div><div class="casAuthors">Watkins Paul B; Watkins Paul B</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and translational science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">122-129</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The drug-induced liver injury (DILI)-sim Initiative is a public-private partnership involving scientists from industry, academia, and the US Food and Drug Administration (FDA).  The Initiative uses quantitative systems toxicology (QST) to build and refine a model (DILIsym) capable of understanding and predicting liver safety liabilities in new drug candidates and to optimize interpretation of liver safety biomarkers used in clinical studies.  Insights gained to date include the observation that most dose-dependent hepatotoxicity can be accounted for by combinations of just three mechanisms (oxidative stress, interference with mitochondrial respiration, and alterations in bile acid homeostasis) and the importance of noncompetitive inhibition of bile acid transporters.  The effort has also provided novel insight into species and interpatient differences in susceptibility, structure-activity relationships, and the role of nonimmune mechanisms in delayed idiosyncratic hepatotoxicity.  The model is increasingly used to evaluate new drug candidates and several clinical trials are underway that will test the model's ability to prospectively predict liver safety.  With more refinement, in the future, it may be possible to use the DILIsym predictions to justify reduction in the size of some clinical trials.  The mature model could also potentially assist physicians in managing the liver safety of their patients as well as aid in the diagnosis of DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ3frvpxgtD7e2mnZh2OgS0fW6udTcc2eYW3NYrHj2EDrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfjt1ygug%253D%253D&md5=9e73cf24b1c0eb3166b6d1a3875224a9</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1111%2Fcts.12629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12629%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DP.%26atitle%3DThe%2520DILI-sim%2520Initiative%253A%2520Insights%2520into%2520Hepatotoxicity%2520Mechanisms%2520and%2520Biomarker%2520Interpretation%26jtitle%3DClinical%2520and%2520Translational%2520Science%26date%3D2019%26volume%3D12%26spage%3D122%26epage%3D129%26doi%3D10.1111%2Fcts.12629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shoda, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battista, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siler, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisetsky, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B. A.</span></span> <span> </span><span class="NLM_article-title">Mechanistic Modelling of Drug-Induced Liver Injury: Investigating the Role of Innate Immune Responses</span>. <i>Gene Regul. Syst. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">117762501769607</span>, <span class="refDoi"> DOI: 10.1177/1177625017696074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1177%2F1177625017696074" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=117762501769607&author=L.+K.+Shodaauthor=C.+Battistaauthor=S.+Q.+Silerauthor=D.+S.+Pisetskyauthor=P.+B.+Watkinsauthor=B.+A.+Howell&title=Mechanistic+Modelling+of+Drug-Induced+Liver+Injury%3A+Investigating+the+Role+of+Innate+Immune+Responses&doi=10.1177%2F1177625017696074"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1177%2F1177625017696074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1177625017696074%26sid%3Dliteratum%253Aachs%26aulast%3DShoda%26aufirst%3DL.%2BK.%26aulast%3DBattista%26aufirst%3DC.%26aulast%3DSiler%26aufirst%3DS.%2BQ.%26aulast%3DPisetsky%26aufirst%3DD.%2BS.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DHowell%26aufirst%3DB.%2BA.%26atitle%3DMechanistic%2520Modelling%2520of%2520Drug-Induced%2520Liver%2520Injury%253A%2520Investigating%2520the%2520Role%2520of%2520Innate%2520Immune%2520Responses%26jtitle%3DGene%2520Regul.%2520Syst.%2520Biol.%26date%3D2017%26volume%3D11%26spage%3D117762501769607%26doi%3D10.1177%2F1177625017696074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siler, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoda, L. K. M.</span></span> <span> </span><span class="NLM_article-title">The Role of Quantitative Systems Pharmacology Modeling in the Prediction and Explanation of Idiosyncratic Drug-Induced Liver Injury</span>. <i>Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/j.dmpk.2016.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.dmpk.2016.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28129975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCnsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=40-45&author=J.+L.+Woodheadauthor=P.+B.+Watkinsauthor=B.+A.+Howellauthor=S.+Q.+Silerauthor=L.+K.+M.+Shoda&title=The+Role+of+Quantitative+Systems+Pharmacology+Modeling+in+the+Prediction+and+Explanation+of+Idiosyncratic+Drug-Induced+Liver+Injury&doi=10.1016%2Fj.dmpk.2016.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">The role of quantitative systems pharmacology modeling in the prediction and explanation of idiosyncratic drug-induced liver injury</span></div><div class="casAuthors">Woodhead, Jeffrey L.; Watkins, Paul B.; Howell, Brett A.; Siler, Scott Q.; Shoda, Lisl K. M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-45</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Idiosyncratic drug-induced liver injury (iDILI) is a serious concern in drug development.  The rarity and multifactorial nature of iDILI makes it difficult to predict and explain.  Recently, human leukocyte antigen (HLA) allele assocns. have provided strong support for a role of an adaptive immune response in the pathogenesis of many iDILI cases; however, it is likely that an adaptive immune attack requires several preceding events.  Quant. systems pharmacol. (QSP), an in silico modeling technique that leverages known physiol. and the results of in vitro expts. in order to make predictions about how drugs affect biol. processes, is proposed as a potentially useful tool for predicting and explaining crit. events that likely precede immune-mediated iDILI, as well as the immune attack itself.  DILIsym, a QSP platform for drug-induced liver injury, has demonstrated success in predicting the presence of delayed hepatocellular stress events that likely precede the iDILI cascade, and has successfully predicted hepatocellular stress likely underlying iDILI attributed to troglitazone and tolvaptan.  The incorporation of a model of the adaptive immune system into DILIsym would represent and important advance.  In summary, QSP methods can play a key role in the future prediction and understanding of both immune-mediated and non-immune-mediated iDILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKgWaqDH4nabVg90H21EOLACvtfcHk0lhGMPN0mRHrsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCnsb%252FO&md5=bc564d3a6f7572c4443b84e0506f4327</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1016%2Fj.dmpk.2016.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dmpk.2016.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DWoodhead%26aufirst%3DJ.%2BL.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DHowell%26aufirst%3DB.%2BA.%26aulast%3DSiler%26aufirst%3DS.%2BQ.%26aulast%3DShoda%26aufirst%3DL.%2BK.%2BM.%26atitle%3DThe%2520Role%2520of%2520Quantitative%2520Systems%2520Pharmacology%2520Modeling%2520in%2520the%2520Prediction%2520and%2520Explanation%2520of%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DDrug%2520Metab.%2520Pharmacokinet.%26date%3D2017%26volume%3D32%26spage%3D40%26epage%3D45%26doi%3D10.1016%2Fj.dmpk.2016.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarskog, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilliard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfirevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourches, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neale, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shianna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szatkiewicz, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tropsha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Oord, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascorbi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dettling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazit, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goff, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holden, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rujescu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werge, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josiassen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, P. F.</span></span> <span> </span><span class="NLM_article-title">Clozapine-Induced Agranulocytosis is Associated with Rare HLA-DQB1 and HLA-B Alleles</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">4757</span>, <span class="refDoi"> DOI: 10.1038/ncomms5757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fncomms5757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25187353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVWgs7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=4757&author=J.+I.+Goldsteinauthor=L.+F.+Jarskogauthor=C.+Hilliardauthor=A.+Alfirevicauthor=L.+Duncanauthor=D.+Fourchesauthor=H.+Huangauthor=M.+Lekauthor=B.+M.+Nealeauthor=S.+Ripkeauthor=K.+Shiannaauthor=J.+P.+Szatkiewiczauthor=A.+Tropshaauthor=E.+J.+van+den+Oordauthor=I.+Cascorbiauthor=M.+Dettlingauthor=E.+Gazitauthor=D.+C.+Goffauthor=A.+L.+Holdenauthor=D.+L.+Kellyauthor=A.+K.+Malhotraauthor=J.+Nielsenauthor=M.+Pirmohamedauthor=D.+Rujescuauthor=T.+Wergeauthor=D.+L.+Levyauthor=R.+C.+Josiassenauthor=J.+L.+Kennedyauthor=J.+A.+Liebermanauthor=M.+J.+Dalyauthor=P.+F.+Sullivan&title=Clozapine-Induced+Agranulocytosis+is+Associated+with+Rare+HLA-DQB1+and+HLA-B+Alleles&doi=10.1038%2Fncomms5757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles</span></div><div class="casAuthors">Goldstein, Jacqueline I.; Fredrik Jarskog, L.; Hilliard, Chris; Alfirevic, Ana; Duncan, Laramie; Fourches, Denis; Huang, Hailiang; Lek, Monkol; Neale, Benjamin M.; Ripke, Stephan; Shianna, Kevin; Szatkiewicz, Jin P.; Tropsha, Alexander; van den Oord, Edwin J. C. G.; Cascorbi, Ingolf; Dettling, Michael; Gazit, Ephraim; Goff, Donald C.; Holden, Arthur L.; Kelly, Deanna L.; Malhotra, Anil K.; Nielsen, Jimmi; Pirmohamed, Munir; Rujescu, Dan; Werge, Thomas; Levy, Deborah L.; Josiassen, Richard C.; Kennedy, James L.; Lieberman, Jeffrey A.; Daly, Mark J.; Sullivan, Patrick F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4757</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Clozapine is a particularly effective antipsychotic medication but its use is curtailed by the risk of clozapine-induced agranulocytosis/granulocytopenia (CIAG), a severe adverse drug reaction occurring in up to 1% of treated individuals.  Identifying genetic risk factors for CIAG could enable safer and more widespread use of clozapine.  Here we perform the largest and most comprehensive genetic study of CIAG to date by interrogating 163 cases using genome-wide genotyping and whole-exome sequencing.  We find that two loci in the major histocompatibility complex are independently assocd. with CIAG: a single amino acid in HLA-DQB1 (126Q) (P=4.7 × 10-14, odds ratio (OR)=0.19, 95% confidence interval (CI)=0.12-0.29) and an amino acid change in the extracellular binding pocket of HLA-B (158T) (P=6.4 × 10-10, OR=3.3, 95% CI=2.3-4.9).  These assocns. dovetail with the roles of these genes in immunogenetic phenotypes and adverse drug responses for other medications, and provide insight into the pathophysiol. of CIAG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyzYFvwAybFbVg90H21EOLACvtfcHk0lhGMPN0mRHrsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVWgs7fE&md5=0252d111b83a3071d256f29e7d3e1d68</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1038%2Fncomms5757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms5757%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DJ.%2BI.%26aulast%3DJarskog%26aufirst%3DL.%2BF.%26aulast%3DHilliard%26aufirst%3DC.%26aulast%3DAlfirevic%26aufirst%3DA.%26aulast%3DDuncan%26aufirst%3DL.%26aulast%3DFourches%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DLek%26aufirst%3DM.%26aulast%3DNeale%26aufirst%3DB.%2BM.%26aulast%3DRipke%26aufirst%3DS.%26aulast%3DShianna%26aufirst%3DK.%26aulast%3DSzatkiewicz%26aufirst%3DJ.%2BP.%26aulast%3DTropsha%26aufirst%3DA.%26aulast%3Dvan%2Bden%2BOord%26aufirst%3DE.%2BJ.%26aulast%3DCascorbi%26aufirst%3DI.%26aulast%3DDettling%26aufirst%3DM.%26aulast%3DGazit%26aufirst%3DE.%26aulast%3DGoff%26aufirst%3DD.%2BC.%26aulast%3DHolden%26aufirst%3DA.%2BL.%26aulast%3DKelly%26aufirst%3DD.%2BL.%26aulast%3DMalhotra%26aufirst%3DA.%2BK.%26aulast%3DNielsen%26aufirst%3DJ.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DRujescu%26aufirst%3DD.%26aulast%3DWerge%26aufirst%3DT.%26aulast%3DLevy%26aufirst%3DD.%2BL.%26aulast%3DJosiassen%26aufirst%3DR.%2BC.%26aulast%3DKennedy%26aufirst%3DJ.%2BL.%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26aulast%3DDaly%26aufirst%3DM.%2BJ.%26aulast%3DSullivan%26aufirst%3DP.%2BF.%26atitle%3DClozapine-Induced%2520Agranulocytosis%2520is%2520Associated%2520with%2520Rare%2520HLA-DQB1%2520and%2520HLA-B%2520Alleles%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D4757%26doi%3D10.1038%2Fncomms5757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcaida, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yerly, D.</span></span> <span> </span><span class="NLM_article-title">Oxypurinol Directly and Immediately Activates the Drug-Specific T-cells via the Preferential use of HLA-B*58:01</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">2984</span>– <span class="NLM_lpage">2993</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1302306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.4049%2Fjimmunol.1302306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24591375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslamtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2014&pages=2984-2993&author=J.+Yunauthor=M.+J.+Marcaidaauthor=K.+K.+Erikssonauthor=H.+Jaminauthor=S.+Fontanaauthor=W.+J.+Pichlerauthor=D.+Yerly&title=Oxypurinol+Directly+and+Immediately+Activates+the+Drug-Specific+T-cells+via+the+Preferential+use+of+HLA-B*58%3A01&doi=10.4049%2Fjimmunol.1302306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Oxypurinol Directly and Immediately Activates the Drug-Specific T Cells via the Preferential Use of HLA-B*58:01</span></div><div class="casAuthors">Yun, James; Marcaida, Maria J.; Eriksson, Klara K.; Jamin, Heidi; Fontana, Stefano; Pichler, Werner J.; Yerly, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2984-2993</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Allopurinol (ALP) hypersensitivity is a major cause of severe cutaneous adverse reactions and is strongly assocd. with the HLA-B*58:01 allele.  However, it can occur in the absence of this allele with identical clin. manifestations.  The immune mechanism of ALP-induced severe cutaneous adverse reactions is poorly understood, and the T cell-reactivity pattern in patients with or without the HLA-B*58:01 allele is not known.  To understand the interactions among the drug, HLA, and TCR, we generated T cell lines that react to ALP or its metabolite oxypurinol (OXP) from HLA-B*58:01+ and HLA-B*58:01- donors and assessed their reactivity.  ALP/OXP-specific T cells reacted immediately to the addn. of the drugs and bypassed intracellular Ag processing, which is consistent with the "pharmacol. interaction with immune receptors" (p-i) concept.  This direct activation occurred regardless of HLA-B*58:01 status.  Although most OXP-specific T cells from HLA-B*58:01+ donors were restricted by the HLA-B*58:01 mol. for drug recognition, ALP-specific T cells also were restricted to other MHC class I mols.  This can be explained by in silico docking data that suggest that OXP binds to the peptide-binding groove of HLA-B*58:01 with higher affinity.  The ensuing T cell responses elicited by ALP or OXP were not limited to particular TCR Vβ repertoires.  We conclude that the drug-specific T cells are activated by OXP bound to HLA-B*58:01 through the p-i mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3f-hrTxlgnbVg90H21EOLACvtfcHk0lhABNfAoybsxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslamtrc%253D&md5=280089b00c4e97d5f93bc9c63298732c</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1302306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1302306%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DJ.%26aulast%3DMarcaida%26aufirst%3DM.%2BJ.%26aulast%3DEriksson%26aufirst%3DK.%2BK.%26aulast%3DJamin%26aufirst%3DH.%26aulast%3DFontana%26aufirst%3DS.%26aulast%3DPichler%26aufirst%3DW.%2BJ.%26aulast%3DYerly%26aufirst%3DD.%26atitle%3DOxypurinol%2520Directly%2520and%2520Immediately%2520Activates%2520the%2520Drug-Specific%2520T-cells%2520via%2520the%2520Preferential%2520use%2520of%2520HLA-B%252A58%253A01%26jtitle%3DJ.%2520Immunol.%26date%3D2014%26volume%3D192%26spage%3D2984%26epage%3D2993%26doi%3D10.4049%2Fjimmunol.1302306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isogai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyadera, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotozono, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokunaga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirayama, N.</span></span> <span> </span><span class="NLM_article-title">Silico Risk Assessment of HLA-A*02:06-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Caused by Cold Medicine Ingredients</span>. <i>J. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2013</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.1155/2013/514068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1155%2F2013%2F514068" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2013&publication_year=2013&pages=1&author=H.+Isogaiauthor=H.+Miyaderaauthor=M.+Uetaauthor=C.+Sotozonoauthor=S.+Kinoshitaauthor=K.+Tokunagaauthor=N.+Hirayama&title=Silico+Risk+Assessment+of+HLA-A*02%3A06-Associated+Stevens-Johnson+Syndrome+and+Toxic+Epidermal+Necrolysis+Caused+by+Cold+Medicine+Ingredients&doi=10.1155%2F2013%2F514068"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1155%2F2013%2F514068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2013%252F514068%26sid%3Dliteratum%253Aachs%26aulast%3DIsogai%26aufirst%3DH.%26aulast%3DMiyadera%26aufirst%3DH.%26aulast%3DUeta%26aufirst%3DM.%26aulast%3DSotozono%26aufirst%3DC.%26aulast%3DKinoshita%26aufirst%3DS.%26aulast%3DTokunaga%26aufirst%3DK.%26aulast%3DHirayama%26aufirst%3DN.%26atitle%3DSilico%2520Risk%2520Assessment%2520of%2520HLA-A%252A02%253A06-Associated%2520Stevens-Johnson%2520Syndrome%2520and%2520Toxic%2520Epidermal%2520Necrolysis%2520Caused%2520by%2520Cold%2520Medicine%2520Ingredients%26jtitle%3DJ.%2520Toxicol.%26date%3D2013%26volume%3D2013%26spage%3D1%26doi%3D10.1155%2F2013%2F514068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustine, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meid, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubeau, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span> <span> </span><span class="NLM_article-title">Idelalisib in Waldenstrom Macroglobulinemia: High Incidence of Hepatotoxicity</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1002</span>– <span class="NLM_lpage">1004</span>, <span class="refDoi"> DOI: 10.1080/10428194.2016.1222380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1080%2F10428194.2016.1222380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27562445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=1002-1004&author=J.+J.+Castilloauthor=J.+N.+Gustineauthor=K.+Meidauthor=T.+Dubeauauthor=G.+Yangauthor=L.+Xuauthor=Z.+R.+Hunterauthor=S.+P.+Treon&title=Idelalisib+in+Waldenstrom+Macroglobulinemia%3A+High+Incidence+of+Hepatotoxicity&doi=10.1080%2F10428194.2016.1222380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Idelalisib in Waldenstrom macroglobulinemia: high incidence of hepatotoxicity</span></div><div class="casAuthors">Castillo, Jorge J.; Gustine, Joshua N.; Meid, Kirsten; Dubeau, Toni; Yang, Guang; Xu, Lian; Hunter, Zachary R.; Treon, Steven P.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1002-1004</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1029-2403</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  This article discussed about the safety and efficacy of idelalisib in patients with relapsed and/or refractory symptomatic Waldenstrom macroglobulinemia with emphasis on high incidence of hepatotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriIP_LOa-K9LVg90H21EOLACvtfcHk0lhABNfAoybsxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKju7s%253D&md5=6e3b5367086dfe001268fdb0c5a97df7</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1080%2F10428194.2016.1222380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428194.2016.1222380%26sid%3Dliteratum%253Aachs%26aulast%3DCastillo%26aufirst%3DJ.%2BJ.%26aulast%3DGustine%26aufirst%3DJ.%2BN.%26aulast%3DMeid%26aufirst%3DK.%26aulast%3DDubeau%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DHunter%26aufirst%3DZ.%2BR.%26aulast%3DTreon%26aufirst%3DS.%2BP.%26atitle%3DIdelalisib%2520in%2520Waldenstrom%2520Macroglobulinemia%253A%2520High%2520Incidence%2520of%2520Hepatotoxicity%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2017%26volume%3D58%26spage%3D1002%26epage%3D1004%26doi%3D10.1080%2F10428194.2016.1222380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelosof, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avigan, M. I.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxicity of Immune Checkpoint Inhibitors: An Evolving Picture of Risk Associated with a Vital Class of Immunotherapy Agents</span>. <i>Liver Int.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">976</span>– <span class="NLM_lpage">987</span>, <span class="refDoi"> DOI: 10.1111/liv.13746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1111%2Fliv.13746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29603856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC1MnnsFKrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=976-987&author=D.+L.+Suzmanauthor=L.+Pelosofauthor=A.+Rosenbergauthor=M.+I.+Avigan&title=Hepatotoxicity+of+Immune+Checkpoint+Inhibitors%3A+An+Evolving+Picture+of+Risk+Associated+with+a+Vital+Class+of+Immunotherapy+Agents&doi=10.1111%2Fliv.13746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents</span></div><div class="casAuthors">Suzman Daniel L; Pelosof Lorraine; Rosenberg Amy; Avigan Mark I</div><div class="citationInfo"><span class="NLM_cas:title">Liver international : official journal of the International Association for the Study of the Liver</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">976-987</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Immune checkpoint inhibitors (ICIs) block CTLA-4, PD-1 and PD-L1, or other molecules that control antitumour activities of lymphocytes.  These products are associated with a broad array of immune-related toxicities affecting a variety of organs, including the liver.  ICI-associated immune-mediated hepatitis (IMH) ranges in severity between mild and life-threatening and is marked by findings that bear both similarities as well as differences with idiopathic autoimmune hepatitis.  Hepatotoxic events are often detected in clinical trials of ICIs that are powered for efficacy.  Risk levels for ICI-induced liver injury may be impacted by the specific checkpoint molecule targeted for treatment, the ICI dose levels, and the presence of a pre-existing autoimmune diathesis, chronic infection or tumour cells which infiltrate the liver parenchyma.  When patients develop liver injury during ICI treatment, a prompt assessment of the cause of injury, in conjunction with the application of measures to optimally manage the adverse event, should be made.  Strategies to manage the risk of IMH include the performance of pretreatment liver tests with regular monitoring during and after ICI treatment and patient education.  Using Common Terminology Criteria for Adverse Events developed at the National Cancer Institute to measure the severity level of liver injury, recommended actions may include continued ICI treatment with close patient monitoring, ICI treatment suspension or discontinuation and/or administration of corticosteroids or, when necessary, a non-steroidal immunosuppressive agent.  The elucidation of reliable predictors of tumour-specific ICI treatment responses, as well as an increased susceptibility for clinically serious immune-related adverse events, would help optimize treatment decisions for individual patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSU8v9_-AyU18zK395ZObgVfW6udTcc2eblvnMR6SQ8i7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnnsFKrsA%253D%253D&md5=6397551e975f58e11217038c28044f3e</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1111%2Fliv.13746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fliv.13746%26sid%3Dliteratum%253Aachs%26aulast%3DSuzman%26aufirst%3DD.%2BL.%26aulast%3DPelosof%26aufirst%3DL.%26aulast%3DRosenberg%26aufirst%3DA.%26aulast%3DAvigan%26aufirst%3DM.%2BI.%26atitle%3DHepatotoxicity%2520of%2520Immune%2520Checkpoint%2520Inhibitors%253A%2520An%2520Evolving%2520Picture%2520of%2520Risk%2520Associated%2520with%2520a%2520Vital%2520Class%2520of%2520Immunotherapy%2520Agents%26jtitle%3DLiver%2520Int.%26date%3D2018%26volume%3D38%26spage%3D976%26epage%3D987%26doi%3D10.1111%2Fliv.13746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Metushi, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">Treatment of PD-1–/– Mice with Amodiaquine and Anti-CTLA4 Leads to Liver Injury Similar to Idiosyncratic Liver Injury in Patients</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1332</span>, <span class="refDoi"> DOI: 10.1002/hep.27549</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.27549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25283142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlt1Wktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=1332&author=I.+G.+Metushiauthor=M.+A.+Hayesauthor=J.+Uetrecht&title=Treatment+of+PD-1%E2%80%93%2F%E2%80%93+Mice+with+Amodiaquine+and+Anti-CTLA4+Leads+to+Liver+Injury+Similar+to+Idiosyncratic+Liver+Injury+in+Patients&doi=10.1002%2Fhep.27549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of PD-1-/- mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients</span></div><div class="casAuthors">Metushi, Imir G.; Hayes, M. Anthony; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1332-1342</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The mechanism of idiosyncratic drug-induced liver injury (IDILI) remains poorly understood, to a large degree because of the lack of a valid animal model.  Recently, we reported an animal model in which treatment of female C57BL/6 mice with amodiaquine (AQ) resulted in mild liver injury with a delayed onset and resoln. despite continued treatment.  Such adaptation is a common outcome in the IDILI caused by drugs that can cause liver failure.  We had hypothesized that most IDILI is immune-mediated and adaptation represents immune tolerance.  In this study we found that AQ treatment of Cbl-b-/- and PD-1-/- mice, which have impaired immune tolerance, resulted in a slightly greater injury.  Cotreatment of C57BL/6 with AQ and anti-CTLA4 also resulted in a greater increase in ALT than treatment with AQ alone; however, these mice also had an increase in T regulatory (Treg) cells and T helper cells expressing PD-1 and CTLA4.  The increase in these cells implies the induction of immune tolerance, and the alanine aminotransferase (ALT) activity in these mice returned to normal despite continued treatment.  Cotreatment of PD-1-/- mice with anti-CTLA4 antibody and AQ resulted in the greatest increase in ALT (200-300 U/L), and necroinflammatory responses characterized by portal infiltration of lymphocytes with interface hepatitis.  The lymphocyte infiltration included T and B cells, and the CD8+ T cells produced perforin and granzyme.  In addn., the ALT activity in PD-1-/- mice cotreated with anti-CTLA4 antibody and AQ did not return to normal, as it had in other mice.  Conclusion: We report here the first animal model of IDILI that is similar to the IDILI that occurs in humans, and it was accomplished by inhibiting immune tolerance. (Hepatol. 2015;61:1332-1342).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeeeZ25zmWHLVg90H21EOLACvtfcHk0lhGeQcnP4hjyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlt1Wktbc%253D&md5=2c6bb52d8d58e9fcb2a40999e6dc3aa4</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1002%2Fhep.27549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27549%26sid%3Dliteratum%253Aachs%26aulast%3DMetushi%26aufirst%3DI.%2BG.%26aulast%3DHayes%26aufirst%3DM.%2BA.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DTreatment%2520of%2520PD-1%25E2%2580%2593%252F%25E2%2580%2593%2520Mice%2520with%2520Amodiaquine%2520and%2520Anti-CTLA4%2520Leads%2520to%2520Liver%2520Injury%2520Similar%2520to%2520Idiosyncratic%2520Liver%2520Injury%2520in%2520Patients%26jtitle%3DHepatology%26date%3D2015%26volume%3D61%26spage%3D1332%26doi%3D10.1002%2Fhep.27549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Latchman, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobel, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klemm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuchroo, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span> <span> </span><span class="NLM_article-title">PD-L1-Deficient Mice Show that PD-L1 on T-cells, Antigen-Presenting Cells, and Host Tissues Negatively Regulates T-cells</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">10691</span>– <span class="NLM_lpage">10696</span>, <span class="refDoi"> DOI: 10.1073/pnas.0307252101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1073%2Fpnas.0307252101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=15249675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtFWmtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=10691-10696&author=Y.+E.+Latchmanauthor=S.+C.+Liangauthor=Y.+Wuauthor=T.+Chernovaauthor=R.+A.+Sobelauthor=M.+Klemmauthor=V.+K.+Kuchrooauthor=G.+J.+Freemanauthor=A.+H.+Sharpe&title=PD-L1-Deficient+Mice+Show+that+PD-L1+on+T-cells%2C+Antigen-Presenting+Cells%2C+and+Host+Tissues+Negatively+Regulates+T-cells&doi=10.1073%2Fpnas.0307252101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells</span></div><div class="casAuthors">Latchman, Yvette E.; Liang, Spencer C.; Wu, Yin; Chernova, Tatyana; Sobel, Raymond A.; Klemm, Martina; Kuchroo, Vijay K.; Freeman, Gordon J.; Sharpe, Arlene H.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">10691-10696</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Both pos. and neg. regulatory roles have been suggested for the B7 family member PD-L1(B7-H1).  PD-L1 is expressed on antigen-presenting cells (APCs), activated T cells, and a variety of tissues, but the functional significance of PD-L1 on each cell type is not yet clear.  To dissect the functions of PD-L1 in vivo, we generated PD-L1-deficient (PD-L1-/-) mice.  CD4+ and CD8+ T cell responses were markedly enhanced in PD-L1-/- mice compared with wild-type mice in vitro and in vivo.  PD-L1-/- dendritic cells stimulated greater wild-type CD4+ T cell responses than wild-type dendritic cells, and PD-L1-/- CD4+ T cells produced more cytokines than wild-type CD4+ T cells in vitro, demonstrating an inhibitory role for PD-L1 on APCs and T cells.  In vivo CD8+ T cell responses also were significantly enhanced, indicating that PD-L1 has a role in limiting the expansion or survival of CD8+ T cells.  Studies using the myelin oligodendrocyte model of exptl. autoimmune encephalomyelitis showed that PD-L1 on T cells and in host tissues limits responses of self-reactive CD4+ T cells in vivo.  PD-L1 deficiency converted the 129S4/SvJae strain from a resistant to exptl. autoimmune encephalomyelitis-susceptible strain.  Transfer of encephalitogenic T cells from wild-type mice into PD-L1-/- recipients led to exacerbated disease.  Disease was even more severe in PD-L1-/- recipients of PD-L1-/- T cells.  These results demonstrate that PD-L1 on T cells, APCs, and host tissue inhibits naive and effector T cell responses and plays a crit. role in T cell tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9eZ_56053k7Vg90H21EOLACvtfcHk0lhGeQcnP4hjyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtFWmtrg%253D&md5=8a48db5e1a8007f10012657beac2bb00</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0307252101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0307252101%26sid%3Dliteratum%253Aachs%26aulast%3DLatchman%26aufirst%3DY.%2BE.%26aulast%3DLiang%26aufirst%3DS.%2BC.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DChernova%26aufirst%3DT.%26aulast%3DSobel%26aufirst%3DR.%2BA.%26aulast%3DKlemm%26aufirst%3DM.%26aulast%3DKuchroo%26aufirst%3DV.%2BK.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26atitle%3DPD-L1-Deficient%2520Mice%2520Show%2520that%2520PD-L1%2520on%2520T-cells%252C%2520Antigen-Presenting%2520Cells%252C%2520and%2520Host%2520Tissues%2520Negatively%2520Regulates%2520T-cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D10691%26epage%3D10696%26doi%3D10.1073%2Fpnas.0307252101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okkenhaug, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilancio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farjot, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priddle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peskett, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salpekar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterfield, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaesebroeck, B.</span></span> <span> </span><span class="NLM_article-title">Impaired B- and T-cell Antigen Receptor Signaling in P110delta PI 3-kinase Mutant Mice</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>297</i></span>,  <span class="NLM_fpage">1031</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1126/science.1073560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1126%2Fscience.1073560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=12130661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmt1Cktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=297&publication_year=2002&pages=1031-1034&author=K.+Okkenhaugauthor=A.+Bilancioauthor=G.+Farjotauthor=H.+Priddleauthor=S.+Sanchoauthor=E.+Peskettauthor=W.+Pearceauthor=S.+E.+Meekauthor=A.+Salpekarauthor=M.+D.+Waterfieldauthor=A.+J.+Smithauthor=B.+Vanhaesebroeck&title=Impaired+B-+and+T-cell+Antigen+Receptor+Signaling+in+P110delta+PI+3-kinase+Mutant+Mice&doi=10.1126%2Fscience.1073560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Impaired B and T cell antigen receptor signaling in p110δ PI 3-kinase mutant mice</span></div><div class="casAuthors">Okkenhaug, Klaus; Bilancio, Antonio; Farjot, Geraldine; Priddle, Helen; Sancho, Sara; Peskett, Emma; Pearce, Wayne; Meek, Stephen E.; Salpekar, Ashreena; Waterfield, Michael D.; Smith, Andrew J. H.; Vanhaesebroeck, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">297</span>
        (<span class="NLM_cas:issue">5583</span>),
    <span class="NLM_cas:pages">1031-1034</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Class IA phosphoinositide 3-kinases (PI3Ks) are a family of p85/p110 heterodimeric lipid kinases that generate second messenger signals downstream of tyrosine kinases, thereby controlling cell metab., growth, proliferation, differentiation, motility, and survival.  Mammals express three class IA catalytic subunits: p110α, p110β, and p110δ.  It is unclear to what extent these p110 isoforms have overlapping or distinct biol. roles.  Mice expressing a catalytically inactive form of p110δ (p110δD910A) were generated by gene targeting.  Antigen receptor signaling in B and T cells was impaired and immune responses in vivo were attenuated in p110δ mutant mice.  They also developed inflammatory bowel disease.  These results reveal a selective role for p110δ in immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAY2T-yP_kmbVg90H21EOLACvtfcHk0lhGeQcnP4hjyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmt1Cktb4%253D&md5=c931a202635098a5d973a5903b8a6f9f</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1126%2Fscience.1073560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1073560%26sid%3Dliteratum%253Aachs%26aulast%3DOkkenhaug%26aufirst%3DK.%26aulast%3DBilancio%26aufirst%3DA.%26aulast%3DFarjot%26aufirst%3DG.%26aulast%3DPriddle%26aufirst%3DH.%26aulast%3DSancho%26aufirst%3DS.%26aulast%3DPeskett%26aufirst%3DE.%26aulast%3DPearce%26aufirst%3DW.%26aulast%3DMeek%26aufirst%3DS.%2BE.%26aulast%3DSalpekar%26aufirst%3DA.%26aulast%3DWaterfield%26aufirst%3DM.%2BD.%26aulast%3DSmith%26aufirst%3DA.%2BJ.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26atitle%3DImpaired%2520B-%2520and%2520T-cell%2520Antigen%2520Receptor%2520Signaling%2520in%2520P110delta%2520PI%25203-kinase%2520Mutant%2520Mice%26jtitle%3DScience%26date%3D2002%26volume%3D297%26spage%3D1031%26epage%3D1034%26doi%3D10.1126%2Fscience.1073560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref233"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref233'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uno, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikh, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepulveda, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaesebroeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balfour Sartor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plevy, S. E.</span></span> <span> </span><span class="NLM_article-title">Altered Macrophage Function Contributes to Colitis in Mice Defective in the Phosphoinositide-3 Kinase Subunit p110δ</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">1642</span>– <span class="NLM_lpage">1653</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2010.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1053%2Fj.gastro.2010.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=20637203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKhurrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2010&pages=1642-1653&author=J.+K.+Unoauthor=K.+N.+Raoauthor=K.+Matsuokaauthor=S.+Z.+Sheikhauthor=T.+Kobayashiauthor=F.+Liauthor=E.+C.+Steinbachauthor=A.+R.+Sepulvedaauthor=B.+Vanhaesebroeckauthor=R.+Balfour+Sartorauthor=S.+E.+Plevy&title=Altered+Macrophage+Function+Contributes+to+Colitis+in+Mice+Defective+in+the+Phosphoinositide-3+Kinase+Subunit+p110%CE%B4&doi=10.1053%2Fj.gastro.2010.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Altered Macrophage Function Contributes to Colitis in Mice Defective in the Phosphoinositide-3 Kinase Subunit p110δ</span></div><div class="casAuthors">Uno, Jennifer K.; Rao, Kavitha N.; Matsuoka, Katsuyoshi; Sheikh, Shehzad Z.; Kobayashi, Taku; Li, Fengling; Steinbach, Erin C.; Sepulveda, Antonia R.; Vanhaesebroeck, Bart; Sartor, R. Balfour; Plevy, Scott E.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1642-1653</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Innate immune responses are crucial for host defense against pathogens but need to be tightly regulated to prevent chronic inflammation.  Initial characterization of mice with a targeted inactivating mutation in the p110δ subunit of phosphoinositide 3-kinase (PI3K p110δD910A/D910A) revealed defects in B- and T-cell signaling and chronic colitis.  Here, we further characterize features of inflammatory bowel diseases in these mice and investigate underlying innate immune defects.  Colons and macrophages from PI3K p110δD910A/D910A mice were evaluated for colonic inflammation and innate immune dysfunction.  Colonic p110δ mRNA expression was examd. in interleukin (IL)-10-/- and wild-type germ-free mice during transition to a conventional microbiota.  To assess polygenic impact on development of colitis, p110δD910A/D910A mice were backcrossed to IL-10-/- mice.  A mild spontaneous colitis was shown in PI3K p110δD910A/D910A mice at 8 wk, with inflammation increasing with age.  An inflammatory mucosal and systemic cytokine profile was characterized by expression of IL-12/23.  In PI3K p110δD910A/D910A macrophages, augmented toll-like receptor signaling and defective bactericidal activity were obsd.  Consistent with an important homeostatic role for PI3K p110δ, wild-type mice raised in a germ-free environment markedly up-regulated colonic PI3K p110δ expression with the introduction of the enteric microbiota; however, colitis-prone IL-10-/- mice did not.  Moreover, PI3K p110δD910A/D910A mice crossed to IL-10-/- mice developed severe colitis at an early age.  This study describes a novel model of exptl. colitis that highlights the importance of PI3K p110δ in maintaining mucosal homeostasis and could provide insight into the pathogenesis of human inflammatory bowel disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUVFyJRMQWdLVg90H21EOLACvtfcHk0li9JWTei1EjJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKhurrE&md5=6d431d69d8fde80be91f87d45f313c5e</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2010.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2010.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DUno%26aufirst%3DJ.%2BK.%26aulast%3DRao%26aufirst%3DK.%2BN.%26aulast%3DMatsuoka%26aufirst%3DK.%26aulast%3DSheikh%26aufirst%3DS.%2BZ.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DSteinbach%26aufirst%3DE.%2BC.%26aulast%3DSepulveda%26aufirst%3DA.%2BR.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DBalfour%2BSartor%26aufirst%3DR.%26aulast%3DPlevy%26aufirst%3DS.%2BE.%26atitle%3DAltered%2520Macrophage%2520Function%2520Contributes%2520to%2520Colitis%2520in%2520Mice%2520Defective%2520in%2520the%2520Phosphoinositide-3%2520Kinase%2520Subunit%2520p110%25CE%25B4%26jtitle%3DGastroenterology%26date%3D2010%26volume%3D139%26spage%3D1642%26epage%3D1653%26doi%3D10.1053%2Fj.gastro.2010.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref234"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref234'); return false;" data-citation="" class="refNumLink">233</a></strong><div class="NLM_citation" id="cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Button, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caggiano, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iaci, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parry, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanulis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Transient Changes in Hepatic Physiology That Alter Bilirubin and Bile Acid Transport May Explain Elevations in Liver Chemistries Observed in Clinical Trials of GGF2 (Cimaglermin Alfa)</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfx222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfx222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29069498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFelsbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2018&pages=401-411&author=M.+Mosedaleauthor=D.+Buttonauthor=J.+P.+Jacksonauthor=K.+M.+Freemanauthor=K.+R.+Brouwerauthor=A.+O.+Caggianoauthor=A.+Eisenauthor=J.+F.+Iaciauthor=T.+J.+Parryauthor=R.+Stanulisauthor=M.+Srinivasauthor=P.+B.+Watkins&title=Transient+Changes+in+Hepatic+Physiology+That+Alter+Bilirubin+and+Bile+Acid+Transport+May+Explain+Elevations+in+Liver+Chemistries+Observed+in+Clinical+Trials+of+GGF2+%28Cimaglermin+Alfa%29&doi=10.1093%2Ftoxsci%2Fkfx222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">Transient changes in hepatic physiology that alter bilirubin and bile acid transport may explain elevations in liver chemistries observed in clinical trials of GGF2 (cimaglermin alfa)</span></div><div class="casAuthors">Mosedale, Merrie; Button, Donald; Jackson, Jonathan P.; Freeman, Kimberly M.; Brouwer, Kenneth R.; Caggiano, Anthony O.; Eisen, Andrew; Iaci, Jennifer F.; Parry, Tom J.; Stanulis, Ric; Srinivas, Maya; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">401-411</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">GGF2 is a recombinant human neuregulin-1b in development for chronic heart failure.  Phase 1 clin. trials of GGF2 were put on hold when transient elevations in serum aminotransferases and total bilirubin were obsd. in 2 of 43 subjects who received single doses of GGF2 at 1.5 or 0.378 mg/kg.  However, aminotransferase elevations were modest and not typical of liver injury sufficient to result in elevated serum bilirubin.  Cynomolgus monkeys administered a single 15 mg/kg dose of GGF2 had similar transient elevations in serum aminotransferases and bilirubin as well as transient elevations in serum bile acids.  However, no hepatocellular necrosis was obsd. in liver biopsies obtained during peak elevations.  When sandwich-cultured human hepatocytes were treated with GGF2 for up to 72 h at concns. approx. 0.8-fold av. plasma Cmax for the 0.378 mg/kg dose, no cytotoxicity was obsd.  Gene expression profiling identified approx. 50% redns. in mRNAs coding for bilirubin transporters and bile acid conjugating enzymes, as well as changes in expression of addnl. genes mimicking the interleukin-6-mediated acute phase response.  Similar gene expression changes were obsd. in GGF2-treated HepG2 cells and primary monkey hepatocytes.  Addnl. studies conducted in sandwich-cultured human hepatocytes revealed a transient and GGF2 concn.-dependent decrease in hepatocyte bile acid content and biliary clearance of taurocholate without affecting biliary taurocholate efflux.  Taken together, these data suggest that GGF2 does not cause significant hepatocellular death, but transiently modifies hepatic handling of bilirubin and bile acids, effects that may account for the elevations in serum bilirubin obsd. in the clin. trial subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8ItjPW8agQrVg90H21EOLACvtfcHk0li9JWTei1EjJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFelsbnK&md5=0ba31fc908e2649adacab42bd420dc50</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfx222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfx222%26sid%3Dliteratum%253Aachs%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DButton%26aufirst%3DD.%26aulast%3DJackson%26aufirst%3DJ.%2BP.%26aulast%3DFreeman%26aufirst%3DK.%2BM.%26aulast%3DBrouwer%26aufirst%3DK.%2BR.%26aulast%3DCaggiano%26aufirst%3DA.%2BO.%26aulast%3DEisen%26aufirst%3DA.%26aulast%3DIaci%26aufirst%3DJ.%2BF.%26aulast%3DParry%26aufirst%3DT.%2BJ.%26aulast%3DStanulis%26aufirst%3DR.%26aulast%3DSrinivas%26aufirst%3DM.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DTransient%2520Changes%2520in%2520Hepatic%2520Physiology%2520That%2520Alter%2520Bilirubin%2520and%2520Bile%2520Acid%2520Transport%2520May%2520Explain%2520Elevations%2520in%2520Liver%2520Chemistries%2520Observed%2520in%2520Clinical%2520Trials%2520of%2520GGF2%2520%2528Cimaglermin%2520Alfa%2529%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D161%26spage%3D401%26epage%3D411%26doi%3D10.1093%2Ftoxsci%2Fkfx222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref235"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref235'); return false;" data-citation="" class="refNumLink">234</a></strong><div class="NLM_citation" id="cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björnsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeff, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoofnagle, J. H.</span></span> <span> </span><span class="NLM_article-title">Liver Injury from Herbal and Dietary Supplements</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">363</span>– <span class="NLM_lpage">373</span>, <span class="refDoi"> DOI: 10.1002/hep.28813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.28813" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27677775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisVOm" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2017&pages=363-373&author=V.+Navarroauthor=I.+Khanauthor=E.+Bj%C3%B6rnssonauthor=L.+B.+Seeffauthor=J.+Serranoauthor=J.+H.+Hoofnagle&title=Liver+Injury+from+Herbal+and+Dietary+Supplements&doi=10.1002%2Fhep.28813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Liver injury from herbal and dietary supplements</span></div><div class="casAuthors">Navarro, Victor J.; Khan, Ikhlas; Bjoernsson, Einar; Seeff, Leonard B.; Serrano, Jose; Hoofnagle, Jay H.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">363-373</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Herbal and dietary supplements (HDS) are used increasingly both in the United States and worldwide, and HDS-induced liver injury in the United States has increased proportionally.  Current challenges in the diagnosis and management of HDS-induced liver injury were the focus of a 2-day research symposium sponsored by the American Assocn. for the Study of Liver Disease and the National Institutes of Health.  HDS-induced liver injury now accounts for 20% of cases of hepatotoxicity in the United States based on research data.  The major implicated agents include anabolic steroids, green tea ext., and multi-ingredient nutritional supplements.  Anabolic steroids marketed as bodybuilding supplements typically induce a prolonged cholestatic but ultimately self-limiting liver injury that has a distinctive serum biochem. as well as histol. phenotype.  Green tea ext. and many other products, in contrast, tend to cause an acute hepatitis-like injury.  Currently, however, the majority of cases of HDS-assocd. liver injury are due to multi-ingredient nutritional supplements, and the component responsible for the toxicity is usually unknown or can only be suspected.  HDS-induced liver injury presents many clin. and research challenges in diagnosis, identification of the responsible constituents, treatment, and prevention.  Also important are improvements in regulatory oversight of nonprescription products to guarantee their constituents and ensure purity and safety.  The confident identification of injurious ingredients within HDS will require strategic alignments among clinicians, chemists, and toxicologists.  The ultimate goal should be to prohibit or more closely regulate potentially injurious ingredients and thus promote public safety. (Hepatol. 2017;65:363-373).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx6VCePKGkc7Vg90H21EOLACvtfcHk0li9JWTei1EjJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisVOm&md5=953f3b55242b62d6c5d125675269c8ef</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1002%2Fhep.28813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.28813%26sid%3Dliteratum%253Aachs%26aulast%3DNavarro%26aufirst%3DV.%26aulast%3DKhan%26aufirst%3DI.%26aulast%3DBj%25C3%25B6rnsson%26aufirst%3DE.%26aulast%3DSeeff%26aufirst%3DL.%2BB.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DHoofnagle%26aufirst%3DJ.%2BH.%26atitle%3DLiver%2520Injury%2520from%2520Herbal%2520and%2520Dietary%2520Supplements%26jtitle%3DHepatology%26date%3D2017%26volume%3D65%26spage%3D363%26epage%3D373%26doi%3D10.1002%2Fhep.28813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref236"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref236'); return false;" data-citation="" class="refNumLink">235</a></strong><div class="NLM_citation" id="cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonkovsky, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davern, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeff, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherker, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talwalkar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuppalanchi, R.</span></span> <span> </span><span class="NLM_article-title">Liver injury from Herbals and Dietary Supplements in the US Drug Induced Liver Injury Network</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1399</span>– <span class="NLM_lpage">1408</span>, <span class="refDoi"> DOI: 10.1002/hep.27317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.27317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25043597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC2cbktFWquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=1399-1408&author=V.+J.+Navarroauthor=H.+Barnhartauthor=H.+L.+Bonkovskyauthor=T.+Davernauthor=R.+J.+Fontanaauthor=L.+Grantauthor=K.+R.+Reddyauthor=L.+B.+Seeffauthor=J.+Serranoauthor=A.+H.+Sherkerauthor=A.+Stolzauthor=J.+Talwalkarauthor=M.+Vegaauthor=R.+Vuppalanchi&title=Liver+injury+from+Herbals+and+Dietary+Supplements+in+the+US+Drug+Induced+Liver+Injury+Network&doi=10.1002%2Fhep.27317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network</span></div><div class="casAuthors">Navarro Victor J; Barnhart Huiman; Bonkovsky Herbert L; Davern Timothy; Fontana Robert J; Grant Lafaine; Reddy K Rajender; Seeff Leonard B; Serrano Jose; Sherker Averell H; Stolz Andrew; Talwalkar Jayant; Vega Maricruz; Vuppalanchi Raj</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Baltimore, Md.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1399-408</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  The Drug-Induced Liver Injury Network (DILIN) studies hepatotoxicity caused by conventional medications as well as herbals and dietary supplements (HDS).  To characterize hepatotoxicity and its outcomes from HDS versus medications, patients with hepatotoxicity attributed to medications or HDS were enrolled prospectively between 2004 and 2013.  The study took place among eight U.S. referral centers that are part of the DILIN.  Consecutive patients with liver injury referred to a DILIN center were eligible.  The final sample comprised 130 (15.5%) of all subjects enrolled (839) who were judged to have experienced liver injury caused by HDS.  Hepatotoxicity caused by HDS was evaluated by expert opinion.  Demographic and clinical characteristics and outcome assessments, including death and liver transplantation (LT), were ascertained.  Cases were stratified and compared according to the type of agent implicated in liver injury; 45 had injury caused by bodybuilding HDS, 85 by nonbodybuilding HDS, and 709 by medications.  Liver injury caused by HDS increased from 7% to 20% (P < 0.001) during the study period.  Bodybuilding HDS caused prolonged jaundice (median, 91 days) in young men, but did not result in any fatalities or LT.  The remaining HDS cases presented as hepatocellular injury, predominantly in middle-aged women, and, more frequently, led to death or transplantation, compared to injury from medications (13% vs. 3%; P < 0.05).  CONCLUSIONS:  The proportion of liver injury cases attributed to HDS in DILIN has increased significantly.  Liver injury from nonbodybuilding HDS is more severe than from bodybuilding HDS or medications, as evidenced by differences in unfavorable outcomes (death and transplantation). (Hepatology 2014;60:1399-1408).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTl84hUN1bKNTW1zwg2yUK5fW6udTcc2ebNJb_LSp6BcLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbktFWquw%253D%253D&md5=381aee1513c48e776b6d4e1e2e398073</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1002%2Fhep.27317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27317%26sid%3Dliteratum%253Aachs%26aulast%3DNavarro%26aufirst%3DV.%2BJ.%26aulast%3DBarnhart%26aufirst%3DH.%26aulast%3DBonkovsky%26aufirst%3DH.%2BL.%26aulast%3DDavern%26aufirst%3DT.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DGrant%26aufirst%3DL.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DSeeff%26aufirst%3DL.%2BB.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DSherker%26aufirst%3DA.%2BH.%26aulast%3DStolz%26aufirst%3DA.%26aulast%3DTalwalkar%26aufirst%3DJ.%26aulast%3DVega%26aufirst%3DM.%26aulast%3DVuppalanchi%26aufirst%3DR.%26atitle%3DLiver%2520injury%2520from%2520Herbals%2520and%2520Dietary%2520Supplements%2520in%2520the%2520US%2520Drug%2520Induced%2520Liver%2520Injury%2520Network%26jtitle%3DHepatology%26date%3D2014%26volume%3D60%26spage%3D1399%26epage%3D1408%26doi%3D10.1002%2Fhep.27317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref237"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref237'); return false;" data-citation="" class="refNumLink">236</a></strong><div class="NLM_citation" id="cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucena, M. I.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxicity Induced by Herbal and Dietary Supplements</span>. <i>Semin. Liver Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1055/s-0034-1375958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1055%2Fs-0034-1375958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24879982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFKktLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=172-193&author=V.+J.+Navarroauthor=M.+I.+Lucena&title=Hepatotoxicity+Induced+by+Herbal+and+Dietary+Supplements&doi=10.1055%2Fs-0034-1375958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity induced by herbal and dietary supplements</span></div><div class="casAuthors">Navarro, Victor J.; Lucena, M. Isabel</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Liver Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">172-193</span>CODEN:
                <span class="NLM_cas:coden">SLDIEE</span>;
        ISSN:<span class="NLM_cas:issn">0272-8087</span>.
    
            (<span class="NLM_cas:orgname">Thieme Medical Publishers, Inc.</span>)
        </div><div class="casAbstract">A review.  Herbals and dietary supplements (HDS) can cause hepatotoxicity.  Regulation of HDS varies across the globe.  In the United States, it is defined by a law that is now two decades old.  More recent regulatory approaches in Europe still do not require testing for premarket safety.  The true incidence of hepatotoxicity from HDS is unknown.  The presentation is most often with a hepatocellular enzyme pattern, and the outcomes can be severe, leading to transplantation in some circumstances.  The diagnosis of hepatotoxicity due to HDS is made in the same way as for drugs.  However, patients often must be coaxed into revealing a history of use.  No causality assessment approach is perfectly suited for hepatotoxicity from HDS, but the Roussel Uclaf Causality Assessment Method is most used.  Future endeavors must focus on defining epidemiol., establishing an accepted nomenclature, and identifying culprit ingredients, predisposing host factors, and useful biomarkers for injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYgHJJa3yGVLVg90H21EOLACvtfcHk0lhrK2bR64ovig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFKktLbJ&md5=afd8a31116b704b8943b687d64f6cc45</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1055%2Fs-0034-1375958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0034-1375958%26sid%3Dliteratum%253Aachs%26aulast%3DNavarro%26aufirst%3DV.%2BJ.%26aulast%3DLucena%26aufirst%3DM.%2BI.%26atitle%3DHepatotoxicity%2520Induced%2520by%2520Herbal%2520and%2520Dietary%2520Supplements%26jtitle%3DSemin.%2520Liver%2520Dis.%26date%3D2014%26volume%3D34%26spage%3D172%26epage%3D193%26doi%3D10.1055%2Fs-0034-1375958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref238"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref238'); return false;" data-citation="" class="refNumLink">237</a></strong><div class="NLM_citation" id="cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avigan, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozersky, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeff, L. B.</span></span> <span> </span><span class="NLM_article-title">Scientific and Regulatory Perspectives in Herbal and Dietary Supplement Associated Hepatotoxicity in the United States</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">331</span>, <span class="refDoi"> DOI: 10.3390/ijms17030331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.3390%2Fijms17030331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26950122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmslCjsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=331&author=M.+I.+Aviganauthor=R.+P.+Mozerskyauthor=L.+B.+Seeff&title=Scientific+and+Regulatory+Perspectives+in+Herbal+and+Dietary+Supplement+Associated+Hepatotoxicity+in+the+United+States&doi=10.3390%2Fijms17030331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">Scientific and regulatory perspectives in herbal and dietary supplement associated hepatotoxicity in the United States</span></div><div class="casAuthors">Avigan, Mark I.; Mozersky, Robert P.; Seeff, Leonard B.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">331/1-331/30</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">In the United States (US), the risk of hepatotoxicity linked to the widespread use of certain herbal products has gained increased attention among regulatory scientists.  Based on current US law, all dietary supplements sold domestically, including botanical supplements, are regulated by the Food and Drug Administration (FDA) as a special category of foods.  Under this designation, regulatory scientists do not routinely evaluate the efficacy of these products prior to their marketing, despite the content variability and phytochem. complexity that often characterizes them.  Nonetheless, there has been notable progress in the development of advanced scientific methods to qual. and quant. measure ingredients and screen for contaminants and adulterants in botanical products when hepatotoxicity is recognized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU3lxaFVazY7Vg90H21EOLACvtfcHk0lhrK2bR64ovig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmslCjsbw%253D&md5=21284ae03ae5ab84ff703837612535c7</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.3390%2Fijms17030331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms17030331%26sid%3Dliteratum%253Aachs%26aulast%3DAvigan%26aufirst%3DM.%2BI.%26aulast%3DMozersky%26aufirst%3DR.%2BP.%26aulast%3DSeeff%26aufirst%3DL.%2BB.%26atitle%3DScientific%2520and%2520Regulatory%2520Perspectives%2520in%2520Herbal%2520and%2520Dietary%2520Supplement%2520Associated%2520Hepatotoxicity%2520in%2520the%2520United%2520States%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2016%26volume%3D17%26spage%3D331%26doi%3D10.3390%2Fijms17030331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref239"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref239'); return false;" data-citation="" class="refNumLink">238</a></strong><div class="NLM_citation" id="cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avula, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeff, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, J.</span></span> <span> </span><span class="NLM_article-title">The Contents of Herbal and Dietary Supplements Implicated in Liver Injury in the United States Are Frequently Mislabeled</span>. <i>Hepatology Communications</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">792</span>– <span class="NLM_lpage">794</span>, <span class="refDoi"> DOI: 10.1002/hep4.1346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep4.1346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=31168513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BB3M3jslWitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&pages=792-794&author=V.+Navarroauthor=B.+Avulaauthor=I.+Khanauthor=M.+Vermaauthor=L.+Seeffauthor=J.+Serranoauthor=A.+Stolzauthor=R.+Fontanaauthor=J.+Ahmad&title=The+Contents+of+Herbal+and+Dietary+Supplements+Implicated+in+Liver+Injury+in+the+United+States+Are+Frequently+Mislabeled&doi=10.1002%2Fhep4.1346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">The Contents of Herbal and Dietary Supplements Implicated in Liver Injury in the United States Are Frequently Mislabeled</span></div><div class="casAuthors">Navarro Victor; Verma Manisha; Seeff Leonard; Avula Bharathi; Khan Ikhlas; Serrano Jose; Stolz Andrew; Fontana Robert; Ahmad Jawad</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">792-794</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The U.S.  Drug Induced Liver Injury Network assayed the contents of herbal and dietary supplements collected from patients enrolled into its prospective study.  The aim was to determine the accuracy of product labels, and to identify known hepatotoxins.  Using high-performance liquid chromatography coupled with mass spectrometry to assay 272 product, 51% were found to be mislabeled; that is, to have chemical contents that did not match the label.  Appearance enhancement, sexual performance, and weight loss products were most commonly mislabeled.  Whether the mislabeling contributed to liver injury is under study; however, the high mislabeling rate underscores the need for more stringent regulation of supplements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTS15c7NYEdo2gRQsDqrjW_fW6udTcc2ebGG4h463MiE7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3jslWitQ%253D%253D&md5=d56603af15a23bfc81f02a5c10898774</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1002%2Fhep4.1346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep4.1346%26sid%3Dliteratum%253Aachs%26aulast%3DNavarro%26aufirst%3DV.%26aulast%3DAvula%26aufirst%3DB.%26aulast%3DKhan%26aufirst%3DI.%26aulast%3DVerma%26aufirst%3DM.%26aulast%3DSeeff%26aufirst%3DL.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DStolz%26aufirst%3DA.%26aulast%3DFontana%26aufirst%3DR.%26aulast%3DAhmad%26aufirst%3DJ.%26atitle%3DThe%2520Contents%2520of%2520Herbal%2520and%2520Dietary%2520Supplements%2520Implicated%2520in%2520Liver%2520Injury%2520in%2520the%2520United%2520States%2520Are%2520Frequently%2520Mislabeled%26jtitle%3DHepatology%2520Communications%26date%3D2019%26volume%3D3%26spage%3D792%26epage%3D794%26doi%3D10.1002%2Fhep4.1346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref240"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref240'); return false;" data-citation="" class="refNumLink">239</a></strong><div class="NLM_citation" id="cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Church, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatti, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaddy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchill, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Threadgill, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrill, A. H.</span></span> <span> </span><span class="NLM_article-title">Sensitivity to Hepatotoxicity Due to Epigallocatechin Gallate is Affected by Genetic Background in Diversity Outbred Mice</span>. <i>Food Chem. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.fct.2014.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.fct.2014.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25446466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyhtL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2015&pages=19-26&author=R.+J.+Churchauthor=D.+M.+Gattiauthor=T.+J.+Urbanauthor=N.+Longauthor=X.+Yangauthor=Q.+Shiauthor=J.+S.+Eaddyauthor=M.+Mosedaleauthor=S.+Ballardauthor=G.+A.+Churchillauthor=V.+Navarroauthor=P.+B.+Watkinsauthor=D.+W.+Threadgillauthor=A.+H.+Harrill&title=Sensitivity+to+Hepatotoxicity+Due+to+Epigallocatechin+Gallate+is+Affected+by+Genetic+Background+in+Diversity+Outbred+Mice&doi=10.1016%2Fj.fct.2014.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Sensitivity to hepatotoxicity due to epigallocatechin gallate is affected by genetic background in diversity outbred mice</span></div><div class="casAuthors">Church, Rachel J.; Gatti, Daniel M.; Urban, Thomas J.; Long, Nanye; Yang, Xi; Shi, Qiang; Eaddy, J. Scott; Mosedale, Merrie; Ballard, Shawn; Churchill, Gary A.; Navarro, Victor; Watkins, Paul B.; Threadgill, David W.; Harrill, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Food and Chemical Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19-26</span>CODEN:
                <span class="NLM_cas:coden">FCTOD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-6915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Consumer use of herbal and dietary supplements has recently grown in the United States and, with increased use, reports of rare adverse reactions have emerged.  One such supplement is green tea ext., contg. the polyphenol epigallocatechin gallate (EGCG), which has been shown to be hepatotoxic at high doses in animal models.  The Drug-Induced Liver Injury Network has identified multiple patients who have experienced liver injury ascribed to green tea ext. consumption and the relationship to dose has not been straightforward, indicating that differences in sensitivity may contribute to the adverse response in susceptible people.  The Diversity Outbred (DO), a genetically heterogeneous mouse population, provides a potential platform for study of interindividual toxicity responses to green tea ext.  Within the DO population, an equal exposure to EGCG (50 mg/kg; daily for three days) was found to be tolerated in the majority of mice; however, a small fraction of the animals (16%; 43/272) exhibited severe hepatotoxicity (10-86.8% liver necrosis) that is analogous to the clin. cases.  The data indicate that the DO mice may provide a platform for informing risk of rare, adverse reactions that may occur in consumer populations upon ingestion of concd. herbal products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCbJ0epg2AYbVg90H21EOLACvtfcHk0lguyw5M8lQatA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyhtL3K&md5=94a7be801676411bc6ec6592aa52826c</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1016%2Fj.fct.2014.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.fct.2014.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DChurch%26aufirst%3DR.%2BJ.%26aulast%3DGatti%26aufirst%3DD.%2BM.%26aulast%3DUrban%26aufirst%3DT.%2BJ.%26aulast%3DLong%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DEaddy%26aufirst%3DJ.%2BS.%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DBallard%26aufirst%3DS.%26aulast%3DChurchill%26aufirst%3DG.%2BA.%26aulast%3DNavarro%26aufirst%3DV.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DThreadgill%26aufirst%3DD.%2BW.%26aulast%3DHarrill%26aufirst%3DA.%2BH.%26atitle%3DSensitivity%2520to%2520Hepatotoxicity%2520Due%2520to%2520Epigallocatechin%2520Gallate%2520is%2520Affected%2520by%2520Genetic%2520Background%2520in%2520Diversity%2520Outbred%2520Mice%26jtitle%3DFood%2520Chem.%2520Toxicol.%26date%3D2015%26volume%3D76%26spage%3D19%26epage%3D26%26doi%3D10.1016%2Fj.fct.2014.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref241"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref241'); return false;" data-citation="" class="refNumLink">240</a></strong><div class="NLM_citation" id="cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span>; <span class="NLM_string-name">Cho, T. E.</span>; <span class="NLM_string-name">Wang, S.</span>; <span class="NLM_string-name">Yeung, K.</span></span> <span> </span><span class="NLM_article-title">Using PD-1 Knockout Mice to Test the Potential of Green Tea Extract and (−)-Epigallocatechin Gallate (EGCG) to Cause Idiosyncratic Drug-Induced Liver Injury (IDILI)</span>. Presented at the Society of Toxicology Annual Meeting, San Antonio, TX, March 11–15, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+Uetrecht&author=T.+E.+Cho&author=S.+Wang&author=K.+Yeung&title=Using+PD-1+Knockout+Mice+to+Test+the+Potential+of+Green+Tea+Extract+and+%28%E2%88%92%29-Epigallocatechin+Gallate+%28EGCG%29+to+Cause+Idiosyncratic+Drug-Induced+Liver+Injury+%28IDILI%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DUsing%2520PD-1%2520Knockout%2520Mice%2520to%2520Test%2520the%2520Potential%2520of%2520Green%2520Tea%2520Extract%2520and%2520%2528%25E2%2588%2592%2529-Epigallocatechin%2520Gallate%2520%2528EGCG%2529%2520to%2520Cause%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%2520%2528IDILI%2529%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref242"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref242'); return false;" data-citation="" class="refNumLink">241</a></strong><div class="NLM_citation" id="cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miousse, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosanke, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avula, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ElSohly, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurley, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koturbash, I.</span></span> <span> </span><span class="NLM_article-title">Safety Assessment of the Dietary Supplement OxyELITE Pro (New Formula) in Inbred and Outbred Mouse Strains</span>. <i>Food Chem. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.1016/j.fct.2017.08.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.fct.2017.08.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28843594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVOjtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2017&pages=194-209&author=I.+R.+Miousseauthor=C.+M.+Skinnerauthor=H.+Linauthor=L.+E.+Ewingauthor=S.+D.+Kosankeauthor=D.+K.+Williamsauthor=B.+Avulaauthor=I.+A.+Khanauthor=M.+A.+ElSohlyauthor=B.+J.+Gurleyauthor=I.+Koturbash&title=Safety+Assessment+of+the+Dietary+Supplement+OxyELITE+Pro+%28New+Formula%29+in+Inbred+and+Outbred+Mouse+Strains&doi=10.1016%2Fj.fct.2017.08.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">Safety assessment of the dietary supplement OxyELITE Pro (New Formula) in inbred and outbred mouse strains</span></div><div class="casAuthors">Miousse, Isabelle R.; Skinner, Charles M.; Lin, Haixia; Ewing, Laura E.; Kosanke, Stanley D.; Williams, D. Keith; Avula, Bharathi; Khan, Ikhlas A.; El Sohly, Mahmoud A.; Gurley, Bill J.; Koturbash, Igor</div><div class="citationInfo"><span class="NLM_cas:title">Food and Chemical Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">Part_1</span>),
    <span class="NLM_cas:pages">194-209</span>CODEN:
                <span class="NLM_cas:coden">FCTOD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-6915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Herbal dietary supplements have gained wide acceptance as alternatives to conventional therapeutic agents despite concerns regarding their efficacy and safety.  In 2013, a spate of severe liver injuries across the United States was linked to the dietary supplement OxyELITE Pro-New Formula (OEP-NF), a multi-ingredient product marketed for wt. loss and exercise performance enhancement.  The principal goal of this study was to assess the hepatotoxic potential of OEP-NF in outbred and inbred mouse models.  In an acute toxicity study, significant mortality was obsd. after administering 10X and 3X mouse-equiv. doses (MED) of OEP-NF, resp.  Increases in liver/body wt. ratio, ALT and AST were obsd. in female B6C3F1 mice after gavaging 2X and 1.5X MED of OEP-NF.  Similar findings were obsd. in a 90-day feeding study.  These alterations were paralleled by altered expression of gene- and microRNA-signatures of hepatotoxicity, including Cd36, Nqo1, Aldoa, Txnrd1, Scd1 and Ccng1, as well as miR-192, miR-193a and miR-125b and were most pronounced in female B6C3F1 mice.  Body wt. loss, obsd. at week 1, was followed by wt. gain throughout the feeding studies.  These findings bolster safety and efficacy concerns for OEP-NF, and argue strongly for implementation of pre-market toxicity studies within the dietary supplement industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprwt2_0903rrVg90H21EOLACvtfcHk0lguyw5M8lQatA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVOjtr7I&md5=4325989d729fc3842ab9069451b9b74e</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1016%2Fj.fct.2017.08.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.fct.2017.08.025%26sid%3Dliteratum%253Aachs%26aulast%3DMiousse%26aufirst%3DI.%2BR.%26aulast%3DSkinner%26aufirst%3DC.%2BM.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DEwing%26aufirst%3DL.%2BE.%26aulast%3DKosanke%26aufirst%3DS.%2BD.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DAvula%26aufirst%3DB.%26aulast%3DKhan%26aufirst%3DI.%2BA.%26aulast%3DElSohly%26aufirst%3DM.%2BA.%26aulast%3DGurley%26aufirst%3DB.%2BJ.%26aulast%3DKoturbash%26aufirst%3DI.%26atitle%3DSafety%2520Assessment%2520of%2520the%2520Dietary%2520Supplement%2520OxyELITE%2520Pro%2520%2528New%2520Formula%2529%2520in%2520Inbred%2520and%2520Outbred%2520Mouse%2520Strains%26jtitle%3DFood%2520Chem.%2520Toxicol.%26date%3D2017%26volume%3D109%26spage%3D194%26epage%3D209%26doi%3D10.1016%2Fj.fct.2017.08.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref243"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref243'); return false;" data-citation="" class="refNumLink">242</a></strong><div class="NLM_citation" id="cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heidemann, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleiner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span> <span> </span><span class="NLM_article-title">Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: A Case Series</span>. <i>Dig. Dis. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2741</span>– <span class="NLM_lpage">2748</span>, <span class="refDoi"> DOI: 10.1007/s10620-016-4181-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs10620-016-4181-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27142670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsFWntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2016&pages=2741-2748&author=L.+A.+Heidemannauthor=V.+J.+Navarroauthor=J.+Ahmadauthor=P.+H.+Hayashiauthor=A.+Stolzauthor=D.+E.+Kleinerauthor=R.+J.+Fontana&title=Severe+Acute+Hepatocellular+Injury+Attributed+to+OxyELITE+Pro%3A+A+Case+Series&doi=10.1007%2Fs10620-016-4181-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit243R"><div class="casContent"><span class="casTitleNuber">243</span><div class="casTitle"><span class="NLM_cas:atitle">Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: A Case Series</span></div><div class="casAuthors">Heidemann, Lauren A.; Navarro, Victor J.; Ahmad, Jawad; Hayashi, Paul H.; Stolz, Andrew; Kleiner, David E.; Fontana, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Digestive Diseases and Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2741-2748</span>CODEN:
                <span class="NLM_cas:coden">DDSCDJ</span>;
        ISSN:<span class="NLM_cas:issn">0163-2116</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background/Aim: Herbal and dietary supplement (HDS) hepatotoxicity is increasingly being reported in the USA.  This case series describes the presenting clin. features and outcomes of seven patients with liver injury attributed to OxyELITE Pro enrolled in the Drug-Induced Liver Injury Network (DILIN) study.  Methods: The 6-mo outcomes of patients with hepatotoxicity attributed to OxyELITE Pro enrolled in the DILIN prospective registry between 2004 and 2015 are presented.  Results: Six of the seven patients (86 %) presented in 2013 with symptoms of hepatitis and acute hepatocellular injury.  The median duration of OxyELITE Pro use was 18 wk (range 5-102 wk).  Median age was 36 years (range 28-62), 86 % were female, and 43 % were Asian.  One patient had rash, none had eosinophilia, and three had antinuclear antibody reactivity.  The median peak ALT was 2242 U/L, alk. phosphatase 284 U/L and bilirubin 15.0 mg/dL.  Six patients (86 %) were hospitalized, three developed acute liver failure and two underwent liver transplantation.  DILIN causality scores for OxyELITE Pro were definite in 1, highly likely in 3, probable in 2, and possible in 1.  Four of the five patients without liver transplant recovered completely within 6 mo, while one patient had mild residual ALT elevations.  Conclusions: Seven cases of severe acute hepatocellular injury attributed to OxyELITE Pro are reported.  These results reinforce the need to assess for HDS supplement use in patients presenting with unexplained acute hepatitis and point to the need for addnl. regulatory oversight of HDS products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCRYRV1rfSHbVg90H21EOLACvtfcHk0lhOl8BcdIXU0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsFWntr0%253D&md5=0c95cd630cd67bbd2886e61f16b219fc</span></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1007%2Fs10620-016-4181-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10620-016-4181-7%26sid%3Dliteratum%253Aachs%26aulast%3DHeidemann%26aufirst%3DL.%2BA.%26aulast%3DNavarro%26aufirst%3DV.%2BJ.%26aulast%3DAhmad%26aufirst%3DJ.%26aulast%3DHayashi%26aufirst%3DP.%2BH.%26aulast%3DStolz%26aufirst%3DA.%26aulast%3DKleiner%26aufirst%3DD.%2BE.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26atitle%3DSevere%2520Acute%2520Hepatocellular%2520Injury%2520Attributed%2520to%2520OxyELITE%2520Pro%253A%2520A%2520Case%2520Series%26jtitle%3DDig.%2520Dis.%2520Sci.%26date%3D2016%26volume%3D61%26spage%3D2741%26epage%3D2748%26doi%3D10.1007%2Fs10620-016-4181-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref244"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref244'); return false;" data-citation="" class="refNumLink">243</a></strong><div class="NLM_citation" id="cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonkovsky, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeff, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avula, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirulli, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleiner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoofnagle, J. H.</span></span> <span> </span><span class="NLM_article-title">Severe and Protracted Cholestasis in 44 Young Men Taking Bodybuilding Supplements: Assessment of Genetic, Clinical and Chemical Risk Factors</span>. <i>Aliment. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1195</span>– <span class="NLM_lpage">1204</span>, <span class="refDoi"> DOI: 10.1111/apt.15211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1111%2Fapt.15211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30934130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXns1Cgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2019&pages=1195-1204&author=A.+Stolzauthor=V.+Navarroauthor=P.+H.+Hayashiauthor=R.+J.+Fontanaauthor=H.+X.+Barnhartauthor=J.+Guauthor=N.+P.+Chalasaniauthor=M.+M.+Vegaauthor=H.+L.+Bonkovskyauthor=L.+B.+Seeffauthor=J.+Serranoauthor=B.+Avulaauthor=I.+A.+Khanauthor=E.+T.+Cirulliauthor=D.+E.+Kleinerauthor=J.+H.+Hoofnagle&title=Severe+and+Protracted+Cholestasis+in+44+Young+Men+Taking+Bodybuilding+Supplements%3A+Assessment+of+Genetic%2C+Clinical+and+Chemical+Risk+Factors&doi=10.1111%2Fapt.15211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors</span></div><div class="casAuthors">Stolz, Andrew; Navarro, Victor; Hayashi, Paul H.; Fontana, Robert J.; Barnhart, Huiman X.; Gu, Jiezhun; Chalasani, Naga P.; Vega, Maricruz M.; Bonkovsky, Herbert L.; Seeff, Leonard B.; Serrano, Jose; Avula, Bharathi; Khan, Ikhlas A.; Cirulli, Elizabeth T.; Kleiner, David E.; Hoofnagle, Jay H.</div><div class="citationInfo"><span class="NLM_cas:title">Alimentary Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1195-1204</span>CODEN:
                <span class="NLM_cas:coden">APTHEN</span>;
        ISSN:<span class="NLM_cas:issn">0269-2813</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Bodybuilding supplements can cause a profound cholestatic syndrome.  Aim : To describe the drug-Induced liver injury network's experience with liver injury due to bodybuilding supplements.  Methods : Liver injury pattern, severity and outcomes, potential genetic assocns., and exposure to anabolic steroids by product anal. were analyzed in prospectively enrolled subjects with bodybuilding supplement-induced liver injury with causality scores of probable or higher.  Results : Forty-four males (mean age 33 years) developed liver injury with a median latency of 73 days.  Forty-one per cent presented with hepatocellular pattern of liver injury as defined by the R > 5 ([Fold elevation of ALT] ÷ [Fold elevation of Alk Phos]) (mean, range = 6.4, 0.5-31.4, n = 42) despite all presenting with clin. features of cholestatic liver injury (100% with jaundice and 84% with pruritus).  Liver biopsy (59% of subjects) demonstrated a mild hepatitis and profound cholestasis in most without bile duct injury, loss or fibrosis.  Seventy-one per cent were hospitalised, and none died or required liver transplantation.  In some, chem. anal. revealed anabolic steroid controlled substances not listed on the label.  No enrichment of genetic variants assocd. with cholestatic syndromes was found, although mutations in ABCB11 (present in up to 20%) were significantly different than in ethnically matched controls.  Conclusions : Patients with bodybuilding supplements liver injury uniformly presented with cholestatic injury, which slowly resolved.  The ingested products often contained anabolic steroids not identified on the label, and no enrichment in genetic variants was found, indicating a need for addnl. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkUvPk3oIZiLVg90H21EOLACvtfcHk0lhOl8BcdIXU0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXns1Cgu7s%253D&md5=7cfadf71ac56eb9efb72059a97705749</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1111%2Fapt.15211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fapt.15211%26sid%3Dliteratum%253Aachs%26aulast%3DStolz%26aufirst%3DA.%26aulast%3DNavarro%26aufirst%3DV.%26aulast%3DHayashi%26aufirst%3DP.%2BH.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DBarnhart%26aufirst%3DH.%2BX.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DChalasani%26aufirst%3DN.%2BP.%26aulast%3DVega%26aufirst%3DM.%2BM.%26aulast%3DBonkovsky%26aufirst%3DH.%2BL.%26aulast%3DSeeff%26aufirst%3DL.%2BB.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DAvula%26aufirst%3DB.%26aulast%3DKhan%26aufirst%3DI.%2BA.%26aulast%3DCirulli%26aufirst%3DE.%2BT.%26aulast%3DKleiner%26aufirst%3DD.%2BE.%26aulast%3DHoofnagle%26aufirst%3DJ.%2BH.%26atitle%3DSevere%2520and%2520Protracted%2520Cholestasis%2520in%252044%2520Young%2520Men%2520Taking%2520Bodybuilding%2520Supplements%253A%2520Assessment%2520of%2520Genetic%252C%2520Clinical%2520and%2520Chemical%2520Risk%2520Factors%26jtitle%3DAliment.%2520Pharmacol.%2520Ther.%26date%3D2019%26volume%3D49%26spage%3D1195%26epage%3D1204%26doi%3D10.1111%2Fapt.15211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232'],'ref233':['cit233'],'ref234':['cit234'],'ref235':['cit235'],'ref236':['cit236'],'ref237':['cit237'],'ref238':['cit238'],'ref239':['cit239'],'ref240':['cit240'],'ref241':['cit241'],'ref242':['cit242'],'ref243':['cit243'],'ref244':['cit244']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 11 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Bryan H. Norman</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11397-11419. <a href="https://doi.org/10.1021/acs.jmedchem.0c00524" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00524</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00524%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDrug%252BInduced%252BLiver%252BInjury%252B%252528DILI%252529.%252BMechanisms%252Band%252BMedicinal%252BChemistry%252BAvoidance%25252FMitigation%252BStrategies%26aulast%3DNorman%26aufirst%3DBryan%2BH.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D30032020%26date%3D19062020%26date%3D08062020%26volume%3D63%26issue%3D20%26spage%3D11397%26epage%3D11419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William A.  Murphy</span>, <span class="hlFld-ContribAuthor ">Chitra  Saran</span>, <span class="hlFld-ContribAuthor ">Paavo  Honkakoski</span>, <span class="hlFld-ContribAuthor ">Kim L.R.  Brouwer</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanism‐Based Experimental Models for the Evaluation of BSEP Inhibition and DILI. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 261-306. <a href="https://doi.org/10.1002/9781119171003.ch9" title="DOI URL">https://doi.org/10.1002/9781119171003.ch9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119171003.ch9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119171003.ch9%26sid%3Dliteratum%253Aachs%26atitle%3DMechanism%2525E2%252580%252590Based%252BExperimental%252BModels%252Bfor%252Bthe%252BEvaluation%252Bof%252BBSEP%252BInhibition%252Band%252BDILI%26aulast%3DMurphy%26aufirst%3DWilliam%2BA.%26date%3D2021%26date%3D2021%26spage%3D261%26epage%3D306%26pub%3DWiley%26atitle%3DTransporters%252Band%252BDrug%2525E2%252580%252590Metabolizing%252BEnzymes%252Bin%252BDrug%252BToxicity%26aulast%3DLi%26aufirst%3DAlbert%2BP.%26date%3D2021%26date%3D2021%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Albert P.  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Overview. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-9. <a href="https://doi.org/10.1002/9781119171003.ch1" title="DOI URL">https://doi.org/10.1002/9781119171003.ch1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119171003.ch1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119171003.ch1%26sid%3Dliteratum%253Aachs%26atitle%3DOverview%26aulast%3DLi%26aufirst%3DAlbert%2BP.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D9%26pub%3DWiley%26atitle%3DTransporters%252Band%252BDrug%2525E2%252580%252590Metabolizing%252BEnzymes%252Bin%252BDrug%252BToxicity%26aulast%3DLi%26aufirst%3DAlbert%2BP.%26date%3D2021%26date%3D2021%26volume%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samantha Christine  Sernoskie</span>, <span class="hlFld-ContribAuthor ">Alison  Jee</span>, <span class="hlFld-ContribAuthor ">Jack Paul  Uetrecht</span>, . </span><span class="cited-content_cbyCitation_article-title">The Emerging Role of the Innate Immune Response in Idiosyncratic Drug Reactions. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Reviews</span><span> <strong>2021,</strong> <em>73 </em>
                                    (3)
                                     , 861-896. <a href="https://doi.org/10.1124/pharmrev.120.000090" title="DOI URL">https://doi.org/10.1124/pharmrev.120.000090</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/pharmrev.120.000090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fpharmrev.120.000090%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Reviews%26atitle%3DThe%252BEmerging%252BRole%252Bof%252Bthe%252BInnate%252BImmune%252BResponse%252Bin%252BIdiosyncratic%252BDrug%252BReactions%26aulast%3DSernoskie%26aufirst%3DSamantha%2BChristine%26date%3D2021%26date%3D2021%26volume%3D73%26issue%3D3%26spage%3D861%26epage%3D896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yue  Wu</span>, <span class="hlFld-ContribAuthor ">Jieqiang  Zhu</span>, <span class="hlFld-ContribAuthor ">Peter  Fu</span>, <span class="hlFld-ContribAuthor ">Weida  Tong</span>, <span class="hlFld-ContribAuthor ">Huixiao  Hong</span>, <span class="hlFld-ContribAuthor ">Minjun  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Machine Learning for Predicting Risk of Drug-Induced Autoimmune Diseases by Structural Alerts and Daily Dose. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Environmental Research and Public Health</span><span> <strong>2021,</strong> <em>18 </em>
                                    (13)
                                     , 7139. <a href="https://doi.org/10.3390/ijerph18137139" title="DOI URL">https://doi.org/10.3390/ijerph18137139</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijerph18137139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijerph18137139%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Environmental%2520Research%2520and%2520Public%2520Health%26atitle%3DMachine%252BLearning%252Bfor%252BPredicting%252BRisk%252Bof%252BDrug-Induced%252BAutoimmune%252BDiseases%252Bby%252BStructural%252BAlerts%252Band%252BDaily%252BDose%26aulast%3DWu%26aufirst%3DYue%26date%3D2021%26date%3D2021%26volume%3D18%26issue%3D13%26spage%3D7139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas A.  Baillie</span>. </span><span class="cited-content_cbyCitation_article-title">Approaches to mitigate the risk of serious adverse reactions in covalent drug design. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>16 </em>
                                    (3)
                                     , 275-287. <a href="https://doi.org/10.1080/17460441.2021.1832079" title="DOI URL">https://doi.org/10.1080/17460441.2021.1832079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1832079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1832079%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DApproaches%252Bto%252Bmitigate%252Bthe%252Brisk%252Bof%252Bserious%252Badverse%252Breactions%252Bin%252Bcovalent%252Bdrug%252Bdesign%26aulast%3DBaillie%26aufirst%3DThomas%2BA.%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D3%26spage%3D275%26epage%3D287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brendan  Le Daré</span>, <span class="hlFld-ContribAuthor ">Pierre-Jean  Ferron</span>, <span class="hlFld-ContribAuthor ">Thomas  Gicquel</span>. </span><span class="cited-content_cbyCitation_article-title">Il était une fois l’hépatotoxicité…. </span><span class="cited-content_cbyCitation_journal-name">médecine/sciences</span><span> <strong>2021,</strong> <em>37 </em>
                                    (3)
                                     , 235-241. <a href="https://doi.org/10.1051/medsci/2021009" title="DOI URL">https://doi.org/10.1051/medsci/2021009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1051/medsci/2021009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1051%2Fmedsci%2F2021009%26sid%3Dliteratum%253Aachs%26jtitle%3Dm%25C3%25A9decine%252Fsciences%26atitle%3DIl%252B%2525C3%2525A9tait%252Bune%252Bfois%252Bl%2525E2%252580%252599h%2525C3%2525A9patotoxicit%2525C3%2525A9%2525E2%252580%2525A6%26aulast%3DLe%2BDar%25C3%25A9%26aufirst%3DBrendan%26date%3D2021%26date%3D2021%26volume%3D37%26issue%3D3%26spage%3D235%26epage%3D241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marina  Villanueva-Paz</span>, <span class="hlFld-ContribAuthor ">Laura  Morán</span>, <span class="hlFld-ContribAuthor ">Nuria  López-Alcántara</span>, <span class="hlFld-ContribAuthor ">Cristiana  Freixo</span>, <span class="hlFld-ContribAuthor ">Raúl J.  Andrade</span>, <span class="hlFld-ContribAuthor ">M Isabel  Lucena</span>, <span class="hlFld-ContribAuthor ">Francisco Javier  Cubero</span>. </span><span class="cited-content_cbyCitation_article-title">Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. </span><span class="cited-content_cbyCitation_journal-name">Antioxidants</span><span> <strong>2021,</strong> <em>10 </em>
                                    (3)
                                     , 390. <a href="https://doi.org/10.3390/antiox10030390" title="DOI URL">https://doi.org/10.3390/antiox10030390</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/antiox10030390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fantiox10030390%26sid%3Dliteratum%253Aachs%26jtitle%3DAntioxidants%26atitle%3DOxidative%252BStress%252Bin%252BDrug-Induced%252BLiver%252BInjury%252B%252528DILI%252529%25253A%252BFrom%252BMechanisms%252Bto%252BBiomarkers%252Bfor%252BUse%252Bin%252BClinical%252BPractice%26aulast%3DVillanueva-Paz%26aufirst%3DMarina%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D3%26spage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yunzhou  Li</span>, <span class="hlFld-ContribAuthor ">Huiping  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Drug-Induced Liver Injury. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-820472-6.00008-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-820472-6.00008-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820472-6.00008-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820472-6.00008-6%26sid%3Dliteratum%253Aachs%26atitle%3DDrug-Induced%252BLiver%252BInjury%26aulast%3DLi%26aufirst%3DYunzhou%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BBiomedical%252BSciences%26date%3D2021%26volume%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul B.  Watkins</span>. </span><span class="cited-content_cbyCitation_article-title">DILIsym: Quantitative systems toxicology impacting drug development. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Toxicology</span><span> <strong>2020,</strong> <em>23-24 </em>, 67-73. <a href="https://doi.org/10.1016/j.cotox.2020.06.003" title="DOI URL">https://doi.org/10.1016/j.cotox.2020.06.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cotox.2020.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cotox.2020.06.003%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Toxicology%26atitle%3DDILIsym%25253A%252BQuantitative%252Bsystems%252Btoxicology%252Bimpacting%252Bdrug%252Bdevelopment%26aulast%3DWatkins%26aufirst%3DPaul%2BB.%26date%3D2020%26volume%3D23-24%26spage%3D67%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hernan A.  Bazan</span>, <span class="hlFld-ContribAuthor ">Surjyadipta  Bhattacharjee</span>, <span class="hlFld-ContribAuthor ">Carolina  Burgos</span>, <span class="hlFld-ContribAuthor ">Javier  Recio</span>, <span class="hlFld-ContribAuthor ">Valentina  Abet</span>, <span class="hlFld-ContribAuthor ">Amanda R.  Pahng</span>, <span class="hlFld-ContribAuthor ">Bokkyoo  Jun</span>, <span class="hlFld-ContribAuthor ">Jessica  Heap</span>, <span class="hlFld-ContribAuthor ">Alexander J.  Ledet</span>, <span class="hlFld-ContribAuthor ">William C.  Gordon</span>, <span class="hlFld-ContribAuthor ">Scott  Edwards</span>, <span class="hlFld-ContribAuthor ">Dennis  Paul</span>, <span class="hlFld-ContribAuthor ">Julio  Alvarez-Builla</span>, <span class="hlFld-ContribAuthor ">Nicolas G.  Bazan</span>. </span><span class="cited-content_cbyCitation_article-title">A novel pipeline of 2-(benzenesulfonamide)-N-(4-hydroxyphenyl) acetamide analgesics that lack hepatotoxicity and retain antipyresis. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>202 </em>, 112600. <a href="https://doi.org/10.1016/j.ejmech.2020.112600" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112600</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112600%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bnovel%252Bpipeline%252Bof%252B2-%252528benzenesulfonamide%252529-N-%2525284-hydroxyphenyl%252529%252Bacetamide%252Banalgesics%252Bthat%252Black%252Bhepatotoxicity%252Band%252Bretain%252Bantipyresis%26aulast%3DBazan%26aufirst%3DHernan%2BA.%26date%3D2020%26volume%3D202%26spage%3D112600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/medium/jm9b01297_0005.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/large/jm9b01297_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01297&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/medium/jm9b01297_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/large/jm9b01297_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Serum liver chemistries of a patient experiencing idiosyncratic drug-induced liver injury (IDILI). Serial values of serum alkaline phosphate (ALP), aspartate aminotransferase (AST), total bilirubin (BILI), and alanine aminotransferase (ALT) are plotted as times the upper limit of normal (×ULN) against number of days since first drug exposure for a patient in the TEMPO 3:4 (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) clinical trial (NCT00428948). The shaded areas correspond to periods of active treatment. Figure used with permission from Otsuka Pharmaceutical Development and Commercialization, Inc.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/large/jm9b01297_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01297&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/medium/jm9b01297_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/large/jm9b01297_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Example eDISH (evaluation of Drug-Induced Serious Hepatotoxicity) plot. The peak total serum bilirubin and peak serum alanine aminotransferase (ALT) values expressed as times upper limit of normal (×ULN) are plotted on a log<sub>10</sub> scale for each subject in a clinical trial. The plot is divided into 4 quadrants by a horizontal line corresponding to a serum bilirubin 2×ULN and a vertical line corresponding to ALT 3×ULN. This eDISH plot was created from an actual clinical trial that included more than 3900 subjects randomized to either the experimental drug “X” in red triangles or the control drug “C” as a comparator in green circle (1:1). There is an imbalance of drug “X” patients in the upper right (Hy’s law) and lower right (Temple’s corollary) quadrants suggesting abnormal liver chemistries are the result of the study drug. The eDISH plot shown here was provided by Dr. John Senior and is used with his permission. Dr. Senior has not published this figure elsewhere.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/large/jm9b01297_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01297&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/medium/jm9b01297_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/large/jm9b01297_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Proposed pathogeneses of idiosyncratic adverse drug reactions (IADRs). Most IADRs appear to be immune-mediated and are triggered by the release of danger signals from stress cells, which facilitate an adaptive immune attack. Underlying cell stress and the presentation of drug-induced neoantigen by human leukocyte antigen (HLA) risk alleles make certain individuals more susceptible to clinically significant injury. Some evidence also suggests the potential for heterologous immunity to support an adaptive immune attack in the absence of danger signals as well as a non-immune-mediated pathway whereby cellular stress results in overt injury without an adaptive immune attack.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/large/jm9b01297_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01297&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/medium/jm9b01297_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/large/jm9b01297_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Hypotheses for neoantigen presentation. Three main hypotheses explain how human leukocyte antigen (HLA) molecules stimulate T-cell activation during an idiosyncratic adverse drug reaction. In the hapten model, HLA molecules present drug-modified peptides formed by covalent binding of reactive metabolites to cellular proteins. In the pharmacological interaction model, a drug binds noncovalently to either the HLA molecule or the T-cell receptor resulting in peptide-independent T-cell activation. In the altered peptide binding repertoire model, drugs or their metabolites bind noncovalently to the peptide-binding pocket of the HLA molecule, changing its chemistry and altering the self-peptide repertoire presented by the HLA molecule.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01297/20200618/images/large/jm9b01297_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01297&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04160" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04160" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 243 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Usui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Human Leukocyte Antigen and Idiosyncratic Adverse Drug Reactions</span>. <i>Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1016/j.dmpk.2016.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.dmpk.2016.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28017537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCgtb7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=21-30&author=T.+Usuiauthor=D.+J.+Naisbitt&title=Human+Leukocyte+Antigen+and+Idiosyncratic+Adverse+Drug+Reactions&doi=10.1016%2Fj.dmpk.2016.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Human leukocyte antigen and idiosyncratic adverse drug reactions</span></div><div class="casAuthors">Usui, Toru; Naisbitt, Dean J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-30</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A clin. assocn. between a specific human leukocyte antigen (HLA) allele and idiosyncratic adverse drug reactions (IADRs) is a strong indication that IADRs are mediated by the adaptive immune system.  For example, it is well-established that HLA-B*15:02 and HLA-B*57:01 are assocd. with carbamazepine-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and abacavir-induced hypersensitivity/flucloxacillin-induced liver injury, resp.  Drug-specific T-cells whose response is restricted by specific HLA risk alleles have been detected from IADR patients, also suggesting an adaptive immune pathogenesis.  T-cells from carbamazepine SJS/TEN patients are activated by direct pharmacol. interaction between carbamazepine and HLA-B*15:02 expressed on antigen presenting cells (APCs).  Abacavir-specific, HLA-B*57:01-restricted T-cells are activated by APCs presenting peptides which are only displayed by the HLA mol. when abacavir is bound during peptide loading.  Finally, HLA-B*57:01-restricted activation of T-cells from patients with flucloxacillin-induced liver injury is dependent on processing of drug protein adducts.  Based on these observations, it is now possible to utilize blood from healthy drug-na.ovrddot.ive volunteers to study the priming of na.ovrddot.ive T-cells to drugs.  Future development of these methodologies may lead to the development of assays that predict intrinsic immunogenicity of drugs and chems. at the preclin. stage of drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0jKwp87-Gt7Vg90H21EOLACvtfcHk0ljp66orLQsjdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCgtb7L&md5=74802983719a85747be51fb3161912e4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.dmpk.2016.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dmpk.2016.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DUsui%26aufirst%3DT.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DHuman%2520Leukocyte%2520Antigen%2520and%2520Idiosyncratic%2520Adverse%2520Drug%2520Reactions%26jtitle%3DDrug%2520Metab.%2520Pharmacokinet.%26date%3D2017%26volume%3D32%26spage%3D21%26epage%3D30%26doi%3D10.1016%2Fj.dmpk.2016.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Idiosyncratic Adverse Drug Reactions: Current Concepts</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">808</span>, <span class="refDoi"> DOI: 10.1124/pr.113.007450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fpr.113.007450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23476052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslCjurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=779-808&author=J.+Uetrechtauthor=D.+J.+Naisbitt&title=Idiosyncratic+Adverse+Drug+Reactions%3A+Current+Concepts&doi=10.1124%2Fpr.113.007450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Idiosyncratic adverse drug reactions: current concepts</span></div><div class="casAuthors">Uetrecht, Jack; Naisbitt, Dean J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">779-808, 30 pp.</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Idiosyncratic drug reactions are a significant cause of morbidity and mortality for patients; they also markedly increase the uncertainty of drug development.  The major targets are skin, liver, and bone marrow.  Clin. characteristics suggest that IDRs are immune mediated, and there is substantive evidence that most, but not all, IDRs are caused by chem. reactive species.  However, rigorous mechanistic studies are very difficult to perform, esp. in the absence of valid animal models.  Models to explain how drugs or reactive metabolites interact with the MHC/T-cell receptor complex include the hapten and P-I models, and most recently it was found that abacavir can interact reversibly with MHC to alter the endogenous peptides that are presented to T cells.  The discovery of HLA mols. as important risk factors for some IDRs has also significantly contributed to our understanding of these adverse reactions, but it is not yet clear what fraction of IDRs have a strong HLA dependence.  In addn., with the exception of abacavir, most patients who have the HLA that confers a higher IDR risk with a specific drug will not have an IDR when treated with that drug.  Interindividual differences in T-cell receptors and other factors also presumably play a role in detg. which patients will have an IDR.  The immune response represents a delicate balance, and immune tolerance may be the dominant response to a drug that can cause IDRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-edQNrNURDbVg90H21EOLACvtfcHk0liKY-7zwqqksw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslCjurc%253D&md5=4c64ceb706119a57010fd5085510d8f0</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1124%2Fpr.113.007450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.113.007450%26sid%3Dliteratum%253Aachs%26aulast%3DUetrecht%26aufirst%3DJ.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DIdiosyncratic%2520Adverse%2520Drug%2520Reactions%253A%2520Current%2520Concepts%26jtitle%3DPharmacol.%2520Rev.%26date%3D2013%26volume%3D65%26spage%3D779%26epage%3D808%26doi%3D10.1124%2Fpr.113.007450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, S.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, J.</span></span> <span> </span><span class="NLM_article-title">The Skin as a Metabolic and Immune-Competent Organ: Implications for Drug-Induced Skin Rash</span>. <i>J. Immunotoxicol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1080/1547691X.2018.1514444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1080%2F1547691X.2018.1514444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30318948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFSqtbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=1-12&author=A.+Sharmaauthor=Y.+Saitoauthor=S.-I.+Hungauthor=D.+Naisbittauthor=J.+Uetrechtauthor=J.+Bussiere&title=The+Skin+as+a+Metabolic+and+Immune-Competent+Organ%3A+Implications+for+Drug-Induced+Skin+Rash&doi=10.1080%2F1547691X.2018.1514444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The skin as a metabolic and immune-competent organ: implications fordrug-induced skin rash</span></div><div class="casAuthors">Sharma, Amy; Saito, Yoshiro; Hung, Shuen-Iu; Naisbitt, Dean; Uetrecht, Jack; Bussiere, Jeanine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunotoxicology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">JIOMAP</span>;
        ISSN:<span class="NLM_cas:issn">1547-691X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Current advances in the study of cutaneous adverse drug reactions can be attributed to the recent understanding that the skin is both a metabolically and immunol. competent organ.  The ability of the skin to serve as a protective barrier with limited drug biotransformation ability, yet highly active immune function, has provided insights into its biol. capability.  While the immune response of the skin to drugs is vastly different from that of the liver due to evolutionary conditioning, it frequently occurs in response to various drug classes and manifests as a spectrum of hypersensitivity reactions.  The skin is a common site of adverse and idiosyncratic drug reactions; drug-specific T-cells, as well as involvement of an innate immune response, appear to be key mechanistic drivers in such scenarios.  Assocn. of other factors such as human leukocyte antigen (HLA) polymorphisms may play a significant role for particular drugs.  This review aims to integrate emerging findings into proposed mechanisms of drug metab. and immunity in the skin that are likely responsible for rashes and other local allergic responses.  These unique biol. aspects of the skin, and their translation into implications for drug development and the use of animal models, will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrIZYXUQ2TorVg90H21EOLACvtfcHk0liKY-7zwqqksw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFSqtbbJ&md5=8b25ef5392836e209c4b0b594a730b2b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1080%2F1547691X.2018.1514444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1547691X.2018.1514444%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DSaito%26aufirst%3DY.%26aulast%3DHung%26aufirst%3DS.-I.%26aulast%3DNaisbitt%26aufirst%3DD.%26aulast%3DUetrecht%26aufirst%3DJ.%26aulast%3DBussiere%26aufirst%3DJ.%26atitle%3DThe%2520Skin%2520as%2520a%2520Metabolic%2520and%2520Immune-Competent%2520Organ%253A%2520Implications%2520for%2520Drug-Induced%2520Skin%2520Rash%26jtitle%3DJ.%2520Immunotoxicol.%26date%3D2019%26volume%3D16%26spage%3D1%26epage%3D12%26doi%3D10.1080%2F1547691X.2018.1514444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">How Reactive Metabolites Induce an Immune Response That Sometimes Leads to an Idiosyncratic Drug Reaction</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.6b00357</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.6b00357" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslagsb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2017&pages=295-314&author=T.+Choauthor=J.+Uetrecht&title=How+Reactive+Metabolites+Induce+an+Immune+Response+That+Sometimes+Leads+to+an+Idiosyncratic+Drug+Reaction&doi=10.1021%2Facs.chemrestox.6b00357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">How Reactive Metabolites Induce an Immune Response That Sometimes Leads to an Idiosyncratic Drug Reaction</span></div><div class="casAuthors">Cho, Tiffany; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">295-314</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Little is known with certainty about the mechanisms of idiosyncratic drug reactions (IDRs); however, there is substantive evidence that reactive metabolites are involved in most, but not all, IDRs.  In addn., evidence also suggests that most IDRs are immune mediated.  That raises the question of how reactive metabolites induce an immune response that can lead to an IDR.  The dominant hypotheses are the hapten and danger hypotheses.  These are complementary hypotheses: a reactive metabolite can act as a hapten to produce neoantigens, and it can also cause cell damage leading to the release of danger-assocd. mol. pattern mols. that activate antigen presenting cells.  Both are required for an immune response.  In addn., drugs may induce an immune response through inflammasome activation.  The authors have found examples in which the ability to activate inflammasomes differentiated drugs that cause IDRs from similar drugs that do not.  There are other hypotheses that do not involve an immune mechanism such as mitochondrial injury and bile salt export pump (BSEP) inhibition.  With some possible exception, these hypotheses are unlikely to be able to completely explain IDRs.  However, some types of mitochondrial injury or BSEP inhibition could produce danger signals.  The major mechanism that protects individuals from IDRs appears to be immune tolerance.  Consistent with this hypothesis, the authors used checkpoint inhibition to develop the first animal model of idiosyncratic drug-induced liver injury that has the same characteristics as the idiosyncratic injury in humans.  This was accomplished by treating Pd-1-/- mice with anti-CTLA-4 antibodies and amodiaquine.  The combination of the Pd-1-/- mouse and anti-CTLA-4 also unmasks the ability of other drugs such as isoniazid to cause delayed type liver injury.  This model should allow rigorous testing of mechanistic hypotheses that was impossible in the past.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHhl49wBgcXLVg90H21EOLACvtfcHk0lg-2tvBnGbOkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslagsb3M&md5=04137ee96f32fea06c39a22eea4e4200</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.6b00357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.6b00357%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DT.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DHow%2520Reactive%2520Metabolites%2520Induce%2520an%2520Immune%2520Response%2520That%2520Sometimes%2520Leads%2520to%2520an%2520Idiosyncratic%2520Drug%2520Reaction%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2017%26volume%3D30%26spage%3D295%26epage%3D314%26doi%3D10.1021%2Facs.chemrestox.6b00357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gates, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nykamp, D.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Hypersensitivity Reactions: Cutaneous Eruptions</span>. <i>US Pharmacist</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=32-36&author=A.+Gatesauthor=S.+Cullenauthor=D.+Nykamp&title=Drug-Induced+Hypersensitivity+Reactions%3A+Cutaneous+Eruptions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGates%26aufirst%3DA.%26aulast%3DCullen%26aufirst%3DS.%26aulast%3DNykamp%26aufirst%3DD.%26atitle%3DDrug-Induced%2520Hypersensitivity%2520Reactions%253A%2520Cutaneous%2520Eruptions%26jtitle%3DUS%2520Pharmacist%26date%3D2017%26volume%3D42%26spage%3D32%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms</span>. <i>J. Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2018</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.1155/2018/5163129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1155%2F2018%2F5163129" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2018&publication_year=2018&pages=1&author=H.+Watanabe&title=Recent+Advances+in+Drug-Induced+Hypersensitivity+Syndrome%2FDrug+Reaction+with+Eosinophilia+and+Systemic+Symptoms&doi=10.1155%2F2018%2F5163129"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1155%2F2018%2F5163129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2018%252F5163129%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DH.%26atitle%3DRecent%2520Advances%2520in%2520Drug-Induced%2520Hypersensitivity%2520Syndrome%252FDrug%2520Reaction%2520with%2520Eosinophilia%2520and%2520Systemic%2520Symptoms%26jtitle%3DJ.%2520Immunol.%2520Res.%26date%3D2018%26volume%3D2018%26spage%3D1%26doi%3D10.1155%2F2018%2F5163129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoetzenecker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saulite, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glatz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid-Grendelmeier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guenova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozzio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, L. E.</span></span> <span> </span><span class="NLM_article-title">Toxic Epidermal Necrolysis</span>. <i>F1000Research</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">951</span>, <span class="refDoi"> DOI: 10.12688/f1000research.7574.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.12688%2Ff1000research.7574.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmslSmsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=951&author=W.+Hoetzeneckerauthor=T.+Mehraauthor=I.+Sauliteauthor=M.+Glatzauthor=P.+Schmid-Grendelmeierauthor=E.+Guenovaauthor=A.+Cozzioauthor=L.+E.+French&title=Toxic+Epidermal+Necrolysis&doi=10.12688%2Ff1000research.7574.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Toxic epidermal necrolysis [version 1; referees: 3 approved]</span></div><div class="casAuthors">Hoetzenecker, Wolfram; Mehra, Tarun; Saulite, Ieva; Glatz, Martin; Schmid-Grendelmeier, Peter; Guenova, Emmanuella; Cozzio, Antonio; French, Lars E.</div><div class="citationInfo"><span class="NLM_cas:title">F1000Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">951/1-951/9</span>CODEN:
                <span class="NLM_cas:coden">FRESJL</span>;
        ISSN:<span class="NLM_cas:issn">2046-1402</span>.
    
            (<span class="NLM_cas:orgname">F1000 Research Ltd.</span>)
        </div><div class="casAbstract">Toxic epidermal necrolysis (TEN) is a rare, life-threatening drug-induced skindisease with a mortality rate of approx. 30%.  The clin. hallmark of TENis a marked skin detachment caused by extensive keratinocyte cell deathassocd. with mucosal involvement.  The exact pathogenic mechanism ofTEN is still uncertain.  Recent advances in this field have led to the identificationof several factors that might contribute to the induction of excessive apoptosisof keratinocytes.  In addn., specific human leukocyte antigen types seem tobe assocd. with certain drugs and the development of TEN.  Aswell-controlled studies are lacking, patients are treated with variousimmunomodulators (e.g. i.v. Ig) in addn. to the bestsupportive care.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH69EM19oG1bVg90H21EOLACvtfcHk0lg-2tvBnGbOkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmslSmsLs%253D&md5=924e30ee037c4cbde26cfafa570d876f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.12688%2Ff1000research.7574.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12688%252Ff1000research.7574.1%26sid%3Dliteratum%253Aachs%26aulast%3DHoetzenecker%26aufirst%3DW.%26aulast%3DMehra%26aufirst%3DT.%26aulast%3DSaulite%26aufirst%3DI.%26aulast%3DGlatz%26aufirst%3DM.%26aulast%3DSchmid-Grendelmeier%26aufirst%3DP.%26aulast%3DGuenova%26aufirst%3DE.%26aulast%3DCozzio%26aufirst%3DA.%26aulast%3DFrench%26aufirst%3DL.%2BE.%26atitle%3DToxic%2520Epidermal%2520Necrolysis%26jtitle%3DF1000Research%26date%3D2016%26volume%3D5%26spage%3D951%26doi%3D10.12688%2Ff1000research.7574.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span> <i>LiverTox Database</i>. <a href="https://livertox.nlm.nih.gov" class="extLink">https://livertox.nlm.nih.gov</a> (accessed Jul 16, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+LiverTox+Database.+https%3A%2F%2Flivertox.nlm.nih.gov+%28accessed+Jul+16%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DLiverTox%2520Database%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonkovsky, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talwalkar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bach, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beavers, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonkovsky, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvo, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conjeevaram, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dieterich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPaola, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durazo, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everhart, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghabril, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalreddy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoofnagle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplowitz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liangpunsakul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherker, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuppalanchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacks, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesney, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groseclose, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFadden, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melgoza, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikhail, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milstein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morlan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosado, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yalamanchili, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClanahan-Crowder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragavan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rostami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puglisi-Scharenbroich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrance, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Raaphorst, R.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">1340</span>– <span class="NLM_lpage">1352</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2015.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1053%2Fj.gastro.2015.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25754159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC2MnisVamtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2015&pages=1340-1352&author=N.+Chalasaniauthor=H.+L.+Bonkovskyauthor=R.+Fontanaauthor=W.+Leeauthor=A.+Stolzauthor=J.+Talwalkarauthor=K.+R.+Reddyauthor=P.+B.+Watkinsauthor=V.+Navarroauthor=H.+Barnhartauthor=J.+Guauthor=J.+Serranoauthor=J.+Ahmadauthor=N.+Bachauthor=M.+Bansalauthor=H.+X.+Barnhartauthor=K.+Beaversauthor=H.+Bonkovskyauthor=F.+O.+Calvoauthor=C.+Changauthor=H.+Conjeevaramauthor=G.+Connerauthor=J.+Darlingauthor=Y.+de+Boerauthor=D.+Dieterichauthor=F.+DiPaolaauthor=F.+A.+Durazoauthor=J.+E.+Everhartauthor=R.+J.+Fontanaauthor=M.+S.+Ghabrilauthor=D.+Goldsteinauthor=V.+Gopalreddyauthor=P.+Grewalauthor=P.+H.+Hayashiauthor=J.+Hoofnagleauthor=N.+Kaplowitzauthor=S.+Liangpunsakulauthor=S.+Lichtmanauthor=L.+Liuauthor=V.+J.+Navarroauthor=J.+Odinauthor=S.+Rossiauthor=M.+Russoauthor=T.+Schianoauthor=J.+Serranoauthor=A.+H.+Sherkerauthor=R.+Vuppalanchiauthor=P.+Watkinsauthor=S.+Zacksauthor=A.+Balascoauthor=K.+Chesneyauthor=A.+Corneauthor=S.+Cummingsauthor=G.+Grosecloseauthor=A.+Hammettauthor=J.+Hookerauthor=V.+Kesarauthor=S.+Maoauthor=K.+Marksauthor=R.+McFaddenauthor=Y.+Melgozaauthor=S.+Mikhailauthor=S.+Milsteinauthor=W.+Morlanauthor=V.+Peacockauthor=N.+Rosadoauthor=T.+Russellauthor=M.+Vegaauthor=M.+Vermaauthor=P.+Walkerauthor=R.+Yalamanchiliauthor=M.+McClanahan-Crowderauthor=K.+Galanauthor=T.+Chauauthor=K.+Ragavanauthor=H.+Rostamiauthor=C.+Puglisi-Scharenbroichauthor=R.+J.+Torranceauthor=R.+Van+Raaphorst&title=Features+and+Outcomes+of+899+Patients+With+Drug-Induced+Liver+Injury%3A+The+DILIN+Prospective+Study&doi=10.1053%2Fj.gastro.2015.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study</span></div><div class="casAuthors">Chalasani Naga; Bonkovsky Herbert L; Fontana Robert; Lee William; Stolz Andrew; Talwalkar Jayant; Reddy K Rajendar; Watkins Paul B; Navarro Victor; Barnhart Huiman; Gu Jiezhun; Serrano Jose</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1340-52.e7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND & AIMS:  The Drug-Induced Liver Injury Network is conducting a prospective study of patients with DILI in the United States.  We present characteristics and subgroup analyses from the first 1257 patients enrolled in the study.  METHODS:  In an observational longitudinal study, we began collecting data on eligible individuals with suspected DILI in 2004, following them for 6 months or longer.  Subjects were evaluated systematically for other etiologies, causes, and severity of DILI.  RESULTS:  Among 1257 enrolled subjects with suspected DILI, the causality was assessed in 1091 patients, and 899 were considered to have definite, highly likely, or probable DILI.  Ten percent of patients died or underwent liver transplantation, and 17% had chronic liver injury.  In the 89 patients (10%) with pre-existing liver disease, DILI appeared to be more severe than in those without (difference not statistically significant; P = .09) and mortality was significantly higher (16% vs 5.2%; P < .001).  Azithromycin was the implicated agent in a higher proportion of patients with pre-existing liver disease compared with those without liver disease (6.7% vs 1.5%; P = .006).  Forty-one cases with latency ≤7 days were caused predominantly by antimicrobial agents (71%).  Two most common causes for 60 DILI cases with latency >365 days were nitrofurantoin (25%) or minocycline (17%).  There were no differences in outcomes of patients with short vs long latency of DILI.  Compared with individuals younger than 65 years, individuals 65 years or older (n = 149) were more likely to have cholestatic injury, although mortality and rate of liver transplantation did not differ.  Nine patients (1%) had concomitant severe skin reactions; implicated agents were lamotrigine, azithromycin, carbamazepine, moxifloxacin, cephalexin, diclofenac, and nitrofurantoin.  Four of these patients died.  CONCLUSIONS:  Mortality from DILI is significantly higher in individuals with pre-existing liver disease or concomitant severe skin reactions compared with patients without.  Additional studies are needed to confirm the association between azithromycin and increased DILI in patients with chronic liver disease.  Older age and short or long latencies are not associated with DILI mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsG7qp96NL_5ZoeNcnHOQ9fW6udTcc2eaLL0Q2UvdT47ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnisVamtA%253D%253D&md5=e91d2b1872162ec5b9fa2f991851a5fe</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2015.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2015.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DBonkovsky%26aufirst%3DH.%2BL.%26aulast%3DFontana%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DStolz%26aufirst%3DA.%26aulast%3DTalwalkar%26aufirst%3DJ.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DNavarro%26aufirst%3DV.%26aulast%3DBarnhart%26aufirst%3DH.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DAhmad%26aufirst%3DJ.%26aulast%3DBach%26aufirst%3DN.%26aulast%3DBansal%26aufirst%3DM.%26aulast%3DBarnhart%26aufirst%3DH.%2BX.%26aulast%3DBeavers%26aufirst%3DK.%26aulast%3DBonkovsky%26aufirst%3DH.%26aulast%3DCalvo%26aufirst%3DF.%2BO.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DConjeevaram%26aufirst%3DH.%26aulast%3DConner%26aufirst%3DG.%26aulast%3DDarling%26aufirst%3DJ.%26aulast%3Dde%2BBoer%26aufirst%3DY.%26aulast%3DDieterich%26aufirst%3DD.%26aulast%3DDiPaola%26aufirst%3DF.%26aulast%3DDurazo%26aufirst%3DF.%2BA.%26aulast%3DEverhart%26aufirst%3DJ.%2BE.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DGhabril%26aufirst%3DM.%2BS.%26aulast%3DGoldstein%26aufirst%3DD.%26aulast%3DGopalreddy%26aufirst%3DV.%26aulast%3DGrewal%26aufirst%3DP.%26aulast%3DHayashi%26aufirst%3DP.%2BH.%26aulast%3DHoofnagle%26aufirst%3DJ.%26aulast%3DKaplowitz%26aufirst%3DN.%26aulast%3DLiangpunsakul%26aufirst%3DS.%26aulast%3DLichtman%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNavarro%26aufirst%3DV.%2BJ.%26aulast%3DOdin%26aufirst%3DJ.%26aulast%3DRossi%26aufirst%3DS.%26aulast%3DRusso%26aufirst%3DM.%26aulast%3DSchiano%26aufirst%3DT.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DSherker%26aufirst%3DA.%2BH.%26aulast%3DVuppalanchi%26aufirst%3DR.%26aulast%3DWatkins%26aufirst%3DP.%26aulast%3DZacks%26aufirst%3DS.%26aulast%3DBalasco%26aufirst%3DA.%26aulast%3DChesney%26aufirst%3DK.%26aulast%3DCorne%26aufirst%3DA.%26aulast%3DCummings%26aufirst%3DS.%26aulast%3DGroseclose%26aufirst%3DG.%26aulast%3DHammett%26aufirst%3DA.%26aulast%3DHooker%26aufirst%3DJ.%26aulast%3DKesar%26aufirst%3DV.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DMarks%26aufirst%3DK.%26aulast%3DMcFadden%26aufirst%3DR.%26aulast%3DMelgoza%26aufirst%3DY.%26aulast%3DMikhail%26aufirst%3DS.%26aulast%3DMilstein%26aufirst%3DS.%26aulast%3DMorlan%26aufirst%3DW.%26aulast%3DPeacock%26aufirst%3DV.%26aulast%3DRosado%26aufirst%3DN.%26aulast%3DRussell%26aufirst%3DT.%26aulast%3DVega%26aufirst%3DM.%26aulast%3DVerma%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DP.%26aulast%3DYalamanchili%26aufirst%3DR.%26aulast%3DMcClanahan-Crowder%26aufirst%3DM.%26aulast%3DGalan%26aufirst%3DK.%26aulast%3DChau%26aufirst%3DT.%26aulast%3DRagavan%26aufirst%3DK.%26aulast%3DRostami%26aufirst%3DH.%26aulast%3DPuglisi-Scharenbroich%26aufirst%3DC.%26aulast%3DTorrance%26aufirst%3DR.%2BJ.%26aulast%3DVan%2BRaaphorst%26aufirst%3DR.%26atitle%3DFeatures%2520and%2520Outcomes%2520of%2520899%2520Patients%2520With%2520Drug-Induced%2520Liver%2520Injury%253A%2520The%2520DILIN%2520Prospective%2520Study%26jtitle%3DGastroenterology%26date%3D2015%26volume%3D148%26spage%3D1340%26epage%3D1352%26doi%3D10.1053%2Fj.gastro.2015.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sundaram, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björnsson, E. S.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Cholestasis</span>. <i>Hepatology Communications</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">726</span>– <span class="NLM_lpage">735</span>, <span class="refDoi"> DOI: 10.1002/hep4.1088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep4.1088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29404489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC1MvnslCntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=726-735&author=V.+Sundaramauthor=E.+S.+Bj%C3%B6rnsson&title=Drug-Induced+Cholestasis&doi=10.1002%2Fhep4.1088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced cholestasis</span></div><div class="casAuthors">Sundaram Vinay; Bjornsson Einar S; Bjornsson Einar S</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">726-735</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cholestatic drug-induced liver injury (DILI) can be a diagnostic challenge due to a large differential diagnosis, variability in clinical presentation, and lack of serologic biomarkers associated with this condition.  The clinical presentation of drug-induced cholestasis includes bland cholestasis, cholestatic hepatitis, secondary sclerosing cholangitis, and vanishing bile duct syndrome.  The associate mortality of cholestatic DILI can be as high as 10%, and thus prompt recognition and removal of the offending agent is of critical importance.  Several risk factors have been identified for drug-induced cholestasis, including older age, genetic determinants, and properties of certain medications.  Antibiotics, particularly amoxicillin/clavulanate, remain the predominant cause of cholestatic DILI, although a variety of other medications associated with this condition have been identified.  In this review, we summarize the presentation, clinical approach, risk factors, implicated medications, and management of drug-induced cholestatic liver injury. (Hepatology Communications 2017;1:726-735).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRmYTpNzQyiyyjiVMCqkKxVfW6udTcc2ebAaGw1D1WZMLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvnslCntA%253D%253D&md5=8f71169b72194615d27fc38caa5d9d63</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fhep4.1088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep4.1088%26sid%3Dliteratum%253Aachs%26aulast%3DSundaram%26aufirst%3DV.%26aulast%3DBj%25C3%25B6rnsson%26aufirst%3DE.%2BS.%26atitle%3DDrug-Induced%2520Cholestasis%26jtitle%3DHepatology%2520Communications%26date%3D2017%26volume%3D1%26spage%3D726%26epage%3D735%26doi%3D10.1002%2Fhep4.1088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, K. V.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Hematologic Disorders</span>. In  <i>Pharmacotherapy: A Pathophysiologic Approach [Online]</i>, <span class="NLM_contrib-group"><span class="NLM_string-name">DiPiro, J. T.</span>, <span class="NLM_string-name">Talbert, R. L.</span>, <span class="NLM_string-name">Yee, G. C.</span>, <span class="NLM_string-name">Matzke, G. R.</span>, <span class="NLM_string-name">Wells, B. G.</span>, <span class="NLM_string-name">Posey, L. M.</span></span>, Eds; <span class="NLM_publisher-name">The McGraw-Hill Companies</span>: <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">2014</span>; <a href="http://accesspharmacy.mhmedical.com/content.aspx?bookid=689&amp;sectionid=48811451" class="extLink">http://accesspharmacy.mhmedical.com/content.aspx?bookid=689&sectionid=48811451</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=K.+V.+Raoauthor=J.+T.+DiPiro&author=R.+L.+Talbert&author=G.+C.+Yee&author=G.+R.+Matzke&author=B.+G.+Wells&author=L.+M.+Posey&title=Pharmacotherapy%3A+A+Pathophysiologic+Approach+%5BOnline%5D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DK.%2BV.%26atitle%3DDrug-Induced%2520Hematologic%2520Disorders%26btitle%3DPharmacotherapy%253A%2520A%2520Pathophysiologic%2520Approach%2520%255BOnline%255D%26aulast%3DDiPiro%26aufirst%3DJ.%2BT.%26pub%3DThe%2520McGraw-Hill%2520Companies%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, N. J.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Autoimmunity</span>. <i>Best Practice & Research Clinical Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">688</span>, <span class="refDoi"> DOI: 10.1016/j.berh.2004.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.berh.2004.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=15454126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvVyrt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=677-688&author=N.+J.+Olsen&title=Drug-Induced+Autoimmunity&doi=10.1016%2Fj.berh.2004.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced autoimmunity</span></div><div class="casAuthors">Olsen, Nancy J.</div><div class="citationInfo"><span class="NLM_cas:title">Best Practice & Research, Clinical Rheumatology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">677-688</span>CODEN:
                <span class="NLM_cas:coden">BPRCC7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Drug induced autoimmune syndromes have been recognized for many years.  The classical presentation is that of drug-induced lupus, a generally milder version of the idiopathic disorder that is assocd. with prodn. of antihistone antibodies.  This pattern is now changing, in part due to the many new drugs that have been introduced into clin. practice for treatment of autoimmune diseases, including both conventional pharmaceuticals and biologicals.  The no. and complexity of drug-induced autoimmune syndromes has increased, and many are now assocd. with autoantibodies that have been classically defined as limited to idiopathic disease states.  Furthermore, some of these drug-induced syndromes have life-threatening complications, so that recognition of drug-induced disease has become more difficult at a time when it is more urgent to establish a correct diagnosis.  Many reports are limited to case descriptions, and few controlled investigations have been carried out.  Nevertheless, it is possible to derive an approach to considering possible mechanisms by which these processes may take place.  This chapter will consider these proposed mechanisms, using some of the implicated drugs to illustrate possible pathogenetic pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC9NIY-PLgeLVg90H21EOLACvtfcHk0lg2-vjOO9_5zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvVyrt7o%253D&md5=0acc4f7ceb3a1ced935de6f0eb6b44ca</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.berh.2004.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.berh.2004.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DOlsen%26aufirst%3DN.%2BJ.%26atitle%3DDrug-Induced%2520Autoimmunity%26jtitle%3DBest%2520Practice%2520%2526%2520Research%2520Clinical%2520Rheumatology%26date%3D2004%26volume%3D18%26spage%3D677%26epage%3D688%26doi%3D10.1016%2Fj.berh.2004.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Liver Injury: Advances in Mechanistic Understanding that will Inform Risk Management</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1002/cpt.564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fcpt.564" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27861792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC2snnvVKktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2017&pages=469-480&author=M.+Mosedaleauthor=P.+B.+Watkins&title=Drug-Induced+Liver+Injury%3A+Advances+in+Mechanistic+Understanding+that+will+Inform+Risk+Management&doi=10.1002%2Fcpt.564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management</span></div><div class="casAuthors">Mosedale M; Watkins P B</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">469-480</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug-induced liver injury (DILI) is a major public health problem.  Intrinsic (dose-dependent) DILI associated with acetaminophen overdose is the number one cause of acute liver failure in the US.  However, the most problematic type of DILI impacting drug development is idiosyncratic, occurring only very rarely among treated patients and often only after several weeks or months of treatment with the offending drug.  Recent advances in our understanding of the pathogenesis of DILI suggest that three mechanisms may underlie most hepatocyte effects in response to both intrinsic and idiosyncratic DILI drugs: mitochondrial dysfunction, oxidative stress, and alterations in bile acid homeostasis.  However, in some cases hepatocyte stress promotes an immune response that results in clinically important idiosyncratic DILI.  This review discusses recent advances in our understanding of the pathogenesis of both intrinsic and idiosyncratic DILI as well as emerging tools and techniques that will likely improve DILI risk identification and management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR25FSIZrIShTDnmmyUf5qOfW6udTcc2eZKK7LEwOldc7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snnvVKktw%253D%253D&md5=e1a7d722b411b70d71cd539caf3c74f4</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fcpt.564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.564%26sid%3Dliteratum%253Aachs%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DDrug-Induced%2520Liver%2520Injury%253A%2520Advances%2520in%2520Mechanistic%2520Understanding%2520that%2520will%2520Inform%2520Risk%2520Management%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2017%26volume%3D101%26spage%3D469%26epage%3D480%26doi%3D10.1002%2Fcpt.564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplowitz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alpers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blais, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smotzer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwiec, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, C.</span></span> <span> </span><span class="NLM_article-title">Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1103</span>– <span class="NLM_lpage">1113</span>, <span class="refDoi"> DOI: 10.1007/s40264-015-0327-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs40264-015-0327-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26188764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1WqtrnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2015&pages=1103-1113&author=P.+Watkinsauthor=J.+Lewisauthor=N.+Kaplowitzauthor=D.+Alpersauthor=J.+Blaisauthor=D.+Smotzerauthor=H.+Krasaauthor=J.+Ouyangauthor=V.+Torresauthor=F.+Czerwiecauthor=C.+Zimmer&title=Clinical+Pattern+of+Tolvaptan-Associated+Liver+Injury+in+Subjects+with+Autosomal+Dominant+Polycystic+Kidney+Disease%3A+Analysis+of+Clinical+Trials+Database&doi=10.1007%2Fs40264-015-0327-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database</span></div><div class="casAuthors">Watkins, Paul B.; Lewis, James H.; Kaplowitz, Neil; Alpers, David H.; Blais, Jaime D.; Smotzer, Dan M.; Krasa, Holly; Ouyang, John; Torres, Vicente E.; Czerwiec, Frank S.; Zimmer, Christopher A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1103-1113</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Introduction: Subjects with autosomal dominant polycystic kidney disease (ADPKD) who were taking tolvaptan experienced aminotransferase elevations more frequently than those on placebo in the TEMPO 3:4 (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) clin. trial.  Methods: An independent, blinded, expert Hepatic Adjudication Committee re-examd. data from TEMPO 3:4 and its open-label extension TEMPO 4:4, as well as from long-term (>14 mo) non-ADPKD tolvaptan trials, using the 5-point Drug-Induced Liver Injury Network classification.  Results: In TEMPO 3:4, 1445 subjects were randomized 2:1 (tolvaptan vs. placebo) and 1441 had post-baseline assessments of hepatic injury.  Sixteen patients on tolvaptan and one on placebo had significant aminotransferase elevations judged to be at least probably related to study drug.  No assocn. with dose or systemic exposure was found.  Two of 957 subjects taking tolvaptan (0.2 %) and zero of 484 taking placebo met the definition of a Hy's Law case.  One addnl. Hy's Law case was identified in a TEMPO 4:4 subject who had received placebo in the lead study.  The onset of a hepatocellular injury occurred between 3 and 18 mo after starting tolvaptan, with gradual resoln. over the subsequent 1-4 mo.  None of the events were assocd. with liver failure or chronic liver injury/dysfunction.  No imbalance in hepatic events was obsd. between tolvaptan and placebo in lower-dose clin. trials of patients with hyponatremia, heart failure, or cirrhosis.  Conclusions: Although hepatocellular injury following long-term tolvaptan treatment in ADPKD subjects was infrequent and reversible, the potential for serious irreversible injury exists.  Regular monitoring of transaminase levels is warranted in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR0To30kwUDLVg90H21EOLACvtfcHk0lhh_ye6Q3yvJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1WqtrnM&md5=25e79ef6354010591b01ef150ad069af</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs40264-015-0327-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40264-015-0327-3%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DP.%26aulast%3DLewis%26aufirst%3DJ.%26aulast%3DKaplowitz%26aufirst%3DN.%26aulast%3DAlpers%26aufirst%3DD.%26aulast%3DBlais%26aufirst%3DJ.%26aulast%3DSmotzer%26aufirst%3DD.%26aulast%3DKrasa%26aufirst%3DH.%26aulast%3DOuyang%26aufirst%3DJ.%26aulast%3DTorres%26aufirst%3DV.%26aulast%3DCzerwiec%26aufirst%3DF.%26aulast%3DZimmer%26aufirst%3DC.%26atitle%3DClinical%2520Pattern%2520of%2520Tolvaptan-Associated%2520Liver%2520Injury%2520in%2520Subjects%2520with%2520Autosomal%2520Dominant%2520Polycystic%2520Kidney%2520Disease%253A%2520Analysis%2520of%2520Clinical%2520Trials%2520Database%26jtitle%3DDrug%2520Saf.%26date%3D2015%26volume%3D38%26spage%3D1103%26epage%3D1113%26doi%3D10.1007%2Fs40264-015-0327-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guest, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokoluk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacCrimmon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">Examination of Possible Toxic and Immune Mechanisms of Clozapine-Induced Agranulocytosis</span>. <i>Toxicology</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1016/S0300-483X(98)00110-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2FS0300-483X%2898%2900110-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=9881934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADyaK1MXjs1artA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=1998&pages=53-65&author=I.+Guestauthor=B.+Sokolukauthor=J.+MacCrimmonauthor=J.+Uetrecht&title=Examination+of+Possible+Toxic+and+Immune+Mechanisms+of+Clozapine-Induced+Agranulocytosis&doi=10.1016%2FS0300-483X%2898%2900110-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis</span></div><div class="casAuthors">Guest, I.; Sokoluk, B.; MacCrimmon, J.; Uetrecht, J.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-65</span>CODEN:
                <span class="NLM_cas:coden">TXCYAC</span>;
        ISSN:<span class="NLM_cas:issn">0300-483X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">Three patients who developed agranulocytosis and 7 patients who demonstrated neutropenia during therapy with clozapine were investigated, as well as 5 patients who were asymptomatic while on clozapine.  One of the 3 agranulocytic patients had previously developed severe neutropenia during clozapine therapy.  Mature neutrophils were examd. to det. if these cells demonstrated increased susceptibility to clozapine or clozapine oxidn. products that had been generated chem.  Increased susceptibility was found in the cells of some patients, but this was not a consistent finding.  The effects of clozapine or its chem. generated oxidn. products were examd. on the development of hematopoietic precursor cells derived from the peripheral blood.  Clozapine oxidn. products, but not clozapine, concn.-dependently and directly inhibited colony formation of all lineages; there was no evidence of a specific sensitivity of the myeloid precursors.  Serum from one of the 3 patients who developed agranulocytosis was inhibitory to the growth of all precursor cells at a concn. of 10% but none of the plasmas were inhibitory.  In 6 patients with neutropenia or agranulocytosis, attempts were made to isolate antigen-specific T cells, wherein the antigen was a hapten carrier complex of clozapine oxidn. products covalently bound to leukocyte macromols.  No clozapine product-specific clones to these antigens were detected.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowGuTpweE_A7Vg90H21EOLACvtfcHk0lhh_ye6Q3yvJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjs1artA%253D%253D&md5=b326874fa7b165f04af31c283cd9607e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0300-483X%2898%2900110-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0300-483X%252898%252900110-3%26sid%3Dliteratum%253Aachs%26aulast%3DGuest%26aufirst%3DI.%26aulast%3DSokoluk%26aufirst%3DB.%26aulast%3DMacCrimmon%26aufirst%3DJ.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DExamination%2520of%2520Possible%2520Toxic%2520and%2520Immune%2520Mechanisms%2520of%2520Clozapine-Induced%2520Agranulocytosis%26jtitle%3DToxicology%26date%3D1998%26volume%3D131%26spage%3D53%26epage%3D65%26doi%3D10.1016%2FS0300-483X%2898%2900110-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunk, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annan, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, C. D.</span></span> <span> </span><span class="NLM_article-title">Rechallenge with Clozapine Following Leucopenia or Neutropenia During Previous Therapy</span>. <i>Br. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1192/bjp.188.3.255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1192%2Fbjp.188.3.255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=16507968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD287itVakuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2006&pages=255-263&author=L.+R.+Dunkauthor=L.+J.+Annanauthor=C.+D.+Andrews&title=Rechallenge+with+Clozapine+Following+Leucopenia+or+Neutropenia+During+Previous+Therapy&doi=10.1192%2Fbjp.188.3.255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Rechallenge with clozapine following leucopenia or neutropenia during previous therapy</span></div><div class="casAuthors">Dunk Louisa R; Annan Linda J; Andrews Christopher D</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of psychiatry : the journal of mental science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">255-63</span>
        ISSN:<span class="NLM_cas:issn">0007-1250</span>.
    </div><div class="casAbstract">BACKGROUND:  Further treatment with clozapine is contraindicated in any patient who has previously experienced leucopenia or neutropenia during clozapine therapy.  AIMS:  To investigate the results of such a rechallenge in 53 patients.  METHOD:  An analysis was made of the demographic, haematological and outcome data of patients in the UK and Ireland who were rechallenged with clozapine following leucopenia or neutropenia during previous clozapine therapy.  RESULTS:  Of 53 patients who were rechallenged, 20 (38%) experienced a further blood dyscrasia.  In 17 of these 20 patients (85%) the second blood dyscrasia was more severe (P<0.001), in 12 (60%) it lasted longer (P=0.0368) and in 17 (85%) it occurred more quickly on rechallenge (P<0.001).  Of the original 53 patients, 55% (29 patients) are still receiving clozapine.  CONCLUSIONS:  No clear risk factor for repeat blood dyscrasias was identified.  Despite this, after risks and benefits have been considered, rechallenge may well be justified in some patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSK6av-76959X6HPRus0rAafW6udTcc2eZTVTI2Z0PJ6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287itVakuw%253D%253D&md5=1cada1ab10ce36f544a870ecb9bd24d4</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1192%2Fbjp.188.3.255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1192%252Fbjp.188.3.255%26sid%3Dliteratum%253Aachs%26aulast%3DDunk%26aufirst%3DL.%2BR.%26aulast%3DAnnan%26aufirst%3DL.%2BJ.%26aulast%3DAndrews%26aufirst%3DC.%2BD.%26atitle%3DRechallenge%2520with%2520Clozapine%2520Following%2520Leucopenia%2520or%2520Neutropenia%2520During%2520Previous%2520Therapy%26jtitle%3DBr.%2520J.%2520Psychiatry%26date%3D2006%26volume%3D188%26spage%3D255%26epage%3D263%26doi%3D10.1192%2Fbjp.188.3.255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senior, J. R.</span></span> <span> </span><span class="NLM_article-title">Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1007/s40264-014-0182-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs40264-014-0182-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24190573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFWhurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2014&pages=9-17&author=J.+R.+Senior&title=Evolution+of+the+Food+and+Drug+Administration+Approach+to+Liver+Safety+Assessment+for+New+Drugs%3A+Current+Status+and+Challenges&doi=10.1007%2Fs40264-014-0182-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges</span></div><div class="casAuthors">Senior, John R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">S1</span>),
    <span class="NLM_cas:pages">9-17</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Prompted by approval in 1997 of troglitazone and bromfenac, two drugs that promptly began to show serious and sometimes fatal liver toxicity, we began at the Food and Drug Administration (FDA) a series of annual conferences in 1999 to consider issues of drug-induced liver injury (DILI).  First inviting reviewers of new drug applications we opened the audiences in 2001 to pharmaceutical industry and academic consultants to industry and FDA, and slides shown at the meetings were posted on the internet to be available at the website of the American Assocn. for the Study of Liver Diseases (AASLD)-go to (http://www.aasld.org/dili/Pages/default.aspx).  Observations by Dr. Hyman J. Zimmerman that "drug-induced hepatocellular jaundice is a serious lesion" with possible mortality formed a basis for developing a computer program to plot peak serum values for alanine aminotransferase (ALT) and total bilirubin (TBL) in an x-y log-log graph for all subjects enrolled in clin. trials.  This program had the capability to show the time course of all liver tests for individuals who had both hepatocellular injury and reduced whole liver function, plus clin. narratives to diagnose the severity and most likely cause of the abnormalities.  We called the program eDISH (for evaluation of Drug-Induced Serious Hepatotoxicity), and began in 2004 to use it to assess DILI in clin. trial subjects.  From 2008, comments made by the presenters at the conferences about their slides and ensuing discussions have been added to the website.  All this has raised awareness of the problem, and since 1997, the FDA has not had to withdraw a single drug because of post-marketing hepatotoxicity.  Many issues still remain to be resolved; among the most controversial is the best method to est. likelihood that a given liver injury was actually caused by the drug in question.  On Nov. 9, 2012, a workshop was convened to discuss the best practices for the assessment of drug-induced liver injury (DILI) in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj6ysSzll7_7Vg90H21EOLACvtfcHk0lizKe4qxfihyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFWhurfN&md5=6d7cb5602cdead46918aaa30be6e7aa9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs40264-014-0182-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40264-014-0182-7%26sid%3Dliteratum%253Aachs%26aulast%3DSenior%26aufirst%3DJ.%2BR.%26atitle%3DEvolution%2520of%2520the%2520Food%2520and%2520Drug%2520Administration%2520Approach%2520to%2520Liver%2520Safety%2520Assessment%2520for%2520New%2520Drugs%253A%2520Current%2520Status%2520and%2520Challenges%26jtitle%3DDrug%2520Saf.%26date%3D2014%26volume%3D37%26spage%3D9%26epage%3D17%26doi%3D10.1007%2Fs40264-014-0182-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrill, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fier, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaddy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoine, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishimoto, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisetsky, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">The Effects of Heparins on the Liver: Application of Mechanistic Serum Biomarkers in a Randomized Study in Healthy Volunteers</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1038/clpt.2012.40</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fclpt.2012.40" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22739141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOmt77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=214-220&author=A.+H.+Harrillauthor=J.+Roachauthor=I.+Fierauthor=J.+S.+Eaddyauthor=C.+L.+Kurtzauthor=D.+J.+Antoineauthor=D.+M.+Spencerauthor=T.+K.+Kishimotoauthor=D.+S.+Pisetskyauthor=B.+K.+Parkauthor=P.+B.+Watkins&title=The+Effects+of+Heparins+on+the+Liver%3A+Application+of+Mechanistic+Serum+Biomarkers+in+a+Randomized+Study+in+Healthy+Volunteers&doi=10.1038%2Fclpt.2012.40"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The Effects of Heparins on the Liver: Application of Mechanistic Serum Biomarkers in a Randomized Study in Healthy Volunteers</span></div><div class="casAuthors">Harrill, A. H.; Roach, J.; Fier, I.; Eaddy, J. S.; Kurtz, C. L.; Antoine, D. J.; Spencer, D. M.; Kishimoto, T. K.; Pisetsky, D. S.; Park, B. K.; Watkins, P. B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">214-220</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Heparins have been reported to cause elevations in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) but have not been assocd. with clin. significant liver injury.  The mechanisms underlying these benign lab. abnormalities are unknown.  Forty-eight healthy men were randomized to receive s.c. injections of unfractionated heparin (UFH; 150 U/kg), enoxaparin sodium (1 mg/kg), dalteparin sodium (120 IU/kg), or adomiparin sodium (125 IU/kg; a novel heparin) every 12 h for 4.5 days.  Asymptomatic elevations in serum ALT or AST were obsd. in >90% of the subjects.  Elevations were also obsd. in the levels of serum sorbitol dehydrogenase (SDH), glutamate dehydrogenase (GLDH), miR-122, high-mobility group box-1 protein (including the acetylated form), full-length keratin 18, and DNA.  Keratin 18 fragments, which are apoptosis biomarkers, were not detected.  Biomarker profiles did not differ significantly across heparin treatments.  We conclude that heparins as a class cause self-limited and mild hepatocyte necrosis with secondary activation of an innate immune response.  Clin. Pharmacol. & Therapeutics (2012); 92 2, 214-220. doi:10.1038/clpt.2012.40.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj70owfsaO2bVg90H21EOLACvtfcHk0lhAfmiMIIdw-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOmt77N&md5=dc304ec6d6338fe7bad99414c47c8035</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2012.40&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2012.40%26sid%3Dliteratum%253Aachs%26aulast%3DHarrill%26aufirst%3DA.%2BH.%26aulast%3DRoach%26aufirst%3DJ.%26aulast%3DFier%26aufirst%3DI.%26aulast%3DEaddy%26aufirst%3DJ.%2BS.%26aulast%3DKurtz%26aufirst%3DC.%2BL.%26aulast%3DAntoine%26aufirst%3DD.%2BJ.%26aulast%3DSpencer%26aufirst%3DD.%2BM.%26aulast%3DKishimoto%26aufirst%3DT.%2BK.%26aulast%3DPisetsky%26aufirst%3DD.%2BS.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DThe%2520Effects%2520of%2520Heparins%2520on%2520the%2520Liver%253A%2520Application%2520of%2520Mechanistic%2520Serum%2520Biomarkers%2520in%2520a%2520Randomized%2520Study%2520in%2520Healthy%2520Volunteers%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D92%26spage%3D214%26epage%3D220%26doi%3D10.1038%2Fclpt.2012.40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrill, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menguy-Vacheron, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayyosi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benzerdjeb, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Benign Elevations in Serum Aminotransferases and Biomarkers of Hepatotoxicity in Healthy Volunteers Treated with Cholestyramine</span>. <i>BMC Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">42</span>, <span class="refDoi"> DOI: 10.1186/2050-6511-15-42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1186%2F2050-6511-15-42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25086653" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVymsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=42&author=R.+Singhalauthor=A.+H.+Harrillauthor=F.+Menguy-Vacheronauthor=Z.+Jayyosiauthor=H.+Benzerdjebauthor=P.+B.+Watkins&title=Benign+Elevations+in+Serum+Aminotransferases+and+Biomarkers+of+Hepatotoxicity+in+Healthy+Volunteers+Treated+with+Cholestyramine&doi=10.1186%2F2050-6511-15-42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine</span></div><div class="casAuthors">Singhal, Rohit; Harrill, Alison H.; Menguy-Vacheron, Francoise; Jayyosi, Zaid; Benzerdjeb, Hadj; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42/1-42/7, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">BPTMAB</span>;
        ISSN:<span class="NLM_cas:issn">2050-6511</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: There are currently no serum biomarkers capable of distinguishing elevations in serum alanine aminotransferase (ALT) that portend serious liver injury potential from benign elevations such as those occurring during cholestyramine treatment.  The aim of the research was to test the hypothesis that newly proposed biomarkers of hepatotoxicity would not significantly rise in serum during elevations in serum ALT assocd. with cholestyramine treatment, which has never been assocd. with clin. relevant liver injury.  Methods: In a double-blind placebo-controlled trial, cholestyramine (8g) was administered for 11 days to healthy adult volunteers.  Serum from subjects with elevations in alanine aminotransferase (ALT) exceeding three-fold the upper limit of normal (ULN) were utilized for biomarker quantification.  Results: In 11 of 67 subjects, cholestyramine treatment resulted in ALT elevation by >3x ULN (mean 6.9 fold; range 3-28 fold).  In these 11 subjects, there was a 22.4-fold mean increase in serum levels of miR-122 relative to baseline, supporting a liver origin of the serum ALT.  Significant elevations were noted in mean levels of necrosis biomarkers sorbitol dehydrogenase (8.1 fold), cytokeratin 18 (2.1 fold) and HMGB1 (1.7 fold).  Caspase-cleaved cytokeratin 18, a biomarker of apoptosis was also significantly elevated (1.7 fold).  A rise in glutamate dehydrogenase (7.3 fold) may support mitochondrial dysfunction.  Conclusion: All toxicity biomarkers measured in this study were elevated along with ALT, confirming the liver origin and reflecting both hepatocyte necrosis and apoptosis.  Since cholestyramine treatment has no clin. liver safety concerns, we conclude that interpretation of the biomarkers studied may not be straightforward in the context of assessing liver safety of new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3WPNvNbROvLVg90H21EOLACvtfcHk0lhAfmiMIIdw-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVymsL3K&md5=476887066d141eb23b94d7309a6fca9a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1186%2F2050-6511-15-42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2050-6511-15-42%26sid%3Dliteratum%253Aachs%26aulast%3DSinghal%26aufirst%3DR.%26aulast%3DHarrill%26aufirst%3DA.%2BH.%26aulast%3DMenguy-Vacheron%26aufirst%3DF.%26aulast%3DJayyosi%26aufirst%3DZ.%26aulast%3DBenzerdjeb%26aufirst%3DH.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DBenign%2520Elevations%2520in%2520Serum%2520Aminotransferases%2520and%2520Biomarkers%2520of%2520Hepatotoxicity%2520in%2520Healthy%2520Volunteers%2520Treated%2520with%2520Cholestyramine%26jtitle%3DBMC%2520Pharmacol.%2520Toxicol.%26date%3D2014%26volume%3D15%26spage%3D42%26doi%3D10.1186%2F2050-6511-15-42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Drug Safety Sciences and the Bottleneck in Drug Development</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">788</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.1038/clpt.2011.63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fclpt.2011.63" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21593756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC3MrjtlWqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=788-790&author=P.+B.+Watkins&title=Drug+Safety+Sciences+and+the+Bottleneck+in+Drug+Development&doi=10.1038%2Fclpt.2011.63"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Drug safety sciences and the bottleneck in drug development</span></div><div class="casAuthors">Watkins P B</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">788-90</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">During a recent review of a new drug application for treatment of a chronic disease, US Food and Drug Administration (FDA) regulators agreed with the sponsor's assessment of efficacy.  However, it was noted that two subjects receiving active treatment experienced abnormal liver chemistries that possibly, but not definitely, indicated a liver safety liability.  The sponsor was told that a prerequisite for approval would be a new clinical trial involving 20,000 patients treated for 1 year, with 10,000 receiving the new drug and 10,000 receiving a comparator treatment.  The sponsor is now faced with the substantial costs involved in undertaking such a large study, the loss of patent life during the conduct and analysis of the study, and the prospect of losing in-class market position.  If the drug is ultimately approved, this detour will result in costs and potential revenue loss to the sponsor of well over $1 billion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWkDdhCnw1Wrt7lRqEFUJVfW6udTcc2eY4U-LzsL7sdLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrjtlWqtw%253D%253D&md5=cfa06a5bf9b31277c106d5e99b0c9931</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2011.63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2011.63%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DDrug%2520Safety%2520Sciences%2520and%2520the%2520Bottleneck%2520in%2520Drug%2520Development%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2011%26volume%3D89%26spage%3D788%26epage%3D790%26doi%3D10.1038%2Fclpt.2011.63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Temple, R. R.</span></span> <span> </span><span class="NLM_article-title">Hy’s Law: Predicting Serious Hepatotoxicity</span>. <i>Pharmacoepidemiol. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1002/pds.1211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fpds.1211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=16552790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD287nsVCltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2006&pages=241-243&author=R.+R.+Temple&title=Hy%E2%80%99s+Law%3A+Predicting+Serious+Hepatotoxicity&doi=10.1002%2Fpds.1211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Hy's law: predicting serious hepatotoxicity</span></div><div class="casAuthors">Temple Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacoepidemiology and drug safety</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">241-3</span>
        ISSN:<span class="NLM_cas:issn">1053-8569</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmBz12ppIx2fx2phytoz6_fW6udTcc2eY4U-LzsL7sdLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287nsVCltQ%253D%253D&md5=c2f8d93ccdab933ef7f3aea6e95067fe</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fpds.1211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpds.1211%26sid%3Dliteratum%253Aachs%26aulast%3DTemple%26aufirst%3DR.%2BR.%26atitle%3DHy%25E2%2580%2599s%2520Law%253A%2520Predicting%2520Serious%2520Hepatotoxicity%26jtitle%3DPharmacoepidemiol.%2520Drug%2520Saf.%26date%3D2006%26volume%3D15%26spage%3D241%26epage%3D243%26doi%3D10.1002%2Fpds.1211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucena, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelaez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachkoria, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ruiz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Munoz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Grande, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizarro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duran, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero-Gomez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borras, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmeron, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Vivaldi, R.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-year Period</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2005.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1053%2Fj.gastro.2005.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=16083708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD2MvhvFyktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2005&pages=512-521&author=R.+J.+Andradeauthor=M.+I.+Lucenaauthor=M.+C.+Fernandezauthor=G.+Pelaezauthor=K.+Pachkoriaauthor=E.+Garcia-Ruizauthor=B.+Garcia-Munozauthor=R.+Gonzalez-Grandeauthor=A.+Pizarroauthor=J.+A.+Duranauthor=M.+Jimenezauthor=L.+Rodrigoauthor=M.+Romero-Gomezauthor=J.+M.+Navarroauthor=R.+Planasauthor=J.+Costaauthor=A.+Borrasauthor=A.+Solerauthor=J.+Salmeronauthor=R.+Martin-Vivaldi&title=Drug-Induced+Liver+Injury%3A+An+Analysis+of+461+Incidences+Submitted+to+the+Spanish+Registry+Over+a+10-year+Period&doi=10.1053%2Fj.gastro.2005.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period</span></div><div class="casAuthors">Andrade Raul J; Lucena M Isabel; Fernandez M Carmen; Pelaez Gloria; Pachkoria Ketevan; Garcia-Ruiz Elena; Garcia-Munoz Beatriz; Gonzalez-Grande Rocio; Pizarro Angeles; Duran Jose Antonio; Jimenez Manuel; Rodrigo Luis; Romero-Gomez Manuel; Navarro Jose Maria; Planas Ramon; Costa Joan; Borras Africa; Soler Aina; Salmeron Javier; Martin-Vivaldi Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">512-21</span>
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    </div><div class="casAbstract">BACKGROUND & AIMS:  Progress in the understanding of susceptibility factors to drug-induced liver injury (DILI) and outcome predictability are hampered by the lack of systematic programs to detect bona fide cases.  METHODS:  A cooperative network was created in 1994 in Spain to identify all suspicions of DILI following a prospective structured report form.  The liver damage was characterized according to hepatocellular, cholestatic, and mixed laboratory criteria and to histologic criteria when available.  Further evaluation of causality assessment was centrally performed.  RESULTS:  Since April 1994 to August 2004, 461 out of 570 submitted cases, involving 505 drugs, were deemed to be related to DILI.  The antiinfective group of drugs was the more frequently incriminated, amoxicillin-clavulanate accounting for the 12.8% of the whole series.  The hepatocellular pattern of damage was the most common (58%), was inversely correlated with age (P < .0001), and had the worst outcome (Cox regression, P < .034).  Indeed, the incidence of liver transplantation and death in this group was 11.7% if patients had jaundice at presentation, whereas the corresponding figure was 3.8% in nonjaundiced patients (P < .04).  Factors associated with the development of fulminant hepatic failure were female sex (OR = 25; 95% CI: 4.1-151; P < .0001), hepatocellular damage (OR = 7.9; 95% CI: 1.6-37; P < .009), and higher baseline plasma bilirubin value (OR = 1.15; 95% CI: 1.09-1.22; P < .0001).  CONCLUSIONS:  Patients with drug-induced hepatocellular jaundice have 11.7% chance of progressing to death or transplantation.  Amoxicillin-clavulanate stands out as the most common drug related to DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQdodEUXiJBaUh5eUSa2oe_fW6udTcc2eb5cJwGVM5S67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MvhvFyktQ%253D%253D&md5=11589fa53b8a0aed57ac3c2ce40d9372</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2005.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2005.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3DLucena%26aufirst%3DM.%2BI.%26aulast%3DFernandez%26aufirst%3DM.%2BC.%26aulast%3DPelaez%26aufirst%3DG.%26aulast%3DPachkoria%26aufirst%3DK.%26aulast%3DGarcia-Ruiz%26aufirst%3DE.%26aulast%3DGarcia-Munoz%26aufirst%3DB.%26aulast%3DGonzalez-Grande%26aufirst%3DR.%26aulast%3DPizarro%26aufirst%3DA.%26aulast%3DDuran%26aufirst%3DJ.%2BA.%26aulast%3DJimenez%26aufirst%3DM.%26aulast%3DRodrigo%26aufirst%3DL.%26aulast%3DRomero-Gomez%26aufirst%3DM.%26aulast%3DNavarro%26aufirst%3DJ.%2BM.%26aulast%3DPlanas%26aufirst%3DR.%26aulast%3DCosta%26aufirst%3DJ.%26aulast%3DBorras%26aufirst%3DA.%26aulast%3DSoler%26aufirst%3DA.%26aulast%3DSalmeron%26aufirst%3DJ.%26aulast%3DMartin-Vivaldi%26aufirst%3DR.%26atitle%3DDrug-Induced%2520Liver%2520Injury%253A%2520An%2520Analysis%2520of%2520461%2520Incidences%2520Submitted%2520to%2520the%2520Spanish%2520Registry%2520Over%2520a%252010-year%2520Period%26jtitle%3DGastroenterology%26date%3D2005%26volume%3D129%26spage%3D512%26epage%3D521%26doi%3D10.1053%2Fj.gastro.2005.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleiner, D. E.</span></span> <span> </span><span class="NLM_article-title">Histopathological Evaluation of Drug-Induced Liver Disease</span>. In  <i>Drug-Induced Liver Disease</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplowitz, N.</span>, <span class="NLM_string-name">DeLeve, L. D.</span></span>, Eds; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Boston</span>, <span class="NLM_year">2013</span>; pp  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">263</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2FB978-0-12-387817-5.00015-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=241-263&author=D.+E.+Kleinerauthor=N.+Kaplowitz&author=L.+D.+DeLeve&title=Drug-Induced+Liver+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-387817-5.00015-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-387817-5.00015-7%26sid%3Dliteratum%253Aachs%26aulast%3DKleiner%26aufirst%3DD.%2BE.%26atitle%3DHistopathological%2520Evaluation%2520of%2520Drug-Induced%2520Liver%2520Disease%26btitle%3DDrug-Induced%2520Liver%2520Disease%26aulast%3DKaplowitz%26aufirst%3DN.%26pub%3DAcademic%2520Press%26date%3D2013%26spage%3D241%26epage%3D263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Czaja, A. J.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Autoimmune-Like Hepatitis</span>. <i>Dig. Dis. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">958</span>– <span class="NLM_lpage">976</span>, <span class="refDoi"> DOI: 10.1007/s10620-011-1611-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs10620-011-1611-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21327704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjt1Ggtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2011&pages=958-976&author=A.+J.+Czaja&title=Drug-Induced+Autoimmune-Like+Hepatitis&doi=10.1007%2Fs10620-011-1611-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Induced Autoimmune-Like Hepatitis</span></div><div class="casAuthors">Czaja, Albert J.</div><div class="citationInfo"><span class="NLM_cas:title">Digestive Diseases and Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">958-976</span>CODEN:
                <span class="NLM_cas:coden">DDSCDJ</span>;
        ISSN:<span class="NLM_cas:issn">0163-2116</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The clin. phenotype of classical autoimmune hepatitis can be mimicked by idiosyncratic drug-induced liver injury, and differentiation can be difficult.  The goals of this review are to enumerate the major agents of drug-induced autoimmune-like hepatitis, describe the clin. findings and risk factors assocd. with it, detail the clin. tools by which to assess causality, discuss putative pathogenic mechanisms, and describe treatment and outcome.  The frequency of drug-induced autoimmune-like hepatitis among patients with classical features of autoimmune hepatitis is 9%.  Minocycline and nitrofurantoin are implicated in 90% of cases.  Female predominance, acute onset, and absence of cirrhosis at presentation are important clin. manifestations.  Genetic factors affecting phase I and phase II transformations of the drug, polymorphisms that protect against cellular oxidative stress, and human leukocyte antigens that modulate the immune response may be important pathogenic components.  Clin. judgment is the mainstay of diagnosis as structured diagnostic methods for drug-induced liver injury are imperfect.  The covalent binding of a reactive drug metabolite to a hepatocyte surface protein (commonly a phase I or phase II enzyme), formation of a neoantigen, activation of CD8 T lymphocytes with nonselective antigen receptors, and deficient immune regulatory mechanisms are the main bases for a transient loss of self-tolerance.  Discontinuation of the offending drug is the essential treatment.  Spontaneous improvement usually ensues within 1 mo.  Corticosteroid therapy is warranted for symptomatic severe disease, and it is almost invariably effective.  Relapse after corticosteroid withdrawal probably does not occur, and its absence distinguishes drug-induced disease from classical autoimmune hepatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm1OZEGHbs0bVg90H21EOLACvtfcHk0lhc9Lc4rTwkSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjt1Ggtb0%253D&md5=346cf130bb3bdd66d956f1d8aba00eb4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs10620-011-1611-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10620-011-1611-4%26sid%3Dliteratum%253Aachs%26aulast%3DCzaja%26aufirst%3DA.%2BJ.%26atitle%3DDrug-Induced%2520Autoimmune-Like%2520Hepatitis%26jtitle%3DDig.%2520Dis.%2520Sci.%26date%3D2011%26volume%3D56%26spage%3D958%26epage%3D976%26doi%3D10.1007%2Fs10620-011-1611-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">How to Diagnose and Exclude Drug-Induced Liver Injury</span>. <i>Digestive Diseases</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">472</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1159/000374091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1159%2F000374091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FhvVerug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=472-476&author=P.+B.+Watkins&title=How+to+Diagnose+and+Exclude+Drug-Induced+Liver+Injury&doi=10.1159%2F000374091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">How to Diagnose and Exclude Drug-Induced Liver Injury</span></div><div class="casAuthors">Watkins Paul B</div><div class="citationInfo"><span class="NLM_cas:title">Digestive diseases (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">472-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The diagnosis of drug-induced liver injury (DILI) is largely a diagnosis of exclusion because, with the possible exception of protein:drug adducts in paracetamol overdose, there are no laboratory, biopsy or imaging tests that alone are capable of establishing an unequivocal diagnosis of DILI.  However, it is increasingly appreciated that drugs that cause DILI typically have characteristic clinical presentations or 'signatures' that can be very useful in the diagnosis of DILI.  Indeed, knowing a drug's DILI signature (or sometimes signatures) and the incidence rate of DILI during treatment with that drug are perhaps the most useful pieces of historical information in arriving at the diagnosis of DILI.  Components of the signature include the typical latency from the onset of treatment, whether there are extrahepatic manifestations, whether the injury is hepatocellular, cholestatic or mixed, and sometimes characteristic features on biopsy or serological testing (e.g. liver autoantibodies).  A major advance has been the establishment of the LiverTox website (http://livertox.nih.gov/) which provides open access to standardized entries for over 600 different drugs, including the characteristic clinical presentations of DILI when known.  LiverTox will also calculate the causality score for individual cases using the RUCAM instrument and case-specific data entered by the site user.  However, the problem with standard diagnostic instruments such as the RUCAM is that DILI signatures are not incorporated into the scoring system.  The person entering data must therefore subjectively weigh the RUCAM score with the characteristic DILI signature(s) of the drug to arrive at a diagnosis.  In the future, it should be possible to construct improved diagnostic instruments that objectively incorporate DILI signatures, data-based estimates of the incidence rates of DILI from each implicated drug, and perhaps genetic variants associated with the risk of DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREa92slMahjzAyhZbj3lKdfW6udTcc2ea_4jqC9fAeb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FhvVerug%253D%253D&md5=ac12afa642c94e2343940d0be7f3a709</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1159%2F000374091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000374091%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DHow%2520to%2520Diagnose%2520and%2520Exclude%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DDigestive%2520Diseases%26date%3D2015%26volume%3D33%26spage%3D472%26epage%3D476%26doi%3D10.1159%2F000374091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tillmann, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockey, D. C.</span></span> <span> </span><span class="NLM_article-title">Novel Approaches to Causality Adjudication in Drug-Induced Liver Disease</span>. <i>Current Hepatology Reports</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">276</span>– <span class="NLM_lpage">282</span>, <span class="refDoi"> DOI: 10.1007/s11901-018-0416-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs11901-018-0416-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30766772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BB3cfjslejsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=276-282&author=H.+L.+Tillmannauthor=H.+X.+Barnhartauthor=J.+Serranoauthor=D.+C.+Rockey&title=Novel+Approaches+to+Causality+Adjudication+in+Drug-Induced+Liver+Disease&doi=10.1007%2Fs11901-018-0416-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Approaches to Causality Adjudication in Drug-Induced Liver Disease</span></div><div class="casAuthors">Tillmann Hans L; Barnhart Huiman X; Serrano Jose; Rockey Don C</div><div class="citationInfo"><span class="NLM_cas:title">Current hepatology reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">276-282</span>
        ISSN:<span class="NLM_cas:issn">2195-9595</span>.
    </div><div class="casAbstract">Purpose of Review:  Drug induced liver injury (DILI) is a complex diagnosis dominantly based of exclusion.  Recent Findings:  Currently available causality assessment instruments are considered to be suboptimal.  Expert opinion appears to be best method to adjudicate causality, but is impractical to implement on a wide scale basis.  Thus, new approaches are needed, for example improving the specificity of current scoring systems.  A further option would be to develop a system that utilizes computer-based scoring - which would reduce human error.  Additionally, it would be ideal to have available drug specific scoring systems, based on drugs' characteristic "phenotypes" (presentation and pattern of injury).  Eventually, a validated system could be integrated within the electronic health information system.  Summary:  This review highlights an avenue to an improved Causality Assessment Tool.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRNezzR2Kp6CsKL0FlyGHDofW6udTcc2eaKjb5pVQLgtLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfjslejsw%253D%253D&md5=2e005370d0d5633d351e69c5874d9137</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2Fs11901-018-0416-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11901-018-0416-8%26sid%3Dliteratum%253Aachs%26aulast%3DTillmann%26aufirst%3DH.%2BL.%26aulast%3DBarnhart%26aufirst%3DH.%2BX.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DRockey%26aufirst%3DD.%2BC.%26atitle%3DNovel%2520Approaches%2520to%2520Causality%2520Adjudication%2520in%2520Drug-Induced%2520Liver%2520Disease%26jtitle%3DCurrent%2520Hepatology%2520Reports%26date%3D2018%26volume%3D17%26spage%3D276%26epage%3D282%26doi%3D10.1007%2Fs11901-018-0416-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whritenour, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tartaro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Volkenburg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonkovsky, H. L.</span></span> <span> </span><span class="NLM_article-title">Development of a Modified Lymphocyte Transformation Test for Diagnosing Drug-Induced Liver Injury Associated with an Adaptive Immune Response</span>. <i>J. Immunotoxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1080/1547691X.2016.1254305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1080%2F1547691X.2016.1254305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28121193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1WksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=31-38&author=J.+Whritenourauthor=M.+Koauthor=Q.+Zongauthor=J.+Wangauthor=K.+Tartaroauthor=P.+Schneiderauthor=E.+Olsonauthor=M.+Van+Volkenburgauthor=J.+Serranoauthor=P.+Hayashiauthor=R.+Fontanaauthor=N.+Chalasaniauthor=H.+L.+Bonkovsky&title=Development+of+a+Modified+Lymphocyte+Transformation+Test+for+Diagnosing+Drug-Induced+Liver+Injury+Associated+with+an+Adaptive+Immune+Response&doi=10.1080%2F1547691X.2016.1254305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response</span></div><div class="casAuthors">Whritenour, Jessica; Ko, Mira; Zong, Qing; Wang, Jianying; Tartaro, Karrie; Schneider, Patricia; Olson, Ellen; Van Volkenburg, Maria; Serrano, Jose; Hayashi, Paul; Fontana, Robert; Chalasani, Naga; Bonkovsky, Herbert L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunotoxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-38</span>CODEN:
                <span class="NLM_cas:coden">JIOMAP</span>;
        ISSN:<span class="NLM_cas:issn">1547-691X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">In this test, peripheral blood mononuclear cells (PBMC) collected from a subject are incubated with drug(s) suspected of causing the reaction.  Cell proliferation, measured by the incorporation of [3H]-thymidine into new DNA, is considered evidence of a drug-specific immune response.  The objectives of the current studies were to: (1) develop and optimize a modified version of the LTT (mLTT) and (2) investigate the feasibility of using the mLTT for diagnosing DILI assocd. with an adaptive immune response and identifying the responsible drug.  PBMC collected from donors with a history of drug hypersensitivity reactions to specific drugs (manifested as skin rash) were used as pos. controls for assay optimization.  Following optimization, samples collected from 24 subjects enrolled in the U.  S. Drug-Induced Liver Injury Network (DILIN) were tested in the mLTT.  Using cytokine and granzyme B prodn. as the primary endpoints to demonstrate lymphocyte sensitization to a specific drug, most samples from the DILIN subjects failed to respond.  However, robust pos. mLTT responses were obsd. for two of four samples from three DILIN subjects with hepatitis due to isoniazid (INH).  We conclude that the mLTT, as performed here on frozen and thawed PBMC, is not a reliable test for diagnosing DILI caused by all drugs, but that it may be useful for confirming the role of the adaptive immune response in DILI ascribed to INH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmjypgYZ-O97Vg90H21EOLACvtfcHk0lhBLl_G2ZtP6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1WksLk%253D&md5=7ae0eec7baadb62eaee400e3a33479c3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1080%2F1547691X.2016.1254305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1547691X.2016.1254305%26sid%3Dliteratum%253Aachs%26aulast%3DWhritenour%26aufirst%3DJ.%26aulast%3DKo%26aufirst%3DM.%26aulast%3DZong%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTartaro%26aufirst%3DK.%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DOlson%26aufirst%3DE.%26aulast%3DVan%2BVolkenburg%26aufirst%3DM.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DHayashi%26aufirst%3DP.%26aulast%3DFontana%26aufirst%3DR.%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DBonkovsky%26aufirst%3DH.%2BL.%26atitle%3DDevelopment%2520of%2520a%2520Modified%2520Lymphocyte%2520Transformation%2520Test%2520for%2520Diagnosing%2520Drug-Induced%2520Liver%2520Injury%2520Associated%2520with%2520an%2520Adaptive%2520Immune%2520Response%26jtitle%3DJ.%2520Immunotoxicol.%26date%3D2017%26volume%3D14%26spage%3D31%26epage%3D38%26doi%3D10.1080%2F1547691X.2016.1254305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benesic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragoi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchholtz, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerbes, A. L.</span></span> <span> </span><span class="NLM_article-title">Development and Validation of a Test to Identify Drugs That Cause Idiosyncratic Drug-Induced Liver Injury</span>. <i>Clin. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1488</span>– <span class="NLM_lpage">1494</span>, <span class="refDoi"> DOI: 10.1016/j.cgh.2018.04.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.cgh.2018.04.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29723689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVelsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=1488-1494&author=A.+Benesicauthor=I.+Rotterauthor=D.+Dragoiauthor=S.+Weberauthor=M.+L.+Buchholtzauthor=A.+L.+Gerbes&title=Development+and+Validation+of+a+Test+to+Identify+Drugs+That+Cause+Idiosyncratic+Drug-Induced+Liver+Injury&doi=10.1016%2Fj.cgh.2018.04.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Development and Validation of a Test to Identify Drugs That Cause Idiosyncratic Drug-Induced Liver Injury</span></div><div class="casAuthors">Benesic, Andreas; Rotter, Isabelle; Dragoi, Diana; Weber, Sabine; Buchholtz, Marie-Luise; Gerbes, Alexander L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Gastroenterology and Hepatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1488-1494.e5</span>CODEN:
                <span class="NLM_cas:coden">CGHLAW</span>;
        ISSN:<span class="NLM_cas:issn">1542-3565</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Idiosyncratic drug-induced liver injury (iDILI) is one of the most challenging diagnoses in hepatol.  It is frequently impossible to identify the agent that has caused iDILI in patients who take multiple medicines.  We developed an in vitro method to identify drugs that cause liver injury in patients, based on drug toxicity to monocyte-derived hepatocyte-like (MH) cells from patient blood samples.  We then collected data on patients who were re-exposed to drugs found to be toxic in the MH test to validate test performance.We performed a prospective study of patients referred to the University Hospital in Munich, Germany, with acute liver injury believed to be caused by medications (300 patients were enrolled in the study and we present data from 40 patients with iDILI and re-exposure to implicated drugs).  We collected data from patients on medical history, lab. test and imaging results, findings from biopsy analyses, and medications taken.  Blood samples were collected from all patients and MH cells were isolated and cultured for 10 days.  MH cells were then incubated with drugs to which each patient had been exposed, and toxicity was measured based on release of lactate dehydrogenase.  Agents found to be toxic to MH cells were considered as candidates for the cause of liver injury.  Patients were followed up for up to 6 mo after liver injury and data on drug re-exposures and subsequent liver damage within the following 3 to 24 mo were assocd. with findings from MH tests.Our test identified 10 drugs that were toxic to MH cells from 13 patients (amoxicillin/clavulanate to cells from 2 patients; diclofenac to cells from 2 patients; methylprednisolone to cells from 2 patients; and atorvastatin, metamizole, pembrolizumab, piperacillin/tazobactam, moxifloxacin, duloxetine, or sertraline each to cells from 1 patient).  Thirteen patients had a recurrence of liver injury after inadvertent re-exposure to a single drug, and the MH test correctly identified 12 of the 13 drugs that caused these liver re-injury events.  All 86 drugs that were not toxic to MH cells in our assay were safely resumed by patients and were not assocd. with liver re-injury in 27 patients.  Therefore, the MH test identifies drugs that cause liver injury with 92.3% sensitivity and 100% specificity (1 false-neg. and 12 true-pos. results).We developed a test to identify drugs that cause liver injury in patients based on their toxicity to MH cells isolated from patients with DILI.  We validated results from the assay and found it to identify drugs that cause DILI with 92.3% sensitivity and 100% specificity.  The MH cell test could be a tool to identify causes of iDILI, even in patients taking multiple medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTpp8A27bGm7Vg90H21EOLACvtfcHk0lhBLl_G2ZtP6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVelsLw%253D&md5=0da2f11bd70b211b4158bcd934df55d8</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.cgh.2018.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cgh.2018.04.049%26sid%3Dliteratum%253Aachs%26aulast%3DBenesic%26aufirst%3DA.%26aulast%3DRotter%26aufirst%3DI.%26aulast%3DDragoi%26aufirst%3DD.%26aulast%3DWeber%26aufirst%3DS.%26aulast%3DBuchholtz%26aufirst%3DM.%2BL.%26aulast%3DGerbes%26aufirst%3DA.%2BL.%26atitle%3DDevelopment%2520and%2520Validation%2520of%2520a%2520Test%2520to%2520Identify%2520Drugs%2520That%2520Cause%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DClin.%2520Gastroenterol.%2520Hepatol.%26date%3D2018%26volume%3D16%26spage%3D1488%26epage%3D1494%26doi%3D10.1016%2Fj.cgh.2018.04.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonkovsky, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span> <span> </span><span class="NLM_article-title">ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury</span>. <i>Am. J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">950</span>– <span class="NLM_lpage">966</span>, <span class="refDoi"> DOI: 10.1038/ajg.2014.131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fajg.2014.131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24935270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC2cfivFarug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2014&pages=950-966&author=N.+P.+Chalasaniauthor=P.+H.+Hayashiauthor=H.+L.+Bonkovskyauthor=V.+J.+Navarroauthor=W.+M.+Leeauthor=R.+J.+Fontana&title=ACG+Clinical+Guideline%3A+The+Diagnosis+and+Management+of+Idiosyncratic+Drug-Induced+Liver+Injury&doi=10.1038%2Fajg.2014.131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury</span></div><div class="casAuthors">Chalasani Naga P; Hayashi Paul H; Bonkovsky Herbert L; Navarro Victor J; Lee William M; Fontana Robert J</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">950-66; quiz 967</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Idiosyncratic drug-induced liver injury (DILI) is a rare adverse drug reaction and it can lead to jaundice, liver failure, or even death.  Antimicrobials and herbal and dietary supplements are among the most common therapeutic classes to cause DILI in the Western world.  DILI is a diagnosis of exclusion and thus careful history taking and thorough work-up for competing etiologies are essential for its timely diagnosis.  In this ACG Clinical Guideline, the authors present an evidence-based approach to diagnosis and management of DILI with special emphasis on DILI due to herbal and dietary supplements and DILI occurring in individuals with underlying liver disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqpcTQqrOghUewzGPswiWOfW6udTcc2ebEbNYNVnWTkrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfivFarug%253D%253D&md5=1f44c3ef81598631d299a029efb2756c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fajg.2014.131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fajg.2014.131%26sid%3Dliteratum%253Aachs%26aulast%3DChalasani%26aufirst%3DN.%2BP.%26aulast%3DHayashi%26aufirst%3DP.%2BH.%26aulast%3DBonkovsky%26aufirst%3DH.%2BL.%26aulast%3DNavarro%26aufirst%3DV.%2BJ.%26aulast%3DLee%26aufirst%3DW.%2BM.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26atitle%3DACG%2520Clinical%2520Guideline%253A%2520The%2520Diagnosis%2520and%2520Management%2520of%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DAm.%2520J.%2520Gastroenterol.%26date%3D2014%26volume%3D109%26spage%3D950%26epage%3D966%26doi%3D10.1038%2Fajg.2014.131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, C.</span></span> <span> </span><span class="NLM_article-title">Exosomes Derived from Human Menstrual Blood-Derived Stem Cells Alleviate Fulminant Hepatic Failure</span>. <i>Stem Cell Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">9</span>, <span class="refDoi"> DOI: 10.1186/s13287-016-0453-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1186%2Fs13287-016-0453-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28115012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVahtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=9&author=L.+Chenauthor=B.+Xiangauthor=X.+Wangauthor=C.+Xiang&title=Exosomes+Derived+from+Human+Menstrual+Blood-Derived+Stem+Cells+Alleviate+Fulminant+Hepatic+Failure&doi=10.1186%2Fs13287-016-0453-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Exosomes derived from human menstrual blood-derived stem cells alleviate fulminant hepatic failure</span></div><div class="casAuthors">Chen, Lu; Xiang, Bingyu; Wang, Xiaojun; Xiang, Charlie</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cell Research & Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9/1-9/15</span>CODEN:
                <span class="NLM_cas:coden">SCRTEK</span>;
        ISSN:<span class="NLM_cas:issn">1757-6512</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Human menstrual blood-derived stem cells (MenSCs) are a novel source of MSCs that provide the advantage of being easy to collect and isolate.  Exosomes contain some mRNAs and adhesion mols. that can potentially impact cellular and animal physiol.  This study aimed to investigate the therapeutic potential of MenSC-derived exosomes (MenSC-Ex) on AML12 cells (in vitro) and D-GalN/LPS-induced FHF mice (in vivo).  Methods: Transmission electron microscopy and Western blot were used to identify MenSC-Ex.  Antibody array was used to examine cytokine levels on MenSC-Ex.  MenSC-Ex were treated in D-GalN/LPS-induced AML12 in vitro.  Cell proliferation and apoptosis were measured.  MenSC-Ex were injected into the tail veins of mice 24 h before treatment with D-GalN/LPS.  Blood and liver tissues served as physiol. and biochem. indexes.  The no. of liver mononuclear cells (MNCs) and the amt. of the active apoptotic protein caspase-3 were detd. to elaborate the mechanism of hepatoprotective activity.  Results: Human menstrual blood-derived stem cell-derived exosomes (MenSC-Ex) are bi-lipid membrane vesicles that have a round, ball-like shape with a diam. of approx. 30-100 nm.  Cytokine arrays have shown that MenSC-Ex expressed cytokines, including ICAM-1, angiopoietin-2, Axl, angiogenin, IGFBP-6, osteoprotegerin, IL-6, and IL-8.  MenSC-Ex markedly improved liver function, enhanced survival rates, and inhibited liver cell apoptosis at 6 h after transplantation.  MenSC-Ex migrated to sites of injury and to AML12 cells (a mouse hepatocyte cell line), resp.  Moreover, MenSC-Ex reduced the no. of liver mononuclear cells (MNCs) and the amt. of the active apoptotic protein caspase-3 in injured livers.  Conclusions: In conclusion, our results provide preliminary evidence for the anti-apoptotic capacity of MenSC-Ex in FHF and suggest that MenSC-Ex may be an alternative therapeutic approach to treat FHF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9kJmxHJd9-LVg90H21EOLACvtfcHk0ljG8yTNbHTgIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVahtrc%253D&md5=e23837efa46a114ce1ed8560a4ed897a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1186%2Fs13287-016-0453-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13287-016-0453-6%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DXiang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXiang%26aufirst%3DC.%26atitle%3DExosomes%2520Derived%2520from%2520Human%2520Menstrual%2520Blood-Derived%2520Stem%2520Cells%2520Alleviate%2520Fulminant%2520Hepatic%2520Failure%26jtitle%3DStem%2520Cell%2520Res.%2520Ther.%26date%3D2017%26volume%3D8%26spage%3D9%26doi%3D10.1186%2Fs13287-016-0453-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Q.</span></span> <span> </span><span class="NLM_article-title">Extracellular Vesicles Secreted by Human Adipose-derived Stem Cells (hASCs) Improve Survival Rate of Rats with Acute Liver Failure by Releasing lncRNA H19</span>. <i>EBioMedicine</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1016/j.ebiom.2018.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.ebiom.2018.07.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30077720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ltFWltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2018&pages=231-242&author=Y.+Jinauthor=J.+Wangauthor=H.+Liauthor=S.+Gaoauthor=R.+Shiauthor=D.+Yangauthor=X.+Wangauthor=X.+Wangauthor=L.+Zhuauthor=X.+Wangauthor=C.+Chenauthor=K.+Ningauthor=Z.+Gaoauthor=J.+Xuauthor=Q.+Fu&title=Extracellular+Vesicles+Secreted+by+Human+Adipose-derived+Stem+Cells+%28hASCs%29+Improve+Survival+Rate+of+Rats+with+Acute+Liver+Failure+by+Releasing+lncRNA+H19&doi=10.1016%2Fj.ebiom.2018.07.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular Vesicles Secreted by Human Adipose-derived Stem Cells (hASCs) Improve Survival Rate of Rats with Acute Liver Failure by Releasing lncRNA H19</span></div><div class="casAuthors">Jin Yinpeng; Fu Qingchun; Wang Junyi; Li Hongchao; Wang Xiaojin; Chen Chengwei; Gao Shane; Yang Danjing; Zhu Liang; Shi Rongfeng; Wang Xianli; Wang Xi; Ning Ke; Gao Zhengliang; Xu Jun</div><div class="citationInfo"><span class="NLM_cas:title">EBioMedicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">231-242</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">It has previously been reported that human adipose-derived stem cells (hASCs) can promote the regeneration of damaged tissues in rats with liver failure through a 'paracrine effect'.  Here we demonstrate a therapeutic effect of hASCs derived Extracellular Vesicles (EVs) on rat models with acute liver failure, as shown by the improvement of the survival rate by >70% compared to controls.  Gene sequencing of rat liver revealed an increase in human long-chain non-coding RNA (lncRNA) H19 after hASC-derived EVs transplantation.  When the H19 coding sequence was silenced in hASCs and EVs were then collected for treatment of rats with liver failure, we saw a decrease in the survival rate to 40%, compared to treatment with EVs generated from non-silenced hASCs.  These data indicate that lncRNA H19 may be a potential therapeutic target for the treatment of liver failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZqYsXdx6sLBLDWw4HIq2sfW6udTcc2ebEbNYNVnWTkrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ltFWltQ%253D%253D&md5=dae51f757bf502340b05d643bad34206</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.ebiom.2018.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ebiom.2018.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DNing%26aufirst%3DK.%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DQ.%26atitle%3DExtracellular%2520Vesicles%2520Secreted%2520by%2520Human%2520Adipose-derived%2520Stem%2520Cells%2520%2528hASCs%2529%2520Improve%2520Survival%2520Rate%2520of%2520Rats%2520with%2520Acute%2520Liver%2520Failure%2520by%2520Releasing%2520lncRNA%2520H19%26jtitle%3DEBioMedicine%26date%3D2018%26volume%3D34%26spage%3D231%26epage%3D242%26doi%3D10.1016%2Fj.ebiom.2018.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Damania, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaiman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teotia, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span> <span> </span><span class="NLM_article-title">Mesenchymal Stromal Cell-Derived Exosome-Rich Fractionated Secretome Confers a Hepatoprotective Effect in Liver Injury</span>. <i>Stem Cell Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">31</span>, <span class="refDoi"> DOI: 10.1186/s13287-017-0752-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1186%2Fs13287-017-0752-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29409540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsVOnsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=31&author=A.+Damaniaauthor=D.+Jaimanauthor=A.+K.+Teotiaauthor=A.+Kumar&title=Mesenchymal+Stromal+Cell-Derived+Exosome-Rich+Fractionated+Secretome+Confers+a+Hepatoprotective+Effect+in+Liver+Injury&doi=10.1186%2Fs13287-017-0752-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Mesenchymal stromal cell-derived exosome-rich fractionated secretome confers a hepatoprotective effect in liver injury</span></div><div class="casAuthors">Damania, Apeksha; Jaiman, Deepika; Teotia, Arun Kumar; Kumar, Ashok</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cell Research & Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31</span>CODEN:
                <span class="NLM_cas:coden">SCRTEK</span>;
        ISSN:<span class="NLM_cas:issn">1757-6512</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Mesenchymal stromal cells (MSCs) are an attractive therapeutic agent in regenerative medicine.  Recently, there has been a paradigm shift from differentiation of MSCs to their paracrine effects at the injury site.  Several reports elucidate the role of trophic factors secreted by MSCs toward the repair of injured tissues.  We hypothesize that fractionating the MSC secretome will enrich exosomes contg. sol. bioactive mols., improving its therapeutic potential for liver failure.  Methods: Rat bone marrow MSCs were isolated and the conditioned media filtered, concd. and ultracentrifuged to generate fractionated secretome.  This secretome was characterized for the presence of exosomes and recovery from liver injury assessed in in-vitro liver injury models.  The results were further validated in vivo.  Results: Studies on in-vitro liver injury models using acetaminophen and hydrogen peroxide show better cell recovery and reduced cytotoxicity in the presence of fractionated as opposed to unfractionated secretome.  Further, the cells showed reduced oxidative stress in the presence of fractionated secretome, suggesting a potential antioxidative effect.  These results were further validated in vivo in liver failure models, wherein improved liver regeneration in the presence of fractionated secretome (0.819 ± 0.035) was obsd. as compared to unfractionated secretome (0.718 ± 0.042).  Conclusions: The work presented is a proof of concept that fractionating the secretome enriches certain bioactive mols. involved in the repair and recovery of injured liver tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS3PyU0drJ1rVg90H21EOLACvtfcHk0liAq8vNF3d0hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsVOnsrs%253D&md5=94fbf271520e952ac07548c1083923c1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1186%2Fs13287-017-0752-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13287-017-0752-6%26sid%3Dliteratum%253Aachs%26aulast%3DDamania%26aufirst%3DA.%26aulast%3DJaiman%26aufirst%3DD.%26aulast%3DTeotia%26aufirst%3DA.%2BK.%26aulast%3DKumar%26aufirst%3DA.%26atitle%3DMesenchymal%2520Stromal%2520Cell-Derived%2520Exosome-Rich%2520Fractionated%2520Secretome%2520Confers%2520a%2520Hepatoprotective%2520Effect%2520in%2520Liver%2520Injury%26jtitle%3DStem%2520Cell%2520Res.%2520Ther.%26date%3D2018%26volume%3D9%26spage%3D31%26doi%3D10.1186%2Fs13287-017-0752-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fiore, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzolini, G. D.</span></span> <span> </span><span class="NLM_article-title">Taking Advantage of the Potential of Mesenchymal Stromal Cells in Liver Regeneration: Cells and Extracellular Vesicles as Therapeutic Strategies</span>. <i>World Journal of Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2427</span>– <span class="NLM_lpage">2440</span>, <span class="refDoi"> DOI: 10.3748/wjg.v24.i23.2427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.3748%2Fwjg.v24.i23.2427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29930465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Cnt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=2427-2440&author=E.+J.+Fioreauthor=L.+M.+Dominguezauthor=J.+Bayoauthor=M.+G.+Garciaauthor=G.+D.+Mazzolini&title=Taking+Advantage+of+the+Potential+of+Mesenchymal+Stromal+Cells+in+Liver+Regeneration%3A+Cells+and+Extracellular+Vesicles+as+Therapeutic+Strategies&doi=10.3748%2Fwjg.v24.i23.2427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Taking advantage of the potential of mesenchymal stromal cells in liver regeneration: cells and extracellular vesicles as therapeutic strategies</span></div><div class="casAuthors">Fiore, Esteban Juan; Dominguez, Luciana Maria; Bayo, Juan; Garcia, Mariana Gabriela; Mazzolini, Guillermo Daniel</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2427-2440</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">2219-2840</span>.
    
            (<span class="NLM_cas:orgname">Baishideng Publishing Group Inc.</span>)
        </div><div class="casAbstract">Cell-based therapies for acute and chronic liver diseases are under continuous progress.  Mesenchymal stem/stromal cells (MSCs) are multipotent cells able to migrate selectively to damaged tissue and contribute to its healing and regeneration.  The MSC pro-regenerative effect occurs due to their immunomodulatory capacity and their ability to produce factors that promote cell protection and survival.  Likewise, it has been obsd. that part of their paracrine effect is mediated by MSC-derived extracellular vesicles (EVs).  EVs contain proteins, lipids and nucleic acids (DNA, mRNA, miRNA, lncRNA) from the cell of origin, allowing for intercellular communication.  Recently, different studies have demonstrated that MSC-derived EVs could reproduce, at least in part, the biol. effects obtained by MSC-based therapies.  Moreover, due to EVs' stability for long periods of time and easy isolation methods they have become a therapeutic option to MSCs treatments.  This review summarizes the latest results achieved in clin. trials using MSCs as cell therapy for liver regeneration, the role of EVs in liver physiopathol. and the potential of MSCderived EVs as intercellular mediators and therapeutic tools in liver diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1f-E7ppLEF7Vg90H21EOLACvtfcHk0liAq8vNF3d0hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Cnt78%253D&md5=d082b7a2e22108da260a4ff9e7e48017</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v24.i23.2427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v24.i23.2427%26sid%3Dliteratum%253Aachs%26aulast%3DFiore%26aufirst%3DE.%2BJ.%26aulast%3DDominguez%26aufirst%3DL.%2BM.%26aulast%3DBayo%26aufirst%3DJ.%26aulast%3DGarcia%26aufirst%3DM.%2BG.%26aulast%3DMazzolini%26aufirst%3DG.%2BD.%26atitle%3DTaking%2520Advantage%2520of%2520the%2520Potential%2520of%2520Mesenchymal%2520Stromal%2520Cells%2520in%2520Liver%2520Regeneration%253A%2520Cells%2520and%2520Extracellular%2520Vesicles%2520as%2520Therapeutic%2520Strategies%26jtitle%3DWorld%2520Journal%2520of%2520Gastroenterology%26date%3D2018%26volume%3D24%26spage%3D2427%26epage%3D2440%26doi%3D10.3748%2Fwjg.v24.i23.2427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Church, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kullak-Ublick, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubrecht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonkovsky, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goepfert, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, N. M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcinak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ormarsdottir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schomaker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuppe-Koistinen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolenski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arber, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Bommel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poynard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Candidate Biomarkers for the Diagnosis and Prognosis of Drug-Induced Liver Injury: An International Collaborative Effort</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">773</span>, <span class="refDoi"> DOI: 10.1002/hep.29802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.29802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29357190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2019&pages=760-773&author=R.+J.+Churchauthor=G.+A.+Kullak-Ublickauthor=J.+Aubrechtauthor=H.+L.+Bonkovskyauthor=N.+Chalasaniauthor=R.+J.+Fontanaauthor=J.+C.+Goepfertauthor=F.+Hackmanauthor=N.+M.+P.+Kingauthor=S.+Kirbyauthor=P.+Kirbyauthor=J.+Marcinakauthor=S.+Ormarsdottirauthor=S.+J.+Schomakerauthor=I.+Schuppe-Koistinenauthor=F.+Wolenskiauthor=N.+Arberauthor=M.+Merzauthor=J.+M.+Sauerauthor=R.+J.+Andradeauthor=F.+van+Bommelauthor=T.+Poynardauthor=P.+B.+Watkins&title=Candidate+Biomarkers+for+the+Diagnosis+and+Prognosis+of+Drug-Induced+Liver+Injury%3A+An+International+Collaborative+Effort&doi=10.1002%2Fhep.29802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort</span></div><div class="casAuthors">Church, Rachel J.; Kullak-Ublick, Gerd A.; Aubrecht, Jiri; Bonkovsky, Herbert L.; Chalasani, Naga; Fontana, Robert J.; Goepfert, Jens C.; Hackman, Frances; King, Nicholas M. P.; Kirby, Simon; Kirby, Patrick; Marcinak, John; Ormarsdottir, Sif; Schomaker, Shelli J.; Schuppe-Koistinen, Ina; Wolenski, Francis; Arber, Nadir; Merz, Michael; Sauer, John-Michael; Andrade, Raul J.; van Boemmel, Florian; Poynard, Thierry; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">760-773</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Current blood biomarkers are suboptimal in detecting drug-induced liver injury (DILI) and predicting its outcome.  We sought to characterize the natural variabilty and performance characteristics of 14 promising DILI biomarker candidates.  Serum or plasma from multiple cohorts of healthy volunteers (n = 192 and n = 81), subjects who safely took potentially hepatotoxic drugs without adverse effects (n = 55 and n = 92) and DILI patients (n = 98, n = 28, and n = 143) were assayed for microRNA-122 (miR-122), glutamate dehydrogenase (GLDH), total cytokeratin 18 (K18), caspase cleaved K18, glutathione S-transferase α, alpha-fetoprotein, arginase-1, osteopontin (OPN), sorbitol dehydrogenase, fatty acid binding protein, cadherin-5, macrophage colony-stimulating factor receptor (MCSFR), paraoxonase 1 (normalized to prothrombin protein), and leukocyte cell-derived chemotaxin-2.  Most candidate biomarkers were significantly altered in DILI cases compared with healthy volunteers.  GLDH correlated more closely with gold std. alanine aminotransferase than miR-122, and there was a surprisingly wide inter- and intra-individual variability of miR-122 levels among healthy volunteers.  Serum K18, OPN, and MCSFR levels were most strongly assocd. with liver-related death or transplantation within 6 mo of DILI onset.  Prediction of prognosis among DILI patients using the Model for End-Stage Liver Disease was improved by incorporation of K18 and MCSFR levels.  Conclusion: GLDH appears to be more useful than miR-122 in identifying DILI patients, and K18, OPN, and MCSFR are promising candidates for prediction of prognosis during an acute DILI event.  Serial assessment of these biomarkers in large prospective studies will help further delineate their role in DILI diagnosis and management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT0gXwr0GW4rVg90H21EOLACvtfcHk0liAq8vNF3d0hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKit7k%253D&md5=c5a84dcfbc1e0c5e7bc7d90d6b6b1a30</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fhep.29802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.29802%26sid%3Dliteratum%253Aachs%26aulast%3DChurch%26aufirst%3DR.%2BJ.%26aulast%3DKullak-Ublick%26aufirst%3DG.%2BA.%26aulast%3DAubrecht%26aufirst%3DJ.%26aulast%3DBonkovsky%26aufirst%3DH.%2BL.%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DGoepfert%26aufirst%3DJ.%2BC.%26aulast%3DHackman%26aufirst%3DF.%26aulast%3DKing%26aufirst%3DN.%2BM.%2BP.%26aulast%3DKirby%26aufirst%3DS.%26aulast%3DKirby%26aufirst%3DP.%26aulast%3DMarcinak%26aufirst%3DJ.%26aulast%3DOrmarsdottir%26aufirst%3DS.%26aulast%3DSchomaker%26aufirst%3DS.%2BJ.%26aulast%3DSchuppe-Koistinen%26aufirst%3DI.%26aulast%3DWolenski%26aufirst%3DF.%26aulast%3DArber%26aufirst%3DN.%26aulast%3DMerz%26aufirst%3DM.%26aulast%3DSauer%26aufirst%3DJ.%2BM.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3Dvan%2BBommel%26aufirst%3DF.%26aulast%3DPoynard%26aufirst%3DT.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DCandidate%2520Biomarkers%2520for%2520the%2520Diagnosis%2520and%2520Prognosis%2520of%2520Drug-Induced%2520Liver%2520Injury%253A%2520An%2520International%2520Collaborative%2520Effort%26jtitle%3DHepatology%26date%3D2019%26volume%3D69%26spage%3D760%26epage%3D773%26doi%3D10.1002%2Fhep.29802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">Immune Mechanisms of Idiosyncratic Drug-Induced Liver Injury</span>. <i>Journal of Clinical and Translational Research</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.18053/jctres.03.2017S1.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.18053%2Fjctres.03.2017S1.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30873473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFKjtbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=145-156&author=A.+Makauthor=J.+Uetrecht&title=Immune+Mechanisms+of+Idiosyncratic+Drug-Induced+Liver+Injury&doi=10.18053%2Fjctres.03.2017S1.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Immune mechanisms of idiosyncratic drug-induced liver injury</span></div><div class="casAuthors">Mak, Alastair; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical and Translational Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">Spec.Iss.1</span>),
    <span class="NLM_cas:pages">145-156</span>CODEN:
                <span class="NLM_cas:coden">JCTRGT</span>;
        ISSN:<span class="NLM_cas:issn">2424-810X</span>.
    
            (<span class="NLM_cas:orgname">Whioce Publishing Pte. Ltd.</span>)
        </div><div class="casAbstract">Idiosyncratic drug reactions (IDRs) continue to be an important issue.  Specifically, idiosyncratic drug-induced liver injury (IDILI) is the most likely IDR to lead to drug withdrawal, and it accounts for a significant portion of all cases of acute liver failure.  In addn., IDRs are unpredictable and their mechanisms are not well understood.  There is increasing clin. evidence that most IDILI is immune mediated.  Several immune mediated mechanistic hypotheses exist such as the hapten and danger hypothesis; however, they do not completely explain the idiosyn-cratic nature of these reactions.  Extensive mechanistic studies are needed to better understand these reactions; however, it is impossible to do controlled expts. in humans, and previous animal models did not properly model IDILI.  If IDILI is immune mediated and the major factor preventing liver injury in patients is immune tolerance, then a plausible method to develop an animal model of IDILI would be to impair immune tolerance.  This hypothesis has shown promise in developing valid animal models of IDILI as demonstrated by a halothane induced liver injury mouse model developed by depleting myeloid derived suppressor cells (MDSCs), as well as an amodiaquine-, isoniazid- and nevirapine-induced liver injury mouse model developed by impairing immune tolerance by blocking PD-1 and CTLA-4, two immune checkpoint inhibitors.  Further characterization and validation of these models is required; however, it is likely that they will make it possible to perform mechanistic studies that have been impossible in the past.  Relevance for patients: Idiosyncratic drug-induced liver injury can be serious leading to liver transplantation or death.  Their idiosyncratic nature makes mechanistic studies very difficult.  However, with the development of the first animal model that is similar to the liver injury that occurs in humans, it will be possible to study the mechanisms involved.  With a better mechanistic understanding it should be possible to test drug candidates and produce safer drugs.  In addn., it should be possible to design better treatments when drug-induced liver injury does occur.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJWvDxGcnjELVg90H21EOLACvtfcHk0ljNcVtsnLqqvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFKjtbvF&md5=6e7295c2d9294d0c1533025c5a18cf40</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.18053%2Fjctres.03.2017S1.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18053%252Fjctres.03.2017S1.001%26sid%3Dliteratum%253Aachs%26aulast%3DMak%26aufirst%3DA.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DImmune%2520Mechanisms%2520of%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DJournal%2520of%2520Clinical%2520and%2520Translational%2520Research%26date%3D2017%26volume%3D3%26spage%3D145%26epage%3D156%26doi%3D10.18053%2Fjctres.03.2017S1.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mennicke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawodniak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yawalkar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stickel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keogh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inderbitzin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candinas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, W. J.</span></span> <span> </span><span class="NLM_article-title">Fulminant Liver Failure After Vancomycin in a Sulfasalazine-Induced DRESS Syndrome: Fatal Recurrence After Liver Transplantation</span>. <i>Am. J. Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2197</span>– <span class="NLM_lpage">2202</span>, <span class="refDoi"> DOI: 10.1111/j.1600-6143.2009.02788.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1111%2Fj.1600-6143.2009.02788.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19706026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD1MrnvFOhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=2197-2202&author=M.+Mennickeauthor=A.+Zawodniakauthor=M.+Kellerauthor=L.+Wilkensauthor=N.+Yawalkarauthor=F.+Stickelauthor=A.+Keoghauthor=D.+Inderbitzinauthor=D.+Candinasauthor=W.+J.+Pichler&title=Fulminant+Liver+Failure+After+Vancomycin+in+a+Sulfasalazine-Induced+DRESS+Syndrome%3A+Fatal+Recurrence+After+Liver+Transplantation&doi=10.1111%2Fj.1600-6143.2009.02788.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation</span></div><div class="casAuthors">Mennicke M; Zawodniak A; Keller M; Wilkens L; Yawalkar N; Stickel F; Keogh A; Inderbitzin D; Candinas D; Pichler W J</div><div class="citationInfo"><span class="NLM_cas:title">American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2197-202</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">DRESS syndrome (drug rash with eosinophilia and systemic symptoms) is a rare drug hypersensitivity reaction with a significant mortality.  We describe a 60-year-old man with polyarthritis treated with sulfasalazine who developed DRESS and fulminant liver failure after additional vancomycin treatment.  Liver histology revealed infiltration of granzymeB+ CD3+ lymphocytes in close proximity to apoptotic hepatocytes.  After a superurgent liver transplantation and initial recovery, the patient developed recurrent generalized exanthema and eosinophilia, but only moderate hepatitis.  Histology showed infiltration of FasL+ lymphocytes and eosinophils in the transplanted liver.  Treatment with high-dose methylprednisolone was unsuccessful.  Postmortem examination revealed extensive necrosis of the liver transplant.  This case report illustrates that patients with DRESS may develop fulminant liver failure and that DRESS recurrence can recur in the transplanted liver.  Histological and immunological investigations suggest an important role of granzymeB and FasL mediated cell death in DRESS associated hepatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7_g-4lumu8u3MPKNEWB5RfW6udTcc2eY_yrwEAgV0cLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrnvFOhsw%253D%253D&md5=eaa9c39e6ecc32c2e4a43342928bb7c9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-6143.2009.02788.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-6143.2009.02788.x%26sid%3Dliteratum%253Aachs%26aulast%3DMennicke%26aufirst%3DM.%26aulast%3DZawodniak%26aufirst%3DA.%26aulast%3DKeller%26aufirst%3DM.%26aulast%3DWilkens%26aufirst%3DL.%26aulast%3DYawalkar%26aufirst%3DN.%26aulast%3DStickel%26aufirst%3DF.%26aulast%3DKeogh%26aufirst%3DA.%26aulast%3DInderbitzin%26aufirst%3DD.%26aulast%3DCandinas%26aufirst%3DD.%26aulast%3DPichler%26aufirst%3DW.%2BJ.%26atitle%3DFulminant%2520Liver%2520Failure%2520After%2520Vancomycin%2520in%2520a%2520Sulfasalazine-Induced%2520DRESS%2520Syndrome%253A%2520Fatal%2520Recurrence%2520After%2520Liver%2520Transplantation%26jtitle%3DAm.%2520J.%2520Transplant.%26date%3D2009%26volume%3D9%26spage%3D2197%26epage%3D2202%26doi%3D10.1111%2Fj.1600-6143.2009.02788.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maria, V. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Victorino, R. M. M.</span></span> <span> </span><span class="NLM_article-title">Diagnostic Value of Specific T-cell Reactivity to Drugs in 95 cases of Drug-Induced Liver Injury</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.1136/gut.41.4.534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1136%2Fgut.41.4.534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=9391255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADyaK1c%252Flt1Kntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1997&pages=534-540&author=V.+A.+J.+Mariaauthor=R.+M.+M.+Victorino&title=Diagnostic+Value+of+Specific+T-cell+Reactivity+to+Drugs+in+95+cases+of+Drug-Induced+Liver+Injury&doi=10.1136%2Fgut.41.4.534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury</span></div><div class="casAuthors">Maria V A; Victorino R M</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">534-40</span>
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    </div><div class="casAbstract">BACKGROUND:  Diagnosis of drug induced liver injury is usually based on a temporal relation between drug intake and clinical picture as well as on the exclusion of alternative causes.  More precise diagnosis has been attempted by using in vitro specific T cell reactivity to drugs but the test has never reached general acceptability because of frequent negative results which could be explained, in part, by prostaglandin producing suppressor cells (PPSC).  AIM:  To analyse the diagnostic value of a modified test where lymphocyte responses to drugs are detected in the presence of a prostaglandin inhibitor.  PATIENTS:  Ninety five patients with a clinical diagnosis of drug induced liver injury, 106 healthy controls, 35 individuals with recent exposure to the same drugs without adverse effects, and 15 patients with liver disease unrelated to drugs.  METHODS:  Peripheral blood mononuclear cells (PBMC) were cultured in the presence of drugs alone and in the presence of drugs and a prostaglandin inhibitor.  Responses were assessed by 3H-thymidine incorporation in lymphocytes.  Results were expressed as counts per minute and as stimulation indexes (SI).  RESULTS:  When PBMC were stimulated with drugs alone, lymphocyte sensitisation to drugs (SI > 2) was detected in 26% of the cases.  This was noticeably increased (56%) when a prostaglandin inhibitor was added to the cultures.  No reactivity was found in controls.  In patients with possible sensitivity to several drugs, lymphocyte reactivity was detected to only one drug.  The severity of the lesions, as assessed by aminotransferase concentrations and disease duration, was lower in patients with evidence of PPSC.  CONCLUSIONS:  This new approach is useful for the diagnosis of drug induced liver injury, particularly in patients exposed to more than one drug; furthermore, the presence of putative PPSC is associated with less severe forms of drug induced hepatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRw9JTpmjfHwZVVjGoY74BafW6udTcc2eY_yrwEAgV0cLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c%252Flt1Kntg%253D%253D&md5=e234d0af23bd224a8da6f3ec29f91048</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1136%2Fgut.41.4.534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgut.41.4.534%26sid%3Dliteratum%253Aachs%26aulast%3DMaria%26aufirst%3DV.%2BA.%2BJ.%26aulast%3DVictorino%26aufirst%3DR.%2BM.%2BM.%26atitle%3DDiagnostic%2520Value%2520of%2520Specific%2520T-cell%2520Reactivity%2520to%2520Drugs%2520in%252095%2520cases%2520of%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DGut%26date%3D1997%26volume%3D41%26spage%3D534%26epage%3D540%26doi%3D10.1136%2Fgut.41.4.534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Q. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Set Up Drug Lymphocyte Simtulation Test (3H-TdR) and Observe its Application in Drug-Induced Liver Injury</span>. <i>Chinese Journal of Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">190</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.3760/cma.j.issn.1007-3418.2012.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.3760%2Fcma.j.issn.1007-3418.2012.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22475137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC38nlsFWltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=190-192&author=G.+Y.+Chenauthor=C.+W.+Chenauthor=Q.+C.+Fuauthor=X.+J.+Wangauthor=L.+D.+Niauthor=X.+H.+Jiangauthor=F.+Zhouauthor=L.+Q.+Shiauthor=R.+T.+Laiauthor=J.+Yang&title=Set+Up+Drug+Lymphocyte+Simtulation+Test+%283H-TdR%29+and+Observe+its+Application+in+Drug-Induced+Liver+Injury&doi=10.3760%2Fcma.j.issn.1007-3418.2012.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Set up drug lymphocyte stimulation test (3H-TdR) and observe its application in drug-induced liver injury</span></div><div class="casAuthors">Chen Gao-yan; Chen Cheng-wei; Fu Qing-chun; Wang Xiao-jin; Ni Liu-da; Jiang Xiao-hua; Zhou Feng; Shi Li-qin; Lai Rong-tao; Yang Jun</div><div class="citationInfo"><span class="NLM_cas:title">Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">190-2</span>
        ISSN:<span class="NLM_cas:issn">1007-3418</span>.
    </div><div class="casAbstract">OBJECTIVE:  To set up the drug lymphocyte stimulation test (DLST), as a diagnosis means for DILI which was immunity idiosyncrasy, improve the Diagnosis, level of DILI.  METHOD:  For the 59 patients who diagnosed as DILI, we separated their PBMC, exploring to the suspicious drug which caused DILI, then use the methods 3H-TdR to test, according to the mixed degree to clear the PBMC count which specific activated by drug.We also set up drug group, negative control and Positive control at the same time.  Preliminary experiments was including the best dose of PHA and the best concentration of the drug.  We set up 40 healthy group in our experiments as a control, and explore them on the same drug every time.  We test the two groups at the same time.  We handled the results use t-test.  RESULTS:  The methods 3H-TdR could be exactly reflect the PBMC's proliferation degree nearly the same when they were be stimulation by PHA or the sensitive drug.  When the DILI patients were explore to the suspicious drug, their stimulation index (SI) Obviously higher than 1.8.  Form this test, there were 28 in 59 patients of DILI's group were positive (47.46%), SI was from 1.9 to 43.08, the average was 22.49, the healthy group SI was lower than 1.8, the SI of DILI's group was significantly higher than healthy group (5.78+/-0.75/1.16+/-0.25, P less than 0.05).  Our test suggested DLST has Higher specificity (94.92%) and sensitivity (47.46%).  CONCLUSION:  DLST was significance for the patients who diagnosed as immunity idiosyncrasy's DILI, it's reflected these patients' Proliferation of PBMC when explored to the suspicious drug for the second time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRx1x9qp9bAtjjk2McQZ6XmfW6udTcc2eZ_RdGz5N9iUbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38nlsFWltA%253D%253D&md5=8cd79be34300ee0a1c09655ace8e5c66</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.3760%2Fcma.j.issn.1007-3418.2012.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3760%252Fcma.j.issn.1007-3418.2012.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%2BY.%26aulast%3DChen%26aufirst%3DC.%2BW.%26aulast%3DFu%26aufirst%3DQ.%2BC.%26aulast%3DWang%26aufirst%3DX.%2BJ.%26aulast%3DNi%26aufirst%3DL.%2BD.%26aulast%3DJiang%26aufirst%3DX.%2BH.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DL.%2BQ.%26aulast%3DLai%26aufirst%3DR.%2BT.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DSet%2520Up%2520Drug%2520Lymphocyte%2520Simtulation%2520Test%2520%25283H-TdR%2529%2520and%2520Observe%2520its%2520Application%2520in%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DChinese%2520Journal%2520of%2520Hepatology%26date%3D2012%26volume%3D20%26spage%3D190%26epage%3D192%26doi%3D10.3760%2Fcma.j.issn.1007-3418.2012.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monshi, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulkner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earnshaw, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfirevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cederbrant, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Human Leukocyte Antigen (HLA)-B*57:01-Restricted Activation of Drug-Specific T-cells Provides the Immunological Basis for Flucloxacillin-Induced Liver Injury</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1002/hep.26077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.26077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22987284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Wgsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=727-739&author=M.+M.+Monshiauthor=L.+Faulknerauthor=A.+Gibsonauthor=R.+E.+Jenkinsauthor=J.+Farrellauthor=C.+J.+Earnshawauthor=A.+Alfirevicauthor=K.+Cederbrantauthor=A.+K.+Dalyauthor=N.+Frenchauthor=M.+Pirmohamedauthor=B.+K.+Parkauthor=D.+J.+Naisbitt&title=Human+Leukocyte+Antigen+%28HLA%29-B*57%3A01-Restricted+Activation+of+Drug-Specific+T-cells+Provides+the+Immunological+Basis+for+Flucloxacillin-Induced+Liver+Injury&doi=10.1002%2Fhep.26077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury</span></div><div class="casAuthors">Monshi, Manal M.; Faulkner, Lee; Gibson, Andrew; Jenkins, Rosalind E.; Farrell, John; Earnshaw, Caroline J.; Alfirevic, Ana; Cederbrant, Karin; Daly, Ann K.; French, Neil; Pirmohamed, Munir; Park, B. Kevin; Naisbitt, Dean J.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">727-739</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The role of the adaptive immune system in adverse drug reactions that target the liver has not been defined.  For flucloxacillin, a delay in the reaction onset and identification of human leukocyte antigen (HLA)-B*57:01 as a susceptibility factor are indicative of an immune pathogenesis.  Thus, we characterize flucloxacillin-responsive CD4+ and CD8+ T cells from patients with liver injury and show that naive CD45RA+CD8+ T cells from volunteers expressing HLA-B*57:01 are activated with flucloxacillin when dendritic cells present the drug antigen.  T-cell clones expressing CCR4 and CCR9 migrated toward CCL17 and CCL 25, and secreted interferon-gamma (IFN-γ), T helper (Th)2 cytokines, perforin, granzyme B, and FasL following drug stimulation.  Flucloxacillin bound covalently to selective lysine residues on albumin in a time-dependent manner and the level of binding correlated directly with the stimulation of clones.  Activation of CD8+ clones with flucloxacillin was processing-dependent and restricted by HLA-B*57:01 and the closely related HLA-B*58:01.  Clones displayed addnl. reactivity against β-lactam antibiotics including oxacillin, cloxacillin, and dicloxacillin, but not abacavir or nitroso sulfamethoxazole.  Conclusion: This work defines the immune basis for flucloxacillin-induced liver injury and links the genetic assocn. to the iatrogenic disease. (HEPATOl. 2013;).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3-F3d0GIwbrVg90H21EOLACvtfcHk0limTR1PehhpjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Wgsrw%253D&md5=6f96155f39ac26549bd2b6c64a9bad6d</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fhep.26077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26077%26sid%3Dliteratum%253Aachs%26aulast%3DMonshi%26aufirst%3DM.%2BM.%26aulast%3DFaulkner%26aufirst%3DL.%26aulast%3DGibson%26aufirst%3DA.%26aulast%3DJenkins%26aufirst%3DR.%2BE.%26aulast%3DFarrell%26aufirst%3DJ.%26aulast%3DEarnshaw%26aufirst%3DC.%2BJ.%26aulast%3DAlfirevic%26aufirst%3DA.%26aulast%3DCederbrant%26aufirst%3DK.%26aulast%3DDaly%26aufirst%3DA.%2BK.%26aulast%3DFrench%26aufirst%3DN.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DHuman%2520Leukocyte%2520Antigen%2520%2528HLA%2529-B%252A57%253A01-Restricted%2520Activation%2520of%2520Drug-Specific%2520T-cells%2520Provides%2520the%2520Immunological%2520Basis%2520for%2520Flucloxacillin-Induced%2520Liver%2520Injury%26jtitle%3DHepatology%26date%3D2013%26volume%3D57%26spage%3D727%26epage%3D739%26doi%3D10.1002%2Fhep.26077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Usui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitaker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoine, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Detection of Drug-Responsive T-Lymphocytes in a Case of Fatal Antituberculosis Drug-Related Liver Injury</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1795</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.6b00393</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.6b00393" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslyms7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=1793-1795&author=T.+Usuiauthor=P.+Whitakerauthor=X.+Mengauthor=J.+Watsonauthor=D.+J.+Antoineauthor=N.+S.+Frenchauthor=B.+K.+Parkauthor=D.+J.+Naisbitt&title=Detection+of+Drug-Responsive+T-Lymphocytes+in+a+Case+of+Fatal+Antituberculosis+Drug-Related+Liver+Injury&doi=10.1021%2Facs.chemrestox.6b00393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of Drug-Responsive T-Lymphocytes in a Case of Fatal Antituberculosis Drug-Related Liver Injury</span></div><div class="casAuthors">Usui, Toru; Whitaker, Paul; Meng, Xiaoli; Watson, John; Antoine, Daniel J.; French, Neil S.; Park, B. Kevin; Naisbitt, Dean J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1793-1795</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antituberculosis (TB) drug exposure is assocd. with a mild elevation of liver enzymes that occasionally develops into severe liver injury.  Herein, we identify ethambutol- and rifampicin-specific CD4+ and CD8+ T-cell clones in a patient with fatal anti TB-related liver injury.  The clones were activated to proliferate and secrete IFN-γ, Il-13, and granzyme B following drug treatment.  Drug-responsive T-cells may contribute to the pathogenesis of antituberculosis-related liver failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMUCjx14Dns7Vg90H21EOLACvtfcHk0li1iJoZFVAVPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslyms7fI&md5=8fca79d3da776eea74b89da16ce24be0</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.6b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.6b00393%26sid%3Dliteratum%253Aachs%26aulast%3DUsui%26aufirst%3DT.%26aulast%3DWhitaker%26aufirst%3DP.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DWatson%26aufirst%3DJ.%26aulast%3DAntoine%26aufirst%3DD.%2BJ.%26aulast%3DFrench%26aufirst%3DN.%2BS.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DDetection%2520of%2520Drug-Responsive%2520T-Lymphocytes%2520in%2520a%2520Case%2520of%2520Fatal%2520Antituberculosis%2520Drug-Related%2520Liver%2520Injury%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26spage%3D1793%26epage%3D1795%26doi%3D10.1021%2Facs.chemrestox.6b00393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span> <span> </span><span class="NLM_article-title">Pharmacogenomics of Adverse Drug Reactions</span>. <i>Genome Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">5</span>, <span class="refDoi"> DOI: 10.1186/gm409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1186%2Fgm409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23360680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1yktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=5&author=A.+K.+Daly&title=Pharmacogenomics+of+Adverse+Drug+Reactions&doi=10.1186%2Fgm409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacogenomics of adverse drug reactions</span></div><div class="casAuthors">Daly, Ann K.</div><div class="citationInfo"><span class="NLM_cas:title">Genome Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5</span>CODEN:
                <span class="NLM_cas:coden">GMEECG</span>;
        ISSN:<span class="NLM_cas:issn">1756-994X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Considerable progress has been made in identifying genetic risk factors for idiosyncratic adverse drug reactions in the past 30 years.  These reactions can affect various tissues and organs, including liver, skin, muscle and heart, in a drug-dependent manner.  Using both candidate gene and genome-wide assocn. studies, various genes that make contributions of varying extents to each of these forms of reactions have been identified.  Many of the assocns. identified for reactions affecting the liver and skin involve human leukocyte antigen (HLA) genes and for reactions relating to the drugs abacavir and carbamazepine, HLA genotyping is now in routine use prior to drug prescription.  Other HLA assocns. are not sufficiently specific for translation but are still of interest in relation to underlying mechanisms for the reactions.  Progress on non-HLA genes affecting adverse drug reactions has been less, but some important assocns., such as those of SLCO1B1 and statin myopathy, KCNE1 and drug-induced QT prolongation and NAT2 and isoniazid-induced liver injury, are considered.  Future prospects for identification of addnl. genetic risk factors for the various adverse drug reactions are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXuYo7jkxMqbVg90H21EOLACvtfcHk0li1iJoZFVAVPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1yktL4%253D&md5=aa5107124ec6df9f6897148249dda11f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1186%2Fgm409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgm409%26sid%3Dliteratum%253Aachs%26aulast%3DDaly%26aufirst%3DA.%2BK.%26atitle%3DPharmacogenomics%2520of%2520Adverse%2520Drug%2520Reactions%26jtitle%3DGenome%2520Med.%26date%3D2013%26volume%3D5%26spage%3D5%26doi%3D10.1186%2Fgm409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicoletti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulthard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alshabeeb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grove, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucena, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitland-van
der Zee, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molokhia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadelius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">245</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1002/cpt.1375</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fcpt.1375" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30661239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlegsrzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2019&pages=245-253&author=P.+Nicolettiauthor=G.+P.+Aithalauthor=T.+C.+Chamberlainauthor=S.+Coulthardauthor=M.+Alshabeebauthor=J.+I.+Groveauthor=R.+J.+Andradeauthor=E.+Bjornssonauthor=J.+F.+Dillonauthor=P.+Hallbergauthor=M.+I.+Lucenaauthor=A.+H.+Maitland-van%0Ader+Zeeauthor=J.+H.+Martinauthor=M.+Molokhiaauthor=M.+Pirmohamedauthor=M.+Wadeliusauthor=Y.+Shenauthor=M.+R.+Nelsonauthor=A.+K.+Daly&title=Drug-Induced+Liver+Injury+due+to+Flucloxacillin%3A+Relevance+of+Multiple+Human+Leukocyte+Antigen+Alleles&doi=10.1002%2Fcpt.1375"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles</span></div><div class="casAuthors">Nicoletti, Paola; Aithal, Guruprasad P.; Chamberlain, Thomas C.; Coulthard, Sally; Alshabeeb, Mohammad; Grove, Jane I.; Andrade, Raul J.; Bjornsson, Einar; Dillon, John F.; Hallberg, Par; Lucena, M. Isabel; Maitland-van der Zee, Anke H.; Martin, Jennifer H.; Molokhia, Mariam; Pirmohamed, Munir; Wadelius, Mia; Shen, Yufeng; Nelson, Matthew R.; Daly, Ann K.; the International Drug-Induced Liver Injury Consortium</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">245-253</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Some patients prescribed flucloxacillin (∼ 0.01%) develop drug-induced liver injury (DILI).  HLA-B*57:01 is an established genetic risk factor for flucloxacillin DILI.  To consolidate this finding, identify addnl. genetic factors, and assess relevance of risk factors for flucloxacillin DILI in relation to DILI due to other penicillins, we performed a genomewide assocn. study involving 197 flucloxacillin DILI cases and 6,835 controls.  We imputed single-nucleotide polymorphism and human leukocyte antigen (HLA) genotypes.  HLA-B*57:01 was the major risk factor (allelic odds ratio (OR) = 36.62; P = 2.67 × 10-97).  HLA-B*57:03 also showed an assocn. (OR = 79.21; P = 1.2 × 10-6).  Within the HLA-B protein sequence, imputation showed valine97, common to HLA-B*57:01 and HLA-B*57:03, had the largest effect (OR = 38.1; P = 9.7 × 10-97).  We found no HLA-B*57 assocn. with DILI due to other isoxazolyl penicillins (n = 6) or amoxicillin (n = 15) and no significant non-HLA signals for any penicillin-related DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoACu10fRdvrbVg90H21EOLACvtfcHk0li1iJoZFVAVPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlegsrzI&md5=5d4d4432d7fbe3803a97367fa9b26ac2</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fcpt.1375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.1375%26sid%3Dliteratum%253Aachs%26aulast%3DNicoletti%26aufirst%3DP.%26aulast%3DAithal%26aufirst%3DG.%2BP.%26aulast%3DChamberlain%26aufirst%3DT.%2BC.%26aulast%3DCoulthard%26aufirst%3DS.%26aulast%3DAlshabeeb%26aufirst%3DM.%26aulast%3DGrove%26aufirst%3DJ.%2BI.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3DBjornsson%26aufirst%3DE.%26aulast%3DDillon%26aufirst%3DJ.%2BF.%26aulast%3DHallberg%26aufirst%3DP.%26aulast%3DLucena%26aufirst%3DM.%2BI.%26aulast%3DMaitland-van%2Bder%2BZee%26aufirst%3DA.%2BH.%26aulast%3DMartin%26aufirst%3DJ.%2BH.%26aulast%3DMolokhia%26aufirst%3DM.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DWadelius%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DNelson%26aufirst%3DM.%2BR.%26aulast%3DDaly%26aufirst%3DA.%2BK.%26atitle%3DDrug-Induced%2520Liver%2520Injury%2520due%2520to%2520Flucloxacillin%253A%2520Relevance%2520of%2520Multiple%2520Human%2520Leukocyte%2520Antigen%2520Alleles%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2019%26volume%3D106%26spage%3D245%26epage%3D253%26doi%3D10.1002%2Fcpt.1375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saide, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulkner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tailor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Characterization of Amoxicillin- and Clavulanic Acid-Specific T-cells in Patients with Amoxicillin-Clavulanate–Induced Liver Injury</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">887</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1002/hep.27912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.27912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25998949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVSnt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=887-899&author=S.-H.+Kimauthor=K.+Saideauthor=J.+Farrellauthor=L.+Faulknerauthor=A.+Tailorauthor=M.+Ogeseauthor=A.+K.+Dalyauthor=M.+Pirmohamedauthor=B.+K.+Parkauthor=D.+J.+Naisbitt&title=Characterization+of+Amoxicillin-+and+Clavulanic+Acid-Specific+T-cells+in+Patients+with+Amoxicillin-Clavulanate%E2%80%93Induced+Liver+Injury&doi=10.1002%2Fhep.27912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury</span></div><div class="casAuthors">Kim, Seung-Hyun; Saide, Katy; Farrell, John; Faulkner, Lee; Tailor, Arun; Ogese, Monday; Daly, Ann K.; Pirmohamed, Munir; Park, B. Kevin; Naisbitt, Dean J.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">887-899</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) frequently has a delayed onset with several human leukocyte antigen (HLA) genotypes affecting susceptibility, indicating a potential role for the adaptive immune system in the disease.  The aim of this study was to investigate whether drug-responsive T lymphocytes are detectable in patients who developed DILI with the combination, antimicrobial amoxicillin-clavulanate.  Lymphocytes from 6 of 7 patients were found to proliferate and/or secrete interferon-gamma (IFN-γ) when cultured with amoxicillin and/or clavulanic acid.  Amoxicillin (n = 105) and clavulanic acid (n = 16) responsive CD4+ and CD8+ T-cell clones expressing CCR, chemokine (C-C motif) receptor 4, CCR9, and chemokine (C-X-C motif) receptor 3 were generated from patients with and without HLA risk alleles; no cross-reactivity was obsd. between the two drug antigens.  Amoxicillin clones were found to secrete a heterogeneous panel of mediators, including IFN-γ, interleukin-22 and cytolytic mols.  In contrast, cytokine secretion by the clavulanic acid clones was more restricted.  CD4+ and CD8+ clones were major histocompatibility complex class II and I restricted, resp., with the drug antigen being presented to CD4+ clones in the context of HLA-DR mols.  Several pieces of evidence indicate that the clones were activated by a hapten mechanism: First, professional antigen-presenting cells (APCs) were required for optimal activation; second, pulsing APCs for 4-16 h activated the clones; and third, inhibition of processing abrogated the proliferative response and cytokine release.  Conclusion: Both amoxicillin- and clavulanic acid-specific T cells participate in the liver injury that develops in certain patients exposed to amoxicillin-clavulanate. (Hepatol. 2015;62:887-899).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrFlLkmOMif7Vg90H21EOLACvtfcHk0lg6FWl1g5f6qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVSnt73O&md5=caa23f4135999e0a1b5d30109161a4bd</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fhep.27912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27912%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DSaide%26aufirst%3DK.%26aulast%3DFarrell%26aufirst%3DJ.%26aulast%3DFaulkner%26aufirst%3DL.%26aulast%3DTailor%26aufirst%3DA.%26aulast%3DOgese%26aufirst%3DM.%26aulast%3DDaly%26aufirst%3DA.%2BK.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DCharacterization%2520of%2520Amoxicillin-%2520and%2520Clavulanic%2520Acid-Specific%2520T-cells%2520in%2520Patients%2520with%2520Amoxicillin-Clavulanate%25E2%2580%2593Induced%2520Liver%2520Injury%26jtitle%3DHepatology%26date%3D2015%26volume%3D62%26spage%3D887%26epage%3D899%26doi%3D10.1002%2Fhep.27912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nattrass, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulkner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocanson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoine, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Activation of Flucloxacillin-Specific CD8+ T-Cells With the Potential to Promote Hepatocyte Cytotoxicity in a Mouse Model</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfv077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfv077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25877613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFSrur3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2015&pages=146-156&author=R.+Nattrassauthor=L.+Faulknerauthor=M.+Vocansonauthor=D.+J.+Antoineauthor=A.+Kiparauthor=G.+Kennaauthor=J.-F.+Nicolasauthor=B.+K.+Parkauthor=D.+J.+Naisbitt&title=Activation+of+Flucloxacillin-Specific+CD8%2B+T-Cells+With+the+Potential+to+Promote+Hepatocyte+Cytotoxicity+in+a+Mouse+Model&doi=10.1093%2Ftoxsci%2Fkfv077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of flucloxacillin-specific CD8+ T-cells with the potential to promote hepatocyte cytotoxicity in a mouse model</span></div><div class="casAuthors">Nattrass, Ryan; Faulkner, Lee; Vocanson, Marc; Antoine, Daniel J.; Kipar, Anja; Kenna, Gerry; Nicolas, Jean-Francois; Park, B. Kevin; Naisbitt, Dean J.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">146-156</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">There are currently no animal models of drug-induced liver injury (DILI) where the adaptive immune system has been shown to damage the liver.  Thus, it is difficult to explore the mechanistic basis of the tissue injury.  The aim of this study was to use C57BL/6 CD4+-deficient mice with a mutation in the αβ gene encoding for Major histocompatibilty complex (MHC) class II mols. to (1) develop a mouse model of flucloxacillin sensitization, (2) explore whether drug-specific CD8+ kill primary hepatocytes, and (3) analyze perturbations in liver integrity following oral exposure to flucloxacillin.  CD8+ T-cells from lymph nodes of flucloxacillin-sensitized mice were stimulated to proliferate, secrete interferon (IFN-γ) and granzyme B, and induce hepatocyte apoptosis in a concn.-dependent manner following ex vivo stimulation.  The T-cell response was antigen-specific; T-cells were not activated with other β-lactam antibiotics.  Furthermore, T-cell responses only occurred in the presence of flucloxacillin-pulsed antigen presenting cells.  In sep. expts., flucloxacillin-specific T-cells were induced to migrate to the mesenteric lymph nodes using retinoic acid, prior to administration of oral flucloxacillin, and anal. of plasma biomarkers of liver injury.  Oral exposure to flucloxacillin resulted in mild elevations in alanine aminotransferase, liver, and gall bladder leukocyte infiltration and a marked swelling of the gall bladder.  Thus, CD4+-deficient mice represent a promising model to study the role of the adaptive immune system in DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQyA9aFnqx6LVg90H21EOLACvtfcHk0lg6FWl1g5f6qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFSrur3I&md5=7b249008d0ab4db014dfa5dcbdc67b61</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfv077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfv077%26sid%3Dliteratum%253Aachs%26aulast%3DNattrass%26aufirst%3DR.%26aulast%3DFaulkner%26aufirst%3DL.%26aulast%3DVocanson%26aufirst%3DM.%26aulast%3DAntoine%26aufirst%3DD.%2BJ.%26aulast%3DKipar%26aufirst%3DA.%26aulast%3DKenna%26aufirst%3DG.%26aulast%3DNicolas%26aufirst%3DJ.-F.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DActivation%2520of%2520Flucloxacillin-Specific%2520CD8%252B%2520T-Cells%2520With%2520the%2520Potential%2520to%2520Promote%2520Hepatocyte%2520Cytotoxicity%2520in%2520a%2520Mouse%2520Model%26jtitle%3DToxicol.%2520Sci.%26date%3D2015%26volume%3D146%26spage%3D146%26epage%3D156%26doi%3D10.1093%2Ftoxsci%2Fkfv077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urban, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G. P.</span></span> <span> </span><span class="NLM_article-title">Genetic Basis of Drug-Induced Liver Injury: Present and Future</span>. <i>Semin. Liver Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1055/s-0034-1375954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1055%2Fs-0034-1375954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24879978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFKktLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=123-133&author=T.+J.+Urbanauthor=A.+K.+Dalyauthor=G.+P.+Aithal&title=Genetic+Basis+of+Drug-Induced+Liver+Injury%3A+Present+and+Future&doi=10.1055%2Fs-0034-1375954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic basis of drug-induced liver injury: present and future</span></div><div class="casAuthors">Urban, Thomas J.; Daly, Ann K.; Aithal, Guruprasad P.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Liver Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-133</span>CODEN:
                <span class="NLM_cas:coden">SLDIEE</span>;
        ISSN:<span class="NLM_cas:issn">0272-8087</span>.
    
            (<span class="NLM_cas:orgname">Thieme Medical Publishers, Inc.</span>)
        </div><div class="casAbstract">A review.  There is considerable evidence that susceptibility to idiosyncratic drug-induced liver injury (DILI) is genetically detd.  Though genetic assocns. with DILI have been reported since the 1980s, the development of genome-wide assocn. studies has enabled genetic risk factors for DILI, in common with other diseases, to be detected and confirmed more confidently.  Human leukocyte antigen (HLA) genotype has been demonstrated to be a strong risk factor for development of DILI with a range of drugs and the underlying mechanism, probably involving presentation of a drug-peptide complex to T cells is increasingly well understood.  However, specific HLA alleles are not assocd. with all forms of DILI and non-HLA genetic risk factors, esp. those relating to drug disposition, also appear to contribute.  For some drugs, there is evidence of a dual role for HLA and drug metab. genes.  Though the assocns. with non-HLA genes have been less well replicated than the HLA assocns., there is increasing evidence that drug metab. genes such as NAT2 and UGT2B7 contribute to some forms of DILI.  Translating current genetic findings on DILI susceptibility to the clinic has been relatively slow, but some progress is now being made.  In the future, DNA sequencing may lead to the identification of rare variants that contribute to DILI.  Developments in the related area of epigenomics and in the development of improved models for DILI by use of genetically defined induced pluripotent stem cells should improve understanding of the biol. of DILI and inform drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyBRvYDxpDarVg90H21EOLACvtfcHk0lg6FWl1g5f6qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFKktLbM&md5=cbd2144470fc55bed98056f11ac4ccfd</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1055%2Fs-0034-1375954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0034-1375954%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DT.%2BJ.%26aulast%3DDaly%26aufirst%3DA.%2BK.%26aulast%3DAithal%26aufirst%3DG.%2BP.%26atitle%3DGenetic%2520Basis%2520of%2520Drug-Induced%2520Liver%2520Injury%253A%2520Present%2520and%2520Future%26jtitle%3DSemin.%2520Liver%2520Dis.%26date%3D2014%26volume%3D34%26spage%3D123%26epage%3D133%26doi%3D10.1055%2Fs-0034-1375954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogese, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adair, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tailor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulkner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enyindah, B. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz-Nieto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ressel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eagle, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitteringham, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betts, C.</span></span> <span> </span><span class="NLM_article-title">Exosomal Transport of Hepatocyte-Derived Drug-Modified Proteins to the Immune System</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1732</span>– <span class="NLM_lpage">1749</span>, <span class="refDoi"> DOI: 10.1002/hep.30701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.30701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=31070244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVCltLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2019&pages=1732-1749&author=M.+O.+Ogeseauthor=R.+E.+Jenkinsauthor=K.+Adairauthor=A.+Tailorauthor=X.+Mengauthor=L.+Faulknerauthor=B.+O.+Enyindahauthor=A.+Schofieldauthor=R.+Diaz-Nietoauthor=L.+Resselauthor=G.+L.+Eagleauthor=N.+R.+Kitteringhamauthor=C.+E.+Goldringauthor=B.+K.+Parkauthor=D.+J.+Naisbittauthor=C.+Betts&title=Exosomal+Transport+of+Hepatocyte-Derived+Drug-Modified+Proteins+to+the+Immune+System&doi=10.1002%2Fhep.30701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Exosomal Transport of Hepatocyte-Derived Drug-Modified Proteins to the Immune System</span></div><div class="casAuthors">Ogese, Monday O.; Jenkins, Rosalind E.; Adair, Kareena; Tailor, Arun; Meng, Xiaoli; Faulkner, Lee; Enyindah, Bright O.; Schofield, Amy; Diaz-Nieto, Rafael; Ressel, Lorenzo; Eagle, Gina L.; Kitteringham, Neil R.; Goldring, Chris E.; Park, B. Kevin; Naisbitt, Dean J.; Betts, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1732-1749</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Idiosyncratic drug-induced liver injury (DILI) is a rare, often difficult-to-predict adverse reaction with complex pathomechanisms.  However, it is now evident that certain forms of DILI are immune-mediated and may involve the activation of drug-specific T cells.  Exosomes are cell-derived vesicles that carry RNA, lipids, and protein cargo from their cell of origin to distant cells, and they may play a role in immune activation.  Herein, primary human hepatocytes were treated with drugs assocd. with a high incidence of DILI (flucloxacillin, amoxicillin, isoniazid, and nitroso-sulfamethoxazole) to characterize the proteins packaged within exosomes that are subsequently transported to dendritic cells for processing.  Exosomes measured between 50 and 100 nm and expressed enriched CD63.  Liq. chromatog.-tandem mass spectrometry (LC/MS-MS) identified 2,109 proteins, with 608 proteins being quantified across all exosome samples.  Data are available through ProteomeXchange with identifier PXD010760.  Anal. of gene ontologies revealed that exosomes mirrored whole human liver tissue in terms of the families of proteins present, regardless of drug treatment.  However, exosomes from nitroso-sulfamethoxazole-treated hepatocytes selectively packaged a specific subset of proteins.  LC/MS-MS also revealed the presence of hepatocyte-derived exosomal proteins covalently modified with amoxicillin, flucloxacillin, and nitroso-sulfamethoxazole.  Uptake of exosomes by monocyte-derived dendritic cells occurred silently, mainly through phagocytosis, and was inhibited by latrunculin A. An amoxicillin-modified 9-mer peptide derived from the exosomal transcription factor protein SRY (sex detg. region Y)-box 30 activated naive T cells from human leukocyte antigen A*02:01-pos. human donors.  Conclusion: This study shows that exosomes have the potential to transmit drug-specific hepatocyte-derived signals to the immune system and provide a pathway for the induction of drug hapten-specific T-cell responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodQeCN-3P47LVg90H21EOLACvtfcHk0lhwtRK1F6h2Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVCltLjN&md5=0952f8d99dbc0499d352db5cb9d8d5c3</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fhep.30701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.30701%26sid%3Dliteratum%253Aachs%26aulast%3DOgese%26aufirst%3DM.%2BO.%26aulast%3DJenkins%26aufirst%3DR.%2BE.%26aulast%3DAdair%26aufirst%3DK.%26aulast%3DTailor%26aufirst%3DA.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DFaulkner%26aufirst%3DL.%26aulast%3DEnyindah%26aufirst%3DB.%2BO.%26aulast%3DSchofield%26aufirst%3DA.%26aulast%3DDiaz-Nieto%26aufirst%3DR.%26aulast%3DRessel%26aufirst%3DL.%26aulast%3DEagle%26aufirst%3DG.%2BL.%26aulast%3DKitteringham%26aufirst%3DN.%2BR.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DBetts%26aufirst%3DC.%26atitle%3DExosomal%2520Transport%2520of%2520Hepatocyte-Derived%2520Drug-Modified%2520Proteins%2520to%2520the%2520Immune%2520System%26jtitle%3DHepatology%26date%3D2019%26volume%3D70%26spage%3D1732%26epage%3D1749%26doi%3D10.1002%2Fhep.30701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holman, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCluyse, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Subtoxic Alterations in Hepatocyte-Derived Exosomes: An Early Step in Drug-Induced Liver Injury?</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">375</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfw047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfw047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26962055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGntb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2016&pages=365-375&author=N.+S.+Holmanauthor=M.+Mosedaleauthor=K.+K.+Wolfauthor=E.+L.+LeCluyseauthor=P.+B.+Watkins&title=Subtoxic+Alterations+in+Hepatocyte-Derived+Exosomes%3A+An+Early+Step+in+Drug-Induced+Liver+Injury%3F&doi=10.1093%2Ftoxsci%2Fkfw047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Subtoxic alterations in hepatocyte-derived exosomes: an early step in drug-induced liver injury?</span></div><div class="casAuthors">Holman, Natalie S.; Mosedale, Merrie; Wolf, Kristina K.; LeCluyse, Edward L.; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">365-375</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a significant clin. and economic problem in the United States, yet the mechanisms that underlie DILI remain poorly understood.  Resent evidence suggests that signaling mols. released by stressed hepatocytes can trigger immune responses that may be common across DILI mechanisms.  Extracellular vesicles released by hepatocytes, principally hepatocyte-derived exosomes (HDEs), may constitute one such signal.  To examine HDE alterations as a function of drug-induced stress, this work utilized prototypical hepatotoxicant acetaminophen (APAP) in male Sprague-Dawley (SD) rats, SD rat hepatocytes, and primary human hepatocytes.  HDE were isolated using ExoQuick pptn. reagent and analyzed by quantification of the liver-specific RNAs albumin and microRNA-122 (miR-122).  In vivo, significant elevations in circulating exosomal albumin mRNA were obsd. at subtoxic APAP exposures.  Significant increases in exosomal albumin mRNA were also obsd. in primary rat hepatocytes at subtoxic APAP concns.  In primary human hepatocytes, APAP elicited increases in both exosomal albumin mRNA and exosomal miR-122 without overt cytotoxicity.  However, the no. of HDE produced in vitro in response to APAP did not increase with exosomal RNA quantity.  The authors conclude that significant drug-induced alterations in the liver-specific RNA content of HDE occur at subtoxic APAP exposures in vivo and in vitro, and that these changes appear to reflect selective packaging rather than changes in exosome no.  The current findings demonstrate that translationally relevant HDE alterations occur in the absence of overt hepatocellular toxicity, and support the hypothesis that HDE released by stressed hepatocytes may mediate early immune responses in DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroiwY93SPy6rVg90H21EOLACvtfcHk0li6RsIsNpehsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGntb7J&md5=ac3ce5a27e6d283d768d49cc9d9ee01b</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfw047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfw047%26sid%3Dliteratum%253Aachs%26aulast%3DHolman%26aufirst%3DN.%2BS.%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DWolf%26aufirst%3DK.%2BK.%26aulast%3DLeCluyse%26aufirst%3DE.%2BL.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DSubtoxic%2520Alterations%2520in%2520Hepatocyte-Derived%2520Exosomes%253A%2520An%2520Early%2520Step%2520in%2520Drug-Induced%2520Liver%2520Injury%253F%26jtitle%3DToxicol.%2520Sci.%26date%3D2016%26volume%3D151%26spage%3D365%26epage%3D375%26doi%3D10.1093%2Ftoxsci%2Fkfw047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaddy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trask, J. O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holman, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCluyse, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khetani, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brock, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">miR-122 Release in Exosomes Precedes Overt Tolvaptan-Induced Necrosis in a Primary Human Hepatocyte Micropatterned Coculture Model</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfx206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfx206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29029277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFelsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2018&pages=149-158&author=M.+Mosedaleauthor=J.+S.+Eaddyauthor=J.+O.+J.+Traskauthor=N.+S.+Holmanauthor=K.+K.+Wolfauthor=E.+LeCluyseauthor=B.+R.+Wareauthor=S.+R.+Khetaniauthor=J.+Luauthor=W.+J.+Brockauthor=S.+E.+Rothauthor=P.+B.+Watkins&title=miR-122+Release+in+Exosomes+Precedes+Overt+Tolvaptan-Induced+Necrosis+in+a+Primary+Human+Hepatocyte+Micropatterned+Coculture+Model&doi=10.1093%2Ftoxsci%2Fkfx206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">miR-122 release in exosomes precedes overt tolvaptan-induced necrosis in a primary human hepatocyte micropatterned coculture model</span></div><div class="casAuthors">Mosedale, Merrie; Eaddy, J. Scott; Trask, O. Joseph Jr.; Holman, Natalie S.; Wolf, Kristina K.; LeCluyse, Edward; Ware, Brenton R.; Khetani, Salman R.; Lu, Jingtao; Brock, William J.; Roth, Sharin E.; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">149-158</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Idiosyncratic drug-induced liver injury (IDILI) is thought to often result froman adaptive immune attack on the liver.  However, it has been proposed that the cascade of events culminating in an adaptive immune response begins with drug-induced hepatocyte stress, release of exosomal danger signals, and innate immune activation, all of which may occur in the absence of significant hepatocelluar death.  A micropatterned coculture model (HepatoPac) was used to explore the possibility that changes in exosome content precede overt necrosis in response to the IDILI drug tolvaptan.  Hepatocytes from 3 human donors were exposed to a range of tolvaptan concns. bracketing plasma Cmax or DMSO control continuously for 4, 24, or 72 h.  Although alanine aminotransferase release was not significantly affected at any concn., tolvaptan exposures at approx. 30-fold median plasma Cmax resulted in increased release of exosomal microRNA-122 (miR-122) into the medium.  Cellular imaging and microarray anal. revealed that the most significant increases in exosomal miR-122 were assocd. with programmed cell death and small increases in membrane permeability.  However, early increases in exosome miR-122 were more assocd. with mitochondrial-induced apoptosis and oxidative stress.  Taken together, these data suggest that tolvaptan treatment induces cellular stress and exosome release of miR-122 in primary human hepatocytes in the absence of overt necrosis, providing direct demonstration of this with a drug capable of causing IDILI.  In susceptible individuals, these early events may occur at pharmacol. concns. of tolvaptan and may promote an adaptive immune attack that ultimately results in clin. significant liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjwmACAPa6i7Vg90H21EOLACvtfcHk0li6RsIsNpehsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFelsbvI&md5=4f440e3508b5d29ac6fc39d64d3d2eac</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfx206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfx206%26sid%3Dliteratum%253Aachs%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DEaddy%26aufirst%3DJ.%2BS.%26aulast%3DTrask%26aufirst%3DJ.%2BO.%2BJ.%26aulast%3DHolman%26aufirst%3DN.%2BS.%26aulast%3DWolf%26aufirst%3DK.%2BK.%26aulast%3DLeCluyse%26aufirst%3DE.%26aulast%3DWare%26aufirst%3DB.%2BR.%26aulast%3DKhetani%26aufirst%3DS.%2BR.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DBrock%26aufirst%3DW.%2BJ.%26aulast%3DRoth%26aufirst%3DS.%2BE.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DmiR-122%2520Release%2520in%2520Exosomes%2520Precedes%2520Overt%2520Tolvaptan-Induced%2520Necrosis%2520in%2520a%2520Primary%2520Human%2520Hepatocyte%2520Micropatterned%2520Coculture%2520Model%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D161%26spage%3D149%26epage%3D158%26doi%3D10.1093%2Ftoxsci%2Fkfx206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, S.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, E. J.</span></span> <span> </span><span class="NLM_article-title">Evolving Models of the Immunopathogenesis of T-cell-Mediated Drug Allergy: The Role of Host, Pathogens, and Drug Response</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2015.05.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jaci.2015.05.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26254049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12rsbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2015&pages=219-234&author=K.+D.+Whiteauthor=W.-H.+Chungauthor=S.-I.+Hungauthor=S.+Mallalauthor=E.+J.+Phillips&title=Evolving+Models+of+the+Immunopathogenesis+of+T-cell-Mediated+Drug+Allergy%3A+The+Role+of+Host%2C+Pathogens%2C+and+Drug+Response&doi=10.1016%2Fj.jaci.2015.05.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response</span></div><div class="casAuthors">White, Katie D.; Chung, Wen-Hung; Hung, Shuen-Iu; Mallal, Simon; Phillips, Elizabeth J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-234</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Immune-mediated (IM) adverse drug reactions (ADRs) are an underrecognized source of preventable morbidity, mortality, and cost.  Increasingly, genetic variation in the HLA loci is assocd. with risk of severe reactions, highlighting the importance of T-cell immune responses in the mechanisms of both B cell-mediated and primary T cell-mediated IM-ADRs.  In this review we summarize the role of host genetics, microbes, and drugs in IM-ADR development; expand on the existing models of IM-ADR pathogenesis to address multiple unexplained observations; discuss the implications of this work in clin. practice today; and describe future applications for preclin. drug toxicity screening, drug design, and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2lSDJLiAjDrVg90H21EOLACvtfcHk0lhHr6ZnFATFyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12rsbjN&md5=09693c0e84273d633373bd79c20849dd</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2015.05.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2015.05.050%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DK.%2BD.%26aulast%3DChung%26aufirst%3DW.-H.%26aulast%3DHung%26aufirst%3DS.-I.%26aulast%3DMallal%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DE.%2BJ.%26atitle%3DEvolving%2520Models%2520of%2520the%2520Immunopathogenesis%2520of%2520T-cell-Mediated%2520Drug%2520Allergy%253A%2520The%2520Role%2520of%2520Host%252C%2520Pathogens%252C%2520and%2520Drug%2520Response%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2015%26volume%3D136%26spage%3D219%26epage%3D234%26doi%3D10.1016%2Fj.jaci.2015.05.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castrejon, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Ghaiesh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Stimulation of Human T-cells with Sulfonamides and Sulfonamide Metabolites</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2009.10.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jaci.2009.10.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=20159253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitVKhsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2010&pages=411-418&author=J.+L.+Castrejonauthor=N.+Berryauthor=S.+El-Ghaieshauthor=B.+Gerberauthor=W.+J.+Pichlerauthor=B.+K.+Parkauthor=D.+J.+Naisbitt&title=Stimulation+of+Human+T-cells+with+Sulfonamides+and+Sulfonamide+Metabolites&doi=10.1016%2Fj.jaci.2009.10.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of human T cells with sulfonamides and sulfonamide metabolites</span></div><div class="casAuthors">Castrejon, J. Luis; Berry, Neil; El-Ghaiesh, Sabah; Gerber, Basil; Pichler, Werner J.; Park, B. Kevin; Naisbitt, Dean J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">411-418, S411/1-S411/4</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Exposure to sulfonamides is assocd. with a high incidence of hypersensitivity reactions.  Antigen-specific T cells are involved in the pathogenesis; however, the nature of the antigen interacting with specific T-cell receptors is not fully defined.  We sought to explore the frequency of sulfamethoxazole (SMX)- and SMX metabolite-specific T cells in hypersensitive patients, delineate the specificity of clones, define mechanisms of presentation, and explore addnl. reactivity with structurally related sulfonamide metabolites.  SMX- and SMX metabolite-specific T-cell clones were generated from 3 patients.  Antigen specificity, mechanisms of antigen presentation, and cross-reactivity of specific clones were then explored.  Low-lying energy conformations of drugs (metabolites) were modeled, and the energies available for protein binding was estd.  Lymphocytes proliferated with parent drugs (SMX, sulfadiazine, and sulfapyridine) and both hydroxylamine and nitroso metabolites.  Three patterns of drug (metabolite) stimulation were seen: 44% were SMX metabolite specific, 43% were stimulated with SMX metabolites and SMX, and 14% were stimulated with SMX alone.  Most metabolite-responsive T cells were stimulated with nitroso SMX-modified protein through a hapten mechanism involving processing.  In contrast to SMX-responsive clones, which were highly specific, greater than 50% of nitroso SMX-specific clones were stimulated with nitroso metabolites of sulfapyridine and sulfadiazine but not nitrosobenzene.  Pharmacophore modeling showed that the summation of available binding energies for protein interactions and the preferred spatial arrangement of atoms in each mol. det. a drug's potential to stimulate specific T cells.  Nitroso sulfonamide metabolites form potent antigenic determinants for T cells from hypersensitive patients.  T-cell responses against drugs (metabolites) bound directly to MHC or MHC/peptide complexes can occur through cross-reactivity with the haptenic immunogen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxff8n31sG1LVg90H21EOLACvtfcHk0lhHr6ZnFATFyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitVKhsbo%253D&md5=bebcd1e7c74d6eaa47f50ca2de14acfa</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2009.10.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2009.10.031%26sid%3Dliteratum%253Aachs%26aulast%3DCastrejon%26aufirst%3DJ.%2BL.%26aulast%3DBerry%26aufirst%3DN.%26aulast%3DEl-Ghaiesh%26aufirst%3DS.%26aulast%3DGerber%26aufirst%3DB.%26aulast%3DPichler%26aufirst%3DW.%2BJ.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DStimulation%2520of%2520Human%2520T-cells%2520with%2520Sulfonamides%2520and%2520Sulfonamide%2520Metabolites%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2010%26volume%3D125%26spage%3D411%26epage%3D418%26doi%3D10.1016%2Fj.jaci.2009.10.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schnyder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhart, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnyder-Frutig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Greyerz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, W. J.</span></span> <span> </span><span class="NLM_article-title">Recognition of Sulfamethoxazole and Its Reactive Metabolites by Drug-Specific CD4+ T-cells from Allergic Individuals</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">6647</span>– <span class="NLM_lpage">6654</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.164.12.6647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.4049%2Fjimmunol.164.12.6647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10843725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktFWlu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2000&pages=6647-6654&author=B.+Schnyderauthor=C.+Burkhartauthor=K.+Schnyder-Frutigauthor=S.+von+Greyerzauthor=D.+J.+Naisbittauthor=M.+Pirmohamedauthor=B.+K.+Parkauthor=W.+J.+Pichler&title=Recognition+of+Sulfamethoxazole+and+Its+Reactive+Metabolites+by+Drug-Specific+CD4%2B+T-cells+from+Allergic+Individuals&doi=10.4049%2Fjimmunol.164.12.6647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals</span></div><div class="casAuthors">Schnyder, Benno; Burkhart, Christoph; Schnyder-Frutig, Karin; Von Greyerz, Salome; Naisbitt, Dean J.; Pirmohamed, Munir; Park, B. Kevin; Pichler, Werner J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6647-6654</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The recognition of the antibiotic sulfamethoxazole (SMX) by T cells is usually explained with the hapten-carrier model.  However, recent investigations have revealed a MHC-restricted but processing- and metab.-independent pathway of drug presentation.  This suggested a labile, low-affinity binding of SMX to MHC-peptide complexes on APC.  To study the role of covalent vs. noncovalent drug presentation in SMX allergy, we analyzed the proliferative response of PBMC and T cell clones from patients with SMX allergy to SMX and its reactive oxidative metabolites SMX-hydroxylamine and nitroso-SMX.  Although the great majority of T cell clones were specific for noncovalently bound SMX, PBMC and a small fraction of clones responded to nitroso-SMX-modified cells or were cross-reactive.  Rapid down-regulation of TCR expression in T cell clones upon stimulation indicated a processing-independent activation irresp. of specificity for covalently or noncovalently presented Ag.  In conclusion, our data show that recognition of SMX presented in covalent and noncovalent bound form is possible by the same TCR but that the former is the exception rather than the rule.  The scarcity of cross-reactivity between covalently and noncovalently bound SMX suggests that the primary stimulation may be directed to the noncovalently bound SMX.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJO6K4Vbe0PrVg90H21EOLACvtfcHk0lhHr6ZnFATFyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktFWlu7w%253D&md5=a5ab55b68f0f566dd9b0c6aa220521aa</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.164.12.6647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.164.12.6647%26sid%3Dliteratum%253Aachs%26aulast%3DSchnyder%26aufirst%3DB.%26aulast%3DBurkhart%26aufirst%3DC.%26aulast%3DSchnyder-Frutig%26aufirst%3DK.%26aulast%3Dvon%2BGreyerz%26aufirst%3DS.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DPichler%26aufirst%3DW.%2BJ.%26atitle%3DRecognition%2520of%2520Sulfamethoxazole%2520and%2520Its%2520Reactive%2520Metabolites%2520by%2520Drug-Specific%2520CD4%252B%2520T-cells%2520from%2520Allergic%2520Individuals%26jtitle%3DJ.%2520Immunol.%26date%3D2000%26volume%3D164%26spage%3D6647%26epage%3D6654%26doi%3D10.4049%2Fjimmunol.164.12.6647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, W. J.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Interaction of Drugs with Antigen-Specific Immune Receptors: The P-I Concept</span>. <i>Current Opinion in Allergy and Clinical Immunology</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1097/00130832-200208000-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1097%2F00130832-200208000-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=12130944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD38zotFKktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=301-305&author=W.+J.+Pichler&title=Pharmacological+Interaction+of+Drugs+with+Antigen-Specific+Immune+Receptors%3A+The+P-I+Concept&doi=10.1097%2F00130832-200208000-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept</span></div><div class="casAuthors">Pichler Werner J</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in allergy and clinical immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">301-5</span>
        ISSN:<span class="NLM_cas:issn">1528-4050</span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  Drug allergies are examples of immune reactions to small molecular compounds.  In many drug allergies drug specific CD4+ and CD8+ T-cells can be detected, which recognize small chemicals via their alphabeta-T-cell receptor in a major histocompatibility complex dependent way.  In this review a new concept of drug presentation to T-cells is presented.  RECENT FINDINGS:  Drugs were stimulatory for T-cells if they bound covalently to peptides or proteins, but also if the drug had structural features allowing it to bind in a labile way (noncovalently) to the major histocompatibility peptide complex.  This latter binding method has some similarities to superantigen stimulations and can explain allergies to drugs that are not metabolized.  It has been described in patients with maculopapular, bullous and neutrophilic drug eruption, as well as in contact dermatitis.  SUMMARY:  Noncovalent drug presentation leads to the stimulation of immune cells, namely T-cells.  The drug needs two surface molecules (one inert serving as a scaffold, major histocompatibility complex, and one reactive, T-cell receptor) to exert its function.  Although two receptor structures are involved, the process is reminiscent of a pharmacological interaction between a drug and its receptors and, from the phrase pharmacological interaction with immune receptors, was thus termed the p-i concept.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQPU8-88-HE48K3uFsUIZtkfW6udTcc2eYAKJam_2Slnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38zotFKktw%253D%253D&md5=6bd40e531934a8e8993dbe1e9bc14697</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1097%2F00130832-200208000-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00130832-200208000-00003%26sid%3Dliteratum%253Aachs%26aulast%3DPichler%26aufirst%3DW.%2BJ.%26atitle%3DPharmacological%2520Interaction%2520of%2520Drugs%2520with%2520Antigen-Specific%2520Immune%2520Receptors%253A%2520The%2520P-I%2520Concept%26jtitle%3DCurrent%2520Opinion%2520in%2520Allergy%2520and%2520Clinical%2520Immunology%26date%3D2002%26volume%3D2%26spage%3D301%26epage%3D305%26doi%3D10.1097%2F00130832-200208000-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, S. I.</span></span> <span> </span><span class="NLM_article-title">Direct Interaction Between HLA-B and Carbamazepine Activates T-cells in Patients with Stevens-Johnson Syndrome</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">1562</span>– <span class="NLM_lpage">1569</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2011.12.990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jaci.2011.12.990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22322005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvVSis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2012&pages=1562-1569&author=C.+Y.+Weiauthor=W.+H.+Chungauthor=H.+W.+Huangauthor=Y.+T.+Chenauthor=S.+I.+Hung&title=Direct+Interaction+Between+HLA-B+and+Carbamazepine+Activates+T-cells+in+Patients+with+Stevens-Johnson+Syndrome&doi=10.1016%2Fj.jaci.2011.12.990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome</span></div><div class="casAuthors">Wei, Chun-Yu; Chung, Wen-Hung; Huang, Hsiao-Wen; Chen, Yuan-Tsong; Hung, Shuen-Iu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1562-1569.e5</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Increasing studies have revealed that HLA alleles are the major genetic determinants of drug hypersensitivity; however, the underlying mol. mechanism remains unclear.  We adopted the HLA-B*1502 genetic predisposition to carbamazepine (CBZ)-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) as a model to study the pathol. role of HLA in delayed-type drug hypersensitivity.  We in vitro expanded CBZ-specific cytotoxic T lymphocytes (CTLs) from patients with CBZ-induced SJS/TEN and analyzed the interaction between HLA-B and CBZ analogs based on CTL response, surface plasmon resonance, peptide-binding assay, site-directed mutagenesis, and computer modeling.  The endogenous peptide-loaded HLA-B*1502 mol. presented CBZ to CTLs without the involvement of intracellular drug metab. or antigen processing.  The HLA-B*1502/peptide/β2-microglobulin protein complex showed binding affinity toward chems. sharing 5-carboxamide on the tricyclic ring, as with CBZ.  However, modifications of the ring structure of CBZ altered HLA-B*1502 binding and CTL response.  In addn. to HLA-B*1502, other HLA-B75 family members could also present CBZ to activate CTLs, whereas members of the HLA-B62 and HLA-B72 families could not.  Three residues (Asn63, Ile95, and Leu156) in the peptide-binding groove of HLA-B*1502 were involved in CBZ presentation and CTL activation.  In particular, Asn63 shared by members of the B75 family was the key residue.  Computer simulations revealed a preferred mol. conformation of the 5-carboxamide group of CBZ and the side chain of Arg62 on the B pocket of HLA-B*1502.  This study demonstrates a direct interaction of HLA with drugs, provides a detailed mol. mechanism of HLA-assocd. drug hypersensitivity, and has clin. correlations for CBZ-related drug-induced SJS/TEN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7V-QcS3xDUbVg90H21EOLACvtfcHk0lh08jpjIEMZOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvVSis7c%253D&md5=885e402115e3681b3bd8e83b94b99c3f</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2011.12.990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2011.12.990%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DC.%2BY.%26aulast%3DChung%26aufirst%3DW.%2BH.%26aulast%3DHuang%26aufirst%3DH.%2BW.%26aulast%3DChen%26aufirst%3DY.%2BT.%26aulast%3DHung%26aufirst%3DS.%2BI.%26atitle%3DDirect%2520Interaction%2520Between%2520HLA-B%2520and%2520Carbamazepine%2520Activates%2520T-cells%2520in%2520Patients%2520with%2520Stevens-Johnson%2520Syndrome%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2012%26volume%3D129%26spage%3D1562%26epage%3D1569%26doi%3D10.1016%2Fj.jaci.2011.12.990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenfels, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogese, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCluskey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfirevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span> <span> </span><span class="NLM_article-title">HLA Restriction of Carbamazepine-Specific T-Cell Clones from an HLA-A*31:01-Positive Hypersensitive Patient</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1021/tx400460w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx400460w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVCjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=175-177&author=M.+Lichtenfelsauthor=J.+Farrellauthor=M.+O.+Ogeseauthor=C.+C.+Bellauthor=S.+Eckleauthor=J.+McCluskeyauthor=B.+K.+Parkauthor=A.+Alfirevicauthor=D.+J.+Naisbittauthor=M.+Pirmohamed&title=HLA+Restriction+of+Carbamazepine-Specific+T-Cell+Clones+from+an+HLA-A*31%3A01-Positive+Hypersensitive+Patient&doi=10.1021%2Ftx400460w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">HLA Restriction of Carbamazepine-Specific T-Cell Clones from an HLA-A*31:01-Positive Hypersensitive Patient</span></div><div class="casAuthors">Lichtenfels, Maike; Farrell, John; Ogese, Monday O.; Bell, Catherine C.; Eckle, Sidonia; McCluskey, James; Park, B. Kevin; Alfirevic, Ana; Naisbitt, Dean J.; Pirmohamed, Munir</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-177</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HLA-A*31:01 is assocd. with carbamazepine (CBZ) hypersensitivity in Caucasian and Japanese populations.  Herein, we show that HLA-A*31:01+ restricted the activation of carbamazepine-specific CD8+ T-cells, which provides an immunol. basis for the genetic assocn.  Furthermore, CD4+ T-cells were activated with carbamazepine in a HLA-DRB1*04:04-restricted manner, indicating that a common HLA haplotype may contribute to the multiclonal T-cell response seen in European patients with CBZ hypersensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-DGTPJO8k9bVg90H21EOLACvtfcHk0lh08jpjIEMZOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVCjt7g%253D&md5=f2351fd4240680583e4b8603232b7321</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Ftx400460w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx400460w%26sid%3Dliteratum%253Aachs%26aulast%3DLichtenfels%26aufirst%3DM.%26aulast%3DFarrell%26aufirst%3DJ.%26aulast%3DOgese%26aufirst%3DM.%2BO.%26aulast%3DBell%26aufirst%3DC.%2BC.%26aulast%3DEckle%26aufirst%3DS.%26aulast%3DMcCluskey%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DAlfirevic%26aufirst%3DA.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DPirmohamed%26aufirst%3DM.%26atitle%3DHLA%2520Restriction%2520of%2520Carbamazepine-Specific%2520T-Cell%2520Clones%2520from%2520an%2520HLA-A%252A31%253A01-Positive%2520Hypersensitive%2520Patient%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2014%26volume%3D27%26spage%3D175%26epage%3D177%26doi%3D10.1021%2Ftx400460w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenfels, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfirevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachulski, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Activation of Carbamazepine-Responsive T-cell Clones with Metabolically Inert Halogenated Derivatives</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">495</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2013.02.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jaci.2013.02.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23672781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnslChsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2013&pages=493-495&author=J.+Farrellauthor=M.+Lichtenfelsauthor=A.+Sullivanauthor=E.+C.+Elliottauthor=A.+Alfirevicauthor=A.+V.+Stachulskiauthor=M.+Pirmohamedauthor=D.+J.+Naisbittauthor=B.+K.+Park&title=Activation+of+Carbamazepine-Responsive+T-cell+Clones+with+Metabolically+Inert+Halogenated+Derivatives&doi=10.1016%2Fj.jaci.2013.02.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of carbamazepine-responsive T-cell clones with metabolically inert halogenated derivatives</span></div><div class="casAuthors">Farrell, John; Lichtenfels, Maike; Sullivan, Andrew; Elliott, Emma C.; Alfirevic, Ana; Stachulski, Andrew V.; Pirmohamed, Munir; Naisbitt, Dean J.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">493-495</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  This article presents the activation of carbamazepine (CBZ)-responsive T-cell clones with metabolically inert halogenated derivs.  CBZ-responsive CD4+ and CD8+ T lymphocytes have been isolated from patients presenting with reactions of varying severity and characterized in terms of immunol. function and drug cross-reactivity.  They developed an alternative strategy to explore whether CBZ-responsive T cells are activated via a metab. independent pathway.  Two series of derivs. of CBZ, namely, 2-monohalo and 2,8-dihalo compds., were prepd. and their ability to activate CBZ-responsive T-cell clones was explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre3mPl_9Ev0LVg90H21EOLACvtfcHk0lh08jpjIEMZOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnslChsrg%253D&md5=2b8ee1560f83a77058a30fbcbc106d8c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2013.02.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2013.02.045%26sid%3Dliteratum%253Aachs%26aulast%3DFarrell%26aufirst%3DJ.%26aulast%3DLichtenfels%26aufirst%3DM.%26aulast%3DSullivan%26aufirst%3DA.%26aulast%3DElliott%26aufirst%3DE.%2BC.%26aulast%3DAlfirevic%26aufirst%3DA.%26aulast%3DStachulski%26aufirst%3DA.%2BV.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DActivation%2520of%2520Carbamazepine-Responsive%2520T-cell%2520Clones%2520with%2520Metabolically%2520Inert%2520Halogenated%2520Derivatives%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2013%26volume%3D132%26spage%3D493%26epage%3D495%26doi%3D10.1016%2Fj.jaci.2013.02.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warrington, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorski, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwenk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehon, A. H.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Isoniazid-Associated Hepatitis by Immunological Tests</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">104</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=668195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADyaE1c3htlGruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1978&pages=97-104&author=R.+J.+Warringtonauthor=K.+S.+Tseauthor=B.+A.+Gorskiauthor=R.+Schwenkauthor=A.+H.+Sehon&title=Evaluation+of+Isoniazid-Associated+Hepatitis+by+Immunological+Tests"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of isoniazid-associated hepatitis by immunological tests</span></div><div class="casAuthors">Warrington R J; Tse K S; Gorski B A; Schwenk R; Sehon A H</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and experimental immunology</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-104</span>
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    </div><div class="casAbstract">In a retrospective study of patients developing hepatitis or persistent serum glutamic oxaloacetic transaminase (SGOT) elevations while receiving isoniazid, it was found that the lymphocyte transformation test (LTT) was positive in nineteen cases (95%) in response to stimulation by isoniazid, isonicotinic acid and conjugates of these compounds with human serum albumin.  However, no significant amount of antibody against isoniazid was detected in the sera of these patients by a sensitive radioimmunoassay.  By contrast, no positive LTT was seen in normal controls or in patients receiving isoniazid without evidence of liver damage, while in patients with transient SGOT abnormalities, the LTT was positive only at the time of liver dysfunction.  There was no correlation between the degree of lymphocyte transformation and the severity of liver damage.  However, there were differences in the patterns of response to the four stimulatory preparations used.  Thus patients with overt hepatitis most frequently responded to isoniazid, while individuals with only SGOT abnormalities showed stimulation in the LTT more often with a conjugate of isonicotinic acid and human serum albumin.  It appears, therefore, that the presence of isoniazid-induced liver damage is associated with the presence of cellular hypersensitivity to the drug.  The differences in lymphocyte reactivity in the two groups might indicate a potential means of predicting which individuals are at increased risk of developing overt hepatitis when exhibiting evidence of minor liver dysfunction while receiving isoniazid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHo2nJZaPdlkNHe_gFldTbfW6udTcc2eZ5fck0jqfeQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE1c3htlGruw%253D%253D&md5=7f3919ec2c35d189fbb271db8bc5f371</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWarrington%26aufirst%3DR.%2BJ.%26aulast%3DTse%26aufirst%3DK.%2BS.%26aulast%3DGorski%26aufirst%3DB.%2BA.%26aulast%3DSchwenk%26aufirst%3DR.%26aulast%3DSehon%26aufirst%3DA.%2BH.%26atitle%3DEvaluation%2520of%2520Isoniazid-Associated%2520Hepatitis%2520by%2520Immunological%2520Tests%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D1978%26volume%3D32%26spage%3D97%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illing, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhaidari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Modification of the Cyclopropyl Moiety of Abacavir Provides Insight into the Structure Activity Relationship Between HLA-B*57:01 Binding and T-cell Activation</span>. <i>Allergy</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="refDoi"> DOI: 10.1111/all.14057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1111%2Fall.14057" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=P.+J.+Thomsonauthor=P.+T.+Illingauthor=J.+Farrellauthor=M.+Alhaidariauthor=C.+C.+Bellauthor=N.+Berryauthor=P.+M.+O%E2%80%99Neillauthor=A.+W.+Purcellauthor=K.+B.+Parkauthor=D.+J.+Naisbitt&title=Modification+of+the+Cyclopropyl+Moiety+of+Abacavir+Provides+Insight+into+the+Structure+Activity+Relationship+Between+HLA-B*57%3A01+Binding+and+T-cell+Activation&doi=10.1111%2Fall.14057"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1111%2Fall.14057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fall.14057%26sid%3Dliteratum%253Aachs%26aulast%3DThomson%26aufirst%3DP.%2BJ.%26aulast%3DIlling%26aufirst%3DP.%2BT.%26aulast%3DFarrell%26aufirst%3DJ.%26aulast%3DAlhaidari%26aufirst%3DM.%26aulast%3DBell%26aufirst%3DC.%2BC.%26aulast%3DBerry%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26aulast%3DPurcell%26aufirst%3DA.%2BW.%26aulast%3DPark%26aufirst%3DK.%2BB.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DModification%2520of%2520the%2520Cyclopropyl%2520Moiety%2520of%2520Abacavir%2520Provides%2520Insight%2520into%2520the%2520Structure%2520Activity%2520Relationship%2520Between%2520HLA-B%252A57%253A01%2520Binding%2520and%2520T-cell%2520Activation%26jtitle%3DAllergy%26date%3D2019%26doi%3D10.1111%2Fall.14057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Illing, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivian, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharadwaj, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjer-Nielsen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gras, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossjohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCluskey, J.</span></span> <span> </span><span class="NLM_article-title">Immune Self-Reactivity Triggered by Drug-Modified HLA-Peptide Repertoire</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>486</i></span>,  <span class="NLM_fpage">554</span>– <span class="NLM_lpage">558</span>, <span class="refDoi"> DOI: 10.1038/nature11147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fnature11147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22722860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVSqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=554-558&author=P.+T.+Illingauthor=J.+P.+Vivianauthor=N.+L.+Dudekauthor=L.+Kostenkoauthor=Z.+Chenauthor=M.+Bharadwajauthor=J.+J.+Milesauthor=L.+Kjer-Nielsenauthor=S.+Grasauthor=N.+A.+Williamsonauthor=S.+R.+Burrowsauthor=A.+W.+Purcellauthor=J.+Rossjohnauthor=J.+McCluskey&title=Immune+Self-Reactivity+Triggered+by+Drug-Modified+HLA-Peptide+Repertoire&doi=10.1038%2Fnature11147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Immune self-reactivity triggered by drug-modified HLA-peptide repertoire</span></div><div class="casAuthors">Illing, Patricia T.; Vivian, Julian P.; Dudek, Nadine L.; Kostenko, Lyudmila; Chen, Zhenjun; Bharadwaj, Mandvi; Miles, John J.; Kjer-Nielsen, Lars; Gras, Stephanie; Williamson, Nicholas A.; Burrows, Scott R.; Purcell, Anthony W.; Rossjohn, Jamie; McCluskey, James</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7404</span>),
    <span class="NLM_cas:pages">554-558</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human leukocyte antigens (HLAs) are highly polymorphic proteins that initiate immunity by presenting pathogen-derived peptides to T cells.  HLA polymorphisms mostly map to the antigen-binding cleft, thereby diversifying the repertoire of self-derived and pathogen-derived peptide antigens selected by different HLA allotypes.  A growing no. of immunol. based drug reactions, including abacavir hypersensitivity syndrome (AHS) and carbamazepine-induced Stevens-Johnson syndrome (SJS), are assocd. with specific HLA alleles.  However, little is known about the underlying mechanisms of these assocns., including AHS, a prototypical HLA-assocd. drug reaction occurring exclusively in individuals with the common histocompatibility allele HLA-B*57:01, and with a relative risk of more than 1,000 (refs. 6, 7).  We show that unmodified abacavir binds non-covalently to HLA-B*57:01, lying across the bottom of the antigen-binding cleft and reaching into the F-pocket, where a carboxy-terminal tryptophan typically anchors peptides bound to HLA-B*57:01.  Abacavir binds with exquisite specificity to HLA-B*57:01, changing the shape and chem. of the antigen-binding cleft, thereby altering the repertoire of endogenous peptides that can bind HLA-B*57:01.  In this way, abacavir guides the selection of new endogenous peptides, inducing a marked alteration in immunol. self'.  The resultant peptide-centric altered self' activates abacavir-specific T-cells, thereby driving polyclonal CD8 T-cell activation and a systemic reaction manifesting as AHS.  We also show that carbamazepine, a widely used anti-epileptic drug assocd. with hypersensitivity reactions in HLA-B*15:02 individuals, binds to this allotype, producing alterations in the repertoire of presented self peptides.  Our findings simultaneously highlight the importance of HLA polymorphism in the evolution of pharmacogenomics and provide a general mechanism for some of the growing no. of HLA-linked hypersensitivities that involve small-mol. drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGremSgwwlcpEbVg90H21EOLACvtfcHk0lj-Ft0iCaCXUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVSqu7c%253D&md5=ff02cbeb2f129205c0269a2c7fbee4ed</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fnature11147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11147%26sid%3Dliteratum%253Aachs%26aulast%3DIlling%26aufirst%3DP.%2BT.%26aulast%3DVivian%26aufirst%3DJ.%2BP.%26aulast%3DDudek%26aufirst%3DN.%2BL.%26aulast%3DKostenko%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DBharadwaj%26aufirst%3DM.%26aulast%3DMiles%26aufirst%3DJ.%2BJ.%26aulast%3DKjer-Nielsen%26aufirst%3DL.%26aulast%3DGras%26aufirst%3DS.%26aulast%3DWilliamson%26aufirst%3DN.%2BA.%26aulast%3DBurrows%26aufirst%3DS.%2BR.%26aulast%3DPurcell%26aufirst%3DA.%2BW.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DMcCluskey%26aufirst%3DJ.%26atitle%3DImmune%2520Self-Reactivity%2520Triggered%2520by%2520Drug-Modified%2520HLA-Peptide%2520Repertoire%26jtitle%3DNature%26date%3D2012%26volume%3D486%26spage%3D554%26epage%3D558%26doi%3D10.1038%2Fnature11147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faridi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramarathinam, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivian, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illing, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mifsud, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gearing, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertzog, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ternette, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossjohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croft, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, A. W.</span></span> <span> </span><span class="NLM_article-title">A Subset of HLA-I Peptides are not Genomically Templated: Evidence for Cis- and Trans-Spliced Peptide Ligands</span>. <i>Science Immunology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">eaar3947</span>, <span class="refDoi"> DOI: 10.1126/sciimmunol.aar3947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1126%2Fsciimmunol.aar3947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30315122" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=eaar3947&author=P.+Faridiauthor=C.+Liauthor=S.+H.+Ramarathinamauthor=J.+P.+Vivianauthor=P.+T.+Illingauthor=N.+A.+Mifsudauthor=R.+Ayalaauthor=J.+Songauthor=L.+J.+Gearingauthor=P.+J.+Hertzogauthor=N.+Ternetteauthor=J.+Rossjohnauthor=N.+P.+Croftauthor=A.+W.+Purcell&title=A+Subset+of+HLA-I+Peptides+are+not+Genomically+Templated%3A+Evidence+for+Cis-+and+Trans-Spliced+Peptide+Ligands&doi=10.1126%2Fsciimmunol.aar3947"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1126%2Fsciimmunol.aar3947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciimmunol.aar3947%26sid%3Dliteratum%253Aachs%26aulast%3DFaridi%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DRamarathinam%26aufirst%3DS.%2BH.%26aulast%3DVivian%26aufirst%3DJ.%2BP.%26aulast%3DIlling%26aufirst%3DP.%2BT.%26aulast%3DMifsud%26aufirst%3DN.%2BA.%26aulast%3DAyala%26aufirst%3DR.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DGearing%26aufirst%3DL.%2BJ.%26aulast%3DHertzog%26aufirst%3DP.%2BJ.%26aulast%3DTernette%26aufirst%3DN.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DCroft%26aufirst%3DN.%2BP.%26aulast%3DPurcell%26aufirst%3DA.%2BW.%26atitle%3DA%2520Subset%2520of%2520HLA-I%2520Peptides%2520are%2520not%2520Genomically%2520Templated%253A%2520Evidence%2520for%2520Cis-%2520and%2520Trans-Spliced%2520Peptide%2520Ligands%26jtitle%3DScience%2520Immunology%26date%3D2018%26volume%3D3%26spage%3Deaar3947%26doi%3D10.1126%2Fsciimmunol.aar3947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donaldson, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatnagar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pe’er, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floratos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernal, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordell, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, C. P.</span></span> <span> </span><span class="NLM_article-title">HLA-B*5701 Genotype is a Major Determinant of Drug-Induced Liver Injury Due to Flucloxacillin</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">816</span>– <span class="NLM_lpage">819</span>, <span class="refDoi"> DOI: 10.1038/ng.379</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fng.379" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19483685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1alu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2009&pages=816-819&author=A.+K.+Dalyauthor=P.+T.+Donaldsonauthor=P.+Bhatnagarauthor=Y.+Shenauthor=I.+Pe%E2%80%99erauthor=A.+Floratosauthor=M.+J.+Dalyauthor=D.+B.+Goldsteinauthor=S.+Johnauthor=M.+R.+Nelsonauthor=J.+Grahamauthor=B.+K.+Parkauthor=J.+F.+Dillonauthor=W.+Bernalauthor=H.+J.+Cordellauthor=M.+Pirmohamedauthor=G.+P.+Aithalauthor=C.+P.+Day&title=HLA-B*5701+Genotype+is+a+Major+Determinant+of+Drug-Induced+Liver+Injury+Due+to+Flucloxacillin&doi=10.1038%2Fng.379"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin</span></div><div class="casAuthors">Daly, Ann K.; Donaldson, Peter T.; Bhatnagar, Pallav; Shen, Yufeng; Pe'er, Itsik; Floratos, Aris; Daly, Mark J.; Goldstein, David B.; John, Sally; Nelson, Matthew R.; Graham, Julia; Park, B. Kevin; Dillon, John F.; Bernal, William; Cordell, Heather J.; Pirmohamed, Munir; Aithal, Guruprasad P.; Day, Christopher P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">816-819</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is an important cause of serious liver disease.  The antimicrobial agent flucloxacillin is a common cause of DILI, but the genetic basis for susceptibility remains unclear.  We conducted a genome-wide assocn. (GWA) study using 866,399 markers in 51 cases of flucloxacillin DILI and 282 controls matched for sex and ancestry.  The GWA showed an assocn. peak in the major histocompatibility complex (MHC) region with the strongest assocn. (P = 8.7 × 10-33) seen for rs2395029[G], a marker in complete linkage disequil. (LD) with HLA-B*5701.  Further MHC genotyping, which included 64 flucloxacillin-tolerant controls, confirmed the assocn. with HLA-B*5701 (OR = 80.6, P = 9.0 × 10-19).  The assocn. was replicated in a second cohort of 23 cases.  In HLA-B*5701 carrier cases, rs10937275 in ST6GAL1 on chromosome 3 also showed genome-wide significance (OR = 4.1, P = 1.4 × 10-8).  These findings provide new insights into the mechanism of flucloxacillin DILI and have the potential to substantially improve diagnosis of this serious disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPN1H1yEwIN7Vg90H21EOLACvtfcHk0lgL-mkuvc58Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1alu7o%253D&md5=d147759fd2863b2f575595a73723ac10</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fng.379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.379%26sid%3Dliteratum%253Aachs%26aulast%3DDaly%26aufirst%3DA.%2BK.%26aulast%3DDonaldson%26aufirst%3DP.%2BT.%26aulast%3DBhatnagar%26aufirst%3DP.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DPe%25E2%2580%2599er%26aufirst%3DI.%26aulast%3DFloratos%26aufirst%3DA.%26aulast%3DDaly%26aufirst%3DM.%2BJ.%26aulast%3DGoldstein%26aufirst%3DD.%2BB.%26aulast%3DJohn%26aufirst%3DS.%26aulast%3DNelson%26aufirst%3DM.%2BR.%26aulast%3DGraham%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DDillon%26aufirst%3DJ.%2BF.%26aulast%3DBernal%26aufirst%3DW.%26aulast%3DCordell%26aufirst%3DH.%2BJ.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DAithal%26aufirst%3DG.%2BP.%26aulast%3DDay%26aufirst%3DC.%2BP.%26atitle%3DHLA-B%252A5701%2520Genotype%2520is%2520a%2520Major%2520Determinant%2520of%2520Drug-Induced%2520Liver%2520Injury%2520Due%2520to%2520Flucloxacillin%26jtitle%3DNat.%2520Genet.%26date%3D2009%26volume%3D41%26spage%3D816%26epage%3D819%26doi%3D10.1038%2Fng.379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinsson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cederbrant, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jirholt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mucs, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madeyski-Bengtson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havarinasab, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hultman, P.</span></span> <span> </span><span class="NLM_article-title">HLA-DR7 and HLA-DQ2: Transgenic Mouse Strains Tested as a Model System for Ximelagatran Hepatotoxicity</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e0184744</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0184744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1371%2Fjournal.pone.0184744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28934241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVyktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e0184744&author=H.+Lundgrenauthor=K.+Martinssonauthor=K.+Cederbrantauthor=J.+Jirholtauthor=D.+Mucsauthor=K.+Madeyski-Bengtsonauthor=S.+Havarinasabauthor=P.+Hultman&title=HLA-DR7+and+HLA-DQ2%3A+Transgenic+Mouse+Strains+Tested+as+a+Model+System+for+Ximelagatran+Hepatotoxicity&doi=10.1371%2Fjournal.pone.0184744"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">HLA-DR7 and HLA-DQ2: Transgenic mouse strains tested as a model system for ximelagatran</span></div><div class="casAuthors">Lundgren, Hanna; Martinsson, Klara; Cederbrant, Karin; Jirholt, Johan; Mucs, Daniel; Madeyski-Bengtson, Katja; Havarinasab, Said; Hultman, Per</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0184744/1-e0184744/16</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The oral thrombin inhibitor ximelagatran was withdrawn in the late clin. trial phase because it adversely affected the liver.  In approx. 8% of treated patients, druginduced liver injury (DILI) was expressed as transient alanine transaminase (ALT) elevations.  No evidence of DILI had been revealed in the pre-clin. in vivo studies.  A whole genome scan study performed on the clin. study material identified a strong genetic assocn. between the major histocompatibility complex alleles for human leukocyte antigens (HLA) (HLA-DR7 and HLA-DQ2) and elevated ALT levels in treated patients.  An immunemediated pathogenesis was suggested.  Here, we evaluated whether HLA transgenic mice models could be used to investigate whether the expression of relevant HLA mols. was enough to reproduce the DILI effects in humans.  In silico modeling performed in this study revealed assocn. of both ximelagatran (pro-drug) and melagatran (active drug) to the antigen-presenting groove of the homol. modelled HLA-DR7 mol. suggesting "altered repertoire" as a key initiating event driving development of DILI in humans.  Transgenic mouse strains (tgms) expressing HLA of serotype HLA-DR7 (HLA-DRB1 *0701, -DRA*0102), and HLA-DQ2 (HLA-DQB1 *0202,-DQA1 *0201) were created.  These two lines were crossed with a human (h)CD4 transgenic line, generating the two tgms DR7xhCD4 and DQ2xhCD4.  To investigate whether the DILI effects obsd. in humans could be reproduced in tgms, the mice were treated for 28 days with ximelagatran.  Results revealed no signs of DILI when biomarkers for liver toxicity were measured and histopathol. was evaluated.  In the ximelagatran case, presence of relevant HLA-expression in a preclin. model did not fulfil the prerequisite for reproducing DILI obsd. in patients.  Nonetheless, for the first time an HLA-transgenic mouse model has been investigated for use in HLA-assocd. DILI induced by a low mol. wt. compd.  This study shows that mimicking of genetic susceptibility, expressed as DILI-assocd. HLA-types in mice, is not sufficient for reproducing the complex pathogenesis leading to DILI in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnsKHH13qUfrVg90H21EOLACvtfcHk0lgL-mkuvc58Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVyktro%253D&md5=9687fb0a68fa79c91b5b9955c8dc30a8</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0184744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0184744%26sid%3Dliteratum%253Aachs%26aulast%3DLundgren%26aufirst%3DH.%26aulast%3DMartinsson%26aufirst%3DK.%26aulast%3DCederbrant%26aufirst%3DK.%26aulast%3DJirholt%26aufirst%3DJ.%26aulast%3DMucs%26aufirst%3DD.%26aulast%3DMadeyski-Bengtson%26aufirst%3DK.%26aulast%3DHavarinasab%26aufirst%3DS.%26aulast%3DHultman%26aufirst%3DP.%26atitle%3DHLA-DR7%2520and%2520HLA-DQ2%253A%2520Transgenic%2520Mouse%2520Strains%2520Tested%2520as%2520a%2520Model%2520System%2520for%2520Ximelagatran%2520Hepatotoxicity%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26spage%3De0184744%26doi%3D10.1371%2Fjournal.pone.0184744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Susukida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span> <span> </span><span class="NLM_article-title">An Animal Model of Abacavir-Induced HLA-Mediated Liver Injury</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">723</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfy001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfy001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29319822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGjtL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2018&pages=713-723&author=B.+Songauthor=S.+Aokiauthor=C.+Liuauthor=T.+Susukidaauthor=K.+Ito&title=An+Animal+Model+of+Abacavir-Induced+HLA-Mediated+Liver+Injury&doi=10.1093%2Ftoxsci%2Fkfy001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">An animal model of abacavir-induced HLA-mediated liver injury</span></div><div class="casAuthors">Song, Binbin; Aoki, Shigeki; Liu, Cong; Susukida, Takeshi; Ito, Kousei</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">713-723</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Genome-wide assocn. studies indicate that several idiosyncratic adverse drug reactions are highly assocd. with specific human leukocyte antigen (HLA) alleles.  For instance, abacavir, a human immunodeficiency virus reverse transcriptase inhibitor, induces multiorgan toxicity exclusively in patients carrying the HLA-B*57:01 allele.  However, the underlying mechanism is unclear due to a lack of appropriate animal models.  Previously, the authors developed HLA-B*57:01 transgenic mice and found that topical application of abacavir to the ears induced proliferation of CD8+ lymphocytes in local lymph nodes.  Here, the authors attempted to reproduce abacavir-induced liver injury in these mice.  However, oral administration of abacavir alone to HLA-B*57:01 transgenic mice did not increase levels of the liver injury marker alanine aminotransferase.  Considering the importance of innate immune activation in mouse liver, the authors treated mice with CpG oligodeoxynucleotide, a toll-like receptor 9 agonist, plus abacavir.  This resulted in a marked increase in alanine aminotransferase, pathol. changes in liver, increased nos. of activated CD8+ T cells, and tissue infiltration by immune cells exclusively in HLA-B*57:01 transgenic mice.  These results indicate that CpG oligodeoxynucleotide-induced inflammatory reactions and/or innate immune activation are necessary for abacavir-induced HLA-mediated liver injury characterized by infiltration of CD8+ T cells.  Thus, the authors developed the first mouse model of HLA-mediated abacavir-induced idiosyncratic liver injury.  Further investigation will show that the proposed HLA-mediated liver injury model can be applied to other combinations of drugs and HLA types, thereby improving drug development and contributing to the development of personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW7EsMjfSMO7Vg90H21EOLACvtfcHk0lhRUhw73aeSDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGjtL3J&md5=b124c2e2eaf3d83757cfc5ee240fdf26</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfy001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfy001%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DB.%26aulast%3DAoki%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DSusukida%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DK.%26atitle%3DAn%2520Animal%2520Model%2520of%2520Abacavir-Induced%2520HLA-Mediated%2520Liver%2520Injury%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D162%26spage%3D713%26epage%3D723%26doi%3D10.1093%2Ftoxsci%2Fkfy001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Susukida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Immune-Mediated Idiosyncratic Drug Toxicity Using Chimeric HLA Transgenic Mice</span>. <i>Arch. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">1177</span>– <span class="NLM_lpage">1188</span>, <span class="refDoi"> DOI: 10.1007/s00204-017-2112-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs00204-017-2112-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29150704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVaru73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2018&pages=1177-1188&author=T.+Susukidaauthor=S.+Aokiauthor=K.+Kogoauthor=S.+Fujimoriauthor=B.+Songauthor=C.+Liuauthor=S.+Sekineauthor=K.+Ito&title=Evaluation+of+Immune-Mediated+Idiosyncratic+Drug+Toxicity+Using+Chimeric+HLA+Transgenic+Mice&doi=10.1007%2Fs00204-017-2112-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of immune-mediated idiosyncratic drug toxicity using chimeric HLA transgenic mice</span></div><div class="casAuthors">Susukida, Takeshi; Aoki, Shigeki; Kogo, Kotaro; Fujimori, Sota; Song, Binbin; Liu, Cong; Sekine, Shuichi; Ito, Kousei</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Toxicology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1177-1188</span>CODEN:
                <span class="NLM_cas:coden">ARTODN</span>;
        ISSN:<span class="NLM_cas:issn">0340-5761</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Immune-mediated idiosyncratic drug toxicity (IDT) is a rare adverse drug reaction, potentially resulting in death.  Although genome-wide assocn. studies suggest that the occurrence of immune-mediated IDT is strongly assocd. with specific human leukocyte antigen (HLA) allotypes, these assocns. have not yet been prospectively demonstrated.  In this study, we focused on HLA-B*57:01 and abacavir (ABC)-induced immune-mediated IDT, and constructed transgenic mice carrying chimeric HLA-B*57:01 (B*57:01-Tg) to det. if this in vivo model may be useful for evaluating immune-mediated IDT.  Local lymph node assay (LLNA) results demonstrated that percentages of BrdU+, IL-2+, and IFN-γ+ in CD8+ T cells of ABC (50 mg/kg/day)-applied B*57:01-Tg mice were significantly higher than those in littermates (LMs), resulting in the infiltration of inflammatory cells into the ear.  These immune responses were not obsd. in B*57:03-Tg mice (neg. control).  Furthermore, oral administration of 1% (vol./vol.) ABC significantly increased the percentage of CD44highCD62Llow CD8+ memory T cells in lymph nodes and spleen derived from B*57:01-Tg mice, but not in those from B*57:03-Tg mice and LMs.  These results suggest that B*57:01-Tg mice potentially enable the reprodn. and evaluation of HLA-B*57:01 and ABC-induced immune-mediated IDT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJRVkP4iJdnLVg90H21EOLACvtfcHk0lhRUhw73aeSDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVaru73M&md5=d9355684f8b8e8a8379a9f78707ab5a5</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1007%2Fs00204-017-2112-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00204-017-2112-9%26sid%3Dliteratum%253Aachs%26aulast%3DSusukida%26aufirst%3DT.%26aulast%3DAoki%26aufirst%3DS.%26aulast%3DKogo%26aufirst%3DK.%26aulast%3DFujimori%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DSekine%26aufirst%3DS.%26aulast%3DIto%26aufirst%3DK.%26atitle%3DEvaluation%2520of%2520Immune-Mediated%2520Idiosyncratic%2520Drug%2520Toxicity%2520Using%2520Chimeric%2520HLA%2520Transgenic%2520Mice%26jtitle%3DArch.%2520Toxicol.%26date%3D2018%26volume%3D92%26spage%3D1177%26epage%3D1188%26doi%3D10.1007%2Fs00204-017-2112-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J. P.</span></span> <span> </span><span class="NLM_article-title">The Danger Hypothesis Applied to Idiosyncratic Drug Reactions</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>196</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1007/978-3-642-00663-0_18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2F978-3-642-00663-0_18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvVymsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=196&publication_year=2010&pages=493-509&author=J.+Liauthor=J.+P.+Uetrecht&title=The+Danger+Hypothesis+Applied+to+Idiosyncratic+Drug+Reactions&doi=10.1007%2F978-3-642-00663-0_18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The danger hypothesis applied to idiosyncratic drug reactions</span></div><div class="casAuthors">Li, Jinze; Uetrecht, Jack P.</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">196</span>
        (<span class="NLM_cas:issue">Adverse Drug Reactions</span>),
    <span class="NLM_cas:pages">493-509</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  The danger hypothesis has had a profound effect on the way immunologists view the immune response.  This hypothesis proposes that the major determinant of whether an immune response is mounted against some agent is detd. by whether that agent causes some type of cell damage.  Assuming that most idiosyncratic drug reactions (IDRs) are immune-mediated, this hypothesis also has the potential to explain many aspects of the mechanism of these adverse drug reactions.  For example, most IDRs appear to be caused by chem. metabolites rather than the parent drug, but not all drugs that form reactive metabolites are assocd. with a significant incidence of IDRs.  Therefore, using the danger hypothesis, one feature of a drug candidate that may predict whether it causes an IDR is whether the drug, or more likely its reactive metabolites, cause cell damage.  Although the range of mols. that can act as danger signals is unknown, the most attractive candidates are high mobility group box 1 protein (HMGB1), heat shock proteins, and S100 proteins.  These mols. act through the same receptors (toll-like receptors) as pathogen-assocd. mols. that stimulate the immune system.  Therefore, other environmental factors such as infections or trauma might det. which patients would be at increased risk for IDRs.  Although there are examples where this appears to be the case, in most cases there are no obvious environmental factors that det. IDR risk.  In addn., in animal models of immune-mediated reactions, stimulation of toll-like receptors often does not increase the immune response, and depending on the timing, it can actually be protective.  Therefore, there may be addnl. unknown control mechanisms that are involved.  A better understanding of these fundamental immune mechanisms has the potential to have a significant impact on many areas of medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKLzlKF4sicrVg90H21EOLACvtfcHk0lhRUhw73aeSDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvVymsrg%253D&md5=e1b075a21b78cf86be7f7db001b66e13</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-00663-0_18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-00663-0_18%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DUetrecht%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520Danger%2520Hypothesis%2520Applied%2520to%2520Idiosyncratic%2520Drug%2520Reactions%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2010%26volume%3D196%26spage%3D493%26epage%3D509%26doi%3D10.1007%2F978-3-642-00663-0_18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matzinger, P.</span></span> <span> </span><span class="NLM_article-title">Tolerance, Danger, and the Extended Family</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">1045</span>, <span class="refDoi"> DOI: 10.1146/annurev.iy.12.040194.005015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1146%2Fannurev.iy.12.040194.005015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=8011301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADyaK2c3otVOqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1994&pages=991-1045&author=P.+Matzinger&title=Tolerance%2C+Danger%2C+and+the+Extended+Family&doi=10.1146%2Fannurev.iy.12.040194.005015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Tolerance, danger, and the extended family</span></div><div class="casAuthors">Matzinger P</div><div class="citationInfo"><span class="NLM_cas:title">Annual review of immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">991-1045</span>
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    </div><div class="casAbstract">For many years immunologists have been well served by the viewpoint that the immune system's primary goal is to discriminate between self and non-self.  I believe that it is time to change viewpoints and, in this essay, I discuss the possibility that the immune system does not care about self and non-self, that its primary driving force is the need to detect and protect against danger, and that it does not do the job alone, but receives positive and negative communications from an extended network of other bodily tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTVb5k9OJxBRAwxfk_AGB-EfW6udTcc2ebvWsYONUGbQbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c3otVOqsA%253D%253D&md5=c806a2e1f1e03be07f55f01e69c11e77</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1146%2Fannurev.iy.12.040194.005015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.iy.12.040194.005015%26sid%3Dliteratum%253Aachs%26aulast%3DMatzinger%26aufirst%3DP.%26atitle%3DTolerance%252C%2520Danger%252C%2520and%2520the%2520Extended%2520Family%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D1994%26volume%3D12%26spage%3D991%26epage%3D1045%26doi%3D10.1146%2Fannurev.iy.12.040194.005015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittkowski, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Disease: a ’DAMP’ View of Inflammatory Arthritis</span>. <i>Nat. Clin. Pract. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">382</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1038/ncprheum0531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fncprheum0531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=17599072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntVCitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=382-390&author=D.+Foellauthor=H.+Wittkowskiauthor=J.+Roth&title=Mechanisms+of+Disease%3A+a+%E2%80%99DAMP%E2%80%99+View+of+Inflammatory+Arthritis&doi=10.1038%2Fncprheum0531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Disease: a 'DAMP' view of inflammatory arthritis</span></div><div class="casAuthors">Foell, Dirk; Wittkowski, Helmut; Roth, Johannes</div><div class="citationInfo"><span class="NLM_cas:title">Nature Clinical Practice Rheumatology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">382-390</span>CODEN:
                <span class="NLM_cas:coden">NCPRCF</span>;
        ISSN:<span class="NLM_cas:issn">1745-8382</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Innate immunity achieves our primary host defense by recognizing invading microorganisms through pathogen-assocd. mol. patterns (PAMPs) and by reacting to tissue damage signals called damage-assocd. mol. patterns (DAMPs).  DAMP mols., including high mobility group box 1 protein (HMGB-1), heat-shock proteins (HSPs), uric acid, altered matrix proteins, and S100 proteins, represent important danger signals that mediate inflammatory responses through the receptor for advanced glycation end-products (RAGE, also known as AGER) and Toll-like receptors, after release from activated or necrotic cells.  The terms 'alarmins' and 'endokines' have also been proposed for DAMP mols.  A prototypic DAMP mol., the nuclear protein HMGB-1, is either passively released by necrotic cells or actively secreted with delay by activated cells.  S100A8, S100A9, and S100A12 are calcium-binding proteins expressed in the cytoplasm of phagocytes.  They are rapidly secreted by activated monocytes or neutrophils, which are abundant in inflamed synovial tissue.  HSPs are involved in the crosstalk between innate and adaptive immune systems, and primarily mediate immune regulatory functions.  Multiple pos. feedback loops between DAMPs and PAMPs and their overlapping receptors temporally and spatially drive these processes and may represent the mol. basis for the observation that infections, as well as nonspecific stress factors, can trigger flares in rheumatic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwzk-PVFew-bVg90H21EOLACvtfcHk0lh-NosJB3d5yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntVCitr0%253D&md5=2edaed8247735e833fc62ca2a417b250</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fncprheum0531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncprheum0531%26sid%3Dliteratum%253Aachs%26aulast%3DFoell%26aufirst%3DD.%26aulast%3DWittkowski%26aufirst%3DH.%26aulast%3DRoth%26aufirst%3DJ.%26atitle%3DMechanisms%2520of%2520Disease%253A%2520a%2520%25E2%2580%2599DAMP%25E2%2580%2599%2520View%2520of%2520Inflammatory%2520Arthritis%26jtitle%3DNat.%2520Clin.%2520Pract.%2520Rheumatol.%26date%3D2007%26volume%3D3%26spage%3D382%26epage%3D390%26doi%3D10.1038%2Fncprheum0531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Murphy, B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, C.</span></span> <span> </span><span class="NLM_article-title">The Role of Damage Associated Molecular Pattern Molecules in Acetaminophen-Induced Liver Injury in Mice</span>. <i>Toxicol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">387</span>, <span class="refDoi"> DOI: 10.1016/j.toxlet.2009.11.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.toxlet.2009.11.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19931603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1yltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2010&pages=387&author=B.+V.+Martin-Murphyauthor=M.+P.+Holtauthor=C.+Ju&title=The+Role+of+Damage+Associated+Molecular+Pattern+Molecules+in+Acetaminophen-Induced+Liver+Injury+in+Mice&doi=10.1016%2Fj.toxlet.2009.11.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">The role of damage associated molecular pattern molecules in acetaminophen-induced liver injury in mice</span></div><div class="casAuthors">Martin-Murphy, Brittany V.; Holt, Michael P.; Ju, Cynthia</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">387-394</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The idiosyncratic nature, severity and poor diagnosis of drug-induced liver injury (DILI) make these reactions a major safety issue during drug development, as well as the most common cause for the withdrawal of drugs from the pharmaceutical market.  Elucidation of the underlying mechanism(s) is necessary for identifying predisposing factors and developing strategies in the treatment and prevention of DILI.  Acetaminophen (APAP) is a widely used over the counter therapeutic that is known to be effective and safe at therapeutic doses.  However, in overdose situations fatal and non-fatal hepatic necrosis can result.  Evidence suggests that the chem. reactive metabolite of the drug initiates hepatocyte damage and that inflammatory innate immune responses also occur within the liver, leading to the exacerbation and progression of tissue injury.  Here we investigate whether following APAP-induced liver injury (AILI) damaged hepatocytes release "danger" signals or damage assocd. mol. pattern (DAMP) mols., which induce pro-inflammatory activation of hepatic macrophages, further contributing to the progression of liver injury.  Our study demonstrated a clear activation of Kupffer cells following early exposure to APAP (1 h).  Activation of a murine macrophage cell line, RAW cells, was also obsd. following treatment with liver perfusate from APAP-treated mice, or with culture supernatant of APAP-challenged hepatocytes.  Moreover, in these media, the DAMP mols., heat-shock protein-70 (HSP-70) and high mobility group box-1 (HMGB1) were detected.  Overall, these findings reveal that DAMP mols. released from damaged and necrotic hepatocytes may serve as a crucial link between the initial hepatocyte damage and the activation of innate immune cells following APAP-exposure, and that DAMPs may represent a potential therapeutic target for AILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSwUyM34SGDbVg90H21EOLACvtfcHk0lh-NosJB3d5yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1yltLs%253D&md5=ce792cac71b7ca60e4251527cebf3c7a</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.toxlet.2009.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.toxlet.2009.11.016%26sid%3Dliteratum%253Aachs%26aulast%3DMartin-Murphy%26aufirst%3DB.%2BV.%26aulast%3DHolt%26aufirst%3DM.%2BP.%26aulast%3DJu%26aufirst%3DC.%26atitle%3DThe%2520Role%2520of%2520Damage%2520Associated%2520Molecular%2520Pattern%2520Molecules%2520in%2520Acetaminophen-Induced%2520Liver%2520Injury%2520in%2520Mice%26jtitle%3DToxicol.%2520Lett.%26date%3D2010%26volume%3D192%26spage%3D387%26doi%3D10.1016%2Fj.toxlet.2009.11.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maiuri, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breier, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gora, L. F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkins, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganey, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, R. A.</span></span> <span> </span><span class="NLM_article-title">Cytotoxic Synergy Between Cytokines and NSAIDs Associated With Idiosyncratic Hepatotoxicity Is Driven by Mitogen-Activated Protein Kinases</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfv091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfv091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25953702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC2Mfhsl2itA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2015&pages=265-280&author=A.+R.+Maiuriauthor=A.+B.+Breierauthor=L.+F.+J.+Goraauthor=R.+V.+Parkinsauthor=P.+E.+Ganeyauthor=R.+A.+Roth&title=Cytotoxic+Synergy+Between+Cytokines+and+NSAIDs+Associated+With+Idiosyncratic+Hepatotoxicity+Is+Driven+by+Mitogen-Activated+Protein+Kinases&doi=10.1093%2Ftoxsci%2Fkfv091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Cytotoxic Synergy Between Cytokines and NSAIDs Associated With Idiosyncratic Hepatotoxicity Is Driven by Mitogen-Activated Protein Kinases</span></div><div class="casAuthors">Maiuri Ashley R; Breier Anna B; Gora Lukas F J; Parkins Robert V; Ganey Patricia E; Roth Robert A</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological sciences : an official journal of the Society of Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">265-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most frequent causes of idiosyncratic, drug-induced liver injury (IDILI).  Mechanisms of IDILI are unknown, but immune responses are suspected to underlie them.  In animal models of IDILI, the cytokines tumor necrosis factor-alpha (TNFα) and interferon-gamma (IFNγ) are essential to the pathogenesis.  Some drugs associated with IDILI interact with cytokines to kill hepatocytes in vitro, and mitogen-activated protein kinases (MAPKs) might play a role.  We tested the hypothesis that caspases and MAPKs are involved in NSAID/cytokine-induced cytotoxicity.  NSAIDs that are acetic acid (AA) derivatives and associated with IDILI synergized with TNFα in causing cytotoxicity in HepG2 cells, and IFNγ enhanced this interaction.  NSAIDs that are propionic acid (PA) derivatives and cause IDILI that is of less clinical concern also synergized with TNFα, but IFNγ was without effect.  Caspase inhibition prevented cytotoxicity from AA and PA derivative/cytokine treatment.  Treatment with a representative AA or PA derivative induced activation of the MAPKs c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK), and p38.  Inhibition of either JNK or ERK reduced cytotoxicity from cytokine interactions with AA derivatives.  In contrast, an ERK inhibitor potentiated cytotoxicity from cytokine interactions with PA derivatives.  An AA derivative but not a PA derivative enhanced IFNγ-mediated activation of STAT-1, and this enhancement was ERK-dependent.  These findings raise the possibility that some IDILI reactions result from drug/cytokine synergy involving caspases and MAPKs and suggest that, even for drugs within the same pharmacologic class, synergy with cytokines occurs by different kinase signaling mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnlTZNshuJKbBItaL1WaVAfW6udTcc2ebN510bXZkH5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mfhsl2itA%253D%253D&md5=e6154caabbf62b0847ed2b373100504a</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfv091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfv091%26sid%3Dliteratum%253Aachs%26aulast%3DMaiuri%26aufirst%3DA.%2BR.%26aulast%3DBreier%26aufirst%3DA.%2BB.%26aulast%3DGora%26aufirst%3DL.%2BF.%2BJ.%26aulast%3DParkins%26aufirst%3DR.%2BV.%26aulast%3DGaney%26aufirst%3DP.%2BE.%26aulast%3DRoth%26aufirst%3DR.%2BA.%26atitle%3DCytotoxic%2520Synergy%2520Between%2520Cytokines%2520and%2520NSAIDs%2520Associated%2520With%2520Idiosyncratic%2520Hepatotoxicity%2520Is%2520Driven%2520by%2520Mitogen-Activated%2520Protein%2520Kinases%26jtitle%3DToxicol.%2520Sci.%26date%3D2015%26volume%3D146%26spage%3D265%26epage%3D280%26doi%3D10.1093%2Ftoxsci%2Fkfv091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holman, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nautiyal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thacker, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otieno, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCluyse, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span> <span> </span><span class="NLM_article-title">Hepatocyte-Derived Exosomes Promote Liver Immune Tolerance: Possible Implications for Idiosyncratic Drug-Induced Liver Injury</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfz112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfz112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=31093666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFSmsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2019&pages=499-508&author=N.+S.+Holmanauthor=R.+J.+Churchauthor=M.+Nautiyalauthor=K.+A.+Roseauthor=S.+E.+Thackerauthor=M.+A.+Otienoauthor=K.+K.+Wolfauthor=E.+LeCluyseauthor=P.+B.+Watkinsauthor=M.+Mosedale&title=Hepatocyte-Derived+Exosomes+Promote+Liver+Immune+Tolerance%3A+Possible+Implications+for+Idiosyncratic+Drug-Induced+Liver+Injury&doi=10.1093%2Ftoxsci%2Fkfz112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatocyte-derived exosomes promote liver immune tolerance: possible implications for idiosyncratic drug-induced liver injury</span></div><div class="casAuthors">Holman, Natalie S.; Church, Rachel J.; Nautiyal, Manisha; Rose, Kelly A.; Thacker, Sarah E.; Otieno, Monicah A.; Wolf, Kristina K.; LeCluyse, Edward; Watkins, Paul B.; Mosedale, Merrie</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">499-508</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Most idiosyncratic drug-induced liver injury appears to result from an adaptive immune attack on the liver.  Recent evidence suggests that the T-cell response may be facilitated by the loss of immune tolerance.  In this study, we explored the hypothesis that constitutively released hepatocyte-derived exosomes (HDE) are important for maintaining normal liver immune tolerance.  Exosomes were isolated from the conditioned medium of primary human hepatocytes via polymer pptn.  Mock controls were prepd. by processing fresh medium that was not hepatocyte exposed with pptn. reagent.  THP-1 monocytes were then treated with HDE or an equiv. vol. of mock control for 24 h, followed by a 6-h stimulation with LPS.  HDE exposure resulted in a significant decrease in the LPS-induced media levels of interleukin-1β and interleukin-8.  Gene expression profiling performed in THP-1 cells just prior to LPS-induced stimulation identified a significant decrease among genes assocd. with innate immune response.  MicroRNA (miRNA) profiling was performed on the HDE to identify exosome contents that may drive immune suppression.  Many of the predicted mRNA target genes for the most abundant microRNAs in HDE were among the differentially expressed genes in THP-1 cells.  Taken together, our data suggest that HDE play a role in maintaining normal liver immune tolerance.  Future expts. will explore the possibility that drugs causing idiosyncratic liver injury promote the loss of homeostatic HDE signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBGUZREf5DlrVg90H21EOLACvtfcHk0ljdDyOUbtzNWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFSmsr8%253D&md5=0ef0bd7f4acfd31fdc8571dccee64f6e</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfz112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfz112%26sid%3Dliteratum%253Aachs%26aulast%3DHolman%26aufirst%3DN.%2BS.%26aulast%3DChurch%26aufirst%3DR.%2BJ.%26aulast%3DNautiyal%26aufirst%3DM.%26aulast%3DRose%26aufirst%3DK.%2BA.%26aulast%3DThacker%26aufirst%3DS.%2BE.%26aulast%3DOtieno%26aufirst%3DM.%2BA.%26aulast%3DWolf%26aufirst%3DK.%2BK.%26aulast%3DLeCluyse%26aufirst%3DE.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DMosedale%26aufirst%3DM.%26atitle%3DHepatocyte-Derived%2520Exosomes%2520Promote%2520Liver%2520Immune%2520Tolerance%253A%2520Possible%2520Implications%2520for%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DToxicol.%2520Sci.%26date%3D2019%26volume%3D170%26spage%3D499%26epage%3D508%26doi%3D10.1093%2Ftoxsci%2Fkfz112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warrington, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhilips-Feener, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutherford, W. J.</span></span> <span> </span><span class="NLM_article-title">The Predictive Value of the Lymphocyte Transformation Test in Isoniazid-Associated Hepatitis</span>. <i>Clin. Exp. Allergy</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2222.1982.tb02521.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1111%2Fj.1365-2222.1982.tb02521.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1982&pages=217-222&author=R.+J.+Warringtonauthor=S.+McPhilips-Feenerauthor=W.+J.+Rutherford&title=The+Predictive+Value+of+the+Lymphocyte+Transformation+Test+in+Isoniazid-Associated+Hepatitis&doi=10.1111%2Fj.1365-2222.1982.tb02521.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2222.1982.tb02521.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2222.1982.tb02521.x%26sid%3Dliteratum%253Aachs%26aulast%3DWarrington%26aufirst%3DR.%2BJ.%26aulast%3DMcPhilips-Feener%26aufirst%3DS.%26aulast%3DRutherford%26aufirst%3DW.%2BJ.%26atitle%3DThe%2520Predictive%2520Value%2520of%2520the%2520Lymphocyte%2520Transformation%2520Test%2520in%2520Isoniazid-Associated%2520Hepatitis%26jtitle%3DClin.%2520Exp.%2520Allergy%26date%3D1982%26volume%3D12%26spage%3D217%26epage%3D222%26doi%3D10.1111%2Fj.1365-2222.1982.tb02521.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">Supernatant from Hepatocyte Cultures with Drugs That Cause Idiosyncratic Liver Injury Activates Macrophage Inflammasomes</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1327</span>– <span class="NLM_lpage">1332</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.7b00065</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.7b00065" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVWrsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2017&pages=1327-1332&author=R.+Katoauthor=J.+Uetrecht&title=Supernatant+from+Hepatocyte+Cultures+with+Drugs+That+Cause+Idiosyncratic+Liver+Injury+Activates+Macrophage+Inflammasomes&doi=10.1021%2Facs.chemrestox.7b00065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Supernatant from Hepatocyte Cultures with Drugs That Cause Idiosyncratic Liver Injury Activates Macrophage Inflammasomes</span></div><div class="casAuthors">Kato, Ryuji; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1327-1332</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is increasing evidence that most idiosyncratic drug-induced liver injury (IDILI) is immune mediated, and in most cases reactive metabolites appear to be responsible for induction of this immune response.  Reactive metabolites can cause cell damage with the release of damage-assocd. mol. patterns (DAMPs), which is thought to be involved in immune activation.  Presumably the reason that the liver is a common target of idiosyncratic drug reactions is because it is the major site of drug metab. and reactive metabolite formation.  Inflammasomes can be activated by DAMPs, and this may be a common mechanism by which DAMPs initiate an immune response.  In this study we tested the ability of drugs to induce the release of DAMPs that activate inflammasomes.  The drugs tested were amodiaquine and nevirapine; both are assocd. with significant incidences of severe IDILI.  The hepatocytes were a human hepatocarcinoma functional liver cell-4 (FLC-4) cell line.  For detection of inflammasome activation we used the human macrophage cell line, THP-1 cells.  We found that the supernatant from the incubation of both drugs with FLC-4 cells for 7 days led to increased caspase-1 activity and prodn. of IL-1β by THP-1 cells.  However, amodiaquine alone also directly activated THP-1 cells.  This is presumably because the myeloperoxidase in THP-1 cells can bioactivate amodiaquine to a reactive metabolite.  In contrast, nevirapine, requires cytochromes P 450 for reactive metabolite formation, and therefore required incubation with hepatocytes.  These results support the hypothesis that reactive metabolites of drugs can cause the release of DAMPs, which in turn can activate inflammasomes.  Inflammasome activation may be an important step in the activation of the immune system by drugs, which in some patients can lead to IDILI.  Our in vitro model is simple and convenient for evaluating inflammasome activation, and this may be a method to screen drugs for IDILI risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppuorD391X5bVg90H21EOLACvtfcHk0ljdDyOUbtzNWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVWrsL0%253D&md5=65a15e116b586703ccdcb5dcd463db82</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.7b00065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.7b00065%26sid%3Dliteratum%253Aachs%26aulast%3DKato%26aufirst%3DR.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DSupernatant%2520from%2520Hepatocyte%2520Cultures%2520with%2520Drugs%2520That%2520Cause%2520Idiosyncratic%2520Liver%2520Injury%2520Activates%2520Macrophage%2520Inflammasomes%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2017%26volume%3D30%26spage%3D1327%26epage%3D1332%26doi%3D10.1021%2Facs.chemrestox.7b00065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span> <span> </span><span class="NLM_article-title">A Novel Cell-Based Assay for the Evaluation of Immune- and Inflammatory-Related Gene Expression as Biomarkers for the Risk Assessment of Drug-Induced Liver Injury</span>. <i>Toxicol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>241</i></span>,  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/j.toxlet.2015.10.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.toxlet.2015.10.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26546780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWiurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=241&publication_year=2016&pages=60-70&author=S.+Odaauthor=K.+Matsuoauthor=A.+Nakajimaauthor=T.+Yokoi&title=A+Novel+Cell-Based+Assay+for+the+Evaluation+of+Immune-+and+Inflammatory-Related+Gene+Expression+as+Biomarkers+for+the+Risk+Assessment+of+Drug-Induced+Liver+Injury&doi=10.1016%2Fj.toxlet.2015.10.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">A novel cell-based assay for the evaluation of immune- and inflammatory-related gene expression as biomarkers for the risk assessment of drug-induced liver injury</span></div><div class="casAuthors">Oda, Shingo; Matsuo, Kentaro; Nakajima, Akira; Yokoi, Tsuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">241</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">60-70</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a major problem in drug development.  Although some in vitro methods assessing DILI risk that utilize hepatic cell death or cellular stress as markers have been developed, the predictive ability of these tests is low.  In this study, we sought to develop a novel cell-based assay for the risk assessment of DILI that considers drug metab. as well as immune- and inflammatory-related gene expression.  To accomplish this goal, human hepatoma HepaRG or HepG2 cells were treated with 96 drugs with different clin. DILI risks.  The conditioned media were subsequently used to treat human promyelocytic leukemia HL-60 cells, and the mRNA expression levels of immune- and inflammatory-related genes in the cells were measured.  An area under the receiver operating characteristic curve (ROC-AUC) was calcd. to evaluate the predictive performance of the mRNA levels as markers to discriminate DILI risk.  The expression of interleukin-8 (IL-8) in HL-60 cells treated with conditioned media from HepaRG cells (HL-60/HepaRG) exhibited the highest ROC-AUC value of 0.758, followed by the expression of IL-1β in HL-60/HepaRG (ROC-AUC: 0.726).  Notably, the ROC-AUC values of these genes were higher in HL-60/HepaRG than in HL-60/HepG2, which suggests that HL-60/HepaRG has a higher potential for detecting the metabolic activation of drugs.  An integrated score calcd. from the levels of S100 calcium-binding protein A9 (S100A9), IL-1β, and IL-8 more precisely detd. the DILI risks than individual gene expression did.  The developed cell-based assay that utilizes immune-related gene expression would aid in the assessment of potential DILI risks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolp_CRnBjbYLVg90H21EOLACvtfcHk0ljdDyOUbtzNWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWiurrI&md5=447abef4f90e655cdbf54415cb0c486d</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.toxlet.2015.10.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.toxlet.2015.10.029%26sid%3Dliteratum%253Aachs%26aulast%3DOda%26aufirst%3DS.%26aulast%3DMatsuo%26aufirst%3DK.%26aulast%3DNakajima%26aufirst%3DA.%26aulast%3DYokoi%26aufirst%3DT.%26atitle%3DA%2520Novel%2520Cell-Based%2520Assay%2520for%2520the%2520Evaluation%2520of%2520Immune-%2520and%2520Inflammatory-Related%2520Gene%2520Expression%2520as%2520Biomarkers%2520for%2520the%2520Risk%2520Assessment%2520of%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DToxicol.%2520Lett.%26date%3D2016%26volume%3D241%26spage%3D60%26epage%3D70%26doi%3D10.1016%2Fj.toxlet.2015.10.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kegel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeiffer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhardt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeilinger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nüssler, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seehofer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damm, G.</span></span> <span> </span><span class="NLM_article-title">Subtoxic Concentrations of Hepatotoxic Drugs Lead to Kupffer Cell Activation in a Human In Vitro Liver Model: An Approach to Study DILI</span>. <i>Mediators Inflammation</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.1155/2015/640631</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1155%2F2015%2F640631" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=1&author=V.+Kegelauthor=E.+Pfeifferauthor=B.+Burkhardtauthor=J.+L.+Liuauthor=K.+Zeilingerauthor=A.+K.+N%C3%BCsslerauthor=D.+Seehoferauthor=G.+Damm&title=Subtoxic+Concentrations+of+Hepatotoxic+Drugs+Lead+to+Kupffer+Cell+Activation+in+a+Human+In+Vitro+Liver+Model%3A+An+Approach+to+Study+DILI&doi=10.1155%2F2015%2F640631"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1155%2F2015%2F640631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F640631%26sid%3Dliteratum%253Aachs%26aulast%3DKegel%26aufirst%3DV.%26aulast%3DPfeiffer%26aufirst%3DE.%26aulast%3DBurkhardt%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%2BL.%26aulast%3DZeilinger%26aufirst%3DK.%26aulast%3DN%25C3%25BCssler%26aufirst%3DA.%2BK.%26aulast%3DSeehofer%26aufirst%3DD.%26aulast%3DDamm%26aufirst%3DG.%26atitle%3DSubtoxic%2520Concentrations%2520of%2520Hepatotoxic%2520Drugs%2520Lead%2520to%2520Kupffer%2520Cell%2520Activation%2520in%2520a%2520Human%2520In%2520Vitro%2520Liver%2520Model%253A%2520An%2520Approach%2520to%2520Study%2520DILI%26jtitle%3DMediators%2520Inflammation%26date%3D2015%26volume%3D2015%26spage%3D1%26doi%3D10.1155%2F2015%2F640631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogese, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulkner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copple, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoine, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmasry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betts, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Characterization of Drug-Specific Signaling Between Primary Human Hepatocytes and Immune Cells</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">76</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfx069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfx069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28444390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2017&pages=76-89&author=M.+O.+Ogeseauthor=L.+Faulknerauthor=R.+E.+Jenkinsauthor=N.+S.+Frenchauthor=I.+M.+Coppleauthor=D.+J.+Antoineauthor=M.+Elmasryauthor=H.+Malikauthor=C.+E.+Goldringauthor=B.+K.+Parkauthor=C.+J.+Bettsauthor=D.+J.+Naisbitt&title=Characterization+of+Drug-Specific+Signaling+Between+Primary+Human+Hepatocytes+and+Immune+Cells&doi=10.1093%2Ftoxsci%2Fkfx069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of drug-specific signaling between primary human hepatocytes and immune cells</span></div><div class="casAuthors">Ogese, Monday O.; Faulkner, Lee; Jenkins, Roz E.; French, Neil S.; Copple, Ian M.; Antoine, Daniel J.; Elmasry, Mohamed; Malik, Hasan; Goldring, Christopher E.; Park, Brian Kevin; Betts, Catherine J.; Naisbitt, Dean J.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">76-89</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">It is now apparent that antigen-specific T-cells are activated in certain patients with drug-induced liver injury (DILI).  Since cross-talk between hepatocytes and immune cells is likely to be crit. in detg. the outcome of drug exposure, the aim of this study was to profile the signals released by drug-treated hepatocytes and to characterize the impact of these mols. on dendritic cells.  Human hepatocytes were exposed to 3 drugs (flucloxacillin, amoxicillin, and isoniazid) assocd. with DILI potentially mediated by the adaptive immune system as drug-specific T-cells have been isolated from DILI patients, and the metabolite nitroso-sulfamethoxazole (SMX-NO).  Hepatocyte toxicity, cytokine release and activation of oxidative stress pathways were measured.  Supernatants were transferred to monocyte-derived dendritic cells and cell phenotype and function were assessed.  High-mobility group box 1 protein (HMGB1) and lactate dehydrogenase release as well as ATP depletion occurred in a drug-, time-, and concn.-dependent manner with SMX-NO and flucloxacillin, whereas isoniazid and amoxicillin were nontoxic.  Furthermore, drug-induced activation of nuclear factor (erythroid-derived 2)-like 2 marker genes was obsd. when hepatocytes were exposed to test drugs.  The disulfide isoform of HMGB1 stimulated dendritic cell cytokine release and enhanced the priming of naive T-cells.  Incubation of dendritic cells with supernatant from drug-treated hepatocytes resulted in 2 distinct cytokine profiles.  SMX-NO/flucloxacillin stimulated secretion of TNF-α, IL-6, IL-1α, and IL-1-β.  Isoniazid which did not induce significant hepatocyte toxicity, compared with SMX-NO and flucloxacillin, stimulated the release of a panel of cytokines including the above and IFN-γ, IL-12, IL-17A, IP-10, and IL-10.  Collectively, our study identifies drug-specific signaling pathways between hepatocytes and immune cells that could influence whether drug exposure will result in an immune response and tissue injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdL9BBxr7IyrVg90H21EOLACvtfcHk0ljOnXYkeGGGSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOjtLg%253D&md5=9df2f3b00b5e497d4fe21ffb7a070caf</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfx069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfx069%26sid%3Dliteratum%253Aachs%26aulast%3DOgese%26aufirst%3DM.%2BO.%26aulast%3DFaulkner%26aufirst%3DL.%26aulast%3DJenkins%26aufirst%3DR.%2BE.%26aulast%3DFrench%26aufirst%3DN.%2BS.%26aulast%3DCopple%26aufirst%3DI.%2BM.%26aulast%3DAntoine%26aufirst%3DD.%2BJ.%26aulast%3DElmasry%26aufirst%3DM.%26aulast%3DMalik%26aufirst%3DH.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DBetts%26aufirst%3DC.%2BJ.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DCharacterization%2520of%2520Drug-Specific%2520Signaling%2520Between%2520Primary%2520Human%2520Hepatocytes%2520and%2520Immune%2520Cells%26jtitle%3DToxicol.%2520Sci.%26date%3D2017%26volume%3D158%26spage%3D76%26epage%3D89%26doi%3D10.1093%2Ftoxsci%2Fkfx069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weston, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">An Impaired Immune Tolerance Animal Model Distinguishes the Potential of Troglitazone/Pioglitazone and Tolcapone/Entacapone to Cause IDILI</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">412</span>– <span class="NLM_lpage">420</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfx219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfx219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29087505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFelsbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2018&pages=412-420&author=A.+Makauthor=R.+Katoauthor=K.+Westonauthor=A.+Hayesauthor=J.+Uetrecht&title=An+Impaired+Immune+Tolerance+Animal+Model+Distinguishes+the+Potential+of+Troglitazone%2FPioglitazone+and+Tolcapone%2FEntacapone+to+Cause+IDILI&doi=10.1093%2Ftoxsci%2Fkfx219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">An Impaired Immune Tolerance Animal Model Distinguishes the potential of troglitazone/pioglitazone and tolcapone/entacapone to cause IDILI</span></div><div class="casAuthors">Mak, Alastair; Kato, Ryuji; Weston, Kyle; Hayes, Anthony; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">412-420</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The authors have developed an animal model of amodiaquine-induced liver injury that has characteristics very similar to idiosyncratic drug-induced liver injury (IDILI) in humans by impairing immune tolerance using a PD1-/- mouse and cotreatment with anti-CTLA-4.  To test the usefulness of this model as a general model for human IDILI risk, pairs of drugs with similar structures were tested, one of which is assocd. with a relatively high risk of IDILI and the other not.  One such pair is troglitazone and pioglitazone; troglitazone has caused fatal cases of IDILI while pioglitazone is quite safe.  Another pair is tolcapone and entacapone; tolcapone can cause serious IDILI; in contrast, although entacapone has been reported to cause liver injury, it is relatively safe.  PD1-/- mice treated with anti-CTLA-4 and troglitazone or tolcapone displayed liver injury as detd. by ALT levels and histol., while pioglitazone and entacapone showed less signs of liver injury.  One possible mechanism by which drugs could induce an immune response leading to IDILI is by causing the release of danger-assocd. mol. pattern mols. that activate inflammasomes.  The authors found that the supernatants from incubations of troglitazone, tolcapone, or entacapone with hepatocytes were also able to activate inflammasomes in macrophages, while the supernatant from pioglitazone incubations did not.  These results are consistent with an immune mechanism for troglitazone- and tolcapone-induced IDILI and add to the evidence that this may be a general model for IDILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0YdeyLT3wMbVg90H21EOLACvtfcHk0ljOnXYkeGGGSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFelsbbE&md5=4ecb0b2a5b1c9c808fd1b6c37aead328</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfx219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfx219%26sid%3Dliteratum%253Aachs%26aulast%3DMak%26aufirst%3DA.%26aulast%3DKato%26aufirst%3DR.%26aulast%3DWeston%26aufirst%3DK.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DAn%2520Impaired%2520Immune%2520Tolerance%2520Animal%2520Model%2520Distinguishes%2520the%2520Potential%2520of%2520Troglitazone%252FPioglitazone%2520and%2520Tolcapone%252FEntacapone%2520to%2520Cause%2520IDILI%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D161%26spage%3D412%26epage%3D420%26doi%3D10.1093%2Ftoxsci%2Fkfx219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spraggs, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budde, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briley, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bing, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooser, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardon, L. R.</span></span> <span> </span><span class="NLM_article-title">HLA-DQA1*02:01 is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women with Advanced Breast Cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">667</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1200/JCO.2010.31.3197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1200%2FJCO.2010.31.3197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21245432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvVSrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=667-673&author=C.+F.+Spraggsauthor=L.+R.+Buddeauthor=L.+P.+Brileyauthor=N.+Bingauthor=C.+J.+Coxauthor=K.+S.+Kingauthor=J.+C.+Whittakerauthor=V.+E.+Mooserauthor=A.+J.+Prestonauthor=S.+H.+Steinauthor=L.+R.+Cardon&title=HLA-DQA1*02%3A01+is+a+Major+Risk+Factor+for+Lapatinib-Induced+Hepatotoxicity+in+Women+with+Advanced+Breast+Cancer&doi=10.1200%2FJCO.2010.31.3197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">HLA-DQA1 02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer</span></div><div class="casAuthors">Spraggs, Colin F.; Budde, Laura R.; Briley, Linda P.; Bing, Nan; Cox, Charles J.; King, Karen S.; Whittaker, John C.; Mooser, Vincent E.; Preston, Alaknanda J.; Stein, Steven H.; Cardon, Lon R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">667-673</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Hepatobiliary adverse events (AEs) have been obsd. in a small proportion of patients with metastatic breast cancer (MBC) treated with lapatinib.  This study sought to identify gene variants assocd. with lapatinib-induced ALT elevation and hepatobiliary AEs.  A two-stage pharmacogenetic investigation of ALT elevation was conducted in lapatinib-treated patients with MBC.  Exploratory marker identification evaluated classical HLA alleles, candidate genes, and genome-wide screening in 37 cases with ALT greater than 3 times the upper limit of normal (ULN) and 286 controls with ALT ≤ 1 × ULN, selected from 901 lapatinib-treated patients in 12 trials.  Markers achieving prespecified assocn. thresholds were progressed to an independent confirmatory data set of 24 ALT cases and 155 controls selected from a subsequent trial of 374 lapatinib-treated patients.  Of 58 variants assocd. with ALT elevation in the exploratory data set, four exceeded the prespecified significance threshold in the confirmatory anal.  These variants reside in the same MHC genomic locus and include HLA-DQA1*02:01.  In the confirmatory study, DQA1*02:01 allele carriage was present in 71 % of ALT cases and in 21 % of controls (P <.001; odds ratio, 9.0; 95% CI, 3.2 to 27.4).  As a predictor of liver safety risk in ALT cases vs. noncases, DQA1*02:01 had neg. and pos. predictive values of 0.97 (95% CI, 0.95 to 0.99) and 0.17 (95% CI 0.10 to 0.26), resp.  These results support a role for immune mechanisms in lapatinib-induced hepatotoxicity.  Further work is required to det. whether testing for DQA1*02:01 allele carriage is clin. useful in managing liver safety risk during lapatinib treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5sBETh7j-ZbVg90H21EOLACvtfcHk0li1r0pprv-NQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvVSrsr8%253D&md5=ad80f1ca768b431c1172d6e980f2ddd5</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.31.3197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.31.3197%26sid%3Dliteratum%253Aachs%26aulast%3DSpraggs%26aufirst%3DC.%2BF.%26aulast%3DBudde%26aufirst%3DL.%2BR.%26aulast%3DBriley%26aufirst%3DL.%2BP.%26aulast%3DBing%26aufirst%3DN.%26aulast%3DCox%26aufirst%3DC.%2BJ.%26aulast%3DKing%26aufirst%3DK.%2BS.%26aulast%3DWhittaker%26aufirst%3DJ.%2BC.%26aulast%3DMooser%26aufirst%3DV.%2BE.%26aulast%3DPreston%26aufirst%3DA.%2BJ.%26aulast%3DStein%26aufirst%3DS.%2BH.%26aulast%3DCardon%26aufirst%3DL.%2BR.%26atitle%3DHLA-DQA1%252A02%253A01%2520is%2520a%2520Major%2520Risk%2520Factor%2520for%2520Lapatinib-Induced%2520Hepatotoxicity%2520in%2520Women%2520with%2520Advanced%2520Breast%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D667%26epage%3D673%26doi%3D10.1200%2FJCO.2010.31.3197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singer, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewitzky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klickstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulding, C. A.</span></span> <span> </span><span class="NLM_article-title">A Genome-Wide Study Identifies HLA Alleles Associated with Lumiracoxib-Related Liver Injury</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">714</span>, <span class="refDoi"> DOI: 10.1038/ng.632</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fng.632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=20639878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFCgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=711-714&author=J.+B.+Singerauthor=S.+Lewitzkyauthor=E.+Leroyauthor=F.+Yangauthor=X.+Zhaoauthor=L.+Klicksteinauthor=T.+M.+Wrightauthor=J.+Meyerauthor=C.+A.+Paulding&title=A+Genome-Wide+Study+Identifies+HLA+Alleles+Associated+with+Lumiracoxib-Related+Liver+Injury&doi=10.1038%2Fng.632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury</span></div><div class="casAuthors">Singer, Jonathan B.; Lewitzky, Steve; Leroy, Elisabeth; Yang, Fan; Zhao, Xiaojun; Klickstein, Lloyd; Wright, Timothy M.; Meyer, Joanne; Paulding, Charles A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">711-714</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Lumiracoxib is a selective cyclooxygenase-2 inhibitor developed for the symptomatic treatment of osteoarthritis and acute pain.  Concerns over hepatotoxicity have contributed to the withdrawal or non-approval of lumiracoxib in most major drug markets worldwide.  We performed a case-control genome-wide assocn. study on 41 lumiracoxib-treated patients with liver injury (cases) and 176 matched lumiracoxib-treated patients without liver injury (controls).  Several SNPs from the MHC class II region showed strong evidence of assocn. (the top SNP was rs9270986 with P = 2.8 × 10-10).  These findings were replicated in an independent set of 98 lumiracoxib-treated cases and 405 matched lumiracoxib-treated controls (top SNP rs3129900, P = 4.4 × 10-12).  Fine mapping identified a strong assocn. to a common HLA haplotype (HLA-DRB1*1501-HLA-DQB1*0602-HLA-DRB5*0101-HLA-DQA1*0102, most significant allele P = 6.8 × 10-25, allelic odds ratio = 5.0, 95% CI 3.6-7.0).  These results offer the potential to improve the safety profile of lumiracoxib by identifying individuals at elevated risk for liver injury and excluding them from lumiracoxib treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc6MCbQPbb0rVg90H21EOLACvtfcHk0li1r0pprv-NQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFCgur4%253D&md5=f2ce43639e3ddc3ca0a3757095feae54</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1038%2Fng.632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.632%26sid%3Dliteratum%253Aachs%26aulast%3DSinger%26aufirst%3DJ.%2BB.%26aulast%3DLewitzky%26aufirst%3DS.%26aulast%3DLeroy%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DKlickstein%26aufirst%3DL.%26aulast%3DWright%26aufirst%3DT.%2BM.%26aulast%3DMeyer%26aufirst%3DJ.%26aulast%3DPaulding%26aufirst%3DC.%2BA.%26atitle%3DA%2520Genome-Wide%2520Study%2520Identifies%2520HLA%2520Alleles%2520Associated%2520with%2520Lumiracoxib-Related%2520Liver%2520Injury%26jtitle%3DNat.%2520Genet.%26date%3D2010%26volume%3D42%26spage%3D711%26epage%3D714%26doi%3D10.1038%2Fng.632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kindmark, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jawaid, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbron, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barratt, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bengtsson, O. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cederbrant, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagerstrom-Fermer, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dukes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firth, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrod, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinel, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billing-Clason, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardon, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">March, R. E.</span></span> <span> </span><span class="NLM_article-title">Genome-Wide Pharmacogenetic Investigation of a Hepatic Adverse Event Without Clinical Signs of Immunopathology Suggests an Underlying Immune Pathogenesis</span>. <i>Pharmacogenomics J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">195</span>, <span class="refDoi"> DOI: 10.1038/sj.tpj.6500458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fsj.tpj.6500458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=17505501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVagsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=186-195&author=A.+Kindmarkauthor=A.+Jawaidauthor=C.+G.+Harbronauthor=B.+J.+Barrattauthor=O.+F.+Bengtssonauthor=T.+B.+Anderssonauthor=S.+Carlssonauthor=K.+E.+Cederbrantauthor=N.+J.+Gibsonauthor=M.+Armstrongauthor=M.+E.+Lagerstrom-Fermerauthor=A.+Dellsenauthor=E.+M.+Brownauthor=M.+Thorntonauthor=C.+Dukesauthor=S.+C.+Jenkinsauthor=M.+A.+Firthauthor=G.+O.+Harrodauthor=T.+H.+Pinelauthor=S.+M.+Billing-Clasonauthor=L.+R.+Cardonauthor=R.+E.+March&title=Genome-Wide+Pharmacogenetic+Investigation+of+a+Hepatic+Adverse+Event+Without+Clinical+Signs+of+Immunopathology+Suggests+an+Underlying+Immune+Pathogenesis&doi=10.1038%2Fsj.tpj.6500458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis</span></div><div class="casAuthors">Kindmark, A.; Jawaid, A.; Harbron, C. G.; Barratt, B. J.; Bengtsson, O. F.; Andersson, T. B.; Carlsson, S.; Cederbrant, K. E.; Gibson, N. J.; Armstrong, M.; Lagerstroem-Fermer, M. E.; Dellsen, A.; Brown, E. M.; Thornton, M.; Dukes, C.; Jenkins, S. C.; Firth, M. A.; Harrod, G. O.; Pinel, T. H.; Billing-Clason, S. M. E.; Cardon, L. R.; March, R. E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenomics Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">186-195</span>CODEN:
                <span class="NLM_cas:coden">PJHOAZ</span>;
        ISSN:<span class="NLM_cas:issn">1470-269X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">One of the major goals of pharmacogenetics is to elucidate mechanisms and identify patients at increased risk of adverse events (AEs).  To date, however, there have been only a few successful examples of this type of approach.  In this paper, we describe a retrospective case-control pharmacogenetic study of an AE of unknown mechanism, characterized by elevated levels of serum alanine aminotransferase (ALAT) during long-term treatment with the oral direct thrombin inhibitor ximelagatran.  The study was based on 74 cases and 130 treated controls and included both a genome-wide tag single nucleotide polymorphism and large-scale candidate gene anal.  A strong genetic assocn. between elevated ALAT and the MHC alleles DRB1*07 and DQA1*02 was discovered and replicated, suggesting a possible immune pathogenesis.  Consistent with this hypothesis, immunol. studies suggest that ximelagatran may have the ability to act as a contact sensitizer, and hence be able to stimulate an adaptive immune response.  Published online 15 May 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6dn3QDHI3urVg90H21EOLACvtfcHk0li1r0pprv-NQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVagsb0%253D&md5=38bd24cda5f22464cd73e2b2f45c98a8</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fsj.tpj.6500458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.tpj.6500458%26sid%3Dliteratum%253Aachs%26aulast%3DKindmark%26aufirst%3DA.%26aulast%3DJawaid%26aufirst%3DA.%26aulast%3DHarbron%26aufirst%3DC.%2BG.%26aulast%3DBarratt%26aufirst%3DB.%2BJ.%26aulast%3DBengtsson%26aufirst%3DO.%2BF.%26aulast%3DAndersson%26aufirst%3DT.%2BB.%26aulast%3DCarlsson%26aufirst%3DS.%26aulast%3DCederbrant%26aufirst%3DK.%2BE.%26aulast%3DGibson%26aufirst%3DN.%2BJ.%26aulast%3DArmstrong%26aufirst%3DM.%26aulast%3DLagerstrom-Fermer%26aufirst%3DM.%2BE.%26aulast%3DDellsen%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DE.%2BM.%26aulast%3DThornton%26aufirst%3DM.%26aulast%3DDukes%26aufirst%3DC.%26aulast%3DJenkins%26aufirst%3DS.%2BC.%26aulast%3DFirth%26aufirst%3DM.%2BA.%26aulast%3DHarrod%26aufirst%3DG.%2BO.%26aulast%3DPinel%26aufirst%3DT.%2BH.%26aulast%3DBilling-Clason%26aufirst%3DS.%2BM.%26aulast%3DCardon%26aufirst%3DL.%2BR.%26aulast%3DMarch%26aufirst%3DR.%2BE.%26atitle%3DGenome-Wide%2520Pharmacogenetic%2520Investigation%2520of%2520a%2520Hepatic%2520Adverse%2520Event%2520Without%2520Clinical%2520Signs%2520of%2520Immunopathology%2520Suggests%2520an%2520Underlying%2520Immune%2520Pathogenesis%26jtitle%3DPharmacogenomics%2520J.%26date%3D2008%26volume%3D8%26spage%3D186%26epage%3D195%26doi%3D10.1038%2Fsj.tpj.6500458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chisari, F. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isogawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieland, S. F.</span></span> <span> </span><span class="NLM_article-title">Pathogenesis of Hepatitis B Virus Infection</span>. <i>Pathol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">258</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.1016/j.patbio.2009.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.patbio.2009.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=20116937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvV2jsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2010&pages=258-266&author=F.+V.+Chisariauthor=M.+Isogawaauthor=S.+F.+Wieland&title=Pathogenesis+of+Hepatitis+B+Virus+Infection&doi=10.1016%2Fj.patbio.2009.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Pathogenesis of hepatitis B virus infection</span></div><div class="casAuthors">Chisari, F. V.; Isogawa, M.; Wieland., S. F.</div><div class="citationInfo"><span class="NLM_cas:title">Pathologie Biologie</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">258-266</span>CODEN:
                <span class="NLM_cas:coden">PTBIAN</span>;
        ISSN:<span class="NLM_cas:issn">0369-8114</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The adaptive immune response is thought to be responsible for viral clearance and disease pathogenesis during hepatitis B virus infection.  It is generally acknowledged that the humoral antibody response contributes to the clearance of circulating virus particles and the prevention of viral spread within the host while the cellular immune response eliminates infected cells.  The T cell response to the hepatitis B virus (HBV) is vigorous, polyclonal and multispecific in acutely infected patients who successfully clear the virus and relatively weak and narrowly focussed in chronically infected patients, suggesting that clearance of HBV is T cell dependent.  The pathogenetic and antiviral potential of the cytotoxic T lymphocyte (CTL) response to HBV has been proven by the induction of a severe necroinflammatory liver disease following the adoptive transfer of HBsAg specific CTL into HBV transgenic mice.  Remarkably, the CTLs also purge HBV replicative intermediates from the liver by secreting type 1 inflammatory cytokines thereby limiting virus spread to uninfected cells and reducing the degree of immunopathol. required to terminate the infection.  Persistent HBV infection is characterized by a weak adaptive immune response, thought to be due to inefficient CD4+ T cell priming early in the infection and subsequent development of a quant. and qual. ineffective CD8+ T cell response.  Other factors that could contribute to viral persistence are immunol. tolerance, mutational epitope inactivation, T cell receptor antagonism, incomplete down-regulation of viral replication and infection of immunol. privileged tissues.  However, these pathways become apparent only in the setting of an ineffective immune response, which is, therefore, the fundamental underlying cause.  Persistent infection is characterized by chronic liver cell injury, regeneration, inflammation, widespread DNA damage and insertional deregulation of cellular growth control genes, which, collectively, lead to cirrhosis of the liver and hepatocellular carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnEg6GUmggjbVg90H21EOLACvtfcHk0liL-EL4UdJ4qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvV2jsrg%253D&md5=2194598068d4a6a248c5f848d4cdad8a</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.patbio.2009.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.patbio.2009.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DChisari%26aufirst%3DF.%2BV.%26aulast%3DIsogawa%26aufirst%3DM.%26aulast%3DWieland%26aufirst%3DS.%2BF.%26atitle%3DPathogenesis%2520of%2520Hepatitis%2520B%2520Virus%2520Infection%26jtitle%3DPathol.%2520Biol.%26date%3D2010%26volume%3D58%26spage%3D258%26epage%3D266%26doi%3D10.1016%2Fj.patbio.2009.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garside, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoe, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesnut-Speelman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerry Kenna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrior, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgartner, J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the Use of Imaging Parameters for the Detection of Compound-Induced Hepatotoxicity in 384-Well Cultures of HepG2 Cells and Cryopreserved Primary Human Hepatocytes</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2013.10.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.tiv.2013.10.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24189122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2l" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=171-181&author=H.+Garsideauthor=K.+F.+Marcoeauthor=J.+Chesnut-Speelmanauthor=A.+J.+Fosterauthor=D.+Muthasauthor=J.+Gerry+Kennaauthor=U.+Warriorauthor=J.+Bowesauthor=J.+Baumgartner&title=Evaluation+of+the+Use+of+Imaging+Parameters+for+the+Detection+of+Compound-Induced+Hepatotoxicity+in+384-Well+Cultures+of+HepG2+Cells+and+Cryopreserved+Primary+Human+Hepatocytes&doi=10.1016%2Fj.tiv.2013.10.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes</span></div><div class="casAuthors">Garside, Helen; Marcoe, Karen F.; Chesnut-Speelman, Jessica; Foster, Alison J.; Muthas, Daniel; Gerry Kenna, J.; Warrior, Usha; Bowes, Joanne; Baumgartner, James</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171-181</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a major cause of failed drug development, withdrawal and restricted usage.  Therefore screening assays which aid selection of candidate drugs with reduced propensity to cause DILI are required.  We have investigated the toxicity of 144 drugs, 108 of which caused DILI, using assays identified in the literature as having some predictivity for hepatotoxicity.  The validated assays utilized either HepG2 cells, HepG2 cells in the presence of rat S9 fraction or isolated human hepatocytes.  All parameters were quantified by multiplexed and automated high content fluorescence microscopy, at appropriate time points after compd. administration (4, 24 or 48 h).  The individual endpoint which identified drugs that caused DILI with greatest precision was maximal fold induction in CM-H2DFFDA staining in hepatocytes after 24 h (41% sensitivity, 86% specificity).  However, hierarchical clustering anal. of all endpoints provided the most sensitive identification of drugs which caused DILI (58% sensitivity, 75% specificity).  We conclude that multi-parametric high content cell toxicity assays can enable in vitro detection of drugs that have high propensity to cause DILI in vivo but that many DILI compds. exhibit few in vitro signals when evaluated using these assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjbBh0hQC-vrVg90H21EOLACvtfcHk0liL-EL4UdJ4qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2l&md5=e7ab3e52c8972b18fd1d9dc256b1a9a4</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2013.10.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2013.10.015%26sid%3Dliteratum%253Aachs%26aulast%3DGarside%26aufirst%3DH.%26aulast%3DMarcoe%26aufirst%3DK.%2BF.%26aulast%3DChesnut-Speelman%26aufirst%3DJ.%26aulast%3DFoster%26aufirst%3DA.%2BJ.%26aulast%3DMuthas%26aufirst%3DD.%26aulast%3DGerry%2BKenna%26aufirst%3DJ.%26aulast%3DWarrior%26aufirst%3DU.%26aulast%3DBowes%26aufirst%3DJ.%26aulast%3DBaumgartner%26aufirst%3DJ.%26atitle%3DEvaluation%2520of%2520the%2520Use%2520of%2520Imaging%2520Parameters%2520for%2520the%2520Detection%2520of%2520Compound-Induced%2520Hepatotoxicity%2520in%2520384-Well%2520Cultures%2520of%2520HepG2%2520Cells%2520and%2520Cryopreserved%2520Primary%2520Human%2520Hepatocytes%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2014%26volume%3D28%26spage%3D171%26epage%3D181%26doi%3D10.1016%2Fj.tiv.2013.10.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takemura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Bile Canalicular Network Formation in Rat Sandwich Cultured Hepatocytes by Drugs Associated with Risk of Severe Liver Injury</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2016.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.tiv.2016.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27256767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVygtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=121-130&author=A.+Takemuraauthor=A.+Izakiauthor=S.+Sekineauthor=K.+Ito&title=Inhibition+of+Bile+Canalicular+Network+Formation+in+Rat+Sandwich+Cultured+Hepatocytes+by+Drugs+Associated+with+Risk+of+Severe+Liver+Injury&doi=10.1016%2Fj.tiv.2016.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of bile canalicular network formation in rat sandwich cultured hepatocytes by drugs associated with risk of severe liver injury</span></div><div class="casAuthors">Takemura, Akinori; Izaki, Aya; Sekine, Shuichi; Ito, Kousei</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">121-130</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Idiosyncratic drug-induced liver injury is a clin. concern with serious consequences.  Although many preclin. screening methods have been proposed, it remains difficult to identify compds. assocd. with this rare but potentially fatal liver condition.  Here, the authors propose a novel assay system to assess the risk of liver injury.  Rat primary hepatocytes were cultured in a sandwich configuration, which enables the formation of a typical bile canalicular network.  From day 2 to 3, test drugs, mostly selected from a list of cholestatic drugs, were administered, and the length of the network was semi-quant. measured by immunofluorescence.  Liver injury risk information was collected from drug labels and was compared with in vitro measurements.  Of 23 test drugs examd., 15 exhibited potent inhibition of bile canalicular network formation (<60% of control).  Effects on cell viability were negligible or minimal as confirmed by lactose dehydrogenase leakage and cellular ATP content assays.  For the potent 15 drugs, IC50 values were detd.  Finally, max. daily dose divided by the inhibition const. gave good sepn. of the highest risk of severe liver toxicity drugs such as troglitazone, benzbromarone, flutamide, and amiodarone from lower risk drugs.  In conclusion, inhibitory effect on the bile canalicular network formation obsd. in in vitro sandwich cultured hepatocytes evaluates a new aspect of drug toxicity, particularly assocd. with aggravation of liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8z2P9vsiA2rVg90H21EOLACvtfcHk0liL-EL4UdJ4qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVygtLc%253D&md5=e386a9850ce87c1426a0236f1b713ad7</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2016.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2016.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DTakemura%26aufirst%3DA.%26aulast%3DIzaki%26aufirst%3DA.%26aulast%3DSekine%26aufirst%3DS.%26aulast%3DIto%26aufirst%3DK.%26atitle%3DInhibition%2520of%2520Bile%2520Canalicular%2520Network%2520Formation%2520in%2520Rat%2520Sandwich%2520Cultured%2520Hepatocytes%2520by%2520Drugs%2520Associated%2520with%2520Risk%2520of%2520Severe%2520Liver%2520Injury%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2016%26volume%3D35%26spage%3D121%26epage%3D130%26doi%3D10.1016%2Fj.tiv.2016.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Staden, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyanaraman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalanzi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afshari, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamadeh, H. K.</span></span> <span> </span><span class="NLM_article-title">A Multifactorial Approach to Hepatobiliary Transporter Assessment Enables Improved Therapeutic Compound Development</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">216</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kft176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkft176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23956101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslyktLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2013&pages=216-241&author=R.+E.+Morganauthor=C.+J.+van+Stadenauthor=Y.+Chenauthor=N.+Kalyanaramanauthor=J.+Kalanziauthor=R.+T.+Dunnauthor=C.+A.+Afshariauthor=H.+K.+Hamadeh&title=A+Multifactorial+Approach+to+Hepatobiliary+Transporter+Assessment+Enables+Improved+Therapeutic+Compound+Development&doi=10.1093%2Ftoxsci%2Fkft176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">A Multifactorial Approach to Hepatobiliary Transporter Assessment Enables Improved Therapeutic Compound Development</span></div><div class="casAuthors">Morgan, Ryan E.; van Staden, Carlo J.; Chen, Yuan; Kalyanaraman, Natarajan; Kalanzi, Jackson; Dunn, Robert T., II; Afshari, Cynthia A.; Hamadeh, Hisham K.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">216-241</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The bile salt export pump (BSEP) is expressed at the canalicular domain of hepatocytes, where it serves as the primary route of elimination for monovalent bile acids (BAs) into the bile canaliculi.  The most compelling evidence linking dysfunction in BA transport with liver injury in humans is found with carriers of mutations that render BSEP nonfunctional.  Based on mounting evidence, there appears to be a strong assocn. between drug-induced BSEP interference and liver injury in humans; however, causality has not been established.  For this reason, drug-induced BSEP interference is best considered a susceptibility factor for liver injury as other host- or drug-related properties may contribute to the development of hepatotoxicity.  To better understand the assocn. between BSEP interference and liver injury in humans, over 600 marketed or withdrawn drugs were evaluated in BSEP expressing membrane vesicles.  The example of a compd. that failed during phase 1 human trials is also described, AMG 009.  AMG 009 showed evidence of liver injury in humans that was not predicted by preclin. safety studies, and BSEP inhibition was implicated.  For 109 of the drugs with some effect on in vitro BSEP function, clin. use, assocns. with hepatotoxicity, pharmacokinetic data, and other information were annotated.  A steady state concn. (Css) for each of these annotated drugs was estd., and a ratio between this value and measured IC50 potency values were calcd. in an attempt to relate exposure to in vitro potencies.  When factoring for exposure, 95% of the annotated compds. with a Css/BSEP IC50 ratio ≥ 0.1 were assocd. with some form of liver injury.  We then investigated the relationship between clin. evidence of liver injury and effects to multidrug resistance-assocd. proteins (MRPs) believed to play a role in BA homeostasis.  The effect of 600+ drugs on MRP2, MRP3, and MRP4 function was also evaluated in membrane vesicle assays.  Drugs with a Css/BSEP IC50 ratio ≥ 0.1 and a Css/MRP IC50 ratio ≥ 0.1 had almost a 100% correlation with some evidence of liver injury in humans.  These data suggest that integration of exposure data, and knowledge of an effect to not only BSEP but also one or more of the MRPs, is a useful tool for informing the potential for liver injury due to altered BA transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpD5nu_33Zak7Vg90H21EOLACvtfcHk0liw55QCsV9gKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslyktLzF&md5=4a8875a08056620e4c398049c43e2e5b</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkft176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkft176%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DR.%2BE.%26aulast%3Dvan%2BStaden%26aufirst%3DC.%2BJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKalyanaraman%26aufirst%3DN.%26aulast%3DKalanzi%26aufirst%3DJ.%26aulast%3DDunn%26aufirst%3DR.%2BT.%26aulast%3DAfshari%26aufirst%3DC.%2BA.%26aulast%3DHamadeh%26aufirst%3DH.%2BK.%26atitle%3DA%2520Multifactorial%2520Approach%2520to%2520Hepatobiliary%2520Transporter%2520Assessment%2520Enables%2520Improved%2520Therapeutic%2520Compound%2520Development%26jtitle%3DToxicol.%2520Sci.%26date%3D2013%26volume%3D136%26spage%3D216%26epage%3D241%26doi%3D10.1093%2Ftoxsci%2Fkft176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Lechón, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolosa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donato, M. T.</span></span> <span> </span><span class="NLM_article-title">Metabolic Activation and Drug-Induced LiverIinjury: In Vitro Approaches for the Safety Risk Assessment of New Drugs</span>. <i>J. Appl. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">752</span>– <span class="NLM_lpage">768</span>, <span class="refDoi"> DOI: 10.1002/jat.3277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fjat.3277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26691983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGgtbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=752-768&author=M.+J.+G%C3%B3mez-Lech%C3%B3nauthor=L.+Tolosaauthor=M.+T.+Donato&title=Metabolic+Activation+and+Drug-Induced+LiverIinjury%3A+In+Vitro+Approaches+for+the+Safety+Risk+Assessment+of+New+Drugs&doi=10.1002%2Fjat.3277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs</span></div><div class="casAuthors">Gomez-Lechon, M. Jose; Tolosa, Laia; Donato, M. Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">752-768</span>CODEN:
                <span class="NLM_cas:coden">JJATDK</span>;
        ISSN:<span class="NLM_cas:issn">0260-437X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a significant leading cause of hepatic dysfunction, drug failure during clin. trials and post-market withdrawal of approved drugs.  Many cases of DILI are unexpected reactions of an idiosyncratic nature that occur in a small group of susceptible individuals.  Intensive research efforts have been made to understand better the idiosyncratic DILI and to identify potential risk factors.  Metabolic bioactivation of drugs to form reactive metabolites is considered an initiation mechanism for idiosyncratic DILI.  Reactive species may interact irreversibly with cell macromols. (covalent binding, oxidative damage), and alter their structure and activity.  This review focuses on proposed in vitro screening strategies to predict and reduce idiosyncratic hepatotoxicity assocd. with drug bioactivation.  Compd. incubation with metabolically competent biol. systems (liver-derived cells, subcellular fractions), in combination with methods to reveal the formation of reactive intermediates (e.g., formation of adducts with liver proteins, metabolite trapping or enzyme inhibition assays), are approaches commonly used to screen the reactivity of new mols. in early drug development.  Several cell-based assays have also been proposed for the safety risk assessment of bioactivable compds.  Copyright © 2015 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQyrfU4dgs07Vg90H21EOLACvtfcHk0liw55QCsV9gKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGgtbzN&md5=364ff94e07264c106f9509d61d4e9a1f</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1002%2Fjat.3277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjat.3277%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25B3mez-Lech%25C3%25B3n%26aufirst%3DM.%2BJ.%26aulast%3DTolosa%26aufirst%3DL.%26aulast%3DDonato%26aufirst%3DM.%2BT.%26atitle%3DMetabolic%2520Activation%2520and%2520Drug-Induced%2520LiverIinjury%253A%2520In%2520Vitro%2520Approaches%2520for%2520the%2520Safety%2520Risk%2520Assessment%2520of%2520New%2520Drugs%26jtitle%3DJ.%2520Appl.%2520Toxicol.%26date%3D2016%26volume%3D36%26spage%3D752%26epage%3D768%26doi%3D10.1002%2Fjat.3277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swiss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Human Drug-Induced Liver Injury Severity is Highly Associated with Dual Inhibition of Liver Mitochondrial Function and Bile Salt Export Pump</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1015</span>– <span class="NLM_lpage">1022</span>, <span class="refDoi"> DOI: 10.1002/hep.27206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.27206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24799086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=1015-1022&author=M.+D.+Aleoauthor=Y.+Luoauthor=R.+Swissauthor=P.+D.+Boninauthor=D.+M.+Potterauthor=Y.+Will&title=Human+Drug-Induced+Liver+Injury+Severity+is+Highly+Associated+with+Dual+Inhibition+of+Liver+Mitochondrial+Function+and+Bile+Salt+Export+Pump&doi=10.1002%2Fhep.27206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump</span></div><div class="casAuthors">Aleo, Michael D.; Luo, Yi; Swiss, Rachel; Bonin, Paul D.; Potter, David M.; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1015-1022</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) accounts for 20-40% of all instances of clin. hepatic failure and is a common reason for withdrawal of an approved drug or discontinuation of a potentially new drug from clin./nonclin. development.  Numerous individual risk factors contribute to the susceptibility to human DILI and its severity that are either compd.- and/or patient-specific.  Compd.-specific primary mechanisms linked to DILI include: cytotoxicity, reactive metabolite formation, inhibition of bile salt export pump (BSEP), and mitochondrial dysfunction.  Since BSEP is an energy-dependent protein responsible for the efflux of bile acids from hepatocytes, it was hypothesized that humans exposed to drugs that impair both mitochondrial energetics and BSEP functional activity are more sensitive to more severe manifestations of DILI than drugs that only have a single liability factor.  As annotated in the United States National Center for Toxicol. Research Liver Toxicity Knowledge Base (NCTR-LTKB), the inhibitory properties of 24 Most-DILI-, 28 Less-DILI-, and 20 No-DILI-concern drugs were investigated.  Drug potency for inhibiting BSEP or mitochondrial activity was generally correlated across human DILI concern categories.  However, drugs with dual potency as mitochondrial and BSEP inhibitors were highly assocd. with more severe human DILI, more restrictive product safety labeling related to liver injury, and appear more sensitive to the drug exposure (Cmax) where more restrictive labeling occurs.  Conclusion: These data affirm that severe manifestations of human DILI are multifactorial, highly assocd. with combinations of drug potency specifically related to known mechanisms of DILI (like mitochondrial and BSEP inhibition), and, along with patient-specific factors, lead to differences in the severity and exposure thresholds assocd. with clin. DILI. (Hepatol. 2014;60:1015-1022).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIKfBrKEsFMbVg90H21EOLACvtfcHk0liw55QCsV9gKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtbnJ&md5=9bc646d27738ab811ebc526d520c83bf</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1002%2Fhep.27206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27206%26sid%3Dliteratum%253Aachs%26aulast%3DAleo%26aufirst%3DM.%2BD.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DSwiss%26aufirst%3DR.%26aulast%3DBonin%26aufirst%3DP.%2BD.%26aulast%3DPotter%26aufirst%3DD.%2BM.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DHuman%2520Drug-Induced%2520Liver%2520Injury%2520Severity%2520is%2520Highly%2520Associated%2520with%2520Dual%2520Inhibition%2520of%2520Liver%2520Mitochondrial%2520Function%2520and%2520Bile%2520Salt%2520Export%2520Pump%26jtitle%3DHepatology%26date%3D2014%26volume%3D60%26spage%3D1015%26epage%3D1022%26doi%3D10.1002%2Fhep.27206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dykens, J.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial Toxicity Assessment in Industry – A Decade of Technology Development and Insight</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1061</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1517/17425255.2014.939628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1517%2F17425255.2014.939628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25023361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC2cbisVKnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=1061-1067&author=Y.+Willauthor=J.+Dykens&title=Mitochondrial+Toxicity+Assessment+in+Industry+%E2%80%93+A+Decade+of+Technology+Development+and+Insight&doi=10.1517%2F17425255.2014.939628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial toxicity assessment in industry--a decade of technology development and insight</span></div><div class="casAuthors">Will Yvonne; Dykens James</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on drug metabolism & toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1061-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpQipcnBZdL6cY7HFp97qMfW6udTcc2ebYNUUPR6IFs7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbisVKnsw%253D%253D&md5=9e0d90f03938471154fec1353ebce3fe</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1517%2F17425255.2014.939628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2014.939628%26sid%3Dliteratum%253Aachs%26aulast%3DWill%26aufirst%3DY.%26aulast%3DDykens%26aufirst%3DJ.%26atitle%3DMitochondrial%2520Toxicity%2520Assessment%2520in%2520Industry%2520%25E2%2580%2593%2520A%2520Decade%2520of%2520Technology%2520Development%2520and%2520Insight%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2014%26volume%3D10%26spage%3D1061%26epage%3D1067%26doi%3D10.1517%2F17425255.2014.939628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Q.</span></span> <span> </span><span class="NLM_article-title">Role of Nrf2 in Oxidative Stress and Toxicity</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">426</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-011112-140320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1146%2Fannurev-pharmtox-011112-140320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23294312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjt1Wguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=401-426&author=Q.+Ma&title=Role+of+Nrf2+in+Oxidative+Stress+and+Toxicity&doi=10.1146%2Fannurev-pharmtox-011112-140320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Nrf2 in oxidative stress and toxicity</span></div><div class="casAuthors">Ma, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">401-426</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Organismal life encounters reactive oxidants from internal metab. and environmental toxicant exposure.  Reactive oxygen and nitrogen species cause oxidative stress and are traditionally viewed as being harmful.  On the other hand, controlled prodn. of oxidants in normal cells serves useful purposes to regulate signaling pathways.  Reactive oxidants are counterbalanced by complex antioxidant defense systems regulated by a web of pathways to ensure that the response to oxidants is adequate for the body's needs.  A recurrent theme in oxidant signaling and antioxidant defense is reactive cysteine thiol-based redox signaling.  The nuclear factor erythroid 2-related factor 2 (Nrf2) is an emerging regulator of cellular resistance to oxidants.  Nrf2 controls the basal and induced expression of an array of antioxidant response element-dependent genes to regulate the physiol. and pathophysiol. outcomes of oxidant exposure.  This review discusses the impact of Nrf2 on oxidative stress and toxicity and how Nrf2 senses oxidants and regulates antioxidant defense.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3hN1BQDMlrbVg90H21EOLACvtfcHk0lg15KiGQuC8-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjt1Wguro%253D&md5=71d4fbc6734d49f3e9b2c262057d7288</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-011112-140320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-011112-140320%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DQ.%26atitle%3DRole%2520of%2520Nrf2%2520in%2520Oxidative%2520Stress%2520and%2520Toxicity%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2013%26volume%3D53%26spage%3D401%26epage%3D426%26doi%3D10.1146%2Fannurev-pharmtox-011112-140320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">The Combination of Anti-CTLA-4 and PD1–/– Mice Unmasks the Potential of Isoniazid and Nevirapine To Cause Liver Injury</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2287</span>– <span class="NLM_lpage">2291</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.5b00305</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.5b00305" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGms7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=2287-2291&author=A.+Makauthor=J.+Uetrecht&title=The+Combination+of+Anti-CTLA-4+and+PD1%E2%80%93%2F%E2%80%93+Mice+Unmasks+the+Potential+of+Isoniazid+and+Nevirapine+To+Cause+Liver+Injury&doi=10.1021%2Facs.chemrestox.5b00305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">The Combination of Anti-CTLA-4 and PD1-/- Mice Unmasks the Potential of Isoniazid and Nevirapine To Cause Liver Injury</span></div><div class="casAuthors">Mak, Alastair; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2287-2291</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Our lab. recently reported what we believe is the first valid animal model of idiosyncratic drug-induced liver injury (IDILI) by treating PD1-/- mice with an anti-CTLA-4 antibody and amodiaquine (AQ).  PD1 and CTLA-4 are important immune checkpoint receptors that are involved in inducing immune tolerance.  This model was able to produce significant liver injury that looks very similar to the liver injury seen in humans.  Although this model was shown to work with AQ, the question becomes whether blocking immune tolerance would unmask the potential of other drugs to cause IDILI.  In this study, we tested isoniazid and nevirapine, both drugs with significant histories of causing IDILI in humans even though they do not cause significant injury in animals with doses that result in therapeutic blood levels.  Both drugs in combination with these immune checkpoint inhibitors caused mild but significant delayed onset liver injury, which is similar to the mild injury that they can cause in humans.  INH-induced liver injury in this model was assocd. with an increase in NK cells, while NVP-induced liver injury was assocd. with a greater increase in CD8 T cells.  Although the liver injury caused by these drugs in this model was mild, these results suggest that impairing immune tolerance may be a general method for unmasking the potential of drugs to cause IDILI and therefore provide a screening tool for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob4JP-cXxhkrVg90H21EOLACvtfcHk0lg_eRmTFiurBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGms7fK&md5=be8bcacb6398f26a4c62a36c59e30492</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.5b00305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.5b00305%26sid%3Dliteratum%253Aachs%26aulast%3DMak%26aufirst%3DA.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DThe%2520Combination%2520of%2520Anti-CTLA-4%2520and%2520PD1%25E2%2580%2593%252F%25E2%2580%2593%2520Mice%2520Unmasks%2520the%2520Potential%2520of%2520Isoniazid%2520and%2520Nevirapine%2520To%2520Cause%2520Liver%2520Injury%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2015%26volume%3D28%26spage%3D2287%26epage%3D2291%26doi%3D10.1021%2Facs.chemrestox.5b00305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thalhofer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leidner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, A.</span></span> <span> </span><span class="NLM_article-title">OX40, PD-1 and CTLA-4 are Selectively Expressed on Tumor-Infiltrating T-cells in Head and Neck Cancer</span>. <i>Clin. Transl. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e70</span>, <span class="refDoi"> DOI: 10.1038/cti.2016.16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fcti.2016.16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27195113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFSkurfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=e70&author=R.+Montlerauthor=R.+B.+Bellauthor=C.+Thalhoferauthor=R.+Leidnerauthor=Z.+Fengauthor=B.+A.+Foxauthor=A.+C.+Chengauthor=T.+G.+Buiauthor=C.+Tuckerauthor=H.+Hoenauthor=A.+Weinberg&title=OX40%2C+PD-1+and+CTLA-4+are+Selectively+Expressed+on+Tumor-Infiltrating+T-cells+in+Head+and+Neck+Cancer&doi=10.1038%2Fcti.2016.16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer</span></div><div class="casAuthors">Montler, Ryan; Bell, R. Bryan; Thalhofer, Colin; Leidner, Rom; Feng, Zipei; Fox, Bernard A.; Cheng, Allen C.; Bui, Tuan G.; Tucker, Christopher; Hoen, Helena; Weinberg, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e70/1-e70/8</span>CODEN:
                <span class="NLM_cas:coden">CTILBR</span>;
        ISSN:<span class="NLM_cas:issn">2050-0068</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">The tumor microenvironment of squamous cell carcinoma of the head and neck (SCCHN) has been shown to be immune suppressive.  Therefore, strategies aimed at overcoming this issue could have a pos. therapeutic impact.  Hence, we investigated the expression of the known immune-modulatory proteins OX40, programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-assocd. protein 4 (CTLA-4) in SCCHN on different T-cell subsets of tumor-infiltrating lymphocytes (TIL) to ascertain whether these proteins could potentially be targeted alone or in combination for future clin. trials.  T cells from peripheral blood (PBL) and tumor were analyzed for the expression of OX40, PD-1 and CTLA-4 in 29 patients undergoing surgery.  These proteins were all expressed significantly higher in T-cell subsets isolated from tumors compared with PBL of the same patient.  OX40 expression was significantly greater in the TIL regulatory T-cell (Treg) population relative to conventional CD4 and CD8 TIL or the Treg isolated from PBL.  PD-1 expression was increased in all T-cell subsets relative to PBL.  CTLA-4 was also increased in all TIL subsets relative to blood, and similar to OX40, its highest level of expression was obsd. in the Treg TIL.  The highest frequency of PD-1, CTLA-4 and OX40 triple-pos. cells were found in the Treg population isolated from the tumor.  We analyzed both human papilloma virus-pos. and -neg. patients and found similar levels and expression patterns of these two patient populations for all three proteins.  These data suggest that there may be therapeutic advantages of targeting these pathways independently or in combination for patients with this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsLAIBXx5IL7Vg90H21EOLACvtfcHk0lg_eRmTFiurBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFSkurfM&md5=0003a5c6c4332927cef1185a742f7e65</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1038%2Fcti.2016.16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcti.2016.16%26sid%3Dliteratum%253Aachs%26aulast%3DMontler%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DR.%2BB.%26aulast%3DThalhofer%26aufirst%3DC.%26aulast%3DLeidner%26aufirst%3DR.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DFox%26aufirst%3DB.%2BA.%26aulast%3DCheng%26aufirst%3DA.%2BC.%26aulast%3DBui%26aufirst%3DT.%2BG.%26aulast%3DTucker%26aufirst%3DC.%26aulast%3DHoen%26aufirst%3DH.%26aulast%3DWeinberg%26aufirst%3DA.%26atitle%3DOX40%252C%2520PD-1%2520and%2520CTLA-4%2520are%2520Selectively%2520Expressed%2520on%2520Tumor-Infiltrating%2520T-cells%2520in%2520Head%2520and%2520Neck%2520Cancer%26jtitle%3DClin.%2520Transl.%2520Immunol.%26date%3D2016%26volume%3D5%26spage%3De70%26doi%3D10.1038%2Fcti.2016.16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sfanos, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeker, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marzo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span> <span> </span><span class="NLM_article-title">Human Prostate-Infiltrating CD8+ T Lymphocytes are Oligoclonal and PD-1+</span>. <i>Prostate</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1694</span>– <span class="NLM_lpage">1703</span>, <span class="refDoi"> DOI: 10.1002/pros.21020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fpros.21020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19670224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSntr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=1694-1703&author=K.+S.+Sfanosauthor=T.+C.+Brunoauthor=A.+K.+Meekerauthor=A.+M.+De+Marzoauthor=W.+B.+Isaacsauthor=C.+G.+Drake&title=Human+Prostate-Infiltrating+CD8%2B+T+Lymphocytes+are+Oligoclonal+and+PD-1%2B&doi=10.1002%2Fpros.21020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-I+</span></div><div class="casAuthors">Sfanos, Karen S.; Bruno, Tullia C.; Meeker, Alan K.; de Marzo, Angelo M.; Isaacs, William B.; Drake, Charles G.</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1694-1703</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Prostate-infiltrating CD8+ T lymphocytes (CD8+ PIL) are prevalent in men with prostate cancer (PCa), however, it is unclear whether the presence of such cells reflects a non-specific immune infiltrate or an oligoclonal, antigen-driven adaptive immune response.  We investigated the complexity of the T-cell receptor (TCR) repertoire in the prostate gland by examg. the diversity of CD8+ TCR β chain variable region (Vβ) gene sequences in both the peripheral blood and prostates of cancer patients.  Vβ repertoire anal. was performed by family-specific Vβ spectratyping and flow cytometry, as well as direct sequence anal. (5' RACE and cloning).  Programmed cell death 1 (PD-1 or PDCD1) expression on peripheral blood CD8+ T cells and CD8+ PIL was analyzed by flow cytometry.  CD8+ PIL isolated from cancer patients exhibited restricted TCR Vβ gene usage, and identical clones were identified in multiple sites within the prostate.  Furthermore, CD8+ PIL express high levels of the inhibitory receptor PD-1, a cell surface protein assocd. with an "exhausted" CD8+ T-cell phenotype.  CD8+ PIL appear to have undergone clonal expansion in response to an as yet unidentified antigen; however, due to the high expression of PD-1, these cells are likely incapable of mounting an effective immune response.  The results provide an important basis for further efforts aimed at the identification of specific antigens involved in prostatic inflammation, and suggest that PD-1 blockade may be useful in immunotherapy for PCa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX5j8BOnqzDrVg90H21EOLACvtfcHk0lgqDJXXGkbGxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSntr%252FI&md5=27b14cc6b8325ac891216c9609b6fd49</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1002%2Fpros.21020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpros.21020%26sid%3Dliteratum%253Aachs%26aulast%3DSfanos%26aufirst%3DK.%2BS.%26aulast%3DBruno%26aufirst%3DT.%2BC.%26aulast%3DMeeker%26aufirst%3DA.%2BK.%26aulast%3DDe%2BMarzo%26aufirst%3DA.%2BM.%26aulast%3DIsaacs%26aufirst%3DW.%2BB.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26atitle%3DHuman%2520Prostate-Infiltrating%2520CD8%252B%2520T%2520Lymphocytes%2520are%2520Oligoclonal%2520and%2520PD-1%252B%26jtitle%3DProstate%26date%3D2009%26volume%3D69%26spage%3D1694%26epage%3D1703%26doi%3D10.1002%2Fpros.21020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadzadeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heemskerk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunderlich, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. A.</span></span> <span> </span><span class="NLM_article-title">Tumor Antigen-Specific CD8 T-cells Infiltrating the Tumor Express High Levels of PD-1 and are Functionally Impaired</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">1537</span>– <span class="NLM_lpage">1544</span>, <span class="refDoi"> DOI: 10.1182/blood-2008-12-195792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1182%2Fblood-2008-12-195792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19423728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVyiur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=1537-1544&author=M.+Ahmadzadehauthor=L.+A.+Johnsonauthor=B.+Heemskerkauthor=J.+R.+Wunderlichauthor=M.+E.+Dudleyauthor=D.+E.+Whiteauthor=S.+A.+Rosenberg&title=Tumor+Antigen-Specific+CD8+T-cells+Infiltrating+the+Tumor+Express+High+Levels+of+PD-1+and+are+Functionally+Impaired&doi=10.1182%2Fblood-2008-12-195792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired</span></div><div class="casAuthors">Ahmadzadeh, Mojgan; Johnson, Laura A.; Heemskerk, Bianca; Wunderlich, John R.; Dudley, Mark E.; White, Donald E.; Rosenberg, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1537-1544</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Tumor antigen-specific T cells are found within melanomas, yet tumors continue to grow.  Although the tumor microenvironment is thought to influence the suppression of tumor-reactive T cells, the underlying mechanisms for this T-cell dysfunction are not clear.  Here, we report that the majority of tumor infiltrating T lymphocytes (TIL), including MART-1/Melan-A melanoma antigen-specific CD8 T cells, predominantly expressed PD-1, in contrast to T cells in normal tissues and peripheral blood T lymphocytes (PBL).  PD-1+ TIL expressed CTLA-4 and Ki-67, markers that were not expressed by PD-1- TIL and T cells in the normal tissues and PBL.  Moreover, PD-1+ TIL were primarily HLA-DR+ and CD127-, in contrast to PD-1- TIL.  Effector cytokine prodn. by PD-1+ TIL was impaired compared with PD-1- TIL and PBL.  Collectively, the phenotypic and functional characterizations of TIL revealed a significantly higher frequency and level of PD-1 expression on TIL compared with normal tissue T-cell infiltrates and PBL, and PD-1 expression correlated with an exhausted phenotype and impaired effector function.  These findings suggest that the tumor microenvironment can lead to up-regulation of PD-1 on tumor-reactive T cells and contribute to impaired antitumor immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP9XeRjO6F3LVg90H21EOLACvtfcHk0lgqDJXXGkbGxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVyiur3K&md5=81e4f19724e3a03abc8df9982e32ea90</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-12-195792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-12-195792%26sid%3Dliteratum%253Aachs%26aulast%3DAhmadzadeh%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DL.%2BA.%26aulast%3DHeemskerk%26aufirst%3DB.%26aulast%3DWunderlich%26aufirst%3DJ.%2BR.%26aulast%3DDudley%26aufirst%3DM.%2BE.%26aulast%3DWhite%26aufirst%3DD.%2BE.%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26atitle%3DTumor%2520Antigen-Specific%2520CD8%2520T-cells%2520Infiltrating%2520the%2520Tumor%2520Express%2520High%2520Levels%2520of%2520PD-1%2520and%2520are%2520Functionally%2520Impaired%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D1537%26epage%3D1544%26doi%3D10.1182%2Fblood-2008-12-195792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span> <span> </span><span class="NLM_article-title">PD-L1 Expression in Human Cancers and its Association with Clinical Outcomes</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">5023</span>– <span class="NLM_lpage">5039</span>, <span class="refDoi"> DOI: 10.2147/OTT.S105862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.2147%2FOTT.S105862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27574444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsFyjsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=5023-5039&author=X.+Wangauthor=F.+Tengauthor=L.+Kongauthor=J.+Yu&title=PD-L1+Expression+in+Human+Cancers+and+its+Association+with+Clinical+Outcomes&doi=10.2147%2FOTT.S105862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L1 expression in human cancers and its association with clinical outcomes</span></div><div class="casAuthors">Wang, Xin; Teng, Feifei; Kong, Li; Yu, Jinming</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5023-5039</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">PD-L1 is an immunoinhibitory mol. that suppresses the activation of T cells, leading to the progression of tumors.  Overexpression of PD-L1 in cancers such as gastric cancer, hepatocellular carcinoma, renal cell carcinoma, esophageal cancer, pancreatic cancer, ovarian cancer, and bladder cancer is assocd. with poor clin. outcomes.  In contrast, PD-L1 expression correlates with better clin. outcomes in breast cancer and merkel cell carcinoma.  The prognostic value of PD-L1 expression in lung cancer, colorectal cancer, and melanoma is controversial.  Blocking antibodies that target PD-1 and PD-L1 have achieved remarkable response rates in cancer patients who have PD-L1-overexpressing tumors.  However, using PD-L1 as an exclusive predictive biomarker for cancer immunotherapy is questionable due to the low accuracy of PD-L1 immunohistochem. staining.  Factors that affect the accuracy of PD-L1 immunohistochem. staining are as follows.  First, antibodies used in different studies have different sensitivity.  Second, in different studies, the cut-off value of PD-L1 staining positivity is different.  Third, PD-L1 expression in tumors is not uniform, and sampling time and location may affect the results of PD-L1 staining.  Therefore, better understanding of tumor microenvironment and use of other biomarkers such as gene marker and combined index are necessary to better identify patients who will benefit from PD-1/PD-L1 checkpoint blockade therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp67AMdNDVDzLVg90H21EOLACvtfcHk0lgqDJXXGkbGxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsFyjsbk%253D&md5=3042a7ee3c4c3ebedbee389c61a189fb</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.2147%2FOTT.S105862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S105862%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTeng%26aufirst%3DF.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DJ.%26atitle%3DPD-L1%2520Expression%2520in%2520Human%2520Cancers%2520and%2520its%2520Association%2520with%2520Clinical%2520Outcomes%26jtitle%3DOncoTargets%2520Ther.%26date%3D2016%26volume%3D9%26spage%3D5023%26epage%3D5039%26doi%3D10.2147%2FOTT.S105862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span> <span> </span><span class="NLM_article-title">Immune Checkpoint Inhibitor Toxicity in 2018Immune Checkpoint Inhibitor ToxicityImmune Checkpoint Inhibitor Toxicity</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>320</i></span>,  <span class="NLM_fpage">1702</span>– <span class="NLM_lpage">1703</span>, <span class="refDoi"> DOI: 10.1001/jama.2018.13995</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1001%2Fjama.2018.13995" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30286224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BB3czlvVGqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2018&pages=1702-1703&author=D.+B.+Johnsonauthor=S.+Chandraauthor=J.+A.+Sosman&title=Immune+Checkpoint+Inhibitor+Toxicity+in+2018Immune+Checkpoint+Inhibitor+ToxicityImmune+Checkpoint+Inhibitor+Toxicity&doi=10.1001%2Fjama.2018.13995"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Immune Checkpoint Inhibitor Toxicity in 2018</span></div><div class="casAuthors">Johnson Douglas B; Johnson Douglas B; Chandra Sunandana; Sosman Jeffrey A; Chandra Sunandana; Sosman Jeffrey A</div><div class="citationInfo"><span class="NLM_cas:title">JAMA</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1702-1703</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTthrEhc_RnYZdYoSR9eyvsfW6udTcc2ea64jFX91IJULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czlvVGqsQ%253D%253D&md5=60fe59cb297bff50df9de6ab6b0c30b3</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1001%2Fjama.2018.13995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2018.13995%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BB.%26aulast%3DChandra%26aufirst%3DS.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26atitle%3DImmune%2520Checkpoint%2520Inhibitor%2520Toxicity%2520in%25202018Immune%2520Checkpoint%2520Inhibitor%2520ToxicityImmune%2520Checkpoint%2520Inhibitor%2520Toxicity%26jtitle%3DJAMA%26date%3D2018%26volume%3D320%26spage%3D1702%26epage%3D1703%26doi%3D10.1001%2Fjama.2018.13995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thong, B. Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chia, F. L.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, T.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, K.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. W.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G. Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, H.-H.</span></span> <span> </span><span class="NLM_article-title">A Retrospective Study on Sequential Desensitization-Rechallenge for Antituberculosis Drug Allergy</span>. <i>Asia Pacific Allergy</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.5415/apallergy.2014.4.3.156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.5415%2Fapallergy.2014.4.3.156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25097851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC2cbptlKqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=156-163&author=B.+Y.-H.+Thongauthor=F.+L.-A.+Chiaauthor=S.-C.+Tanauthor=T.-C.+Tanauthor=K.-P.+Leongauthor=J.+W.-L.+Tanauthor=C.-Y.+Tangauthor=J.-F.+Houauthor=G.+Y.-L.+Chanauthor=H.-H.+Chng&title=A+Retrospective+Study+on+Sequential+Desensitization-Rechallenge+for+Antituberculosis+Drug+Allergy&doi=10.5415%2Fapallergy.2014.4.3.156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">A retrospective study on sequential desensitization-rechallenge for antituberculosis drug allergy</span></div><div class="casAuthors">Thong Bernard Yu-Hor; Chia Faith Li-Ann; Tan Sze-Chin; Tan Teck-Choon; Leong Khai-Pang; Tan Justina Wei-Lyn; Tang Chwee-Ying; Hou Jin-Feng; Chan Grace Yin-Lai; Chng Hiok-Hee</div><div class="citationInfo"><span class="NLM_cas:title">Asia Pacific allergy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">156-63</span>
        ISSN:<span class="NLM_cas:issn">2233-8276</span>.
    </div><div class="casAbstract">BACKGROUND:  Antituberculosis (anti-TB) drug allergy often involves multiple concurrently administered drugs which subsequently need to be reinitiated as no better alternatives exist.  OBJECTIVE:  To describe the results of tailored sequential desensitization-rechallenge (D-R) for anti-TB drug allergy.  METHODS:  Consecutive patients who had undergone D-R to anti-TB drugs between 1 September 1997 and 31 January 2012 were recruited.  Following resolution of the acute reaction, anti-TB drug was restarted at 1:6,000 to 1:3 of the final daily dose (FDD), with gradual single or multiple step daily dose escalation to the FDD.  Subsequent drugs were sequentially added ≥3 days later when the preceding drug was tolerated.  Full blood count and liver function tests were monitored prior to addition of each new drug.  RESULTS:  There were 11 patients of whom 10 were male, predominantly Chinese (8 patients).  Regimens comprised at least 3 drugs: isoniazid (INH), rifampicin (RIF), ethambutol (EMB), pyrazinamide (PZA), or streptomycin.  All patients had nonimmediate reactions, with cutaneous eruptions, where maculopapular exanthema (MPE) was the most common (8 patients).  Drug-induced hypersensitivity syndrome (DIHS) occurred in 6 patients, and Stevens Johnson syndrome (SJS) in 2 patients.  D-R to INH was successful in 7/9 patients (77.8%) and to RIF/EMB/PZA/streptomycin in all.  Of the 2 patients who failed INH D-R, 1 developed fever and MPE on day 3, the other MPE on day 8.  D-R with INH and RIF respectively was successful in 2 patients with SJS.  Among DIHS patients, 1 failed D-R with INH (fever and MPE on day 3).  There were 23/25 (92%) successful D-R among the 11 patients.  All patients completed TB treatment of ≥5 months' duration with no cases of drug-resistant TB.  CONCLUSION:  Tailored sequential TB drug D-R is successful where no better alternative therapies are available, with careful dose escalation and close monitoring, and after a careful risk-benefit assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYiFuHFerby669lAbTj9rGfW6udTcc2eZr-7nTGEJHnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbptlKqtQ%253D%253D&md5=4ba392bb795c4aad9d7ccf0f33e233c6</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.5415%2Fapallergy.2014.4.3.156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5415%252Fapallergy.2014.4.3.156%26sid%3Dliteratum%253Aachs%26aulast%3DThong%26aufirst%3DB.%2BY.-H.%26aulast%3DChia%26aufirst%3DF.%2BL.-A.%26aulast%3DTan%26aufirst%3DS.-C.%26aulast%3DTan%26aufirst%3DT.-C.%26aulast%3DLeong%26aufirst%3DK.-P.%26aulast%3DTan%26aufirst%3DJ.%2BW.-L.%26aulast%3DTang%26aufirst%3DC.-Y.%26aulast%3DHou%26aufirst%3DJ.-F.%26aulast%3DChan%26aufirst%3DG.%2BY.-L.%26aulast%3DChng%26aufirst%3DH.-H.%26atitle%3DA%2520Retrospective%2520Study%2520on%2520Sequential%2520Desensitization-Rechallenge%2520for%2520Antituberculosis%2520Drug%2520Allergy%26jtitle%3DAsia%2520Pacific%2520Allergy%26date%3D2014%26volume%3D4%26spage%3D156%26epage%3D163%26doi%3D10.5415%2Fapallergy.2014.4.3.156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tiegs, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohse, A. W.</span></span> <span> </span><span class="NLM_article-title">Immune Tolerance: What is Unique About the Liver</span>. <i>J. Autoimmun.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1016/j.jaut.2009.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jaut.2009.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19717280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlGjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=1-6&author=G.+Tiegsauthor=A.+W.+Lohse&title=Immune+Tolerance%3A+What+is+Unique+About+the+Liver&doi=10.1016%2Fj.jaut.2009.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Immune tolerance: What is unique about the liver</span></div><div class="casAuthors">Tiegs, Gisa; Lohse, Ansgar W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Autoimmunity</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">JOAUEP</span>;
        ISSN:<span class="NLM_cas:issn">0896-8411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The liver tolerance effect' mediates local and systemic tolerance to self and foreign antigens and has been attributed to specialized resident cells expressing anti-inflammatory mediators and inhibitory cell surface ligands for T cell activation.  Non-parenchymal liver cells responsible for the tolerogenic properties of the liver are the resident dendritic cells (DCs), which comprise myeloid as well as plasmacytoid DCs, liver sinusoidal endothelial cells (LSECs), Kupffer cells (KCs) as well as hepatic stellate cells (HSCs), also known as Ito cells.  These cells mediate immunosuppression by prodn. of anti-inflammatory cytokines such as IL-10 and TGFβ as well as by expression of the neg. co-stimulator for T cell activation programmed cell death ligand-1 (PD-L1).  An interesting observation in this context is that knockout of IL-10 or PD-L1 (or the receptor PD-1) does not necessarily result in inflammatory liver damage whereas transgenic inhibition of TGFβ signaling induces liver disease in mice resembling chronic cholangitis.  However, depending on the mouse model and on the type of injury, e.g. autoimmune disease, allograft rejection or viral infection, IL-10 or TGFβ and/or PD-1 as well as cytotoxic T lymphocyte antigen-4 (CTLA-4) contribute to the immunosuppressive mechanisms of CD4+CD25+Foxp3+ regulatory T cells (Tregs), which seem to be converted in the liver from infiltrating conventional naive CD4+ T cells and/or effector CD4+ T cells to control the disease.  Finally, hepatocytes also contribute to the liver tolerance effect' by expression of MHC class II mols., probably low levels of co-stimulatory mols. and high levels of the co-inhibitory mol. PD-L1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTUl_U-lwVm7Vg90H21EOLACvtfcHk0liU-o6K6WP0qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlGjsb4%253D&md5=20308fb0ed7a86d8404ee75caff8e3a9</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.jaut.2009.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaut.2009.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DTiegs%26aufirst%3DG.%26aulast%3DLohse%26aufirst%3DA.%2BW.%26atitle%3DImmune%2520Tolerance%253A%2520What%2520is%2520Unique%2520About%2520the%2520Liver%26jtitle%3DJ.%2520Autoimmun.%26date%3D2010%26volume%3D34%26spage%3D1%26epage%3D6%26doi%3D10.1016%2Fj.jaut.2009.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cirulli, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicoletti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucena, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molokhia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafnar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">1707</span>– <span class="NLM_lpage">1716</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2019.01.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1053%2Fj.gastro.2019.01.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30664875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXns1GltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2019&pages=1707-1716&author=E.+T.+Cirulliauthor=P.+Nicolettiauthor=K.+Abramsonauthor=R.+J.+Andradeauthor=E.+S.+Bjornssonauthor=N.+Chalasaniauthor=R.+J.+Fontanaauthor=P.+Hallbergauthor=Y.+J.+Liauthor=M.+I.+Lucenaauthor=N.+Longauthor=M.+Molokhiaauthor=M.+R.+Nelsonauthor=J.+A.+Odinauthor=M.+Pirmohamedauthor=T.+Rafnarauthor=J.+Serranoauthor=K.+Stefanssonauthor=A.+Stolzauthor=A.+K.+Dalyauthor=G.+P.+Aithalauthor=P.+B.+Watkins&title=A+Missense+Variant+in+PTPN22+is+a+Risk+Factor+for+Drug-induced+Liver+Injury&doi=10.1053%2Fj.gastro.2019.01.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury</span></div><div class="casAuthors">Cirulli, Elizabeth T.; Nicoletti, Paola; Abramson, Karen; Andrade, Raul J.; Bjornsson, Einar S.; Chalasani, Naga; Fontana, Robert J.; Hallberg, Par; Li, Yi Ju; Lucena, M. Isabel; Long, Nanye; Molokhia, Mariam; Nelson, Matthew R.; Odin, Joseph A.; Pirmohamed, Munir; Rafnar, Thorunn; Serrano, Jose; Stefansson, Kari; Stolz, Andrew; Daly, Ann K.; Aithal, Guruprasad P.; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1707-1716.e2</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We performed genetic analyses of a multiethnic cohort of patients with idiosyncratic drug-induced liver injury (DILI) to identify variants assocd. with susceptibility.  We performed a genome-wide assocn. study of 2048 individuals with DILI (cases) and 12,429 individuals without (controls).  Our anal. included subjects of European (1806 cases and 10,397 controls), African American (133 cases and 1,314 controls), and Hispanic (109 cases and 718 controls) ancestry.  We analyzed DNA from 113 Icelandic cases and 239,304 controls to validate our findings.  We assocd. idiosyncratic DILI with rs2476601, a nonsynonymous polymorphism that encodes a substitution of tryptophan with arginine in the protein tyrosine phosphatase, nonreceptor type 22 gene (PTPN22) (odds ratio [OR] 1.44; 95% confidence interval [CI] 1.28-1.62; P = 1.2 × 10-9 and replicated the finding in the validation set (OR 1.48; 95% CI 1.09-1.99; P = .01)).  The minor allele frequency showed the same effect size (OR > 1) among ethnic groups.  The strongest assocn. was with amoxicillin and clavulanate-assocd. DILI in persons of European ancestry (OR 1.62; 95% CI 1.32-1.98; P = 4.0 × 10-6; allele frequency = 13.3%), but the polymorphism was assocd. with DILI of other causes (OR 1.37; 95% CI 1.21-1.56; P = 1.5 × 10-6; allele frequency = 11.5%).  Among amoxicillin- and clavulanate-assocd. cases of European ancestry, rs2476601 doubled the risk for DILI among those with the HLA risk alleles A*02:01 and DRB1*15:01.  In a genome-wide assocn. study, we identified rs2476601 in PTPN22 as a non-HLA variant that assocs. with risk of liver injury caused by multiple drugs and validated our finding in a sep. cohort.  This variant has been assocd. with increased risk of autoimmune diseases, providing support for the concept that alterations in immune regulation contribute to idiosyncratic DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptv1LCetJnerVg90H21EOLACvtfcHk0liU-o6K6WP0qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXns1GltbY%253D&md5=d63acc4a517bcab6fc1e4276ef2f766c</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2019.01.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2019.01.034%26sid%3Dliteratum%253Aachs%26aulast%3DCirulli%26aufirst%3DE.%2BT.%26aulast%3DNicoletti%26aufirst%3DP.%26aulast%3DAbramson%26aufirst%3DK.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3DBjornsson%26aufirst%3DE.%2BS.%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DHallberg%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DY.%2BJ.%26aulast%3DLucena%26aufirst%3DM.%2BI.%26aulast%3DLong%26aufirst%3DN.%26aulast%3DMolokhia%26aufirst%3DM.%26aulast%3DNelson%26aufirst%3DM.%2BR.%26aulast%3DOdin%26aufirst%3DJ.%2BA.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DRafnar%26aufirst%3DT.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DStefansson%26aufirst%3DK.%26aulast%3DStolz%26aufirst%3DA.%26aulast%3DDaly%26aufirst%3DA.%2BK.%26aulast%3DAithal%26aufirst%3DG.%2BP.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DA%2520Missense%2520Variant%2520in%2520PTPN22%2520is%2520a%2520Risk%2520Factor%2520for%2520Drug-induced%2520Liver%2520Injury%26jtitle%3DGastroenterology%26date%3D2019%26volume%3D156%26spage%3D1707%26epage%3D1716%26doi%3D10.1053%2Fj.gastro.2019.01.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burn, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Blanco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cope, A. P.</span></span> <span> </span><span class="NLM_article-title">Why is PTPN22 a Good Candidate Susceptibility Gene for Autoimmune Disease?</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>585</i></span>,  <span class="NLM_fpage">3689</span>– <span class="NLM_lpage">3698</span>, <span class="refDoi"> DOI: 10.1016/j.febslet.2011.04.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.febslet.2011.04.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21515266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFSis7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=585&publication_year=2011&pages=3689-3698&author=G.+L.+Burnauthor=L.+Svenssonauthor=C.+Sanchez-Blancoauthor=M.+Sainiauthor=A.+P.+Cope&title=Why+is+PTPN22+a+Good+Candidate+Susceptibility+Gene+for+Autoimmune+Disease%3F&doi=10.1016%2Fj.febslet.2011.04.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Why is PTPN22 a good candidate susceptibility gene for autoimmune disease?</span></div><div class="casAuthors">Burn, Garth L.; Svensson, Lena; Sanchez-Blanco, Cristina; Saini, Manoj; Cope, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">585</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3689-3698</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The PTPN22 locus is one of the strongest risk factors outside of the major histocompatibility complex that assocs. with autoimmune diseases.  PTPN22 encodes lymphoid protein tyrosine phosphatase (Lyp) which is expressed exclusively in immune cells.  A single base change in the coding region of this gene resulting in an arginine to tryptophan amino acid substitution within a polyproline binding motif assocs. with type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosis, Hashimoto's thyroiditis, Graves disease, Addison's disease, Myasthenia Gravis, vitiligo, systemic sclerosis juvenile idiopathic arthritis and psoriatic arthritis.  Here, the authors review the current understanding of the PTPN22 locus from a genetic, geog., biochem. and functional perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOSppGQyuZ57Vg90H21EOLACvtfcHk0lhJg7KRF2m5Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFSis7%252FL&md5=4521c8655b07be45008dad58a801d1c0</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2011.04.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2011.04.032%26sid%3Dliteratum%253Aachs%26aulast%3DBurn%26aufirst%3DG.%2BL.%26aulast%3DSvensson%26aufirst%3DL.%26aulast%3DSanchez-Blanco%26aufirst%3DC.%26aulast%3DSaini%26aufirst%3DM.%26aulast%3DCope%26aufirst%3DA.%2BP.%26atitle%3DWhy%2520is%2520PTPN22%2520a%2520Good%2520Candidate%2520Susceptibility%2520Gene%2520for%2520Autoimmune%2520Disease%253F%26jtitle%3DFEBS%2520Lett.%26date%3D2011%26volume%3D585%26spage%3D3689%26epage%3D3698%26doi%3D10.1016%2Fj.febslet.2011.04.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stanford, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottini, N.</span></span> <span> </span><span class="NLM_article-title">PTPN22: The Archetypal Non-HLA Autoimmunity Gene</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">602</span>– <span class="NLM_lpage">611</span>, <span class="refDoi"> DOI: 10.1038/nrrheum.2014.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fnrrheum.2014.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25003765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFCkt77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=602-611&author=S.+M.+Stanfordauthor=N.+Bottini&title=PTPN22%3A+The+Archetypal+Non-HLA+Autoimmunity+Gene&doi=10.1038%2Fnrrheum.2014.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">PTPN22: the archetypal non-HLA autoimmunity gene</span></div><div class="casAuthors">Stanford, Stephanie M.; Bottini, Nunzio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">602-611</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  PTPN22 encodes a tyrosine phosphatase that is expressed by haematopoietic cells and functions as a key regulator of immune homeostasis by inhibiting T-cell receptor signalling and by selectively promoting type I interferon responses after activation of myeloid-cell pattern-recognition receptors.  A single nucleotide polymorphism of PTPN22, 1858C>T (rs2476601), disrupts an interaction motif in the protein, and is the most important non-HLA genetic risk factor for rheumatoid arthritis and the second most important for juvenile idiopathic arthritis.  PTPN22 exemplifies a shared autoimmunity gene, affecting the pathogenesis of systemic lupus erythematosus, vasculitis and other autoimmune diseases.  In this Review, we explore the role of PTPN22 in autoimmune connective tissue disease, with particular emphasis on candidate-gene and genome-wide assocn. studies and clin. variability of disease.  We also propose a no. of PTPN22-dependent functional models of the pathogenesis of autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdec0zXDfJr7Vg90H21EOLACvtfcHk0lhJg7KRF2m5Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFCkt77E&md5=d4f9f8fa45baa963c27c212755e05456</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2014.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2014.109%26sid%3Dliteratum%253Aachs%26aulast%3DStanford%26aufirst%3DS.%2BM.%26aulast%3DBottini%26aufirst%3DN.%26atitle%3DPTPN22%253A%2520The%2520Archetypal%2520Non-HLA%2520Autoimmunity%2520Gene%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2014%26volume%3D10%26spage%3D602%26epage%3D611%26doi%3D10.1038%2Fnrrheum.2014.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">Effects of Immunization and Checkpoint Inhibition on Amodiaquine-Induced Liver Injury</span>. <i>J. Immunotoxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1080/1547691X.2017.1290716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1080%2F1547691X.2017.1290716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28279082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktFWjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=89-94&author=A.+Makauthor=A.+Johnstonauthor=J.+Uetrecht&title=Effects+of+Immunization+and+Checkpoint+Inhibition+on+Amodiaquine-Induced+Liver+Injury&doi=10.1080%2F1547691X.2017.1290716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of immunization and checkpoint inhibition on amodiaquine-induced liver injury</span></div><div class="casAuthors">Mak, Alastair; Johnston, Alexander; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunotoxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-94</span>CODEN:
                <span class="NLM_cas:coden">JIOMAP</span>;
        ISSN:<span class="NLM_cas:issn">1547-691X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">If idiosyncratic drug-induced liver injury (IDILI) is immune-mediated, it is possible that an individual's prior exposure to antigens may affect their susceptibility to IDILI.  An individual's repertoire of memory immune cells is shaped by every past exposure to antigens.  Subsequent drug-induced adverse drug reactions may therefore involve an immune cell's cross reactivity between a prior antigen and resulting drug-modified proteins.  Therefore in this expt., mice were immunized with amodiaquine (AQ)-modified hepatic proteins to mimic a previous exposure; treated with a RIBI adjuvant and anti-CD40 antibodies to stimulate an immune response; and, treated with anti-PD1 and anti-CTLA-4 antibodies prior to AQ treatment in order to overcome immune tolerance.  This treatment led to greater liver injury than treatment with AQ alone.  However, the mice did not develop serious liver injury.  PD1-/- mice were then immunized and treated with AQ and anti-CTLA-4 antibodies so that immune tolerance would be impaired, both during immunization and also during AQ treatment.  However, even this did not result in liver failure, and the liver injury was not significantly increased relative to un-immunized PD1-/- mice treated with anti-CTLA-4 and AQ.  From these results we conclude that, although previous antigen exposure may affect the risk of IDILI, it appears that a very strong stimulus is required, and impairing immune tolerance remains the most effective method for producing an animal model of IDILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLUPDIbD5Z0bVg90H21EOLACvtfcHk0lhJg7KRF2m5Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktFWjt7Y%253D&md5=2c4c7f1565bee1d31ea492ed97f686f8</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1080%2F1547691X.2017.1290716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1547691X.2017.1290716%26sid%3Dliteratum%253Aachs%26aulast%3DMak%26aufirst%3DA.%26aulast%3DJohnston%26aufirst%3DA.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DEffects%2520of%2520Immunization%2520and%2520Checkpoint%2520Inhibition%2520on%2520Amodiaquine-Induced%2520Liver%2520Injury%26jtitle%3DJ.%2520Immunotoxicol.%26date%3D2017%26volume%3D14%26spage%3D89%26epage%3D94%26doi%3D10.1080%2F1547691X.2017.1290716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Depta, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, W. J.</span></span> <span> </span><span class="NLM_article-title">Cross-Reactivity with Drugs at the T-cell Level</span>. <i>Current Opinion in Allergy and Clinical Immunology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1097/00130832-200308000-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1097%2F00130832-200308000-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=12865769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptlahu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=261-267&author=J.+P.+Deptaauthor=W.+J.+Pichler&title=Cross-Reactivity+with+Drugs+at+the+T-cell+Level&doi=10.1097%2F00130832-200308000-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Cross-reactivity with drugs at the T cell level</span></div><div class="casAuthors">Depta, Jan P. H.; Pichler, Werner J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">261-267</span>CODEN:
                <span class="NLM_cas:coden">COACCS</span>;
        ISSN:<span class="NLM_cas:issn">1528-4050</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Purpose of review Cross-reactivity with drugs is an important clin. problem in drug hypersensitivity.  Once a patient is labeled 'drug-allergic' all drugs of the same class are withheld and future therapeutic interventions are limited.  Here the authors review cross-reactivity with drugs at the T cell level.  Recent findings Anal. of T cell recognition of various classes of drugs (β-lactam antibiotics, sulfonamides, local anesthetics) using T cell clones suggests that at the T cell level the whole structure, in particular the core and to a lesser degree side chains, are recognized.  Summary It is necessary to differentiate cross-reactivity mediated by T cells and antibodies as only the latter seem to recognize side chains exclusively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjsGqKpA1lRbVg90H21EOLACvtfcHk0liVnha0x-6Nng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptlahu70%253D&md5=9ec4c3ec858f5d3cded7afc85c7a94ad</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1097%2F00130832-200308000-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00130832-200308000-00005%26sid%3Dliteratum%253Aachs%26aulast%3DDepta%26aufirst%3DJ.%2BP.%26aulast%3DPichler%26aufirst%3DW.%2BJ.%26atitle%3DCross-Reactivity%2520with%2520Drugs%2520at%2520the%2520T-cell%2520Level%26jtitle%3DCurrent%2520Opinion%2520in%2520Allergy%2520and%2520Clinical%2520Immunology%26date%3D2003%26volume%3D3%26spage%3D261%26epage%3D267%26doi%3D10.1097%2F00130832-200308000-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, P. G.</span></span> <span> </span><span class="NLM_article-title">The Two Faces of Heterologous Immunity: Protection or Immunopathology</span>. <i>J. Leukocyte Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1189/jlb.0713386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1189%2Fjlb.0713386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24212098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVOisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2014&pages=405-416&author=S.+Sharmaauthor=P.+G.+Thomas&title=The+Two+Faces+of+Heterologous+Immunity%3A+Protection+or+Immunopathology&doi=10.1189%2Fjlb.0713386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">The two faces of heterologous immunity: protection or immunopathology</span></div><div class="casAuthors">Sharma, Shalini; Thomas, Paul G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-416, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Society for Leukocyte Biology</span>)
        </div><div class="casAbstract">A review.  Immunity to previously encountered viruses can alter responses to unrelated pathogens.  This phenomenon, which is known as heterologous immunity, has been well established in animal model systems.  Heterologous immunity appears to be relatively common and may be beneficial by boosting protective responses.  However, heterologous reactivity can also result in severe immunopathol.  The key features that define heterologous immune modulation include alterations in the CD4+ and CD8- T cell compartments and changes in viral dynamics and disease progression.  In this review, we discuss recent advances and the current understanding of antiviral immunity in heterologous infections.  The difficulties of studying these complex heterologous infections in humans are discussed, with special ref. to the variations in HLA haplotypes and uncertainties about individuals' infection history.  Despite these limitations, epidemiol. analyses in humans and the data from mouse models of coinfection can be applied toward advancing the design of therapeutics and vaccination strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx0Ka-JDzfd7Vg90H21EOLACvtfcHk0liVnha0x-6Nng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVOisbc%253D&md5=42fc699256776ad36c83926825fb15d9</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1189%2Fjlb.0713386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.0713386%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DP.%2BG.%26atitle%3DThe%2520Two%2520Faces%2520of%2520Heterologous%2520Immunity%253A%2520Protection%2520or%2520Immunopathology%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2014%26volume%3D95%26spage%3D405%26epage%3D416%26doi%3D10.1189%2Fjlb.0713386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pavlos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanjalla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallal, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, E. J.</span></span> <span> </span><span class="NLM_article-title">Severe Delayed Drug Reactions: Role of Genetics and Viral Infections</span>. <i>Immunol. Allergy Clin. North Am.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">785</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1016/j.iac.2017.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.iac.2017.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28965641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FktVOitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=785-815&author=R.+Pavlosauthor=K.+D.+Whiteauthor=C.+Wanjallaauthor=S.+A.+Mallalauthor=E.+J.+Phillips&title=Severe+Delayed+Drug+Reactions%3A+Role+of+Genetics+and+Viral+Infections&doi=10.1016%2Fj.iac.2017.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Severe Delayed Drug Reactions: Role of Genetics and Viral Infections</span></div><div class="casAuthors">Pavlos Rebecca; White Katie D; Wanjalla Celestine; Mallal Simon A; Phillips Elizabeth J</div><div class="citationInfo"><span class="NLM_cas:title">Immunology and allergy clinics of North America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">785-815</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Adverse drug reactions (ADRs) are a significant source of patient morbidity and mortality and represent a major burden to health care systems and drug development.  Up to 50% of such reactions are preventable.  Although many ADRs can be predicted based on the on-target pharmacologic activity, ADRs arising from drug interactions with off-target receptors are recognized.  Off-target ADRs include the immune-mediated ADRs (IM-ADRs) and pharmacologic drug effects.  In this review, we discuss what is known about the immunogenetics and pathogenesis of IM-ADRs and the hypothesized role of heterologous immunity in the development of IM-ADRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQp7-aOJsEAoZcXNb62YGmbfW6udTcc2eY4lQyiqMUG6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FktVOitg%253D%253D&md5=21f9835291cfffeae352236238db4d3b</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.iac.2017.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.iac.2017.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DPavlos%26aufirst%3DR.%26aulast%3DWhite%26aufirst%3DK.%2BD.%26aulast%3DWanjalla%26aufirst%3DC.%26aulast%3DMallal%26aufirst%3DS.%2BA.%26aulast%3DPhillips%26aufirst%3DE.%2BJ.%26atitle%3DSevere%2520Delayed%2520Drug%2520Reactions%253A%2520Role%2520of%2520Genetics%2520and%2520Viral%2520Infections%26jtitle%3DImmunol.%2520Allergy%2520Clin.%2520North%2520Am.%26date%3D2017%26volume%3D37%26spage%3D785%26epage%3D815%26doi%3D10.1016%2Fj.iac.2017.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strhyn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keane, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinnon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer-Pannwitt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudieri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Orsogna, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrov, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, E.</span></span> <span> </span><span class="NLM_article-title">Abacavir-Reactive Memory T-cells are Present in Drug Naive Individuals</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e0117160</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0117160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1371%2Fjournal.pone.0117160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25674793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVGrsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0117160&author=A.+Lucasauthor=M.+Lucasauthor=A.+Strhynauthor=N.+M.+Keaneauthor=E.+McKinnonauthor=R.+Pavlosauthor=E.+M.+Moranauthor=V.+Meyer-Pannwittauthor=S.+Gaudieriauthor=L.+D%E2%80%99Orsognaauthor=S.+Kalamsauthor=D.+A.+Ostrovauthor=S.+Buusauthor=B.+Petersauthor=S.+Mallalauthor=E.+Phillips&title=Abacavir-Reactive+Memory+T-cells+are+Present+in+Drug+Naive+Individuals&doi=10.1371%2Fjournal.pone.0117160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Abacavir-reactive memory T cells are present in drug naive individuals</span></div><div class="casAuthors">Lucas, Andrew; Lucas, Michaela; Strhyn, Anette; Keane, Niamh M.; McKinnon, Elizabeth; Pavlos, Rebecca; Moran, Ellen M.; Meyer-Pannwitt, Viola; Gaudieri, Silvana; D'Orsogna, Lloyd; Kalams, Spyros; Ostrov, David A.; Buus, Soeren; Peters, Bjoern; Mallal, Simon; Phillips, Elizabeth</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e0117160/1-e0117160/16</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Fifty-five percent of individuals with HLA-B*57:01 exposed to the antiretroviral drug abacavir develop a hypersensitivity reaction (HSR) that has been attributed to naive T-cell responses to neo-antigen generated by the drug.  Immunol. confirmed abacavir HSR can manifest clin. in less than 48 h following first exposure suggesting that, at least in some cases, abacavir HSR is due to re-stimulation of a pre-existing memory T-cell population rather than priming of a high frequency naive T-cell population.  Methods: To det. whether a pre-existing abacavir reactive memory T-cell population contributes to early abacavir HSR symptoms, we studied the abacavir specific naive or memory T-cell response using HLA-B*57:01 pos. HSR patients or healthy controls using ELISpot assay, intra-cellular cytokine staining and tetramer labeling.  Results: Abacavir reactive CD8+ T-cell responses were detected in vitro in one hundred percent of abacavir unexposed HLA-B*57:01 pos. healthy donors.  Abacavir-specific CD8+ T cells from such donors can be expanded from sorted memory, and sorted naive, CD8+ T cells without need for autologous CD4+ T cells.  Conclusions: We propose that these pre-existing abacavir-reactive memory CD8+ T-cell responses must have been primed by earlier exposure to another foreign antigen and that these T cells cross-react with an abacavir-HLA-B*57:01-endogenous peptide ligand complex, in keeping with the model of heterologous immunity proposed in transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGP2OSzHNfaLVg90H21EOLACvtfcHk0lhWRMXXUQTGUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVGrsrvJ&md5=278bb38997ebc639c1ee1868d9d95443</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0117160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0117160%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DA.%26aulast%3DLucas%26aufirst%3DM.%26aulast%3DStrhyn%26aufirst%3DA.%26aulast%3DKeane%26aufirst%3DN.%2BM.%26aulast%3DMcKinnon%26aufirst%3DE.%26aulast%3DPavlos%26aufirst%3DR.%26aulast%3DMoran%26aufirst%3DE.%2BM.%26aulast%3DMeyer-Pannwitt%26aufirst%3DV.%26aulast%3DGaudieri%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Orsogna%26aufirst%3DL.%26aulast%3DKalams%26aufirst%3DS.%26aulast%3DOstrov%26aufirst%3DD.%2BA.%26aulast%3DBuus%26aufirst%3DS.%26aulast%3DPeters%26aufirst%3DB.%26aulast%3DMallal%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DE.%26atitle%3DAbacavir-Reactive%2520Memory%2520T-cells%2520are%2520Present%2520in%2520Drug%2520Naive%2520Individuals%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0117160%26doi%3D10.1371%2Fjournal.pone.0117160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, K. L.</span></span> <span> </span><span class="NLM_article-title">Systems Pharmacology Modeling Predicts Delayed Presentation and Species Differences in Bile Acid-Mediated Troglitazone Hepatotoxicity</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">598</span>, <span class="refDoi"> DOI: 10.1038/clpt.2014.158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fclpt.2014.158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25068506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyltrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2014&pages=589-598&author=K.+Yangauthor=J.+L.+Woodheadauthor=P.+B.+Watkinsauthor=B.+A.+Howellauthor=K.+L.+Brouwer&title=Systems+Pharmacology+Modeling+Predicts+Delayed+Presentation+and+Species+Differences+in+Bile+Acid-Mediated+Troglitazone+Hepatotoxicity&doi=10.1038%2Fclpt.2014.158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Systems Pharmacology Modeling Predicts Delayed Presentation and Species Differences in Bile Acid-Mediated Troglitazone Hepatotoxicity</span></div><div class="casAuthors">Yang, K.; Woodhead, J. L.; Watkins, P. B.; Howell, B. A.; Brouwer, K. L. R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">589-598</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Troglitazone (TGZ) causes delayed, life-threatening drug-induced liver injury in some patients but was not hepatotoxic in rats.  This study investigated altered bile acid homeostasis as a mechanism of TGZ hepatotoxicity using a systems pharmacol. model incorporating drug/metabolite disposition, bile acid physiol./pathophysiol., hepatocyte life cycle, and liver injury biomarkers.  In the simulated human population, TGZ (200-600 mg/day × 6 mo) resulted in delayed increases in serum alanine transaminase >3× the upper limit of normal in 0.3-5.1%, with concomitant bilirubin elevations >2× the upper limit of normal in 0.3-3.6%, of the population.  By contrast, pioglitazone (15-45 mg/day × 6 mo) did not elicit hepatotoxicity, consistent with clin. data.  TGZ was not hepatotoxic in the simulated rat population.  In summary, mechanistic modeling based only on bile acid effects accurately predicted the incidence, delayed presentation, and species differences in TGZ hepatotoxicity, in addn. to predicting the relative liver safety of pioglitazone.  Systems pharmacol. models integrating physiol. and exptl. data can evaluate drug-induced liver injury mechanisms and may be useful to predict the hepatotoxic potential of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSRsvjs2JmfLVg90H21EOLACvtfcHk0lhWRMXXUQTGUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyltrrP&md5=4167aafc1abad72d6a30c20c2f82c318</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2014.158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2014.158%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DK.%26aulast%3DWoodhead%26aufirst%3DJ.%2BL.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DHowell%26aufirst%3DB.%2BA.%26aulast%3DBrouwer%26aufirst%3DK.%2BL.%26atitle%3DSystems%2520Pharmacology%2520Modeling%2520Predicts%2520Delayed%2520Presentation%2520and%2520Species%2520Differences%2520in%2520Bile%2520Acid-Mediated%2520Troglitazone%2520Hepatotoxicity%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2014%26volume%3D96%26spage%3D589%26epage%3D598%26doi%3D10.1038%2Fclpt.2014.158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brock, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoaf, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grammatopoulos, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siler, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoda, L. K.</span></span> <span> </span><span class="NLM_article-title">Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfw193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfw193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27655350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFajt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2017&pages=61-74&author=J.+L.+Woodheadauthor=W.+J.+Brockauthor=S.+E.+Rothauthor=S.+E.+Shoafauthor=K.+L.+Brouwerauthor=R.+Churchauthor=T.+N.+Grammatopoulosauthor=L.+Stilesauthor=S.+Q.+Silerauthor=B.+A.+Howellauthor=M.+Mosedaleauthor=P.+B.+Watkinsauthor=L.+K.+Shoda&title=Application+of+a+Mechanistic+Model+to+Evaluate+Putative+Mechanisms+of+Tolvaptan+Drug-Induced+Liver+Injury+and+Identify+Patient+Susceptibility+Factors&doi=10.1093%2Ftoxsci%2Fkfw193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Application of a mechanistic model to evaluate putative mechanisms of tolvaptan drug-induced liver injury and identify patient susceptibility factors</span></div><div class="casAuthors">Woodhead, Jeffrey L.; Brock, William J.; Roth, Sharin E.; Shoaf, Susan E.; Brouwer, Kim L. R.; Church, Rachel; Grammatopoulos, Tom N.; Stiles, Linsey; Siler, Scott Q.; Howell, Brett A.; Mosedale, Merrie; Watkins, Paul B.; Shoda, Lisl K. M.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-74</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Tolvaptan is a selective vasopressin V2 receptor antagonist, approved in several countries for the treatment of hyponatremia and autosomal dominant polycystic kidney disease (ADPKD).  No liver injury has been obsd. with tolvaptan treatment in healthy subjects and in non-ADPKD indications, but ADPKD clin. trials showed evidence of drug-induced liver injury (DILI).  Although all DILI events resolved, addnl. monitoring in tolvaptan-treated ADPKD patients is required.  In vitro assays identified alterations in bile acid disposition and inhibition of mitochondrial respiration as potential mechanisms underlying tolvaptan hepatotoxicity.  This report details the application of DILIsym software to det. whether these mechanisms could account for the liver safety profile of tolvaptan obsd. in ADPKD clin. trials.  DILIsym simulations included physiol. based pharmacokinetic ests. of hepatic exposure for tolvaptan and 2 metabolites, and their effects on hepatocyte bile acid transporters and mitochondrial respiration.  The frequency of predicted alanine aminotransferase (ALT) elevations, following simulated 90/30 mg split daily dosing, was 7.9% compared with clin. observations of 4.4% in ADPKD trials.  Toxicity was multifactorial as inhibition of bile acid transporters and mitochondrial respiration contributed to the simulated DILI.  Furthermore, simulation anal. identified both pre-treatment risk factors and on-treatment biomarkers predictive of simulated DILI.  The simulations demonstrated that in vivo hepatic exposure to tolvaptan and the DM-4103 metabolite, combined with these 2 mechanisms of toxicity, were sufficient to account for the initiation of tolvaptan-mediated DILI.  Identification of putative risk-factors and potential novel biomarkers provided insight for the development of mechanism-based tolvaptan risk-mitigation strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpiYRo4rMfDLVg90H21EOLACvtfcHk0lhWRMXXUQTGUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFajt7Y%253D&md5=4a4f9d8389bf27b898eb2ed1adf5bb69</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfw193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfw193%26sid%3Dliteratum%253Aachs%26aulast%3DWoodhead%26aufirst%3DJ.%2BL.%26aulast%3DBrock%26aufirst%3DW.%2BJ.%26aulast%3DRoth%26aufirst%3DS.%2BE.%26aulast%3DShoaf%26aufirst%3DS.%2BE.%26aulast%3DBrouwer%26aufirst%3DK.%2BL.%26aulast%3DChurch%26aufirst%3DR.%26aulast%3DGrammatopoulos%26aufirst%3DT.%2BN.%26aulast%3DStiles%26aufirst%3DL.%26aulast%3DSiler%26aufirst%3DS.%2BQ.%26aulast%3DHowell%26aufirst%3DB.%2BA.%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DShoda%26aufirst%3DL.%2BK.%26atitle%3DApplication%2520of%2520a%2520Mechanistic%2520Model%2520to%2520Evaluate%2520Putative%2520Mechanisms%2520of%2520Tolvaptan%2520Drug-Induced%2520Liver%2520Injury%2520and%2520Identify%2520Patient%2520Susceptibility%2520Factors%26jtitle%3DToxicol.%2520Sci.%26date%3D2017%26volume%3D155%26spage%3D61%26epage%3D74%26doi%3D10.1093%2Ftoxsci%2Fkfw193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isley, W. L.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxicity of Thiazolidinediones</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">586</span>, <span class="refDoi"> DOI: 10.1517/14740338.2.6.581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1517%2F14740338.2.6.581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=14585066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvFertrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=581-586&author=W.+L.+Isley&title=Hepatotoxicity+of+Thiazolidinediones&doi=10.1517%2F14740338.2.6.581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity of thiazolidinediones</span></div><div class="casAuthors">Isley, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">581-586</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Thiazolidinediones are insulin sensitizers now widely used for the treatment of Type 2 diabetes mellitus.  The initial marketed drug in this class, troglitazone, was removed from the market worldwide after approx. 3 yr of use due to rare but severe hepatotoxicity, which sometimes resulted in liver failure leading to the need for liver transplantation, or even death.  The unpredictability of such liver toxicity made the use of troglitazone highly problematic.  Fortunately, the two newer drugs in this class, rosiglitazone and pioglitazone, have a much larger margin of safety for liver toxicity.  Very rare reports of liver toxicity, usually milder and reversible, have been seen with these drugs.  Therefore, while pharmacovigilance for hepatotoxicity is probably still warranted, the practitioner and patient can be fairly confident that these drugs are safe from a liver standpoint.  Finally, recent work would suggest that these agents may prove useful to reduce hepatic fat in patients with non-alc. steatohepatitis, and may possibly protect against adverse metabolic consequences and the ultimate development of cirrhosis in patients with fatty livers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQgG8CxGlRbLVg90H21EOLACvtfcHk0lg3lFGBgMGVbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvFertrg%253D&md5=2b69829bb735bf4851d2130be0004c80</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1517%2F14740338.2.6.581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.2.6.581%26sid%3Dliteratum%253Aachs%26aulast%3DIsley%26aufirst%3DW.%2BL.%26atitle%3DHepatotoxicity%2520of%2520Thiazolidinediones%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2003%26volume%3D2%26spage%3D581%26epage%3D586%26doi%3D10.1517%2F14740338.2.6.581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weston, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">Activation of Inflammasomes by Agents Causing Idiosyncratic Skin Reactions: A Possible Biomarker</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">951</span>, <span class="refDoi"> DOI: 10.1021/tx5001333</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx5001333" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVGmt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=949-951&author=J.+K.+Westonauthor=J.+Uetrecht&title=Activation+of+Inflammasomes+by+Agents+Causing+Idiosyncratic+Skin+Reactions%3A+A+Possible+Biomarker&doi=10.1021%2Ftx5001333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of Inflammasomes by Agents Causing Idiosyncratic Skin Reactions: A Possible Biomarker</span></div><div class="casAuthors">Weston, J. Kyle; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">949-951</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chem. reactive drugs and drugs that form reactive metabolites often cause idiosyncratic drug reactions (IDRs); however, not all such drugs are assocd. with IDRs.  Most IDRs appear to be immune mediated; therefore, the ability of a drug to induce an immune response may be the determinant of which drugs will cause IDRs.  Inflammasome activation plays an important role in the initiation of an immune response.  In this study, we studied two pairs of similar chem. reactive drugs, telaprevir/boceprevir and di-Me fumarate/ethacrynic acid.  In both pairs, the drug assocd. with skin reactions activated inflammasomes in THP-1 cells, and the drug not assocd. with skin reactions did not.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFQpmKwqoQibVg90H21EOLACvtfcHk0lg3lFGBgMGVbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVGmt7w%253D&md5=264b29824e6f6487f8294adbc2393f71</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Ftx5001333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx5001333%26sid%3Dliteratum%253Aachs%26aulast%3DWeston%26aufirst%3DJ.%2BK.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DActivation%2520of%2520Inflammasomes%2520by%2520Agents%2520Causing%2520Idiosyncratic%2520Skin%2520Reactions%253A%2520A%2520Possible%2520Biomarker%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2014%26volume%3D27%26spage%3D949%26epage%3D951%26doi%3D10.1021%2Ftx5001333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lammert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einarsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niklasson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span> <span> </span><span class="NLM_article-title">Relationship Between Daily Dose of Oral Medications and Idiosyncratic Drug-Induced Liver Injury: Search for Signals</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2003</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1002/hep.22272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.22272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=18454504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVagt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=2003-2009&author=C.+Lammertauthor=S.+Einarssonauthor=C.+Sahaauthor=A.+Niklassonauthor=E.+Bjornssonauthor=N.+Chalasani&title=Relationship+Between+Daily+Dose+of+Oral+Medications+and+Idiosyncratic+Drug-Induced+Liver+Injury%3A+Search+for+Signals&doi=10.1002%2Fhep.22272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals</span></div><div class="casAuthors">Lammert, Craig; Einarsson, Stefan; Saha, Chandan; Niklasson, Anna; Bjornsson, Einar; Chalasani, Naga</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2003-2009</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Idiosyncratic drug-induced liver injury (DILI) is traditionally thought not to be dose-related.  However, it has been pointed out that most medicines that were withdrawn from marketing or received a black-box warning because of hepatotoxicity were prescribed at daily doses greater than 50 mg/day.  To examine the relationship between daily dose of medications and idiosyncratic DILI, we conducted a study with two aims.  First, using two pharmaceutical databases, we examd. the relationship between daily dose of commonly prescribed medicines in the United States and reported frequency of their selected hepatic adverse events.  Second, we examd. serious DILI cases reported to the Swedish Adverse Drug Reactions Advisory Committee (1970-2004) for any signals supporting the relationship between daily dose and idiosyncratic DILI.  Medications were categorized into ≤10 mg/day, 11-49 mg/day, and ≥50 mg/day groups.  Among US prescription medicines, a statistically significant relationship was obsd. between daily dose of oral medicines and reports of liver failure (P = 0.009), liver transplantation (P < 0.001), and death caused by DILI (P = 0.004) but not alanine aminotransferase (ALT) > 3 × upper limit of normal (P = 0.10) or jaundice (P = 0.16).  Of 598 eligible Swedish DILI cases, 9% belonged to the ≤10 mg/day group, 14.2% to the 11-49 mg/day group, and 77% of cases were caused by medications given at dose ≥50 mg/day.  A statistically significant relationship was noted between daily dose and poor outcome (death or liver transplantation) of Swedish DILI cases (2%, 9.4%, and 13.2% in ≤10, 11-49, and ≥50 mg/day groups, resp., P = 0.03).  Conclusion: These data suggest a relationship between daily doses of oral prescription medications and idiosyncratic DILI.  More studies are needed to validate these observations and to explore their implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-pByO6X3Hk7Vg90H21EOLACvtfcHk0lg3lFGBgMGVbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVagt7w%253D&md5=f497d61a5253cc653c2d955232471d65</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1002%2Fhep.22272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.22272%26sid%3Dliteratum%253Aachs%26aulast%3DLammert%26aufirst%3DC.%26aulast%3DEinarsson%26aufirst%3DS.%26aulast%3DSaha%26aufirst%3DC.%26aulast%3DNiklasson%26aufirst%3DA.%26aulast%3DBjornsson%26aufirst%3DE.%26aulast%3DChalasani%26aufirst%3DN.%26atitle%3DRelationship%2520Between%2520Daily%2520Dose%2520of%2520Oral%2520Medications%2520and%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%253A%2520Search%2520for%2520Signals%26jtitle%3DHepatology%26date%3D2008%26volume%3D47%26spage%3D2003%26epage%3D2009%26doi%3D10.1002%2Fhep.22272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lammert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niklasson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span> <span> </span><span class="NLM_article-title">Oral Medications with Significant Hepatic Metabolism at Higher Risk for Hepatic Adverse Events</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">615</span>– <span class="NLM_lpage">620</span>, <span class="refDoi"> DOI: 10.1002/hep.23317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.23317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19839004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisVGnsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=615-620&author=C.+Lammertauthor=E.+Bjornssonauthor=A.+Niklassonauthor=N.+Chalasani&title=Oral+Medications+with+Significant+Hepatic+Metabolism+at+Higher+Risk+for+Hepatic+Adverse+Events&doi=10.1002%2Fhep.23317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events</span></div><div class="casAuthors">Lammert, Craig; Bjornsson, Einar; Niklasson, Anna; Chalasani, Naga</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">615-620</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Reactive metabolites generated by hepatic metab. are thought to play an important role in the pathogenesis of drug-induced liver injury (DILI), but supporting data are limited.  If this is true, then compds. with significant hepatic metab. should cause more DILI than those without it.  We conducted a study to examine the relationship between hepatic metab. and DILI of prescription medications.  We systematically extd. the metab. characteristics of 207 of the most widely prescribed oral medications in the United States.  Compds. with >50% hepatic metab. were characterized as those with significant hepatic metab. (n = 149).  Hepatic adverse events of interest were alanine aminotransferase >3 times the upper limit of normal, jaundice, liver failure, liver transplantation, or fatal DILI.  Compared with compds. with lesser hepatic metab., compds. belonging to the significant hepatic metab. group had significantly higher frequency of alanine aminotransferase >3 times the upper limit of normal (35% vs. 11%, P = 0.001), liver failure (28% vs. 9%, P = 0.004), and fatal DILI (23% vs. 4%, P = 0.001), but not jaundice (46% vs. 35%, P = 0.2) or liver transplantation (9% vs. 2%, P = 0.11).  Twelve compds. with no hepatic metab. had no reports of liver failure, liver transplantation, or fatal DILI.  When the relationship between hepatic adverse events and combination of hepatic metab. and daily dose was examd., compds. with both significant hepatic metab. and daily dose >50 mg (n = 50) were significantly more hepatotoxic than compds. belonging to other groups.  Compared with medications without biliary excretion, compds. with biliary excretion (n = 50) had significantly higher frequency of jaundice (74% vs. 40%, P = 0.0001).  Conclusion: Our study finds an important relationship between a compd.'s metab. profile and reports of hepatic adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG7fKH0KK8ObVg90H21EOLACvtfcHk0ljmM-1h6KjGYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisVGnsr8%253D&md5=ba90a857ce677fddb63ac6f3136c6b3b</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1002%2Fhep.23317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.23317%26sid%3Dliteratum%253Aachs%26aulast%3DLammert%26aufirst%3DC.%26aulast%3DBjornsson%26aufirst%3DE.%26aulast%3DNiklasson%26aufirst%3DA.%26aulast%3DChalasani%26aufirst%3DN.%26atitle%3DOral%2520Medications%2520with%2520Significant%2520Hepatic%2520Metabolism%2520at%2520Higher%2520Risk%2520for%2520Hepatic%2520Adverse%2520Events%26jtitle%3DHepatology%26date%3D2010%26volume%3D51%26spage%3D615%26epage%3D620%26doi%3D10.1002%2Fhep.23317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borlak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span> <span> </span><span class="NLM_article-title">High Lipophilicity and High Daily Dose of Oral Medications are Associated with Significant Eisk for Drug-Induced Liver Injury</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1002/hep.26208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.26208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23258593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVaisrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=388-396&author=M.+Chenauthor=J.+Borlakauthor=W.+Tong&title=High+Lipophilicity+and+High+Daily+Dose+of+Oral+Medications+are+Associated+with+Significant+Eisk+for+Drug-Induced+Liver+Injury&doi=10.1002%2Fhep.26208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury</span></div><div class="casAuthors">Chen, Minjun; Borlak, Juergen; Tong, Weida</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">388-396</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a leading cause of drug failure in clin. trials and a major reason for drug withdrawals from the market.  Although there is evidence that dosages of ≥100 mg/day are assocd. with increased risk for hepatotoxicity, many drugs are safe at such dosages.  There is an unmet need to predict risk for DILI more reliably, and lipophilicity might be a contributing factor.  We analyzed the combined factors of daily dose and lipophilicity for 164 US Food and Drug Administration-approved oral medications and obsd. high risk for hepatotoxicity (odds ratio [OR], 14.05; P < 0.001) for drugs given at dosages ≥100 mg/day and octanol-water partition coeff. (logP) ≥3.  This defined the "rule-of-two.".  Similar results were obtained for an independent set of 179 oral medications with 85% of the rule-of-two positives being assocd. with hepatotoxicity (OR, 3.89; P < 0.01).  Using the World Health Organization's Anatomical Therapeutic Chem. classification system, the rule-of-two performed best in predicting DILI in seven therapeutic categories.  Among 15 rule-of-two positives, 14 were withdrawn from hepatotoxic drugs, and one was over-the-counter medication labeled for liver injury.  We addnl. examd. drug pairs that have similar chem. structures and act on the same mol. target but differ in their potential for DILI.  Again, the rule-of-two predicted hepatotoxicity reliably.  Finally, the rule-of-two was applied to clin. case studies to identify hepatotoxic drugs in complex comedication regimes to further demonstrate its use.  Conclusion: Apart from dose, lipophilicity contributes significantly to risk for hepatotoxicity.  Applying the rule-of-two is an appropriate means of estg. risk for DILI compared with dose alone. (HEPATOl. 2013).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1EE02L_JCdLVg90H21EOLACvtfcHk0ljmM-1h6KjGYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVaisrrM&md5=a88e02ff29653bdeee53b59a4da46d06</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1002%2Fhep.26208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26208%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DBorlak%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DW.%26atitle%3DHigh%2520Lipophilicity%2520and%2520High%2520Daily%2520Dose%2520of%2520Oral%2520Medications%2520are%2520Associated%2520with%2520Significant%2520Eisk%2520for%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DHepatology%26date%3D2013%26volume%3D58%26spage%3D388%26epage%3D396%26doi%3D10.1002%2Fhep.26208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borlak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span> <span> </span><span class="NLM_article-title">A Model to Predict Severity of Drug-Induced Liver Injury in Humans</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">931</span>– <span class="NLM_lpage">940</span>, <span class="refDoi"> DOI: 10.1002/hep.28678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.28678" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27302180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOnu7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=931-940&author=M.+Chenauthor=J.+Borlakauthor=W.+Tong&title=A+Model+to+Predict+Severity+of+Drug-Induced+Liver+Injury+in+Humans&doi=10.1002%2Fhep.28678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A Model to predict severity of drug-induced liver injury in humans</span></div><div class="casAuthors">Chen, Minjun; Borlak, Juergen; Tong, Weida</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">931-940</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a major public health concern, and improving its prediction remains an unmet challenge.  Recently, we reported the Rule-of-2 (RO2) and found lipophilicity (logP ≥3) and daily dose ≥100 mg of oral medications to be assocd. with significant risk for DILI; however, the RO2 failed to est. grades of DILI severity.  In an effort to develop a quant. metrics, we analyzed the assocn. of daily dose, logP, and formation of reactive metabolites (RM) in a large set of Food and Drug Administration-approved oral medications and found factoring RM into the RO2 to highly improve DILI prediction.  Based on these parameters and by considering n = 354 drugs, an algorithm to assign a DILI score was developed.  In univariate and multivariate logistic regression analyses the algorithm (i.e., DILI score model) defined the relative contribution of daily dose, logP, and RM and permitted a quant. assessment of risk of clin. DILI.  Furthermore, a clear relationship between calcd. DILI scores and DILI risk was obtained when applied to three independent studies.  The DILI score model was also functional with drug pairs defined by similar chem. structure and mode of action but divergent toxicities.  Specifically, for drug pairs where the RO2 failed, the DILI score correctly identified toxic drugs.  Finally, the model was applied to n = 159 clin. cases collected from the National Institutes of Health's LiverTox database to demonstrate that the DILI score correlated with the severity of clin. outcome.  Conclusions: Based on daily dose, lipophilicity, and RM, a DILI score algorithm was developed that provides a scale of assessing the severity of DILI risk in humans assocd. with oral medications. (Hepatol. 2016;64:931-940).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA-kETAgqI3rVg90H21EOLACvtfcHk0ljmM-1h6KjGYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOnu7bF&md5=5970854540c3f9230be77bde710c4d99</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1002%2Fhep.28678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.28678%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DBorlak%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DW.%26atitle%3DA%2520Model%2520to%2520Predict%2520Severity%2520of%2520Drug-Induced%2520Liver%2520Injury%2520in%2520Humans%26jtitle%3DHepatology%26date%3D2016%26volume%3D64%26spage%3D931%26epage%3D940%26doi%3D10.1002%2Fhep.28678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the Relevance of DILI Predictive Hypotheses in Early Drug Development: Review of In Vitro Methodologies vs BDDCS Classification</span>. <i>Toxicol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.1039/C8TX00016F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1039%2FC8TX00016F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnvVSrsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=358-370&author=R.+Chanauthor=L.+Z.+Benet&title=Evaluation+of+the+Relevance+of+DILI+Predictive+Hypotheses+in+Early+Drug+Development%3A+Review+of+In+Vitro+Methodologies+vs+BDDCS+Classification&doi=10.1039%2FC8TX00016F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the relevance of DILI predictive hypotheses in early drug development: review of in vitro methodologies vs. BDDCS classification</span></div><div class="casAuthors">Chan, Rosa; Benet, Leslie Z.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Research (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">358-370</span>CODEN:
                <span class="NLM_cas:coden">TROEE8</span>;
        ISSN:<span class="NLM_cas:issn">2045-4538</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a major safety concern; it occurs frequently; it is idiosyncratic; it cannot be adequately predicted; and a multitude of underlying mechanisms has been postulated.  A no. of exptl. approaches to predict human DILI have been proposed utilizing in vitro screening such as inhibition of mitochondrial function, hepatobiliary transporter inhibition, reactive metabolite formation with and without covalent binding, and cellular health, but they have achieved only minimal success.  Several studies have shown total administered dose alone or in combination with drug lipophilicity to be correlated with a higher risk of DILI.  However, it would be best to have a predictive DILI methodol. early in drug development, long before the clin. dose is known.  Here we discuss the extent to which Biopharmaceutics Drug Disposition Classification System (BDDCS) defining characteristics, independent of knowing actual drug pharmacokinetics/pharmacodynamics and dose, can be used to evaluate prior published predictive proposals.  Our results show that BDDCS Class 2 drugs exhibit the highest DILI severity, and that all of the short-lived published methodologies evaluated here, except when daily dose is known, do not yield markedly better predictions than BDDCS.  The assertion that extensively metabolized compds. are at higher risk of developing DILI is confirmed, but can be enhanced by differentiating BDDCS Class 2 from Class 1 drugs.  Conclusion: Our published analyses suggest that comparison of proposed DILI prediction methodologies with BDDCS classification is a useful tool to evaluate the potential reliability of newly proposed algorithms, although BDDCS classification itself is not sufficiently predictive.  Almost all of the predictive DILI metrics do no better than just avoiding BDDCS Class 2 drugs, although some early data with microliver platforms enabling long-enduring metabolic competency show promising results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDY0LjdtqlS7Vg90H21EOLACvtfcHk0ljmM-1h6KjGYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnvVSrsrc%253D&md5=de8366882fcfab9866301c784f57c264</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1039%2FC8TX00016F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8TX00016F%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DR.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26atitle%3DEvaluation%2520of%2520the%2520Relevance%2520of%2520DILI%2520Predictive%2520Hypotheses%2520in%2520Early%2520Drug%2520Development%253A%2520Review%2520of%2520In%2520Vitro%2520Methodologies%2520vs%2520BDDCS%2520Classification%26jtitle%3DToxicol.%2520Res.%26date%3D2018%26volume%3D7%26spage%3D358%26epage%3D370%26doi%3D10.1039%2FC8TX00016F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broccatelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span> <span> </span><span class="NLM_article-title">BDDCS Applied to Over 900 Drugs</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">547</span>, <span class="refDoi"> DOI: 10.1208/s12248-011-9290-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1208%2Fs12248-011-9290-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21818695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFamsbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=519-547&author=L.+Z.+Benetauthor=F.+Broccatelliauthor=T.+I.+Oprea&title=BDDCS+Applied+to+Over+900+Drugs&doi=10.1208%2Fs12248-011-9290-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">BDDCS Applied to Over 900 Drugs</span></div><div class="casAuthors">Benet, Leslie Z.; Broccatelli, Fabio; Oprea, Tudor I.</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">519-547</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Here, we compile the Biopharmaceutics Drug Disposition Classification System (BDDCS) classification for 927 drugs, which include 30 active metabolites.  Of the 897 parent drugs, 78.8% (707) are administered orally.  Where the lowest measured soly. is found, this value is reported for 72.7% (513) of these orally administered drugs and a dose no. is recorded.  The measured values are reported for percent excreted unchanged in urine, LogP, and LogD 7.4 when available.  For all 927 compds., the in silico parameters for predicted Log soly. in water, calcd. LogP, polar surface area, and the no. of hydrogen bond acceptors and hydrogen bond donors for the active moiety are also provided, thereby allowing comparison analyses for both in silico and exptl. measured values.  We discuss the potential use of BDDCS to est. the disposition characteristics of novel chems. (new mol. entities) in the early stages of drug discovery and development.  Transporter effects in the intestine and the liver are not clin. relevant for BDDCS class 1 drugs, but potentially can have a high impact for class 2 (efflux in the gut, and efflux and uptake in the liver) and class 3 (uptake and efflux in both gut and liver) drugs.  A combination of high dose and low soly. is likely to cause BDDCS class 4 to be underpopulated in terms of approved drugs (N = 53 compared with over 200 each in classes 1-3).  The influence of several measured and in silico parameters in the process of BDDCS category assignment is discussed in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSAqjf7Z_OBLVg90H21EOLACvtfcHk0lg04Gw3M-CiIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFamsbfE&md5=911d3f2df96e05a2fbf5955abfb2917c</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1208%2Fs12248-011-9290-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-011-9290-9%26sid%3Dliteratum%253Aachs%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26aulast%3DBroccatelli%26aufirst%3DF.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26atitle%3DBDDCS%2520Applied%2520to%2520Over%2520900%2520Drugs%26jtitle%3DAAPS%2520J.%26date%3D2011%26volume%3D13%26spage%3D519%26epage%3D547%26doi%3D10.1208%2Fs12248-011-9290-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonkovsky, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davern, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochon, J.</span></span> <span> </span><span class="NLM_article-title">Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">1924</span>– <span class="NLM_lpage">1934</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2008.09.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1053%2Fj.gastro.2008.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=18955056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252FhvFGhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2008&pages=1924-1934&author=N.+Chalasaniauthor=R.+J.+Fontanaauthor=H.+L.+Bonkovskyauthor=P.+B.+Watkinsauthor=T.+Davernauthor=J.+Serranoauthor=H.+Yangauthor=J.+Rochon&title=Causes%2C+Clinical+Features%2C+and+Outcomes+From+a+Prospective+Study+of+Drug-Induced+Liver+Injury+in+the+United+States&doi=10.1053%2Fj.gastro.2008.09.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States</span></div><div class="casAuthors">Chalasani Naga; Fontana Robert J; Bonkovsky Herbert L; Watkins Paul B; Davern Timothy; Serrano Jose; Yang Hongqiu; Rochon James</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1924-34, 1934.e1-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND & AIMS:  Idiosyncratic drug-induced liver injury (DILI) is among the most common causes of acute liver failure in the United States, accounting for approximately 13% of cases.  A prospective study was begun in 2003 to recruit patients with suspected DILI and create a repository of biological samples for analysis.  This report summarizes the causes, clinical features, and outcomes from the first 300 patients enrolled.  METHODS:  Patients with suspected DILI were enrolled based on predefined criteria and followed up for at least 6 months.  Patients with acetaminophen liver injury were excluded.  RESULTS:  DILI was caused by a single prescription medication in 73% of the cases, by dietary supplements in 9%, and by multiple agents in 18%.  More than 100 different agents were associated with DILI; antimicrobials (45.5%) and central nervous system agents (15%) were the most common.  Causality was considered to be definite in 32%, highly likely in 41%, probable in 14%, possible in 10%, and unlikely in 3%.  Acute hepatitis C virus (HCV) infection was the final diagnosis in 4 of 9 unlikely cases.  Six months after enrollment, 14% of patients had persistent laboratory abnormalities and 8% had died; the cause of death was liver related in 44%.  CONCLUSIONS:  DILI is caused by a wide array of medications, herbal supplements, and dietary supplements.  Antibiotics are the single largest class of agents that cause DILI.  Acute HCV infection should be excluded in patients with suspected DILI by HCV RNA testing.  The overall 6-month mortality was 8%, but the majority of deaths were not liver related.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQT5sqgDsZJNhpyrDyM_m9cfW6udTcc2ebK9C9Yo8LkJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252FhvFGhsg%253D%253D&md5=59c54e59eb7304f7e4c0e8599a866b31</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2008.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2008.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DBonkovsky%26aufirst%3DH.%2BL.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DDavern%26aufirst%3DT.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DRochon%26aufirst%3DJ.%26atitle%3DCauses%252C%2520Clinical%2520Features%252C%2520and%2520Outcomes%2520From%2520a%2520Prospective%2520Study%2520of%2520Drug-Induced%2520Liver%2520Injury%2520in%2520the%2520United%2520States%26jtitle%3DGastroenterology%26date%3D2008%26volume%3D135%26spage%3D1924%26epage%3D1934%26doi%3D10.1053%2Fj.gastro.2008.09.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucena, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplowitz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Cortes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero-Gomez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruguera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robles-Diaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-González, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmeron, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Odriozola, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Alvarez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borraz, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, R.</span></span> <span> </span><span class="NLM_article-title">Phenotypic Characterization of Idiosyncratic Drug-Induced Liver Injury: The Influence of Age and Sex</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2001</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1002/hep.22895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.22895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19475693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD1Mzos1yrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=2001-2009&author=M.+I.+Lucenaauthor=R.+J.+Andradeauthor=N.+Kaplowitzauthor=M.+Garc%C3%ADa-Cortesauthor=M.+C.+Fern%C3%A1ndezauthor=M.+Romero-Gomezauthor=M.+Brugueraauthor=H.+Hallalauthor=M.+Robles-Diazauthor=J.+F.+Rodriguez-Gonz%C3%A1lezauthor=J.+M.+Navarroauthor=J.+Salmeronauthor=P.+Martinez-Odriozolaauthor=R.+P%C3%A9rez-Alvarezauthor=Y.+Borrazauthor=R.+Hidalgo&title=Phenotypic+Characterization+of+Idiosyncratic+Drug-Induced+Liver+Injury%3A+The+Influence+of+Age+and+Sex&doi=10.1002%2Fhep.22895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex</span></div><div class="casAuthors">Lucena M Isabel; Andrade Raul J; Kaplowitz Neil; Garcia-Cortes Miren; Fernandez M Carmen; Romero-Gomez Manuel; Bruguera Miguel; Hallal Hacibe; Robles-Diaz Mercedes; Rodriguez-Gonzalez Jose F; Navarro Jose Maria; Salmeron Javier; Martinez-Odriozola Pedro; Perez-Alvarez Ramon; Borraz Yolanda; Hidalgo Ramon</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Baltimore, Md.)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2001-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Increased age and female sex are suggested risk factors for drug-induced hepatotoxicity (DILI).  We studied the influence of these variables on the propensity to develop DILI, as well as its clinical expression and outcome.  All cases of DILI submitted to the Spanish Registry between April 1994 and August 2007 were analyzed.  Six hundred three DILI cases (310 men; mean age, 54 years) showed a similar sex distribution, reaching two peaks in the 40- to 49-year-old and 60- to 69-year-old age groups.  No cases were recorded in the 20- to 29-year-old group.  Patients aged > or =60 years accounted for 46% of the cases, with a male predominance (158 males, 118 females; P= 0.009), as opposed to younger patients.  Older age was independently associated with cholestatic type of injury (odds ratio for an age interval for 1 year: 1.024 [95% confidence interval: 1.010-1.038]; male/female ratio, 1:2; P = 0.001) and younger age with hepatocellular damage (odds ratio: 0.983 [95% confidence interval: 0.972-0.994]; female/male ratio, 1:2; P = 0.002).  In the mixed group, no age effect was evident.  Outcome with fulminant liver failure/liver transplantation was more frequently encountered in women (P < 0.01). conclusion: Neither older age nor female sex are predisposing factors to overall DILI.  However, older age is a determinant for cholestatic damage with a male predominance, whereas younger age is associated with cytolytic damage and a female overrepresentation.  Women distinctly exhibit the worst outcome.  Knowledge of these phenotypic associations could guide differential diagnosis and attribution of causality in DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRVzo3zCJgVG2hHGZei4OW9fW6udTcc2eZxFMRgDpbhgLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mzos1yrtA%253D%253D&md5=aad2355fabd27cdfecefe3ba053007be</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1002%2Fhep.22895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.22895%26sid%3Dliteratum%253Aachs%26aulast%3DLucena%26aufirst%3DM.%2BI.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3DKaplowitz%26aufirst%3DN.%26aulast%3DGarc%25C3%25ADa-Cortes%26aufirst%3DM.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DM.%2BC.%26aulast%3DRomero-Gomez%26aufirst%3DM.%26aulast%3DBruguera%26aufirst%3DM.%26aulast%3DHallal%26aufirst%3DH.%26aulast%3DRobles-Diaz%26aufirst%3DM.%26aulast%3DRodriguez-Gonz%25C3%25A1lez%26aufirst%3DJ.%2BF.%26aulast%3DNavarro%26aufirst%3DJ.%2BM.%26aulast%3DSalmeron%26aufirst%3DJ.%26aulast%3DMartinez-Odriozola%26aufirst%3DP.%26aulast%3DP%25C3%25A9rez-Alvarez%26aufirst%3DR.%26aulast%3DBorraz%26aufirst%3DY.%26aulast%3DHidalgo%26aufirst%3DR.%26atitle%3DPhenotypic%2520Characterization%2520of%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%253A%2520The%2520Influence%2520of%2520Age%2520and%2520Sex%26jtitle%3DHepatology%26date%3D2009%26volume%3D49%26spage%3D2001%26epage%3D2009%26doi%3D10.1002%2Fhep.22895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lampson, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasar, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matos, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassenti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davids, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freedman, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnason, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipps, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span> <span> </span><span class="NLM_article-title">Idelalisib Given Front-Line for Treatment of Chronic Lymphocytic Leukemia Causes Frequent Immune-Mediated Hepatotoxicity</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-03-707133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1182%2Fblood-2016-03-707133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27247136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1egtrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=195-203&author=B.+L.+Lampsonauthor=S.+N.+Kasarauthor=T.+R.+Matosauthor=E.+A.+Morganauthor=L.+Rassentiauthor=M.+S.+Davidsauthor=D.+C.+Fisherauthor=A.+S.+Freedmanauthor=C.+A.+Jacobsonauthor=P.+Armandauthor=J.+S.+Abramsonauthor=J.+E.+Arnasonauthor=T.+J.+Kippsauthor=J.+Feinauthor=S.+Fernandesauthor=J.+Hannaauthor=J.+Ritzauthor=H.+T.+Kimauthor=J.+R.+Brown&title=Idelalisib+Given+Front-Line+for+Treatment+of+Chronic+Lymphocytic+Leukemia+Causes+Frequent+Immune-Mediated+Hepatotoxicity&doi=10.1182%2Fblood-2016-03-707133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity</span></div><div class="casAuthors">Lampson, Benjamin L.; Kasar, Siddha N.; Matos, Tiago R.; Morgan, Elizabeth A.; Rassenti, Laura; Davids, Matthew S.; Fisher, David C.; Freedman, Arnold S.; Jacobson, Caron A.; Armand, Philippe; Abramson, Jeremy S.; Arnason, Jon E.; Kipps, Thomas J.; Fein, Joshua; Fernandes, Stacey; Hanna, John; Ritz, Jerome; Kim, Haesook T.; Brown, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-203</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Idelalisib is a small-mol. inhibitor of PI3Kδ with demonstrated efficacy for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL).  To evaluate idelalisib as front-line therapy, we enrolled 24 subjects in a phase 2 study consisting of 2 mo of idelalisib monotherapy followed by 6 mo of combination therapy with idelalisib and the anti-CD20 antibody ofatumumab.  After a median follow-up period of 14.7 mo, hepatotoxicity was found to be a frequent and often severe adverse event.  A total of 19 subjects (79%) experienced either grade ≥1 ALT or AST elevation during the study, and 13 subjects (54%) experienced grade ≥3 transaminitis.  The median time to development of transaminitis was 28 days, occurring before ofatumumab introduction.  Younger age and mutated Ig heavy chain status were significant risk factors for the development of hepatotoxicity.  Multiple lines of evidence suggest that this hepatotoxicity was immune mediated.  A lymphocytic infiltrate was seen on liver biopsy specimens taken from 2 subjects with transaminitis, and levels of the proinflammatory cytokines CCL-3 and CCL-4 were higher in subjects experiencing hepatotoxicity.  All cases of transaminitis resolved either by holding the drug, initiating immunosuppressants, or both, and rates of recurrent toxicity were lower in patients taking steroids when idelalisib was reinitiated.  A decrease in peripheral blood regulatory T cells was seen in patients experiencing toxicity on therapy, which is consistent with an immune-mediated mechanism.  These results suggest that caution should be taken as drugs within this class are developed for CLL, particularly in younger patients who have not received prior disease-specific therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFWd0SBaN9E7Vg90H21EOLACvtfcHk0li_mMinhSCXew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1egtrfK&md5=eec3c52d470b0b70266f7ecc3f7d8de0</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-03-707133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-03-707133%26sid%3Dliteratum%253Aachs%26aulast%3DLampson%26aufirst%3DB.%2BL.%26aulast%3DKasar%26aufirst%3DS.%2BN.%26aulast%3DMatos%26aufirst%3DT.%2BR.%26aulast%3DMorgan%26aufirst%3DE.%2BA.%26aulast%3DRassenti%26aufirst%3DL.%26aulast%3DDavids%26aufirst%3DM.%2BS.%26aulast%3DFisher%26aufirst%3DD.%2BC.%26aulast%3DFreedman%26aufirst%3DA.%2BS.%26aulast%3DJacobson%26aufirst%3DC.%2BA.%26aulast%3DArmand%26aufirst%3DP.%26aulast%3DAbramson%26aufirst%3DJ.%2BS.%26aulast%3DArnason%26aufirst%3DJ.%2BE.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26aulast%3DFein%26aufirst%3DJ.%26aulast%3DFernandes%26aufirst%3DS.%26aulast%3DHanna%26aufirst%3DJ.%26aulast%3DRitz%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DH.%2BT.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26atitle%3DIdelalisib%2520Given%2520Front-Line%2520for%2520Treatment%2520of%2520Chronic%2520Lymphocytic%2520Leukemia%2520Causes%2520Frequent%2520Immune-Mediated%2520Hepatotoxicity%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D195%26epage%3D203%26doi%3D10.1182%2Fblood-2016-03-707133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirnadel-Farrant, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span> <span> </span><span class="NLM_article-title">Age-Related Differences in Reporting of Drug-Associated Liver Injury: Data-Mining of WHO Safety Report Database</span>. <i>Regul. Toxicol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">526</span>, <span class="refDoi"> DOI: 10.1016/j.yrtph.2014.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.yrtph.2014.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25236535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFylu7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2014&pages=519-526&author=C.+M.+Huntauthor=N.+A.+Yuenauthor=H.+A.+Stirnadel-Farrantauthor=A.+Suzuki&title=Age-Related+Differences+in+Reporting+of+Drug-Associated+Liver+Injury%3A+Data-Mining+of+WHO+Safety+Report+Database&doi=10.1016%2Fj.yrtph.2014.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Age-related differences in reporting of drug-associated liver injury: Data-mining of WHO Safety Report Database</span></div><div class="casAuthors">Hunt, Christine M.; Yuen, Nancy A.; Stirnadel-Farrant, Heide A.; Suzuki, Ayako</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Toxicology and Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">519-526</span>CODEN:
                <span class="NLM_cas:coden">RTOPDW</span>;
        ISSN:<span class="NLM_cas:issn">0273-2300</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Age-differences in the frequency and manifestations of drug-induced liver injury are not fully characterized.  Data-mining analyses were performed to assess the impact of age on liver event reporting frequency with different phenotypes and agents.  236 Drugs assocd. with hepatotoxicity were evaluated using the Empirical Bayes Geometric Mean (EBGM) of the relative reporting ratio with 90% confidence interval (EB05 and EB95) calcd. for the age groups: 0-17, 18-64, and ≥ 65 years (or elderly), for overall, serious (acute liver failure), hepatocellular, and cholestatic liver injury, using the WHO Safety Report Database.  Overall, cases of age 0-17, 18-64, and 65 years or older comprised 6%, 62%, and 32% of liver event reports.  Acute liver failure and hepatocellular injury were more frequently reported among children compared to adults and the elderly while reports with cholestatic injury were more frequent among the elderly (p < 0.00001).  A potential to cause mitochondrial dysfunction was more prevalent among the drugs with increased pediatric reporting frequency while high lipophilicity and biliary excretion were more common among the drugs assocd. with higher reporting frequency in the elderly.  Age-specific phenotypes and potential drug properties assocd. with age-specific hepatotoxicity were identified in reported liver events; further analyses are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVgXetphoe4rVg90H21EOLACvtfcHk0li_mMinhSCXew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFylu7fI&md5=5874a7d5ed45b1d332d2ad2e217c3a21</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.yrtph.2014.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yrtph.2014.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DHunt%26aufirst%3DC.%2BM.%26aulast%3DYuen%26aufirst%3DN.%2BA.%26aulast%3DStirnadel-Farrant%26aufirst%3DH.%2BA.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DAge-Related%2520Differences%2520in%2520Reporting%2520of%2520Drug-Associated%2520Liver%2520Injury%253A%2520Data-Mining%2520of%2520WHO%2520Safety%2520Report%2520Database%26jtitle%3DRegul.%2520Toxicol.%2520Pharmacol.%26date%3D2014%26volume%3D70%26spage%3D519%26epage%3D526%26doi%3D10.1016%2Fj.yrtph.2014.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J. H.</span></span> <span> </span><span class="NLM_article-title">Causality Assessment of Drug-Induced Hepatotoxicity: Promises and Pitfalls</span>. <i>Clinics in Liver Disease</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">505</span>, <span class="refDoi"> DOI: 10.1016/j.cld.2007.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.cld.2007.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=17723916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD2srgsVGgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=477-505&author=M.+A.+Shapiroauthor=J.+H.+Lewis&title=Causality+Assessment+of+Drug-Induced+Hepatotoxicity%3A+Promises+and+Pitfalls&doi=10.1016%2Fj.cld.2007.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Causality assessment of drug-induced hepatotoxicity: promises and pitfalls</span></div><div class="casAuthors">Shapiro Max A; Lewis James H</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in liver disease</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">477-505, v</span>
        ISSN:<span class="NLM_cas:issn">1089-3261</span>.
    </div><div class="casAbstract">Drug-induced liver injury is the leading cause of acute liver failure in the United States, but the ability to ascribe hepatic injury confidently to a specific drug remains a challenging and often difficult pursuit.  This article explores the ongoing challenges inherent in what is currently a clinical process of elimination made in the attempt of assigning causality in drug-induced liver injury.  In particular, it points out the shortcomings and pitfalls that often limit the applicability of the causality-assessment methodologies currently in use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSMBsH1AK2WBQ8IxFYvehhofW6udTcc2eZa3afyfQu1FLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srgsVGgsA%253D%253D&md5=0dbe5e5d01a6b1c79df99249b246904d</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.cld.2007.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cld.2007.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DM.%2BA.%26aulast%3DLewis%26aufirst%3DJ.%2BH.%26atitle%3DCausality%2520Assessment%2520of%2520Drug-Induced%2520Hepatotoxicity%253A%2520Promises%2520and%2520Pitfalls%26jtitle%3DClinics%2520in%2520Liver%2520Disease%26date%3D2007%26volume%3D11%26spage%3D477%26epage%3D505%26doi%3D10.1016%2Fj.cld.2007.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björnsson, E.</span></span> <span> </span><span class="NLM_article-title">Risk Factors for Idiosyncratic Drug-Induced Liver Injury</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">2246</span>– <span class="NLM_lpage">2259</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2010.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1053%2Fj.gastro.2010.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=20394749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnslaku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2010&pages=2246-2259&author=N.+Chalasaniauthor=E.+Bj%C3%B6rnsson&title=Risk+Factors+for+Idiosyncratic+Drug-Induced+Liver+Injury&doi=10.1053%2Fj.gastro.2010.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Risk factors for idiosyncratic drug-induced liver injury</span></div><div class="casAuthors">Chalasani, Naga; Bjornsson, Einar</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2246-2259</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Idiosyncratic drug-induced liver injury (DILI) is a rare disorder that is not related directly to dosage and little is known about individuals who are at increased risk.  There are no suitable preclin. models for the study of idiosyncratic DILI and its pathogenesis is poorly understood.  It is likely to arise from complex interactions among genetic, nongenetic host susceptibility, and environmental factors.  Nongenetic risk factors include age, sex, and other diseases (eg, chronic liver disease or human immunodeficiency virus infection).  Compd.-specific risk factors include daily dose, metab. characteristics, and propensity for drug interactions.  Alc. consumption has been proposed as a risk factor for DILI from medications, but there is insufficient evidence to support this.  Many studies have explored genetic defects that might be involved in pathogenesis and focused on genes involved in drug metab. and the immune response.  Multicenter databases of patients with DILI (the United States Drug Induced Liver Injury Network, DILIGEN, and the Spanish DILI registry) are important tools for clin. and genetic research.  A genome-wide assocn. study of flucloxacillin hepatotoxicity has yielded groundbreaking results and many similar studies are underway.  Nonetheless, DILI is challenging to investigate because of its rarity, the lack of exptl. models, the no. of medications that might cause it, and challenges to diagnosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8ybOkEsO25rVg90H21EOLACvtfcHk0ljeghkcK_QEFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnslaku7c%253D&md5=ed4fc7b289b9ffadeca654a26f4f2d5d</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2010.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2010.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DBj%25C3%25B6rnsson%26aufirst%3DE.%26atitle%3DRisk%2520Factors%2520for%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DGastroenterology%26date%3D2010%26volume%3D138%26spage%3D2246%26epage%3D2259%26doi%3D10.1053%2Fj.gastro.2010.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Björnsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidsdottir, L.</span></span> <span> </span><span class="NLM_article-title">The Long-Term Follow-Up After Idiosyncratic Drug-Induced Liver Injury with Jaundice</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">511</span>– <span class="NLM_lpage">517</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2008.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jhep.2008.10.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19155082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD1M7jtVyhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=511-517&author=E.+Bj%C3%B6rnssonauthor=L.+Davidsdottir&title=The+Long-Term+Follow-Up+After+Idiosyncratic+Drug-Induced+Liver+Injury+with+Jaundice&doi=10.1016%2Fj.jhep.2008.10.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice</span></div><div class="casAuthors">Bjornsson Einar; Davidsdottir Loa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hepatology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">511-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND/AIMS:  Chronic evolution after drug-induced liver injury (DILI) has been reported.  How often this leads to liver-related morbidity and mortality is unexplored.  METHODS:  Patients who survived DILI and concomitant jaundice reported to the Swedish Adverse Drug Reaction Advisory Committee (1970-2004) were linked to the Swedish Hospital Discharge and Cause of Death Registries.  RESULTS:  Among the 712 survivors, 27 could not be retrieved but 685 patients could be linked to the registries, 392 females (57.2%) and 293 males (42.8%) median age 58 (41-74), a mean follow-up of 10 years.  A total of 23/685 (3.4%) patients had been hospitalized for liver disease and 5 had liver-related mortality.  Eight patients developed cirrhosis (7 decompensated, 5 died), 5 had "cryptogenic" cirrhosis in which DILI might have played a role in this development.  Duration of therapy before DILI was longer in patients with liver-related morbidity/mortality (135+/-31 days vs. 53+/-3; p<0.0001).  Autoimmune hepatitis developed in 5/23 (22%), all of female gender after a mean of 5.8 years.  CONCLUSIONS:  Development of clinically important liver disease after severe DILI associated with jaundice is rare after acute DILI.  However decompensated "cryptogenic" cirrhosis developed in some patients with fatal outcome in which DILI might have played a role in this development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRg9_4T70gbzN1QT_1O5WBYfW6udTcc2eZa3afyfQu1FLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M7jtVyhuw%253D%253D&md5=2512fe7c905edb38578722b689bb02ae</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2008.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2008.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DBj%25C3%25B6rnsson%26aufirst%3DE.%26aulast%3DDavidsdottir%26aufirst%3DL.%26atitle%3DThe%2520Long-Term%2520Follow-Up%2520After%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%2520with%2520Jaundice%26jtitle%3DJ.%2520Hepatol.%26date%3D2009%26volume%3D50%26spage%3D511%26epage%3D517%26doi%3D10.1016%2Fj.jhep.2008.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waxman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, M. G.</span></span> <span> </span><span class="NLM_article-title">Sex Differences in the Expression of Hepatic Drug Metabolizing Enzymes</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1124/mol.109.056705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fmol.109.056705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19483103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlehu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2009&pages=215-228&author=D.+J.+Waxmanauthor=M.+G.+Holloway&title=Sex+Differences+in+the+Expression+of+Hepatic+Drug+Metabolizing+Enzymes&doi=10.1124%2Fmol.109.056705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Sex differences in the expression of hepatic drug metabolizing enzymes</span></div><div class="casAuthors">Waxman, David J.; Holloway, Minita G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">215-228</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Sex differences in pharmacokinetics and pharmacodynamics characterize many drugs and contribute to individual differences in drug efficacy and toxicity.  Sex-based differences in drug metab. are the primary cause of sex-dependent pharmacokinetics and reflect underlying sex differences in the expression of hepatic enzymes active in the metab. of drugs, steroids, fatty acids and environmental chems., including cytochromes P 450 (P450s), sulfotransferases, glutathione transferases, and UDP-glucuronosyltransferases.  Studies in the rat and mouse liver models have identified more than 1000 genes whose expression is sex-dependent; together, these genes impart substantial sexual dimorphism to liver metabolic function and pathophysiol.  Sex differences in drug metab. and pharmacokinetics also occur in humans and are due in part to the female-predominant expression of CYP3A4, the most important P 450 catalyst of drug metab. in human liver.  The sexually dimorphic expression of P450s and other liver-expressed genes is regulated by the temporal pattern of plasma growth hormone (GH) release by the pituitary gland, which shows significant sex differences.  These differences are most pronounced in rats and mice, where plasma GH profiles are highly pulsatile (intermittent) in male animals vs. more frequent (nearly continuous) in female animals.  This review discusses key features of the cell signaling and mol. regulatory mechanisms by which these sex-dependent plasma GH patterns impart sex specificity to the liver.  Moreover, the essential role proposed for the GH-activated transcription factor signal transducer and activator of transcription (STAT) 5b, and for hepatic nuclear factor (HNF) 4α, as mediators of the sex-dependent effects of GH on the liver, is evaluated.  Together, these studies of the cellular, mol., and gene regulatory mechanisms that underlie sex-based differences in liver gene expression have provided novel insights into the physiol. regulation of both xenobiotic and endobiotic metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrzB5ktzQW-bVg90H21EOLACvtfcHk0ljeghkcK_QEFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlehu74%253D&md5=2aa405139f26021e6833bc16aa8bc873</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1124%2Fmol.109.056705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.109.056705%26sid%3Dliteratum%253Aachs%26aulast%3DWaxman%26aufirst%3DD.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BG.%26atitle%3DSex%2520Differences%2520in%2520the%2520Expression%2520of%2520Hepatic%2520Drug%2520Metabolizing%2520Enzymes%26jtitle%3DMol.%2520Pharmacol.%26date%3D2009%26volume%3D76%26spage%3D215%26epage%3D228%26doi%3D10.1124%2Fmol.109.056705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westerkam, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stave, G. M.</span></span> <span> </span><span class="NLM_article-title">Effect of Age and Gender on the Activity of Human Hepatic CYP3A</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(92)90010-G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2F0006-2952%2892%2990010-G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1642641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADyaK38XlsVakurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1992&pages=275-283&author=C.+M.+Huntauthor=W.+R.+Westerkamauthor=G.+M.+Stave&title=Effect+of+Age+and+Gender+on+the+Activity+of+Human+Hepatic+CYP3A&doi=10.1016%2F0006-2952%2892%2990010-G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of age and gender on the activity of human hepatic CYP3A</span></div><div class="casAuthors">Hunt, Christine M.; Westerkam, William R.; Stave, Gregg M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-83</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">Many pharmacokinetic investigations in the elderly population reveal decreased clearance of lipophilic drugs metabolized by the cytochrome P 450 enzymes; however, few studies have evaluated aging-dependent or gender-related changes in specific cytochrome P 450 enzymes.  The clearance of quinidine, midazolam, triazolam, erythromycin, and lidocaine declines with age; these drugs are metabolized by the isoform, CYP3A.  To det. whether these metabolic effects are due to changes in CYP3A, the effects of age and gender on CYP3A activity were examd.  The activity of the human hepatic cytochrome P 450, CYP3A, was quantified in vitro as erythromycin N-demethylation in microsomes prepd. from forty-three resected human liver specimens obtained from patients, age 27 to 83, with normal liver function.  Erythromycin N-demethylation varied 5-fold in human liver microsomes.  CYP3A activity was 24% higher in females than males.  CYP3A activity did not correlate with age, smoking status, ethanol consumption or percent ideal body wt.  Large interindividual differences and a small female-specific increase in CYP3A activity were obtained.  However, CYP3A activity was unaffected by age over the range of 27-83 yr, suggesting that the aging-related alteration in the clearance of CYP3A substrates is secondary to changes in liver blood flow, size, or drug binding and distribution with aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQbRM_ZoUzhbVg90H21EOLACvtfcHk0lgeeOLkMuEBqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlsVakurk%253D&md5=e2ceb29451028f837e2ec85107b14c73</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2892%2990010-G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252892%252990010-G%26sid%3Dliteratum%253Aachs%26aulast%3DHunt%26aufirst%3DC.%2BM.%26aulast%3DWesterkam%26aufirst%3DW.%2BR.%26aulast%3DStave%26aufirst%3DG.%2BM.%26atitle%3DEffect%2520of%2520Age%2520and%2520Gender%2520on%2520the%2520Activity%2520of%2520Human%2520Hepatic%2520CYP3A%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1992%26volume%3D44%26spage%3D275%26epage%3D283%26doi%3D10.1016%2F0006-2952%2892%2990010-G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitcomb, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, G. D.</span></span> <span> </span><span class="NLM_article-title">Association of Acetaminophen Hepatotoxicity with Fasting and Ethanol Use</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">1845</span>– <span class="NLM_lpage">1850</span>, <span class="refDoi"> DOI: 10.1001/jama.1994.03520230055038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1001%2Fjama.1994.03520230055038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=7990219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADyaK2MXjsVehtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1994&pages=1845-1850&author=D.+C.+Whitcombauthor=G.+D.+Block&title=Association+of+Acetaminophen+Hepatotoxicity+with+Fasting+and+Ethanol+Use&doi=10.1001%2Fjama.1994.03520230055038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Association of acetaminophen hepatotoxicity with fasting and ethanol use</span></div><div class="casAuthors">Whitcomb, David C.; Block, Geoffrey D.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">1845-50</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    </div><div class="casAbstract">The authors evaluated the assocn. of fasting and alc. use with hepatotoxicity from acetaminophen ingested for therapeutic reasons.  A total of 126,779 discharge summaries from Jan. 1987 to July 1993 were reviewed using a comprehensive, whole-text-indexed medical database to identify all patients with acetaminophen ingestion and hepatotoxicity.  These patients were categorized according to the intended acetaminophen use and dose of acetaminophen ingested.  The independent variables of chronic alc. use, recent alc. use, and recent fasting were detd. for all patients.  Forty-nine patients with acetaminophen hepatotoxicity (aspartate aminotransferase >1000 U/L) were identified.  Twenty-one patients (43%) ingested acetaminophen for therapeutic purposes.  All patients with hepatotoxicity took more than the recommended limit of 4 g/d.  Recent fasting was more common than recent alc. use among those who suffered hepatotoxicity after a dose of 4 to 10 g of acetaminophen per day.  Recent alc. use was more common in the group who took more than 10 g/d than in those who took 4 to 10 g/d.  Acetaminophen hepatotoxicity after a dose of 4 to 10 g/d was assocd. with fasting and less commonly with alc. use.  Patients who developed hepatotoxicity after taking acetaminophen doses of greater than 10 g/d for therapeutic purposes were alc. users.  Acetaminophen hepatotoxicity after an overdose appears to be enhanced by fasting in addn. to alc. ingestion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreLEcGgu-PcbVg90H21EOLACvtfcHk0lgeeOLkMuEBqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjsVehtr0%253D&md5=bd72da1b4f5dcde3e0802880ab286777</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1001%2Fjama.1994.03520230055038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.1994.03520230055038%26sid%3Dliteratum%253Aachs%26aulast%3DWhitcomb%26aufirst%3DD.%2BC.%26aulast%3DBlock%26aufirst%3DG.%2BD.%26atitle%3DAssociation%2520of%2520Acetaminophen%2520Hepatotoxicity%2520with%2520Fasting%2520and%2520Ethanol%2520Use%26jtitle%3DJAMA%26date%3D1994%26volume%3D272%26spage%3D1845%26epage%3D1850%26doi%3D10.1001%2Fjama.1994.03520230055038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fromenty, B.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Liver Injury in Obesity</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">824</span>– <span class="NLM_lpage">826</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2012.12.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jhep.2012.12.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23298629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC3s3ns1ykug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=824-826&author=B.+Fromenty&title=Drug-Induced+Liver+Injury+in+Obesity&doi=10.1016%2Fj.jhep.2012.12.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced liver injury in obesity</span></div><div class="casAuthors">Fromenty Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">824-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQo_N9NDTw3XjEC-75aqa5AfW6udTcc2eYOm3A7CBBxmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3ns1ykug%253D%253D&md5=b31b0ad9fe440e8d1f56d1ea799e2f76</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.12.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.12.018%26sid%3Dliteratum%253Aachs%26aulast%3DFromenty%26aufirst%3DB.%26atitle%3DDrug-Induced%2520Liver%2520Injury%2520in%2520Obesity%26jtitle%3DJ.%2520Hepatol.%26date%3D2013%26volume%3D58%26spage%3D824%26epage%3D826%26doi%3D10.1016%2Fj.jhep.2012.12.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Begriche, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robin, M.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgne-Sanchez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromenty, B.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Toxicity on Mitochondria and Lipid Metabolism: Mechanistic Diversity and Deleterious Consequences for the Liver</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">794</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2010.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jhep.2010.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21145849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjs12hsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=773-794&author=K.+Begricheauthor=J.+Massartauthor=M.-A.+Robinauthor=A.+Borgne-Sanchezauthor=B.+Fromenty&title=Drug-Induced+Toxicity+on+Mitochondria+and+Lipid+Metabolism%3A+Mechanistic+Diversity+and+Deleterious+Consequences+for+the+Liver&doi=10.1016%2Fj.jhep.2010.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced toxicity on mitochondria and lipid metabolism: Mechanistic diversity and deleterious consequences for the liver</span></div><div class="casAuthors">Begriche, Karima; Massart, Julie; Robin, Marie-Anne; Borgne-Sanchez, Annie; Fromenty, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">773-794</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Numerous investigations have shown that mitochondrial dysfunction is a major mechanism of drug-induced liver injury, which involves the parent drug or a reactive metabolite generated through cytochromes P 450.  Depending of their nature and their severity, the mitochondrial alterations are able to induce mild to fulminant hepatic cytolysis and steatosis (lipid accumulation), which can have different clin. and pathol. features.  Microvesicular steatosis, a potentially severe liver lesion usually assocd. with liver failure and profound hypoglycemia, is due to a major inhibition of mitochondrial fatty acid oxidn. (FAO).  Macrovacuolar steatosis, a relatively benign liver lesion in the short term, can be induced not only by a moderate redn. of mitochondrial FAO but also by an increased hepatic de novo lipid synthesis and a decreased secretion of VLDL-assocd. triglycerides.  Moreover, recent investigations suggest that some drugs could favor lipid deposition in the liver through primary alterations of white adipose tissue (WAT) homeostasis.  If the treatment is not interrupted, steatosis can evolve toward steatohepatitis, which is characterized not only by lipid accumulation but also by necroinflammation and fibrosis.  Although the mechanisms involved in this aggravation are not fully characterized, it appears that overprodn. of reactive oxygen species by the damaged mitochondria could play a salient role.  Numerous factors could favor drug-induced mitochondrial and metabolic toxicity, such as the structure of the parent mol., genetic predispositions (in particular those involving mitochondrial enzymes), alc. intoxication, hepatitis virus C infection, and obesity.  In obese and diabetic patients, some drugs may induce acute liver injury more frequently while others may worsen the pre-existent steatosis (or steatohepatitis).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodLkniNhTZzLVg90H21EOLACvtfcHk0lgdljPTdtDWqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjs12hsr8%253D&md5=ff6a28895ffcc230cb438565b164f207</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2010.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2010.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DBegriche%26aufirst%3DK.%26aulast%3DMassart%26aufirst%3DJ.%26aulast%3DRobin%26aufirst%3DM.-A.%26aulast%3DBorgne-Sanchez%26aufirst%3DA.%26aulast%3DFromenty%26aufirst%3DB.%26atitle%3DDrug-Induced%2520Toxicity%2520on%2520Mitochondria%2520and%2520Lipid%2520Metabolism%253A%2520Mechanistic%2520Diversity%2520and%2520Deleterious%2520Consequences%2520for%2520the%2520Liver%26jtitle%3DJ.%2520Hepatol.%26date%3D2011%26volume%3D54%26spage%3D773%26epage%3D794%26doi%3D10.1016%2Fj.jhep.2010.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aubert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begriche, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knockaert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromenty, B.</span></span> <span> </span><span class="NLM_article-title">Increased Expression of Cytochrome P450 2E1 in Nonalcoholic Fatty Liver Disease: Mechanisms and Pathophysiological Role</span>. <i>Clin. Res. Hepatol. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">630</span>– <span class="NLM_lpage">637</span>, <span class="refDoi"> DOI: 10.1016/j.clinre.2011.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.clinre.2011.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21664213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKkt73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2011&pages=630-637&author=J.+Aubertauthor=K.+Begricheauthor=L.+Knockaertauthor=M.+A.+Robinauthor=B.+Fromenty&title=Increased+Expression+of+Cytochrome+P450+2E1+in+Nonalcoholic+Fatty+Liver+Disease%3A+Mechanisms+and+Pathophysiological+Role&doi=10.1016%2Fj.clinre.2011.04.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: Mechanisms and pathophysiological role</span></div><div class="casAuthors">Aubert, J.; Begriche, K.; Knockaert, L.; Robin, M. A.; Fromenty, B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinics and Research in Hepatology and Gastroenterology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">630-637</span>CODEN:
                <span class="NLM_cas:coden">CRHGAQ</span>;
        ISSN:<span class="NLM_cas:issn">2210-7401</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Summary: Due to the worldwide surge in obesity and type 2 diabetes, the increased incidence of nonalcoholic fatty liver disease (NAFLD) is a major concern for the public health.  Indeed, NAFLD encompasses a large spectrum of conditions ranging from fatty liver to nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis in some patients.  A better understanding of the mechanisms involved in fatty liver and its progression into NASH is important in order to develop efficient drugs able to alleviate these liver diseases.  Although numerous investigations pointed to reactive oxygen species (ROS) as key players in the progression of fatty liver to NASH, their exact source is still uncertain.  Besides the mitochondrial respiratory chain, cytochrome P 450 2E1 (CYP2E1) has recently emerged as another potentially important cause of ROS overprodn.  Indeed, higher hepatic CYP2E1 expression and activity have been frequently obsd. in the context of obesity and NAFLD.  It is currently unknown why CYP2E1 is enhanced in these dysmetabolic diseases, although increased hepatic levels of fatty acids and insulin resistance might play a role.  Nonetheless, higher hepatic CYP2E1 could play a significant role in the pathophysiol. of NASH by inducing lipid peroxidn. and oxidative damage of key cellular components.  Moreover, CYP2E1-mediated overprodn. of ROS could promote hepatic insulin resistance, which can further aggravate fatty liver.  Since a significant amt. of CYP2E1 can be located within liver mitochondria, higher levels of CYP2E1 in NAFLD could also have detrimental effects on mitochondrial function.  Finally, increased CYP2E1 activity during NAFLD could enhance the susceptibility of some patients to the hepatotoxicity of different xenobiotics through the CYP2E1-mediated generation of harmful reactive metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon0hpSrJzUPLVg90H21EOLACvtfcHk0lgdljPTdtDWqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKkt73J&md5=c2673f123a705b69cd65812c9228886f</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.clinre.2011.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinre.2011.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DAubert%26aufirst%3DJ.%26aulast%3DBegriche%26aufirst%3DK.%26aulast%3DKnockaert%26aufirst%3DL.%26aulast%3DRobin%26aufirst%3DM.%2BA.%26aulast%3DFromenty%26aufirst%3DB.%26atitle%3DIncreased%2520Expression%2520of%2520Cytochrome%2520P450%25202E1%2520in%2520Nonalcoholic%2520Fatty%2520Liver%2520Disease%253A%2520Mechanisms%2520and%2520Pathophysiological%2520Role%26jtitle%3DClin.%2520Res.%2520Hepatol.%2520Gastroenterol.%26date%3D2011%26volume%3D35%26spage%3D630%26epage%3D637%26doi%3D10.1016%2Fj.clinre.2011.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Massart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begriche, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromenty, B.</span></span> <span> </span><span class="NLM_article-title">Role of Nonalcoholic Fatty Liver Disease as Risk Factor for Drug-Induced Hepatotoxicity</span>. <i>Journal of Clinical and Translational Research</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.18053/jctres.03.2017S1.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.18053%2Fjctres.03.2017S1.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28691103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFKjtbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=212-232&author=J.+Massartauthor=K.+Begricheauthor=C.+Moreauauthor=B.+Fromenty&title=Role+of+Nonalcoholic+Fatty+Liver+Disease+as+Risk+Factor+for+Drug-Induced+Hepatotoxicity&doi=10.18053%2Fjctres.03.2017S1.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity</span></div><div class="casAuthors">Massart, Julie; Begriche, Karima; Moreau, Caroline; Fromenty, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical and Translational Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">Spec.Iss.1</span>),
    <span class="NLM_cas:pages">212-232</span>CODEN:
                <span class="NLM_cas:coden">JCTRGT</span>;
        ISSN:<span class="NLM_cas:issn">2424-810X</span>.
    
            (<span class="NLM_cas:orgname">Whioce Publishing Pte. Ltd.</span>)
        </div><div class="casAbstract">Background: Obesity is often assocd. with nonalcoholic fatty liver disease (NAFLD), which refers to a large spectrum of hepatic lesions including fatty liver, nonalcoholic steatohepatitis (NASH) and cirrhosis.  Different investigations showed or suggested that obesity and NAFLD are able to increase the risk of hepatotoxicity of different drugs.  Some of these drugs could induce more frequently an acute hepatitis in obese individuals whereas others could worsen pre-existing NAFLD.  Aim: The main objective of the present review was to collect the available information regarding the role of NAFLD as risk factor for drug-induced hepatotoxicity.  For this purpose, we performed a data-mining anal. using different queries including drug-induced liver injury (or DILI), drug-induced hepatotoxicity, fatty liver, nonalcoholic fatty liver disease (or NAFLD), steatosis and obesity.  The main data from the collected articles are reported in this review and when available, some pathophysiol. hypotheses are put forward.  Relevance for patients: Drugs that could pose a potential risk in obese patients include compds. belonging to different pharmacol. classes such as acetaminophen, halothane, methotrexate, rosiglitazone, stavudine and tamoxifen.  For some of these drugs, exptl. investigations in obese rodents confirmed the clin. observations and unveiled different pathophysiol. mechanisms which could explain why these pharmaceuticals are particularly hepatotoxic in obesity and NAFLD.  Other drugs such as pentoxifylline, phenobarbital and omeprazole might also pose a risk but more investigations are required to det. whether this risk is significant or not.  Because obese people often take several drugs for the treatment of different obesity-related diseases such as type 2 diabetes, hyperlipidemia and coronary heart disease, it is urgent to identify the main pharmaceuticals that can cause acute hepatitis on a fatty liver background or induce NAFLD worsening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBLqPxfWSHXrVg90H21EOLACvtfcHk0lgdljPTdtDWqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFKjtbjO&md5=8b314f290b17146340a1a3cdb6d4085a</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.18053%2Fjctres.03.2017S1.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18053%252Fjctres.03.2017S1.006%26sid%3Dliteratum%253Aachs%26aulast%3DMassart%26aufirst%3DJ.%26aulast%3DBegriche%26aufirst%3DK.%26aulast%3DMoreau%26aufirst%3DC.%26aulast%3DFromenty%26aufirst%3DB.%26atitle%3DRole%2520of%2520Nonalcoholic%2520Fatty%2520Liver%2520Disease%2520as%2520Risk%2520Factor%2520for%2520Drug-Induced%2520Hepatotoxicity%26jtitle%3DJournal%2520of%2520Clinical%2520and%2520Translational%2520Research%26date%3D2017%26volume%3D3%26spage%3D212%26epage%3D232%26doi%3D10.18053%2Fjctres.03.2017S1.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woolsey, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirona, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaton, M. D.</span></span> <span> </span><span class="NLM_article-title">CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1484</span>, <span class="refDoi"> DOI: 10.1124/dmd.115.065979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fdmd.115.065979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26231377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVOhs7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=1484&author=S.+J.+Woolseyauthor=S.+E.+Mansellauthor=R.+B.+Kimauthor=R.+G.+Tironaauthor=M.+D.+Beaton&title=CYP3A+Activity+and+Expression+in+Nonalcoholic+Fatty+Liver+Disease&doi=10.1124%2Fdmd.115.065979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">CYP3A activity and expression in nonalcoholic fatty liver disease</span></div><div class="casAuthors">Woolsey, Sarah J.; Mansell, Sara E.; Kim, Richard B.; Tirona, Rommel G.; Beaton, Melanie D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1484-1490</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease in the Western world, given its assocn. with obesity, type 2 diabetes, and dyslipidemia.  Medications are widely used in NAFLD to manage comorbid conditions, and there is significant interest in developing new drug therapies to treat the disease.  Despite this, little is known about the effects of NAFLD on drug metab.  We examd. the activity and expression of the major drug-metabolizing enzyme subfamily, CYP3A, in subjects with NAFLD as well as in mouse and cellular models.  CYP3A activity was detd. in healthy volunteers and subjects with biopsy-proven NAFLD by oral midazolam phenotyping and measurement of plasma 4β-hydroxycholesterol, an endogenous metabolic biomarker.  CYP3A4 transcriptional activity, metabolic activity, and expression were also assessed in a mouse and cellular model of NAFLD.  Subjects with nonalcoholic steatohepatitis (NASH) had 2.4-fold higher plasma midazolam levels compared with controls.  Plasma 4β-hydroxycholesterol was 51% and 37% lower than controls in subjects with simple steatosis and NASH, resp.  Fibrosis was assocd. with 57% lower plasma 4β-hydroxycholesterol levels than controls.  Furthermore, hepatic CYP3A4 mRNA expression in NASH was 69% lower than control livers.  CYP3A4 gene luciferase activity in the livers of NAFLD mice was 38% lower than that of controls.  Lipid-loaded Huh7 human hepatoma cells had a 38% redn. in CYP3A4 activity and 80% lower CYP3A4 mRNA expression compared with the control.  CYP3A activity is reduced in human NAFLD in addn. to mouse and in vitro cell models of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE7X6u5ZS-WLVg90H21EOLACvtfcHk0licTxf8evppNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVOhs7bK&md5=3ce7d7219ebd23b6c3150a9fcff5d19e</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.065979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.065979%26sid%3Dliteratum%253Aachs%26aulast%3DWoolsey%26aufirst%3DS.%2BJ.%26aulast%3DMansell%26aufirst%3DS.%2BE.%26aulast%3DKim%26aufirst%3DR.%2BB.%26aulast%3DTirona%26aufirst%3DR.%2BG.%26aulast%3DBeaton%26aufirst%3DM.%2BD.%26atitle%3DCYP3A%2520Activity%2520and%2520Expression%2520in%2520Nonalcoholic%2520Fatty%2520Liver%2520Disease%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D1484%26doi%3D10.1124%2Fdmd.115.065979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cobbina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhlaghi, F.</span></span> <span> </span><span class="NLM_article-title">Non-Alcoholic Fatty Liver Disease - Pathogenesis, Classification, and Effect on Drug Metabolizing Enzymes and Transporters</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1080/03602532.2017.1293683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1080%2F03602532.2017.1293683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28303724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXks1Kiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=197-211&author=E.+Cobbinaauthor=F.+Akhlaghi&title=Non-Alcoholic+Fatty+Liver+Disease+-+Pathogenesis%2C+Classification%2C+and+Effect+on+Drug+Metabolizing+Enzymes+and+Transporters&doi=10.1080%2F03602532.2017.1293683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters</span></div><div class="casAuthors">Cobbina, Enoch; Akhlaghi, Fatemeh</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-211</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Non-alc. fatty liver disease (NAFLD) is a spectrum of liver disorders.  It is defined by the presence of steatosis in more than 5% of hepatocytes with little or no alc. consumption.  Insulin resistance, the metabolic syndrome or type 2 diabetes and genetic variants of PNPLA3 or TM6SF2 seem to play a role in the pathogenesis of NAFLD.  The pathol. progression of NAFLD follows tentatively a "three-hit" process namely steatosis, lipotoxicity and inflammation.  The presence of steatosis, oxidative stress and inflammatory mediators like TNF-α and IL-6 has been implicated in the alterations of nuclear factors such as CAR, PXR, PPAR-α in NAFLD.  These factors may result in altered expression and activity of drug metabolizing enzymes (DMEs) or transporters.  Existing evidence suggests that the effect of NAFLD on CYP3A4, CYP2E1 and MRP3 is more consistent across rodent and human studies.  CYP3A4 activity is down-regulated in NASH whereas the activity of CYP2E1 and the efflux transporter MRP3 is up-regulated.  However, it is not clear how the majority of CYPs, UGTs, SULTs and transporters are influenced by NAFLD either in vivo or in vitro.  The alterations assocd. with NAFLD could be a potential source of drug variability in patients and could have serious implications for the safety and efficacy of xenobiotics.  In this review, we summarize the effects of NAFLD on the regulation, expression and activity of major DMEs and transporters.  We also discuss the potential mechanisms underlying these alterations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTPTZhmrzaNbVg90H21EOLACvtfcHk0licTxf8evppNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXks1Kiur0%253D&md5=333c5a64d395a86c668b768665250ea5</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1080%2F03602532.2017.1293683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F03602532.2017.1293683%26sid%3Dliteratum%253Aachs%26aulast%3DCobbina%26aufirst%3DE.%26aulast%3DAkhlaghi%26aufirst%3DF.%26atitle%3DNon-Alcoholic%2520Fatty%2520Liver%2520Disease%2520-%2520Pathogenesis%252C%2520Classification%252C%2520and%2520Effect%2520on%2520Drug%2520Metabolizing%2520Enzymes%2520and%2520Transporters%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2017%26volume%3D49%26spage%3D197%26epage%3D211%26doi%3D10.1080%2F03602532.2017.1293683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dzierlenga, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargraves, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ainslie, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderah, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paine, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherrington, N.</span></span> <span> </span><span class="NLM_article-title">J. Mechanistic Basis of Altered Morphine Disposition in Nonalcoholic Steatohepatitis</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.220764</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fjpet.114.220764" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25512370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVKnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=462-470&author=A.+L.+Dzierlengaauthor=J.+D.+Clarkeauthor=T.+L.+Hargravesauthor=G.+R.+Ainslieauthor=T.+W.+Vanderahauthor=M.+F.+Paineauthor=N.+Cherrington&title=J.+Mechanistic+Basis+of+Altered+Morphine+Disposition+in+Nonalcoholic+Steatohepatitis&doi=10.1124%2Fjpet.114.220764"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis</span></div><div class="casAuthors">Dzierlenga, Anika L.; Clarke, John D.; Hargraves, Tiffanie L.; Ainslie, Garrett R.; Vanderah, Todd W.; Paine, Mary F.; Cherrington, Nathan J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">462-470/1-462-470/9, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Morphine is metabolized in humans to morphine-3-glucuronide (M3G) and the pharmacol. active morphine-6-glucuronide (M6G).  The hepatobiliary disposition of both metabolites relies upon multidrug resistance-assocd. proteins Mrp3 and Mrp2, located on the sinusoidal and canalicularmembrane, resp.  Nonalcoholic steatohepatitis (NASH), the severe stage of nonalcoholic fatty liver disease, alters xenobiotic metabolizing enzyme and transporter function.  The purpose of this study was to det. whether NASH contributes to the large interindividual variability and postoperative adverse events assocd. with morphine therapy.  Male Sprague-Dawley rats were fed a control diet or a methionine- and choline-deficient diet to induce NASH.  Radiolabeled morphine (2.5 mg/kg, 30 μCi/kg) was administered i.v., and plasma and bile (0-150 or 0-240 min), liver and kidney, and cumulative urine were analyzed formorphine and M3G.  The antinociceptive response to M6G (5 mg/kg) was assessed (0-12 h) after direct i.p. administration since rats do not produce M6G.  NASH caused a net decrease in morphine concns. in the bile and plasma and a net increase in theM3G/morphine plasma area under the concn.-time curve ratio, consistent with upregulation of UDP-glucuronosyltransferase Ugt2b1.  Despite increased systemic exposure to M3G, NASH resulted in decreased biliary excretion and hepatic accumulation of M3G.  This shift toward systemic retention is consistent with the mislocalization of canalicular Mrp2 and increased expression of sinusoidalMrp3 in NASH andmay correlate to increased antinociception by M6G.  Increased metab. and altered transporter regulation in NASH provide a mechanistic basis for interindividual variability in morphine disposition that may lead to opioid-related toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR82k_nEVe-bVg90H21EOLACvtfcHk0licTxf8evppNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVKnt74%253D&md5=8765d9b42b2495b629272c7234ff8302</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220764&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220764%26sid%3Dliteratum%253Aachs%26aulast%3DDzierlenga%26aufirst%3DA.%2BL.%26aulast%3DClarke%26aufirst%3DJ.%2BD.%26aulast%3DHargraves%26aufirst%3DT.%2BL.%26aulast%3DAinslie%26aufirst%3DG.%2BR.%26aulast%3DVanderah%26aufirst%3DT.%2BW.%26aulast%3DPaine%26aufirst%3DM.%2BF.%26aulast%3DCherrington%26aufirst%3DN.%26atitle%3DJ.%2520Mechanistic%2520Basis%2520of%2520Altered%2520Morphine%2520Disposition%2520in%2520Nonalcoholic%2520Steatohepatitis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D462%26epage%3D470%26doi%3D10.1124%2Fjpet.114.220764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganey, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, R. A.</span></span> <span> </span><span class="NLM_article-title">Idiosyncratic Drug-Induced Liver Injury and the Role of Inflammatory Stress with an Emphasis on an Animal Model of Trovafloxacin Hepatotoxicity</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfq168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfq168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=20538741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlSmtbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2010&pages=7-18&author=P.+J.+Shawauthor=P.+E.+Ganeyauthor=R.+A.+Roth&title=Idiosyncratic+Drug-Induced+Liver+Injury+and+the+Role+of+Inflammatory+Stress+with+an+Emphasis+on+an+Animal+Model+of+Trovafloxacin+Hepatotoxicity&doi=10.1093%2Ftoxsci%2Fkfq168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Idiosyncratic Drug-Induced Liver Injury and the Role of Inflammatory Stress with an Emphasis on an Animal Model of Trovafloxacin Hepatotoxicity</span></div><div class="casAuthors">Shaw, Patrick J.; Ganey, Patricia E.; Roth, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-18</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Idiosyncratic adverse drug reactions (IADRs) occur in a minority of patients yet account for the majority of postmarketing use restrictions by the Food and Drug Administration.  Despite the impact of these toxicities, the underlying mechanisms are still poorly understood.  Animal models of IADRs would be beneficial in understanding mechanisms and in developing assays with predictive potential.  Recent work exploring the interactions between inflammatory stress and drugs assocd. with human idiosyncratic drug-induced liver injury (IDILI) has led to the development of the first animal models that apply to a range of drugs.  Here, we discuss hypotheses for the mechanisms of IDILI and focus on a murine model of trovafloxacin-induced hepatotoxicity as an example related to the inflammatory stress hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVzwriDrT1ArVg90H21EOLACvtfcHk0licTxf8evppNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlSmtbfI&md5=464b676027dd284cd1f17a917626c678</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfq168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfq168%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DP.%2BJ.%26aulast%3DGaney%26aufirst%3DP.%2BE.%26aulast%3DRoth%26aufirst%3DR.%2BA.%26atitle%3DIdiosyncratic%2520Drug-Induced%2520Liver%2520Injury%2520and%2520the%2520Role%2520of%2520Inflammatory%2520Stress%2520with%2520an%2520Emphasis%2520on%2520an%2520Animal%2520Model%2520of%2520Trovafloxacin%2520Hepatotoxicity%26jtitle%3DToxicol.%2520Sci.%26date%3D2010%26volume%3D118%26spage%3D7%26epage%3D18%26doi%3D10.1093%2Ftoxsci%2Fkfq168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganey, P. E.</span></span> <span> </span><span class="NLM_article-title">Animal Models of Idiosyncratic Drug-Induced Liver Injury-Current Status</span>. <i>Crit. Rev. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">723</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.3109/10408444.2011.575765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.3109%2F10408444.2011.575765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21726137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2jtLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=723-739&author=R.+A.+Rothauthor=P.+E.+Ganey&title=Animal+Models+of+Idiosyncratic+Drug-Induced+Liver+Injury-Current+Status&doi=10.3109%2F10408444.2011.575765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of idiosyncratic drug-induced liver injury-Current status</span></div><div class="casAuthors">Roth, Robert A.; Ganey, Patricia E.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">723-739</span>CODEN:
                <span class="NLM_cas:coden">CRTXB2</span>;
        ISSN:<span class="NLM_cas:issn">1040-8444</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The infrequent occurrence of idiosyncratic reactions and their dependence on individual sensitivity factors allow them to go undetected in current preclin. safety evaluation using conventional animal tests.  Better predictive models for idiosyncratic, drug-induced liver injury (IDILI) would enable the preclin. elimination of drug candidates with idiosyncrasy liability and could provide evidence for a mode of action for these responses, suggest early biomarkers of IDILI, and lead to the development of mechanism-based, in vitro screens.  Desirable characteristics of an animal model include the prodn. of liver injury in a large fraction of animals of relatively inexpensive species/strains and the ability to distinguish drugs that cause IDILI in humans from ones that do not.  The mechanistic basis for idiosyncratic reactions remains poorly understood.  However, attempts at animal model development have been made based on several hypothesized modes of action of IDILI.  These hypotheses have centered on drug disposition polymorphisms, adaptive immunity, mitochondrial dysfunction, failure to adapt to modest injury, inflammatory stress, and multiple determinants, and the success in achieving animal models of liver injury for each of these is discussed.  Despite numerous challenges assocd. with animal models of IDILI, some models have emerged and are proving useful in exploring potential mechanisms.  Current animal models are not perfect, but they hold promise for increasing the prediction and understanding of human idiosyncratic drug reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrysTJ_2vetHLVg90H21EOLACvtfcHk0li7WeXJJuN1CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2jtLbP&md5=bb2bc8b56819940b421ccfeb95104bc8</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.3109%2F10408444.2011.575765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10408444.2011.575765%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DR.%2BA.%26aulast%3DGaney%26aufirst%3DP.%2BE.%26atitle%3DAnimal%2520Models%2520of%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury-Current%2520Status%26jtitle%3DCrit.%2520Rev.%2520Toxicol.%26date%3D2011%26volume%3D41%26spage%3D723%26epage%3D739%26doi%3D10.3109%2F10408444.2011.575765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, E. T.</span></span> <span> </span><span class="NLM_article-title">Regulation of Cytochromes P450 During Inflammation and Infection</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1129</span>– <span class="NLM_lpage">1188</span>, <span class="refDoi"> DOI: 10.3109/03602539709002246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.3109%2F03602539709002246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=9421688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADyaK1cXhtlGqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1997&pages=1129-1188&author=E.+T.+Morgan&title=Regulation+of+Cytochromes+P450+During+Inflammation+and+Infection&doi=10.3109%2F03602539709002246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of cytochromes P450 during inflammation and infection</span></div><div class="casAuthors">Morgan, Edward T.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1129-1188</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Marcel Dekker, Inc.</span>)
        </div><div class="casAbstract">A review with 281 refs.  Major topics include: the cytochrome P 450 system; effects of inflammation and infection in vivo, role of cytokines and interferons; other possible mediators; mechanisms, signaling pathways and second messengers; effects of extrahepatic P 450.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi-01bksaCt7Vg90H21EOLACvtfcHk0li7WeXJJuN1CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtlGqsw%253D%253D&md5=b14bc73ff99167f69c9ea26306141959</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.3109%2F03602539709002246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602539709002246%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DE.%2BT.%26atitle%3DRegulation%2520of%2520Cytochromes%2520P450%2520During%2520Inflammation%2520and%2520Infection%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D1997%26volume%3D29%26spage%3D1129%26epage%3D1188%26doi%3D10.3109%2F03602539709002246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Theken, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kannon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poloyac, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. R.</span></span> <span> </span><span class="NLM_article-title">Activation of the Acute Inflammatory Response Alters Cytochrome P450 Expression and Eicosanoid Metabolism</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.035287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fdmd.110.035287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=20947618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1emsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=22-29&author=K.+N.+Thekenauthor=Y.+Dengauthor=M.+A.+Kannonauthor=T.+M.+Millerauthor=S.+M.+Poloyacauthor=C.+R.+Lee&title=Activation+of+the+Acute+Inflammatory+Response+Alters+Cytochrome+P450+Expression+and+Eicosanoid+Metabolism&doi=10.1124%2Fdmd.110.035287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism</span></div><div class="casAuthors">Theken, Katherine N.; Deng, Yangmei; Kannon, M. Alison; Miller, Tricia M.; Poloyac, Samuel M.; Lee, Craig R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-29</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cytochrome P 450 (P 450)-mediated metab. of arachidonic acid regulates inflammation in hepatic and extrahepatic tissue.  CYP2C/CYP2J-derived epoxyeicosatrienoic and dihydroxyeicosatrienoic acids (EET+DHET) elicit anti-inflammatory effects, whereas CYP4A/CYP4F-derived 20-hydroxyeicosatetraenoic acid (20-HETE) is proinflammatory.  Because the impact of inflammation on P 450-mediated formation of endogenous eicosanoids is unclear, we evaluated P 450 mRNA levels and P 450 epoxygenase (EET+DHET) and ω-hydroxylase (20-HETE) metabolic activity in liver, kidney, lung, and heart in mice 3, 6, 24, and 48 h after i.p. lipopolysaccharide (LPS) (1mg/kg) or saline administration.  Hepatic Cyp2c29, Cyp2c44, and Cyp2j5 mRNA levels and EET+DHET formation were significantly lower 24 and 48 h after LPS administration.  Hepatic Cyp4a12a, Cyp4a12b, and Cyp4f13 mRNA levels and 20-HETE formation were also significantly lower at 24 h, but recovered to baseline at 48 h, resulting in a significantly higher 20-HETE/EET+DHET formation rate ratio compared with that for saline-treated mice.  Renal P 450 mRNA levels and P 450-mediated eicosanoid metab. were similarly suppressed 24 h after LPS treatment.  Pulmonary EET+DHET formation was lower at all time points after LPS administration, whereas 20-HETE formation was suppressed in a time-dependent manner, with the lowest formation rate obsd. at 24 h.  No differences in EET+DHET or 20-HETE formation were obsd. in heart.  Collectively, these data demonstrate that acute activation of the innate immune response alters P 450 expression and eicosanoid metab. in mice in an isoform-, tissue-, and time-dependent manner.  Further study is necessary to det. whether therapeutic restoration of the functional balance between the P 450 epoxygenase and ω-hydroxylase pathways is an effective anti-inflammatory strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq32OfpeaemhbVg90H21EOLACvtfcHk0li7WeXJJuN1CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1emsw%253D%253D&md5=00b9c04ab16f0b948381857a25309990</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.035287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.035287%26sid%3Dliteratum%253Aachs%26aulast%3DTheken%26aufirst%3DK.%2BN.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DKannon%26aufirst%3DM.%2BA.%26aulast%3DMiller%26aufirst%3DT.%2BM.%26aulast%3DPoloyac%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DC.%2BR.%26atitle%3DActivation%2520of%2520the%2520Acute%2520Inflammatory%2520Response%2520Alters%2520Cytochrome%2520P450%2520Expression%2520and%2520Eicosanoid%2520Metabolism%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D22%26epage%3D29%26doi%3D10.1124%2Fdmd.110.035287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikemura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, M.</span></span> <span> </span><span class="NLM_article-title">Altered Functions and Expressions of Drug Transporters in Liver, Kidney and Intestine in Disorders of Local and Remote Organs: Possible Role of Oxidative Stress in the Pathogenesis</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">907</span>– <span class="NLM_lpage">920</span>, <span class="refDoi"> DOI: 10.1517/17425250903008525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1517%2F17425250903008525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19619071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovVCjur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=907-920&author=K.+Ikemuraauthor=T.+Iwamotoauthor=M.+Okuda&title=Altered+Functions+and+Expressions+of+Drug+Transporters+in+Liver%2C+Kidney+and+Intestine+in+Disorders+of+Local+and+Remote+Organs%3A+Possible+Role+of+Oxidative+Stress+in+the+Pathogenesis&doi=10.1517%2F17425250903008525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Altered functions and expressions of drug transporters in liver, kidney and intestine in disorders of local and remote organs: possible role of oxidative stress in the pathogenesis</span></div><div class="casAuthors">Ikemura, Kenji; Iwamoto, Takuya; Okuda, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">907-920</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Oxidative stress is important in the pathogenesis of various diseases.  Drug transporters expressed in the liver, kidney and intestine regulate the distribution, elimination and absorption of drugs.  These procedures of drugs in diseases of these organs, mediated by drug transporters, often fluctuate and thereby cause inter- and intra-individual pharmacokinetic variability.  Objective: In the present review article, we explore recent reports demonstrating the variance of expressions and/or functions of drug transporters in diseases of the liver, kidney and intestine, in which oxidative stress is involved at least in part in their etiol., and summarize perspectives for further study and the application to clin. situations.  Results/conclusion: Various ATP binding cassette and solute carrier transporter expressions were up- or down-regulated in remote organs as well as in the local organ of diseases when these organs were injured, at least in part by oxidative stress, suggesting that oxidative stress is a factor affecting the expression and function of drug transporters.  The present review provides useful information for further investigation on the roles of drug transporters in inter- and intra-individual pharmacokinetic variability and for refining dosing regimens in the state of organ diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphyDUV1wbypLVg90H21EOLACvtfcHk0lg8q8FTS2Zzeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovVCjur0%253D&md5=8d4f8b193695fd71c3f8c08cd881c2a0</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1517%2F17425250903008525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425250903008525%26sid%3Dliteratum%253Aachs%26aulast%3DIkemura%26aufirst%3DK.%26aulast%3DIwamoto%26aufirst%3DT.%26aulast%3DOkuda%26aufirst%3DM.%26atitle%3DAltered%2520Functions%2520and%2520Expressions%2520of%2520Drug%2520Transporters%2520in%2520Liver%252C%2520Kidney%2520and%2520Intestine%2520in%2520Disorders%2520of%2520Local%2520and%2520Remote%2520Organs%253A%2520Possible%2520Role%2520of%2520Oxidative%2520Stress%2520in%2520the%2520Pathogenesis%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2009%26volume%3D5%26spage%3D907%26epage%3D920%26doi%3D10.1517%2F17425250903008525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verbeeck, R. K.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and Dosage Adjustment in Patients with Hepatic Dysfunction</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1147</span>, <span class="refDoi"> DOI: 10.1007/s00228-008-0553-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs00228-008-0553-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=18762933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVCktL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2008&pages=1147&author=R.+K.+Verbeeck&title=Pharmacokinetics+and+Dosage+Adjustment+in+Patients+with+Hepatic+Dysfunction&doi=10.1007%2Fs00228-008-0553-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction</span></div><div class="casAuthors">Verbeeck, Roger K.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1147-1161</span>CODEN:
                <span class="NLM_cas:coden">EJCPAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The liver plays a central role in the pharmacokinetics of the majority of drugs.  Liver dysfunction may not only reduce the blood/plasma clearance of drugs eliminated by hepatic metab. or biliary excretion, it can also affect plasma protein binding, which in turn could influence the processes of distribution and elimination.  Portal-systemic shunting, which is common in advanced liver cirrhosis, may substantially decrease the presystemic elimination (i.e., first-pass effect) of high extn. drugs following their oral administration, thus leading to a significant increase in the extent of absorption.  Chronic liver diseases are assocd. with variable and non-uniform redns. in drug-metabolizing activities.  For example, the activity of the various CYP450 enzymes seems to be differentially affected in patients with cirrhosis.  Glucuronidation is often considered to be affected to a lesser extent than CYP450-mediated reactions in mild to moderate cirrhosis but can also be substantially impaired in patients with advanced cirrhosis.  Patients with advanced cirrhosis often have impaired renal function and dose adjustment may, therefore, also be necessary for drugs eliminated by renal exctretion.  In addn., patients with liver cirrhosis are more sensitive to the central adverse effects of opioid analgesics and the renal adverse effects of NSAIDs.  In contrast, a decreased therapeutic effect has been noted in cirrhotic patients with β-adrenoceptor antagonists and certain diuretics.  Unfortunately, there is no simple endogenous marker to predict hepatic function with respect to the elimination capacity of specific drugs.  Several quant. liver tests that measure the elimination of marker substrates such as galactose, sorbitol, antipyrine, caffeine, erythromycin, and midazolam, have been developed and evaluated, but no single test has gained widespread clin. use to adjust dosage regimens for drugs in patients with hepatic dysfunction.  The semi-quant. Child-Pugh score is frequently used to assess the severity of liver function impairment, but only offers the clinician rough guidance for dosage adjustment because it lacks the sensitivity to quantitate the specific ability of the liver to metabolize individual drugs.  The recommendations of the Food and Drug Administration (FDA) and the European Medicines Evaluation Agency (EMEA) to study the effect of liver disease on the pharmacokinetics of drugs under development is clearly aimed at generating, if possible, specific dosage recommendations for patients with hepatic dysfunction.  However, the limitations of the Child-Pugh score are acknowledged, and further research is needed to develop more sensitive liver function tests to guide drug dosage adjustment in patients with hepatic dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr50zLqmEKs_rVg90H21EOLACvtfcHk0lg8q8FTS2Zzeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVCktL3F&md5=2c521b5fd0e5037c692cc47385186116</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1007%2Fs00228-008-0553-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-008-0553-z%26sid%3Dliteratum%253Aachs%26aulast%3DVerbeeck%26aufirst%3DR.%2BK.%26atitle%3DPharmacokinetics%2520and%2520Dosage%2520Adjustment%2520in%2520Patients%2520with%2520Hepatic%2520Dysfunction%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D64%26spage%3D1147%26doi%3D10.1007%2Fs00228-008-0553-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J. H.</span></span> <span> </span><span class="NLM_article-title">The Rational Use of Potentially Hepatotoxic Medications in Patients with Underlying Liver Disease</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1517/14740338.1.2.159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1517%2F14740338.1.2.159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=12904150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslOlt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=159-172&author=J.+H.+Lewis&title=The+Rational+Use+of+Potentially+Hepatotoxic+Medications+in+Patients+with+Underlying+Liver+Disease&doi=10.1517%2F14740338.1.2.159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">The rational use of potentially hepatotoxic medications in patients with underlying liver disease</span></div><div class="casAuthors">Lewis, James H.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-172</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Given the fact that as many as 9% of all adverse drug reactions involve toxic effects on the liver and with upwards of 50% of all cases of fulminant hepatic failure being ascribed to acetaminophen and other agents, the safe use of medications takes on an even greater importance whenever the prescription of potentially hepatotoxic drugs to patients with underlying liver disease is considered.  In general, it is thought that most drugs can be safely administered in the setting of liver disease without an increased risk of hepatotoxicity, although the evidence on which this statement is based often relies more on clin. judgement than on clin. studies.  Several drugs appear to have an increased risk of hepatotoxicity in patients with underlying liver disease based on either clin. reports or extrapolated pharmacol. data.  These agents, including methotrexate, niacin, and the antiretroviral and antituberculosis drugs, carry warnings about their use in patients with a variety of liver conditions.  The data supporting the hepatotoxic risk of scores of addnl. drugs, such as the 3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors ("statins"), the newer thiazolidinediones (rosiglitazone, pioglitazone), and tamoxifen, among others, in patients with liver disease are generally lacking by evidence-based studies.  However, clin. and biochem. monitoring is routinely recommended or required, often to make up for the lack of information on the true risk of clin. significant liver toxicity of these agents in individuals both with and without underlying liver disease.  This article will review what is and what is not known about prescribing in the setting of acute and chronic liver disease and offers recommendations to help promote the safe and rational use of potentially hepatotoxic medications in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk0KI0C9cZtrVg90H21EOLACvtfcHk0lg8q8FTS2Zzeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslOlt78%253D&md5=9571cfa4427e1d5a41aaa884f6519c65</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1517%2F14740338.1.2.159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.1.2.159%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DJ.%2BH.%26atitle%3DThe%2520Rational%2520Use%2520of%2520Potentially%2520Hepatotoxic%2520Medications%2520in%2520Patients%2520with%2520Underlying%2520Liver%2520Disease%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2002%26volume%3D1%26spage%3D159%26epage%3D172%26doi%3D10.1517%2F14740338.1.2.159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munoz-Garrido, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marin, J. J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perugorria, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urribarri, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erice, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sáez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uriz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarvide, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Concepcion, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monte, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos-Laso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hijona, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Agüero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzioni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuers, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masyuk, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaRusso, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bujanda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drenth, J. P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banales, J. M.</span></span> <span> </span><span class="NLM_article-title">Ursodeoxycholic Acid Inhibits Hepatic Cystogenesis in Experimental Models of Polycystic Liver Disease</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">952</span>– <span class="NLM_lpage">961</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2015.05.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jhep.2015.05.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26044126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Gru7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2015&pages=952-961&author=P.+Munoz-Garridoauthor=J.+J.+G.+Marinauthor=M.+J.+Perugorriaauthor=A.+D.+Urribarriauthor=O.+Ericeauthor=E.+S%C3%A1ezauthor=M.+Urizauthor=S.+Sarvideauthor=A.+Portuauthor=A.+R.+Concepcionauthor=M.+R.+Romeroauthor=M.+J.+Monteauthor=A.+Santos-Lasoauthor=E.+Hijonaauthor=R.+Jimenez-Ag%C3%BCeroauthor=M.+Marzioniauthor=U.+Beuersauthor=T.+V.+Masyukauthor=N.+F.+LaRussoauthor=J.+Prietoauthor=L.+Bujandaauthor=J.+P.+H.+Drenthauthor=J.+M.+Banales&title=Ursodeoxycholic+Acid+Inhibits+Hepatic+Cystogenesis+in+Experimental+Models+of+Polycystic+Liver+Disease&doi=10.1016%2Fj.jhep.2015.05.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease</span></div><div class="casAuthors">Munoz-Garrido, Patricia; Marin, Jose J. G.; Perugorria, Maria J.; Urribarri, Aura D.; Erice, Oihane; Saez, Elena; Uriz, Miriam; Sarvide, Sarai; Portu, Ainhoa; Concepcion, Axel R.; Romero, Marta R.; Monte, Maria J.; Santos-Laso, Alvaro; Hijona, Elizabeth; Jimenez-Aguero, Raul; Marzioni, Marco; Beuers, Ulrich; Masyuk, Tatyana V.; LaRusso, Nicholas F.; Prieto, Jesus; Bujanda, Luis; Drenth, Joost P. H.; Banales, Jesus M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">952-961</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Polycystic liver diseases (PLDs) are genetic disorders characterized by progressive biliary cystogenesis.  Current therapies show short-term and/or modest beneficial effects.  Cystic cholangiocytes hyperproliferate as a consequence of diminished intracellular calcium levels ([Ca2+]i).  Here, the therapeutic value of ursodeoxycholic acid (UDCA) was investigated.Effect of UDCA was examd. in vitro and in polycystic (PCK) rats.  Hepatic cystogenesis and fibrosis, and the bile acid (BA) content were evaluated from the liver, bile, serum, and kidneys by HPLC-MS/MS.Chronic treatment of PCK rats with UDCA inhibits hepatic cystogenesis and fibrosis, and improves their motor behavior.  As compared to wild-type animals, PCK rats show increased BA concn. ([BA]) in liver, similar hepatic Cyp7a1 mRNA levels, and diminished [BA] in bile.  Likewise, [BA] is increased in cystic fluid of PLD patients compared to their matched serum levels.  In PCK rats, UDCA decreases the intrahepatic accumulation of cytotoxic BA, normalizes their diminished [BA] in bile, increases the BA secretion in bile and diminishes the increased [BA] in kidneys.  In vitro, UDCA inhibits the hyperproliferation of polycystic human cholangiocytes via a PI3K/AKT/MEK/ERK1/2-dependent mechanism without affecting apoptosis.  Finally, the presence of glycodeoxycholic acid promotes the proliferation of polycystic human cholangiocytes, which is inhibited by both UDCA and tauro-UDCA.UDCA was able to halt the liver disease of a rat model of PLD through inhibiting cystic cholangiocyte hyperproliferation and decreasing the levels of cytotoxic BA species in the liver, which suggests the use of UDCA as a potential therapeutic tool for PLD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS2p7ZhTEokbVg90H21EOLACvtfcHk0lgX5dXL2rvJ8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Gru7fM&md5=7195e515a1315a842a1b6f10017c110a</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2015.05.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2015.05.023%26sid%3Dliteratum%253Aachs%26aulast%3DMunoz-Garrido%26aufirst%3DP.%26aulast%3DMarin%26aufirst%3DJ.%2BJ.%2BG.%26aulast%3DPerugorria%26aufirst%3DM.%2BJ.%26aulast%3DUrribarri%26aufirst%3DA.%2BD.%26aulast%3DErice%26aufirst%3DO.%26aulast%3DS%25C3%25A1ez%26aufirst%3DE.%26aulast%3DUriz%26aufirst%3DM.%26aulast%3DSarvide%26aufirst%3DS.%26aulast%3DPortu%26aufirst%3DA.%26aulast%3DConcepcion%26aufirst%3DA.%2BR.%26aulast%3DRomero%26aufirst%3DM.%2BR.%26aulast%3DMonte%26aufirst%3DM.%2BJ.%26aulast%3DSantos-Laso%26aufirst%3DA.%26aulast%3DHijona%26aufirst%3DE.%26aulast%3DJimenez-Ag%25C3%25BCero%26aufirst%3DR.%26aulast%3DMarzioni%26aufirst%3DM.%26aulast%3DBeuers%26aufirst%3DU.%26aulast%3DMasyuk%26aufirst%3DT.%2BV.%26aulast%3DLaRusso%26aufirst%3DN.%2BF.%26aulast%3DPrieto%26aufirst%3DJ.%26aulast%3DBujanda%26aufirst%3DL.%26aulast%3DDrenth%26aufirst%3DJ.%2BP.%2BH.%26aulast%3DBanales%26aufirst%3DJ.%2BM.%26atitle%3DUrsodeoxycholic%2520Acid%2520Inhibits%2520Hepatic%2520Cystogenesis%2520in%2520Experimental%2520Models%2520of%2520Polycystic%2520Liver%2520Disease%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D63%26spage%3D952%26epage%3D961%26doi%3D10.1016%2Fj.jhep.2015.05.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span> <span> </span><span class="NLM_article-title">High Daily Dose and Being a Substrate of Cytochrome P450 Enzymes Are Two Important Predictors of Drug-Induced Liver Injury</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">744</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1124/dmd.113.056267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fdmd.113.056267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24464804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosFGktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=744-750&author=K.+Yuauthor=X.+Gengauthor=M.+Chenauthor=J.+Zhangauthor=B.+Wangauthor=K.+Ilicauthor=W.+Tong&title=High+Daily+Dose+and+Being+a+Substrate+of+Cytochrome+P450+Enzymes+Are+Two+Important+Predictors+of+Drug-Induced+Liver+Injury&doi=10.1124%2Fdmd.113.056267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury</span></div><div class="casAuthors">Yu, Ke; Geng, Xingchao; Chen, Minjun; Zhang, Jie; Wang, Bingshun; Ilic, Katarina; Tong, Weida</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">744-750, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is complicated and difficult to predict.  It has been obsd. that drugs with extensive hepatic metab. have a higher likelihood of causing DILI.  Cytochrome P 450 (P 450) enzymes are primarily involved in hepatic metab.  Identifying the assocns. of DILI with drugs that are P 450 substrates, inhibitors, or inducers will be extremely helpful to clinicians during the decision-making process of caring for a patient suspected of having DILI.  We collected metab. data on P 450 enzymes for 254 orally administered drugs in the Liver Toxicity Knowledge Base Benchmark Dataset with a known daily dose, and applied logistic regression to identify these assocns.  We revealed that drugs that are substrates of P 450 enzymes have a higher likelihood of causing DILI [odds ratio (OR), 3.99; 95% confidence interval (95% CI), 2.07-7.67; P < 0.0001], which is dose-independent, and drugs that are P 450 inhibitors have a higher likelihood of generating DILI only when they are administered at high daily doses (OR, 6.03; 95% CI, 1.32-27.5; P = 0.0098).  However, drugs that are P 450 inducers are not obsd. to be assocd. with DILI (OR, 1.55; 95% CI, 0.65-3.68; P = 0.3246).  Our findings will be useful in identifying the suspected medication as a cause of liver injury in clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1ZV-WvbMYx7Vg90H21EOLACvtfcHk0lgX5dXL2rvJ8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosFGktbc%253D&md5=167814960cb745e13e343242709bb585</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1124%2Fdmd.113.056267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.113.056267%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.%26aulast%3DGeng%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DIlic%26aufirst%3DK.%26aulast%3DTong%26aufirst%3DW.%26atitle%3DHigh%2520Daily%2520Dose%2520and%2520Being%2520a%2520Substrate%2520of%2520Cytochrome%2520P450%2520Enzymes%2520Are%2520Two%2520Important%2520Predictors%2520of%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2014%26volume%3D42%26spage%3D744%26epage%3D750%26doi%3D10.1124%2Fdmd.113.056267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Björnsson, E. S.</span></span> <span> </span><span class="NLM_article-title">Epidemiology and Risk Factors for Idiosyncratic Drug-Induced Liver Injury</span>. <i>Semin. Liver Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1055/s-0034-1375953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1055%2Fs-0034-1375953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24879977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFKktLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=115-122&author=E.+S.+Bj%C3%B6rnsson&title=Epidemiology+and+Risk+Factors+for+Idiosyncratic+Drug-Induced+Liver+Injury&doi=10.1055%2Fs-0034-1375953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology and risk factors for idiosyncratic drug-induced liver injury</span></div><div class="casAuthors">Bjornsson, Einar S.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Liver Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-122</span>CODEN:
                <span class="NLM_cas:coden">SLDIEE</span>;
        ISSN:<span class="NLM_cas:issn">0272-8087</span>.
    
            (<span class="NLM_cas:orgname">Thieme Medical Publishers, Inc.</span>)
        </div><div class="casAbstract">A review.  Idiosyncratic drug-induced liver injury (DILI) is, like other adverse effects of drugs, underreported and underestimated in most epidemiol. studies based on registries of DILI cases and reporting systems (e.g., Medwatch).  The same is probably true for prospective population-based studies, although they are much more likely to mirror the true incidence of DILI.  Despite these challenges, the epidemiol. of DILI remains of utmost importance and is gradually coming into better focus.  A recent population based study found a crude incidence of ∼19 cases per 100,000 per yr.  Certain agents are particularly noteworthy for their DILI risk.  Amoxicillin-clavulanate continues to be the most commonly implicated agent occurring in ∼1 out of 2,300 users.  Some others that standout with significantly higher risk include azathioprine and infliximab.  Although statin-induced hepatotoxicity has been well documented, the risk is probably quite low.  Overall, the majority of DILI in children and adults is assocd. with either antibiotics or anticonvulsants.  Drug-induced liver injury assocd. with i.v. given drugs does not show any major differences from DILI due to orally administered agents.  Unfortunately, our understanding of pretherapy risk assessment remains rudimentary for the most part.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE_OCTKYzViLVg90H21EOLACvtfcHk0lgX5dXL2rvJ8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFKktLnL&md5=21644cb03bd63872249a1937e94cab4b</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1055%2Fs-0034-1375953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0034-1375953%26sid%3Dliteratum%253Aachs%26aulast%3DBj%25C3%25B6rnsson%26aufirst%3DE.%2BS.%26atitle%3DEpidemiology%2520and%2520Risk%2520Factors%2520for%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DSemin.%2520Liver%2520Dis.%26date%3D2014%26volume%3D34%26spage%3D115%26epage%3D122%26doi%3D10.1055%2Fs-0034-1375953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thiele, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazurkiewicz-Beldzinska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benbadis, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommerville, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gawlowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazurkiewicz
Beldzinska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitosek
Szewczyk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinborn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zolnowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benbadis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciliberto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dlugos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filloux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flamini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haut, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraddi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenfeld, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seltzer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellhaas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiele, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thio, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilfong, A.</span></span> <span> </span><span class="NLM_article-title">Cannabidiol in Patients with Seizures Associated with Lennox-Gastaut Syndrome (GWPCARE4): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>391</i></span>,  <span class="NLM_fpage">1085</span>– <span class="NLM_lpage">1096</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)30136-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2FS0140-6736%2818%2930136-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29395273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlWltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=2018&pages=1085-1096&author=E.+A.+Thieleauthor=E.+D.+Marshauthor=J.+A.+Frenchauthor=M.+Mazurkiewicz-Beldzinskaauthor=S.+R.+Benbadisauthor=C.+Joshiauthor=P.+D.+Lyonsauthor=A.+Taylorauthor=C.+Robertsauthor=K.+Sommervilleauthor=B.+Gunningauthor=J.+Gawlowiczauthor=P.+Lisewskiauthor=M.+Mazurkiewicz%0ABeldzinskaauthor=K.+Mitosek%0ASzewczykauthor=B.+Steinbornauthor=M.+Zolnowskaauthor=E.+Hughesauthor=A.+McLellanauthor=S.+Benbadisauthor=M.+Cilibertoauthor=G.+Clarkauthor=D.+Dlugosauthor=F.+Fillouxauthor=R.+Flaminiauthor=J.+Frenchauthor=M.+Frostauthor=S.+Hautauthor=C.+Joshiauthor=S.+Kapoorauthor=S.+Kesslerauthor=L.+Lauxauthor=P.+Lyonsauthor=E.+Marshauthor=D.+Mooreauthor=R.+Morseauthor=V.+Nagaraddiauthor=W.+Rosenfeldauthor=L.+Seltzerauthor=R.+Shellhaasauthor=J.+Sullivanauthor=E.+Thieleauthor=L.+L.+Thioauthor=D.+Wangauthor=A.+Wilfong&title=Cannabidiol+in+Patients+with+Seizures+Associated+with+Lennox-Gastaut+Syndrome+%28GWPCARE4%29%3A+A+Randomised%2C+Double-Blind%2C+Placebo-Controlled+Phase+3+Trial&doi=10.1016%2FS0140-6736%2818%2930136-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial</span></div><div class="casAuthors">Thiele, Elizabeth A.; Marsh, Eric D.; French, Jacqueline A.; Mazurkiewicz-Beldzinska, Maria; Benbadis, Selim R.; Joshi, Charuta; Lyons, Paul D.; Taylor, Adam; Roberts, Claire; Sommerville, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">391</span>
        (<span class="NLM_cas:issue">10125</span>),
    <span class="NLM_cas:pages">1085-1096</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with Lennox-Gastaut syndrome, a rare, severe form of epileptic encephalopathy, are frequently treatment resistant to available medications.  No controlled studies have investigated the use of cannabidiol for patients with seizures assocd. with Lennox-Gastaut syndrome.  We therefore assessed the efficacy and safety of cannabidiol as an add-on anticonvulsant therapy in this population of patients.  In this randomised, double-blind, placebo-controlled trial done at 24 clin. sites in the USA, the Netherlands, and Poland, we investigated the efficacy of cannabidiol as add-on therapy for drop seizures in patients with treatment-resistant Lennox-Gastaut syndrome.  Eligible patients (aged 2-55 years) had Lennox-Gastaut syndrome, including a history of slow (<3 Hz) spike-and-wave patterns on EEG, evidence of more than one type of generalised seizure for at least 6 mo, at least two drop seizures per wk during the 4-wk baseline period, and had not responded to treatment with at least two antiepileptic drugs.  Patients were randomly assigned (1:1) using an interactive voice response system, stratified by age group, to receive 20 mg/kg oral cannabidiol daily or matched placebo for 14 wk.  All patients, caregivers, investigators, and individuals assessing data were masked to group assignment.  The primary endpoint was percentage change from baseline in monthly frequency of drop seizures during the treatment period, analyzed in all patients who received at least one dose of study drug and had post-baseline efficacy data.  All randomly assigned patients were included in the safety analyses.  This study is registered with ClinicalTrials.gov, no. NCT02224690.  Between Apr. 28, 2015, and Oct 15, 2015, we randomly assigned 171 patients to receive cannabidiol (n=86) or placebo (n=85). 14 patients in the cannabidiol group and one in the placebo group discontinued study treatment; all randomly assigned patients received at least one dose of study treatment and had post-baseline efficacy data.  The median percentage redn. in monthly drop seizure frequency from baseline was 43·9% (IQR -69·6 to -1·9) in the cannibidiol group and 21·8% (IQR -45·7 to 1·7) in the placebo group.  The estd. median difference between the treatment groups was -17·21 (95% CI -30·32 to -4·09; p=0·0135) during the 14-wk treatment period.  Adverse events occurred in 74 (86%) of 86 patients in the cannabidiol group and 59 (69%) of 85 patients in the placebo group; most were mild or moderate.  The most common adverse events were diarrhoea, somnolence, pyrexia, decreased appetite, and vomiting. 12 (14%) patients in the cannabidiol group and one (1%) patient in the placebo group withdrew from the study because of adverse events.  One patient (1%) died in the cannabidiol group, but this was considered unrelated to treatment.  Add-on cannabidiol is efficacious for the treatment of patients with drop seizures assocd. with Lennox-Gastaut syndrome and is generally well tolerated.  The long-term efficacy and safety of cannabidiol is currently being assessed in the open-label extension of this trial.GW Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFsV2mzpliMbVg90H21EOLACvtfcHk0lg9QspZdwMN0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlWltb8%253D&md5=f414a696a22a0cf480eaa19c380eae7a</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2930136-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252930136-3%26sid%3Dliteratum%253Aachs%26aulast%3DThiele%26aufirst%3DE.%2BA.%26aulast%3DMarsh%26aufirst%3DE.%2BD.%26aulast%3DFrench%26aufirst%3DJ.%2BA.%26aulast%3DMazurkiewicz-Beldzinska%26aufirst%3DM.%26aulast%3DBenbadis%26aufirst%3DS.%2BR.%26aulast%3DJoshi%26aufirst%3DC.%26aulast%3DLyons%26aufirst%3DP.%2BD.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DRoberts%26aufirst%3DC.%26aulast%3DSommerville%26aufirst%3DK.%26aulast%3DGunning%26aufirst%3DB.%26aulast%3DGawlowicz%26aufirst%3DJ.%26aulast%3DLisewski%26aufirst%3DP.%26aulast%3DMazurkiewicz%2BBeldzinska%26aufirst%3DM.%26aulast%3DMitosek%2BSzewczyk%26aufirst%3DK.%26aulast%3DSteinborn%26aufirst%3DB.%26aulast%3DZolnowska%26aufirst%3DM.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DMcLellan%26aufirst%3DA.%26aulast%3DBenbadis%26aufirst%3DS.%26aulast%3DCiliberto%26aufirst%3DM.%26aulast%3DClark%26aufirst%3DG.%26aulast%3DDlugos%26aufirst%3DD.%26aulast%3DFilloux%26aufirst%3DF.%26aulast%3DFlamini%26aufirst%3DR.%26aulast%3DFrench%26aufirst%3DJ.%26aulast%3DFrost%26aufirst%3DM.%26aulast%3DHaut%26aufirst%3DS.%26aulast%3DJoshi%26aufirst%3DC.%26aulast%3DKapoor%26aufirst%3DS.%26aulast%3DKessler%26aufirst%3DS.%26aulast%3DLaux%26aufirst%3DL.%26aulast%3DLyons%26aufirst%3DP.%26aulast%3DMarsh%26aufirst%3DE.%26aulast%3DMoore%26aufirst%3DD.%26aulast%3DMorse%26aufirst%3DR.%26aulast%3DNagaraddi%26aufirst%3DV.%26aulast%3DRosenfeld%26aufirst%3DW.%26aulast%3DSeltzer%26aufirst%3DL.%26aulast%3DShellhaas%26aufirst%3DR.%26aulast%3DSullivan%26aufirst%3DJ.%26aulast%3DThiele%26aufirst%3DE.%26aulast%3DThio%26aufirst%3DL.%2BL.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWilfong%26aufirst%3DA.%26atitle%3DCannabidiol%2520in%2520Patients%2520with%2520Seizures%2520Associated%2520with%2520Lennox-Gastaut%2520Syndrome%2520%2528GWPCARE4%2529%253A%2520A%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Phase%25203%2520Trial%26jtitle%3DLancet%26date%3D2018%26volume%3D391%26spage%3D1085%26epage%3D1096%26doi%3D10.1016%2FS0140-6736%2818%2930136-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gopaul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, F.</span></span> <span> </span><span class="NLM_article-title">Effects of Age and Polytherapy, Risk Factors of Valproic Acid (VPA) Hepatotoxicity, on the Excretion of Thiol Conjugates of (E)-2,4-diene VPA in People with Epilepsy Taking VPA</span>. <i>Epilepsia</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">322</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1046/j.1528-1157.2003.07202.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1046%2Fj.1528-1157.2003.07202.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=12614387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD3sXislejs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=322-328&author=S.+Gopaulauthor=K.+Farrellauthor=F.+Abbott&title=Effects+of+Age+and+Polytherapy%2C+Risk+Factors+of+Valproic+Acid+%28VPA%29+Hepatotoxicity%2C+on+the+Excretion+of+Thiol+Conjugates+of+%28E%29-2%2C4-diene+VPA+in+People+with+Epilepsy+Taking+VPA&doi=10.1046%2Fj.1528-1157.2003.07202.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (E)-2,4-diene VPA in people with epilepsy taking VPA</span></div><div class="casAuthors">Gopaul, Sashi; Farrell, Kevin; Abbott, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsia</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">322-328</span>CODEN:
                <span class="NLM_cas:coden">EPILAK</span>;
        ISSN:<span class="NLM_cas:issn">0013-9580</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">Valproic acid (VPA) is an antiepileptic drug (AED) used for generalized and absence seizures.  It has a rare but potentially fatal hepatotoxicity side effect, and many researchers believe that reactive metabolites of VPA could be involved.  We demonstrated here that the thiol conjugates of (E)-2,4-diene VPA were significantly elevated in a high-risk group of patients.  Thirty-four patients with seizures were divided into three groups.  Group A (n = 14) were being treated with VPA; group B (n = 12) received VPA as well as other AEDs that do not induce P 450-VPA metab.; and group C (n = 8) received VPA and AEDs that induce P 450-VPA metab.  The NAC conjugates of (E)-2,4-diene VPA (NAC I and NAC II) were identified in the urine of patients by gas chromatog./mass spectrog. NICI anal.  VPA monotherapy (group A) or VPA polytherapy with non-P 450-enzyme-inducing drugs (group B), showed that patients younger than 7.5 yr excreted significantly higher concns. of the two conjugates compared with older patients (older than 7.5 yr) in the same groups (p < 0.05).  Patients receiving VPA polytherapy with P 450-enzyme-inducing drugs were all older than 7.5 yr (group C).  They excreted significantly higher concns. of NAC I and NAC II compared with patients in groups A and B who were older than 7.5 yr (p < 0.05).  There were no significant differences in the excretion of NAC I and NAC II between patients in group C and those who were 7.5 yr or younger in groups A and B.  High doses of VPA also were a significant factor assocd. with elevated NAC I and NAC II among young patients and in polytherapy patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgfL67k65A1bVg90H21EOLACvtfcHk0lg9QspZdwMN0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXislejs7g%253D&md5=ae958701597c9f28ae9579dc75631c43</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1046%2Fj.1528-1157.2003.07202.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1528-1157.2003.07202.x%26sid%3Dliteratum%253Aachs%26aulast%3DGopaul%26aufirst%3DS.%26aulast%3DFarrell%26aufirst%3DK.%26aulast%3DAbbott%26aufirst%3DF.%26atitle%3DEffects%2520of%2520Age%2520and%2520Polytherapy%252C%2520Risk%2520Factors%2520of%2520Valproic%2520Acid%2520%2528VPA%2529%2520Hepatotoxicity%252C%2520on%2520the%2520Excretion%2520of%2520Thiol%2520Conjugates%2520of%2520%2528E%2529-2%252C4-diene%2520VPA%2520in%2520People%2520with%2520Epilepsy%2520Taking%2520VPA%26jtitle%3DEpilepsia%26date%3D2003%26volume%3D44%26spage%3D322%26epage%3D328%26doi%3D10.1046%2Fj.1528-1157.2003.07202.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steele, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DesPrez, R. M.</span></span> <span> </span><span class="NLM_article-title">Toxic Hepatitis with Isoniazid and Rifampin: A Meta-analysis</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1378/chest.99.2.465</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1378%2Fchest.99.2.465" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1824929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADyaK3M7hsVCisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1991&pages=465-471&author=M.+A.+Steeleauthor=R.+F.+Burkauthor=R.+M.+DesPrez&title=Toxic+Hepatitis+with+Isoniazid+and+Rifampin%3A+A+Meta-analysis&doi=10.1378%2Fchest.99.2.465"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Toxic hepatitis with isoniazid and rifampin. A meta-analysis</span></div><div class="casAuthors">Steele M A; Burk R F; DesPrez R M</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">465-71</span>
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR_mzx6NCDNniO2kE7krGOBfW6udTcc2eY35qsieRRa4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3M7hsVCisA%253D%253D&md5=63005c74fb861178efd94a9bdc4275d1</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1378%2Fchest.99.2.465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.99.2.465%26sid%3Dliteratum%253Aachs%26aulast%3DSteele%26aufirst%3DM.%2BA.%26aulast%3DBurk%26aufirst%3DR.%2BF.%26aulast%3DDesPrez%26aufirst%3DR.%2BM.%26atitle%3DToxic%2520Hepatitis%2520with%2520Isoniazid%2520and%2520Rifampin%253A%2520A%2520Meta-analysis%26jtitle%3DChest%26date%3D1991%26volume%3D99%26spage%3D465%26epage%3D471%26doi%3D10.1378%2Fchest.99.2.465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Abajo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madurga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez, L. A. G.</span></span> <span> </span><span class="NLM_article-title">Acute and Clinically Relevant Drug-Induced Liver Injury: A Population Based Case-Control Study</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2004.02133.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1111%2Fj.1365-2125.2004.02133.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=15206996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD2czgsFWrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2004&pages=71-80&author=F.+J.+de+Abajoauthor=D.+Monteroauthor=M.+Madurgaauthor=L.+A.+G.+Rodr%C3%ADguez&title=Acute+and+Clinically+Relevant+Drug-Induced+Liver+Injury%3A+A+Population+Based+Case-Control+Study&doi=10.1111%2Fj.1365-2125.2004.02133.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Acute and clinically relevant drug-induced liver injury: a population based case-control study</span></div><div class="casAuthors">de Abajo Francisco J; Montero Dolores; Madurga Mariano; Garcia Rodriguez Luis A</div><div class="citationInfo"><span class="NLM_cas:title">British journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">71-80</span>
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    </div><div class="casAbstract">AIMS:  To provide quantitative information about the absolute and relative risks of acute and clinically relevant drug-induced liver injury.  METHODS:  We performed a population-based case-control study using the UK-based General Practice Research Database as the source of information.  A total of 1,636,792 persons subjects aged 5-75 years old registered in the database from 1 January, 1994 to 31 December, 1999 were followed-up for a total of 5,404,705 person-years.  Cases were identified by an exhaustive computer search, then reviewed manually and finally validated against the clinical records.  Only idiopathic cases serious enough to be referred to hospital or a consultant were selected.  A total of 5000 controls were randomly sampled from the person-time of study cohort.  Current users were defined if a prescription ended within 15 days of the index date, and nonusers if there was no prescription before the index date.  RESULTS:  One hundred and twenty-eight patients were considered as valid cases, being the crude incidence rate of 2.4 (95% confidence interval: 2.0, 2.8) per 100 000 person-years.  The strongest associations were found with chlorpromazine (adjusted odds ratio (AOR); 95% CI = 416; 45, 3840), amoxicillin/clavulanic acid (AOR = 94.8; 27.8, 323), flucloxacillin (AOR = 17.7; 4.4, 71.0), macrolides (AOR = 6.9; 2.3, 21.0), tetracyclines (AOR = 6.2; 2.4, 15.8); metoclopramide (AOR = 6.2; 1.8, 21.3); chlorpheniramine (AOR = 9.6; 1.9, 49.7); betahistine (AOR = 15.3; 2.9, 80.7); sulphasalazine (AOR = 25.5; 6.0, 109); azathioprine (AOR = 10.5; 1.4, 76.4), diclofenac (AOR = 4.1; 1.9, 8.8) and antiepileptics (AOR = 5.1; 1.9, 13.7).  A dose-effect was apparent for diclofenac, amoxicillin/clavulanic acid and flucloxacillin.  The combination of two or more hepatotoxic drugs increased the risk by a factor of 6.  The highest crude incidence rates were found for chlorpromazine, azathioprine, and sulfasalazine (about 1 per 1000 users).  CONCLUSIONS:  Idiopathic, acute and clinically relevant liver injury, which has the use of drugs as the most probable aetiology, is a rare event in the general population.  The relative risks of 40 drugs/therapeutic classes are provided, along with the crude incidence rates for 15 of them where a statistical association was found.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAed3RzDrPsQ5nADWVYHg1fW6udTcc2eY35qsieRRa4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czgsFWrsQ%253D%253D&md5=575c1cf4631f60ccd88c534b49d92c77</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2004.02133.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2004.02133.x%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BAbajo%26aufirst%3DF.%2BJ.%26aulast%3DMontero%26aufirst%3DD.%26aulast%3DMadurga%26aufirst%3DM.%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DL.%2BA.%2BG.%26atitle%3DAcute%2520and%2520Clinically%2520Relevant%2520Drug-Induced%2520Liver%2520Injury%253A%2520A%2520Population%2520Based%2520Case-Control%2520Study%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2004%26volume%3D58%26spage%3D71%26epage%3D80%26doi%3D10.1111%2Fj.1365-2125.2004.02133.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagheri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapeyre-Mestre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cambus, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdiguié, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montastruc, J. L.</span></span> <span> </span><span class="NLM_article-title">Detection and Incidence of Drug-Induced Liver Injuries in Hospital: A Prospective Analysis from Laboratory Signals</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2125.2000.00282.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1046%2Fj.1365-2125.2000.00282.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=11069443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD3cXos1OltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2000&pages=479-484&author=H.+Bagheriauthor=F.+Michelauthor=M.+Lapeyre-Mestreauthor=E.+Lagierauthor=J.+P.+Cambusauthor=P.+Valdigui%C3%A9author=J.+L.+Montastruc&title=Detection+and+Incidence+of+Drug-Induced+Liver+Injuries+in+Hospital%3A+A+Prospective+Analysis+from+Laboratory+Signals&doi=10.1046%2Fj.1365-2125.2000.00282.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals</span></div><div class="casAuthors">Bagheri, H.; Michel, F.; Lapeyre-Mestre, M.; Lagier, E.; Cambus, J. P.; Valdiguie, P.; Montastruc, J. L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">479-484</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Aims: Liver damage remains the most frequent type of adverse drug reaction (ADRs) that can lead to the withdrawal of a drug from the market.  The abnormal lab. data identified by computerized hospital information systems can be used in order to improve the detection of ADRs.  Our objectives were to assess the detection and incidence of drug-induced liver abnormalities in a university hospital inpatient population and to evaluate the underreporting rate of drug-induced liver injury.  Methods: We conducted a prospective study performed 1 wk per mo from June to Oct. 1997.  We selected patients by a computerized process using biochem. lab. data, based on serum enzyme values, alanine aminotransferase (over 2 fold normal) and alk. phosphatase (over 1.5 fold normal).  Results: Among 1976 ALT and 1814 AP assays performed during the period of the study, 156 (7.9%) and 159 (8.8%) tests, resp., fell into the selected criteria.  These concerned 147 patients.  Among these patients, 13 (8.8%) cases of drug-induced liver injuries were suspected.  Seven cases were asymptomatic.  Six cases were classified as serious by these criteria: hospitalization to investigate the cause of health status impairment (4 patients), prolongation of hospitalization (1 patient) and life-threatening (1 patient).  Using the hospitalization database, the incidence of drug-induced liver injuries was estd. as 6.6 per 1000 inpatients a week.  Only 1 case was reported by physicians in the same period.  Conclusions: Computerization of biochem. data would allow the development of systems to improve detection of drug-induced injury.  Moreover, underreporting remains important for such potentially serious ADRs, even in a university hospital.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQe7ootxixvbVg90H21EOLACvtfcHk0lhuhtuZ97MUEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXos1OltLw%253D&md5=6b4ae7abec357ac5ecaf66f35bbe08ed</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2125.2000.00282.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2125.2000.00282.x%26sid%3Dliteratum%253Aachs%26aulast%3DBagheri%26aufirst%3DH.%26aulast%3DMichel%26aufirst%3DF.%26aulast%3DLapeyre-Mestre%26aufirst%3DM.%26aulast%3DLagier%26aufirst%3DE.%26aulast%3DCambus%26aufirst%3DJ.%2BP.%26aulast%3DValdigui%25C3%25A9%26aufirst%3DP.%26aulast%3DMontastruc%26aufirst%3DJ.%2BL.%26atitle%3DDetection%2520and%2520Incidence%2520of%2520Drug-Induced%2520Liver%2520Injuries%2520in%2520Hospital%253A%2520A%2520Prospective%2520Analysis%2520from%2520Laboratory%2520Signals%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2000%26volume%3D50%26spage%3D479%26epage%3D484%26doi%3D10.1046%2Fj.1365-2125.2000.00282.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Björnsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalaitzakis, E.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxicity Associated with Statins: Reports of Idiosyncratic Liver Injury Post-Marketing</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">374</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2011.07.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jhep.2011.07.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21889469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC387ltFWrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=374-380&author=E.+Bj%C3%B6rnssonauthor=E.+I.+Jacobsenauthor=E.+Kalaitzakis&title=Hepatotoxicity+Associated+with+Statins%3A+Reports+of+Idiosyncratic+Liver+Injury+Post-Marketing&doi=10.1016%2Fj.jhep.2011.07.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing</span></div><div class="casAuthors">Bjornsson Einar; Jacobsen Elin I; Kalaitzakis Evangelos</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hepatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">374-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND & AIMS:  Limited data exist on drug-induced liver injury (DILI) associated with statins.  METHODS:  Reports on adverse reactions suspected to be due to statins received by the Swedish Adverse Drug Reactions Advisory Committe 1988-2010 were analyzed.  Only cases with >5×upper limit of normal (ULN) in aminotransferases and/or alkaline phosphatase >2×ULN were included.  RESULTS:  The most common types of ADRs suspected were DILI in 124/217 (57%) cases.  A total of 73/124 (59%) cases had at least possible relationship, median age 64 years (57-73), 55% males, whereas 25/124 cases (20%) were excluded due to mild elevations of liver tests and 26 due to unlikely relationship and/or lack of data.  A statin-related DILI episode was reported in 1.2/100,000 users.  Atorvastatin was implicated in 30/73 (41%) cases, simvastatin in 28 (38%), fluvastatin (15%), and others.  Two patients died of acute liver failure, one underwent liver transplantation and 25 (34%) had jaundice.  Three patients were rechallenged with the same statin producing similar patterns of liver injury.  The median duration of therapy was 90 days (30-120), 120 (39-248) for atorvastatin, and 75 (30-150) for simvastatin (NS).  Cholestatic/mixed injury was more common with atorvastatin, 17/30 (56%) than with simvastatin, 7/28 (24%) (p=0.018).  CONCLUSIONS:  Idiosyncratic liver injury associated with statins is rare but can be severe.  After recovery, a similar pattern of liver injury can be reproduced on re-exposure.  Most patients experience liver injury 3-4 months after start of therapy.  Atorvastatin is mostly associated with cholestatic liver injury whereas hepatocellular injury is more common with simvastatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSj20RUU6aR1-98rul4nhSdfW6udTcc2ebEKDIstFRwC7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387ltFWrsA%253D%253D&md5=16c57d35cc321bbe57cdcaa9c14b30b3</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2011.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2011.07.023%26sid%3Dliteratum%253Aachs%26aulast%3DBj%25C3%25B6rnsson%26aufirst%3DE.%26aulast%3DJacobsen%26aufirst%3DE.%2BI.%26aulast%3DKalaitzakis%26aufirst%3DE.%26atitle%3DHepatotoxicity%2520Associated%2520with%2520Statins%253A%2520Reports%2520of%2520Idiosyncratic%2520Liver%2520Injury%2520Post-Marketing%26jtitle%3DJ.%2520Hepatol.%26date%3D2012%26volume%3D56%26spage%3D374%26epage%3D380%26doi%3D10.1016%2Fj.jhep.2011.07.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, J. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1002/cpt.1437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fcpt.1437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30937887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FgslKjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2019&pages=317-328&author=A.+Sharmaauthor=M.+M.+Buschmannauthor=J.+A.+Gilbert&title=Pharmacomicrobiomics%3A+The+Holy+Grail+to+Variability+in+Drug+Response%3F&doi=10.1002%2Fcpt.1437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?</span></div><div class="casAuthors">Sharma Anukriti; Gilbert Jack A; Buschmann Mary M; Gilbert Jack A</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">317-328</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The human body, with 3.0 × 10(13) cells and more than 3.8 × 10(13) microorganisms, has nearly a one-to-one ratio of resident microbes to human cells.  Initiatives like the Human Microbiome Project, American Gut, and Flemish Gut have identified associations between microbial taxa and human health.  The study of interactions between microbiome and pharmaceutical agents, i.e., pharmacomicrobiomics, has revealed an instrumental role of the microbiome in modulating drug response that alters the therapeutic outcomes.  In this review, we present our current comprehension of the relationship of the microbiome, host biology, and pharmaceutical agents such as cardiovascular drugs, analgesics, and chemotherapeutic agents to human disease and treatment outcomes.  We also discuss the significance of studying diet-gene-drug interactions and further address the key challenges associated with pharmacomicrobiomics.  Finally, we examine proposed models employing systems biology for the application of pharmacomicrobiomics and other -omics data, and provide approaches to elucidate microbiome-drug interactions to improve future translation to personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQS1WiW-1KCW7HHuJhbyicZfW6udTcc2ebEKDIstFRwC7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FgslKjtg%253D%253D&md5=b29c6bba4bd8b4a2c88ff3d4e6317542</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1002%2Fcpt.1437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.1437%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DBuschmann%26aufirst%3DM.%2BM.%26aulast%3DGilbert%26aufirst%3DJ.%2BA.%26atitle%3DPharmacomicrobiomics%253A%2520The%2520Holy%2520Grail%2520to%2520Variability%2520in%2520Drug%2520Response%253F%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2019%26volume%3D106%26spage%3D317%26epage%3D328%26doi%3D10.1002%2Fcpt.1437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Viaud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccheri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mignot, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daillere, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enot, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfirschke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engblom, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittet, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlitzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginhoux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apetoh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chachaty, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woerther, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecobichon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clermont, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bizet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaboriau-Routhiau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerf-Bensussan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opolon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yessaad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryffel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elson, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dore, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepage, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boneca, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiringhelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zitvogel, L.</span></span> <span> </span><span class="NLM_article-title">The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>342</i></span>,  <span class="NLM_fpage">971</span>– <span class="NLM_lpage">976</span>, <span class="refDoi"> DOI: 10.1126/science.1240537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1126%2Fscience.1240537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24264990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2htL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2013&pages=971-976&author=S.+Viaudauthor=F.+Saccheriauthor=G.+Mignotauthor=T.+Yamazakiauthor=R.+Daillereauthor=D.+Hannaniauthor=D.+P.+Enotauthor=C.+Pfirschkeauthor=C.+Engblomauthor=M.+J.+Pittetauthor=A.+Schlitzerauthor=F.+Ginhouxauthor=L.+Apetohauthor=E.+Chachatyauthor=P.+L.+Woertherauthor=G.+Eberlauthor=M.+Berardauthor=C.+Ecobichonauthor=D.+Clermontauthor=C.+Bizetauthor=V.+Gaboriau-Routhiauauthor=N.+Cerf-Bensussanauthor=P.+Opolonauthor=N.+Yessaadauthor=E.+Vivierauthor=B.+Ryffelauthor=C.+O.+Elsonauthor=J.+Doreauthor=G.+Kroemerauthor=P.+Lepageauthor=I.+G.+Bonecaauthor=F.+Ghiringhelliauthor=L.+Zitvogel&title=The+Intestinal+Microbiota+Modulates+the+Anticancer+Immune+Effects+of+Cyclophosphamide&doi=10.1126%2Fscience.1240537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide</span></div><div class="casAuthors">Viaud, Sophie; Saccheri, Fabiana; Mignot, Gregoire; Yamazaki, Takahiro; Daillere, Romain; Hannani, Dalil; Enot, David P.; Pfirschke, Christina; Engblom, Camilla; Pittet, Mikael J.; Schlitzer, Andreas; Ginhoux, Florent; Apetoh, Lionel; Chachaty, Elisabeth; Woerther, Paul-Louis; Eberl, Gerard; Berard, Marion; Ecobichon, Chantal; Clermont, Dominique; Bizet, Chantal; Gaboriau-Routhiau, Valerie; Cerf-Bensussan, Nadine; Opolon, Paule; Yessaad, Nadia; Vivier, Eric; Ryffel, Bernhard; Elson, Charles O.; Dore, Joel; Kroemer, Guido; Lepage, Patricia; Boneca, Ivo Gomperts; Ghiringhelli, Francois; Zitvogel, Laurence</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">6161</span>),
    <span class="NLM_cas:pages">971-976</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Cyclophosphamide is one of several clin. important cancer drugs whose therapeutic efficacy is due in part to their ability to stimulate antitumor immune responses.  Studying mouse models, we demonstrate that cyclophosphamide alters the compn. of microbiota in the small intestine and induces the translocation of selected species of Gram-pos. bacteria into secondary lymphoid organs.  There, these bacteria stimulate the generation of a specific subset of "pathogenic" T helper 17 (pTH17) cells and memory TH1 immune responses.  Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram-pos. bacteria showed a redn. in pTH17 responses, and their tumors were resistant to cyclophosphamide.  Adoptive transfer of pTH17 cells partially restored the antitumor efficacy of cyclophosphamide.  These results suggest that the gut microbiota help shape the anticancer immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpBoPVll8hyrVg90H21EOLACvtfcHk0lgFch1VODR9PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2htL3P&md5=dc90561d9098bf963ea7bf39effe78d1</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1126%2Fscience.1240537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1240537%26sid%3Dliteratum%253Aachs%26aulast%3DViaud%26aufirst%3DS.%26aulast%3DSaccheri%26aufirst%3DF.%26aulast%3DMignot%26aufirst%3DG.%26aulast%3DYamazaki%26aufirst%3DT.%26aulast%3DDaillere%26aufirst%3DR.%26aulast%3DHannani%26aufirst%3DD.%26aulast%3DEnot%26aufirst%3DD.%2BP.%26aulast%3DPfirschke%26aufirst%3DC.%26aulast%3DEngblom%26aufirst%3DC.%26aulast%3DPittet%26aufirst%3DM.%2BJ.%26aulast%3DSchlitzer%26aufirst%3DA.%26aulast%3DGinhoux%26aufirst%3DF.%26aulast%3DApetoh%26aufirst%3DL.%26aulast%3DChachaty%26aufirst%3DE.%26aulast%3DWoerther%26aufirst%3DP.%2BL.%26aulast%3DEberl%26aufirst%3DG.%26aulast%3DBerard%26aufirst%3DM.%26aulast%3DEcobichon%26aufirst%3DC.%26aulast%3DClermont%26aufirst%3DD.%26aulast%3DBizet%26aufirst%3DC.%26aulast%3DGaboriau-Routhiau%26aufirst%3DV.%26aulast%3DCerf-Bensussan%26aufirst%3DN.%26aulast%3DOpolon%26aufirst%3DP.%26aulast%3DYessaad%26aufirst%3DN.%26aulast%3DVivier%26aufirst%3DE.%26aulast%3DRyffel%26aufirst%3DB.%26aulast%3DElson%26aufirst%3DC.%2BO.%26aulast%3DDore%26aufirst%3DJ.%26aulast%3DKroemer%26aufirst%3DG.%26aulast%3DLepage%26aufirst%3DP.%26aulast%3DBoneca%26aufirst%3DI.%2BG.%26aulast%3DGhiringhelli%26aufirst%3DF.%26aulast%3DZitvogel%26aufirst%3DL.%26atitle%3DThe%2520Intestinal%2520Microbiota%2520Modulates%2520the%2520Anticancer%2520Immune%2520Effects%2520of%2520Cyclophosphamide%26jtitle%3DScience%26date%3D2013%26volume%3D342%26spage%3D971%26epage%3D976%26doi%3D10.1126%2Fscience.1240537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsih, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. T.</span></span> <span> </span><span class="NLM_article-title">Medical Genetics: A Marker for Stevens-Johnson Syndrome</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>428</i></span>,  <span class="NLM_fpage">486</span>, <span class="refDoi"> DOI: 10.1038/428486a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2F428486a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=15057820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=428&publication_year=2004&pages=486&author=W.+H.+Chungauthor=S.+I.+Hungauthor=H.+S.+Hongauthor=M.+S.+Hsihauthor=L.+C.+Yangauthor=H.+C.+Hoauthor=J.+Y.+Wuauthor=Y.+T.+Chen&title=Medical+Genetics%3A+A+Marker+for+Stevens-Johnson+Syndrome&doi=10.1038%2F428486a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Medical genetics: A marker for Stevens-Johnson syndrome</span></div><div class="casAuthors">Chung, Wen-Hung; Hung, Shuen-Iu; Hong, Hong-Shang; Hsih, Mo-Song; Yang, Li-Cheng; Ho, Hsin-Chun; Wu, Jer-Yuarn; Chen, Yuan-Tsong</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">428</span>
        (<span class="NLM_cas:issue">6982</span>),
    <span class="NLM_cas:pages">486</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here authors show that there is a strong assocn. in Han Chinese between a genetic marker, the human leukocyte antigen HLA-B*1502, and Stevens-Johnson syndrome induced by carbamazepine, a drug commonly prescribed for the treatment of seizures.  We studied 44 patients with carbamazepine-induced Stevens-Johnson syndrome (CBZ-SJS), including five with overlapping toxic epidermal necrolysis, in whom the clin. morphol. fulfilled Roujeau's diagnostic criteria.  All participants were Han Chinese residing in Taiwan.  We found that, compared with controls, there was no significant assocn. between any of the cytochrome-P 450 single-nucleotide polymorphisms and occurrence of CBZ-SJS.  However, the alleles B*1502, Cw*0801, A*101 and DRBI*1202 within the HLA region occurred at increased frequency in CBZ-SJS patients relative to the controls.  In particular, HLA-B*1502 was present in 100 % (44/44) of CBZ-SJS patients but in only 3 % (3/101) of CBZ-tolerant patients and in 8.6 % (8/93) of the general population.  Carbamazepine is the drug most commonly assocd. with the syndrome in Asians (accounting for 25-33 % of cases), whereas only 5-6 % of Caucasian CBZ-SJS cases are caused by it.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvVRYJCxSi4LVg90H21EOLACvtfcHk0lgY6XxQmEOf3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gksro%253D&md5=846bf7823089da347fa3c2446479ba64</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2F428486a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F428486a%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DW.%2BH.%26aulast%3DHung%26aufirst%3DS.%2BI.%26aulast%3DHong%26aufirst%3DH.%2BS.%26aulast%3DHsih%26aufirst%3DM.%2BS.%26aulast%3DYang%26aufirst%3DL.%2BC.%26aulast%3DHo%26aufirst%3DH.%2BC.%26aulast%3DWu%26aufirst%3DJ.%2BY.%26aulast%3DChen%26aufirst%3DY.%2BT.%26atitle%3DMedical%2520Genetics%253A%2520A%2520Marker%2520for%2520Stevens-Johnson%2520Syndrome%26jtitle%3DNature%26date%3D2004%26volume%3D428%26spage%3D486%26doi%3D10.1038%2F428486a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ozeki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushiroda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yowang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirakata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikezawa, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iijima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamatani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span></span> <span> </span><span class="NLM_article-title">Genome-Wide Association Study Identifies HLA-A*3101 Allele as a Genetic Risk Factor for Carbamazepine-Induced Cutaneous Adverse Drug Reactions in Japanese Population</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1034</span>– <span class="NLM_lpage">1041</span>, <span class="refDoi"> DOI: 10.1093/hmg/ddq537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Fhmg%2Fddq537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21149285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=1034-1041&author=T.+Ozekiauthor=T.+Mushirodaauthor=A.+Yowangauthor=A.+Takahashiauthor=M.+Kuboauthor=Y.+Shirakataauthor=Z.+Ikezawaauthor=M.+Iijimaauthor=T.+Shioharaauthor=K.+Hashimotoauthor=N.+Kamataniauthor=Y.+Nakamura&title=Genome-Wide+Association+Study+Identifies+HLA-A*3101+Allele+as+a+Genetic+Risk+Factor+for+Carbamazepine-Induced+Cutaneous+Adverse+Drug+Reactions+in+Japanese+Population&doi=10.1093%2Fhmg%2Fddq537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population</span></div><div class="casAuthors">Ozeki, Takeshi; Mushiroda, Taisei; Yowang, Amara; Takahashi, Atsushi; Kubo, Michiaki; Shirakata, Yuji; Ikezawa, Zenro; Iijima, Masafumi; Shiohara, Tetsuo; Hashimoto, Koji; Kamatani, Naoyuki; Nakamura, Yusuke</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1034-1041</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">An anticonvulsant, carbamazepine (CBZ), is known to show incidences of cutaneous adverse drug reactions (cADRs) including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug-induced hypersensitivity syndrome (DIHS).  To identify a gene(s) susceptible to CBZ-induced cADRs, we conducted a genome-wide assocn. study (GWAS) in 53 subjects with the CBZ-induced cADRs, including SJS, TEN and DIHS, and 882 subjects of a general population in Japan.  Among the single nucleotide polymorphisms (SNPs) analyzed in the GWAS, 12 SNPs showed significant assocn. with CBZ-induced cADRs, and rs1633021 showed the smallest P-value for assocn. with CBZ-induced cADRs (P = 1.18 × 10-13).  These SNPs were located within a 430 kb linkage disequil. block on chromosome 6p21.33, including the HLA-A locus.  Thus, we genotyped the individual HLA-A alleles in 61 cases and 376 patients who showed no cADRs by administration of CBZ (CBZ-tolerant controls) and found that HLA-A*3101 was present in 60.7% (37/61) of the patients with CBZ-induced cADRs, but in only 12.5% (47/376) of the CBZ-tolerant controls (odds ratio = 10.8, 95% confidence interval 5.9-19.6, P = 3.64 × 10-15), implying that this allele has the 60.7% sensitivity and 87.5% specificity when we apply HLA-A*3101 as a risk predictor for CBZ-induced cADRs.  Although DIHS is clin. distinguished from SJS and TEN, our data presented here have indicated that they share a common genetic factor as well as a common pathophysiol. mechanism.  Our findings should provide useful information for making a decision of individualized medication of anticonvulsants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_q8MQFTFQ8rVg90H21EOLACvtfcHk0lgY6XxQmEOf3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylsL8%253D&md5=b40ce17f94927af4ca1732fe8f482afc</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddq537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddq537%26sid%3Dliteratum%253Aachs%26aulast%3DOzeki%26aufirst%3DT.%26aulast%3DMushiroda%26aufirst%3DT.%26aulast%3DYowang%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DA.%26aulast%3DKubo%26aufirst%3DM.%26aulast%3DShirakata%26aufirst%3DY.%26aulast%3DIkezawa%26aufirst%3DZ.%26aulast%3DIijima%26aufirst%3DM.%26aulast%3DShiohara%26aufirst%3DT.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DKamatani%26aufirst%3DN.%26aulast%3DNakamura%26aufirst%3DY.%26atitle%3DGenome-Wide%2520Association%2520Study%2520Identifies%2520HLA-A%252A3101%2520Allele%2520as%2520a%2520Genetic%2520Risk%2520Factor%2520for%2520Carbamazepine-Induced%2520Cutaneous%2520Adverse%2520Drug%2520Reactions%2520in%2520Japanese%2520Population%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2011%26volume%3D20%26spage%3D1034%26epage%3D1041%26doi%3D10.1093%2Fhmg%2Fddq537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfirevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourgeois, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasperaviciute, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sills, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bakker, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinthapalli, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molokhia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaila, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhusaini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shianna, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radtke, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinzen, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walley, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandolfo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depondt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sisodiya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deloukas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delanty, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalleri, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span> <span> </span><span class="NLM_article-title">HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">1134</span>– <span class="NLM_lpage">1143</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1013297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1056%2FNEJMoa1013297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21428769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVyhurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=1134-1143&author=M.+McCormackauthor=A.+Alfirevicauthor=S.+Bourgeoisauthor=J.+J.+Farrellauthor=D.+Kasperaviciuteauthor=M.+Carringtonauthor=G.+J.+Sillsauthor=T.+Marsonauthor=X.+Jiaauthor=P.+I.+de+Bakkerauthor=K.+Chinthapalliauthor=M.+Molokhiaauthor=M.+R.+Johnsonauthor=G.+D.+O%E2%80%99Connorauthor=E.+Chailaauthor=S.+Alhusainiauthor=K.+V.+Shiannaauthor=R.+A.+Radtkeauthor=E.+L.+Heinzenauthor=N.+Walleyauthor=M.+Pandolfoauthor=W.+Pichlerauthor=B.+K.+Parkauthor=C.+Depondtauthor=S.+M.+Sisodiyaauthor=D.+B.+Goldsteinauthor=P.+Deloukasauthor=N.+Delantyauthor=G.+L.+Cavalleriauthor=M.+Pirmohamed&title=HLA-A*3101+and+Carbamazepine-Induced+Hypersensitivity+Reactions+in+Europeans&doi=10.1056%2FNEJMoa1013297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans</span></div><div class="casAuthors">McCormack, Mark; Alfirevic, Ana; Bourgeois, Stephane; Farrell, John J.; Kasperaviciute, Dalia; Carrington, Mary; Sills, Graeme J.; Marson, Tony; Jia, Xiaoming; de Bakker, Paul I. W.; Chinthapalli, Krishna; Molokhia, Mariam; Johnson, Michael R.; O'Connor, Gerard D.; Chaila, Elijah; Alhusaini, Saud; Shianna, Kevin V.; Radtke, Rodney A.; Heinzen, Erin L.; Pandolfo, Massimo; Pichler, Werner; Park, Kevin; Depondt, Chantal; Sisodiya, Sanjay M.; Goldstein, David B.; Deloukas, Panos; Delanty, Norman; Cavalleri, Gianpiero L.; Pirmohamed, Munir</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1134-1143</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Carbamazepine causes various forms of hypersensitivity reactions, ranging from maculopapular exanthema to severe blistering reactions.  The HLA-B*1502 allele was shown to be strongly correlated with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) in the Han Chinese and other Asian populations but not in European populations.  The authors performed a genome wide assocn. study of samples obtained from 22 subjects with carbamazepine-induced hypersensitivity syndrome, 43 subjects with carbamazepine-induced maculopapular exanthema, and 3987 control subjects, all of European descent.  The authors tested for an assocn. between disease and HLA alleles through proxy single-nucleotide polymorphisms and imputation, confirming assocns. by high-resoln. sequence-based HLA typing.  The authors replicated the assocns. in samples from 145 subjects with carbamazepine-induced hypersensitivity reactions.  The HLA-A*3101 allele, which has a prevalence of 2 to 5% in Northern European populations, was significantly assocd. with the hypersensitivity syndrome. An independent genome wide assocn. study of samples from subjects with maculopapular exanthema also showed an assocn. with the HLA-A*3101 allele.  Follow-up genotyping confirmed the variant as a risk factor for the hypersensitivity syndrome (odds ratio, 12.41; 95% confidence interval [CI], 1.27 to 121.03), maculopapular exanthema (odds ratio, 8.33; 95% CI, 3.59 to 19.36), and SJS-TEN (odds ratio, 25.93; 95% CI, 4.93 to 116.18).  The presence of the HLA-A*3101 allele was assocd. with carbamazepine-induced hypersensitivity reactions among subjects of Northern European ancestry.  The presence of the allele increased the risk from 5.0% to 26.0%, whereas its absence reduced the risk from 5.0% to 3.8%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGvFkpTSvSKbVg90H21EOLACvtfcHk0lgY6XxQmEOf3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVyhurs%253D&md5=740cf875c2de09f30c95303ce9a5dc43</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1013297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1013297%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormack%26aufirst%3DM.%26aulast%3DAlfirevic%26aufirst%3DA.%26aulast%3DBourgeois%26aufirst%3DS.%26aulast%3DFarrell%26aufirst%3DJ.%2BJ.%26aulast%3DKasperaviciute%26aufirst%3DD.%26aulast%3DCarrington%26aufirst%3DM.%26aulast%3DSills%26aufirst%3DG.%2BJ.%26aulast%3DMarson%26aufirst%3DT.%26aulast%3DJia%26aufirst%3DX.%26aulast%3Dde%2BBakker%26aufirst%3DP.%2BI.%26aulast%3DChinthapalli%26aufirst%3DK.%26aulast%3DMolokhia%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DM.%2BR.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DG.%2BD.%26aulast%3DChaila%26aufirst%3DE.%26aulast%3DAlhusaini%26aufirst%3DS.%26aulast%3DShianna%26aufirst%3DK.%2BV.%26aulast%3DRadtke%26aufirst%3DR.%2BA.%26aulast%3DHeinzen%26aufirst%3DE.%2BL.%26aulast%3DWalley%26aufirst%3DN.%26aulast%3DPandolfo%26aufirst%3DM.%26aulast%3DPichler%26aufirst%3DW.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DDepondt%26aufirst%3DC.%26aulast%3DSisodiya%26aufirst%3DS.%2BM.%26aulast%3DGoldstein%26aufirst%3DD.%2BB.%26aulast%3DDeloukas%26aufirst%3DP.%26aulast%3DDelanty%26aufirst%3DN.%26aulast%3DCavalleri%26aufirst%3DG.%2BL.%26aulast%3DPirmohamed%26aufirst%3DM.%26atitle%3DHLA-A%252A3101%2520and%2520Carbamazepine-Induced%2520Hypersensitivity%2520Reactions%2520in%2520Europeans%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D1134%26epage%3D1143%26doi%3D10.1056%2FNEJMoa1013297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicoletti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEvoy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucena, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadelius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kainu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molokhia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shear, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sills, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanno, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floratos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfirevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span> <span> </span><span class="NLM_article-title">Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">1028</span>– <span class="NLM_lpage">1036</span>, <span class="refDoi"> DOI: 10.1002/cpt.1493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fcpt.1493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=31066027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSjurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2019&pages=1028-1036&author=P.+Nicolettiauthor=S.+Barrettauthor=L.+McEvoyauthor=A.+K.+Dalyauthor=G.+Aithalauthor=M.+I.+Lucenaauthor=R.+J.+Andradeauthor=M.+Wadeliusauthor=P.+Hallbergauthor=C.+Stephensauthor=E.+S.+Bjornssonauthor=P.+Friedmannauthor=K.+Kainuauthor=T.+Laitinenauthor=A.+Marsonauthor=M.+Molokhiaauthor=E.+Phillipsauthor=W.+Pichlerauthor=A.+Romanoauthor=N.+Shearauthor=G.+Sillsauthor=L.+K.+Tannoauthor=A.+Swaleauthor=A.+Floratosauthor=Y.+Shenauthor=M.+R.+Nelsonauthor=P.+B.+Watkinsauthor=M.+J.+Dalyauthor=A.+P.+Morrisauthor=A.+Alfirevicauthor=M.+Pirmohamed&title=Shared+Genetic+Risk+Factors+Across+Carbamazepine-Induced+Hypersensitivity+Reactions&doi=10.1002%2Fcpt.1493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions</span></div><div class="casAuthors">Nicoletti, Paola; Barrett, Sarah; McEvoy, Laurence; Daly, Ann K.; Aithal, Guruprasad; Lucena, M. Isabel; Andrade, Raul J.; Wadelius, Mia; Hallberg, Paer; Stephens, Camilla; Bjornsson, Einar S.; Friedmann, Peter; Kainu, Kati; Laitinen, Tarja; Marson, Anthony; Molokhia, Mariam; Phillips, Elizabeth; Pichler, Werner; Romano, Antonino; Shear, Neil; Sills, Graeme; Tanno, Luciana K.; Swale, Ashley; Floratos, Aris; Shen, Yufeng; Nelson, Matthew R.; Watkins, Paul B.; Daly, Mark J.; Morris, Andrew P.; Alfirevic, Ana; Pirmohamed, Munir</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1028-1036</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Meta-anal. of shared genetic risk factors across carbamazepine-induced hypersensitivity reactions in European populations.  Carbamazepine (CBZ) causes life-threating T-cell-mediated hypersensitivity reactions, including serious cutaneous adverse reactions (SCARs) and drug-induced liver injury (CBZ-DILI).  In order to evaluate shared or phenotype-specific genetic predisposing factors for CBZ hypersensitivity reactions, we performed a meta-anal. of two genomewide assocn. studies (GWAS) on a total of 43 well-phenotyped Northern and Southern European CBZ-SCAR cases and 10,701 population controls and a GWAS on 12 CBZ-DILI cases and 8,438 ethnically matched population controls.  HLA-A*31:01 was identified as the strongest genetic predisposing factor for both CBZ-SCAR (odds ratio (OR) = 8.0; 95% CI 4.10-15.80; P = 1.2 × 10-9) and CBZ-DILI (OR = 7.3; 95% CI 2.47-23.67; P = 0.0004) in European populations.  The assocn. with HLA-A*31:01 in patients with SCAR was mainly driven by hypersensitivity syndrome (OR = 12.9; P = 2.1 × 10-9) rather than by Stevens-Johnson syndrome/toxic epidermal necrolysis cases, which showed an assocn. with HLA-B*57:01.  We also identified a novel risk locus mapping to ALK only for CBZ-SCAR cases, which needs replication in addnl. cohorts and functional evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroGgeHufcsLbVg90H21EOLACvtfcHk0lgxedCLwHUt6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSjurvL&md5=e0115f78175ec7ba7c5bb413526cc309</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1002%2Fcpt.1493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.1493%26sid%3Dliteratum%253Aachs%26aulast%3DNicoletti%26aufirst%3DP.%26aulast%3DBarrett%26aufirst%3DS.%26aulast%3DMcEvoy%26aufirst%3DL.%26aulast%3DDaly%26aufirst%3DA.%2BK.%26aulast%3DAithal%26aufirst%3DG.%26aulast%3DLucena%26aufirst%3DM.%2BI.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3DWadelius%26aufirst%3DM.%26aulast%3DHallberg%26aufirst%3DP.%26aulast%3DStephens%26aufirst%3DC.%26aulast%3DBjornsson%26aufirst%3DE.%2BS.%26aulast%3DFriedmann%26aufirst%3DP.%26aulast%3DKainu%26aufirst%3DK.%26aulast%3DLaitinen%26aufirst%3DT.%26aulast%3DMarson%26aufirst%3DA.%26aulast%3DMolokhia%26aufirst%3DM.%26aulast%3DPhillips%26aufirst%3DE.%26aulast%3DPichler%26aufirst%3DW.%26aulast%3DRomano%26aufirst%3DA.%26aulast%3DShear%26aufirst%3DN.%26aulast%3DSills%26aufirst%3DG.%26aulast%3DTanno%26aufirst%3DL.%2BK.%26aulast%3DSwale%26aufirst%3DA.%26aulast%3DFloratos%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DNelson%26aufirst%3DM.%2BR.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DDaly%26aufirst%3DM.%2BJ.%26aulast%3DMorris%26aufirst%3DA.%2BP.%26aulast%3DAlfirevic%26aufirst%3DA.%26aulast%3DPirmohamed%26aufirst%3DM.%26atitle%3DShared%2520Genetic%2520Risk%2520Factors%2520Across%2520Carbamazepine-Induced%2520Hypersensitivity%2520Reactions%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2019%26volume%3D106%26spage%3D1028%26epage%3D1036%26doi%3D10.1002%2Fcpt.1493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mallal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamotte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, F. T.</span></span> <span> </span><span class="NLM_article-title">Association Between Presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and Hypersensitivity to HIV-1 Reverse-Transcriptase Inhibitor Abacavir</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(02)07873-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2FS0140-6736%2802%2907873-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=11888582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvVWhsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2002&pages=727-732&author=S.+Mallalauthor=D.+Nolanauthor=C.+Wittauthor=G.+Maselauthor=A.+M.+Martinauthor=C.+Mooreauthor=D.+Sayerauthor=A.+Castleyauthor=C.+Mamotteauthor=D.+Maxwellauthor=I.+Jamesauthor=F.+T.+Christiansen&title=Association+Between+Presence+of+HLA-B*5701%2C+HLA-DR7%2C+and+HLA-DQ3+and+Hypersensitivity+to+HIV-1+Reverse-Transcriptase+Inhibitor+Abacavir&doi=10.1016%2FS0140-6736%2802%2907873-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir</span></div><div class="casAuthors">Mallal, S.; Nolan, D.; Witt, C.; Masel, G.; Martin, A. M.; Moore, C.; Sayer, D.; Castley, A.; Mamotte, C.; Maxwell, D.; James, I.; Christiansen, F. T.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">9308</span>),
    <span class="NLM_cas:pages">727-732</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Lancet Publishing Group</span>)
        </div><div class="casAbstract">The use of abacavir, a potent HIV-1 nucleoside-analog reverse-transcriptase inhibitor, is complicated by a potentially life-threatening hypersensitivity syndrome in about 5% of cases.  Genetic factors influencing the immune response to abacavir might confer susceptibility.  We aimed to find assocns. between MHC alleles and abacavir hypersensitivity in HIV-1-pos. individuals treated with abacavir.  MHC region typing was done in the first 200 Western Australian HIV Cohort Study participants exposed to abacavir.  Definite abacavir hypersensitivity was identified in 18 cases, and was excluded in 167 individuals with more than 6 wk exposure to the drug (abacavir tolerant).  Fifteen individuals experienced some symptoms but did not meet criteria for abacavir hypersensitivity.  The p values were cor. for comparisons of multiple HLA alleles (pc) by multiplication of the raw p value by the estd. no. of HLA alleles present within the loci examd.  HLA-B*5701 was present in 14 (78%) of the 18 patients with abacavir hypersensitivity, and in four (2%) of the 167 abacavir tolerant patients (odds ratio 117 [95% CI 29-481], pc<0.0001), and the HLA-DR7 and HLA-DQ3 combination was found in 13 (72%) of hypersensitive and five (3%) of tolerant patients (73 [20-268], pc<0.0001).  HLA-B*5701, HLA-DR7, and HLA-DQ3 were present in combination in 13 (72%) hypersensitive patients and none of the tolerant patients (822 [43-15 675], pc<0.0001).  Other MHC markers also present on the 57.1 ancestral haplotype to which the three markers above belong confirmed the presence of haplotype-specific linkage disequil., and mapped potential susceptibility loci to a region bounded by C4A6 and HLA-C.  Within the entire abacavir-exposed cohort (n=200), presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 had a pos. predictive value for hypersensitivity of 100%, and a neg. predictive value of 97%.  Thus, genetic susceptibility to abacavir hypersensitivity is carried on the 57.1 ancestral haplotype.  In our population, withholding abacavir in those with HLA-B*5701, HLA-DR7, and HLA-DQ3 should reduce the prevalence of hypersensitivity from 9% to 2.5% without inappropriately denying abacavir to any patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9p8i0yTY3kLVg90H21EOLACvtfcHk0lgxedCLwHUt6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvVWhsbY%253D&md5=783b93a506a0a930e493e96239de125b</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2802%2907873-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252802%252907873-X%26sid%3Dliteratum%253Aachs%26aulast%3DMallal%26aufirst%3DS.%26aulast%3DNolan%26aufirst%3DD.%26aulast%3DWitt%26aufirst%3DC.%26aulast%3DMasel%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DMoore%26aufirst%3DC.%26aulast%3DSayer%26aufirst%3DD.%26aulast%3DCastley%26aufirst%3DA.%26aulast%3DMamotte%26aufirst%3DC.%26aulast%3DMaxwell%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DI.%26aulast%3DChristiansen%26aufirst%3DF.%2BT.%26atitle%3DAssociation%2520Between%2520Presence%2520of%2520HLA-B%252A5701%252C%2520HLA-DR7%252C%2520and%2520HLA-DQ3%2520and%2520Hypersensitivity%2520to%2520HIV-1%2520Reverse-Transcriptase%2520Inhibitor%2520Abacavir%26jtitle%3DLancet%26date%3D2002%26volume%3D359%26spage%3D727%26epage%3D732%26doi%3D10.1016%2FS0140-6736%2802%2907873-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hetherington, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosteller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shortino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spreen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dow, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fling, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurmond, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roses, A. D.</span></span> <span> </span><span class="NLM_article-title">Genetic Variations in HLA-B Region and Hypersensitivity Reactions to Abacavir</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">1121</span>– <span class="NLM_lpage">1122</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(02)08158-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2FS0140-6736%2802%2908158-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=11943262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1ehsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2002&pages=1121-1122&author=S.+Hetheringtonauthor=A.+R.+Hughesauthor=M.+Mostellerauthor=D.+Shortinoauthor=K.+L.+Bakerauthor=W.+Spreenauthor=E.+Laiauthor=K.+Daviesauthor=A.+Handleyauthor=D.+J.+Dowauthor=M.+E.+Flingauthor=M.+Stocumauthor=C.+Bowmanauthor=L.+M.+Thurmondauthor=A.+D.+Roses&title=Genetic+Variations+in+HLA-B+Region+and+Hypersensitivity+Reactions+to+Abacavir&doi=10.1016%2FS0140-6736%2802%2908158-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic variations in HLA-B region and hypersensitivity reactions to abacavir</span></div><div class="casAuthors">Hetherington, Seth; Hughes, Arlene R.; Mosteller, Michael; Shortino, Denise; Baker, Katherine L.; Spreen, William; Lai, Eric; Davies, Kirstie; Handley, Abigail; Dow, David J.; Fling, Mary E.; Stocum, Michael; Bowman, Clive; Thurmond, Linda M.; Roses, Allen D.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">9312</span>),
    <span class="NLM_cas:pages">1121-1122</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Lancet Publishing Group</span>)
        </div><div class="casAbstract">Hypersensitivity to abacavir affects about 4% of patients who receive the drug for HIV-1 infection.  The authors did a retrospective, case-control study to identify multiple markers in the vicinity of HLA-B assocd. with hypersensitivity reactions.  HLA-B57 was present in 39 (46%) of 84 patients vs. 4 (4%) of 113 controls.  However, because of low nos. of women and other ethnic groups enrolled, these findings relate largely to white men.  The lower sensitivity of HLA-B57 for predicting hypersensitivity to abacavir identified in this study compared with a previous report highlights that predictive values for markers will vary across populations.  Clin. monitoring and management of hypersensitivity reactions among patients receiving abacavir must remain unchanged.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSCmus_J04RbVg90H21EOLACvtfcHk0lggHaYjE6H0eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1ehsLw%253D&md5=5550e472c7dc48fcaa2e2e040113c593</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2802%2908158-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252802%252908158-8%26sid%3Dliteratum%253Aachs%26aulast%3DHetherington%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DA.%2BR.%26aulast%3DMosteller%26aufirst%3DM.%26aulast%3DShortino%26aufirst%3DD.%26aulast%3DBaker%26aufirst%3DK.%2BL.%26aulast%3DSpreen%26aufirst%3DW.%26aulast%3DLai%26aufirst%3DE.%26aulast%3DDavies%26aufirst%3DK.%26aulast%3DHandley%26aufirst%3DA.%26aulast%3DDow%26aufirst%3DD.%2BJ.%26aulast%3DFling%26aufirst%3DM.%2BE.%26aulast%3DStocum%26aufirst%3DM.%26aulast%3DBowman%26aufirst%3DC.%26aulast%3DThurmond%26aufirst%3DL.%2BM.%26aulast%3DRoses%26aufirst%3DA.%2BD.%26atitle%3DGenetic%2520Variations%2520in%2520HLA-B%2520Region%2520and%2520Hypersensitivity%2520Reactions%2520to%2520Abacavir%26jtitle%3DLancet%26date%3D2002%26volume%3D359%26spage%3D1121%26epage%3D1122%26doi%3D10.1016%2FS0140-6736%2802%2908158-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilar, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfirevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span> <span> </span><span class="NLM_article-title">Cost-Effectiveness Analysis of HLA B*5701 Genotyping in Preventing Abacavir Hypersensitivity</span>. <i>Pharmacogenetics</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.1097/00008571-200406000-00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1097%2F00008571-200406000-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=15247625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD2czlsVCltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=335-342&author=D.+A.+Hughesauthor=F.+J.+Vilarauthor=C.+C.+Wardauthor=A.+Alfirevicauthor=B.+K.+Parkauthor=M.+Pirmohamed&title=Cost-Effectiveness+Analysis+of+HLA+B*5701+Genotyping+in+Preventing+Abacavir+Hypersensitivity&doi=10.1097%2F00008571-200406000-00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity</span></div><div class="casAuthors">Hughes Dyfrig A; Vilar F Javier; Ward Charlotte C; Alfirevic Ana; Park B Kevin; Pirmohamed Munir</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">335-42</span>
        ISSN:<span class="NLM_cas:issn">0960-314X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Abacavir, a human immunodeficiency virus-1 (HIV-1) nucleoside-analogue reverse transcriptase inhibitor, causes severe hypersensitivity in 4-8% of patients.  HLA B*5701 is a known genetic risk factor for abacavir hypersensitivity in Caucasians.  Our aim was to confirm the presence of this genetic factor in our patients, and to determine whether genotyping for HLA B*5701 would be a cost-effective use of healthcare resources.  METHODS:  Patients with and without abacavir hypersensitivity were identified from a UK HIV clinic.  Patients were genotyped for HLA B*5701, and pooled data used for calculation of test characteristics.  The cost-effectiveness analysis incorporated the cost of testing, cost of treating abacavir hypersensitivity, and the cost and selection of alternative antiretroviral regimens.  A probabilistic decision analytic model (comparing testing versus no testing) was formulated and Monte Carlo simulations performed.  RESULTS:  Of the abacavir hypersensitive patients, six (46%) were HLA B*5701 positive, compared to five (10%) of the non-hypersensitive patients (odds ratio 7.9 [95% confidence intervals 1.5-41.4], P = 0.006).  Pooling of our data on HLA B*5701 with published data resulted in a pooled odds ratio of 29 (95% CI 6.4-132.3; P < 0.0001).  The cost-effectiveness model demonstrated that depending on the choice of comparator, routine testing for HLA B*5701 ranged from being a dominant strategy (less expensive and more beneficial than not testing) to an incremental cost-effectiveness ratio (versus no testing) of Euro 22,811 per hypersensitivity reaction avoided.  CONCLUSIONS:  Abacavir hypersensitivity is associated with HLA B*5701, and pre-prescription pharmacogenetic testing for this appears to be a cost-effective use of healthcare resources.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZ8wMZhrtbR4kFb3mqPUYDfW6udTcc2eaXiqPFczsKwLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czlsVCltQ%253D%253D&md5=302d6f4264d5d393f34d016d37508a65</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1097%2F00008571-200406000-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00008571-200406000-00002%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%2BA.%26aulast%3DVilar%26aufirst%3DF.%2BJ.%26aulast%3DWard%26aufirst%3DC.%2BC.%26aulast%3DAlfirevic%26aufirst%3DA.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DPirmohamed%26aufirst%3DM.%26atitle%3DCost-Effectiveness%2520Analysis%2520of%2520HLA%2520B%252A5701%2520Genotyping%2520in%2520Preventing%2520Abacavir%2520Hypersensitivity%26jtitle%3DPharmacogenetics%26date%3D2004%26volume%3D14%26spage%3D335%26epage%3D342%26doi%3D10.1097%2F00008571-200406000-00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mallal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carosi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomažič, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jägel-Guedes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugina, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozyrev, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cid, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitch, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorborn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benbow, A.</span></span> <span> </span><span class="NLM_article-title">HLA-B*5701 Screening for Hypersensitivity to Abacavir</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">568</span>– <span class="NLM_lpage">579</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0706135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1056%2FNEJMoa0706135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=18256392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FpvF2rsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2008&pages=568-579&author=S.+Mallalauthor=E.+Phillipsauthor=G.+Carosiauthor=J.-M.+Molinaauthor=C.+Workmanauthor=J.+Toma%C5%BEi%C4%8Dauthor=E.+J%C3%A4gel-Guedesauthor=S.+Ruginaauthor=O.+Kozyrevauthor=J.+F.+Cidauthor=P.+Hayauthor=D.+Nolanauthor=S.+Hughesauthor=A.+Hughesauthor=S.+Ryanauthor=N.+Fitchauthor=D.+Thorbornauthor=A.+Benbow&title=HLA-B*5701+Screening+for+Hypersensitivity+to+Abacavir&doi=10.1056%2FNEJMoa0706135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">HLA-B*5701 screening for hypersensitivity to abacavir</span></div><div class="casAuthors">Mallal Simon; Phillips Elizabeth; Carosi Giampiero; Molina Jean-Michel; Workman Cassy; Tomazic Janez; Jagel-Guedes Eva; Rugina Sorin; Kozyrev Oleg; Cid Juan Flores; Hay Phillip; Nolan David; Hughes Sara; Hughes Arlene; Ryan Susanna; Fitch Nicholas; Thorborn Daren; Benbow Alastair</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">568-79</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Hypersensitivity reaction to abacavir is strongly associated with the presence of the HLA-B*5701 allele.  This study was designed to establish the effectiveness of prospective HLA-B*5701 screening to prevent the hypersensitivity reaction to abacavir.  METHODS:  This double-blind, prospective, randomized study involved 1956 patients from 19 countries, who were infected with human immunodeficiency virus type 1 and who had not previously received abacavir.  We randomly assigned patients to undergo prospective HLA-B*5701 screening, with exclusion of HLA-B*5701-positive patients from abacavir treatment (prospective-screening group), or to undergo a standard-of-care approach of abacavir use without prospective HLA-B*5701 screening (control group).  All patients who started abacavir were observed for 6 weeks.  To immunologically confirm, and enhance the specificity of, the clinical diagnosis of hypersensitivity reaction to abacavir, we performed epicutaneous patch testing with the use of abacavir.  RESULTS:  The prevalence of HLA-B*5701 was 5.6% (109 of 1956 patients).  Of the patients receiving abacavir, 72% were men, 84% were white, and 18% had not previously received antiretroviral therapy.  Screening eliminated immunologically confirmed hypersensitivity reaction (0% in the prospective-screening group vs. 2.7% in the control group, P<0.001), with a negative predictive value of 100% and a positive predictive value of 47.9%.  Hypersensitivity reaction was clinically diagnosed in 93 patients, with a significantly lower incidence in the prospective-screening group (3.4%) than in the control group (7.8%) (P<0.001).  CONCLUSIONS:  HLA-B*5701 screening reduced the risk of hypersensitivity reaction to abacavir.  In predominantly white populations, similar to the one in this study, 94% of patients do not carry the HLA-B*5701 allele and are at low risk for hypersensitivity reaction to abacavir.  Our results show that a pharmacogenetic test can be used to prevent a specific toxic effect of a drug. (ClinicalTrials.gov number, NCT00340080.)</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeqda-fRQMhoJKJbLTgsvCfW6udTcc2eaXiqPFczsKwLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FpvF2rsw%253D%253D&md5=0427497c47a4c695dc083092f4f5f9d5</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0706135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0706135%26sid%3Dliteratum%253Aachs%26aulast%3DMallal%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DE.%26aulast%3DCarosi%26aufirst%3DG.%26aulast%3DMolina%26aufirst%3DJ.-M.%26aulast%3DWorkman%26aufirst%3DC.%26aulast%3DToma%25C5%25BEi%25C4%258D%26aufirst%3DJ.%26aulast%3DJ%25C3%25A4gel-Guedes%26aufirst%3DE.%26aulast%3DRugina%26aufirst%3DS.%26aulast%3DKozyrev%26aufirst%3DO.%26aulast%3DCid%26aufirst%3DJ.%2BF.%26aulast%3DHay%26aufirst%3DP.%26aulast%3DNolan%26aufirst%3DD.%26aulast%3DHughes%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DS.%26aulast%3DFitch%26aufirst%3DN.%26aulast%3DThorborn%26aufirst%3DD.%26aulast%3DBenbow%26aufirst%3DA.%26atitle%3DHLA-B%252A5701%2520Screening%2520for%2520Hypersensitivity%2520to%2520Abacavir%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D358%26spage%3D568%26epage%3D579%26doi%3D10.1056%2FNEJMoa0706135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wuillemin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krähenbühl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yerly, D.</span></span> <span> </span><span class="NLM_article-title">HLA Haplotype Determines Hapten or p-i T Cell Reactivity to Flucloxacillin</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">4956</span>– <span class="NLM_lpage">4964</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1202949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.4049%2Fjimmunol.1202949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23596311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFyqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2013&pages=4956-4964&author=N.+Wuilleminauthor=J.+Adamauthor=S.+Fontanaauthor=S.+Kr%C3%A4henb%C3%BChlauthor=W.+J.+Pichlerauthor=D.+Yerly&title=HLA+Haplotype+Determines+Hapten+or+p-i+T+Cell+Reactivity+to+Flucloxacillin&doi=10.4049%2Fjimmunol.1202949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">HLA Haplotype Determines Hapten or p-i T Cell Reactivity to Flucloxacillin</span></div><div class="casAuthors">Wuillemin, Natascha; Adam, Jacqueline; Fontana, Stefano; Kraehenbuehl, Stephan; Pichler, Werner J.; Yerly, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4956-4964</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a main cause of drug withdrawal.  A particularly interesting example is flucloxacillin (FLUX)-DILI, which is assocd. with the HLA-B*57:01 allele.  At present, the mechanism of FLUX-DILI is not understood, but the HLA assocn. suggests a role for activated T cells in the pathomechanism of liver damage.  To understand the interaction among FLUX, HLA mols., and T cells, we generated FLUX-reacting T cells from FLUX-naive HLA-B*57:01+ and HLA-B*57:01- healthy donors and investigated the mechanism of T cell stimulation.  We found that FLUX stimulates CD8+ T cells in two distinct manners.  On one hand, FLUX was stably presented on various HLA mols., resistant to extensive washing and dependent on proteasomal processing, suggesting a hapten mechanism.  On the other hand, in HLA-B*57:01+ individuals, we obsd. a pharmacol. interaction with immune receptors (p-i)-based T cell reactivity.  FLUX was presented in a labile manner that was further characterized by independence of proteasomal processing and immediate T cell clone activation upon stimulation with FLUX in soln.  This p-i-based T cell stimulation was restricted to the HLA-B*57:01 allele.  We conclude that the presence of HLA-B*57:01 drives CD8+ T cell responses to the penicillin-deriv. FLUX toward nonhapten mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDSgHu8CXs2rVg90H21EOLACvtfcHk0lhoGs1MSnO6cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFyqu70%253D&md5=8e90dd3b91a1adadee1eca2975863406</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1202949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1202949%26sid%3Dliteratum%253Aachs%26aulast%3DWuillemin%26aufirst%3DN.%26aulast%3DAdam%26aufirst%3DJ.%26aulast%3DFontana%26aufirst%3DS.%26aulast%3DKr%25C3%25A4henb%25C3%25BChl%26aufirst%3DS.%26aulast%3DPichler%26aufirst%3DW.%2BJ.%26aulast%3DYerly%26aufirst%3DD.%26atitle%3DHLA%2520Haplotype%2520Determines%2520Hapten%2520or%2520p-i%2520T%2520Cell%2520Reactivity%2520to%2520Flucloxacillin%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D190%26spage%3D4956%26epage%3D4964%26doi%3D10.4049%2Fjimmunol.1202949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yaseen, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saide, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monshi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tailor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulkner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Promiscuous T-cell Responses to Drugs and Drug-Haptens</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">474</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2015.02.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jaci.2015.02.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25910715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntVCitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2015&pages=474-476&author=F.+S.+Yaseenauthor=K.+Saideauthor=S.-H.+Kimauthor=M.+Monshiauthor=A.+Tailorauthor=S.+Woodauthor=X.+Mengauthor=R.+Jenkinsauthor=L.+Faulknerauthor=A.+K.+Dalyauthor=M.+Pirmohamedauthor=B.+K.+Parkauthor=D.+J.+Naisbitt&title=Promiscuous+T-cell+Responses+to+Drugs+and+Drug-Haptens&doi=10.1016%2Fj.jaci.2015.02.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Promiscuous T-cell responses to drugs and drug-haptens</span></div><div class="casAuthors">Yaseen, Fiazia S.; Saide, Katy; Kim, Seung-Hyun; Monshi, Manal; Tailor, Arun; Wood, Sally; Meng, Xiaoli; Jenkins, Rosalind; Faulkner, Lee; Daly, Ann K.; Pirmohamed, Munir; Park, B. Kevin; Naisbitt, Dean J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">474-476.e8</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">This paper describes on promiscuous T-cell responses to drugs and drug-haptens.  β-Lactam-induced liver injury has shown T cells are activated through hapten.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKpwe8BAJ7_bVg90H21EOLACvtfcHk0lhoGs1MSnO6cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntVCitbs%253D&md5=dc9494342fb70bd8c37d6d5baef40eb9</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2015.02.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2015.02.036%26sid%3Dliteratum%253Aachs%26aulast%3DYaseen%26aufirst%3DF.%2BS.%26aulast%3DSaide%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DMonshi%26aufirst%3DM.%26aulast%3DTailor%26aufirst%3DA.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DJenkins%26aufirst%3DR.%26aulast%3DFaulkner%26aufirst%3DL.%26aulast%3DDaly%26aufirst%3DA.%2BK.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DPromiscuous%2520T-cell%2520Responses%2520to%2520Drugs%2520and%2520Drug-Haptens%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2015%26volume%3D136%26spage%3D474%26epage%3D476%26doi%3D10.1016%2Fj.jaci.2015.02.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R. C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsih, M.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, P.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choon, S.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaniwa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azukizawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, S.-I.</span></span> <span> </span><span class="NLM_article-title">Genetic Variants Associated with Phenytoin-Related Severe Cutaneous Adverse Reactions</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>312</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">534</span>, <span class="refDoi"> DOI: 10.1001/jama.2014.7859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1001%2Fjama.2014.7859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25096692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC2cbptlSjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2014&pages=525-534&author=W.-H.+Chungauthor=W.-C.+Changauthor=Y.-S.+Leeauthor=Y.-Y.+Wuauthor=C.-H.+Yangauthor=H.-C.+Hoauthor=M.-J.+Chenauthor=J.-Y.+Linauthor=R.+C.-Y.+Huiauthor=J.-C.+Hoauthor=W.-M.+Wuauthor=T.-J.+Chenauthor=T.+Wuauthor=Y.-R.+Wuauthor=M.-S.+Hsihauthor=P.-H.+Tuauthor=C.-N.+Changauthor=C.-N.+Hsuauthor=T.-L.+Wuauthor=S.-E.+Choonauthor=C.-K.+Hsuauthor=D.-Y.+Chenauthor=C.-S.+Liuauthor=C.-Y.+Linauthor=N.+Kaniwaauthor=Y.+Saitoauthor=Y.+Takahashiauthor=R.+Nakamuraauthor=H.+Azukizawaauthor=Y.+Shiauthor=T.-H.+Wangauthor=S.-S.+Chuangauthor=S.-F.+Tsaiauthor=C.-J.+Changauthor=Y.-S.+Changauthor=S.-I.+Hung&title=Genetic+Variants+Associated+with+Phenytoin-Related+Severe+Cutaneous+Adverse+Reactions&doi=10.1001%2Fjama.2014.7859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic variants associated with phenytoin-related severe cutaneous adverse reactions</span></div><div class="casAuthors">Chung Wen-Hung; Chang Wan-Chun; Wu Ying-Ying; Hung Shuen-Iu; Lee Yun-Shien; Yang Chih-Hsun; Chen Ming-Jing; Hui Rosaline Chung-Yee; Ho Hsin-Chun; Lin Jing-Yi; Ho Ji-Chen; Wu Wei-Ming; Chen Ting-Jui; Wu Tony; Wu Yih-Ru; Hsih Mo-Song; Tu Po-Hsun; Chang Chen-Nen; Hsu Chien-Ning; Wu Tsu-Lan; Choon Siew-Eng; Hsu Chao-Kai; Chen Der-Yuan; Liu Chin-San; Lin Ching-Yuang; Kaniwa Nahoko; Saito Yoshiro; Nakamura Ryosuke; Takahashi Yukitoshi; Azukizawa Hiroaki; Shi Yongyong; Wang Tzu-Hao; Chuang Shiow-Shuh; Tsai Shih-Feng; Chang Chee-Jen; Chang Yu-Sun</div><div class="citationInfo"><span class="NLM_cas:title">JAMA</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">525-34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">IMPORTANCE:  The antiepileptic drug phenytoin can cause cutaneous adverse reactions, ranging from maculopapular exanthema to severe cutaneous adverse reactions, which include drug reactions with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis.  The pharmacogenomic basis of phenytoin-related severe cutaneous adverse reactions remains unknown.  OBJECTIVE:  To investigate the genetic factors associated with phenytoin-related severe cutaneous adverse reactions.  DESIGN, SETTING, AND PARTICIPANTS:  Case-control study conducted in 2002-2014 among 105 cases with phenytoin-related severe cutaneous adverse reactions (n=61 Stevens-Johnson syndrome/toxic epidermal necrolysis and n=44 drug reactions with eosinophilia and systemic symptoms), 78 cases with maculopapular exanthema, 130 phenytoin-tolerant control participants, and 3655 population controls from Taiwan, Japan, and Malaysia.  A genome-wide association study (GWAS), direct sequencing of the associated loci, and replication analysis were conducted using the samples from Taiwan.  The initial GWAS included samples of 60 cases with phenytoin-related severe cutaneous adverse reactions and 412 population controls from Taiwan.  The results were validated in (1) 30 cases with severe cutaneous adverse reactions and 130 phenytoin-tolerant controls from Taiwan, (2) 9 patients with Stevens-Johnson syndrome/toxic epidermal necrolysis and 2869 population controls from Japan, and (3) 6 cases and 374 population controls from Malaysia.  MAIN OUTCOMES AND MEASURES:  Specific genetic factors associated with phenytoin-related severe cutaneous adverse reactions.  RESULTS:  The GWAS discovered a cluster of 16 single-nucleotide polymorphisms in CYP2C genes at 10q23.33 that reached genome-wide significance.  Direct sequencing of CYP2C identified missense variant rs1057910 (CYP2C9*3) that showed significant association with phenytoin-related severe cutaneous adverse reactions (odds ratio, 12; 95% CI, 6.6-20; P=1.1 × 10(-17)).  The statistically significant association between CYP2C9*3 and phenytoin-related severe cutaneous adverse reactions was observed in additional samples from Taiwan, Japan, and Malaysia.  A meta-analysis using the data from the 3 populations showed an overall odds ratio of 11 (95% CI, 6.2-18; z=8.58; P < .00001) for CYP2C9*3 association with phenytoin-related severe cutaneous adverse reactions.  Delayed clearance of plasma phenytoin was detected in patients with severe cutaneous adverse reactions, especially CYP2C9*3 carriers, providing a functional link of the associated variants to the disease.  CONCLUSIONS AND RELEVANCE:  This study identified CYP2C variants, including CYP2C9*3, known to reduce drug clearance, as important genetic factors associated with phenytoin-related severe cutaneous adverse reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTu3CMxmr6mMpw7prLlxLOzfW6udTcc2eZphQ6udQUZhrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbptlSjtQ%253D%253D&md5=68b9cb8e5fff2b3f4ffc07a398a60ebd</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1001%2Fjama.2014.7859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2014.7859%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DW.-H.%26aulast%3DChang%26aufirst%3DW.-C.%26aulast%3DLee%26aufirst%3DY.-S.%26aulast%3DWu%26aufirst%3DY.-Y.%26aulast%3DYang%26aufirst%3DC.-H.%26aulast%3DHo%26aufirst%3DH.-C.%26aulast%3DChen%26aufirst%3DM.-J.%26aulast%3DLin%26aufirst%3DJ.-Y.%26aulast%3DHui%26aufirst%3DR.%2BC.-Y.%26aulast%3DHo%26aufirst%3DJ.-C.%26aulast%3DWu%26aufirst%3DW.-M.%26aulast%3DChen%26aufirst%3DT.-J.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DY.-R.%26aulast%3DHsih%26aufirst%3DM.-S.%26aulast%3DTu%26aufirst%3DP.-H.%26aulast%3DChang%26aufirst%3DC.-N.%26aulast%3DHsu%26aufirst%3DC.-N.%26aulast%3DWu%26aufirst%3DT.-L.%26aulast%3DChoon%26aufirst%3DS.-E.%26aulast%3DHsu%26aufirst%3DC.-K.%26aulast%3DChen%26aufirst%3DD.-Y.%26aulast%3DLiu%26aufirst%3DC.-S.%26aulast%3DLin%26aufirst%3DC.-Y.%26aulast%3DKaniwa%26aufirst%3DN.%26aulast%3DSaito%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DR.%26aulast%3DAzukizawa%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.-H.%26aulast%3DChuang%26aufirst%3DS.-S.%26aulast%3DTsai%26aufirst%3DS.-F.%26aulast%3DChang%26aufirst%3DC.-J.%26aulast%3DChang%26aufirst%3DY.-S.%26aulast%3DHung%26aufirst%3DS.-I.%26atitle%3DGenetic%2520Variants%2520Associated%2520with%2520Phenytoin-Related%2520Severe%2520Cutaneous%2520Adverse%2520Reactions%26jtitle%3DJAMA%26date%3D2014%26volume%3D312%26spage%3D525%26epage%3D534%26doi%3D10.1001%2Fjama.2014.7859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hung, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsih, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. T.</span></span> <span> </span><span class="NLM_article-title">Common Risk Allele in Aromatic Antiepileptic-Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Han Chinese</span>. <i>Pharmacogenomics</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.2217/pgs.09.162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.2217%2Fpgs.09.162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=20235791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFSksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=349-356&author=S.+I.+Hungauthor=W.+H.+Chungauthor=Z.+S.+Liuauthor=C.+H.+Chenauthor=M.+S.+Hsihauthor=R.+C.+Huiauthor=C.+Y.+Chuauthor=Y.+T.+Chen&title=Common+Risk+Allele+in+Aromatic+Antiepileptic-Drug-Induced+Stevens-Johnson+Syndrome+and+Toxic+Epidermal+Necrolysis+in+Han+Chinese&doi=10.2217%2Fpgs.09.162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese</span></div><div class="casAuthors">Hung, Shuen-Iu; Chung, Wen-Hung; Liu, Zhi-Sheng; Chen, Chien-Hsiun; Hsih, Mo-Song; Hui, Rosaline Chung-yee; Chu, Chia-Yu; Chen, Yuan-Tsong</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenomics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">349-356</span>CODEN:
                <span class="NLM_cas:coden">PARMFL</span>;
        ISSN:<span class="NLM_cas:issn">1462-2416</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Aims: Compared with other categories of drugs, such as antibiotics and NSAIDs, antiepileptic therapies are assocd. with a high incidence of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  We previously reported that carbamazepine (CBZ)-SJS/TEN is strongly assocd. with the HLA-B*1502 in Han Chinese, which has been confirmed in other Southeast Asian countries where the allele is prevalent.  Here, we extend the study of HLA susceptibility to three different antiepileptic drugs, phenytoin (PHT), lamotrigine (LTG) and oxcarbazepine (OXC), which have structure similarity to CBZ.  Materials & methods: We carried out a case-control assocn. study.  We enrolled 26 PHT-, six LTG- and three OXC-induced SJS/TEN patients, 113 PHT-tolerant and 67 LTG-tolerant subjects who were on the drug, resp., for more than 3 mo without the adverse reactions, and 93 normal subjects from the general population.  The HLA-A, B, C and DRB1 genotypes were detd.  Results: We found that HLA-B*1502 was present in eight out of 26 (30.8%) PHT-SJS/TEN (OR: 5.1; 95% CI: 1.8-15.1; p = 0.0041), two out of six (33%) LTG-SJS (odds ratio [OR]: 5.1; 95% CI: 0.8-33.8; p = 0.1266) and three out of three (100%) OXC-SJS (OR: 80.7; 95% CI: 3.8-1714.4; p = 8.4 × 10-4) patients.  In addn., HLA-B*1301, Cw*0801 and DRB1*1602 also showed an assocn. with PHT-SJS/TEN (p = 0.0128-0.0281; OR: 3.0-4.3).  Conclusion: Our results indicate that OXC, PHT and LTG, which possess an arom. ring just as CBZ does, when causing SJS/TEN, share a common risk allele.  Arom. antiepileptic drugs causing SJS/TEN in HLA-B*1502 carriers may act on a similar pathogenetic mechanism, although other genetic/nongenetic factor(s) may also contribute to the pathomechanism of the disease.  We suggest that arom. antiepileptic drugs, including CBZ, OXC and PHT, should be avoided in the B*1502 carrier and caution should also be exercised for LTG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfWW1PRvCZhLVg90H21EOLACvtfcHk0lio662m9ZxQDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFSksLw%253D&md5=532c0cc0489e7225b540df904cc5115a</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.2217%2Fpgs.09.162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fpgs.09.162%26sid%3Dliteratum%253Aachs%26aulast%3DHung%26aufirst%3DS.%2BI.%26aulast%3DChung%26aufirst%3DW.%2BH.%26aulast%3DLiu%26aufirst%3DZ.%2BS.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DHsih%26aufirst%3DM.%2BS.%26aulast%3DHui%26aufirst%3DR.%2BC.%26aulast%3DChu%26aufirst%3DC.%2BY.%26aulast%3DChen%26aufirst%3DY.%2BT.%26atitle%3DCommon%2520Risk%2520Allele%2520in%2520Aromatic%2520Antiepileptic-Drug-Induced%2520Stevens-Johnson%2520Syndrome%2520and%2520Toxic%2520Epidermal%2520Necrolysis%2520in%2520Han%2520Chinese%26jtitle%3DPharmacogenomics%26date%3D2010%26volume%3D11%26spage%3D349%26epage%3D356%26doi%3D10.2217%2Fpgs.09.162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, F.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-D.</span></span> <span> </span><span class="NLM_article-title">Genetic Polymorphisms of Manganese Superoxide Dismutase, NAD(P)H:quinone Oxidoreductase, Glutathione S-Transferase M1 and T1, and the Susceptibility to Drug-Induced Liver Injury</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2007.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jhep.2007.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=17400324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVahtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=128-134&author=Y.-S.+Huangauthor=W.-J.+Suauthor=Y.-H.+Huangauthor=C.-Y.+Chenauthor=F.-Y.+Changauthor=H.-C.+Linauthor=S.-D.+Lee&title=Genetic+Polymorphisms+of+Manganese+Superoxide+Dismutase%2C+NAD%28P%29H%3Aquinone+Oxidoreductase%2C+Glutathione+S-Transferase+M1+and+T1%2C+and+the+Susceptibility+to+Drug-Induced+Liver+Injury&doi=10.1016%2Fj.jhep.2007.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury</span></div><div class="casAuthors">Huang, Yi-Shin; Su, Wei-Juin; Huang, Yi-Hsiang; Chen, Chih-Yen; Chang, Full-Young; Lin, Han-Chieh; Lee, Shou-Dong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-134</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Drug metabolizing enzymes may be related to drug-induced liver injury (DILI).  Manganese superoxide dismutase (MnSOD), NAD(P)H:quinone oxidoreductase (NQO1), and glutathione S-transferase (GST) are important drug metabolizing enzymes.  We aimed to elucidate the relationship between genetic polymorphisms of these enzymes and the susceptibility to DILI.  A total of 115 patients with DILI and 115 drug-, sex-, and age-matched controls were enrolled.  Their genetic polymorphisms of MnSOD, NQO1, GSTM1, and GSTT1 were assayed.  Sixty-three (54.8%) of DILI patients were incriminated to anti-tuberculosis drugs.  Subjects with a mutant C allele (T/C or C/C genotype) of MnSOD had a higher risk of DILI than those with MnSOD T/T genotype, both in overall drugs studied (adjusted OR: 2.44, 95% C.I.: 1.38-4.30, P = 0.002), and in sub-category of anti-tuberculosis drugs (adjusted OR: 2.47, 95% C.I.: 1.13-5.39, P = 0.02).  In addn., subjects carrying GSTM1 null genotype had increased risk of anti-tuberculosis DILI (adjusted OR: 2.23, 95% C.I.: 1.07-4.67, P = 0.03).  The MnSOD mutant C allele may increase the susceptibility to DILI, and GSTM1 null genotype may be related to anti-tuberculosis drug-induced hepatotoxicity.  Detn. of the MnSOD and GSTM1 genotypes may help identify patients at high risk for DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiBXCXlRUfxbVg90H21EOLACvtfcHk0lio662m9ZxQDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVahtL4%253D&md5=7f04ee34efd309bc61bbe33ab36afbb4</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2007.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2007.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.-S.%26aulast%3DSu%26aufirst%3DW.-J.%26aulast%3DHuang%26aufirst%3DY.-H.%26aulast%3DChen%26aufirst%3DC.-Y.%26aulast%3DChang%26aufirst%3DF.-Y.%26aulast%3DLin%26aufirst%3DH.-C.%26aulast%3DLee%26aufirst%3DS.-D.%26atitle%3DGenetic%2520Polymorphisms%2520of%2520Manganese%2520Superoxide%2520Dismutase%252C%2520NAD%2528P%2529H%253Aquinone%2520Oxidoreductase%252C%2520Glutathione%2520S-Transferase%2520M1%2520and%2520T1%252C%2520and%2520the%2520Susceptibility%2520to%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DJ.%2520Hepatol.%26date%3D2007%26volume%3D47%26spage%3D128%26epage%3D134%26doi%3D10.1016%2Fj.jhep.2007.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucena, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Martín, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulzurrun, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero-Gomez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castiella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durán, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Dios, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guarner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borraz, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agundez, J. A. G.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial Superoxide Dismutase and Glutathione Peroxidase in Idiosyncratic Drug-Induced Liver Injury</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1002/hep.23668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.23668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=20578157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFShtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2010&pages=303-312&author=M.+I.+Lucenaauthor=E.+Garc%C3%ADa-Mart%C3%ADnauthor=R.+J.+Andradeauthor=C.+Mart%C3%ADnezauthor=C.+Stephensauthor=J.+D.+Ruizauthor=E.+Ulzurrunauthor=M.+C.+Fernandezauthor=M.+Romero-Gomezauthor=A.+Castiellaauthor=R.+Planasauthor=J.+A.+Dur%C3%A1nauthor=A.+M.+De+Diosauthor=C.+Guarnerauthor=G.+Sorianoauthor=Y.+Borrazauthor=J.+A.+G.+Agundez&title=Mitochondrial+Superoxide+Dismutase+and+Glutathione+Peroxidase+in+Idiosyncratic+Drug-Induced+Liver+Injury&doi=10.1002%2Fhep.23668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury</span></div><div class="casAuthors">Lucena, M. Isabel; Garcia-Martin, Elena; Andrade, Raul J.; Martinez, Carmen; Stephens, Camilla; Ruiz, Jhon D.; Ulzurrun, Eugenia; Fernandez, M. Carmen; Romero-Gomez, Manuel; Castiella, Augustin; Planas, Ramon; Duran, Jose Antonio; De Dios, Ana Melcon; Guarner, Carlos; Soriano, German; Borraz, Yolanda; Agundez, Jose A. G.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">303-312</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) susceptibility has a potential genetic basis.  We have evaluated possible assocns. between the risk of developing DILI and common genetic variants of the manganese superoxide dismutase (SOD2 Val16Ala) and glutathione peroxidase (GPX1 Pro200Leu) genes, which are involved in mitochondrial oxidative stress management.  Genomic DNA from 185 DILI patients assessed by the Council for International Organizations of Medical Science scale and 270 sex- and age-matched controls were analyzed.  The SOD2 and GPX1 genotyping was performed using polymerase chain reaction restriction fragment length polymorphism and TaqMan probed quant. polymerase chain reaction, resp.  The statistical power to detect the effect of variant alleles with the obsd. odds ratio (OR) was 98.2% and 99.7% for bilateral assocn. of SOD2 and GPX1, resp.  The SOD2 Ala/Ala genotype was assocd. with cholestatic/mixed damage (OR = 2.3; 95% confidence interval [CI] = 1.4-3.8; cor. P [Pc] = 0.0058), whereas the GPX1 Leu/Leu genotype was assocd. with cholestatic injury (OR = 5.1; 95%CI = 1.6-16.0; Pc = 0.0112).  The presence of two or more combined risk alleles (SOD2 Ala and GPX1 Leu) was more frequent in DILI patients (OR = 2.1; 95%CI = 1.4-3.0; Pc = 0.0006).  Patients with cholestatic/mixed injury induced by mitochondria hazardous drugs were more prone to have the SOD2 Ala/Ala genotype (OR = 3.6; 95%CI = 1.4-9.3; Pc = 0.02).  This genotype was also more frequent in cholestatic/mixed DILI induced by pharmaceuticals producing quinone-like or epoxide metabolites (OR = 3.0; 95%CI = 1.7-5.5; Pc = 0.0008) and S-oxides, diazines, nitroanion radicals, or iminium ions (OR = 16.0; 95%CI = 1.8-146.1; Pc = 0.009).  Patients homozygous for the SOD2 Ala allele and the GPX1 Leu allele are at higher risk of developing cholestatic DILI.  SOD2 Ala homozygotes may be more prone to suffer DILI from drugs that are mitochondria hazardous or produce reactive intermediates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKPBg5do7ypbVg90H21EOLACvtfcHk0lhci9KlPW_PXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFShtbc%253D&md5=72eb0f4a53f44f51e1604e8a991fb47b</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1002%2Fhep.23668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.23668%26sid%3Dliteratum%253Aachs%26aulast%3DLucena%26aufirst%3DM.%2BI.%26aulast%3DGarc%25C3%25ADa-Mart%25C3%25ADn%26aufirst%3DE.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DC.%26aulast%3DRuiz%26aufirst%3DJ.%2BD.%26aulast%3DUlzurrun%26aufirst%3DE.%26aulast%3DFernandez%26aufirst%3DM.%2BC.%26aulast%3DRomero-Gomez%26aufirst%3DM.%26aulast%3DCastiella%26aufirst%3DA.%26aulast%3DPlanas%26aufirst%3DR.%26aulast%3DDur%25C3%25A1n%26aufirst%3DJ.%2BA.%26aulast%3DDe%2BDios%26aufirst%3DA.%2BM.%26aulast%3DGuarner%26aufirst%3DC.%26aulast%3DSoriano%26aufirst%3DG.%26aulast%3DBorraz%26aufirst%3DY.%26aulast%3DAgundez%26aufirst%3DJ.%2BA.%2BG.%26atitle%3DMitochondrial%2520Superoxide%2520Dismutase%2520and%2520Glutathione%2520Peroxidase%2520in%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DHepatology%26date%3D2010%26volume%3D52%26spage%3D303%26epage%3D312%26doi%3D10.1002%2Fhep.23668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Usachov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omary, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, P.</span></span> <span> </span><span class="NLM_article-title">Prevalence of Genetic Variants of Keratins 8 and 18 in Patients with Drug-Induced Liver Injury</span>. <i>BMC Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">196</span>, <span class="refDoi"> DOI: 10.1186/s12916-015-0418-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1186%2Fs12916-015-0418-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26286715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1Snsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=196&author=V.+Usachovauthor=T.+J.+Urbanauthor=R.+J.+Fontanaauthor=A.+Grossauthor=S.+Iyerauthor=M.+B.+Omaryauthor=P.+Strnad&title=Prevalence+of+Genetic+Variants+of+Keratins+8+and+18+in+Patients+with+Drug-Induced+Liver+Injury&doi=10.1186%2Fs12916-015-0418-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury</span></div><div class="casAuthors">Usachov, Valentyn; Urban, Thomas J.; Fontana, Robert J.; Gross, Annika; Iyer, Sapna; Omary, M. Bishr; Strnad, Pavel</div><div class="citationInfo"><span class="NLM_cas:title">BMC Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">196/1-196/12</span>CODEN:
                <span class="NLM_cas:coden">BMMECZ</span>;
        ISSN:<span class="NLM_cas:issn">1741-7015</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Keratin 8 and 18 (K8/K18) cytoskeletal proteins protect hepatocytes from undergoing apoptosis and their mutations predispose to adverse outcomes in acute liver failure (ALF).  All known K8/K18 variants occur at relatively non-conserved residues and do not cause keratin cytoskeleton reorganization, whereas epidermal keratin-conserved residue mutations disrupt the keratin cytoskeleton and cause severe skin disease.  The aim of our study was to identify keratin variants in idiosyncratic drug-induced liver injury (DILI).  Methods: Genomic DNA was isolated from 800 patients enrolled in an ongoing US multicenter study, with DILI attributed to a wide range of drugs.  Specific K8/K18 exonic regions were PCR-amplified and screened by denaturing HPLC followed by DNA sequencing.  The functional impact of keratin variants was assessed using cell transfection and immune staining.  Results: Heterozygous and compd. amino acid-altering K8/K18 variants were identified in 86 DILI patients and non-coding variants in 15 subjects.  Five novel amino acid-altering (K8 Lys393Arg, K8 Ala351Val, K8 Ala358Val, K8 Ile346Val, K18 Asp89His) and two non-coding variants were obsd.  Several variants segregated with specific ethnic backgrounds but were found at similar frequencies in DILI subjects and ethnically matched population controls.  Notably, variants in highly conserved residues of K8 Lys393Arg (ezetimibe/simvastatin-related) and K18 Asp89His (isoniazid-related) were found in patients with fatal DILI.  These novel variants also led to keratin network disruption in transfected cells.  Conclusions: Novel K8/K18 cytoskeleton-disrupting variants were identified in two patients and segregated with fatal DILI.  Other non-cytoskeleton-disrupting keratin variants did not preferentially assoc. with DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhgiJGw0iPfbVg90H21EOLACvtfcHk0lhci9KlPW_PXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1Snsrs%253D&md5=0de4f39ed4979aa0f630785af8b0801f</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1186%2Fs12916-015-0418-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12916-015-0418-0%26sid%3Dliteratum%253Aachs%26aulast%3DUsachov%26aufirst%3DV.%26aulast%3DUrban%26aufirst%3DT.%2BJ.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DGross%26aufirst%3DA.%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DOmary%26aufirst%3DM.%2BB.%26aulast%3DStrnad%26aufirst%3DP.%26atitle%3DPrevalence%2520of%2520Genetic%2520Variants%2520of%2520Keratins%25208%2520and%252018%2520in%2520Patients%2520with%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DBMC%2520Med.%26date%3D2015%26volume%3D13%26spage%3D196%26doi%3D10.1186%2Fs12916-015-0418-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urban, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shianna, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucena, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molokhia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floratos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pe’er, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonkovsky, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davern, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talwalkar, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Limited Contribution of Common Genetic Variants to Risk for Liver Injury Due to a Variety of Drugs</span>. <i>Pharmacogenet. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">784</span>– <span class="NLM_lpage">795</span>, <span class="refDoi"> DOI: 10.1097/FPC.0b013e3283589a76</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1097%2FFPC.0b013e3283589a76" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22968431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKgsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=784-795&author=T.+J.+Urbanauthor=Y.+Shenauthor=A.+Stolzauthor=N.+Chalasaniauthor=R.+J.+Fontanaauthor=J.+Rochonauthor=D.+Geauthor=K.+V.+Shiannaauthor=A.+K.+Dalyauthor=M.+I.+Lucenaauthor=M.+R.+Nelsonauthor=M.+Molokhiaauthor=G.+P.+Aithalauthor=A.+Floratosauthor=I.+Pe%E2%80%99erauthor=J.+Serranoauthor=H.+Bonkovskyauthor=T.+J.+Davernauthor=W.+M.+Leeauthor=V.+J.+Navarroauthor=J.+A.+Talwalkarauthor=D.+B.+Goldsteinauthor=P.+B.+Watkins&title=Limited+Contribution+of+Common+Genetic+Variants+to+Risk+for+Liver+Injury+Due+to+a+Variety+of+Drugs&doi=10.1097%2FFPC.0b013e3283589a76"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs</span></div><div class="casAuthors">Urban, Thomas J.; Shen, Yufeng; Stolz, Andrew; Chalasani, Naga; Fontana, Robert J.; Rochon, James; Ge, Dongliang; Shianna, Kevin V.; Daly, Ann K.; Lucena, M. Isabel; Nelson, Matthew R.; Molokhia, Mariam; Aithal, Guruprasad P.; Floratos, Aris; Pe'er, Itsik; Serrano, Jose; Bonkovsky, Herbert; Davern, Timothy J.; Lee, William M.; Navarro, Victor J.; Talwalkar, Jayant A.; Goldstein, David B.; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics and Genomics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">784-795</span>CODEN:
                <span class="NLM_cas:coden">PGHEAI</span>;
        ISSN:<span class="NLM_cas:issn">1744-6872</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background and aims: Drug-induced liver injury (DILI) is a serious adverse drug event that is suspected to have a heritable component.  We carried out a genome-wide assocn. study of 783 individuals of European ancestry who experienced DILI due to more than 200 implicated drugs.  Methods: DILI patients from the US-based Drug-Induced Liver Injury Network (n=401) and three international registries (n=382) were genotyped with the Illumina 1Mduo BeadChip and compared with population controls (n=3001).  Potential assocns. were tested in 307 independent Drug-Induced Liver Injury Network cases.  Results: After accounting for known major histocompatibility complex risk alleles for flucloxacillin-DILI and amoxicillin/clavulanate-DILI, there were no genome-wide significant assocns., including in the major histocompatibility complex region.  Stratification of DILI cases according to clin. phenotypes (injury type, latency, age of onset) also did not show significant assocns.  An anal. of hepatocellular DILI (n=285) restricted to 193 single-nucleotide polymorphisms previously assocd. with autoimmune disease showed a trend assocn. for rs7574865, in the vicinity of signal transducer and activator of transcription 4 (STAT4) (P=4.5×10).  This assocn. was replicated in an independent cohort of 168 hepatocellular DILI cases (P=0.011 and 1.5×10 for combined cohorts).  No significant assocns. were found with stratification by other clin. or demog. variables.  Conclusion: Although not significant at the genome-wide level, the assocn. between hepatocellular DILI and STAT4 is consistent with the emerging role of the immune system in DILI.  However, the lack of genome-wide assocn. study findings supports the idea that strong genetic determinants of DILI may be largely drug-specific or may reflect rare genetic variations, which were not assessed in our study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFgO-sTGumTLVg90H21EOLACvtfcHk0lhci9KlPW_PXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKgsrrP&md5=1071d36d7efb376675f350daf717f5ba</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1097%2FFPC.0b013e3283589a76&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFPC.0b013e3283589a76%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DT.%2BJ.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DStolz%26aufirst%3DA.%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DRochon%26aufirst%3DJ.%26aulast%3DGe%26aufirst%3DD.%26aulast%3DShianna%26aufirst%3DK.%2BV.%26aulast%3DDaly%26aufirst%3DA.%2BK.%26aulast%3DLucena%26aufirst%3DM.%2BI.%26aulast%3DNelson%26aufirst%3DM.%2BR.%26aulast%3DMolokhia%26aufirst%3DM.%26aulast%3DAithal%26aufirst%3DG.%2BP.%26aulast%3DFloratos%26aufirst%3DA.%26aulast%3DPe%25E2%2580%2599er%26aufirst%3DI.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DBonkovsky%26aufirst%3DH.%26aulast%3DDavern%26aufirst%3DT.%2BJ.%26aulast%3DLee%26aufirst%3DW.%2BM.%26aulast%3DNavarro%26aufirst%3DV.%2BJ.%26aulast%3DTalwalkar%26aufirst%3DJ.%2BA.%26aulast%3DGoldstein%26aufirst%3DD.%2BB.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DLimited%2520Contribution%2520of%2520Common%2520Genetic%2520Variants%2520to%2520Risk%2520for%2520Liver%2520Injury%2520Due%2520to%2520a%2520Variety%2520of%2520Drugs%26jtitle%3DPharmacogenet.%2520Genomics%26date%3D2012%26volume%3D22%26spage%3D784%26epage%3D795%26doi%3D10.1097%2FFPC.0b013e3283589a76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urban, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Genetic Basis of Susceptibility to Drug-Induced Liver Injury: What Have We Learned and Where Do We Go from Here?</span>. <i>Pharmacogenomics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">738</span>, <span class="refDoi"> DOI: 10.2217/pgs.12.45</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.2217%2Fpgs.12.45" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22594502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFygu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=735-738&author=T.+J.+Urbanauthor=D.+B.+Goldsteinauthor=P.+B.+Watkins&title=Genetic+Basis+of+Susceptibility+to+Drug-Induced+Liver+Injury%3A+What+Have+We+Learned+and+Where+Do+We+Go+from+Here%3F&doi=10.2217%2Fpgs.12.45"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?</span></div><div class="casAuthors">Urban, Thomas J.; Goldstein, David B.; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenomics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">735-738</span>CODEN:
                <span class="NLM_cas:coden">PARMFL</span>;
        ISSN:<span class="NLM_cas:issn">1462-2416</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Drug-induced liver injury (DILI) represents a particularly significant problem, both in terms of its clin. impact and its economic effects.  Beyond its cost in terms of patient morbidity and mortality, DILI is among the most frequent reasons for late termination of drug development programs and regulatory actions including withdrawal of drugs from the market, resulting in large financial losses to the drug industry that are inevitably passed on to consumers.  For these reasons, much effort has been taken to identify causes of DILI and methods to predict its occurrence.  In line with this, the DILI genetics in the genomic era is reported.  Notably, genetic studies of DILI registries have been successful in identifying unsuspected variants as risk factors and many addnl. insights can be expected as these registries grow and the anal. technol. continues to advance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHl0ub_M1_1rVg90H21EOLACvtfcHk0liM7A2CXviGwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFygu7w%253D&md5=e57a9062c5575ef8d8c20d19955a256a</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.2217%2Fpgs.12.45&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fpgs.12.45%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DT.%2BJ.%26aulast%3DGoldstein%26aufirst%3DD.%2BB.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DGenetic%2520Basis%2520of%2520Susceptibility%2520to%2520Drug-Induced%2520Liver%2520Injury%253A%2520What%2520Have%2520We%2520Learned%2520and%2520Where%2520Do%2520We%2520Go%2520from%2520Here%253F%26jtitle%3DPharmacogenomics%26date%3D2012%26volume%3D13%26spage%3D735%26epage%3D738%26doi%3D10.2217%2Fpgs.12.45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korman, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregersen, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remmers, E. F.</span></span> <span> </span><span class="NLM_article-title">STAT4: Genetics, Mechanisms, and Implications for Autoimmunity</span>. <i>Curr. Allergy Asthma Rep.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">398</span>– <span class="NLM_lpage">403</span>, <span class="refDoi"> DOI: 10.1007/s11882-008-0077-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs11882-008-0077-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=18682104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtV2mu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=398-403&author=B.+D.+Kormanauthor=D.+L.+Kastnerauthor=P.+K.+Gregersenauthor=E.+F.+Remmers&title=STAT4%3A+Genetics%2C+Mechanisms%2C+and+Implications+for+Autoimmunity&doi=10.1007%2Fs11882-008-0077-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">STAT4: genetics, mechanisms, and implications for autoimmunity</span></div><div class="casAuthors">Korman, Benjamin D.; Kastner, Daniel L.; Gregersen, Peter K.; Remmers, Elaine F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Allergy and Asthma Reports</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">398-403</span>CODEN:
                <span class="NLM_cas:coden">CAARC9</span>;
        ISSN:<span class="NLM_cas:issn">1529-7322</span>.
    
            (<span class="NLM_cas:orgname">Current Medicine Group LLC</span>)
        </div><div class="casAbstract">A review.  Recent advances in genetics and technol. have led to breakthroughs in understanding the genes that predispose individuals to autoimmune diseases.  A common haplotype of the signal transducer and activator of transcription 4 (STAT4) gene has been shown to be assocd. with susceptibility to rheumatoid arthritis, systemic lupus erythematosus, and primary Sjogren's syndrome.  STAT4 is a transcription factor that transduces interleukin-12, interleukin-23, and type 1 interferon cytokine signals in T cells and monocytes, leading to T-helper type 1 and T-helper type 17 differentiation, monocyte activation, and interferon-γ prodn.  Although the evidence for this assocn. is very strong and well replicated, the exact mechanism by which polymorphisms in this gene lead to disease remains unknown.  In concert with the identification of other disease-assocd. loci, elucidating how the variant form of STAT4 modulates immune function should lead to an improved understanding of the pathophysiol. of autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrpvYj_KwTA7Vg90H21EOLACvtfcHk0liM7A2CXviGwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtV2mu7fN&md5=f3c5d0a47fbee5e18f195123832b64de</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1007%2Fs11882-008-0077-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11882-008-0077-8%26sid%3Dliteratum%253Aachs%26aulast%3DKorman%26aufirst%3DB.%2BD.%26aulast%3DKastner%26aufirst%3DD.%2BL.%26aulast%3DGregersen%26aufirst%3DP.%2BK.%26aulast%3DRemmers%26aufirst%3DE.%2BF.%26atitle%3DSTAT4%253A%2520Genetics%252C%2520Mechanisms%252C%2520and%2520Implications%2520for%2520Autoimmunity%26jtitle%3DCurr.%2520Allergy%2520Asthma%2520Rep.%26date%3D2008%26volume%3D8%26spage%3D398%26epage%3D403%26doi%3D10.1007%2Fs11882-008-0077-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gamazon, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozaffari, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aquino-Michaels, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyler, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, J. C.</span></span>; <span class="NLM_contrib-group">GTEx Consortium</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolae, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, H. K.</span></span> <span> </span><span class="NLM_article-title">A Gene-Based Association Method for Mapping Traits Using Reference Transcriptome Data</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1091</span>– <span class="NLM_lpage">1098</span>, <span class="refDoi"> DOI: 10.1038/ng.3367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fng.3367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26258848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSnurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2015&pages=1091-1098&author=E.+R.+Gamazonauthor=H.+E.+Wheelerauthor=K.+P.+Shahauthor=S.+V.+Mozaffariauthor=K.+Aquino-Michaelsauthor=R.+J.+Carrollauthor=A.+E.+Eylerauthor=J.+C.+Dennyauthor=GTEx+Consortiumauthor=D.+L.+Nicolaeauthor=N.+J.+Coxauthor=H.+K.+Im&title=A+Gene-Based+Association+Method+for+Mapping+Traits+Using+Reference+Transcriptome+Data&doi=10.1038%2Fng.3367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">A gene-based association method for mapping traits using reference transcriptome data</span></div><div class="casAuthors">Gamazon, Eric R.; Wheeler, Heather E.; Shah, Kaanan P.; Mozaffari, Sahar V.; Aquino-Michaels, Keston; Carroll, Robert J.; Eyler, Anne E.; Denny, Joshua C.; Nicolae, Dan L.; Cox, Nancy J.; Im, Hae Kyung</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1091-1098</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Genome-wide assocn. studies (GWAS) have identified thousands of variants robustly assocd. with complex traits.  However, the biol. mechanisms underlying these assocns. are, in general, not well understood.  We propose a gene-based assocn. method called PrediXcan that directly tests the mol. mechanisms through which genetic variation affects phenotype.  The approach ests. the component of gene expression detd. by an individual's genetic profile and correlates 'imputed' gene expression with the phenotype under investigation to identify genes involved in the etiol. of the phenotype.  Genetically regulated gene expression is estd. using whole-genome tissue-dependent prediction models trained with ref. transcriptome data sets.  PrediXcan enjoys the benefits of gene-based approaches such as reduced multiple-testing burden and a principled approach to the design of follow-up expts.  Our results demonstrate that PrediXcan can detect known and new genes assocd. with disease traits and provide insights into the mechanism of these assocns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9YzUegwecY7Vg90H21EOLACvtfcHk0liM7A2CXviGwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSnurbM&md5=6a2090092fef663aa910996d21b09068</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1038%2Fng.3367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.3367%26sid%3Dliteratum%253Aachs%26aulast%3DGamazon%26aufirst%3DE.%2BR.%26aulast%3DWheeler%26aufirst%3DH.%2BE.%26aulast%3DShah%26aufirst%3DK.%2BP.%26aulast%3DMozaffari%26aufirst%3DS.%2BV.%26aulast%3DAquino-Michaels%26aufirst%3DK.%26aulast%3DCarroll%26aufirst%3DR.%2BJ.%26aulast%3DEyler%26aufirst%3DA.%2BE.%26aulast%3DDenny%26aufirst%3DJ.%2BC.%26aulast%3D%26aulast%3DNicolae%26aufirst%3DD.%2BL.%26aulast%3DCox%26aufirst%3DN.%2BJ.%26aulast%3DIm%26aufirst%3DH.%2BK.%26atitle%3DA%2520Gene-Based%2520Association%2520Method%2520for%2520Mapping%2520Traits%2520Using%2520Reference%2520Transcriptome%2520Data%26jtitle%3DNat.%2520Genet.%26date%3D2015%26volume%3D47%26spage%3D1091%26epage%3D1098%26doi%3D10.1038%2Fng.3367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozyra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingelman-Sundberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M.</span></span> <span> </span><span class="NLM_article-title">Rare Genetic Variants in Cellular Transporters, Metabolic Enzymes, and Nuclear Receptors Can be Important Determinants of Interindividual Differences in Drug Response</span>. <i>Genet. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">20</span>, <span class="refDoi"> DOI: 10.1038/gim.2016.33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fgim.2016.33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27101133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVSkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=20&author=M.+Kozyraauthor=M.+Ingelman-Sundbergauthor=V.+M.+Lauschke&title=Rare+Genetic+Variants+in+Cellular+Transporters%2C+Metabolic+Enzymes%2C+and+Nuclear+Receptors+Can+be+Important+Determinants+of+Interindividual+Differences+in+Drug+Response&doi=10.1038%2Fgim.2016.33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response</span></div><div class="casAuthors">Kozyra, Mikael; Ingelman-Sundberg, Magnus; Lauschke, Volker M.</div><div class="citationInfo"><span class="NLM_cas:title">Genetics in Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-29</span>CODEN:
                <span class="NLM_cas:coden">GEMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1098-3600</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Purpose: In this study we characterized the genetic variability of 146 clin. relevant genes influencing drug pharmacokinetics in African and European subpopulations, which are key determinants for interindividual variations in drug efficacy and adverse drug reactions.  Results: In total, we found 12,152 SNVs in exons, 312 of which were novel.  The majority of variants were rare (minor allele frequency (MAF) <1%; 92.9%) and nonsynonymous (56.2%).  We calcd. that individuals of European and African descent harbor, on av., 100.8 and 121.4 variants across the 146 pharmacogenes studied, resp.  Addnl., by analyzing variation patterns across these populations, we pinpointed potential priority genes for population-adjusted genetic profiling strategies.  Furthermore, we estd., based on our variant frequency analyses, that approx. 30-40% of functional variability in pharmacogenes can be attributed to rare variants.  Conclusions: Our results indicate that these clin. important genes are genetically highly variable and differ considerably between populations.  Furthermore, the large extent of rare variants emphasizes the need for sequencing-based approaches and effective functionality predictions to allow for true personalized medicine.  Genet Med19 1, 20-29.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodEM1G6w3_E7Vg90H21EOLACvtfcHk0lgWgeooeW9FSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVSkuw%253D%253D&md5=61a99ed4639030a950ab2946c8ad29df</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1038%2Fgim.2016.33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fgim.2016.33%26sid%3Dliteratum%253Aachs%26aulast%3DKozyra%26aufirst%3DM.%26aulast%3DIngelman-Sundberg%26aufirst%3DM.%26aulast%3DLauschke%26aufirst%3DV.%2BM.%26atitle%3DRare%2520Genetic%2520Variants%2520in%2520Cellular%2520Transporters%252C%2520Metabolic%2520Enzymes%252C%2520and%2520Nuclear%2520Receptors%2520Can%2520be%2520Important%2520Determinants%2520of%2520Interindividual%2520Differences%2520in%2520Drug%2520Response%26jtitle%3DGenet.%2520Med.%26date%3D2017%26volume%3D19%26spage%3D20%26doi%3D10.1038%2Fgim.2016.33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khera, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaffin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aragam, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roselli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lander, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubitz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellinor, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kathiresan, S.</span></span> <span> </span><span class="NLM_article-title">Genome-Wide Polygenic Scores for Common Diseases Identify Individuals with Risk Equivalent to Monogenic Mutations</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1219</span>– <span class="NLM_lpage">1224</span>, <span class="refDoi"> DOI: 10.1038/s41588-018-0183-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fs41588-018-0183-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30104762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFSqtbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=1219-1224&author=A.+V.+Kheraauthor=M.+Chaffinauthor=K.+G.+Aragamauthor=M.+E.+Haasauthor=C.+Roselliauthor=S.+H.+Choiauthor=P.+Natarajanauthor=E.+S.+Landerauthor=S.+A.+Lubitzauthor=P.+T.+Ellinorauthor=S.+Kathiresan&title=Genome-Wide+Polygenic+Scores+for+Common+Diseases+Identify+Individuals+with+Risk+Equivalent+to+Monogenic+Mutations&doi=10.1038%2Fs41588-018-0183-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations</span></div><div class="casAuthors">Khera, Amit V.; Chaffin, Mark; Aragam, Krishna G.; Haas, Mary E.; Roselli, Carolina; Choi, Seung Hoan; Natarajan, Pradeep; Lander, Eric S.; Lubitz, Steven A.; Ellinor, Patrick T.; Kathiresan, Sekar</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1219-1224</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A key public health need is to identify individuals at high risk for a given disease to enable enhanced screening or preventive therapies.  Because most common diseases have a genetic component, one important approach is to stratify individuals based on inherited DNA variation1.  Proposed clin. applications have largely focused on finding carriers of rare monogenic mutations at several-fold increased risk.  Although most disease risk is polygenic in nature2-5, it has not yet been possible to use polygenic predictors to identify individuals at risk comparable to monogenic mutations.  Here, we develop and validate genome-wide polygenic scores for five common diseases.  The approach identifies 8.0, 6.1, 3.5, 3.2, and 1.5% of the population at greater than threefold increased risk for coronary artery disease, atrial fibrillation, type 2 diabetes, inflammatory bowel disease, and breast cancer, resp.  For coronary artery disease, this prevalence is 20-fold higher than the carrier frequency of rare monogenic mutations conferring comparable risk6.  We propose that it is time to contemplate the inclusion of polygenic risk prediction in clin. care, and discuss relevant issues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp3C1W_UEEELVg90H21EOLACvtfcHk0lgWgeooeW9FSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFSqtbbI&md5=18d34103bd53bccddfab5f6db9fb0787</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1038%2Fs41588-018-0183-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41588-018-0183-z%26sid%3Dliteratum%253Aachs%26aulast%3DKhera%26aufirst%3DA.%2BV.%26aulast%3DChaffin%26aufirst%3DM.%26aulast%3DAragam%26aufirst%3DK.%2BG.%26aulast%3DHaas%26aufirst%3DM.%2BE.%26aulast%3DRoselli%26aufirst%3DC.%26aulast%3DChoi%26aufirst%3DS.%2BH.%26aulast%3DNatarajan%26aufirst%3DP.%26aulast%3DLander%26aufirst%3DE.%2BS.%26aulast%3DLubitz%26aufirst%3DS.%2BA.%26aulast%3DEllinor%26aufirst%3DP.%2BT.%26aulast%3DKathiresan%26aufirst%3DS.%26atitle%3DGenome-Wide%2520Polygenic%2520Scores%2520for%2520Common%2520Diseases%2520Identify%2520Individuals%2520with%2520Risk%2520Equivalent%2520to%2520Monogenic%2520Mutations%26jtitle%3DNat.%2520Genet.%26date%3D2018%26volume%3D50%26spage%3D1219%26epage%3D1224%26doi%3D10.1038%2Fs41588-018-0183-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moggs, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meehan, R. R.</span></span> <span> </span><span class="NLM_article-title">Epigenetic Profiles as Defined Signatures of Xenobiotic Exposure</span>. <i>Mutat. Res., Genet. Toxicol. Environ. Mutagen.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>764–765</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1016/j.mrgentox.2013.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.mrgentox.2013.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24001620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVOnt7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=764%E2%80%93765&publication_year=2014&pages=3-9&author=J.+P.+Thomsonauthor=J.+G.+Moggsauthor=C.+R.+Wolfauthor=R.+R.+Meehan&title=Epigenetic+Profiles+as+Defined+Signatures+of+Xenobiotic+Exposure&doi=10.1016%2Fj.mrgentox.2013.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic profiles as defined signatures of xenobiotic exposure</span></div><div class="casAuthors">Thomson, John P.; Moggs, Jonathan G.; Wolf, C. Roland; Meehan, Richard R.</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research, Genetic Toxicology and Environmental Mutagenesis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">764-765</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3-9</span>CODEN:
                <span class="NLM_cas:coden">MRGMFI</span>;
        ISSN:<span class="NLM_cas:issn">1383-5718</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  With the advent of high resoln. sequencing technologies there has been increasing interest in the study of genome-wide epigenetic modification patterns that govern the underlying gene expression events of a particular cell or tissue type.  There is now mounting evidence that perturbations to the epigenetic landscape occur during a host of cellular processes including normal proliferation/differentiation and aberrant outcomes such as carcinogenesis.  Furthermore, epigenetic perturbations have been assocd. with exposure to a range of drugs and toxicants, including non-genotoxic carcinogens (NGCs).  Although a variety of epigenetic modifications induced by NGCs have been studied previously, recent genome-wide integrated epigenomic and transcriptomic studies reveal for the first time the extent and dynamic nature of the epigenetic perturbations resulting from xenobiotic exposure.  The interrogation and integration of one such epigenetic mark, the newly discovered 5-hydroxymethylcytosine (5hmC) modification, reveals that drug treatment assocd. perturbations of the epigenome can result in unique epigenetic signatures.  This review focuses on how recent advances in the field of epigenetics can enhance our mechanistic understanding of xenobiotic exposure and provide novel safety biomarkers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKBFN5ST1B97Vg90H21EOLACvtfcHk0lgWgeooeW9FSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVOnt7jM&md5=8719f213f1c117fac193f515843ad5c6</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.mrgentox.2013.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mrgentox.2013.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DThomson%26aufirst%3DJ.%2BP.%26aulast%3DMoggs%26aufirst%3DJ.%2BG.%26aulast%3DWolf%26aufirst%3DC.%2BR.%26aulast%3DMeehan%26aufirst%3DR.%2BR.%26atitle%3DEpigenetic%2520Profiles%2520as%2520Defined%2520Signatures%2520of%2520Xenobiotic%2520Exposure%26jtitle%3DMutat.%2520Res.%252C%2520Genet.%2520Toxicol.%2520Environ.%2520Mutagen.%26date%3D2014%26volume%3D764%25E2%2580%2593765%26spage%3D3%26epage%3D9%26doi%3D10.1016%2Fj.mrgentox.2013.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span> <i>Guidance for Industry: M3(R2) Nonclinical Safety
Studies for the
Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals</i>. <span class="NLM_publisher-name">U.S. Department of Health and Human Services, U.S.
Food and Drug Administration, Center for Drug Evaluation and Research,
Center for Biologics Evaluation and Research</span>: <span class="NLM_publisher-loc">Washington, DC</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Guidance+for+Industry%3A+M3%28R2%29+Nonclinical+Safety%0AStudies+for+the%0AConduct+of+Human+Clinical+Trials+and+Marketing+Authorization+for+Pharmaceuticals.+U.S.+Department+of+Health+and+Human+Services%2C+U.S.%0AFood+and+Drug+Administration%2C+Center+for+Drug+Evaluation+and+Research%2C%0ACenter+for+Biologics+Evaluation+and+Research%3A+Washington%2C+DC%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGuidance%2520for%2520Industry%253A%2520M3%2528R2%2529%2520Nonclinical%2520Safety%250AStudies%2520for%2520the%250AConduct%2520of%2520Human%2520Clinical%2520Trials%2520and%2520Marketing%2520Authorization%2520for%2520Pharmaceuticals%26pub%3DU.S.%2520Department%2520of%2520Health%2520and%2520Human%2520Services%252C%2520U.S.%250AFood%2520and%2520Drug%2520Administration%252C%2520Center%2520for%2520Drug%2520Evaluation%2520and%2520Research%252C%250ACenter%2520for%2520Biologics%2520Evaluation%2520and%2520Research%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolaja, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lilly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sipes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracken, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Deun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller, A.</span></span> <span> </span><span class="NLM_article-title">Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals</span>. <i>Regul. Toxicol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1006/rtph.2000.1399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1006%2Frtph.2000.1399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=11029269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntF2gu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2000&pages=56-67&author=H.+Olsonauthor=G.+Bettonauthor=D.+Robinsonauthor=K.+Thomasauthor=A.+Monroauthor=G.+Kolajaauthor=P.+Lillyauthor=J.+Sandersauthor=G.+Sipesauthor=W.+Brackenauthor=M.+Doratoauthor=K.+Van+Deunauthor=P.+Smithauthor=B.+Bergerauthor=A.+Heller&title=Concordance+of+the+Toxicity+of+Pharmaceuticals+in+Humans+and+in+Animals&doi=10.1006%2Frtph.2000.1399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals</span></div><div class="casAuthors">Olson, Harry; Betton, Graham; Robinson, Denise; Thomas, Karluss; Monro, Alastair; Kolaja, Gerald; Lilly, Patrick; Sanders, James; Sipes, Glenn; Bracken, William; Dorato, Michael; Van Deun, Koen; Smith, Peter; Berger, Bruce; Heller, Allen</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Toxicology and Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-67</span>CODEN:
                <span class="NLM_cas:coden">RTOPDW</span>;
        ISSN:<span class="NLM_cas:issn">0273-2300</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review is given with 29 refs. on the results of a multinational pharmaceutical company survey and the outcome of an International Life Sciences Institute (ILSI) Workshop (Apr. 1999), which served to better understand concordance of the toxicity of pharmaceuticals obsd. in humans with that obsd. in exptl. animals.  The Workshop included representatives from academia, the multinational pharmaceutical industry, and international regulatory scientists.  The main aim of this project was to examine the strengths and weaknesses of animal studies to predict human toxicity (HT).  The database was developed from a survey which covered only those compds. where HTs were identified during clin. development of new pharmaceuticals, detg. whether animal toxicity studies identified concordant target organ toxicities in humans.  Data collected included codified compds., therapeutic category, the HT organ system affected, and the species and duration of studies in which the corresponding HT was either 1st identified or not obsd.  This survey includes input from 12 pharmaceutical companies with data compiled from 150 compds. with 221 HT events reported.  Multiple HTs were reported in 47 cases.  The results showed the true pos. HT concordance rate of 71% for rodent and nonrodent species, with nonrodents alone being predictive for 63% of HTs and rodents alone for 43%.  The highest incidence of overall concordance was seen in hematol., gastrointestinal, and cardiovascular HTs, and the least was seen in cutaneous HT.  Where animal models, in 1 or more species, identified concordant HT, 94% were 1st obsd. in studies of 1 mo or less in duration.  These survey results support the value of in vivo toxicol. studies to predict for many significant HTs assocd. with pharmaceuticals and have helped to identify HT categories that may benefit from improved methods.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEmD_XsaoSaLVg90H21EOLACvtfcHk0lhGSwVdJneX3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntF2gu7k%253D&md5=8555af1a059d6e3811ade843d77e5f04</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1006%2Frtph.2000.1399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Frtph.2000.1399%26sid%3Dliteratum%253Aachs%26aulast%3DOlson%26aufirst%3DH.%26aulast%3DBetton%26aufirst%3DG.%26aulast%3DRobinson%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DK.%26aulast%3DMonro%26aufirst%3DA.%26aulast%3DKolaja%26aufirst%3DG.%26aulast%3DLilly%26aufirst%3DP.%26aulast%3DSanders%26aufirst%3DJ.%26aulast%3DSipes%26aufirst%3DG.%26aulast%3DBracken%26aufirst%3DW.%26aulast%3DDorato%26aufirst%3DM.%26aulast%3DVan%2BDeun%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DBerger%26aufirst%3DB.%26aulast%3DHeller%26aufirst%3DA.%26atitle%3DConcordance%2520of%2520the%2520Toxicity%2520of%2520Pharmaceuticals%2520in%2520Humans%2520and%2520in%2520Animals%26jtitle%3DRegul.%2520Toxicol.%2520Pharmacol.%26date%3D2000%26volume%3D32%26spage%3D56%26epage%3D67%26doi%3D10.1006%2Frtph.2000.1399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Festing, M. W.</span></span> <span> </span><span class="NLM_article-title">Improving Toxicity Screening and Drug Development by Using Genetically Defined Strains</span>. In  <i>Mouse Models for Drug Discovery</i> [Online], <span class="NLM_contrib-group"><span class="NLM_string-name">Proetzel, G.</span>, <span class="NLM_string-name">Wiles, M. V.</span></span>, Eds; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">Totowa, NJ</span>, <span class="NLM_year">2010</span>; pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">21</span>, <a href="https://link.springer.com/protocol/10.1007%2F978-1-60761-058-8_1" class="extLink">https://link.springer.com/protocol/10.1007%2F978-1-60761-058-8_1</a>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2F978-1-60761-058-8_1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=1-21&author=M.+W.+Festingauthor=G.+Proetzel&author=M.+V.+Wiles&title=Mouse+Models+for+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1007%2F978-1-60761-058-8_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-60761-058-8_1%26sid%3Dliteratum%253Aachs%26aulast%3DFesting%26aufirst%3DM.%2BW.%26atitle%3DImproving%2520Toxicity%2520Screening%2520and%2520Drug%2520Development%2520by%2520Using%2520Genetically%2520Defined%2520Strains%26btitle%3DMouse%2520Models%2520for%2520Drug%2520Discovery%26aulast%3DProetzel%26aufirst%3DG.%26pub%3DHumana%2520Press%26date%3D2010%26spage%3D1%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballet, F.</span></span> <span> </span><span class="NLM_article-title">Preventing Drug-Induced Liver Injury: How Useful Are Animal Models?</span>. <i>Digestive Diseases</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">485</span>, <span class="refDoi"> DOI: 10.1159/000374093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1159%2F000374093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FhvVeruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=477-485&author=F.+Ballet&title=Preventing+Drug-Induced+Liver+Injury%3A+How+Useful+Are+Animal+Models%3F&doi=10.1159%2F000374093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Preventing Drug-Induced Liver Injury: How Useful Are Animal Models?</span></div><div class="casAuthors">Ballet Francois</div><div class="citationInfo"><span class="NLM_cas:title">Digestive diseases (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">477-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug-induced liver injury (DILI) is the most common organ toxicity encountered in regulatory animal toxicology studies required prior to the clinical development of new drug candidates.  Very few reports have evaluated the value of these studies for predicting DILI in humans.  Indeed, compounds inducing liver toxicity in regulatory toxicology studies are not always correlated with a risk of DILI in humans.  Conversely, compounds associated with the occurrence of DILI in phase 3 studies or after market release are often tested negative in regulatory toxicology studies.  Idiosyncratic DILI is a rare event that is precipitated in an individual by the simultaneous occurrence of several critical factors.  These factors may relate to the host (e.g. human leukocyte antigen polymorphism, inflammation), the drug (e.g. reactive metabolites) or the environment (e.g. diet/microbiota).  This type of toxicity therefore cannot be detected in conventional animal toxicology studies.  Several animal models have recently been proposed for the identification of drugs with the potential to cause idiosyncratic DILI: rats treated with lipopolysaccharide, Sod2(+/-) mice, panels of inbred mouse strains or chimeric mice with humanized livers.  These models are not suitable for use in the prospective screening of new drug candidates.  Humans therefore constitute the best model for predicting and assessing idiopathic DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREa92slMahj0NHe_gFldTbfW6udTcc2ebFGN1o5e5jtbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FhvVeruw%253D%253D&md5=5467900bc48ca5b22eb9eae9cfca76da</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1159%2F000374093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000374093%26sid%3Dliteratum%253Aachs%26aulast%3DBallet%26aufirst%3DF.%26atitle%3DPreventing%2520Drug-Induced%2520Liver%2520Injury%253A%2520How%2520Useful%2520Are%2520Animal%2520Models%253F%26jtitle%3DDigestive%2520Diseases%26date%3D2015%26volume%3D33%26spage%3D477%26epage%3D485%26doi%3D10.1159%2F000374093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shenton, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J. P.</span></span> <span> </span><span class="NLM_article-title">Evidence of an Immune-Mediated Mechanism for an Idiosyncratic Nevirapine-Induced Reaction in the Female Brown Norway Rat</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1799</span>– <span class="NLM_lpage">813</span>, <span class="refDoi"> DOI: 10.1021/tx0501132</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx0501132" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1WmtLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=1799-813&author=J.+M.+Shentonauthor=M.+Popovicauthor=J.+Chenauthor=M.+J.+Massonauthor=J.+P.+Uetrecht&title=Evidence+of+an+Immune-Mediated+Mechanism+for+an+Idiosyncratic+Nevirapine-Induced+Reaction+in+the+Female+Brown+Norway+Rat&doi=10.1021%2Ftx0501132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence of an Immune-Mediated Mechanism for an Idiosyncratic Nevirapine-Induced Reaction in the Female Brown Norway Rat</span></div><div class="casAuthors">Shenton, Jacintha M.; Popovic, Marija; Chen, Jie; Masson, Mary Jane; Uetrecht, Jack P.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1799-1813</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Previously, the authors reported a new animal model of an idiosyncratic drug reaction in which nevirapine causes a skin rash in some rats that has characteristics similar to the reaction that occurs in humans.  Strong evidence that the reaction is immune-mediated was found; specifically, low-dose pretreatment induced tolerance, while with rechallenge, the time to onset decreased and the severity increased.  Furthermore, splenocytes from rechallenged rats transferred rash susceptibility to naive recipients.  The authors now report the results of studies to explore the immune aspects of this reaction.  T cells were found to play an important role, as demonstrated by their ability to adoptively transfer susceptibility to the skin reaction.  Of these T cells, CD4+ cells are the likely effectors because they were capable of transferring susceptibility and the reaction was delayed in rats partially depleted of CD4+ T cells.  In contrast, it appears that CD8+ T cells are not essential, as CD8+ T cells were unable to transfer sensitivity to a naive animal and rats depleted of CD8+ T cells still developed skin rash.  Unlike the penicillamine model, where the authors have demonstrated that the tolerance induced by low-dose treatment is immune-mediated, tolerance induced by low-dose nevirapine appears to be largely due to induction of metab. as it can be overcome by inhibition of cytochrome P 450.  Pretreatment with the immunosuppressants, cyclosporine and tacrolimus, prevented the rash and even led to resoln. of the rash during nevirapine treatment.  These studies reinforce the hypothesis that the reaction in this model is similar to that which occurs in humans.  In particular, the finding that CD4+ T cells may play a central role in this model fits with the observation that the incidence of idiosyncratic reactions to nevirapine in humans appears to be lower in patients with low CD4+ counts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrVpZSoKuQBbVg90H21EOLACvtfcHk0lgY_6XNhub87g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1WmtLnK&md5=38b5c9bcd0afcd4c4521dc64663f88e0</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1021%2Ftx0501132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx0501132%26sid%3Dliteratum%253Aachs%26aulast%3DShenton%26aufirst%3DJ.%2BM.%26aulast%3DPopovic%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMasson%26aufirst%3DM.%2BJ.%26aulast%3DUetrecht%26aufirst%3DJ.%2BP.%26atitle%3DEvidence%2520of%2520an%2520Immune-Mediated%2520Mechanism%2520for%2520an%2520Idiosyncratic%2520Nevirapine-Induced%2520Reaction%2520in%2520the%2520Female%2520Brown%2520Norway%2520Rat%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2005%26volume%3D18%26spage%3D1799%26epage%3D813%26doi%3D10.1021%2Ftx0501132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. S.</span></span> <span> </span><span class="NLM_article-title">Sex Differences in Nevirapine Rash</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">2096</span>– <span class="NLM_lpage">2097</span>, <span class="refDoi"> DOI: 10.1086/324088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1086%2F324088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=11712101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BD3MnmsFGrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2001&pages=2096-2097&author=K.+H.+Wongauthor=K.+C.+W.+Chanauthor=S.+S.+Lee&title=Sex+Differences+in+Nevirapine+Rash&doi=10.1086%2F324088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Sex differences in nevirapine rash</span></div><div class="casAuthors">Wong K H; Chan K C; Lee S S</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2096-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLq5PIOwr5z6__Jf7-eMvJfW6udTcc2eZExnaNKuVPKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnmsFGrtA%253D%253D&md5=4f315dc55aa3d1913b1e05a3320e8927</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1086%2F324088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F324088%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DK.%2BH.%26aulast%3DChan%26aufirst%3DK.%2BC.%2BW.%26aulast%3DLee%26aufirst%3DS.%2BS.%26atitle%3DSex%2520Differences%2520in%2520Nevirapine%2520Rash%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2001%26volume%3D33%26spage%3D2096%26epage%3D2097%26doi%3D10.1086%2F324088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novalen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">Bioactivation of Nevirapine to a Reactive Quinone Methide: Implications for Liver Injury</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1708</span>– <span class="NLM_lpage">1719</span>, <span class="refDoi"> DOI: 10.1021/tx300172s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx300172s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVaktr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=1708-1719&author=A.+M.+Sharmaauthor=Y.+Liauthor=M.+Novalenauthor=M.+A.+Hayesauthor=J.+Uetrecht&title=Bioactivation+of+Nevirapine+to+a+Reactive+Quinone+Methide%3A+Implications+for+Liver+Injury&doi=10.1021%2Ftx300172s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Bioactivation of Nevirapine to a Reactive Quinone Methide: Implications for Liver Injury</span></div><div class="casAuthors">Sharma, Amy M.; Li, Yan; Novalen, Maria; Hayes, M. Anthony; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1708-1719</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nevirapine (NVP) treatment is assocd. with a significant incidence of liver injury.  We developed an anti-NVP antiserum to det. the presence and pattern of covalent binding of NVP to mouse, rat, and human hepatic tissues.  Covalent binding to hepatic microsomes from male C57BL/6 mice and male Brown Norway rats was detected on Western blots; the major protein had a mass of ∼55 kDa.  Incubation of NVP with rat CYP3A1 and 2C11 or human CYP3A4 also led to covalent binding.  Treatment of female Brown Norway rats or C57BL/6 mice with NVP led to extensive covalent binding to a wide range of proteins.  Co-treatment with 1-aminobenzotriazole dramatically changed the pattern of binding.  The covalent binding of 12-hydroxy-NVP, the pathway that leads to a skin rash, was much less than that of NVP, both in vitro and in vivo.  An analog of NVP in which the Me hydrogens were replaced by deuterium also produced less covalent binding than NVP.  These data provide strong evidence that covalent binding of NVP in the liver is due to a quinone methide formed by oxidn. of the Me group.  Attempts were made to develop an animal model of NVP-induced liver injury in mice.  There was a small increase in ALT in some NVP-treated male C57BL/6 mice at 3 wk that resolved despite continued treatment.  Male Cbl-b-/- mice dosed with NVP had an increase in ALT of >200 U/L, which also resolved despite continued treatment.  Liver histol. in these animals showed focal areas of complete necrosis, while most of the liver appeared normal.  This is a different pattern from the histol. of NVP-induced liver injury in humans.  This is the first study to report hepatic covalent binding of NVP and also liver injury in mice.  It is likely that the quinone methide metabolite is responsible for NVP-induced liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYYNCsPNMXnbVg90H21EOLACvtfcHk0lgY_6XNhub87g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVaktr3O&md5=c2f53129a4cd77706c95c391661c96ca</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1021%2Ftx300172s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx300172s%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DA.%2BM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DNovalen%26aufirst%3DM.%26aulast%3DHayes%26aufirst%3DM.%2BA.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DBioactivation%2520of%2520Nevirapine%2520to%2520a%2520Reactive%2520Quinone%2520Methide%253A%2520Implications%2520for%2520Liver%2520Injury%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2012%26volume%3D25%26spage%3D1708%26epage%3D1719%26doi%3D10.1021%2Ftx300172s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venuto, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vladutiu, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brentjens, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andres, G. A.</span></span> <span> </span><span class="NLM_article-title">Effects of Prolonged Administration of D-Penicillamine or Captopril in Various Strains of Rats: Brown Norway Rats Treated with D-penicillamine Develop Autoantibodies, Circulating Immune Complexes, and Disseminated Intravascular Coagulation</span>. <i>Clin. Immunol. Immunopathol.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">142</span>– <span class="NLM_lpage">155</span>, <span class="refDoi"> DOI: 10.1016/0090-1229(84)90015-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2F0090-1229%2884%2990015-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=6365381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADyaL2cXps1KksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1984&pages=142-155&author=A.+J.+Donkerauthor=R.+C.+Venutoauthor=A.+O.+Vladutiuauthor=J.+R.+Brentjensauthor=G.+A.+Andres&title=Effects+of+Prolonged+Administration+of+D-Penicillamine+or+Captopril+in+Various+Strains+of+Rats%3A+Brown+Norway+Rats+Treated+with+D-penicillamine+Develop+Autoantibodies%2C+Circulating+Immune+Complexes%2C+and+Disseminated+Intravascular+Coagulation&doi=10.1016%2F0090-1229%2884%2990015-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of prolonged administration of D-penicillamine or captopril in various strains of rats.  Brown Norway rats treated with D-penicillamine develop autoantibodies, circulating immune complexes, and disseminated intravascular coagulation</span></div><div class="casAuthors">Donker, Ab J.; Venuto, Rocco C.; Vladutiu, Adrian O.; Brentjens, Jan R.; Andres, Giuseppe A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology and Immunopathology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">142-55</span>CODEN:
                <span class="NLM_cas:coden">CLIIAT</span>;
        ISSN:<span class="NLM_cas:issn">0090-1229</span>.
    </div><div class="casAbstract">D-Penicillamine  [52-67-5] and captopril  [62571-86-2], 2 drugs that induce autoimmune manifestations in man, were administered orally for 5 - 10 mo to various strains of rats.  Three to 8 wk after D-penicillamine administration in a dosage of 20-50 mg daily, 73% of Brown Norway (BN) rats became ill.  The disease was characterized by wt. loss, dermatitis, and a high mortality presumably caused by disseminated intravascular coagulation.  Microscopy revealed widespread granulomatous and necrotic lesions.  The plasma of these animals contained antinulcear antibodies and immune complexes.  In the kidney deposits of IgG were found in a linear pattern along the glomerular basement membrane.  IgG eluted from diseased kidneys bound both in vitro and in vivo to kidney basement membranes.  BN rats initially receiving 5 mg of D-penicillamine daily and subsequently 20 and 50 mg daily did not develop disease.  No adverse effects were noted in Lewis (LEW) and Sprague-Dawley (SD) rats treated with 20 or 50 mg of D-penicillamine daily, nor in BN and LEW rats treated with 20 mg of captopril daily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZbrY2u0xY7rVg90H21EOLACvtfcHk0lgAqXBT9nUV1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXps1KksA%253D%253D&md5=c11b77d857d51da9c9e931fdbf40c7d2</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2F0090-1229%2884%2990015-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0090-1229%252884%252990015-1%26sid%3Dliteratum%253Aachs%26aulast%3DDonker%26aufirst%3DA.%2BJ.%26aulast%3DVenuto%26aufirst%3DR.%2BC.%26aulast%3DVladutiu%26aufirst%3DA.%2BO.%26aulast%3DBrentjens%26aufirst%3DJ.%2BR.%26aulast%3DAndres%26aufirst%3DG.%2BA.%26atitle%3DEffects%2520of%2520Prolonged%2520Administration%2520of%2520D-Penicillamine%2520or%2520Captopril%2520in%2520Various%2520Strains%2520of%2520Rats%253A%2520Brown%2520Norway%2520Rats%2520Treated%2520with%2520D-penicillamine%2520Develop%2520Autoantibodies%252C%2520Circulating%2520Immune%2520Complexes%252C%2520and%2520Disseminated%2520Intravascular%2520Coagulation%26jtitle%3DClin.%2520Immunol.%2520Immunopathol.%26date%3D1984%26volume%3D30%26spage%3D142%26epage%3D155%26doi%3D10.1016%2F0090-1229%2884%2990015-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tournade, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vial, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druet, P.</span></span> <span> </span><span class="NLM_article-title">D-Penicillamine-Induced Autoimmunity in Brown-Norway Rats. Similarities with HgCl2-Induced Autoimmunity</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">2985</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=2139074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADyaK3cXit12nt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=1990&pages=2985&author=H.+Tournadeauthor=L.+Pelletierauthor=R.+Pasquierauthor=M.+C.+Vialauthor=C.+Mandetauthor=P.+Druet&title=D-Penicillamine-Induced+Autoimmunity+in+Brown-Norway+Rats.+Similarities+with+HgCl2-Induced+Autoimmunity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">D-Penicillamine-induced autoimmunity in Brown-Norway rats.  Similarities with mercury(II) chloride-induced autoimmunity</span></div><div class="casAuthors">Tournade, Herve; Pelletier, Lucette; Pasquier, Regine; Vial, Marie Cecile; Mandet, Chantal; Druet, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2985-91</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    </div><div class="casAbstract">p-Penicillamine (DP) has been previously shown to induce an autoimmune disease in Brown-Norway (BN) rats, characterized by a dermatitis, by the prodn. of antinuclear antibodies, by the formation of circulating immune complexes, and by linear IgG deposits along the glomerular basement membrane.  These manifestations are quite similar to those obsd. in mercuric chloride (HgCl2)-induced autoimmunity.  The mechanism of the latter disease has been recently partly elucidated.  The aim of this study was to compare DP and HgCl2-induced autoimmunity in BN rats and to compare the mechanisms involved in both situations.  A transient increase in the no. of spleen cells, affecting B cells and CD4+ T cells, and an increase in serum IgE concn., previously reported in HgCl2-induced autoimmunity, were obsd. during DP treatment.  Autoreactive anti-class II T cells able to proliferate not only in the presence of autologous B cells but also in the presence of syngeneic normal B cells were found in DP-treated BN rats.  Spontaneous regulation occurred, assocd. with the disappearance of autoreactive T cells.  Suppressor CD8+ T cells were not involved in this phenomenon.  Mechanisms involved in both the induction and the regulation of DP-induced autoimmunity seem to be quite similar to those reported in HgCl2-induced autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI81XQfeyASbVg90H21EOLACvtfcHk0lgAqXBT9nUV1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXit12nt78%253D&md5=385ab1d0d2ba61f6906b81151cc4d045</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTournade%26aufirst%3DH.%26aulast%3DPelletier%26aufirst%3DL.%26aulast%3DPasquier%26aufirst%3DR.%26aulast%3DVial%26aufirst%3DM.%2BC.%26aulast%3DMandet%26aufirst%3DC.%26aulast%3DDruet%26aufirst%3DP.%26atitle%3DD-Penicillamine-Induced%2520Autoimmunity%2520in%2520Brown-Norway%2520Rats.%2520Similarities%2520with%2520HgCl2-Induced%2520Autoimmunity%26jtitle%3DJ.%2520Immunol.%26date%3D1990%26volume%3D144%26spage%3D2985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saito, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kase, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitaichi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, H.</span></span> <span> </span><span class="NLM_article-title">Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Mouse Model Generated by Using PBMCs and the Skin of Patients</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">434</span>– <span class="NLM_lpage">441</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2012.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.jaci.2012.09.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23111236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2hsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2013&pages=434-441&author=N.+Saitoauthor=N.+Yoshiokaauthor=R.+Abeauthor=H.+Qiaoauthor=Y.+Fujitaauthor=D.+Hoshinaauthor=A.+Sutoauthor=S.+Kaseauthor=N.+Kitaichiauthor=M.+Ozakiauthor=H.+Shimizu&title=Stevens-Johnson+Syndrome%2FToxic+Epidermal+Necrolysis+Mouse+Model+Generated+by+Using+PBMCs+and+the+Skin+of+Patients&doi=10.1016%2Fj.jaci.2012.09.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients</span></div><div class="casAuthors">Saito, Nao; Yoshioka, Naoya; Abe, Riichiro; Qiao, Hongjiang; Fujita, Yasuyuki; Hoshina, Daichi; Suto, Asuka; Kase, Satoru; Kitaichi, Nobuyoshi; Ozaki, Michitaka; Shimizu, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">434-441.e9</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening cutaneous reactions caused by drugs or infections and exhibiting widespread epidermal necrosis.  Currently, there is no animal model that reproduces SJS/TEN symptoms.  We sought to develop a novel mouse model of SJS/TEN by using PBMCs and skin from patients who had recovered from SJS/TEN.  For our mouse model, patients' PBMCs were injected i.v. into immunocompromised NOD/Shi-scid, IL-2Rγnull (NOG) mice, followed by oral administration of a causative drug.  Subsequently, to replace human skin, unaffected skin specimens obtained from patients who had recovered from SJS/TEN were grafted onto NOG mice, after which patient-derived PBMCs and the causative drug were applied.  Mice injected with PBMCs from patients with SJS/TEN and given the causative drug showed marked conjunctival congestion and numerous cell death of conjunctival epithelium, whereas there were no symptoms in mice injected with PBMCs from patients with ordinary drug skin reactions.  CD8+ T lymphocyte-depleted PBMCs from patients with SJS/TEN did not elicit these symptoms.  In addn., skin-grafted mice showed darkening of the skin-grafted areas.  Cleaved caspase-3 staining showed that dead keratinocytes were more numerous in the skin-grafted mice than in the healthy control animals.We have established a novel human-oriented SJS/TEN mouse model and proved the importance of CD8+ T lymphocytes in SJS/TEN pathogenesis.  The mouse model promises to promote diagnostic and therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobR9oslIGMi7Vg90H21EOLACvtfcHk0lgAqXBT9nUV1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2hsbvE&md5=0bf206589ce1be23523e9b683a181cf7</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2012.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2012.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DSaito%26aufirst%3DN.%26aulast%3DYoshioka%26aufirst%3DN.%26aulast%3DAbe%26aufirst%3DR.%26aulast%3DQiao%26aufirst%3DH.%26aulast%3DFujita%26aufirst%3DY.%26aulast%3DHoshina%26aufirst%3DD.%26aulast%3DSuto%26aufirst%3DA.%26aulast%3DKase%26aufirst%3DS.%26aulast%3DKitaichi%26aufirst%3DN.%26aulast%3DOzaki%26aufirst%3DM.%26aulast%3DShimizu%26aufirst%3DH.%26atitle%3DStevens-Johnson%2520Syndrome%252FToxic%2520Epidermal%2520Necrolysis%2520Mouse%2520Model%2520Generated%2520by%2520Using%2520PBMCs%2520and%2520the%2520Skin%2520of%2520Patients%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2013%26volume%3D131%26spage%3D434%26epage%3D441%26doi%3D10.1016%2Fj.jaci.2012.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kakuni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tateno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span> <span> </span><span class="NLM_article-title">Chimeric Mice with a Humanized Liver as an Animal Model of Troglitazone-Induced Liver Injury</span>. <i>Toxicol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>214</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.toxlet.2012.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.toxlet.2012.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22902350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGqt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=2012&pages=9-18&author=M.+Kakuniauthor=M.+Moritaauthor=K.+Matsuoauthor=Y.+Katohauthor=M.+Nakajimaauthor=C.+Tatenoauthor=T.+Yokoi&title=Chimeric+Mice+with+a+Humanized+Liver+as+an+Animal+Model+of+Troglitazone-Induced+Liver+Injury&doi=10.1016%2Fj.toxlet.2012.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury</span></div><div class="casAuthors">Kakuni, Masakazu; Morita, Mayu; Matsuo, Kentaro; Katoh, Yumiko; Nakajima, Miki; Tateno, Chise; Yokoi, Tsuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-18</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Troglitazone (Tro) is a thiazolidinedione antidiabetic drug that was withdrawn from the market due to its assocn. with idiosyncratic severe liver injury.  Tro has never induced liver injury in exptl. animals in vivo.  It was assumed that the species differences between human and exptl. animals in the pharmaco- or toxicokinetics of Tro might be assocd. with these observations.  In this study, we investigated whether a chimeric mouse with a humanized liver that we previously established, whose replacement index with human hepatocytes is up to 92% can reproduce Tro-induced liver injury.  When the chimeric mice were orally administered Tro for 14 or 23 days (1000 mg/kg/day), serum alanine aminotransferase (ALT) was significantly increased by 2.1- and 3.6-fold, resp.  Co-administration of L-buthionine sulfoximine (10 mM in drinking water), an inhibitor of glutathione (GSH) synthesis, unexpectedly prevented the Tro-dependent increase of ALT, which suggests that the GSH scavenging pathway will not be involved in Tro-induced liver injury.  To elucidate the mechanism of the onset of liver injury, hepatic GSH content, the level of oxidative stress markers and phase I and phase II drug metabolizing enzymes were detd.  However, these factors were not assocd. with Tro-induced liver injury.  An immune-mediated reaction may be assocd. with Tro-induced liver toxicity in vivo, because the chimeric mouse is derived from an immunodeficient SCID mouse.  In conclusion, we successfully reproduced Tro-induced liver injury using chimeric mice with a humanized liver, which provides a new animal model for studying idiosyncratic drug-induced liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM-Wl_A79CkrVg90H21EOLACvtfcHk0liiksLw_0Dd8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGqt7fK&md5=fad97513650e303a766d15c2175cfaad</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2Fj.toxlet.2012.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.toxlet.2012.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DKakuni%26aufirst%3DM.%26aulast%3DMorita%26aufirst%3DM.%26aulast%3DMatsuo%26aufirst%3DK.%26aulast%3DKatoh%26aufirst%3DY.%26aulast%3DNakajima%26aufirst%3DM.%26aulast%3DTateno%26aufirst%3DC.%26aulast%3DYokoi%26aufirst%3DT.%26atitle%3DChimeric%2520Mice%2520with%2520a%2520Humanized%2520Liver%2520as%2520an%2520Animal%2520Model%2520of%2520Troglitazone-Induced%2520Liver%2520Injury%26jtitle%3DToxicol.%2520Lett.%26date%3D2012%26volume%3D214%26spage%3D9%26epage%3D18%26doi%3D10.1016%2Fj.toxlet.2012.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanoh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugahara, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizane, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tateno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotake, Y.</span></span> <span> </span><span class="NLM_article-title">Changes in Bile Acid Concentrations after Administration of Ketoconazole or Rifampicin to Chimeric Mice with Humanized Liver</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1366</span>– <span class="NLM_lpage">1375</span>, <span class="refDoi"> DOI: 10.1248/bpb.b19-00249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1248%2Fbpb.b19-00249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=31366871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjt1WntL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2019&pages=1366-1375&author=S.+Sanohauthor=Y.+Tamuraauthor=C.+Fujinoauthor=G.+Sugaharaauthor=Y.+Yoshizaneauthor=A.+Yanagiauthor=K.+Kisohauthor=Y.+Ishidaauthor=C.+Tatenoauthor=S.+Ohtaauthor=Y.+Kotake&title=Changes+in+Bile+Acid+Concentrations+after+Administration+of+Ketoconazole+or+Rifampicin+to+Chimeric+Mice+with+Humanized+Liver&doi=10.1248%2Fbpb.b19-00249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Changes in bile acid concentrations after administration of ketoconazole or rifampicin to chimeric mice with humanized liver</span></div><div class="casAuthors">Sanoh, Seigo; Tamura, Yuka; Fujino, Chieri; Sugahara, Go; Yoshizane, Yasumi; Yanagi, Ami; Kisoh, Keishi; Ishida, Yuji; Tateno, Chise; Ohta, Shigeru; Kotake, Yaichiro</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1366-1375</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a common side effect of several medications and is considered a major factor responsible for the discontinuation of drugs during their development.  Cholestasis is a DILI that results from impairment of bile acid transporters, such as the bile salt export pump (BSEP), leading to accumulation of bile acids.  Both in vitro and in vivo studies are required to predict the risk of drug-induced cholestasis.  In the present study, we used chimeric mice with humanized liver as a model to study drug-induced cholestasis.  Administration of a single dose of ketoconazole or rifampicin, known to potentially cause cholestasis by inhibiting BSEP, did not result in elevated levels of alk. phosphatase (ALP), which are known hepatic biomarkers.  The concn. of taurodeoxycholic acid increased in the liver after ketoconazole administration, whereas rifampicin resulted in increased tauromuricholic acid and taurocholic acid (TCA) levels in the liver and plasma.  Furthermore, rifampicin resulted in an increase in the uniform distribution of a compd. with m/z 514.3, presumed as TCA through imaging mass spectrometry.  The mRNA levels of bile acid-related genes were also altered after treatment with ketoconazole or rifampicin.  We believe these observations to be a part of a feedback mechanism to decrease bile acid concns.  The changes in bile acid concns. results may reflect the initial responses of the human body to cholestasis.  Furthermore, these findings may contribute to the screening of drug candidates, thereby avoiding drug-induced cholestasis during clin. trials and drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhoXuor93-97Vg90H21EOLACvtfcHk0liiksLw_0Dd8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjt1WntL8%253D&md5=1c86982ef829ee21850198d0977e00a3</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1248%2Fbpb.b19-00249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.b19-00249%26sid%3Dliteratum%253Aachs%26aulast%3DSanoh%26aufirst%3DS.%26aulast%3DTamura%26aufirst%3DY.%26aulast%3DFujino%26aufirst%3DC.%26aulast%3DSugahara%26aufirst%3DG.%26aulast%3DYoshizane%26aufirst%3DY.%26aulast%3DYanagi%26aufirst%3DA.%26aulast%3DKisoh%26aufirst%3DK.%26aulast%3DIshida%26aufirst%3DY.%26aulast%3DTateno%26aufirst%3DC.%26aulast%3DOhta%26aufirst%3DS.%26aulast%3DKotake%26aufirst%3DY.%26atitle%3DChanges%2520in%2520Bile%2520Acid%2520Concentrations%2520after%2520Administration%2520of%2520Ketoconazole%2520or%2520Rifampicin%2520to%2520Chimeric%2520Mice%2520with%2520Humanized%2520Liver%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2019%26volume%3D42%26spage%3D1366%26epage%3D1375%26doi%3D10.1248%2Fbpb.b19-00249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michie, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillgren, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span> <span> </span><span class="NLM_article-title">Chimeric TK-NOG Mice: A Predictive Model for Cholestatic Human Liver Toxicity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.220798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fjpet.114.220798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25424997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=274-80&author=D.+Xuauthor=M.+Wuauthor=S.+Nishimuraauthor=T.+Nishimuraauthor=S.+A.+Michieauthor=M.+Zhengauthor=Z.+Yangauthor=A.+J.+Yatesauthor=J.+S.+Dayauthor=K.+M.+Hillgrenauthor=S.+T.+Takedaauthor=Y.+Guanauthor=Y.+Guoauthor=G.+Peltz&title=Chimeric+TK-NOG+Mice%3A+A+Predictive+Model+for+Cholestatic+Human+Liver+Toxicity&doi=10.1124%2Fjpet.114.220798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric TK-NOG mice: a predictive model for cholestatic human liver toxicity</span></div><div class="casAuthors">Xu, Dan; Wu, Manhong; Nishimura, Sachiko; Nishimura, Toshihiko; Michie, Sara A.; Zheng, Ming; Yang, Zicheng; Yates, Alexander John; Day, Jeffrey S.; Hillgren, Kathleen M.; Takeda, Saori Takedai; Guan, Yuan; Guo, Yingying; Peltz, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">274-280/1-274-280/7, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Due to the substantial interspecies differences in drug metab. and disposition, drug-induced liver injury (DILI) in humans is often not predicted by studies performed in animal species.  For example, a drug (bosentan) used to treat pulmonary artery hypertension caused unexpected cholestatic liver toxicity in humans, which was not predicted by preclin. toxicol. studies in multiple animal species.  In this study, we demonstrate that NOG mice expressing a thymidine kinase transgene (TK-NOG) with humanized livers have a humanized profile of biliary excretion of a test (cefmetazole) drug, which was shown by an in situ perfusion study to result from interspecies differences in the rate of biliary transport and in liver retention of this drug.  We also found that readily detectable cholestatic liver injury develops in TK-NOG mice with humanized livers after 1 wk of treatment with bosentan (160, 32, or 6 mg/kg per day by mouth), whereas liver toxicity did not develop in control mice after 1 mo of treatment.  The lab. and histol. features of bosentan-induced liver toxicity in humanized mice mirrored that of human subjects.  Because DILI has become a significant public health problem, drug safety could be improved if preclin. toxicol. studies were performed using humanized TK-NOG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5khL8nmAAJrVg90H21EOLACvtfcHk0liiksLw_0Dd8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOgsrk%253D&md5=cc802f944e90d89cfea6b888f04d093a</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220798%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DNishimura%26aufirst%3DS.%26aulast%3DNishimura%26aufirst%3DT.%26aulast%3DMichie%26aufirst%3DS.%2BA.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYates%26aufirst%3DA.%2BJ.%26aulast%3DDay%26aufirst%3DJ.%2BS.%26aulast%3DHillgren%26aufirst%3DK.%2BM.%26aulast%3DTakeda%26aufirst%3DS.%2BT.%26aulast%3DGuan%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DPeltz%26aufirst%3DG.%26atitle%3DChimeric%2520TK-NOG%2520Mice%253A%2520A%2520Predictive%2520Model%2520for%2520Cholestatic%2520Human%2520Liver%2520Toxicity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D274%26epage%3D80%26doi%3D10.1124%2Fjpet.114.220798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bility, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, L.</span></span> <span> </span><span class="NLM_article-title">Modeling Hepatitis B Virus Infection, Immunopathology and Therapy in Mice</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2015.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.antiviral.2015.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26099683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVyiur3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=1-8&author=L.+Chengauthor=F.+Liauthor=M.+T.+Bilityauthor=C.+M.+Murphyauthor=L.+Su&title=Modeling+Hepatitis+B+Virus+Infection%2C+Immunopathology+and+Therapy+in+Mice&doi=10.1016%2Fj.antiviral.2015.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling hepatitis B virus infection, immunopathology and therapy in mice</span></div><div class="casAuthors">Cheng, Liang; Li, Feng; Bility, Moses T.; Murphy, Christopher M.; Su, Lishan</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Despite the availability of a preventive vaccine, chronic hepatitis B virus (HBV) infection-induced liver diseases continue to be a major global public health problem.  HBV naturally infects only humans and chimpanzees.  This narrow host range has hindered our ability to study the characteristics of the virus and how it interacts with its host.  It is thus important to establish small animal models to study HBV infection, persistence, clearance and the immunopathogenesis of chronic hepatitis B.  In this review, we briefly summarize currently available animal models for HBV research, then focus on mouse models, esp. the recently developed humanized mice that can support HBV infection and immunopathogenesis in vivo.  This article is part of a symposium in Antiviral Research on "From the discovery of the Australia antigen to the development of new curative therapies for hepatitis B: an unfinished story.".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCH0J63BWnB7Vg90H21EOLACvtfcHk0liUGLlYTavpjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVyiur3M&md5=f368a373c70c50c27f1bba05561e18ba</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2015.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2015.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DBility%26aufirst%3DM.%2BT.%26aulast%3DMurphy%26aufirst%3DC.%2BM.%26aulast%3DSu%26aufirst%3DL.%26atitle%3DModeling%2520Hepatitis%2520B%2520Virus%2520Infection%252C%2520Immunopathology%2520and%2520Therapy%2520in%2520Mice%26jtitle%3DAntiviral%2520Res.%26date%3D2015%26volume%3D121%26spage%3D1%26epage%3D8%26doi%3D10.1016%2Fj.antiviral.2015.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrill, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeSmet, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaddy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paine, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tidwell, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">A Mouse Diversity Panel Approach Reveals the Potential for Clinical Kidney Injury Due to DB289 Not Predicted by Classical Rodent Models</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">426</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfs238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfs238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22940726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs12ltbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2012&pages=416-426&author=A.+H.+Harrillauthor=K.+D.+DeSmetauthor=K.+K.+Wolfauthor=A.+S.+Bridgesauthor=J.+S.+Eaddyauthor=C.+L.+Kurtzauthor=J.+E.+Hallauthor=M.+F.+Paineauthor=R.+R.+Tidwellauthor=P.+B.+Watkins&title=A+Mouse+Diversity+Panel+Approach+Reveals+the+Potential+for+Clinical+Kidney+Injury+Due+to+DB289+Not+Predicted+by+Classical+Rodent+Models&doi=10.1093%2Ftoxsci%2Fkfs238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">A Mouse Diversity Panel Approach Reveals the Potential for Clinical Kidney Injury Due to DB289 Not Predicted by Classical Rodent Models</span></div><div class="casAuthors">Harrill, Alison H.; DeSmet, Kristina D.; Wolf, Kristina K.; Bridges, Arlene S.; Eaddy, J. Scott; Kurtz, C. Lisa; Hall, J. Ed.; Paine, Mary F.; Tidwell, Richard R.; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">416-426</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">DB289 is the first oral drug shown in clin. trials to have efficacy in treating African trypanosomiasis (African sleeping sickness).  Mild liver toxicity was noted but was not treatment limiting.  However, development of DB289 was terminated when several treated subjects developed severe kidney injury, a liability not predicted from preclin. testing.  We tested the hypothesis that the kidney safety liability of DB289 would be detected in a mouse diversity panel (MDP) comprised of 34 genetically diverse inbred mouse strains.  MDP mice received 10 days of oral treatment with DB289 or vehicle and classical renal biomarkers blood urea nitrogen (BUN) and serum creatinine (sCr), as well as urine biomarkers of kidney injury were measured.  While BUN and sCr remained within ref. ranges, marked elevations were obsd. for kidney injury mol.-1 (KIM-1) in the urine of sensitive mouse strains.  KIM-1 elevations were not always coincident with elevations in alanine aminotransferase (ALT), suggesting that renal injury was not linked to hepatic injury.  Genome-wide assocn. analyses of KIM-1 elevations indicated that genes participating in cholesterol and lipid biosynthesis and transport, oxidative stress, and cytokine release may play a role in DB289 renal injury.  Taken together, the data resulting from this study highlight the utility of using an MDP to predict clin. relevant toxicities, to identify relevant toxicity biomarkers that may translate into the clinic, and to identify potential mechanisms underlying toxicities.  In addn., the sensitive mouse strains identified in this study may be useful in screening next-in-class compds. for renal injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRrTVMJbDVJbVg90H21EOLACvtfcHk0liUGLlYTavpjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs12ltbzO&md5=1420cc12c19db122bf10edf12253c731</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfs238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfs238%26sid%3Dliteratum%253Aachs%26aulast%3DHarrill%26aufirst%3DA.%2BH.%26aulast%3DDeSmet%26aufirst%3DK.%2BD.%26aulast%3DWolf%26aufirst%3DK.%2BK.%26aulast%3DBridges%26aufirst%3DA.%2BS.%26aulast%3DEaddy%26aufirst%3DJ.%2BS.%26aulast%3DKurtz%26aufirst%3DC.%2BL.%26aulast%3DHall%26aufirst%3DJ.%2BE.%26aulast%3DPaine%26aufirst%3DM.%2BF.%26aulast%3DTidwell%26aufirst%3DR.%2BR.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DA%2520Mouse%2520Diversity%2520Panel%2520Approach%2520Reveals%2520the%2520Potential%2520for%2520Clinical%2520Kidney%2520Injury%2520Due%2520to%2520DB289%2520Not%2520Predicted%2520by%2520Classical%2520Rodent%2520Models%26jtitle%3DToxicol.%2520Sci.%26date%3D2012%26volume%3D130%26spage%3D416%26epage%3D426%26doi%3D10.1093%2Ftoxsci%2Fkfs238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrill, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbourt, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stylianou, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boorman, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sackler, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tennant, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paigen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contractor, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiltshire, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusyn, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Threadgill, D. W.</span></span> <span> </span><span class="NLM_article-title">Mouse Population-Guided Resequencing Reveals that Variants in CD44 Contribute to Acetaminophen-Induced Liver Injury in Humans</span>. <i>Genome Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1507</span>– <span class="NLM_lpage">1515</span>, <span class="refDoi"> DOI: 10.1101/gr.090241.108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1101%2Fgr.090241.108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=19416960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCjsLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1507-1515&author=A.+H.+Harrillauthor=P.+B.+Watkinsauthor=S.+Suauthor=P.+K.+Rossauthor=D.+E.+Harbourtauthor=I.+M.+Stylianouauthor=G.+A.+Boormanauthor=M.+W.+Russoauthor=R.+S.+Sacklerauthor=S.+C.+Harrisauthor=P.+C.+Smithauthor=R.+Tennantauthor=M.+Bogueauthor=K.+Paigenauthor=C.+Harrisauthor=T.+Contractorauthor=T.+Wiltshireauthor=I.+Rusynauthor=D.+W.+Threadgill&title=Mouse+Population-Guided+Resequencing+Reveals+that+Variants+in+CD44+Contribute+to+Acetaminophen-Induced+Liver+Injury+in+Humans&doi=10.1101%2Fgr.090241.108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans</span></div><div class="casAuthors">Harrill, Alison H.; Watkins, Paul B.; Su, Stephen; Ross, Pamela K.; Harbourt, David E.; Stylianou, Ioannis M.; Boorman, Gary A.; Russo, Mark W.; Sackler, Richard S.; Harris, Stephen C.; Smith, Philip C.; Tennant, Raymond; Bogue, Molly; Paigen, Kenneth; Harris, Christopher; Contractor, Tanupriya; Wiltshire, Timothy; Rusyn, Ivan; Threadgill, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Genome Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1507-1515</span>CODEN:
                <span class="NLM_cas:coden">GEREFS</span>;
        ISSN:<span class="NLM_cas:issn">1088-9051</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Interindividual variability in response to chems. and drugs is a common regulatory concern.  It is assumed that xenobiotic-induced adverse reactions have a strong genetic basis, but many mechanism-based investigations have not been successful in identifying susceptible individuals.  While recent advances in pharmacogenetics of adverse drug reactions show promise, the small size of the populations susceptible to important adverse events limits the utility of whole-genome assocn. studies conducted entirely in humans.  We present a strategy to identify genetic polymorphisms that may underlie susceptibility to adverse drug reactions.  First, in a cohort of healthy adults who received the max. recommended dose of acetaminophen (4 g/d × 7 d), we confirm that about one third of subjects develop elevations in serum alanine aminotransferase, indicative of liver injury.  To identify the genetic basis for this susceptibility, a panel of 36 inbred mouse strains was used to model genetic diversity.  Mice were treated with 300 mg/kg or a range of addnl. acetaminophen doses, and the extent of liver injury was quantified.  We then employed whole-genome assocn. anal. and targeted sequencing to det. that polymorphisms in Ly86, Cd44, Cd59a, and Capn8 correlate strongly with liver injury and demonstrated that dose-curves vary with background.  Finally, we demonstrated that variation in the orthologous human gene, CD44, is assocd. with susceptibility to acetaminophen in two independent cohorts.  Our results indicate a role for CD44 in modulation of susceptibility to acetaminophen hepatotoxicity.  These studies demonstrate that a diverse mouse population can be used to understand and predict adverse toxicity in heterogeneous human populations through guided resequencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdp8pLW2ETNbVg90H21EOLACvtfcHk0liUGLlYTavpjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCjsLrN&md5=6d5bc91005f3c7ebb0da039bdfdf3c04</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1101%2Fgr.090241.108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgr.090241.108%26sid%3Dliteratum%253Aachs%26aulast%3DHarrill%26aufirst%3DA.%2BH.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DSu%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DP.%2BK.%26aulast%3DHarbourt%26aufirst%3DD.%2BE.%26aulast%3DStylianou%26aufirst%3DI.%2BM.%26aulast%3DBoorman%26aufirst%3DG.%2BA.%26aulast%3DRusso%26aufirst%3DM.%2BW.%26aulast%3DSackler%26aufirst%3DR.%2BS.%26aulast%3DHarris%26aufirst%3DS.%2BC.%26aulast%3DSmith%26aufirst%3DP.%2BC.%26aulast%3DTennant%26aufirst%3DR.%26aulast%3DBogue%26aufirst%3DM.%26aulast%3DPaigen%26aufirst%3DK.%26aulast%3DHarris%26aufirst%3DC.%26aulast%3DContractor%26aufirst%3DT.%26aulast%3DWiltshire%26aufirst%3DT.%26aulast%3DRusyn%26aufirst%3DI.%26aulast%3DThreadgill%26aufirst%3DD.%2BW.%26atitle%3DMouse%2520Population-Guided%2520Resequencing%2520Reveals%2520that%2520Variants%2520in%2520CD44%2520Contribute%2520to%2520Acetaminophen-Induced%2520Liver%2520Injury%2520in%2520Humans%26jtitle%3DGenome%2520Res.%26date%3D2009%26volume%3D19%26spage%3D1507%26epage%3D1515%26doi%3D10.1101%2Fgr.090241.108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adkins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrill, A. H.</span></span> <span> </span><span class="NLM_article-title">Dysregulation of Protein Degradation Pathways May Mediate the Liver Injury and Phospholipidosis Associated with a Cationic Amphiphilic Antibiotic Drug</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2014.06.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.taap.2014.06.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24967691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ylurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2014&pages=21-29&author=M.+Mosedaleauthor=H.+Wuauthor=C.+L.+Kurtzauthor=S.+P.+Schmidtauthor=K.+Adkinsauthor=A.+H.+Harrill&title=Dysregulation+of+Protein+Degradation+Pathways+May+Mediate+the+Liver+Injury+and+Phospholipidosis+Associated+with+a+Cationic+Amphiphilic+Antibiotic+Drug&doi=10.1016%2Fj.taap.2014.06.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Dysregulation of protein degradation pathways may mediate the liver injury and phospholipidosis associated with a cationic amphiphilic antibiotic drug</span></div><div class="casAuthors">Mosedale, Merrie; Wu, Hong; Kurtz, C. Lisa; Schmidt, Stephen P.; Adkins, Karissa; Harrill, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-29</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A large no. of antibiotics are known to cause drug-induced liver injury in the clinic; however, interpreting clin. risk is not straightforward owing to a lack of predictivity of the toxicity by std. preclin. species and a poor understanding of the mechanisms of toxicity.  An example is PF-04287881, a novel ketolide antibiotic that caused elevations in liver function tests in Phase I clin. studies.  In this study, a mouse diversity panel (MDP), comprised of 34 genetically diverse, inbred mouse strains, was utilized to model the toxicity obsd. with PF-04287881 treatment and investigate potential mechanisms that may mediate the liver response.  Significant elevations in serum alanine aminotransferase (ALT) levels in PF-04287881-treated animals relative to vehicle-treated controls were obsd. in the majority (88%) of strains tested following a seven day exposure.  The av. fold elevation in ALT varied by genetic background and correlated with microscopic findings of hepatocellular hypertrophy, hepatocellular single cell necrosis, and Kupffer cell vacuolation (confirmed as phospholipidosis) in the liver.  Global liver mRNA expression was evaluated in a subset of four strains to identify transcript and pathway differences that distinguish susceptible mice from resistant mice in the context of PF-04287881 treatment.  The protein ubiquitination pathway was highly enriched among genes assocd. with PF-04287881-induced hepatocellular necrosis.  Expression changes assocd. with PF-04287881-induced phospholipidosis included genes involved in drug transport, phospholipid metab., and lysosomal function.  The findings suggest that perturbations in genes involved in protein degrdn. leading to accumulation of oxidized proteins may mediate the liver injury induced by this drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNLHHUlGcgfrVg90H21EOLACvtfcHk0lgGlRQT89yGXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ylurbM&md5=1444245692c443411401dd03c8d4b282</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2014.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2014.06.013%26sid%3Dliteratum%253Aachs%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DKurtz%26aufirst%3DC.%2BL.%26aulast%3DSchmidt%26aufirst%3DS.%2BP.%26aulast%3DAdkins%26aufirst%3DK.%26aulast%3DHarrill%26aufirst%3DA.%2BH.%26atitle%3DDysregulation%2520of%2520Protein%2520Degradation%2520Pathways%2520May%2520Mediate%2520the%2520Liver%2520Injury%2520and%2520Phospholipidosis%2520Associated%2520with%2520a%2520Cationic%2520Amphiphilic%2520Antibiotic%2520Drug%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2014%26volume%3D280%26spage%3D21%26epage%3D29%26doi%3D10.1016%2Fj.taap.2014.06.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Court, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazarika, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasiadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenblatt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span> <span> </span><span class="NLM_article-title">Candidate Gene Polymorphisms in Patients with Acetaminophen-Induced Acute Liver Failure</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1124/dmd.113.053546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fdmd.113.053546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24104197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=28-32&author=M.+H.+Courtauthor=I.+Peterauthor=S.+Hazarikaauthor=M.+Vasiadiauthor=D.+J.+Greenblattauthor=W.+Lee&title=Candidate+Gene+Polymorphisms+in+Patients+with+Acetaminophen-Induced+Acute+Liver+Failure&doi=10.1124%2Fdmd.113.053546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Candidate gene polymorphisms in patients with acetaminophen-induced acute liver failure</span></div><div class="casAuthors">Court, Michael H.; Peter, Inga; Hazarika, Suwagami; Vasiadi, Magdalini; Greenblatt, David J.; Lee, William M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-32</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Acetaminophen is a leading cause of acute liver failure (ALF).  Genetic differences might predispose some individuals to develop ALF.  In this exploratory study, we evaluated genotype frequency differences among patients enrolled by the ALF Study Group who had developed ALF either intentionally from a single-time-point overdose of acetaminophen (n = 78), unintentionally after chronic high doses of acetaminophen (n = 79), or from causes other than acetaminophen (n = 103).  The polymorphisms evaluated included those in genes encoding putative acetaminophen-metabolizing enzymes (UGT1A1, UGT1A6, UGT1A9, UGT2B15, SULT1A1, CYP2E1, and CYP3A5) as well as CD44 and BHMT1.  Individuals carrying the CYP3A5 rs776746 A allele were overrepresented among ALF patients who had intentionally overdosed with acetaminophen, with an odds ratio of 2.3 (95% confidence interval, 1.1-4.9; P = 0.034) compared with all other ALF patients.  This finding is consistent with the enhanced bioactivation of acetaminophen by the CYP3A5 enzyme.  Persons homozygous for the CD44 rs1467558 A allele were also overrepresented among patients who had unintentionally developed ALF from chronic acetaminophen use, with an odds ratio of 4.0 (1.0-17.2, P = 0.045) compared with all other ALF subjects.  This finding confirms a prior study that found elevated serum liver enzyme levels in healthy volunteers with the CD44 rs1467558 AA genotype who had consumed high doses of acetaminophen for up to 2 wk.  However, both genetic assocns. were considered relatively weak, and they were not statistically significant after adjustment for multiple comparisons testing.  Nevertheless, both CYP3A5 rs776746 and CD44 rs1467558 warrant further investigation as potential genomic markers of enhanced risk of acetaminophen-induced ALF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy9fglTdO0F7Vg90H21EOLACvtfcHk0lgGlRQT89yGXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOntA%253D%253D&md5=3d53dcc38b8fed63ee45608f2c03637d</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1124%2Fdmd.113.053546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.113.053546%26sid%3Dliteratum%253Aachs%26aulast%3DCourt%26aufirst%3DM.%2BH.%26aulast%3DPeter%26aufirst%3DI.%26aulast%3DHazarika%26aufirst%3DS.%26aulast%3DVasiadi%26aufirst%3DM.%26aulast%3DGreenblatt%26aufirst%3DD.%2BJ.%26aulast%3DLee%26aufirst%3DW.%26atitle%3DCandidate%2520Gene%2520Polymorphisms%2520in%2520Patients%2520with%2520Acetaminophen-Induced%2520Acute%2520Liver%2520Failure%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2014%26volume%3D42%26spage%3D28%26epage%3D32%26doi%3D10.1124%2Fdmd.113.053546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group">Collaborative Cross Consortium</span> <span> </span><span class="NLM_article-title">The Genome Architecture of the Collaborative Cross
Mouse Genetic Reference Population</span>. <i>Genetics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1534/genetics.111.132639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1534%2Fgenetics.111.132639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22345608" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2012&pages=389-401&author=Collaborative+Cross+Consortium&title=The+Genome+Architecture+of+the+Collaborative+Cross%0AMouse+Genetic+Reference+Population&doi=10.1534%2Fgenetics.111.132639"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1534%2Fgenetics.111.132639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1534%252Fgenetics.111.132639%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DThe%2520Genome%2520Architecture%2520of%2520the%2520Collaborative%2520Cross%250AMouse%2520Genetic%2520Reference%2520Population%26jtitle%3DGenetics%26date%3D2012%26volume%3D190%26spage%3D389%26epage%3D401%26doi%3D10.1534%2Fgenetics.111.132639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelada, S. N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aylor, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chines, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutledge, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesler, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchill, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo-Manuel de Villena, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, F. S.</span></span> <span> </span><span class="NLM_article-title">Integrative Genetic Analysis of Allergic Inflammation in the Murine Lung</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">436</span>– <span class="NLM_lpage">445</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2013-0501OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1165%2Frcmb.2013-0501OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24693920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yqt7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2014&pages=436-445&author=S.+N.+P.+Keladaauthor=D.+E.+Carpenterauthor=D.+L.+Aylorauthor=P.+Chinesauthor=H.+Rutledgeauthor=E.+J.+Cheslerauthor=G.+A.+Churchillauthor=F.+Pardo-Manuel+de+Villenaauthor=D.+A.+Schwartzauthor=F.+S.+Collins&title=Integrative+Genetic+Analysis+of+Allergic+Inflammation+in+the+Murine+Lung&doi=10.1165%2Frcmb.2013-0501OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Integrative genetic analysis of allergic inflammation in the murine lung</span></div><div class="casAuthors">Kelada, Samir N. P.; Carpenter, Danielle E.; Aylor, David L.; Chines, Peter; Rutledge, Holly; Chesler, Elissa J.; Churchill, Gary A.; de Villena, Fernando Pardo-Manuel; Schwartz, David A.; Collins, Francis S.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">436-445</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Airway allergen exposure induces inflammation among individuals with atopy that is characterized by altered airway gene expression, elevated levels of T helper type 2 cytokines, mucus hypersecretion, and airflow obstruction.  To identify the genetic determinants of the airway allergen response, we employed a systems genetics approach.  We applied a house dust mite mouse model of allergic airway disease to 151 incipient lines of the Collaborative Cross, a new mouse genetic ref. population, and measured serum IgE, airway eosinophilia, and gene expression in the lung.  Allergen-induced serum IgE and airway eosinophilia were not correlated.  We detected quant. trait loci (QTL) for airway eosinophilia on chromosome (Chr) 11 (71.802-87.098 megabases [Mb]) and allergen-induced IgE on Chr 4 (13.950-31.660 Mb).  More than 4,500 genes expressed in the lung had gene expression QTL (eQTL), the majority of which were located near the gene itself.  However, we also detected approx. 1,700 trans-eQTL, and many of these trans-eQTL clustered into two regions on Chr 2.  We show that one of these loci (at 147.6 Mb) is assocd. with the expression of more than 100 genes, and, using bioinformatics resources, fine-map this locus to a 53 kb-long interval.  We also use the gene expression and eQTL data to identify a candidate gene, Tlcd2, for the eosinophil QTL.  Our results demonstrate that hallmark allergic airway disease phenotypes are assocd. with distinct genetic loci on Chrs 4 and 11, and that gene expression in the allergically inflamed lung is controlled by both cis and trans regulatory factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0rzmqd-rT17Vg90H21EOLACvtfcHk0lgGlRQT89yGXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yqt7rM&md5=c8e917b86757045ca2080d5bb0a3bd29</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2013-0501OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2013-0501OC%26sid%3Dliteratum%253Aachs%26aulast%3DKelada%26aufirst%3DS.%2BN.%2BP.%26aulast%3DCarpenter%26aufirst%3DD.%2BE.%26aulast%3DAylor%26aufirst%3DD.%2BL.%26aulast%3DChines%26aufirst%3DP.%26aulast%3DRutledge%26aufirst%3DH.%26aulast%3DChesler%26aufirst%3DE.%2BJ.%26aulast%3DChurchill%26aufirst%3DG.%2BA.%26aulast%3DPardo-Manuel%2Bde%2BVillena%26aufirst%3DF.%26aulast%3DSchwartz%26aufirst%3DD.%2BA.%26aulast%3DCollins%26aufirst%3DF.%2BS.%26atitle%3DIntegrative%2520Genetic%2520Analysis%2520of%2520Allergic%2520Inflammation%2520in%2520the%2520Murine%2520Lung%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2014%26volume%3D51%26spage%3D436%26epage%3D445%26doi%3D10.1165%2Frcmb.2013-0501OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rutledge, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aylor, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chines, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrowski, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesler, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchill, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Villena, F. P.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelada, S. N. P.</span></span> <span> </span><span class="NLM_article-title">Genetic Regulation of Zfp30, CXCL1, and Neutrophilic Inflammation in Murine Lung</span>. <i>Genetics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>198</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">745</span>, <span class="refDoi"> DOI: 10.1534/genetics.114.168138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1534%2Fgenetics.114.168138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25114278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFGhurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2014&pages=735-745&author=H.+Rutledgeauthor=D.+L.+Aylorauthor=D.+E.+Carpenterauthor=B.+C.+Peckauthor=P.+Chinesauthor=L.+E.+Ostrowskiauthor=E.+J.+Cheslerauthor=G.+A.+Churchillauthor=F.+P.-M.+de+Villenaauthor=S.+N.+P.+Kelada&title=Genetic+Regulation+of+Zfp30%2C+CXCL1%2C+and+Neutrophilic+Inflammation+in+Murine+Lung&doi=10.1534%2Fgenetics.114.168138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic regulation of Zfp30, CXCL1, and neutrophilic inflammation in murine lung</span></div><div class="casAuthors">Rutledge, Holly; Aylor, David L.; Carpenter, Danielle E.; Peck, Bailey C.; Chines, Peter; Ostrowski, Lawrence E.; Chesler, Elissa J.; Churchill, Gary A.; de Villena, Fernando Pardo-Manuel; Kelada, Samir N. P.</div><div class="citationInfo"><span class="NLM_cas:title">Genetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">735-745</span>CODEN:
                <span class="NLM_cas:coden">GENTAE</span>;
        ISSN:<span class="NLM_cas:issn">0016-6731</span>.
    
            (<span class="NLM_cas:orgname">Genetics Society of America</span>)
        </div><div class="casAbstract">Allergic asthma is a complex disease characterized in part by granulocytic inflammation of the airways.  In addn. to eosinophils, neutrophils (PMN) are also present, particularly in cases of severe asthma.  We sought to identify the genetic determinants of neutrophilic inflammation in a mouse model of house dust mite (HDM)-induced asthma.  We applied an HDM model of allergic asthma to the eight founder strains of the Collaborative Cross (CC) and 151 incipient lines of the CC (preCC).  Lung lavage fluid was analyzed for PMN count and the concn. of CXCL1, a hallmark PMN chemokine.  PMN and CXCL1 were strongly correlated in preCC mice.  We used quant. trait locus (QTL) mapping to identify three variants affecting PMN, one of which colocalized with a QTL for CXCL1 on chromosome (Chr) 7.  We used lung eQTL data to implicate a variant in the gene Zfp30 in the CXCL1/PMN response.  This genetic variant regulates both CXCL1 and PMN by altering Zfp30 expression, and we model the relationships between the QTL and these three endophenotypes.  We show that Zfp30 is expressed in airway epithelia in the normal mouse lung and that altering Zfp30 expression in vitro affects CXCL1 responses to an immune stimulus.  Our results provide strong evidence that Zfp30 is a novel regulator of neutrophilic airway inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr1IcZKYAhBrVg90H21EOLACvtfcHk0lh82RIzNMjeyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFGhurzO&md5=39652996ab332d4eb74a91e9b52ef16c</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1534%2Fgenetics.114.168138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1534%252Fgenetics.114.168138%26sid%3Dliteratum%253Aachs%26aulast%3DRutledge%26aufirst%3DH.%26aulast%3DAylor%26aufirst%3DD.%2BL.%26aulast%3DCarpenter%26aufirst%3DD.%2BE.%26aulast%3DPeck%26aufirst%3DB.%2BC.%26aulast%3DChines%26aufirst%3DP.%26aulast%3DOstrowski%26aufirst%3DL.%2BE.%26aulast%3DChesler%26aufirst%3DE.%2BJ.%26aulast%3DChurchill%26aufirst%3DG.%2BA.%26aulast%3Dde%2BVillena%26aufirst%3DF.%2BP.-M.%26aulast%3DKelada%26aufirst%3DS.%2BN.%2BP.%26atitle%3DGenetic%2520Regulation%2520of%2520Zfp30%252C%2520CXCL1%252C%2520and%2520Neutrophilic%2520Inflammation%2520in%2520Murine%2520Lung%26jtitle%3DGenetics%26date%3D2014%26volume%3D198%26spage%3D735%26epage%3D745%26doi%3D10.1534%2Fgenetics.114.168138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brock, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiltshire, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaddy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keele, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corty, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdar, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfw269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfw269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28115652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2017&pages=438-54&author=M.+Mosedaleauthor=Y.+Kimauthor=W.+J.+Brockauthor=S.+E.+Rothauthor=T.+Wiltshireauthor=J.+S.+Eaddyauthor=G.+R.+Keeleauthor=R.+W.+Cortyauthor=Y.+Xieauthor=W.+Valdarauthor=P.+B.+Watkins&title=Candidate+Risk+Factors+and+Mechanisms+for+Tolvaptan-Induced+Liver+Injury+Are+Identified+Using+a+Collaborative+Cross+Approach&doi=10.1093%2Ftoxsci%2Fkfw269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Candidate risk factors and mechanisms for tolvaptan-induced liver injury are identified using a collaborative cross approach</span></div><div class="casAuthors">Mosedale, Merrie; Kim, Yunjung; Brock, William J.; Roth, Sharin E.; Wiltshire, Tim; Eaddy, J. Scott; Keele, Gregory R.; Corty, Robert W.; Xie, Yuying; Valdar, William; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">438-454</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Clin. trials of tolvaptan showed it to be a promising candidate for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) but also revealed potential for idiosyncratic drug-induced liver injury (DILI) in this patient population.  To identify risk factors and mechanisms underlying tolvaptan DILI, 8 mice in each of 45 strains of the genetically diverse Collaborative Cross (CC) mouse population were treated with a single oral dose of either tolvaptan or vehicle.  Significant elevations in plasma alanine aminotransferase (ALT) were obsd. in tolvaptan-treated animals in 3 of the 45 strains.  Genetic mapping coupled with transcriptomic anal. in the liver was used to identify several candidate susceptibility genes including epoxide hydrolase 2, interferon regulatory factor 3, and mitochondrial fission factor.  Gene pathway anal. revealed that oxidative stress and immune response pathways were activated in response to tolvaptan treatment across all strains, but genes involved in regulation of bile acid homeostasis were most assocd. with tolvaptan-induced elevations in ALT.  Secretory leukocyte peptidase inhibitor (Slpi) mRNA was also induced in the susceptible strains and was assocd. with increased plasma levels of Slpi protein, suggesting a potential serum marker for DILI susceptibility.  In summary, tolvaptan induced signs of oxidative stress, mitochondrial dysfunction, and innate immune response in all strains, but variation in bile acid homeostasis was most assocd. with susceptibility to the liver response.  This CC study has indicated potential mechanisms underlying tolvaptan DILI and biomarkers of susceptibility that may be useful in managing the risk of DILI in ADPKD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr17_b9VGbVSLVg90H21EOLACvtfcHk0lh82RIzNMjeyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOrtLc%253D&md5=5957b4b87f571986f5e63cb08dd9e388</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfw269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfw269%26sid%3Dliteratum%253Aachs%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DBrock%26aufirst%3DW.%2BJ.%26aulast%3DRoth%26aufirst%3DS.%2BE.%26aulast%3DWiltshire%26aufirst%3DT.%26aulast%3DEaddy%26aufirst%3DJ.%2BS.%26aulast%3DKeele%26aufirst%3DG.%2BR.%26aulast%3DCorty%26aufirst%3DR.%2BW.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DValdar%26aufirst%3DW.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DCandidate%2520Risk%2520Factors%2520and%2520Mechanisms%2520for%2520Tolvaptan-Induced%2520Liver%2520Injury%2520Are%2520Identified%2520Using%2520a%2520Collaborative%2520Cross%2520Approach%26jtitle%3DToxicol.%2520Sci.%26date%3D2017%26volume%3D156%26spage%3D438%26epage%3D54%26doi%3D10.1093%2Ftoxsci%2Fkfw269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaddy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corty, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nautiyal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdar, W.</span></span> <span> </span><span class="NLM_article-title">Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">278</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfz199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfz199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=31501888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BB3MrmvVKisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2019&pages=265-278&author=M.+Mosedaleauthor=Y.+Caiauthor=J.+S.+Eaddyauthor=R.+W.+Cortyauthor=M.+Nautiyalauthor=P.+B.+Watkinsauthor=W.+Valdar&title=Identification+of+Candidate+Risk+Factor+Genes+for+Human+Idelalisib+Toxicity+Using+a+Collaborative+Cross+Approach&doi=10.1093%2Ftoxsci%2Fkfz199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach</span></div><div class="casAuthors">Mosedale Merrie; Cai Yanwei; Eaddy John Scott; Nautiyal Manisha; Watkins Paul B; Mosedale Merrie; Watkins Paul B; Cai Yanwei; Corty Robert W; Valdar William; Valdar William</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological sciences : an official journal of the Society of Toxicology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">265-278</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Idelalisib is a phosphatidylinositol 3-kinase inhibitor highly selective for the delta isoform that has shown good efficacy in treating chronic lymphocytic leukemia and follicular lymphoma.  In clinical trials, however, idelalisib was associated with rare, but potentially serious liver and lung toxicities.  In this study, we used the Collaborative Cross (CC) mouse population to identify genetic factors associated with the drug response that may inform risk management strategies for idelalisib in humans.  Eight male mice (4 matched pairs) from 50 CC lines were treated once daily for 14 days by oral gavage with either vehicle or idelalisib at a dose selected to achieve clinically relevant peak plasma concentrations (150 mg/kg/day).  The drug was well tolerated across all CC lines, and there were no observations of overt liver injury.  Differences across CC lines were seen in drug concentration in plasma samples collected at the approximate Tmax on study Days 1, 7, and 14.  There were also small but statistically significant treatment-induced alterations in plasma total bile acids and microRNA-122, and these may indicate early hepatocellular stress required for immune-mediated hepatotoxicity in humans.  Idelalisib treatment further induced significant elevations in the total cell count of terminal bronchoalveolar lavage fluid, which may be analogous to pneumonitis observed in the clinic.  Genetic mapping identified loci associated with interim plasma idelalisib concentration and the other 3 treatment-related endpoints.  Thirteen priority candidate quantitative trait genes identified in CC mice may now guide interrogation of risk factors for adverse drug responses associated with idelalisib in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcST5jzZDklkoyA3UY9EwTNrfW6udTcc2eb9Iw_5b_6muLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrmvVKisg%253D%253D&md5=63ccb346610d3a5b875d04937debb07c</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfz199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfz199%26sid%3Dliteratum%253Aachs%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DEaddy%26aufirst%3DJ.%2BS.%26aulast%3DCorty%26aufirst%3DR.%2BW.%26aulast%3DNautiyal%26aufirst%3DM.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DValdar%26aufirst%3DW.%26atitle%3DIdentification%2520of%2520Candidate%2520Risk%2520Factor%2520Genes%2520for%2520Human%2520Idelalisib%2520Toxicity%2520Using%2520a%2520Collaborative%2520Cross%2520Approach%26jtitle%3DToxicol.%2520Sci.%26date%3D2019%26volume%3D172%26spage%3D265%26epage%3D278%26doi%3D10.1093%2Ftoxsci%2Fkfz199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norona, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presnell, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Bioprinted Liver Provides Early Insight Into the Role of Kupffer Cells in TGF-β1 and Methotrexate-Induced Fibrogenesis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">e0208958</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0208958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1371%2Fjournal.pone.0208958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30601836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtFemsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=e0208958&author=L.+M.+Noronaauthor=D.+G.+Nguyenauthor=D.+A.+Gerberauthor=S.+C.+Presnellauthor=M.+Mosedaleauthor=P.+B.+Watkins&title=Bioprinted+Liver+Provides+Early+Insight+Into+the+Role+of+Kupffer+Cells+in+TGF-%CE%B21+and+Methotrexate-Induced+Fibrogenesis&doi=10.1371%2Fjournal.pone.0208958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Bioprinted liver provides early insight into the role of Kupffer cells in TGF-β1 and methotrexate-induced fibrogenesis</span></div><div class="casAuthors">Norona, Leah M.; Nguyen, Deborah G.; Gerber, David A.; Presnell, Sharon C.; Mosedale, Merrie; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0208958</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Hepatic fibrosis develops from a series of complex interactions among resident and recruited cells making it a challenge to replicate using std. in vitro approaches.  While studies have demonstrated the importance of macrophages in fibrogenesis, the role of Kupffer cells (KCs) in modulating the initial response remains elusive.  Previous work demonstrated utility of 3D bioprinted liver to recapitulate basic fibrogenic features following treatment with fibrosis-assocd. agents.  In the present study, culture conditions were modified to recapitulate a gradual accumulation of collagen within the tissues over an extended exposure timeframe.  Under these conditions, KCs were added to the model to examine their impact on the injury/fibrogenic response following cytokine and drug stimuli.  A 28-day exposure to 10 ng/mL TGF-β1 and 0.209μM methotrexate (MTX) resulted in sustained LDH release which was attenuated when KCs were incorporated in the model.  Assessment of miR-122 confirmed early hepatocyte injury in response to TGF-β1 that appeared delayed in the presence of KCs, whereas MTX-induced increases in miR-122 were obsd. when KCs were incorporated in the model.  Although the collagen responses were mild under the conditions tested to mimic early fibrotic injury, a global redn. in cytokines was obsd. in the KC-modified tissue model following treatment.  Furthermore, gene expression profiling suggests KCs have a significant impact on baseline tissue function over time and an important modulatory role dependent on the context of injury.  Although the no. of differentially expressed genes across treatments was comparable, pathway enrichment suggests distinct, KC- and time-dependent changes in the transcriptome for each agent.  As such, the incorporation of KCs and impact on baseline tissue homeostasis may be important in recapitulating temporal dynamics of the fibrogenic response to different agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy4mffnFbGT7Vg90H21EOLACvtfcHk0ljOe7AtxBGkVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtFemsrs%253D&md5=48818594853bc65261ccd75d9f16ef4a</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0208958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0208958%26sid%3Dliteratum%253Aachs%26aulast%3DNorona%26aufirst%3DL.%2BM.%26aulast%3DNguyen%26aufirst%3DD.%2BG.%26aulast%3DGerber%26aufirst%3DD.%2BA.%26aulast%3DPresnell%26aufirst%3DS.%2BC.%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DBioprinted%2520Liver%2520Provides%2520Early%2520Insight%2520Into%2520the%2520Role%2520of%2520Kupffer%2520Cells%2520in%2520TGF-%25CE%25B21%2520and%2520Methotrexate-Induced%2520Fibrogenesis%26jtitle%3DPLoS%2520One%26date%3D2019%26volume%3D14%26spage%3De0208958%26doi%3D10.1371%2Fjournal.pone.0208958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laifenfeld, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swiss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macoritto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younis, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawton, M.</span></span> <span> </span><span class="NLM_article-title">Utilization of Causal Reasoning of Hepatic Gene Expression in Rats to Identify Molecular Pathways of Idiosyncratic Drug-Induced Liver Injury</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">234</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kft232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkft232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24136188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslKi" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2014&pages=234-248&author=D.+Laifenfeldauthor=L.+Qiuauthor=R.+Swissauthor=J.+Parkauthor=M.+Macorittoauthor=Y.+Willauthor=H.+S.+Younisauthor=M.+Lawton&title=Utilization+of+Causal+Reasoning+of+Hepatic+Gene+Expression+in+Rats+to+Identify+Molecular+Pathways+of+Idiosyncratic+Drug-Induced+Liver+Injury&doi=10.1093%2Ftoxsci%2Fkft232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Utilization of Causal Reasoning of Hepatic Gene Expression in Rats to Identify Molecular Pathways of Idiosyncratic Drug-Induced Liver Injury</span></div><div class="casAuthors">Laifenfeld, Daphna; Qiu, Luping; Swiss, Rachel; Park, Jennifer; Macoritto, Michael; Will, Yvonne; Younis, Husam S.; Lawton, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">234-248</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) represents a leading cause of acute liver failure.  Although DILI can be discovered in preclin. animal toxicol. studies and/or early clin. trials, some human DILI reactions, termed idiosyncratic DILI (IDILI), are less predictable, occur in a small no. of individuals, and do not follow a clear dose-response relationship.  The emergence of IDILI poses a crit. health challenge for patients and a financial challenge for the pharmaceutical industry.  Understanding the cellular and mol. mechanisms underlying IDILI is key to the development of models that can assess potential IDILI risk.  This study used Reverse Causal Reasoning (RCR), a method to assess activation of mol. signaling pathways, on gene expression data from rats treated with IDILI or pharmacol./chem. comparators (NON-DILI) at the max. tolerated dose to identify mechanistic pathways underlying IDILI.  Detailed mol. networks involved in mitochondrial injury, inflammation, and endoplasmic reticulum (ER) stress were found in response to IDILI drugs but not neg. controls (NON-DILI).  In vitro assays assessing mitochondrial or ER function confirmed the effect of IDILI compds. on these systems.  Together our work suggests that using gene expression data can aid in understanding mechanisms underlying IDILI and can guide in vitro screening for IDILI.  Specifically, RCR should be considered for compds. that do not show evidence of DILI in preclin. animal studies pos. for mitochondrial dysfunction and ER stress assays, esp. when the therapeutic index toward projected human max. drug plasma concn. is low.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUMD1yuyUx8bVg90H21EOLACvtfcHk0ljOe7AtxBGkVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslKi&md5=7c705c16d5f51e5d1fa94ae16444b6a8</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkft232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkft232%26sid%3Dliteratum%253Aachs%26aulast%3DLaifenfeld%26aufirst%3DD.%26aulast%3DQiu%26aufirst%3DL.%26aulast%3DSwiss%26aufirst%3DR.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DMacoritto%26aufirst%3DM.%26aulast%3DWill%26aufirst%3DY.%26aulast%3DYounis%26aufirst%3DH.%2BS.%26aulast%3DLawton%26aufirst%3DM.%26atitle%3DUtilization%2520of%2520Causal%2520Reasoning%2520of%2520Hepatic%2520Gene%2520Expression%2520in%2520Rats%2520to%2520Identify%2520Molecular%2520Pathways%2520of%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DToxicol.%2520Sci.%26date%3D2014%26volume%3D137%26spage%3D234%26epage%3D248%26doi%3D10.1093%2Ftoxsci%2Fkft232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandon Parker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piechta, L.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark
Kao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jim Proctor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheyen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillian, M. K.</span></span> <span> </span><span class="NLM_article-title">Oxidative Stress/Reactive Metabolite Gene Expression Signature in Rat Liver Detects Idiosyncratic Hepatotoxicants</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2014.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.taap.2014.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24486436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlSrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2014&pages=189-197&author=A.+Leoneauthor=A.+Nieauthor=J.+Brandon+Parkerauthor=S.+Sawantauthor=L.-A.+Piechtaauthor=M.+F.+Kelleyauthor=L.+Mark%0AKaoauthor=S.+Jim+Proctorauthor=G.+Verheyenauthor=M.+D.+Johnsonauthor=P.+G.+Lordauthor=M.+K.+McMillian&title=Oxidative+Stress%2FReactive+Metabolite+Gene+Expression+Signature+in+Rat+Liver+Detects+Idiosyncratic+Hepatotoxicants&doi=10.1016%2Fj.taap.2014.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress/reactive metabolite gene expression signature in rat liver detects idiosyncratic hepatotoxicants</span></div><div class="casAuthors">Leone, Angelique; Nie, Alex; Brandon Parker, J.; Sawant, Sharmilee; Piechta, Leigh-Anne; Kelley, Michael F.; Mark Kao, L.; Jim Proctor, S.; Verheyen, Geert; Johnson, Mark D.; Lord, Peter G.; McMillian, Michael K.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">189-197</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Previously we reported a gene expression signature in rat liver for detecting a specific type of oxidative stress (OS) related to reactive metabolites (RM).  High doses of the drugs disulfiram, ethinyl estradiol and nimesulide were used with another dozen paradigm OS/RM compds., and three other drugs flutamide, phenacetin and sulindac were identified by this signature.  In a second study, antiepileptic drugs were compared for covalent binding and their effects on OS/RM; felbamate, carbamazepine, and phenobarbital produced robust OS/RM gene expression.  In the present study, liver RNA samples from drug-treated rats from more recent expts. were examd. for statistical fit to the OS/RM signature.  Of all 97 drugs examd., in addn. to the nine drugs noted above, 19 more were identified as OS/RM-producing compds.-chlorpromazine, clozapine, cyproterone acetate, dantrolene, dipyridamole, glibenclamide, isoniazid, ketoconazole, methapyrilene, naltrexone, nifedipine, sulfamethoxazole, tamoxifen, coumarin, ritonavir, amitriptyline, valproic acid, enalapril, and chloramphenicol.  Importantly, all of the OS/RM drugs listed above have been linked to idiosyncratic hepatotoxicity, excepting chloramphenicol, which does not have a package label for hepatotoxicity, but does have a black box warning for idiosyncratic bone marrow suppression.  Most of these drugs are not acutely toxic in the rat.  The OS/RM signature should be useful to avoid idiosyncratic hepatotoxicity of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov3sR9PpDDorVg90H21EOLACvtfcHk0lh1vois3TpSAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlSrsLk%253D&md5=88c5135241b01e996b0b5022aa0e5dab</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2014.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2014.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DLeone%26aufirst%3DA.%26aulast%3DNie%26aufirst%3DA.%26aulast%3DBrandon%2BParker%26aufirst%3DJ.%26aulast%3DSawant%26aufirst%3DS.%26aulast%3DPiechta%26aufirst%3DL.-A.%26aulast%3DKelley%26aufirst%3DM.%2BF.%26aulast%3DMark%2BKao%26aufirst%3DL.%26aulast%3DJim%2BProctor%26aufirst%3DS.%26aulast%3DVerheyen%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DM.%2BD.%26aulast%3DLord%26aufirst%3DP.%2BG.%26aulast%3DMcMillian%26aufirst%3DM.%2BK.%26atitle%3DOxidative%2520Stress%252FReactive%2520Metabolite%2520Gene%2520Expression%2520Signature%2520in%2520Rat%2520Liver%2520Detects%2520Idiosyncratic%2520Hepatotoxicants%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2014%26volume%3D275%26spage%3D189%26epage%3D197%26doi%3D10.1016%2Fj.taap.2014.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span> <span> </span><span class="NLM_article-title">Mouse Population-Based Approaches to Investigate Adverse Drug Reactions</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1787</span>– <span class="NLM_lpage">1795</span>, <span class="refDoi"> DOI: 10.1124/dmd.118.082834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fdmd.118.082834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30045843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVeitbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=1787-1795&author=M.+Mosedale&title=Mouse+Population-Based+Approaches+to+Investigate+Adverse+Drug+Reactions&doi=10.1124%2Fdmd.118.082834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Mouse population-based approaches to investigate adverse drug reactions</span></div><div class="casAuthors">Mosedale, Merrie</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1787-1795</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Genetic variation is now recognized as a key factor in the toxicity of pharmaceutical agents.  However, genetic diversity is not present in std. nonclin. toxicol. models, and small clin. studies (phase I/II) may not include enough subjects to identify toxicity liabilities assocd. with less common susceptibility factors.  As a result, many drugs pass through preclin. and early clin. studies before safety concerns are realized.  Furthermore, when adverse drug reactions are idiosyncratic in nature, suggesting a role for rare genetic variants in the toxicity susceptibility, even large clin. studies (phase III) are often underpowered (due to low population frequency and/or small effect size of the risk factor) to identify assocns. that may be used for precision medicine risk mitigation strategies.  Genetically diverse mouse populations can be used to help overcome the limitations of std. nonclin. and clin. studies and to model toxicity responses that require genetic susceptibility factors.  Furthermore, mouse population-based approaches can be used to: 1) identify sensitive strains that canserveasascreening tool for next-in-class compds., 2) identify genetic susceptibility factors that can be used for risk mitigation strategies, and 3) studymechanisms underlying drug toxicity.  This review describes genetically diverse mouse populations and provides examples of their utility in investigating adverse drug response.  It also explores recent efforts to adapt mouse population-based approaches to in vitro platforms, thereby enabling the incorporation of genetic diversity and the identification of genetic risk factors and mechanisms assocd. with drug toxicity susceptibility at all stages of drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfF60XymZkv7Vg90H21EOLACvtfcHk0lh1vois3TpSAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVeitbfI&md5=fe98211b89bf87206f2d050c978123ad</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1124%2Fdmd.118.082834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.118.082834%26sid%3Dliteratum%253Aachs%26aulast%3DMosedale%26aufirst%3DM.%26atitle%3DMouse%2520Population-Based%2520Approaches%2520to%2520Investigate%2520Adverse%2520Drug%2520Reactions%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26spage%3D1787%26epage%3D1795%26doi%3D10.1124%2Fdmd.118.082834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuberi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, C.</span></span> <span> </span><span class="NLM_article-title">Mouse Models for Drug Discovery. Can New Tools and Technology Improve Translational Power?</span>. <i>ILAR J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1093/ilar/ilw021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Filar%2Filw021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28053071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGqtLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=178-185&author=A.+Zuberiauthor=C.+Lutz&title=Mouse+Models+for+Drug+Discovery.+Can+New+Tools+and+Technology+Improve+Translational+Power%3F&doi=10.1093%2Filar%2Filw021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Mouse models for drug discovery. can new tools and technology improve translational power?</span></div><div class="casAuthors">Zuberi, Aamir; Lutz, Cathleen</div><div class="citationInfo"><span class="NLM_cas:title">ILAR Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">178-185</span>CODEN:
                <span class="NLM_cas:coden">IJLOAC</span>;
        ISSN:<span class="NLM_cas:issn">1084-2020</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The use of mouse models in biomedical research and preclin. drug evaluation is on the rise.  The advent of new mol. genome-altering technologies such as CRISPR/Cas9 allows for genetic mutations to be introduced into the germ line of a mouse faster and less expensively than previous methods.  In addn., the rapid progress in the development and use of somatic transgenesis using viral vectors, as well as manipulations of gene expression with siRNAs and antisense oligonucleotides, allow for even greater exploration into genomics and systems biol.  These technol. advances come at a time when cost redns. in genome sequencing have led to the identification of pathogenic mutations in patient populations, providing unprecedented opportunities in the use of mice to model human disease.  The ease of genetic engineering in mice also offers a potential paradigm shift in resource sharing and the speed by which models are made available in the public domain.  Predictively, the knowledge alone that a model can be quickly remade will provide relief to resources encumbered by licensing and Material Transfer Agreements.  For decades, mouse strains have provided an exquisite exptl. tool to study the pathophysiol. of the disease and assess therapeutic options in a genetically defined system.  However, a major limitation of the mouse has been the limited genetic diversity assocd. with common lab. mice.  This has been overcome with the recent development of the Collaborative Cross and Diversity Outbred mice.  These strains provide new tools capable of replicating genetic diversity to that approaching the diversity found in human populations.  The Collaborative Cross and Diversity Outbred strains thus provide a means to observe and characterize toxicity or efficacy of new therapeutic drugs for a given population.  The combination of traditional and contemporary mouse genome editing tools, along with the addn. of genetic diversity in new modeling systems, are synergistic and serve to make the mouse a better model for biomedical research, enhancing the potential for preclin. drug discovery and personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGcnARubI6j7Vg90H21EOLACvtfcHk0lh1vois3TpSAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGqtLvI&md5=bbfb508bc9b6ec366a0491fd57971b6f</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1093%2Filar%2Filw021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Filar%252Filw021%26sid%3Dliteratum%253Aachs%26aulast%3DZuberi%26aufirst%3DA.%26aulast%3DLutz%26aufirst%3DC.%26atitle%3DMouse%2520Models%2520for%2520Drug%2520Discovery.%2520Can%2520New%2520Tools%2520and%2520Technology%2520Improve%2520Translational%2520Power%253F%26jtitle%3DILAR%2520J.%26date%3D2016%26volume%3D57%26spage%3D178%26epage%3D185%26doi%3D10.1093%2Filar%2Filw021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Godoy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolleyn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böttger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braeuning, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budinsky, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhardt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camussi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig Rowlands, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damm, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirsch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donato, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drasdo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eakins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonsato, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraczek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebhardt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glanemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Lechón, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groothuis, G. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustavsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guyot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallifax, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Häussinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellerbrand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoehme, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzhütter, H.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeschke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keitel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelm, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kevin Park, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kordes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kullak-Ublick, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCluyse, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luebke-Wheeler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maltman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matz-Soja, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMullen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merfort, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mwinyi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussler, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinga, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pampaloni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przyborski, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogiers, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schelcher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stelzer, E. H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stieger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stöber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thasler, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaecke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinken, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarborough, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hengstler, J. G.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in 2D and 3D In Vitro Systems Using Primary Hepatocytes, Alternative Hepatocyte Sources and Non-parenchymal Liver Cells and Their Use in Investigating Mechanisms of Hepatotoxicity, Cell Signaling and ADME</span>. <i>Arch. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">1315</span>– <span class="NLM_lpage">1530</span>, <span class="refDoi"> DOI: 10.1007/s00204-013-1078-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs00204-013-1078-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23974980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlahtr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=1315-1530&author=P.+Godoyauthor=N.+J.+Hewittauthor=U.+Albrechtauthor=M.+E.+Andersenauthor=N.+Ansariauthor=S.+Bhattacharyaauthor=J.+G.+Bodeauthor=J.+Bolleynauthor=C.+Bornerauthor=J.+B%C3%B6ttgerauthor=A.+Braeuningauthor=R.+A.+Budinskyauthor=B.+Burkhardtauthor=N.+R.+Cameronauthor=G.+Camussiauthor=C.-S.+Choauthor=Y.-J.+Choiauthor=J.+Craig+Rowlandsauthor=U.+Dahmenauthor=G.+Dammauthor=O.+Dirschauthor=M.+T.+Donatoauthor=J.+Dongauthor=S.+Dooleyauthor=D.+Drasdoauthor=R.+Eakinsauthor=K.+S.+Ferreiraauthor=V.+Fonsatoauthor=J.+Fraczekauthor=R.+Gebhardtauthor=A.+Gibsonauthor=M.+Glanemannauthor=C.+E.+P.+Goldringauthor=M.+J.+G%C3%B3mez-Lech%C3%B3nauthor=G.+M.+M.+Groothuisauthor=L.+Gustavssonauthor=C.+Guyotauthor=D.+Hallifaxauthor=S.+Hammadauthor=A.+Haywardauthor=D.+H%C3%A4ussingerauthor=C.+Hellerbrandauthor=P.+Hewittauthor=S.+Hoehmeauthor=H.-G.+Holzh%C3%BCtterauthor=J.+B.+Houstonauthor=J.+Hrachauthor=K.+Itoauthor=H.+Jaeschkeauthor=V.+Keitelauthor=J.+M.+Kelmauthor=B.+Kevin+Parkauthor=C.+Kordesauthor=G.+A.+Kullak-Ublickauthor=E.+L.+LeCluyseauthor=P.+Luauthor=J.+Luebke-Wheelerauthor=A.+Lutzauthor=D.+J.+Maltmanauthor=M.+Matz-Sojaauthor=P.+McMullenauthor=I.+Merfortauthor=S.+Messnerauthor=C.+Meyerauthor=J.+Mwinyiauthor=D.+J.+Naisbittauthor=A.+K.+Nusslerauthor=P.+Olingaauthor=F.+Pampaloniauthor=J.+Piauthor=L.+Plutaauthor=S.+A.+Przyborskiauthor=A.+Ramachandranauthor=V.+Rogiersauthor=C.+Roweauthor=C.+Schelcherauthor=K.+Schmichauthor=M.+Schwarzauthor=B.+Singhauthor=E.+H.+K.+Stelzerauthor=B.+Stiegerauthor=R.+St%C3%B6berauthor=Y.+Sugiyamaauthor=C.+Tettaauthor=W.+E.+Thaslerauthor=T.+Vanhaeckeauthor=M.+Vinkenauthor=T.+S.+Weissauthor=A.+Wideraauthor=C.+G.+Woodsauthor=J.+J.+Xuauthor=K.+M.+Yarboroughauthor=J.+G.+Hengstler&title=Recent+Advances+in+2D+and+3D+In+Vitro+Systems+Using+Primary+Hepatocytes%2C+Alternative+Hepatocyte+Sources+and+Non-parenchymal+Liver+Cells+and+Their+Use+in+Investigating+Mechanisms+of+Hepatotoxicity%2C+Cell+Signaling+and+ADME&doi=10.1007%2Fs00204-013-1078-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME</span></div><div class="casAuthors">Godoy, Patricio; Hewitt, Nicola J.; Albrecht, Ute; Andersen, Melvin E.; Ansari, Nariman; Bhattacharya, Sudin; Bode, Johannes Georg; Bolleyn, Jennifer; Borner, Christoph; Boettger, Jan; Braeuning, Albert; Budinsky, Robert A.; Burkhardt, Britta; Cameron, Neil R.; Camussi, Giovanni; Cho, Chong-Su; Choi, Yun-Jaie; Craig Rowlands, J.; Dahmen, Uta; Damm, Georg; Dirsch, Olaf; Donato, Maria Teresa; Dong, Jian; Dooley, Steven; Drasdo, Dirk; Eakins, Rowena; Ferreira, Karine Sa; Fonsato, Valentina; Fraczek, Joanna; Gebhardt, Rolf; Gibson, Andrew; Glanemann, Matthias; Goldring, Chris E. P.; Gomez-Lechon, Maria Jose; Groothuis, Geny M. M.; Gustavsson, Lena; Guyot, Christelle; Hallifax, David; Hammad, Seddik; Hayward, Adam; Haeussinger, Dieter; Hellerbrand, Claus; Hewitt, Philip; Hoehme, Stefan; Holzhuetter, Hermann-Georg; Houston, J. Brian; Hrach, Jens; Ito, Kiyomi; Jaeschke, Hartmut; Keitel, Verena; Kelm, Jens M.; Kevin Park, B.; Kordes, Claus; Kullak-Ublick, Gerd A.; LeCluyse, Edward L.; Lu, Peng; Luebke-Wheeler, Jennifer; Lutz, Anna; Maltman, Daniel J.; Matz-Soja, Madlen; McMullen, Patrick; Merfort, Irmgard; Messner, Simon; Meyer, Christoph; Mwinyi, Jessica; Naisbitt, Dean J.; Nussler, Andreas K.; Olinga, Peter; Pampaloni, Francesco; Pi, Jingbo; Pluta, Linda; Przyborski, Stefan A.; Ramachandran, Anup; Rogiers, Vera; Rowe, Cliff; Schelcher, Celine; Schmich, Kathrin; Schwarz, Michael; Singh, Bijay; Stelzer, Ernst H. K.; Stieger, Bruno; Stoeber, Regina; Sugiyama, Yuichi; Tetta, Ciro; Thasler, Wolfgang E.; Vanhaecke, Tamara; Vinken, Mathieu; Weiss, Thomas S.; Widera, Agata; Woods, Courtney G.; Xu, Jinghai James; Yarborough, Kathy M.; Hengstler, Jan G.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1315-1530</span>CODEN:
                <span class="NLM_cas:coden">ARTODN</span>;
        ISSN:<span class="NLM_cas:issn">0340-5761</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This review encompasses the most important advances in liver functions and hepatotoxicity and analyzes which mechanisms can be studied in vitro.  In a complex architecture of nested, zonated lobules, the liver consists of approx. 80 % hepatocytes and 20 % non-parenchymal cells, the latter being involved in a secondary phase that may dramatically aggravate the initial damage.  Hepatotoxicity, as well as hepatic metab., is controlled by a set of nuclear receptors (including PXR, CAR, HNF-4α, FXR, LXR, SHP, VDR and PPAR) and signaling pathways.  When isolating liver cells, some pathways are activated, e.g., the RAS/MEK/ERK pathway, whereas others are silenced (e.g. HNF-4α), resulting in up- and downregulation of hundreds of genes.  An understanding of these changes is crucial for a correct interpretation of in vitro data.  The possibilities and limitations of the most useful liver in vitro systems are summarized, including three-dimensional culture techniques, co-cultures with non-parenchymal cells, hepatospheres, precision cut liver slices and the isolated perfused liver.  Also discussed is how closely hepatoma, stem cell and iPS cell-derived hepatocyte-like-cells resemble real hepatocytes.  Finally, a summary is given of the state of the art of liver in vitro and math. modeling systems that are currently used in the pharmaceutical industry with an emphasis on drug metab., prediction of clearance, drug interaction, transporter studies and hepatotoxicity.  One key message is that despite our enthusiasm for in vitro systems, we must never lose sight of the in vivo situation.  Although hepatocytes have been isolated for decades, the hunt for relevant alternative systems has only just begun.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowud2b2y7hPrVg90H21EOLACvtfcHk0lg9DgVBFw1Okg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlahtr3N&md5=7a6e41a2612c81c6c67fc89362c01e2d</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1007%2Fs00204-013-1078-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00204-013-1078-5%26sid%3Dliteratum%253Aachs%26aulast%3DGodoy%26aufirst%3DP.%26aulast%3DHewitt%26aufirst%3DN.%2BJ.%26aulast%3DAlbrecht%26aufirst%3DU.%26aulast%3DAndersen%26aufirst%3DM.%2BE.%26aulast%3DAnsari%26aufirst%3DN.%26aulast%3DBhattacharya%26aufirst%3DS.%26aulast%3DBode%26aufirst%3DJ.%2BG.%26aulast%3DBolleyn%26aufirst%3DJ.%26aulast%3DBorner%26aufirst%3DC.%26aulast%3DB%25C3%25B6ttger%26aufirst%3DJ.%26aulast%3DBraeuning%26aufirst%3DA.%26aulast%3DBudinsky%26aufirst%3DR.%2BA.%26aulast%3DBurkhardt%26aufirst%3DB.%26aulast%3DCameron%26aufirst%3DN.%2BR.%26aulast%3DCamussi%26aufirst%3DG.%26aulast%3DCho%26aufirst%3DC.-S.%26aulast%3DChoi%26aufirst%3DY.-J.%26aulast%3DCraig%2BRowlands%26aufirst%3DJ.%26aulast%3DDahmen%26aufirst%3DU.%26aulast%3DDamm%26aufirst%3DG.%26aulast%3DDirsch%26aufirst%3DO.%26aulast%3DDonato%26aufirst%3DM.%2BT.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DDooley%26aufirst%3DS.%26aulast%3DDrasdo%26aufirst%3DD.%26aulast%3DEakins%26aufirst%3DR.%26aulast%3DFerreira%26aufirst%3DK.%2BS.%26aulast%3DFonsato%26aufirst%3DV.%26aulast%3DFraczek%26aufirst%3DJ.%26aulast%3DGebhardt%26aufirst%3DR.%26aulast%3DGibson%26aufirst%3DA.%26aulast%3DGlanemann%26aufirst%3DM.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%2BP.%26aulast%3DG%25C3%25B3mez-Lech%25C3%25B3n%26aufirst%3DM.%2BJ.%26aulast%3DGroothuis%26aufirst%3DG.%2BM.%2BM.%26aulast%3DGustavsson%26aufirst%3DL.%26aulast%3DGuyot%26aufirst%3DC.%26aulast%3DHallifax%26aufirst%3DD.%26aulast%3DHammad%26aufirst%3DS.%26aulast%3DHayward%26aufirst%3DA.%26aulast%3DH%25C3%25A4ussinger%26aufirst%3DD.%26aulast%3DHellerbrand%26aufirst%3DC.%26aulast%3DHewitt%26aufirst%3DP.%26aulast%3DHoehme%26aufirst%3DS.%26aulast%3DHolzh%25C3%25BCtter%26aufirst%3DH.-G.%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26aulast%3DHrach%26aufirst%3DJ.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DJaeschke%26aufirst%3DH.%26aulast%3DKeitel%26aufirst%3DV.%26aulast%3DKelm%26aufirst%3DJ.%2BM.%26aulast%3DKevin%2BPark%26aufirst%3DB.%26aulast%3DKordes%26aufirst%3DC.%26aulast%3DKullak-Ublick%26aufirst%3DG.%2BA.%26aulast%3DLeCluyse%26aufirst%3DE.%2BL.%26aulast%3DLu%26aufirst%3DP.%26aulast%3DLuebke-Wheeler%26aufirst%3DJ.%26aulast%3DLutz%26aufirst%3DA.%26aulast%3DMaltman%26aufirst%3DD.%2BJ.%26aulast%3DMatz-Soja%26aufirst%3DM.%26aulast%3DMcMullen%26aufirst%3DP.%26aulast%3DMerfort%26aufirst%3DI.%26aulast%3DMessner%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DC.%26aulast%3DMwinyi%26aufirst%3DJ.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DNussler%26aufirst%3DA.%2BK.%26aulast%3DOlinga%26aufirst%3DP.%26aulast%3DPampaloni%26aufirst%3DF.%26aulast%3DPi%26aufirst%3DJ.%26aulast%3DPluta%26aufirst%3DL.%26aulast%3DPrzyborski%26aufirst%3DS.%2BA.%26aulast%3DRamachandran%26aufirst%3DA.%26aulast%3DRogiers%26aufirst%3DV.%26aulast%3DRowe%26aufirst%3DC.%26aulast%3DSchelcher%26aufirst%3DC.%26aulast%3DSchmich%26aufirst%3DK.%26aulast%3DSchwarz%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DStelzer%26aufirst%3DE.%2BH.%2BK.%26aulast%3DStieger%26aufirst%3DB.%26aulast%3DSt%25C3%25B6ber%26aufirst%3DR.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DTetta%26aufirst%3DC.%26aulast%3DThasler%26aufirst%3DW.%2BE.%26aulast%3DVanhaecke%26aufirst%3DT.%26aulast%3DVinken%26aufirst%3DM.%26aulast%3DWeiss%26aufirst%3DT.%2BS.%26aulast%3DWidera%26aufirst%3DA.%26aulast%3DWoods%26aufirst%3DC.%2BG.%26aulast%3DXu%26aufirst%3DJ.%2BJ.%26aulast%3DYarborough%26aufirst%3DK.%2BM.%26aulast%3DHengstler%26aufirst%3DJ.%2BG.%26atitle%3DRecent%2520Advances%2520in%25202D%2520and%25203D%2520In%2520Vitro%2520Systems%2520Using%2520Primary%2520Hepatocytes%252C%2520Alternative%2520Hepatocyte%2520Sources%2520and%2520Non-parenchymal%2520Liver%2520Cells%2520and%2520Their%2520Use%2520in%2520Investigating%2520Mechanisms%2520of%2520Hepatotoxicity%252C%2520Cell%2520Signaling%2520and%2520ADME%26jtitle%3DArch.%2520Toxicol.%26date%3D2013%26volume%3D87%26spage%3D1315%26epage%3D1530%26doi%3D10.1007%2Fs00204-013-1078-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolters, J. E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van
Breda, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinjans, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kok, T. M.</span></span> <span> </span><span class="NLM_article-title">Development of Novel Tools for the In Vitro Investigation of Drug-Induced Liver Injury</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1523</span>– <span class="NLM_lpage">1537</span>, <span class="refDoi"> DOI: 10.1517/17425255.2015.1065814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1517%2F17425255.2015.1065814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26155718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsl2ntbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=1523-1537&author=J.+Jiangauthor=J.+E.+J.+Woltersauthor=S.+G.+van%0ABredaauthor=J.+C.+Kleinjansauthor=T.+M.+de+Kok&title=Development+of+Novel+Tools+for+the+In+Vitro+Investigation+of+Drug-Induced+Liver+Injury&doi=10.1517%2F17425255.2015.1065814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Development of novel tools for the in vitro investigation of drug-induced liver injury</span></div><div class="casAuthors">Jiang, Jian; Wolters, Jarno EJ; van Breda, Simone G.; Kleinjans, Jos C.; de Kok, Theo M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1523-1537</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Due to its complex mechanisms and unpredictable occurrence, drug-induced liver injury (DILI) complicates drug identification and classification.  Since species-specific differences in metab. and pharmacokinetics exist, data obtained from animal studies may not be sufficient to predict DILI in humans.  Over the last few decades, numerous in vitro models have been developed to replace animal testing.  The advantages and disadvantages of commonly used liver-derived in vitro models (e.g., cell lines, hepatocyte models, liver slices, three-dimensional (3D) hepatospheres, etc.) are discussed.  Toxicogenomics-based methodologies (genomics, epigenomics, transcriptomics, proteomics and metabolomics) and next-generation sequencing have also been used to enhance the reliability of DILI prediction.  This review presents an overview of the currently used alternative toxicol. models and of the most advanced approaches in the field of DILI research.  It seems unlikely that a single in vitro system will be able to mimic the complex interactions in the human liver.  Three-dimensional multicellular systems may bridge the gap between conventional 2D models and in vivo clin. studies in humans and provide a reliable basis for hepatic toxicity assay development.  Next-generation sequencing technologies, in comparison to microarray-based technologies, may overcome the current limitations and are promising for the development of predictive models in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_sXCiIcEkYrVg90H21EOLACvtfcHk0lg9DgVBFw1Okg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsl2ntbvF&md5=af6cd477d64ae1fdc65701827f4ef39b</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1517%2F17425255.2015.1065814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2015.1065814%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWolters%26aufirst%3DJ.%2BE.%2BJ.%26aulast%3Dvan%2BBreda%26aufirst%3DS.%2BG.%26aulast%3DKleinjans%26aufirst%3DJ.%2BC.%26aulast%3Dde%2BKok%26aufirst%3DT.%2BM.%26atitle%3DDevelopment%2520of%2520Novel%2520Tools%2520for%2520the%2520In%2520Vitro%2520Investigation%2520of%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2015%26volume%3D11%26spage%3D1523%26epage%3D1537%26doi%3D10.1517%2F17425255.2015.1065814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Messner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarkova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelm, J. M.</span></span> <span> </span><span class="NLM_article-title">Multi-Cell Type Human Liver Microtissues for Hepatotoxicity Testing</span>. <i>Arch. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1007/s00204-012-0968-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs00204-012-0968-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=23143619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Cqtr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=209-213&author=S.+Messnerauthor=I.+Agarkovaauthor=W.+Moritzauthor=J.+M.+Kelm&title=Multi-Cell+Type+Human+Liver+Microtissues+for+Hepatotoxicity+Testing&doi=10.1007%2Fs00204-012-0968-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-cell type human liver microtissues for hepatotoxicity testing</span></div><div class="casAuthors">Messner, S.; Agarkova, I.; Moritz, W.; Kelm, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">209-213</span>CODEN:
                <span class="NLM_cas:coden">ARTODN</span>;
        ISSN:<span class="NLM_cas:issn">0340-5761</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Current 2-dimensional hepatic model systems often fail to predict chem. induced hepatotoxicity due to the loss of a hepatocyte-specific phenotype in culture.  For more predictive in vitro models, hepatocytes have to be maintained in a 3-dimensional environment that allows for polarization and cell-cell contacts.  Preferably, the model will reflect an in vivo-like multi-cell type environment necessary for liver-like responses.  Here, we report the characterization of a multi-cell type microtissue model, generated from primary human hepatocytes and liver-derived non-parenchymal cells.  Liver microtissues were stable and functional for 5 wk in culture enabling, for example, long-term toxicity testing of acetaminophen and diclofenac.  In addn., Kupffer cells were responsive to inflammatory stimuli such as LPS demonstrating the possibility to detect inflammation-mediated toxicity as exemplified by the drug trovafloxacin.  Herewith, we present a novel 3D liver model for routine testing in 96-well format capable of reducing the risk of unwanted toxic effects in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQq2Hv7htlwLVg90H21EOLACvtfcHk0li3cwCyFmifgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Cqtr%252FE&md5=c7a46017126bb80d6983c09bf71c3592</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1007%2Fs00204-012-0968-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00204-012-0968-2%26sid%3Dliteratum%253Aachs%26aulast%3DMessner%26aufirst%3DS.%26aulast%3DAgarkova%26aufirst%3DI.%26aulast%3DMoritz%26aufirst%3DW.%26aulast%3DKelm%26aufirst%3DJ.%2BM.%26atitle%3DMulti-Cell%2520Type%2520Human%2520Liver%2520Microtissues%2520for%2520Hepatotoxicity%2520Testing%26jtitle%3DArch.%2520Toxicol.%26date%3D2013%26volume%3D87%26spage%3D209%26epage%3D213%26doi%3D10.1007%2Fs00204-012-0968-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tostões, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leite, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björquist, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrondo, M. J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alves, P. M.</span></span> <span> </span><span class="NLM_article-title">Human Liver Cell Spheroids in Extended Perfusion Bioreactor Culture for Repeated-Dose Drug Testing</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1227</span>– <span class="NLM_lpage">1236</span>, <span class="refDoi"> DOI: 10.1002/hep.24760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.24760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22031499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1yjs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1227-1236&author=R.+M.+Tost%C3%B5esauthor=S.+B.+Leiteauthor=M.+Serraauthor=J.+Jensenauthor=P.+Bj%C3%B6rquistauthor=M.+J.+T.+Carrondoauthor=C.+Britoauthor=P.+M.+Alves&title=Human+Liver+Cell+Spheroids+in+Extended+Perfusion+Bioreactor+Culture+for+Repeated-Dose+Drug+Testing&doi=10.1002%2Fhep.24760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Human liver cell spheroids in extended perfusion bioreactor culture for repeated-dose drug testing</span></div><div class="casAuthors">Tostoes, Rui M.; Leite, Sofia B.; Serra, Margarida; Jensen, Janne; Bjoerquist, Petter; Carrondo, Manuel J. T.; Brito, Catarina; Alves, Paula M.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1227-1236</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Primary cultures of human hepatocyte spheroids are a promising in vitro model for long-term studies of hepatic metab. and cytotoxicity.  The lack of robust methodologies to culture cell spheroids, as well as a poor characterization of human hepatocyte spheroid architecture and liver-specific functionality, have hampered a widespread adoption of this three-dimensional culture format.  In this work, an automated perfusion bioreactor was used to obtain and maintain human hepatocyte spheroids.  These spheroids were cultured for 3-4 wk in serum-free conditions, sustaining their phase I enzyme expression and permitting repeated induction during long culture times; rate of albumin and urea synthesis, as well as phase I and II drug-metabolizing enzyme gene expression and activity of spheroid hepatocyte cultures, presented reproducible profiles, despite basal interdonor variability (n = 3 donors).  Immunofluorescence microscopy of human hepatocyte spheroids after 3-4 wk of long-term culture confirmed the presence of the liver-specific markers, hepatocyte nuclear factor 4α, albumin, cytokeratin 18, and cytochrome P 450 3A.  Moreover, immunostaining of the atypical protein kinase C apical marker, as well as the excretion of a fluorescent dye, evidenced that these spheroids spontaneously assemble a functional bile canaliculi network, extending from the surface to the interior of the spheroids, after 3-4 wk of culture.  Conclusion: Perfusion bioreactor cultures of primary human hepatocyte spheroids maintain a liver-specific activity and architecture and are thus suitable for drug testing in a long-term, repeated-dose format. (HEPATOl. 2012).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppAQ4NtBK0grVg90H21EOLACvtfcHk0li3cwCyFmifgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1yjs70%253D&md5=a20fe734e748c3d84ec5b90cab1d498d</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1002%2Fhep.24760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.24760%26sid%3Dliteratum%253Aachs%26aulast%3DTost%25C3%25B5es%26aufirst%3DR.%2BM.%26aulast%3DLeite%26aufirst%3DS.%2BB.%26aulast%3DSerra%26aufirst%3DM.%26aulast%3DJensen%26aufirst%3DJ.%26aulast%3DBj%25C3%25B6rquist%26aufirst%3DP.%26aulast%3DCarrondo%26aufirst%3DM.%2BJ.%2BT.%26aulast%3DBrito%26aufirst%3DC.%26aulast%3DAlves%26aufirst%3DP.%2BM.%26atitle%3DHuman%2520Liver%2520Cell%2520Spheroids%2520in%2520Extended%2520Perfusion%2520Bioreactor%2520Culture%2520for%2520Repeated-Dose%2520Drug%2520Testing%26jtitle%3DHepatology%26date%3D2012%26volume%3D55%26spage%3D1227%26epage%3D1236%26doi%3D10.1002%2Fhep.24760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, D. F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moro, S. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renblom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredriksson
Puigvert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dankers, A. C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeys, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sison-Young, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordling, Å.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mkrtchian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitteringham, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingelman-Sundberg, M.</span></span> <span> </span><span class="NLM_article-title">Characterization of Primary Human Hepatocyte Spheroids as a Model System for Drug-Induced Liver Injury, Liver Function and Disease</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">25187</span>, <span class="refDoi"> DOI: 10.1038/srep25187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fsrep25187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27143246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsVenurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=25187&author=C.+C.+Bellauthor=D.+F.+G.+Hendriksauthor=S.+M.+L.+Moroauthor=E.+Ellisauthor=J.+Walshauthor=A.+Renblomauthor=L.+Fredriksson%0APuigvertauthor=A.+C.+A.+Dankersauthor=F.+Jacobsauthor=J.+Snoeysauthor=R.+L.+Sison-Youngauthor=R.+E.+Jenkinsauthor=%C3%85.+Nordlingauthor=S.+Mkrtchianauthor=B.+K.+Parkauthor=N.+R.+Kitteringhamauthor=C.+E.+P.+Goldringauthor=V.+M.+Lauschkeauthor=M.+Ingelman-Sundberg&title=Characterization+of+Primary+Human+Hepatocyte+Spheroids+as+a+Model+System+for+Drug-Induced+Liver+Injury%2C+Liver+Function+and+Disease&doi=10.1038%2Fsrep25187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease</span></div><div class="casAuthors">Bell, Catherine C.; Hendriks, Delilah F. G.; Moro, Sabrina M. L.; Ellis, Ewa; Walsh, Joanne; Renblom, Anna; Fredriksson Puigvert, Lisa; Dankers, Anita C. A.; Jacobs, Frank; Snoeys, Jan; Sison-Young, Rowena L.; Jenkins, Rosalind E.; Nordling, Aasa; Mkrtchian, Souren; Park, B. Kevin; Kitteringham, Neil R.; Goldring, Christopher E. P.; Lauschke, Volker M.; Ingelman-Sundberg, Magnus</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25187</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Liver biol. and function, drug-induced liver injury (DILI) and liver diseases are difficult to study using current in vitro models such as primary human hepatocyte (PHH) monolayer cultures, as their rapid de-differentiation restricts their usefulness substantially.  Thus, we have developed and extensively characterized an easily scalable 3D PHH spheroid system in chem.-defined, serum-free conditions.  Using whole proteome analyses, we found that PHH spheroids cultured this way were similar to the liver in vivo and even retained their inter-individual variability.  Furthermore, PHH spheroids remained phenotypically stable and retained morphol., viability, and hepatocyte-specific functions for culture periods of at least 5 wk.  We show that under chronic exposure, the sensitivity of the hepatocytes drastically increased and toxicity of a set of hepatotoxins was detected at clin. relevant concns.  An interesting example was the chronic toxicity of fialuridine for which hepatotoxicity was mimicked after repeated-dosing in the PHH spheroid model, not possible to detect using previous in vitro systems.  Addnl., we provide proof-of-principle that PHH spheroids can reflect liver pathologies such as cholestasis, steatosis and viral hepatitis.  Combined, our results demonstrate that the PHH spheroid system presented here constitutes a versatile and promising in vitro system to study liver function, liver diseases, drug targets and long-term DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXCMcqP2wXk7Vg90H21EOLACvtfcHk0li3cwCyFmifgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsVenurs%253D&md5=ffb2cbc26578c469a618a2ebe8590e1a</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1038%2Fsrep25187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep25187%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DC.%2BC.%26aulast%3DHendriks%26aufirst%3DD.%2BF.%2BG.%26aulast%3DMoro%26aufirst%3DS.%2BM.%2BL.%26aulast%3DEllis%26aufirst%3DE.%26aulast%3DWalsh%26aufirst%3DJ.%26aulast%3DRenblom%26aufirst%3DA.%26aulast%3DFredriksson%2BPuigvert%26aufirst%3DL.%26aulast%3DDankers%26aufirst%3DA.%2BC.%2BA.%26aulast%3DJacobs%26aufirst%3DF.%26aulast%3DSnoeys%26aufirst%3DJ.%26aulast%3DSison-Young%26aufirst%3DR.%2BL.%26aulast%3DJenkins%26aufirst%3DR.%2BE.%26aulast%3DNordling%26aufirst%3D%25C3%2585.%26aulast%3DMkrtchian%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DKitteringham%26aufirst%3DN.%2BR.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%2BP.%26aulast%3DLauschke%26aufirst%3DV.%2BM.%26aulast%3DIngelman-Sundberg%26aufirst%3DM.%26atitle%3DCharacterization%2520of%2520Primary%2520Human%2520Hepatocyte%2520Spheroids%2520as%2520a%2520Model%2520System%2520for%2520Drug-Induced%2520Liver%2520Injury%252C%2520Liver%2520Function%2520and%2520Disease%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D25187%26doi%3D10.1038%2Fsrep25187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramaiahgari, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waidyanatha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVito, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paules, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, S. S.</span></span> <span> </span><span class="NLM_article-title">Three-Dimensional (3D) HepaRG Spheroid Model With Physiologically Relevant Xenobiotic Metabolism Competence and Hepatocyte Functionality for Liver Toxicity Screening</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfx194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfx194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29077947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOrsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2017&pages=189-190&author=S.+C.+Ramaiahgariauthor=S.+Waidyanathaauthor=D.+Dixonauthor=M.+J.+DeVitoauthor=R.+S.+Paulesauthor=S.+S.+Ferguson&title=Three-Dimensional+%283D%29+HepaRG+Spheroid+Model+With+Physiologically+Relevant+Xenobiotic+Metabolism+Competence+and+Hepatocyte+Functionality+for+Liver+Toxicity+Screening&doi=10.1093%2Ftoxsci%2Fkfx194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Three-dimensional (3D) HepaRG spheroid model with physiologically relevant xenobiotic metabolism competence and hepatocyte functionality for liver toxicity screening [Erratum to document cited in CA168:323580]</span></div><div class="casAuthors">Ramaiahgari, Sreenivasa C.; Waidyanatha, Suramya; Dixon, Darlene; DeVito, Michael J.; Paules, Richard S.; Ferguson, Stephen S.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">189-190</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqppm5oIHdSK7Vg90H21EOLACvtfcHk0lge3eMyKB7ftQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOrsLzI&md5=99d9adb48c2e79d4d4d65231093f1ede</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfx194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfx194%26sid%3Dliteratum%253Aachs%26aulast%3DRamaiahgari%26aufirst%3DS.%2BC.%26aulast%3DWaidyanatha%26aufirst%3DS.%26aulast%3DDixon%26aufirst%3DD.%26aulast%3DDeVito%26aufirst%3DM.%2BJ.%26aulast%3DPaules%26aufirst%3DR.%2BS.%26aulast%3DFerguson%26aufirst%3DS.%2BS.%26atitle%3DThree-Dimensional%2520%25283D%2529%2520HepaRG%2520Spheroid%2520Model%2520With%2520Physiologically%2520Relevant%2520Xenobiotic%2520Metabolism%2520Competence%2520and%2520Hepatocyte%2520Functionality%2520for%2520Liver%2520Toxicity%2520Screening%26jtitle%3DToxicol.%2520Sci.%26date%3D2017%26volume%3D160%26spage%3D189%26epage%3D190%26doi%3D10.1093%2Ftoxsci%2Fkfx194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kermanizadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Løhr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roursgaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunness, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelm, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Møller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loft, S.</span></span> <span> </span><span class="NLM_article-title">Hepatic Toxicology Following Single and Multiple Exposure of Engineered Nanomaterials Utilising a Novel Primary Human 3D Liver Microtissue Model</span>. <i>Part. Fibre Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">56</span>, <span class="refDoi"> DOI: 10.1186/s12989-014-0056-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1186%2Fs12989-014-0056-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25326698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVyhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=56&author=A.+Kermanizadehauthor=M.+L%C3%B8hrauthor=M.+Roursgaardauthor=S.+Messnerauthor=P.+Gunnessauthor=J.+M.+Kelmauthor=P.+M%C3%B8llerauthor=V.+Stoneauthor=S.+Loft&title=Hepatic+Toxicology+Following+Single+and+Multiple+Exposure+of+Engineered+Nanomaterials+Utilising+a+Novel+Primary+Human+3D+Liver+Microtissue+Model&doi=10.1186%2Fs12989-014-0056-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatic toxicology following single and multiple exposure of engineered nanomaterials utilising a novel primary human 3D liver microtissue model</span></div><div class="casAuthors">Kermanizadeh, Ali; Loehr, Mille; Roursgaard, Martin; Messner, Simon; Gunness, Patrina; Kelm, Jens M.; Moeller, Peter; Stone, Vicki; Loft, Steffen</div><div class="citationInfo"><span class="NLM_cas:title">Particle and Fibre Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">56/1-56/30, 30 pp.</span>CODEN:
                <span class="NLM_cas:coden">PFTABQ</span>;
        ISSN:<span class="NLM_cas:issn">1743-8977</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background The liver has a crucial role in metabolic homeostasis as well as being the principal detoxification center of the body, removing xenobiotics and waste products which could potentially include some nanomaterials (NM).  With the ever increasing public and occupational exposure assocd. with accumulative prodn. of nanomaterials, there is an urgent need to consider the possibility of detrimental health consequences of engineered NM exposure.  It has been shown that exposure via inhalation, intratracheal instillation or ingestion can result in NM translocation to the liver.  Traditional in vitro or ex vivo hepatic nanotoxicol. models are often limiting and/or troublesome (i.e. reduced metab. enzymes, lacking important cell populations, unstable with very high variability, etc.).  Methods In order to rectify these issues and for the very first time we have utilized a 3D human liver microtissue model to investigate the toxicol. effects assocd. with a single or multiple exposure of a panel of engineered NMs (Ag, ZnO, MWCNT and a pos. charged TiO2).  Results Here we demonstrate that the repeated exposure of the NMs is more damaging to the liver tissue as in comparison to a single exposure with the adverse effects more significant following treatment with the Ag and ZnO as compared with the TiO2 and MWCNT NMs (in terms of cytotoxicity, cytokine secretion, lipid peroxidn. and genotoxicity).  Conclusions Overall, this study demonstrates that the human microtissue model utilized herein is an excellent candidate for replacement of traditional in vitro single cell hepatic models and further progression of liver nanotoxicol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoun93iSUGt37Vg90H21EOLACvtfcHk0lge3eMyKB7ftQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVyhtg%253D%253D&md5=0a1b9f92c787dcea01ff149102ac8128</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1186%2Fs12989-014-0056-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12989-014-0056-2%26sid%3Dliteratum%253Aachs%26aulast%3DKermanizadeh%26aufirst%3DA.%26aulast%3DL%25C3%25B8hr%26aufirst%3DM.%26aulast%3DRoursgaard%26aufirst%3DM.%26aulast%3DMessner%26aufirst%3DS.%26aulast%3DGunness%26aufirst%3DP.%26aulast%3DKelm%26aufirst%3DJ.%2BM.%26aulast%3DM%25C3%25B8ller%26aufirst%3DP.%26aulast%3DStone%26aufirst%3DV.%26aulast%3DLoft%26aufirst%3DS.%26atitle%3DHepatic%2520Toxicology%2520Following%2520Single%2520and%2520Multiple%2520Exposure%2520of%2520Engineered%2520Nanomaterials%2520Utilising%2520a%2520Novel%2520Primary%2520Human%25203D%2520Liver%2520Microtissue%2520Model%26jtitle%3DPart.%2520Fibre%2520Toxicol.%26date%3D2014%26volume%3D11%26spage%3D56%26doi%3D10.1186%2Fs12989-014-0056-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crogan-Grundy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presnell, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, A. B.</span></span> <span> </span><span class="NLM_article-title">Bioprinted 3D Primary Liver Tissues Allow Assessment of Organ-Level Response to Clinical Drug Induced Toxicity</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0158674</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0158674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1371%2Fjournal.pone.0158674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27387377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVKnurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0158674&author=D.+G.+Nguyenauthor=J.+Funkauthor=J.+B.+Robbinsauthor=C.+Crogan-Grundyauthor=S.+C.+Presnellauthor=T.+Singerauthor=A.+B.+Roth&title=Bioprinted+3D+Primary+Liver+Tissues+Allow+Assessment+of+Organ-Level+Response+to+Clinical+Drug+Induced+Toxicity&doi=10.1371%2Fjournal.pone.0158674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro</span></div><div class="casAuthors">Nguyen, Deborah G.; Funk, Juergen; Robbins, Justin B.; Crogan-Grundy, Candace; Presnell, Sharon C.; Singer, Thomas; Roth, Adrian B.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e0158674/1-e0158674/17</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Modeling clin. relevant tissue responses using cell models poses a significant challenge for drug development, in particular for drug induced liver injury (DILI).  This is mainly because existing liver models lack longevity and tissue-level complexity which limits their utility in predictive toxicol.  In this study, we established and characterized novel bioprinted human liver tissue mimetics comprised of patient-derived hepatocytes and nonparenchymal cells in a defined architecture.  Scaffold-free assembly of different cell types in an in vivo-relevant architecture allowed for histol. anal. that revealed distinct intercellular hepatocyte junctions, CD31+ endothelial networks, and desmin pos., smooth muscle actin neg. quiescent stellates.  Unlike what was seen in 2D hepatocyte cultures, the tissues maintained levels of ATP, Albumin as well as expression and drug-induced enzyme activity of Cytochrome P450s over 4 wk in culture.  To assess the ability of the 3D liver cultures to model tissue-level DILI, dose responses of Trovafloxacin, a drug whose hepatotoxic potential could not be assessed by std. pre-clin. models, were compared to the structurally related non-toxic drug Levofloxacin.  Trovafloxacin induced significant, dosedependent toxicity at clin. relevant doses (≤ 4uM).  Interestingly, Trovafloxacin toxicity was obsd. without lipopolysaccharide stimulation and in the absence of resident macrophages in contrast to earlier reports.  Together, these results demonstrate that 3D bioprinted liver tissues can both effectively model DILI and distinguish between highly related compds. with differential profile.  Thus, the combination of patient-derived primary cells with bioprinting technol. here for the first time demonstrates superior performance in terms of mimicking human drug response in a known target organ at the tissue level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYl7I6xmS4qrVg90H21EOLACvtfcHk0lge3eMyKB7ftQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVKnurnI&md5=3444083b1e6affcca18ae9063c66ae90</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0158674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0158674%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DD.%2BG.%26aulast%3DFunk%26aufirst%3DJ.%26aulast%3DRobbins%26aufirst%3DJ.%2BB.%26aulast%3DCrogan-Grundy%26aufirst%3DC.%26aulast%3DPresnell%26aufirst%3DS.%2BC.%26aulast%3DSinger%26aufirst%3DT.%26aulast%3DRoth%26aufirst%3DA.%2BB.%26atitle%3DBioprinted%25203D%2520Primary%2520Liver%2520Tissues%2520Allow%2520Assessment%2520of%2520Organ-Level%2520Response%2520to%2520Clinical%2520Drug%2520Induced%2520Toxicity%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0158674%26doi%3D10.1371%2Fjournal.pone.0158674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norona, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presnell, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCluyse, E. L.</span></span> <span> </span><span class="NLM_article-title">Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfw169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfw169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27605418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktlWltbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2016&pages=354-367&author=L.+M.+Noronaauthor=D.+G.+Nguyenauthor=D.+A.+Gerberauthor=S.+C.+Presnellauthor=E.+L.+LeCluyse&title=Modeling+Compound-Induced+Fibrogenesis+In+Vitro+Using+Three-Dimensional+Bioprinted+Human+Liver+Tissues&doi=10.1093%2Ftoxsci%2Fkfw169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling compound-induced fibrogenesis in vitro using three-dimensional bioprinted human liver tissues</span></div><div class="casAuthors">Norona, Leah M.; Nguyen, Deborah G.; Gerber, David A.; Presnell, Sharon C.; LeCluyse, Edward L.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">354-367</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Compd.-induced liver injury leading to fibrosis remains a challenge for the development of an Adverse Outcome Pathway useful for human risk assessment.  Latency to detection and lack of early, systematically detectable biomarkers make it difficult to characterize the dynamic and complex intercellular interactions that occur during progressive liver injury.  Here, we demonstrate the utility of bioprinted tissue constructs comprising primary hepatocytes, hepatic stellate cells, and endothelial cells to model methotrexate- and thioacetamide-induced liver injury leading to fibrosis.  Repeated, low-concn. exposure to these compds. enabled the detection and differentiation of multiple modes of liver injury, including hepatocellular damage, and progressive fibrogenesis characterized by the deposition and accumulation of fibrillar collagens in patterns analogous to those described in clin. samples obtained from patients with fibrotic liver injury.  Transient cytokine prodn. and upregulation of fibrosis-assocd. genes ACTA2 and COL1A1 mimics hallmark features of a classic wound-healing response.  A surge in proinflammatory cytokines (eg, IL-8, IL-1β) during the early culture time period is followed by concn.- and treatment-dependent alterations in immunomodulatory and chemotactic cytokines such as IL-13, IL-6, and MCP-1.  These combined data provide strong proof-of-concept that 3D bioprinted liver tissues can recapitulate drug-, chem.-, and TGF-β1-induced fibrogenesis at the cellular, mol., and histol. levels and underscore the value of the model for further exploration of compd.-specific fibrogenic responses.  This novel system will enable a more comprehensive characterization of key attributes unique to fibrogenic agents during the onset and progression of liver injury as well as mechanistic insights, thus improving compd. risk assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS9EosUREC5rVg90H21EOLACvtfcHk0li3CAKxlCbUkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktlWltbo%253D&md5=e3174cf98f9138eb75aa18abde6bcaba</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfw169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfw169%26sid%3Dliteratum%253Aachs%26aulast%3DNorona%26aufirst%3DL.%2BM.%26aulast%3DNguyen%26aufirst%3DD.%2BG.%26aulast%3DGerber%26aufirst%3DD.%2BA.%26aulast%3DPresnell%26aufirst%3DS.%2BC.%26aulast%3DLeCluyse%26aufirst%3DE.%2BL.%26atitle%3DModeling%2520Compound-Induced%2520Fibrogenesis%2520In%2520Vitro%2520Using%2520Three-Dimensional%2520Bioprinted%2520Human%2520Liver%2520Tissues%26jtitle%3DToxicol.%2520Sci.%26date%3D2016%26volume%3D154%26spage%3D354%26epage%3D367%26doi%3D10.1093%2Ftoxsci%2Fkfw169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vivares, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salle-Lefort, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arabeyre-Fabre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penarier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremond, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moliner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallas, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klieber, S.</span></span> <span> </span><span class="NLM_article-title">Morphological Behaviour and Metabolic Capacity of Cryopreserved Human Primary Hepatocytes Cultivated in a Perfused Multiwell Device</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.3109/00498254.2014.944612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.3109%2F00498254.2014.944612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25068923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVaqsL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=29-44&author=A.+Vivaresauthor=S.+Salle-Lefortauthor=C.+Arabeyre-Fabreauthor=R.+Ngoauthor=G.+Penarierauthor=M.+Bremondauthor=P.+Molinerauthor=J.-F.+Gallasauthor=G.+Fabreauthor=S.+Klieber&title=Morphological+Behaviour+and+Metabolic+Capacity+of+Cryopreserved+Human+Primary+Hepatocytes+Cultivated+in+a+Perfused+Multiwell+Device&doi=10.3109%2F00498254.2014.944612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device</span></div><div class="casAuthors">Vivares, Aurelie; Salle-Lefort, Sandrine; Arabeyre-Fabre, Catherine; Ngo, Robert; Penarier, Geraldine; Bremond, Michele; Moliner, Patricia; Gallas, Jean-Francois; Fabre, Gerard; Klieber, Sylvie</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-44</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">1. The quant. prediction of the pharmacokinetic parameters of a drug from data obtained using human in vitro systems remains a significant challenge i.e. prediction of metabolic clearance in humans and estn. of the relative contribution of enzymes involved in the clearance.  This has become particularly problematic for low turnover compds.  2. Having human hepatocytes with stable cellular function over several days that adequately mimic the complexity of the physiol. environment would be a major advance.  Thus, we evaluated human hepatocytes, maintained in culture during 7 days in the microfluidic LiverChip® system, in terms of morphol. appearance, relative mRNA expression of phase I and II enzymes and transporters as a function of time, and metabolic capacity using probe substrates.  3. The results showed that mRNA levels of the major genes for enzymes involved in drug metab. were well-maintained over a 7-day period of culture.  Furthermore, after 4 days of culture, in the Liverchip® device, human hepatocytes exhibited higher or similar CYPs activities compared to 1 day of culture in 2D-static conditions.  4. The functional data were supported by light/electron microscopies and immunohistochem. showing viable tissue structure and well-differentiated human hepatocytes: presence of cell junctions, glycogen storage, and bile canaliculi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4Ixn_wkAcULVg90H21EOLACvtfcHk0li3CAKxlCbUkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVaqsL3J&md5=d905bfe7b3092d34fae2230e434d769e</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.3109%2F00498254.2014.944612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2014.944612%26sid%3Dliteratum%253Aachs%26aulast%3DVivares%26aufirst%3DA.%26aulast%3DSalle-Lefort%26aufirst%3DS.%26aulast%3DArabeyre-Fabre%26aufirst%3DC.%26aulast%3DNgo%26aufirst%3DR.%26aulast%3DPenarier%26aufirst%3DG.%26aulast%3DBremond%26aufirst%3DM.%26aulast%3DMoliner%26aufirst%3DP.%26aulast%3DGallas%26aufirst%3DJ.-F.%26aulast%3DFabre%26aufirst%3DG.%26aulast%3DKlieber%26aufirst%3DS.%26atitle%3DMorphological%2520Behaviour%2520and%2520Metabolic%2520Capacity%2520of%2520Cryopreserved%2520Human%2520Primary%2520Hepatocytes%2520Cultivated%2520in%2520a%2520Perfused%2520Multiwell%2520Device%26jtitle%3DXenobiotica%26date%3D2015%26volume%3D45%26spage%3D29%26epage%3D44%26doi%3D10.3109%2F00498254.2014.944612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terelius, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figler, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marukian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collado, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackey, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qualls, C. W.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackman, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wamhoff, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dash, A.</span></span> <span> </span><span class="NLM_article-title">Transcriptional Profiling Suggests that Nevirapine and Ritonavir Cause Drug-Induced Liver Injury Through Distinct Mechanisms in Primary Human Hepatocytes</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>255</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2015.11.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.cbi.2015.11.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26626330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVemtL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=2016&pages=31-44&author=Y.+Tereliusauthor=R.+A.+Figlerauthor=S.+Marukianauthor=M.+S.+Colladoauthor=M.+J.+Lawsonauthor=A.+J.+Mackeyauthor=D.+Mankaauthor=C.+W.+Quallsauthor=B.+R.+Blackmanauthor=B.+R.+Wamhoffauthor=A.+Dash&title=Transcriptional+Profiling+Suggests+that+Nevirapine+and+Ritonavir+Cause+Drug-Induced+Liver+Injury+Through+Distinct+Mechanisms+in+Primary+Human+Hepatocytes&doi=10.1016%2Fj.cbi.2015.11.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes</span></div><div class="casAuthors">Terelius, Ylva; Figler, Robert A.; Marukian, Svetlana; Collado, Maria S.; Lawson, Mark J.; Mackey, Aaron J.; Manka, David; Qualls, Charles W. Jr.; Blackman, Brett R.; Wamhoff, Brian R.; Dash, Ajit</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">255</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-44</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Drug induced liver injury (DILI), a major cause of pre- and post-approval failure, is challenging to predict pre-clin. due to varied underlying direct and indirect mechanisms.  Nevirapine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) and Ritonavir, a protease inhibitor, are antiviral drugs that cause clin. DILI with different phenotypes via different mechanisms.  Assessing DILI in vitro in hepatocyte cultures typically requires drug exposures significantly higher than clin. plasma Cmax concns., making clin. interpretations of mechanistic pathway changes challenging.  We previously described a system that uses liver-derived hemodynamic blood flow and transport parameters to restore primary human hepatocyte biol., and drug responses at concns. relevant to in vivo or clin. exposure levels.  Using this system, primary hepatocytes from 5 human donors were exposed to concns. approximating clin. therapeutic and supra-therapeutic levels of Nevirapine (11.3 and 175.0 μM) and Ritonavir (3.5 and 62.4 μM) for 48 h.  Whole genome transcriptomics was performed by RNAseq along with functional assays for metabolic activity and function.  We obsd. effects at both doses, but a greater no. of genes were differentially expressed with higher probability at the toxic concns.  At the toxic doses, both drugs showed direct cholestatic potential with Nevirapine increasing bile synthesis and Ritonavir inhibiting bile acid transport.  Clear differences in antigen presentation were noted, with marked activation of MHC Class I by Nevirapine and suppression by Ritonavir.  This suggests CD8+ T cell involvement for Nevirapine and possibly NK Killer cells for Ritonavir.  Both compds. induced several drug metabolizing genes (including CYP2B6, CYP3A4 and UGT1A1), mediated by CAR activation in Nevirapine and PXR in Ritonavir.  Unlike Ritonavir, Nevirapine did not increase fatty acid synthesis or activate the respiratory electron chain with simultaneous mitochondrial uncoupling supporting clin. reports of a lower propensity for steatosis.  This in vitro study offers insights into the disparate direct and immune-mediated toxicity mechanisms underlying Nevirapine and Ritonavir toxicity in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPJRgkob9Ig7Vg90H21EOLACvtfcHk0lizMuGIdha0AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVemtL3P&md5=6859f4b344b3c7e3e7186dda03fb999d</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2015.11.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2015.11.023%26sid%3Dliteratum%253Aachs%26aulast%3DTerelius%26aufirst%3DY.%26aulast%3DFigler%26aufirst%3DR.%2BA.%26aulast%3DMarukian%26aufirst%3DS.%26aulast%3DCollado%26aufirst%3DM.%2BS.%26aulast%3DLawson%26aufirst%3DM.%2BJ.%26aulast%3DMackey%26aufirst%3DA.%2BJ.%26aulast%3DManka%26aufirst%3DD.%26aulast%3DQualls%26aufirst%3DC.%2BW.%26aulast%3DBlackman%26aufirst%3DB.%2BR.%26aulast%3DWamhoff%26aufirst%3DB.%2BR.%26aulast%3DDash%26aufirst%3DA.%26atitle%3DTranscriptional%2520Profiling%2520Suggests%2520that%2520Nevirapine%2520and%2520Ritonavir%2520Cause%2520Drug-Induced%2520Liver%2520Injury%2520Through%2520Distinct%2520Mechanisms%2520in%2520Primary%2520Human%2520Hepatocytes%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2016%26volume%3D255%26spage%3D31%26epage%3D44%26doi%3D10.1016%2Fj.cbi.2015.11.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span> <span> </span><span class="NLM_article-title">Application of Hepatocyte-Like Cells to Enhance Hepatic Safety Risk Assessment in Drug Discovery</span>. <i>Philos. Trans. R. Soc., B</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">20170228</span>, <span class="refDoi"> DOI: 10.1098/rstb.2017.0228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1098%2Frstb.2017.0228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29786562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Olt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2018&pages=20170228&author=D.+P.+Williams&title=Application+of+Hepatocyte-Like+Cells+to+Enhance+Hepatic+Safety+Risk+Assessment+in+Drug+Discovery&doi=10.1098%2Frstb.2017.0228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Application of hepatocyte-like cells to enhance hepatic safety risk assessment in drug discovery</span></div><div class="casAuthors">Williams, Dominic P.</div><div class="citationInfo"><span class="NLM_cas:title">Philosophical Transactions of the Royal Society, B: Biological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">1750</span>),
    <span class="NLM_cas:pages">20170228/1-20170228/8</span>CODEN:
                <span class="NLM_cas:coden">PTRBAE</span>;
        ISSN:<span class="NLM_cas:issn">0962-8436</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">Hepatic stress and injury from drugs continues to be a major concern within the pharmaceutical industry, leading to preclin. and clin. attrition precautionary warnings and post-market withdrawal of drugs.  There is a requirement for more predictive and mechanistically accurate models to aid risk assessment.  Primary human hepatocytes, subject to isolation stress, cryopreservation, donor-to-donor variation and a relatively short period of functional capability in two-dimensional cultures, are not suitable for high-throughput screening procedures.  There are two areas within the drug discovery pipeline that the generation of a stable, metabolically functional hepatocyte-like cell with unlimited supply would have major impact.  First, in routine, cell health risk-assessment assays where hepatic cell lines are typically deployed.  Second, at later stages of the drug discovery pipeline approaching candidate nomination where bespoke/investigational studies refining and understanding the risk to patients use patient-derived induced pluripotent stem cell (iPSC) hepatocytes retaining characteristics from the patient, e.g.  HLA susceptibility alleles, iPSC hepatocytes with defined disease phenotypes or genetic characteristics that have the potential to make the hepatocyte more sensitive to a particular stress mechanism.  Functionality of patient-centric hepatocyte- like cells is likely to be enhanced when coupled with emerging culture systems, such as three-dimensional spheroids or microphysiol. systems.  Ultimately, the aspiration to confidently use human-relevant in vitro models to predict human-specific hepatic toxicity depends on the integration of promising emerging technologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof8RZ4jjszpbVg90H21EOLACvtfcHk0lizMuGIdha0AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Olt7g%253D&md5=e29e9972bc5afbb753af387b76cf3169</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1098%2Frstb.2017.0228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frstb.2017.0228%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26atitle%3DApplication%2520of%2520Hepatocyte-Like%2520Cells%2520to%2520Enhance%2520Hepatic%2520Safety%2520Risk%2520Assessment%2520in%2520Drug%2520Discovery%26jtitle%3DPhilos.%2520Trans.%2520R.%2520Soc.%252C%2520B%26date%3D2018%26volume%3D373%26spage%3D20170228%26doi%3D10.1098%2Frstb.2017.0228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Claire, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, K. R.</span></span> <span> </span><span class="NLM_article-title">Automated Applications of Sandwich-Cultured Hepatocytes in the Evaluation of Hepatic Drug Transport</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1177/1087057111400192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1177%2F1087057111400192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=21393626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVKgtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=427-435&author=C.+H.+Perryauthor=W.+R.+Smithauthor=R.+L.+St.+Claireauthor=K.+R.+Brouwer&title=Automated+Applications+of+Sandwich-Cultured+Hepatocytes+in+the+Evaluation+of+Hepatic+Drug+Transport&doi=10.1177%2F1087057111400192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Automated applications of sandwich-cultured hepatocytes in the evaluation of hepatic drug transport</span></div><div class="casAuthors">Perry, Cassandra H.; Smith, William R.; St. Claire, Robert L., III; Brouwer, Kenneth R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">427-435</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Predictions of the absorption, distribution, metab., excretion, and toxicity of compds. in pharmaceutical development are essential aspects of the drug discovery process.  B-CLEAR is an in vitro system that uses sandwich-cultured hepatocytes to evaluate and predict in vivo hepatobiliary disposition (hepatic uptake, biliary excretion, and biliary clearance), transporter-based hepatic drug-drug interactions, and potential drug-induced hepatotoxicity.  Automation of predictive technologies is an advantageous and preferred format in drug discovery.  In this study, manual and automated studies are investigated and equivalence is demonstrated.  In addn., automated applications using model probe substrates and inhibitors to assess the cholestatic potential of drugs and evaluate hepatic drug transport are examd.  The successful automation of this technol. provides a more reproducible and less labor-intensive approach, reducing potential operator error in complex studies and facilitating technol. transfer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS5dDgVCuY2bVg90H21EOLACvtfcHk0lizMuGIdha0AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVKgtr0%253D&md5=236fcfaca75cca5c05cc2f60b6b22a02</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1177%2F1087057111400192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057111400192%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DC.%2BH.%26aulast%3DSmith%26aufirst%3DW.%2BR.%26aulast%3DSt.%2BClaire%26aufirst%3DR.%2BL.%26aulast%3DBrouwer%26aufirst%3DK.%2BR.%26atitle%3DAutomated%2520Applications%2520of%2520Sandwich-Cultured%2520Hepatocytes%2520in%2520the%2520Evaluation%2520of%2520Hepatic%2520Drug%2520Transport%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2011%26volume%3D16%26spage%3D427%26epage%3D435%26doi%3D10.1177%2F1087057111400192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Susukida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nozaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokizono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span> <span> </span><span class="NLM_article-title">Prediction of the Clinical Risk of Drug-Induced Cholestatic Liver Injury Using an In Vitro Sandwich Cultured Hepatocyte Assay</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1760</span>– <span class="NLM_lpage">1768</span>, <span class="refDoi"> DOI: 10.1124/dmd.115.065425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fdmd.115.065425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26329788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjtlyhtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=1760-1768&author=T.+Susukidaauthor=S.+Sekineauthor=M.+Nozakiauthor=M.+Tokizonoauthor=K.+Ito&title=Prediction+of+the+Clinical+Risk+of+Drug-Induced+Cholestatic+Liver+Injury+Using+an+In+Vitro+Sandwich+Cultured+Hepatocyte+Assay&doi=10.1124%2Fdmd.115.065425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of the clinical risk of drug-induced cholestatic liver injury using an in vitro sandwich cultured hepatocyte assay</span></div><div class="casAuthors">Susukida, Takeshi; Sekine, Shuichi; Nozaki, Mayuka; Tokizono, Mayuko; Ito, Kousei</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1760-1768</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is of concern to the pharmaceutical industry, and reliable preclin. screens are required.  Previously, we established an in vitro bile acid-dependent hepatotoxicity assay that mimics cholestatic DILI in vivo.  Here, we confirmed that this assay can predict cholestatic DILI in clin. situations by comparing in vitro cytotoxicity data with in vivo risk.  For 38 drugs, the frequencies of abnormal increases in serum alk. phosphatase (ALP), transaminases, gamma glutamyltranspeptidase (γGT), and bilirubin were collected from interview forms.  Drugs with frequencies of serum marker increases higher than 1% were classified as high DILI risk compds.  In vitro cytotoxicity was assessed by monitoring lactate dehydrogenase release from rat and human sandwich-cultured hepatocytes (SCRHs and SCHHs) incubated with the test drugs (50 μM) for 24 h in the absence or presence of a bile acids mixt.  Receiver operating characteristic analyses gave optimal cutoff toxicity values of 19.5% and 9.2% for ALP and transaminases in SCRHs, resp.  Using this cutoff, high- and low-risk drugs were sepd. with 65.4-78.6% sensitivity and 66.7-79.2% specificity.  Good sepn. was also achieved using SCHHs.  In conclusion, cholestatic DILI risk can be successfully predicted using a sandwich-cultured hepatocyte-based assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGOSZmxhKYD7Vg90H21EOLACvtfcHk0lizMuGIdha0AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjtlyhtbg%253D&md5=41ab968eddd9f1c4e87a6062c93d5671</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.065425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.065425%26sid%3Dliteratum%253Aachs%26aulast%3DSusukida%26aufirst%3DT.%26aulast%3DSekine%26aufirst%3DS.%26aulast%3DNozaki%26aufirst%3DM.%26aulast%3DTokizono%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DK.%26atitle%3DPrediction%2520of%2520the%2520Clinical%2520Risk%2520of%2520Drug-Induced%2520Cholestatic%2520Liver%2520Injury%2520Using%2520an%2520In%2520Vitro%2520Sandwich%2520Cultured%2520Hepatocyte%2520Assay%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D1760%26epage%3D1768%26doi%3D10.1124%2Fdmd.115.065425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oorts, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachellier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacharias, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annaert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span> <span> </span><span class="NLM_article-title">Drug-Induced Cholestasis Risk Assessment in Sandwich-Cultured Human Hepatocytes</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2016.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.tiv.2016.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27046439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVynt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=179-186&author=M.+Oortsauthor=A.+Bazeauthor=P.+Bachellierauthor=B.+Heydauthor=T.+Zachariasauthor=P.+Annaertauthor=L.+Richert&title=Drug-Induced+Cholestasis+Risk+Assessment+in+Sandwich-Cultured+Human+Hepatocytes&doi=10.1016%2Fj.tiv.2016.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced cholestasis risk assessment in sandwich-cultured human hepatocytes</span></div><div class="casAuthors">Oorts, Marlies; Baze, Audrey; Bachellier, Philippe; Heyd, Bruno; Zacharias, Thomas; Annaert, Pieter; Richert, Lysiane</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">179-186</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drug-induced cholestasis (DIC) is recognized as one of the prime mechanisms for DILI.  Hence, earlier detection of drug candidates with cholestatic signature is crucial.  Recently, the authors introduced an in vitro model for DIC and evaluated its performance with several cholestatic drugs.  The authors presently expand on the validation of this model by 14 training compds. (TCs) of the EU-EFPIA IMI project MIP-DILI.  Several batches of human hepatocytes in sandwich-culture were qualified for DIC assessment by verifying the bile acid-dependent increase in sensitivity to the toxic effects of cyclosporin A.  The cholestatic potential of the TCs was expressed by detg. the drug-induced cholestasis index (DICI).  A safety margin (SM) was calcd. as the ratio of the lowest TC concn. with a DICI ≤0.80 to the Cmax,total.  Nefazodone, bosentan, perhexiline and troglitazone were flagged for cholestasis (SM <30).  The hepatotoxic (but non-cholestatic) compds., amiodarone, diclofenac, fialuridine and ximelagatran, and all non-hepatotoxic compds. were cleared as "safe" for DIC.  Tolcapone and paracetamol yielded DICI-based SM values equal to or higher than those based on cytotoxicity, thus excluding DIC as a DILI mechanism.  This hepatocyte-based in vitro assay provides a unique tool for early and reliable identification of drug candidates with cholestasis risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE3lS_2gwnVbVg90H21EOLACvtfcHk0ljtiWJpNWtp0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVynt7o%253D&md5=0026ecbc5a6631f15e88daf497c675ae</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2016.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2016.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DOorts%26aufirst%3DM.%26aulast%3DBaze%26aufirst%3DA.%26aulast%3DBachellier%26aufirst%3DP.%26aulast%3DHeyd%26aufirst%3DB.%26aulast%3DZacharias%26aufirst%3DT.%26aulast%3DAnnaert%26aufirst%3DP.%26aulast%3DRichert%26aufirst%3DL.%26atitle%3DDrug-Induced%2520Cholestasis%2520Risk%2520Assessment%2520in%2520Sandwich-Cultured%2520Human%2520Hepatocytes%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2016%26volume%3D34%26spage%3D179%26epage%3D186%26doi%3D10.1016%2Fj.tiv.2016.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burbank, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burban, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharanek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guguen-Guillouzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillouzo, A.</span></span> <span> </span><span class="NLM_article-title">Early Alterations of Bile Canaliculi Dynamics and the Rho Kinase/Myosin Light Chain Kinase Pathway Are Characteristics of Drug-Induced Intrahepatic Cholestasis</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1780</span>– <span class="NLM_lpage">1793</span>, <span class="refDoi"> DOI: 10.1124/dmd.116.071373</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1124%2Fdmd.116.071373" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27538918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=1780-1793&author=M.+G.+Burbankauthor=A.+Burbanauthor=A.+Sharanekauthor=R.+J.+Weaverauthor=C.+Guguen-Guillouzoauthor=A.+Guillouzo&title=Early+Alterations+of+Bile+Canaliculi+Dynamics+and+the+Rho+Kinase%2FMyosin+Light+Chain+Kinase+Pathway+Are+Characteristics+of+Drug-Induced+Intrahepatic+Cholestasis&doi=10.1124%2Fdmd.116.071373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Early alterations of bile canaliculi dynamics and the Rho Kinase/myosin light chain kinase pathway are characteristics of drug-induced intrahepatic cholestasis</span></div><div class="casAuthors">Burbank, Matthew G.; Burban, Audrey; Sharanek, Ahmad; Weaver, Richard J.; Guguen-Guillouzo, Christiane; Guillouzo, Andre</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1780-1793</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Intrahepatic cholestasis represents 20%-40%of drug-induced injuries from which a large proportion remains unpredictable.  We aimed to investigate mechanisms underlying drug-induced cholestasis and improve its early detection using human HepaRG cells and a set of 12 cholestatic drugs and six noncholestatic drugs.  In this study, we analyzed bile canaliculi dynamics, Rho kinase (ROCK)/myosin light chain kinase (MLCK) pathway implication, efflux inhibition of taurocholate [a predominant bile salt export pump (BSEP) substrate], and expression of the major canalicular and basolateral bile acid transporters.  We demonstrated that 12 cholestatic drugs classified on the basis of reported clin. findings caused disturbances of both bile canaliculi dynamics, characterized by either dilatation or constriction, and alteration of the ROCK/MLCK signaling pathway, whereas noncholestatic compds., by contrast, had no effect.  Cotreatment with ROCK inhibitor Y-27632 [4-(1-aminoethyl)-N-(4-pyridyl) cyclohexanecarboxamide dihydrochloride] and MLCK activator calmodulin reduced bile canaliculi constriction and dilatation, resp., confirming the role of these pathways in drug-induced intrahepatic cholestasis.  By contrast, inhibition of taurocholate efflux and/or human BSEP overexpressed in membrane vesicles was not obsd. with all cholestatic drugs; moreover, examples of noncholestatic compds. were reportedly found to inhibit BSEP.  Transcripts levels of major bile acid transporters were detd. after 24-h treatment.  BSEP, Na+-taurocholate cotransporting polypeptide, and org. anion transporting polypeptide B were downregulated with most cholestatic and some noncholestatic drugs, whereas deregulation of multidrug resistance-assocd. proteins was more variable, probably mainly reflecting secondary effects.  Together, our results show that cholestatic drugs consistently cause an early alteration of bile canaliculi dynamics assocd. with modulation of ROCK/MLCK and these changes are more specific than efflux inhibition measurements alone as predictive nonclin. markers of drug-induced cholestasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrco-uclmICXrVg90H21EOLACvtfcHk0ljtiWJpNWtp0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKqsr8%253D&md5=3dc99c76abf38da1c8d8aaa12ee0b6d9</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.071373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.071373%26sid%3Dliteratum%253Aachs%26aulast%3DBurbank%26aufirst%3DM.%2BG.%26aulast%3DBurban%26aufirst%3DA.%26aulast%3DSharanek%26aufirst%3DA.%26aulast%3DWeaver%26aufirst%3DR.%2BJ.%26aulast%3DGuguen-Guillouzo%26aufirst%3DC.%26aulast%3DGuillouzo%26aufirst%3DA.%26atitle%3DEarly%2520Alterations%2520of%2520Bile%2520Canaliculi%2520Dynamics%2520and%2520the%2520Rho%2520Kinase%252FMyosin%2520Light%2520Chain%2520Kinase%2520Pathway%2520Are%2520Characteristics%2520of%2520Drug-Induced%2520Intrahepatic%2520Cholestasis%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2016%26volume%3D44%26spage%3D1780%26epage%3D1793%26doi%3D10.1124%2Fdmd.116.071373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharanek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burban, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burbank, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Guevel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillouzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guguen-Guillouzo, C.</span></span> <span> </span><span class="NLM_article-title">Rho-Kinase/Myosin Light Chain Kinase Pathway Plays a Key Role in the Impairment of Bile Canaliculi Dynamics Induced by Cholestatic Drugs</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>, <span class="refDoi"> DOI: 10.1038/srep24709</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fsrep24709" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27169750" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=A.+Sharanekauthor=A.+Burbanauthor=M.+Burbankauthor=R.+Le+Guevelauthor=R.+Liauthor=A.+Guillouzoauthor=C.+Guguen-Guillouzo&title=Rho-Kinase%2FMyosin+Light+Chain+Kinase+Pathway+Plays+a+Key+Role+in+the+Impairment+of+Bile+Canaliculi+Dynamics+Induced+by+Cholestatic+Drugs&doi=10.1038%2Fsrep24709"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1038%2Fsrep24709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep24709%26sid%3Dliteratum%253Aachs%26aulast%3DSharanek%26aufirst%3DA.%26aulast%3DBurban%26aufirst%3DA.%26aulast%3DBurbank%26aufirst%3DM.%26aulast%3DLe%2BGuevel%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DGuillouzo%26aufirst%3DA.%26aulast%3DGuguen-Guillouzo%26aufirst%3DC.%26atitle%3DRho-Kinase%252FMyosin%2520Light%2520Chain%2520Kinase%2520Pathway%2520Plays%2520a%2520Key%2520Role%2520in%2520the%2520Impairment%2520of%2520Bile%2520Canaliculi%2520Dynamics%2520Induced%2520by%2520Cholestatic%2520Drugs%26jtitle%3DSci.%2520Rep.%26date%3D2016%26doi%3D10.1038%2Fsrep24709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faulkner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinsson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoyo-Castelazo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cederbrant, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuppe-Koistinen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tugwood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">The Development of In Vitro Culture Methods to Characterize Primary T-Cell Responses to Drugs</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfs080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfs080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=22331489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtVaqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2012&pages=150-158&author=L.+Faulknerauthor=K.+Martinssonauthor=A.+Santoyo-Castelazoauthor=K.+Cederbrantauthor=I.+Schuppe-Koistinenauthor=H.+Powellauthor=J.+Tugwoodauthor=D.+J.+Naisbittauthor=B.+K.+Park&title=The+Development+of+In+Vitro+Culture+Methods+to+Characterize+Primary+T-Cell+Responses+to+Drugs&doi=10.1093%2Ftoxsci%2Fkfs080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">The Development of In Vitro Culture Methods to Characterize Primary T-Cell Responses to Drugs</span></div><div class="casAuthors">Faulkner, Lee; Martinsson, Klara; Santoyo-Castelazo, Anahi; Cederbrant, Karin; Schuppe-Koistinen, Ina; Powell, Helen; Tugwood, Jonathan; Naisbitt, Dean J.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">150-158</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Editor's Highlight: This paper reports an in vitro cell culture system from human donors for the prediction of the allergic potential of drugs.  Naive T cells were cultured in the presence of a drug and tested for transformation of the naive phenotype into a memory phenotype.  These results demonstrate a system that can predict possible drug allergy resulting in serious adverse effects in a system that does not utilize exptl. animals.  Adverse drug reactions represent a major stumbling block to drug development and those with an immune etiol. are the most difficult to predict.  We have developed an in vitro T-cell priming culture method using peripheral blood from healthy volunteers to assess the allergenic potential of drugs.  The drug metabolite nitroso sulfamethoxazole (SMX-NO) was used as a model drug allergen to establish optimum assay conditions.  Naive T cells were cocultured with monocyte-derived dendritic cells at a ratio of 25:1 in the presence of the drug for a period of 8 days, to expand the no. of drug-responsive T cells.  The T cells were then incubated with fresh dendritic cells, and drug and their antigen responsiveness analyzed using readouts for proliferation, cytokine secretion, and cell phenotype.  All five volunteers showed dose-dependent proliferation as measured by 5-(and 6)-carboxyfluorescein diacetate succinimidyl ester content and by 3H-thymidine uptake.  CD4 T cells that had divided in the presence of SMX-NO had changed from a naive phenotype (CD45RA+) to a memory phenotype (CD45RO+).  These memory T cells expressed the chemokine receptors CCR2, CCR4, and CXCR3 suggesting a mixt. of TH1 and TH2 cells in the responding population, with a propensity for homing to the skin.  Drug stimulation was also assocd. with the secretion of a mixt. of TH1 cytokines (interferon γ) and TH2 cytokines (interleukin [IL]-5 and IL-13) as detected by ELISpot.  We are currently developing this approach to investigate the allergenic potential of other drugs, including those where an assocn. between specific human leukocyte antigen alleles and susceptibility to an immunol. reaction has been established.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYOaBDU6Mb8bVg90H21EOLACvtfcHk0lik8KeR8xwRZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtVaqsbs%253D&md5=c3625da18d39f0b0a9ce667f61186cb7</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfs080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfs080%26sid%3Dliteratum%253Aachs%26aulast%3DFaulkner%26aufirst%3DL.%26aulast%3DMartinsson%26aufirst%3DK.%26aulast%3DSantoyo-Castelazo%26aufirst%3DA.%26aulast%3DCederbrant%26aufirst%3DK.%26aulast%3DSchuppe-Koistinen%26aufirst%3DI.%26aulast%3DPowell%26aufirst%3DH.%26aulast%3DTugwood%26aufirst%3DJ.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DThe%2520Development%2520of%2520In%2520Vitro%2520Culture%2520Methods%2520to%2520Characterize%2520Primary%2520T-Cell%2520Responses%2520to%2520Drugs%26jtitle%3DToxicol.%2520Sci.%26date%3D2012%26volume%3D127%26spage%3D150%26epage%3D158%26doi%3D10.1093%2Ftoxsci%2Fkfs080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGill, M. R.</span></span> <span> </span><span class="NLM_article-title">The Problem With Predictive Values: Are We Using the Right Metrics for Preclinical Prediction of Drug Hepatotoxicity?</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfy157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfy157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30165627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovFSgur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2018&pages=3-4&author=M.+R.+McGill&title=The+Problem+With+Predictive+Values%3A+Are+We+Using+the+Right+Metrics+for+Preclinical+Prediction+of+Drug+Hepatotoxicity%3F&doi=10.1093%2Ftoxsci%2Fkfy157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">The problem with predictive values: are we using the right metrics for preclinical prediction of drug hepatotoxicity?</span></div><div class="casAuthors">McGill, Mitchell R.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-5</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A polemic in response to Vorrink et al. ((2018), 163(2), 655-665).  Vorrink et al used predictive values as a way of expressing the ability of novel in vitro model systems to predict drug-induced liver injury (DILI), and as metrics that can be used to compare those systems, however, the author believes use of predictive values in that way is problematic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU_IIGlc7QhbVg90H21EOLACvtfcHk0lik8KeR8xwRZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovFSgur0%253D&md5=7ecebfd6929ed1bfa1a92e69eaa400a1</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfy157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfy157%26sid%3Dliteratum%253Aachs%26aulast%3DMcGill%26aufirst%3DM.%2BR.%26atitle%3DThe%2520Problem%2520With%2520Predictive%2520Values%253A%2520Are%2520We%2520Using%2520the%2520Right%2520Metrics%2520for%2520Preclinical%2520Prediction%2520of%2520Drug%2520Hepatotoxicity%253F%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D165%26spage%3D3%26epage%3D4%26doi%3D10.1093%2Ftoxsci%2Fkfy157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">Deep Learning for Drug-Induced Liver Injury</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2085</span>– <span class="NLM_lpage">2093</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.5b00238</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.5b00238" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1ShsLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=2085-2093&author=Y.+Xuauthor=Z.+Daiauthor=F.+Chenauthor=S.+Gaoauthor=J.+Peiauthor=L.+Lai&title=Deep+Learning+for+Drug-Induced+Liver+Injury&doi=10.1021%2Facs.jcim.5b00238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Deep Learning for Drug-Induced Liver Injury</span></div><div class="casAuthors">Xu, Youjun; Dai, Ziwei; Chen, Fangjin; Gao, Shuaishi; Pei, Jianfeng; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2085-2093</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) has been the single most frequent cause of safety-related drug marketing withdrawals for the past 50 years.  Recently, deep learning (DL) has been successfully applied in many fields due to its exceptional and automatic learning ability.  In this study, DILI prediction models were developed using DL architectures, and the best model trained on 475 drugs predicted an external validation set of 198 drugs with an accuracy of 86.9%, sensitivity of 82.5%, specificity of 92.9%, and area under the curve of 0.955, which is better than the performance of previously described DILI prediction models.  Furthermore, with deep anal., we also identified important mol. features that are related to DILI.  Such DL models could improve the prediction of DILI risk in humans.  The DL DILI prediction models are freely available at http://www.repharma.cn/DILIserver/DILI_home.php.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrELKXx1N9qkLVg90H21EOLACvtfcHk0lik8KeR8xwRZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1ShsLvO&md5=fad73f248e2caab2fb17dd0b1191e6e5</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.5b00238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.5b00238%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26aulast%3DDai%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DDeep%2520Learning%2520for%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2015%26volume%3D55%26spage%3D2085%26epage%3D2093%26doi%3D10.1021%2Facs.jcim.5b00238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, W.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Predicting Drug-Induced Liver Injury in Human With Naive Bayes Classifier Approach</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">889</span>– <span class="NLM_lpage">898</span>, <span class="refDoi"> DOI: 10.1007/s10822-016-9972-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs10822-016-9972-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27640149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFart7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=889-898&author=H.+Zhangauthor=L.+Dingauthor=Y.+Zouauthor=S.-Q.+Huauthor=H.-G.+Huangauthor=W.-B.+Kongauthor=J.+Zhang&title=Predicting+Drug-Induced+Liver+Injury+in+Human+With+Naive+Bayes+Classifier+Approach&doi=10.1007%2Fs10822-016-9972-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting drug-induced liver injury in human with Naive Bayes classifier approach</span></div><div class="casAuthors">Zhang, Hui; Ding, Lan; Zou, Yi; Hu, Shui-Qing; Huang, Hai-Guo; Kong, Wei-Bao; Zhang, Ji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">889-898</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is one of the major safety concerns in drug development.  Although various toxicol. studies assessing DILI risk have been developed, these methods were not sufficient in predicting DILI in humans.  Thus, developing new tools and approaches to better predict DILI risk in humans has become an important and urgent task.  In this study, we aimed to develop a computational model for assessment of the DILI risk with using a larger scale human dataset and Naive Bayes classifier.  The established Naive Bayes prediction model was evaluated by 5-fold cross validation and an external test set.  For the training set, the overall prediction accuracy of the 5-fold cross validation was 94.0 %.  The sensitivity, specificity, pos. predictive value and neg. predictive value were 97.1, 89.2, 93.5 and 95.1 %, resp.  The test set with the concordance of 72.6 %, sensitivity of 72.5 %, specificity of 72.7 %, pos. predictive value of 80.4 %, neg. predictive value of 63.2 %.  Furthermore, some important mol. descriptors related to DILI risk and some toxic/non-toxic fragments were identified.  Thus, we hope the prediction model established here would be employed for the assessment of human DILI risk, and the obtained mol. descriptors and substructures should be taken into consideration in the design of new candidate compds. to help medicinal chemists rationally select the chems. with the best prospects to be effective and safe.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-qMnd2ladibVg90H21EOLACvtfcHk0ljq8p3HxxZdtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFart7fK&md5=0b614b8703babf37fd675515b8ccd37b</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1007%2Fs10822-016-9972-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-016-9972-6%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DS.-Q.%26aulast%3DHuang%26aufirst%3DH.-G.%26aulast%3DKong%26aufirst%3DW.-B.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DPredicting%2520Drug-Induced%2520Liver%2520Injury%2520in%2520Human%2520With%2520Naive%2520Bayes%2520Classifier%2520Approach%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2016%26volume%3D30%26spage%3D889%26epage%3D898%26doi%3D10.1007%2Fs10822-016-9972-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span> <span> </span><span class="NLM_article-title">In silico Prediction of Drug Induced Liver Toxicity Using Substructure Pattern Recognition Method</span>. <i>Mol. Inf.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">136</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1002/minf.201500055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fminf.201500055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27491923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVShsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=136-144&author=C.+Zhangauthor=F.+Chengauthor=W.+Liauthor=G.+Liuauthor=P.+W.+Leeauthor=Y.+Tang&title=In+silico+Prediction+of+Drug+Induced+Liver+Toxicity+Using+Substructure+Pattern+Recognition+Method&doi=10.1002%2Fminf.201500055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">In silico Prediction of Drug Induced Liver Toxicity Using Substructure Pattern Recognition Method</span></div><div class="casAuthors">Zhang, Chen; Cheng, Feixiong; Li, Weihua; Liu, Guixia; Lee, Philip W.; Tang, Yun</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Informatics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">136-144</span>CODEN:
                <span class="NLM_cas:coden">MIONBS</span>;
        ISSN:<span class="NLM_cas:issn">1868-1743</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a leading cause of acute liver failure in the US and less severe liver injury worldwide.  It is also one of the major reasons of drug withdrawal from the market.  Thus, DILI has become one of the most important concerns of drugs, and should be predicted in very early stage of drug discovery process.  In this study, a comprehensive data set contg. 1317 diverse compds. was collected from publications.  Then, high accuracy classification models were built using five machine learning methods based on MACCS and FP4 fingerprints after evaluating by substructure pattern recognition method.  The best model was built using SVM method together with FP4 fingerprint at the IG value threshold of 0.0005.  Its overall predictive accuracies were 79.7 % and 64.5 % for the training and test sets, sep., which yielded overall accuracy of 75.0 % for the external validation dataset, consisting of 88 compds. collected from a benchmark DILI database - the Liver Toxicity Knowledge Base.  This model could be used for drug-induced liver toxicity prediction.  Moreover, some key substructure patterns correlated with drug-induced liver toxicity were also identified as structural alerts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo6jbeXslRa7Vg90H21EOLACvtfcHk0ljq8p3HxxZdtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVShsb8%253D&md5=7c13fa883243c41f61b037c3b579f490</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1002%2Fminf.201500055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fminf.201500055%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DCheng%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DP.%2BW.%26aulast%3DTang%26aufirst%3DY.%26atitle%3DIn%2520silico%2520Prediction%2520of%2520Drug%2520Induced%2520Liver%2520Toxicity%2520Using%2520Substructure%2520Pattern%2520Recognition%2520Method%26jtitle%3DMol.%2520Inf.%26date%3D2016%26volume%3D35%26spage%3D136%26epage%3D144%26doi%3D10.1002%2Fminf.201500055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pekthong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varnek, A.</span></span> <span> </span><span class="NLM_article-title">Prediction of Drug Induced Liver Injury Using Molecular and Biological Descriptors</span>. <i>Comb. Chem. High Throughput Screening</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.2174/1386207318666150305144650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.2174%2F1386207318666150305144650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25747442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsFynsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2015&pages=315-322&author=C.+Mullerauthor=D.+Pekthongauthor=E.+Alexandreauthor=G.+Marcouauthor=D.+Horvathauthor=L.+Richertauthor=A.+Varnek&title=Prediction+of+Drug+Induced+Liver+Injury+Using+Molecular+and+Biological+Descriptors&doi=10.2174%2F1386207318666150305144650"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Drug Induced Liver Injury Using Molecular and Biological Descriptors</span></div><div class="casAuthors">Muller, Christophe; Pekthong, Dumrongsak; Alexandre, Eliane; Marcou, Gilles; Horvath, Dragos; Richert, Lysiane; Varnek, Alexandre</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry & High Throughput Screening</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">315-322</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">In this paper we report quant. structure-activity models linking in vivo Drug-Induced Liver Injury (DILI) of org. mols. with some parameters both measured exptl. in vitro and calcd. theor. from the mol. structure.  At the first step, a small database contg. information of DILI in humans was created and annotated by exptl. obsd. information concerning hepatotoxic effects.  Thus, for each compd. a binary annotation 'yes/no' was applied to DILI and seven endpoints causing different liver pathologies in humans: Cholestasis (CH), Oxidative Stress (OS), Mitochondrial injury (MT), Cirrhosis and Steatosis (CS), Hepatitis (HS), Hepatocellular (HC), and Reactive Metabolite (RM).  Different machine-learning methods were used to build classification models linking DILI with mol. structure: Support Vector Machines, Artificial Neural Networks and Random Forests.  Three types of models were developed: (i) involving mol. descriptors calcd. directly from chem. structure, (ii) involving selected endpoints as 'biol.' descriptors, and (iii) involving both types of descriptors.  It has been found that the models based solely on mol. descriptors have much weaker prediction performance than those involving in vivo measured endpoints.  Taking into account difficulties in obtaining of in vivo data, at the validation stage we used instead five endpoints (CH, CS, HC, MT and OS) measured in vitro in human hepatocyte cultures.  The models involving either some of exptl. in vitro endpoints or their combination with theor. calcd. ones correctly predict DILI for 9 out of 10 ref. compds. of the external test set.  This opens an interesting perspective to use for DILI predictions a combination of theor. calcd. parameters and measured in vitro biol. data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1Pul5Lc9XSbVg90H21EOLACvtfcHk0ljq8p3HxxZdtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsFynsL0%253D&md5=71853f6a83715ca61ea1d55a8c4a330f</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.2174%2F1386207318666150305144650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1386207318666150305144650%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DPekthong%26aufirst%3DD.%26aulast%3DAlexandre%26aufirst%3DE.%26aulast%3DMarcou%26aufirst%3DG.%26aulast%3DHorvath%26aufirst%3DD.%26aulast%3DRichert%26aufirst%3DL.%26aulast%3DVarnek%26aufirst%3DA.%26atitle%3DPrediction%2520of%2520Drug%2520Induced%2520Liver%2520Injury%2520Using%2520Molecular%2520and%2520Biological%2520Descriptors%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2015%26volume%3D18%26spage%3D315%26epage%3D322%26doi%3D10.2174%2F1386207318666150305144650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P.</span></span> <span> </span><span class="NLM_article-title">The DILI-sim Initiative: Insights into Hepatotoxicity Mechanisms and Biomarker Interpretation</span>. <i>Clinical and Translational Science</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1111/cts.12629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1111%2Fcts.12629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30762301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BB3cfjt1ygug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=122-129&author=P.+Watkins&title=The+DILI-sim+Initiative%3A+Insights+into+Hepatotoxicity+Mechanisms+and+Biomarker+Interpretation&doi=10.1111%2Fcts.12629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">The DILI-sim Initiative: Insights into Hepatotoxicity Mechanisms and Biomarker Interpretation</span></div><div class="casAuthors">Watkins Paul B; Watkins Paul B</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and translational science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">122-129</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The drug-induced liver injury (DILI)-sim Initiative is a public-private partnership involving scientists from industry, academia, and the US Food and Drug Administration (FDA).  The Initiative uses quantitative systems toxicology (QST) to build and refine a model (DILIsym) capable of understanding and predicting liver safety liabilities in new drug candidates and to optimize interpretation of liver safety biomarkers used in clinical studies.  Insights gained to date include the observation that most dose-dependent hepatotoxicity can be accounted for by combinations of just three mechanisms (oxidative stress, interference with mitochondrial respiration, and alterations in bile acid homeostasis) and the importance of noncompetitive inhibition of bile acid transporters.  The effort has also provided novel insight into species and interpatient differences in susceptibility, structure-activity relationships, and the role of nonimmune mechanisms in delayed idiosyncratic hepatotoxicity.  The model is increasingly used to evaluate new drug candidates and several clinical trials are underway that will test the model's ability to prospectively predict liver safety.  With more refinement, in the future, it may be possible to use the DILIsym predictions to justify reduction in the size of some clinical trials.  The mature model could also potentially assist physicians in managing the liver safety of their patients as well as aid in the diagnosis of DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ3frvpxgtD7e2mnZh2OgS0fW6udTcc2ebxqrPwrVlQBLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfjt1ygug%253D%253D&md5=9e73cf24b1c0eb3166b6d1a3875224a9</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1111%2Fcts.12629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12629%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DP.%26atitle%3DThe%2520DILI-sim%2520Initiative%253A%2520Insights%2520into%2520Hepatotoxicity%2520Mechanisms%2520and%2520Biomarker%2520Interpretation%26jtitle%3DClinical%2520and%2520Translational%2520Science%26date%3D2019%26volume%3D12%26spage%3D122%26epage%3D129%26doi%3D10.1111%2Fcts.12629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shoda, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battista, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siler, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisetsky, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B. A.</span></span> <span> </span><span class="NLM_article-title">Mechanistic Modelling of Drug-Induced Liver Injury: Investigating the Role of Innate Immune Responses</span>. <i>Gene Regul. Syst. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">117762501769607</span>, <span class="refDoi"> DOI: 10.1177/1177625017696074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1177%2F1177625017696074" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=117762501769607&author=L.+K.+Shodaauthor=C.+Battistaauthor=S.+Q.+Silerauthor=D.+S.+Pisetskyauthor=P.+B.+Watkinsauthor=B.+A.+Howell&title=Mechanistic+Modelling+of+Drug-Induced+Liver+Injury%3A+Investigating+the+Role+of+Innate+Immune+Responses&doi=10.1177%2F1177625017696074"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1177%2F1177625017696074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1177625017696074%26sid%3Dliteratum%253Aachs%26aulast%3DShoda%26aufirst%3DL.%2BK.%26aulast%3DBattista%26aufirst%3DC.%26aulast%3DSiler%26aufirst%3DS.%2BQ.%26aulast%3DPisetsky%26aufirst%3DD.%2BS.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DHowell%26aufirst%3DB.%2BA.%26atitle%3DMechanistic%2520Modelling%2520of%2520Drug-Induced%2520Liver%2520Injury%253A%2520Investigating%2520the%2520Role%2520of%2520Innate%2520Immune%2520Responses%26jtitle%3DGene%2520Regul.%2520Syst.%2520Biol.%26date%3D2017%26volume%3D11%26spage%3D117762501769607%26doi%3D10.1177%2F1177625017696074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siler, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoda, L. K. M.</span></span> <span> </span><span class="NLM_article-title">The Role of Quantitative Systems Pharmacology Modeling in the Prediction and Explanation of Idiosyncratic Drug-Induced Liver Injury</span>. <i>Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/j.dmpk.2016.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.dmpk.2016.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28129975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCnsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=40-45&author=J.+L.+Woodheadauthor=P.+B.+Watkinsauthor=B.+A.+Howellauthor=S.+Q.+Silerauthor=L.+K.+M.+Shoda&title=The+Role+of+Quantitative+Systems+Pharmacology+Modeling+in+the+Prediction+and+Explanation+of+Idiosyncratic+Drug-Induced+Liver+Injury&doi=10.1016%2Fj.dmpk.2016.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">The role of quantitative systems pharmacology modeling in the prediction and explanation of idiosyncratic drug-induced liver injury</span></div><div class="casAuthors">Woodhead, Jeffrey L.; Watkins, Paul B.; Howell, Brett A.; Siler, Scott Q.; Shoda, Lisl K. M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-45</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Idiosyncratic drug-induced liver injury (iDILI) is a serious concern in drug development.  The rarity and multifactorial nature of iDILI makes it difficult to predict and explain.  Recently, human leukocyte antigen (HLA) allele assocns. have provided strong support for a role of an adaptive immune response in the pathogenesis of many iDILI cases; however, it is likely that an adaptive immune attack requires several preceding events.  Quant. systems pharmacol. (QSP), an in silico modeling technique that leverages known physiol. and the results of in vitro expts. in order to make predictions about how drugs affect biol. processes, is proposed as a potentially useful tool for predicting and explaining crit. events that likely precede immune-mediated iDILI, as well as the immune attack itself.  DILIsym, a QSP platform for drug-induced liver injury, has demonstrated success in predicting the presence of delayed hepatocellular stress events that likely precede the iDILI cascade, and has successfully predicted hepatocellular stress likely underlying iDILI attributed to troglitazone and tolvaptan.  The incorporation of a model of the adaptive immune system into DILIsym would represent and important advance.  In summary, QSP methods can play a key role in the future prediction and understanding of both immune-mediated and non-immune-mediated iDILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKgWaqDH4nabVg90H21EOLACvtfcHk0lhNLiliOY9cVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCnsb%252FO&md5=bc564d3a6f7572c4443b84e0506f4327</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1016%2Fj.dmpk.2016.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dmpk.2016.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DWoodhead%26aufirst%3DJ.%2BL.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DHowell%26aufirst%3DB.%2BA.%26aulast%3DSiler%26aufirst%3DS.%2BQ.%26aulast%3DShoda%26aufirst%3DL.%2BK.%2BM.%26atitle%3DThe%2520Role%2520of%2520Quantitative%2520Systems%2520Pharmacology%2520Modeling%2520in%2520the%2520Prediction%2520and%2520Explanation%2520of%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DDrug%2520Metab.%2520Pharmacokinet.%26date%3D2017%26volume%3D32%26spage%3D40%26epage%3D45%26doi%3D10.1016%2Fj.dmpk.2016.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarskog, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilliard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfirevic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourches, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neale, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shianna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szatkiewicz, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tropsha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Oord, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascorbi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dettling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazit, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goff, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holden, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rujescu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werge, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josiassen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, P. F.</span></span> <span> </span><span class="NLM_article-title">Clozapine-Induced Agranulocytosis is Associated with Rare HLA-DQB1 and HLA-B Alleles</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">4757</span>, <span class="refDoi"> DOI: 10.1038/ncomms5757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1038%2Fncomms5757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25187353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVWgs7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=4757&author=J.+I.+Goldsteinauthor=L.+F.+Jarskogauthor=C.+Hilliardauthor=A.+Alfirevicauthor=L.+Duncanauthor=D.+Fourchesauthor=H.+Huangauthor=M.+Lekauthor=B.+M.+Nealeauthor=S.+Ripkeauthor=K.+Shiannaauthor=J.+P.+Szatkiewiczauthor=A.+Tropshaauthor=E.+J.+van+den+Oordauthor=I.+Cascorbiauthor=M.+Dettlingauthor=E.+Gazitauthor=D.+C.+Goffauthor=A.+L.+Holdenauthor=D.+L.+Kellyauthor=A.+K.+Malhotraauthor=J.+Nielsenauthor=M.+Pirmohamedauthor=D.+Rujescuauthor=T.+Wergeauthor=D.+L.+Levyauthor=R.+C.+Josiassenauthor=J.+L.+Kennedyauthor=J.+A.+Liebermanauthor=M.+J.+Dalyauthor=P.+F.+Sullivan&title=Clozapine-Induced+Agranulocytosis+is+Associated+with+Rare+HLA-DQB1+and+HLA-B+Alleles&doi=10.1038%2Fncomms5757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles</span></div><div class="casAuthors">Goldstein, Jacqueline I.; Fredrik Jarskog, L.; Hilliard, Chris; Alfirevic, Ana; Duncan, Laramie; Fourches, Denis; Huang, Hailiang; Lek, Monkol; Neale, Benjamin M.; Ripke, Stephan; Shianna, Kevin; Szatkiewicz, Jin P.; Tropsha, Alexander; van den Oord, Edwin J. C. G.; Cascorbi, Ingolf; Dettling, Michael; Gazit, Ephraim; Goff, Donald C.; Holden, Arthur L.; Kelly, Deanna L.; Malhotra, Anil K.; Nielsen, Jimmi; Pirmohamed, Munir; Rujescu, Dan; Werge, Thomas; Levy, Deborah L.; Josiassen, Richard C.; Kennedy, James L.; Lieberman, Jeffrey A.; Daly, Mark J.; Sullivan, Patrick F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4757</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Clozapine is a particularly effective antipsychotic medication but its use is curtailed by the risk of clozapine-induced agranulocytosis/granulocytopenia (CIAG), a severe adverse drug reaction occurring in up to 1% of treated individuals.  Identifying genetic risk factors for CIAG could enable safer and more widespread use of clozapine.  Here we perform the largest and most comprehensive genetic study of CIAG to date by interrogating 163 cases using genome-wide genotyping and whole-exome sequencing.  We find that two loci in the major histocompatibility complex are independently assocd. with CIAG: a single amino acid in HLA-DQB1 (126Q) (P=4.7 × 10-14, odds ratio (OR)=0.19, 95% confidence interval (CI)=0.12-0.29) and an amino acid change in the extracellular binding pocket of HLA-B (158T) (P=6.4 × 10-10, OR=3.3, 95% CI=2.3-4.9).  These assocns. dovetail with the roles of these genes in immunogenetic phenotypes and adverse drug responses for other medications, and provide insight into the pathophysiol. of CIAG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyzYFvwAybFbVg90H21EOLACvtfcHk0lhNLiliOY9cVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVWgs7fE&md5=0252d111b83a3071d256f29e7d3e1d68</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1038%2Fncomms5757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms5757%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DJ.%2BI.%26aulast%3DJarskog%26aufirst%3DL.%2BF.%26aulast%3DHilliard%26aufirst%3DC.%26aulast%3DAlfirevic%26aufirst%3DA.%26aulast%3DDuncan%26aufirst%3DL.%26aulast%3DFourches%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DLek%26aufirst%3DM.%26aulast%3DNeale%26aufirst%3DB.%2BM.%26aulast%3DRipke%26aufirst%3DS.%26aulast%3DShianna%26aufirst%3DK.%26aulast%3DSzatkiewicz%26aufirst%3DJ.%2BP.%26aulast%3DTropsha%26aufirst%3DA.%26aulast%3Dvan%2Bden%2BOord%26aufirst%3DE.%2BJ.%26aulast%3DCascorbi%26aufirst%3DI.%26aulast%3DDettling%26aufirst%3DM.%26aulast%3DGazit%26aufirst%3DE.%26aulast%3DGoff%26aufirst%3DD.%2BC.%26aulast%3DHolden%26aufirst%3DA.%2BL.%26aulast%3DKelly%26aufirst%3DD.%2BL.%26aulast%3DMalhotra%26aufirst%3DA.%2BK.%26aulast%3DNielsen%26aufirst%3DJ.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DRujescu%26aufirst%3DD.%26aulast%3DWerge%26aufirst%3DT.%26aulast%3DLevy%26aufirst%3DD.%2BL.%26aulast%3DJosiassen%26aufirst%3DR.%2BC.%26aulast%3DKennedy%26aufirst%3DJ.%2BL.%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26aulast%3DDaly%26aufirst%3DM.%2BJ.%26aulast%3DSullivan%26aufirst%3DP.%2BF.%26atitle%3DClozapine-Induced%2520Agranulocytosis%2520is%2520Associated%2520with%2520Rare%2520HLA-DQB1%2520and%2520HLA-B%2520Alleles%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D4757%26doi%3D10.1038%2Fncomms5757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcaida, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yerly, D.</span></span> <span> </span><span class="NLM_article-title">Oxypurinol Directly and Immediately Activates the Drug-Specific T-cells via the Preferential use of HLA-B*58:01</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">2984</span>– <span class="NLM_lpage">2993</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1302306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.4049%2Fjimmunol.1302306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24591375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslamtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2014&pages=2984-2993&author=J.+Yunauthor=M.+J.+Marcaidaauthor=K.+K.+Erikssonauthor=H.+Jaminauthor=S.+Fontanaauthor=W.+J.+Pichlerauthor=D.+Yerly&title=Oxypurinol+Directly+and+Immediately+Activates+the+Drug-Specific+T-cells+via+the+Preferential+use+of+HLA-B*58%3A01&doi=10.4049%2Fjimmunol.1302306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Oxypurinol Directly and Immediately Activates the Drug-Specific T Cells via the Preferential Use of HLA-B*58:01</span></div><div class="casAuthors">Yun, James; Marcaida, Maria J.; Eriksson, Klara K.; Jamin, Heidi; Fontana, Stefano; Pichler, Werner J.; Yerly, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2984-2993</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Allopurinol (ALP) hypersensitivity is a major cause of severe cutaneous adverse reactions and is strongly assocd. with the HLA-B*58:01 allele.  However, it can occur in the absence of this allele with identical clin. manifestations.  The immune mechanism of ALP-induced severe cutaneous adverse reactions is poorly understood, and the T cell-reactivity pattern in patients with or without the HLA-B*58:01 allele is not known.  To understand the interactions among the drug, HLA, and TCR, we generated T cell lines that react to ALP or its metabolite oxypurinol (OXP) from HLA-B*58:01+ and HLA-B*58:01- donors and assessed their reactivity.  ALP/OXP-specific T cells reacted immediately to the addn. of the drugs and bypassed intracellular Ag processing, which is consistent with the "pharmacol. interaction with immune receptors" (p-i) concept.  This direct activation occurred regardless of HLA-B*58:01 status.  Although most OXP-specific T cells from HLA-B*58:01+ donors were restricted by the HLA-B*58:01 mol. for drug recognition, ALP-specific T cells also were restricted to other MHC class I mols.  This can be explained by in silico docking data that suggest that OXP binds to the peptide-binding groove of HLA-B*58:01 with higher affinity.  The ensuing T cell responses elicited by ALP or OXP were not limited to particular TCR Vβ repertoires.  We conclude that the drug-specific T cells are activated by OXP bound to HLA-B*58:01 through the p-i mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3f-hrTxlgnbVg90H21EOLACvtfcHk0liyVY20PaLzSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslamtrc%253D&md5=280089b00c4e97d5f93bc9c63298732c</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1302306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1302306%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DJ.%26aulast%3DMarcaida%26aufirst%3DM.%2BJ.%26aulast%3DEriksson%26aufirst%3DK.%2BK.%26aulast%3DJamin%26aufirst%3DH.%26aulast%3DFontana%26aufirst%3DS.%26aulast%3DPichler%26aufirst%3DW.%2BJ.%26aulast%3DYerly%26aufirst%3DD.%26atitle%3DOxypurinol%2520Directly%2520and%2520Immediately%2520Activates%2520the%2520Drug-Specific%2520T-cells%2520via%2520the%2520Preferential%2520use%2520of%2520HLA-B%252A58%253A01%26jtitle%3DJ.%2520Immunol.%26date%3D2014%26volume%3D192%26spage%3D2984%26epage%3D2993%26doi%3D10.4049%2Fjimmunol.1302306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isogai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyadera, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotozono, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokunaga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirayama, N.</span></span> <span> </span><span class="NLM_article-title">Silico Risk Assessment of HLA-A*02:06-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Caused by Cold Medicine Ingredients</span>. <i>J. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2013</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.1155/2013/514068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1155%2F2013%2F514068" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2013&publication_year=2013&pages=1&author=H.+Isogaiauthor=H.+Miyaderaauthor=M.+Uetaauthor=C.+Sotozonoauthor=S.+Kinoshitaauthor=K.+Tokunagaauthor=N.+Hirayama&title=Silico+Risk+Assessment+of+HLA-A*02%3A06-Associated+Stevens-Johnson+Syndrome+and+Toxic+Epidermal+Necrolysis+Caused+by+Cold+Medicine+Ingredients&doi=10.1155%2F2013%2F514068"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1155%2F2013%2F514068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2013%252F514068%26sid%3Dliteratum%253Aachs%26aulast%3DIsogai%26aufirst%3DH.%26aulast%3DMiyadera%26aufirst%3DH.%26aulast%3DUeta%26aufirst%3DM.%26aulast%3DSotozono%26aufirst%3DC.%26aulast%3DKinoshita%26aufirst%3DS.%26aulast%3DTokunaga%26aufirst%3DK.%26aulast%3DHirayama%26aufirst%3DN.%26atitle%3DSilico%2520Risk%2520Assessment%2520of%2520HLA-A%252A02%253A06-Associated%2520Stevens-Johnson%2520Syndrome%2520and%2520Toxic%2520Epidermal%2520Necrolysis%2520Caused%2520by%2520Cold%2520Medicine%2520Ingredients%26jtitle%3DJ.%2520Toxicol.%26date%3D2013%26volume%3D2013%26spage%3D1%26doi%3D10.1155%2F2013%2F514068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustine, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meid, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubeau, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span> <span> </span><span class="NLM_article-title">Idelalisib in Waldenstrom Macroglobulinemia: High Incidence of Hepatotoxicity</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1002</span>– <span class="NLM_lpage">1004</span>, <span class="refDoi"> DOI: 10.1080/10428194.2016.1222380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1080%2F10428194.2016.1222380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27562445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=1002-1004&author=J.+J.+Castilloauthor=J.+N.+Gustineauthor=K.+Meidauthor=T.+Dubeauauthor=G.+Yangauthor=L.+Xuauthor=Z.+R.+Hunterauthor=S.+P.+Treon&title=Idelalisib+in+Waldenstrom+Macroglobulinemia%3A+High+Incidence+of+Hepatotoxicity&doi=10.1080%2F10428194.2016.1222380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Idelalisib in Waldenstrom macroglobulinemia: high incidence of hepatotoxicity</span></div><div class="casAuthors">Castillo, Jorge J.; Gustine, Joshua N.; Meid, Kirsten; Dubeau, Toni; Yang, Guang; Xu, Lian; Hunter, Zachary R.; Treon, Steven P.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1002-1004</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1029-2403</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  This article discussed about the safety and efficacy of idelalisib in patients with relapsed and/or refractory symptomatic Waldenstrom macroglobulinemia with emphasis on high incidence of hepatotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriIP_LOa-K9LVg90H21EOLACvtfcHk0liyVY20PaLzSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKju7s%253D&md5=6e3b5367086dfe001268fdb0c5a97df7</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1080%2F10428194.2016.1222380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428194.2016.1222380%26sid%3Dliteratum%253Aachs%26aulast%3DCastillo%26aufirst%3DJ.%2BJ.%26aulast%3DGustine%26aufirst%3DJ.%2BN.%26aulast%3DMeid%26aufirst%3DK.%26aulast%3DDubeau%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DHunter%26aufirst%3DZ.%2BR.%26aulast%3DTreon%26aufirst%3DS.%2BP.%26atitle%3DIdelalisib%2520in%2520Waldenstrom%2520Macroglobulinemia%253A%2520High%2520Incidence%2520of%2520Hepatotoxicity%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2017%26volume%3D58%26spage%3D1002%26epage%3D1004%26doi%3D10.1080%2F10428194.2016.1222380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelosof, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avigan, M. I.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxicity of Immune Checkpoint Inhibitors: An Evolving Picture of Risk Associated with a Vital Class of Immunotherapy Agents</span>. <i>Liver Int.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">976</span>– <span class="NLM_lpage">987</span>, <span class="refDoi"> DOI: 10.1111/liv.13746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1111%2Fliv.13746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29603856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC1MnnsFKrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=976-987&author=D.+L.+Suzmanauthor=L.+Pelosofauthor=A.+Rosenbergauthor=M.+I.+Avigan&title=Hepatotoxicity+of+Immune+Checkpoint+Inhibitors%3A+An+Evolving+Picture+of+Risk+Associated+with+a+Vital+Class+of+Immunotherapy+Agents&doi=10.1111%2Fliv.13746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents</span></div><div class="casAuthors">Suzman Daniel L; Pelosof Lorraine; Rosenberg Amy; Avigan Mark I</div><div class="citationInfo"><span class="NLM_cas:title">Liver international : official journal of the International Association for the Study of the Liver</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">976-987</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Immune checkpoint inhibitors (ICIs) block CTLA-4, PD-1 and PD-L1, or other molecules that control antitumour activities of lymphocytes.  These products are associated with a broad array of immune-related toxicities affecting a variety of organs, including the liver.  ICI-associated immune-mediated hepatitis (IMH) ranges in severity between mild and life-threatening and is marked by findings that bear both similarities as well as differences with idiopathic autoimmune hepatitis.  Hepatotoxic events are often detected in clinical trials of ICIs that are powered for efficacy.  Risk levels for ICI-induced liver injury may be impacted by the specific checkpoint molecule targeted for treatment, the ICI dose levels, and the presence of a pre-existing autoimmune diathesis, chronic infection or tumour cells which infiltrate the liver parenchyma.  When patients develop liver injury during ICI treatment, a prompt assessment of the cause of injury, in conjunction with the application of measures to optimally manage the adverse event, should be made.  Strategies to manage the risk of IMH include the performance of pretreatment liver tests with regular monitoring during and after ICI treatment and patient education.  Using Common Terminology Criteria for Adverse Events developed at the National Cancer Institute to measure the severity level of liver injury, recommended actions may include continued ICI treatment with close patient monitoring, ICI treatment suspension or discontinuation and/or administration of corticosteroids or, when necessary, a non-steroidal immunosuppressive agent.  The elucidation of reliable predictors of tumour-specific ICI treatment responses, as well as an increased susceptibility for clinically serious immune-related adverse events, would help optimize treatment decisions for individual patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSU8v9_-AyU18zK395ZObgVfW6udTcc2eYroey7m5r9n7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnnsFKrsA%253D%253D&md5=6397551e975f58e11217038c28044f3e</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1111%2Fliv.13746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fliv.13746%26sid%3Dliteratum%253Aachs%26aulast%3DSuzman%26aufirst%3DD.%2BL.%26aulast%3DPelosof%26aufirst%3DL.%26aulast%3DRosenberg%26aufirst%3DA.%26aulast%3DAvigan%26aufirst%3DM.%2BI.%26atitle%3DHepatotoxicity%2520of%2520Immune%2520Checkpoint%2520Inhibitors%253A%2520An%2520Evolving%2520Picture%2520of%2520Risk%2520Associated%2520with%2520a%2520Vital%2520Class%2520of%2520Immunotherapy%2520Agents%26jtitle%3DLiver%2520Int.%26date%3D2018%26volume%3D38%26spage%3D976%26epage%3D987%26doi%3D10.1111%2Fliv.13746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Metushi, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">Treatment of PD-1–/– Mice with Amodiaquine and Anti-CTLA4 Leads to Liver Injury Similar to Idiosyncratic Liver Injury in Patients</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1332</span>, <span class="refDoi"> DOI: 10.1002/hep.27549</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.27549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25283142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlt1Wktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=1332&author=I.+G.+Metushiauthor=M.+A.+Hayesauthor=J.+Uetrecht&title=Treatment+of+PD-1%E2%80%93%2F%E2%80%93+Mice+with+Amodiaquine+and+Anti-CTLA4+Leads+to+Liver+Injury+Similar+to+Idiosyncratic+Liver+Injury+in+Patients&doi=10.1002%2Fhep.27549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of PD-1-/- mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients</span></div><div class="casAuthors">Metushi, Imir G.; Hayes, M. Anthony; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1332-1342</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The mechanism of idiosyncratic drug-induced liver injury (IDILI) remains poorly understood, to a large degree because of the lack of a valid animal model.  Recently, we reported an animal model in which treatment of female C57BL/6 mice with amodiaquine (AQ) resulted in mild liver injury with a delayed onset and resoln. despite continued treatment.  Such adaptation is a common outcome in the IDILI caused by drugs that can cause liver failure.  We had hypothesized that most IDILI is immune-mediated and adaptation represents immune tolerance.  In this study we found that AQ treatment of Cbl-b-/- and PD-1-/- mice, which have impaired immune tolerance, resulted in a slightly greater injury.  Cotreatment of C57BL/6 with AQ and anti-CTLA4 also resulted in a greater increase in ALT than treatment with AQ alone; however, these mice also had an increase in T regulatory (Treg) cells and T helper cells expressing PD-1 and CTLA4.  The increase in these cells implies the induction of immune tolerance, and the alanine aminotransferase (ALT) activity in these mice returned to normal despite continued treatment.  Cotreatment of PD-1-/- mice with anti-CTLA4 antibody and AQ resulted in the greatest increase in ALT (200-300 U/L), and necroinflammatory responses characterized by portal infiltration of lymphocytes with interface hepatitis.  The lymphocyte infiltration included T and B cells, and the CD8+ T cells produced perforin and granzyme.  In addn., the ALT activity in PD-1-/- mice cotreated with anti-CTLA4 antibody and AQ did not return to normal, as it had in other mice.  Conclusion: We report here the first animal model of IDILI that is similar to the IDILI that occurs in humans, and it was accomplished by inhibiting immune tolerance. (Hepatol. 2015;61:1332-1342).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeeeZ25zmWHLVg90H21EOLACvtfcHk0li2EToNxGCNYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlt1Wktbc%253D&md5=2c6bb52d8d58e9fcb2a40999e6dc3aa4</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1002%2Fhep.27549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27549%26sid%3Dliteratum%253Aachs%26aulast%3DMetushi%26aufirst%3DI.%2BG.%26aulast%3DHayes%26aufirst%3DM.%2BA.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DTreatment%2520of%2520PD-1%25E2%2580%2593%252F%25E2%2580%2593%2520Mice%2520with%2520Amodiaquine%2520and%2520Anti-CTLA4%2520Leads%2520to%2520Liver%2520Injury%2520Similar%2520to%2520Idiosyncratic%2520Liver%2520Injury%2520in%2520Patients%26jtitle%3DHepatology%26date%3D2015%26volume%3D61%26spage%3D1332%26doi%3D10.1002%2Fhep.27549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Latchman, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobel, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klemm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuchroo, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span> <span> </span><span class="NLM_article-title">PD-L1-Deficient Mice Show that PD-L1 on T-cells, Antigen-Presenting Cells, and Host Tissues Negatively Regulates T-cells</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">10691</span>– <span class="NLM_lpage">10696</span>, <span class="refDoi"> DOI: 10.1073/pnas.0307252101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1073%2Fpnas.0307252101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=15249675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtFWmtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=10691-10696&author=Y.+E.+Latchmanauthor=S.+C.+Liangauthor=Y.+Wuauthor=T.+Chernovaauthor=R.+A.+Sobelauthor=M.+Klemmauthor=V.+K.+Kuchrooauthor=G.+J.+Freemanauthor=A.+H.+Sharpe&title=PD-L1-Deficient+Mice+Show+that+PD-L1+on+T-cells%2C+Antigen-Presenting+Cells%2C+and+Host+Tissues+Negatively+Regulates+T-cells&doi=10.1073%2Fpnas.0307252101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells</span></div><div class="casAuthors">Latchman, Yvette E.; Liang, Spencer C.; Wu, Yin; Chernova, Tatyana; Sobel, Raymond A.; Klemm, Martina; Kuchroo, Vijay K.; Freeman, Gordon J.; Sharpe, Arlene H.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">10691-10696</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Both pos. and neg. regulatory roles have been suggested for the B7 family member PD-L1(B7-H1).  PD-L1 is expressed on antigen-presenting cells (APCs), activated T cells, and a variety of tissues, but the functional significance of PD-L1 on each cell type is not yet clear.  To dissect the functions of PD-L1 in vivo, we generated PD-L1-deficient (PD-L1-/-) mice.  CD4+ and CD8+ T cell responses were markedly enhanced in PD-L1-/- mice compared with wild-type mice in vitro and in vivo.  PD-L1-/- dendritic cells stimulated greater wild-type CD4+ T cell responses than wild-type dendritic cells, and PD-L1-/- CD4+ T cells produced more cytokines than wild-type CD4+ T cells in vitro, demonstrating an inhibitory role for PD-L1 on APCs and T cells.  In vivo CD8+ T cell responses also were significantly enhanced, indicating that PD-L1 has a role in limiting the expansion or survival of CD8+ T cells.  Studies using the myelin oligodendrocyte model of exptl. autoimmune encephalomyelitis showed that PD-L1 on T cells and in host tissues limits responses of self-reactive CD4+ T cells in vivo.  PD-L1 deficiency converted the 129S4/SvJae strain from a resistant to exptl. autoimmune encephalomyelitis-susceptible strain.  Transfer of encephalitogenic T cells from wild-type mice into PD-L1-/- recipients led to exacerbated disease.  Disease was even more severe in PD-L1-/- recipients of PD-L1-/- T cells.  These results demonstrate that PD-L1 on T cells, APCs, and host tissue inhibits naive and effector T cell responses and plays a crit. role in T cell tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9eZ_56053k7Vg90H21EOLACvtfcHk0li2EToNxGCNYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtFWmtrg%253D&md5=8a48db5e1a8007f10012657beac2bb00</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0307252101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0307252101%26sid%3Dliteratum%253Aachs%26aulast%3DLatchman%26aufirst%3DY.%2BE.%26aulast%3DLiang%26aufirst%3DS.%2BC.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DChernova%26aufirst%3DT.%26aulast%3DSobel%26aufirst%3DR.%2BA.%26aulast%3DKlemm%26aufirst%3DM.%26aulast%3DKuchroo%26aufirst%3DV.%2BK.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26atitle%3DPD-L1-Deficient%2520Mice%2520Show%2520that%2520PD-L1%2520on%2520T-cells%252C%2520Antigen-Presenting%2520Cells%252C%2520and%2520Host%2520Tissues%2520Negatively%2520Regulates%2520T-cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D10691%26epage%3D10696%26doi%3D10.1073%2Fpnas.0307252101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okkenhaug, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilancio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farjot, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priddle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peskett, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salpekar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterfield, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaesebroeck, B.</span></span> <span> </span><span class="NLM_article-title">Impaired B- and T-cell Antigen Receptor Signaling in P110delta PI 3-kinase Mutant Mice</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>297</i></span>,  <span class="NLM_fpage">1031</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1126/science.1073560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1126%2Fscience.1073560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=12130661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmt1Cktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=297&publication_year=2002&pages=1031-1034&author=K.+Okkenhaugauthor=A.+Bilancioauthor=G.+Farjotauthor=H.+Priddleauthor=S.+Sanchoauthor=E.+Peskettauthor=W.+Pearceauthor=S.+E.+Meekauthor=A.+Salpekarauthor=M.+D.+Waterfieldauthor=A.+J.+Smithauthor=B.+Vanhaesebroeck&title=Impaired+B-+and+T-cell+Antigen+Receptor+Signaling+in+P110delta+PI+3-kinase+Mutant+Mice&doi=10.1126%2Fscience.1073560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Impaired B and T cell antigen receptor signaling in p110δ PI 3-kinase mutant mice</span></div><div class="casAuthors">Okkenhaug, Klaus; Bilancio, Antonio; Farjot, Geraldine; Priddle, Helen; Sancho, Sara; Peskett, Emma; Pearce, Wayne; Meek, Stephen E.; Salpekar, Ashreena; Waterfield, Michael D.; Smith, Andrew J. H.; Vanhaesebroeck, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">297</span>
        (<span class="NLM_cas:issue">5583</span>),
    <span class="NLM_cas:pages">1031-1034</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Class IA phosphoinositide 3-kinases (PI3Ks) are a family of p85/p110 heterodimeric lipid kinases that generate second messenger signals downstream of tyrosine kinases, thereby controlling cell metab., growth, proliferation, differentiation, motility, and survival.  Mammals express three class IA catalytic subunits: p110α, p110β, and p110δ.  It is unclear to what extent these p110 isoforms have overlapping or distinct biol. roles.  Mice expressing a catalytically inactive form of p110δ (p110δD910A) were generated by gene targeting.  Antigen receptor signaling in B and T cells was impaired and immune responses in vivo were attenuated in p110δ mutant mice.  They also developed inflammatory bowel disease.  These results reveal a selective role for p110δ in immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAY2T-yP_kmbVg90H21EOLACvtfcHk0li2EToNxGCNYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmt1Cktb4%253D&md5=c931a202635098a5d973a5903b8a6f9f</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1126%2Fscience.1073560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1073560%26sid%3Dliteratum%253Aachs%26aulast%3DOkkenhaug%26aufirst%3DK.%26aulast%3DBilancio%26aufirst%3DA.%26aulast%3DFarjot%26aufirst%3DG.%26aulast%3DPriddle%26aufirst%3DH.%26aulast%3DSancho%26aufirst%3DS.%26aulast%3DPeskett%26aufirst%3DE.%26aulast%3DPearce%26aufirst%3DW.%26aulast%3DMeek%26aufirst%3DS.%2BE.%26aulast%3DSalpekar%26aufirst%3DA.%26aulast%3DWaterfield%26aufirst%3DM.%2BD.%26aulast%3DSmith%26aufirst%3DA.%2BJ.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26atitle%3DImpaired%2520B-%2520and%2520T-cell%2520Antigen%2520Receptor%2520Signaling%2520in%2520P110delta%2520PI%25203-kinase%2520Mutant%2520Mice%26jtitle%3DScience%26date%3D2002%26volume%3D297%26spage%3D1031%26epage%3D1034%26doi%3D10.1126%2Fscience.1073560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref233"><div class="reference"><strong class="refLabel"><a href="#ref233" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uno, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikh, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepulveda, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaesebroeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balfour Sartor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plevy, S. E.</span></span> <span> </span><span class="NLM_article-title">Altered Macrophage Function Contributes to Colitis in Mice Defective in the Phosphoinositide-3 Kinase Subunit p110δ</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">1642</span>– <span class="NLM_lpage">1653</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2010.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1053%2Fj.gastro.2010.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=20637203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKhurrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2010&pages=1642-1653&author=J.+K.+Unoauthor=K.+N.+Raoauthor=K.+Matsuokaauthor=S.+Z.+Sheikhauthor=T.+Kobayashiauthor=F.+Liauthor=E.+C.+Steinbachauthor=A.+R.+Sepulvedaauthor=B.+Vanhaesebroeckauthor=R.+Balfour+Sartorauthor=S.+E.+Plevy&title=Altered+Macrophage+Function+Contributes+to+Colitis+in+Mice+Defective+in+the+Phosphoinositide-3+Kinase+Subunit+p110%CE%B4&doi=10.1053%2Fj.gastro.2010.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Altered Macrophage Function Contributes to Colitis in Mice Defective in the Phosphoinositide-3 Kinase Subunit p110δ</span></div><div class="casAuthors">Uno, Jennifer K.; Rao, Kavitha N.; Matsuoka, Katsuyoshi; Sheikh, Shehzad Z.; Kobayashi, Taku; Li, Fengling; Steinbach, Erin C.; Sepulveda, Antonia R.; Vanhaesebroeck, Bart; Sartor, R. Balfour; Plevy, Scott E.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1642-1653</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Innate immune responses are crucial for host defense against pathogens but need to be tightly regulated to prevent chronic inflammation.  Initial characterization of mice with a targeted inactivating mutation in the p110δ subunit of phosphoinositide 3-kinase (PI3K p110δD910A/D910A) revealed defects in B- and T-cell signaling and chronic colitis.  Here, we further characterize features of inflammatory bowel diseases in these mice and investigate underlying innate immune defects.  Colons and macrophages from PI3K p110δD910A/D910A mice were evaluated for colonic inflammation and innate immune dysfunction.  Colonic p110δ mRNA expression was examd. in interleukin (IL)-10-/- and wild-type germ-free mice during transition to a conventional microbiota.  To assess polygenic impact on development of colitis, p110δD910A/D910A mice were backcrossed to IL-10-/- mice.  A mild spontaneous colitis was shown in PI3K p110δD910A/D910A mice at 8 wk, with inflammation increasing with age.  An inflammatory mucosal and systemic cytokine profile was characterized by expression of IL-12/23.  In PI3K p110δD910A/D910A macrophages, augmented toll-like receptor signaling and defective bactericidal activity were obsd.  Consistent with an important homeostatic role for PI3K p110δ, wild-type mice raised in a germ-free environment markedly up-regulated colonic PI3K p110δ expression with the introduction of the enteric microbiota; however, colitis-prone IL-10-/- mice did not.  Moreover, PI3K p110δD910A/D910A mice crossed to IL-10-/- mice developed severe colitis at an early age.  This study describes a novel model of exptl. colitis that highlights the importance of PI3K p110δ in maintaining mucosal homeostasis and could provide insight into the pathogenesis of human inflammatory bowel disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUVFyJRMQWdLVg90H21EOLACvtfcHk0liXDid4TFpmBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKhurrE&md5=6d431d69d8fde80be91f87d45f313c5e</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2010.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2010.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DUno%26aufirst%3DJ.%2BK.%26aulast%3DRao%26aufirst%3DK.%2BN.%26aulast%3DMatsuoka%26aufirst%3DK.%26aulast%3DSheikh%26aufirst%3DS.%2BZ.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DSteinbach%26aufirst%3DE.%2BC.%26aulast%3DSepulveda%26aufirst%3DA.%2BR.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DBalfour%2BSartor%26aufirst%3DR.%26aulast%3DPlevy%26aufirst%3DS.%2BE.%26atitle%3DAltered%2520Macrophage%2520Function%2520Contributes%2520to%2520Colitis%2520in%2520Mice%2520Defective%2520in%2520the%2520Phosphoinositide-3%2520Kinase%2520Subunit%2520p110%25CE%25B4%26jtitle%3DGastroenterology%26date%3D2010%26volume%3D139%26spage%3D1642%26epage%3D1653%26doi%3D10.1053%2Fj.gastro.2010.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref234"><div class="reference"><strong class="refLabel"><a href="#ref234" class="rightTabRefNumLink">233</a></strong><div class="NLM_citation" id="rightTab-cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Button, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caggiano, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iaci, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parry, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanulis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span> <span> </span><span class="NLM_article-title">Transient Changes in Hepatic Physiology That Alter Bilirubin and Bile Acid Transport May Explain Elevations in Liver Chemistries Observed in Clinical Trials of GGF2 (Cimaglermin Alfa)</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfx222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1093%2Ftoxsci%2Fkfx222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=29069498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFelsbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2018&pages=401-411&author=M.+Mosedaleauthor=D.+Buttonauthor=J.+P.+Jacksonauthor=K.+M.+Freemanauthor=K.+R.+Brouwerauthor=A.+O.+Caggianoauthor=A.+Eisenauthor=J.+F.+Iaciauthor=T.+J.+Parryauthor=R.+Stanulisauthor=M.+Srinivasauthor=P.+B.+Watkins&title=Transient+Changes+in+Hepatic+Physiology+That+Alter+Bilirubin+and+Bile+Acid+Transport+May+Explain+Elevations+in+Liver+Chemistries+Observed+in+Clinical+Trials+of+GGF2+%28Cimaglermin+Alfa%29&doi=10.1093%2Ftoxsci%2Fkfx222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">Transient changes in hepatic physiology that alter bilirubin and bile acid transport may explain elevations in liver chemistries observed in clinical trials of GGF2 (cimaglermin alfa)</span></div><div class="casAuthors">Mosedale, Merrie; Button, Donald; Jackson, Jonathan P.; Freeman, Kimberly M.; Brouwer, Kenneth R.; Caggiano, Anthony O.; Eisen, Andrew; Iaci, Jennifer F.; Parry, Tom J.; Stanulis, Ric; Srinivas, Maya; Watkins, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">401-411</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">GGF2 is a recombinant human neuregulin-1b in development for chronic heart failure.  Phase 1 clin. trials of GGF2 were put on hold when transient elevations in serum aminotransferases and total bilirubin were obsd. in 2 of 43 subjects who received single doses of GGF2 at 1.5 or 0.378 mg/kg.  However, aminotransferase elevations were modest and not typical of liver injury sufficient to result in elevated serum bilirubin.  Cynomolgus monkeys administered a single 15 mg/kg dose of GGF2 had similar transient elevations in serum aminotransferases and bilirubin as well as transient elevations in serum bile acids.  However, no hepatocellular necrosis was obsd. in liver biopsies obtained during peak elevations.  When sandwich-cultured human hepatocytes were treated with GGF2 for up to 72 h at concns. approx. 0.8-fold av. plasma Cmax for the 0.378 mg/kg dose, no cytotoxicity was obsd.  Gene expression profiling identified approx. 50% redns. in mRNAs coding for bilirubin transporters and bile acid conjugating enzymes, as well as changes in expression of addnl. genes mimicking the interleukin-6-mediated acute phase response.  Similar gene expression changes were obsd. in GGF2-treated HepG2 cells and primary monkey hepatocytes.  Addnl. studies conducted in sandwich-cultured human hepatocytes revealed a transient and GGF2 concn.-dependent decrease in hepatocyte bile acid content and biliary clearance of taurocholate without affecting biliary taurocholate efflux.  Taken together, these data suggest that GGF2 does not cause significant hepatocellular death, but transiently modifies hepatic handling of bilirubin and bile acids, effects that may account for the elevations in serum bilirubin obsd. in the clin. trial subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8ItjPW8agQrVg90H21EOLACvtfcHk0liXDid4TFpmBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFelsbnK&md5=0ba31fc908e2649adacab42bd420dc50</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfx222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfx222%26sid%3Dliteratum%253Aachs%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DButton%26aufirst%3DD.%26aulast%3DJackson%26aufirst%3DJ.%2BP.%26aulast%3DFreeman%26aufirst%3DK.%2BM.%26aulast%3DBrouwer%26aufirst%3DK.%2BR.%26aulast%3DCaggiano%26aufirst%3DA.%2BO.%26aulast%3DEisen%26aufirst%3DA.%26aulast%3DIaci%26aufirst%3DJ.%2BF.%26aulast%3DParry%26aufirst%3DT.%2BJ.%26aulast%3DStanulis%26aufirst%3DR.%26aulast%3DSrinivas%26aufirst%3DM.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26atitle%3DTransient%2520Changes%2520in%2520Hepatic%2520Physiology%2520That%2520Alter%2520Bilirubin%2520and%2520Bile%2520Acid%2520Transport%2520May%2520Explain%2520Elevations%2520in%2520Liver%2520Chemistries%2520Observed%2520in%2520Clinical%2520Trials%2520of%2520GGF2%2520%2528Cimaglermin%2520Alfa%2529%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D161%26spage%3D401%26epage%3D411%26doi%3D10.1093%2Ftoxsci%2Fkfx222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref235"><div class="reference"><strong class="refLabel"><a href="#ref235" class="rightTabRefNumLink">234</a></strong><div class="NLM_citation" id="rightTab-cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björnsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeff, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoofnagle, J. H.</span></span> <span> </span><span class="NLM_article-title">Liver Injury from Herbal and Dietary Supplements</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">363</span>– <span class="NLM_lpage">373</span>, <span class="refDoi"> DOI: 10.1002/hep.28813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.28813" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27677775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisVOm" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2017&pages=363-373&author=V.+Navarroauthor=I.+Khanauthor=E.+Bj%C3%B6rnssonauthor=L.+B.+Seeffauthor=J.+Serranoauthor=J.+H.+Hoofnagle&title=Liver+Injury+from+Herbal+and+Dietary+Supplements&doi=10.1002%2Fhep.28813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Liver injury from herbal and dietary supplements</span></div><div class="casAuthors">Navarro, Victor J.; Khan, Ikhlas; Bjoernsson, Einar; Seeff, Leonard B.; Serrano, Jose; Hoofnagle, Jay H.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">363-373</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Herbal and dietary supplements (HDS) are used increasingly both in the United States and worldwide, and HDS-induced liver injury in the United States has increased proportionally.  Current challenges in the diagnosis and management of HDS-induced liver injury were the focus of a 2-day research symposium sponsored by the American Assocn. for the Study of Liver Disease and the National Institutes of Health.  HDS-induced liver injury now accounts for 20% of cases of hepatotoxicity in the United States based on research data.  The major implicated agents include anabolic steroids, green tea ext., and multi-ingredient nutritional supplements.  Anabolic steroids marketed as bodybuilding supplements typically induce a prolonged cholestatic but ultimately self-limiting liver injury that has a distinctive serum biochem. as well as histol. phenotype.  Green tea ext. and many other products, in contrast, tend to cause an acute hepatitis-like injury.  Currently, however, the majority of cases of HDS-assocd. liver injury are due to multi-ingredient nutritional supplements, and the component responsible for the toxicity is usually unknown or can only be suspected.  HDS-induced liver injury presents many clin. and research challenges in diagnosis, identification of the responsible constituents, treatment, and prevention.  Also important are improvements in regulatory oversight of nonprescription products to guarantee their constituents and ensure purity and safety.  The confident identification of injurious ingredients within HDS will require strategic alignments among clinicians, chemists, and toxicologists.  The ultimate goal should be to prohibit or more closely regulate potentially injurious ingredients and thus promote public safety. (Hepatol. 2017;65:363-373).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx6VCePKGkc7Vg90H21EOLACvtfcHk0lghtfLnVgwIAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisVOm&md5=953f3b55242b62d6c5d125675269c8ef</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1002%2Fhep.28813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.28813%26sid%3Dliteratum%253Aachs%26aulast%3DNavarro%26aufirst%3DV.%26aulast%3DKhan%26aufirst%3DI.%26aulast%3DBj%25C3%25B6rnsson%26aufirst%3DE.%26aulast%3DSeeff%26aufirst%3DL.%2BB.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DHoofnagle%26aufirst%3DJ.%2BH.%26atitle%3DLiver%2520Injury%2520from%2520Herbal%2520and%2520Dietary%2520Supplements%26jtitle%3DHepatology%26date%3D2017%26volume%3D65%26spage%3D363%26epage%3D373%26doi%3D10.1002%2Fhep.28813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref236"><div class="reference"><strong class="refLabel"><a href="#ref236" class="rightTabRefNumLink">235</a></strong><div class="NLM_citation" id="rightTab-cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonkovsky, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davern, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeff, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherker, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talwalkar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuppalanchi, R.</span></span> <span> </span><span class="NLM_article-title">Liver injury from Herbals and Dietary Supplements in the US Drug Induced Liver Injury Network</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1399</span>– <span class="NLM_lpage">1408</span>, <span class="refDoi"> DOI: 10.1002/hep.27317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep.27317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25043597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BC2cbktFWquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=1399-1408&author=V.+J.+Navarroauthor=H.+Barnhartauthor=H.+L.+Bonkovskyauthor=T.+Davernauthor=R.+J.+Fontanaauthor=L.+Grantauthor=K.+R.+Reddyauthor=L.+B.+Seeffauthor=J.+Serranoauthor=A.+H.+Sherkerauthor=A.+Stolzauthor=J.+Talwalkarauthor=M.+Vegaauthor=R.+Vuppalanchi&title=Liver+injury+from+Herbals+and+Dietary+Supplements+in+the+US+Drug+Induced+Liver+Injury+Network&doi=10.1002%2Fhep.27317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network</span></div><div class="casAuthors">Navarro Victor J; Barnhart Huiman; Bonkovsky Herbert L; Davern Timothy; Fontana Robert J; Grant Lafaine; Reddy K Rajender; Seeff Leonard B; Serrano Jose; Sherker Averell H; Stolz Andrew; Talwalkar Jayant; Vega Maricruz; Vuppalanchi Raj</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Baltimore, Md.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1399-408</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  The Drug-Induced Liver Injury Network (DILIN) studies hepatotoxicity caused by conventional medications as well as herbals and dietary supplements (HDS).  To characterize hepatotoxicity and its outcomes from HDS versus medications, patients with hepatotoxicity attributed to medications or HDS were enrolled prospectively between 2004 and 2013.  The study took place among eight U.S. referral centers that are part of the DILIN.  Consecutive patients with liver injury referred to a DILIN center were eligible.  The final sample comprised 130 (15.5%) of all subjects enrolled (839) who were judged to have experienced liver injury caused by HDS.  Hepatotoxicity caused by HDS was evaluated by expert opinion.  Demographic and clinical characteristics and outcome assessments, including death and liver transplantation (LT), were ascertained.  Cases were stratified and compared according to the type of agent implicated in liver injury; 45 had injury caused by bodybuilding HDS, 85 by nonbodybuilding HDS, and 709 by medications.  Liver injury caused by HDS increased from 7% to 20% (P < 0.001) during the study period.  Bodybuilding HDS caused prolonged jaundice (median, 91 days) in young men, but did not result in any fatalities or LT.  The remaining HDS cases presented as hepatocellular injury, predominantly in middle-aged women, and, more frequently, led to death or transplantation, compared to injury from medications (13% vs. 3%; P < 0.05).  CONCLUSIONS:  The proportion of liver injury cases attributed to HDS in DILIN has increased significantly.  Liver injury from nonbodybuilding HDS is more severe than from bodybuilding HDS or medications, as evidenced by differences in unfavorable outcomes (death and transplantation). (Hepatology 2014;60:1399-1408).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTl84hUN1bKNTW1zwg2yUK5fW6udTcc2eael_QSKZRhj7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbktFWquw%253D%253D&md5=381aee1513c48e776b6d4e1e2e398073</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1002%2Fhep.27317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27317%26sid%3Dliteratum%253Aachs%26aulast%3DNavarro%26aufirst%3DV.%2BJ.%26aulast%3DBarnhart%26aufirst%3DH.%26aulast%3DBonkovsky%26aufirst%3DH.%2BL.%26aulast%3DDavern%26aufirst%3DT.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DGrant%26aufirst%3DL.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DSeeff%26aufirst%3DL.%2BB.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DSherker%26aufirst%3DA.%2BH.%26aulast%3DStolz%26aufirst%3DA.%26aulast%3DTalwalkar%26aufirst%3DJ.%26aulast%3DVega%26aufirst%3DM.%26aulast%3DVuppalanchi%26aufirst%3DR.%26atitle%3DLiver%2520injury%2520from%2520Herbals%2520and%2520Dietary%2520Supplements%2520in%2520the%2520US%2520Drug%2520Induced%2520Liver%2520Injury%2520Network%26jtitle%3DHepatology%26date%3D2014%26volume%3D60%26spage%3D1399%26epage%3D1408%26doi%3D10.1002%2Fhep.27317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref237"><div class="reference"><strong class="refLabel"><a href="#ref237" class="rightTabRefNumLink">236</a></strong><div class="NLM_citation" id="rightTab-cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucena, M. I.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxicity Induced by Herbal and Dietary Supplements</span>. <i>Semin. Liver Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1055/s-0034-1375958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1055%2Fs-0034-1375958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=24879982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFKktLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=172-193&author=V.+J.+Navarroauthor=M.+I.+Lucena&title=Hepatotoxicity+Induced+by+Herbal+and+Dietary+Supplements&doi=10.1055%2Fs-0034-1375958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity induced by herbal and dietary supplements</span></div><div class="casAuthors">Navarro, Victor J.; Lucena, M. Isabel</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Liver Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">172-193</span>CODEN:
                <span class="NLM_cas:coden">SLDIEE</span>;
        ISSN:<span class="NLM_cas:issn">0272-8087</span>.
    
            (<span class="NLM_cas:orgname">Thieme Medical Publishers, Inc.</span>)
        </div><div class="casAbstract">A review.  Herbals and dietary supplements (HDS) can cause hepatotoxicity.  Regulation of HDS varies across the globe.  In the United States, it is defined by a law that is now two decades old.  More recent regulatory approaches in Europe still do not require testing for premarket safety.  The true incidence of hepatotoxicity from HDS is unknown.  The presentation is most often with a hepatocellular enzyme pattern, and the outcomes can be severe, leading to transplantation in some circumstances.  The diagnosis of hepatotoxicity due to HDS is made in the same way as for drugs.  However, patients often must be coaxed into revealing a history of use.  No causality assessment approach is perfectly suited for hepatotoxicity from HDS, but the Roussel Uclaf Causality Assessment Method is most used.  Future endeavors must focus on defining epidemiol., establishing an accepted nomenclature, and identifying culprit ingredients, predisposing host factors, and useful biomarkers for injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYgHJJa3yGVLVg90H21EOLACvtfcHk0lghtfLnVgwIAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFKktLbJ&md5=afd8a31116b704b8943b687d64f6cc45</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1055%2Fs-0034-1375958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0034-1375958%26sid%3Dliteratum%253Aachs%26aulast%3DNavarro%26aufirst%3DV.%2BJ.%26aulast%3DLucena%26aufirst%3DM.%2BI.%26atitle%3DHepatotoxicity%2520Induced%2520by%2520Herbal%2520and%2520Dietary%2520Supplements%26jtitle%3DSemin.%2520Liver%2520Dis.%26date%3D2014%26volume%3D34%26spage%3D172%26epage%3D193%26doi%3D10.1055%2Fs-0034-1375958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref238"><div class="reference"><strong class="refLabel"><a href="#ref238" class="rightTabRefNumLink">237</a></strong><div class="NLM_citation" id="rightTab-cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avigan, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozersky, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeff, L. B.</span></span> <span> </span><span class="NLM_article-title">Scientific and Regulatory Perspectives in Herbal and Dietary Supplement Associated Hepatotoxicity in the United States</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">331</span>, <span class="refDoi"> DOI: 10.3390/ijms17030331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.3390%2Fijms17030331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=26950122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmslCjsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=331&author=M.+I.+Aviganauthor=R.+P.+Mozerskyauthor=L.+B.+Seeff&title=Scientific+and+Regulatory+Perspectives+in+Herbal+and+Dietary+Supplement+Associated+Hepatotoxicity+in+the+United+States&doi=10.3390%2Fijms17030331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">Scientific and regulatory perspectives in herbal and dietary supplement associated hepatotoxicity in the United States</span></div><div class="casAuthors">Avigan, Mark I.; Mozersky, Robert P.; Seeff, Leonard B.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">331/1-331/30</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">In the United States (US), the risk of hepatotoxicity linked to the widespread use of certain herbal products has gained increased attention among regulatory scientists.  Based on current US law, all dietary supplements sold domestically, including botanical supplements, are regulated by the Food and Drug Administration (FDA) as a special category of foods.  Under this designation, regulatory scientists do not routinely evaluate the efficacy of these products prior to their marketing, despite the content variability and phytochem. complexity that often characterizes them.  Nonetheless, there has been notable progress in the development of advanced scientific methods to qual. and quant. measure ingredients and screen for contaminants and adulterants in botanical products when hepatotoxicity is recognized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU3lxaFVazY7Vg90H21EOLACvtfcHk0lghtfLnVgwIAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmslCjsbw%253D&md5=21284ae03ae5ab84ff703837612535c7</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.3390%2Fijms17030331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms17030331%26sid%3Dliteratum%253Aachs%26aulast%3DAvigan%26aufirst%3DM.%2BI.%26aulast%3DMozersky%26aufirst%3DR.%2BP.%26aulast%3DSeeff%26aufirst%3DL.%2BB.%26atitle%3DScientific%2520and%2520Regulatory%2520Perspectives%2520in%2520Herbal%2520and%2520Dietary%2520Supplement%2520Associated%2520Hepatotoxicity%2520in%2520the%2520United%2520States%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2016%26volume%3D17%26spage%3D331%26doi%3D10.3390%2Fijms17030331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref239"><div class="reference"><strong class="refLabel"><a href="#ref239" class="rightTabRefNumLink">238</a></strong><div class="NLM_citation" id="rightTab-cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avula, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeff, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, J.</span></span> <span> </span><span class="NLM_article-title">The Contents of Herbal and Dietary Supplements Implicated in Liver Injury in the United States Are Frequently Mislabeled</span>. <i>Hepatology Communications</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">792</span>– <span class="NLM_lpage">794</span>, <span class="refDoi"> DOI: 10.1002/hep4.1346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1002%2Fhep4.1346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=31168513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A280%3ADC%252BB3M3jslWitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&pages=792-794&author=V.+Navarroauthor=B.+Avulaauthor=I.+Khanauthor=M.+Vermaauthor=L.+Seeffauthor=J.+Serranoauthor=A.+Stolzauthor=R.+Fontanaauthor=J.+Ahmad&title=The+Contents+of+Herbal+and+Dietary+Supplements+Implicated+in+Liver+Injury+in+the+United+States+Are+Frequently+Mislabeled&doi=10.1002%2Fhep4.1346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">The Contents of Herbal and Dietary Supplements Implicated in Liver Injury in the United States Are Frequently Mislabeled</span></div><div class="casAuthors">Navarro Victor; Verma Manisha; Seeff Leonard; Avula Bharathi; Khan Ikhlas; Serrano Jose; Stolz Andrew; Fontana Robert; Ahmad Jawad</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">792-794</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The U.S.  Drug Induced Liver Injury Network assayed the contents of herbal and dietary supplements collected from patients enrolled into its prospective study.  The aim was to determine the accuracy of product labels, and to identify known hepatotoxins.  Using high-performance liquid chromatography coupled with mass spectrometry to assay 272 product, 51% were found to be mislabeled; that is, to have chemical contents that did not match the label.  Appearance enhancement, sexual performance, and weight loss products were most commonly mislabeled.  Whether the mislabeling contributed to liver injury is under study; however, the high mislabeling rate underscores the need for more stringent regulation of supplements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTS15c7NYEdo2gRQsDqrjW_fW6udTcc2eb8fB1wHF4VOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3jslWitQ%253D%253D&md5=d56603af15a23bfc81f02a5c10898774</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1002%2Fhep4.1346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep4.1346%26sid%3Dliteratum%253Aachs%26aulast%3DNavarro%26aufirst%3DV.%26aulast%3DAvula%26aufirst%3DB.%26aulast%3DKhan%26aufirst%3DI.%26aulast%3DVerma%26aufirst%3DM.%26aulast%3DSeeff%26aufirst%3DL.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DStolz%26aufirst%3DA.%26aulast%3DFontana%26aufirst%3DR.%26aulast%3DAhmad%26aufirst%3DJ.%26atitle%3DThe%2520Contents%2520of%2520Herbal%2520and%2520Dietary%2520Supplements%2520Implicated%2520in%2520Liver%2520Injury%2520in%2520the%2520United%2520States%2520Are%2520Frequently%2520Mislabeled%26jtitle%3DHepatology%2520Communications%26date%3D2019%26volume%3D3%26spage%3D792%26epage%3D794%26doi%3D10.1002%2Fhep4.1346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref240"><div class="reference"><strong class="refLabel"><a href="#ref240" class="rightTabRefNumLink">239</a></strong><div class="NLM_citation" id="rightTab-cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Church, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatti, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaddy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchill, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Threadgill, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrill, A. H.</span></span> <span> </span><span class="NLM_article-title">Sensitivity to Hepatotoxicity Due to Epigallocatechin Gallate is Affected by Genetic Background in Diversity Outbred Mice</span>. <i>Food Chem. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.fct.2014.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.fct.2014.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=25446466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyhtL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2015&pages=19-26&author=R.+J.+Churchauthor=D.+M.+Gattiauthor=T.+J.+Urbanauthor=N.+Longauthor=X.+Yangauthor=Q.+Shiauthor=J.+S.+Eaddyauthor=M.+Mosedaleauthor=S.+Ballardauthor=G.+A.+Churchillauthor=V.+Navarroauthor=P.+B.+Watkinsauthor=D.+W.+Threadgillauthor=A.+H.+Harrill&title=Sensitivity+to+Hepatotoxicity+Due+to+Epigallocatechin+Gallate+is+Affected+by+Genetic+Background+in+Diversity+Outbred+Mice&doi=10.1016%2Fj.fct.2014.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Sensitivity to hepatotoxicity due to epigallocatechin gallate is affected by genetic background in diversity outbred mice</span></div><div class="casAuthors">Church, Rachel J.; Gatti, Daniel M.; Urban, Thomas J.; Long, Nanye; Yang, Xi; Shi, Qiang; Eaddy, J. Scott; Mosedale, Merrie; Ballard, Shawn; Churchill, Gary A.; Navarro, Victor; Watkins, Paul B.; Threadgill, David W.; Harrill, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Food and Chemical Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19-26</span>CODEN:
                <span class="NLM_cas:coden">FCTOD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-6915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Consumer use of herbal and dietary supplements has recently grown in the United States and, with increased use, reports of rare adverse reactions have emerged.  One such supplement is green tea ext., contg. the polyphenol epigallocatechin gallate (EGCG), which has been shown to be hepatotoxic at high doses in animal models.  The Drug-Induced Liver Injury Network has identified multiple patients who have experienced liver injury ascribed to green tea ext. consumption and the relationship to dose has not been straightforward, indicating that differences in sensitivity may contribute to the adverse response in susceptible people.  The Diversity Outbred (DO), a genetically heterogeneous mouse population, provides a potential platform for study of interindividual toxicity responses to green tea ext.  Within the DO population, an equal exposure to EGCG (50 mg/kg; daily for three days) was found to be tolerated in the majority of mice; however, a small fraction of the animals (16%; 43/272) exhibited severe hepatotoxicity (10-86.8% liver necrosis) that is analogous to the clin. cases.  The data indicate that the DO mice may provide a platform for informing risk of rare, adverse reactions that may occur in consumer populations upon ingestion of concd. herbal products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCbJ0epg2AYbVg90H21EOLACvtfcHk0lhXhV0ooNgqxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyhtL3K&md5=94a7be801676411bc6ec6592aa52826c</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1016%2Fj.fct.2014.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.fct.2014.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DChurch%26aufirst%3DR.%2BJ.%26aulast%3DGatti%26aufirst%3DD.%2BM.%26aulast%3DUrban%26aufirst%3DT.%2BJ.%26aulast%3DLong%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DEaddy%26aufirst%3DJ.%2BS.%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DBallard%26aufirst%3DS.%26aulast%3DChurchill%26aufirst%3DG.%2BA.%26aulast%3DNavarro%26aufirst%3DV.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DThreadgill%26aufirst%3DD.%2BW.%26aulast%3DHarrill%26aufirst%3DA.%2BH.%26atitle%3DSensitivity%2520to%2520Hepatotoxicity%2520Due%2520to%2520Epigallocatechin%2520Gallate%2520is%2520Affected%2520by%2520Genetic%2520Background%2520in%2520Diversity%2520Outbred%2520Mice%26jtitle%3DFood%2520Chem.%2520Toxicol.%26date%3D2015%26volume%3D76%26spage%3D19%26epage%3D26%26doi%3D10.1016%2Fj.fct.2014.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref241"><div class="reference"><strong class="refLabel"><a href="#ref241" class="rightTabRefNumLink">240</a></strong><div class="NLM_citation" id="rightTab-cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span>; <span class="NLM_string-name">Cho, T. E.</span>; <span class="NLM_string-name">Wang, S.</span>; <span class="NLM_string-name">Yeung, K.</span></span> <span> </span><span class="NLM_article-title">Using PD-1 Knockout Mice to Test the Potential of Green Tea Extract and (−)-Epigallocatechin Gallate (EGCG) to Cause Idiosyncratic Drug-Induced Liver Injury (IDILI)</span>. Presented at the Society of Toxicology Annual Meeting, San Antonio, TX, March 11–15, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+Uetrecht&author=T.+E.+Cho&author=S.+Wang&author=K.+Yeung&title=Using+PD-1+Knockout+Mice+to+Test+the+Potential+of+Green+Tea+Extract+and+%28%E2%88%92%29-Epigallocatechin+Gallate+%28EGCG%29+to+Cause+Idiosyncratic+Drug-Induced+Liver+Injury+%28IDILI%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DUsing%2520PD-1%2520Knockout%2520Mice%2520to%2520Test%2520the%2520Potential%2520of%2520Green%2520Tea%2520Extract%2520and%2520%2528%25E2%2588%2592%2529-Epigallocatechin%2520Gallate%2520%2528EGCG%2529%2520to%2520Cause%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%2520%2528IDILI%2529%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref242"><div class="reference"><strong class="refLabel"><a href="#ref242" class="rightTabRefNumLink">241</a></strong><div class="NLM_citation" id="rightTab-cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miousse, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosanke, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avula, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ElSohly, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurley, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koturbash, I.</span></span> <span> </span><span class="NLM_article-title">Safety Assessment of the Dietary Supplement OxyELITE Pro (New Formula) in Inbred and Outbred Mouse Strains</span>. <i>Food Chem. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.1016/j.fct.2017.08.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1016%2Fj.fct.2017.08.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=28843594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVOjtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2017&pages=194-209&author=I.+R.+Miousseauthor=C.+M.+Skinnerauthor=H.+Linauthor=L.+E.+Ewingauthor=S.+D.+Kosankeauthor=D.+K.+Williamsauthor=B.+Avulaauthor=I.+A.+Khanauthor=M.+A.+ElSohlyauthor=B.+J.+Gurleyauthor=I.+Koturbash&title=Safety+Assessment+of+the+Dietary+Supplement+OxyELITE+Pro+%28New+Formula%29+in+Inbred+and+Outbred+Mouse+Strains&doi=10.1016%2Fj.fct.2017.08.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">Safety assessment of the dietary supplement OxyELITE Pro (New Formula) in inbred and outbred mouse strains</span></div><div class="casAuthors">Miousse, Isabelle R.; Skinner, Charles M.; Lin, Haixia; Ewing, Laura E.; Kosanke, Stanley D.; Williams, D. Keith; Avula, Bharathi; Khan, Ikhlas A.; El Sohly, Mahmoud A.; Gurley, Bill J.; Koturbash, Igor</div><div class="citationInfo"><span class="NLM_cas:title">Food and Chemical Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">Part_1</span>),
    <span class="NLM_cas:pages">194-209</span>CODEN:
                <span class="NLM_cas:coden">FCTOD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-6915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Herbal dietary supplements have gained wide acceptance as alternatives to conventional therapeutic agents despite concerns regarding their efficacy and safety.  In 2013, a spate of severe liver injuries across the United States was linked to the dietary supplement OxyELITE Pro-New Formula (OEP-NF), a multi-ingredient product marketed for wt. loss and exercise performance enhancement.  The principal goal of this study was to assess the hepatotoxic potential of OEP-NF in outbred and inbred mouse models.  In an acute toxicity study, significant mortality was obsd. after administering 10X and 3X mouse-equiv. doses (MED) of OEP-NF, resp.  Increases in liver/body wt. ratio, ALT and AST were obsd. in female B6C3F1 mice after gavaging 2X and 1.5X MED of OEP-NF.  Similar findings were obsd. in a 90-day feeding study.  These alterations were paralleled by altered expression of gene- and microRNA-signatures of hepatotoxicity, including Cd36, Nqo1, Aldoa, Txnrd1, Scd1 and Ccng1, as well as miR-192, miR-193a and miR-125b and were most pronounced in female B6C3F1 mice.  Body wt. loss, obsd. at week 1, was followed by wt. gain throughout the feeding studies.  These findings bolster safety and efficacy concerns for OEP-NF, and argue strongly for implementation of pre-market toxicity studies within the dietary supplement industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprwt2_0903rrVg90H21EOLACvtfcHk0liTfe6sZJX4Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVOjtr7I&md5=4325989d729fc3842ab9069451b9b74e</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1016%2Fj.fct.2017.08.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.fct.2017.08.025%26sid%3Dliteratum%253Aachs%26aulast%3DMiousse%26aufirst%3DI.%2BR.%26aulast%3DSkinner%26aufirst%3DC.%2BM.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DEwing%26aufirst%3DL.%2BE.%26aulast%3DKosanke%26aufirst%3DS.%2BD.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DAvula%26aufirst%3DB.%26aulast%3DKhan%26aufirst%3DI.%2BA.%26aulast%3DElSohly%26aufirst%3DM.%2BA.%26aulast%3DGurley%26aufirst%3DB.%2BJ.%26aulast%3DKoturbash%26aufirst%3DI.%26atitle%3DSafety%2520Assessment%2520of%2520the%2520Dietary%2520Supplement%2520OxyELITE%2520Pro%2520%2528New%2520Formula%2529%2520in%2520Inbred%2520and%2520Outbred%2520Mouse%2520Strains%26jtitle%3DFood%2520Chem.%2520Toxicol.%26date%3D2017%26volume%3D109%26spage%3D194%26epage%3D209%26doi%3D10.1016%2Fj.fct.2017.08.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref243"><div class="reference"><strong class="refLabel"><a href="#ref243" class="rightTabRefNumLink">242</a></strong><div class="NLM_citation" id="rightTab-cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heidemann, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleiner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span> <span> </span><span class="NLM_article-title">Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: A Case Series</span>. <i>Dig. Dis. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2741</span>– <span class="NLM_lpage">2748</span>, <span class="refDoi"> DOI: 10.1007/s10620-016-4181-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1007%2Fs10620-016-4181-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=27142670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsFWntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2016&pages=2741-2748&author=L.+A.+Heidemannauthor=V.+J.+Navarroauthor=J.+Ahmadauthor=P.+H.+Hayashiauthor=A.+Stolzauthor=D.+E.+Kleinerauthor=R.+J.+Fontana&title=Severe+Acute+Hepatocellular+Injury+Attributed+to+OxyELITE+Pro%3A+A+Case+Series&doi=10.1007%2Fs10620-016-4181-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit243R"><div class="casContent"><span class="casTitleNuber">243</span><div class="casTitle"><span class="NLM_cas:atitle">Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: A Case Series</span></div><div class="casAuthors">Heidemann, Lauren A.; Navarro, Victor J.; Ahmad, Jawad; Hayashi, Paul H.; Stolz, Andrew; Kleiner, David E.; Fontana, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Digestive Diseases and Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2741-2748</span>CODEN:
                <span class="NLM_cas:coden">DDSCDJ</span>;
        ISSN:<span class="NLM_cas:issn">0163-2116</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background/Aim: Herbal and dietary supplement (HDS) hepatotoxicity is increasingly being reported in the USA.  This case series describes the presenting clin. features and outcomes of seven patients with liver injury attributed to OxyELITE Pro enrolled in the Drug-Induced Liver Injury Network (DILIN) study.  Methods: The 6-mo outcomes of patients with hepatotoxicity attributed to OxyELITE Pro enrolled in the DILIN prospective registry between 2004 and 2015 are presented.  Results: Six of the seven patients (86 %) presented in 2013 with symptoms of hepatitis and acute hepatocellular injury.  The median duration of OxyELITE Pro use was 18 wk (range 5-102 wk).  Median age was 36 years (range 28-62), 86 % were female, and 43 % were Asian.  One patient had rash, none had eosinophilia, and three had antinuclear antibody reactivity.  The median peak ALT was 2242 U/L, alk. phosphatase 284 U/L and bilirubin 15.0 mg/dL.  Six patients (86 %) were hospitalized, three developed acute liver failure and two underwent liver transplantation.  DILIN causality scores for OxyELITE Pro were definite in 1, highly likely in 3, probable in 2, and possible in 1.  Four of the five patients without liver transplant recovered completely within 6 mo, while one patient had mild residual ALT elevations.  Conclusions: Seven cases of severe acute hepatocellular injury attributed to OxyELITE Pro are reported.  These results reinforce the need to assess for HDS supplement use in patients presenting with unexplained acute hepatitis and point to the need for addnl. regulatory oversight of HDS products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCRYRV1rfSHbVg90H21EOLACvtfcHk0liTfe6sZJX4Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsFWntr0%253D&md5=0c95cd630cd67bbd2886e61f16b219fc</span></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1007%2Fs10620-016-4181-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10620-016-4181-7%26sid%3Dliteratum%253Aachs%26aulast%3DHeidemann%26aufirst%3DL.%2BA.%26aulast%3DNavarro%26aufirst%3DV.%2BJ.%26aulast%3DAhmad%26aufirst%3DJ.%26aulast%3DHayashi%26aufirst%3DP.%2BH.%26aulast%3DStolz%26aufirst%3DA.%26aulast%3DKleiner%26aufirst%3DD.%2BE.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26atitle%3DSevere%2520Acute%2520Hepatocellular%2520Injury%2520Attributed%2520to%2520OxyELITE%2520Pro%253A%2520A%2520Case%2520Series%26jtitle%3DDig.%2520Dis.%2520Sci.%26date%3D2016%26volume%3D61%26spage%3D2741%26epage%3D2748%26doi%3D10.1007%2Fs10620-016-4181-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref244"><div class="reference"><strong class="refLabel"><a href="#ref244" class="rightTabRefNumLink">243</a></strong><div class="NLM_citation" id="rightTab-cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonkovsky, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeff, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avula, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirulli, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleiner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoofnagle, J. H.</span></span> <span> </span><span class="NLM_article-title">Severe and Protracted Cholestasis in 44 Young Men Taking Bodybuilding Supplements: Assessment of Genetic, Clinical and Chemical Risk Factors</span>. <i>Aliment. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1195</span>– <span class="NLM_lpage">1204</span>, <span class="refDoi"> DOI: 10.1111/apt.15211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=10.1111%2Fapt.15211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=30934130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;key=1%3ACAS%3A528%3ADC%252BC1MXns1Cgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2019&pages=1195-1204&author=A.+Stolzauthor=V.+Navarroauthor=P.+H.+Hayashiauthor=R.+J.+Fontanaauthor=H.+X.+Barnhartauthor=J.+Guauthor=N.+P.+Chalasaniauthor=M.+M.+Vegaauthor=H.+L.+Bonkovskyauthor=L.+B.+Seeffauthor=J.+Serranoauthor=B.+Avulaauthor=I.+A.+Khanauthor=E.+T.+Cirulliauthor=D.+E.+Kleinerauthor=J.+H.+Hoofnagle&title=Severe+and+Protracted+Cholestasis+in+44+Young+Men+Taking+Bodybuilding+Supplements%3A+Assessment+of+Genetic%2C+Clinical+and+Chemical+Risk+Factors&doi=10.1111%2Fapt.15211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors</span></div><div class="casAuthors">Stolz, Andrew; Navarro, Victor; Hayashi, Paul H.; Fontana, Robert J.; Barnhart, Huiman X.; Gu, Jiezhun; Chalasani, Naga P.; Vega, Maricruz M.; Bonkovsky, Herbert L.; Seeff, Leonard B.; Serrano, Jose; Avula, Bharathi; Khan, Ikhlas A.; Cirulli, Elizabeth T.; Kleiner, David E.; Hoofnagle, Jay H.</div><div class="citationInfo"><span class="NLM_cas:title">Alimentary Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1195-1204</span>CODEN:
                <span class="NLM_cas:coden">APTHEN</span>;
        ISSN:<span class="NLM_cas:issn">0269-2813</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Bodybuilding supplements can cause a profound cholestatic syndrome.  Aim : To describe the drug-Induced liver injury network's experience with liver injury due to bodybuilding supplements.  Methods : Liver injury pattern, severity and outcomes, potential genetic assocns., and exposure to anabolic steroids by product anal. were analyzed in prospectively enrolled subjects with bodybuilding supplement-induced liver injury with causality scores of probable or higher.  Results : Forty-four males (mean age 33 years) developed liver injury with a median latency of 73 days.  Forty-one per cent presented with hepatocellular pattern of liver injury as defined by the R > 5 ([Fold elevation of ALT] ÷ [Fold elevation of Alk Phos]) (mean, range = 6.4, 0.5-31.4, n = 42) despite all presenting with clin. features of cholestatic liver injury (100% with jaundice and 84% with pruritus).  Liver biopsy (59% of subjects) demonstrated a mild hepatitis and profound cholestasis in most without bile duct injury, loss or fibrosis.  Seventy-one per cent were hospitalised, and none died or required liver transplantation.  In some, chem. anal. revealed anabolic steroid controlled substances not listed on the label.  No enrichment of genetic variants assocd. with cholestatic syndromes was found, although mutations in ABCB11 (present in up to 20%) were significantly different than in ethnically matched controls.  Conclusions : Patients with bodybuilding supplements liver injury uniformly presented with cholestatic injury, which slowly resolved.  The ingested products often contained anabolic steroids not identified on the label, and no enrichment in genetic variants was found, indicating a need for addnl. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkUvPk3oIZiLVg90H21EOLACvtfcHk0liTfe6sZJX4Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXns1Cgu7s%253D&md5=7cfadf71ac56eb9efb72059a97705749</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1111%2Fapt.15211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fapt.15211%26sid%3Dliteratum%253Aachs%26aulast%3DStolz%26aufirst%3DA.%26aulast%3DNavarro%26aufirst%3DV.%26aulast%3DHayashi%26aufirst%3DP.%2BH.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DBarnhart%26aufirst%3DH.%2BX.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DChalasani%26aufirst%3DN.%2BP.%26aulast%3DVega%26aufirst%3DM.%2BM.%26aulast%3DBonkovsky%26aufirst%3DH.%2BL.%26aulast%3DSeeff%26aufirst%3DL.%2BB.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DAvula%26aufirst%3DB.%26aulast%3DKhan%26aufirst%3DI.%2BA.%26aulast%3DCirulli%26aufirst%3DE.%2BT.%26aulast%3DKleiner%26aufirst%3DD.%2BE.%26aulast%3DHoofnagle%26aufirst%3DJ.%2BH.%26atitle%3DSevere%2520and%2520Protracted%2520Cholestasis%2520in%252044%2520Young%2520Men%2520Taking%2520Bodybuilding%2520Supplements%253A%2520Assessment%2520of%2520Genetic%252C%2520Clinical%2520and%2520Chemical%2520Risk%2520Factors%26jtitle%3DAliment.%2520Pharmacol.%2520Ther.%26date%3D2019%26volume%3D49%26spage%3D1195%26epage%3D1204%26doi%3D10.1111%2Fapt.15211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01297&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-12%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01297%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01297" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799f73b6e4b3c94","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
